PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kuhl, H; Kruip, J; Seidler, A; Krieger-Liszkay, A; Bunker, M; Bald, D; Scheidig, AJ; Rogner, M				Kuhl, H; Kruip, J; Seidler, A; Krieger-Liszkay, A; Bunker, M; Bald, D; Scheidig, AJ; Rogner, M			Towards structural determination of the water-splitting enzyme - Purification, crystallization, and preliminary crystallographic studies of photosystem ii from a thermophilic cyanobacterium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; OXYGEN-EVOLVING COMPLEX; SYNECHOCOCCUS SP; D1 POLYPEPTIDE; GREEN PLANTS; RESOLUTION; PROTEIN; TYROSINE-161; ORGANIZATION; MICROSCOPY	A photosystem II preparation from the thermophilic cyanobacterium Synechococcus elongatus, which is especially suitable for three-dimensional crystallization in a fully active form was developed. The efficient purification method applied here yielded 10 mg of protein of a homogenous dimeric complex of about 500 kDa within 2 days. Detailed characterization of the preparation demonstrated a fully active electron transport chain from the manganese cluster to plastoquinone in the Q(B) binding site. The oxygen-evolving activity, 5000-6000 mu mol of O-2/(h.mg of chlorophyll), was the highest so far reported and is maintained even at temperatures as high as 50 degrees C, The crystals obtained by the vapor diffusion method diffracted to a resolution of 4.3 Angstrom The space group was determined to be P2(1)2(1)2(1) with four photosystem II dimers per unit cell. Analysis of the redissolved crystals revealed that activity, supramolecular organization, and subunit composition were maintained during crystallization.	Ruhr Univ Bochum, Fac Biol, Dept Plant Biochem, D-44780 Bochum, Germany; Univ Freiburg, Inst Biol 2, Dept Plant Biochem, D-79104 Freiburg, Germany; Tokyo Inst Technol, CREST Team 13, Yokohama, Kanagawa 2268503, Japan; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Ruhr University Bochum; University of Freiburg; Tokyo Institute of Technology; Max Planck Society	Rogner, M (corresponding author), Ruhr Univ Bochum, Fac Biol, Dept Plant Biochem, Universitatsstr 150, D-44780 Bochum, Germany.	matthias.roegner@ruhr-uni-bochum.de	Scheidig, Axel/C-9141-2011	Krieger-Liszkay, Anja/0000-0001-7141-4129				BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175; Boekema EJ, 1998, EUR J BIOCHEM, V252, P268, DOI 10.1046/j.1432-1327.1998.2520268.x; Boussac A, 1998, BIOCHEMISTRY-US, V37, P8995, DOI 10.1021/bi980195b; CASTENHOLZ RW, 1969, BACTERIOL REV, V33, P476, DOI 10.1128/MMBR.33.4.476-504.1969; CHAYEN NE, 1992, J CRYST GROWTH, V122, P176, DOI 10.1016/0022-0248(92)90241-A; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEKKER JP, 1988, BIOCHIM BIOPHYS ACTA, V936, P307, DOI 10.1016/0005-2728(88)90006-0; DEMETER S, 1984, BIOCHIM BIOPHYS ACTA, V764, P24, DOI 10.1016/0005-2728(84)90136-1; DINER RA, 1996, ADV PHOTOSYNTHESIS L, P213; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; ICHIMURA T, 1992, PLANT CELL PHYSIOL, V33, P299, DOI 10.1093/oxfordjournals.pcp.a078254; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; Kruip J, 1999, J BIOL CHEM, V274, P18181, DOI 10.1074/jbc.274.26.18181; KRUIP J, 1999, J CHROMATOGR LIBR, V61, P785; Kuhl H, 1999, EUR J BIOCHEM, V266, P453, DOI 10.1046/j.1432-1327.1999.00877.x; Kuhl H, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1001; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; Nakazato K, 1996, J MOL BIOL, V257, P225, DOI 10.1006/jmbi.1996.0158; NAVARRO JA, 1995, ARCH BIOCHEM BIOPHYS, V318, P46, DOI 10.1006/abbi.1995.1202; NISHIYAMA Y, 1994, PLANT PHYSIOL, V105, P1313, DOI 10.1104/pp.105.4.1313; Rhee KH, 1997, NATURE, V389, P522, DOI 10.1038/39103; Rhee KH, 1998, NATURE, V396, P283, DOI 10.1038/24421; ROGNER M, 1987, FEBS LETT, V219, P207, DOI 10.1016/0014-5793(87)81217-6; Rogner M, 1996, TRENDS BIOCHEM SCI, V21, P44, DOI 10.1016/0968-0004(96)80862-0; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P97; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Wenk SO, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1537; Wenk SO, 2000, J CHROMATOGR B, V737, P131, DOI 10.1016/S0378-4347(99)00525-3; YAMAOKA T, 1978, PLANT CELL PHYSIOL, V19, P943, DOI 10.1093/oxfordjournals.pcp.a075684; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122; Zouni A, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P925	41	89	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20652	20659		10.1074/jbc.M001321200	http://dx.doi.org/10.1074/jbc.M001321200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10748017	hybrid			2022-12-27	WOS:000088084500062
J	Baumer, S; Ide, T; Jacobi, C; Johann, A; Gottschalk, G; Deppenmeier, U				Baumer, S; Ide, T; Jacobi, C; Johann, A; Gottschalk, G; Deppenmeier, U			The F420H2 dehydrogenase from Methanosarcina mazei is a redox-driven proton pump closely related to NADH dehydrogenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; COMPLETE GENOME SEQUENCE; BOUND ELECTRON-TRANSPORT; UBIQUINONE OXIDOREDUCTASE; METHANOGENIC ARCHAEA; ENERGY-CONSERVATION; ESCHERICHIA-COLI; HETERODISULFIDE OXIDOREDUCTASE; METHANOLOBUS-TINDARIUS; ARCHAEOGLOBUS-FULGIDUS	The F420H2 dehydrogenase is part of the energy conserving electron transport system of the methanogenic archaeon Methanosarcina mazei Gal, Here it is shown that cofactor F420H2-dependent reduction of 2-hydroxy-phenazine as catalyzed by the membrane-bound enzyme is coupled to proton translocation across the cytoplasmic membrane, exhibiting a stoichiometry of 0.9 H+ translocated per two electrons transferred. The electrochemical proton gradient thereby generated was shown to drive ATP synthesis from ADP + Pi. The gene cluster encoding the F420H2 dehydrogenase of M. mazei Gol comprises 12 genes that are referred to as fpoA, B, C, D, H, I, J, K, L, M, N, and O. Analysis of the deduced amino acid sequences revealed that the enzyme is closely related to proton translocating NADH dehydrogenases of respiratory chains from bacteria (NDH-1) and eukarya (complex I). Like the NADH-dependent enzymes, the F420H2 dehydrogenase is composed of three subcomplexes. The gene products FpoA, EF, J, K, L, M, and N are highly hydrophobic and are homologous to subunits that form the membrane integral module of NDH-1. FpoB, C, D, and I have their counterparts in the amphipathic membrane-associated module of NDH-1. Homologues to the hydrophilic NADH-oxidizing input module are not present in M. mazei Gill, Instead, the gene product FpoF maS be responsible for F420H2 oxidation and may function as the electron input part, Thus, the F420H2 dehydrogenase from M. mazei Gol resembles eukaryotic and bacterial proton transiocating NADH dehydrogenases in many ways. The enzyme from the methanogenic archaeon functions as a NDB-1/complex I homologue and is equipped with an alternative electron input unit for the oxidation of reduced cofactor F-420 and a modified output module adopted to the reduction of methanophenazine.	Univ Gottingen, Abt Allgemeine Mikrobiol, D-37077 Gottingen, Germany; Univ Gottingen, Gottingen Genom Lab, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany	University of Gottingen; University of Gottingen	Deppenmeier, U (corresponding author), Univ Gottingen, Abt Allgemeine Mikrobiol, Grisebachstr 8, D-37077 Gottingen, Germany.		Borriss, Rainer/C-5026-2012	Borriss, Rainer/0000-0003-3726-1004				Abken HJ, 1997, FEMS MICROBIOL LETT, V154, P231, DOI 10.1111/j.1574-6968.1997.tb12649.x; Abken HJ, 1998, J BACTERIOL, V180, P2027, DOI 10.1128/JB.180.8.2027-2032.1998; Baumer S, 1998, FEBS LETT, V428, P295, DOI 10.1016/S0014-5793(98)00555-9; Brodersen J, 1999, EUR J BIOCHEM, V259, P218, DOI 10.1046/j.1432-1327.1999.00017.x; BROWN JW, 1989, CRIT REV MICROBIOL, V16, P287, DOI 10.3109/10408418909105479; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Deppenmeier U, 1996, ARCH MICROBIOL, V165, P149, DOI 10.1007/BF01692856; Deppenmeier U, 1999, FEBS LETT, V457, P291, DOI 10.1016/S0014-5793(99)01026-1; DEPPENMEIER U, 1990, P NATL ACAD SCI USA, V87, P9449, DOI 10.1073/pnas.87.23.9449; Dupuis A, 1998, BBA-BIOENERGETICS, V1364, P147, DOI 10.1016/S0005-2728(98)00025-5; Dutton PL, 1998, BBA-BIOENERGETICS, V1364, P245, DOI 10.1016/S0005-2728(98)00031-0; Finel M, 1998, BBA-BIOENERGETICS, V1364, P112, DOI 10.1016/S0005-2728(98)00022-X; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; Friedrich T, 1997, J THEOR BIOL, V187, P529, DOI 10.1006/jtbi.1996.0387; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; HAASE P, 1992, EUR J BIOCHEM, V203, P527, DOI 10.1111/j.1432-1033.1992.tb16579.x; HEILIG R, 1999, PYROCOCCUS ABYSSI GE; Ide T, 1999, J BACTERIOL, V181, P4076, DOI 10.1128/JB.181.13.4076-4080.1999; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KUNOW J, 1994, EUR J BIOCHEM, V223, P503, DOI 10.1111/j.1432-1033.1994.tb19019.x; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; MANN S, 1970, ARCH MIKROBIOL, V71, P304, DOI 10.1007/BF00417128; Muller V, 1999, J BIOENERG BIOMEMBR, V31, P15, DOI 10.1023/A:1005451311009; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Ohnishi T, 1998, BBA-BIOENERGETICS, V1365, P301, DOI 10.1016/S0005-2728(98)00082-6; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; Westenberg DJ, 1999, FEMS MICROBIOL LETT, V170, P389, DOI 10.1111/j.1574-6968.1999.tb13399.x; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; Yano T, 1997, J BIOL CHEM, V272, P4201, DOI 10.1074/jbc.272.7.4201	32	89	110	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17968	17973		10.1074/jbc.M000650200	http://dx.doi.org/10.1074/jbc.M000650200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10751389	hybrid			2022-12-27	WOS:000087659400010
J	Bermingham, A; Bottomley, JR; Primrose, WU; Derrick, JP				Bermingham, A; Bottomley, JR; Primrose, WU; Derrick, JP			Equilibrium and kinetic studies of substrate binding to 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHESIS FAS GENE; HYDROXYMETHYLDIHYDROPTERIN PYROPHOSPHOKINASE; DIHYDROPTEROATE SYNTHASE; STREPTOCOCCUS-PNEUMONIAE; DIHYDRONEOPTERIN ALDOLASE; PLASMODIUM-FALCIPARUM; FOLATE BIOSYNTHESIS; PROTEIN; SEQUENCE; 7,8-DIHYDRO-6-HYDROXYMETHYLPTERIN-PYROPHOSPHOKINASE	6-Hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK) catalyzes the pyrophosphorylation of 6-hydroxymethyl-7,8-dihydropterin (HMDP) by ATP to form 6-hydroxymethyl-7,8-dihydropterin pyrophosphate, an intermediate in the pathway for folic acid biosynthesis. The enzyme has been identified as a potential target for antimicrobial drugs. Equilibrium binding studies showed that Escherichia coli HPPK-bound ATP or the nonhydrolyzable ATP analogue alpha,beta-methyleneadenosine triphosphate (AMPCPP) with high affinity. The fluorescent ATP analogue 2'(3')-O-(N-methylanthraniloyl) adenosine 5'-triphosphate (MANT-ATP) exhibited a substantial fluorescence enhancement upon binding to HPPK with an equilibrium dissociation constant comparable with that for ATP (10.4 and 4.5 mu M, respectively). The apoenzyme did not bind the second substrate HMDP, however, unless AMPCPP was present, suggesting that the enzyme binds ATP first, followed by HMDP. Equilibrium titration of HPPK into HMDP and AMPCPP showed an enhancement of fluorescence from the pterin ring of the substrate, and a dissociation constant of 36 nM was deduced for HMDP binding to the HPPK.AMPCPP binary complex, Stopped flow fluorimetry measurements showed that the rate constants for the binding of MANT-ATP and AMPCPP to HPPK were relatively slow (3.9 x 10(5) and 1.05 x 10(5) M-1 s(-1), respectively) compared with the on rate for binding of HMDP to the HPPK.AMPCPP binary complex. The significance of these results with respect to the crystal structures of HPPK is discussed.	Univ Manchester, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; PanTherix Ltd, Glasgow G20 0SP, Lanark, Scotland	University of Manchester	Derrick, JP (corresponding author), Univ Manchester, Dept Biomol Sci, Sackville St, Manchester M60 1QD, Lancs, England.	Jeremy.Derrick@umist.ac.uk		Derrick, Jeremy/0000-0002-4350-5354				BALLANTINE SP, 1994, PROTEIN EXPRES PURIF, V5, P371, DOI 10.1006/prep.1994.1054; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS DR, 1994, EUR J BIOCHEM, V224, P397, DOI 10.1111/j.1432-1033.1994.00397.x; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P109; FUTTERMAN S, 1957, J BIOL CHEM, V228, P1031; Gutfreund H, 1995, KINETICS LIFE SCI; Hennig M, 1999, J MOL BIOL, V287, P211, DOI 10.1006/jmbi.1999.2623; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; LOPEZ P, 1990, J BACTERIOL, V172, P4766, DOI 10.1128/jb.172.9.4766-4774.1990; LOPEZ P, 1993, J BACTERIOL, V175, P2214, DOI 10.1128/JB.175.8.2214-2220.1993; Pashley TV, 1997, MOL BIOCHEM PARASIT, V86, P37, DOI 10.1016/S0166-6851(97)90004-9; Rebeille F, 1997, EMBO J, V16, P947, DOI 10.1093/emboj/16.5.947; RICHEY DP, 1969, J BIOL CHEM, V244, P1582; RICHEY DP, 1971, METHODS ENZYMOL B, V18, P765; SHIOTA T, 1984, CHEM BIOCH FOLATES, P121; Stammers DK, 1999, FEBS LETT, V456, P49, DOI 10.1016/S0014-5793(99)00860-1; TALARICO TL, 1991, J BACTERIOL, V173, P7029, DOI 10.1128/jb.173.21.7029-7032.1991; TALARICO TL, 1992, J BACTERIOL, V174, P5971, DOI 10.1128/jb.174.18.5971-5977.1992; TRIGLIA T, 1994, P NATL ACAD SCI USA, V91, P7149, DOI 10.1073/pnas.91.15.7149; Vinnicombe HG, 1999, BIOCHEM BIOPH RES CO, V258, P752, DOI 10.1006/bbrc.1999.0695; VOLPE F, 1992, GENE, V112, P213, DOI 10.1016/0378-1119(92)90378-3; VOLPE F, 1993, EUR J BIOCHEM, V216, P449, DOI 10.1111/j.1432-1033.1993.tb18163.x; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WEISMAN RA, 1964, J BIOL CHEM, V239, P326; Wood H., 1975, CHEM BIOL PTERIDINES, P27; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Xiao B, 1999, STRUCTURE, V7, P489, DOI 10.1016/S0969-2126(99)80065-3	29	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17962	17967		10.1074/jbc.M000331200	http://dx.doi.org/10.1074/jbc.M000331200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10751386	hybrid			2022-12-27	WOS:000087659400009
J	Shimizu, T; Ihara, K; Maesaki, R; Kuroda, S; Kaibuchi, K; Hakoshima, T				Shimizu, T; Ihara, K; Maesaki, R; Kuroda, S; Kaibuchi, K; Hakoshima, T			An open conformation of switch I revealed by the crystal structure of a Mg2+-free form of RHOA complexed with GDP - Implications for the GDP/GTP exchange mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; DBL HOMOLOGY DOMAIN; G-PROTEIN; FLUORESCENCE SPECTROSCOPY; GTP ANALOG; BINDING; ACTIVATION; INSIGHTS; FAMILY; SITE	Mg2+ ions are essential for guanosine triphosphatase (GTPase) activity and play key roles in guanine nucleotide binding and preserving the structural integrity of GTP-binding proteins. We determined the crystal structure of a small GTPase RHOA complexed with GDP in the absence of Mg2+ at 2.0-Angstrom resolution Elimination of a Mg2+ ion induces significant conformational changes in the switch I region that opens up the nucleotide-binding site. Similar structural changes have been observed in the switch regions of Ha Ras bound to its guanine nucleotide exchange factor, Sos. This RHOA-GDP structure reveals an important regulatory role for Mg2+ and suggests that guanine nucleotide exchange factor may utilize this feature of snitch I to produce an open conformation in GDP/GTP exchange.	Nara Inst Sci & Technol, Div Struct Biol, Nara 6300101, Japan; Nara Inst Sci & Technol, Signal Transduct, Nara 6300101, Japan	Nara Institute of Science & Technology; Nara Institute of Science & Technology	Hakoshima, T (corresponding author), Nara Inst Sci & Technol, Div Struct Biol, 8916-5 Takayama, Nara 6300101, Japan.		KURODA, SHINYA/G-4961-2014					Aelst L, 1997, GENE DEV, V11, P2295; Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Al-Karadaghi S, 1996, STRUCTURE, V4, P555, DOI 10.1016/S0969-2126(96)00061-5; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; Freymann DM, 1999, NAT STRUCT BIOL, V6, P793, DOI 10.1038/11572; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; HALL A, 1986, J BIOL CHEM, V261, P963; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; JOHN J, 1993, J BIOL CHEM, V268, P923; JOHN J, 1988, J BIOL CHEM, V263, P11792; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pan JY, 1996, J BIOL CHEM, V271, P1322, DOI 10.1074/jbc.271.3.1322; Pan JY, 1998, BIOESSAYS, V20, P516, DOI 10.1002/(SICI)1521-1878(199806)20:6<516::AID-BIES11>3.0.CO;2-3; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; Rudolph MG, 1999, PROTEIN SCI, V8, P778; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Simon I, 1996, J BIOL CHEM, V271, P20470, DOI 10.1074/jbc.271.34.20470; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699	42	50	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18311	18317		10.1074/jbc.M910274199	http://dx.doi.org/10.1074/jbc.M910274199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748207	hybrid			2022-12-27	WOS:000087659400056
J	Girotto, D; Fabbro, C; Braghetta, P; Vitale, P; Volpin, D; Bressan, GM				Girotto, D; Fabbro, C; Braghetta, P; Vitale, P; Volpin, D; Bressan, GM			Analysis of transcription of the Col6a1 gene in a specific set of tissues suggests a new variant of enhancer region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE-SPECIFIC ENHANCER; ALPHA-1(VI) COLLAGEN GENE; TRANSGENIC MICE; EXPRESSION; PROMOTER; IDENTIFICATION; SEQUENCE; SOX9; SITE; DIFFERENTIATION	The region extending from -5.4 to -3.9 kilobase pairs from the transcription start site of the Col6a1 gene has been previously shown to contain sequences activating tissue-specific transcription in articular cartilage, intervertebral disks, subepidermal, and vibrissae mesenchyme and peripheral nervous system (Braghetta, P., Fabbro, C., Piccolo, S., Marvulli, D., Bonaldo, P., Volpin, D., and Bressan, G. M. (1996) J, Cell Biol. 135, 1163-1177). Analysis of expression of deletions of this region in transgenic mice has identified the 383-base pair fragment E-L as the most active sequence of the region. Linker-scanning mutagenesis analysis of segment E-J, which spans the 5' 245 base pairs of E-L and is sufficient for high frequency expression in articular cartilage, showed that all the mutations reduced transcription considerably, suggesting that the integrity of the entire cluster of elements is necessary for enhancer activity. Electrophoretic mobility shift assays with nuclear extracts derived from various sources showed that fragment E-J binds numerous transcription factors (at least 22). These factors are present in most cells, expressing and nonexpressing alpha 1(VI) collagen mRNA, but in different relative proportions, and none of them appears to be cell type-specific. Several lines of evidence indicate that sequence elements of the enhancer may have different functional roles in various cells. The data configure the -5.4/-3.9 region of the Col6a1 gene as a new type of tissue-specific enhancer, characterized by a variety of tissues supporting its activation and by the dependence of its function only on ubiquitous transcription factors. This type of enhancer is postulated to be particularly important for genes such as those of the extracellular matrix, which are often expressed with broad tissue specificity.	Univ Padua, Inst Histol & Embryol, I-35100 Padua, Italy	University of Padua	Bressan, GM (corresponding author), Univ Padua, Inst Histol & Embryol, Via G Colombo 3, I-35100 Padua, Italy.	bressan@civ.bio.unipd.it	Braghetta, Paola/K-5478-2016	Braghetta, Paola/0000-0003-2547-8679				Arnone MI, 1997, DEVELOPMENT, V124, P1851; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; BONALDO P, 1993, MATRIX, V13, P223, DOI 10.1016/S0934-8832(11)80006-5; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Boyes J, 1996, EMBO J, V15, P2496, DOI 10.1002/j.1460-2075.1996.tb00607.x; Braghetta P, 1997, EUR J BIOCHEM, V247, P200, DOI 10.1111/j.1432-1033.1997.00200.x; Braghetta P, 1996, J CELL BIOL, V135, P1163, DOI 10.1083/jcb.135.4.1163; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fabbro C, 1999, J BIOL CHEM, V274, P1759, DOI 10.1074/jbc.274.3.1759; Goodbourn S, 1990, Semin Cancer Biol, V1, P89; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; MALLEINGERIN F, 1993, P NATL ACAD SCI USA, V90, P3289, DOI 10.1073/pnas.90.8.3289; MARIGO V, 1992, EUR J CELL BIOL, V57, P254; MESSING A, 1994, J NEUROSCI, V14, P3533; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; PFEIFFER SE, 1972, P NATL ACAD SCI USA, V69, P2885, DOI 10.1073/pnas.69.10.2885; PICCOLO S, 1995, J BIOL CHEM, V270, P19583, DOI 10.1074/jbc.270.33.19583; Ptashne M, 1998, CURR BIOL, V8, pR812, DOI 10.1016/S0960-9822(07)00508-8; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STAMATOYANNOPOULOS JA, 1995, EMBO J, V14, P106, DOI 10.1002/j.1460-2075.1995.tb06980.x; VALLE PL, 1993, J CELL BIOL, V121, P1173, DOI 10.1083/jcb.121.5.1173; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	36	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17381	17390		10.1074/jbc.M000075200	http://dx.doi.org/10.1074/jbc.M000075200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747869	hybrid			2022-12-27	WOS:000087485000025
J	Slepnev, VI; Ochoa, GC; Butler, MH; De Camilli, P				Slepnev, VI; Ochoa, GC; Butler, MH; De Camilli, P			Tandem arrangement of the clathrin and AP-2 binding domains in amphiphysin 1 and disruption of clathrin coat function by amphiphysin fragments comprising these sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ENDOCYTOSIS; NERVE-TERMINALS; ALPHA-ADAPTIN; APPENDAGE DOMAIN; SH3 DOMAIN; PROTEIN; DYNAMIN; FAMILY; EPS15; COMPLEX	Amphiphysin 1 and 2 are proteins implicated in the recycling of synaptic vesicles in nerve terminals. They interact with dynamin and synaptojanin via their COOH-terminal SH3 domain, whereas their central regions contain binding sites for clathrin and for the clathrin adaptor AP-2, We have defined here amino acids of amphiphysin 1 crucial for binding to AP-2 and clathrin, Overexpression in Chinese hamster ovary cells of an amphiphysin 1 fragment that binds both AP-2 and clathrin resulted in a segregation of clathrin, which acquired a diffuse distribution, from AP-2, which accumulated at patches also positive for Eps15, These effects correlated with a block in clathrin-mediated endocytosis. A fragment selectively interacting with clathrin produced a similar effect. These results can be explained by the binding of amphiphysin to the NH2-terminal domain of clathrin and by a competition with the binding of this domain to the beta-subunit of AP-2 and AP180. The interaction of amphiphysin 1 with either clathrin or AP-2 did not prevent its interaction with dynamin, supporting the existence of tertiary complexes between these proteins. Together with previous evidence indicating a direct interaction between amphiphysin and membrane lipids, these findings support a model in which amphiphysin acts as a multifunctional adaptor linking the membrane to coat proteins and coat proteins to dynamin and synaptojanin.	Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, 295 Congress Ave, New Haven, CT 06510 USA.				NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Colwill K, 1999, GENETICS, V152, P881; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DECAMILLI P, 2000, SYNAPSES; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; Iannolo G, 1997, CANCER RES, V57, P240; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; Musacchio A, 1999, MOL CELL, V3, P761, DOI 10.1016/S1097-2765(01)80008-3; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Ramjaun AR, 1999, J BIOL CHEM, V274, P19785, DOI 10.1074/jbc.274.28.19785; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5	40	97	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17583	17589		10.1074/jbc.M910430199	http://dx.doi.org/10.1074/jbc.M910430199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748223	hybrid			2022-12-27	WOS:000087485000054
J	Yeagley, D; Moll, J; Vinson, CA; Quinn, PG				Yeagley, D; Moll, J; Vinson, CA; Quinn, PG			Characterization of elements mediating regulation of phosphoenolpyruvate carboxykinase gene transcription by protein kinase A and insulin - Identification of a distinct complex formed in cells that mediate insulin inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING-PROTEIN; DOMINANT-NEGATIVE INHIBITOR; DNA-BINDING; CAMP INDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; MULTIHORMONAL REGULATION; SIGNALING PATHWAYS; 3T3-L1 ADIPOCYTES; CATALYTIC SUBUNIT; LEUCINE ZIPPER	The in vivo pattern of induction of phosphoenolpyruvate carboxykinase (PEPCK) gene transcription by cAMP and its inhibition by insulin is reproduced in H4IIe cells and is mediated by a bipartite cAMP/insulin response unit (C/IRU) consisting of a cAMP response element (-95/-87) and an upstream enhancer, AC (-271/-225), Studies in HepG2 cells showed that binding of AP-1 and CAAT/enhancer-binding protein (C/EBP) to AC is required for induction by cAMP, but insulin did not inhibit cAMP-induced PEPCK expression in HepG2 cells. Binding of H4IIe nuclear proteins to an AC element probe was inhibited by antibodies or a consensus site for C/EBP, but not AP-1, Transfection with dominant negative bZIP factors, which prevent endogenous factors from binding to DNA, showed that elimination of cAMP regulatory element-binding protein CREB or C/EBP activity blocked induction by protein kinase A (PRA), whereas elimination of AP-1 activity had no effect. In addition, promoters with multiple CREB sites, or a single CREB site and multiple C/EBP sites, mediated PKA induction, but this was inhibited to no greater extent than basal activity was by insulin. These results indicate that an AC factor other than C/EBP must mediate insulin inhibition. An A-site probe (-265/-247) or a probe across the middle of the AC element (-256/-237) competed for complexes formed by factors other than AP-1 or C/EBP, However, analysis of competitor oligonucleotides and antibodies for candidate factors failed to identify other factors. Scanning mutations throughout the AC element interfered with induction but allowed us to define five overlapping sites for regulatory factors in AC and to design probes binding just one or two factors, Comparison of the protein-DNA complexes formed on these smaller probes revealed that a specific complex present in rat liver and H4IIe cell nuclear extracts differed from those formed by HepG2 cell nuclear extracts. Our results suggest that multiple factors binding the AC element of the C/IRU interact with each other and CREB to regulate PEPCK induction by cAMP and inhibition by insulin and that the unique factor expressed in H4IIe cells is a candidate for involvement in insulin regulation of PKA-induced PEPCK gene transcription.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Quinn, PG (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, H166,500 Univ Dr, Hershey, PA 17033 USA.	pquinn@psu.edu			PHS HHS [R01 43871] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; BEALE E, 1984, DIABETES, V33, P328, DOI 10.2337/diabetes.33.4.328; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; Gaunitz F, 1997, BIOL CHEM, V378, P11, DOI 10.1515/bchm.1997.378.1.11; GIESE K, 1994, P NATL ACAD SCI USA, V91, P3368, DOI 10.1073/pnas.91.8.3368; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; HOWARD P, 1991, J BIOL CHEM, V266, P10189; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Laser B, 1996, J BIOL CHEM, V271, P28984, DOI 10.1074/jbc.271.46.28984; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Olive M, 1996, J BIOL CHEM, V271, P2040, DOI 10.1074/jbc.271.4.2040; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; Pierreux CE, 1999, P NATL ACAD SCI USA, V96, P8961, DOI 10.1073/pnas.96.16.8961; QUINN PG, 1994, J BIOL CHEM, V269, P14375; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; QUINN PG, 1993, J BIOL CHEM, V268, P16999; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; WOODGETT JR, 1993, ADV SEC MESS PHOSPH, V28, P261; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	49	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17814	17820		10.1074/jbc.M909842199	http://dx.doi.org/10.1074/jbc.M909842199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748164	hybrid			2022-12-27	WOS:000087485000084
J	Roig, J; Huang, ZD; Lytle, C; Traugh, JA				Roig, J; Huang, ZD; Lytle, C; Traugh, JA			p21-activated protein kinase gamma-PAK is translocated and activated in response to hyperosmolarity - Implication of Cdc42 and phosphoinositide 3-kinase in a two-step mechanism for gamma-PAK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; CASPASE-MEDIATED ACTIVATION; GTP-BINDING PROTEINS; ALPHA-PAK; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; STE20/PAK FAMILY; XENOPUS OOCYTES	A member of the family of p21-activated protein kinases, gamma-PAK, has cytostatic properties and is activated during apoptosis and in response to DNA damage. To determine whether gamma-PAK is activated by other types of cell stress and to assess its mechanism of activation, the response of gamma-PAK to hyperosmotic stress was examined. In 3T3-L1 mouse fibroblasts, there are two pools of gamma-PAK: the majority of the protein kinase is soluble and has low specific activity, whereas gamma-PAK associated with the particulate fraction has significantly higher specific activity. Hyperosmolarity promotes translocation of gamma-PAK from the soluble to the particulate fraction; this parallels activation of the protein kinase. Activation but not translocation of gamma-PAK is wortmannin-sensitive, suggesting the involvement of a phosphoinositide 3-kinase-related activity. gamma-PAK translocation in response to hyperosmolarity parallels Cdc42 translocation to the particulate fraction in vivo and can be induced in vitro by guanosine 5'-3-O-(thio)triphosphate. Cotransfection of gamma-PAK with constitutively active Cdc42 induces gamma-PAK activation and translocation, whereas inactive Cdc42 inhibits both processes in response to hyperosmotic stress, suggesting that Cdc42 has a role in the translocation and activation of gamma-PAK. alpha-PAK is not activated in response to hyperosmolarity in 3T3-L1 cells. A two-step model of gamma-PAK activation is presented.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Biomed Sci, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Traugh, JA (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	jolinda.traugh@ucr.edu	Lytle, Christian/X-2836-2019; Roig, Joan/E-2836-2017	Lytle, Christian/0000-0001-5442-1546; Roig, Joan/0000-0002-3872-4712	NIGMS NIH HHS [GM26738] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Chang YWE, 1997, J BIOL CHEM, V272, P28252, DOI 10.1074/jbc.272.45.28252; Clerk A, 1997, FEBS LETT, V403, P23, DOI 10.1016/S0014-5793(97)00020-3; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Ding JB, 1996, J BIOL CHEM, V271, P24869, DOI 10.1074/jbc.271.40.24869; Faure S, 1999, J BIOL CHEM, V274, P3573, DOI 10.1074/jbc.274.6.3573; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Kost B, 1999, J CELL BIOL, V145, P317, DOI 10.1083/jcb.145.2.317; Kultz D, 1998, J EXP BIOL, V201, P3015; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Low SY, 1997, FASEB J, V11, P1111, DOI 10.1096/fasebj.11.13.9367345; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Lytle C, 1998, AM J PHYSIOL-CELL PH, V274, pC1002, DOI 10.1152/ajpcell.1998.274.4.C1002; Ma L, 1998, J CELL BIOL, V140, P1125; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Roig J, 1999, J BIOL CHEM, V274, P31119, DOI 10.1074/jbc.274.44.31119; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SACHS JR, 1996, MOL BIOL MEMBRANE TR, P375; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Shrode LD, 1998, CONTRIB NEPHROL, V123, P79, DOI 10.1159/000059922; TERADA Y, 1994, J BIOL CHEM, V269, P31296; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; Tuazon PT, 1999, FASEB J, V13, pA1490; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Waldegger S, 1997, MINER ELECTROL METAB, V23, P201; Wang J, 1999, J BIOL CHEM, V274, P31641, DOI 10.1074/jbc.274.44.31641; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	63	55	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16933	16940		10.1074/jbc.M001627200	http://dx.doi.org/10.1074/jbc.M001627200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748040	hybrid			2022-12-27	WOS:000087392200076
J	Narahari, J; Ma, R; Wang, M; Walden, WE				Narahari, J; Ma, R; Wang, M; Walden, WE			The aconitase function of iron regulatory protein 1 - Genetic studies in yeast implicate its role in iron-mediated redox regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE ELEMENT-BINDING; PEROXISOMAL BETA-OXIDATION; SACCHAROMYCES-CEREVISIAE; RNA-BINDING; ISOCITRATE DEHYDROGENASE; MITOCHONDRIAL ACONITASE; FERRIREDUCTASE ACTIVITY; CYTOPLASMIC ACONITASE; FERRIC REDUCTASE; NADPH OXIDASE	Iron regulatory proteins (IRP) are sequence-specific RNA-binding proteins that mediate iron-responsive gene regulation in animals. IRP1 is also the cytosolic isoform of aconitase (c-aconitase). This latter activity could complement a mitochondrial aconitase mutation (acol) in Saccharomyces cerevisiae to restore glutamate prototrophy. In yeast, the c-aconitase activity of IRP1 was responsive to iron availability in the growth medium. Although IRP1 expression rescued acol yeast from glutamate auxotrophy, cells remained growth-limited by glutamate, displaying a slow-growth phenotype on glutamate-free media. Second site mutations conferring enhanced cytosolic aconitase-dependent (ECA) growth were recovered. Relative c-aconitase activity was increased in extracts of strains harboring these mutations. One of the ECA mutations was found to be in the gene encoding cytosolic NADP(+)-dependent isocitrate dehydrogenase (IDP2). This mutation, an insertion of a Ty delta element into the 5' region of IDP2, markedly elevates expression of Idp2p in glucose media. Our results demonstrate the physiological significance of the aconitase activity of IRP1 and provide insight into the role of c-aconitase with respect to iron and cytoplasmic redox regulation.	Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Walden, WE (corresponding author), Univ Illinois, Dept Microbiol & Immunol, M-C 790,835 S Wolcott, Chicago, IL 60612 USA.	wwalden@uic.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047281] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47281] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKOMPONG T, 1995, J BIOL CHEM, V270, P20937, DOI 10.1074/jbc.270.36.20937; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BODANESS RS, 1982, BIOCHEM BIOPH RES CO, V108, P1709, DOI 10.1016/S0006-291X(82)80108-3; Boeke J.D., 1991, MOL CELLULAR BIOL YE, V1, P193; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Brazzolotto X, 1999, J BIOL CHEM, V274, P21625, DOI 10.1074/jbc.274.31.21625; Brown NM, 1998, P NATL ACAD SCI USA, V95, P15235, DOI 10.1073/pnas.95.26.15235; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; Chen OS, 1997, J NUTR, V127, P238, DOI 10.1093/jn/127.2.238; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; Eisenstein RS, 1997, CH MICROBIOL SER, P157; FARRELL HM, 1995, ARCH BIOCHEM BIOPHYS, V321, P199, DOI 10.1006/abbi.1995.1386; Ferreira GC, 1999, INT J BIOCHEM CELL B, V31, P995, DOI 10.1016/S1357-2725(99)00066-7; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; GANGLOFF SP, 1990, MOL CELL BIOL, V10, P3551, DOI 10.1128/MCB.10.7.3551; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAN O, 1995, J NUTR, V125, P1291; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; Hassett RF, 1998, J BIOL CHEM, V273, P7628, DOI 10.1074/jbc.273.13.7628; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; Henderson ER, 1996, J BIOL CHEM, V271, P4900; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; INMAN RS, 1994, BIOCHEMISTRY-US, V33, P11850, DOI 10.1021/bi00205a022; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; JENNINGS GT, 1990, BIOCHIM BIOPHYS ACTA, V1034, P219, DOI 10.1016/0304-4165(90)90080-G; JORDAN I, 1994, BIOCHEM J, V302, P875, DOI 10.1042/bj3020875; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; Minard KI, 1998, J BIOL CHEM, V273, P31486, DOI 10.1074/jbc.273.47.31486; Minard KI, 1999, J BIOL CHEM, V274, P3402, DOI 10.1074/jbc.274.6.3402; OGUR M, 1964, BIOCHEM BIOPH RES CO, V14, P193, DOI 10.1016/0006-291X(64)90254-2; Parkes JG, 1997, TOXICOLOGY, V117, P141, DOI 10.1016/S0300-483X(96)03566-4; PATINO MM, 1992, J BIOL CHEM, V267, P19011; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; Rose MD., 1990, METHODS YEAST GENETI; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Schalinske KL, 1996, J BIOL CHEM, V271, P7168, DOI 10.1074/jbc.271.12.7168; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; SIKORSKI RS, 1989, GENETICS, V122, P19; Theil EC, 1998, MET IONS BIOL SYST, V35, P403; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; Waldo G. S., 1996, COMPREHENSIVE SUPRAM, V5, P65; WINKLER BS, 1986, EXP EYE RES, V43, P829, DOI 10.1016/S0014-4835(86)80013-6; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Zhao WN, 1996, BIOCHEMISTRY-US, V35, P7873, DOI 10.1021/bi9605189	61	51	51	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16227	16234		10.1074/jbc.M910450199	http://dx.doi.org/10.1074/jbc.M910450199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748225	hybrid			2022-12-27	WOS:000087291400084
J	Ujita, M; Misra, AK; McAuliffe, J; Hindsgaul, O; Fukuda, M				Ujita, M; Misra, AK; McAuliffe, J; Hindsgaul, O; Fukuda, M			Poly-N-acetyllactosamine extension in N-glycans and core 2-and core 4-branched O-glycans is differentially controlled by i-extension enzyme and different members of the beta 1,4-galactosyltransferase gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; HAMSTER OVARY CELLS; LINKED SUGAR CHAINS; HUMAN-ERYTHROCYTE-MEMBRANE; MOLECULAR-CLONING; CARBOHYDRATE STRUCTURE; EXPRESSION CLONING; UDP-GALACTOSE; GASTRIC MUCIN; HL-60 CELLS	Poly-N-acetyllactosamines are attached to N-glycans, O-glycans, and glycolipids and serve as underlying glycans that provide functional oligosaccharides such as sialyl Lewis(X), Poly-N-acetyllactosaminyl repeats are synthesized by the alternate addition of beta 1,3-linked Glc-NAc and beta 1,4-linked Gal by i-extension enzyme (iGnT) and a member of the beta 1,4-galactosyltransferase (beta 4Gal-T) gene family. In the present study, we first found that poly-N-acetyllactosamines in N-glycans are most efficiently synthesized by beta 4Gal-TI and iGnT, We also found that iGnT acts less efficiently on accepters containing increasing numbers of N-acetyllactosamine repeats, in contrast to beta 4Gal-TI, which exhibits no significant change. In O-glycan biosynthesis, N-acetyllactosamine extension of core 4 branches was found to be synthesized most efficiently by iGnT and beta 4Gal-TI, in contrast to core 2 branch synthesis, which requires iGnT and beta 4Gal-TIV. Poly-N-acetyllactosamine extension of core 4 branches is, however, less efficient than that of N-glycans or core 2 branches. Such inefficiency is apparently due to competition between a donor substrate and acceptor in both galactosylation and N-acetylglucosaminylation, since a core 4-branched acceptor contains both Gal and GlcNAc terminals. These results, taken together, indicate that poly-N-acetyllactosamine synthesis in N-glycans and core 2- and core 4-branched O-glycans is achieved by iGnT and distinct members of the beta 4Gal-T gene family. The results also exemplify intricate interactions between accepters and specific glycosyltransferases, which play important roles in how poly-N-acetyllactosamines are synthesized in different acceptor molecules.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	minoru@burnham-inst.org			NCI NIH HHS [P01 CA71932, R01 CA48737, R37 CA33000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048737, P01CA071932, R37CA033000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Bakker H, 1997, J BIOL CHEM, V272, P18580, DOI 10.1074/jbc.272.30.18580; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; BOCK K, 1992, CARBOHYD RES, V228, P1, DOI 10.1016/S0008-6215(00)90544-5; BROCKHAUSEN I, 1983, CAN J BIOCHEM CELL B, V61, P1322, DOI 10.1139/o83-169; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; Cho SK, 1997, J BIOL CHEM, V272, P13622, DOI 10.1074/jbc.272.21.13622; DABROWSKI U, 1984, J BIOL CHEM, V259, P7648; DO KY, 1990, BIOCHEM BIOPH RES CO, V173, P1123, DOI 10.1016/S0006-291X(05)80902-7; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; FUKUDA M, 1988, J BIOL CHEM, V263, P5314; Fukuda M, 1999, J CELL BIOL, V147, P467, DOI 10.1083/jcb.147.3.467; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; FUKUDA M, 1984, J BIOL CHEM, V259, P925; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUDA MN, 1982, J BIOL CHEM, V257, P446; HANISCH FG, 1989, J BIOL CHEM, V264, P872; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; HOKKE CH, 1995, EUR J BIOCHEM, V228, P981, DOI 10.1111/j.1432-1033.1995.tb20350.x; HOUNSELL EF, 1980, BIOCHEM BIOPH RES CO, V92, P1143, DOI 10.1016/0006-291X(80)90406-4; JARNEFELT J, 1978, J BIOL CHEM, V253, P8006; KANIE O, 1993, CARBOHYD RES, V243, P139, DOI 10.1016/0008-6215(93)84087-M; KRUSIUS T, 1978, EUR J BIOCHEM, V92, P289, DOI 10.1111/j.1432-1033.1978.tb12747.x; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LEE N, 1990, J BIOL CHEM, V265, P20476; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; LOWE BJ, 1997, MOL GLYCOBIOLOGY, P163; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MAEMURA K, 1994, TETRAHEDRON-ASYMMETR, V5, P2093, DOI 10.1016/S0957-4166(00)86286-2; McAuliffe JC, 1999, BIOORG MED CHEM LETT, V9, P2855, DOI 10.1016/S0960-894X(99)00485-0; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1943; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; PAULSEN H, 1993, LIEBIGS ANN CHEM, P737; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; Ujita M, 1999, J BIOL CHEM, V274, P16717, DOI 10.1074/jbc.274.24.16717; Ujita M, 1999, J BIOL CHEM, V274, P9296, DOI 10.1074/jbc.274.14.9296; WANG WC, 1991, J BIOL CHEM, V266, P23185; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; YANG JM, 1994, GLYCOBIOLOGY, V4, P873, DOI 10.1093/glycob/4.6.873; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; YOSHIMA H, 1980, J BIOL CHEM, V255, P793; ZDEBSKA E, 1983, CARBOHYD RES, V120, P113, DOI 10.1016/0008-6215(83)88011-2	60	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15868	15875		10.1074/jbc.M001034200	http://dx.doi.org/10.1074/jbc.M001034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747980	hybrid			2022-12-27	WOS:000087291400037
J	Sekiya, I; Tsuji, K; Koopman, P; Watanabe, H; Yamada, Y; Shinomiya, K; Nifuji, A; Noda, M				Sekiya, I; Tsuji, K; Koopman, P; Watanabe, H; Yamada, Y; Shinomiya, K; Nifuji, A; Noda, M			SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRY-RELATED GENE; CHONDROCYTE-SPECIFIC ENHANCER; AUTOSOMAL SEX REVERSAL; RAT OSTEO-SARCOMA; II COLLAGEN GENE; TRANSGENIC MICE; CAMPOMELIC DYSPLASIA; MOUSE; DNA; CHONDROGENESIS	SOX9 is a transcription factor that plays a key role in chondrogenesis, Aggrecan is one of the major structural components in cartilage; however, the molecular mechanism of aggrecan gene regulation has not yet been fully elucidated, TC6 is a clonal chondrocytic cell line derived from articular cartilage, The purpose of this study was to examine whether SOX9 modulates aggrecan gene expression and to further identify molecules that regulate Sox9 expression in TC6 cells. SOX9 overexpression in TC6 cells enhanced by similar to 3-fold the transcriptional activity of the AgCAT-8 construct containing S-kilobase (kb) promoter/first exon/first intron fragments of the aggrecan gene. SOX9 enhancement of aggrecan promoter activity was lost when we deleted a 4.5-kb fragment from the 3'-end of the 8-kb fragment corresponding to the region including the first intron, In TC6 cells, SOX9 enhanced the transcriptional activity of a reporter construct containing the Sry/Sox consensus sequence >10-fold. SOX9 enhancement of aggrecan gene promoter activity and SOX9 transactivation through the Sry/Sox consensus sequence were not observed in osteoblastic osteosarcoma cells (ROS17/2.8), indicating the dependence on the cellular background. Northern blot analysis indicated that TC6 cells constitutively express Sox9 mRNA at relatively low levels. To examine regulation of Sox9 gene expression, we investigated the effects of calciotropic hormones and cytokines, Among these, retinoic acid (RA) specifically enhanced Sox9 mRNA expression in TC6 cells. The basal levels of Sox9 expression and its enhancement by RA were observed similarly at both permissive (33 degrees C) and nonpermissive (39 degrees C) temperatures. Furthermore, RA treatment enhanced the transcriptional activity of a reporter construct containing the Sry/Sox consensus sequence in TC6 cells. Moreover, RA treatment also enhanced the transcriptional activity of another reporter construct containing the enhancer region of the type II procollagen gene in TC6 cells. These observations indicate that SOX9 enhances aggrecan promoter activity and that its expression is up-regulated by RA in TC6 cells.	Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Pharmacol, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Dept Orthopaed Surg, Tokyo 101, Japan; Univ Queensland, Ctr Cellular & Mol Biol, Brisbane, Qld 4072, Australia; NIDCR, Dev Biol Lab, NIH, Bethesda, MD 20892 USA	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Queensland; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Noda, M (corresponding author), Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Pharmacol, Chiyoda Ku, 2-3-10 Kanda Surugadai, Tokyo 1010062, Japan.	noda.mph@mri.tmd.ac.jp	Nifuji, Akira/AAX-7907-2021; Koopman, Peter A/C-9416-2009	Nifuji, Akira/0000-0002-8182-4380; Koopman, Peter A/0000-0001-6939-0914				Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BENYA PD, 1986, DEV BIOL, V118, P296, DOI 10.1016/0012-1606(86)90096-5; BERTHOLD A, 1990, BIOMED BIOCHIM ACTA, V49, P1243; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; HORTON WE, 1987, DEV BIOL, V123, P508, DOI 10.1016/0012-1606(87)90409-X; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; Kamachi Y, 1999, MOL CELL BIOL, V19, P107; Kent J, 1996, DEVELOPMENT, V122, P2813; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; Mataga N, 1996, J BONE MINER RES, V11, P1646; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; MUIR H, 1995, BIOESSAYS, V17, P1039, DOI 10.1002/bies.950171208; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; NODA M, 1987, J BONE MINER RES, V2, P161; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; Yamaguchi M, 1998, P NATL ACAD SCI USA, V95, P7491, DOI 10.1073/pnas.95.13.7491; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F	38	397	418	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10738	10744		10.1074/jbc.275.15.10738	http://dx.doi.org/10.1074/jbc.275.15.10738			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753864	hybrid			2022-12-27	WOS:000086466600006
J	Morelli, X; Czjzek, M; Hatchikian, CE; Bornet, O; Fontecilla-Camps, JC; Palma, NP; Moura, JJG; Guerlesquin, F				Morelli, X; Czjzek, M; Hatchikian, CE; Bornet, O; Fontecilla-Camps, JC; Palma, NP; Moura, JJG; Guerlesquin, F			Structural model of the Fe-hydrogenase/cytochrome c(553) complex combining transverse relaxation-optimized spectroscopy experiments and soft docking calculations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-VULGARIS HILDENBOROUGH; CYTOCHROME C(553); CRYSTAL-STRUCTURE; DESULFURICANS ATCC-7757; ANGSTROM RESOLUTION; ELECTRON-TRANSFER; NMR; DEHYDROGENASE; BACTERIA; SULFATE	Fe-hydrogenase is a 54-kDa iron-sulfur enzyme essential for hydrogen cycling in sulfate-reducing bacteria. The x-ray structure of Desulfovibrio desulfuricans Fehydrogenase has recently been solved, but structural information on the recognition of its redox partners is essential to understand the structure-function relationships of the enzyme. In the present work, we have obtained a structural model of the complex of Fe-hydrogenase with its redox partner, the cytochrome c(553), combining docking calculations and NMR experiments. The putative models of the complex demonstrate that the small subunit of the hydrogenase has an important role in the complex formation with the redox partner; 50% of the interacting site on the hydrogenase involves the small subunit. The closest contact between the redox centers is observed between Cys-38, a ligand of the distal cluster of the hydrogenase and Cys-10, a ligand of the heme in the cytochrome. The electron pathway from the distal cluster of the Fe-hydrogenase to the heme of cytochrome c(553) was investigated using the software Greenpath and indicates that the observed cysteine/cysteine contact has an essential role. The spatial arrangement of the residues on the interface of the complex is very similar to that already described in the ferredoxin-cytochrome c(553) complex, which therefore, is a very good model for the interacting domain of the Fe-hydrogenase-cytochrome c(553).	CNRS, IBSM, Unite Bioenerget & Ingn Prot, Marseille 20, France; CEA, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Cristallog & Cristallogenese Prot, Grenoble, France; Univ Nova Lisboa, Fac Ciencias & Tecnol, Ctr Quim Fina & Biotecnol, Dept Quim, P-1200 Lisbon, Portugal; Inst Super Ciencias Saude, Sul, Portugal	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Universidade Nova de Lisboa	Guerlesquin, F (corresponding author), CNRS, IBSM, Unite Bioenerget & Ingn Prot, Marseille 20, France.		morelli, xavier/A-9218-2016; Moura, José J G/D-6426-2013	morelli, xavier/0000-0001-8101-7901; Moura, José J G/0000-0002-4726-2388; Palma, Nuno/0000-0002-9396-2131				ADAMS MWW, 1980, BIOCHIM BIOPHYS ACTA, V594, P105, DOI 10.1016/0304-4173(80)90007-5; BADZIONG W, 1980, ARCH MICROBIOL, V125, P167, DOI 10.1007/BF00403215; Blackledge MJ, 1996, PROTEINS, V24, P178, DOI 10.1002/(SICI)1097-0134(199602)24:2<178::AID-PROT5>3.0.CO;2-F; BLACKLEDGE MJ, 1995, J MOL BIOL, V245, P661, DOI 10.1006/jmbi.1994.0054; BLANCHARD L, 1993, EUR J BIOCHEM, V218, P293, DOI 10.1111/j.1432-1033.1993.tb18377.x; BOUSSEAU M, 1986, J AM CHEM SOC, V108, P1908, DOI 10.1021/ja00268a032; Czjzek M, 1996, STRUCTURE, V4, P395, DOI 10.1016/S0969-2126(96)00045-7; Davidson VL, 1996, BIOCHEMISTRY-US, V35, P8120, DOI 10.1021/bi952854f; FAUQUE G, 1988, FEMS MICROBIOL LETT, V54, P299, DOI 10.1111/j.1574-6968.1988.tb02748.x; HATCHIKIAN EC, 1992, EUR J BIOCHEM, V209, P357, DOI 10.1111/j.1432-1033.1992.tb17297.x; Hatchikian EC, 1999, J BACTERIOL, V181, P2947, DOI 10.1128/JB.181.9.2947-2952.1999; Hu YL, 1999, J MOL BIOL, V286, P899, DOI 10.1006/jmbi.1998.2488; Morelli X, 2000, BIOCHEMISTRY-US, V39, P2530, DOI 10.1021/bi992306s; Morelli X, 1999, FEBS LETT, V460, P77, DOI 10.1016/S0014-5793(99)01299-5; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; PALMA PN, 2000, IN PRESS PROTEINS ST; Peck H.D., 1993, SULFATE REDUCING BAC, DOI [10.1007/978-1-4613-9263-7_3, DOI 10.1007/978-1-4613-9263-7_3]; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Pervushin KV, 1998, J BIOMOL NMR, V12, P345, DOI 10.1023/A:1008268930690; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; Postgate J.R., 1984, SULFATE REDUCING BAC, V2nd; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sebban-Kreuzer C, 1998, BIOCHEMISTRY-US, V37, P8331, DOI 10.1021/bi980142u; Sebban-Kreuzer C, 1998, EUR J BIOCHEM, V251, P787, DOI 10.1046/j.1432-1327.1998.2510787.x; Tormay P, 1997, J BACTERIOL, V179, P576, DOI 10.1128/jb.179.3.576-582.1997; VERHAGEN MFJM, 1994, EUR J BIOCHEM, V221, P821, DOI 10.1111/j.1432-1033.1994.tb18796.x; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777	28	45	46	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23204	23210		10.1074/jbc.M909835199	http://dx.doi.org/10.1074/jbc.M909835199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10748163	hybrid			2022-12-27	WOS:000088419400083
J	Bodmer, JL; Meier, P; Tschopp, J; Schneider, P				Bodmer, JL; Meier, P; Tschopp, J; Schneider, P			Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ANTITUMOR-ACTIVITY; COMPLEX; ACTIVATION; RESOLUTION; APOPTOSIS; FAMILY; DEATH	Unlike other tumor necrosis factor family members, the cytotoxic ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo-2L contains an unpaired cysteine residue (Cys(230)) in its receptor-binding domain. Here we show that the biological activity of both soluble recombinant TRAIL and cell-associated, full-length TRAIL is critically dependent on the presence of Cys(230). Mutation of Cys(230) to alanine or serine strongly affected its ability to kill target cells. Binding to its receptors was decreased by at least 200-fold, and the stability of its trimeric structure was reduced. In recombinant TRAIL, Cys(230) was found engaged either in interchain disulfide bridge formation, resulting in poorly active TRAIL, or in the chelation of one zinc atom per TRAIL trimer in the active, pro-apoptotic form of TRAIL.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Lab Cantonal, CH-1066 Epalinges, Switzerland	University of Lausanne	Schneider, P (corresponding author), Univ Lausanne, Inst Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.			Schneider, Pascal/0000-0003-0677-9409				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; Degli-Esposti M, 1999, J LEUKOCYTE BIOL, V65, P535, DOI 10.1002/jlb.65.5.535; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Schneider P, 1997, J BIOL CHEM, V272, P18827, DOI 10.1074/jbc.272.30.18827; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	15	120	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20632	20637		10.1074/jbc.M909721199	http://dx.doi.org/10.1074/jbc.M909721199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10748154	Green Published, hybrid			2022-12-27	WOS:000088084500059
J	Cases-Gonzalez, CE; Gutierrez-Rivas, M; Menendez-Arias, L				Cases-Gonzalez, CE; Gutierrez-Rivas, M; Menendez-Arias, L			Coupling ribose selection to fidelity of DNA synthesis - The role of Tyr-115 of human immunodeficiency virus type 1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; MISPAIR EXTENSION KINETICS; POLYMERASE-I; CRYSTAL-STRUCTURES; TEMPLATE-PRIMER; RNA-POLYMERASE; MANGANESE MUTAGENESIS; MUTATIONAL ANALYSIS; FUNCTIONAL-ANALYSIS; TERNARY COMPLEXES	The catalytic efficiency of incorporation of deoxyribonucleotides by wild-type human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) was around 100-fold higher than for dideoxyribonucleotides, in Mg2+-catalyzed reactions, and more than 10,000-fold higher than for nucleotides having a 2'-hydroxyl group in Mg2+- and Mn2+-catalyzed reactions. Mutant RTs with nonconservative substitutions affecting Tyr-115 (Y115V, Y115A, and Y115G) showed a dramatic reduction in their ability to discriminate against ribonucleotides in the presence of both cations. However, selectivity of deoxyribonucleotides versus ribonucleotides was not affected in mutants Y115W and F160W. The substitution of Tyr-115 with Val or Gly had no effect on discrimination against dideoxyribonucleotides, but these mutants were less efficient than the wild-type RT in discriminating against cordycepin 5'-triphosphate. We also show that Tyr-115 is involved in fidelity of DNA synthesis, but substitutions at this position have different effects depending on the metal cofactor used in the assays. In Mg2+-catalyzed reactions, removal of the side chain of Tyr-115 reduced misinsertion and mispair extension fidelity, while opposite effects were observed in Mn2+-catalyzed reactions. Our results indicate that the aromatic side chain of Tyr-115 plays a role as a "steric gate" preventing the incorporation of nucleotides with a 2'-hydroxyl group in a cation-independent manner, while its influence on fidelity could be modulated by Mg2+ or Mn2+.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Menendez-Arias, L (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain.		Rivas, Mónica Gutiérrez/G-9713-2016; Arias, Luis Menendez/N-7447-2016; Menendez Arias, Luis/G-2436-2016	Rivas, Mónica Gutiérrez/0000-0001-9752-7498; Arias, Luis Menendez/0000-0002-1251-6640; 				Arts EJ, 1998, PROG NUCLEIC ACID RE, V58, P339; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Bebenek K, 1993, REVERSE TRANSCRIPTAS, P85; BECKMAN RA, 1985, BIOCHEMISTRY-US, V24, P5810, DOI 10.1021/bi00342a019; Bonnin A, 1999, J MOL BIOL, V290, P241, DOI 10.1006/jmbi.1999.2900; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Brandis JW, 1996, BIOCHEMISTRY-US, V35, P2189, DOI 10.1021/bi951682j; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; CIRINO NM, 1995, BIOCHEMISTRY-US, V34, P9936, DOI 10.1021/bi00031a016; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DONLIN MJ, 1994, BIOCHEMISTRY-US, V33, P14908, DOI 10.1021/bi00253a030; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; ELDEIRY WS, 1988, BIOCHEMISTRY-US, V27, P546, DOI 10.1021/bi00402a007; ELDEIRY WS, 1984, P NATL ACAD SCI-BIOL, V81, P7378, DOI 10.1073/pnas.81.23.7378; Gao GX, 1998, J VIROL, V72, P5905, DOI 10.1128/JVI.72.7.5905-5911.1998; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; Gardner AF, 1999, NUCLEIC ACIDS RES, V27, P2545, DOI 10.1093/nar/27.12.2545; GOODMAN MF, 1983, J BIOL CHEM, V258, P3469; Gutierrez-Rivas M, 1999, J MOL BIOL, V290, P615, DOI 10.1006/jmbi.1999.2880; HALL ZW, 1968, J MOL BIOL, V36, P321, DOI 10.1016/0022-2836(68)90158-7; Harris D, 1998, BIOCHEMISTRY-US, V37, P9630, DOI 10.1021/bi980549z; Harris D, 1998, J BIOL CHEM, V273, P33624, DOI 10.1074/jbc.273.50.33624; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang Y, 1997, BIOCHEMISTRY-US, V36, P8231, DOI 10.1021/bi962674l; Kraynov VS, 1997, BIOCHEM J, V323, P103, DOI 10.1042/bj3230103; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; Li SX, 1999, BIOCHEMISTRY-US, V38, P4800, DOI 10.1021/bi9827058; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Loeb LA, 1999, P NATL ACAD SCI USA, V96, P1492, DOI 10.1073/pnas.96.4.1492; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; MartinHernandez AM, 1996, EMBO J, V15, P4434, DOI 10.1002/j.1460-2075.1996.tb00816.x; MartinHernandez AM, 1997, NUCLEIC ACIDS RES, V25, P1383, DOI 10.1093/nar/25.7.1383; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Menendez-Arias L, 1998, BIOCHEMISTRY-US, V37, P16636, DOI 10.1021/bi981830g; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; Olivares I, 1999, J VIROL, V73, P6293, DOI 10.1128/JVI.73.8.6293-6298.1999; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Preston BD, 1996, TRENDS MICROBIOL, V4, P16, DOI 10.1016/0966-842X(96)81500-9; Ricchetti M, 1996, BIOCHEMISTRY-US, V35, P14970, DOI 10.1021/bi961274v; RICCHETTI M, 1993, EMBO J, V12, P387, DOI 10.1002/j.1460-2075.1993.tb05670.x; SARAFIANOS SG, 1995, BIOCHEMISTRY-US, V34, P7207, DOI 10.1021/bi00021a036; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SEAL G, 1979, J BIOL CHEM, V254, P5229; SIROVER MA, 1977, J BIOL CHEM, V252, P3605; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; Telesnitsky A., 1997, P121; Tisdale M, 1997, ANTIMICROB AGENTS CH, V41, P1094, DOI 10.1128/AAC.41.5.1094; Valverde-Garduno V, 1998, J MOL EVOL, V47, P73, DOI 10.1007/PL00006364; Vartanian JP, 1999, J GEN VIROL, V80, P1983, DOI 10.1099/0022-1317-80-8-1983; WAKEFIELD JK, 1992, J VIROL, V66, P6806, DOI 10.1128/JVI.66.11.6806-6812.1992; Wilson JE, 1996, J BIOL CHEM, V271, P13656, DOI 10.1074/jbc.271.23.13656	59	71	72	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19759	19767		10.1074/jbc.M910361199	http://dx.doi.org/10.1074/jbc.M910361199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748215	hybrid			2022-12-27	WOS:000087941300046
J	Tang, J; Kao, PN; Herschman, HR				Tang, J; Kao, PN; Herschman, HR			Protein-arginine methyltransferase I, the predominant protein-arginine methyltransferase in cells, interacts with and is regulated by interleukin enhancer-binding factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-REACTION AMPLIFICATION; FIBROBLAST GROWTH-FACTOR; HYBRID DNA TEMPLATES; ACTIVATED T-CELLS; SUBCELLULAR-LOCALIZATION; N-METHYLTRANSFERASE; YEAST PROTEINS; HUMAN HOMOLOG; GENE; RNA	Arginine methylation is a common post-translation modification found in many proteins. Protein-arginine methyltransferase I (PRMT1) contributes >90% of type I protein-arginine methyltransferase activity in cells and tissues. To expand our knowledge on the regulation and role of PRMT1 in cells, we used the yeast two-hybrid system to identify proteins that interact with PRMT1. One of the interacting proteins we cloned is interleukin enhancer-binding factor 3 (ILF3), also known as M phase phosphoprotein 4, ILF3 is closely related to nuclear factor 90 (NF90), Using an immunofluorescence analysis, we determined that ILF3 and PRMT1 co-localize in the nucleus. Moreover, PRMT1 and ILF3 co-precipitate in immunoprecipitation assays and can be isolated together in "pull-down" experiments using recombinant fusion proteins. ILF3 is a robust substrate for methylation by PRMT1 and can modulate PRMT1 activity in in vitro methylation assays. Deletion studies demonstrated that the COOH-terminal region of ILF3, which is rich in arginine, glycine, and serine, is responsible for the strong interaction between PRMT1 and ILF3 and is the site of ILF3 methylation by PRMT1. Although ILF3 and NF90 are highly similar, they differ in their carboxyl-terminal regions. Because of this difference, NF90 does not interact with PRMT1, is a much poorer substrate than ILF3 for PRMT1-dependent methylation, and does not modulate PRMT1 enzyme activity.	Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Stanford University	Herschman, HR (corresponding author), Univ Calif Los Angeles, Sch Med, Inst Mol Biol, 611 Charles E Young Dr E, Los Angeles, CA 90095 USA.				NATIONAL CANCER INSTITUTE [T32CA009056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039624, U19AI034567, U01AI034567] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09056] Funding Source: Medline; NIAID NIH HHS [AI39624, AI34567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aoki Y, 1998, AM J PHYSIOL-LUNG C, V275, pL1164, DOI 10.1152/ajplung.1998.275.6.L1164; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Buaas FW, 1999, MAMM GENOME, V10, P451, DOI 10.1007/s003359901022; CHANG FN, 1978, BIOCHIM BIOPHYS ACTA, V518, P89, DOI 10.1016/0005-2787(78)90118-1; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; KAKIMOTO Y, 1970, J BIOL CHEM, V245, P5751; KAO PN, 1994, J BIOL CHEM, V269, P20691; KRAUSE S, 1994, EXP CELL RES, V214, P75, DOI 10.1006/excr.1994.1235; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; LEE HW, 1973, J BIOL CHEM, V248, P4194; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; Liao HJ, 1998, P NATL ACAD SCI USA, V95, P8514, DOI 10.1073/pnas.95.15.8514; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Ma XJ, 1996, GENE DEV, V10, P1327, DOI 10.1101/gad.10.11.1327; Marcoulatos P, 1996, J INTERF CYTOK RES, V16, P1035, DOI 10.1089/jir.1996.16.1035; Marcoulatos P, 1998, J INTERF CYTOK RES, V18, P351, DOI 10.1089/jir.1998.18.351; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Orford RL, 1998, MOL CELL BIOL, V18, P5557, DOI 10.1128/MCB.18.9.5557; PAIK WK, 1968, J BIOL CHEM, V243, P2108; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; SOMMER A, 1989, BIOCHEM BIOPH RES CO, V160, P1267, DOI 10.1016/S0006-291X(89)80140-8; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; VARNUM BC, 1994, J CELL PHYSIOL, V158, P205, DOI 10.1002/jcp.1041580125; Wang SL, 1997, DEV BIOL, V188, P322, DOI 10.1006/dbio.1997.8655; Zobel-Thropp P, 1998, J BIOL CHEM, V273, P29283, DOI 10.1074/jbc.273.45.29283	39	156	164	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19866	19876		10.1074/jbc.M000023200	http://dx.doi.org/10.1074/jbc.M000023200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10749851	hybrid			2022-12-27	WOS:000087941300060
J	Cha, JY; Kim, H; Kim, KS; Hur, MW; Ahn, YH				Cha, JY; Kim, H; Kim, KS; Hur, MW; Ahn, YH			Identification of transacting factors responsible for the tissue-specific expression of human glucose transporter type 2 isoform gene - Cooperative role of hepatocyte nuclear factors 1 alpha and 3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-SPECIFIC TRANSCRIPTION; PANCREATIC BETA-CELL; TRANS-ACTING FACTORS; GLUT2 EXPRESSION; INSULIN GENE; PROMOTER; BINDING; ACTIVATION; METABOLISM; ENHANCER	We investigated transacting factors binding to the cis-element important in tissue-specific expression of the human glucose transporter type 2 isoform (GLUT2) gene. By transient transfection assay, we determined that the 227-base pair fragment upstream of the ATG start site contained promoter activity and that the region from +87 to +132 (site C) was responsible for tissue-specific expression. DNase I footprinting and electrophoretic mobility shift assay indicated that site C contained one binding site for hepatocyte nuclear factor 1 (HNF1) and two binding sites for HNF3 The mutations at positions +101 and +103, which are considered to be critical in binding HNF1 and HNF3, resulted in a 53% decrease in promoter activity, whereas the mutation of the proximal HNF3 binding site (+115 and +117) reduced promoter activity by 28%. The mutations of these four sites resulted in marked decrease (70%) in promoter activity as well as diminished bindings of HNF1 and HNF3, A to G mutation, which causes conversion of the HNF1 and HNF3 binding sequence to the NF-Y binding site, resulted in a 22% decrease in promoter activity. We identified that both HNF1 and HNF3 function as transcriptional activators in GLUTS gene expression. Coexpression of the pGL+74 (+74 to +301) construct with the HNF1 alpha and HNF3 beta expression vectors in NIH 3T3 cells showed the synergistic effect on GLUTS promoter activity compared with the expression of HNF1 alpha, HNF3 beta, or a combination of HNF1 beta and HNF3 beta. These data suggest that HNF1 alpha and HNF3 beta may be the most important players in the tissue-specific expression of the human GLUTS gene.	Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, Seodaemun Gu, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Inst Genet Sci, Seodaemun Gu, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Ahn, YH (corresponding author), Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, Seodaemun Gu, 134 Shinchon Dong, Seoul 120752, South Korea.	yha111@yumc.yonsei.ac.kr	AHN, Yong Ho/H-6712-2017; Kim, Hail/C-1849-2011	AHN, Yong Ho/0000-0002-4133-0757; Kim, Hail/0000-0002-6652-1349; Cha, JI-Young/0000-0002-8557-6214				AXELROD JD, 1983, BIOCHEMISTRY-US, V22, P2222, DOI 10.1021/bi00278a025; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; BONNY C, 1995, MOL ENDOCRINOL, V9, P1413, DOI 10.1210/me.9.10.1413; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; De Simone V, 1991, CURR OPIN CELL BIOL, V3, P960, DOI 10.1016/0955-0674(91)90114-E; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; ESPINAS ML, 1995, MOL CELL BIOL, V15, P5346; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; GREGORI C, 1994, NUCLEIC ACIDS RES, V22, P1242, DOI 10.1093/nar/22.7.1242; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; Kim JW, 1998, BIOCHEM J, V336, P83, DOI 10.1042/bj3360083; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MIURA N, 1993, NUCLEIC ACIDS RES, V21, P3731, DOI 10.1093/nar/21.16.3731; NITSCH D, 1993, MOL CELL BIOL, V13, P4494, DOI 10.1128/MCB.13.8.4494; OHNEDA M, 1993, DIABETES, V42, P1065, DOI 10.2337/diabetes.42.7.1065; ORCI L, 1990, P NATL ACAD SCI USA, V87, P9953, DOI 10.1073/pnas.87.24.9953; POSTIC C, 1993, BIOCHEM J, V293, P119, DOI 10.1042/bj2930119; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; TAKEDA J, 1993, DIABETES, V42, P773, DOI 10.2337/diabetes.42.5.773; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; Tomura H, 1999, J BIOL CHEM, V274, P12975, DOI 10.1074/jbc.274.19.12975; Tronche F, 1997, J MOL BIOL, V266, P231, DOI 10.1006/jmbi.1996.0760; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701	42	77	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18358	18365		10.1074/jbc.M909536199	http://dx.doi.org/10.1074/jbc.M909536199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748140	hybrid, Green Published			2022-12-27	WOS:000087659400062
J	Gasull, T; DeGregorio-Rocasolano, N; Zapata, A; Trullas, R				Gasull, T; DeGregorio-Rocasolano, N; Zapata, A; Trullas, R			Choline release and inhibition of phosphatidylcholine synthesis precede excitotoxic neuronal death but not neurotoxicity induced by serum deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-D-ASPARTATE; CULTURED CORTICAL-NEURONS; CEREBELLAR GRANULE CELLS; ARACHIDONIC-ACID RELEASE; PHOSPHOLIPASE-D; NMDA RECEPTOR; MEDIATED EXCITOTOXICITY; HIPPOCAMPAL SLICES; CEREBRAL-CORTEX; NITRIC-OXIDE	N-Methyl-D-aspartate (NMDA) receptor overactivation has been proposed to induce excitotoxic neuronal death by enhancing membrane phospholipid degradation. In previous studies, we have shown that NMDA releases choline and reduces membrane phosphatidylcholine in vivo. We now observed that glutamate and NMDA induce choline release in primary neuronal cortical cell cultures. This effect is Ca2+-dependent and is blocked by MK-801 ((+)5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate). In cortical neurons, the NMDA receptor-mediated choline release precedes excitotoxic cell death but not neuronal death induced by either osmotic lysis or serum deprivation. Glutamate, at concentrations that release arachidonic acid, does not release choline in cerebellar granule cells, unless these cells are rendered susceptible to excitotoxic death by energy deprivation. The NMDA-evoked release of choline is not mediated by phospholipases A(2) or C. Moreover, NMDA does not activate phospholipase D in cortical cells. However, NMDA inhibits incorporation of [methyl-H-3]choline into both membrane phosphatidylcholine and sphingomyelin. These results show that the increase in extracellular choline induced by NMDA receptor activation is directly related with excitotoxic cell death and indicate that choline release is an early event of the excitotoxic process produced by inhibition of phosphatidylcholine synthesis and not by activation of membrane phospholipid degradation.	Inst Invest Biomed August Pi I Sunyer, Consejo Super Invest Cient, Inst Invest Biomed, Neurobiol Unit, Barcelona 08036, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Trullas, R (corresponding author), Inst Invest Biomed August Pi I Sunyer, Consejo Super Invest Cient, Inst Invest Biomed, Neurobiol Unit, Rossello 161, Barcelona 08036, Spain.		Trullas, Ramon/D-2197-2016; De Gregorio - Rocasolano, Nuria/M-1523-2014	Trullas, Ramon/0000-0001-7951-9881; GASULL, TERESA/0000-0002-9321-1741; De Gregorio - Rocasolano, Nuria/0000-0001-5248-7525				ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; BOJE KM, 1993, BRAIN RES, V603, P207, DOI 10.1016/0006-8993(93)91239-O; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BOSS V, 1992, J NEUROCHEM, V59, P2340; BOSS V, 1994, MOL PHARMACOL, V45, P1177; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; Cheung NS, 1998, NEUROPHARMACOLOGY, V37, P1419, DOI 10.1016/S0028-3908(98)00123-3; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DAWSON RMC, 1967, BIOCHEM J, V102, P205, DOI 10.1042/bj1020205; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; Farooqui AA, 1997, J NEUROCHEM, V69, P889; Fossom LH, 1995, MOL PHARMACOL, V48, P981; Gwag BJ, 1997, NEUROSCIENCE, V77, P393, DOI 10.1016/S0306-4522(96)00473-3; Hokin LE, 1996, ADV ENZYME REGUL, V36, P229, DOI 10.1016/0065-2571(95)00021-6; HOLLER T, 1993, J NEUROCHEM, V61, P1569, DOI 10.1111/j.1471-4159.1993.tb13659.x; KLEIN J, 1990, J NEUROCHEM, V55, P1231, DOI 10.1111/j.1471-4159.1990.tb03129.x; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; LAZAREWICZ JW, 1988, NEUROPHARMACOLOGY, V27, P765, DOI 10.1016/0028-3908(88)90088-3; Leist M, 1997, BIOCHEM BIOPH RES CO, V236, P1, DOI 10.1006/bbrc.1997.6890; Li YH, 1998, P NATL ACAD SCI USA, V95, P7748, DOI 10.1073/pnas.95.13.7748; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LLAHI S, 1992, J BIOL CHEM, V267, P3679; LYSKO PG, 1989, BRAIN RES, V499, P258, DOI 10.1016/0006-8993(89)90773-7; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MILLINGTON WR, 1982, J NEUROCHEM, V38, P1748, DOI 10.1111/j.1471-4159.1982.tb06658.x; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Rudolph JG, 1997, NEUROSCI LETT, V221, P149, DOI 10.1016/S0304-3940(96)13313-9; SANFELIU C, 1990, BRAIN RES, V526, P241, DOI 10.1016/0006-8993(90)91228-9; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHIMOHAMA S, 1995, J NEUROSCI RES, V41, P418, DOI 10.1002/jnr.490410315; SMITH SS, 1993, MOL PHARMACOL, V43, P1; VANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; Viu E, 1998, J PHARMACOL EXP THER, V285, P527; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; YAN GM, 1994, BRAIN RES, V656, P43, DOI 10.1016/0006-8993(94)91364-1; Zapata A, 2000, SYNAPSE, V35, P272, DOI 10.1002/(SICI)1098-2396(20000315)35:4<272::AID-SYN5>3.0.CO;2-B; Zapata A, 1998, J NEUROSCI, V18, P3597; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413	42	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18350	18357		10.1074/jbc.M910468199	http://dx.doi.org/10.1074/jbc.M910468199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748226	hybrid			2022-12-27	WOS:000087659400061
J	MacDonald, JIS; Gryz, EA; Kubu, CJ; Verdi, JM; Meakin, SO				MacDonald, JIS; Gryz, EA; Kubu, CJ; Verdi, JM; Meakin, SO			Direct binding of the signaling adapter protein Grb2 to the activation loop tyrosines on the nerve growth factor receptor tyrosine kinase, TrkA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR BETA-RECEPTOR; NEURITE OUTGROWTH; CELLS; SHC; IDENTIFICATION; TRANSDUCTION; DOMAIN; DIFFERENTIATION; INSULIN; SITES	We demonstrate that the signaling adapter, Grb2, binds directly to the neurotrophin receptor tyrosine kinase, TrkA Grb2 binding to TrkA is independent of Shc, FRS-2, phospholipase C gamma-1, rAPS, and SH2B and is observed in in vitro binding assays, yeast two-hybrid assays, and in co-immunoprecipitation assays. Grb2 binding to TrkA is mediated by the central SH2 domain, requires a kinase-active TrkA, and is phosphotyrosine-dependent. By analyzing a series of rat TrkA mutants, we demonstrate that Grb2 binds to the carboxyl-terminal residue, Tyr(794), as well as to the activation loop tyrosines, Tyr(683) and Tyr(684). By using acidic amino acid substitutions of the activation loop tyrosines on TrkA, we can stimulate constitutive kinase activity and TrkA-Shc interactions but, importantly, abolish TrkA/Grb2 binding. Thus, in addition to providing the first evidence of direct Grb2 binding to the neurotrophin receptor, TrkA, these data provide the first direct evidence that the activation loop tyrosines of a receptor tyrosine kinase, in addition to their essential role in kinase activation, also serve a direct role in the recruitment of intracellular signaling molecules.	John P Robarts Res Inst, Neurodegeneration Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Physiol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Meakin, SO (corresponding author), John P Robarts Res Inst, Neurodegeneration Grp, 100 Perth Dr, London, ON N6A 5K8, Canada.	smeakin@rri.on.ca	Meakin, Susan/K-8823-2013	Meakin, Susan/0000-0003-2469-6615				Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gryz EA, 2000, ONCOGENE, V19, P417, DOI 10.1038/sj.onc.1203330; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; James P, 1996, GENETICS, V144, P1425; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MacDonald JIS, 1999, J MOL NEUROSCI, V13, P141, DOI 10.1385/JMN:13:1-2:141; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Meakin SO, 1997, J NEUROCHEM, V69, P954; Meakin SO, 1998, J NEUROCHEM, V71, P1875; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Moodie SA, 1999, J BIOL CHEM, V274, P11186, DOI 10.1074/jbc.274.16.11186; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Oligino L, 1997, J BIOL CHEM, V272, P29046, DOI 10.1074/jbc.272.46.29046; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Pei ZD, 1997, ARCH BIOCHEM BIOPHYS, V345, P103, DOI 10.1006/abbi.1997.0245; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RICCI A, 1995, ONCOGENE, V11, P1519; Rui LY, 1999, J BIOL CHEM, V274, P10590, DOI 10.1074/jbc.274.15.10590; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Vidal M, 1999, J MOL BIOL, V290, P717, DOI 10.1006/jmbi.1999.2899; WAHL MI, 1990, J BIOL CHEM, V265, P3944; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18225	18233		10.1074/jbc.M001862200	http://dx.doi.org/10.1074/jbc.M001862200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748052	hybrid			2022-12-27	WOS:000087659400044
J	Bremnes, T; Paasche, JD; Mehlum, A; Sandberg, C; Bremnes, B; Attramadal, H				Bremnes, T; Paasche, JD; Mehlum, A; Sandberg, C; Bremnes, B; Attramadal, H			Regulation and intracellular trafficking pathways of the endothelin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; COATED VESICLE FORMATION; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; MOLECULAR CHARACTERIZATION; CIRCULATING ENDOTHELIN-1; SIGNAL-TRANSDUCTION; ET(B) RECEPTORS; PIT FORMATION	The effects of endothelin (ET) are mediated via the G protein-coupled receptors ETA and ETB. However, the mechanisms of ET receptor desensitization, internalization, and intracellular trafficking are poorly understood. The aim of the present study was to investigate the molecular mechanisms of ET receptor regulation and to characterize the intracellular pathways of ET-stimulated ETA and ETB receptors, By analysis of ETA and ETB receptor internalization in transfected Chinese hamster ovary cells in the presence of overexpressed beta ARK, beta-arrestin-1, beta-arrestin-2, or dynamin as well as dominant negative mutants of these regulators, we have demonstrated that both ET receptor subtypes follow an arrestin- and dynamin/clathrin-dependent mechanism of internalization. Fluorescence microscopy of Chinese hamster ovary and COS cells expressing green fluorescent protein (GFP)-tagged ET receptors revealed that the ETA and ETB subtypes were targeted to different intracellular routes after ET stimulation. While ETB-GFP followed a recycling pathway and colocalized with transferrin in the pericentriolar recycling compartment, ETB-GFP was targeted to lysosomes after ET-induced internalization. Both receptor subtypes colocalized with Rab5 in classical early endosomes, indicating that this compartment is a common early intermediate for the two ET receptors during intracellular transport. The distinct intracellular routes of ET-stimulated ETA and ETB receptors may explain the persistent signal response through the ETA receptor and the transient response through the ETB receptor. Furthermore, lysosomal targeting of the ETB receptor could serve as a biochemical mechanism for clearance of plasma endothelin via this subtype.	Univ Oslo, Natl Hosp Norway, Cardiovasc Res Ctr, MSD,Inst Surg Res, N-0027 Oslo, Norway; Merck Sharp & Dohme Ltd, Cardiovasc Res Ctr, N-0027 Oslo, Norway; Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo	Attramadal, H (corresponding author), Univ Oslo, Natl Hosp Norway, Cardiovasc Res Ctr, MSD,Inst Surg Res, 32 Pilestredet, N-0027 Oslo, Norway.	havarda@rh.uio.no		Attramadal, Havard/0000-0001-9506-0687				ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CHUN MY, 1995, J BIOL CHEM, V270, P10855, DOI 10.1074/jbc.270.18.10855; CLOZEL M, 1992, BIOCHEM BIOPH RES CO, V186, P867, DOI 10.1016/0006-291X(92)90826-7; Cramer H, 1997, BIOCHEMISTRY-US, V36, P13325, DOI 10.1021/bi9708848; CYR CR, 1993, J BIOL CHEM, V268, P26071; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; Dupuis J, 1996, J APPL PHYSIOL, V81, P1510, DOI 10.1152/jappl.1996.81.4.1510; Edwardson JM, 1999, LIFE SCI, V64, P487, DOI 10.1016/S0024-3205(98)00592-X; ELSHOURBAGY NA, 1993, J BIOL CHEM, V268, P3873; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; FUKURODA T, 1994, BIOCHEM BIOPH RES CO, V199, P1461, DOI 10.1006/bbrc.1994.1395; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; Kobayashi T, 1997, LIFE SCI, V62, P185, DOI 10.1016/S0024-3205(97)01064-3; Krueger KM, 1997, J BIOL CHEM, V272, P5; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MELLMAN I, 1992, J EXP BIOL, V172, P39; MORELAND S, 1992, BIOCHEM BIOPH RES CO, V184, P100, DOI 10.1016/0006-291X(92)91163-K; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; Olkkonen VM, 1997, INT REV CYTOL, V176, P1, DOI 10.1016/S0074-7696(08)61608-3; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; TAKASUKA T, 1992, J BIOCHEM-TOKYO, V112, P396, DOI 10.1093/oxfordjournals.jbchem.a123911; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VON ZM, 1992, J BIOL CHEM, V267, P3530; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; YANAGISAWA M, 1989, BIOCHEM PHARMACOL, V38, P1877; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	59	198	203	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17596	17604		10.1074/jbc.M000142200	http://dx.doi.org/10.1074/jbc.M000142200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747877	hybrid			2022-12-27	WOS:000087485000056
J	Chabes, A; Thelander, L				Chabes, A; Thelander, L			Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED POSTTRANSCRIPTIONAL MODULATION; S-PHASE; RECOMBINANT MOUSE; EXPRESSION; SUBUNIT; DEOXYRIBONUCLEOTIDE; TRANSFORMATION; PURIFICATION; LOCALIZATION; P34(CDC2)	Ribonucleotide reductase (RNR) plays a central role in the formation and control of the optimal levels of deoxyribonucleoside triphosphates, which are required for DNA replication and DNA repair processes. Mammalian RNRs are composed of two nonidentical subunits, proteins R1 and R2, The levels of the limiting R2 protein control overall RNR activity during the mammalian cell cycle, being undetectable in G(1) phase and increasing in S phase. We show that in proliferating mammalian cells, the transcription of the R2 gene, once activated in the beginning of S phase, reaches its maximum 6-7 h later and then declines. Surprisingly, DNA damage and replication blocks neither increase nor prolong the R2 promoter activity in S phase. Instead, the cell cycle activity of the mammalian enzyme is controlled by an S phase/ DNA damage-specific stabilization of the R2 protein, which is effective until cells pass into mitosis.	Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden	Umea University	Chabes, A (corresponding author), Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden.			Chabes, Andrei/0000-0003-1708-8259				AKERBLOM L, 1981, P NATL ACAD SCI-BIOL, V78, P2159, DOI 10.1073/pnas.78.4.2159; BJORKLUND S, 1992, EMBO J, V11, P4953, DOI 10.1002/j.1460-2075.1992.tb05602.x; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Chan AK, 1999, BBA-MOL CELL RES, V1448, P363, DOI 10.1016/S0167-4889(98)00115-3; CHAN AK, 1993, BIOCHEMISTRY-US, V32, P12835, DOI 10.1021/bi00210a036; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Deshaies RJ, 1997, CURR OPIN GENET DEV, V7, P7, DOI 10.1016/S0959-437X(97)80103-7; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; Fan HZ, 1996, P NATL ACAD SCI USA, V93, P14036, DOI 10.1073/pnas.93.24.14036; Filatov D, 1996, J BIOL CHEM, V271, P23698, DOI 10.1074/jbc.271.39.23698; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P611; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HENGSTSCHLAGER M, 1994, CELL GROWTH DIFFER, V5, P1389; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; LEWIS WH, 1978, J CELL PHYSIOL, V94, P287, DOI 10.1002/jcp.1040940306; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MANN GJ, 1988, CANCER RES, V48, P5151; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MCCLARTY GA, 1988, BIOCHEMISTRY-US, V27, P7524, DOI 10.1021/bi00419a052; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MEUTH M, 1974, CELL, V3, P367, DOI 10.1016/0092-8674(74)90052-X; MURPHREE S, 1969, EXP CELL RES, V58, P118, DOI 10.1016/0014-4827(69)90121-9; NORDENSKJOLD BA, 1970, J BIOL CHEM, V245, P5360; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Sutterluety H, 1996, J MOL BIOL, V259, P383, DOI 10.1006/jmbi.1996.0327; SUTTLE DP, 1979, J BIOL CHEM, V254, P4602; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER M, 1985, J BIOL CHEM, V260, P2737; WEINBERG G, 1981, P NATL ACAD SCI-BIOL, V78, P2447, DOI 10.1073/pnas.78.4.2447	35	133	134	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17747	17753		10.1074/jbc.M000799200	http://dx.doi.org/10.1074/jbc.M000799200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747958	hybrid			2022-12-27	WOS:000087485000075
J	Cox, KH; Rai, R; Distler, M; Daugherty, JR; Coffman, JA; Cooper, TG				Cox, KH; Rai, R; Distler, M; Daugherty, JR; Coffman, JA; Cooper, TG			Saccharomyces cerevisiae GATA sequences function as TATA elements during nitrogen catabolite repression and when Gln3p is excluded from the nucleus by overproduction of Ure2p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; SATURATION MUTAGENESIS; PROTEIN-KINASE; PRION; LOCALIZATION; PROMOTERS; REGULATOR; STRESS; BOX	Saccharomyces cerevisiae selectively uses good nitrogen sources (glutamine) in preference to poor ones (proline) by repressing GATA factor-dependent transcription of the genes needed to transport and catabolize poor nitrogen sources, a physiological process designated nitrogen catabolite repression (NCR), We show that some NCR-sensitive genes (CAN1, DAL5, DUR1,2, and DUR3) produce two transcripts of slightly different sizes. Synthesis of the shorter transcript is NCR-sensitive and that of the longer transcript is not. The longer transcript also predominates in gEn3 Delta mutants irrespective of the nitrogen source provided. We demonstrate that the longer mRNA species arises through the use of an alternative transcription start site generated by Gln3p-binding sites (GATAAs) being able to act as surrogate TATA elements. The ability of GATAAs to serve as surrogate TATAs, i.e, when synthesis of the shorter, NCR-sensitive transcripts are inhibited, correlates with sequestration of enhanced green fluorescent protein (EGFP)-Gln3p in the cytoplasm in a way that is indistinguishable from that seen with EGFP-Ure2p, However, when the shorter, NCR-sensitive DAL5 transcript predominates, EGFP-Gln3p is nuclear. These data suggest that the mechanism underlying NCR involves the cytoplasmic association of Ure2p with Gln3p, an interaction that prevents Gln3p from reaching it is binding sites upstream of NCR-sensitive genes.	Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA.			Cooper, Terrance G./0000-0002-7651-9963; Coffman, Jonathan/0000-0001-5843-538X	NIGMS NIH HHS [GM-35642, R01 GM035642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIRD WC, 1994, J BIOL CHEM, V269, P883; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Beeser AE, 1999, J BACTERIOL, V181, P2472, DOI 10.1128/JB.181.8.2472-2476.1999; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P1009; BYSANI N, 1991, J BACTERIOL, V173, P4977, DOI 10.1128/jb.173.16.4977-4982.1991; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; Coffman JA, 1996, MOL CELL BIOL, V16, P847; Coffman JA, 1997, J BACTERIOL, V179, P3416, DOI 10.1128/jb.179.11.3416-3429.1997; COFFMAN JA, 1994, J BACTERIOL, V176, P7476, DOI 10.1128/JB.176.24.7476-7483.1994; COFFMAN JA, 1995, J BACTERIOL, V177, P6910, DOI 10.1128/jb.177.23.6910-6918.1995; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; COOPER TG, 1992, J BACTERIOL, V174, P48, DOI 10.1128/jb.174.1.48-55.1992; Cooper TG, 1996, MYCOTA, V3, P139; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; Cunningham TS, 2000, J BIOL CHEM, V275, P14408, DOI 10.1074/jbc.275.19.14408; DAUGHERTY JR, 1993, J BACTERIOL, V175, P64, DOI 10.1128/JB.175.1.64-73.1993; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; DRILLIEN R, 1973, BIOCHEM BIOPH RES CO, V53, P367, DOI 10.1016/0006-291X(73)90671-2; Edskes HK, 1999, GENETICS, V153, P585; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; GRENSON M, 1970, J BACTERIOL, V103, P770, DOI 10.1128/JB.103.3.770-777.1970; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hardwick JS, 1999, NAT GENET, V23, P49, DOI 10.1038/14319; Kraus RJ, 1996, NUCLEIC ACIDS RES, V24, P1531, DOI 10.1093/nar/24.8.1531; Maddelein ML, 1999, MOL CELL BIOL, V19, P4516; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; RAI R, 1995, YEAST, V11, P247, DOI 10.1002/yea.320110307; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Scott S, 2000, J BIOL CHEM, V275, P7198, DOI 10.1074/jbc.275.10.7198; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	39	69	72	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17611	17618		10.1074/jbc.M001648200	http://dx.doi.org/10.1074/jbc.M001648200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748041	hybrid, Green Accepted			2022-12-27	WOS:000087485000058
J	Anderson, PJ; Nesset, A; Dharmawardana, KR; Bock, PE				Anderson, PJ; Nesset, A; Dharmawardana, KR; Bock, PE			Role of proexosite I in factor Va-dependent substrate interactions of prothrombin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-XA; PHOSPHOLIPID-VESICLES; HEAVY-CHAIN; EXOSITE-I; PROTEIN-C; THROMBIN; COMPLEX; SITE; BINDING; CHROMATOGRAPHY	Regulatory exosite I of thrombin is present on prothrombin in a precursor state (proexosite I) that specifically binds the Tyr(63)-sulfated peptide, hirudin(54-65) (Hir(54-65)(SO3-)) and the nonsulfated analog. The role of proexosite I in the mechanism of factor Va acceleration of prothrombin activation was investigated in kinetic studies of the effects of peptide binding. The initial rate of human prothrombin activation by factor Xa was inhibited by the peptides in the presence of factor Va but not in the absence of the cofactor. Factor Xa and factor Va did not bind the peptide with significant affinity compared with prothrombin. Maximum inhibition reduced the factor Va-accelerated rate to a level indistinguishable from the rate in the absence of the cofactor. The effect of Hir54-65(SO,) On the kinetics of prothrombin activation obeyed a model in which binding of the peptide to proexosite I prevented productive prothrombin interactions with the factor Xa-factor Va complex. Comparison of human and bovine prothrombin as substrates demonstrated a similar correlation between peptide binding and inhibition of factor Va acceleration. Inhibition of prothrombin activation by hirudin peptides was opposed by assembly on phospholipid vesicles of the membrane-bound factor Xa-factor-Va-prothrombin complex. Factor Va interactions of human and bovine prothrombin activation are concluded to share a common mechanism in which proexosite I participates in productive interactions of prothrombin as the substrate of the factor Xa-factor Va complex, possibly by directly mediating productive prothrombin-factor Va binding.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, C3321A Med Ctr N, Nashville, TN 37232 USA.	paul.bock@mcmail.vanderbilt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038779, T32HL007751, R01HL038779] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02832, HL38779, HL07751] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BILLY D, 1995, J BIOL CHEM, V270, P26883, DOI 10.1074/jbc.270.45.26883; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BODE W, 1992, PROTEIN SCI, V1, P426; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; ESMON CT, 1974, J BIOL CHEM, V249, P7791; GITEL SN, 1973, P NATL ACAD SCI USA, V70, P1344, DOI 10.1073/pnas.70.5.1344; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HORTIN GL, 1990, BLOOD, V76, P946; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KOTKOW KJ, 1995, J BIOL CHEM, V270, P4551, DOI 10.1074/jbc.270.9.4551; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; LIU LW, 1991, J BIOL CHEM, V266, P23632; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1990, BLOOD, V76, P1; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NEW RRC, 1990, LIPOSOMES PRACTICAL, P108; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; ROSING J, 1980, J BIOL CHEM, V255, P274; ROSING J, 1989, COAGULATION LIPIDS, P160; Segel I. H., 1975, ENZYME KINETICS, P203; SEGEL IH, 1975, ENZYME KINETICS, P258; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; WU QY, 1994, J BIOL CHEM, V269, P3725	36	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16435	16442		10.1074/jbc.M001255200	http://dx.doi.org/10.1074/jbc.M001255200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748008	hybrid			2022-12-27	WOS:000087392200007
J	Henricksen, LA; Tom, S; Liu, Y; Bambara, RA				Henricksen, LA; Tom, S; Liu, Y; Bambara, RA			Inhibition of flap endonuclease 1 by flap secondary structure and relevance to repeat sequence expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; EUKARYOTIC DNA-REPLICATION; NUCLEOTIDE EXCISION-REPAIR; CALF RTH-1 NUCLEASE; SACCHAROMYCES-CEREVISIAE; HUMAN FEN1; MAMMALIAN 5'-EXONUCLEASE; TRINUCLEOTIDE REPEAT; 3' EXONUCLEASE; HUMAN-DISEASE	Recent genetic evidence indicates that null mutants of the 5'-flap endonuclease (FEN1) result in an expansion of repetitive sequences. The substrate for FEN1 is a flap formed by natural 5'-end displacement of the short intermediates of lagging strand replication, FEN1 binds the 5'-end of the flap, tracks to the point of annealing at the base of the flap, and then cleaves. Here Re examine mechanisms by which foldback structures within the flap could contribute to repeat expansions. Cleavage by FEN1 was reduced with increased length of the foldback. However, even the longest foldbacks were cleaved at a low rate. Substrates containing the repetitive sequence CTG also were cleaved at a reduced rate, Bubble substrates, likely intermediates in repeat expansions, were inhibitory. Neither replication protein A nor proliferating cell nuclear antigen were able to assist in the removal of secondary structure within a flap. We propose that FEN1 cleaves natural foldbacks at a reduced rate. However, although the cleavage delay is not likely to influence the overall process of chromosomal replication, specific foldbacks could inhibit cleavage sufficiently to result in duplication of the foldback sequence.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18961, GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alleva JL, 1998, NUCLEIC ACIDS RES, V26, P3645, DOI 10.1093/nar/26.16.3645; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; Bibikova M, 1998, J BIOL CHEM, V273, P34222, DOI 10.1074/jbc.273.51.34222; Biswas EE, 1997, BIOCHEMISTRY-US, V36, P5955, DOI 10.1021/bi962890u; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Frank P, 1998, FEBS LETT, V421, P23, DOI 10.1016/S0014-5793(97)01528-7; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gacy AM, 1998, BIOCHEMISTRY-US, V37, P9426, DOI 10.1021/bi980157s; GACY AM, 1995, CELL, V81, P533; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Greene AL, 1999, HUM MOL GENET, V8, P2263, DOI 10.1093/hmg/8.12.2263; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henricksen LA, 1998, LEUKEMIA RES, V22, P1, DOI 10.1016/S0145-2126(97)00113-6; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Huang L, 1996, BIOCHEMISTRY-US, V35, P9266, DOI 10.1021/bi9603074; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; Kunkel TA, 1997, CELL, V88, P155, DOI 10.1016/S0092-8674(00)81832-2; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Maurer DJ, 1998, MOL CELL BIOL, V18, P4597, DOI 10.1128/MCB.18.8.4597; McMurray CT, 1999, P NATL ACAD SCI USA, V96, P1823, DOI 10.1073/pnas.96.5.1823; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Sayers JR, 1998, NAT STRUCT BIOL, V5, P668, DOI 10.1038/1358; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; WAGA S, 1994, J BIOL CHEM, V269, P10923; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Xie YL, 1999, GENETICS, V151, P499	61	90	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16420	16427		10.1074/jbc.M909635199	http://dx.doi.org/10.1074/jbc.M909635199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748145	hybrid			2022-12-27	WOS:000087392200005
J	Debrabant, A; Ghedin, E; Dwyer, DM				Debrabant, A; Ghedin, E; Dwyer, DM			Dissection of the functional domains of the Leishmania surface membrane 3 '-nucleotidase/nuclease, a unique member of the class I nuclease family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DONOVANI PROMASTIGOTES; GENE; 5'-NUCLEOTIDASE; LOCALIZATION; PURIFICATION; TRYPANOSOMA; AMASTIGOTES; EXPRESSION; RESOLUTION; CLONING	Class I nucleases are a family of enzymes that specifically hydrolyze single-stranded nucleic acids. Recently, we characterized the gene encoding a new member of this family, the 3'-nucleotidase/nuclease (Ld3'NT/NU) of the parasitic protozoan Leishmania donovani. The Ld3'NT/NU is unique as it is the only class I nuclease that is a cell surface membrane-anchored protein. Currently, we used a homologous episomal expression system to dissect the functional domains of the Ld3'NT/NU. Our results showed that its N-terminal signal peptide targeted this protein into the endoplasmic reticulum, Using Ld3'NT/NU-green fluorescent protein chimeras, we showed that the C-terminal domain of the Ld3'NT/NU functioned to anchor this protein into the parasite cell surface membrane. Further, removal of the Ld3'NT/NU C-terminal domain resulted in its release/secretion as a fully active enzyme. Moreover, deletion of its single N-linked glycosylation site showed that such glycosylation was not required for the enzymatic functions of the Ld3'NT/NU. Thus, using the fidelity of a homologous expression system, we have defined some of the functional domains of this unique member of the class I nuclease family.	NIAID, Cell Biol Sect, Parasit Dis Lab, Div Intramural Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Dwyer, DM (corresponding author), NIAID, Cell Biol Sect, Parasit Dis Lab, Div Intramural Res,NIH, Bethesda, MD 20892 USA.		Ghedin, Elodie/Y-5654-2019	Ghedin, Elodie/0000-0002-1515-725X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000162, ZIAAI000745, Z01AI000745] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoyagi S, 1998, FEBS LETT, V429, P134, DOI 10.1016/S0014-5793(98)00563-8; BANGS JD, 1993, J CELL SCI, V105, P1101; BATES PA, 1993, FEMS MICROBIOL LETT, V107, P53, DOI 10.1111/j.1574-6968.1993.tb06003.x; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; CAMPBELL TA, 1991, MOL BIOCHEM PARASIT, V47, P109, DOI 10.1016/0166-6851(91)90153-W; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; DEBRABANT A, 1995, MOL BIOCHEM PARASIT, V71, P51, DOI 10.1016/0166-6851(95)00035-Y; DWYER DM, 1984, MOL BIOCHEM PARASIT, V10, P139, DOI 10.1016/0166-6851(84)90002-1; FRASER MJ, 1993, NUCLEASES, P171; Ghedin E, 1998, J BIOL CHEM, V273, P22997, DOI 10.1074/jbc.273.36.22997; GOTTLIEB M, 1989, PARASITOL TODAY, V5, P257, DOI 10.1016/0169-4758(89)90259-7; GOTTLIEB M, 1983, MOL BIOCHEM PARASIT, V7, P303, DOI 10.1016/0166-6851(83)90013-0; Joshi M, 1996, MOL BIOCHEM PARASIT, V81, P53, DOI 10.1016/0166-6851(96)02676-X; Lee BR, 1995, APPL MICROBIOL BIOT, V44, P425; MCNEELY T B, 1990, Glycobiology, V1, P63, DOI 10.1093/glycob/1.1.63; Nakhasi HL, 1998, PARASITOL TODAY, V14, P157, DOI 10.1016/S0169-4758(97)01180-0; NEUBERT TA, 1990, J BIOL CHEM, V265, P7236; Romier C, 1998, PROTEINS, V32, P414, DOI 10.1002/(SICI)1097-0134(19980901)32:4<414::AID-PROT2>3.3.CO;2-5; SACCI JB, 1990, EXP PARASITOL, V71, P158, DOI 10.1016/0014-4894(90)90018-8; Shishido K, 1982, NUCLEASES, P155; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sullivan JT, 1998, P NATL ACAD SCI USA, V95, P5145, DOI 10.1073/pnas.95.9.5145; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6; ZLOTNICK GW, 1987, COMP BIOCHEM PHYS B, V87, P629, DOI 10.1016/0305-0491(87)90063-0	25	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16366	16372		10.1074/jbc.M908725199	http://dx.doi.org/10.1074/jbc.M908725199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748102	hybrid			2022-12-27	WOS:000087291400103
J	LaCount, DJ; Hanson, SF; Schneider, CL; Friesen, PD				LaCount, DJ; Hanson, SF; Schneider, CL; Friesen, PD			Caspase inhibitor P35 and inhibitor of apoptosis Op-IAP block in vivo proteolytic activation of an effector caspase at different steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; PROGRAMMED CELL-DEATH; ANTIAPOPTOTIC PROTEIN P35; BACULOVIRUS P35; CAENORHABDITIS-ELEGANS; DROSOPHILA HOMOLOG; SUPPRESSOR P35; INSECT CELLS; GENE; FAMILY	Signal-induced activation of caspases, the critical protease effecters of apoptosis, requires proteolytic processing of their inactive proenzymes, Consequently, regulation of procaspase processing is critical to apoptotic execution. We report here that baculovirus pancaspase inhibitor P35 and inhibitor of apoptosis Op-IAP prevent caspase activation in vivo, but at different steps. By monitoring proteolytic processing of endogenous Sf-caspase-1, an insect group II effector caspase, we show that Op-IAP blocked the first activation cleavage at TETD down arrow G between the large and small caspase subunits, In contrast, P35 failed to affect this cleavage, but functioned downstream to block maturation cleavages (DXXD down arrow (G/A)) of the large subunit, Substitution of P35's reactive site residues with TETDG failed to increase its effectiveness for blocking TETD down arrow G processing of pro-Sf-caspase-1, despite wild-type function for suppressing apoptosis. These data are consistent with the involvement of a novel initiator caspase that is resistant to P35, but directly or indirectly inhibitable by Op-IAP. The conservation of TETD down arrow G processing sites among insect effector caspases, including Drosophila drICE and DCP-1, suggests that in vivo activation of these group II caspases involves a P35-insensitive caspase and supports a model wherein apical and effector caspases function through a proteolytic cascade to execute apoptosis in insects.	Univ Wisconsin, Coll Agr & Life Sci, Bock Labs, Inst Mol Virol, Madison, WI 53706 USA; Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Grad Sch, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Friesen, PD (corresponding author), Univ Wisconsin, Coll Agr & Life Sci, Bock Labs, Inst Mol Virol, 1525 Linden Dr, Madison, WI 53706 USA.				NCI NIH HHS [CA09075] Funding Source: Medline; NIAID NIH HHS [AI40482] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040482, R56AI040482] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Ahmad M, 1997, J BIOL CHEM, V272, P1421, DOI 10.1074/jbc.272.3.1421; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bergmann A, 1998, ONCOGENE, V17, P3215, DOI 10.1038/sj.onc.1202586; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CARTIER JL, 1994, J VIROL, V68, P7728, DOI 10.1128/JVI.68.12.7728-7737.1994; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Clem RJ, 1997, TRENDS CELL BIOL, V7, P337, DOI 10.1016/S0962-8924(97)01088-X; Clem RJ, 1996, CELL DEATH DIFFER, V3, P9; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Davidson FF, 1998, NATURE, V391, P587, DOI 10.1038/35385; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fisher AJ, 1999, EMBO J, V18, P2031, DOI 10.1093/emboj/18.8.2031; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Hardwick JM, 1998, SEMIN CELL DEV BIOL, V9, P339, DOI 10.1006/scdb.1998.0243; Harvey AJ, 1997, MOL CELL BIOL, V17, P2835, DOI 10.1128/MCB.17.5.2835; Harvey AJ, 1997, CELL DEATH DIFFER, V4, P733, DOI 10.1038/sj.cdd.4400294; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; HAY BA, 1994, DEVELOPMENT, V120, P2121; HERSHBERGER PA, 1992, J VIROL, V66, P5525, DOI 10.1128/JVI.66.9.5525-5533.1992; HERSHBERGER PA, 1994, J VIROL, V68, P3467, DOI 10.1128/JVI.68.6.3467-3477.1994; Hozak RR, 2000, MOL CELL BIOL, V20, P1877, DOI 10.1128/MCB.20.5.1877-1885.2000; Izquierdo M, 1999, EMBO J, V18, P156, DOI 10.1093/emboj/18.1.156; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; LaCount DJ, 1997, J VIROL, V71, P1530, DOI 10.1128/JVI.71.2.1530-1537.1997; LEE HH, 1978, J VIROL, V27, P754, DOI 10.1128/JVI.27.3.754-767.1978; Manji GA, 1997, J VIROL, V71, P4509, DOI 10.1128/JVI.71.6.4509-4516.1997; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Miller LK, 1998, SEMIN VIROL, V8, P445, DOI 10.1006/smvy.1998.0149; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Seshagiri S, 1997, P NATL ACAD SCI USA, V94, P13606, DOI 10.1073/pnas.94.25.13606; Song ZW, 1999, TRENDS CELL BIOL, V9, pM49, DOI 10.1016/S0968-0004(99)01485-1; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Tamm I, 1998, CANCER RES, V58, P5315; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; THIEM SM, 1989, J VIROL, V63, P2008, DOI 10.1128/JVI.63.5.2008-2018.1989; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; White E, 1998, SEMIN VIROL, V8, P505, DOI 10.1006/smvy.1998.0155; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w; Zoog SJ, 1999, J BIOL CHEM, V274, P25995, DOI 10.1074/jbc.274.37.25995	69	86	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15657	15664		10.1074/jbc.M000791200	http://dx.doi.org/10.1074/jbc.M000791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747956	hybrid			2022-12-27	WOS:000087291400010
J	Lopez, ME; Korc, M				Lopez, ME; Korc, M			A novel type I fibroblast growth factor receptor activates mitogenic signaling in the absence of detectable tyrosine phosphorylation of FRS2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; LIGAND-BINDING SPECIFICITY; FGF-RECEPTOR; POINT MUTATION; IMMUNOGLOBULIN DOMAIN; ACIDIC FGF; BASIC-FGF; FAMILY; FORM; EXPRESSION	A novel variant of the fibroblast growth factor receptor type 1 (FGFR-1) was identified in human placental RNA. In this receptor (FGFR-1L) portions of the second and third immunoglobulin-like (Ig-like) domains are deleted. To determine whether FGFR-1L was functional, full-length variant (pSV/FGFR-1L) and wild-type (pSV/FGFR-1) receptors were stably transfected into rat L6 myoblasts cells. Transfected L6 clones expressed respective proteins and bound I-125-labeled FGF-8 with K-d values of 99 PM (FGFR-1) and 26 PM (FGFR-1L). FGF-1 and FGF-8 competed efficiently with I-125-FGF-2 for binding to FGFR-1 and FGFR-1L, whereas FGF-4 was less efficient. FGF-1, FGF-8, and FGF-4 enhanced mitogen-activated protein kinase (MAPK) activity, increased steady-state c-fos mRNA levels, and stimulated proliferation through either receptor, whereas KGF was without effect. FGFR-1 expressing clones exhibited ligand-induced tyrosine phosphorylation of fibroblast growth factor receptor substrate 2 (FRS2), a 90-kDa adaptor protein that links FGFR-1 activation to the MAPK cascade. In contrast, tyrosine phosphorylation of FRS2 was not evident with FGFR-1L. In addition, phospholipase C-gamma was not tyrosine phosphorylated via activated FGFR-1L. These findings indicate that FGFR-1L binds FGF-1 and FGF-S with high affinity and is capable of mitogenic signaling, but may activate MAPK to occur via non-classical signaling intermediates.	Univ Calif Irvine, Dept Med, Div Endocrinol Diabet & Metab, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Div Endocrinol Diabet & Metab, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Pharmacol, Div Endocrinol Diabet & Metab, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Korc, M (corresponding author), Univ Calif Irvine, Dept Med, Div Endocrinol Diabet & Metab, C240, Irvine, CA 92697 USA.				NCI NIH HHS [CA-40162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cote GJ, 1997, J BIOL CHEM, V272, P1054, DOI 10.1074/jbc.272.2.1054; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DELL KR, 1992, J BIOL CHEM, V267, P21225; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; EISEMANN A, 1991, ONCOGENE, V6, P1195; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HOU JZ, 1992, J BIOL CHEM, V267, P17804; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOBRIN MS, 1993, CANCER RES, V53, P4741; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Larocca D, 1998, HYBRIDOMA, V17, P21, DOI 10.1089/hyb.1998.17.21; MARICS I, 1989, ONCOGENE, V4, P335; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORIAI T, 1994, P NATL ACAD SCI USA, V91, P10217, DOI 10.1073/pnas.91.21.10217; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURGUE B, 1994, CANCER RES, V54, P5206; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	46	11	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15933	15939		10.1074/jbc.M909299199	http://dx.doi.org/10.1074/jbc.M909299199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748122	hybrid			2022-12-27	WOS:000087291400045
J	Ruchaud-Sparagano, MH; Walker, TR; Rossi, AG; Haslett, C; Dransfield, I				Ruchaud-Sparagano, MH; Walker, TR; Rossi, AG; Haslett, C; Dransfield, I			Soluble E-selectin acts in synergy with platelet-activating factor to activate neutrophil beta(2)-integrins - Role of tyrosine kinases and Ca2+ mobilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ADHESION; P-SELECTIN; LEUKOCYTE ADHESION; GLYCOPROTEIN LIGAND-1; PHOSPHOLIPASE A(2); INTEGRIN LFA-1; PHOSPHORYLATION; CALCIUM; STORES; MAC-1	Selectins play a critical role in neutrophil recruitment to sites of inflammation, in tethering and rolling of neutrophils on vascular endothelium, as well as triggering beta(2)-integrin-mediated adhesion. We have previously demonstrated potential pro-inflammatory effects of soluble E-selectin upon neutrophil effector functions, using a soluble recombinant molecule (E-zz), which increased beta(2)-integrin-mediated adhesion, decreased beta(2)-integrin-dependent migration, and triggered reactive oxygen species generation and release. In this study, we have examined the intracellular signals following neutrophil activation by soluble E-selectin, We show that exposure of neutrophils to E-selectin and platelet-activating factor (PAF) in combination induced a synergistic effect upon beta(2)-integrin-mediated adhesion. Although soluble E-selectin did not induce Ca2+ mobilization in neutrophils by itself, elevation of intracellular Ca2+ was specifically prolonged in response to PAF but not leukotriene B-4 or N-formyl-Met-Leu-Phe. The prolonged Ca2+ mobilization observed in the presence of E-selectin was dependent on Ca2+ influx from intracellular stores rather than influx of extracellular Ca2+ through SKF 96365-sensitive channels. The specific alteration of Ca2+ mobilization reported here appears not to have a role in the synergistic effects of E-selectin and PAF upon neutrophil O-2(.) release but may be involved in augmentation of beta(2)-integrin-mediated adhesion.	Univ Edinburgh, Sch Med, Resp Med Unit, Rayne Lab, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Ruchaud-Sparagano, MH (corresponding author), Univ Edinburgh, Sch Med, Resp Med Unit, Rayne Lab, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.			Dransfield, Ian/0000-0001-5848-7059				ALTIERI DC, 1991, J IMMUNOL, V147, P1891; Blanks JE, 1998, EUR J IMMUNOL, V28, P433, DOI 10.1002/(SICI)1521-4141(199802)28:02<433::AID-IMMU433>3.0.CO;2-U; COOPER D, 1994, J IMMUNOL, V153, P3199; CrockettTorabi E, 1997, AM J PHYSIOL-HEART C, V272, pH1302, DOI 10.1152/ajpheart.1997.272.3.H1302; DEMAUREX N, 1992, J CLIN INVEST, V90, P830, DOI 10.1172/JCI115958; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Feldhaus MJ, 1998, J IMMUNOL, V161, P6280; FoyouziYoussefi R, 1997, BIOCHEM J, V322, P709, DOI 10.1042/bj3220709; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haller H, 1997, J IMMUNOL, V158, P1061; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MALECH HD, 1988, NEW ENGL J MED, V317, P687; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; NACCACHE PH, 1985, BIOCHEM BIOPH RES CO, V130, P677, DOI 10.1016/0006-291X(85)90470-X; OELAHERTY JO, 1993, J BIOL CHEM, V268, P14708; OTROVSKY L, 1998, BLOOD, V91, P3028; Phillips ML, 1995, J CLIN INVEST, V96, P2898, DOI 10.1172/JCI118361; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ruchaud-Sparagano MH, 1998, EUR J IMMUNOL, V28, P80, DOI 10.1002/(SICI)1521-4141(199801)28:01<80::AID-IMMU80>3.0.CO;2-7; SIMON SI, 1995, J IMMUNOL, V155, P1502; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steeber DA, 1997, J IMMUNOL, V159, P952; Stewart MP, 1996, J IMMUNOL, V156, P1810; STOCKS SC, 1995, J LEUKOCYTE BIOL, V58, P40, DOI 10.1002/jlb.58.1.40; Varon D, 1998, BLOOD, V91, P500, DOI 10.1182/blood.V91.2.500.500_500_507; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; Williams MA, 1999, J LEUKOCYTE BIOL, V65, P725, DOI 10.1002/jlb.65.6.725; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522	37	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15758	15764		10.1074/jbc.M907390199	http://dx.doi.org/10.1074/jbc.M907390199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748085	hybrid			2022-12-27	WOS:000087291400023
J	Steinberg, SJ; Mihalik, SJ; Kim, DG; Cuebas, DA; Watkins, PA				Steinberg, SJ; Mihalik, SJ; Kim, DG; Cuebas, DA; Watkins, PA			The human liver-specific homolog of very long-chain acyl-CoA synthetase is cholate: CoA ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A-LIGASE; ACID TRANSPORT PROTEIN; RAT-LIVER; PHYTANIC ACID; SUBCELLULAR-DISTRIBUTION; N-ACYLTRANSFERASE; ALPHA-OXIDATION; CHOLIC-ACID; BILE; PURIFICATION	Unconjugated bile acids must be activated to their CoA thioesters before conjugation to taurine or glycine can occur. A human homolog of very long-chain acyl-CoA synthetase, hVLCS-H2, has two requisite properties of a bile acid:CoA ligase, liver specificity and an endoplasmic reticulum subcellular localization. We investigated the ability of this enzyme to activate the primary bile acid, cholic acid, to its CoA derivative. When expressed in COS-1 cells, hVLCS-H2 exhibited cholate:CoA ligase (choloyl-CoA synthetase) activity with both nonisotopic and radioactive assays. Other long- and very long-chain acyl-CoA synthetases were incapable of activating cholate. Endogenous choloyl-CoA synthetase activity was also detected in liver-derived HepG2 cells but not in kidney-derived COS-1 cells. Our results are consistent with a role for hVLCS-H2 in the re-activation and re-conjugation of bile acids entering liver from the enterohepatic circulation rather than in de novo bile acid synthesis.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; SW Missouri State Univ, Dept Chem, Springfield, MO 65804 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Missouri State University	Watkins, PA (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.			Watkins, Paul A./0000-0002-3246-1405	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037355] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10981] Funding Source: Medline; NINDS NIH HHS [NS10553, NS 37355] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bahar RJ, 1999, GASTROENTEROL CLIN N, V28, P27, DOI 10.1016/S0889-8553(05)70042-X; BJORKHEM I, 1992, J LIPID RES, V33, P455; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; KASE BF, 1989, J BIOL CHEM, V264, P9220; KELLEY M, 1994, BIOCHEM J, V304, P945, DOI 10.1042/bj3040945; KILLENBERG PG, 1978, J LIPID RES, V19, P24; Kurosawa T, 1998, ANAL CHIM ACTA, V365, P249, DOI 10.1016/S0003-2670(97)00601-6; LIM WC, 1981, BIOCHEM J, V197, P611, DOI 10.1042/bj1970611; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALLONEE DH, 1992, J BACTERIOL, V174, P2065, DOI 10.1128/JB.174.7.2065-2071.1992; MIYAZAWA S, 1985, J BIOCHEM, V98, P723, DOI 10.1093/oxfordjournals.jbchem.a135330; MURALIDHARAN VB, 1984, J BIOL CHEM, V259, P3021; POLOKOFF MA, 1977, J BIOL CHEM, V252, P1167; Russel DW, 1994, LIVER DIS CHILDREN, P81; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHULZ H, 1974, J BIOL CHEM, V249, P2704; SIMION FA, 1983, BIOCHEMISTRY-US, V22, P5029, DOI 10.1021/bi00290a023; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; Steinberg SJ, 1999, MOL GENET METAB, V68, P32, DOI 10.1006/mgme.1999.2883; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; Uchida Y, 1996, J BIOCHEM, V119, P565; VESSEY DA, 1987, J BIOL CHEM, V262, P5360; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Watkins PA, 1996, J LIPID RES, V37, P2288; Watkins PA, 1999, PROSTAG LEUKOTR ESS, V60, P323, DOI 10.1016/S0952-3278(99)80007-6; WATKINS PA, 1994, BBA-LIPID LIPID MET, V1214, P288, DOI 10.1016/0005-2760(94)90075-2; Wheeler JB, 1997, ARCH BIOCHEM BIOPHYS, V348, P15, DOI 10.1006/abbi.1997.0391	27	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15605	15608		10.1074/jbc.C000015200	http://dx.doi.org/10.1074/jbc.C000015200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10749848	Green Published, hybrid			2022-12-27	WOS:000087291400002
J	Dallmann, HG; Kim, S; Pritchard, AE; Marians, KJ; McHenry, CS				Dallmann, HG; Kim, S; Pritchard, AE; Marians, KJ; McHenry, CS			Characterization of the unique C terminus of the Escherichia coli tau DnaX protein - Monomeric C-tau binds alpha and DnaB and can partially replace tau in reconstituted replication forks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; COORDINATED LEADING-STRAND; GAMMA-SUBUNIT; BETA-SUBUNIT; INITIATION COMPLEX; EPSILON-SUBUNIT; GENE-PRODUCT; IDENTIFICATION; PURIFICATION; CHROMOSOME	A contact between the dimeric tau subunit within the DNA polymerase III holoenzyme and the DnaB helicase is required for replication fork propagation at physiologically-relevant rates (Kim, S., Dallmann, H. G., ;cHenry, C. S., and Marians, K. J. (1996) Cell 84, 643-650). In this report, we exploit the OmpT protease to generate C-tau a protein containing only the unique C-terminal sequences of tau, free of the sequences shared with the alternative gamma frameshifting product of dnaX. We have established that C-tau is a monomer by sedimentation equilibrium and sedimentation velocity ultracentrifugation, Monomeric C-tau. binds the oc catalytic subunit of DNA polymerase III with a 1:1 stoichiometry, C-tau also binds DnaB, revealed by a coupled immunoblotting method. C-tau restores the rapid replication rate of inefficient forks reconstituted with only the gamma dnaX gene product. The acceleration of the DnaB helicase can be observed in the absence of primase, when only leading-strand replication occurs. This indicates that C-tau bound only to the leading-strand polymerase, can trigger the conformational change necessary for DnaB to assume the fast, physiologically relevant form.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Cornell Univ, Grad Sch Med Sci, Grad Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Cornell University; Memorial Sloan Kettering Cancer Center	Dallmann, HG (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036255, R01GM034557, R37GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36255, R37 GM034557, GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDLER M, 1975, J MOL BIOL, V94, P127, DOI 10.1016/0022-2836(75)90410-6; Cohn E. J., 1943, PROTEINS AMINO ACIDS; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; JOHANSON KO, 1982, J BIOL CHEM, V257, P2310; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KODAIRA M, 1983, MOL GEN GENET, V192, P80, DOI 10.1007/BF00327650; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; MAKI H, 1988, J BIOL CHEM, V263, P6570; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; McRorie D. K., 1993, SELF ASS SYSTEMS ANA; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; MOK M, 1987, J BIOL CHEM, V262, P16644; MULLIN DA, 1983, MOL GEN GENET, V192, P73, DOI 10.1007/BF00327649; MURAMATSU N, 1988, ANAL BIOCHEM, V168, P345, DOI 10.1016/0003-2697(88)90328-4; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; Pritchard AE, 1996, J BIOL CHEM, V271, P10291, DOI 10.1074/jbc.271.17.10291; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; TOUGU K, 1994, J BIOL CHEM, V269, P4675; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WEINER JH, 1976, P NATL ACAD SCI USA, V73, P752, DOI 10.1073/pnas.73.3.752; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4074; [No title captured]	41	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15512	15519		10.1074/jbc.M909257199	http://dx.doi.org/10.1074/jbc.M909257199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748120	Green Submitted, hybrid			2022-12-27	WOS:000087128300099
J	Macfarlane, WM; Campbell, SC; Elrick, LJ; Oates, V; Bermano, G; Lindley, KJ; Aynsley-Green, A; Dunne, MJ; James, RFL; Docherty, K				Macfarlane, WM; Campbell, SC; Elrick, LJ; Oates, V; Bermano, G; Lindley, KJ; Aynsley-Green, A; Dunne, MJ; James, RFL; Docherty, K			Glucose regulates islet amyloid polypeptide gene transcription in a PDX1-and calcium-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; INSULIN UPSTREAM FACTOR-1; TRANSGENIC MICE; DIABETES-MELLITUS; FACTOR IUF1; EXPRESSION; AMYLIN; METABOLISM; PROMOTER	Islet amyloid polypeptide (IAPP) and insulin are expressed in the p-cells of the islets of Langerhans, They are co-secreted in response to changes in glucose concentration, and their mRNA levels are also regulated by glucose. The promoters of both genes share similar cis-acting sequence elements, and both bind the homeodomain transcription factor PDX1, which plays an important role in the regulation of the insulin promoter and insulin mRNA levels by glucose. Here we examine the role of PDX1 in the regulation of the human IAPP promoter by glucose. The experiments were facilitated by the availability of a human p-cell line (NES2Y) that lacks PDX1, NES2Y cells also lack operational K-ATP channels, resulting in a loss of control of calcium signaling. We have previously used these cells to show that glucose regulation of the insulin gene is dependent on PDX1, but not calcium. In the mouse p-cell line Mine, glucose (16 mM) Stimulated a 3.5-4-fold increase in the activity of a -222 to +450 IAPP promoter construct compared with values observed in 0.5 mM glucose. In NES2Y cells, glucose failed to stimulate transcriptional activation of the IAPP promoter. Overexpression of PDX1 in NES2Y cells failed to reinstate glucose-responsive control of the IAPP promoter, Glucose effects on the IAPP promoter were observed only in the presence of PDX1 when normal calcium signaling was restored by overexpression of the two K-ATP channel subunits SUR1 and Kir6.2. The importance of calcium was further emphasized by an experiment in which glucose-stimulated LAPP promoter activity was inhibited by the calcium channel blocker verapamil (50 mu M). Verapamil was further shown to inhibit the stimulatory effect of glucose on IAPP mRNA levels, These results demonstrate that like the insulin promoter, glucose regulation of the IAPP promoter is dependent on the activity of PDX1, but unlike the insulin promoter, it additionally requires the activity of another, as yet uncharacterized factor(s), the activity of which is calcium-dependent.	Univ Aberdeen, Dept Mol & Cell Biol, Inst Med Sci, Aberdeen AB25 2ZD, Scotland; Univ London, Inst Child Hlth, London WC1N 1EH, England; Univ Sheffield, Dept Biomed Sci, Western Bank, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Inst Mol Physiol, Sheffield S10 2TN, S Yorkshire, England; Univ Leicester, Leicester Royal Infirm, Dept Surg, Leicester LE2 7LX, Leics, England	University of Aberdeen; University of London; University College London; University of Sheffield; University of Sheffield; University of Leicester	Docherty, K (corresponding author), Univ Aberdeen, Dept Mol & Cell Biol, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.			Bermano, Giovanna/0000-0001-6027-6437; Docherty, Kevin/0000-0001-6765-2060				Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; ALAM T, 1992, DIABETES, V41, P508, DOI 10.2337/diabetes.41.4.508; BrethertonWatt D, 1996, BIOCHEM J, V313, P495, DOI 10.1042/bj3130495; BUTLER PC, 1990, DIABETES, V39, P752, DOI 10.2337/diabetes.39.6.752; Butler Peter C., 1994, P381; Carty MD, 1997, J BIOL CHEM, V272, P11986, DOI 10.1074/jbc.272.18.11986; COOPER GJS, 1994, ENDOCR REV, V15, P163, DOI 10.1210/er.15.2.163; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; DEKONING EJP, 1994, P NATL ACAD SCI USA, V91, P8467, DOI 10.1073/pnas.91.18.8467; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; DOCHERTY K, 1999, ADV MOL CEL, V29, P103; FOX N, 1993, FEBS LETT, V323, P40, DOI 10.1016/0014-5793(93)81444-5; Gasa R, 1997, REGUL PEPTIDES, V68, P99, DOI 10.1016/S0167-0115(96)02109-X; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GIDDINGS SJ, 1993, AM J PHYSIOL, V265, pE259, DOI 10.1152/ajpendo.1993.265.2.E259; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; Janson J, 1996, P NATL ACAD SCI USA, V93, P7283, DOI 10.1073/pnas.93.14.7283; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KAHN SE, 1990, DIABETES, V39, P634, DOI 10.2337/diabetes.39.5.634; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; LEIGHTON B, 1988, NATURE, V335, P632, DOI 10.1038/335632a0; LONDON NJM, 1994, CLIN TRANSPLANT, V8, P421; Macfarlane WM, 1997, FEBS LETT, V413, P304, DOI 10.1016/S0014-5793(97)00874-0; Macfarlane WM, 2000, DIABETES, V49, P418, DOI 10.2337/diabetes.49.3.418; MacFarlane WM, 1999, J BIOL CHEM, V274, P34059, DOI 10.1074/jbc.274.48.34059; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MADSEN OD, 1991, MOL ENDOCRINOL, V5, P143, DOI 10.1210/mend-5-1-143; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; Mulder H, 1996, AM J PHYSIOL-ENDOC M, V271, pE1008, DOI 10.1152/ajpendo.1996.271.6.E1008; NOVIALS A, 1993, DIABETES, V42, P1514, DOI 10.2337/diabetes.42.10.1514; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; Stoffers DA, 1997, TRENDS ENDOCRIN MET, V8, P145, DOI 10.1016/S1043-2760(97)00008-8; Verchere CB, 1996, P NATL ACAD SCI USA, V93, P3492, DOI 10.1073/pnas.93.8.3492; Wang M, 1996, MOL ENDOCRINOL, V10, P243, DOI 10.1210/me.10.3.243; WESTERMARK P, 1987, P NATL ACAD SCI USA, V84, P3881, DOI 10.1073/pnas.84.11.3881; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; YOUNG DA, 1990, AM J PHYSIOL, V259, pE457, DOI 10.1152/ajpendo.1990.259.3.E457	40	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15330	15335		10.1074/jbc.M908045199	http://dx.doi.org/10.1074/jbc.M908045199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748090	hybrid			2022-12-27	WOS:000087128300075
J	Yoo, SH; Jeon, CJ				Yoo, SH; Jeon, CJ			Inositol 1,4,5-trisphosphate receptor/Ca2+ channel modulatory role of chromogranin A, a Ca2+ storage protein of secretory granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED CHROMAFFIN VESICLES; PH-DEPENDENT INTERACTION; TRISPHOSPHATE RECEPTOR; CONFORMATIONAL CHANGE; CA-2+ RELEASE; IP3 RECEPTOR; CALCIUM; BINDING; EXPRESSION; MEMBRANE	The secretory granules of neuroendocrine cells, which contain large amounts of Ca2+ and chromogranins, have been demonstrated to release Ca2+ in response to inositol 1,4,5-trisphosphate (IP3), indicating the IP3-sensitive intracellular Ca2+ store role of secretory granules. In our previous study, chromogranin A (CGA) was shown to interact with several secretory granule membrane proteins, including the IP3 receptor (IP3R), at the intravesicular pH 5.5 (Yoo, S. H, (1994) J, Biol, Chem, 269, 12001-12006); To examine the functional aspect of this coupling, we measured the IP3-mediated Ca2+ release property of the IP3R reconstituted into liposomes in the presence and absence of CGA. Presence of CGA in the IP3R-reconstituted liposome significantly enhanced the IP3-mediated Ca2+ release from the liposomes, Moreover, the number of IP3 bound to the reconstituted IP3R increased. The fluorescence energy transfer and IP3R Trp fluorescence quenching studies indicated that the structure of reconstituted IP3R becomes more ordered and exposed in the presence of CGA, suggesting that the coupled CGA in the liposome caused structural changes of the IP3R, changing it to a structure that is better suited to IF, binding and subsequent Ca2+ release, These results appear to underscore the physiological significance of IP3R-CGA coupling in the secretory granules.	Korea Adv Inst Sci & Technol, Natl Creat Res Initiat, Ctr Secretory Granule Res, Ctr Biomed Res,Yu Sung Gu, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Yoo, SH (corresponding author), Korea Adv Inst Sci & Technol, Natl Creat Res Initiat, Ctr Secretory Granule Res, Ctr Biomed Res,Yu Sung Gu, Taejon 305701, South Korea.	shyoo@cais.kaist.ac.kr						BLONDEL O, 1995, TRENDS NEUROSCI, V18, P157, DOI 10.1016/0166-2236(95)93894-4; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; CASEY RP, 1977, BIOCHEMISTRY-US, V16, P972, DOI 10.1021/bi00624a025; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KOLCHENS S, 1993, CHEM PHYS LIPIDS, V65, P1, DOI 10.1016/0009-3084(93)90076-F; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MATTER N, 1993, J BIOL CHEM, V268, P732; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; REIFFEN FU, 1986, FEBS LETT, V195, P327, DOI 10.1016/0014-5793(86)80187-9; SIMON JP, 1989, BIOCHEM J, V262, P1; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VASKOVSKY VE, 1975, J CHROMATOGR, V114, P129, DOI 10.1016/S0021-9673(00)85249-8; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; WATRAS J, 1991, J NEUROSCI, V11, P3239; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1990, BIOCHIM BIOPHYS ACTA, V1040, P66, DOI 10.1016/0167-4838(90)90146-7; YOO SH, 1994, J BIOL CHEM, V269, P12001; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1990, J BIOL CHEM, V265, P13446; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030	46	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15067	15073		10.1074/jbc.M909391199	http://dx.doi.org/10.1074/jbc.M909391199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748130	hybrid			2022-12-27	WOS:000087128300042
J	LaCount, MW; Zhang, EL; Chen, YP; Han, KP; Whitton, MM; Lincoln, DE; Woodin, SA; Lebioda, L				LaCount, MW; Zhang, EL; Chen, YP; Han, KP; Whitton, MM; Lincoln, DE; Woodin, SA; Lebioda, L			The crystal structure and amino acid sequence of dehaloperoxidase from Amphitrite ornata indicate common ancestry with globins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOTOMASTUS-LOBATUS CHLOROPEROXIDASE; HEME IRON LIGAND; HISTIDINE; REACTIVITY; PEROXIDASE; MYOGLOBIN	The full-length, protein coding sequence for dehaloperoxidase was obtained using a reverse genetic approach and a cDNA library from marine worm Amphitrite ornata, The crystal structure of the dehaloperoxidase (DHP) was determined by the multiple isomorphous replacement method and was refined at 1.8-Angstrom resolution. The enzyme fold is that of the globin family and, together with the amino acid sequence information, indicates that the enzyme evolved from an ancient oxygen carrier. The peroxidase activity of DHP arose mainly through changes in the positions of the proximal and distal histidines relative to those seen in globins, The structure of a complex of DHP with 4-iodophenol is also reported, and it shows that in contrast to larger heme peroxidases DHP binds organic substrates in the distal cavity, The binding is facilitated by the histidine swinging in and out of the cavity, The modeled position of the oxygen atom bound to the heme suggests that the enzymatic reaction proceeds via direct attack of the oxygen atom on the carbon atom bound to the halogen atom.	Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Ann Arbor, MI 48105 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Pfizer	Lebioda, L (corresponding author), Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.	lebioda@mail.chem.sc.edu	Woodin, Sarah A/K-8481-2014	Woodin, Sarah A/0000-0001-5615-2212				ATOR MA, 1987, J BIOL CHEM, V262, P1542; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOLOGNESI M, 1989, J MOL BIOL, V205, P529, DOI 10.1016/0022-2836(89)90224-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen YP, 1996, J BIOL CHEM, V271, P4609; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DAWSON JH, 1976, J AM CHEM SOC, V98, P3707, DOI 10.1021/ja00428a054; Fielman KT, 1999, MAR ECOL PROG SER, V181, P1, DOI 10.3354/meps181001; Franzen S, 1998, J AM CHEM SOC, V120, P4658, DOI 10.1021/ja973212d; FUSHITANI K, 1986, COMP BIOCHEM PHYS B, V84, P137, DOI 10.1016/0305-0491(86)90283-X; *GEN COMP GROUP, 1997, WISC PACK VERS 9 1; GROVES JT, 1994, INORG CHEM, V33, P5065, DOI 10.1021/ic00100a035; Lebioda L, 1999, NATURE, V401, P445, DOI 10.1038/46728; Matsui T, 1999, J BIOL CHEM, V274, P2838, DOI 10.1074/jbc.274.5.2838; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; MORRIS SC, 1979, PHILOS T R SOC B, V285, P227, DOI 10.1098/rstb.1979.0006; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; Poulos TL, 1996, J BIOL INORG CHEM, V1, P356, DOI 10.1007/s007750050064; Roach MP, 1997, BIOCHEMISTRY-US, V36, P2197, DOI 10.1021/bi9621371; Sack JS, 1997, METHOD ENZYMOL, V277, P158, DOI 10.1016/S0076-6879(97)77011-3; WEBER RE, 1977, COMP BIOCHEM PHYS A, V56, P179, DOI 10.1016/0300-9629(77)90182-7; WOODIN SA, 1993, J CHEM ECOL, V19, P517, DOI 10.1007/BF00994322; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123; Zhang E, 1996, ACTA CRYSTALLOGR D, V52, P1191, DOI 10.1107/S0907444996007974	26	93	93	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18712	18716		10.1074/jbc.M001194200	http://dx.doi.org/10.1074/jbc.M001194200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10751397	hybrid			2022-12-27	WOS:000087815900015
J	Straub, SG; Kornreich, B; Oswald, RE; Nemeth, EF; Sharp, GWG				Straub, SG; Kornreich, B; Oswald, RE; Nemeth, EF; Sharp, GWG			The calcimimetic R-467 potentiates insulin secretion in pancreatic beta cells by activation of a nonspecific cation channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; EXTRACELLULAR CA2+-SENSING RECEPTOR; STIMULATION TEST; PHOSPHOLIPASE-C; RAT; CA2+; EXPRESSION; CLONING; RELEASE; DIMERIZATION	The extracellular, G protein-linked Ca2+-sensing receptor (CaSR), first identified in the parathyroid gland, is expressed in several tissues and cells and can be activated by Ca2+ and some other inorganic cations and organic polycations. Calcimimetics such as NPS (R)-N-(3-phenylpropyl)-alpha-methyl-3-methoxybenzylamine hydrochloride (R-467), a phenylalkylamine, are thought to activate CaSR by allosterically increasing the affinity of the receptor for Ca2+. When tested for its effect on insulin release in C57BL/6 mice, R-467 had no effect under basal conditions but enhanced both phases of glucose-stimulated release. The beta HC9 cell also responded to R-467 and to the enantiomer S-467 with a stimulation of insulin release. In subsequent studies with the beta HC9 cell, it was found that the stimulatory effect was due to activation of a nonspecific cation channel, depolarization of the beta-cell, and increased Ca2+ entry. No other stimulatory mechanism was uncovered. The depolarization of the cell induced by the calcimimetic could be due to a direct action on the channel or via the CaSR. However, it appeared not to be mediated by G(i), G(o), G(q/11), or G(s). The novel mode of action of the calcimimetic, combined with the glucose-dependence of the stimulation on islets, raises the possibility of a totally new class of drugs that will stimulate insulin secretion during hyperglycemia but which will not cause hypoglycemia.	Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14850 USA; NPS Pharmaceut Inc, Salt Lake City, UT 84108 USA	Cornell University	Sharp, GWG (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14850 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054243, R01DK042063] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-54243, R01-DK-42063] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abernethy LJ, 1998, ARCH DIS CHILD, V78, P359, DOI 10.1136/adc.78.4.359; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1999, VITAM HORM, V55, P1; Bruce JIE, 1999, J BIOL CHEM, V274, P20561, DOI 10.1074/jbc.274.29.20561; CHANG WH, 1995, AM J PHYSIOL-ENDOC M, V269, pE864, DOI 10.1152/ajpendo.1995.269.5.E864; Chattopadhyay N, 1998, AM J PHYSIOL-GASTR L, V274, pG122, DOI 10.1152/ajpgi.1998.274.1.G122; Chattopadhyay N, 1997, BIOCHEM BIOPH RES CO, V233, P801, DOI 10.1006/bbrc.1997.6553; Cheng I, 1999, GASTROENTEROLOGY, V116, P118, DOI 10.1016/S0016-5085(99)70235-0; Desfleurs E, 1999, PFLUG ARCH EUR J PHY, V437, P716, DOI 10.1007/s004240050837; GARRETT JE, 1995, ENDOCRINOLOGY, V136, P5202, DOI 10.1210/en.136.11.5202; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hammerland LG, 1998, MOL PHARMACOL, V53, P1083; HOLZ GG, 1995, J BIOL CHEM, V270, P17749, DOI 10.1074/jbc.270.30.17749; Kato M, 1997, SURGERY, V122, P1203, DOI 10.1016/S0039-6060(97)90228-2; Kifor O, 1997, J BONE MINER RES, V12, P715, DOI 10.1359/jbmr.1997.12.5.715; KIKUCHI M, 1974, DIABETES, V23, P550, DOI 10.2337/diab.23.6.550; KOMATSU M, 1995, ENDOCRINOLOGY, V136, P1857, DOI 10.1210/en.136.5.1857; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Leech CA, 1997, J BIOL CHEM, V272, P17987, DOI 10.1074/jbc.272.29.17987; Leech CA, 1998, DIABETES, V47, P1066, DOI 10.2337/diabetes.47.7.1066; McGehee DS, 1997, J PHYSIOL-LONDON, V502, P31, DOI 10.1111/j.1469-7793.1997.031bl.x; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Nemeth EF, 1996, PEDIATR NEPHROL, V10, P275; Noda M, 1996, DIABETES, V45, P1766, DOI 10.2337/diabetes.45.12.1766; OShea D, 1996, J CLIN ENDOCR METAB, V81, P1623, DOI 10.1210/jc.81.4.1623; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Pereira PL, 1998, RADIOLOGY, V206, P703, DOI 10.1148/radiology.206.3.9494488; Rasschaert J, 1999, BIOCHEM BIOPH RES CO, V264, P615, DOI 10.1006/bbrc.1999.1577; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Rogers KV, 1997, BRAIN RES, V744, P47, DOI 10.1016/S0006-8993(96)01070-0; ROJAS E, 1990, FEBS LETT, V261, P265, DOI 10.1016/0014-5793(90)80568-4; ROLAND PE, 1994, HUMAN BRAIN MAPPING, V2, P1; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SILVA AM, 1994, J BIOL CHEM, V269, P17095; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; WILSON HA, 1985, J CELL PHYSIOL, V125, P72, DOI 10.1002/jcp.1041250110; YADA T, 1989, J BIOL CHEM, V264, P2455; Ye CP, 1996, BIOCHEM BIOPH RES CO, V226, P572, DOI 10.1006/bbrc.1996.1396; Ye CP, 1996, BIOCHEM BIOPH RES CO, V224, P271, DOI 10.1006/bbrc.1996.1019; Ye CP, 1997, BRAIN RES BULL, V44, P75, DOI 10.1016/S0361-9230(97)00088-9; Yoshida N, 1998, BONE, V22, P495, DOI 10.1016/S8756-3282(98)00038-6	44	32	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18777	18784		10.1074/jbc.M000090200	http://dx.doi.org/10.1074/jbc.M000090200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10751384	hybrid			2022-12-27	WOS:000087815900024
J	Bender, AT; Demady, DR; Osawa, Y				Bender, AT; Demady, DR; Osawa, Y			Ubiquitination of neuronal nitric-oxide synthase in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED INACTIVATION; PROTEASOME PATHWAY; IN-VIVO; DEGRADATION; PHOSPHORYLATION; HEME; HSP90; 3,5-DICARBETHOXY-2,6-DIMETHYL-4-ETHYL-1,4-DIHYDROPYRIDINE; GELDANAMYCIN; ISOZYMES	It is established that suicide inactivation of neuronal nitric-oxide synthase (nNOS) with guanidine compounds, or inhibition of the hsp90-based chaperone system with geldanamycin, leads to the enhanced proteolytic degradation of nNOS. This regulated proteolysis is mediated, in part, by the proteasome. We show here with the use of human embryonic kidney 293 cells transfected with nNOS that inhibition of the proteasome with lactacystin leads to the accumulation of immunodetectable higher molecular mass forms of nNOS, Some of these higher molecular mass forms were immunoprecipitated by an anti-ubiquitin antibody, indicating that they are nNOS-polyubiquitin conjugates. Moreover, the predominant nNOS-ubiquitin conjugate detected in human embryonic kidney 293 cells, as well as in rat brain cytosol, migrates on SDS-polyacrylamide gels with a mobility near that for the native monomer of nNOS and likely represents a conjugate containing a few or perhaps one ubiquitin, Studies in vitro with the use of I-125-ubiquitin and reticulocyte extracts could mimic this ubiquitination reaction, which was dependent on ATP, The hemedeficient monomeric form of nNOS is preferentially ubiquitinated over that of the heme-sufficient functionally active homodimer, Thus, we have shown for the first time that ubiquitination of nNOS occurs and is likely involved in the regulated proteolytie removal of nonfunctional enzyme.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Osawa, Y (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.				NIEHS NIH HHS [ES08365] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008365] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; BORNHEIM LM, 1987, MOL PHARMACOL, V32, P299; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chen E, 1998, J BIOL CHEM, V273, P35201, DOI 10.1074/jbc.273.52.35201; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CORREIA MA, 1987, ARCH BIOCHEM BIOPHYS, V258, P436, DOI 10.1016/0003-9861(87)90365-1; CORREIA MA, 1992, ARCH BIOCHEM BIOPHYS, V297, P228, DOI 10.1016/0003-9861(92)90666-K; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DINERMAN JL, 1994, NEUROPHARMACOLOGY, V33, P1245, DOI 10.1016/0028-3908(94)90023-X; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; HECKER M, 1994, J NEUROCHEM, V62, P1524; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Korsmeyer KK, 1999, ARCH BIOCHEM BIOPHYS, V365, P31, DOI 10.1006/abbi.1999.1138; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; LUNETTA JM, 1989, MOL PHARMACOL, V35, P10; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Nakatsuka M, 1998, DRUG METAB DISPOS, V26, P497; Noguchi S, 2000, J BIOL CHEM, V275, P2376, DOI 10.1074/jbc.275.4.2376; PETERS JM, 1998, UBIQUITIN BIOL CELL; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SOKOLIK CW, 1991, J BIOL CHEM, V266, P9100; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TIERNEY DJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P9, DOI 10.1016/0003-9861(92)90358-4; Wang HF, 1999, ARCH BIOCHEM BIOPHYS, V365, P45, DOI 10.1006/abbi.1999.1139; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wolff DJ, 1998, EUR J PHARMACOL, V350, P325, DOI 10.1016/S0014-2999(98)00267-2; YAO KQ, 1993, J BIOL CHEM, V268, P59	39	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17407	17411		10.1074/jbc.M000155200	http://dx.doi.org/10.1074/jbc.M000155200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10751385	hybrid			2022-12-27	WOS:000087485000028
J	Mittl, PRE; Luthy, L; Hunziker, P; Grutter, MG				Mittl, PRE; Luthy, L; Hunziker, P; Grutter, MG			The cysteine-rich protein a from Helicobacter pylori is a beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; NEURAL NETWORKS; GASTRIC-CANCER; COCCOID FORMS; INFECTION; SEQUENCE; STOMACH; CAGA; IDENTIFICATION; PURIFICATION	Among the large number of hypothetical proteins within the genomes of Helicobacter pylori, there is a family of unique and highly disulfide-bridged proteins, designated family 12, for which no function could originally be assigned. Sequence analysis revealed that members of this family possess a modular architecture of alpha/beta-units and a stringent pattern of cysteine residues. The H. pylori cysteine-rich protein A (HcpA), which is a member of this family, was expressed and refolded from inclusion bodies. Six pairs of cysteine residues, which are separated by exactly seven residues, form disulfide bridges. HcpA is a beta-lactamase. It slowly hydrolyzes 6-aminopenicillinic acid and 7-aminocephalosporanic acid (ACA) derivatives. The turnover for 6-aminopenicillinic acid derivatives is 23 times greater than for ACA derivatives. The enzyme is efficiently inhibited by cloxacillin and oxacillin but not by ACA derivatives or metal chelators, We suggest that all family 12 members possess similar activities and might be involved in the synthesis of the cell wall peptidoglycan. They might also be responsible for amoxicillin resistance of certain H. pylori strains.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Mittl, PRE (corresponding author), Univ Zurich, Inst Biochem, Winterthurer Str 190, CH-8057 Zurich, Switzerland.		Mittl, Peer/E-5352-2017					Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BLASER MJ, 1995, CANCER RES, V55, P2111; Blumberg P M, 1974, Methods Enzymol, V34, P401; BRENNER DG, 1984, BIOCHEMISTRY-US, V23, P5833, DOI 10.1021/bi00319a024; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Cao P, 1998, INFECT IMMUN, V66, P2984, DOI 10.1128/IAI.66.6.2984-2986.1998; CHAN WY, 1994, AM J CLIN PATHOL, V102, P503, DOI 10.1093/ajcp/102.4.503; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P187; Costa K, 1999, J BACTERIOL, V181, P3710, DOI 10.1128/JB.181.12.3710-3715.1999; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dore MP, 1999, HELICOBACTER, V4, P154, DOI 10.1046/j.1523-5378.1999.99310.x; Eck M, 1997, GASTROENTEROLOGY, V112, P1482, DOI 10.1016/S0016-5085(97)70028-3; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; GALLENI M, 1995, J CHEMOTHERAPY, V7, P3, DOI 10.1179/joc.1995.7.1.3; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; Graham DY, 1998, HELICOBACTER, V3, P145, DOI 10.1046/j.1523-5378.1998.08031.x; GREENE RF, 1974, J BIOL CHEM, V249, P5388; JANAS B, 1995, AM J GASTROENTEROL, V90, P1829; KELLY JA, 1986, SCIENCE, V231, P1429, DOI 10.1126/science.3082007; Krishnamurthy P, 1999, J BACTERIOL, V181, P5107, DOI 10.1128/JB.181.16.5107-5110.1999; LAKAYE B, 1994, BIOCHEM J, V300, P141, DOI 10.1042/bj3000141; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; MARSHALL BJ, 1990, GASTROENTEROLOGY, V99, P697, DOI 10.1016/0016-5085(90)90957-3; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; Matagne A, 1998, BIOCHEM J, V330, P581, DOI 10.1042/bj3300581; McGee DJ, 1999, CURR TOP MICROBIOL, V241, P155; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pace C N, 1986, Methods Enzymol, V131, P266; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Rost B, 1996, METHOD ENZYMOL, V266, P525; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Van Nuland NAJ, 1998, BIOCHEMISTRY-US, V37, P622, DOI 10.1021/bi9717946; WARREN JR, 1983, LANCET, V1, P1273; Zhao GS, 1999, ANTIMICROB AGENTS CH, V43, P1124, DOI 10.1128/AAC.43.5.1124	38	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17693	17699		10.1074/jbc.M001869200	http://dx.doi.org/10.1074/jbc.M001869200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748053	hybrid			2022-12-27	WOS:000087485000069
J	Pahl, PMB; Yan, XD; Hodges, YK; Rosenthal, EA; Horwitz, MA; Horwitz, LD				Pahl, PMB; Yan, XD; Hodges, YK; Rosenthal, EA; Horwitz, MA; Horwitz, LD			An exochelin of Mycobacterium tuberculosis reversibly arrests growth of human vascular smooth muscle cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE-ACTIVITY; BREAST-CANCER CELLS; CYCLE PROGRESSION; IRON CHELATORS; MESSENGER-RNA; IN-VITRO; INHIBITION; PROLIFERATION; EXPRESSION; INJURY	Proliferation of vascular smooth muscle cells (VSMC) is characteristic of restenosis following balloon angioplasty. We show here that a low concentration of a novel iron chelator, desferri-exochelin 772SM, reversibly arrests the growth of human VSMC in vitro, specifically in G(0)/G(1) and S phases. The lipophilic desferri-exochelin is effective more rapidly and at a 10-fold lower concentration than the nonlipophilic iron chelator deferoxamine. Treatment of growth-synchronized VSMC with the desferri-exochelin results in down-regulation of cyclin E/Cdk2 and cyclin A/Cdk2 activity but does not affect the cyclin D/Cdk4/retinoblastoma phosphorylation pathway. Both DNA replication and RNA transcription are inhibited in exochelin-treated cells, but protein synthesis is not. The ability of desferri-exochelin 772SM to reversibly block the growth of VSMC in vitro with no apparent cytotoxicity suggests that the exochelin may be useful as a therapeutic agent to limit restenosis in injured vessels.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Cardiol, Denver, CO 80262 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California Los Angeles	Horwitz, LD (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Cardiol, 4200 E 9th Ave,Box B130, Denver, CO 80262 USA.			Horwitz, Lawrence/0000-0001-5328-6020	NCRR NIH HHS [M01-RR00069] Funding Source: Medline; NHLBI NIH HHS [HL55291] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000069] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055291] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357-2725(96)00178-1; BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036; BERGERON RJ, 1984, BIOCHEM BIOPH RES CO, V121, P848, DOI 10.1016/0006-291X(84)90755-1; Braun-Dullaeus RC, 1998, CIRCULATION, V98, P82, DOI 10.1161/01.CIR.98.1.82; BRODIE C, 1993, CANCER RES, V53, P3968; CLOWES AW, 1983, LAB INVEST, V49, P208; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; GANESHAGURU K, 1980, BIOCHEM PHARMACOL, V29, P1275, DOI 10.1016/0006-2952(80)90285-3; GOBIN J, 1995, P NATL ACAD SCI USA, V92, P5189, DOI 10.1073/pnas.92.11.5189; Gobin J, 1996, J EXP MED, V183, P1527, DOI 10.1084/jem.183.4.1527; Hodges-Garcia YK, 1998, IN VITRO CELL DEV-AN, V34, P364, DOI 10.1007/s11626-998-0016-y; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Horwitz LD, 1998, P NATL ACAD SCI USA, V95, P5263, DOI 10.1073/pnas.95.9.5263; Howland MA, 1996, J TOXICOL-CLIN TOXIC, V34, P491, DOI 10.3109/15563659609028006; Jarvis TC, 1996, RNA, V2, P419; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Kulp KS, 1996, EXP CELL RES, V229, P60, DOI 10.1006/excr.1996.0343; Kulp KS, 1996, TOXICOL APPL PHARM, V139, P356, DOI 10.1006/taap.1996.0176; LLOYD JB, 1991, BIOCHEM PHARMACOL, V41, P1361, DOI 10.1016/0006-2952(91)90109-I; LUCAS JJ, 1995, BLOOD, V86, P2268, DOI 10.1182/blood.V86.6.2268.bloodjournal8662268; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIANO JM, 1993, AM J PATHOL, V142, P715; PORRECA E, 1994, ARTERIOSCLER THROMB, V14, P299, DOI 10.1161/01.ATV.14.2.299; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SPEIR E, 1992, CIRCULATION, V86, P538, DOI 10.1161/01.CIR.86.2.538; VANREYK DM, 1992, INT J IMMUNOPHARMACO, V14, P925, DOI 10.1016/0192-0561(92)90092-Y; Wei GL, 1997, CIRC RES, V80, P418, DOI 10.1161/01.res.0000435858.35902.ea; XU JH, 1991, ONCOGENE, V6, P1139; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	32	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17821	17826		10.1074/jbc.M909918199	http://dx.doi.org/10.1074/jbc.M909918199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748174	hybrid			2022-12-27	WOS:000087485000085
J	Brahms, H; Raymackers, J; Union, A; de Keyser, F; Meheus, L; Luhrmann, R				Brahms, H; Raymackers, J; Union, A; de Keyser, F; Meheus, L; Luhrmann, R			The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; MONOCLONAL-ANTIBODIES; D AUTOANTIGEN; ARGININE METHYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; AUTOIMMUNE-DISEASES; SNRNP PROTEINS; U1 SNRNP; IN-VITRO	The Sm proteins B/B', D1, D2, D3, E, F, and G are components of the small nuclear ribonucleoproteins U1, U2, U4/U6, and U5 that are essential for the splicing of pre-mRNAs in eukaryotes. D1 and D3 are among the most common antigens recognized by anti-Sm autoantibodies, an autoantibody population found exclusively in patients afflicted with systemic lupus erythematosus. Here we demonstrate by protein sequencing and mass spectrometry that all arginines in the C-terminal arginine-glycine (RG) dipeptide repeats of the human Sm proteins D1 and D3, isolated from HeLa small nuclear ribonucleoproteins, contain symmetrical dimethylarginines (sDMAs), a posttranslational modification thus far only identified in the myelin basic protein. The further finding that human D1 individually overexpressed in baculovirus-infected insect cells contains asymmetrical dimethyl-arginines suggests that the symmetrical, dimethylation of the RG repeats in D1 and D3 is dependent on the assembly status of D1 and D3. In antibody binding studies, 10 of 11 anti-Sm patient sera tested, as web as the monoclonal antibody Y12, reacted with a chemically synthesized C-terminal. peptide of DI containing sDMA, but not with peptides containing asymmetrically modified or nonmodified arginines. These results thus demonstrate that the sDMA-modified C terminus of D1 forms a major linear epitope for anti-Sm autoantibodies and Y12 and further suggest that posttranslational modifications of Sm proteins play a role in the etiology of systemic lupus erythematosus.	Innogenet NV, B-9052 Ghent, Belgium; Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany; Max Planck Inst Biophys Chem, Dept Cellular Biochem, D-37070 Gottingen, Germany; Ghent Univ Hosp, Dept Rheumatol, B-9000 Ghent, Belgium	Innogenetics NV; Max Planck Society; Ghent University; Ghent University Hospital	Meheus, L (corresponding author), Innogenet NV, Ind Zwijnaarde 7,Box 4, B-9052 Ghent, Belgium.	Lydie_Meheus@innogenetics.com; R.Luehrmann@gwdg.de						Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; BACH M, 1990, METHOD ENZYMOL, V181, P232; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; BARAKAT S, 1990, CLIN EXP IMMUNOL, V81, P256; Brahms H, 1997, ARTHRITIS RHEUM-US, V40, P672, DOI 10.1002/art.1780400412; Branston N M, 1982, Neurol Res, V4, P1; Burge CB, 1999, RNA WORLD, P525; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; COOPER M, 1995, EMBO J, V14, P2066, DOI 10.1002/j.1460-2075.1995.tb07198.x; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; Fury M, 1999, J AUTOIMMUN, V12, P91, DOI 10.1006/jaut.1998.0266; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; Hasegawa H, 1998, ARTHRITIS RHEUM-US, V41, P1040, DOI 10.1002/1529-0131(199806)41:6<1040::AID-ART10>3.0.CO;2-2; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; HIRAKATA M, 1993, J IMMUNOL, V150, P3592; HOCH SO, 1994, MANUAL BIOL MARKERS, P1; JAMES JA, 1994, CLIN EXP IMMUNOL, V98, P419; JENSEN L, 1988, J AUTOIMMUN, V1, P73, DOI 10.1016/0896-8411(88)90078-9; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kim S, 1997, INT J BIOCHEM CELL B, V29, P743, DOI 10.1016/S1357-2725(97)00009-5; LEHMEIER T, 1994, P NATL ACAD SCI USA, V91, P12317, DOI 10.1073/pnas.91.25.12317; LEHMEIER T, 1990, NUCLEIC ACIDS RES, V18, P6475, DOI 10.1093/nar/18.22.6475; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MINOTA S, 1991, J IMMUNOL, V146, P2249; NELISSEN RLH, 1994, EMBO J, V13, P4113, DOI 10.1002/j.1460-2075.1994.tb06729.x; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; Ou YC, 1997, CLIN IMMUNOL IMMUNOP, V83, P310, DOI 10.1006/clin.1997.4355; PLESSEL G, 1994, MOL CELL BIOL, V14, P4160, DOI 10.1128/MCB.14.6.4160; POLLET DE, 1991, CLIN CHEM, V37, P1700; Pruijn GJM, 1997, J AUTOIMMUN, V10, P127, DOI 10.1006/jaut.1996.0123; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; RAWAL N, 1995, BBA-PROTEIN STRUCT M, V1248, P11, DOI 10.1016/0167-4838(94)00213-Z; Riemekasten G, 1998, J CLIN INVEST, V102, P754, DOI 10.1172/JCI2749; RIVKIN E, 1994, J AUTOIMMUN, V7, P119, DOI 10.1006/jaut.1994.1009; ROKEACH LA, 1992, GENE, V118, P247, DOI 10.1016/0378-1119(92)90195-U; ROKEACH LA, 1992, MOL BIOL REP, V16, P165, DOI 10.1007/BF00464704; ROKEACH LA, 1992, CLIN IMMUNOL IMMUNOP, V65, P315, DOI 10.1016/0090-1229(92)90163-I; ROKEACH LA, 1990, J IMMUNOL, V144, P1015; ROKEACH LA, 1988, P NATL ACAD SCI USA, V85, P4832, DOI 10.1073/pnas.85.13.4832; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROY J, 1995, MOL CELL BIOL, V15, P445, DOI 10.1128/MCB.15.1.445; RYMOND BC, 1993, P NATL ACAD SCI USA, V90, P848, DOI 10.1073/pnas.90.3.848; SABBATINI A, 1993, J RHEUMATOL, V20, P1679; Schellekens GA, 1998, J CLIN INVEST, V101, P273, DOI 10.1172/JCI1316; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TAX WJM, 1995, KIDNEY INT, V48, P666, DOI 10.1038/ki.1995.336; Union A, 1998, ARTHRITIS RHEUM, V41, pS84; Utz PJ, 1998, ARTHRITIS RHEUM, V41, P1152, DOI 10.1002/1529-0131(199807)41:7<1152::AID-ART3>3.0.CO;2-L; vanVenrooij WJ, 1995, CURR OPIN IMMUNOL, V7, P819, DOI 10.1016/0952-7915(95)80054-9; VONMUHLEN CA, 1995, SEMIN ARTHRITIS RHEU, V24, P323, DOI 10.1016/S0049-0172(95)80004-2; WAGATSUMA M, 1993, MOL IMMUNOL, V30, P1491, DOI 10.1016/0161-5890(93)90457-M; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8	60	242	257	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17122	17129		10.1074/jbc.M000300200	http://dx.doi.org/10.1074/jbc.M000300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747894	hybrid, Green Published			2022-12-27	WOS:000087392200101
J	Gamero, AM; Larner, AC				Gamero, AM; Larner, AC			Signaling via the T cell antigen receptor induces phosphorylation of Stat1 on serine 727	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; IFN-GAMMA; GENETIC-EVIDENCE; MICE LACKING; MAP KINASE; ACTIVATION; TRANSDUCTION; ZAP-70; ALPHA; TRANSCRIPTION	The Stat1 transcription factor plays a pivotal role in both, the antiviral and antigrowth actions of interferons. Stat1 acquires the ability to bind DNA by becoming phosphorylated on Tyr(701). However, to effectively stimulate gene transcription, it must also be phosphorylated on Ser(727). We show that engagement of T cell antigen receptor (TCR)/CD3 complex in either Jurkat cells or peripheral blood lymphocytes stimulates phosphorylation of Ser(727) but not Tyr(701) of Stat1. This process does not require the expression of tyrosine kinases Lck and Zap-70. Interestingly, pretreatment of T cells with the Src kinase inhibitor PP1 completely abrogated CD3-mediated serine phosphorylation of Stat1, whereas inhibitors to MEK1 and phosphatidylinositol 3-kinase had no effect. Phosphorylation of Ser(727) of Stat1 in T cells is not restricted to TCR/CD3 but also results when cells are stimulated via the costimulatory molecule CD28. The combination of CD3 and CD28 did not augment phosphorylation of Stat1 Ser(727). Surprisingly, Stat1-mediated transcriptional activity in response to IFN-alpha was enhanced with CD3 stimulation, whereas CD3 alone had little effect. These findings suggest that Stat1 is a signaling molecule in TCR signaling and may play a role in T cell function.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Larner, AC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave,NB-30, Cleveland, OH 44195 USA.				NCI NIH HHS [CA77741, CA77736] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077741, R01CA077736] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CHAN AC, 1994, J IMMUNOL, V152, P4758; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; Gerwien J, 1999, J IMMUNOL, V163, P1742; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Greenfield EA, 1998, CRIT REV IMMUNOL, V18, P389, DOI 10.1615/CritRevImmunol.v18.i5.10; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Su L, 1999, J BIOL CHEM, V274, P31770, DOI 10.1074/jbc.274.45.31770; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Welte T, 1999, SCIENCE, V283, P222, DOI 10.1126/science.283.5399.222; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	34	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16574	16578		10.1074/jbc.M910149199	http://dx.doi.org/10.1074/jbc.M910149199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748192	hybrid			2022-12-27	WOS:000087392200026
J	Kanoh, Y; Bandyopadhyay, G; Sajan, MP; Standaert, ML; Farese, RV				Kanoh, Y; Bandyopadhyay, G; Sajan, MP; Standaert, ML; Farese, RV			Thiazolidinedione treatment enhances insulin effects on protein kinase C-zeta/lambda activation and glucose transport in adipocytes of nondiabetic and Goto-Kakizaki type II diabetic rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; 3T3-L1 ADIPOCYTES; PHOSPHOINOSITIDE 3-KINASE; GLUT4 TRANSLOCATION; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; SKELETAL-MUSCLE; ADIPOSE-TISSUE; POTENTIAL ROLE; RESISTANCE; EXPRESSION	We evaluated effects of the thiazolidinedione, rosiglitazone, on insulin-induced activation of protein kinase C (PRC)-zeta/lambda and glucose transport in adipocytes of Goto-Kakizaki (GK)-diabetic and nondiabetic rats. Insulin effects on PKC-zeta/lambda and alpha-deoxyglucose uptake were diminished by approximately 50% in GK adipocytes, as compared with control adipocytes. This defect in insulin-induced PKC-zeta/lambda activation was associated with diminished activation of IRS-1-dependent phosphatidylinositol (PI) 3-kinase, and was accompanied by diminished phosphorylation of threonine 410 in the activation loop of PRC-zeta; in contrast, protein kinase B (PKB) activation and phosphorylation were not significantly altered, Rosiglitazone completely reversed defects in insulin-stimulated 2-deoxyglucose uptake, PKC zeta/lambda enzyme activity and PKC-zeta threonine 410 phosphorylation, but had no effect on PI 3-kinase activation or PKB activation/phosphorylation in GK adipocytes. Similarly, in adipocytes of nondiabetic rats, rosiglitazone provoked increases in insulin-stimulated 2-deoxyglucose uptake, PKC-zeta/lambda enzyme activity and phosphorylation of both threonine 410 activation loop and threonine 560 auto-phosphorylation sites in PKC-zeta, but had no effect on PI 3-kinase activation or PKB activation/phosphorylation. Our findings suggest that (a) decreased effects of insulin on glucose transport in adipocytes of GK diabetic rats are due at least in part to diminished phosphorylation/ activation of PKC-zeta/lambda, and (b) thiazolidinediones enhance glucose transport responses to insulin in adipocytes of both diabetic and nondiabetic rats through increases in phosphorylation/activation of PKC-zeta/lambda.	James A Haley Vet Hosp, Res Serv VAR 151, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida	Farese, RV (corresponding author), James A Haley Vet Hosp, Res Serv VAR 151, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	rfarese@com1.med.usf.edu	Farese, Robert/B-3605-2015		NIDDK NIH HHS [R01 DK065969, 2RO1DK38079-09A1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065969, R01DK038079] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELHALIM SM, 1995, DIABETES, V44, P1280, DOI 10.2337/diabetes.44.11.1280; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Begum N, 1998, METABOLISM, V47, P54, DOI 10.1016/S0026-0495(98)90193-7; BISBIS S, 1993, AM J PHYSIOL, V265, pE807, DOI 10.1152/ajpendo.1993.265.5.E807; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; FARESE RV, 1994, P NATL ACAD SCI USA, V91, P11040, DOI 10.1073/pnas.91.23.11040; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Krook A, 1997, DIABETES, V46, P2110, DOI 10.2337/diabetes.46.12.2110; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; ORourke CM, 1997, METABOLISM, V46, P192, DOI 10.1016/S0026-0495(97)90301-2; Pearson SL, 1996, BIOCHEM BIOPH RES CO, V229, P752, DOI 10.1006/bbrc.1996.1876; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shimaya A, 1997, EUR J ENDOCRINOL, V137, P693, DOI 10.1530/eje.0.1370693; Shulman GI, 1999, AM J CARDIOL, V84, p3J; SIZER KM, 1994, MOL CELL ENDOCRINOL, V103, P1, DOI 10.1016/0303-7207(94)90063-9; Song XM, 1999, DIABETES, V48, P664, DOI 10.2337/diabetes.48.3.664; Standaert ML, 1999, J BIOL CHEM, V274, P14074, DOI 10.1074/jbc.274.20.14074; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; Tafuri SR, 1996, ENDOCRINOLOGY, V137, P4706, DOI 10.1210/en.137.11.4706; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WEINSTEIN SP, 1993, METABOLISM, V42, P1365, DOI 10.1016/0026-0495(93)90139-F; YOUNG PW, 1995, DIABETES, V44, P1087, DOI 10.2337/diabetes.44.9.1087	33	64	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16690	16696		10.1074/jbc.M000287200	http://dx.doi.org/10.1074/jbc.M000287200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10749857	hybrid			2022-12-27	WOS:000087392200042
J	Beigneux, AP; Moser, AH; Shigenaga, JK; Grunfeld, C; Feingold, KR				Beigneux, AP; Moser, AH; Shigenaga, JK; Grunfeld, C; Feingold, KR			The acute phase response is associated with retinoid X receptor repression in rodent liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; TUMOR-NECROSIS-FACTOR; ACID TRANSPORT PROTEIN; MESSENGER-RNA LEVELS; GENE-EXPRESSION; SYRIAN-HAMSTERS; FATTY-ACIDS; PPAR-ALPHA; RAT-LIVER; DIFFERENTIAL EXPRESSION	The acute phase response (APR) is associated with decreased hepatic expression of many proteins involved in lipid metabolism. The nuclear hormone receptors peroxisome proliferator-activated receptor alpha (PPAR alpha) and liver X receptor (LXR) play key roles in regulation of hepatic lipid metabolism. Because heterodimerization with RXR is crucial for their action, we hypothesized that a decrease in RXR may be one mechanism to coordinately down-regulate gene expression during APR. We demonstrate that lipopolysaccharide (LPS) induces a rapid, dose-dependent decrease in RXR alpha, RXR beta, and RXR gamma proteins in hamster liver. Maximum inhibition was observed at 4 h for RXR alpha (62%) and RXR beta (50%) and at 2 h for RXR gamma (61%). These decreases were associated with a marked reduction in RXR alpha, RXR beta, and RXR gamma mRNA levels. Increased RNA degradation is likely responsible for the repression of RXR, because LPS did not decrease RXR beta and RXR gamma transcription and only marginally inhibited (38%) RXR alpha transcription. RXR repression was associated with decreased LXR alpha and PPAR alpha mRNA levels and reduced RXR.RXR, RXR.PPAR and RXR.LXR binding activities in nuclear extracts. Furthermore, LPS markedly decreased both basal and Wy-14,643-induced expression of acyl-CoA synthetase, a well characterized PPAR alpha target. The reduction in hepatic RXR levels alone or in association with other nuclear hormone receptors could be a mechanism for coordinately inhibiting the expression of multiple genes during the APR.	Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Dept Med, Metab Sect 111F,Med Serv, San Francisco, CA 94121 USA	University of California System; University of California San Francisco	Feingold, KR (corresponding author), Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Dept Med, Metab Sect 111F,Med Serv, 4150 Clement St, San Francisco, CA 94121 USA.	kfngld@itsa.ucsf.edu			NIAMS NIH HHS [AR 39639] Funding Source: Medline; NIDDK NIH HHS [DK 49448] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049448] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; Barclay TB, 1999, J PHARMACOL EXP THER, V290, P1250; BarreraHernandez G, 1996, J BIOL CHEM, V271, P9969, DOI 10.1074/jbc.271.17.9969; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Belury MA, 1998, TOXICOL APPL PHARM, V151, P254, DOI 10.1006/taap.1998.8443; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; BURKE PA, 1994, SURGERY, V116, P285; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE CF, 1985, J BIOL CHEM, V260, P4363; DiezFernandez C, 1996, BIOCHEM PHARMACOL, V51, P1159, DOI 10.1016/0006-2952(96)00030-5; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Feingold KR, 1996, J LIPID RES, V37, P223; FEINGOLD KR, 1993, J LIPID RES, V34, P2147; FEINGOLD KR, 1995, J LIPID RES, V36, P1474; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Fraser JD, 1997, J BIOL CHEM, V272, P13892, DOI 10.1074/jbc.272.21.13892; Frohnert BI, 1999, J BIOL CHEM, V274, P3970, DOI 10.1074/jbc.274.7.3970; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Hardardottir I, 1995, BIOCHEM SOC T, V23, P1013, DOI 10.1042/bst0231013; HARDARDOTTIR I, 1994, LYMPHOKINE CYTOK RES, V13, P161; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hirano T, 1998, Int Rev Immunol, V16, P249; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEIST M, 1995, AM J PATHOL, V146, P1220; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Memon RA, 1997, J LIPID RES, V38, P1620; Memon RA, 1999, BBA-MOL CELL BIOL L, V1440, P118, DOI 10.1016/S1388-1981(99)00120-1; Memon RA, 1998, AM J PHYSIOL-ENDOC M, V275, pE64, DOI 10.1152/ajpendo.1998.275.1.E64; Memon RA, 1998, AM J PHYSIOL-ENDOC M, V274, pE210, DOI 10.1152/ajpendo.1998.274.2.E210; MORROW JF, 1981, P NATL ACAD SCI-BIOL, V78, P4718, DOI 10.1073/pnas.78.8.4718; Nagao Y, 1998, J CELL BIOCHEM, V69, P189, DOI 10.1002/(SICI)1097-4644(19980501)69:2<189::AID-JCB9>3.0.CO;2-O; Navasa M, 1998, J LIPID RES, V39, P1220; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Reddy S, 1999, J BIOL CHEM, V274, P33050, DOI 10.1074/jbc.274.46.33050; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SONG C, 1995, ANN NY ACAD SCI, V761, P38, DOI 10.1111/j.1749-6632.1995.tb31367.x; STANLEY LA, 1988, EUR J BIOCHEM, V174, P31, DOI 10.1111/j.1432-1033.1988.tb14058.x; Sugawara A, 1998, ENDOCRINOLOGY, V139, P3030, DOI 10.1210/en.139.6.3030; TAKEYAMA N, 1990, AM J PHYSIOL, V259, pE498, DOI 10.1152/ajpendo.1990.259.4.E498; Theodorakis NG, 1999, AM J PHYSIOL-REG I, V276, pR1249, DOI 10.1152/ajpregu.1999.276.5.R1249; Trauner M, 1998, J CLIN INVEST, V101, P2092, DOI 10.1172/JCI1680; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Weiss RE, 1998, ENDOCRINOLOGY, V139, P4945, DOI 10.1210/en.139.12.4945	58	192	194	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16390	16399		10.1074/jbc.M000953200	http://dx.doi.org/10.1074/jbc.M000953200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747970	hybrid			2022-12-27	WOS:000087291400106
J	Wang, C; Deber, CM				Wang, C; Deber, CM			Peptide mimics of the M13 coat protein transmembrane segment - Retention of helix-helix interaction motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MEMBRANE ENVIRONMENTS; CONFORMATIONAL CHANGE; ESCHERICHIA-COLI; BACTERIOPHAGE; DOMAIN; DIMER; HYDROPHOBICITY; DIMERIZATION; MUTATIONS	Sequence-specific noncovalent helix-helix interactions between transmembrane (TM) segments in proteins are investigated by incorporating selected TM sequences into synthetic peptides using the construct CKKK-TM-KKK. The peptides are of suitable hydrophobicity for spontaneous membrane insertion, whereas formation of an N-terminal S-S bond can bring pairs of TM helices into proximity and promote their parallel orientation. Using the propensity of the protein to undergo thermally induced alpha-helix --> beta-sheet transitions as a parameter for helix stability, we compared the wild type and mutant (V29A and V31A) bacteriophage M13 coat proteins with their corresponding TM peptide constructs (M13 residues 24-42). Our results demonstrated that the relevant helix-helix tertiary contacts found in the intact proteins persist in the peptide mimics. Molecular dynamics simulations support the tight "two in-two out" dimerization motif for V31A consistent with mutagenesis data. The overall results reinforce the notion of TM segments as autonomous folding domains and suggest that the generic peptide construct provides a viable reductionist system for membrane protein structural and computational analysis.	Hosp Sick Children, Res Inst, Div Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Deber, CM (corresponding author), Hosp Sick Children, Res Inst, Div Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	deber@sickkids.on.ca						Adams PD, 1996, PROTEINS, V26, P257, DOI 10.1002/(SICI)1097-0134(199611)26:3<257::AID-PROT2>3.0.CO;2-B; ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; CAVALIERI SJ, 1976, J MOL BIOL, V102, P713, DOI 10.1016/0022-2836(76)90287-4; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Deber CM, 1996, NAT STRUCT BIOL, V3, P815, DOI 10.1038/nsb1096-815; DEBER CM, 1993, P NATL ACAD SCI USA, V90, P11648, DOI 10.1073/pnas.90.24.11648; DEBER CM, 1995, BIOPOLYMERS, V37, P295, DOI 10.1002/bip.360370503; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; GROVES JD, 1995, J BIOL CHEM, V270, P9097, DOI 10.1074/jbc.270.16.9097; Haigh NG, 1998, J MOL BIOL, V279, P19, DOI 10.1006/jmbi.1998.1778; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LI ZM, 1991, BIOCHEM BIOPH RES CO, V180, P687; LI ZM, 1993, J BIOL CHEM, V268, P4584; Liu LP, 1996, BIOPOLYMERS, V39, P465, DOI 10.1002/(SICI)1097-0282(199609)39:3<465::AID-BIP17>3.0.CO;2-A; LOO TW, 1994, J BIOL CHEM, V269, P7750; Lu LP, 1998, BIOPOLYMERS, V47, P41, DOI 10.1002/(SICI)1097-0282(1998)47:1<41::AID-BIP6>3.0.CO;2-X; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MAKINO S, 1975, J BIOL CHEM, V250, P4327; MCDONNELL PA, 1993, J MOL BIOL, V233, P447, DOI 10.1006/jmbi.1993.1523; NAKASHIMA Y, 1981, J BIOL CHEM, V256, P5792; NOZAKI Y, 1976, NATURE, V259, P335, DOI 10.1038/259335a0; Papavoine CHM, 1998, J MOL BIOL, V282, P401, DOI 10.1006/jmbi.1998.1860; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; RUSSEL M, 1991, MOL MICROBIOL, V5, P1607, DOI 10.1111/j.1365-2958.1991.tb01907.x; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; SPRUIJT RB, 1991, BIOCHEMISTRY-US, V30, P11147, DOI 10.1021/bi00110a018; SPRUIJT RB, 1989, BIOCHEMISTRY-US, V28, P9158, DOI 10.1021/bi00449a030; Stopar D, 1997, BIOCHEMISTRY-US, V36, P12268, DOI 10.1021/bi970747a; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12726, DOI 10.1021/bi00166a003; Williams KA, 1996, BIOCHEMISTRY-US, V35, P5145, DOI 10.1021/bi952897w	33	39	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16155	16159		10.1074/jbc.M000723200	http://dx.doi.org/10.1074/jbc.M000723200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747951	hybrid			2022-12-27	WOS:000087291400075
J	Wang, DF; Donner, DB; Warren, RS				Wang, DF; Donner, DB; Warren, RS			Homeostatic modulation of cell surface KDR and Flt1 expression and expression of the vascular endothelial cell growth factor (VEGF) receptor mRNAs by VEGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PERMEABILITY FACTOR; TYROSINE KINASE; UP-REGULATION; SIGNAL-TRANSDUCTION; IN-VIVO; DEVELOPMENTAL EXPRESSION; MESSENGER-RNA; FACTOR GENE; PLC-GAMMA	Vascular endothelial cell growth factor (VEGF) is a potent angiogenic factor expressed during embryonic development, during wound healing, and in pathologies dependent on neovascularization, including cancer. Regulation of the receptor tyrosine kinases, KDR and Flt-1, to which VEGF binds on endothelial cells is incompletely understood. Chronic incubation with tumor-conditioned medium or VEGF diminished I-125-VEGF binding to human umbilical vein endothelial cells, incorporation of I-126-VEGF into covalent complexes with KDR and Flt1, and immunoreactive KDR in cell lysates, Receptor down-regulation desensitized VEGF activation of mitogen-activated protein kinase (extracellular signal-regulated kinases 1 and 2) and p38 mitogen-activated protein kinase, Preincubation with VEGF or tumor-conditioned medium down-regulated cell surface receptor expression but up-regulated KDR and Flt-1 mRNAs, an effect abrogated by a neutralizing VEGF antibody. Removal of VEGF from the medium led to recovery of I-125-VEGF binding and resensitization of human umbilical vein endothelial cells. Recovery of receptor expression was inhibited by cycloheximide, indicating that augmented VEGF receptor mRNAs, and not receptor recycling from a cytoplasmic pool, restored responsiveness. As the VEGF receptors promote endothelial cell survival, proliferation, and other events necessary for angiogenesis, the noncoordinate regulation of VEGF receptor proteins and mRNAs suggests that human umbilical vein endothelial cells are protected against inappropriate or prolonged loss of VEGF receptors by a homeostatic mechanism important to endothelial cell function.	Univ Calif San Francisco, Dept Surg, Surg Oncol Lab, San Francisco, CA 94143 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	University of California System; University of California San Francisco; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Warren, RS (corresponding author), Univ Calif San Francisco, Dept Surg, Surg Oncol Lab, 533 Parnassus Ave,Rm U-372, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA084019, R01CA067891, R29CA052863, R55CA067891] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84019, CA52863, CA67891] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Ankoma-Sey V, 1998, ONCOGENE, V17, P115, DOI 10.1038/sj.onc.1201912; Barleon B, 1997, CANCER RES, V57, P5421; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; BREIER G, 1992, DEVELOPMENT, V114, P521; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; BROWN LF, 1993, AM J PATHOL, V143, P1255; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Claffey KP, 1996, CANCER METAST REV, V15, P165, DOI 10.1007/BF00437469; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONNOLLY DT, 1991, J CELL BIOCHEM, V47, P219, DOI 10.1002/jcb.240470306; Damert A, 1997, CANCER RES, V57, P3860; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOTO F, 1993, LAB INVEST, V69, P508; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Guo DQ, 2000, J BIOL CHEM, V275, P11216, DOI 10.1074/jbc.275.15.11216; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM J, 1993, NATURE, V262, P841; KOCH AE, 1994, J IMMUNOL, V152, P4149; Kremer C, 1997, CANCER RES, V57, P3852; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LI J, 1996, AM J PHYSIOL, V270, pH1808; MALDEN LT, 1989, INT J CANCER, V43, P380, DOI 10.1002/ijc.2910430305; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; MATHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MONACCI WT, 1993, AM J PHYSIOL, V264, P995; OHTANI H, 1993, LAB INVEST, V68, P520; PARK JE, 1994, J BIOL CHEM, V269, P25646; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SCHWEIKI D, 1993, J CLIN INVEST, V91, P2235; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1986, CANCER RES, V46, P5629; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Suzuki H, 1999, AM J PHYSIOL-GASTR L, V276, pG92, DOI 10.1152/ajpgi.1999.276.1.G92; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; THIEME H, 1995, DIABETES, V44, P98, DOI 10.2337/diabetes.44.1.98; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Warren RS, 1996, J BIOL CHEM, V271, P29483, DOI 10.1074/jbc.271.46.29483; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	79	60	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15905	15911		10.1074/jbc.M001847200	http://dx.doi.org/10.1074/jbc.M001847200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748050	hybrid			2022-12-27	WOS:000087291400041
J	Zhang, ZS; Torii, N; Furusaka, A; Malayaman, N; Hu, ZY; Liang, TJ				Zhang, ZS; Torii, N; Furusaka, A; Malayaman, N; Hu, ZY; Liang, TJ			Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; HBX PROTEIN; DNA-BINDING; 20S PROTEASOME; SACCHAROMYCES-CEREVISIAE; TRANSACTIVATION FUNCTION; TRANSCRIPTION MACHINERY; REGULATORY COMPLEX; ACTIVATION DOMAINS	Hepatitis B virus (HBV) has a unique fourth open reading frame coding for a 16.5-kDa protein known as hepatitis B virus X protein (HBX), The importance of HEX in the life cycle of HBV has been well established, but the underlying molecular function of HEX remains controversial. We previously identified a proteasome subunit PSMA7 that interacts specifically with HEX in the Saccharomyces cerevisiae two-hybrid system. Here we demonstrate that PSMC1, an ATPase-like subunit of the 19 S proteasome component, also interacts with HEX and PSMA7. Analysis of the interacting domains among PSMA7, PSMC1, and HEX by deletion and site-directed mutagenesis suggested a mutually competitive structural relationship among these polypeptides. The competitive nature of these interactions is further demonstrated using a modified yeast two-hybrid dissociator system. The crucial HEX sequences involved in interaction with PSMA7 and PSMC1 are important for its function as a transcriptional coactivator. HEX, while functioning as a coactivator of AP-1 and acidic activator VP-16 in mammalian cells, had no effect on the transactivation function of their functional orthologs GCN4 and Ga14 in yeast. Overexpression of PSMC1 seemed to suppress the expression of various reporters in mammalian cells; this effect, however, was overcome by coexpression of HEX. In addition, HEX expression inhibited the cellular turnover of c-Jun and ubiquitin-Arg-P-galactosidase, two well known substrates of the ubiquitin-proteasome pathway. Thus, interaction of HEX with the proteasome complex in metazoan cells may underlie the functional basis of proteasome as a cellular target of HEX.	NIDDK, Liver Dis Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Liang, TJ (corresponding author), NIDDK, Liver Dis Sect, NIH, 10 Ctr Dr,Rm 9B16, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK054500, Z01DK054500, Z01DK054502] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARII M, 1992, ONCOGENE, V7, P397; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARUNA Y, 1991, HEPATOLOGY, V13, P417, DOI 10.1002/hep.1840130306; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HINNEBUSCH AG, 1985, P NATL ACAD SCI USA, V82, P498, DOI 10.1073/pnas.82.2.498; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KWEE L, 1992, J VIROL, V66, P4382, DOI 10.1128/JVI.66.7.4382-4389.1992; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Lin Y, 1998, J BIOL CHEM, V273, P27097, DOI 10.1074/jbc.273.42.27097; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1992, J BIOL CHEM, V267, P10515; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; REMACHA M, 1988, J BIOL CHEM, V263, P9094; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; Wang HD, 1998, MOL CELL BIOL, V18, P7086, DOI 10.1128/MCB.18.12.7086; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; ZAHM P, 1988, ONCOGENE, V3, P169; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	56	121	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15157	15165		10.1074/jbc.M910378199	http://dx.doi.org/10.1074/jbc.M910378199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748218	hybrid			2022-12-27	WOS:000087128300054
J	Zeng, Q; Si, XN; Horstmann, H; Xu, Y; Hong, WJ; Pallen, CJ				Zeng, Q; Si, XN; Horstmann, H; Xu, Y; Hong, WJ; Pallen, CJ			Prenylation-dependent association of protein-tyrosine phosphatases PRL-1,-2, and-3 with the plasma membrane and the early endosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAB GERANYLGERANYL TRANSFERASE; FARNESYLTRANSFERASE INHIBITORS; TUMOR-SUPPRESSOR; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; NUCLEAR-LOCALIZATION; CAAX MOTIF; GROWTH; GENE; IDENTIFICATION; GOLGI	PRL-1, -2, and -3 represent a novel class of protein-tyrosine phosphatase with a C-terminal prenylation motif. Although PRL-1 has been suggested to be associated with the nucleus, the presence of three highly homologous members and the existence of a prenylation motif call for a more detailed examination of their subcellular localization. In the present study, we first demonstrate that mouse PRL-1, -2, and -3 are indeed prenylated. Examination of N-terminal epitope-tagged PRL-1, -2, and -3 expressed in transiently transfected cells suggests that PRL-1, -2, and -3 are present on the plasma membrane and intracellular punctate structures. Stable Chinese hamster ovary cells expressing PRL-1 and -3 in an inducible manner were established. When cells were treated with brefeldin A, PRL-1 and -3 accumulated in a collapsed compact structure around the microtubule-organizing center. Furthermore, PRL-1 and -3 redistributed into swollen vacuole-like structures when cells were treated with wortmannin. These characteristics of PRL-1 and -3 are typical for endosomal proteins. Electron microscope immunogold labeling reveals that PRL-1 and -3 are indeed associated with the plasma membrane and the early endosomal compartment. Expression of PRL-3 is detected in the epithelial cells of the small intestine, where PRL-3 is present in punctate structures in the cytoplasm. When cells are treated with FTI-277, a selective farnesyltransferase inhibitor, PRL-1, -2, and -3 shifted into the nucleus. Furthermore, a mutant form of PRL-2 lacking the C-terminal prenylation signal is associated with the nucleus. These results establish that the primary association of PRL-1, -2, and -3 with the membrane of the cell surface and the early endosome is dependent on their prenylation and that nuclear localization of these proteins may be triggered by a regulatory event that inhibits their prenylation.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Pallen, CJ (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		HONG, Wanjin/E-9927-2010; ZENG, Qi/E-9812-2010	Pallen, Catherine/0000-0002-3576-5295				ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Gibbs JB, 1997, CURR OPIN CHEM BIOL, V1, P197, DOI 10.1016/S1367-5931(97)80010-5; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; Lowe SL, 1996, J CELL SCI, V109, P209; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MONTAGNA M, 1995, HUM GENET, V96, P532; MOORES SL, 1991, J BIOL CHEM, V266, P14603; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; Reaves BJ, 1996, J CELL SCI, V109, P749; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Rodriguez-Concepcion M, 1999, EMBO J, V18, P1996, DOI 10.1093/emboj/18.7.1996; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Sepp-Lorenzino L, 1998, J BIOL CHEM, V273, P20243, DOI 10.1074/jbc.273.32.20243; Shack S, 1999, ONCOGENE, V18, P6021, DOI 10.1038/sj.onc.1203002; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STERMER BA, 1994, J LIPID RES, V35, P1133; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; WALKER PA, 1994, BIO-TECHNOL, V12, P601, DOI 10.1038/nbt0694-601; Wong SH, 1998, MOL BIOL CELL, V9, P1549, DOI 10.1091/mbc.9.6.1549; Zeng Q, 1998, ANAL BIOCHEM, V259, P187, DOI 10.1006/abio.1998.2645; Zeng Q, 1998, BIOCHEM BIOPH RES CO, V244, P421, DOI 10.1006/bbrc.1998.8291; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang T, 1997, J CELL BIOL, V139, P1157, DOI 10.1083/jcb.139.5.1157; Zhao ZY, 1996, GENOMICS, V35, P172, DOI 10.1006/geno.1996.0336	54	178	208	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21444	21452		10.1074/jbc.M000453200	http://dx.doi.org/10.1074/jbc.M000453200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10747914	hybrid			2022-12-27	WOS:000088230600066
J	Castets, F; Rakitina, T; Gaillard, S; Moqrich, A; Mattei, MG; Monneron, A				Castets, F; Rakitina, T; Gaillard, S; Moqrich, A; Mattei, MG; Monneron, A			Zinedin, SG2NA, and striatin are calmodulin-binding, WD repeat proteins principally expressed in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTING COILED COILS; SEQUENCE ALIGNMENT; RAT; HYBRIDIZATION; NEURONS; SENSITIVITY; SUBUNIT; CLONING; FAMILY; GENES	Striatin is an intracellular protein characterized by four protein-protein interaction domains, a caveolin-binding motif, a coiled-coil structure, a calmodulin-binding domain, and a WD repeat domain, suggesting that it is a signaling or a scaffold protein. Down-regulation of striatin, which is expressed in a few subsets of neurons, impairs the growth of dendrites as well as rat locomotor activity (Bartoli, M., Ternaux, J. P., Forni, C., Portalier, P., Salin, P., Amalric, M,, and Monneron, A. (1999) J. Neurobiol. 40, 234-243). Zinedin, a "novel" protein described here, and SG2NA share with striatin identical protein-protein interaction domains and the same overall domain structure. A phylogenetic analysis supports the hypothesis that they constitute a multigenic family deriving from an ancestral gene. DNA probes and antibodies raised against specific domains of each protein showed that zinedin is mainly expressed in the central nervous system, whereas SG2NA, of more widespread occurrence, is mainly expressed in the brain and muscle. All three proteins are both cytosolic and membrane-bound. All three bind calmodulin in the presence of Ca2+. In rat brain, SG2NA and striatin are generally not found in the same neurons. Both localize to the soma and dendrites, suggesting that they share a similar type of addressing and closely related functions.	Univ Mediterranee, CNRS, FRE 9041, F-13402 Marseille 20, France; Russian Acad Sci, Chemyakin & Ovchinnikov Inst Bioorgan Chem, Dept Hormonal Regulat, Moscow 117871, Russia; Fac Med Marseille, INSERM, U491, F-13385 Marseille 5, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Castets, F (corresponding author), Univ Mediterranee, CNRS, FRE 9041, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.		Rakitina, Tatiana V/F-8694-2014	Rakitina, Tatiana V/0000-0002-3096-8659; moqrich, aziz/0000-0002-1937-1675; Gaillard, Stephane/0000-0001-9326-5363				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bartoli M, 1999, J NEUROBIOL, V40, P234, DOI 10.1002/(SICI)1097-4695(199908)40:2<234::AID-NEU9>3.3.CO;2-K; Bartoli M, 1998, J BIOL CHEM, V273, P22248, DOI 10.1074/jbc.273.35.22248; BARTOLI M, 1999, EUR C CELL BIOL BOOK, P136; BERCHTOLD MW, 1993, GENOMICS, V16, P461, DOI 10.1006/geno.1993.1211; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bernard V, 1997, J NEUROSCI, V17, P819; Castets F, 1996, J CELL BIOL, V134, P1051, DOI 10.1083/jcb.134.4.1051; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; Haeseleer F, 2000, J BIOL CHEM, V275, P1247, DOI 10.1074/jbc.275.2.1247; HOLLAND PWH, 1994, EVOLUTION DEV MECH, P125; Kachidian P, 1998, NEUROSCIENCE, V85, P111, DOI 10.1016/S0306-4522(97)00593-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; Liu MY, 1997, J BIOL CHEM, V272, P18801, DOI 10.1074/jbc.272.30.18801; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Moqrich A, 1998, GENOMICS, V51, P136, DOI 10.1006/geno.1998.5342; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MURO Y, 1995, BIOCHEM BIOPH RES CO, V207, P1029, DOI 10.1006/bbrc.1995.1288; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pebusque MJ, 1998, MOL BIOL EVOL, V15, P1145, DOI 10.1093/oxfordjournals.molbev.a026022; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Salin P, 1998, J COMP NEUROL, V397, P41; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	29	91	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19970	19977		10.1074/jbc.M909782199	http://dx.doi.org/10.1074/jbc.M909782199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748158	hybrid			2022-12-27	WOS:000087941300074
J	Champeil, P; Menguy, T; Tribet, C; Popot, JL; le Maire, M				Champeil, P; Menguy, T; Tribet, C; Popot, JL; le Maire, M			Interaction of amphipols with sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; MEMBRANE-PROTEIN INSERTION; NON-IONIC DETERGENTS; ADENOSINE-TRIPHOSPHATASE; NONIONIC DETERGENT; CALCIUM-PUMP; TRITON X-100; SOLUBILIZING CONCENTRATIONS; KINETIC CHARACTERIZATION; AMPHIPHILIC POLYMERS	Amphipols are short-chain amphipathic polymers designed to keep membrane proteins soluble in aqueous solutions. We have evaluated the effects of the interaction of amphipols with sarcoplasmic reticulum Ca2+- ATPase either in a membrane-bound or a soluble form. If the addition of amphipols to detergent-solubilized ATPase was followed by removal of detergent, soluble complexes formed, but these complexes retained poor ATPase activity, were not very stable upon long incubation periods, and at high concentrations they experienced aggregation. Nevertheless, adding excess detergent to diluted detergent-free ATPase-amphipol complexes incubated for short periods immediately restored full activity to these complexes, showing that amphipols had protected solubilized ATPase from the rapid and irreversible inactivation that otherwise follows detergent removal. Amphipols also protected solubilized ATPase from the rapid and irreversible inactivation observed in detergent solutions if the ATPase Ca2+ binding sites remain vacant. Moreover, in the presence of Ca2+, amphipol/detergent mixtures stabilized concentrated ATPase against inactivation and aggregation, whether in the presence or absence of lipids, for much longer periods of time (days) than detergent alone. Our observations suggest that mixtures of amphipols and detergents are promising media for handling solubilized Ca2+-ATPase under conditions that would otherwise lead to its irreversible denaturation and/or aggregation.	CEA Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; CEA Saclay, Sect Biophys Prot & Membranes, Dept Biol Cellulaire & Mol, F-91191 Gif Sur Yvette, France; Univ Paris 06, CNRS, UMR 7615, F-75231 Paris 05, France; Ecole Super Phys & Chim Ind Ville Paris, F-75231 Paris 05, France; CNRS, Inst Biol Physicochim, UPR 9052, F-75005 Paris, France	CEA; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Centre National de la Recherche Scientifique (CNRS)	Champeil, P (corresponding author), CEA Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France.	champeil@dsvidf.cea.fr	TRIBET, Christophe/N-3390-2019; TRIBET, christophe/C-2868-2008	TRIBET, Christophe/0000-0002-5953-0968; TRIBET, christophe/0000-0002-5953-0968				ANDERSEN JP, 1982, J BIOL CHEM, V257, P8300; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1983, EUR J BIOCHEM, V134, P205, DOI 10.1111/j.1432-1033.1983.tb07552.x; ANDERSEN JP, 1980, BIOCHIM BIOPHYS ACTA, V603, P84, DOI 10.1016/0005-2736(80)90393-4; ANDERSEN JP, 1986, BIOCHEMISTRY-US, V25, P6439, DOI 10.1021/bi00369a015; BICK RJ, 1991, ARCH BIOCHEM BIOPHYS, V286, P346, DOI 10.1016/0003-9861(91)90050-S; BORDEN KA, 1988, MACROMOLECULES, V21, P2649, DOI 10.1021/ma00186a059; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; Breyton C, 1997, J BIOL CHEM, V272, P21892, DOI 10.1074/jbc.272.35.21892; Cantor RS, 1997, BIOCHEMISTRY-US, V36, P2339, DOI 10.1021/bi9627323; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; Champeil P, 1998, J BIOL CHEM, V273, P6619, DOI 10.1074/jbc.273.12.6619; CHAMPEIL P, 1982, Z NATURFORSCH C, V37, P513; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; Champeil P., 1996, BIOMEMBR, V5, P43; CHIESI M, 1978, ARCH BIOCHEM BIOPHYS, V189, P132, DOI 10.1016/0003-9861(78)90125-X; CHU A, 1983, J BIOL CHEM, V258, P1656; Chung JC, 1996, MACROMOLECULES, V29, P4636, DOI 10.1021/ma9600522; CRAIG WS, 1982, BIOCHEMISTRY-US, V21, P2667, DOI 10.1021/bi00540a014; DEFORESTA B, 1989, BIOCHEMISTRY-US, V28, P2558, DOI 10.1021/bi00432a032; DEFORESTA B, 1994, EUR J BIOCHEM, V223, P359; deForesta B, 1996, EUR J BIOCHEM, V241, P343; DEGENNES PG, 1987, ADV COLLOID INTERFAC, V27, P189, DOI 10.1016/0001-8686(87)85003-0; deMeis L, 1996, BBA-BIOENERGETICS, V1275, P105, DOI 10.1016/0005-2728(96)00058-8; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; GERDES U, 1983, BIOCHIM BIOPHYS ACTA, V734, P180, DOI 10.1016/0005-2736(83)90116-5; HEEGAARD CW, 1990, J BIOL CHEM, V265, P12020; HERMANN R, 1981, BIOCHEMISTRY-US, V20, P5195, DOI 10.1021/bi00521a015; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; Killian JA, 1998, BBA-REV BIOMEMBRANES, V1376, P401, DOI 10.1016/S0304-4157(98)00017-3; Kragh-Hansen U, 1998, BIOPHYS J, V75, P2932, DOI 10.1016/S0006-3495(98)77735-5; KRAGHHANSEN U, 1993, BIOCHEMISTRY-US, V32, P1648, DOI 10.1021/bi00057a032; LEMAIRE M, 1987, BIOCHEMISTRY-US, V26, P4803, DOI 10.1021/bi00389a030; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LEMAIRE M, 1987, BIOCHEM J, V243, P399, DOI 10.1042/bj2430399; leMaire M, 1996, ACS SYM SER, V635, P36; LEMAIRE M, 1989, ANAL BIOCHEM, V177, P50, DOI 10.1016/0003-2697(89)90012-2; LEMAIRE M, 1978, J BIOL CHEM, V253, P7051; LEMAIRE M, 1986, SARCOPLASMIC RETICUL, P101; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LUND S, 1989, J BIOL CHEM, V264, P4907; MCINTOSH DB, 1985, BIOCHEMISTRY-US, V24, P1244, DOI 10.1021/bi00326a029; MCINTOSH DB, 1984, BIOCHEMISTRY-US, V23, P1959, DOI 10.1021/bi00304a012; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; Menguy T, 1998, ANAL BIOCHEM, V264, P141, DOI 10.1006/abio.1998.2854; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; Moller J. V., 1986, PROGR PROTEIN LIPID, P147; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MOLLER JV, 1988, METHOD ENZYMOL, V157, P261; NAVARRO J, 1984, BIOCHEMISTRY-US, V23, P130, DOI 10.1021/bi00296a021; PATERNOSTRE MT, 1988, BIOCHEMISTRY-US, V27, P2668, DOI 10.1021/bi00408a006; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; Porcar I, 1999, MACROMOLECULES, V32, P3922, DOI 10.1021/ma981805i; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; ROMANO VA, 1995, STRATEGIES SIZE EXCL, V635, P88; ROSS DC, 1987, J BIOL CHEM, V262, P2042; SIMMONDS AC, 1982, BIOCHIM BIOPHYS ACTA, V693, P398, DOI 10.1016/0005-2736(82)90447-3; SORENSON MM, 1977, BIOCHIM BIOPHYS ACTA, V465, P210, DOI 10.1016/0005-2736(77)90075-X; STAFFORD WF, 1992, ANAL ULTRACENTRIFUGA, P359; TIRRELL DA, 1985, ANN NY ACAD SCI, V446, P237, DOI 10.1111/j.1749-6632.1985.tb18404.x; Tribet C, 1996, P NATL ACAD SCI USA, V93, P15047, DOI 10.1073/pnas.93.26.15047; Tribet C, 1998, J PHYS CHEM B, V102, P1327, DOI 10.1021/jp973022p; Tribet C, 1997, LANGMUIR, V13, P5570, DOI 10.1021/la970136j; Tribet C, 1998, BIOCHIMIE, V80, P475, DOI 10.1016/S0300-9084(00)80014-0; VARSANYI M, 1983, EMBO J, V2, P1543, DOI 10.1002/j.1460-2075.1983.tb01621.x; VILSEN B, 1987, EUR J BIOCHEM, V170, P421, DOI 10.1111/j.1432-1033.1987.tb13716.x; VILSEN B, 1988, J CHROMATOGR, V442, P229, DOI 10.1016/S0021-9673(00)94471-6; WANG KT, 1988, POLYM BULL, V20, P577, DOI 10.1007/BF00263675; WANG TK, 1991, ACS SYM SER, V467, P218; Xia J., 1994, MACROMOLECULAR COMPL; YAMAMOTO T, 1982, J BIOCHEM, V91, P477, DOI 10.1093/oxfordjournals.jbchem.a133720; [No title captured]	77	86	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18623	18637		10.1074/jbc.M000470200	http://dx.doi.org/10.1074/jbc.M000470200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10747917	hybrid			2022-12-27	WOS:000087815900004
J	Klezovitch, O; Formato, M; Cherchi, GM; Weisgraber, KH; Scanu, AM				Klezovitch, O; Formato, M; Cherchi, GM; Weisgraber, KH; Scanu, AM			Structural determinants in the C-terminal domain of apolipoprotein E mediating binding to the protein core of human aortic biglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY ATHEROSCLEROTIC PLAQUES; DERMATAN SULFATE PROTEOGLYCANS; VASCULAR SMOOTH-MUSCLE; CELL-SURFACE RECEPTORS; DENSITY-LIPOPROTEIN; ALZHEIMERS-DISEASE; E APOPROTEIN; SUBENDOTHELIAL MATRIX; EXTRACELLULAR-MATRIX; AQUEOUS-SOLUTION	Apolipoprotein (apo) E-containing high density lipoprotein particles were reported to interact in vitro with the proteoglycan biglycan (Bg), but the direct participation of apoE in this binding was not defined. To this end, we examined the in vitro binding of apoE complexed with dimyristoylphosphatidylcholine (DMPC) to human aortic Bg before and after glycosaminoglycan (GAG) depletion. In a solid-phase assay, apoE DMPC bound to Bg and GAG-depleted protein core in a similar manner, suggesting a protein-protein mode of interaction. The binding was decreased in the presence of 1 M NaCl and was partially inhibited by either positively (0.2 M lysine, arginine) or negatively charged (0.2 nr aspartic, glutamic) amino acids. A recombinant apoE fragment representing the C-terminal 10-kDa domain, complexed with DMPC, bound as efficiently as full-length apoE, whereas the N-terminal 22-kDa domain was inactive. Similar results were obtained with a gel mobility shift assay. Competition studies using a series of recombinant truncated apoEs showed that the charged segment in the C-terminal domain between residues 223 and 230 was involved in the binding. Overall, our results demonstrate that the C-terminal domain contains elements critical for the binding of apoE to the Bg protein core and that this binding is ionic in nature and independent of GAGs.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Sassari, Dept Physiol Biochem & Cellular Sci, I-07100 Sassari, Italy; Univ Calif San Francisco, Dept Pathol, Cardiovasc Res Inst, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA	University of Chicago; University of Chicago; University of Sassari; University of California System; University of California San Francisco; The J David Gladstone Institutes	Klezovitch, O (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC5041, Chicago, IL 60637 USA.			Formato, Marilena/0000-0001-9207-5787	NHLBI NIH HHS [HL41633, HL63115-01, HL-18577] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633, P01HL018577, R01HL063115] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adler A J, 1973, Methods Enzymol, V27, P675; AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Aleshkov SB, 1999, BIOCHEMISTRY-US, V38, P8918, DOI 10.1021/bi982002q; ALHAKIM A, 1991, ANAL BIOCHEM, V195, P68, DOI 10.1016/0003-2697(91)90296-6; ASUNDI V, 1990, EUR J CELL BIOL, V52, P98; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; Boisvert WA, 1999, J LIPID RES, V40, P806; BRADLEY WA, 1982, BIOCHEM BIOPH RES CO, V109, P1360, DOI 10.1016/0006-291X(82)91927-1; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P524, DOI 10.1021/bi9819778; CAMEJO G, 1989, ATHEROSCLEROSIS, V79, P121, DOI 10.1016/0021-9150(89)90116-0; CASTANO EM, 1995, J BIOL CHEM, V270, P17610, DOI 10.1074/jbc.270.29.17610; CHANG CT, 1978, ANAL BIOCHEM, V91, P12; CHERCHI GM, 1994, BBA-LIPID LIPID MET, V1212, P345, DOI 10.1016/0005-2760(94)90209-7; COINU R, 1993, HAEMATOLOGICA, V78, P270; CRESPO P, 1990, BIOCHEM BIOPH RES CO, V168, P733, DOI 10.1016/0006-291X(90)92383-B; Davignon J, 1999, CLIN CHIM ACTA, V286, P115, DOI 10.1016/S0009-8981(99)00097-2; Desurmont C, 2000, ARTERIOSCL THROM VAS, V20, P435, DOI 10.1161/01.ATV.20.2.435; DONG LM, 1994, J BIOL CHEM, V269, P22358; EDELSTEIN C, 1972, J BIOL CHEM, V247, P5842; Forstner M, 1999, PROTEIN EXPRES PURIF, V17, P267, DOI 10.1006/prep.1999.1144; Hocking AM, 1998, MATRIX BIOL, V17, P1; HUANG DY, 1995, EXP NEUROL, V136, P251, DOI 10.1006/exnr.1995.1101; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1984, J BIOL CHEM, V259, P7261; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; Klezovitch O, 1998, J BIOL CHEM, V273, P23856, DOI 10.1074/jbc.273.37.23856; KRESSE H, 1994, EUR J CLIN CHEM CLIN, V32, P259; Krishnan P, 1999, J BIOL CHEM, V274, P10945, DOI 10.1074/jbc.274.16.10945; Linton MF, 1999, CURR OPIN LIPIDOL, V10, P97, DOI 10.1097/00041433-199904000-00003; Mahley RW, 1999, J LIPID RES, V40, P1; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1977, J BIOL CHEM, V252, P7279; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; MURATA K, 1989, ATHEROSCLEROSIS, V78, P69, DOI 10.1016/0021-9150(89)90160-3; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; OBRIEN KD, 1994, AM J PATHOL, V144, P538; OSWALD B, 1986, BIOCHEM BIOPH RES CO, V141, P158, DOI 10.1016/S0006-291X(86)80348-5; Paka L, 1999, J BIOL CHEM, V274, P36403, DOI 10.1074/jbc.274.51.36403; Pillot T, 1999, J NEUROCHEM, V72, P230, DOI 10.1046/j.1471-4159.1999.0720230.x; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; SALOMON RN, 1992, P NATL ACAD SCI USA, V89, P2814, DOI 10.1073/pnas.89.7.2814; SAXENA U, 1995, ARTERIOSCL THROM VAS, V15, P1240, DOI 10.1161/01.ATV.15.8.1240; SAXENA U, 1993, J BIOL CHEM, V268, P14812; STEVENS RL, 1976, J CLIN INVEST, V58, P470, DOI 10.1172/JCI108491; Tsukamoto K, 1999, ARTERIOSCL THROM VAS, V19, P2162, DOI 10.1161/01.ATV.19.9.2162; WASTY F, 1993, DIABETOLOGIA, V36, P316, DOI 10.1007/BF00400234; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	55	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18913	18918		10.1074/jbc.M909644199	http://dx.doi.org/10.1074/jbc.M909644199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10751422	hybrid			2022-12-27	WOS:000087815900041
J	Hale, TK; Myers, C; Maitra, R; Kolzau, T; Nishizawa, M; Braithwaite, AW				Hale, TK; Myers, C; Maitra, R; Kolzau, T; Nishizawa, M; Braithwaite, AW			Maf transcriptionally activates the mouse p53 promoter and causes a p53-dependent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; NUCLEAR ONCOPROTEIN; GENE-EXPRESSION; AP-1 SITE; KAPPA-B; V-MAF; FOS; APOPTOSIS; PROTEIN; DIFFERENTIATION	An increase in the level of the tumor suppressor protein p53 can induce cell cycle arrest or cell. death. Although mechanisms for regulating the life span of p53 have been described, there is growing evidence that transcriptional regulation of the p53 gene contributes significantly to controlling p53 protein levels and therefore the fate of a cell. However, the signal transduction pathways that lead to transcriptional activation of the p53 gene are poorly understood. The oncoprotein v-Maf and its cellular counterparts belong to the large combinatorially complex basic leucine zipper family of transcription factors, which include the AP1 family. To date few cellular targets of c-Maf have been identified, It is demonstrated here that v-Maf can bind as a homodimer to a variant Maf recognition element located between -66 and -54 upstream in the mouse p53 promoter. V-Maf and its cellular counterparts are shown to activate p53 expression through this site. The ability of v-Waf to activate p53 expression is modulated by AP1 family members. In addition, overexpression of v-Maf in primary cells leads to a p53-dependent cell death. Thus, Maf and members of the AP1 family are able to regulate p53 expression through this site in the p53 promoter.	Univ Otago, Dunedin Sch Med, Dept Pathol, Dunedin, New Zealand; Scripps Res Inst, Res Inst, La Jolla, CA 92037 USA	University of Otago; Scripps Research Institute	Hale, TK (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, POB 913, Dunedin, New Zealand.							Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Balint E, 1996, CANCER RES, V56, P1648; BELLETT AJD, 1979, J CELL PHYSIOL, V101, P33, DOI 10.1002/jcp.1041010106; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Feng ZW, 1998, ONCOGENE, V17, P2593, DOI 10.1038/sj.onc.1202195; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GINSBERG D, 1990, ONCOGENE, V5, P1285; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALE TK, 1995, NUCLEIC ACIDS RES, V23, P663, DOI 10.1093/nar/23.4.663; Hansen R, 1995, ONCOGENE, V11, P2535; Hansen RS, 1996, ONCOGENE, V13, P995; HARLOW E, 1989, IMMUNOBLOTTING LAB M, P471; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 1996, ONCOGENE, V12, P53; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; Lane D, 1998, NATURE, V394, P616, DOI 10.1038/29166; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Liebermann DA, 1998, INT J ONCOL, V12, P685; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McHenry JZ, 1998, ONCOGENE, V17, P1131, DOI 10.1038/sj.onc.1202044; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reed Michael, 1993, Gene Expression, V3, P95; RIDGWAY PJ, 1994, J VIROL, V68, P7178, DOI 10.1128/JVI.68.11.7178-7187.1994; Sakai M, 1997, ONCOGENE, V14, P745, DOI 10.1038/sj.onc.1200869; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOINI Y, 1992, VIRCHOWS ARCH A, V421, P415, DOI 10.1007/BF01606914; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUN XG, 1995, MOL CELL BIOL, V15, P4489; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163	54	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17991	17999		10.1074/jbc.M000921200	http://dx.doi.org/10.1074/jbc.M000921200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10747965	hybrid			2022-12-27	WOS:000087659400014
J	Abu-Soud, HM; Ichimori, K; Presta, A; Stuehr, DJ				Abu-Soud, HM; Ichimori, K; Presta, A; Stuehr, DJ			Electron transfer, oxygen binding, and nitric oxide feedback inhibition in endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SPECTROSCOPIC CHARACTERIZATION; CATALYTIC ACTIVITY; REDUCTASE DOMAIN; LOW-TEMPERATURE; L-ARGININE; TETRAHYDROBIOPTERIN; ACTIVATION; COMPLEX; CALMODULIN	We studied steps that make up the initial and steady-state phases of nitric oxide (NO) synthesis to understand how activity of bovine endothelial NO synthase (eNOS) is regulated. Stopped-flow analysis of NADPH-dependent flavin reduction showed the rate increased from 0.13 to 86 s(-1) upon calmodulin binding, but this supported slow heme reduction in the presence of either Arg or N-omega-hydroxy-L-arginine (0.005 and 0.014 s(-1), respectively, at 10 degrees C). O-2 binding to ferrous eNOS generated a transient ferrous dioxy species (Soret peak at 427 nm) whose formation and decay kinetics indicate it can participate in NO synthesis. The kinetics of heme-NO complex formation were characterized under anaerobic conditions and during the initial phase of NO synthesis. During catalysis heme-NO complex formation required buildup of relatively high solution NO concentrations (>50 nM), which were easily achieved with N-omega-hydroxy-L-arginine but not with Arg as substrate. Heme-NO complex formation caused eNOS NADPH oxidation and citrulline synthesis to decrease 3-fold and the apparent K-m for O-2 to increase 6-fold. Our main conclusions are: 1) The slow steady-state rate of NO synthesis by eNOS is primarily because of slow electron transfer from its reductase domain to the heme, rather than heme-NO complex formation or other aspects of catalysis. 2) eNOS forms relatively little heme-NO complex during NO synthesis from Arg, implying NO feedback inhibition has a minimal role. These properties distinguish eNOS from the other NOS isoforms and provide a foundation to better understand its role in physiology and pathology.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, NC-10,9500 Euclid Ave, Cleveland, OH 44195 USA.				NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Adak S, 1999, J BIOL CHEM, V274, P26907, DOI 10.1074/jbc.274.38.26907; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HEMMENS B, 1997, METHOD MOL BIOL, V100, P1; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; Igarashi J, 1999, P NATL ACAD SCI USA, V96, P12583, DOI 10.1073/pnas.96.22.12583; JONES DP, 1978, J BIOL CHEM, V253, P4874; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Moali C, 1998, BIOCHEMISTRY-US, V37, P10453, DOI 10.1021/bi980742t; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; Nelin LD, 1996, AM J PHYSIOL-HEART C, V271, pH8, DOI 10.1152/ajpheart.1996.271.1.H8; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Presta A, 1997, NITRIC OXIDE-BIOL CH, V1, P74, DOI 10.1006/niox.1996.0110; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Scheele JS, 1999, J BIOL CHEM, V274, P13105, DOI 10.1074/jbc.274.19.13105; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220	43	105	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17349	17357		10.1074/jbc.M000050200	http://dx.doi.org/10.1074/jbc.M000050200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10749853	hybrid			2022-12-27	WOS:000087485000021
J	Le, H; Browning, KS; Gallie, DR				Le, H; Browning, KS; Gallie, DR			The phosphorylation state of poly(A)-binding protein specifies its binding to poly(A) RNA and its interaction with eukaryotic initiation factor (eIF) 4F, eIFiso4F, and eIF4B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 4G EIF4G; TRANSLATION INITIATION; MESSENGER-RNA; WHEAT-GERM; FUNCTIONAL DOMAINS; ISOZYME FORM; SACCHAROMYCES-CEREVISIAE; 3T3-L1 CELLS; HEAT-SHOCK; CAP	The poly(A)-binding protein (PABP) interacts with the eukaryotic initiation factor (eIF) 4G (or eIFiso4G), the large subunit of eIF4F (or eIFiso4F) to promote translation initiation. In plants, PABP also interacts with eIF4B, a factor that assists eIF4F function. PABP is a phosphoprotein, although the function of its phosphorylation has not been previously investigated. In this study, we have purified the phosphorylated and hypophosphorylated isoforms of PABP from wheat to examine whether its phosphorylation state affects its binding to poly(A) RNA and its interaction with eIF4G, eIFiso4G, or elF4B, Phosphorylated PABP exhibited cooperative binding to poly(A) RNA even under non-stoichiometric binding conditions, whereas multiple molecules of hypophosphorylated PABP bound to poly(A) RNA only after free poly(A) RNA was no longer available. Together, phosphorylated and hypophosphorylated PABP exhibited synergistic binding. eIF4B interacted with PABP in a phosphorylation state-specific manner; native eIF4B increased the RNA binding activity specifically of phosphorylated PABP and was greater than 14-fold more effective than was recombinant eIF4B, whereas eIF4F promoted the cooperative binding of hypophosphorylated PABP, These data suggest that the phosphorylation state of PABP specifies the type of binding to poly(A) RNA and its interaction with its partner proteins.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of California System; University of California Riverside; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Gallie, DR (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	drgallie@citrus.ucr.edu						BAER BW, 1980, P NATL ACAD SCI-BIOL, V77, P1890, DOI 10.1073/pnas.77.4.1890; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; BROWNING KS, 1987, J BIOL CHEM, V262, P538; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; DRAWBRIDGE J, 1990, MOL CELL BIOL, V10, P3994, DOI 10.1128/MCB.10.8.3994; FENG L, 1994, MOL CELL BIOL, V14, P5139, DOI 10.1128/MCB.14.8.5139; Fraser CS, 1999, J BIOL CHEM, V274, P196, DOI 10.1074/jbc.274.1.196; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; GALLIE DR, 1994, J BIOL CHEM, V269, P7174; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; Gallie DR, 1998, PLANT J, V14, P715, DOI 10.1046/j.1365-313x.1998.00175.x; Gallie DR, 1997, J BIOL CHEM, V272, P1046, DOI 10.1074/jbc.272.2.1046; GALLIE DR, 1989, PLANT CELL, V1, P301, DOI 10.1105/tpc.1.3.301; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gallie DR, 1996, PLANT MOL BIOL, V32, P145, DOI 10.1007/BF00039381; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; Le H, 1998, J BIOL CHEM, V273, P20084, DOI 10.1074/jbc.273.32.20084; Le H, 1997, EUR J BIOCHEM, V243, P350, DOI 10.1111/j.1432-1033.1997.0350a.x; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Metz AM, 1996, J BIOL CHEM, V271, P31033, DOI 10.1074/jbc.271.49.31033; Metz AM, 1999, BIOCHEM BIOPH RES CO, V266, P314, DOI 10.1006/bbrc.1999.1814; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1993, BIOCHIMIE, V75, P985, DOI 10.1016/0300-9084(93)90149-M; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; Smith BL, 1997, J STRUCT BIOL, V119, P109, DOI 10.1006/jsbi.1997.3864; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; WEBSTER C, 1991, J BIOL CHEM, V266, P23341; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; ZANCHIN NIT, 1995, J BIOL CHEM, V270, P26505, DOI 10.1074/jbc.270.44.26505	48	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17452	17462		10.1074/jbc.M001186200	http://dx.doi.org/10.1074/jbc.M001186200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747998	hybrid			2022-12-27	WOS:000087485000035
J	Patel, YM; Lane, MD				Patel, YM; Lane, MD			Mitotic clonal expansion during preadipocyte differentiation: Calpain-mediated turnover of p27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; ADIPOCYTE DIFFERENTIATION; 3T3-L1 PREADIPOCYTES; C/EBP-ALPHA; CELL-CYCLE; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; DOWN-REGULATION; MICE LACKING; G1 PHASE	Evidence is presented that calpain, a calcium-activated protease, degrades the cyclin-dependent kinase inhibitor, p27, during the mitotic clonal expansion phase of 3T3-L1 preadipocyte differentiation. Calpain activity is required during an early stage of the adipocyte differentiation program. Thus, inhibition of calpain with N-acetyl-Leu-Leu-norleucinal (ALLN) blocks clonal expansion and acquisition of the adipocyte phenotype only when added between 12 and 24 h after the induction of differentiation. Likewise, inhibition of calpain by overexpression of calpastatin, the specific endogenous inhibitor of calpain, prevents a-day post-confluent preadipocytes from reentering the cell cycle triggered by the differentiation inducers, Inhibition of calpain with ALLN causes preadipocytes to arrest just prior to S phase and prevents phosphorylation of the retinoblastoma gene product, DNA replication, clonal expansion, and subsequent adipocyte differentiation but does not affect the expression of immediate early genes (i.e. fos, jun, C/EBP beta, and C/EBP delta), Inhibition of calpain by either ALLN or by overexpression of calpastatin blocks the degradation of p27, p27 is degraded in vitro by cell-free extracts from clonally expanding preadipocytes that contain "active" calpain brit not by extracts from pre-mitotic preadipocytes that do not. This action is inhibited by calpastatin or ALLN, Likewise, p27 in preadipocyte extracts is a substrate for purified calpain; this proteolytic action was inhibited by heat inactivation, EGTA, or ALLN. Thus, extracellular signals from the differentiation inducers appear to activate calpain, which degrades p27 allowing density-dependent inhibited preadipocytes to reenter the cell cycle and undergo mitotic clonal expansion.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Patel, YM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.							Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MCNKNIGHT SL, 1992, TRANSCRIPTIONAL REGU, P771; Mellgren RL, 1997, BIOCHEM BIOPH RES CO, V236, P555, DOI 10.1006/bbrc.1997.7003; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NEVINS JR, 1992, SCIENCE, V258, P424; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patel YM, 1999, P NATL ACAD SCI USA, V96, P1279, DOI 10.1073/pnas.96.4.1279; Phelps DE, 1998, CELL GROWTH DIFFER, V9, P595; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SCOTT RE, 1982, P NATL ACAD SCI-BIOL, V79, P845, DOI 10.1073/pnas.79.3.845; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; SMULSON ME, 1995, J BIOL CHEM, V270, P119, DOI 10.1074/jbc.270.1.119; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	41	157	166	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17653	17660		10.1074/jbc.M910445199	http://dx.doi.org/10.1074/jbc.M910445199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10749891	hybrid			2022-12-27	WOS:000087485000064
J	Iyer, S; Kontoyiannis, D; Chevrier, D; Woo, J; Mori, N; Cornejo, M; Kollias, G; Buelow, R				Iyer, S; Kontoyiannis, D; Chevrier, D; Woo, J; Mori, N; Cornejo, M; Kollias, G; Buelow, R			Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA CLASS-I; HEME OXYGENASE-1 HSP32; HEART GRAFT-SURVIVAL; ALPHA MESSENGER-RNA; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; ALLOGRAFT SURVIVAL; CROHNS-DISEASE; D-ISOMERS; MICE	Based on sequences of immunomodulatory peptides derived from the heavy chain of HLA Class I, novel immunomodulatory peptides with increased potency were developed by computer-aided rational design. Allotrap 1258 was characterized in detail and shown to inhibit cell-mediated immune responses in vitro and in vivo. Immunomodulatory activity was associated with the capability of the peptides to modulate heme oxygenase (HO) activity. In this study we analyzed the effect of Allotrap 1258 on cytokine expression. Allotrap 1258 inhibited concanavalin A- and lipopolysaccharide-induced human and mouse tumor necrosis factor (TNF) production in vitro and in vivo but had no effect on interleukin (IL)-1, IL-2, IL-4, IL-6, or IL-10 expression. Experiments with HO-1/KO and iNOS/KO mice showed that Allotrap 1258-mediated inhibition of TNF was independent of HO-1 and iNOS. Quantitation of TNF protein expression and mRNA steady state levels demonstrated that Allotrap 1258-mediated inhibition occurred at the translational level. Deletion of the AU-rich element in the 3'-untranslated region (UTR) of TNF mRNA, a region known to be involved in TNF mRNA translation, had minimal effect on Allotrap 1258-mediated inhibition. However, replacement of the TNF 3'-UTR with the human globin 3'-UTR rendered the peptide inactive. This demonstrates that besides AU-rich elements, other sequences in the 3'-UTR of TNF mRNA are involved in translational control of TNF expression. Such sequences are necessary for Allotrap 1258 mediated inhibition of TNF production.	SangStat, Transplant Co, Fremont, CA 94555 USA; Hellen Pasteur Inst, Genet Mol Lab, Athens 11521, Greece		Iyer, S (corresponding author), SangStat, Transplant Co, 6300 Dumbarton Circle, Fremont, CA 94555 USA.		Kollias, George/A-7079-2012	Kollias, George/0000-0003-1867-3150; Kontoyiannis, Dimitris/0000-0003-4682-9490				Alexopoulou L, 1997, EUR J IMMUNOL, V27, P2588, DOI 10.1002/eji.1830271018; BALLA J, 1995, AM J PHYSIOL-LUNG C, V268, pL321, DOI 10.1152/ajplung.1995.268.2.L321; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BUELOW R, 1995, TRANSPLANTATION, V59, P455; BUELOW R, 1995, TRANSPLANTATION, V59, P649, DOI 10.1097/00007890-199503150-00001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYBERGER C, 1993, TRANSPLANT P, V25, P477; CUTURI MC, 1995, TRANSPLANTATION, V59, P661, DOI 10.1097/00007890-199503150-00003; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; EWING JF, 1994, J PHARMACOL EXP THER, V271, P408; Gao L, 1996, J HEART LUNG TRANSPL, V15, P78; Grassy G, 1998, NAT BIOTECHNOL, V16, P748, DOI 10.1038/nbt0898-748; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Hanaway MJ, 1996, TRANSPLANTATION, V61, P1222, DOI 10.1097/00007890-199604270-00018; Hel Z, 1996, MOL CELL BIOL, V16, P5579; Hel Z, 1998, NUCLEIC ACIDS RES, V26, P2803, DOI 10.1093/nar/26.11.2803; Iyer S, 1998, J BIOL CHEM, V273, P2692, DOI 10.1074/jbc.273.5.2692; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kollias G, 1999, IMMUNOL REV, V169, P175, DOI 10.1111/j.1600-065X.1999.tb01315.x; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; KRUYS V, 1993, J EXP MED, V177, P1383, DOI 10.1084/jem.177.5.1383; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; MELLER J, 1987, NATURE, V325, P265; NISCO S, 1994, J IMMUNOL, V152, P3786; NOESSNER E, 1996, J EXP MED, V183, P339; Pasparakis Manolis, 1996, Cytokine and Growth Factor Reviews, V7, P223, DOI 10.1016/S1359-6101(96)00031-7; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; PROBERT L, 1993, J IMMUNOL, V151, P1894; Raju VS, 1996, J PHARMACOL EXP THER, V277, P1814; ROTHE J, 1993, NATURE, V364, P792; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TIEGS G, 1989, BIOCHEM PHARMACOL, V38, P627, DOI 10.1016/0006-2952(89)90208-6; VanDeventer SJH, 1997, GUT, V40, P443, DOI 10.1136/gut.40.4.443; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Woo J, 1997, TRANSPLANTATION, V64, P1460, DOI 10.1097/00007890-199711270-00015; WOO J, 1995, TRANSPLANTATION, V60, P1156, DOI 10.1097/00007890-199511270-00017; Woo J, 1998, TRANSPL IMMUNOL, V6, P84, DOI 10.1016/S0966-3274(98)80022-1	45	39	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17051	17057		10.1074/jbc.M909219199	http://dx.doi.org/10.1074/jbc.M909219199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748117	hybrid			2022-12-27	WOS:000087392200091
J	Saura, CA; Tomita, T; Soriano, S; Takahashi, M; Leem, JY; Honda, T; Koo, EH; Iwatsubo, T; Thinakaran, G				Saura, CA; Tomita, T; Soriano, S; Takahashi, M; Leem, JY; Honda, T; Koo, EH; Iwatsubo, T; Thinakaran, G			The nonconserved hydrophilic loop domain of presenilin (PS) is not required for PS endoproteolysis or enhanced A beta 42 production mediated by familial early onset Alzheimer's disease-linked PS variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; IN-VIVO; PROTEOLYTIC FRAGMENTS; MISSENSE MUTATIONS; BETA-CATENIN; CLEAVAGE; GENE; APOPTOSIS; COMPLEX; PHOSPHORYLATION	Presenilin 1 (PS1) and presenilin 2 (PS2) are polytopic membrane proteins that are mutated in the majority of early onset familial Alzheimer's disease (FAD) cases. Two lines of evidence establish a critical role for PS in the production of beta-amyloid peptides (A beta). FAD-linked PS mutations elevate the levels of highly amyloidogenic A beta ending at residue 42 (A beta 42), and cells with ablated PS1 alleles secrete low levels of A beta. Several recent reports have shown that the hydrophilic loop (HL) domain, located between transmembrane domains 6 and 7, contains sites for phosphorylation, caspase cleavage, and sequences that bind several PS-interacting proteins. In the present report, we examined the metabolism of PS polypeptides lacking the HL domain and the influence of these molecules on A beta production. We report that the deletion of the HL domain does not have a deleterious effect on the regulated endoproteolysis of PS, saturable accumulation of PS fragments, or the self-association of PS fragments. A beta production was not significantly altered in cells expressing HL-deleted PS polypeptides compared with cells expressing full-length PS. Importantly, deletion of the HL domain did not affect FAD mutation-mediated elevation in the production of A beta 42. Furthermore, the deletion of the HL domain did not impair the role of PS1 or PS2 in facilitating Notch processing. Thus, our results argue against a biologically or pathologically relevant role for the HL domain phosphorylation and caspase cleavage and the association of PS HL domain-interacting proteins, in amyloid precursor protein metabolism and A beta production or Notch cleavage.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Knapp Res Ctr R212, Chicago, IL 60637 USA; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Tokyo 1130033, Japan; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; RIKEN, Brain Sci Inst, Wako, Saitama 3510198, Japan	University of Chicago; University of Tokyo; University of California System; University of California San Diego; Johns Hopkins University; RIKEN	Thinakaran, G (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Knapp Res Ctr R212, 924 E 57th St, Chicago, IL 60637 USA.		Saura, Carlos A/D-2727-2011; Tomita, Taisuke/L-5427-2015; Saura, Carlos A/AFM-9239-2022	Saura, Carlos A/0000-0003-3692-5657; Tomita, Taisuke/0000-0002-0075-5943; 	NIA NIH HHS [1PO1 AG14248] Funding Source: Medline; NINDS NIH HHS [NS28121] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS028121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG014248] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berechid BE, 1999, CURR BIOL, V9, P1493, DOI 10.1016/S0960-9822(00)80121-9; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brockhaus M, 1998, NEUROREPORT, V9, P1481, DOI 10.1097/00001756-199805110-00043; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Grunberg J, 1998, BIOCHEMISTRY-US, V37, P2263, DOI 10.1021/bi972106l; Honda T, 1999, J NEUROCHEM, V72, P255, DOI 10.1046/j.1471-4159.1999.0720255.x; Kang DE, 1999, J NEUROSCI, V19, P4229; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sisodia SS, 1999, AM J HUM GENET, V65, P7, DOI 10.1086/302475; Stahl B, 1999, J BIOL CHEM, V274, P9141, DOI 10.1074/jbc.274.14.9141; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Thinakaran G, 1999, J CLIN INVEST, V104, P1321, DOI 10.1172/JCI8728; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	49	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17136	17142		10.1074/jbc.M909624199	http://dx.doi.org/10.1074/jbc.M909624199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748144	hybrid			2022-12-27	WOS:000087392200103
J	Joseph, SK; Bokkala, S; Boehning, D; Zeigler, S				Joseph, SK; Bokkala, S; Boehning, D; Zeigler, S			Factors determining the composition of inositol trisphosphate receptor hetero-oligomers expressed in COS cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITE; 1,4,5-TRISPHOSPHATE RECEPTOR; DOWN-REGULATION; K+ CHANNELS; TYPE-1; CA2+; CALCIUM; STOICHIOMETRY; LOCALIZATION; ASSOCIATION	COS-7 cells were transiently transfected with type I and type III myo-inositol 1,4,5-trisphosphate receptor (IP3R) isoforms to study the processes underlying assembly and oligomerization of these tetrameric proteins. A FLAG epitope was engineered on to the N terminus of the type III IP3R to distinguish the transfected from the endogenous isoform, This was not necessary for the type I IP3R since the endogenous levels of this isoform were extremely low. Based on sucrose gradient analysis, the transfected type I or FLAG-type III IP(3)Rs assembled into tetramers, Confocal immunofluorescence experiments confirmed that the constructs were primarily targeted to the endoplasmic reticulum, Recombinant type I IP3R expressed in COS cells over a 48-h period showed a negligible capacity to form hetero-oligomers with endogenous type III IP(3)Rs, based upon coimmunoprecipitation assays. However, substantial formation of hetero-oligomers was observed between recombinant receptors when the cells were simultaneously transfected with type I and FLAG-type III IP(3)Rs, Co-immunoprecipitation experiments using lysates from metabolically labeled cells allowed the quantitation of homo- and hetero-oligomers in cells transfected with different ratios of type I and FLAG-type III IP3R DNA. These studies show that the relative expression level of the two isoforms influences the fraction of hetero-oligomers formed. However, the proportion of hetero-oligomers formed were less than predicted by a binomial model in which the association of subunits is assumed to be random. In doubly transfected cells, the early kinetics of S-35 label incorporation into homotetramers showed a lag period corresponding to the time taken to synthesize a full-length receptor. However, hetero-oligomers were synthesized with a longer lag period, suggesting that there may be kinetic constraints that favor homo-oligomers over hetero-oligomers.	Thomas Jefferson Univ, Sch Med, Dept Pathol & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Joseph, SK (corresponding author), Thomas Jefferson Univ, Sch Med, Dept Pathol & Cell Biol, 1020 Locust St,Rm 230A JAH, Philadelphia, PA 19107 USA.	Suresh.Joseph@mail.tju.edu	Boehning, Darren/I-8539-2015	Boehning, Darren/0000-0001-7920-6922	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010971, T32AA007463] Funding Source: NIH RePORTER; NIAAA NIH HHS [T32-AA07463, R01-AA10971] Funding Source: Medline; NIGMS NIH HHS [R01-GM58574] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOEHNING D, 2000, IN PRESS J BIOL CHEM, V275; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; Cardy TJA, 1997, BIOCHEM J, V328, P785, DOI 10.1042/bj3280785; Cardy TJA, 1998, BIOCHEM J, V334, P447, DOI 10.1042/bj3340447; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; HOROWITZ MS, 1999, VIROLOGY, V39, P682; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Lin C, 2000, J BIOL CHEM, V275, P2305, DOI 10.1074/jbc.275.4.2305; Liu DT, 1998, NEURON, V21, P235, DOI 10.1016/S0896-6273(00)80530-9; Mak DOD, 2000, J GEN PHYSIOL, V115, P241, DOI 10.1085/jgp.115.3.241; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIKOSHIBA K, 1999, CALCIUM CELLULAR REG; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; Nucifora FC, 1996, MOL BIOL CELL, V7, P949, DOI 10.1091/mbc.7.6.949; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; Ramos-Franco J, 1998, BIOPHYS J, V75, P2783, DOI 10.1016/S0006-3495(98)77721-5; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sheng ZF, 1998, METHOD ENZYMOL, V293, P17; Tu LW, 1999, BIOPHYS J, V76, P2004, DOI 10.1016/S0006-3495(99)77358-3; WARD CL, 1994, J BIOL CHEM, V269, P25710; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 1998, MOL PHARMACOL, V53, P656, DOI 10.1124/mol.53.4.656; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591	40	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16084	16090		10.1074/jbc.M000506200	http://dx.doi.org/10.1074/jbc.M000506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747920	hybrid			2022-12-27	WOS:000087291400065
J	Bhattacharyya, R; Wedegaertner, PB				Bhattacharyya, R; Wedegaertner, PB			G alpha(13) requires palmitoylation for plasma membrane localization, Rho-dependent signaling, and promotion of p115-RhoGEF membrane binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; NUCLEOTIDE EXCHANGE FACTOR; HETEROTRIMERIC G-PROTEINS; LYSOPHOSPHATIDIC ACID; FATTY ACYLATION; LIPID MODIFICATIONS; FAMILY GTPASES; GROWTH-FACTOR; RGS PROTEINS; P115 RHOGEF	Most heterotrimeric G protein alpha subunits are covalently modified by palmitate attached to one or more N-terminal cysteine residues. Although a wide variety of proteins undergo palmitoylation, the role of this fatty acid modification in G protein signaling is not well understood. Thus, we examined the role of palmitoylation of alpha(13), a G protein alpha subunit that regulates many pathways involved in cell growth. Both N-terminal cysteines at positions 14 and 18 were required for palmitoylation. Mutant alpha(13), in which both cysteines were changed to serines, failed to localize to plasma membranes in transfected cells and failed to activate Rho-dependent serum response factor-mediated transcription and actin stress fiber formation. However, nonpalmitoylated, cysteine to serine mutant alpha(13) retained the ability to co-immunoprecipitate with a direct effector, p115-RhoGEF. Finally, we report the novel observation that activated alpha(13) induces a redistribution of p115-RhoGEF from the cytoplasm to plasma membranes, but non-palmitoylated mutants of alpha(13) fail to cause p115-RhoGEF translocation. These findings identify palmitoylation of alpha(13) as critical for its proper membrane localization and signaling and provide insight into the mechanism of activation of Rho-dependent signaling pathways by alpha(13).	Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University	Wedegaertner, PB (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, 23S S 10th St,839 BLSB, Philadelphia, PA 19107 USA.	P_Wedegaertner@lac.jci.tju.edu			NIGMS NIH HHS [GM56444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056444, R01GM056444, R56GM056444] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhamre S, 1998, J PHARMACOL EXP THER, V286, P1482; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CAMP LA, 1994, J BIOL CHEM, V269, P23212; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Das AK, 1997, J BIOL CHEM, V272, P11021; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALLAK H, 1994, J BIOL CHEM, V269, P4571; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jones TLZ, 1998, BIOCHEMISTRY-US, V37, P3196, DOI 10.1021/bi972253j; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Liu L, 1996, J BIOL CHEM, V271, P23269, DOI 10.1074/jbc.271.38.23269; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Schroeder H, 1996, J CELL BIOL, V134, P647, DOI 10.1083/jcb.134.3.647; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; Wise A, 1997, FEBS LETT, V407, P257, DOI 10.1016/S0014-5793(97)00300-1; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	58	74	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14992	14999		10.1074/jbc.M000415200	http://dx.doi.org/10.1074/jbc.M000415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747909	hybrid			2022-12-27	WOS:000087128300032
J	Lugardon, K; Raffner, R; Goumon, Y; Corti, A; Delmas, A; Bulet, P; Aunis, D; Metz-Boutigue, MH				Lugardon, K; Raffner, R; Goumon, Y; Corti, A; Delmas, A; Bulet, P; Aunis, D; Metz-Boutigue, MH			Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; MEDULLARY CHROMAFFIN GRANULES; RICH ANTIMICROBIAL PEPTIDES; TRACHEAL EPITHELIAL-CELLS; O-GLYCOSYLATION SITES; INNATE IMMUNITY; STAPHYLOCOCCUS-AUREUS; SECRETORY GRANULES; MESSENGER-RNA; DEFENSINS	Vasostatin-1, the natural N-terminal 1-76 chromogranin A (CGA)-derived fragment in bovine sequence, has been purified from chromaffin secretory granules and identified by sequencing and matrix-assisted laser desorption time-of-flight mass spectrometry. This peptide, which displays antibacterial activity against Gram-positive bacteria at micromolar concentrations, is also able to kill a large variety of filamentous fungi and yeast cells in the 1-10 mu M range. We have found that the C-terminal moiety of vasostatin-1 is essential for the antifungal activity, and shorter active peptides have been synthesized. In addition, from the comparison with the activity displayed by related peptides (human recombinant and rat synthetic fragments), we could determine that antibacterial and antifungal activities have different structural requirements. To assess for such activities in vivo, CGA and CGA-derived fragments were identified in secretory material released from human polymorphonuclear neutrophils upon stimulation. Vasostatin-1, which is stored in a large variety of cells (endocrine, neuroendocrine, and neurons) and which is liberated from stimulated chromaffin and immune cells upon stress, may represent a new component active in innate immunity.	INSERM, U338, F-67084 Strasbourg, France; Ist Sci San Raffaele, Dept Biol & Technol Res, I-20132 Milan, Italy; CNRS, Ctr Biophys Mol, UPR 4301, F-45071 Orleans, France; CNRS, Inst Biol Mol & Cellulaire, UPR 9022, F-67084 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Metz-Boutigue, MH (corresponding author), INSERM, U338, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	metz@neurochem.u-strasbg.fr	Dominique, Aunis/W-1419-2019; Corti, Angelo/F-7046-2012; BULET, Philippe/C-8557-2014	Corti, Angelo/0000-0002-0893-6191; Subba, Rajkrishna/0000-0003-0051-0062; BULET, Philippe/0000-0001-9016-265X				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; Atherton E., 1990, SOLID PHASE PEPTIDE; AUNIS D, 1977, J NEUROCHEM, V29, P439, DOI 10.1111/j.1471-4159.1977.tb10692.x; BEVINS CL, 1994, CIBA F SYMP, V186, P250; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BULET P, 1993, J BIOL CHEM, V268, P14893; Charlet M, 1996, J BIOL CHEM, V271, P21808, DOI 10.1074/jbc.271.36.21808; Ciesielski-Treska J, 1998, J BIOL CHEM, V273, P14339, DOI 10.1074/jbc.273.23.14339; COLIN DA, 1994, INFECT IMMUN, V62, P3184, DOI 10.1128/IAI.62.8.3184-3188.1994; Conlon JM, 1996, COMP BIOCHEM PHYS B, V114, P133, DOI 10.1016/0305-0491(95)02132-9; Corti A, 1997, EUR J BIOCHEM, V248, P692, DOI 10.1111/j.1432-1033.1997.00692.x; DEAKIN H, 1963, BIOCHEM J, V89, P296, DOI 10.1042/bj0890296; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; DILLEN L, 1993, NEUROCHEM INT, V22, P315, DOI 10.1016/0197-0186(93)90016-X; FINCKBARBANCON V, 1993, BIOCHIM BIOPHYS ACTA, V1182, P275, DOI 10.1016/0925-4439(93)90069-D; Gadroy P, 1998, J BIOL CHEM, V273, P34087, DOI 10.1074/jbc.273.51.34087; Gasparri A, 1997, J BIOL CHEM, V272, P20835, DOI 10.1074/jbc.272.33.20835; GENNARO R, 1991, BLOOD CELL BIOCH, V3, P335; Goumon Y, 1998, J BIOL CHEM, V273, P29847, DOI 10.1074/jbc.273.45.29847; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARWIG SSL, 1994, FEBS LETT, V342, P281, DOI 10.1016/0014-5793(94)80517-2; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; HELLE KB, 1990, NEUROCHEM INT, V17, P165, DOI 10.1016/0197-0186(90)90139-K; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; HOGUEANGELETTI R, 1996, ENDOCRINOLOGY, V137, P2918; HOGUEANGELETTI R, 1994, ACTA PHYSL SCAND, V152, P11; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IACANGELO AL, 1988, ENDOCRINOLOGY, V122, P2339, DOI 10.1210/endo-122-5-2339; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZURE C, 1990, PEPTIDES, V11, P79, DOI 10.1016/0196-9781(90)90114-K; Lee IH, 1997, FEBS LETT, V400, P158, DOI 10.1016/S0014-5793(96)01374-9; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LIANG F, 1995, ACTA PHYSIOL SCAND, V155, P23, DOI 10.1111/j.1748-1716.1995.tb09944.x; Metz-Boutigue MH, 1998, CELL MOL NEUROBIOL, V18, P249, DOI 10.1023/A:1022573004910; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; MEUNIER O, 1995, CYTOMETRY, V21, P241, DOI 10.1002/cyto.990210304; OSBORN RW, 1995, FEBS LETT, V368, P257, DOI 10.1016/0014-5793(95)00666-W; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; RUSSELL J, 1994, ENDOCRINOLOGY, V135, P337, DOI 10.1210/en.135.1.337; Russell JP, 1996, INFECT IMMUN, V64, P1565, DOI 10.1128/IAI.64.5.1565-1568.1996; SELSTED ME, 1995, TRENDS CELL BIOL, V5, P114, DOI 10.1016/S0962-8924(00)88961-8; SIMON JP, 1989, BIOCHEM J, V262, P1; SMITH AD, 1967, BIOCHEM J, V103, P483, DOI 10.1042/bj1030483; SOSZYNSKI D, 1993, J NEUROENDOCRINOL, V5, P655, DOI 10.1111/j.1365-2826.1993.tb00536.x; Strub JM, 1996, FEBS LETT, V379, P273, DOI 10.1016/0014-5793(95)01529-9; Strub JM, 1996, J BIOL CHEM, V271, P28533, DOI 10.1074/jbc.271.45.28533; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; Strub JM, 1997, J BIOL CHEM, V272, P11928, DOI 10.1074/jbc.272.18.11928; TARR GE, 1986, METHODS PROTEIN MICR, P162; TAUPENOT L, 1995, REGUL PEPTIDES, V56, P71, DOI 10.1016/0167-0115(95)00008-Y; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turquier V, 1999, ENDOCRINOLOGY, V140, P4104, DOI 10.1210/en.140.9.4104; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; Weiss J, 1994, Curr Opin Hematol, V1, P78; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1991, J BIOL CHEM, V266, P13130; Wu MH, 1999, J BIOL CHEM, V274, P29, DOI 10.1074/jbc.274.1.29; YOO SH, 1992, BIOCHEMISTRY-US, V31, P6134, DOI 10.1021/bi00141a025; Yoo SH, 1998, FEBS LETT, V427, P55, DOI 10.1016/S0014-5793(98)00393-7; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U; Zhao CQ, 1997, FEBS LETT, V412, P144, DOI 10.1016/S0014-5793(97)00769-2	70	135	143	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10745	10753		10.1074/jbc.275.15.10745	http://dx.doi.org/10.1074/jbc.275.15.10745			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753865	hybrid			2022-12-27	WOS:000086466600007
J	Ueda, Y; Gong, E; Royer, L; Cooper, PN; Francone, OL; Rubin, EM				Ueda, Y; Gong, E; Royer, L; Cooper, PN; Francone, OL; Rubin, EM			Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; REVERSE CHOLESTEROL TRANSPORT; CORONARY HEART-DISEASE; HUMAN APOLIPOPROTEIN-B; SR-BI; SELECTIVE UPTAKE; HDL CHOLESTEROL; TARGETED MUTATION; MICE; ATHEROSCLEROSIS	Both in vitro and in vivo studies of scavenger receptor class B type I (SR-BT) have implicated it as a likely participant in the metabolism of HDL cholesterol, To investigate the effect of SR-BI on atherogenesis, we examined two lines of SR-BI transgenic mice with high (10-fold increases) and low (2-fold increases) SR-BI expression in an inbred mouse background hemizygous for a human apolipoprotein (apo) B transgene, Unlike non-HDL cholesterol levels that minimally differed in the various groups of animals, HDL cholesterol levels were inversely related to SR-BI expression. Mice with the low expression SR-BI transgene had a 50% reduction in HDL cholesterol, whereas the high expression SR-BI transgene was associated with 2-fold decreases in HDL cholesterol as well as dramatic alterations in HDL composition and size including the near absence of alpha-migrating particles as determined by two-dimensional electrophoresis. The low expression SR-BI/apo B transgenics had more than a 2-fold decrease in the development of diet-induced fatty streak lesions compared with the apo B transgenics (4448 +/- 1908 mu m(2)/aorta to 10133 +/- 4035 mu m(2)/aorta; p < 0.001), whereas the high expression SR-BI/apo B transgenics had an atherogenic response similar to that of the apo B transgenics (14692 +/- 7238 mu m(2)/aorta) but 3-fold greater than the low SR-BI/apo E mice (p < 0.001), The prominent anti-atherogenic effect of moderate SR-BI expression provides in vivo support for the hypothesis that HDL functions to inhibit atherogenesis through its interactions with SR-BI in facilitating reverse cholesterol transport. The failure of the high SR-BI/apo B transgenics to have similar or even greater reductions in atherogenesis suggests that the changes resulting from extremely high SR-BI expression including dramatic changes in lipoproteins may have both pro- and anti-atherogenic consequences, illustrating the complexity of the relationship between SR-BI and atherogenesis.	Lawrence Berkeley Natl Lab, Genome Sci Dept, Berkeley, CA 94720 USA; Pfizer Inc, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Pfizer	Rubin, EM (corresponding author), Lawrence Berkeley Natl Lab, Genome Sci Dept, 1 Cyclotron Rd,MS-84-171, Berkeley, CA 94720 USA.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; CALLOW MJ, 1995, J CLIN INVEST, V96, P1639, DOI 10.1172/JCI118203; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; CHASE MB, 1998, CIRCULATION, V97, P202; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fluiter K, 1998, J BIOL CHEM, V273, P8434, DOI 10.1074/jbc.273.14.8434; Francone OL, 1997, J LIPID RES, V38, P813; Francone OL, 1996, J LIPID RES, V37, P1268; Griffin JH, 1999, J CLIN INVEST, V103, P219, DOI 10.1172/JCI5006; KEYS A, 1980, LANCET, V2, P603; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1999, CURR OPIN LIPIDOL, V10, P491, DOI 10.1097/00041433-199912000-00003; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; NISHINA PM, 1990, J LIPID RES, V31, P859; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Xu SZ, 1997, J LIPID RES, V38, P1289; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	32	158	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20368	20373		10.1074/jbc.M000730200	http://dx.doi.org/10.1074/jbc.M000730200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10751392	hybrid			2022-12-27	WOS:000088084500022
J	Zhang, W; Razani, B; Altschuler, Y; Bouzahzah, B; Mostov, KE; Pestell, RG; Lisanti, MP				Zhang, W; Razani, B; Altschuler, Y; Bouzahzah, B; Mostov, KE; Pestell, RG; Lisanti, MP			Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3) - Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; NITRIC-OXIDE SYNTHASE; RICH MEMBRANE DOMAINS; SRC TYROSINE KINASES; SMOOTH-MUSCLE CELLS; D7S522 LOCUS 7Q31.1; ROUS-SARCOMA VIRUS; IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; INTEGRIN RECEPTORS	Caveolin-1 is a principal component of caveolae membranes that may function as a transformation suppressor. For example, the human caveolin-1 gene is localized to a suspected tumor suppressor locus (D7S522; 7q31.1) that is deleted in human cancers, including mammary carcinomas. However, little is known about the role of caveolins in regulating cell movement, a critical parameter in determining metastatic potential. Here, we examine the role of caveolin-1 in cell movement. For this purpose, me employed an established cellular model, MTLn3, a metastatic rat mammary adenocarcinoma cell line. In this system, epidermal growth factor (EGF) stimulation induces rapid lamellipod extension and cell migration. Interestingly, we find that MTLn3 cells fail to express detectable levels of endogenous caveolin-1. To restore caveolin-1 expression in MTLn3 cells efficiently, we employed an inducible adenoviral gene delivery system to achieve tightly controlled expression of caveolin-1. We show here that caveolin-1 expression in MTLn3 cells inhibits EGF-stimulated lamellipod extension and cell migration and blocks their anchorage-independent growth, Under these conditions, EGF-induced activation of the p42/44 mitogen-activated protein kinase cascade is also blunted. Our results suggest that caveolin-1 expression in motile MTLn3 cells induces a non-motile phenotype.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco	Lisanti, MP (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, Rm 202,Golding Bldg,1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018	Lisanti, Michael/0000-0003-2034-1382; Razani, Babak/0000-0002-7172-9240; mostov, keith/0000-0002-8123-6247	NCI NIH HHS [CA-09060] Funding Source: Medline; NHLBI NIH HHS [P50-HL56399] Funding Source: Medline; NIGMS NIH HHS [T32-GM-07288] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACSADI G, 1994, HUM MOL GENET, V3, P579, DOI 10.1093/hmg/3.4.579; Bailly M, 1998, EXP CELL RES, V241, P285, DOI 10.1006/excr.1998.4031; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; BLAY J, 1985, J CELL PHYSIOL, V124, P107, DOI 10.1002/jcp.1041240117; Chan AY, 1998, J CELL SCI, V111, P199; Cospedal R, 1999, CARDIOVASC RES, V41, P708, DOI 10.1016/S0008-6363(98)00232-6; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; GROTENDORST GR, 1989, J CELL PHYSIOL, V139, P617, DOI 10.1002/jcp.1041390323; HOELTING T, 1994, J CLIN ENDOCR METAB, V79, P401, DOI 10.1210/jc.79.2.401; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; LICHTNER RB, 1993, CLIN EXP METASTAS, V11, P113, DOI 10.1007/BF00880072; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 1999, J BIOL CHEM, V274, P15781, DOI 10.1074/jbc.274.22.15781; NERI A, 1981, INT J CANCER, V28, P731, DOI 10.1002/ijc.2910280612; NERI A, 1982, J NATL CANCER I, V68, P507; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PEDERSEN PH, 1994, INT J CANCER, V56, P255, DOI 10.1002/ijc.2910560219; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Sipeki S, 1999, CELL SIGNAL, V11, P885, DOI 10.1016/S0898-6568(99)00060-1; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, CELL MOL BIOL, V43, P293; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; WELCH DR, 1983, INVAS METAST, V3, P65; Wells A, 2000, ADV CANCER RES, V78, P31; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F	62	122	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20717	20725		10.1074/jbc.M909895199	http://dx.doi.org/10.1074/jbc.M909895199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10748172	hybrid			2022-12-27	WOS:000088084500070
J	Maatta, A; Ruhrberg, C; Watt, RM				Maatta, A; Ruhrberg, C; Watt, RM			Structure and regulation of the envoplakin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INVOLUCRIN PROMOTER; ETS TRANSCRIPTION FACTORS; TRANSGENIC MICE; GENOMIC ORGANIZATION; INTERMEDIATE FILAMENTS; EPIDERMOLYSIS-BULLOSA; MUSCULAR-DYSTROPHY; EPITHELIAL-CELLS; PLAKIN FAMILY; CDNA CLONING	Envoplakin, a member of the plakin family of proteins, is a component of desmosomes and the epidermal cornified envelope. To understand how envoplakin expression is regulated, we have analyzed the structure of the mouse envoplakin gene and characterized the promoters of both the human and mouse genes. The mouse gene consists of 22 exons and maps to chromosome 11E1, syntenic to the location of the human gene on 17q25. The exon-intron structure of the mouse envoplakin gene is common to all members of the plakin family: the N-terminal protein domain is encoded by 21 small exons, and the central rod domain and the C-terminal globular domain are coded by a single large exon, The C terminus shows the highest sequence conservation between mouse and human envoplakins and between envoplakin and the other family members. The N terminus is also conserved, with sequence homology extending to Drosophila Kakapo. A region between nucleotides -101 and 288 was necessary for promoter activity in transiently transfected primary keratinocytes. This region is highly conserved between the human and mouse genes and contains at least two different positively acting elements identified by site-directed mutagenesis and electrophoretic mobility shift assays. Mutation of a GC box binding Sp1 and Sp3 proteins or a combined E box and Kruppel-like element interacting with unidentified nuclear proteins virtually abolished promoter activity. 600 base pairs of the mouse upstream sequence was sufficient to drive expression of a beta-galactosidase reporter gene in the suprabasal layers of epidermis, esophagus, and forestomach of transgenic mice, Thus, we have identified a regulatory region in the envoplakin gene that can account for the expression pattern of the endogenous protein in stratified squamous epithelia.	Imperial Canc Res Fund, Keratinocyte Lab, London WC2A 3PX, England	Cancer Research UK	Watt, RM (corresponding author), Imperial Canc Res Fund, Keratinocyte Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	f.watt@icrf.icnet.uk	Ruhrberg, Christiana/C-6404-2009	Ruhrberg, Christiana/0000-0002-3212-9381; Watt, Fiona/0000-0001-9151-5154; Maatta, Arto/0000-0003-3759-1310				Adams MJ, 1998, BIOCHEM J, V329, P165; Aho S, 1998, GENOMICS, V48, P242, DOI 10.1006/geno.1997.5188; Aho S, 1999, GENOMICS, V56, P160, DOI 10.1006/geno.1998.5704; Andra K, 1997, GENE DEV, V11, P3143, DOI 10.1101/gad.11.23.3143; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Burgeson RE, 1997, CURR OPIN CELL BIOL, V9, P651, DOI 10.1016/S0955-0674(97)80118-4; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; DiSepio D, 1999, DIFFERENTIATION, V64, P225, DOI 10.1046/j.1432-0436.1999.6440225.x; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; GREEN KJ, 1988, P NATL ACAD SCI USA, V85, P2613, DOI 10.1073/pnas.85.8.2613; Gregory SL, 1998, J CELL BIOL, V143, P1271, DOI 10.1083/jcb.143.5.1271; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; Ishida-Yamamoto A, 1998, EXP DERMATOL, V7, P1, DOI 10.1111/j.1600-0625.1998.tb00295.x; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; Jaakkola P, 1998, ONCOGENE, V17, P1279, DOI 10.1038/sj.onc.1202002; Jaakkola P, 1998, FASEB J, V12, P959, DOI 10.1096/fasebj.12.11.959; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; Kiyokawa C, 1998, J INVEST DERMATOL, V111, P1236, DOI 10.1046/j.1523-1747.1998.00449.x; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Lee JH, 1996, J BIOL CHEM, V271, P4561; Leung CL, 1999, J CELL BIOL, V147, P1275, DOI 10.1083/jcb.147.6.1275; LIN JH, 1995, P NATL ACAD SCI USA, V92, P679, DOI 10.1073/pnas.92.3.679; Lyon ME, 1986, MOUSE NEWS LETT, V74, P96; Maatta A, 1999, J BIOL CHEM, V274, P9891, DOI 10.1074/jbc.274.14.9891; Mahoney MG, 1998, J INVEST DERMATOL, V111, P308, DOI 10.1046/j.1523-1747.1998.00279.x; Marekov LN, 1998, J BIOL CHEM, V273, P17763, DOI 10.1074/jbc.273.28.17763; McLean WHI, 1996, GENE DEV, V10, P1724, DOI 10.1101/gad.10.14.1724; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Montgomery JC, 1997, MAMM GENOME, V7, pS190, DOI 10.1007/s003359900323; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; Nikolic B, 1996, J CELL BIOL, V134, P1455, DOI 10.1083/jcb.134.6.1455; Park GT, 1999, J BIOL CHEM, V274, P26599, DOI 10.1074/jbc.274.37.26599; Risk JM, 1999, GENOMICS, V59, P234, DOI 10.1006/geno.1999.5857; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; Ruhrberg C, 1997, J CELL BIOL, V139, P1835, DOI 10.1083/jcb.139.7.1835; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; Ruhrberg C, 1996, GENOMICS, V37, P381, DOI 10.1006/geno.1996.0573; Ruhrberg C, 1997, CURR OPIN GENET DEV, V7, P392, DOI 10.1016/S0959-437X(97)80154-2; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; Sato H, 1999, GENOMICS, V56, P303, DOI 10.1006/geno.1998.5721; Sato H, 1998, MAMM GENOME, V9, P20, DOI 10.1007/s003359900673; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; Smith FJD, 1996, NAT GENET, V13, P450, DOI 10.1038/ng0896-450; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; Strumpf D, 1998, J CELL BIOL, V143, P1259, DOI 10.1083/jcb.143.5.1259; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; TAMAI K, 1993, J CLIN INVEST, V92, P814, DOI 10.1172/JCI116655; Watt FM, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P113; WICHE G, 1991, J CELL BIOL, V114, P83, DOI 10.1083/jcb.114.1.83; Wiche G, 1998, J CELL SCI, V111, P2477; WICHE G, 1983, J CELL BIOL, V97, P887, DOI 10.1083/jcb.97.3.887; Yamada K, 1997, HUM MOL GENET, V6, P2223, DOI 10.1093/hmg/6.13.2223; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang YM, 1999, CELL, V98, P229, DOI 10.1016/S0092-8674(00)81017-X	65	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19857	19865		10.1074/jbc.M001028200	http://dx.doi.org/10.1074/jbc.M001028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10747979	hybrid			2022-12-27	WOS:000087941300059
J	Popov, SG; Krishna, UM; Falck, JR; Wilkie, TM				Popov, SG; Krishna, UM; Falck, JR; Wilkie, TM			Ca2+/calmodulin reverses phosphatidylinositol 3,4,5-trisphosphate-dependent inhibition of regulators of G protein-signaling GTPase-activating protein activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING; RGS PROTEINS; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; ALPHA-SUBUNITS; LIPID PRODUCTS; IN-VITRO; DOMAIN; ANALOGS; TRANSLOCATION	Regulators of G protein signaling (RGS proteins) are GTPase-activating proteins (GAPs) for G(i) and/or G(q) class G protein alpha subunits. RGS GAP activity is inhibited by phosphatidylinositol 3,4,5-trisphosphate (PIP3) but not by other lipid phosphoinositides or diacylglycerol. Both the negatively charged head group and long chain fatty acids (C16) are required for binding and inhibition of GAP activity. Amino acid substitutions in helix 5 within the RGS domain of RGS4 reduce binding affinity and inhibition by PIP3 but do not affect inhibition of GAP activity By palmitoylation. Conversely, the GAP activity of a palmitoylation-resistant mutant RGS4 is inhibited by PIP3. Calmodulin binds all RGS proteins we tested in a Ca2+-dependent manner but does not directly affect GAP activity. Indeed, Ca2+/calmodulin binds a complex of RGS4 and a transition state analog of G alpha(i1)-GDP-AlF4-. Ca2+/calmodulin reverses PIP3-mediated but not palmitoylation-mediated inhibition of GAP activity. Ca2+/calmodulin competition with PIP3 may provide an intracellular mechanism for feedback regulation of Ca2+ signaling evoked by G protein-coupled agonists.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wilkie, TM (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Falck, John/0000-0002-9219-7845	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47890] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arbuzova A, 1997, J BIOL CHEM, V272, P27167, DOI 10.1074/jbc.272.43.27167; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Diverse-Pierluissi MA, 1999, J BIOL CHEM, V274, P14490, DOI 10.1074/jbc.274.20.14490; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Dulin NO, 1999, MOL CELL BIOL, V19, P714; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Falck JR, 1999, TETRAHEDRON LETT, V40, P8771, DOI 10.1016/S0040-4039(99)01877-8; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hayashi N, 1997, J BIOL CHEM, V272, P7639, DOI 10.1074/jbc.272.12.7639; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Luo X, 1999, J BIOL CHEM, V274, P17684, DOI 10.1074/jbc.274.25.17684; MATSUBARA M, 1996, BIOCHEMISTRY-US, V35, P1451; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; OLWIN BB, 1983, METHOD ENZYMOL, V102, P148; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reddy KK, 1997, BIOORG MED CHEM LETT, V7, P2115, DOI 10.1016/S0960-894X(97)00370-3; REDDY KK, 1995, J ORG CHEM, V60, P3385, DOI 10.1021/jo00116a023; ROSS ER, 2000, IN PRSS ANN REV BIOC, V69; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yu JH, 1996, EMBO J, V15, P5184, DOI 10.1002/j.1460-2075.1996.tb00903.x; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhang XY, 1998, BIOCHEMISTRY-US, V37, P12395, DOI 10.1021/bi9807512; ZHENG B, 1999, IN PRESS ANN REV PHA	37	106	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18962	18968		10.1074/jbc.M001128200	http://dx.doi.org/10.1074/jbc.M001128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10747990	hybrid			2022-12-27	WOS:000087815900047
J	King, CC; Zenke, FT; Dawson, PE; Dutil, EM; Newton, AC; Hemmings, BA; Bokoch, GM				King, CC; Zenke, FT; Dawson, PE; Dutil, EM; Newton, AC; Hemmings, BA; Bokoch, GM			Sphingosine is a novel activator of 3-phosphoinositide-dependent kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; B-ALPHA; IN-VIVO; PHOSPHORYLATION; PDK1; IDENTIFICATION; INHIBITION; SITES	3-Phosphoinositide-dependent kinase 1 (PDK1) has preciously been shown to phosphorylate the activation loop of several AGC kinase family members. In this study we show that p21-activated kinase I, the activity of which is regulated by the GTP-bound form of Cdc42 and Rac and by sphingosine, is phosphorylated by PDK1. Phosphorylation of p21-activated kinase 1 by PDK1 occurred only in the presence of sphingosine, which increased PDK1 autophosphorylation 25-fold. Sphingosine increased PDK1 autophosphorylation in a concentration-dependent manner and significantly increased phosphate incorporation into known PDK1 substrates. Studies on the lipid requirement for PDK1 activation found that both sphingosine isoforms and stearlyamine also increased PDK1 autophosphorylation. However, C-10-sphingosine, octylamine, and stearic acid were unable to increase PDK1 autophosphorylation, indicating that both a positive charge and a lipid tail containing at least a C-10-carbon backbone were required for PDK1 activation. Three PDK1 autophosphorylation sites were identified after stimulation with sphingosine in a serine-rich region located between the kinase domain and the pleckstrin homology domain using two-dimensional phosphopeptide maps and matrix assisted laser desorption/ionization mass spectroscopy. Increased phosphorylation of endogenous Akt at threonine 308 was observed in COS-7 cells expressing wild type PDK1, but not catalytically inactive PDK1, when cellular sphingosine levels were elevated by treatment with sphingomyelinase. Sphingosine thus appears to be a true PDK1 activator.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego; Friedrich Miescher Institute for Biomedical Research	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol & Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bokoch@scripps.edu		Zenke, Frank/0000-0002-2226-3755	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154, R01GM039434] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43154, GM39434] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Fatatis A, 1997, J BIOL CHEM, V272, P4351, DOI 10.1074/jbc.272.7.4351; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; Hashizume T, 1996, J BIOCHEM-TOKYO, V120, P61; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	24	88	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18108	18113		10.1074/jbc.M909663199	http://dx.doi.org/10.1074/jbc.M909663199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748151	hybrid			2022-12-27	WOS:000087659400029
J	Terry, CF; Loukaci, V; Green, FR				Terry, CF; Loukaci, V; Green, FR			Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; ACUTE-PHASE RESPONSES; NF-KAPPA-B; DNA-BINDING; RHEUMATOID-ARTHRITIS; ESTROGEN-RECEPTOR; MULTIPLE-MYELOMA; FACTORS NF-IL6; CELLS PRODUCE	Interleukin 6 (IL6) plays key roles in hematopoiesis, immune, and acute phase responses. Dysregulated IL6 expression is implicated in diseases such as atherosclerosis and arthritis. We have examined the functional effect of four polymorphisms in the IL6 promoter (-597G-->A, -572G-->C, -373A(n)T(n), -174G-->C) by identifying the naturally occurring haplotypes and comparing their effects on reporter gene expression. The results indicate different transcriptional regulation in the ECV304 cell line compared with the HeLa cell line, suggesting cell type-specific regulation of IL6 expression. The haplotypes showed functional differences in the ECV304 cell line; transcription was higher from the GG9/11G haplotype and lower from the AG8/12G allele. The differences suggest that more than one of the polymorphic sites is functional; the base differences at distinct polymorphic sites do not act independently of one another, and one polymorphism influences the functional effect of variation at other polymorphic sites. These results show that genetic polymorphisms in the promoter influence IL6 transcription not by a simple additive mechanism but rather through complex interactions determined by the haplotype.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England; INSERM, SC7, F-75005 Paris, France	University of Oxford; Institut National de la Sante et de la Recherche Medicale (Inserm)	Green, FR (corresponding author), Wellcome Trust Ctr Human Genet, BHF Mol Cardiol Lab, Roosevelt Dr, Oxford OX3 7BN, England.	fronag@well.ox.ac.uk						AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; DEBENEDETTI F, 1991, ARTHRITIS RHEUM, V34, P1158, DOI 10.1002/art.1780340912; Fanning GC, 1997, TISSUE ANTIGENS, V50, P23, DOI 10.1111/j.1399-0039.1997.tb02829.x; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; Fey G H, 1990, Prog Liver Dis, V9, P89; Filella X, 1998, CYTOKINE, V10, P993, DOI 10.1006/cyto.1998.0387; Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; HIRANO T, 1987, P NATL ACAD SCI USA, V84, P228, DOI 10.1073/pnas.84.1.228; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Keavney B, 1998, HUM MOL GENET, V7, P1745, DOI 10.1093/hmg/7.11.1745; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KISHIMOTO T, 1992, CIBA F SYMP, V167, P5; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kopf M, 1995, ANN NY ACAD SCI, V762, P308; Mantovani L, 1998, FEBS LETT, V429, P426; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MAY LT, 1988, J BIOL CHEM, V263, P7760; McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PODOR TJ, 1989, ANN NY ACAD SCI, V557, P374; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1991, P NATL ACAD SCI USA, V88, P7086, DOI 10.1073/pnas.88.16.7086; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Ray P, 1997, FEBS LETT, V409, P79, DOI 10.1016/S0014-5793(97)00487-0; RODRIGUEZ C, 1994, FEBS LETT, V341, P156, DOI 10.1016/0014-5793(94)80448-6; SEINO Y, 1994, CYTOKINE, V6, P87, DOI 10.1016/1043-4666(94)90013-2; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; YOSHIZAKI K, 1989, BLOOD, V74, P1360	40	668	703	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18138	18144		10.1074/jbc.M000379200	http://dx.doi.org/10.1074/jbc.M000379200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10747905	hybrid			2022-12-27	WOS:000087659400033
J	Goh, ELK; Zhu, T; Yakar, S; LeRoith, D; Lobie, PE				Goh, ELK; Zhu, T; Yakar, S; LeRoith, D; Lobie, PE			CrkII participation in the cellular effects of growth hormone and insulin-like growth factor-1 - Phosphatidylinositol-3 kinase dependent and independent effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; STIMULATES TYROSINE PHOSPHORYLATION; FACTOR-I IGF; RECEPTOR SUBSTRATE-1; V-CRK; C-CRK; ACTIN CYTOSKELETON; SIGNALING MOLECULE; ADAPTER PROTEIN; ACTIVATION	We have examined the role of CrkII in the cellular response to both human growth hormone (hGH) and human insulin-like growth factor-1 (hIGF-1). We have demonstrated that overexpression of the adaptor molecule enhances both basal phosphatidylinositol 3-kinase (PI3-hinase) activity and also dramatically enhances the ability of both hormones to stimulate PI 3-kinase activity in the cell. Many of the effects of CrkII overexpression on hGH- and hIGF-1-stimulated cellular function can then be attributed to CrkII enhancement of PI 3-kinase stimulation by these hormones. Thus, CrkII-enhanced PI 3-kinase activity is used to enhance actin filament reorganization in response to both hGH and hIGF-1, to enhance stress activated protein kinase (SAPK) activity in response to hGH, and to diminish STAT5-mediated transcription in response to hGH. It is apparent, however, that CrkII also regulates cellular function independent of its ability to stimulate PI 3-kinase activity. This is evidenced by the ability of CrkII, in a PI 3-kinase-independent manner, to diminish the activation of p44/42 mitogen-activated protein kinase in response to both hGH and hIGF-1 and to inhibit the activation of SAPK by hIGF-1, Therefore, despite the common use of CrkII to activate PI 3-kinase, CrkII also allows hGH or hIGF-1 to selectively switch the activation of SAPK. Thus, common utilization of CrkII by hGH and hIGF-1 allows the execution of common cellular effects of these hormones, concomitant with the retention of hormonal specificity.	Inst Mol & Cell Biol, Singapore 117609, Singapore; NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Lobie, PE (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Goh, Eyleen/A-8006-2013	Goh, Eyleen/0000-0002-8244-6959				Al-Sakkaf KA, 1997, J MOL ENDOCRINOL, V19, P347, DOI 10.1677/jme.0.0190347; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Auger KR, 1996, J BIOL CHEM, V271, P23452, DOI 10.1074/jbc.271.38.23452; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BUTLER AA, 1994, MOL CELL ENDOCRINOL, V101, P321, DOI 10.1016/0303-7207(94)90249-6; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Fernandez L, 1998, ENDOCRINOLOGY, V139, P1815, DOI 10.1210/en.139.4.1815; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Goh ELK, 1997, ENDOCRINOLOGY, V138, P3207, DOI 10.1210/en.138.8.3207; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P433; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Li E, 1998, J VIROL, V72, P8806, DOI 10.1128/JVI.72.11.8806-8812.1998; Mak P, 1996, FEBS LETT, V397, P183, DOI 10.1016/S0014-5793(96)01179-9; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Nievers MG, 1997, J CELL SCI, V110, P389; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; Ota J, 1998, BIOCHEM BIOPH RES CO, V252, P779, DOI 10.1006/bbrc.1998.9445; Parrizas M, 1997, J BIOL CHEM, V272, P154; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Sorokin A, 1998, BIOCHEM J, V334, P595, DOI 10.1042/bj3340595; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682	42	18	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17683	17692		10.1074/jbc.M001972200	http://dx.doi.org/10.1074/jbc.M001972200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748058	hybrid			2022-12-27	WOS:000087485000068
J	Reese, JC; Zhang, Z; Kurpad, H				Reese, JC; Zhang, Z; Kurpad, H			Identification of a yeast transcription factor IID subunit, TSG2/TAF48	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; HISTONE-LIKE TAFS; IN-VIVO; PROMOTER SELECTIVITY; COMPLEX; ACTIVATION; TAF(II)S; SAGA; CORE; COACTIVATOR	The RNA polymerase II general transcription factor TFIID is a complex containing the TATA-binding protein (TBP) and associated factors (TAFs). We have used a mutant allele of the gene encoding yeast TAF(II)68/61p to analyze its function in vivo. We provide biochemical and genetic evidence that the C-terminal cw-helix of TAF(II)68/61p is required for its direct interaction with TBP, the stable incorporation of TBP into the TFIID complex, the integrity of the TFIID complex, and the transcription of most genes in vivo. This is the first evidence that a yeast TAF(II) other than TAF(II)145/130 interacts with TBP, and the implications of this on the interpretation of data obtained studying TAF(II) mutants in vivo are discussed. We have identified a high copy suppressor of the TAF68/61 mutation, TSG2, that has sequence similarity to a region of the SAGA subunit Ada1. We demonstrate that it directly interacts with TAF(II)68/61p in vitro, is a component of TFIID, is required for the stability of the complex in vivo, and is necessary for the transcription of many yeast genes. On the basis of these functions, we propose that Tsg(2)/TAF(II)48p is the histone 2A-like dimerization partner for the histone 2B-like TAF(II)68/61p in the yeast TFIID complex.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Reese, JC (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, 203 Althouse Lab, University Pk, PA 16802 USA.	jcr8@psu.edu		reese, joseph/0000-0003-3578-4266	NIGMS NIH HHS [R01 GM058672, GM58672] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058672] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Burley SK, 1997, CURR OPIN STRUC BIOL, V7, P94, DOI 10.1016/S0959-440X(97)80012-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Sanders SL, 2000, J BIOL CHEM, V275, P13895, DOI 10.1074/jbc.275.18.13895; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	38	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17391	17398		10.1074/jbc.M001635200	http://dx.doi.org/10.1074/jbc.M001635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10751405	hybrid			2022-12-27	WOS:000087485000026
J	Soulages, JL; Arrese, EL				Soulages, JL; Arrese, EL			Dynamics and hydration of the alpha-helices of apolipophorin III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT LIPOPROTEIN; AMPHIPATHIC HELIX; LIPID TRANSPORT; DIACYLGLYCEROL; SPECTROSCOPY; LIPOPHORIN; SURFACE; BINDING; STABILIZATION; FLUORESCENCE	Apolipophorin III (apoLp-III) is an exchangeable apolipoprotein whose structure is represented as a bundle of five amphipathic alpha-helices. In order to study the properties of the helical domains of apolipophorin III, we designed and obtained five single-tryptophan mutants of Locusta migratoria apoLp-III, The proteins were studied by UV absorption spectroscopy, time-resolved and steady-state fluorescence spectroscopy, and circular dichroism, Fluorescence anisotropy, near-UV CD and solute fluorescence quenching studies indicate that the Trp residues in helices 1 (N-terminal) and 5 (C-terminal) have the highest conformational flexibility, These two residues also showed the highest degree of hydration. Trp residues in helices 3 and 4 display the lowest mobility, as assessed by fluorescence anisotropy and near UV CD, The Trp residue in helix 2 is protected from the solvent but shows high mobility. As inferred from the properties of the Trp residues, helices 1 and 5 appear to have the highest conformational flexibility. Helix 2 has an intermediate mobility, whereas helices 3 and 4 appear to constitute a highly ordered domain. From the configuration of the helices in the tertiary structure of the protein, we estimated the relative strength of the five interhelical interactions of apoLp-III. These interactions can be ordered according to their apparent stabilizing strengths as: helix 3-helix 4 > helix 2-helix 3 > helix 4-helix 1 approximate to helix a-helix 5 > helix 1-helix 5, A new model for the conformational change that is expected to occur upon binding of the apolipoprotein to lipid is proposed. This model is significantly different from the currently accepted model (Breiter, D, R,, Kanost, M, R,, Benning, M. Ri,, Wesemberg, G,, Law, J, H,, Wells, M, A, Rayment, I., and Holden, M, (1991) Biochemistry 30, 603-608), The model presented here predicts that the relaxation of the tertiary structure and the concomitant exposure of the hydrophobic core take place through the disruption of the weak interhelical contacts between helices 1 and 5, To some extent, the weakness of the heir 1-helix 5 interaction would be due to the parallel arrangement of these helices.	Oklahoma State Univ, Dept Biochem & Mol Biol, Noble Res Ctr 355, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Soulages, JL (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Noble Res Ctr 355, Stillwater, OK 74078 USA.	jose@biochem.okstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055622, R01GM055622] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 55622] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; BLACKLOCK BJ, 1994, INSECT BIOCHEM MOLEC, V24, P855, DOI 10.1016/0965-1748(94)90015-9; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; EFTKIN MR, 1987, BIOCH BIOPHYS ACTA B, V91, P343; Eisenberg S., 1990, CURR OPIN LIPIDOL, V1, P205; ELWELL ML, 1977, BIOCHIM BIOPHYS ACTA, V494, P367, DOI 10.1016/0005-2795(77)90166-0; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; LAKOWICZ JR, 1994, PHOTOCHEM PHOTOBIOL, V60, P205, DOI 10.1111/j.1751-1097.1994.tb05092.x; Narayanaswami V, 1996, J BIOL CHEM, V271, P26855, DOI 10.1074/jbc.271.43.26855; POWNALL HJ, 1992, STRUCTURE FUNCTION A, P1; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1992, J LIPID RES, V33, P141; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; Soulages JL, 1996, BIOCHEMISTRY-US, V35, P5191, DOI 10.1021/bi952794d; Soulages JL, 1998, BIOCHEMISTRY-US, V37, P10203, DOI 10.1021/bi980622l; SOULAGES JL, 1994, BIOCHEMISTRY-US, V33, P3245, DOI 10.1021/bi00177a015; Soulages JL, 1998, BIOPHYS J, V75, P484, DOI 10.1016/S0006-3495(98)77537-X; SOULAGES JL, 1995, P NATL ACAD SCI USA, V92, P5650, DOI 10.1073/pnas.92.12.5650; Soulages JL, 1998, BIOCHEM BIOPH RES CO, V243, P372, DOI 10.1006/bbrc.1998.8099; SOULAGES JL, 1994, ADV PROTEIN CHEM, V45, P371; Sreerama N, 1999, PROTEIN SCI, V8, P370; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; Wang JJ, 1997, J BIOL CHEM, V272, P17912, DOI 10.1074/jbc.272.29.17912; WEERS PMM, 1994, BIOCHEMISTRY-US, V33, P3617, DOI 10.1021/bi00178a019; Weers PMM, 1998, BBA-LIPID LIPID MET, V1393, P99, DOI 10.1016/S0005-2760(98)00063-0; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249	29	23	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17501	17509		10.1074/jbc.M909661199	http://dx.doi.org/10.1074/jbc.M909661199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748149	hybrid			2022-12-27	WOS:000087485000042
J	Becchetti, A; Kemendy, AE; Stockand, JD; Sariban-Sohraby, S; Eaton, DC				Becchetti, A; Kemendy, AE; Stockand, JD; Sariban-Sohraby, S; Eaton, DC			Methylation increases the open probability of the epithelial sodium channel in A6 epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING TUBULE; RAS-RELATED PROTEINS; CARBOXYL METHYLATION; APICAL MEMBRANE; NA CHANNELS; BOVINE BRAIN; PARTIAL-PURIFICATION; ALDOSTERONE ACTION; CELL LINE; TRANSPORT	We used single channel methods on A6 renal cells to study the regulation by methylation reactions of epithelial sodium channels. 3-Deazaadenosine (3-DZA), a methyltransferase blocker, produced a 5-fold decrease in sodium transport and a 6-fold decrease in apical sodium channel activity by decreasing channel open probability (P-o). 3-Deazaadenosine also blocked the increase in channel open probability associated with addition of aldosterone. Sodium channel activity in excised "inside-out" patches usually decreased within 1-2 min; in the presence of S-adenosyl-L-methionine (AdoMet), activity persisted for 5-8 min. Sodium channel mean time open (t(open) ) before and after patch excision was higher in the presence of AdoMet than in untreated excised patches but less than t(open) in cell-attached patches. Sodium channel activity in excised patches exposed to both AdoMet and GTP usually remained stable for more than 10 min, and P-o and the number of active channels per patch were close to values in cell-attached patches from untreated cells. These findings suggest that a methylation reaction contributes to the activity of epithelial sodium channels in A6 cells and is directed to some regulatory element closely connected with the channel, whose activity also depends on the presence of intracellular GTP.	Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Cell & Mol Signaling, Atlanta, GA 30322 USA; Free Univ Brussels, Lab Physiol & Physiopathol, B-1070 Brussels, Belgium	Emory University; Emory University; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Eaton, DC (corresponding author), Emory Univ, Sch Med, Dept Physiol, 1648 Pierce Dr NE, Atlanta, GA 30322 USA.			Eaton, Douglas/0000-0002-2686-6692; Stockand, James/0000-0002-3817-4319	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037963] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK37963] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBADAWI NF, 1998, FASEB J, V12, P421; ASHER C, 1992, J BIOL CHEM, V267, P16061; Aswad DW, 1989, CURR OPIN CELL BIOL, V1, P1182, DOI 10.1016/S0955-0674(89)80069-9; BACKLUND PS, 1988, J BIOL CHEM, V263, P15864; BAXENDALE LM, 1987, FASEB J, V46, P495; BAXENDALECOX LM, 1999, AM J PHYSIOL, V273, pC1650; BECCHETTI A, 1994, FASEB J, V8, pA339; Bilodeau D, 1999, CELL SIGNAL, V11, P45, DOI 10.1016/S0898-6568(98)00030-8; BLAZERYOST B, 1982, BIOCHIM BIOPHYS ACTA, V719, P158, DOI 10.1016/0304-4165(82)90320-8; BlazerYost BL, 1997, AM J PHYSIOL-CELL PH, V272, pC1928, DOI 10.1152/ajpcell.1997.272.6.C1928; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; CHU LLH, 1972, J MEMBRANE BIOL, V10, P291, DOI 10.1007/BF01867862; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; COLQUHOUN D, 1983, FITTING STAT ANAL SI, P191; Desrosiers RR, 1999, ARCH BIOCHEM BIOPHYS, V367, P333, DOI 10.1006/abbi.1999.1283; EATON DC, 1991, MEMBRANE TRANSPORT B, P73; Frindt G, 1996, AM J PHYSIOL-RENAL, V271, pF1086; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; GARTY H, 1983, J GEN PHYSIOL, V81, P785, DOI 10.1085/jgp.81.6.785; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GEHEB M, 1984, BIOCHEM J, V218, P221, DOI 10.1042/bj2180221; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; GINGRAS D, 1992, BIOCHIM BIOPHYS ACTA, V1136, P150, DOI 10.1016/0167-4889(92)90250-F; HAMILTON KL, 1986, MEMBRANE BIOCHEM, V6, P149, DOI 10.3109/09687688609065447; HORISBERGER JD, 1992, HYPERTENSION, V19, P221, DOI 10.1161/01.HYP.19.3.221; ISMAILOV II, 1994, J BIOL CHEM, V269, P22193; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; KEMENDY AE, 1989, FASEB J, V3, P861; KLEYMAN TR, 1994, AM J PHYSIOL, V266, pF506, DOI 10.1152/ajprenal.1994.266.3.F506; LAHAV M, 1973, ENDOCRINOLOGY, V92, P1685, DOI 10.1210/endo-92-6-1685; LIEN EL, 1976, BIOCHIM BIOPHYS ACTA, V421, P210, DOI 10.1016/0304-4165(76)90287-7; LING BN, 1991, AM J PHYSIOL, V261, pF933, DOI 10.1152/ajprenal.1991.261.6.F933; Ling BN, 1997, J BIOL CHEM, V272, P594; LOBET Y, 1989, BIOCHIM BIOPHYS ACTA, V997, P224, DOI 10.1016/0167-4838(89)90191-X; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; MARUNAKA Y, 1991, AM J PHYSL, V260; Middleton P, 1998, FASEB J, V12, pA982; MINTZ E, 1986, J THEOR BIOL, V123, P21, DOI 10.1016/S0022-5193(86)80232-6; OHARA A, 1991, BIOPHYS J, V59, P648; PACHA J, 1993, J GEN PHYSIOL, V102, P25, DOI 10.1085/jgp.102.1.25; PALMER LG, 1982, J MEMBRANE BIOL, V64, P91, DOI 10.1007/BF01870771; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; PALMER LG, 1988, J GEN PHYSIOL, V92, P121, DOI 10.1085/jgp.92.1.121; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; SARIBANSOHRABY S, 1995, AM J PHYSIOL-CELL PH, V268, pC557, DOI 10.1152/ajpcell.1995.268.3.C557; SARIBANSOHRABY S, 1993, J BIOL CHEM, V268, P26613; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SARIBANSOHRABY S, 1995, KIDNEY INT, V48, P965, DOI 10.1038/ki.1995.378; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Stockand JD, 1999, J BIOL CHEM, V274, P26912, DOI 10.1074/jbc.274.38.26912; Stockand JD, 1999, FASEB J, V13, pA67; SZERLIP H, 1991, J AM SOC NEPHROL, V2, P1108; VOLKER C, 1995, METHOD ENZYMOL, V255, P65; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43; XIE HY, 1994, BIOCHEM BIOPH RES CO, V203, P1710, DOI 10.1006/bbrc.1994.2383; XIE HY, 1994, J BIOL CHEM, V269, P1981; YAMANE HK, 1989, J BIOL CHEM, V264, P20100; Yoo BC, 1998, EXP MOL MED, V30, P227, DOI 10.1038/emm.1998.33; ZIMMERMAN TP, 1980, BIOCHEMISTRY-US, V19, P2252, DOI 10.1021/bi00551a040	63	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16550	16559		10.1074/jbc.M000954200	http://dx.doi.org/10.1074/jbc.M000954200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747971	hybrid			2022-12-27	WOS:000087392200023
J	Botelho, RJ; Hackam, DJ; Schreiber, AD; Grinstein, S				Botelho, RJ; Hackam, DJ; Schreiber, AD; Grinstein, S			Role of COPI in phagosome maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; MYCOBACTERIUM-TUBERCULOSIS PHAGOSOME; MACROPHAGE FC-RECEPTORS; ADP-RIBOSYLATION FACTOR; VACUOLAR H+-ATPASE; BREFELDIN-A; MULTIVESICULAR ENDOSOMES; MEMBRANE-PROTEINS; EPSILON-COP; INTRACELLULAR TRAFFICKING	Phagosomes mature by sequentially fusing with endosomes and lysosomes. Vesicle budding is presumed to occur concomitantly, mediating the retrieval of plasmalemmal components and the regulation of phagosomal size. We analyzed whether fission of vesicles from phagosomes requires COPI, a multimeric complex known to be involved in budding from the Golgi and endosomes. The role of COPI was studied using ldlF cells, that harbor a temperature-sensitive mutation in E-COP, a subunit of the coatomer complex. These cells were made phagocytic toward IgG-opsonized particles by heterologous expression of human Fc gamma RIIA receptors. Following incubation at the restrictive temperature, epsilon-COP was degraded in these cells and their Golgi complex dispersed. Nevertheless, phagocytosis persisted for hours in cells devoid of epsilon-COP. Retrieval of transferrin receptors from phagosomes became inefficient in the absence of epsilon-COP, while clearance of the Fc gamma RIIA receptors was unaffected. This indicates that fission of vesicles from the phagosomal membrane involves at least two mechanisms, one of which requires intact COPI. Traffic of fluid-phase markers and aggregated IgG-receptor complexes along the endocytic pathway was abnormal in epsilon-COP-deficient cells. In contrast, phagosome fusion with endosomes and lysosomes was unimpaired. Moreover, the resulting phagolysosomes were highly acidic. Similar results were obtained in RAW264.7 macrophages treated with brefeldin A, which precludes COPI assembly by interfering with the activation of adenosine ribosylation factor. These data indicate that neither phagosome formation nor maturation are absolutely dependent on COPI. Our findings imply that phagosomal maturation differs from endosomal progression, which appears to be more dependent on COPI-mediated formation of carrier vesicles.	Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Pennsylvania	Botelho, RJ (corresponding author), Div Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Botelho, Roberto J/B-9145-2013	Botelho, Roberto J/0000-0002-7820-0999; Hackam, David/0000-0001-5195-8807	NIAID NIH HHS [AI-22193] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI022193, R01AI022193] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGGELER J, 1982, J CELL BIOL, V94, P613, DOI 10.1083/jcb.94.3.613; AlvarezDominguez C, 1997, J CELL SCI, V110, P731; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BERON W, 1995, TRENDS CELL BIOL, V5, P100, DOI 10.1016/S0962-8924(00)88958-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Clemens DL, 1996, J EXP MED, V184, P1349, DOI 10.1084/jem.184.4.1349; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; deChastellier C, 1997, EUR J CELL BIOL, V74, P49; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; Deretic V, 1997, ELECTROPHORESIS, V18, P2542, DOI 10.1002/elps.1150181409; Desjardins M, 1997, J CELL SCI, V110, P2303; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Downey GP, 1999, J BIOL CHEM, V274, P28436, DOI 10.1074/jbc.274.40.28436; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GEISOW MJ, 1981, J CELL BIOL, V89, P645, DOI 10.1083/jcb.89.3.645; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; Haas A, 1998, MOL MEMBR BIOL, V15, P103, DOI 10.3109/09687689809074522; Hackam DJ, 1997, J BIOL CHEM, V272, P29810, DOI 10.1074/jbc.272.47.29810; Hackam DJ, 1998, J EXP MED, V188, P351, DOI 10.1084/jem.188.2.351; Hackam DJ, 1998, P NATL ACAD SCI USA, V95, P11691, DOI 10.1073/pnas.95.20.11691; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; HOBBIE L, 1994, J BIOL CHEM, V269, P20958; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; Ichimura T, 1997, EUR J CELL BIOL, V74, P41; INDIK ZK, 1995, IMMUNOL LETT, V44, P133, DOI 10.1016/0165-2478(94)00204-5; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; Kwiatkowska K, 1999, BIOESSAYS, V21, P422, DOI 10.1002/(SICI)1521-1878(199905)21:5<422::AID-BIES9>3.0.CO;2-#; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG T, 1988, EUR J CELL BIOL, V46, P39; LEUNG KP, 1982, EUR J CELL BIOL, V29, P1; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LUKACS GL, 1990, J BIOL CHEM, V265, P21099; LUKACS GL, 1991, J BIOL CHEM, V266, P24540; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; MELLMAN IS, 1983, J CELL BIOL, V96, P887, DOI 10.1083/jcb.96.3.887; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; MULLER WA, 1983, J CELL BIOL, V96, P29, DOI 10.1083/jcb.96.1.29; MULLER WA, 1980, J CELL BIOL, V86, P292, DOI 10.1083/jcb.86.1.292; MULLER WA, 1980, J CELL BIOL, V86, P304, DOI 10.1083/jcb.86.1.304; MURPHY RF, 1991, TRENDS CELL BIOL, V1, P72; NAGARAJAN S, 1995, J BIOL CHEM, V270, P25762, DOI 10.1074/jbc.270.43.25762; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; OVERLY CC, 1995, P NATL ACAD SCI USA, V92, P3156, DOI 10.1073/pnas.92.8.3156; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PITT A, 1992, J CLIN INVEST, V90, P1978, DOI 10.1172/JCI116077; PITT A, 1992, J BIOL CHEM, V267, P126; Ramachandra L, 1999, J IMMUNOL, V162, P3263; ROEDERER M, 1990, EUR J CELL BIOL, V51, P229; RYTER A, 1985, COMP IMMUNOL MICROB, V8, P119, DOI 10.1016/0147-9571(85)90039-6; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P89, DOI 10.1016/S0962-8924(00)88956-4; THILO L, 1995, J CELL SCI, V108, P1791; vanDeurs B, 1996, EUR J CELL BIOL, V69, P343; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; WARD DM, 1995, J CELL BIOL, V129, P1229, DOI 10.1083/jcb.129.5.1229; WHITNEY JA, 1995, CELL, V83, P703; WOOD SA, 1992, J CELL BIOL, V119, P273, DOI 10.1083/jcb.119.2.273; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	71	44	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15717	15727		10.1074/jbc.M910068199	http://dx.doi.org/10.1074/jbc.M910068199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748188	hybrid			2022-12-27	WOS:000087291400018
J	Gilbert, M; Shaw, WJ; Long, JR; Nelson, K; Drobny, GP; Giachelli, CM; Stayton, PS				Gilbert, M; Shaw, WJ; Long, JR; Nelson, K; Drobny, GP; Giachelli, CM; Stayton, PS			Chimeric peptides of statherin and osteopontin that bind hydroxyapatite and mediate cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALIVARY STATHERIN; CRYSTALS; MINERALIZATION; CONFORMATION; ADSORPTION; SEQUENCES; INTEGRIN; PROTEINS; DOMAINS; SURFACE	Extracellular matrix proteins play hey roles in controlling the activities of osteoblasts and osteoclasts in bone remodeling. These bone-specific extracellular matrix proteins contain amino acid sequences that mediate cell adhesion, and many of the bone-specific matrix proteins also contain acidic domains that interact with the mineral surface and may orient the signaling domains. Here we report a fusion peptide design that is based on this natural approach for the display of signaling peptide sequences at biomineral surfaces. Salivary statherin contains a 15-amino acid hydroxyapatite binding domain (N15) that is loosely helical in solution. To test whether N15 can serve to orient active peptide sequences on hydroxyapatite, the RGD and flanking residues from osteopontin were fused to the C terminus. The fusion peptides bound tightly to hydroxyapatite, and the N15-PGRGDS peptide mediated the dose-dependent adhesion of Mo alpha(V), melanoma cells when immobilized on the hydroxyapatite surface. Experiments with an integrin-sorted Mo alpha(V), subpopulation demonstrated that the alpha(V)beta(3), integrin was the primary receptor target for the fusion peptide. Solid state NMR experiments showed that the RGD portion of the hydrated fusion peptide is highly dynamic on the hydroxyapatite surface. This fusion peptide framework may thus provide a straightforward design for immobilizing bioactive sequences on hydroxyapatite for biomaterials, tissue engineering, and vaccine applications.	Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stayton, PS (corresponding author), Univ Washington, Dept Bioengn, Box 352125, Seattle, WA 98195 USA.		Stayton, Patrick/C-1975-2018; Long, Joanna/ABD-7599-2021	Stayton, Patrick/0000-0001-6939-6371; Long, Joanna/0000-0002-5572-6859; Shaw, Wendy/0000-0002-4696-7415	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE012554] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 12554-01] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Amano A, 1996, INFECT IMMUN, V64, P4249, DOI 10.1128/IAI.64.10.4249-4254.1996; Beekman NJCM, 1999, VACCINE, V17, P2043, DOI 10.1016/S0264-410X(98)00407-1; BOSKEY AL, 1995, ANN NY ACAD SCI, V760, P249, DOI 10.1111/j.1749-6632.1995.tb44635.x; BUTLER WT, 1995, ANN NY ACAD SCI, V760, P6, DOI 10.1111/j.1749-6632.1995.tb44615.x; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; Fujisawa R, 1997, MATRIX BIOL, V16, P21, DOI 10.1016/S0945-053X(97)90113-X; Fujisawa R, 1996, BBA-PROTEIN STRUCT M, V1292, P53, DOI 10.1016/0167-4838(95)00190-5; FUJISAWA R, 1991, BIOCHIM BIOPHYS ACTA, V1075, P56; Goldberg HA, 1996, CONNECT TISSUE RES, V35, P385, DOI 10.3109/03008209609029216; GORSKI JP, 1992, CALCIFIED TISSUE INT, V50, P391, DOI 10.1007/BF00296767; HERZFELD J, 1980, J CHEM PHYS, V73, P6021, DOI 10.1063/1.440136; JOHNSSON M, 1993, CRIT REV ORAL BIOL M, V4, P371, DOI 10.1177/10454411930040031601; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; LIESKE JC, 1995, AM J PHYSIOL-RENAL, V268, pF604, DOI 10.1152/ajprenal.1995.268.4.F604; Long JR, 1998, P NATL ACAD SCI USA, V95, P12083, DOI 10.1073/pnas.95.21.12083; RAJ PA, 1992, J BIOL CHEM, V267, P5968; RAMASUBBU N, 1993, CRIT REV ORAL BIOL M, V4, P363, DOI 10.1177/10454411930040031501; Ruocco MJ, 1996, BIOPHYS J, V71, P1776, DOI 10.1016/S0006-3495(96)79378-5; Shaw WJ, 2000, J AM CHEM SOC, V122, P1709, DOI 10.1021/ja9842823; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Sood A., 1998, Indian Journal of Experimental Biology, V36, P849	21	104	124	1	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16213	16218		10.1074/jbc.M001773200	http://dx.doi.org/10.1074/jbc.M001773200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748043	hybrid			2022-12-27	WOS:000087291400082
J	Kaut, A; Lange, H; Diekert, K; Kispal, G; Lill, R				Kaut, A; Lange, H; Diekert, K; Kispal, G; Lill, R			Isa1p is a component of the mitochondrial machinery for maturation of cellular iron-sulfur proteins and requires conserved cysteine residues for function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-CLUSTER; AZOTOBACTER-VINELANDII; YEAST MITOCHONDRIA; INTERMEMBRANE SPACE; ABC TRANSPORTER; INNER MEMBRANE; IMPORT; IDENTIFICATION; BIOSYNTHESIS	In eukaryotes, mitochondria execute a central task in the assembly of cellular iron-sulfur (Fe/S) proteins. The organelles synthesize their own set of Fe/S proteins, and they initiate the generation of extramitochondrial Fe/S proteins, In the present study, we identify the mitochondrial matrix protein Isa1p of Saccharomyces cerevisiae as a new member of the Fe/S cluster biosynthesis machinery, Isa1p belongs to a family of homologous proteins present in prokaryotes and eukaryotes. Deletion of the ISA1 gene results in the loss of mitochondrial DNA precluding the use of the Delta isa1 strain for functional analysis. Cells in which Isa1p was depleted by regulated gene expression maintained the mitochondrial DNA, yet the cells displayed retarded growth on nonfermentable carbon sources, This finding indicates the importance of Isa1p for mitochondrial function. Deficiency of Isa1p caused a defect in mitochondrial Fe/S protein assembly. Moreover, Isa1p was required for maturation of cytosolic Fe/S proteins, Two cysteine residues in a conserved sequence motif characterizing the Isa1p protein family were found to be essential for Isa1p function in the biogenesis of both intra- and extramitochondrial Fe/S proteins. Our findings suggest a function for Isa1p in the binding of iron or an intermediate of Fe/S cluster assembly.	Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany	Philipps University Marburg	Lill, R (corresponding author), Univ Marburg, Inst Zytobiol & Zytopathol, Robert Koch Str 5, D-35033 Marburg, Germany.	Lill@mailer.uni-marburg.de		Lill, Roland/0000-0002-8345-6518; Lange, Heike/0000-0002-8222-3448				AGAR JN, 2000, IN PRESS J BIOL INOR; Barros MH, 1999, GENE, V233, P197, DOI 10.1016/S0378-1119(99)00137-7; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Craig EA, 1999, BIOL CHEM, V380, P1167, DOI 10.1515/BC.1999.148; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Harlow E., 1988, ANTIBODIES LAB MANUA; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; JENSEN LT, 2000, IN PRESS MOL CELL BI; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Kispal G, 1996, J BIOL CHEM, V271, P24458, DOI 10.1074/jbc.271.40.24458; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; KOHLHAW GB, 1988, METHOD ENZYMOL, V166, P423; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; MASEPOHL B, 1993, MOL GEN GENET, V238, P369, DOI 10.1007/BF00291996; MEIJER WG, 1992, J BACTERIOL, V174, P3855, DOI 10.1128/jb.174.12.3855-3866.1992; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; SCHRAUTEMEIER B, 1994, J BACTERIOL, V176, P1037, DOI 10.1128/JB.176.4.1037-1046.1994; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; STEINER H, 1995, J BIOL CHEM, V270, P22842, DOI 10.1074/jbc.270.39.22842; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; WOONTNER M, 1990, J BIOL CHEM, V265, P8979; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZELENAYATROITSKAYA O, 1995, EMBO J, V14, P3268, DOI 10.1002/j.1460-2075.1995.tb07330.x; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	46	111	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15955	15961		10.1074/jbc.M909502199	http://dx.doi.org/10.1074/jbc.M909502199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748136	hybrid			2022-12-27	WOS:000087291400048
J	Smolen, JE; Petersen, TK; Koch, C; O'Keefe, SJ; Hanlon, WA; Seo, S; Pearson, D; Fossett, MC; Simon, SI				Smolen, JE; Petersen, TK; Koch, C; O'Keefe, SJ; Hanlon, WA; Seo, S; Pearson, D; Fossett, MC; Simon, SI			L-selectin signaling of neutrophil adhesion and degranulation involves p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; ELECTROPERMEABILIZED HUMAN NEUTROPHILS; CYTOSOLIC PHOSPHOLIPASE A(2); ANTIBODY-INDUCED ENGAGEMENT; ADHERENT HUMAN NEUTROPHILS; TYROSINE PHOSPHORYLATION; POLYMORPHONUCLEAR LEUKOCYTES; RESPIRATORY BURST; FACTOR-ALPHA	The adhesion molecules known as selectins mediate the capture of neutrophils from the bloodstream, We have previously reported that ligation and cross-linking of L-selectin on the neutrophil surface enhances the adhesive function of beta(2)-integrins in a synergistic manner with chemotactic agonists. In this work, we examined degranulation and adhesion of neutrophils in response to cross-linking of L-selectin and addition of interleukin-8. Cross-linking of L-selectin induced priming of degranulation that was similar to that observed with the alkaloid cytochalasin B. Activation mediated by L-selectin of neutrophil shape change and adhesion through CD11b/CD18 were strongly blocked by Merck C, an imidazole-based inhibitor of p38 mitogen-activated protein kinase (MAPK), but not by a structurally similar non-binding regioisomer. Priming by L-selectin of the release of secondary, tertiary, and secretory, but not primary, granules was blocked by inhibition of p38 MAPK, Peak phosphorylation of p38 MAPK was observed within 1 min of cross-linking L-selectin, whereas phosphorylation of ERK1/2 was highest at 10 min. Phosphorylation of p38 MAPK, but not ERK1/2, was inhibited by Merck C, These data suggest that signal transduction as a result of clustering L-selectin utilizes p38 MAPK to effect neutrophil shape change, integrin activation, and the release of secondary, tertiary, and secretory granules.	Baylor Coll Med, Childrens Nutr Res Ctr, Dept Pediat, Leukocyte Biol Sect, Houston, TX 77030 USA; Royal Vet & Agr Univ, Dept Clin Studies, Cent Lab, DK-1870 Frederiksberg C, Denmark; Merck Res Labs, Dept Immunol & Rheumatol, Rahway, NJ 07065 USA; Univ Calif Davis, Davis, CA 95616 USA	Baylor College of Medicine; University of Copenhagen; Merck & Company; University of California System; University of California Davis	Smolen, JE (corresponding author), Baylor Coll Med, Childrens Nutr Res Ctr, Dept Pediat, Leukocyte Biol Sect, 1100 Bates,Rm 6014, Houston, TX 77030 USA.				NHLBI NIH HHS [R01 HL42550] Funding Source: Medline; NIAID NIH HHS [R01 AI 31652] Funding Source: Medline; NIDDK NIH HHS [R01 DK 32471] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032471] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAINTON DF, 1973, J CELL BIOL, V58, P249, DOI 10.1083/jcb.58.2.249; BENTWOOD BJ, 1980, J IMMUNOL, V124, P855; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BEZWODA WR, 1985, CLIN CHIM ACTA, V151, P61, DOI 10.1016/0009-8981(85)90235-9; Brenner B, 1997, IMMUNOLOGY, V92, P214, DOI 10.1046/j.1365-2567.1997.00336.x; BRETZ U, 1974, J CELL BIOL, V63, P251, DOI 10.1083/jcb.63.1.251; BRITTINGER G, 1968, J CELL BIOL, V37, P394, DOI 10.1083/jcb.37.2.394; BUTTRUM SM, 1993, BLOOD, V82, P1165; Coffer PJ, 1997, IMMUNOL LETT, V57, P27, DOI 10.1016/S0165-2478(97)00067-9; Crockett-Torabi E, 1998, J LEUKOCYTE BIOL, V63, P1; CROCKETTTORABI E, 1995, J IMMUNOL, V154, P2291; CrockettTorabi E, 1997, AM J PHYSIOL-HEART C, V272, pH1302, DOI 10.1152/ajpheart.1997.272.3.H1302; DAPINO P, 1993, CLIN EXP IMMUNOL, V94, P533; Detmers PA, 1998, J IMMUNOL, V161, P1921; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; ESTENSEN RD, 1974, NATURE, V248, P347, DOI 10.1038/248347a0; Fernandez R, 1998, J IMMUNOL, V160, P5154; Frohlich D, 1998, BLOOD, V91, P2558, DOI 10.1182/blood.V91.7.2558.2558_2558_2564; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GADD SJ, 1994, IMMUNOLOGY, V81, P611; Gopalan PK, 1997, J IMMUNOL, V158, P367; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; HAMMER DA, 1992, BIOPHYS J, V63, P35, DOI 10.1016/S0006-3495(92)81577-1; HANLON WA, 1991, J LEUKOCYTE BIOL, V50, P43, DOI 10.1002/jlb.50.1.43; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; HELLMAN B, 1989, EXP CLIN ENDOCRINOL, V93, P125, DOI 10.1055/s-0029-1210845; HENRICKS PAJ, 1984, IMMUNOLOGY, V52, P671; HETHERINGTON SV, 1983, J IMMUNOL METHODS, V65, P183, DOI 10.1016/0022-1759(83)90314-9; Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; HUGHES BJ, 1992, J CLIN INVEST, V90, P1687, DOI 10.1172/JCI116041; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Liles WC, 1995, J LEUKOCYTE BIOL, V58, P690, DOI 10.1002/jlb.58.6.690; Liverton NJ, 1999, J MED CHEM, V42, P2180, DOI 10.1021/jm9805236; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; Mocsai A, 1997, BIOCHEM PHARMACOL, V54, P781, DOI 10.1016/S0006-2952(97)00245-1; Nahas N, 1996, BIOCHEM J, V313, P503, DOI 10.1042/bj3130503; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; NgSikorski J, 1996, J CELL SCI, V109, P2361; Nick JA, 1996, J IMMUNOL, V156, P4867; NIESSEN HWM, 1991, CELL SIGNAL, V3, P625, DOI 10.1016/0898-6568(91)90039-W; NIESSEN HWM, 1992, CELL SIGNAL, V4, P501, DOI 10.1016/0898-6568(92)90019-5; PETREQUIN PR, 1987, BLOOD, V69, P605; Pillinger MH, 1996, J BIOL CHEM, V271, P12049, DOI 10.1074/jbc.271.20.12049; Rainger GE, 1997, CURR BIOL, V7, P316, DOI 10.1016/S0960-9822(06)00155-2; Rane MJ, 1997, J IMMUNOL, V159, P5070; Schnyder B, 1998, BIOCHEM J, V331, P489, DOI 10.1042/bj3310489; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; SIMON SI, 1990, J CELL BIOL, V111, P2747, DOI 10.1083/jcb.111.6.2747; Simon SI, 2000, J IMMUNOL, V164, P4348, DOI 10.4049/jimmunol.164.8.4348; SIMON SI, 1995, J IMMUNOL, V155, P1502; Simon SI, 1999, J IMMUNOL, V163, P2891; SIMON SI, 1992, J IMMUNOL, V149, P2765; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SMOLEN JE, 1981, BIOCHIM BIOPHYS ACTA, V672, P197, DOI 10.1016/0304-4165(81)90393-7; SMOLEN JE, 1990, BIOCHIM BIOPHYS ACTA, V1052, P133, DOI 10.1016/0167-4889(90)90068-O; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; Steeber DA, 1997, J IMMUNOL, V159, P952; STEVENSON KB, 1987, J IMMUNOL, V139, P3759; Suzuki K, 1999, BLOOD, V93, P341, DOI 10.1182/blood.V93.1.341.401k09_341_349; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; TODD RF, 1984, J CLIN INVEST, V74, P1280, DOI 10.1172/JCI111538; Todd RF, 1997, J LAB CLIN MED, V129, P492, DOI 10.1016/S0022-2143(97)90003-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsang YTM, 1997, J IMMUNOL, V159, P4566; WACKER WEC, 1956, NEW ENGL J MED, V255, P449, DOI 10.1056/NEJM195609062551001; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; WALZOG B, 1994, J LEUKOCYTE BIOL, V56, P625, DOI 10.1002/jlb.56.5.625; WATERMAN WH, 1995, BIOCHEM J, V307, P39, DOI 10.1042/bj3070039; Waterman WH, 1996, BIOCHEM J, V319, P17, DOI 10.1042/bj3190017; Wize J, 1998, INFLAMM RES, V47, P325, DOI 10.1007/s000110050336; Yan SR, 1998, J LEUKOCYTE BIOL, V64, P401, DOI 10.1002/jlb.64.3.401; ZAMAN W, 1994, J BIOCHEM-TOKYO, V115, P238, DOI 10.1093/oxfordjournals.jbchem.a124324; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; Zu YL, 1998, J IMMUNOL, V160, P1982	86	120	126	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15876	15884		10.1074/jbc.M906232199	http://dx.doi.org/10.1074/jbc.M906232199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748078	hybrid			2022-12-27	WOS:000087291400038
J	Walker, SJ; Wu, WJ; Cerione, RA; Brown, HA				Walker, SJ; Wu, WJ; Cerione, RA; Brown, HA			Activation of phospholipase D1 by Cdc42 requires the rho insert region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; GTP-BINDING PROTEINS; FAMILY GTPASES; EFFECTOR; TRANSFORMATION; ARF; PHOSPHORYLATION; SITES; ALPHA	Members of the Rho subfamily of GTP-binding proteins are implicated in the regulation of phospholipase D (PLD). In the present study, we demonstrate a physical association between a Rho family member, Cdc42, and PLD1. Binding of Cdc42 to PLD1 and subsequent activation are GTP-dependent. Although binding of Cdc42 to PLD1 does not require geranylgeranylation, activation of PLD1 is dependent on this lipid modification of Cdc42. Specific point mutations in the switch I region of Cdc42 abolish binding to and, therefore, activation of PLD1 by Cdc42. Deletion of the Rho insert region, which consists of residues 120-189, from Cdc42 does not interfere with binding to PLD1 but inhibits Cdc42 stimulated PLD1 activity. Interestingly, deletion of the insert region from Cdc42 also inhibits activation of PLD1 by Arf and protein kinase C. With the lack of specific inhibitors of PLD activity, the insert deletion mutant of Cdc42 (designated (Delta L8)Cdc42) is a novel reagent for in vitro studies of PLD1 regulation, as well as for in vivo studies of Cdc42-mediated signaling pathways leading to PLD1 activation. Because the insert region is required for the transforming activity of Cdc42, regulation of PLD1 by this region on Cdc42 is of major interest.	Cornell Univ, Dept Mol Med, Ctr Vet Med, Field Biochem Mol & Cell Biol, Ithaca, NY 14853 USA	Cornell University	Walker, SJ (corresponding author), Cornell Univ, Dept Mol Med, Ctr Vet Med, Field Biochem Mol & Cell Biol, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM58516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hess JA, 1997, J BIOL CHEM, V272, P1615, DOI 10.1074/jbc.272.3.1615; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; OLSON SC, 1991, J BIOL CHEM, V266, P17236; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Wu WJ, 1997, J BIOL CHEM, V272, P26153, DOI 10.1074/jbc.272.42.26153; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035	33	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15665	15668		10.1074/jbc.M000076200	http://dx.doi.org/10.1074/jbc.M000076200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747870	hybrid			2022-12-27	WOS:000087291400011
J	Zhang, ZL; Kolls, JK; Oliver, P; Good, D; Schwarzenberger, PO; Joshi, MS; Ponthier, JL; Lancaster, JR				Zhang, ZL; Kolls, JK; Oliver, P; Good, D; Schwarzenberger, PO; Joshi, MS; Ponthier, JL; Lancaster, JR			Activation of tumor necrosis factor-alpha-converting enzyme-mediated ectodomain shedding by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; SYNTHASE-DEFICIENT MICE; MATRIX METALLOPROTEINASES; DISINTEGRIN; MECHANISM; EXPRESSION; PRECURSOR; RECEPTORS; ENDOTOXIN; PROTEINS	Ectodomain shedding of cell surface proteins is an important process in a wide variety of physiological and developmental events. Recently, tumor necrosis factor-alpha-converting enzyme (TACE) has been found to play an essential role in the shedding of several critical surface proteins, which is evidenced by multiple developmental defects exhibited by TACE knockout mice. However, little is known about the physiological activation of TACE, Here, we show that nitric oxide (NO) activates TACE-mediated ectodomain shedding. Using an in vitro model of TACE activation, we show that NO activates TACE by nitrosation of the inhibitory motif of the TACE prodomain. Thus, NO production activates the release of cytokines, cytokine receptors, and adhesion molecules, and NO may be involved in other ectodomain shedding processes.	Tulane Univ, Sch Med, Hlth Sci Gene Therapy Program, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Surg, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Physiol, New Orleans, LA 70112 USA	Tulane University; Tulane University; Tulane University; Tulane University; Tulane University	Kolls, JK (corresponding author), Tulane Univ, Sch Med, Hlth Sci Gene Therapy Program, 1430 Tulane Ave, New Orleans, LA 70112 USA.		Schwarzenberger, Paul/AAZ-2174-2021; Kolls, Jay/AAH-1829-2019	Kolls, Jay/0000-0001-5151-6304	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA010384, F32AA005543] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL62052-01] Funding Source: Medline; NIAAA NIH HHS [F32-AA05543, R29AA10384] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CHAUDHRI G, 1989, J IMMUNOL, V143, P1290; DIGNASS AU, 1995, DIGEST DIS SCI, V40, P1859, DOI 10.1007/BF02208647; EIGLER A, 1993, BIOCHEM BIOPH RES CO, V196, P494, DOI 10.1006/bbrc.1993.2277; FEELISCH M, 1996, METHODS NITRIC OXIDE, P521; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Lefer DJ, 1999, AM J PHYSIOL-HEART C, V276, pH1943, DOI 10.1152/ajpheart.1999.276.6.H1943; LIU P, 1995, SHOCK, V3, P56, DOI 10.1097/00024382-199503010-00010; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; MURRELL GAC, 1995, BIOCHEM BIOPH RES CO, V206, P15, DOI 10.1006/bbrc.1995.1003; Okamoto T, 1997, ARCH BIOCHEM BIOPHYS, V342, P261, DOI 10.1006/abbi.1997.0127; Panja A, 1998, J IMMUNOL, V161, P3675; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PHILIPPE C, 1993, IMMUNOLOGY, V80, P300; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Trachtman H, 1996, BIOCHEM BIOPH RES CO, V218, P704, DOI 10.1006/bbrc.1996.0125; Wang SB, 1997, J BIOL CHEM, V272, P5959, DOI 10.1074/jbc.272.9.5959; Williams DM, 1997, INFECT IMMUN, V65, P2876, DOI 10.1128/IAI.65.7.2876-2882.1997; WINK DA, 1995, ARCH BIOCHEM BIOPHYS, V319, P402, DOI 10.1006/abbi.1995.1310; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275	34	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15839	15844		10.1074/jbc.M000604200	http://dx.doi.org/10.1074/jbc.M000604200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747938	hybrid			2022-12-27	WOS:000087291400033
J	Tso, SC; Shenoy, SK; Quinn, BN; Yu, L				Tso, SC; Shenoy, SK; Quinn, BN; Yu, L			Subunit IV of cytochrome bc(1) complex from Rhodobacter sphaeroides - Localization of regions essential for interaction with the three-subunit core complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; UBIQUINONE-BINDING PROTEINS; C REDUCTASE; MITOCHONDRIAL; IDENTIFICATION; CLONING; DERIVATIVES; DOMAIN; HEAD	Recombinant subunit IV mutants which identify the regions essential for restoration of bc(1) activity to the three-subunit core complex of Rhodobacter sphaeroides were generated and characterized. Four C-terminal truncated mutants: IV(1-109), IV(1-85), IV(1-76), and IV(1-40) had 100, 0, 0, and 0% of reconstitutive activity of the wild-type TV, indicating that residues 86-109 are essential. TV(1-109) is associated with the core complex in the same manner as the wild-type IV while mutants IV(1-85), IV(1-76), and TV(1-40) do not associate with the core complex, indicating that suhunit IV requires its transmembrane helix region (residues 86-109) for assembly into the bc(1) complex. Since GST-IV(86-109) fusion protein has little reconstitutive activity, some region(s) in residues 1-85 are required for bc(1) activity restoration after subunit IV is incorporated into the complex through the transmembrane helix, presumably by interaction with cytochrome b in the core complex. The interacting regions are identified as residues 41-53 and 77-85, since mutants IV(21-109), IV(41-109), TV(54-109), and IV(77-109) had 95, 98, 53, and 53% of the reconstitutive activity of the wild-type TV. These two interacting regions are on the cytoplasmic side of the chromatophore membrane and closed to the DE loop and helix G of cytochrome b, respectively.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, L (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.		Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663				CHEN YR, 1994, BIOCHEMISTRY-US, V33, P10207, DOI 10.1021/bi00199a050; CHEN YR, 1995, J BIOL CHEM, V270, P11496, DOI 10.1074/jbc.270.19.11496; Chen YR, 1996, J BIOL CHEM, V271, P2057, DOI 10.1074/jbc.271.4.2057; DONOHUE TJ, 1988, BIOCHEMISTRY-US, V27, P1918, DOI 10.1021/bi00406a018; GONZALEZHALPHEN D, 1991, J BIOL CHEM, V266, P3870; HUNTER DN, 1988, BIOCHEMISTRY-US, V193, P265; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KRIAUCIUNAS A, 1989, BIOCHIM BIOPHYS ACTA, V976, P70, DOI 10.1016/S0005-2728(89)80190-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LA LB, 1991, BIOCHIM BIOPHYS ACTA, V1057, P215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIJUNGDAHL PP, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ROBERTSON DE, 1993, BIOCHEMISTRY-US, V32, P1310, DOI 10.1021/bi00056a016; Sambrook J., 2002, MOL CLONING LAB MANU; Schagger H, 1995, METHOD ENZYMOL, V260, P82, DOI 10.1016/0076-6879(95)60132-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; Tian H, 1997, J BIOL CHEM, V272, P23722, DOI 10.1074/jbc.272.38.23722; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; USUI S, 1991, J BIOL CHEM, V266, P15644; WU J, 1995, BIOCHEM J, V305, P823, DOI 10.1042/bj3050823; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG XH, 1986, J BIOL CHEM, V261, P2282; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YU L, 1985, J BIOL CHEM, V260, P963; YU L, 1995, J BIOL CHEM, V270, P25634, DOI 10.1074/jbc.270.43.25634; YU L, 1991, BIOCHEMISTRY-US, V30, P4934, DOI 10.1021/bi00234a014; YU L, 1987, BIOCHEMISTRY-US, V26, P3658, DOI 10.1021/bi00386a060; Yu L, 1999, J BIOENERG BIOMEMBR, V31, P251, DOI 10.1023/A:1005423913639; YU L, 1992, J BIOL CHEM, V267, P24508; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x	34	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15287	15294		10.1074/jbc.M907367199	http://dx.doi.org/10.1074/jbc.M907367199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748084	hybrid			2022-12-27	WOS:000087128300070
J	Strassburg, CP; Kneip, S; Topp, J; Obermayer-Straub, P; Barut, A; Tukey, RH; Manns, MP				Strassburg, CP; Kneip, S; Topp, J; Obermayer-Straub, P; Barut, A; Tukey, RH; Manns, MP			Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER; HYODEOXYCHOLIC ACID; CDNA CLONING; COS-1 CELLS; HUMAN COLON; BILE-ACIDS; 1A LOCUS; EXPRESSION; GLUCURONIDATION; IDENTIFICATION	UDP-glucuronosyltransferases (UGTs) convert dietary constituents, drugs, and environmental mutagens to inactive hydrophilic glucuronides. Recent studies have shown that the expression of the UGT1 and UGT2 gene families is regulated in a tissue-specific fashion. Human small intestine represents a major site of resorption of dietary constituents and orally administered drugs and plays an important role in extrahepatic UGT directed metabolism. Expression of 13 UGT1A and UGT2B genes coupled with functional and catalytic analyses were studied using 18 small intestinal and 16 hepatic human tissue samples. Hepatic expression of UGT gene transcripts was without interindividual variation. In contrast, a polymorphic expression pattern of all the UGT genes was demonstrated in duodenal, jejunal, and ileal mucosa, with the exception of UGT1A10. To complement these studies, interindividual expression of UGT proteins and catalytic activities were also demonstrated. Hyodeoxycholic acid glucuronidation, catalyzed primarily by UGT2B4 and UGT2B7, showed a 7-fold interindividual variation in small intestinal duodenal samples, in contrast to limited variation in the presence of 4-methylumbelliferone, a substrate glucuronidated by most UGT1A and UGT2B gene products. Linkage of RNA expression patterns to protein abundance were also made with several mono-specific antibodies-to the UGTs. These results are in contrast to a total absence of polymorphic variation in gene expression, protein abundance, and catalytic activity in liver. In addition, the small intestine exhibits considerable catalytic-activity toward most of the different classes of substrates accepted for glucuronidation by the UGTs, which is:supported by immunofluorescence analysis of UGT1A protein in the mucosal cell layer of the small intestine. Thus, tissue-specific and interindividual polymorphic regulation of UGT1A and UGT2B genes in small intestine is identified and implicated as molecular biological determinant contributing to interindividual prehepatic drug and xenobiotic metabolism in humans.	Hannover Med Sch, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Hannover Medical School; University of California System; University of California San Diego; University of California System; University of California San Diego	Strassburg, CP (corresponding author), Hannover Med Sch, Dept Gastroenterol & Hepatol, Carl Neuberg Str 1, D-30625 Hannover, Germany.				NIGMS NIH HHS [GM49135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beaulieu M, 1997, DNA CELL BIOL, V16, P1143, DOI 10.1089/dna.1997.16.1143; Beaulieu M, 1996, J BIOL CHEM, V271, P22855, DOI 10.1074/jbc.271.37.22855; Beaulieu M, 1998, BIOCHEM BIOPH RES CO, V248, P44, DOI 10.1006/bbrc.1998.8908; Belanger A, 1998, J STEROID BIOCHEM, V65, P301, DOI 10.1016/S0960-0760(97)00183-0; Burchell B, 1998, Adv Pharmacol, V42, P335; CHEN F, 1993, BIOCHEMISTRY-US, V32, P10648, DOI 10.1021/bi00091a015; Cheng ZQ, 1998, ARCH BIOCHEM BIOPHYS, V356, P301, DOI 10.1006/abbi.1998.0781; Dutton G.F., 1980, GLUCURONIDATION DRUG; FOURNELGIGLEUX S, 1989, FEBS LETT, V243, P119, DOI 10.1016/0014-5793(89)80111-5; Gall WE, 1999, J STEROID BIOCHEM, V70, P101, DOI 10.1016/S0960-0760(99)00088-6; Green MD, 1998, DRUG METAB DISPOS, V26, P860; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; HARTMANN F, 1982, J CLIN INVEST, V70, P23, DOI 10.1172/JCI110598; JACKSON MR, 1987, BIOCHEM J, V242, P581, DOI 10.1042/bj2420581; Jedlitschky G, 1999, BIOCHEM J, V340, P837, DOI 10.1042/0264-6021:3400837; JIN CJ, 1993, BIOCHEM BIOPH RES CO, V194, P496, DOI 10.1006/bbrc.1993.1847; King CD, 1999, ARCH BIOCHEM BIOPHYS, V365, P156, DOI 10.1006/abbi.1999.1155; Lampe JW, 1999, PHARMACOGENETICS, V9, P341, DOI 10.1097/00008571-199906000-00009; MATERN S, 1984, J CLIN INVEST, V74, P402, DOI 10.1172/JCI111435; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; Mojarrabi B, 1996, BIOCHEM BIOPH RES CO, V225, P785, DOI 10.1006/bbrc.1996.1251; Mojarrabi B, 1997, BIOCHEM BIOPH RES CO, V238, P775, DOI 10.1006/bbrc.1997.7388; Mojarrabi B, 1998, BIOCHEM BIOPH RES CO, V247, P704, DOI 10.1006/bbrc.1998.8843; MONAGHAN G, 1994, GENOMICS, V23, P496, DOI 10.1006/geno.1994.1531; PARQUET M, 1985, FEBS LETT, V189, P183, DOI 10.1016/0014-5793(85)81020-6; Radominska-Pandya A, 1998, BBA-LIPID LIPID MET, V1394, P199, DOI 10.1016/S0005-2760(98)00115-5; RITTER JK, 1992, BIOCHEMISTRY-US, V31, P3409, DOI 10.1021/bi00128a015; RITTER JK, 1991, J BIOL CHEM, V266, P1043; RITTER JK, 1990, J BIOL CHEM, V265, P7900; Strassburg CP, 1996, J HEPATOL, V25, P859, DOI 10.1016/S0168-8278(96)80290-X; STRASSBURG CP, 1992, CANCER RES, V52, P815; Strassburg CP, 1997, MOL PHARMACOL, V52, P212, DOI 10.1124/mol.52.2.212; Strassburg CP, 1998, MOL PHARMACOL, V54, P647; Strassburg CP, 1997, CANCER RES, V57, P2979; Strassburg CP, 1999, BIOCHEM J, V338, P489, DOI 10.1042/0264-6021:3380489; Strassburg CP, 1999, GASTROENTEROLOGY, V116, P149, DOI 10.1016/S0016-5085(99)70239-8; Strassburg CP, 1998, J BIOL CHEM, V273, P8719, DOI 10.1074/jbc.273.15.8719; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465	39	199	206	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36164	36171		10.1074/jbc.M002180200	http://dx.doi.org/10.1074/jbc.M002180200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10748067	hybrid			2022-12-27	WOS:000165382000074
J	Andersson, J; Westman, M; Sahlin, M; Sjoberg, BM				Andersson, J; Westman, M; Sahlin, M; Sjoberg, BM			Cysteines involved in radical generation and catalysis of class III anaerobic ribonucleotide reductase - A protein engineering study of bacteriophage T4 NrdD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; IRON-SULFUR CENTER; SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; PHENOTYPIC SELECTION; ACTIVATING ENZYME; MECHANISM; R1; 5'-DIPHOSPHATE; MUTANT	Class III ribonucleotide reductase (RNR) is an anaerobic glycyl radical enzyme that catalyzes the reduction of ribonucleotides to deoxyribonucleotides. We have investigated the importance in the reaction mechanism of nine conserved cysteine residues in class III RNR from bacteriophage T4, By using site-directed mutagenesis, we show that two of the cysteines, Cys-79 and Cys-290, are directly involved in the reaction mechanism. Based on the positioning of these two residues in the active site region of the known three-dimensional structure of the phage T4 enzyme, and their structural equivalence to two cysteine residues in the active site region of the aerobic class I RNR, we suggest that Cys-290 participates in the reaction mechanism by forming a transient thiyl radical and that Cys-79 participates in the actual reduction of the substrate. Our results provide strong experimental evidence for a similar radical-based reaction mechanism in all classes of RNR but also identify important differences between class III RNR and the other classes of RNR as regards the reduction per se. We also identify a cluster of four cysteines (Cys-543, Cys-546, Cys-561, and Cys-564) in the C-terminal part of the class III enzyme, which are essential for formation of the glycyl radical. These cysteines make up a CX2C-CX2C motif in the vicinity of the stable radical at Gly-580. We propose that the four cysteines are involved in radical transfer between Gly-580 and the cofactor S-adenosylmethionine of the activating NrdG enzyme needed for glycyl radical generation.	Stockholm Univ, Dept Mol Biol, SE-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Mol Biol, SE-10691 Stockholm, Sweden.	bitte@molbio.su.se		Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; Ashley GW, 1997, TETRAHEDRON, V53, P12005, DOI 10.1016/S0040-4020(97)00713-8; Becker A, 1999, NAT STRUCT BIOL, V6, P969; Behravan G, 1995, BBA-GENE STRUCT EXPR, V1264, P323, DOI 10.1016/0167-4781(95)00168-9; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; Eklund H, 1999, STRUCT FOLD DES, V7, pR257, DOI 10.1016/S0969-2126(00)80019-2; ELIASSON R, 1994, J BIOL CHEM, V269, P26116; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; FREY M, 1994, J BIOL CHEM, V269, P12432; Hesslinger C, 1998, MOL MICROBIOL, V27, P477, DOI 10.1046/j.1365-2958.1998.00696.x; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KING DS, 1995, BIOCHEM BIOPH RES CO, V206, P731, DOI 10.1006/bbrc.1995.1103; KNAPPE J, 1995, METHOD ENZYMOL, V258, P343; KNAPPE J, 1993, BIOCHEM SOC T, V21, P731, DOI 10.1042/bst0210731; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lawrence CC, 1999, P NATL ACAD SCI USA, V96, P8979, DOI 10.1073/pnas.96.16.8979; Leuthner B, 1998, MOL MICROBIOL, V28, P615, DOI 10.1046/j.1365-2958.1998.00826.x; LIU A, 2000, IN PRESS J BIOL CHEM, V275; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; Mulliez E, 1999, J BIOL INORG CHEM, V4, P614, DOI 10.1007/s007750050385; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; Olcott MC, 1998, J BIOL CHEM, V273, P24853, DOI 10.1074/jbc.273.38.24853; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; PARAST CV, 1995, BIOCHEMISTRY-US, V34, P5712, DOI 10.1021/bi00017a002; Persson AL, 1998, J BIOL CHEM, V273, P31016, DOI 10.1074/jbc.273.47.31016; Persson AL, 1997, J BIOL CHEM, V272, P31533, DOI 10.1074/jbc.272.50.31533; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; Stubbe J, 1998, P NATL ACAD SCI USA, V95, P2723, DOI 10.1073/pnas.95.6.2723; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; VANDERDONK WA, 1995, J AM CHEM SOC, V117, P8908, DOI 10.1021/ja00140a003; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; Young P, 1996, J BIOL CHEM, V271, P20770, DOI 10.1074/jbc.271.34.20770	43	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19449	19455		10.1074/jbc.M001278200	http://dx.doi.org/10.1074/jbc.M001278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748010	hybrid			2022-12-27	WOS:000087941300004
J	Miyaura, C; Inada, M; Suzawa, T; Sugimoto, Y; Ushikubi, F; Ichikawa, A; Narumiya, S; Suda, T				Miyaura, C; Inada, M; Suzawa, T; Sugimoto, Y; Ushikubi, F; Ichikawa, A; Narumiya, S; Suda, T			Impaired bone resorption to prostaglandin E-2 in prostaglandin E receptor EP4-knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL INDUCTION; INTERLEUKIN-1 RECEPTOR; GROWTH-FACTOR; OSTEOBLASTS; LACKING; OVARIECTOMY; SUBTYPES; INVITRO	Prostaglandin E-2 (PGE(2)) acts as a potent stimulator of bone resorption. In this study, we first clarified in normal ddy mice the involvement of protein kinase A and induction of matrix metalloproteinases (MMPs) in PGE(2)-induced bone resorption, and then identified PGE receptor subtype(s) mediating this PGE(2) action using mice lacking each subtype (EP1, EP2, EP3, and EP4) of PGE receptor. In calvarial culture obtained from normal ddy mice, both PGE(2) and dibutyryl cyclic AMP (Bt(2)cAMP) stimulated bone resorption and induced MMPs including MMP-2 and MMP-13. Addition of an inhibitor of protein kinase A, H89, or an inhibitor of MMPs, BB94, significantly suppressed bone-resorbing activity induced by PGE(2). In calvarial culture from EP1-, EP2-, and EP3-knockout mice, PGE(2) stimulated bone resorption to an extent similar to that found in calvaria from the wild-type mice. On the other hand, a marked reduction in bone resorption to PGE(2) was found in the calvarial culture from EP4-knockout mice. The impaired bone resorption to PGE(2) was also detected in long bone cultures from EP4-knockout mice. Bt(2)cAMP greatly stimulated bone resorption similarly in both wild-type and EP4-knockout mice. Induction of MMP-2 and MMP-13 by PGE(2) was greatly impaired in calvarial culture from EP4-knockout mice, but Bt(2)cAMP stimulated MMPs induction similarly in the wild-type and EP4-knockout mice. These findings suggest that PGE(2) stimulates bone resorption by a cAMP-dependent mechanism via the EP4 receptor.	Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 1428555, Japan; Kyoto Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Kyoto 6068501, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan; Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Biochem, Tokyo 1920392, Japan	Showa University; Kyoto University; Kyoto University; Tokyo University of Pharmacy & Life Sciences	Suda, T (corresponding author), Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.		inada, masaki/D-1581-2013; Sugimoto, Yukihiko/AAV-6470-2021; miyaura, chisato/D-1864-2013	inada, masaki/0000-0002-5066-8506; Sugimoto, Yukihiko/0000-0001-6973-932X; miyaura, chisato/0000-0002-2548-8191				AKATSU T, 1991, J BONE MINER RES, V6, P183; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; Everts V, 1999, FASEB J, V13, P1219, DOI 10.1096/fasebj.13.10.1219; HAKEDA Y, 1986, J CELL PHYSIOL, V128, P155, DOI 10.1002/jcp.1041280204; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P539, DOI 10.1172/JCI118066; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; KIMBLE RB, 1994, J CLIN INVEST, V93, P1959, DOI 10.1172/JCI117187; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338; Lorenzo JA, 1998, ENDOCRINOLOGY, V139, P3022, DOI 10.1210/en.139.6.3022; MIYAURA C, 1995, J BONE MINER RES, V10, P1365; Nguyen MT, 1997, NATURE, V390, P78, DOI 10.1038/36342; Onoe Y, 1996, J IMMUNOL, V156, P758; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; RAISZ LG, 1979, PROSTAGLANDINS, V17, P905, DOI 10.1016/0090-6980(79)90061-3; Sakuma Y, 2000, J BONE MINER RES, V15, P218, DOI 10.1359/jbmr.2000.15.2.218; SATO K, 1986, BIOCHEM BIOPH RES CO, V138, P618, DOI 10.1016/S0006-291X(86)80541-1; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Suda M, 1996, ENDOCRINOLOGY, V137, P1698, DOI 10.1210/en.137.5.1698; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SUGIMOTO Y, 1994, AM J PHYSIOL, V266, pF823, DOI 10.1152/ajprenal.1994.266.5.F823; Tai H, 1997, ENDOCRINOLOGY, V138, P2372, DOI 10.1210/en.138.6.2372; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; USHIKUBI F, 1995, J LIPID MEDIAT CELL, V12, P343, DOI 10.1016/0929-7855(95)00022-I; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481	28	162	173	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19819	19823		10.1074/jbc.M002079200	http://dx.doi.org/10.1074/jbc.M002079200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10749873	hybrid			2022-12-27	WOS:000087941300053
J	Peters, GH; Iversen, LF; Branner, S; Andersen, HS; Mortensen, SB; Olsen, OH; Moller, KB; Moller, NPH				Peters, GH; Iversen, LF; Branner, S; Andersen, HS; Mortensen, SB; Olsen, OH; Moller, KB; Moller, NPH			Residue 259 is a key determinant of substrate specificity of protein-tyrosine phosphatases 1B and alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; INSULIN-RECEPTOR; INHIBITOR DESIGN; STRUCTURAL BASIS; MALACHITE GREEN; PEPTIDE; IDENTIFICATION; INTERMEDIATE; RECOGNITION; HYDROLYSIS	The aim of this study was to define the structural elements that determine the differences in substrate recognition capacity of two protein-tyrosine phosphatases (PTPs), PTP1B and PTP alpha, both suggested to be negative regulators of insulin signaling. Since the Ac-DADE(pY)L-NH2 peptide is well recognized by PTP1B, but less efficiently by PTP alpha, it was chosen as a tool for these analyses, C alpha regiovariation analyses and primary sequence alignments indicate that residues 47, 48, 258, and 259 (PTP1B numbering) define a selectivity-determining region. By analyzing a set of DADE(pY)L analogs with a series of PTP mutants in which these four residues were exchanged between PTP1B and PTP alpha, either in combination or alone, we here demonstrate that the key selectivity-determining residue is 259, In PTP alpha, this residue is a glutamine causing steric hindrance and in PTP1B a glycine allowing broad substrate recognition. Significantly, replacing Gln(259) with a glycine almost turns PTP alpha into a PTP1B-like enzyme. By using a novel set of PTP inhibitors and x-ray crystallography, we further provide evidence that Gln(259) in PTP alpha plays a dual role leading to restricted substrate recognition (directly via steric hindrance) and reduced catalytic activity (indirectly via Gln(262)). Both effects may indicate that PTPa: regulates highly selective signal transduction processes.	Tech Univ Denmark, Dept Chem, Membrane & Stat Phys Grp, DK-2800 Lyngby, Denmark; Novo Nordisk AS, Prot Chem, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Signal Transduction, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Med Chem Res 1, DK-2760 Malov, Denmark; Novo Nordisk AS, Med Chem Res 4, DK-2760 Malov, Denmark	Technical University of Denmark; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk	Moller, NPH (corresponding author), Tech Univ Denmark, Dept Chem, Membrane & Stat Phys Grp, DK-2800 Lyngby, Denmark.	ghp@kemi.dtu.dk; nphm@novo.dk	Peters, Günther H.J./T-7100-2017	Peters, Günther H.J./0000-0001-9754-2663				Andersen HS, 2000, J BIOL CHEM, V275, P7101, DOI 10.1074/jbc.275.10.7101; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Buist P, 1999, BIOCHEMISTRY-US, V38, P914, DOI 10.1021/bi981936b; Burke TR, 1998, BIOPOLYMERS, V47, P225, DOI 10.1002/(SICI)1097-0282(1998)47:3<225::AID-BIP3>3.0.CO;2-O; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; CARTER SG, 1982, J BIOCHEM BIOPH METH, V7, P7, DOI 10.1016/0165-022X(82)90031-8; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Dunn D, 1996, J BIOL CHEM, V271, P168, DOI 10.1074/jbc.271.1.168; EKMAN P, 1993, ANAL BIOCHEM, V214, P138, DOI 10.1006/abio.1993.1468; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Evans J L, 1999, Expert Opin Investig Drugs, V8, P139, DOI 10.1517/13543784.8.2.139; FISHER DK, 1994, PHARMACEUT RES, V11, P759, DOI 10.1023/A:1018996817529; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GEWALD K, 1966, CHEM BER-RECL, V99, P94, DOI 10.1002/cber.19660990116; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Huyer G, 1998, ANAL BIOCHEM, V258, P19, DOI 10.1006/abio.1997.2541; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Lammers R, 1997, FEBS LETT, V404, P37, DOI 10.1016/S0014-5793(97)00080-X; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; RAMACHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P4232, DOI 10.1021/bi00132a012; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; Taing M, 1999, BIOCHEMISTRY-US, V38, P3793, DOI 10.1021/bi9813781; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Wrobel J, 1999, J MED CHEM, V42, P3199, DOI 10.1021/jm990260v; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040	46	52	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18201	18209		10.1074/jbc.M910273199	http://dx.doi.org/10.1074/jbc.M910273199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748206	hybrid			2022-12-27	WOS:000087659400041
J	Rezvani, M; Liew, CC				Rezvani, M; Liew, CC			Role of the adenomatous polyposis coli gene product in human cardiac development and disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APC TUMOR-SUPPRESSOR; HEART CDNA LIBRARY; EXPRESSED SEQUENCE TAGS; BETA-CATENIN; CARDIOVASCULAR-SYSTEM; E-CADHERIN; IDENTIFICATION; MUTATIONS; CANCER; CELLS	Expressed sequence tag (EST) and digital Northern analyses of human fetal, adult, and hypertrophic heart cDNA libraries revealed ESTs with high homology to adenomatosis polyposis coli (APC) and its associated protein, beta-catenin, as web as their differential expression, Thus, we hypothesize that the APC/beta-catenin pathway may play a role in cardiac development and disease. Reverse transcriptase-polymerase chain reaction analysis exhibited a higher APC expression in adult compared with fetal and hypertrophic heart but no significant difference in beta-catenin mRNA level. However, beta-catenin protein level was higher in fetal and hypertrophic heart compared with adult heart, suggesting the post-translational regulation of beta-catenin by APC in the cardiovascular system. In nitro antisense inhibition of APC resulted a higher beta-catenin protein expression leading to an incomplete myotube formation, suggesting APC/beta-catenin pathway involvement in myotube development. Western blot analysis further reveals three novel isoforms, APC-F, APC-A, and APC-D, ubiquitously expressed in fetal, adult, and hypertrophic heart, respectively. Isoform switching during development and disease pathogenesis suggests functionally distinct roles for each isoform. These data (i) demonstrate the usefulness of genome-based expression analysis for rapid discovery of differentially expressed genes, (ii) implicate the APC/beta-catenin pathway in the cardiovascular development, and (iii) demonstrate APC isoform switching during cardiac development and disease.	Univ Toronto, Toronto Hosp, Inst Med Sci, Cardiovasc Res Ctr, Toronto, ON M5G 1L5, Canada; Univ Toronto, Toronto Hosp, Cardiac Gene Unit, Toronto, ON M5G 1L5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Liew, CC (corresponding author), Brigham & Womens Hosp, Thorn Bldg,Rm 1326,75 Francis St, Boston, MA 02115 USA.							BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BRODSKY WY, 1980, CELL TISSUE RES, V210, P133; CLAYCOMB WC, 1992, TRENDS CARDIOVAS MED, V2, P231, DOI 10.1016/1050-1738(92)90030-V; CLUBB FJ, 1984, LAB INVEST, V50, P571; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GROSSMAN W, 1980, AM J MED, V69, P576, DOI 10.1016/0002-9343(80)90471-4; GRUVER CL, 1992, TRENDS CARDIOVAS MED, V2, P226, DOI 10.1016/1050-1738(92)90029-R; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; HWANG DM, 1994, J MOL CELL CARDIOL, V26, P1329, DOI 10.1006/jmcc.1994.1151; HWANG DM, 1995, GENOMICS, V30, P293, DOI 10.1006/geno.1995.9874; Hwang DM, 1997, CIRCULATION, V96, P4146; Ilyas M, 1997, J PATHOL, V182, P128; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; LIEW CC, 1993, J MOL CELL CARDIOL, V25, P891, DOI 10.1006/jmcc.1993.1101; LIEW CC, 1994, P NATL ACAD SCI USA, V91, P10645, DOI 10.1073/pnas.91.22.10645; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; MCMAHON DK, 1994, AM J PHYSIOL, V266, pC1795, DOI 10.1152/ajpcell.1994.266.6.C1795; Moon RT, 1997, TRENDS GENET, V13, P256, DOI 10.1016/S0168-9525(97)01196-7; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OLSCHWANG S, 1993, CELL, V75, P959, DOI 10.1016/0092-8674(93)90539-3; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pyles RB, 1998, ONCOGENE, V16, P77, DOI 10.1038/sj.onc.1201505; REZVANI M, 1998, GENOME MAPPING SEQUE, P198; Rumyantsev P P, 1977, Int Rev Cytol, V51, P186; RUMYANTSEV PP, 1991, GROWTH HYPERPLASIA C, P70; Sansoucie D A, 1997, Neonatal Netw, V16, P5; Santoro IM, 1997, CANCER RES, V57, P488; Sheng HM, 1998, CARCINOGENESIS, V19, P543, DOI 10.1093/carcin/19.4.543	32	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18470	18475		10.1074/jbc.M000870200	http://dx.doi.org/10.1074/jbc.M000870200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10749862	hybrid			2022-12-27	WOS:000087659400076
J	Tortorella, MD; Pratta, M; Liu, RQ; Austin, J; Ross, OH; Abbaszade, I; Burn, T; Arner, E				Tortorella, MD; Pratta, M; Liu, RQ; Austin, J; Ross, OH; Abbaszade, I; Burn, T; Arner, E			Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; INTERGLOBULAR DOMAIN; MATRIX METALLOPROTEINASE; CATABOLISM; IDENTIFICATION; DEGRADATION; PROTEOLYSIS; MECHANISM; CLONING; FAMILY	Aggrecan, the major proteoglycan of cartilage that provides its mechanical properties of compressibility and elasticity; is one of the first matrix components to undergo measurable loss in arthritic diseases. Two major sites of proteolytic cleavage have been identified within the interglobular domain (IGD) of the aggrecan core protein, one between amino acids Asn(341)-Phe(342) which is cleaved by matrix metalloproteinases and the other between Glu(373)-Ala(374) that is attributed to aggrecanase. Although several potential aggrecanase-sensitive sites had been identified within the COOH terminus of aggrecan, demonstration that aggrecanase cleaved at these sites awaited isolation and purification of this protease. We have recently cloned human aggrecanase-1 (ADAMTS-4) (Tortorella, M. D., Burn, T. C., Pratta, M. A., Abbaszade, I., Hollis, J. M., Liu, R., Rosenfeld, S. A., Copeland, R. A., Decicco, C. P., Wynn, R., Rockwell, A, Yang, F., Duke, J. L., SoIomon, K., George, H., Bruckner, R., Nagase, H., Itoh, Y., Ellis, D. M., Boss, H., Wiswall, B. H., Murphy, K., Hillman, M. C., Jr., Hollis, G. F., Newton, a C., Magolda, R L., Trzaskos, J. M, and Arner, E. C. (1999) Science 284, 1664-1666) and herein demonstrate that in addition to cleavage at the Glu(373)-Ala(374) bond, this protease cleaves at four sites within the chondroitin-sulfate rich region of the aggrecan core protein, between G2 and G3 globular domains. importantly, we show that this cleavage occurs more efficiently than cleavage within the IGD at the Glu(373)-Ala(374) bond. Cleavage occurred preferentially at the KEEE(1667-1668)GLGS bond to produce both a 140-kDa COOH-terminal fragment and a 375-kDa fragment that retains an intact G1. Cleavage also occurred at the GELE(1480-1481)GRGT bond to produce a 55-kDa COOH-terminal fragment and a G1-containing fragment of 320 hDa Cleavage of this 320-kDa fragment within the IGD at the Glu(373)-Ala(374) bond then occurred to release the 250-kDa BC-3-reactive fragment from the G1 domain. The 140-kDa GLGS-reactive fragment resulting from the preferential cleavage was further processed at two additional cleavage sites, at TAQE(1771-1172)AGEG and at VSQE(1871-1872)LGQR resulting in the formation of a 98-kDa fragment with an intact G3 domain and two small fragments of similar to 20 kDa. These data elucidate the sites and efficiency of cleavage during aggrecan degradation by aggrecanase and suggest potential tools for monitoring aggrecan cleavage in arthritis.	Dupont Merck Pharmaceut Co, Dept Inflammatory Dis Res, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Dept Appl Biotechnol, Wilmington, DE 19880 USA	DuPont; DuPont	Tortorella, MD (corresponding author), Kennedy Inst Rheumatol, 1 Aspenlea Rd, London W6 8LH, England.			Burn, Timothy/0000-0001-6648-4333				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arner EC, 1997, J BIOL CHEM, V272, P9294; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Dudhia J, 1996, BIOCHEM J, V313, P933, DOI 10.1042/bj3130933; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, ORTHOP T, V17, P677; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Ilic MZ, 1998, J BIOL CHEM, V273, P17451, DOI 10.1074/jbc.273.28.17451; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LEULAKIS P, 1992, BIOCHEM J, V264, P589; Miller Chad G., 1994, Methods (Orlando), V6, P315, DOI 10.1006/meth.1994.1032; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; Sandy JD, 1995, ACTA ORTHOP SCAND, V66, P26, DOI 10.3109/17453679509157643; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Tortorella MD, 1998, J BIOL CHEM, V273, P5846, DOI 10.1074/jbc.273.10.5846; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664	24	189	198	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18566	18573		10.1074/jbc.M909383199	http://dx.doi.org/10.1074/jbc.M909383199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10751421	hybrid			2022-12-27	WOS:000087659400089
J	Valentin, G; Chiarelli, L; Fortin, R; Speranza, ML; Galizzi, A; Mattevi, A				Valentin, G; Chiarelli, L; Fortin, R; Speranza, ML; Galizzi, A; Mattevi, A			The allosteric regulation of pyruvate kinase - A site-directed mutagenesis study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYTIC-ANEMIA; ESCHERICHIA-COLI; TRANSITION; SUBSTITUTION; ENZYME; GENE	Pyruvate kinase (PK) is critical for the regulation of the glycolytic pathway. The regulatory properties of Escherichia coli mere investigated by mutating six charged residues involved in interdomain salt bridges (Arg(271), Arg(292), Asp(297), and Lys(413)) and in the binding of the allosteric activator (Lys(382) and Arg(431)). Arg(271) and Lys(413) are located at the interface between A and C domains within one subunit, The R271L and K413Q mutant enzymes exhibit altered kinetic properties. In K413Q, there is partial enzyme activation, whereas R271L is characterized by a bias toward the T-state in the allosteric equilibrium. In the T-state, Arg(292) and Asp(297) form an intersubunit salt bridge. The mutants R292D and D297R are totally inactive. The crystal structure of R292D reveals that the mutant enzyme retains the T-state quaternary structure. However, the mutation induces a reorganization of the interface with the creation of a network of interactions similar to that observed in the crystal structures of R-state yeast and M1 PK proteins. Furthermore, in the R292D structure, two loops that are part of the active site are disordered. The K382Q and R431E mutations were designed to probe the binding site for fructose 1,6-bisphosphate, the allosteric activator. R431E exhibits only slight changes in the regulatory properties. Conversely, K382Q displays a highly altered responsiveness to the activator, suggesting that Lys(382) is involved in both activator binding and allosteric transition mechanism. Taken together, these results support the notion that domain interfaces are critical for the allosteric transition. They couple changes in the tertiary and quaternary structures to alterations in the geometry of the fructose 1,6-bisphosphate and substrate binding sites. These site-directed mutagenesis data are discussed in the light of the molecular basis for the hereditary nonspherocytic hemolytic anemia, which is caused by mutations in human erythrocyte PK gene.	Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy	University of Pavia; University of Pavia	Valentin, G (corresponding author), Univ Pavia, Dept Biochem, Via Taramelli 3B, I-27100 Pavia, Italy.	giovale@unipv.it	Chiarelli, Laurent Roberto/J-8368-2016; Mattevi, Andrea/R-4469-2019; mattevi, andrea/K-5464-2012	Chiarelli, Laurent Roberto/0000-0003-0348-9764; Mattevi, Andrea/0000-0002-9523-7128; mattevi, andrea/0000-0002-9523-7128				Allen SC, 1996, ACTA CRYSTALLOGR D, V52, P499, DOI 10.1107/S0907444995016040; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARONCIANI L, 1995, J CLIN INVEST, V95, P1702, DOI 10.1172/JCI117846; Baronciani L, 1998, BLOOD CELL MOL DIS, V24, P271, DOI 10.1006/bcmd.1998.0193; BUCHER T, 1955, METHOD ENZYMOL, V1, P435, DOI 10.1016/0076-6879(55)01071-9; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; Friesen RHE, 1998, BIOCHEMISTRY-US, V37, P2949, DOI 10.1021/bi971990c; Ikeda Y, 1997, J BIOL CHEM, V272, P20495, DOI 10.1074/jbc.272.33.20495; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; KANNO H, 1994, BLOOD, V83, P2311; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LENZNER C, 1994, BLOOD, V83, P2817, DOI 10.1182/blood.V83.10.2817.2817; Lovell SC, 1998, J MOL BIOL, V276, P839, DOI 10.1006/jmbi.1997.1569; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mattevi A, 1996, FEBS LETT, V389, P15, DOI 10.1016/0014-5793(96)00462-0; MATTEVI A, 1995, STRUCTURE, V3, P729, DOI 10.1016/S0969-2126(01)00207-6; Mesecar AD, 1997, BIOCHEMISTRY-US, V36, P6792, DOI 10.1021/bi962869t; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nickoloff J A, 1996, Methods Mol Biol, V58, P455; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; Rigden DJ, 1999, J MOL BIOL, V291, P615, DOI 10.1006/jmbi.1999.2918; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Valentini G, 1997, BIOL CHEM, V378, P719; VANSCHAFTINGEN E, 1985, EUR J BIOCHEM, V153, P403, DOI 10.1111/j.1432-1033.1985.tb09316.x; WALKER D, 1992, J MOL BIOL, V228, P265, DOI 10.1016/0022-2836(92)90505-E	29	130	134	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18145	18152		10.1074/jbc.M001870200	http://dx.doi.org/10.1074/jbc.M001870200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10751408	hybrid			2022-12-27	WOS:000087659400034
J	Hwang, JR; Siekhaus, DE; Fuller, RS; Taghert, PH; Lindberg, I				Hwang, JR; Siekhaus, DE; Fuller, RS; Taghert, PH; Lindberg, I			Interaction of Drosophila melanogaster prohormone convertase 2 and 7B2 - Insect cell-specific processing and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROENDOCRINE POLYPEPTIDE 7B2; PROPROTEIN CONVERTASES; PROTEIN 7B2; ENZYMATIC CHARACTERIZATION; PITUITARY POLYPEPTIDE; PRECURSOR PROTEINS; SUBTILISIN FAMILY; MESSENGER-RNAS; GENE-PRODUCTS; PC2	The prohormone convertases (PCs) are an evolutionarily ancient group of proteases required for the maturation of neuropeptide and peptide hormone precursors. In Drosophila melanogaster, the homolog of prohormone convertase 2, dPC2 (amontillado), is required for normal hatching behavior, and immunoblotting data indicate that flies express 80- and 75-kDa forms of this protein. Because mouse PC2 (mPC2) requires 7B2, a helper protein for productive maturation, we searched the fly data base for the 7B2 signature motif PPNPCP and identified an expressed sequence tag clone encoding the entire open reading frame for this protein. dPC2 and d7B2 cDNAs were subcloned into expression vectors for transfection into HEK-293 cells; mPC2 and rat 7B2 were used as controls. Although active mPC2 was detected in medium in the presence of either d7B2 or r7B2, dPC2 showed no proteolytic activity upon coexpression of either d7B2 or r7B2. Labeling experiments showed that dPC2 was synthesized but not secreted from HEK-293 cells. However, when dPC2 and either d7B2 or r7B2 were coexpressed in Drosophila S2 cells, abundant immunoreactive dPC2 was secreted into the medium, coincident with the appearance of PC2 activity. Expression and secretion of dPC2 enzyme activity thus appears to require insect cell-specific posttranslational processing events. The significant differences in the cell biology of the insect and mammalian enzymes, with 7B2 absolutely required for secretion of dPC2 and zymogen conversion occurring intracellularly in the case of dPC2 but not mPC2, support the idea that the Drosophila enzyme has specific requirements for maturation and secretion that can be met only in insect cells.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Stanford University; University of Michigan System; University of Michigan; Washington University (WUSTL)	Lindberg, I (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	ilindb@lsumc.edu	Lindberg, Iris/Q-3825-2019; Siekhaus, Daria/AAN-1779-2020	Siekhaus, Daria/0000-0001-8323-8353	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039697, R55GM039697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021749] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK049703, DK49703] Funding Source: Medline; NIGMS NIH HHS [GM39697] Funding Source: Medline; NINDS NIH HHS [NS21749] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AYOUBI TAY, 1990, J BIOL CHEM, V265, P15644; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; Barbero P, 1999, BIOCHEM BIOPH RES CO, V257, P473, DOI 10.1006/bbrc.1999.0495; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; Fortenberry Y, 1999, J NEUROCHEM, V73, P994, DOI 10.1046/j.1471-4159.1999.0730994.x; GOMEZSALADIN E, 1994, CELL MOL NEUROBIOL, V14, P9, DOI 10.1007/BF02088586; Hewes RS, 1998, J NEUROSCI, V18, P7138; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; HU NP, 1994, ONCOGENE, V9, P1021; Johanning K, 1996, J NEUROCHEM, V66, P898; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; Lindberg I, 1998, DNA CELL BIOL, V17, P727, DOI 10.1089/dna.1998.17.727; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; MAINS RE, 1995, MOL ENDOCRINOL, V9, P3, DOI 10.1210/me.9.1.3; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MARTENS GJM, 1989, EUR J BIOCHEM, V181, P75, DOI 10.1111/j.1432-1033.1989.tb14695.x; MBIKAY M, 1994, GENOMICS, V20, P231, DOI 10.1006/geno.1994.1158; MCCORMICK J, 1993, J COMP NEUROL, V338, P279, DOI 10.1002/cne.903380210; McNabb SL, 1997, NEURON, V19, P813, DOI 10.1016/S0896-6273(00)80963-0; Meerabux J, 1996, CANCER RES, V56, P448; MINEO I, 1995, BIOCHEM BIOPH RES CO, V207, P646, DOI 10.1006/bbrc.1995.1236; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Muller L, 1999, J BIOL CHEM, V274, P21471, DOI 10.1074/jbc.274.30.21471; Muller L, 1997, J CELL BIOL, V139, P625, DOI 10.1083/jcb.139.3.625; Muller L, 2000, PROG NUCLEIC ACID RE, V63, P69, DOI 10.1016/S0079-6603(08)60720-5; NAGLE GT, 1995, DNA CELL BIOL, V14, P431, DOI 10.1089/dna.1995.14.431; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nassel DR, 1996, CURR OPIN NEUROBIOL, V6, P842, DOI 10.1016/S0959-4388(96)80036-5; Ottaviani E, 1996, PROG NEUROBIOL, V48, P421, DOI 10.1016/0301-0082(95)00049-6; PAQUET L, 1994, J BIOL CHEM, V269, P19279; PAQUET L, 1991, FEBS LETT, V294, P23, DOI 10.1016/0014-5793(91)81334-5; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Rouille Y, 1997, FEBS LETT, V413, P119, DOI 10.1016/S0014-5793(97)00892-2; Rouille Y, 1997, J BIOL CHEM, V272, P32810, DOI 10.1074/jbc.272.52.32810; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHNEIDER LE, 1993, J COMP NEUROL, V337, P446, DOI 10.1002/cne.903370308; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Seidel B, 1998, DNA CELL BIOL, V17, P1017, DOI 10.1089/dna.1998.17.1017; SHEN FS, 1993, J BIOL CHEM, V268, P24910; Siekhaus DE, 1999, J NEUROSCI, V19, P6942, DOI 10.1523/JNEUROSCI.19-16-06942.1999; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SMIT AB, 1992, FEBS LETT, V312, P213, DOI 10.1016/0014-5793(92)80938-D; Spijker S, 1997, J BIOL CHEM, V272, P4116, DOI 10.1074/jbc.272.7.4116; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Taylor NA, 1997, BIOCHEM J, V321, P367, DOI 10.1042/bj3210367; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANHORSSEN AM, 1995, J BIOL CHEM, V270, P14292; VEENSTRA JA, 1994, BIOCHEM BIOPH RES CO, V204, P292, DOI 10.1006/bbrc.1994.2458; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641; Zhu XR, 1998, J BIOL CHEM, V273, P1158, DOI 10.1074/jbc.273.2.1158	72	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17886	17893		10.1074/jbc.M000032200	http://dx.doi.org/10.1074/jbc.M000032200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10749852	hybrid			2022-12-27	WOS:000087485000093
J	Tamai, E; Belyaeva, TA; Busby, SJW; Tsuchiya, T				Tamai, E; Belyaeva, TA; Busby, SJW; Tsuchiya, T			Mutations that increase the activity of the promoter of the Escherichia coli melibiose operon improve the binding of Me1R, a transcription activator triggered by melibiose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY REGION; DNA-BINDING; PROTEIN; SEQUENCES	MelR is an Escherichia coli transcription factor that activates expression of the melAB operon in response to the presence of melibiose in the environment. MelR stimulates transcription initiation at the melAB promoter by binding to four sites centered at positions -120.5, -100.5, -62.5, and -42.5 upstream of the transcript start point. In a previous study, we described a spontaneous mutant that exhibited increased melAB expression. Sequence analysis showed that this mutant carries five consecutive base changes at positions -49, -50, -51, -52, and -58 upstream of the melAB transcript start. Here we show that these changes improve MelR binding to the target site centered at position -42.5 at the melAB promoter and that this improvement is responsible for increased promoter activity. Thus, the activity of the melAB promoter is fixed by the occupation by MelR of a DNA site that overlaps the -35 hex- amer: MelR appears to be a typical class II-type transcription activator.	Okayama Univ, Fac Pharmaceut Sci, Dept Microbiol, Okayama 7008530, Japan; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	Okayama University; University of Birmingham	Tsuchiya, T (corresponding author), Okayama Univ, Fac Pharmaceut Sci, Dept Microbiol, 3-1-1 Tsushima Naka, Okayama 7008530, Japan.	tsuchiya@phesant.pharm.okayama-u.ac.jp	Busby, Stephen/C-2712-2015	Busby, Stephen/0000-0003-2148-1758; TAMAI, EIJI/0000-0002-0338-5095				Belyaeva TA, 2000, MOL MICROBIOL, V36, P211, DOI 10.1046/j.1365-2958.2000.01849.x; Bourgerie SJ, 1997, NUCLEIC ACIDS RES, V25, P1685, DOI 10.1093/nar/25.9.1685; CASWELL R, 1992, BIOCHEM J, V287, P493, DOI 10.1042/bj2870493; COULONDRE C, 1977, J MOL BIOL, V117, P525, DOI 10.1016/0022-2836(77)90056-0; Gallegos MT, 1997, MICROBIOL MOL BIOL R, V61, P393, DOI 10.1128/.61.4.393-410.1997; HANATANI M, 1984, J BIOL CHEM, V259, P1807; KOLB A, 1995, NUCLEIC ACIDS RES, V23, P819, DOI 10.1093/nar/23.5.819; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEVINTHAL M, 1971, J BACTERIOL, V105, P1047, DOI 10.1128/JB.105.3.1047-1052.1971; LODGE J, 1992, FEMS MICROBIOL LETT, V95, P271; PRESTIDGE LS, 1965, BIOCHIM BIOPHYS ACTA, V100, P591, DOI 10.1016/0304-4165(65)90029-2; Rhodius VA, 1998, CURR OPIN MICROBIOL, V1, P152, DOI 10.1016/S1369-5274(98)80005-2; Savery N. J., 1996, ESSENTIAL TECHNIQUES, P1; SCHMITT R, 1968, J BACTERIOL, V96, P462, DOI 10.1128/JB.96.2.462-471.1968; Tamai E, 1998, J BIOL CHEM, V273, P16860, DOI 10.1074/jbc.273.27.16860; TSUCHIYA T, 1976, J MEMBRANE BIOL, V42, P45; WEBSTER C, 1988, GENE, V68, P297, DOI 10.1016/0378-1119(88)90032-7; WEBSTER C, 1987, GENE, V59, P253, DOI 10.1016/0378-1119(87)90333-7; WEBSTER C, 1989, GENE, V83, P207, DOI 10.1016/0378-1119(89)90106-6; WILLIAMS J, 1994, BIOCHEM J, V300, P757, DOI 10.1042/bj3000757	20	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17058	17063		10.1074/jbc.M000499200	http://dx.doi.org/10.1074/jbc.M000499200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747919				2022-12-27	WOS:000087392200092
J	Rausch, JW; Sathyanarayana, BK; Bona, MK; Le Grice, SFJ				Rausch, JW; Sathyanarayana, BK; Bona, MK; Le Grice, SFJ			Probing contacts between the ribonuclease H domain of HIV-1 reverse transcriptase and nucleic acid by site-specific photocross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; C-TERMINAL DOMAIN; CROSS-LINKING; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; FOOTPRINT ANALYSIS; STRAND TRANSFER; DNA COMPLEX; PRIMER GRIP; PROTEIN	Cys(38) and Cys(280) Of p66/p51 human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) can be converted to Ser without affecting enzyme function. We have exploited this feature to construct and purify "monocysteine" RT derivatives for site-specific modification with the photoactivable cross-linking agent, p-azidophenacyl bromide. Acylation of a unique cysteine residue introduced at the extreme C terminus of the p66 subunit (C-561) With an azidophenacyl group allowed us to probe contacts between residues C-terminal to alpha-helix E' of the RNase H domain and structurally divergent nucleic acid duplexes. In a binary complex of RT and template-primer, we demonstrate efficient cross-linking to primer nucleotides -21 to -24/-25, and template nucleotides -18 to -21, Cross-linking specificity was confirmed by an analogous evaluation following limited primer extension, where the profile is displaced by the register of DNA synthesis. Finally, contact with a DNA primer hybridized to an isogenic RNA or DNA template indicates subtle alterations in cross-linking specificity, suggesting differences in nucleic acid geometry between duplex DNA and RNA/DNA hybrids at the RNase H domain. These data exemplify how site-specific acylation of HIV-1 RT can be used to provide high resolution structural data to complement crystallographic studies.	Natl Canc Inst, Frederick Canc Res & Dev Ctr, HIV Drug Resistance Program, Frederick, MD 21072 USA; Natl Canc Inst, Frederick Canc Res & Dev Ctr, Sci Applicat Int Corp, Frederick, MD 21072 USA; NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Le Grice, SFJ (corresponding author), Natl Canc Inst, Frederick Canc Res & Dev Ctr, HIV Drug Resistance Program, Frederick, MD 21072 USA.	slegrice@mail.ncifcrf.gov			NIGMS NIH HHS [GM 52263] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC010314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052263] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartegi A, 1999, EUR J BIOCHEM, V262, P335, DOI 10.1046/j.1432-1327.1999.00390.x; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; Canard B, 1997, P NATL ACAD SCI USA, V94, P11279, DOI 10.1073/pnas.94.21.11279; Chen CB, 1998, CHEM BIOL, V5, P283, DOI 10.1016/S1074-5521(98)90621-4; Culver GM, 1999, J MOL BIOL, V286, P355, DOI 10.1006/jmbi.1998.2483; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DUMOULIN P, 1993, P NATL ACAD SCI USA, V90, P2030, DOI 10.1073/pnas.90.5.2030; Dumoulin P, 1996, BIOCHEMISTRY-US, V35, P4279, DOI 10.1021/bi9529162; EBRIGHT RH, 1990, P NATL ACAD SCI USA, V87, P2882, DOI 10.1073/pnas.87.8.2882; Endrich MM, 1999, J BIOL CHEM, V274, P5326, DOI 10.1074/jbc.274.9.5326; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; Gotte M, 1998, J BIOL CHEM, V273, P10139, DOI 10.1074/jbc.273.17.10139; Hall KB, 1999, METHODS, V18, P78, DOI 10.1006/meth.1999.0759; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; Jaeger J, 1998, EMBO J, V17, P4535, DOI 10.1093/emboj/17.15.4535; KANG ME, 1995, J BIOL CHEM, V270, P23390, DOI 10.1074/jbc.270.40.23390; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; Mandal AK, 1998, PROTEIN SCI, V7, P1046; Maxam A M, 1980, Methods Enzymol, V65, P499; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; Murakami K, 1997, P NATL ACAD SCI USA, V94, P1709, DOI 10.1073/pnas.94.5.1709; Pan CQ, 1996, BIOCHEMISTRY-US, V35, P4326, DOI 10.1021/bi952040z; PAN CQ, 1995, PROTEIN SCI, V4, P2279, DOI 10.1002/pro.5560041105; Rausch JW, 1996, J MOL BIOL, V257, P500, DOI 10.1006/jmbi.1996.0181; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; Wisniewski M, 1999, J BIOL CHEM, V274, P28175, DOI 10.1074/jbc.274.40.28175; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; WOHRL BM, 1995, SCIENCE, V267, P96, DOI 10.1126/science.7528942; WOHRL BM, 1994, J BIOL CHEM, V269, P8541; YANG SW, 1994, P NATL ACAD SCI USA, V91, P12183, DOI 10.1073/pnas.91.25.12183; Zhou YB, 1998, NATURE, V395, P402, DOI 10.1038/26521	40	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16015	16022		10.1074/jbc.M909808199	http://dx.doi.org/10.1074/jbc.M909808199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748161	hybrid			2022-12-27	WOS:000087291400056
J	Lemercier, C; Verdel, A; Galloo, B; Curtet, S; Brocard, MP; Khochbin, S				Lemercier, C; Verdel, A; Galloo, B; Curtet, S; Brocard, MP; Khochbin, S			mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN; COMPLEX; FAMILY; YEAST; PROTEINS; DIFFERENTIATION; IDENTIFICATION; HDA1P; ROLES; HDAC4	Recently we identified a new family of histone deacetylases in higher eukaryotes related to yeast HDA1 and showed their differentiation-dependent expression. Data presented here indicate that HDAC5 (previously named mHDA1), one member of this family, might be a potent regulator of cell differentiation by interacting specifically with determinant transcription factors. We found that HDAC5 was able to interact in vivo and in vitro with MEF2A a MADS box transcription factor, and to strongly inhibit its transcriptional activity. Surprisingly, this repression was independent of HDAC5 deacetylase domain. The N-terminal non-deacetylase domain of HDAC5 was able to ensure an efficient repression of MEF2A-dependent transcription. We then mapped protein domains involved in the HDAC5-MEF2A interaction and showed that MADS box/MEF2-domain region of MEF2A interacts specifically with a limited region in the N-terminal part of HDAC5 which also possesses a distinct repressor domain. These data show that two independent class II histone deacetylases HDAC4 and HDAC5 are able to interact with members of the MEF2 transcription factor family and regulate their transcriptional activity, thus suggesting a critical role for these deacetylases in the control of cell proliferation/differentiation.	Fac Med, Inst Albert Bonniot, Lab Biol Mol & Cellulaire Differenciat, INSERM,U309,Equipe Chromatine & Express Genes, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Khochbin, S (corresponding author), Fac Med, Inst Albert Bonniot, Lab Biol Mol & Cellulaire Differenciat, INSERM,U309,Equipe Chromatine & Express Genes, Domaine Merci, F-38706 La Tronche, France.	khochbin@ujf-grenoble.fr	CURTET, Sandrine/N-3517-2013; CURTET, Sandrine/E-8217-2019; Verdel, André/M-5201-2013; Khochbin, Saadi/M-8090-2013; Lemercier, Claudie/F-6759-2015	CURTET, Sandrine/0000-0002-9419-8868; Khochbin, Saadi/0000-0002-0455-0857; VERDEL, Andre/0000-0001-6048-3794				Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Gorka C, 1998, J BIOL CHEM, V273, P1208, DOI 10.1074/jbc.273.2.1208; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Huang EY, 2000, GENE DEV, V14, P45; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kao HY, 2000, GENE DEV, V14, P55; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Theissen G, 1996, J MOL EVOL, V43, P484, DOI 10.1007/BF02337521; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Turner BM, 1999, SEMIN CELL DEV BIOL, V10, P165, DOI 10.1006/scdb.1999.0297; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	26	166	170	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15594	15599		10.1074/jbc.M908437199	http://dx.doi.org/10.1074/jbc.M908437199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748098	hybrid, Green Submitted			2022-12-27	WOS:000087128300110
J	Yamada, K; Nakata, M; Horimoto, N; Saito, M; Matsuoka, H; Inagaki, N				Yamada, K; Nakata, M; Horimoto, N; Saito, M; Matsuoka, H; Inagaki, N			Measurement of glucose uptake and intracellular calcium concentration in single, living pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-18 FLUORODEOXYGLUCOSE; TRANSPORTER ISOFORMS; INSULIN-SECRETION; CYTOCHALASIN-B; RAT; EXPRESSION; ISLETS; INHIBITION; METABOLISM; LANGERHANS	There has been no method previously to measure both glucose transport and its effect on the various intracellular functions in single, living mammalian cells. A fluorescent derivative of D-glucose, 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose (2-NBDG), that we have developed has made such measurements possible. COS-1 cells that overexpress the human glucose transporter GLUT2 show significantly greater 2-NBDG uptake than mock transfected cells. Using GLUT2-abundant mouse insulin-secreting clonal MING cells, we found that 2-NBDG was incorporated into the cells in a time- and concentration-dependent manner. The 2-NBDG uptake was inhibited by high concentrations of D-glucose in a dose-dependent manner and also was almost completely inhibited by 10 mu M cytochalasin B. We then measured both glucose uptake and the intracellular calcium concentration ([Ca2+](i)) in single, living pancreatic islet cells. 2-NBDG and fura-2 were used as the tracer of glucose and indicator of intracellular calcium, respectively. All of the cells that showed an increase in [Ca2+](i) in response to a high concentration of glucose (16.8 mM) rapidly incorporated significant 2-NBDG, Immunocytochemical examination confirmed these cells to be insulin-positive beta-cells, All of the cells that showed no significant, rapid 2-NBDG uptake lacked such glucose responsiveness of [Ca2+](i), indicating that these cells were non-beta-cells such as glucagon-positive alpha-cells. These results show the uptake of glucose causing a concomitant increase of [Ca2+](i) in beta-cells, Because 2-NBDG is incorporated into mammalian cells through glucose transporters, it should be useful for the measurement of glucose uptake together with concomitant intracellular activities in many types of single, living mammalian cells.	Akita Univ, Sch Med, Dept Physiol, Akita 0108543, Japan; Tokyo Univ Agr & Technol, Dept Biotechnol, Koganei, Tokyo 1848588, Japan	Akita University; Tokyo University of Agriculture & Technology	Inagaki, N (corresponding author), Akita Univ, Sch Med, Dept Physiol, 1-1-1 Hondo, Akita 0108543, Japan.		Yamada, Katsuya/E-8720-2013; Saito, Mikako/E-6788-2013; Matsuoka, Hideaki/F-6652-2013	Saito, Mikako/0000-0002-7941-6839; Inagaki, Nobuya/0000-0001-8261-2593				ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ATWATER I, 1979, J PHYSIOL-LONDON, V288, P575; AXELROD JD, 1983, BIOCHEMISTRY-US, V22, P2222, DOI 10.1021/bi00278a025; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; Brock CS, 1997, EUR J NUCL MED, V24, P691, DOI 10.1007/BF00841411; Dienel GA, 1997, AM J PHYSIOL-ENDOC M, V273, pE839, DOI 10.1152/ajpendo.1997.273.5.E839; Fujitani S, 1997, BRIT J PHARMACOL, V120, P1191, DOI 10.1038/sj.bjp.0701017; GORUS FK, 1984, J BIOL CHEM, V259, P1196; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIMBERG H, 1995, J BIOL CHEM, V270, P8971, DOI 10.1074/jbc.270.15.8971; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; KLETZIEN RF, 1973, J BIOL CHEM, V248, P711; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; PIPELEERS D, 1987, DIABETOLOGIA, V30, P277, DOI 10.1007/BF00299019; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SOKOLOFF L, 1993, DEV NEUROSCI-BASEL, V15, P194, DOI 10.1159/000111335; SPEIZER L, 1985, BIOCHIM BIOPHYS ACTA, V815, P75, DOI 10.1016/0005-2736(85)90476-6; TURKHEIMER F, 1994, J CEREBR BLOOD F MET, V14, P406, DOI 10.1038/jcbfm.1994.52; YADA T, 1993, ENDOCRINOLOGY, V133, P1685, DOI 10.1210/en.133.4.1685; YASUDA K, 1992, DIABETES, V41, P76, DOI 10.2337/diabetes.41.1.76; Yoshioka K, 1996, BBA-GEN SUBJECTS, V1289, P5, DOI 10.1016/0304-4165(95)00153-0; Yoshioka K, 1996, APPL MICROBIOL BIOT, V46, P400; Yoshioka K, 1996, BIOSCI BIOTECH BIOCH, V60, P1899, DOI 10.1271/bbb.60.1899; Zeller K, 1997, J CEREBR BLOOD F MET, V17, P204, DOI 10.1097/00004647-199702000-00010	27	157	172	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22278	22283		10.1074/jbc.M908048199	http://dx.doi.org/10.1074/jbc.M908048199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10748091	hybrid			2022-12-27	WOS:000088363800072
J	Dulin, NO; Pratt, P; Tiruppathi, C; Niu, JX; Voyno-Yasenetskaya, T; Dunn, MJ				Dulin, NO; Pratt, P; Tiruppathi, C; Niu, JX; Voyno-Yasenetskaya, T; Dunn, MJ			Regulator of G protein signaling RGS3T is localized to the nucleus and induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; MEMBRANE ASSOCIATION; BINDING PROTEIN; P115 RHOGEF; DOMAIN; RECEPTOR; BRAIN; RGS16; GENE; GAIP	RGS3 belongs to a family of the regulators of G protein signaling (RGS). We previously demonstrated that cytosolic RGS3 translocates to the membrane to inhibit Gq/11 signaling (Dulin, N. O., Sorokin, A., Reed, E., Elliott, S., Kehrl, J., and Dunn, M. J. (1999) Mol. Cell. Biol. 19, 714-723). This study examines the properties of a recently identified truncated variant termed RGS3T. Both RGS3 and RGS3T bound to endogenous G alpha(q/11) and inhibited endothelin-1-stimulated calcium mobilization and mitogen-activated protein kinase activity to a similar extent. However, unlike cytosolically localized RGS3, RGS3T was found predominantly in the nucleus and partially in the plasma membrane. Furthermore, RGS3T, but not RGS3, caused cell rounding and membrane blebbing. Finally, 44% of RGS3T-transfected cells underwent apoptosis after serum withdrawal, which was significantly higher than that of RGS3-transfected cells (7%). Peptide sequence analysis revealed two potential nuclear localization signal (NLS) sequences in RGS3T. Further truncation of the RGS3T N terminus containing putative NLSs resulted in a significant reduction of nuclear versus cytoplasmic staining of the protein. Moreover, this truncated RGS3T no longer induced apoptosis. In summary, RGS3 and its truncated variant RGS3T are similar in their ability to inhibit G(q/11) signaling but are different in their intracellular distribution. These data suggest that, in addition to being a GTPase-activating protein, RGS3T has other distinct functions in the nucleus of the cell.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Medical College of Wisconsin; Medical College of Wisconsin	Dulin, NO (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 South Wolcott Ave, Chicago, IL 60612 USA.		voyno-yasenetskaya, tatyana/A-3171-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022563, R37HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056159, R01GM056159] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22563] Funding Source: Medline; NIGMS NIH HHS [GM56159] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1991, BIOCHEM BIOPH RES CO, V180, P1265, DOI 10.1016/S0006-291X(05)81332-4; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Bhattacharya M, 1999, J BIOL CHEM, V274, P15719, DOI 10.1074/jbc.274.22.15719; Brandoli C, 1998, J NEUROSCI, V18, P7953; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chatterjee TK, 1997, GENOMICS, V45, P429, DOI 10.1006/geno.1997.4929; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Crouch MF, 1997, FASEB J, V11, P189, DOI 10.1096/fasebj.11.2.9039962; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gruning W, 1999, AM J PHYSIOL-RENAL, V276, pF535, DOI 10.1152/ajprenal.1999.276.4.F535; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HENDRY IA, 1995, BRAIN RES, V700, P157, DOI 10.1016/0006-8993(95)00945-M; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lu D, 1998, ENDOCRINOLOGY, V139, P365, DOI 10.1210/en.139.1.365; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; Rahman Z, 1999, J NEUROSCI, V19, P2016; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	36	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21317	21323		10.1074/jbc.M910079199	http://dx.doi.org/10.1074/jbc.M910079199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10749886	hybrid			2022-12-27	WOS:000088230600049
J	Abboud, S; Haile, DJ				Abboud, S; Haile, DJ			A novel mammalian iron-regulated protein involved in intracellular iron metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER; NRAMP2; FERRITIN	We have isolated and characterized a novel iron-regulated gene that is homologous to the divalent metal transporter 1 family of metal transporters. This gene, termed metal transporter protein (mtp1), is expressed in tissues involved in body iron homeostasis including the developing and mature reticuloendothelial system, the duodenum, and the pregnant uterus. MTP1 is also expressed in muscle and central nervous system cells in the embryo. At the subcellular level, MTP1 is localized to the basolateral membrane of the duodenal epithelial cell and a cytoplasmic compartment of reticuloendothelial system cells. Overexpression of MTP1 in tissue culture cells results in intracellular iron depletion. In the adult mouse, MTP1 expression in the liver and duodenum are reciprocally regulated. Iron deficiency induces MTP1 expression in the duodenum but down-regulates expression in the liver. These data indicate that MTP1 is an iron-regulated membrane-spanning protein that is involved in intracellular iron metabolism.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; Audie L Murphy Mem Vet Hosp, S Texas Vet Hlth Syst, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Haile, DJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NIDDK NIH HHS [R03DK96009, R01DK53079] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053079] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Canonne-Hergaux F, 1999, BLOOD, V93, P4406, DOI 10.1182/blood.V93.12.4406.412k21_4406_4417; CUSTER G, 1982, AM J HEMATOL, V13, P23, DOI 10.1002/ajh.2830130105; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; GUNSHIN H, 1997, ANTURE, V388, P483; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; Haile DJ, 1999, AM J MED SCI, V318, P230, DOI 10.1097/00000441-199910000-00003; Oates PS, 1997, AM J PHYSIOL-GASTR L, V273, pG636, DOI 10.1152/ajpgi.1997.273.3.G636; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; ROUAULT TA, 1987, P NATL ACAD SCI USA, V84, P6335, DOI 10.1073/pnas.84.18.6335; SIBILLE JC, 1988, HEPATOLOGY, V8, P296, DOI 10.1002/hep.1840080218; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Umbreit JN, 1998, SEMIN HEMATOL, V35, P13; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979	14	966	1020	1	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19906	19912		10.1074/jbc.M000713200	http://dx.doi.org/10.1074/jbc.M000713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10747949	hybrid			2022-12-27	WOS:000087941300065
J	Mashhoon, N; DeMaggio, AJ; Tereshko, V; Bergmeier, SC; Egli, R; Hoekstra, MF; Kuret, J				Mashhoon, N; DeMaggio, AJ; Tereshko, V; Bergmeier, SC; Egli, R; Hoekstra, MF; Kuret, J			Crystal structure of a conformation-selective casein kinase-1 inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; SCHIZOSACCHAROMYCES-POMBE; SUBSTRATE-SPECIFICITY; ALZHEIMERS-DISEASE; TYROSINE KINASES; BASIC RESIDUES; BUDDING YEAST; RECEPTOR; FAMILY	Members of the casein kinase-1 family of protein kinases play an essential role in cell regulation and disease pathogenesis. Unlike most protein kinases, they appear to function as constitutively active enzymes. As a result, selective pharmacological inhibitors can play an important role in dissection of casein kinase-1-dependent processes. To address this need, new small molecule inhibitors of casein kinase-1 acting through ATP-competitive and ATP-noncompetitive mechanisms were isolated on the basis of in vitro screening. Here we report the crystal structure of 3-[(2,4,6-trimethoxyphenyl) methylidenyl]-indolin-2-one (IC261), an ATP-competitive inhibitor with differential activity among casein kinase-1 isoforms, in complex with the catalytic domain of fission yeast casein kinase-1 refined to a crystallographic R-factor of 22.4% at 2.8 Angstrom resolution. The structure reveals that IC261 stabilizes casein kinase-1 in a conformation midway between nucleotide substrate liganded and nonliganded conformations. We propose that adoption of this conformation by casein kinase-1 family members stabilizes a delocalized network of side chain interactions and results in a decreased dissociation rate of inhibitor.	Ohio State Univ, Coll Med, Sch Med, Ctr Biotechnol,Dept Med Biochem, Columbus, OH 43210 USA; ICOS Corp, Bothell, WA 98021 USA; Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA; Ohio State Univ, Coll Pharm, Div Med Chem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; Icos Corporation; Northwestern University; University System of Ohio; Ohio State University	Kuret, J (corresponding author), Ohio State Univ, Coll Med, Sch Med, Ctr Biotechnol,Dept Med Biochem, 1060 Carmack Rd, Columbus, OH 43210 USA.	kuret.a@osu.edu		Bergmeier, Stephen/0000-0003-3891-8442	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056292] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56292] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR VERSION 3 1; CAMBILLAU C, 1997, TURBO FORDO; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; Decottignies A, 1999, J BIOL CHEM, V274, P37139, DOI 10.1074/jbc.274.52.37139; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Ghoshal N, 1999, AM J PATHOL, V155, P1163, DOI 10.1016/S0002-9440(10)65219-4; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; HIDAKA H, 1990, NEUROCHEM RES, V15, P431, DOI 10.1007/BF00969929; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kuret J, 1997, J NEUROCHEM, V69, P2506; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; MEGGIO F, 1990, EUR J BIOCHEM, V187, P89, DOI 10.1111/j.1432-1033.1990.tb15280.x; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Murakami A, 1999, J BIOL CHEM, V274, P3804, DOI 10.1074/jbc.274.6.3804; Narayana N, 1997, STRUCTURE, V5, P921, DOI 10.1016/S0969-2126(97)00246-3; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; Penn RB, 1999, J PHARMACOL EXP THER, V288, P428; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Prade L, 1997, STRUCTURE, V5, P1627, DOI 10.1016/S0969-2126(97)00310-9; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHWAB C, 2000, IN PRESS NEUROBIOL A, V17; Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; VANCURA A, 1994, J BIOL CHEM, V269, P19271; WANG PC, 1994, J BIOL CHEM, V269, P12014; Wang XM, 1996, MOL CELL BIOL, V16, P5375; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Wriggers W, 1997, PROTEINS, V29, P1; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; Xu RM, 1996, P NATL ACAD SCI USA, V93, P6308, DOI 10.1073/pnas.93.13.6308; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	54	122	135	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20052	20060		10.1074/jbc.M001713200	http://dx.doi.org/10.1074/jbc.M001713200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10749871	hybrid			2022-12-27	WOS:000087941300084
J	Daly, NL; Craik, DJ				Daly, NL; Craik, DJ			Acyclic permutants of naturally occurring cyclic proteins - Characterization of cystine knot and beta-sheet formation in the macrocyclic polypeptide kalata B1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULIN-A; HYDROGEN-EXCHANGE; NMR-SPECTROSCOPY; STRUCTURAL MOTIF; PEPTIDE; DIASTEREOMERS; COSY	Kalata B1 is a prototypic member of the unique cyclotide family of macrocyclic polypeptides in which the major structural features are a circular peptide backbone, a triple stranded beta-sheet, and a cystine knot arrangement of three disulfide bonds. The cyclotides are the only naturally occurring family of circular proteins and have prompted us to explore the concept of acyclic permutation, i.e. opening the backbone of a cross-linked circular protein in topologically permuted ways. We have synthesized the complete suite of acyclic permutants of kalata B1 and examined the effect of acyclic permutation on structure and activity. Only two of six topologically distinct backbone loops are critical for folding into the native conformation, and these involve disruption of the embedded ring in the cystine knot. Surprisingly, it is possible to disrupt regions of the p-sheet and still allow folding into native-like structure, provided the cystine knot is intact. Kalata B1 has mild hemolytic activity, but despite the overall structure of the native peptide being retained in all but two cases, none of the acyclic permutants displayed hemolytic activity. This loss of activity is not localized to one particular region and suggests that cyclization is critical for hemolytic activity.	Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia	University of Queensland	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia.		Craik, David/B-1695-2010; Daly, Norelle L/D-4302-2013	Craik, David/0000-0003-0007-6796; Daly, Norelle L/0000-0002-4697-6602				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Boissinot M, 1997, EMBO J, V16, P2171, DOI 10.1093/emboj/16.9.2171; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Chakshusmathi G, 1999, P NATL ACAD SCI USA, V96, P7899, DOI 10.1073/pnas.96.14.7899; Claeson P, 1998, J NAT PROD, V61, P77, DOI 10.1021/np970342r; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Daly NL, 1999, BIOCHEMISTRY-US, V38, P10606, DOI 10.1021/bi990605b; Daly NL, 1999, J MOL BIOL, V285, P333, DOI 10.1006/jmbi.1998.2276; Daquinag AC, 1999, BIOCHEMISTRY-US, V38, P2179, DOI 10.1021/bi9819834; Derua R, 1996, BIOCHEM BIOPH RES CO, V228, P632, DOI 10.1006/bbrc.1996.1708; Dinner AR, 1999, P NATL ACAD SCI USA, V96, P9068, DOI 10.1073/pnas.96.16.9068; Englander SW, 1996, CURR OPIN STRUC BIOL, V6, P18, DOI 10.1016/S0959-440X(96)80090-X; Goransson U, 1999, J NAT PROD, V62, P283, DOI 10.1021/np9803878; GRAN L, 1973, ACTA PHARMACOL TOX, V33, P400; GRAN L, 1973, LLOYDIA, V36, P174; GRAN L, 1973, LLOYDIA, V36, P207; Gran L., 1970, MEDDELELSER NORSK FA, V12, P173; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kondejewski LH, 1999, J BIOL CHEM, V274, P13181, DOI 10.1074/jbc.274.19.13181; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schoepke T., 1993, SCI PHARM, V61, P145; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; Tamaoki H, 1998, PROTEIN ENG, V11, P649, DOI 10.1093/protein/11.8.649; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; Viguera AR, 1996, NAT STRUCT BIOL, V3, P874, DOI 10.1038/nsb1096-874; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002; Wuthrich K, 1986, NMR PROTEINS NUCL AC	35	99	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19068	19075		10.1074/jbc.M000450200	http://dx.doi.org/10.1074/jbc.M000450200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10747913	hybrid			2022-12-27	WOS:000087815900060
J	Jakubik, J; El-Fakahany, EE; Tucek, S				Jakubik, J; El-Fakahany, EE; Tucek, S			Evidence for a tandem two-site model of ligand binding to muscarinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; ANTAGONIST BINDING; MOLECULAR-BASIS; MUSTARD LABELS; M1; ASPARTATE; SUBTYPES; BRAIN; ISOMERIZATION; COOPERATIVITY	After short preincubations with N-[H-3]methylscopolamine ([H-3]NMS) or R(-)-[H-3]quinuclidinyl benzilate ([H-3]QNB), radioligand dissociation from muscarinic M-1 receptors in Chinese hamster ovary cell membranes was fast, monoexponential, and independent of the concentration of unlabeled NMS or QNB added to reveal dissociation. After long preincubations, the dissociation was slow, not monoexponential, and inversely related to the concentration of the unlabeled ligand, Apparently, the unlabeled ligand becomes able to associate with the receptor simultaneously with the already bound radioligand if the preincubation lasts for a long period, and to hinder radioligand dissociation. When the membranes were preincubated with [H-3]NMS and then exposed to benzilylcholine mustard (covalently binding specific ligand), [H-3]NMS dissociation was blocked in wild-type receptors, but not in mutated (D99N) M-1 receptors, Covalently binding [H-3]propylbenzilylcholine mustard detected substantially more binding sites than [H-3]NMS. The observations support a model in which the receptor binding domain has two tandemly arranged subsites for classical ligands, a peripheral one and a central one. Ligands bind to the peripheral subsite first (binding with lower affinity) and translocate to the central subsite (binding with higher affinity). The peripheral subsite of M-1 receptors may include Asp-99, Experimental data on [H-3]NMS and [H-3]QNB association and dissociation perfectly agree with the predictions of the tandem two site model.	Acad Sci Czech Republ, Inst Physiol, CR-14220 Prague, Czech Republic; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; University of Minnesota System; University of Minnesota Twin Cities	Tucek, S (corresponding author), Acad Sci Czech Republ, Inst Physiol, Videnska 1083, CR-14220 Prague, Czech Republic.		Jakubik, Jan/B-7461-2012	Jakubik, Jan/0000-0002-1737-1487	FOGARTY INTERNATIONAL CENTER [R03TW000171] Funding Source: NIH RePORTER; FIC NIH HHS [2-R03-TW00171] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BIRDSALL NJM, 1979, BRIT J PHARMACOL, V66, P337, DOI 10.1111/j.1476-5381.1979.tb13685.x; BIRDSALL NJM, 1987, FED PROC, V46, P2525; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; BURGEN ASV, 1974, BRIT J PHARMACOL, V50, P145, DOI 10.1111/j.1476-5381.1974.tb09602.x; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; EHLERT FJ, 1988, MOL PHARMACOL, V33, P187; ELFAKAHANY EE, 1986, J PHARMACOL EXP THER, V238, P554; ELLER M, 1988, NEUROCHEM INT, V12, P285, DOI 10.1016/0197-0186(88)90166-0; FRASER CM, 1994, PROG NUCLEIC ACID RE, V49, P113; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GILL EW, 1966, MOL PHARMACOL, V2, P284; GUDERMANN T, 1997, ANNU REV NEUROSCI, V20, P389; HAGA K, 1985, J BIOL CHEM, V260, P7927; HEDLUND B, 1982, N-S ARCH PHARMACOL, V320, P3, DOI 10.1007/BF00499064; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Jakubik J, 1996, P NATL ACAD SCI USA, V93, P8705, DOI 10.1073/pnas.93.16.8705; Jakubik J, 1997, MOL PHARMACOL, V52, P172, DOI 10.1124/mol.52.1.172; JAKUBIK J, 1995, J PHARMACOL EXP THER, V274, P1077; JAKUBIK J, 1994, BRIT J PHARMACOL, V113, P1529, DOI 10.1111/j.1476-5381.1994.tb17170.x; JARV J, 1980, J BIOL CHEM, V255, P2649; JARV J, 1988, NEUROCHEM INT, V13, P419, DOI 10.1016/0197-0186(88)90069-1; JARV J, 1979, J BIOL CHEM, V254, P5595; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; KLEIN WL, 1980, BIOCHEM BIOPH RES CO, V93, P1058, DOI 10.1016/0006-291X(80)90596-3; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LEE JH, 1985, J PHARMACOL EXP THER, V233, P707; LEE NH, 1992, J PHARMACOL EXP THER, V262, P312; Lu ZL, 1999, J BIOL CHEM, V274, P7309, DOI 10.1074/jbc.274.11.7309; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; NORDVALL G, 1995, MOL B INT U, P19; Onaran HO, 1999, TRENDS PHARMACOL SCI, V20, P274, DOI 10.1016/S0165-6147(99)01364-4; PAGE KM, 1995, EUR J PHARM-MOLEC PH, V289, P429, DOI 10.1016/0922-4106(95)90151-5; SAUNDERS J, 1989, TRENDS PHARMACOL SCI, P70; SPALDING TA, 1994, J BIOL CHEM, V269, P4092; TUCEK S, 1995, TRENDS PHARMACOL SCI, V16, P205, DOI 10.1016/S0165-6147(00)89023-9; Tucek S., 1997, Life Sciences, V60, P1174, DOI 10.1016/S0024-3205(97)84321-4; WAELBROECK M, 1994, MOL PHARMACOL, V46, P685; WAELBROECK M, 1989, MOL PHARMACOL, V36, P405; WAELBROECK M, 1992, BRIT J PHARMACOL, V105, P97, DOI 10.1111/j.1476-5381.1992.tb14217.x; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	45	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18836	18844		10.1074/jbc.M000112200	http://dx.doi.org/10.1074/jbc.M000112200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10749854	hybrid			2022-12-27	WOS:000087815900032
J	Liu, CH; Gilmont, RR; Benndorf, R; Welsh, MJ				Liu, CH; Gilmont, RR; Benndorf, R; Welsh, MJ			Identification and characterization of a novel protein from sertoli cells, PASS1, that associates with mammalian small stress protein hsp27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ALPHA-B-CRYSTALLIN; EHRLICH ASCITES TUMOR; EMBRYONIC STEM-CELLS; ACTIN POLYMERIZATION; TNF-ALPHA; EXPRESSION; PHOSPHORYLATION; RESISTANCE; GROWTH	hsp27 is involved in development of tolerance to stress, possibly by its involvement in molecular chaperoning, maintenance of glutathione status, and/or modulation of microfilament structure and function. We hypothesize that hsp27 function depends on specific association with other proteins. To discover proteins that associate with hsp27, we made a differentiated rat Sertoli cell cDNA expression library and screened it using the yeast two-hybrid system. We obtained a cDNA coding for a novel protein of 428 amino acids that we have named PASS1 (protein associated with Small stress proteins 1). BLAST searches did not reveal major similarity of PASS1 to any known protein, but the cDNA sequence matched several mouse EST clones and shares 34% homology with a Caenorhabditis elegans genomic sequence. In vitro, bacterially expressed glutathione S-transferase-PASS1 fusion protein bound to hsp27, and hsp27 was co-immunoprecipitated with c-Myc-tagged PASS1 overexpressed in several cell lines. The region of PASS1 responsible for association with hsp27 was identified as existing predominantly between amino acids 108 and 208 of PASS1, Northern hybridization and Western blot analysis demonstrated that PASS1 is expressed in several tissues, with the highest expression occurring in testis, primarily in Sertoli cells. The presence of a 1.4-kilobase PASS1 mRNA in kidney as well as the 1.8-kilobase mRNA seen in other tissues suggests that alternate splicing may occur in this organ. Ectopic expression of PASS1 in two cultured cell lines was observed to inhibit the ability of hsp27 to protect cells against heat shock, indicating that PASS1 does interact with hsp27 in the live cell.	Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Plast & Reconstruct Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Welsh, MJ (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA.		Welsh, Michael/B-1968-2008		NCRR NIH HHS [MO1RR00042] Funding Source: Medline; NIEHS NIH HHS [ES06265] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006265] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arata S, 1997, J CELL PHYSIOL, V170, P19, DOI 10.1002/(SICI)1097-4652(199701)170:1<19::AID-JCP3>3.0.CO;2-O; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 1994, HEAT SHOCK PROTEINS, P335; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BENNDORF R, 1988, BIOCHEM INT, V17, P225; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BITAR KN, 1991, BIOCHEM BIOPH RES CO, V181, P1192, DOI 10.1016/0006-291X(91)92065-R; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; FREDERICK MA, 1994, CURRENT PROTOCOLS MO; GERNOLD M, 1993, DEV GENET, V14, P103, DOI 10.1002/dvg.1020140204; HANASH SM, 1993, P NATL ACAD SCI USA, V90, P3314, DOI 10.1073/pnas.90.8.3314; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HUOT J, 1991, CANCER RES, V51, P5245; Huot J, 1996, CANCER RES, V56, P273; IRELAND ME, 1987, ENDOCRINOLOGY, V120, P1317, DOI 10.1210/endo-120-4-1317; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; IWAKI T, 1994, J CELL BIOL, V125, P1385, DOI 10.1083/jcb.125.6.1385; Joanisse DR, 1998, BIOCHEM BIOPH RES CO, V244, P102, DOI 10.1006/bbrc.1998.8214; KATO K, 1992, J BIOL CHEM, V267, P7718; Kaufman P. B., 1995, HDB MOL CELLULAR MET; KindasMugge I, 1996, CELL GROWTH DIFFER, V7, P1167; KLEMENZ R, 1994, VERH DEUT G, V78, P34; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KNAUF U, 1992, FEBS LETT, V309, P297, DOI 10.1016/0014-5793(92)80793-G; LANDRY J, 1988, RADIAT RES, V113, P426, DOI 10.2307/3577240; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LEVOIE JN, 1995, MOL CELL BIOL, V15, P505; LUTSCH G, 1997, CIRCULATION, V96, P3499; Mairesse N, 1996, CELL BIOL INT, V20, P205, DOI 10.1006/cbir.1996.0025; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; MERCK KB, 1993, MOL BIOL REP, V18, P209, DOI 10.1007/BF01674432; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Piotrowicz RS, 1998, FASEB J, V12, P1481, DOI 10.1096/fasebj.12.14.1481; PITTENGER GL, 1992, ENDOCRINOLOGY, V130, P3207, DOI 10.1210/en.130.6.3207; SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308; SPECTOR NL, 1992, J IMMUNOL, V148, P1668; STAHL J, 1992, DIFFERENTIATION, V51, P33, DOI 10.1111/j.1432-0436.1992.tb00677.x; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; WALSH MT, 1991, HEAT SHOCK DEV, P58; Welsh MJ, 1996, BIOL REPROD, V55, P141, DOI 10.1095/biolreprod55.1.141; Wu W, 1996, TOXICOL APPL PHARM, V141, P330; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936; ZHU Y, 1994, J BIOL CHEM, V269, P22379	53	35	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18724	18731		10.1074/jbc.M001981200	http://dx.doi.org/10.1074/jbc.M001981200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10751411	hybrid			2022-12-27	WOS:000087815900017
J	Goeckeler, ZM; Masaracchia, RA; Zeng, Q; Chew, TL; Gallagher, P; Wysolmerski, RB				Goeckeler, ZM; Masaracchia, RA; Zeng, Q; Chew, TL; Gallagher, P; Wysolmerski, RB			Phosphorylation of myosin light chain kinase by p21-activated kinase PAK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PROTEIN-KINASE; ENDOTHELIAL-CELLS; ISOMETRIC CONTRACTION; PLATELET MYOSIN; ALPHA-PAK; ACTIN; FIBROBLASTS; ACTIVATION; HISTAMINE	Phosphorylation of myosin II regulatory light chains (RLC) by Ca2+/calmodulin-dependent myosin light chain kinase (MLCK) is a critical step in the initiation of smooth muscle and non-muscle cell contraction. Posttranslational modifications to MLCK down-regulate enzyme activity suppressing RLC phosphorylation, myosin II activation, and tension development. Here we report that PAK2, a member of the Rho family of GTPase-dependent kinases, regulates isometric tension development and myosin II RLC phosphorylation in saponin permeabilized endothelial monolayers. PAK2 blunts tension development by 75% while inhibiting diphosphorylation of myosin II RLC. Cdc42-activated placenta and recombinant, constitutively active PAK2 phosphorylate MLCK in vitro with a stoichiometry of 1.71 +/- 0.21 mol of PO4/mol of MLCK. This phosphorylation inhibits MLCK phosphorylation of myosin II RLC. PAK2 catalyzes MLCK phosphorylation on serine residues 439 and 991. Binding calmodulin to MLCK blocks phosphorylation of Ser-991 by PAK2. These results demonstrate that PAK2 can directly phosphorylate MLCK; inhibiting its activity and limiting the development of isometric tension.	St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63104 USA; Univ N Texas, Div Biochem & Mol Biol, Dept Biol Sci, Denton, TX 76203 USA; Indiana Univ, Sch Med, Dept Physiol & Biophys, Indianapolis, IN 46202 USA	Saint Louis University; Saint Louis University; University of North Texas System; University of North Texas Denton; Indiana University System; Indiana University-Purdue University Indianapolis	Wysolmerski, RB (corresponding author), St Louis Univ, Sch Med, Dept Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NHLBI NIH HHS [HL-54245, HL-45788, HL-61952] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054245, R29HL045788, R01HL061952, R01HL045788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1978, J BIOL CHEM, V253, P8347; BRANDON SD, 1991, J BIOL CHEM, V266, P380; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; DANIEL JL, 1992, METHOD ENZYMOL, V215, P78; DELANEROLLE P, 1991, AM J PHYSIOL, V261, pL1, DOI 10.1152/ajplung.1991.261.2.L1; DENNIS PB, 1993, J BIOL CHEM, V268, P19833; ECKOLS TK, 1983, EUR J BIOCHEM, V134, P249, DOI 10.1111/j.1432-1033.1983.tb07558.x; Foster DB, 2000, J BIOL CHEM, V275, P1959, DOI 10.1074/jbc.275.3.1959; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gallagher PJ, 1997, MOL CELL BIOCHEM, V173, P51, DOI 10.1023/A:1006876318155; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; HAEBERLE JR, 1988, J BIOL CHEM, V263, P4424; HASIMOTO Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P41; HASSELL TC, 1988, BIOCHIM BIOPHYS ACTA, V957, P1, DOI 10.1016/0167-4838(88)90151-3; HASSELL TC, 1986, BIOCHEM BIOPH RES CO, V134, P240, DOI 10.1016/0006-291X(86)90553-X; IKEBE M, 1985, J BIOL CHEM, V260, P4547; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; ITOH K, 1992, BIOCHIM BIOPHYS ACTA, V1136, P52, DOI 10.1016/0167-4889(92)90084-O; Kaga S, 1998, J IMMUNOL, V160, P4182; KAMM KE, 1995, REGULATION CONTRACTI, P139; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; LUDOWYKE RI, 1994, CELL MOTIL CYTOSKEL, V29, P354, DOI 10.1002/cm.970290408; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Min W, 1997, J IMMUNOL, V159, P3508; MOY AB, 1993, J CLIN INVEST, V92, P1198, DOI 10.1172/JCI116690; NIHIKAWA M, 1983, J BIOL CHEM, V259, P8429; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P1164; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; Ramos E, 1997, RECEPT SIGNAL TRANS, V7, P99; Rudel T, 1998, J IMMUNOL, V160, P7; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; WYSOLMERSKI RB, 1991, AM J PHYSIOL, V261, pC32, DOI 10.1152/ajpcell.1991.261.1.C32; WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16; Zeng Q, 2000, J CELL SCI, V113, P471; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	51	115	118	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18366	18374		10.1074/jbc.M001339200	http://dx.doi.org/10.1074/jbc.M001339200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748018	hybrid, Green Published			2022-12-27	WOS:000087659400063
J	Wong, RWC; Kwan, RWP; Mak, PHS; Mak, KKL; Sham, MH; Chan, SY				Wong, RWC; Kwan, RWP; Mak, PHS; Mak, KKL; Sham, MH; Chan, SY			Overexpression of epidermal growth factor induced hypospermatogenesis in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA; FACTOR RECEPTOR; EGF-RECEPTOR; EXPRESSION; RAT; DIFFERENTIATION; SPERMATOGENESIS; PRECURSOR; INVITRO; TESTES	The in vivo role of epidermal growth factor (EGF) is not well defined even though its effects on culture cells were well studied, To understand the developmental, physiological, and pathological roles of EGF, we have generated transgenic mice widely expressing human EGF with the use of the beta-actin promoter. EGF and transforming growth factor alpha (TGF alpha) bind with equal affinity to the EGF receptor, a transmembrane tyrosine kinase, to trigger various biological responses, EGF and TGF alpha signaling are implicated in the development of the reproductive system. EGP also plays a physiological role in reproduction, Removal of the salivary gland in rodents, which reduces circulating EGF, reduces spermatogenesis, which can be corrected by EGF replacement. Here we show that in our transgenic males, only few post-meiosis II gametes were found, and the mice were sterile, This resembles a common cause of infertility in humans. Furthermore, the transgenic males had reduced serum testosterone. Our findings contrast the previous report on transgenic mice overexpressing TGF alpha in testis, which showed normal spermatogenesis. These data suggest that EGF is the active ligand for EGF receptor reported in germ cells, and proper EGF expression is important for completion of spermatogenesis.	Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Chan, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China.	sychan@hkucc.hku.hk	Sham, Mai Har/AAX-3781-2020; Sham, Mai Har/C-4387-2009; Wong, Richard W./E-9155-2011	Sham, Mai Har/0000-0003-1179-7839; Chan, Siu Yuen/0000-0001-7262-1293; Mak, Kingston King-Lun/0000-0002-4733-9146; Wong, Ricky Wing Kit/0000-0002-1941-388X; MAK, P H S/0000-0002-8474-3578				BARTLETT JMS, 1990, ENDOCRINOLOGY, V127, P747, DOI 10.1210/endo-127-2-747; BROOKS DE, 1979, J ENDOCRINOL, V82, P293, DOI 10.1677/joe.0.0820293; BYYNY RL, 1972, ENDOCRINOLOGY, V90, P1261, DOI 10.1210/endo-90-5-1261; CALAMANDREI G, 1989, BRAIN RES, V477, P1, DOI 10.1016/0006-8993(89)91387-5; COHEN S, 1962, J BIOL CHEM, V237, P1555; COLGAN TJ, 1980, FERTIL STERIL, V33, P56; DAMJANOV I, 1993, BIOCHEM BIOPH RES CO, V190, P901, DOI 10.1006/bbrc.1993.1134; Dealy CN, 1998, DEV BIOL, V202, P43, DOI 10.1006/dbio.1998.8988; Erwin CR, 1999, AM J PHYSIOL-GASTR L, V277, pG533, DOI 10.1152/ajpgi.1999.277.3.G533; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; Gupta C, 1996, MOL CELL ENDOCRINOL, V123, P89, DOI 10.1016/0303-7207(96)03899-3; HANEJI T, 1991, J ENDOCRINOL, V128, P383, DOI 10.1677/joe.0.1280383; HOGAN B, 1994, MANIPULATING MOUSE E, P232; Kwan RWP, 1999, INT J ONCOL, V15, P281; Lee DCW, 1998, J UROLOGY, V159, P291, DOI 10.1016/S0022-5347(01)64084-9; LIU A, 1994, J UROLOGY, V152, P554, DOI 10.1016/S0022-5347(17)32792-1; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; MEYER JM, 1992, HISTOPATHOLOGY, V21, P25; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; MULLANEY BP, 1992, MOL ENDOCRINOL, V6, P2103, DOI 10.1210/me.6.12.2103; NOGUCHI S, 1990, ENDOCRINOLOGY, V127, P2136, DOI 10.1210/endo-127-5-2136; RADHAKRISHNAN B, 1992, ENDOCRINOLOGY, V131, P3091, DOI 10.1210/en.131.6.3091; RICH KA, 1983, ENDOCRINOLOGY, V113, P2284, DOI 10.1210/endo-113-6-2284; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SHIMA H, 1990, ENDOCRINOLOGY, V127, P3222, DOI 10.1210/endo-127-6-3222; TSUTSUMI O, 1986, SCIENCE, V233, P975, DOI 10.1126/science.3090686; VERHOEVEN G, 1986, MOL CELL ENDOCRINOL, V47, P99, DOI 10.1016/0303-7207(86)90020-1; WEBBER EM, 1994, AM J PATHOL, V145, P398; WELSH TH, 1982, ENDOCRINOLOGY, V110, P1498, DOI 10.1210/endo-110-5-1498; WONG RWC, 2000, IN PRESS MOL BIOTECH; Yan YC, 1998, ARCH ANDROLOGY, V40, P133, DOI 10.3109/01485019808987936; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	32	56	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18297	18301		10.1074/jbc.M001965200	http://dx.doi.org/10.1074/jbc.M001965200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748057	hybrid			2022-12-27	WOS:000087659400054
J	Kimura, N; Matsuo, R; Shibuya, H; Nakashima, K; Taga, T				Kimura, N; Matsuo, R; Shibuya, H; Nakashima, K; Taga, T			BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; BONE MORPHOGENETIC PROTEINS; BETA SIGNAL-TRANSDUCTION; CELL-DEATH; MAP KINASE; FAMILY; BMP; RECEPTORS; CASCADE; GP130	Bone morphogenetic protein 2 (BMPS), a member of the transforming growth factor-beta (TGF-beta) superfamily, regulates a variety of cell fates and functions. At present, the molecular mechanism by which BMPS induces apoptosis has not been fully elucidated. Here we propose a BMPS signaling pathway that mediates apoptosis in mouse hybridoma MH60 cells whose growth is interleukin-6 (IL-6)-dependent. BMP2 dose-dependently induces apoptosis in MH60 cells even in the presence of IL-6. BMPS has no inhibitory effect on the IL-g-induced tyrosine phosphorylation of STAT3, and the bcl-2 gene expression which is known to be regulated by STAT3, suggesting that BMP2-induced apoptosis is not attributed to alteration of the IL-6-mediated bcl-2 pathway. We demonstrate that BMPS induces activation of TGF-beta-activated kinase (TAK1) and subsequent phosphorylation of p38 stress-activated protein kinase. In addition, forced expression of kinase-negative TAXI in MH60 cells blocks BMP2-induced apoptosis. These results indicate that BMP2-induced apoptosis is mediated through the TAK1-p38 pathway in MH60 cells. We also show that MH60-derived transfectants expressing Smad6 are resistant to the apoptotic signal of BMPB. Interestingly, this ectopic expression of Smad6 blocks BMP2-induced TAXI activation and p38 phosphorylation. Moreover, Smad6 can directly bind to TAK1. These findings suggest that Smad6 is likely to function as a negative regulator of the TAK1 pathway in the BMP2 signaling, in addition to the previously reported Smad pathway.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol & Cell Biol, Chiyoda Ku, Tokyo 1010062, Japan; Chulabhorn Res Inst Mol Med Inc, Gene Search Program, Ibaraki, Osaka 3004101, Japan; Natl Inst Basic Biol, Dept Dev Biol, Div Morphogenesis, Okazaki, Aichi 4448585, Japan	Tokyo Medical & Dental University (TMDU); Chulabhorn Research Institute; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Taga, T (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol & Cell Biol, Chiyoda Ku, 2-3-10 Kanda Surugadai, Tokyo 1010062, Japan.	tagamcb@mri.tmd.ac.jp						Butterfield L, 1997, J BIOL CHEM, V272, P10110; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Massague J, 1996, CANCER SURV, V27, P41; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Mostov K, 1997, SCIENCE, V276, P219, DOI 10.1126/science.276.5310.219; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; TRESON SP, 1998, CURR OPIN HEMATOL, V5, P42; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	37	201	214	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17647	17652		10.1074/jbc.M908622199	http://dx.doi.org/10.1074/jbc.M908622199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748100	hybrid			2022-12-27	WOS:000087485000063
J	Maudoux, O; Batoko, H; Oecking, C; Gevaert, K; Vandekerckhove, J; Boutry, M; Morsomme, P				Maudoux, O; Batoko, H; Oecking, C; Gevaert, K; Vandekerckhove, J; Boutry, M; Morsomme, P			A plant plasma membrane H+-ATPase expressed in yeast is activated by phosphorylation at its penultimate residue and binding of 14-3-3 regulatory proteins in the absence of fusicoccin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL REGION; SINGLE-POINT MUTATIONS; SACCHAROMYCES-CEREVISIAE; DEFENSE RESPONSE; FUNGAL PATHOGENS; ENZYME; GENE; 14-3-3-PROTEINS; COMPLEMENTATION; PURIFICATION	The Nicotiana plumbaginifolia plasma membrane H+ ATPase isoform PMA2, equipped with a His, tag, was expressed in Saccharomyces cerevisiae and purified, Unexpectedly, a fraction of the purified tagged PMA2 associated with the two yeast 14-3-3 regulatory proteins, BMH1 and BMH2. This complex was formed in vivo without treatment with fusicoccin, a fungal toxin known to stabilize the equivalent complex in plants. When gel filtration chromatography was used to separate the free ATPase from the 14-3-3.H+-ATPase complex, the complexed ATPase was twice as active as the free form. Trypsin treatment of the complex released a smaller complex, composed of a 14-3-3 dimer and a fragment from the PMA2 C-terminal region. The latter was identified by Edman degradation and mass spectrometry as the PMA2 C-terminal 57 residues, whose penultimate residue (Thr-955) was phosphorylated, In vitro dephosphorylation of this C-terminal fragment prevented binding of 14-3-3 proteins, even in the presence of fusicoccin, Mutation of Thr-955 to alanine, aspartate, or a stop codon prevented PMA2 from complementing the yeast H+-ATPase, These mutations were also introduced in an activated PMA2 mutant (Gln-14 --> Asp) characterized by a higher H+ pumping activity. Each mutation directly modifying Thr-955 prevented 14-3-3 binding, decreased ATPase specific activity, and reduced yeast growth. We conclude that the phosphorylation of Thr-955 is required for 14-3-3 binding and that formation of the complex activates the enzyme.	Univ Catholique Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium; Ruhr Univ Bochum, Lehrstuhl Pflanzenphysiol, D-44780 Bochum, Germany; State Univ Ghent VIB, Dept Biochem, B-9000 Ghent, Belgium	Universite Catholique Louvain; Ruhr University Bochum; Flanders Institute for Biotechnology (VIB); Ghent University	Boutry, M (corresponding author), Univ Catholique Louvain, Unite Biochim Physiol, Croix Sud 2-20, B-1348 Louvain, Belgium.	boutry@fysa.ucl.ac.be	BATOKO, Henri/C-5607-2009; Gevaert, Kris/H-3637-2013; Gevaert, Kris/AAE-4212-2019; Morsomme, Pierre/AAD-9600-2019; Batoko, Henri/Y-4238-2019; Gevaert, Kris/D-6489-2017	Gevaert, Kris/0000-0002-4237-0283; Gevaert, Kris/0000-0002-4237-0283; Batoko, Henri/0000-0002-8256-519X; Gevaert, Kris/0000-0002-4237-0283; Morsomme, Pierre/0000-0001-7780-7230; Boutry, Marc/0000-0002-2315-6900				ADUCCI P, 1995, J EXP BOT, V46, P1463, DOI 10.1093/jxb/46.10.1463; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Annan RS, 1997, J PROTEIN CHEM, V16, P391, DOI 10.1023/A:1026384605285; Baunsgaard L, 1998, PLANT J, V13, P661, DOI 10.1046/j.1365-313X.1998.00083.x; Chung HJ, 1999, TRENDS PLANT SCI, V4, P367, DOI 10.1016/S1360-1385(99)01462-4; DeBoer B, 1997, TRENDS PLANT SCI, V2, P60, DOI 10.1016/S1360-1385(97)82564-2; DeMichelis MI, 1996, PLANT PHYSIOL, V110, P957, DOI 10.1104/pp.110.3.957; Desbrosses G, 1998, EUR J BIOCHEM, V251, P496, DOI 10.1046/j.1432-1327.1998.2510496.x; DeWitt ND, 1995, PLANT CELL, V7, P2053, DOI 10.1105/tpc.7.12.2053; DEXAERDE AD, 1995, J BIOL CHEM, V270, P23828, DOI 10.1074/jbc.270.40.23828; EWING NN, 1994, PLANT PHYSIOL, V106, P547, DOI 10.1104/pp.106.2.547; Fuglsang AT, 1999, J BIOL CHEM, V274, P36774, DOI 10.1074/jbc.274.51.36774; Fullone MR, 1998, J BIOL CHEM, V273, P7698, DOI 10.1074/jbc.273.13.7698; Gevaert K, 1997, J PROTEIN CHEM, V16, P335, DOI 10.1023/A:1026320318489; Gevaert K, 1998, ELECTROPHORESIS, V19, P909, DOI 10.1002/elps.1150190606; Griffin PR, 1995, RAPID COMMUN MASS SP, V9, P1546, DOI 10.1002/rcm.1290091515; HARPER JF, 1994, MOL GEN GENET, V244, P572, DOI 10.1007/BF00282747; Jahn T, 1997, PLANT CELL, V9, P1805, DOI 10.1105/tpc.9.10.1805; JOHANSSON F, 1994, PHYSIOL PLANTARUM, V92, P389; Lanfermeijer FC, 1998, PROTEIN EXPRES PURIF, V12, P29, DOI 10.1006/prep.1997.0788; Lino B, 1998, PLANTA, V204, P352, DOI 10.1007/s004250050266; Luo H, 1999, PLANT PHYSIOL, V119, P627, DOI 10.1104/pp.119.2.627; MICHELET B, 1994, PLANT CELL, V6, P1375, DOI 10.1105/tpc.6.10.1375; MICHELET B, 1995, PLANT PHYSIOL, V108, P1, DOI 10.1104/pp.108.1.1; Moriau L, 1999, PLANT J, V19, P31, DOI 10.1046/j.1365-313X.1999.00495.x; Morsomme P, 1996, EMBO J, V15, P5513, DOI 10.1002/j.1460-2075.1996.tb00936.x; Morsomme P, 1998, J BIOL CHEM, V273, P34837, DOI 10.1074/jbc.273.52.34837; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Oecking C, 1997, PLANT J, V12, P441, DOI 10.1046/j.1365-313X.1997.12020441.x; Olivari C, 1998, PLANT PHYSIOL, V116, P529, DOI 10.1104/pp.116.2.529; Olsson A, 1998, PLANT PHYSIOL, V118, P551, DOI 10.1104/pp.118.2.551; Palmgren MG, 1998, ADV BOT RES, V28, P1; PALMGREN MG, 1993, FEBS LETT, V317, P216, DOI 10.1016/0014-5793(93)81279-9; PALMGREN MG, 1994, J BIOL CHEM, V269, P3027; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; Piotrowski M, 1998, J BIOL CHEM, V273, P30018, DOI 10.1074/jbc.273.45.30018; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHALLER GE, 1988, PLANTA, V173, P508; Schultz TF, 1998, PLANT CELL, V10, P837, DOI 10.1105/tpc.10.5.837; SEKLER I, 1994, PLANT PHYSIOL, V105, P1125, DOI 10.1104/pp.105.4.1125; SUSSMAN MR, 1994, ANNU REV PLANT PHYS, V45, P211, DOI 10.1146/annurev.pp.45.060194.001235; SUZUKI YS, 1992, PLANT PHYSIOL, V99, P1314, DOI 10.1104/pp.99.4.1314; Svennelid F, 1999, PLANT CELL, V11, P2379, DOI 10.1105/tpc.11.12.2379; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VanderHoeven PCJ, 1996, PLANT PHYSIOL, V111, P857, DOI 10.1104/pp.111.3.857; VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45; VERAESTRELLA R, 1994, PLANT PHYSIOL, V104, P209, DOI 10.1104/pp.104.1.209; Xing T, 1996, PLANT CELL, V8, P555, DOI 10.2307/3870332; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	50	118	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17762	17770		10.1074/jbc.M909690199	http://dx.doi.org/10.1074/jbc.M909690199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748153	hybrid			2022-12-27	WOS:000087485000077
J	Bothmann, H; Pluckthun, A				Bothmann, H; Pluckthun, A			The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA - I. Increased functional expression of antibody fragments with and without cis-prolines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEINS; CALCIUM-RELEASE CHANNEL; PROLYL-CIS/TRANS-ISOMERASES; SCFV FRAGMENT; TRIGGER FACTOR; PHAGE DISPLAY; SACCHAROMYCES-CEREVISIAE; FK506-BINDING PROTEINS; MOLECULAR CHAPERONES; RYANODINE RECEPTOR	The production of recombinant proteins in the periplasm of Escherichia coli can be limited by folding problems, leading to periplasmic aggregates. me used a selection system for periplasmic chaperones based on the coexpression of an E. coli library with a poorly expressing antibody single-chain Fv (scFv) fragment displayed on filamentous phage (Bothmann, H., and Pluckthun, A. (1998) Nature Biotechnol. 16, 376-380). By selection for a functional antibody, the protein Skp had been enriched previously and shown to improve periplasmic expression of a wide range of scFv fragments. This selection strategy was now repeated with a library constructed from the genomic DNA of an skp-deficient strain, leading to enrichment of the periplasmic peptidylprolyl cis,trans-isomerase (PPIase) FkpA. Coexpression of FkpA increased the amount of fusion protein displayed on the phage and dramatically improved functional periplasmic expression even of scFv fragments not containing cis-prolines. In contrast, the coexpression of the periplasmic PPIases PpiA and SurA showed no increase in the functional scFv fragment level in the periplasm or displayed on phage. Together with the in vitro data in the accompanying paper (Ramm, K., and Pluckthun, A. (2000) J. Biol. Chem. 275, 17106-17113), we conclude that the effect of FkpA is independent of its PPIase activity.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Pluckthun, A (corresponding author), Univ Zurich, Inst Biochem, Winterthyrerstr 190, CH-8057 Zurich, Switzerland.	plueckthun@biocfebs.unizh.ch	Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306				BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Bothmann H, 1998, NAT BIOTECHNOL, V16, P376, DOI 10.1038/nbt0498-376; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CALLEBAUT I, 1995, FEBS LETT, V374, P211, DOI 10.1016/0014-5793(95)01109-R; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; Chen R, 1996, MOL MICROBIOL, V19, P1287, DOI 10.1111/j.1365-2958.1996.tb02473.x; Dall'Acqua W, 1998, CURR OPIN STRUC BIOL, V8, P443, DOI 10.1016/S0959-440X(98)80121-8; Danese PN, 1997, GENE DEV, V11, P1183, DOI 10.1101/gad.11.9.1183; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; Dartigalongue C, 1998, EMBO J, V17, P3968, DOI 10.1093/emboj/17.14.3968; DAVIS NG, 1985, J MOL BIOL, V181, P111, DOI 10.1016/0022-2836(85)90329-8; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Forsberg G, 1997, J BIOL CHEM, V272, P12430, DOI 10.1074/jbc.272.19.12430; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; Freund C, 1997, FEBS LETT, V407, P42, DOI 10.1016/S0014-5793(97)00306-2; Gothel SF, 1998, BIOCHEMISTRY-US, V37, P13392, DOI 10.1021/bi981253w; Hanes J, 1998, P NATL ACAD SCI USA, V95, P14130, DOI 10.1073/pnas.95.24.14130; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; HORNE SM, 1995, ARCH MICROBIOL, V163, P357, DOI 10.1007/s002030050215; Hottenrott S, 1997, J BIOL CHEM, V272, P15697, DOI 10.1074/jbc.272.25.15697; Huston J S, 1993, Int Rev Immunol, V10, P195, DOI 10.3109/08830189309061696; Jager M, 1997, FEBS LETT, V418, P106, DOI 10.1016/S0014-5793(97)01350-1; Jager M, 1999, J MOL BIOL, V285, P2005, DOI 10.1006/jmbi.1998.2425; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Jung S, 1997, PROTEIN ENG, V10, P959, DOI 10.1093/protein/10.8.959; KERN G, 1994, FEBS LETT, V348, P145, DOI 10.1016/0014-5793(94)00591-5; KLEEREBEZEM M, 1995, MOL MICROBIOL, V18, P313, DOI 10.1111/j.1365-2958.1995.mmi_18020313.x; KNAPPIK A, 1994, BIOTECHNIQUES, V17, P754; KNAPPIK A, 1995, PROTEIN ENG, V8, P81, DOI 10.1093/protein/8.1.81; KNAPPIK A, 1993, BIO-TECHNOL, V11, P77, DOI 10.1038/nbt0193-77; Krebber C, 1997, J MOL BIOL, V268, P607, DOI 10.1006/jmbi.1997.0981; Lazar SW, 1996, J BACTERIOL, V178, P1770, DOI 10.1128/jb.178.6.1770-1773.1996; Lindner P, 1997, BIOTECHNIQUES, V22, P140, DOI 10.2144/97221rr01; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; MELNICK J, 1995, IMMUNOL TODAY, V16, P243, DOI 10.1016/0167-5699(95)80167-7; Missiakas D, 1996, MOL MICROBIOL, V21, P871, DOI 10.1046/j.1365-2958.1996.561412.x; Nieba L, 1997, PROTEIN ENG, V10, P435, DOI 10.1093/protein/10.4.435; Pissavin C, 1997, FEMS MICROBIOL LETT, V157, P59, DOI 10.1111/j.1574-6968.1997.tb12753.x; Pluckthun A, 1996, ANTIBODY ENG PRACTIC, P203; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; Ramm K, 1999, J MOL BIOL, V290, P535, DOI 10.1006/jmbi.1999.2854; Ramm K, 2000, J BIOL CHEM, V275, P17106, DOI 10.1074/jbc.M910234199; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; RINFRET A, 1994, BIOCHEMISTRY-US, V33, P1668, DOI 10.1021/bi00173a008; ROOF WD, 1994, J BIOL CHEM, V269, P2902; Roof WD, 1997, MOL MICROBIOL, V25, P1031, DOI 10.1046/j.1365-2958.1997.5201884.x; Rouviere PE, 1996, GENE DEV, V10, P3170, DOI 10.1101/gad.10.24.3170; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SANCHEZ P, 1990, J IMMUNOL, V144, P2816; SKERRA A, 1991, PROTEIN ENG, V4, P971, DOI 10.1093/protein/4.8.971; SUOMINEN I, 1987, GENE, V61, P165, DOI 10.1016/0378-1119(87)90111-9; TESAR M, 1995, IMMUNOTECHNOLOGY, V1, P53, DOI 10.1016/1380-2933(95)00005-4; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WALL JG, 1995, CURR OPIN BIOTECH, V6, P507, DOI 10.1016/0958-1669(95)80084-0; Worn A, 2000, J BIOL CHEM, V275, P2795, DOI 10.1074/jbc.275.4.2795; Worn A, 1998, FEBS LETT, V427, P357, DOI 10.1016/S0014-5793(98)00463-3; WULFING C, 1994, J BIOL CHEM, V269, P2895	66	145	228	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17100	17105		10.1074/jbc.M910233199	http://dx.doi.org/10.1074/jbc.M910233199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748200	hybrid			2022-12-27	WOS:000087392200098
J	Budd, ME; Choe, WC; Campbell, JL				Budd, ME; Choe, WC; Campbell, JL			The nuclease activity of the yeast Dna2 protein, which is related to the RecB-like nucleases, is essential in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; NUCLEOTIDE EXCISION-REPAIR; WERNER SYNDROME PROTEIN; SACCHAROMYCES-CEREVISIAE; S-PHASE; HOMOLOGOUS RECOMBINATION; REPLICATION; HELICASE; EXONUCLEASE; GENE	Saccharomyces cerevisiae Dna2 protein is required for DNA replication and repair and is associated with multiple biochemical activities: DNA-dependent ATPase, DNA helicase, and DNA nuclease. To investigate which of these activities is important for the cellular functions of Dna2, we have identified separation of function mutations that selectively inactivate the helicase or nuclease. me describe the effect of six such mutations on ATPase, helicase, and nuclease after purification of the mutant proteins from yeast or baculovirus-infected insect cells. A mutation in the Walker A box in the C-terminal third of the protein affects helicase and ATPase but not nuclease; a mutation in the N-terminal domain (amino acid 504) affects ATPase, helicase, and nuclease. Two mutations in the N-terminal domain abolish nuclease but do not reduce helicase activity (amino acids 657 and 675) and identify the putative nuclease active site. Two mutations immediately adjacent to the proposed nuclease active site (amino acids 640 and 693) impair nuclease activity in the absence of ATP but completely abolish nuclease activity in the presence of ATP. These results suggest that, although the Dna2 helicase and nuclease activities can be independently affected by some mutations, the two activities appear to interact, and the nuclease activity is regulated in a complex manner by ATP. Physiological analysis shows that both ATPase and nuclease are important for the essential function of DNA2 in DNA replication and for its role in double-strand break repair. Four of the nuclease mutants are not only loss of function mutations but also exhibit a dominant negative phenotype.	CALTECH, Braun Lab 14775, Pasadena, CA 91125 USA	California Institute of Technology	Campbell, JL (corresponding author), CALTECH, Braun Lab 14775, Pasadena, CA 91125 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; BUDD ME, 1989, MOL CELL BIOL, V9, P365, DOI 10.1128/MCB.9.2.365; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; BUDD ME, 2000, IN PRESS MUTAT RES; BUTTIN G, 1968, COLD SPRING HARB SYM, V33, P259, DOI 10.1101/SQB.1968.033.01.030; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Eki T, 1996, GENOMICS, V37, P408, DOI 10.1006/geno.1996.0581; Fiorentino DF, 1997, MOL BIOL CELL, V8, P2519, DOI 10.1091/mbc.8.12.2519; Formosa T, 1999, GENETICS, V151, P1459; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gould KL, 1998, GENETICS, V149, P1221; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; KUO CL, 1983, P NATL ACAD SCI-BIOL, V80, P6465, DOI 10.1073/pnas.80.21.6465; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; Liu QQ, 2000, J BIOL CHEM, V275, P1615, DOI 10.1074/jbc.275.3.1615; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Moreau S, 1999, MOL CELL BIOL, V19, P556; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1998, P NATL ACAD SCI USA, V95, P2244, DOI 10.1073/pnas.95.5.2244; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Singer MS, 1998, GENETICS, V150, P613; Tanaka H, 1999, MOL CELL BIOL, V19, P1038; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Watt PM, 1996, GENETICS, V144, P935; Yu M, 1998, J MOL BIOL, V283, P797, DOI 10.1006/jmbi.1998.2127	50	119	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16518	16529		10.1074/jbc.M909511199	http://dx.doi.org/10.1074/jbc.M909511199			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748138	hybrid, Green Accepted, Green Submitted			2022-12-27	WOS:000087392200019
J	Kawabata, H; Germain, RS; Vuong, PT; Nakamaki, T; Said, JW; Koeffler, HP				Kawabata, H; Germain, RS; Vuong, PT; Nakamaki, T; Said, JW; Koeffler, HP			Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; K562 CELLS; GENE; EXPRESSION; PROLIFERATION; HEMOCHROMATOSIS; DIFFERENTIATION; TRANSPORTER; INDUCTION; PROTEINS	In most cells, transferrin receptor (TfR1)-mediated endocytosis is a major pathway for cellular iron uptake. We recently cloned the human transferrin receptor 2 (TfR2) gene, which encodes a second receptor for transferrin (Kawabata, H., Yang, R., Hirama, T., Vuong, P, T., Kawano, S., Gombart, A. F., and Koeffler, H. P, (1999) J. Biol. Chen. 274, 20826-20832). In the present study, the regulation of TfR2 expression and function was investigated. A select Chinese hamster ovary (CHO)-TRVb cell line that does not express either TfR1 or TfR2 was stably transfected with either TfR1 or TfR2-alpha cDNA. TfR2-alpha-expressing cells had considerably lower affinity for holotransferrin when compared with TfR1-expressing CHO cells, Interestingly, in contrast to TfR1, expression of TfR2 mRNA in K562 cells was not up-regulated by desferrioxamine (DFO), a cell membrane-permeable iron chelator. In MG63 cells, expression of TfR2 mRNA if as regulated in the cell cycle with the highest expression in late G(1) phase and no expression in G(0)/G(1). DFO reduced cell proliferation and DNA synthesis of CHO-TRVb control cells, whereas it had little effect on TfR2-alpha-expressing CHO cells when measured by clonogenic and cell cycle analysis. In addition, CHO cells that express TfR2-alpha developed into tumors in nude mice whereas CHO control cells did not. In conclusion, TfR2 expression may be regulated by the cell cycle rather than cellular iron status and may support cell growth both in vitro and in vivo.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med,Div Hematol Oncol,Burns & Allen Res Inst, Los Angeles, CA 90048 USA; Showa Univ, Sch Med, Dept Hematol, Tokyo 1428555, Japan; Univ Calif Los Angeles, Sch Med, Ctr Hlth Sci, Dept Pathol, Los Angeles, CA 90095 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Showa University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kawabata, H (corresponding author), Kanazawa Med Univ, Dept Hematol Immunol, 1-1 Daigaku, Uchinada, Ishikawa 9200265, Japan.							Addess KJ, 1997, J MOL BIOL, V274, P72, DOI 10.1006/jmbi.1997.1377; Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417; BRIDGES KR, 1984, J BIOL CHEM, V259, P2970; CHAN RYY, 1992, EXP CELL RES, V202, P326, DOI 10.1016/0014-4827(92)90082-J; CHITAMBAR CR, 1983, J CLIN INVEST, V72, P1314, DOI 10.1172/JCI111087; DEVOS R, 1988, VIRCHOWS ARCH B, V55, P11; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; FURUKAWA T, 1992, LIFE SCI, V50, P2059, DOI 10.1016/0024-3205(92)90572-7; GOLDING S, 1995, SCAND J IMMUNOL, V41, P229, DOI 10.1111/j.1365-3083.1995.tb03558.x; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Heston WDW, 1997, UROLOGY, V49, P104, DOI 10.1016/S0090-4295(97)00177-5; HUBERT N, 1993, J HEPATOL, V18, P301, DOI 10.1016/S0168-8278(05)80274-0; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; Levy JE, 1999, NAT GENET, V21, P396, DOI 10.1038/7727; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; MATTIA E, 1984, J BIOL CHEM, V259, P2689; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MISKIMINS WK, 1986, J CELL BIOL, V103, P1781, DOI 10.1083/jcb.103.5.1781; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; Ponka P, 1998, SEMIN HEMATOL, V35, P35; RAO K, 1986, MOL CELL BIOL, V6, P236, DOI 10.1128/MCB.6.1.236; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; ROUAULT T, 1985, J BIOL CHEM, V260, P4862; SCIOT R, 1987, HEPATOLOGY, V7, P831, DOI 10.1002/hep.1840070507; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; WARD JH, 1984, J BIOL CHEM, V259, P3235; Yang R, 1999, MOL CELL BIOL, V19, P2400	31	197	203	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16618	16625		10.1074/jbc.M908846199	http://dx.doi.org/10.1074/jbc.M908846199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748106	hybrid			2022-12-27	WOS:000087392200032
J	Manninen, A; Renkema, GH; Saksela, K				Manninen, A; Renkema, GH; Saksela, K			Synergistic activation of NFAT by HIV-1 Nef and the Ras/MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL ACTIVATION; FAS LIGAND EXPRESSION; NUCLEAR FACTOR; LYMPHOCYTE-ACTIVATION; TRANSCRIPTION FACTORS; ANTIGEN RECEPTOR; TYROSINE KINASE; GENE-EXPRESSION; CYCLOSPORINE-A	Nef is a lentiviral protein involved in pathogenesis of AIDS, but its molecular mechanisms of action remain incompletely understood. Here we report a novel effect of Nef on lymphocyte signaling, which is mediated via a T cell receptor (TCR)-independent contribution of Nef to induction of nuclear factor of activated T cells (NFAT), a transcription factor that plays a central role in coordinating T cell. activation. Expression of Nef did not significantly alter the basal level of NFAT activity in Jurkat cells nor the increased activity following T cell receptor stimulation by anti-CD3 or anti-CD3 + anti-CD28. We also mimicked NFAT induction by TCR triggering by simultaneous activation of the Ras and calcium signaling pathways with phorbol 12-myristate 13-acetate and ionomycin, respectively, Strikingly, whereas activation of either of these pathways individually did not induce NFAT activity in control cells, in Nef-expressing cells phorbol 12-myristate 13-acetate treatment alone resulted in a 100-fold increase in NFAT-directed gene expression. Experiments with different dominant negative mutant signaling proteins, inhibitory chemicals, and Lck-deficient Jurkat cells revealed that this effect was mediated via activation of calcineurin by Nef-induced changes in calcium metabolism, but was independent of TCR-associated signaling events. This ability of Nef to substitute for triggering of the calcium pathway in induction of NFAT could promote activation of human immunodeficiency virus (HIV)-infected T cells in response to stimuli mediated via TCR or other cell surface receptors under conditions when activation of Ras rather than calcium signaling would otherwise predominate.	Univ Tampere, Inst Med Technol, FIN-33520 Tampere, Finland; Tampere Univ Hosp, Dept Clin Chem, FIN-33521 Tampere, Finland	Tampere University; Tampere University; Tampere University Hospital	Saksela, K (corresponding author), Univ Tampere, Inst Med Technol, Finn Medi 2 Bldg,Rm 4-137,Lenkkeilijankatu 8,POB, FIN-33520 Tampere, Finland.		Renkema, Herma/L-1489-2015; Manninen, Aki/AAC-8067-2019	Renkema, Herma/0000-0002-8174-6538; Manninen, Aki/0000-0002-6263-8101				Alexander L, 1997, J VIROL, V71, P6094, DOI 10.1128/JVI.71.8.6094-6099.1997; BANDRES JC, 1994, J VIROL, V68, P3243, DOI 10.1128/JVI.68.5.3243-3249.1994; Barker SA, 1999, J LEUKOCYTE BIOL, V65, P321, DOI 10.1002/jlb.65.3.321; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Collette Y, 1996, J BIOL CHEM, V271, P6333, DOI 10.1074/jbc.271.11.6333; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Du ZJ, 1996, J VIROL, V70, P4157, DOI 10.1128/JVI.70.6.4157-4161.1996; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; Eder AM, 1998, J BIOL CHEM, V273, P28025, DOI 10.1074/jbc.273.43.28025; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Foti M, 1999, J BIOL CHEM, V274, P34765, DOI 10.1074/jbc.274.49.34765; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Greenway A, 1996, J VIROL, V70, P6701, DOI 10.1128/JVI.70.10.6701-6708.1996; GREENWAY A, 1995, J VIROL, V69, P1842, DOI 10.1128/JVI.69.3.1842-1850.1995; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; Hodge S, 1998, VIROLOGY, V252, P354, DOI 10.1006/viro.1998.9477; Iafrate AJ, 1997, EMBO J, V16, P673, DOI 10.1093/emboj/16.4.673; Kaplan D, 1998, J VIROL, V72, P6279, DOI 10.1128/JVI.72.8.6279-6282.1998; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Luo W, 1997, J VIROL, V71, P9531, DOI 10.1128/JVI.71.12.9531-9537.1997; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; NIEDERMAN TMJ, 1993, VIROLOGY, V194, P338, DOI 10.1006/viro.1993.1264; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Page KA, 1997, J VIROL, V71, P3776, DOI 10.1128/JVI.71.5.3776-3787.1997; Piguet V, 1999, REV MED VIROL, V9, P111, DOI 10.1002/(SICI)1099-1654(199904/06)9:2&lt;111::AID-RMV245&gt;3.0.CO;2-P; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; RIGLEY K, 1995, J IMMUNOL, V154, P1136; ROBERTGUROFF M, 1990, J VIROL, V64, P3391, DOI 10.1128/JVI.64.7.3391-3398.1990; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; Schrager JA, 1999, P NATL ACAD SCI USA, V96, P8167, DOI 10.1073/pnas.96.14.8167; SCHWARTZ O, 1992, AIDS RES HUM RETROV, V8, P545, DOI 10.1089/aid.1992.8.545; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Whetter L, 1998, J VIROL, V72, P6155, DOI 10.1128/JVI.72.7.6155-6158.1998; Xu XN, 1999, J EXP MED, V189, P1489, DOI 10.1084/jem.189.9.1489; Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Zauli G, 1999, BLOOD, V93, P1000, DOI 10.1182/blood.V93.3.1000.403a12_1000_1010; Zegarra-Moran O, 1999, J IMMUNOL, V162, P5359	53	91	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16513	16517		10.1074/jbc.M910032199	http://dx.doi.org/10.1074/jbc.M910032199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748182	hybrid			2022-12-27	WOS:000087392200018
J	Wang, CC; Morales, AJ; Schimmel, P				Wang, CC; Morales, AJ; Schimmel, P			Functional redundancy in the nonspecific RNA binding domain of a class I tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; PROTEIN-KINASE PKR; MINOR-GROOVE; RECOGNITION; DNA; COELECTROPHORESIS; DISCRIMINATION; INTERFERON; FEATURES; COMPLEX	The sequence of a 228-amino acid nonspecific RNA binding domain appended to the N terminus of a eukaryote tRNA synthetase is shown here to have two lysine-rich clusters (LRCs) that are functionally significant in vivo and in vitro. These two LRCs have unrelated sequences and are separated by a spacer of over 100 amino acids. By using a sensitive test for function in vivo, each LRC is shown to be sufficient in the absence of the other. This sufficiency requires fusion of the spacer to either of the LRCs. Experiments in vitro confirmed that the LRCs are each important for RNA binding. Thus, this nonspecific RNA binding domain has two dissimilar lysine-rich sequence elements that are functionally redundant Further experiments suggest that this redundancy is not used to dock two molecules of RNA but rather to enhance the overall affinity for a single RNA molecule.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd,Mail Code BCC-379, La Jolla, CA 92037 USA.	schimmel@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Cahuzac B, 2000, EMBO J, V19, P445, DOI 10.1093/emboj/19.3.445; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; Cilley CD, 1997, RNA, V3, P57; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Frugier M, 1997, P NATL ACAD SCI USA, V94, P11291, DOI 10.1073/pnas.94.21.11291; GALE AJ, 1995, BIOCHEMISTRY-US, V34, P8896, DOI 10.1021/bi00027a042; Glasfeld E, 1997, BIOCHEMISTRY-US, V36, P6739, DOI 10.1021/bi970151n; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KERJAN P, 1994, BBA-GEN SUBJECTS, V1199, P293, DOI 10.1016/0304-4165(94)90009-4; KRAUSS G, 1976, EUR J BIOCHEM, V68, P81, DOI 10.1111/j.1432-1033.1976.tb10766.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LIM WA, 1991, METHOD ENZYMOL, V208, P196; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; Morales AJ, 1999, EMBO J, V18, P3475, DOI 10.1093/emboj/18.12.3475; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PATEL RC, 1992, J BIOL CHEM, V267, P7671; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Wang CC, 1999, J BIOL CHEM, V274, P16508, DOI 10.1074/jbc.274.23.16508; Whelihan EF, 1997, EMBO J, V16, P2968, DOI 10.1093/emboj/16.10.2968; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	29	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17180	17186		10.1074/jbc.M001057200	http://dx.doi.org/10.1074/jbc.M001057200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747983	hybrid			2022-12-27	WOS:000087392200110
J	Gong, DW; Monemdjou, S; Gavrilova, O; Leon, LR; Marcus-Samuels, B; Chou, CJ; Everett, C; Kozak, LP; Li, CL; Deng, CX; Harper, ME; Reitman, ML				Gong, DW; Monemdjou, S; Gavrilova, O; Leon, LR; Marcus-Samuels, B; Chou, CJ; Everett, C; Kozak, LP; Li, CL; Deng, CX; Harper, ME; Reitman, ML			Lack of obesity and normal response to fasting and thyroid hormone in mice lacking uncoupling protein-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; SKELETAL-MUSCLE; MITOCHONDRIAL CARRIER; PROTON TRANSPORT; UP-REGULATION; BODY-WEIGHT; EXPRESSION; FAT; THERMOGENESIS; GENE	Uncoupling protein-3 (UCP3) is a mitochondrial protein that can diminish the mitochondrial membrane potential. Levels of muscle Ucp3 mRNA are increased by thyroid hormone and fasting. Ucp3 has been proposed to influence metabolic efficiency and is a candidate obesity gene. We have produced a Ucp3 knockout mouse to test these hypotheses. The Ucp3 (-/-) mice had no detectable immunoreactive UCP3 by Western blotting. In mitochondria from the knockout mice, proton leak was greatly reduced in muscle, minimally reduced in brown fat, and not reduced at all in liver. These data suggest that UCP3 accounts for much of the proton leak in skeletal muscle. Despite the lack of UCP3, no consistent phenotypic abnormality was observed. The knockout mice were not obese and had normal serum insulin, triglyceride, and leptin levels, with a tendency toward reduced free fatty acids and glucose. Knockout mice showed a normal circadian rhythm in body temperature and motor activity and had normal body temperature responses to fasting, stress, thyroid hormone, and cold exposure. The base-line metabolic rate and respiratory exchange ratio were the same in knockout and control mice, as were the effects of fasting, a beta 3-adrenergic agonist (CL316243), and thyroid hormone on these parameters. The phenotype of Ucp1/Ucp3 double knockout mice was indistinguishable from Ucp1 single knockout mice. These data suggest that Ucp3 is not a major determine. These data suggest that Ucp3 is not a major determinant of metabolic rate but, rather, has other functions.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; NIDDK, Mammalian Genet Sect, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Ottawa; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Harper, ME (corresponding author), NIDDK, Diabet Branch, NIH, Bldg 10,Rm 8N-250, Bethesda, MD 20892 USA.	mharper@uottawa.ca	Reitman, Marc/B-4448-2013; Gong, Dawei/AAB-4283-2020; deng, chuxia/N-6713-2016	Reitman, Marc/0000-0002-0426-9475; Grueter, Carrie/0000-0002-1913-2527; Monemdjou, Shadi/0000-0002-5809-595X; Harper, Mary-Ellen/0000-0003-3864-5886	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001, Z01DK047031] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Banavar JR, 1999, NATURE, V399, P130, DOI 10.1038/20144; BHATTACHARYA SK, 1991, ANAL BIOCHEM, V192, P344, DOI 10.1016/0003-2697(91)90546-6; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; Boss O, 1997, FEBS LETT, V412, P111, DOI 10.1016/S0014-5793(97)00755-2; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; Brand M. D., 1995, BIOENERGETICS, V154, P62; Brand MD, 1998, MOL CELL BIOCHEM, V184, P13, DOI 10.1023/A:1006893619101; Cannon B, 1979, Methods Enzymol, V55, P65; Chung WK, 1999, DIABETES, V48, P1890, DOI 10.2337/diabetes.48.9.1890; Comuzzie AG, 1998, SCIENCE, V280, P1374, DOI 10.1126/science.280.5368.1374; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Echtay KS, 1999, FEBS LETT, V450, P8, DOI 10.1016/S0014-5793(99)00460-3; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gavrilova O, 1999, P NATL ACAD SCI USA, V96, P14623, DOI 10.1073/pnas.96.25.14623; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1999, BIOCHEM BIOPH RES CO, V256, P27, DOI 10.1006/bbrc.1999.0239; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; HIMMSHAGEN J, 1998, HDB OBESITY, P415; Hinz W, 1999, FEBS LETT, V448, P57, DOI 10.1016/S0014-5793(99)00331-2; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; KLEIBER M, 1975, FIRE LIFE, P179; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; KOZAK LP, 2000, IN PRESS ANN REV NUT, V20; Lanni A, 1999, FEBS LETT, V444, P250, DOI 10.1016/S0014-5793(99)00061-7; Larkin S, 1997, BIOCHEM BIOPH RES CO, V240, P222, DOI 10.1006/bbrc.1997.7636; Lee FYJ, 1999, HEPATOLOGY, V29, P677, DOI 10.1002/hep.510290320; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; Matthias A, 1999, J BIOL CHEM, V274, P28150, DOI 10.1074/jbc.274.40.28150; McLean J., 1987, ANIMAL HUMAN CALORIM; Monemdjou S, 1999, AM J PHYSIOL-ENDOC M, V276, pE1073, DOI 10.1152/ajpendo.1999.276.6.E1073; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NICHOLLS DG, 1976, EUR J BIOCHEM, V62, P223, DOI 10.1111/j.1432-1033.1976.tb10151.x; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; Sanchis D, 1998, J BIOL CHEM, V273, P34611, DOI 10.1074/jbc.273.51.34611; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; Tsuboyama-Kasaoka N, 1998, BIOCHEM BIOPH RES CO, V247, P498, DOI 10.1006/bbrc.1998.8818; Urhammer SA, 1998, DIABETOLOGIA, V41, P241, DOI 10.1007/s001250050897; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298; West GB, 1999, SCIENCE, V284, P1677, DOI 10.1126/science.284.5420.1677; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667	56	324	329	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16251	16257		10.1074/jbc.M910177199	http://dx.doi.org/10.1074/jbc.M910177199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748195	hybrid			2022-12-27	WOS:000087291400087
J	Marcic, B; Deddish, PA; Skidgel, RA; Erdos, EG; Minshall, RD; Tan, FL				Marcic, B; Deddish, PA; Skidgel, RA; Erdos, EG; Minshall, RD; Tan, FL			Replacement of the transmembrane anchor in angiotensin I-converting enzyme (ACE) with a glycosylphosphatidylinositol tail affects activation of the B-2 bradykinin receptor by ACE inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CARBOXYPEPTIDASE-M; KININ RECEPTOR; PROTEINS; MEMBRANE; CAVEOLAE; SEQUESTRATION; POTENTIATION; MICRODOMAINS; G-ALPHA(Q)	To investigate further the relationship of angiotensin I-converting enzyme (ACE) inhibitors to activation of the B-2 bradykinin (BK) receptor, we transfected Chinese hamster ovary cells to stably express the human receptor and either wild-type ACE (WT-ACE), an ACE construct with most of the cytosolic portion deleted (Cytdel-ACE), or ACE with a glycosylphosphatidylinositol (GPI) anchor replacing the transmembrane and cytosolic domains (GPI-ACE). BK or its ACE-resistant analogue were the agonists, All activities (arachidonic acid release and calcium mobilization) were blocked by the B-2, antagonist HOE 140. B-2, was desensitized by repeated administration of BK but resensitized to agonist by ACE inhibitors in the cells expressing both B-2 and either WT-ACE or Cyt-del-ACE. In GPI-ACE expressing cells, the B-2 receptor was still activated by the agonists, but ACE inhibitors did not resensitize. Pretreatment with filipin returned the sensitivity to inhibitors. In immunocytochemistry, GPI-ACE showed patchy, uneven distribution on the plasma membrane that was restored by filipin, Thus, ACE inhibitors were inactive as long as GPI-ACE was sequestered in cholesterol-rich membrane domains. WT-ACE and B-2 receptor in Chinese hamster ovary cells co-immunoprecipitated with antibody to receptor, suggesting an interaction on the cell membrane. ACE inhibitors augment BK effects on receptors indirectly only when enzyme and receptor molecules are sterically close, possibly forming a heterodimer.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Erdos, EG (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, M-C 868,835 S Wolcott Ave, Chicago, IL 60612 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058118, R01HL036473, R37HL036473] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK041431, R01DK041431, R29DK041431] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36473, HL58118] Funding Source: Medline; NIDDK NIH HHS [DK41431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; Benzing T, 1999, CIRCULATION, V99, P2034, DOI 10.1161/01.CIR.99.15.2034; BERALDO WT, 1997, KININ SYSTEM, P1; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Carretero Oscar A., 1995, P983; CORVOL P, 1998, HDB PROTEOLYTIC ENZY, P1066; CREMEL G, 1990, ARCH BIOCHEM BIOPHYS, V278, P142, DOI 10.1016/0003-9861(90)90242-Q; DANILOV S, 1994, J BIOL CHEM, V269, P26806; DEDDISH PA, 1990, J BIOL CHEM, V265, P15083; Deddish PA, 1998, HYPERTENSION, V31, P912, DOI 10.1161/01.HYP.31.4.912; DEFENDINI R, 1983, NEUROENDOCRINOLOGY, V37, P32, DOI 10.1159/000123512; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DRAPEAU G, 1988, EUR J PHARMACOL, V155, P193, DOI 10.1016/0014-2999(88)90423-2; Erdos EG, 1999, TRENDS ENDOCRIN MET, V10, P223, DOI 10.1016/S1043-2760(99)00156-3; Erdos EG, 1997, KININ SYSTEM, P112; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gainer JV, 1998, NEW ENGL J MED, V339, P1285, DOI 10.1056/NEJM199810293391804; GAVRAS H, 1978, CIRCULATION, V58, P770, DOI 10.1161/01.CIR.58.5.770; GAVRAS H, 1994, HYPERTENSION, V23, P813, DOI 10.1161/01.HYP.23.6.813; Graves JD, 1999, PHARMACOL THERAPEUT, V82, P111, DOI 10.1016/S0163-7258(98)00056-4; HALL ER, 1976, LIFE SCI, V18, P1299, DOI 10.1016/0024-3205(76)90208-3; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; JANS DA, 1997, MOBILE RECEPTOR HYPO, P63; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis EJ, 1996, CONTRIB NEPHROL, V118, P206; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LINZ W, 1995, PHARMACOL REV, V47, P25; Liu YH, 1996, HYPERTENSION, V27, P7, DOI 10.1161/01.HYP.27.1.7; Marcic B, 1999, HYPERTENSION, V33, P835, DOI 10.1161/01.HYP.33.3.835; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Minshall RD, 1997, CIRC RES, V81, P848; Minshall RD, 1997, AM J CARDIOL, V80, pA132, DOI 10.1016/S0002-9149(97)00468-2; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; Nosjean O, 1997, BBA-REV BIOMEMBRANES, V1331, P153, DOI 10.1016/S0304-4157(97)00005-1; ONDETTI MA, 1994, ANNU REV PHARMACOL, V34, P1; Page I. H., 1988, HYPERTENSION RES MEM; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SKEGGS LT, 1954, J EXP MED, V99, P275, DOI 10.1084/jem.99.3.275; SOUBRIER F, 1993, J HYPERTENS, V11, P471, DOI 10.1097/00004872-199305000-00001; TAN FL, 1995, METHOD ENZYMOL, V248, P663; TAN FL, 1989, J BIOL CHEM, V264, P13165; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; VOGEL R, 1970, Z KLIN CHEM KLIN BIO, V8, P177; YANG HYT, 1967, NATURE, V215, P1402, DOI 10.1038/2151402a0; YANG HYT, 1971, J PHARMACOL EXP THER, V177, P291; Yusuf S, 2000, NEW ENGL J MED, V342, P145	52	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16110	16118		10.1074/jbc.M909490199	http://dx.doi.org/10.1074/jbc.M909490199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748135	hybrid			2022-12-27	WOS:000087291400069
J	Perozzo, R; Jelesarov, I; Bosshard, HR; Folkers, G; Scapozza, L				Perozzo, R; Jelesarov, I; Bosshard, HR; Folkers, G; Scapozza, L			Compulsory order of substrate binding to herpes simplex virus type 1 thymidine kinase - A calorimetric study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-FOLDING THERMODYNAMICS; THYMIDYLATE KINASE; ADENYLATE KINASE; 3-DIMENSIONAL STRUCTURE; MOLECULAR-BASIS; ENERGETICS; COMPLEX; ACYCLOVIR; ENZYME; MICROCALORIMETRY	Isothermal titration calorimetry has been used to investigate the thermodynamic parameters of the binding of thymidine (dT) and ATP to herpes simplex virus type 1 thymidine kinase (HSV1 TK), Binding follows a sequential pathway in which dT binds first and ATP second. The free enzyme does not bind ATP, whose binding site becomes only accessible in the HSV1 TK dT complex. At pH 7.5 and 25 degrees C, the binding constants are 1.9 x 10(5) M-1 for dT and 3.9 x 10(6) M-1 for ATP binding to the binary HSV1 TK dT complex. Binding of both substrates is enthalpy-driven and opposed by a large negative entropy change. The heat capacity change (Delta Cp) obtained from Delta H in the range of 10-25 degrees C is -360 cal K-1 mol(-1) for dT binding and -140 cal K-1 mol(-1) for ATP binding. These large Delta Cp values are incompatible with a rigid body binding model in which the dT and ATP binding sites pre-exist in the free enzyme. Values of Delta Cp and T Delta S strongly indicate large scale conformational adaptation of the active site in sequential substrate binding. The conformational changes seem to be more pronounced in dT binding than in the subsequent ATP binding. Considering the crystal structure of the ternary HSV1 TK dLT ATP complex, a large movement in the dT binding domain and a smaller but substantial movement in the LID domain are proposed to take place when the enzyme changes from the substrate-free, presumably more open and less ordered conformation to the closed and compact conformation of the ternary enzyme-substrate complex.	Swiss Fed Inst Technol, Dept Appl Biosci, CH-8057 Zurich, Switzerland; Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Scapozza, L (corresponding author), Swiss Fed Inst Technol, Dept Appl Biosci, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	scapozza@pharma.ethz.ch		Folkers, Gerd/0000-0002-3620-705X; Scapozza, Leonardo/0000-0003-1079-648X				Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; Baker BM, 1998, METHOD ENZYMOL, V295, P294; Bennett MS, 1999, FEBS LETT, V443, P121, DOI 10.1016/S0014-5793(98)01619-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; Champness JN, 1998, PROTEINS, V32, P350, DOI 10.1002/(SICI)1097-0134(19980815)32:3<350::AID-PROT10>3.0.CO;2-8; CHEN MS, 1979, J BIOL CHEM, V254, P747; CHEN MS, 1978, J BIOL CHEM, V253, P1325; CONNELLY PR, 1992, P NATL ACAD SCI USA, V89, P4781, DOI 10.1073/pnas.89.11.4781; Cooper A, 1994, Methods Mol Biol, V22, P109; Cooper A, 1994, Methods Mol Biol, V22, P137; Degreve B, 1998, J VIROL, V72, P9535; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; FETZER J, 1994, PROTEIN EXPRES PURIF, V5, P432, DOI 10.1006/prep.1994.1062; Gerber S, 1996, BIOCHEM BIOPH RES CO, V225, P263, DOI 10.1006/bbrc.1996.1164; HALPERN ME, 1984, J VIROL, V50, P733, DOI 10.1128/JVI.50.3.733-738.1984; Hubbard S, 1996, NACCESS VERSION 2 1; JANIN J, 1990, J BIOL CHEM, V265, P16027; KELLER PM, 1981, BIOCHEM PHARMACOL, V30, P3071, DOI 10.1016/0006-2952(81)90495-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARDER BA, 1982, J VIROL, V42, P649, DOI 10.1128/JVI.42.2.649-658.1982; LARDER BA, 1983, J GEN VIROL, V64, P523, DOI 10.1099/0022-1317-64-3-523; Lavie A, 1997, NAT STRUCT BIOL, V4, P601, DOI 10.1038/nsb0897-601; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; Luque I, 1998, METHOD ENZYMOL, V295, P100; MAKHATADZE GI, 1993, J MOL BIOL, V232, P639, DOI 10.1006/jmbi.1993.1416; MASSON S, 1993, BIOCHEMISTRY-US, V32, P1025, DOI 10.1021/bi00055a005; McNemar C, 1997, BIOCHEMISTRY-US, V36, P10006, DOI 10.1021/bi9704360; Michael M, 1997, Pharm Acta Helv, V72, P139, DOI 10.1016/S0031-6865(97)00006-X; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; MULLERDIECKMANN HJ, 1994, J MOL BIOL, V236, P361, DOI 10.1006/jmbi.1994.1140; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; Pilger BD, 1999, J BIOL CHEM, V274, P31967, DOI 10.1074/jbc.274.45.31967; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; Privalov PL, 1999, J MOL BIOL, V294, P997, DOI 10.1006/jmbi.1999.3285; Schlauderer GJ, 1996, PROTEIN SCI, V5, P434; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SMEE DF, 1983, ANTIMICROB AGENTS CH, V23, P676, DOI 10.1128/AAC.23.5.676; SPADARI S, 1992, J MED CHEM, V35, P4214, DOI 10.1021/jm00100a029; SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/bi00131a009; SPOLAR RS, 1989, P NATL ACAD SCI USA, V86, P8382, DOI 10.1073/pnas.86.21.8382; STEHLE T, 1990, J MOL BIOL, V211, P249, DOI 10.1016/0022-2836(90)90024-G; Teplyakov A, 1996, EMBO J, V15, P3487, DOI 10.1002/j.1460-2075.1996.tb00717.x; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; WALDMAN AS, 1983, J BIOL CHEM, V258, P1571; WILD K, 1995, FEBS LETT, V368, P289, DOI 10.1016/0014-5793(95)00680-8; Wild K, 1997, PROTEIN SCI, V6, P2097; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404	53	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16139	16145		10.1074/jbc.M000509200	http://dx.doi.org/10.1074/jbc.M000509200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747922	hybrid			2022-12-27	WOS:000087291400073
J	Tcherepanova, I; Puigserver, P; Norris, JD; Spiegelman, BM; McDonnell, DP				Tcherepanova, I; Puigserver, P; Norris, JD; Spiegelman, BM; McDonnell, DP			Modulation of estrogen receptor-alpha transcriptional activity by the coactivator PGC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; NUCLEAR RECEPTOR; POSTMENOPAUSAL WOMEN; PEPTIDE ANTAGONISTS; PROMOTER-CONTEXT; BINDING DOMAIN; BREAST-CANCER; ER-BETA; ACTIVATION; IDENTIFICATION	A transcriptional coactivator of the peroxisome proliferator-activated receptor-gamma (PPAR gamma), PPAR gamma-coactivator-1(PGC-1) interacts in a constitutive manner with the hinge domain of PPAR gamma and enhances its transcriptional activity. In this study we demonstrate that PGC-1 is a coactivator of estrogen receptor-alpha (ER alpha)-dependent transcriptional activity. However the mechanism by which PGC-1 interacts with ER alpha is different from that of PPAR gamma. Specifically, it was determined that the carboxyl terminus of PGC-1 interacts in a ligand-independent manner with the ER alpha hinge domain. In addition, an LXXLL motif within the amino terminus of PGC-1 was shown to interact in an agonist-dependent manner with the AF2 domain within the carboxyl terminus of ER alpha. The ability of PGC-1 to associate with and potentiate the transcriptional activity of an ER alpha-AF2 mutant that is unable to interact with the p160 class of coactivators suggests that this coactivator may have a unique role in estrogen signaling. It is concluded from these studies that PGC-1 is a bona fide ER alpha coactivator, which may serve as a convergence point between PPAR gamma and ER alpha signaling.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Duke University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	McDonnell, DP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.			Norris, John/0000-0001-6553-8053	NIDDK NIH HHS [DK48807] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048807, R37DK048807] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MCDONNELL DP, 1991, MOL CELL BIOL, V11, P4350, DOI 10.1128/MCB.11.9.4350; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MIGLIACCIO S, 1992, ENDOCRINOLOGY, V130, P2617, DOI 10.1210/en.130.5.2617; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; ONATE SA, 1995, SCIENCE, V270, P1354; PARKER MG, 1993, BREAST CANCER RES TR, V26, P131, DOI 10.1007/BF00689686; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	46	179	185	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16302	16308		10.1074/jbc.M001364200	http://dx.doi.org/10.1074/jbc.M001364200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748020	hybrid			2022-12-27	WOS:000087291400094
J	Ali, MS; Sayeski, PP; Bernstein, KE				Ali, MS; Sayeski, PP; Bernstein, KE			Jak2 acts as both a STAT1 kinase and as a molecular bridge linking STAT1 to the angiotensin II AT(1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TYROSINE KINASES; ACTIVATION; PHOSPHORYLATION; PATHWAY; PROTEIN; TRANSCRIPTION; REQUIREMENT; ANTAGONISTS; DOMAINS	Angiotensin II activates the Jak-STAT pathway via the AT(1) receptor. We studied two mutant AT(1) receptors, termed M5 and M6, that contain Y to F substitutions for the tyrosine residues naturally found in the third intracellular loop and the carboxyl terminus. After binding ligand, both the M5 and M6 AT(1) receptors trigger STAT1 tyrosine phosphorylation equivalent to that observed with the wild type receptor, indicating that angiotensin II-mediated phosphorylation of STAT1 is independent of these receptor tyrosine residues. In response to angiotensin II, Jak2 autophosphorylates on tyrosine, and Jak2 and STAT1 physically associate, a process that depends on the SH2 domain of STAT1 in vitro. Evaluation of the wild type, M5, and M6 AT(1) receptors showed that angiotensin II-dependent AT(1) receptor-Jak2-STAT1 complex formation is dependent on catalytically active Jak2, not on the receptor tyrosine residues in the third intracellular loop and carboxyl tail. Immunodepletion of Jak2 virtually eliminated the ligand-dependent binding of STAT1 to the AT(1) receptor. These data indicate that the association of STAT1 with the AT(1) receptor is not strictly bimolecular; it requires Jak2 as both a STAT1 kinase and as a molecular bridge linking STAT1 to the AT(1) receptor.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Emory University	Bernstein, KE (corresponding author), Emory Univ, Dept Pathol, 1639 Pierce Dr,Rm 7107A WMB, Atlanta, GA 30322 USA.			Bernstein, Kenneth/0000-0001-8097-3272	NHLBI NIH HHS [HL61710] Funding Source: Medline; NIDDK NIH HHS [DK39777, DK44280] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039777, R37DK039777, R01DK044280] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; CHARLENE DM, 1997, J MOL CARDIOL, V29, P2513; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DZAU V J, 1987, Journal of Cardiovascular Pharmacology, V10, pS9; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; Novak U, 1996, ONCOGENE, V13, P2607; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PAXTON WG, 1994, BIOCHEM BIOPH RES CO, V200, P260, DOI 10.1006/bbrc.1994.1443; Sayeski PP, 1998, REGUL PEPTIDES, V78, P19, DOI 10.1016/S0167-0115(98)00137-2; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TIMMERMANS PBMWM, 1991, TRENDS PHARMACOL SCI, V12, P55, DOI 10.1016/0165-6147(91)90498-H; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	31	46	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15586	15593		10.1074/jbc.M908931199	http://dx.doi.org/10.1074/jbc.M908931199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748109	hybrid			2022-12-27	WOS:000087128300109
J	Huang, WZ; Zhang, Z; Palzkill, T				Huang, WZ; Zhang, Z; Palzkill, T			Design of potent beta-lactamase inhibitors by phage display of beta-lactamase inhibitory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-CLAVULIGERUS; MUTAGENESIS; SCHEME	beta-Lactamase inhibitory protein (BLIP) binds tightly to several p-lactamases including TEM-1 beta-lactamase (K-i 0.1 NM). The TEM-1 beta-lactamase/BLIP co-crystal structure indicates that two turn regions in BLIP insert into the active site of beta-lactamase to block the binding of beta-lactam antibiotics. Residues from each turn, Asp(49) and Phe(142), mimic interactions made by penicillin G when bound in the beta-lactamase active site. Phage display was used to determine which residues within the turn regions of BLIP are critical for binding TEM-1 beta-lactamase. The sequences of a set of functional mutants from each library indicated that a few sequence types were predominant. These BLIP mutants exhibited K-i values for beta-lactamase inhibition ranging from 0.01 to 0.2 nM. The results indicate that even though BLIP is a potent inhibitor of TEM-1 beta-lactamase, the wild-type sequence of the active site binding region is not optimal and that derivatives of BLIP that bind beta-lactamase extremely tightly can be obtained. Importantly, all of the tight binding BLIP mutants have sequences that would be predicted theoretically to form turn structures.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Palzkill, T (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.				NIAID NIH HHS [AI32956] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI032956, R01AI032956] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; DORAN JL, 1990, J BACTERIOL, V172, P4909, DOI 10.1128/jb.172.9.4909-4918.1990; Gibson TJ, 1984, THESIS CAMBRIDGE U; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang WZ, 1998, ANTIMICROB AGENTS CH, V42, P2893, DOI 10.1128/AAC.42.11.2893; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; JACKSON S, 1994, J AM CHEM SOC, V116, P3220, DOI 10.1021/ja00087a007; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; Lazarus Robert A., 1993, Current Opinion in Biotechnology, V4, P438, DOI 10.1016/0958-1669(93)90009-L; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; Lowman HB., 1991, METHODS COMPANION ME, V3, P205; ONEIL KT, 1995, CURR OPIN STRUC BIOL, V5, P443, DOI 10.1016/0959-440X(95)80027-1; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; PARKER RH, 1987, INFECT CONT HOSP EP, V8, P36, DOI 10.1017/S0195941700066972; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; READING C, 1977, ANTIMICROB AGENTS CH, V11, P852, DOI 10.1128/AAC.11.5.852; Sambrook J., 2002, MOL CLONING LAB MANU; STRYNADKA NCJ, 1994, NATURE, V368, P657, DOI 10.1038/368657a0; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P290, DOI 10.1038/nsb0396-290; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WIEDEMANN B, 1989, J ANTIMICROB CHEMOTH, V24, P1	26	25	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14964	14968		10.1074/jbc.M001285200	http://dx.doi.org/10.1074/jbc.M001285200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748011	hybrid			2022-12-27	WOS:000087128300028
J	Kulms, D; Poppelmann, B; Schwarz, T				Kulms, D; Poppelmann, B; Schwarz, T			Ultraviolet radiation-induced interleukin 6 release in HeLa cells is mediated via membrane events in a DNA damage-independent way	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; PROTECTS TRANSFORMED KERATINOCYTES; INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; EPIDERMAL-CELLS; GROWTH-FACTOR; TNF RECEPTOR; SUNBURN CELL; SKIN-CANCER	Evidence exists that ultraviolet radiation (UV) affects molecular targets in the nucleus or at the cell membrane, UV-induced apoptosis was found to be mediated via DNA damage and activation of death receptors, suggesting that nuclear and membrane effects are not mutually exclusive. To determine whether participation of nuclear and membrane components is also essential for other UV responses, we studied the induction of interleukin-6 (IL-6) by UV, Exposing HeLa cells to UV at 4 degrees C, which inhibits activation of surface receptors, almost completely prevented IL-6 release. Enhanced repair of UV-mediated DNA damage by addition of the DNA repair enzyme photolyase did not affect UV-induced IL-6 production, suggesting that in this case membrane events predominante over nuclear effects. UV-induced IL-6 release is mediated via NF kappa B since the NF kappa B inhibitor MG132 or transfection of cells with a super-repressor form of the NF kappa B inhibitor I kappa B reduced IL-6 release. Transfection with a dominant negative mutant of the signaling protein TRAF-8 reduced IL-6 release upon exposure to W, indicating that UV-induced IL-6 release is mediated by activation of the tumor necrosis factor receptor-1. These data demonstrate that UV can exert biological effects mainly by affecting cell surface receptors and that this is independent of its ability to induce nuclear DNA damage.	Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany	University of Munster	Schwarz, T (corresponding author), Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, Von Esmarchstr 56, D-48149 Munster, Germany.		Kulms, Dagmar/H-1653-2014; Schwarz, Thomas/A-9148-2010					Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Beissert S, 1999, J INVEST DERM SYMP P, V4, P61, DOI 10.1038/sj.jidsp.5640183; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BEUKERS R, 1960, BIOCHIM BIOPHYS ACTA, V41, P550, DOI 10.1016/0006-3002(60)90063-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGRUIJL FR, 1993, CANCER RES, V53, P53; DEVARY Y, 1993, SCIENCE, V261, P442; EKER APM, 1990, J BIOL CHEM, V265, P8009; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; HERLLICH P, 1992, REV PHYSL BIOCH PHAR, V119, P187; HERRLICH P, 1994, CURR OPIN CELL BIOL, V6, P425, DOI 10.1016/0955-0674(94)90036-1; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kibitel J, 1998, PHOTOCHEM PHOTOBIOL, V67, P541, DOI 10.1111/j.1751-1097.1998.tb09452.x; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; KRIPKE ML, 1992, P NATL ACAD SCI USA, V89, P7516, DOI 10.1073/pnas.89.16.7516; KRISTENSEN M, 1993, CLIN EXP IMMUNOL, V94, P354; KRUTMANN J, 1994, J INVEST DERMATOL, V102, P428, DOI 10.1111/1523-1747.ep12372947; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Nishigori C, 1996, P NATL ACAD SCI USA, V93, P10354, DOI 10.1073/pnas.93.19.10354; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Petit-Frere C, 1998, J INVEST DERMATOL, V111, P354, DOI 10.1038/sj.jid.5602962; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Schwarz T, 1998, J PHOTOCH PHOTOBIO B, V44, P91, DOI 10.1016/S1011-1344(98)00126-2; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; SIMON MM, 1994, J INVEST DERMATOL, V102, P422, DOI 10.1111/1523-1747.ep12372194; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TREFZER U, 1993, J CLIN INVEST, V92, P462, DOI 10.1172/JCI116589; WOLF P, 1995, J INVEST DERMATOL, V104, P287, DOI 10.1111/1523-1747.ep12612828; YAROSH D, 1994, TRENDS PHOTOCHEM PHO, V3, P175; YOUNG AR, 1987, PHOTODERMATOLOGY, V4, P127; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	43	32	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15060	15066		10.1074/jbc.M910113199	http://dx.doi.org/10.1074/jbc.M910113199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748190	hybrid			2022-12-27	WOS:000087128300041
J	Soler-Lopez, M; Malinina, L; Subirana, JA				Soler-Lopez, M; Malinina, L; Subirana, JA			Solvent organization in an oligonucleotide crystal - The structure of d(GCGAATTCG)(2) at atomic resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-DNA; WATER-STRUCTURE; HYDRATION; DYNAMICS; DUPLEX; CONFORMATION; REFINEMENT; TRIPLETS; PROTEIN; NETWORK	We describe the crystal structure of d(GCGAATTCG) determined by x-ray diffraction at atomic resolution level (0.89 Angstrom). The duplex structure is practically identical to that described at 2.05 Angstrom resolution (Van Meervelt, L., Vlieghe, D., Dautant, A., Gallois, B., Precigoux, G., and Kennard, O. (1995) Nature 374, 742-744), however about half of the phosphate groups show multiple conformations. The crystal has three regions with different solvent structure. One of them contains several ordered Mg+2 ions and can be considered as an ionic crystal. A second region is formed by a network of ordered water molecules with a polygonal organization that binds three duplexes. The third region is formed by channels of solvent in which very few ordered solvent molecules are visible. The less ordered phosphates are found facing this channel. The latter region provides a view of DNA with highly movable charges, both negative phosphates and counterions, without a precise location.	Univ Politecn Cataluna, Dept Engn Quim, E-08028 Barcelona, Spain; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 117984, Russia	Universitat Politecnica de Catalunya; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Subirana, JA (corresponding author), Univ Politecn Cataluna, Dept Engn Quim, Av Diagonal 647, E-08028 Barcelona, Spain.	subirana@eq.upc.es	Malinina, Lucy/B-8161-2013; Subirana, juan/L-7192-2014	Subirana, juan/0000-0002-1706-9341; Malinina, Lucy/0000-0001-7973-1831				BADGER J, 1991, P NATL ACAD SCI USA, V88, P622, DOI 10.1073/pnas.88.2.622; BERMAN HM, 1992, BIOPHYS J, V63, P751, DOI 10.1016/S0006-3495(92)81649-1; BOUQUIERE JP, 1994, ACTA CRYSTALLOGR B, V50, P566, DOI 10.1107/S0108768194002211; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1996, XPLOR MANUAL VERSION; Chalikian TV, 1999, BIOPOLYMERS, V50, P459, DOI 10.1002/(SICI)1097-0282(19991015)50:5<459::AID-BIP1>3.0.CO;2-B; CHALIKIAN TV, 1994, BIOCHEMISTRY-US, V33, P2394, DOI 10.1021/bi00175a007; CLEMENTI E, 1994, ACS SYM SER, V568, P95; COLL M, 1987, J BIOMOL STRUCT DYN, V4, P797, DOI 10.1080/07391102.1987.10507679; ESNOUF R, 1997, BOBSCRIPT VERS 2 4; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KENNARD O, 1986, J BIOMOL STRUCT DYN, V3, P623, DOI 10.1080/07391102.1986.10508452; LIPSCOMB LA, 1994, BIOCHEMISTRY-US, V33, P3649, DOI 10.1021/bi00178a023; MacArthur MW, 1999, ACTA CRYSTALLOGR D, V55, P994, DOI 10.1107/S0907444999002231; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; Minasov G, 1999, J MOL BIOL, V291, P83, DOI 10.1006/jmbi.1999.2934; Mishima O, 1998, NATURE, V396, P329, DOI 10.1038/24540; *MOL SIM INC, CERIUS 3 1 PROGR; NEIDLE S, 1980, NATURE, V288, P129, DOI 10.1038/288129a0; Ohmine I, 1999, ACCOUNTS CHEM RES, V32, P741, DOI 10.1021/ar970161g; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; Phillips K, 1997, J MOL BIOL, V273, P171, DOI 10.1006/jmbi.1997.1292; Roussel A., 1998, TURBO FRODO VERSION; SAENGER W, 1987, ANNU REV BIOPHYS BIO, V16, P93; Schneider B, 1998, BIOPHYS J, V75, P2422, DOI 10.1016/S0006-3495(98)77686-6; Schneider B, 1995, BIOPHYS J, V69, P2661, DOI 10.1016/S0006-3495(95)80136-0; SHCHYOLKINA AK, 1994, FEBS LETT, V339, P113, DOI 10.1016/0014-5793(94)80396-X; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shui XQ, 1998, BIOCHEMISTRY-US, V37, P16877, DOI 10.1021/bi982063o; Soler-Lopez M, 1999, J BIOL CHEM, V274, P23683, DOI 10.1074/jbc.274.34.23683; SUNDARALINGAM M, 1989, LANDOLDBORNSTEIN NEW, V7, P22; Tereshko V, 1999, J AM CHEM SOC, V121, P3590, DOI 10.1021/ja984346+; VANMEERVELT L, 1995, NATURE, V374, P742, DOI 10.1038/374742a0; Vlieghe D, 1999, ACTA CRYSTALLOGR D, V55, P1495, DOI 10.1107/S0907444999007933; Vlieghe D, 1996, ACTA CRYSTALLOGR D, V52, P766, DOI 10.1107/S0907444996003216	39	54	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23034	23044		10.1074/jbc.M002119200	http://dx.doi.org/10.1074/jbc.M002119200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10749874	hybrid			2022-12-27	WOS:000088419400059
J	Wu, Y; Dowbenko, D; Spencer, S; Laura, R; Lee, J; Gu, QM; Lasky, LA				Wu, Y; Dowbenko, D; Spencer, S; Laura, R; Lee, J; Gu, QM; Lasky, LA			Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; GLIOBLASTOMA CELLS; PROSTATE-CANCER; SIGNALING PATHWAYS; CRYSTAL-STRUCTURE; DISCS LARGE; PTEN; PROTEIN; GENE; LOCALIZATION	PTEN/MMAC is a phosphatase that is mutated in multiple human tumors. PTEN/MMAC dephosphorylates 3-phosphorylated phosphatidylinositol phosphates that activate AKT/protein kinase B (PKB) kinase activity. AKT/PKB is implicated in the inhibition of apoptosis, and cell lines and tumors with mutated PTEN/MMAC show increased AKT/PKB kinase activity and resistance to apoptosis. PTEN/MMAC contains a PDZ domain-binding site, and we show here that the phosphatase binds to a PDZ domain of membrane-associated guanylate kinase with inverted orientation (MAGI) 3, a novel inverted membrane-associated guanylate kinase that localizes to epithelial cell tight junctions. Importantly, MAGI3 and PTEN/MMAC cooperate to modulate the kinase activity of AKT/PKB. These data suggest that MAGIS allows for the juxtaposition of PTEN/MMAC to phospholipid signaling pathways involved with cell survival.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Lasky, LA (corresponding author), Genentech Inc, Dept Mol Oncol, 460 Pt San Bruno Blvd, San Francisco, CA 94080 USA.	lal@gene.com						BIGNER SH, 1988, CANCER RES, V48, P405; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cairns P, 1997, CANCER RES, V57, P4997; Cheney IW, 1998, CANCER RES, V58, P2331; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; Eng C, 1998, INT J ONCOL, V12, P701; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1997, AM J HUM GENET, V61, P1234, DOI 10.1086/301659; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Rasheed BKA, 1997, CANCER RES, V57, P4187; Robertson GP, 1998, P NATL ACAD SCI USA, V95, P9418, DOI 10.1073/pnas.95.16.9418; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tashiro H, 1997, CANCER RES, V57, P3935; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	50	223	235	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21477	21485		10.1074/jbc.M909741199	http://dx.doi.org/10.1074/jbc.M909741199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10748157	hybrid			2022-12-27	WOS:000088230600070
J	Wohnsland, F; Schmitz, AAP; Steinmetz, MO; Aebi, U; Vergeres, G				Wohnsland, F; Schmitz, AAP; Steinmetz, MO; Aebi, U; Vergeres, G			Interaction between actin and the effector peptide of MARCKS-related protein - Identification of functional amino acid segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE SUBSTRATE MARCKS; ABNORMAL BRAIN-DEVELOPMENT; LOW-AFFINITY SITES; C SUBSTRATE; TYROSINE PHOSPHORYLATION; CALMODULIN-BINDING; DIVALENT-CATION; SKELETAL-MUSCLE; BOVINE BRAIN; F-ACTIN	It is widely assumed that the members of the MARCKS protein family, MARCKS (an acronym for myristoylated alanine-rich C kinase substrate) and MARCKS-related protein (MRP), interact with actin via their effector domain, a highly basic segment composed of 24-25 amino acid residues. To clarify the mechanisms by which this interaction takes place, we have examined the effect of a peptide corresponding to the effector domain of MRP, the so-called effector peptide, on both the dynamic and the structural properties of actin, We show that in the absence of cations the effector peptide polymerizes monomeric actin and causes the alignment of the formed filaments into bundle-like structures. Moreover, we document that binding of calmodulin or phosphorylation by protein kinase C both inhibit the actin polymerizing activity of the MRP effector peptide. Finally, several effector peptides were synthesized in which positively charged or hydrophobic segments were deleted or replaced by alanines, Our data suggest that a group of six positively charged amino acid residues at the N-terminus of the peptide is crucial for its interaction with actin. While its actin polymerizing activity critically depends on the presence of all three positively charged segments of the peptide, hydrophobic amino acid residues rather modulate the polymerization velocity.	Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland; Univ Basel, Biozentrum, ME Muller Inst Struct Biol, CH-4056 Basel, Switzerland	University of Basel; University of Basel	Vergeres, G (corresponding author), ZLB Zentrallab, Wankdorfstr 10, CH-3000 Bern 22, Switzerland.		Steinmetz, Michel O/AAA-3349-2022	Steinmetz, Michel O/0000-0001-6157-3687; Schmitz, Arndt/0000-0002-7104-6191				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ATKINS PW, 1997, PHYSICAL CHEM, pA8; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BROWN SS, 1979, J CELL BIOL, V80, P499, DOI 10.1083/jcb.80.2.499; CARLIER MF, 1986, J BIOL CHEM, V261, P785; CARLIER MF, 1986, J BIOL CHEM, V261, P778; Chakravarthy B, 1999, TRENDS NEUROSCI, V22, P12, DOI 10.1016/S0166-2236(98)01288-0; Chen JM, 1996, P NATL ACAD SCI USA, V93, P6275, DOI 10.1073/pnas.93.13.6275; COBURN C, 1993, BIOPHYS J, V64, pA60; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; ESTES JE, 1992, J MUSCLE RES CELL M, V13, P272, DOI 10.1007/BF01766455; FOWLER WE, 1982, J CELL BIOL, V93, P452, DOI 10.1083/jcb.93.2.452; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HANSON J, 1973, PROC R SOC SER B-BIO, V183, P39, DOI 10.1098/rspb.1973.0003; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Li JX, 1996, J BIOL CHEM, V271, P12985, DOI 10.1074/jbc.271.22.12985; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; Manenti S, 1997, FEBS LETT, V419, P95, DOI 10.1016/S0014-5793(97)01438-5; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Myat MM, 1998, CURR BIOL, V8, P677, DOI 10.1016/S0960-9822(98)70273-8; ORIOLAUDIT C, 1978, EUR J BIOCHEM, V87, P371, DOI 10.1111/j.1432-1033.1978.tb12386.x; Porumb T, 1997, EUR BIOPHYS J BIOPHY, V25, P239, DOI 10.1007/s002490050036; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; Schleiff E, 1996, J BIOL CHEM, V271, P26794, DOI 10.1074/jbc.271.43.26794; SCHMITZ A, 1997, NATO ASI SER H, V101, P127; SELDEN LA, 1989, J BIOL CHEM, V264, P9271; SELDEN LA, 1986, J MUSCLE RES CELL M, V7, P215, DOI 10.1007/BF01753554; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Steinmetz MO, 1997, J CELL BIOL, V138, P559, DOI 10.1083/jcb.138.3.559; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Vergeres G, 1998, BIOCHEM J, V330, P5, DOI 10.1042/bj3300005; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; WOHNSLAND F, 2000, IN PRESS BIOPHYS CHE; Wu M, 1996, P NATL ACAD SCI USA, V93, P2110, DOI 10.1073/pnas.93.5.2110; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249	48	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20873	20879		10.1074/jbc.M910298199	http://dx.doi.org/10.1074/jbc.M910298199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10748210	hybrid			2022-12-27	WOS:000088084500092
J	Declais, AC; Marsault, J; Confalonieri, F; de La Tour, CB; Duguet, M				Declais, AC; Marsault, J; Confalonieri, F; de La Tour, CB; Duguet, M			Reverse gyrase, the two domains intimately cooperate to promote positive supercoiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFOLOBUS-SHIBATAE B12; THERMOTOGA-MARITIMA; DNA TOPOISOMERASES; ESCHERICHIA-COLI; I TOPOISOMERASE; GENE STRUCTURE; HELICASE; CLEAVAGE; BINDING; RECONSTITUTION	Reverse gyrases are atypical topoisomerases present in hyperthermophiles and are able to positively supercoil a circular DNA. Despite a number of studies, the mechanism by which they perform this peculiar activity is still unclear. Sequence data suggested that reverse gyrases are composed of two putative domains, a helicase-like and a topoisomerase I, usually in a single polypeptide, Based on these predictions, we have separately expressed the putative domains and the full-length polypeptide of Sulfolobus acidocaldarius reverse gyrase as recombinant proteins in Escherichia coli, We show the following. (i) The full-length recombinant enzyme sustains ATP-dependent positive supercoiling as efficiently as the wild type reverse gyrase, (ii) The topoisomerase domain exhibits a DNA relaxation activity by itself, although relatively low. (iii) We failed to detect helicase activity for both the N-terminal domain and the full-length reverse gyrase, (iv) Simple mixing of the two domains reconstitutes positive supercoiling activity at 75 degrees C, The cooperation between the domains seems specific, as the topoisomerase domain cannot be replaced by another thermophilic topoisomerase I, and the helicase-like cannot be replaced by a true helicase, (v) The helicase-like domain is not capable of promoting stoichiometric DNA unwinding by itself; like the supercoiling activity, unwinding requires the cooperation of both domains, either separately expressed or in a single polypeptide. However, unwinding occurs in the absence of ATP and DNA cleavage, indicating a structural effect upon binding to DNA These results suggest that the N-terminal domain does not directly unwind DNA but acts more likely by driving ATP-dependent conformational changes within the whole enzyme, reminiscent of a protein motor.	Univ Paris Sud, Ctr Orsay,Inst Genet & Microbiol, Lab Enzymol Acides Nucl, CNRS,UMR 8621, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Duguet, M (corresponding author), Univ Paris Sud, Ctr Orsay,Inst Genet & Microbiol, Lab Enzymol Acides Nucl, CNRS,UMR 8621, Bat 400, F-91405 Orsay, France.	duguet@igmors.u-psud.fr		Declais, Anne-Cecile/0000-0002-1904-6469				ANDERA L, 1993, FEMS MICROBIOL LETT, V110, P107, DOI 10.1111/j.1574-6968.1993.tb06303.x; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Buhler C, 1998, NUCLEIC ACIDS RES, V26, P5157, DOI 10.1093/nar/26.22.5157; COLLIN RG, 1988, FEMS MICROBIOL LETT, V55, P235, DOI 10.1111/j.1574-6968.1988.tb13940.x; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; De la Tour CB, 1998, J BACTERIOL, V180, P274, DOI 10.1128/JB.180.2.274-281.1998; delaTour CB, 1995, BBA-GENE STRUCT EXPR, V1264, P279, DOI 10.1016/0167-4781(96)83596-2; Duguet M, 1997, J CELL SCI, V110, P1345; DUGUET M, 1995, NUCL ACIDS MOL BIOL, P85; Forterre P, 1992, Biochem Soc Symp, V58, P99; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; JAXEL C, 1989, EMBO J, V8, P3135, DOI 10.1002/j.1460-2075.1989.tb08466.x; Jaxel C, 1996, NUCLEIC ACIDS RES, V24, P4668, DOI 10.1093/nar/24.23.4668; Jaxel C, 1999, EUR J BIOCHEM, V260, P103, DOI 10.1046/j.1432-1327.1999.00128.x; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KOVALSKY OI, 1990, NUCLEIC ACIDS RES, V18, P2801, DOI 10.1093/nar/18.9.2801; Krah R, 1997, J BIOL CHEM, V272, P13986, DOI 10.1074/jbc.272.21.13986; Le Gac NT, 1998, J BIOL CHEM, V273, P13801, DOI 10.1074/jbc.273.22.13801; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; SHIBATA T, 1987, J BIOL CHEM, V262, P10419; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	28	58	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19498	19504		10.1074/jbc.M910091199	http://dx.doi.org/10.1074/jbc.M910091199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748189	hybrid			2022-12-27	WOS:000087941300011
J	Hutt, DM; Da-Silva, LF; Chang, LH; Prosser, DC; Ngsee, JK				Hutt, DM; Da-Silva, LF; Chang, LH; Prosser, DC; Ngsee, JK			PRA1 inhibits the extraction of membrane-bound Rab GTPase by GDI1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC-VESICLE FUSION; SMALL G-PROTEINS; ENDOPLASMIC-RETICULUM; TRANSPORT GTPASES; BINDING PROTEIN; DISSOCIATION INHIBITOR; INTERACTION CLONING; EXCHANGE FACTOR; PRENYLATED RAB; YEAST VACUOLES	Rab is a family of small Ras-like GTPases regulating intracellular vesicle transport. We have previously reported that prenylated Rab acceptor or PRA1 interacts with Rab GTPases and vesicle-associated membrane protein (VAMP2). Structural prediction programs suggest that PRA1, with its two extensive hydrophobic domains, is likely to be an integral membrane protein. However, subcellular fractionation and immunocytochemical analyses indicated that PRA1 is localized both in the cytosol and tightly associated with the membrane compartment. The membrane bound form can be partially extracted with physiological buffer and urea, suggesting that PRA1 is an extrinsic membrane protein. Deletion of the carboxyl-terminal domain resulted in a protein that behaved as an integral membrane protein, indicating that this domain plays an essential role in maintaining PRA1 in a soluble state. PRA1 can also bind weakly to GDP dissociation inhibitor (GDI), a protein involved in the solubilization of membrane-bound Rab GTPases. Addition of PRA1 inhibited the extraction of membrane-bound Rab3A by GDI, suggesting that membrane localization of Rab GTPases is dependent on the opposing action of PRA1 and GDI. The binding of Rab and VAMPS to PRA1 is mutually exclusive such that Rab3A can displace VAMPS in a preformed VAMP2-PRA1 complex.	Univ Ottawa, Dept Biochem, Loeb Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute	Hutt, DM (corresponding author), Univ Ottawa, Dept Biochem, Loeb Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada.			Prosser, Derek/0000-0002-6738-2758				Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; Bucci C, 1999, BIOCHEM BIOPH RES CO, V258, P657, DOI 10.1006/bbrc.1999.0651; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Collins RN, 1997, J BIOL CHEM, V272, P18281, DOI 10.1074/jbc.272.29.18281; D'Adamo P, 1998, NAT GENET, V19, P134, DOI 10.1038/487; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930; Grote E, 1996, J CELL BIOL, V132, P537, DOI 10.1083/jcb.132.4.537; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HOLZ RW, 1995, METHOD ENZYMOL, V257, P221; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; Lazar T, 1997, TRENDS BIOCHEM SCI, V22, P468, DOI 10.1016/S0968-0004(97)01150-X; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Nuoffer C, 1997, MOL BIOL CELL, V8, P1305, DOI 10.1091/mbc.8.7.1305; OSSIG R, 1995, EMBO J, V14, P3645, DOI 10.1002/j.1460-2075.1995.tb00034.x; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; TAKAI Y, 1993, CIBA F SYMP, V176, P128; Turner MD, 1997, J BIOL CHEM, V272, P13479, DOI 10.1074/jbc.272.21.13479; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WADA I, 1991, J BIOL CHEM, V266, P19599; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yang XP, 1998, EMBO J, V17, P4954, DOI 10.1093/emboj/17.17.4954	47	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18511	18519		10.1074/jbc.M909309199	http://dx.doi.org/10.1074/jbc.M909309199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10751420	hybrid			2022-12-27	WOS:000087659400082
J	Holz, RW; Hlubek, MD; Sorensen, SD; Fisher, SK; Balla, T; Ozaki, S; Prestwich, GD; Stuenkel, EL; Bittner, MA				Holz, RW; Hlubek, MD; Sorensen, SD; Fisher, SK; Balla, T; Ozaki, S; Prestwich, GD; Stuenkel, EL; Bittner, MA			A pleckstrin homology domain specific for phosphatidylinositol 4,5-bisphosphate (PtdIns-4,5-P-2) and fused to green fluorescent protein identifies plasma membrane PtdIns-4,5-P-2 as being important in exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; PHOSPHOLIPASE-C; HIGH-AFFINITY; CA2+-ACTIVATED SECRETION; REGULATED EXOCYTOSIS; INOSITOL PHOSPHATES; SIGNALING MOLECULES; COMMON FOLD; ALPHA-SNAP; BINDING	Kinetically distinct steps can be distinguished in the secretory response from neuroendocrine cells with slow ATP-dependent priming steps preceding the triggering of exocytosis by Ca2+, One of these priming steps involves the maintenance of phosphatidylinositol 4,5-bisphosphate (PtdIns-4,5-P-2) through lipid kinases and is responsible for at least 70% of the ATP-dependent secretion observed in digitonin-permeabilized chromaffin cells. PtdIns-4,5-P-2 is usually thought to reside on the plasma membrane. However, because phosphatidylinositol 4-kinase is an integral chromaffin granule membrane protein, PtdIns-4,5-P-2 important in exocytosis may reside on the chromaffin granule membrane. In the present study we have investigated the localization of PtdIns-1,5-P-2 that is involved in exocytosis by transiently expressing in chromaffin cells a pleckstrin homology (PH) domain that specifically binds PtdIns-4,5-P-2 and is fused to green fluorescent protein (GFP). The PH-GFP protein predominantly associated with the plasma membrane in chromaffin cells without any detectable association with chromaffin granules. Rhodamine-neomycin, which also binds to PtdIns-4,5-P-2, showed a similar subcellular localization. The transiently expressed PH-GFP inhibited exocytosis as measured by both biochemical and electrophysiological techniques. The results indicate that the inhibition was at a step after Ca2+ entry and suggest that plasma membrane PtdIns-4,5-P-2 is important for exocytosis, Expression of PH-GFP also reduced calcium currents, raising the possibility that PtdIns-4,5-P-2 in some manner alters calcium channel function in chromaffin cells.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA; NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Utah System of Higher Education; University of Utah	Holz, RW (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 MSRB 3, Ann Arbor, MI 48109 USA.			Stuenkel, Edward/0000-0001-8225-5725; Balla, Tamas/0000-0002-9077-3335	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632, R01NS036227] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK50127] Funding Source: Medline; NINDS NIH HHS [R01-NS36227, NS29632] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; AGRANOFF BW, 1983, J BIOL CHEM, V258, P2076; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; Barnard RJO, 1996, MOL BIOL CELL, V7, P693, DOI 10.1091/mbc.7.5.693; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BITTNER MA, 1992, J BIOL CHEM, V267, P16226; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BITTNER MA, 1986, J BIOL CHEM, V261, P182; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; BUCKLEY JT, 1971, BIOCHIM BIOPHYS ACTA, V239, P517, DOI 10.1016/0005-2760(71)90047-6; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; Chung SH, 1998, J BIOL CHEM, V273, P10240, DOI 10.1074/jbc.273.17.10240; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; EBERHARD DA, 1987, J NEUROCHEM, V49, P1634, DOI 10.1111/j.1471-4159.1987.tb01037.x; EBERHARD DA, 1991, CELL MOL NEUROBIOL, V11, P357, DOI 10.1007/BF00713279; EICHBERG J, 1965, BIOCHEM J, V96, P644, DOI 10.1042/bj0960644; Engisch KL, 1996, J NEUROSCI, V16, P1359; Engisch KL, 1997, J NEUROSCI, V17, P9010; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HAWTHORNE J N, 1980, Biochemical Society Transactions, V8, P30; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; HOKIN LE, 1964, BIOCHIM BIOPHYS ACTA, V84, P563, DOI 10.1016/0926-6542(64)90126-X; HOKIN MR, 1953, J BIOL CHEM, V203, P967; HOLTZ RW, 1982, J NEUROCHEM, V39, P635; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; HUSEBYE ES, 1988, BIOCHIM BIOPHYS ACTA, V968, P261, DOI 10.1016/0167-4889(88)90015-8; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Khvotchev M, 1998, J BIOL CHEM, V273, P21451, DOI 10.1074/jbc.273.34.21451; KUROSAWA M, 1986, J IMMUNOL, V136, P616; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Loyet KM, 1998, J BIOL CHEM, V273, P8337, DOI 10.1074/jbc.273.14.8337; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; MULLER TW, 1975, J NEUROCHEM, V24, P1155, DOI 10.1111/j.1471-4159.1975.tb03892.x; OSULLIVAN AJ, 1989, BIOSCIENCE REP, V9, P243, DOI 10.1007/BF01116001; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PHILLIPS JH, 1973, BIOCHEM J, V136, P579, DOI 10.1042/bj1360579; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12748, DOI 10.1021/bi00166a006; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; RODRIGUEZ DC, 1992, J CELL BIOL, V119, P797; SCHACHT J, 1976, J NEUROCHEM, V27, P1119, DOI 10.1111/j.1471-4159.1976.tb00318.x; SCHACHT J, 1978, J LIPID RES, V19, P1063; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SORENSEN SD, 1999, J PHARMACOL EXP THER, V52, P827; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; TERBUSH DR, 1992, J NEUROCHEM, V58, P680, DOI 10.1111/j.1471-4159.1992.tb09771.x; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; WHIPPS DE, 1987, BIOCHEM J, V241, P835, DOI 10.1042/bj2410835; WICK PF, 1993, J BIOL CHEM, V268, P10983; Wiedemann C, 1998, J NEUROSCI, V18, P5594; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; WILSON SP, 1996, ANAL BIOCHEM, V226, P212; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129	67	163	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17878	17885		10.1074/jbc.M000925200	http://dx.doi.org/10.1074/jbc.M000925200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747966	hybrid			2022-12-27	WOS:000087485000092
J	Vasiljeva, L; Merits, A; Auvinen, P; Kaariainen, L				Vasiljeva, L; Merits, A; Auvinen, P; Kaariainen, L			Identification of a novel function of the Alphavirus capping apparatus - RNA 5 '-triphosphatase activity of Nsp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS MESSENGER-RNA; NONSTRUCTURAL PROTEIN NSP2; SINDBIS VIRUS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GUANYLYLTRANSFERASE COMPONENT; METHYLTRANSFERASE ACTIVITY; NUCLEOSIDE TRIPHOSPHATASE; STRAND RNA; ENZYME	Both genomic and subgenomic RNAs of the Alphavirus have m(7)G(5')ppp(5')N (cap0 structure) at their 5' end. Previously it has been shown that Alphavirus-specific nonstructural protein Nsp1 has guanine-7N-methyltransferase and guanylyltransferase activities needed in the synthesis of the cap structure. During normal cap synthesis the 5' gamma-phosphate of the nascent viral RNA chain is removed by a specific RNA 5'-triphosphatase before condensation with GMP, delivered by the guanylyltransferase. Using a novel RNA triphosphatase assay, we show here that nonstructural protein Nsp2 (799 amino acids) of Semliki Forest virus specifically cleaves the gamma,beta-triphosphate bond at the 5' end of RNA. The same activity was demonstrated for Nsp2 of Sindbis virus, as well as for the amino-terminal fragment of Semliki Forest virus Nsp2-N (residues 1-470). The carboxy-terminal part of Semliki Forest virus Nsp2-C (residues 471-799) had no RNA triphosphatase activity. Replacement of Lys-192 by Asn in the nucleotide-binding site completely abolished RNA triphosphatase and nucleoside triphosphatase activities of Semliki Forest virus Nsp2 and Nsp2-N. Here we provide biochemical characterization of the newly found function of Nsp2 and discuss the unique properties of the entire Alphavirus-capping apparatus.	Univ Helsinki, Bioctr Viikki, Inst Biotechnol, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland	University of Helsinki		leevi.kaariainen@helsinki.fi	Vasilieva, Lidia/AAU-1473-2020; Merits, Andres/H-3125-2015; Auvinen, Petri/D-5044-2009; Auvinen, Petri/AAP-8117-2021	Merits, Andres/0000-0001-8193-0071; Auvinen, Petri/0000-0002-3947-4778; Vasiljeva, Lidia/0000-0002-1244-8772				Ahola T, 1999, EMBO J, V18, P3164, DOI 10.1093/emboj/18.11.3164; Ahola T, 1997, J VIROL, V71, P392, DOI 10.1128/JVI.71.1.392-397.1997; AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507; BARTON DJ, 1988, J VIROL, V62, P3597, DOI 10.1128/JVI.62.10.3597-3602.1988; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Bisaillon M, 1997, J BIOL CHEM, V272, P29954, DOI 10.1074/jbc.272.47.29954; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CROSS RK, 1981, VIROLOGY, V114, P542, DOI 10.1016/0042-6822(81)90234-8; de Cedron MG, 1999, FEBS LETT, V448, P19, DOI 10.1016/S0014-5793(99)00321-X; DUBIN DT, 1977, VIROLOGY, V77, P457, DOI 10.1016/0042-6822(77)90471-8; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; Gallinari P, 1998, J VIROL, V72, P6758, DOI 10.1128/JVI.72.8.6758-6769.1998; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; Guarino LA, 1998, J VIROL, V72, P10003, DOI 10.1128/JVI.72.12.10003-10010.1998; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HARDY WR, 1989, J VIROL, V63, P4653, DOI 10.1128/JVI.63.11.4653-4664.1989; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; ITOH N, 1987, J BIOL CHEM, V262, P1989; ITOH N, 1984, J BIOL CHEM, V259, P3930; KAARIAINEN L, 1987, J CELL SCI, P231; KERANEN S, 1979, J VIROL, V32, P19; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; LAAKKONEN P, 1994, J VIROL, V68, P7418, DOI 10.1128/JVI.68.11.7418-7425.1994; Laakkonen P, 1996, J BIOL CHEM, V271, P28567, DOI 10.1074/jbc.271.45.28567; Lampio A, 1999, ANTIVIR RES, V42, P35, DOI 10.1016/S0166-3542(99)00011-X; LASTARZA MW, 1994, J VIROL, V68, P5781, DOI 10.1128/JVI.68.9.5781-5791.1994; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; MI S, 1991, VIROLOGY, V184, P423, DOI 10.1016/0042-6822(91)90862-6; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; Myette JR, 1996, J BIOL CHEM, V271, P11945, DOI 10.1074/jbc.271.20.11945; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; PERANEN J, 1995, VIROLOGY, V208, P610, DOI 10.1006/viro.1995.1192; PERANEN J, 1991, J VIROL, V65, P1623; PERANEN J, 1990, J VIROL, V64, P1888; PERANEN J, 1988, J GEN VIROL, V69, P2165, DOI 10.1099/0022-1317-69-9-2165; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; PETTERSSON RF, 1980, EUR J BIOCHEM, V105, P435, DOI 10.1111/j.1432-1033.1980.tb04518.x; RIKKONEN M, 1992, VIROLOGY, V189, P462, DOI 10.1016/0042-6822(92)90570-F; Rikkonen M, 1996, VIROLOGY, V218, P352, DOI 10.1006/viro.1996.0204; RIKKONEN M, 1994, J VIROL, V68, P5804, DOI 10.1128/JVI.68.9.5804-5810.1994; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; SHUMAN S, 1990, METHOD ENZYMOL, V181, P170; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Suopanki J, 1998, J GEN VIROL, V79, P309, DOI 10.1099/0022-1317-79-2-309; TAKKINEN K, 1991, J GEN VIROL, V72, P1627, DOI 10.1099/0022-1317-72-7-1627; Wang HL, 1996, VIROLOGY, V217, P527, DOI 10.1006/viro.1996.0147; WANG YF, 1994, J VIROL, V68, P6466, DOI 10.1128/JVI.68.10.6466-6475.1994; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; WENGLER G, 1991, VIROLOGY, V184, P707, DOI 10.1016/0042-6822(91)90440-M; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587; YAGI Y, 1984, J BIOL CHEM, V259, P4695; YAGI Y, 1983, EMBO J, V2, P611, DOI 10.1002/j.1460-2075.1983.tb01471.x	55	150	153	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17281	17287		10.1074/jbc.M910340199	http://dx.doi.org/10.1074/jbc.M910340199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748213	hybrid			2022-12-27	WOS:000087485000012
J	Rosch, K; Naeher, D; Laird, V; Goder, V; Spiess, M				Rosch, K; Naeher, D; Laird, V; Goder, V; Spiess, M			The topogenic contribution of uncharged amino acids on signal sequence orientation in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; TRANSMEMBRANE SEGMENTS; ER MEMBRANE; HYDROPHOBIC DOMAIN; CHARGED RESIDUES; ANCHOR PROTEINS; TERMINAL DOMAIN; TRANSLOCATION; RECOGNITION; DETERMINANTS	Signal sequences for insertion of proteins into the endoplasmic reticulum induce translocation of either the C- or the N-terminal sequence across the membrane. The end that is translocated is primarily determined by the flanking charges and the hydrophobic domain of the signal. To characterize the hydrophobic contribution to topogenesis, we have challenged the translocation machinery in vivo in transfected COS cells with model proteins differing exclusively in the apolar segment of the signal. Homo-oligomers of hydrophobic amino acids as different in size and shape as Val(19), Trp(19), and Tyr(22) generated functional signal sequences with similar topologies in the membrane. The longer a homo-oligomeric sequence of a given residue, the more N-terminal translocation was obtained, To determine the topogenic contribution of all uncharged amino acids in the context of a hydrophobic signal sequence, two residues in a generic oligoleucine signal were exchanged for all uncharged amino acids. The resulting scale resembles a hydrophobicity scale with the more hydrophobic residues promoting N-terminal translocation. In addition, the helix breakers glycine and proline showed a position-dependent effect, which raises the possibility of a conformational contribution to topogenesis.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Basel	Spiess, M (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.		Goder, Veit/F-8092-2016	Goder, Veit/0000-0003-0854-4873; Spiess, Martin/0000-0001-7139-0550				ARGOS P, 1982, EUR J BIOCHEM, V128, P565; BELTZER JP, 1991, J BIOL CHEM, V266, P973; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Eusebio A, 1998, EXP CELL RES, V241, P181, DOI 10.1006/excr.1998.4042; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Harley CA, 1998, J BIOL CHEM, V273, P24963, DOI 10.1074/jbc.273.38.24963; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; Hatsuzawa K, 1997, J BIOCHEM-TOKYO, V121, P270; Hegde RS, 1998, CELL, V92, P621, DOI 10.1016/S0092-8674(00)81130-7; HIGH S, 1993, J BIOL CHEM, V268, P26745; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LI SC, 1994, NAT STRUCT BIOL, V1, P368, DOI 10.1038/nsb0694-368; Liu LP, 1998, J BIOL CHEM, V273, P23645, DOI 10.1074/jbc.273.37.23645; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Mothes W, 1998, J CELL BIOL, V142, P355, DOI 10.1083/jcb.142.2.355; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1981, EUR J BIOCHEM, V116, P419; WAHLBERG JM, 1995, J CELL BIOL, V130, P285, DOI 10.1083/jcb.130.2.285; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wang L, 1999, FEBS LETT, V457, P316, DOI 10.1016/S0014-5793(99)01075-3; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842	40	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14916	14922		10.1074/jbc.M000456200	http://dx.doi.org/10.1074/jbc.M000456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747915	hybrid			2022-12-27	WOS:000087128300022
J	Hijikata-Okunomiya, A; Tamao, Y; Kikumoto, R; Okamoto, S				Hijikata-Okunomiya, A; Tamao, Y; Kikumoto, R; Okamoto, S			Selective inhibition of Trypsin by (2R,4R)-4-Phenyl-1-[N-alpha-(7-methoxy-2-naphthalenesulfonyl)-L-arginyl]-2-piperidinecarboxylic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; HUMAN-LUNG TRYPTASE; CRYSTAL-STRUCTURE; ACTIVE-SITES; ARGININE; BENZAMIDINE; DERIVATIVES; RESOLUTION; COMPLEXES; GEOMETRY	Evidence is accumulating indicating that trypsin stimulates divergent cellular reactions through the proteinase-activated receptor, in addition to its role as the digestive enzyme. In this report, we introduce (2R,4R)-4-phenyl-1-[N-alpha-(7-methoxy-2-naphthalenesulfonyl)-L-arginyl]-2-piperidinecarboxylic acid as a potent and selective trypsin inhibitor. The agent inhibited trypsin competitively with the K-i value of 0.1 mu M. It inhibited thrombin weakly (K-i = 2 mu M) and did not inhibit plasmin, plasma kallikrein, urokinase, and mast cell tryptase (K-i values for these enzymes are >60 mu M). Comparative studies with several established proteinase inhibitors revealed that the compound was the first small molecular weight trypsin inhibitor without tryptase inhibitory activity. A docking study has provided a plausible explanation for the molecular mechanism of the selective inhibition showing that the agent fits into the active site of trypsin without any severe collision but that it comes into clash at the 4-phenyl group of piperidine ring against the "60-insertion loop" of thrombin and at the 7-methoxy-2-naphthalenesulfonyl group against Gln(98) of tryptase.	Kobe Univ, Sch Med, Fac Hlth Sci, Suma Ku, Kobe, Hyogo 6540142, Japan; Mitsubishi Tokyo Pharmaceut Inc, Yokohama Res Ctr, Aoba Ku, Yokohama, Kanagawa 2270033, Japan; Kobe Res Projects Thrombosis & Hemostasis, Tarumi Ku, Kobe, Hyogo 6550033, Japan	Kobe University	Hijikata-Okunomiya, A (corresponding author), Kobe Univ, Sch Med, Fac Hlth Sci, Suma Ku, Tomogaoka 7-10-2, Kobe, Hyogo 6540142, Japan.	okunomiy@ams.kobe-u.ac.jp						Aoyagi T, 1975, PROTEASES BIOL CONTR, P429; BANNER DW, 1991, J BIOL CHEM, V266, P20085; BODE W, 1990, EUR J BIOCHEM, V193, P175, DOI 10.1111/j.1432-1033.1990.tb19320.x; BRANDSTETTER H, 1992, J MOL BIOL, V226, P1085, DOI 10.1016/0022-2836(92)91054-S; CHEN ZG, 1995, ARCH BIOCHEM BIOPHYS, V322, P198, DOI 10.1006/abbi.1995.1452; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; HIJIKATA A, 1979, THROMB HAEMOSTASIS, V42, P1039; HIJIKATAOKUNOMIYA A, 1992, SEMIN THROMB HEMOST, V18, P135, DOI 10.1055/s-2007-1002418; HIJIKATAOKUNOMIYA A, 1988, J BIOL CHEM, V263, P11269; HIJIKATAOKUNOMIYA A, 1987, THROMB RES, V45, P451, DOI 10.1016/0049-3848(87)90308-2; KIKUMOTO R, 1984, BIOCHEMISTRY-US, V23, P85, DOI 10.1021/bi00296a014; KIKUMOTO R, 1980, J MED CHEM, V23, P1293, DOI 10.1021/jm00186a003; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; MARQUART M, 1983, ACTA CRYSTALLOGR B, V39, P480, DOI 10.1107/S010876818300275X; MATSUZAKI T, 1989, J BIOCHEM-TOKYO, V105, P949, DOI 10.1093/oxfordjournals.jbchem.a122785; OKAMOTO S, 1981, BIOCHEM BIOPH RES CO, V101, P440, DOI 10.1016/0006-291X(81)91279-1; OKAMOTO S, 1975, Kobe Journal of Medical Sciences, V21, P43; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; RACKIS JJ, 1962, ARCH BIOCHEM BIOPHYS, V98, P471, DOI 10.1016/0003-9861(62)90213-8; Ren S, 1997, J IMMUNOL, V159, P3540; SMALAS AO, 1994, PROTEINS, V20, P149, DOI 10.1002/prot.340200205; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; STURZEBECHER J, 1992, BIOL CHEM H-S, V373, P1025, DOI 10.1515/bchm3.1992.373.2.1025; TANAKA T, 1983, J BIOL CHEM, V258, P3552; TULINSKY A, 1994, 1FPC PROTEIN DATA BA; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153	26	5	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18995	18999		10.1074/jbc.M908124199	http://dx.doi.org/10.1074/jbc.M908124199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10748093	hybrid			2022-12-27	WOS:000087815900051
J	Liu, L; Mo, JY; Rodriguez-Belmonte, EM; Lee, MYWT				Liu, L; Mo, JY; Rodriguez-Belmonte, EM; Lee, MYWT			Identification of a fourth subunit of mammalian DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; CATALYTIC SUBUNIT; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; AUXILIARY PROTEIN; CALF THYMUS; REPLICATION; PCNA; PURIFICATION; EXPRESSION	A 12-kDa and two 25-kDa polypeptides were isolated with highly purified calf thymus DNA polymerase delta by conventional chromatography, A 16-mer peptide sequence was obtained from the 12-kDa polypeptide which matched a new open reading frame from a human EST (AA402118) encoding a hypothetical protein of unknown function. The protein was designated as p12. Human EST AA402118 was identified as the putative human homologue of Schizosaccharomyces pombe Cdm1 by a tBlastn search of the EST data base using S. pombe Cdm1, The open reading frame of human EST AA402118 encoded a polypeptide of 107 amino acids with a predicted molecular mass of 12.4 kDa, consistent with the experimental findings. p12 is 25% identical to S pombe Cdm1. Both of the 25-kDa polypeptide sequences matched the hypothetical KIAA0039 protein sequence, recently identified as the third subunit of pol delta. Western blotting of immunoaffinity purified calf thymus pol delta revealed the presence of p125, p50, p68 (the KIAA0039 product), and p12, With the identification of p12 mammalian pol delta can now be shown to consist of four subunits. These studies pave the way for more detailed analysis of the possible functions of the mammalian subunits of pol delta.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Lee, MYWT (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.		Rodríguez-Belmonte, Esther/AAL-5653-2020; Rodríguez-Belmonte, Esther/E-1675-2012	Rodríguez-Belmonte, Esther/0000-0001-8243-1303	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31973] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGERS PMJ, 1988, NUCLEIC ACIDS RES, V16, P6297, DOI 10.1093/nar/16.14.6297; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Huang ME, 1999, MOL GEN GENET, V260, P541, DOI 10.1007/s004380050927; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE MYW, 1991, J BIOL CHEM, V266, P2433; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; MO J, IN PRESS BIOCHEMISTR; Reynolds N, 1999, GENE, V230, P15, DOI 10.1016/S0378-1119(99)00058-X; Reynolds N, 1998, CURR GENET, V34, P250, DOI 10.1007/s002940050394; SUGIMOTO K, 1995, NUCLEIC ACIDS RES, V23, P3493, DOI 10.1093/nar/23.17.3493; Sun YB, 1997, J BIOL CHEM, V272, P13013, DOI 10.1074/jbc.272.20.13013; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSUIMOTO T, 1990, NATURE, V346, P435; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; WAGA S, 1994, J BIOL CHEM, V269, P10923; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZHANG P, 1995, BIOCHEMISTRY-US, V34, P10703, DOI 10.1021/bi00034a002; ZHANG P, 1995, J BIOL CHEM, V270, P7993, DOI 10.1074/jbc.270.14.7993; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; Zhou JQ, 1996, J BIOL CHEM, V271, P29740, DOI 10.1074/jbc.271.47.29740; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; Zuo SJ, 1997, P NATL ACAD SCI USA, V94, P11244, DOI 10.1073/pnas.94.21.11244	32	82	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18739	18744		10.1074/jbc.M001217200	http://dx.doi.org/10.1074/jbc.M001217200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10751307	hybrid			2022-12-27	WOS:000087815900019
J	Breton, S; Wiederhold, T; Marshansky, V; Nsumu, NN; Ramesh, V; Brown, D				Breton, S; Wiederhold, T; Marshansky, V; Nsumu, NN; Ramesh, V; Brown, D			The B1 subunit of the H(+)ATPase is a PDZ domain-binding protein - Colocalization with NHE-RF in renal B-intercalated cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGER REGULATORY FACTOR; VACUOLAR H+-ATPASE; PROTON-PUMPING ATPASE; PLASMA-MEMBRANE; K+ CHANNELS; BETA(2)-ADRENERGIC RECEPTOR; RAT-KIDNEY; FAMILY; LOCALIZATION; EXPRESSION	The 56-kDa B1 subunit of the vacuolar H(+)ATPase has a C-terminal DTAL amino acid motif typical of PDZ-binding proteins that associate with the PDZ protein, NHE-RF (Na+/H+ exchanger regulatory factor). This B1 isoform is amplified in renal intercalated cells, which play a role in distal urinary acid-base transport. In contrast, proximal tubules express the B2 isoform that lacks the C-terminal PDZ-binding motif, Both the B1 56-kDa subunit and the 31-kDa (E) subunit of the H(+)ATPase are pulled down by glutathione S-transferase NHE-RF bound to GSH-Sepharose beads. These subunits associate in vivo as part of the cytoplasmic VI portion of the H(+)ATPase, and the E subunit was co-immunoprecipitated from rat kidney cytosol with NHE-RF antibodies. The interaction of H(+)ATPase subunits with NHE-RF was inhibited by a peptide derived from the C terminus of the El but not the B2 isoform, NHE-RF colocalized with H(+)ATPase in either the apical or the basolateral region of B-type intercalated cells, whereas NHE-RF staining was undetectable in A-intercalated cells. In proximal tubules, NHE-RF was located in the apical brush border. In contrast, H(+)ATPase was concentrated in a distinct membrane domain at the base of the brush border, from which NHE-RF was absent, consistent with the expression of the truncated B2 subunit isoform in this tubule segment. The colocalization of NHE-RF and H(+)ATPase in B- but not A-intercalated cells suggests a role in generating, maintaining, or modulating the variable H(+)ATPase polarity that characterizes the B-cell phenotype.	Massachusetts Gen Hosp E, Renal Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp E, Program Membrane Biol, Charlestown, MA 02129 USA; Massachusetts Gen Hosp E, Mol Neurogenet Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Breton, S (corresponding author), Massachusetts Gen Hosp E, Renal Unit, 149 13th St, Charlestown, MA 02129 USA.	sbreton@receptor.mgh.harvard.edu	Marshansky, Vladimir/AAZ-7890-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042956, R01DK042956, P01DK038452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38452, DK42956] Funding Source: Medline; NINDS NIH HHS [NS24279] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Al-Awqati Q, 1998, AM J PHYSIOL-RENAL, V275, pF183, DOI 10.1152/ajprenal.1998.275.2.F183; AlAwqati Q, 1996, AM J PHYSIOL-CELL PH, V270, pC1571, DOI 10.1152/ajpcell.1996.270.6.C1571; ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; Alper SL, 1997, AM J PHYSIOL-RENAL, V273, pF601, DOI 10.1152/ajprenal.1997.273.4.F601; Bernardo AA, 1999, J CLIN INVEST, V104, P195, DOI 10.1172/JCI5344; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; Brenman JE, 1996, J NEUROSCI, V16, P7407; Breton S, 1995, AM J PHYSIOL-RENAL, V269, pF761, DOI 10.1152/ajprenal.1995.269.6.F761; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; BROWN D, 1988, NATURE, V331, P622, DOI 10.1038/331622a0; BROWN D, 1988, J CLIN INVEST, V82, P2114, DOI 10.1172/JCI113833; Brown D, 1996, PHYSIOL REV, V76, P245, DOI 10.1152/physrev.1996.76.1.245; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; Burke NA, 1999, J GEN PHYSIOL, V113, P71, DOI 10.1085/jgp.113.1.71; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Inanobe A, 1999, J NEUROSCI, V19, P1006; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NELSON RD, 1999, P NATL ACAD SCI USA, V79, P361; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PURCELL H, 1991, AM J PHYSIOL, V261, pF365, DOI 10.1152/ajprenal.1991.261.3.F365; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Sabolic I, 1997, KIDNEY INT, V51, P125, DOI 10.1038/ki.1997.16; SABOLIC I, 1992, J CELL BIOL, V119, P111, DOI 10.1083/jcb.119.1.111; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	39	126	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18219	18224		10.1074/jbc.M909857199	http://dx.doi.org/10.1074/jbc.M909857199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748165	hybrid			2022-12-27	WOS:000087659400043
J	Kensch, O; Connolly, BA; Steinhoff, HJ; McGregor, A; Goody, RS; Restle, T				Kensch, O; Connolly, BA; Steinhoff, HJ; McGregor, A; Goody, RS; Restle, T			HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MAMMARY-TUMOR VIRUS; SINGLE-STRANDED-RNA; CRYSTAL-STRUCTURE; SPIN LABELS; CONFORMATIONAL-CHANGES; ANGSTROM RESOLUTION; INTERSPIN DISTANCES; ESCHERICHIA-COLI; PRIMER GRIP	Systematic evolution of ligands by exponential enrichment (SELEX) is a powerful method for the identification of small oligonucleotides that bind with high affinity and specificity to target proteins. Such DNAs/RNAs are a new class of potential chemotherapeutics that could block the enzymatic activity of pathologically relevant proteins. We have conducted a detailed biochemical study of the interaction of human immunodeficiency virus I (HIV-1) reverse transcriptase (RT) with a SELEX-derived pseudoknot RNA aptamer. Electron paramagnetic resonance spectroscopy of site-directed spin-labeled RT mutants revealed that this aptamer was selected for binding to the "closed" conformation of the enzyme. Kinetic analysis showed that the RNA inhibitor bound to HIV RT in a two-step process, with association rates similar to those described for model DNA/DNA and DNA/RNA substrates. However, the dissociation of the pseudoknot RNA from RT was dramatically slower than observed for model substrates. Equilibrium binding studies revealed an extraordinarily low K-d, of about 25 PM, for the enzyme-aptamer interaction, presumably a consequence of the slow off-rates. Additionally, this pseudoknot aptamer is highly specific for HIV-1 RT, with the closely related HIV-2 enzyme showing a binding affinity close to 4 orders of magnitude lower.	Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany; Newcastle Univ, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Max Planck Society; Newcastle University - UK	Restle, T (corresponding author), Max Planck Inst Mol Physiol, Phys Biochem Abt, Otto Hahn Str 11, D-44227 Dortmund, Germany.	tobias.restle@mpi-dortmund.mpg.de	Goody, Roger S/J-8845-2014; Steinhoff, Heinz-Juergen/H-3791-2014	Goody, Roger S/0000-0002-0772-0444; Steinhoff, Heinz-Juergen/0000-0002-5888-0157				Burke DH, 1996, J MOL BIOL, V264, P650, DOI 10.1006/jmbi.1996.0667; CERTA U, 1986, EMBO J, V5, P3051, DOI 10.1002/j.1460-2075.1986.tb04605.x; CLOSS GL, 1992, J AM CHEM SOC, V114, P3285, DOI 10.1021/ja00035a020; De Clercq E, 1999, FARMACO, V54, P26, DOI 10.1016/S0014-827X(98)00103-7; Deiman BALM, 1997, SEMIN VIROL, V8, P166, DOI 10.1006/smvy.1997.0119; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P7966, DOI 10.1021/bi00082a018; Du ZH, 1997, J MOL BIOL, V270, P464, DOI 10.1006/jmbi.1997.1127; Du ZH, 1996, BIOCHEMISTRY-US, V35, P4187, DOI 10.1021/bi9527350; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; FIORI WR, 1995, BIOPOLYMERS, V37, P243, DOI 10.1002/bip.360370403; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; GREEN L, 1995, J MOL BIOL, V247, P60, DOI 10.1006/jmbi.1994.0122; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P26472; Jaeger J, 1998, EMBO J, V17, P4535, DOI 10.1093/emboj/17.15.4535; Jager Joachim, 1999, Current Opinion in Structural Biology, V9, P21, DOI 10.1016/S0959-440X(99)80004-9; Kang HS, 1997, NUCLEIC ACIDS RES, V25, P1943, DOI 10.1093/nar/25.10.1943; Kolk MH, 1998, SCIENCE, V280, P434, DOI 10.1126/science.280.5362.434; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; McGregor A, 1999, J BIOL CHEM, V274, P2255, DOI 10.1074/jbc.274.4.2255; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P307, DOI 10.1021/bi962114m; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; MULLER B, 1991, J BIOL CHEM, V266, P14709; Patel DJ, 1997, J MOL BIOL, V272, P645, DOI 10.1006/jmbi.1997.1281; Pfeiffer M, 1999, J MOL BIOL, V287, P163, DOI 10.1006/jmbi.1998.2593; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RIETVELD K, 1982, NUCLEIC ACIDS RES, V10, P1929, DOI 10.1093/nar/10.6.1929; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sambrook J, 1994, MOL CLONING LAB MANU; SHEN LX, 1995, J MOL BIOL, V247, P963, DOI 10.1006/jmbi.1995.0193; Souquet M, 1998, BIOCHEMISTRY-US, V37, P12144, DOI 10.1021/bi9731596; STEINHOFF HJ, 1991, EUR BIOPHYS J BIOPHY, V20, P293, DOI 10.1007/BF00450565; Steinhoff HJ, 1997, BIOPHYS J, V73, P3287, DOI 10.1016/S0006-3495(97)78353-X; STUDNICKA GM, 1978, NUCLEIC ACIDS RES, V5, P3365, DOI 10.1093/nar/5.9.3365; Su L, 1999, NAT STRUCT BIOL, V6, P285, DOI 10.1038/6722; Thorgeirsson TE, 1997, J MOL BIOL, V273, P951, DOI 10.1006/jmbi.1997.1362; Thrall SH, 1998, BIOCHEMISTRY-US, V37, P13349; Tiebel B, 1999, J MOL BIOL, V290, P229, DOI 10.1006/jmbi.1999.2875; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Vandamme AM, 1999, DRUGS, V57, P337; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057; Wohrl BM, 1997, J BIOL CHEM, V272, P17581, DOI 10.1074/jbc.272.28.17581	52	67	95	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18271	18278		10.1074/jbc.M001309200	http://dx.doi.org/10.1074/jbc.M001309200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10751399	hybrid			2022-12-27	WOS:000087659400050
J	Peng, HZ; Begg, GE; Harper, SL; Friedman, JR; Speicher, DW; Rauscher, FJ				Peng, HZ; Begg, GE; Harper, SL; Friedman, JR; Speicher, DW; Rauscher, FJ			Biochemical analysis of the Kruppel-associated box (KRAB) transcriptional repression domain - Spectral, kinetic, and stoichiometric properties of the KRAB.KAP-1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; THYROID-HORMONE RECEPTOR; BINDING PROTEIN; GENE; RING; ACTIVATION; EXPRESSION; FAMILY; CELLS; COACTIVATORS	The Kruppel-associated box CE(RAB) domain is a 75-amino acid transcriptional repressor module commonly found in eukaryotic zinc finger proteins. RRAB-mediated gene silencing requires binding to the RING-B box-coiled-coil domain of the corepressor KAP-1. Little is known about the biochemical properties of the KRAB domain or the KRAB.KAP-1 complex. Using purified components, a combination of biochemical and biophysical analyses has revealed that the KRAB domain from the KOX1 protein is predominantly a monomer and that the KAP-1 protein is predominantly a trimer in solution. The analyses of electrophoretic mobility shift assays, GST association assays, and plasmon resonance interaction data have indicated that the KRAB binding to KAP-1 is direct, highly specific, and high affinity The optical biosensor data for the complex was fitted to a model of a one-binding step interaction with fast association and slow dissociation rates, with a calculated bh of 142 nw. The fitted R-max indicated three molecules of KAP-1 binding to one molecule of the KRAB domain, a stoichiometry that is consistent with quantitative SDS-polyacrylsmide gel electrophoresis analysis of the complex. These structural and dynamic parameters of the KRAB/KAP-1 interaction have implications for identifying downstream effecters of RAP-I silencing and the de novo design of new repression domains.	Wistar Inst, Philadelphia, PA 19104 USA	The Wistar Institute	Rauscher, FJ (corresponding author), Wistar Inst, 3601 Spruce St, Philadelphia, PA 19104 USA.		Friedman, Joshua/Q-9367-2019	Friedman, Joshua/0000-0001-9382-8429				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ANDERSSON K, 1998, BIASYMPOSIUM 98; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1993, EMBO J, V12, P1363, DOI 10.1002/j.1460-2075.1993.tb05781.x; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; Boddy MN, 1997, J CELL SCI, V110, P2197; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Cao TY, 1997, J CELL SCI, V110, P1563; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Glass CK, 2000, GENE DEV, V14, P121; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; Han ZG, 1999, J BIOL CHEM, V274, P35741, DOI 10.1074/jbc.274.50.35741; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Laue T.M., 1992, ANAL ULTRACENTRIFUGA; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Liu C, 1999, EXP HEMATOL, V27, P313, DOI 10.1016/S0301-472X(98)00035-6; LOVERING R, 1991, NUCLEIC ACIDS RES, V19, P2921, DOI 10.1093/nar/19.11.2921; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; MORTON TA, 1995, ANAL BIOCHEM, V227, P176, DOI 10.1006/abio.1995.1268; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; PENGUE G, 1995, J VIROL, V69, P6577, DOI 10.1128/JVI.69.10.6577-6580.1995; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REDDY BA, 1991, NUCLEIC ACIDS RES, V19, P6330, DOI 10.1093/nar/19.22.6330; ROSATI M, 1991, NUCLEIC ACIDS RES, V19, P5661, DOI 10.1093/nar/19.20.5661; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Shannon M, 1996, GENOMICS, V33, P112, DOI 10.1006/geno.1996.0166; Shi PY, 1997, BIOTECHNIQUES, V23, P1036, DOI 10.2144/97236bm15; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TOMMERUP N, 1993, HUM MOL GENET, V2, P1571, DOI 10.1093/hmg/2.10.1571; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	51	91	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18000	18010		10.1074/jbc.M001499200	http://dx.doi.org/10.1074/jbc.M001499200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748030	hybrid			2022-12-27	WOS:000087659400015
J	Galdemard, C; Yamagata, H; Brison, O; Lavialle, C				Galdemard, C; Yamagata, H; Brison, O; Lavialle, C			Regulation of FGF-3 gene expression in tumorigenic and non-tumorigenic clones of a human colon carcinoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE INT-2; C-MYC AMPLIFICATION; CHROMATIN STRUCTURE; GROWTH-FACTORS; MOUSE; TRANSCRIPTION; OVEREXPRESSION; RNA; PROMOTERS; REQUIRES	The FGF-3 gene is constitutively expressed in tumorigenic clones from the SW613-S human colon carcinoma cell line but is silent in non-tumorigenic clones. We have investigated the transcriptional mechanisms responsible for this differential expression. Mapping of DNase I-hypersensitive sites throughout the FGF-3 gene and the region extending 15 kilobases upstream disclosed differences in the patterns obtained between tumorigenic and non-tumorigenic cells. Transient expression assays carried out with a reporter gene driven by FGF-3 promoter fragments of various lengths (0.143 to 11 kilobases) did not reproduce the differential regulation of the resident gene between the two cell types. The same constructs did exhibit a differential activity in stable transfectants, suggesting the involvement of a chromatin-based mechanism in this regulation. Under these conditions, even the 143-base pair minimal promoter fragment was able to drive the differential expression of the reporter gene. During the course of these analyses, several transcriptional modulatory elements (mainly activators) were identified in the FGF-3 upstream region and were found to colocalize with DNase I-hypersensitive sites. Moreover, a putative new promoter was discovered 6 kilobases upstream of FGF-8, Altogether, these data provide a basis for the elucidation of the complex regulation of the human FGF-3 gene.	Inst Gustave Roussy, CNRS UMR 1599, Lab Genet Oncol, F-94805 Villejuif, France	UNICANCER; Gustave Roussy	Lavialle, C (corresponding author), Inst Gustave Roussy, CNRS UMR 1599, Lab Genet Oncol, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Lavialle, Christian/O-2329-2019; Lavialle, Christian/B-3775-2009					BROOKES S, 1989, ONCOGENE, V4, P429; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; Djenabi S, 1999, DNA SEQUENCE, V10, P317, DOI 10.3109/10425179909033958; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; GALDEMARD C, 1995, ONCOGENE, V10, P2331; GOLDFARB M, 1991, ONCOGENE, V6, P65; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUNTHER M, 1995, MOL CELL BIOL, V15, P2490; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; LAMONERIE T, 1995, EXP CELL RES, V216, P342, DOI 10.1006/excr.1995.1043; LAVIALLE C, 1988, ONCOGENE, V3, P335; LAVIALLE C, 1990, ONCOGENE, V5, P245; LAVIALLE C, 1989, ANTICANCER RES, V9, P1265; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MODJTAHEDI N, 1992, INT J CANCER, V52, P483, DOI 10.1002/ijc.2910520325; MODJTAHEDI N, 1985, CANCER RES, V45, P4372; Murakami A, 1999, J BIOL CHEM, V274, P17242, DOI 10.1074/jbc.274.24.17242; MURAKAMI A, 1993, NUCLEIC ACIDS RES, V21, P5351, DOI 10.1093/nar/21.23.5351; NICOLAS JF, 1983, COLD SPRING HARBOR C, V10, P469; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; OTOOLE CM, 1983, NATURE, V301, P429, DOI 10.1038/301429a0; Prochasson P, 1999, EXP CELL RES, V248, P243, DOI 10.1006/excr.1999.4402; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	42	8	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17364	17373		10.1074/jbc.M909316199	http://dx.doi.org/10.1074/jbc.M909316199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10749884	hybrid			2022-12-27	WOS:000087485000023
J	Cahill, P; Nason, MW; Ambrose, C; Yao, TY; Thomas, P; Egan, ME				Cahill, P; Nason, MW; Ambrose, C; Yao, TY; Thomas, P; Egan, ME			Identification of the cystic fibrosis transmembrane conductance regulator domains that are important for interactions with ROMK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR; CHLORIDE CHANNEL; XENOPUS OOCYTES; CFTR; CURRENTS; CLONING; RECONSTITUTION; DELTA-F508; FORMS	In addition to functioning as a cAMP-activated chloride channel, the cystic fibrosis transmembrane conductance regulator (CFTR) plays an important role in conferring regulatory properties on other ion channels. It is known, with respect to CFTR regulation of ROMK2 (renally derived K-ATP channel), that the first transmembrane domain and the first nucleotide binding fold domain (NBF1) of CFTR are necessary for this interaction to occur. It has been shown that under conditions that promote phosphorylation, the ROMK2-CFTR interaction is attenuated. To elucidate the complex nature of this interaction, CFTR constructs were co-expressed with ROMK2 in Xenopus oocytes, and two microelectrode voltage clamp experiments were performed. Although the second half of CFTR can act as a functional chloride channel, our results suggest that it does not confer glibenclamide sensitivity on ROMK2, as does the first half of CFTR. The attenuation of the ROMK2-CFTR interaction under conditions that promote phosphorylation is dependent on at least the presence of the R domain of CFTR. We conclude that transmembrane domain 1, NBF1, and the R domain are the CFTR domains involved in the ROMK2-CFTR interaction and that NBF2 and transmembrane domain 2 are not essential. Lastly, the R domain of CFTR is necessary for the attenuation of the ROMK2-CFTR interaction under conditions that promote phosphorylation.	Yale Univ, Sch Med, Dept Pediat, Div Resp Med, New Haven, CT 06520 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA	Yale University; University of Michigan System; University of Michigan	Egan, ME (corresponding author), Yale Univ, Sch Med, Dept Pediat, Div Resp Med, Fitkin Rm 503, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053428] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-03023] Funding Source: Medline; NIDDK NIH HHS [DK-53428, R01 DK053428] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ammala C, 1996, NATURE, V379, P545, DOI 10.1038/379545a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, pC783, DOI 10.1152/ajpcell.1992.262.3.C783; Devidas S, 1998, J BIOL CHEM, V273, P29373, DOI 10.1074/jbc.273.45.29373; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FULMER SB, 1995, P NATL ACAD SCI USA, V92, P6832, DOI 10.1073/pnas.92.15.6832; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; McNicholas CM, 1997, AM J PHYSIOL-RENAL, V273, pF843, DOI 10.1152/ajprenal.1997.273.5.F843; Morales MM, 1996, AM J PHYSIOL-RENAL, V270, pF1038, DOI 10.1152/ajprenal.1996.270.6.F1038; NASON MW, 1997, PEDIAT PULM S14, V217; PIAZZACARROLL T, 1994, CELL PHYSIOL BIOCHEM, V4, P10; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P2674, DOI 10.1073/pnas.95.5.2674; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF599, DOI 10.1152/ajprenal.1994.267.4.F599; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514	29	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16697	16701		10.1074/jbc.M910205199	http://dx.doi.org/10.1074/jbc.M910205199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748197	hybrid			2022-12-27	WOS:000087392200043
J	Osipenko, ON; Barrie, AP; Allen, JM; Gurney, AM				Osipenko, ON; Barrie, AP; Allen, JM; Gurney, AM			Pituitary adenylyl cyclase-activating peptide activates multiple intracellular signaling pathways to regulate ion channels in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; POLYPEPTIDE PACAP RECEPTOR; PROTEIN-COUPLED RECEPTORS; CALCIUM CHANNELS; CATECHOLAMINE SECRETION; RAT GONADOTROPHS; CA2+ RELEASE; EXPRESSION; NEURONS; TRANSDUCTION	Pituitary adenylyl cyclase-activating peptide (PACAP) stimulates calcium transients and catecholamine secretion in adrenal chromaffin and PC12 cells. The PACAP type 1 receptor in these cells couples to both adenylyl cyclase and phospolipase C pathways, but although phospolipase C has been implicated in the response to PACAP, the role of adenylyl cyclase is unclear. In this study, we show that PACAP38 stimulates Ca2+ influx in PC12 cells by activating a cation current that depends upon the dual activation of both the PLC and adenylyl cyclase signaling pathways but does not involve protein kinase C. In activating the current, PACAP38 has to overcome an inhibitory effect of Ras. Thus, in cells expressing a dominant negative form of Ras (PC12asn17-W7), PACAP38 induced larger, more rapidly activating currents. This effect of Ras could be overidden by intracellular guanosine-5'-O-3-(thio)triphosphate (GTP gamma S), suggesting that it was mediated by inhibition of down-stream G proteins. Ras may also inhibit the current through a G protein-independent mechanism, because cAMP analogues activated the current in PC12asn17-W7 cells, provided GTP gamma S was present, but not in PC12 cells expressing wild type Ras. We conclude that coupling of PACAP to both adenylyl cyclase and phospholipase C is required to activate Ca2+ influx in PC12 cells and that tonic inhibition by Ras delays and Limits the response.	Univ Strathclyde, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland; Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Med & Therapeut, Glasgow G12 8QQ, Lanark, Scotland	University of Strathclyde; University of Glasgow; University of Glasgow	Gurney, AM (corresponding author), Univ Strathclyde, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland.							ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; Barnhart DC, 1997, SURGERY, V122, P465, DOI 10.1016/S0039-6060(97)90040-4; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; Beaudet MM, 1998, J NEUROBIOL, V36, P325, DOI 10.1002/(SICI)1097-4695(19980905)36:3<325::AID-NEU2>3.0.CO;2-Y; Braas KM, 1996, ANN NY ACAD SCI, V805, P204; Breault L, 1998, ENDOCR RES, V24, P961, DOI 10.3109/07435809809032716; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; DELPORTE C, 1995, MOL CELL ENDOCRINOL, V107, P71, DOI 10.1016/0303-7207(94)03424-R; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DOROSHENKO P, 1991, J PHYSIOL-LONDON, V436, P711, DOI 10.1113/jphysiol.1991.sp018575; Dun EC, 1996, BRAIN RES, V721, P233, DOI 10.1016/0006-8993(96)00139-4; Fitzgerald EM, 1997, EUR J NEUROSCI, V9, P1252, DOI 10.1111/j.1460-9568.1997.tb01480.x; Geng GJ, 1997, AM J PHYSIOL-REG I, V273, pR1339, DOI 10.1152/ajpregu.1997.273.4.R1339; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hezareh M, 1996, ANN NY ACAD SCI, V805, P315; Hezareh M, 1996, J NEUROENDOCRINOL, V8, P367, DOI 10.1046/j.1365-2826.1996.04645.x; Hezareh M, 1997, AM J PHYSIOL-ENDOC M, V273, pE850, DOI 10.1152/ajpendo.1997.273.5.E850; Hilborn MD, 1998, J NEUROSCI, V18, P590; Inagaki N, 1996, ANN NY ACAD SCI, V805, P44; ISOBE K, 1993, ENDOCRINOLOGY, V132, P1757, DOI 10.1210/en.132.4.1757; Koshimura K, 1997, PEPTIDES, V18, P877, DOI 10.1016/S0196-9781(97)00019-3; Lamouche S, 1999, AM J PHYSIOL-REG I, V276, pR162, DOI 10.1152/ajpregu.1999.276.1.R162; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; Ma HP, 1996, J CLIN INVEST, V97, P2332, DOI 10.1172/JCI118676; Moller K, 1996, REGUL PEPTIDES, V63, P129; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; Przywara DA, 1996, J BIOL CHEM, V271, P10545, DOI 10.1074/jbc.271.18.10545; RAWLINGS SR, 1994, J BIOL CHEM, V269, P5680; ROSARIO LM, 1989, NEUROSCIENCE, V29, P735, DOI 10.1016/0306-4522(89)90145-0; Shioda S, 1997, BRAIN RES, V765, P81, DOI 10.1016/S0006-8993(97)00512-X; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Tanaka K, 1998, J NEUROCHEM, V70, P1652; Tanaka K, 1996, ENDOCRINOLOGY, V137, P956, DOI 10.1210/en.137.3.956; TATSUNO I, 1994, BRAIN RES, V662, P1, DOI 10.1016/0006-8993(94)90790-0; Taupenot L, 1998, J CLIN INVEST, V101, P863, DOI 10.1172/JCI1129; Tonshoff C, 1997, J MOL NEUROSCI, V9, P127, DOI 10.1007/BF02736856; WATANABE T, 1995, AM J PHYSIOL-ENDOC M, V269, pE903, DOI 10.1152/ajpendo.1995.269.5.E903; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0	43	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16626	16631		10.1074/jbc.M909636199	http://dx.doi.org/10.1074/jbc.M909636199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748146	hybrid			2022-12-27	WOS:000087392200033
J	Waldron, RT; Rozengurt, E				Waldron, RT; Rozengurt, E			Oxidative stress induces protein kinase D activation in intact cells - Involvement of Src and dependence on protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SMOOTH-MUSCLE CELLS; TYROSINE PHOSPHORYLATION; REACTIVE OXYGEN; GROWTH-FACTOR; HYDROGEN-PEROXIDE; PHOSPHOLIPASE-C; PHORBOL ESTERS; RAPID ACTIVATION; GENE-EXPRESSION	Protein kinase D (PKD) is a protein serine kinase that is directly stimulated in vitro by phorbol esters and diacylglycerol in the presence of phospholipids, and activated by phorbol esters, neuropeptides, and platelet-derived growth factor via protein kinase C (PKC) in intact cells. Recently, oxidative stress was shown to activate transfected PKC isoforms via tyrosine phosphorylation, but PKD activation was not demonstrated. Here, we report that oxidative stress initiated by addition of H2O2 (0.15-10 mM) to quiescent Swiss 3T3 fibroblasts activates PKD in a dose- and time- dependent manner, as measured by autophosphorylation and phosphorylation of an exogenous substrate, syntide-2. Oxidative stress also activated transfected PKD in COS-7 cells but not a kinase-deficient mutant PKD form or a PKD mutant with critical activating serine residues 744 and 748 mutated to alanines. Genistein, or the specific Src inhibitors PP-1 and PP-2 (1-10 mu M) inhibited H2O2-mediated PKD activation by 45%, indicating that Src contributes to this signaling pathway. PKD activation by H2O2 was also selectively potentiated by cotransfection of PKD together with an active form of Src (v-Src) in COS-7 cells, as compared with PDB-mediated activation. The specific phospholipase C inhibitor, U73122 partly blocked H2O2-mediated but not PDB-mediated PKD activation. In contrast, PKC inhibitors blocked H2O2 or PDB-mediated PKD activation essentially completely; suggesting that whereas Src mediates part of its effects via phospholipase C activation, PKC acts more proximally as an upstream activator of PHD. Together, these studies reveal that oxidative stress activates PKD by initiating distinct Src-dependent and -independent pathways involving PKC.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Warren Hall,Rm 11-124,900 Vet Ave, Los Angeles, CA 90095 USA.		Waldron, Richard Taliesin/ABF-2773-2020	Waldron, Richard Taliesin/0000-0003-3151-6002	NIDDK NIH HHS [DK 55003] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; ARKINSTALL S, 1995, MOL CELL BIOL, V15, P1431; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BORNER C, 1992, J BIOL CHEM, V267, P12900; BRAWN MK, 1995, FREE RADICAL RES, V22, P23, DOI 10.3109/10715769509147525; Brooks G, 1997, J MOL CELL CARDIOL, V29, P2273, DOI 10.1006/jmcc.1997.0466; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; Finkel T, 1999, J LEUKOCYTE BIOL, V65, P337, DOI 10.1002/jlb.65.3.337; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FIORANI M, 1995, BBA-MOL CELL RES, V1269, P98, DOI 10.1016/0167-4889(95)00109-6; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kolios G, 1998, HEPATO-GASTROENTEROL, V45, P1601; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Lee SF, 1996, FREE RADICAL BIO MED, V21, P437, DOI 10.1016/0891-5849(96)00040-8; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Lieb K, 1997, J IMMUNOL, V159, P4952; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Paolucci L, 1999, CANCER RES, V59, P572; QURESHI SA, 1991, ONCOGENE, V6, P995; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; STEVENSON MA, 1994, CANCER RES, V54, P12; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; WEINSTEIN IB, 1991, ENVIRON HEALTH PERSP, V93, P175, DOI 10.2307/3431186; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; Yeo EJ, 1997, BBA-MOL CELL RES, V1356, P308, DOI 10.1016/S0167-4889(97)00006-2; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	61	112	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17114	17121		10.1074/jbc.M908959199	http://dx.doi.org/10.1074/jbc.M908959199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748111	hybrid			2022-12-27	WOS:000087392200100
J	Zhang, Y; Derynck, R				Zhang, Y; Derynck, R			Transcriptional regulation of the transforming growth factor-beta-inducible mouse germ line Ig alpha constant region gene by functional cooperation of Smad, CREB, and AML family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; TUMOR-SUPPRESSOR; DNA-BINDING; SYNERGISTICALLY ACTIVATE; SIGNALING PATHWAYS; C-MYB; PROMOTER; PROTEINS; LEUKEMIA; DOMAIN	Smads regulate transcription of defined genes in response to transforming growth factor-beta (TGF-beta) receptor activation. This process involves functional crosstalk of Smads with transcription factors at responsive DNA elements to achieve maximal transcription activation and specificity. TGF-beta has been shown to induce transcription of the germ line (GL) Ig alpha constant region gene and to direct class switching to IgA antibodies. It has been shown that acute myeloid leukemia (AML) transcription factors cooperate with Smad3 to stimulate transcription from the GL Ig alpha constant region gene promoter. We report here that the TGF-beta-induced transcription from this promoter requires DNA binding of cAMP-response element-binding protein (CREB) to the nearby ATF/cAMP-response element site and of Smads to a nearby Smad binding sequence. At these sites, Smad3/4 cooperates with CREB to activate transcription in response to TGF-beta, and disruption of either binding sequence abolished TGF-beta-induced transcription. In addition, AML1 or AML2 also binds to the promoter and cooperates with Smad3/4, and in this way further enhances the TGF-beta-induced transcriptional activation of the GL Ig alpha promoter. Thus, whereas Smad3/4, CREB, and AML family members bind independently to the respective DNA sequences in the GL Ig alpha promoter, functional synergy of Smads with CREB and AML proteins results in maximal TGF-beta-induced transcription.	Univ Calif San Francisco, Dept Growth & Dev, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Growth & Dev, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Cell Biol Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Derynck, R (corresponding author), Univ Calif San Francisco, Dept Growth & Dev, Cell Biol Program, San Francisco, CA 94143 USA.		Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NATIONAL CANCER INSTITUTE [Z01BC010419, R01CA063101, ZIABC010419] Funding Source: NIH RePORTER; NCI NIH HHS [CA63101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SC, 1993, ONCOGENE, V8, P809; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Choy L, 1998, J BIOL CHEM, V273, P31455, DOI 10.1074/jbc.273.47.31455; Crute BE, 1996, J BIOL CHEM, V271, P26251, DOI 10.1074/jbc.271.42.26251; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEBMAN DA, 1990, P NATL ACAD SCI USA, V87, P3962, DOI 10.1073/pnas.87.10.3962; LEBMAN DA, 1990, J IMMUNOL, V144, P952; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIN YCA, 1992, J IMMUNOL, V149, P2914; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Meyers S, 1996, ONCOGENE, V13, P303; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Parker D, 1996, MOL CELL BIOL, V16, P694; Shi MJ, 1998, J IMMUNOL, V161, P6751; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; SHOCKETT P, 1991, J IMMUNOL, V147, P4374; Stavnezer J, 1996, CURR OPIN IMMUNOL, V8, P199, DOI 10.1016/S0952-7915(96)80058-6; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; Wong C, 1999, MOL CELL BIOL, V19, P1821; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	47	116	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16979	16985		10.1074/jbc.M001526200	http://dx.doi.org/10.1074/jbc.M001526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748032	hybrid			2022-12-27	WOS:000087392200082
J	Hack, ES; Vorobyova, T; Sakash, JB; West, JM; Macol, CP; Herve, G; Williams, MK; Kantrowitz, ER				Hack, ES; Vorobyova, T; Sakash, JB; West, JM; Macol, CP; Herve, G; Williams, MK; Kantrowitz, ER			Characterization of the aspartate transcarbamoylase from Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; RESIDUES 230-245; CATALYTIC CHAIN; STRUCTURAL STABILIZATION; PSEUDOMONAS-FLUORESCENS; REGULATORY SUBUNIT; BACILLUS-SUBTILIS; SWISS-MODEL; PURIFICATION	The genes from the thermophilic archaeabacterium Methanococcus jannaschii that code for the putative catalytic and regulatory chains of aspartate transcarbamoylase were expressed at high levels in Escherichia coli, Only the M. jannaschii PyrB (Mj-PyrB) gene product exhibited catalytic activity. A purification protocol was devised for the Mj-PyrB and M. jannaschii PyrI (Mj-PyrI) gene products. Molecular weight measurements of the Mj-PyrB and Mj-PyrI gene products revealed that the Mj-PyrB gene product is a trimer and the Mj-PyrI gene product is a dimer. Preliminary characterization of the aspartate transcarbamoylase from M. jannaschii cell-free extract revealed that the enzyme has a similar molecular weight to that of the E. coli holoenzyme, Kinetic analysis of the M. jannaschii aspartate transcarbamoylase from the cell-free extract indicates that the enzyme exhibited limited homotropic cooperativity and little if any regulatory properties. The purified Mj-catalytic trimer exhibited hyperbolic kinetics, with an activation energy similar to that observed for the E, coli catalytic trimer, Homology models of the Mj-PyrB and Mj-PyrI gene products were constructed based on the three-dimensional structures of the homologous E. coli proteins. The residues known to be critical for catalysis, regulation, and formation of the quaternary structure from the well characterized E. coli aspartate transcarbamoylase were compared.	Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA; Univ Paris 06, CNRS, UMR 7631, Lab Biochim Signaux Regulateurs Cellulaires & Mol, F-75006 Paris, France	Boston College; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Kantrowitz, ER (corresponding author), Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA.	evan.kantrowitz@bc.edu		Venanzi, Emily/0000-0002-4185-0381	NIGMS NIH HHS [GM26237] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAIR LB, 1972, J BIOL CHEM, V247, P2308; BAKER DP, 1995, PROTEIN EXPRES PURIF, V6, P679, DOI 10.1006/prep.1995.1089; BAKER DP, 1994, J BIOL CHEM, V269, P24608; BAKER DP, 1993, BIOCHEMISTRY-US, V32, P10150, DOI 10.1021/bi00089a034; BERGH ST, 1993, P NATL ACAD SCI USA, V90, P9818, DOI 10.1073/pnas.90.21.9818; BRABSON JS, 1975, J BIOL CHEM, V250, P8664; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEMBOWSKI NJ, 1993, PROTEIN ENG, V6, P123, DOI 10.1093/protein/6.1.123; Dubecq V, 1999, EUR J BIOCHEM, V264, P233, DOI 10.1046/j.1432-1327.1999.00619.x; EISENSTEIN E, 1990, BIOCHEMISTRY-US, V29, P3724, DOI 10.1021/bi00467a019; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HERVE G, 1993, BIOCHEM SOC T, V21, P195, DOI 10.1042/bst0210195; Jin L, 1999, PROTEINS, V37, P729, DOI 10.1002/(SICI)1097-0134(19991201)37:4<729::AID-PROT21>3.0.CO;2-F; JONES ME, 1955, J AM CHEM SOC, V77, P819, DOI 10.1021/ja01608a101; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T, 1982, MOL CLONING LABORATO, P68; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MIDDLETON SA, 1986, P NATL ACAD SCI USA, V83, P5866, DOI 10.1073/pnas.83.16.5866; MIDDLETON SA, 1988, BIOCHEMISTRY-US, V27, P8653, DOI 10.1021/bi00423a022; MIDDLETON SA, 1989, BIOCHEMISTRY-US, V28, P1617, DOI 10.1021/bi00430a029; NEWTON CJ, 1990, P NATL ACAD SCI USA, V87, P2309, DOI 10.1073/pnas.87.6.2309; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Purcarea C, 1997, J BACTERIOL, V179, P4143, DOI 10.1128/jb.179.13.4143-4157.1997; ROBEY EA, 1984, J BIOL CHEM, V259, P1180; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sakash JB, 1998, BIOCHEMISTRY-US, V37, P281, DOI 10.1021/bi972102g; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; SIMMER JP, 1989, P NATL ACAD SCI USA, V86, P4382, DOI 10.1073/pnas.86.12.4382; STEBBINS JW, 1989, BIOCHEMISTRY-US, V28, P2592, DOI 10.1021/bi00432a037; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WILD JR, 1990, ANNU REV MICROBIOL, V44, P193; WU CW, 1973, BIOCHEMISTRY-US, V12, P1400, DOI 10.1021/bi00731a021; ZHANG Y, 1989, BIOCHEMISTRY-US, V28, P7313, DOI 10.1021/bi00444a025; ZHANG Y, 1992, BIOCHEMISTRY-US, V31, P792, DOI 10.1021/bi00118a022; ZHANG Y, 1988, J BIOL CHEM, V263, P1320	47	15	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15820	15827		10.1074/jbc.M909220199	http://dx.doi.org/10.1074/jbc.M909220199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748118	hybrid			2022-12-27	WOS:000087291400030
J	Hsu, AL; Ching, TT; Sen, GT; Wang, DS; Bondada, S; Authi, KS; Chen, CS				Hsu, AL; Ching, TT; Sen, GT; Wang, DS; Bondada, S; Authi, KS; Chen, CS			Novel function of phosphoinositide 3-kinase in T cell Ca2+ signaling - A phosphatidylinositol 3,4,5-trisphosphated-mediated Ca2+ entry mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; INOSITOL 1,3,4,5-TETRAKISPHOSPHATE; LIPID PRODUCTS; PI 3-KINASE; MAST-CELLS; ACTIVATION; RECEPTOR; LYMPHOCYTES; PROTEIN; 1,4,5-TRISPHOSPHATE	This study presents evidence that phosphoinositide (PI) 3-kinase is involved in T cell Ca2+ signaling via a phosphatidylinositol 3,4,5-trisphosphate PI(3,4,5)P-3-sensitive Ca2+ entry pathway. First, exogenous PI(3,4,5)P-3 at concentrations close to its physiological levels induces Ca2+ influx in T cells, whereas PI(3,4)P-2, PI(4,5)P-2, and PI(3)P have no effect on [Ca2+](i). This Ca2+ entry mechanism is cell type-specific as B cells and a number of cell lines examined do not respond to PI(3,4,5)P-3 stimulation. Second, inhibition of PI 3-kinase by wortmannin and by overexpression of the dominant negative inhibitor Delta p85 suppresses anti-CD3-induced Ca2+ response, which could be reversed by subsequent exposure to PI(3,4,5)P-3. Third, PI(3,4,5)P-3 is capable of stimulating Ca2+ efflux from Ca2+-loaded plasma membrane vesicles prepared from Jurkat T cells, suggesting that PI(3,4,5)P-3 interacts with a Ca2+ entry system directly or via a membrane-bound protein. Fourth, although D-myo-inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P-3) mimics PI(3,4,5)P-3 in many aspects of biochemical functions such as membrane binding and Ca2+ transport, we raise evidence that Ins(1,3,4,5)P-3 does not play a role in anti-CD3- or PI(3,4,5)P-3-mediated Ca2+ entry. This PI(3,4,5)P-3-stimulated Ca2+ influx connotes physiological significance, considering the pivotal role of PI 5-kinase in the regulation of T cell function. Given that PI 3-kinase and phospholipase C-gamma form multifunctional complexes downstream of many receptor signaling pathways, we hypothesize that PI(3,4,5)P-3-induced Ca2+ entry acts concertedly with Ins(l,l,B)P-3-induced Ca2+ release in initiating T cell Ca2+ signaling. By using a biotinylated analog of PI(3,4,5)P-3 as the affinity probe, we have detected several putative PI(3,4,5)P-3-binding proteins in T cell plasma membranes.	Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Thrombosis Res Inst, Platelet Sect, London SW3 6LR, England	University of Kentucky; University of Kentucky; Thrombosis Research Institute	Chen, CS (corresponding author), Univ Kentucky, ASTECC Facil, Rm 323B, Lexington, KY 40506 USA.		Hsu, Ao-Lin Allen/AAX-1856-2020	Ching, Tsui-Ting/0000-0001-7650-1766; Hsu, Ao-Lin/0000-0002-2864-3134	NIAID NIH HHS [AI21490] Funding Source: Medline; NIGMS NIH HHS [GM53448] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053448] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Barker SA, 1999, J LEUKOCYTE BIOL, V65, P321, DOI 10.1002/jlb.65.3.321; Bird GSJ, 1996, J BIOL CHEM, V271, P6766, DOI 10.1074/jbc.271.12.6766; Bruyns E, 1998, J EXP MED, V188, P561, DOI 10.1084/jem.188.3.561; CARDENAS ME, 1995, ADV SEC MESS PHOSPH, V30, P281; Ching TT, 1999, J BIOL CHEM, V274, P8611, DOI 10.1074/jbc.274.13.8611; CHUNG SC, 1994, BRIT J PHARMACOL, V113, P861, DOI 10.1111/j.1476-5381.1994.tb17072.x; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Cullen PJ, 1997, BIOCHEM SOC T, V25, P991, DOI 10.1042/bst0250991; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DASILVA CP, 1994, J BIOL CHEM, V269, P12521; deAos I, 1997, J BIOL CHEM, V272, P25310, DOI 10.1074/jbc.272.40.25310; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Eder AM, 1998, J BIOL CHEM, V273, P28025, DOI 10.1074/jbc.273.43.28025; ELDAHER SS, 2000, IN PRESS BLOOD; Gagnon A, 1999, DIABETES, V48, P691, DOI 10.2337/diabetes.48.4.691; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guse AH, 1998, CRIT REV IMMUNOL, V18, P419, DOI 10.1615/CritRevImmunol.v18.i5.20; GUSE AH, 1991, BIOCHEM BIOPH RES CO, V179, P641, DOI 10.1016/0006-291X(91)91420-H; HOLMES RP, 1983, NATURE, V305, P637, DOI 10.1038/305637a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P9776, DOI 10.1021/bi980163o; LU PJ, 1994, BIOCHEMISTRY-US, V33, P11586, DOI 10.1021/bi00204a021; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MUTHUSAMY N, 1991, J IMMUNOL, V147, P2483; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; ORourke F, 1996, BIOCHEM J, V315, P1027, DOI 10.1042/bj3151027; PREMACK BA, 1994, J IMMUNOL, V152, P5226; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; SEI Y, 1995, EXP CELL RES, V216, P222, DOI 10.1006/excr.1995.1028; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; Setoguchi R, 1998, IMMUNOL LETT, V64, P109, DOI 10.1016/S0165-2478(98)00086-8; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; WANG DS, 2000, IN PRESS ANAL BIOCH; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	48	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16242	16250		10.1074/jbc.M002077200	http://dx.doi.org/10.1074/jbc.M002077200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748064	Green Published, hybrid			2022-12-27	WOS:000087291400086
J	Leung, WK; Kim, JJ; Wu, L; Sepulveda, JL; Sepulveda, AR				Leung, WK; Kim, JJ; Wu, L; Sepulveda, JL; Sepulveda, AR			Identification of a second MutL DNA mismatch repair complex (hPMS1 and hMLH1) in human epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; EMBRYONIC FIBROBLASTS; GASTRIC-CANCER; COLON-CANCER; PROMOTER; LINES; GENE; EXPRESSION; MUTATIONS	Deficiencies of MutL DNA mismatch repair-complex proteins (hMLH1, hPMS2, and hPMS1) typically result in microsatellite instability in human cancers. We examined the association patterns of MutL proteins in human epithelial cancer cell lines with (HCT-116, N87, SNU-1, and SNU-638) and without microsatellite instability (HeLa, AGS, KATO-III, and SNU-16). The analysis of hMLH1, hPMS2, and hPMS1 was performed using Northern blot, Western blot, and co-immunoprecipitation studies. Our data provide evidence that MutL proteins form two different complexes, MutL-alpha (hPMS2 and hMLH1) and MutL-beta (hPMS1 and hMLH1). Gastric and colorectal cancer cells lines with microsatellite instability lacked detectable hMLH1. Decreased levels of hMLH1 protein were associated with markedly reduced levels of hPMS2 and hPMS1 proteins, but the RNA levels of hPMS1 and hPMS2 were normal. In this study, we describe the association of hPMS1 with hMLH1 as a heterodimer, in human cells. Furthermore, normal levels of hMLH1 protein appear to be important in maintaining normal levels of hPMS1 and hPMS2 proteins.	Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA; Vet Affairs Med Ctr, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine	Sepulveda, AR (corresponding author), Vet Affairs Med Ctr, Dept Med, 111D,2002 Holcombe Blvd, Houston, TX 77030 USA.		Leung, Wai Keung/B-8140-2011	Leung, Wai Keung/0000-0002-5993-1059				Arzimanoglou II, 1996, CARCINOGENESIS, V17, P1799, DOI 10.1093/carcin/17.9.1799; Buermeyer AB, 1999, CANCER RES, V59, P538; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Fleisher AS, 1999, CANCER RES, V59, P1090; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Halling KC, 1999, AM J PATHOL, V155, P205, DOI 10.1016/S0002-9440(10)65114-0; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Kane MF, 1997, CANCER RES, V57, P808; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Leung SY, 1999, CANCER RES, V59, P159; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MYEROFF LL, 1995, CANCER RES, V55, P5545; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Park JG, 1997, INT J CANCER, V70, P443, DOI 10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Reitmair AH, 1997, CANCER RES, V57, P3765; Sepulveda AR, 1999, AM J GASTROENTEROL, V94, P3034, DOI 10.1016/S0002-9270(99)00509-2; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; Shin KH, 1998, J CANCER RES CLIN, V124, P421, DOI 10.1007/s004320050194; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; Thibodeau SN, 1998, CANCER RES, V58, P1713; UMAR A, 1994, J BIOL CHEM, V269, P14367; Umar A, 1998, GENETICS, V148, P1637	34	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15728	15732		10.1074/jbc.M908768199	http://dx.doi.org/10.1074/jbc.M908768199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748105	hybrid			2022-12-27	WOS:000087291400019
J	Saifudeen, Z; Du, H; Dipp, S; El-Dahr, SS				Saifudeen, Z; Du, H; Dipp, S; El-Dahr, SS			The bradykinin type 2 receptor is a target for p53-mediated transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; SMOOTH-MUSCLE CELLS; BOX-BINDING PROTEIN; WILD-TYPE P53; B-2 RECEPTOR; GENE-EXPRESSION; DNA-BINDING; TUMOR-SUPPRESSOR; GROWTH-FACTOR; IN-VIVO	The bradykinin type 2 receptor (BK2) is a developmentally regulated G protein-coupled receptor that mediates diverse actions such as vascular reactivity, salt and water excretion, inflammatory responses, and cell growth, However, little is known regarding regulation of the BK2 gene. We report here that the rat BK2 receptor is transcriptionally regulated by the tumor suppressor protein p53. The 5'-flanking region of the rat BK2 gene contains two p53-like binding sites: a sequence at -70 base pairs (P1 site) that is conserved in the murine and human BK2 genes; and a sequence at -707 (P2) that is not. The P1 and P2 motifs bind specifically to p53, as assessed by gel mobility shift assays. Transient transfection into HeLa cells of a CAT reporter construct driven by 1.2-kilobases of the BK2 gene 5'-flanking region demonstrated that the BK2 promoter is dose dependently activated by co-expression of wild-type p53, Co-expression of a dominant negative mutant p53 suppresses the activation of BK2 by wild-type p53, Promoter truncation localized the p53-responsive element to the region between -38 and -94 base pairs encompassing the p53-binding P1 sequence. Furthermore, p53-mediated activation of the BK2 promoter is augmented by the transcriptional co-activators, CBP/p300, Interestingly, removal of the P2 site by truncation or site-directed deletion amplifies p88-mediated activation of the BK2 promoter. These results demonstrate that the rat BK2 promoter is a target for p53-mediated activation and suggest a new physiological role for p53 in the regulation of G protein-coupled receptor gene expression.	Tulane Univ, Sch Med, Dept Pediat, Sect Pediat Nephrol, New Orleans, LA 70112 USA	Tulane University	El-Dahr, SS (corresponding author), Tulane Univ, Sch Med, Dept Pediat, Sect Pediat Nephrol, 1430 Tulane Ave, New Orleans, LA 70112 USA.				NIDDK NIH HHS [DK-56264, DK-53595] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056264, R21DK053595] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Alfie ME, 1997, HYPERTENSION, V29, P483, DOI 10.1161/01.HYP.29.1.483; Arai N, 1999, MODERN PATHOL, V12, P604; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Cervenka L, 1999, HYPERTENSION, V34, P176, DOI 10.1161/01.HYP.34.2.176; DEB SP, 1994, ONCOGENE, V9, P1341; Dixon BS, 1996, J BIOL CHEM, V271, P13324, DOI 10.1074/jbc.271.23.13324; El-Dahr SS, 1998, AM J PHYSIOL-RENAL, V275, pF343, DOI 10.1152/ajprenal.1998.275.3.F343; ElDahr SS, 1997, KIDNEY INT, V51, P739, DOI 10.1038/ki.1997.105; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; GU W, 1997, NATURE, V387, P296; Hembree TN, 1996, J CELL PHYSIOL, V169, P248; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; KAMMERER S, 1995, BIOCHEM BIOPH RES CO, V211, P226, DOI 10.1006/bbrc.1995.1800; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu L, 1999, MOL CELL BIOL, V19, P1202; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; Lung CC, 1998, IMMUNOPHARMACOLOGY, V39, P243, DOI 10.1016/S0162-3109(98)00008-3; MA JX, 1994, GENOMICS, V23, P362, DOI 10.1006/geno.1994.1512; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Madeddu P, 1997, CIRCULATION, V96, P3570; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MIYASHITA T, 1995, CELL, V80, P293; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; OWEN NE, 1983, CELL, V32, P979, DOI 10.1016/0092-8674(83)90082-X; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PESQUERO JB, 1994, J BIOL CHEM, V269, P26920; Saifudeen Zubaida, 1998, Journal of the American Society of Nephrology, V9, p367A; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schmidlin F, 1998, MOL PHARMACOL, V53, P1009; Seol DW, 1999, J BIOL CHEM, V274, P3565, DOI 10.1074/jbc.274.6.3565; THUT CJ, 1995, SCIENCE, V267, P110; TRUANT R, 1993, J BIOL CHEM, V268, P2284; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	55	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15557	15562		10.1074/jbc.M909810199	http://dx.doi.org/10.1074/jbc.M909810199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748162	hybrid			2022-12-27	WOS:000087128300105
J	Schmidt, M; Ding, HY; Ramamurthy, V; Mukerji, I; Oliver, D				Schmidt, M; Ding, HY; Ramamurthy, V; Mukerji, I; Oliver, D			Nucleotide binding activity of SecA homodimer is conformationally regulated by temperature and altered by prlD and azi mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSLOCATION ATPASE; RNA HELICASE ACTIVITY; ESCHERICHIA-COLI; SIGNAL SEQUENCE; PREPROTEIN TRANSLOCATION; ESSENTIAL COMPONENT; PRECURSOR PROTEINS; SECRETORY PROTEIN; MEMBRANE-PROTEINS; INNER MEMBRANE	SecA ATPase is critical for protein translocation across the Escherichia coli inner membrane. To understand this activity further, the high affinity nucleotide binding activity of SecA was characterized. We found that at 4 degrees C SecA homodimer binds one ADP molecule with high affinity. This nucleotide binding activity was conformationally regulated by temperature: at low temperature SecA affinity for ADP was high with a slow exchange rate, whereas at high temperature the converse was true. Azi- and PrID-SecA proteins that confer azide-resistant and signal sequence suppressor phenotypes were found to have reduced affinity for ADP and accelerated exchange rates compared with wild type Seek Consistent with this observation, fluorescence and proteolysis studies indicated that these proteins had a conformationally relaxed state at a reduced temperature compared with Seek The level of Azi- and PrID-SecA protein was also elevated in inverted membrane vesicles where it displayed higher membrane ATPase activity. These results provide the first direct evidence for conformational regulation of the SecA-dependent nucleotide cycle, its alteration in azi and prlD mutants, and its relevance to in vivo protein export.	Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA	Wesleyan University	Oliver, D (corresponding author), Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA.	doliver@wesleyan.edu	Schmidt, Marcel/AAV-8054-2021	Schmidt, Marcel/0000-0002-3991-2766	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn T, 1996, J BIOL CHEM, V271, P12372, DOI 10.1074/jbc.271.21.12372; AKITA M, 1990, J BIOL CHEM, V265, P8164; AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; BLAAUWEN T, 1996, BIOCHEMISTRY-US, V35, P11994; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DOLAN KM, 1991, J BIOL CHEM, V266, P23329; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1998, J BIOL CHEM, V273, P21675, DOI 10.1074/jbc.273.34.21675; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; FLOWER AM, 1994, J BACTERIOL, V176, P5607, DOI 10.1128/JB.176.18.5607-5614.1994; FORTIN Y, 1990, J BACTERIOL, V172, P6607, DOI 10.1128/jb.172.11.6607-6610.1990; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HUIE JL, 1995, J BACTERIOL, V177, P3518, DOI 10.1128/jb.177.12.3518-3526.1995; KOONIN EV, 1992, FEBS LETT, V298, P6, DOI 10.1016/0014-5793(92)80009-6; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Lohman TM, 1998, CELL, V93, P9, DOI 10.1016/S0092-8674(00)81139-3; Matsumoto G, 1998, P NATL ACAD SCI USA, V95, P13567, DOI 10.1073/pnas.95.23.13567; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Park SK, 1997, BIOCHEM BIOPH RES CO, V235, P593, DOI 10.1006/bbrc.1997.6834; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; Ramamurthy V, 1998, J BACTERIOL, V180, P6419; Ramamurthy V, 1997, J BIOL CHEM, V272, P23239, DOI 10.1074/jbc.272.37.23239; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; Suzuki H, 1998, MOL MICROBIOL, V29, P331, DOI 10.1046/j.1365-2958.1998.00937.x; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x	50	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15440	15448		10.1074/jbc.M000605200	http://dx.doi.org/10.1074/jbc.M000605200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747939	hybrid			2022-12-27	WOS:000087128300090
J	Chiba, N; Suldan, Z; Freedman, LP; Parvin, JD				Chiba, N; Suldan, Z; Freedman, LP; Parvin, JD			Binding of liganded vitamin D receptor to the vitamin D receptor interacting protein coactivator complex induces interaction with RNA polymerase II holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Because the vitamin D receptor interacting protein (DRIP) coactivator complex shares components with the RNA polymerase II (Pol II) holoenzyme complex, we tested whether the two protein complexes associate in cellular extracts. On initial purification steps, the DRIP complex copurified with the Pol II holoenzyme. Pol II was found to bind to the vitamin D receptor in a ligand-dependent fashion when either nuclear extracts or partially purified preparations were used as sources of DRIP and Pol II holoenzyme. A subpopulation of holoenzyme complexes bound to the receptor because BRCA1, which associates with the Pol II holoenzyme, did not associate with the liganded receptor, and only in certain of the holoenzyme- and DRIP-containing fractions did Pol II bind to the liganded receptor. Immunoprecipitation experiments revealed that the DRIP complex was not pre-associated with the Pol II holoenzyme, hut the interaction between these two complexes was induced only in the presence of receptor and ligand. These data support a model in which the activation of transcription by hormone-bound receptor requires binding to the DRIP coactivator, and this induced ternary complex can then bind to the Pol II holoenzyme to activate transcription.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center	Parvin, JD (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.		Parvin, Jeffrey D/C-8955-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045460, R01DK045460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053504] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45460] Funding Source: Medline; NIGMS NIH HHS [GM53504] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Parvin JD, 1998, CURR OPIN GENET DEV, V8, P565, DOI 10.1016/S0959-437X(98)80012-9; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587	17	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10719	10722		10.1074/jbc.275.15.10719	http://dx.doi.org/10.1074/jbc.275.15.10719			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753860	hybrid			2022-12-27	WOS:000086466600002
J	Assefa, Z; Vantieghem, A; Garmyn, M; Declercq, W; Vandenabeele, P; Vandenheede, JR; Bouillon, R; Merlevede, W; Agostinis, P				Assefa, Z; Vantieghem, A; Garmyn, M; Declercq, W; Vandenabeele, P; Vandenheede, JR; Bouillon, R; Merlevede, W; Agostinis, P			p38 mitogen-activated protein kinase regulates a novel, caspase-independent pathway for the mitochondrial cytochrome c release in ultraviolet B radiation-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; UVB-INDUCED APOPTOSIS; N-TERMINAL KINASE; HUMAN KERATINOCYTES; CELL-DEATH; SIGNALING PATHWAYS; GROWTH-FACTOR; P53; RECEPTORS; PROTEASES	The mechanisms of UVB-induced apoptosis and the role of p38 mitogen-activated protein kinase (MAPK) were investigated in HaCaT cells. UVB doses that induced apoptosis also produced a sustained activation of p38 MAPK and mitochondrial cytochrome c release, leading to pro-caspase-3 activation. Late into the apoptotic process, UVB also induced a caspase-mediated cleavage of Bid. Caspase inhibitors benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone and benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone substantially blocked the WE-induced apoptosis without preventing the release of mitochondrial cytochrome c and the p38 MAPK activation. The inhibition of p38 MAPK counteracted both apoptosis and cytochrome c release as well as the DEVD-amino-4-methylcoumarin cleavage activity without affecting the processing of pro-caspase-8. These results indicate that UVB induces multiple and independent apoptotic pathways, which culminate in pro-caspase-3 activation, and that the initial cytochrome c release is independent of caspase activity. Importantly, we show that a sustained p38 MAPK activation contributes to the UVB-induced apoptosis by mediating the release of mitochondrial cytochrome c into the cytosol.	Katholieke Univ Leuven, Fac Med, Div Biochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fac Med, Dermatol Lab, B-3000 Louvain, Belgium; State Univ Ghent VIB, Dept Mol Biol, B-9000 Ghent, Belgium	KU Leuven; KU Leuven; Flanders Institute for Biotechnology (VIB); Ghent University	Agostinis, P (corresponding author), Katholieke Univ Leuven, Fac Med, Div Biochem, Herestr 49, B-3000 Louvain, Belgium.	patricia.agostinis@med.kuleuven.ac.be	Vandenabeele, Peter/C-8597-2009; Agostinis, Patrizia/AAO-2468-2020; Vandenabeele, Peter/AAD-5793-2022; Assefa, Zerihun/V-5641-2017; Agostinis, Patrizia/ABI-1177-2020	Vandenabeele, Peter/0000-0002-6669-8822; Assefa, Zerihun/0000-0001-7803-5228; Agostinis, Patrizia/0000-0003-1314-2115				Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Boehm JC, 1996, J MED CHEM, V39, P3929, DOI 10.1021/jm960415o; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Butterfield L, 1997, J BIOL CHEM, V272, P10110; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; Henseleit U, 1997, J INVEST DERMATOL, V109, P722, DOI 10.1111/1523-1747.ep12340708; HERRLICH P, 1994, ADV ENZYME REGUL, V34, P381, DOI 10.1016/0065-2571(94)90024-8; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Longstreth J, 1998, J PHOTOCH PHOTOBIO B, V46, P20, DOI 10.1016/S1011-1344(98)00183-3; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madronich S, 1998, J PHOTOCH PHOTOBIO B, V46, P5, DOI 10.1016/S1011-1344(98)00182-1; MIYASHITA T, 1995, CELL, V80, P293; Ozaki I, 1999, J BIOL CHEM, V274, P5310, DOI 10.1074/jbc.274.9.5310; PALOMBELLA VJ, 1989, J BIOL CHEM, V264, P18128; Peus D, 1999, J INVEST DERMATOL, V112, P751, DOI 10.1046/j.1523-1747.1999.00584.x; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Takahashi H, 1997, BIOCHEM BIOPH RES CO, V236, P194, DOI 10.1006/bbrc.1997.6931; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	36	135	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21416	21421		10.1074/jbc.M002634200	http://dx.doi.org/10.1074/jbc.M002634200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10748072	Green Published, hybrid			2022-12-27	WOS:000088230600062
J	Barth, H; Blocker, D; Behlke, J; Bergsma-Schutter, W; Brisson, A; Benz, R; Aktories, K				Barth, H; Blocker, D; Behlke, J; Bergsma-Schutter, W; Brisson, A; Benz, R; Aktories, K			Cellular uptake of Clostridium botulinum C2 toxin requires oligomerization and acidification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTHRAX PROTECTIVE ANTIGEN; ADP-RIBOSYLATES ACTIN; DIPHTHERIA-TOXIN; PLASMA-MEMBRANE; MAMMALIAN-CELLS; RETROGRADE TRANSPORT; BIOLOGICAL-ACTIVITY; BILAYER-MEMBRANES; CHOLERA-TOXIN; LETHAL FACTOR	The actin-ADP-ribosylating binary Clostridium botulinum C2 toxin consists of two individual proteins, the binding/translocation component C2II and the enzyme component C2I. To elicit its cytotoxic action, C2II binds to a receptor on the cell surface and mediates cell entry of C2I via receptor-mediated endocytosis. Here we report that binding of C2II to the surface of target cells requires cleavage of C2II by trypsin, Trypsin cleavage causes oligomerization of the activated C2II (C2IIa) to give SDS-stable heptameric structures, which exhibit a characteristic annular or horseshoe shape and form channels in lipid bilayer membranes. Cytosolic delivery of the enzyme component C2I is blocked by bafilomycin bat Plot by brefeldin A or nocodazole, indicating uptake from an endosomal compartment and requirement of endosomal acidification for cell entry. In the presence of C2IIa and C2I, short term acidification of the extracellular medium (pH 5.4) allows C2I to enter the cytosol directly. Our data indicate that entry of C2 toxin into cells involves (i) activation of C2II by trypsin-cleavage, (ii) oligomerization of cleaved C2IIa to heptamers, (iii) binding of the C2IIa oligomers to the carbohydrate receptor on the cell surface and assembly with C2I, (iv) receptor-mediated endocytosis of both C2 components into endosomes, and finally (v) translocation and release of C2I into the cytosol after acidification of the endosomal compartment.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany; Max Delbruck Zentrum Mol Med, D-13125 Berlin, Germany; Univ Groningen, Dept Biophys Chem, NL-9747 AG Groningen, Netherlands; Univ Wurzburg, Biozentrum, Theodor Boveri Inst, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany	University of Freiburg; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Groningen; University of Wurzburg	Aktories, K (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.		Barth, Holger/E-7920-2013; Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Benz, Roland/0000-0002-9510-9265				AKTORIES K, 1992, MOL MICROBIOL, V6, P2905, DOI 10.1111/j.1365-2958.1992.tb01749.x; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; Barth H, 1998, J BIOL CHEM, V273, P29506, DOI 10.1074/jbc.273.45.29506; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; BEHLKE J, 1997, BIOCHEMISTRY-US, V36, P149; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; CONSIDINE RV, 1991, TOXICON, V29, P913, DOI 10.1016/0041-0101(91)90076-4; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; Eckhardt M, 2000, J BIOL CHEM, V275, P2328, DOI 10.1074/jbc.275.4.2328; EKLUND MW, 1972, APPL MICROBIOL, V24, P108, DOI 10.1128/AEM.24.1.108-113.1972; ESCUYER V, 1991, INFECT IMMUN, V59, P3381, DOI 10.1128/IAI.59.10.3381-3386.1991; FRITZ G, 1995, INFECT IMMUN, V63, P2334, DOI 10.1128/IAI.63.6.2334-2340.1995; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Han S, 1999, NAT STRUCT BIOL, V6, P932, DOI 10.1038/13300; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; Kimura K, 1998, VET MICROBIOL, V62, P27, DOI 10.1016/S0378-1135(98)00195-3; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; MADSHUS IH, 1991, J BIOL CHEM, V266, P17446; MADSHUS IH, 1992, CURR TOP MICROBIOL I, V175, P2; Majoul I, 1998, J CELL BIOL, V143, P601, DOI 10.1083/jcb.143.3.601; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; MONTECUCCO C, 1994, FEBS LETT, V346, P92, DOI 10.1016/0014-5793(94)00449-8; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; OHISHI I, 1985, INFECT IMMUN, V48, P769, DOI 10.1128/IAI.48.3.769-775.1985; OHISHI I, 1990, J BIOCHEM-TOKYO, V107, P420, DOI 10.1093/oxfordjournals.jbchem.a123060; OHISHI I, 1987, INFECT IMMUN, V55, P1461, DOI 10.1128/IAI.55.6.1461-1465.1987; OHISHI I, 1980, INFECT IMMUN, V30, P668; OLSNES S, 2000, IN PRESS HDB EXPT PH; ORLANDI PA, 1993, J BIOL CHEM, V268, P12010; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; POPOFF MR, 1988, INFECT IMMUN, V56, P2299, DOI 10.1128/IAI.56.9.2299-2306.1988; REUNER KH, 1987, EUR J CELL BIOL, V43, P134; SAKAI T, 1991, J BIOCHEM-TOKYO, V109, P528, DOI 10.1093/oxfordjournals.jbchem.a123415; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SCHMID A, 1994, J BIOL CHEM, V269, P16706; SIMPSON LI, 1989, J PHARMACOL EXP THER, V251, P1223; SIMPSON LL, 1982, J PHARMACOL EXP THER, V223, P695; SIMPSON LL, 1989, INFECT IMMUN, V57, P255, DOI 10.1128/IAI.57.1.255-261.1989; Singh Y, 1999, INFECT IMMUN, V67, P1853; STILES BG, 1986, INFECT IMMUN, V54, P683, DOI 10.1128/IAI.54.3.683-688.1986; UMATA T, 1990, J BIOL CHEM, V265, P21940; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; WEGNER A, 1988, J BIOL CHEM, V263, P13739; WERNER G, 1984, J ANTIBIOT, V37, P110, DOI 10.7164/antibiotics.37.110; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626	54	141	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18704	18711		10.1074/jbc.M000596200	http://dx.doi.org/10.1074/jbc.M000596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10749859	hybrid			2022-12-27	WOS:000087815900014
J	Singh, U; Van Itallie, CM; Mitic, LL; Anderson, JM; McClane, BA				Singh, U; Van Itallie, CM; Mitic, LL; Anderson, JM; McClane, BA			CaCo-2 cells treated with Clostridium perfringens enterotoxin form multiple large complex species, one of which contains the tight junction protein occludin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERO CELLS; MEMBRANE-PERMEABILITY; OSMOTIC STABILIZERS; MOLECULAR-CLONING; A ENTEROTOXIN; RABBIT ILEUM; TOXIN; BINDING; RECEPTOR; INVOLVEMENT	The previous model for the action of Clostridium perfringens enterotoxin (CPE) proposed that (i) CPE binds to host cell receptor(s), forming a small (similar to 90 kDa) complex, (ii) the small complex interacts with other eucaryotic protein(s), forming a large (similar to 160 kDa) complex, and (iii) the large complex triggers massive permeability changes, thereby inducing enterocyte death. In the current study, Western immunoblot analysis demonstrated that CPE bound to CaCo-2 human intestinal cells at 37 degrees C forms multiple large complex species, with apparent sizes of similar to 200, similar to 155, and similar to 135 kDa, These immunoblot experiments also revealed that occludin, an similar to 65-kDa tight junction protein, is present in the similar to 200-kDa large complex but absent from the other large complex species. Immunoprecipitation studies confirmed that occludin physically associates with CPE in large complex material and also indicated that occludin is absent from small complex, These results strongly suggest that occludin becomes associated with CPE during formation of the similar to 200-kDa large complex. A postbinding association between CPE and occludin is consistent with the failure of rat fibroblast transfectants expressing occludin to bind CPE in the current study. Those occludin transfectants were also insensitive to CPE, strongly suggesting that occludin expression is not sufficient to confer CPE sensitivity. However, the occludin-containing, similar to 200-kDa large complex may contribute to CPE-induced cytotoxicity, because nontoxic CPE point mutants did not form any large complex species. By showing that large complex material is comprised of several species (one containing occludin), the current studies indicate that CPE action is more complicated than previously appreciated and also provide additional evidence for CPE interactions with tight junction proteins, which could be important for CPE-induced pathophysiology.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06511 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06511 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yale University; Yale University	McClane, BA (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 BSTWR, Pittsburgh, PA 15261 USA.	bamcc@pop.pitt.edu		Anderson, James/0000-0003-2765-7996	NIAID NIH HHS [AI-19844-17] Funding Source: Medline; NIDDK NIH HHS [DK45134, DK34988] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019844, R01AI019844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045134, P30DK034988] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; HANNA PC, 1989, J BACTERIOL, V171, P6815, DOI 10.1128/jb.171.12.6815-6820.1989; HANNA PC, 1991, J BIOL CHEM, V266, P11037; Hardy SP, 1999, J MED MICROBIOL, V48, P235, DOI 10.1099/00222615-48-3-235; HORIGUCHI Y, 1985, FEMS MICROBIOL LETT, V28, P131; HORIGUCHI Y, 1987, INFECT IMMUN, V55, P2912, DOI 10.1128/IAI.55.12.2912-2915.1987; Katahira J, 1997, J BIOL CHEM, V272, P26652, DOI 10.1074/jbc.272.42.26652; Katahira J, 1997, J CELL BIOL, V136, P1239, DOI 10.1083/jcb.136.6.1239; Kokai-Kun JF, 1999, INFECT IMMUN, V67, P5634, DOI 10.1128/IAI.67.11.5634-5641.1999; KokaiKun JF, 1997, INFECT IMMUN, V65, P1014, DOI 10.1128/IAI.65.3.1014-1022.1997; Lapierre LA, 1999, J CELL SCI, V112, P3723; MATSUDA M, 1979, BIOCHEM BIOPH RES CO, V91, P629, DOI 10.1016/0006-291X(79)91568-7; MATSUDA M, 1986, BIOCHEM BIOPH RES CO, V141, P704, DOI 10.1016/S0006-291X(86)80229-7; McClane B. A., 1997, FOOD MICROBIOLOGY FU, P305; MCCLANE BA, 1990, INFECT IMMUN, V58, P3109, DOI 10.1128/IAI.58.9.3109-3115.1990; MCCLANE BA, 1981, BIOCHIM BIOPHYS ACTA, V641, P401, DOI 10.1016/0005-2736(81)90496-X; MCCLANE BA, 1980, BIOCHIM BIOPHYS ACTA, V600, P974, DOI 10.1016/0005-2736(80)90499-X; MCCLANE BA, 1979, J CELL PHYSIOL, V99, P191, DOI 10.1002/jcp.1040990205; MCCLANE BA, 1984, BIOCHIM BIOPHYS ACTA, V777, P99, DOI 10.1016/0005-2736(84)90501-7; MCCLANE BA, 1988, J BIOL CHEM, V263, P2423; McClane BA, 2000, GRAM-POSITIVE PATHOGENS, P551; MCDONEL JL, 1979, BIOCHEM BIOPH RES CO, V87, P497, DOI 10.1016/0006-291X(79)91823-0; MCDONEL JL, 1975, INFECT IMMUN, V12, P1214, DOI 10.1128/IAI.12.5.1214-1218.1975; MCDONEL JL, 1988, METHOD ENZYMOL, V165, P94; Mitic LL, 1999, J CELL BIOL, V146, P683, DOI 10.1083/jcb.146.3.683; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Rahner C, 1999, HEPATOLOGY, V30, p326A; Sarker MR, 1999, MOL MICROBIOL, V33, P946, DOI 10.1046/j.1365-2958.1999.01534.x; SHERMAN S, 1994, J DIARRHOEAL DIS RES, V12, P200; Sonoda N, 1999, J CELL BIOL, V147, P195, DOI 10.1083/jcb.147.1.195; SUGII S, 1988, FEMS MICROBIOL LETT, V52, P85; TOLLESHAUG H, 1982, INFECT IMMUN, V37, P486, DOI 10.1128/IAI.37.2.486-491.1982; VanItallie CM, 1997, J CELL SCI, V110, P1113; WIECKOWSKI EU, 1994, J BIOL CHEM, V269, P10838; Wieckowski EU, 1998, INFECT IMMUN, V66, P5897, DOI 10.1128/IAI.66.12.5897-5905.1998; WNEK AP, 1983, BIOCHEM BIOPH RES CO, V112, P1099, DOI 10.1016/0006-291X(83)91731-X; WNEK AP, 1989, INFECT IMMUN, V57, P574, DOI 10.1128/IAI.57.2.574-581.1989; YONEMURA S, 1995, J CELL SCI, V108, P127	38	82	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18407	18417		10.1074/jbc.M001530200	http://dx.doi.org/10.1074/jbc.M001530200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10749869	hybrid			2022-12-27	WOS:000087659400068
J	Imberty, A; Gautier, C; Lescar, J; Perez, S; Wyns, L				Imberty, A; Gautier, C; Lescar, J; Perez, S; Wyns, L			An unusual carbohydrate binding site revealed by the structures of two Maackia amurensis lectins complexed with sialic acid-containing oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEGUME LECTIN; QUATERNARY STRUCTURE; CONCANAVALIN-A; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURES; HEMAGGLUTININ MAH; RECEPTOR-BINDING; PLANT-LECTINS; SEQUENCE; PROTEIN	Seeds from the legume tree Maackia amurensis contain two lectins that can agglutinate different blood cell types. Their specificity toward sialylated oligosaccharides is unique among legume lectins; the leukoagglutinin preferentially binds to sialyllactosamine (alpha NeuAc(2-3)beta Gal(1-4)beta GlcNAc), whereas the hemagglutinin displays higher affinity for a disialylated tetrasaccharide (alpha NeuAc(2-3) beta Gal(1-3)[alpha NeuAc (2-6)]alpha GalNAc). The three-dimensional structure of the complex between M. amurensis leukoagglutinin and sialyllactose has been determined at 2.75-Angstrom resolution using x-ray crystallography. The carbohydrate binding site consists of a deep cleft that accommodates the three carbohydrate residues of the sialyllactose, The central galactose sits in the primary binding site in an orientation that has not been observed previously in other legume lectins. The carboxyl group of sialic acid establishes a salt bridge with a lysine side chain. The glucose residue is very efficiently docked between two tyrosine aromatic rings. The complex between M. amurensis hemagglutinin and a disialylated tetrasaccharide could be modeled from the leukoagglutinin/sialyllactose crystal structure. The substitution of one tyrosine by an alanine residue is responsible for the difference in fine specificity between the two isolectins. Comparison with other legume lectins indicates that oligosaccharide specificity within this family is achieved by the recycling of structural loops in different combinations.	Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble 09, France; European Synchrotron Radiat Facil, Expt Div, F-38043 Grenoble, France; Free Univ Brussels VIB, Lab Ultrastruct, B-1640 Rhode St Genese, Belgium	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); European Synchrotron Radiation Facility (ESRF); Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Imberty, A (corresponding author), Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, BP 53, F-38041 Grenoble 09, France.	anne.imberty@cermav.cnrs.fr	Imberty, Anne/P-6451-2018	Imberty, Anne/0000-0001-6825-9527; Loris, Remy/0000-0002-8862-3338				BANERJEE R, 1994, P NATL ACAD SCI USA, V91, P227, DOI 10.1073/pnas.91.1.227; BLUNDELL T, 1988, EUR J BIOCHEM, V172, P513, DOI 10.1111/j.1432-1033.1988.tb13917.x; BOYD WC, 1961, TRANSFUSION, V1, P374, DOI 10.1111/j.1537-2995.1961.tb00078.x; Brunger A. T., 1992, X PLOR SYSTEM X RAY; CASSET F, 1995, J BIOL CHEM, V270, P25619, DOI 10.1074/jbc.270.43.25619; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Dao-Thi MH, 1998, ACTA CRYSTALLOGR D, V54, P844, DOI 10.1107/S0907444998001218; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; Drickamer K, 1997, STRUCTURE, V5, P465, DOI 10.1016/S0969-2126(97)00202-5; EDELMAN GM, 1972, P NATL ACAD SCI USA, V69, P2580, DOI 10.1073/pnas.69.9.2580; Elgavish S, 1998, J MOL BIOL, V277, P917, DOI 10.1006/jmbi.1998.1664; ETZLER ME, 1985, ANNU REV PLANT PHYS, V36, P209, DOI 10.1146/annurev.pp.36.060185.001233; Gohier A, 1996, J MOL GRAPH MODEL, V14, P322, DOI 10.1016/S0263-7855(97)00010-6; Hamelryck TW, 1999, J MOL BIOL, V286, P1161, DOI 10.1006/jmbi.1998.2534; Hamelryck TW, 1996, J BIOL CHEM, V271, P20479, DOI 10.1074/jbc.271.34.20479; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; Haseley SR, 1999, ANAL BIOCHEM, V274, P203, DOI 10.1006/abio.1999.4277; IMBERTY A, 1995, GLYCOCONJUGATE J, V12, P331, DOI 10.1007/BF00731336; Imberty A, 1998, CARBOHYDRATE MIMICS, P349; IMBERTY A, 1999, PERSPECTIVES STRUCTU, P392; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Johansson L, 1999, ANAL BIOCHEM, V267, P239, DOI 10.1006/abio.1998.2982; KAKU H, 1993, J BIOL CHEM, V268, P13237; KAWAGUCHI T, 1974, J BIOL CHEM, V249, P2786; KAWAGUCHI T, 1976, BIOCHEMISTRY-US, V15, P4581, DOI 10.1021/bi00666a006; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; KONAMI Y, 1994, J BIOCHEM-TOKYO, V115, P767, DOI 10.1093/oxfordjournals.jbchem.a124408; KONAMI Y, 1994, FEBS LETT, V342, P334, DOI 10.1016/0014-5793(94)80527-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMIEUX RU, 1980, CAN J CHEM, V58, P631, DOI 10.1139/v80-098; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; LORIS R, 1994, J BIOL CHEM, V269, P26722; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Merritt EA, 1997, PROTEIN SCI, V6, P1516, DOI 10.1002/pro.5560060716; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAISMITH JH, 1994, ACTA CRYSTALLOGR D, V50, P847, DOI 10.1107/S0907444994005287; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ng KKS, 1997, BIOCHEMISTRY-US, V36, P979, DOI 10.1021/bi962564e; OHRUI H, 1991, J ORG CHEM, V56, P1726, DOI 10.1021/jo00005a015; Osinaga E, 1997, FEBS LETT, V412, P190, DOI 10.1016/S0014-5793(97)00677-7; PEREZ S, 1994, ADV COMP BIOL, V1, P147; POPPE L, 1992, J BIOMOL NMR, V2, P109, DOI 10.1007/BF01875524; REEKE GN, 1975, J BIOL CHEM, V250, P1525; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; Stehle T, 1996, STRUCTURE, V4, P183, DOI 10.1016/S0969-2126(96)00021-4; STEIN PE, 1994, NAT STRUCT BIOL, V1, P591, DOI 10.1038/nsb0994-591; SWAMINATHAN S, 1995, NAT STRUCT BIOL, V2, P680, DOI 10.1038/nsb0895-680; TOONE EJ, 1994, CURR OPIN STRUC BIOL, V4, P719, DOI 10.1016/S0959-440X(94)90170-8; *TRIP ASS, 1998, SYBYL VERS 6 4; Van Damme EJM, 1998, CRIT REV PLANT SCI, V17, P575, DOI 10.1016/S0735-2689(98)00365-7; VANDAMME EJM, 1997, HDB PLANT LECTINS PR; Waldherr-Teschner M., 1992, Advances in Scientific Visualization, P58; WANG WC, 1988, J BIOL CHEM, V263, P4576; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3; Yamamoto K, 1997, J BIOCHEM-TOKYO, V121, P756; YAMAMOTO K, 1994, GLYCOCONJUGATE J, V11, P572, DOI 10.1007/BF00731308; YOUNG NM, 1992, J MOL BIOL, V228, P924, DOI 10.1016/0022-2836(92)90875-K	64	115	126	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17541	17548		10.1074/jbc.M000560200	http://dx.doi.org/10.1074/jbc.M000560200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747930	hybrid			2022-12-27	WOS:000087485000047
J	Murphy, KM; Streips, UN; Lock, RB				Murphy, KM; Streips, UN; Lock, RB			Bcl-2 inhibits a Fas-induced conformational change in the Bax N terminus and Bax mitochondrial translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; SIGNALING COMPLEX; CELL-DEATH; INDUCED APOPTOSIS; NECROSIS-FACTOR; CD95 FAS/APO-1; BH3 DOMAIN; X-L; CASPASE-8; ACTIVATION	Members of the Bcl-2 family of proteins control the cellular commitment to apoptosis, although their role in Fas-induced apoptosis is ill-defined. In this report we demonstrate that activation of the Fas receptor present on a human breast epithelial cell line resulted in a conformational change in the N terminus of the pro-apoptotic protein Bax. This conformational change appeared to occur in the cytosol and precede Bax translocation to the mitochondria. Overexpression of the anti-apoptotic protein Bcl-2 inhibited both the conformational change of Bax as well as its relocalization to the mitochondria. Bcl-2 overexpression did not, however, inhibit Fas-induced cleavage of both procaspase-8 and the pro-apoptotic protein Bid, indicating that Bcl-2 functions downstream of these events. These results suggest that the mechanism by which Bcl-2 inhibits Bax mitochondrial translocation and subsequent amplification of the apoptotic cascade is not by providing a physical barrier to Bax, but rather by inhibiting an upstream event necessary for Bax conformational change.	Childrens Canc Inst Australia Med Res, Randwick, NSW 2031, Australia; Univ Louisville, Sch Med, Dept Microbiol & Immunol, Louisville, KY 40292 USA	Children's Cancer Institute; University of Louisville	Lock, RB (corresponding author), Childrens Canc Inst Australia Med Res, POB 81,High St, Randwick, NSW 2031, Australia.		Lock, Richard/G-4253-2013	Lock, Richard/0000-0002-3436-9071				Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281	32	118	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17225	17228		10.1074/jbc.C900590199	http://dx.doi.org/10.1074/jbc.C900590199			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10751382	hybrid			2022-12-27	WOS:000087485000002
J	Johnson, DR; Mook-Kanamori, B				Johnson, DR; Mook-Kanamori, B			Dependence of elevated human leukocyte antigen class I molecule expression on increased heavy chain, light chain (beta(2)-,microglobulin), transporter associated with antigen processing, tapasin, and peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA CLASS-I; TUMOR-NECROSIS-FACTOR; MHC; TAP; COMPLEX; VIRUS; GENE; CELLS; BETA-2-MICROGLOBULIN; CALRETICULIN	Human leukocyte antigen (HLA) class I molecule expression was investigated by DNA-mediated gene transfer. Cell surface expression was increased up to 75% by transfection of HLA-A2 or HLA-ES heavy chain genes but not genes encoding light chains (beta(2)-microglobulin (beta(2)m)), transporter associated with antigen processing (TAP), or tapasin. Interferon (IFN) treatment further increased expression of transfected heavy chains, suggesting that IFN inducible molecules support heavy chain expression. IFN induces beta(2)m, TAP, and tapasin mRNAs. Transfected heavy chain expression increased upon cotransfection with genes encoding TAP1 and TAPE but not individual TAP subunits, beta(2)m, or tapasin. Tetracycline inducible heavy chain gene expression was also increased by IFN treatment or TAP cotransfection, suggesting that IFN-induced TAP supports heavy chain maturation, Expression of a mutant that does not interact strongly with TAP, HLA-A2-T134K, was also increased by IFN. Inhibition of TAP-dependent peptide transport by ICP47 reduced heavy chain expression. Expression of HLA-A2, but not HLA-BS, was restored in ICP47 cells by HLA-A2-binding (IP-30) signal peptides. However, these peptides did not further increase transfected HLA-A2 expression, suggesting that peptide availability does not limit heavy chain expression in the absence of ICP47. These results suggest that cytokine-induced TAP supports maturation of HLA class I molecules through combined chaperone and peptide supply functions.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Yale University	Johnson, DR (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med 454, 295 Congress Ave, New Haven, CT 06510 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035099] Funding Source: NIH RePORTER; NIAID NIH HHS [R29-AI35099] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; Benham AM, 1998, J IMMUNOL, V161, P83; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; ESPMARK JA, 1978, TISSUE ANTIGENS, V11, P279, DOI 10.1111/j.1399-0039.1978.tb01259.x; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grandea AG, 1997, IMMUNOGENETICS, V46, P477, DOI 10.1007/s002510050308; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; Herberg JA, 1998, EUR J IMMUNOL, V28, P459, DOI 10.1002/(SICI)1521-4141(199802)28:02<459::AID-IMMU459>3.3.CO;2-Q; HILL A, 1995, P NATL ACAD SCI USA, V92, P341, DOI 10.1073/pnas.92.2.341; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; Johnson DR, 2000, J IMMUNOL METHODS, V233, P119, DOI 10.1016/S0022-1759(99)00121-0; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P5183, DOI 10.1073/pnas.87.13.5183; KAHNPERLES B, 1994, EUR J CELL BIOL, V64, P176; Lewis JW, 1996, CURR BIOL, V6, P873, DOI 10.1016/S0960-9822(02)00611-5; LONG EO, 1991, HUM IMMUNOL, V31, P229, DOI 10.1016/0198-8859(91)90092-N; Ma WL, 1997, J BIOL CHEM, V272, P16585, DOI 10.1074/jbc.272.26.16585; Min W, 1996, J IMMUNOL, V156, P3174; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; PARHAM P, 1979, J IMMUNOL, V123, P342; PeaceBrewer AL, 1996, IMMUNITY, V4, P505, DOI 10.1016/S1074-7613(00)80416-1; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Prasad SA, 1998, EUR J IMMUNOL, V28, P907, DOI 10.1002/(SICI)1521-4141(199803)28:03<907::AID-IMMU907>3.3.CO;2-W; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SEONG RH, 1988, J EXP MED, V167, P288, DOI 10.1084/jem.167.2.288; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; WINTER CC, 1991, J IMMUNOL, V146, P3508	36	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16643	16649		10.1074/jbc.M910035199	http://dx.doi.org/10.1074/jbc.M910035199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748183	hybrid			2022-12-27	WOS:000087392200036
J	Ramm, K; Pluckthun, A				Ramm, K; Pluckthun, A			The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA - II. Isomerase-independent chaperone activity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBODY SCFV FRAGMENT; SHOCK SIGMA-FACTOR; TRIGGER FACTOR; PROLYL ISOMERASE; DISULFIDE BONDS; IN-VITRO; PROTEINS; EVOLUTION; BEHAVIOR; FAMILY	We recently identified FkpA by selecting for the increased yield of antibody single-chain Fv (scFv) fragments in phage display, even of those not containing cis-prolines. We have now investigated the properties of FkpA in vitro. The peptidylprolyl cis-trans-isomerase activity of FkpA was found to be among the highest of any such enzyme with a protein substrate, yet FkpA is not able to enhance the proline-limited refolding rate of the disulfide-free hu4D5-8 scFv fragment, probably due to inaccessibility of Pro-L95. Nevertheless, the yield of the soluble and functional scFv fragment was dramatically increased in vitro in the presence of FkpA. Similar effects were observed for an scFv fragment devoid of cis-prolines. We are thus forced to conclude that the observed folding-assisting function is independent of the isomerase activity of the protein. The beneficial effect of FkpA was found to be due to two components. First, FkpA interacts with early folding intermediates, thus preventing their aggregation. Additionally, it has the ability to reactivate inactive protein, possibly also by binding to a partially unfolded species that may exist in equilibrium with the aggregated form, which may thus be released on a productive pathway. These in vitro measurements therefore fully reflect the in vivo results from periplasmic overexpression of FkpA.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Pluckthun, A (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	plueckthun@biocfebs.unizh.ch	Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306				Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Bothmann H, 2000, J BIOL CHEM, V275, P17100, DOI 10.1074/jbc.M910233199; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; COMPTON LA, 1992, EUR J BIOCHEM, V206, P927, DOI 10.1111/j.1432-1033.1992.tb17002.x; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; Dolinski K, 1997, MOL BIOL CELL, V8, P2267, DOI 10.1091/mbc.8.11.2267; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; Freund C, 1997, FEBS LETT, V407, P42, DOI 10.1016/S0014-5793(97)00306-2; Freund C, 1996, BIOCHEMISTRY-US, V35, P8457, DOI 10.1021/bi952764a; FREUND C, 1997, FOLD DES, V3, P39; Hanes J, 1998, P NATL ACAD SCI USA, V95, P14130, DOI 10.1073/pnas.95.24.14130; Hesterkamp T, 1996, FEBS LETT, V389, P32, DOI 10.1016/0014-5793(96)00582-0; HORNE SM, 1995, ARCH MICROBIOL, V163, P357, DOI 10.1007/s002030050215; Jager M, 1997, FEBS LETT, V418, P106, DOI 10.1016/S0014-5793(97)01350-1; Jager M, 1999, J MOL BIOL, V285, P2005, DOI 10.1006/jmbi.1998.2425; Kabat E. A., 1991, SEQUENCES PROTEINS I; KERN G, 1994, FEBS LETT, V348, P145, DOI 10.1016/0014-5793(94)00591-5; Missiakas D, 1996, MOL MICROBIOL, V21, P871, DOI 10.1046/j.1365-2958.1996.561412.x; MUCKE M, 1994, J MOL BIOL, V239, P713, DOI 10.1006/jmbi.1994.1408; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; RAINA S, 1995, EMBO J, V14, P1043, DOI 10.1002/j.1460-2075.1995.tb07085.x; Ramm K, 1999, J MOL BIOL, V290, P535, DOI 10.1006/jmbi.1999.2854; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; RINFRET A, 1994, BIOCHEMISTRY-US, V33, P1668, DOI 10.1021/bi00173a008; ROUVIERE PE, 1995, EMBO J, V14, P1032, DOI 10.1002/j.1460-2075.1995.tb07084.x; SANCHEZ P, 1990, J IMMUNOL, V144, P2816; Scholz C, 1997, FEBS LETT, V414, P69, DOI 10.1016/S0014-5793(97)00979-4; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; SELSING E, 1982, P NATL ACAD SCI-BIOL, V79, P4681, DOI 10.1073/pnas.79.15.4681; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Worn A, 2000, J BIOL CHEM, V275, P2795, DOI 10.1074/jbc.275.4.2795; Worn A, 1998, FEBS LETT, V427, P357, DOI 10.1016/S0014-5793(98)00463-3; Worn A, 1999, BIOCHEMISTRY-US, V38, P8739, DOI 10.1021/bi9902079; Zarnt T, 1997, J MOL BIOL, V271, P827, DOI 10.1006/jmbi.1997.1206	35	120	195	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17106	17113		10.1074/jbc.M910234199	http://dx.doi.org/10.1074/jbc.M910234199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748201	hybrid			2022-12-27	WOS:000087392200099
J	Sobue, K; Agarwal-Mawal, A; Li, W; Sun, W; Miura, Y; Paudel, HK				Sobue, K; Agarwal-Mawal, A; Li, W; Sun, W; Miura, Y; Paudel, HK			Interaction of neuronal Cdc2-like protein kinase with microtubule-associated protein tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; CYCLIN-DEPENDENT KINASE-5; ALZHEIMER-DISEASE; NEUROFIBRILLARY TANGLES; IN-VITRO; PHOSPHORYLATION; CDK5; TUBULIN; BRAIN; BINDING	Neuronal Cdc2-like protein kinase (NCLK), a similar to 58-kDa heterodimer, was isolated from neuronal microtubules (Ishiguro, K., Takamatsu, M., Tomizawa, K., Omori, A,, Takahashi, M., Arioka, M., Uchida, T. and Imahori, K. (1992) J. Biol. Chem. 267, 10897-10901). The biochemical nature of NCLK-microtubule association is not known. In this study we found that NCLK is released from microtubules upon microtubule disassembly as a 450-kDa species. The 450-kDa species is an NCLK tau complex, and NCLK-bound tau is in a nonphosphorylated state. Tau phosphorylation causes NCLK tau complex dissociation, and phosphorylated tau does not bind to NCLK. In vitro, the Cdk5 subunit of NCLK binds to the microtubule-binding region of tau and NCLK associates with microtubules only in the presence of tau. Our data indicate that in brain extract NCLK is complexed with tau in a tan phosphorylation-dependent manner and that tau anchors NCLK to microtubules. Recently NCLK has been suggested to be aberrantly activated and to hyperphosphorylate tau in Alzheimer's disease brain (Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P, and Tsai, L.-H. (1999) Nature 402, 615-622). Our findings may explain why in Alzheimer's disease NCLK specifically hyperphosphorylates tau, although this kinase has a number of protein substrates in the brain.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada; Nagoya City Univ, Sch Med, Dept Bioregulat Res, Nagoya, Aichi 4678601, Japan	Lady Davis Institute; McGill University; McGill University; Nagoya City University	Paudel, HK (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	mdhp@musica.mcgill.CA						Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BANCHER C, 1991, BRAIN RES, V539, P11, DOI 10.1016/0006-8993(91)90681-K; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CORREAS I, 1990, BIOCHEM J, V269, P61, DOI 10.1042/bj2690061; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; GERVASI C, 1995, MOL BRAIN RES, V33, P192, DOI 10.1016/0169-328X(95)00109-6; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELLMICH MR, 1994, FEBS LETT, V356, P317, DOI 10.1016/0014-5793(94)01298-9; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Huang KX, 2000, P NATL ACAD SCI USA, V97, P5824, DOI 10.1073/pnas.100460897; INO H, 1994, BRAIN RES, V661, P196, DOI 10.1016/0006-8993(94)91197-5; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Lee KY, 1999, NEUROSCI RES, V34, P21, DOI 10.1016/S0168-0102(99)00026-7; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, NEUROBIOL AGING, V16, P263, DOI 10.1016/0197-4580(95)00014-6; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MorishimaKawashima M, 1996, MOL BIOL CELL, V7, P893, DOI 10.1091/mbc.7.6.893; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; NLKOLIC M, 1996, GENE DEV, V10, P816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; PADILLA R, 1990, MOL CELL BIOCHEM, V97, P35; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; Paudel HK, 1997, J BIOL CHEM, V272, P1777; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; SOBUE K, 1981, FEBS LETT, V132, P137, DOI 10.1016/0014-5793(81)80447-4; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Sun DM, 1996, J BIOL CHEM, V271, P14245, DOI 10.1074/jbc.271.24.14245; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VALLEE RB, 1981, J CELL BIOL, V90, P568, DOI 10.1083/jcb.90.3.568; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	50	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16673	16680		10.1074/jbc.M000784200	http://dx.doi.org/10.1074/jbc.M000784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10749861	hybrid			2022-12-27	WOS:000087392200040
J	Wilde, C; Genth, H; Aktories, K; Just, I				Wilde, C; Genth, H; Aktories, K; Just, I			Recognition of RhoA by Clostridium botulinum C3 exoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLTRANSFERASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GENE-PRODUCT; PROTEINS; TOXIN; BINDING; PURIFICATION; RIBOSYLATION; GTPASE	The C3-like ADP-ribosyltransferases exhibit a very confined substrate specificity compared with other Rho-modifying bacterial toxins; they selectively modify the RhoA -B, and -C isoforms but not other members of the Rho or Ras subfamilies. In this study, the amino acid residues involved in the RhoA substrate recognition by C3 from Clostridium botulinum are identified by applying mutational analyses of the nonsubstrate Rac. First, the minimum domain responsible for the recognition by C3 was identified as the N-terminal 90 residues. Second, the combination of the N-terminal basic amino acids ((Rho)Arg(5)-Lys(6)), the acid residues (Rho)Glu(47) and (Rho)GlU(54) only slightly increases ADP-ribosylation but fully restores the binding of the respective mutant Rac to C3. Third, the residues (Rho)GlU(40) and (Rho)Val(43) also participate in binding to C3 but they are mainly involved in the correct formation of the ternary complex between Rho, C3, and NAD(+). Thus, these six residues (Arg(5), Lys(6), Glu(40), Val(43), Glu(47), and Glu(54)) distributed over the N-terminal part of Rho are involved in the correct binding of Rho to C3. Mutant Rac harboring these residues shows a kinetic property with regard to ADP-ribosylation, which is identical with that of RhoA. Differences in the conformation of Rho given by the nucleotide occupancy have only minor effects on ADP-ribosylation.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Just, I (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.		Genth, Harald/HHS-0118-2022; Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Amano M, 1998, TRENDS CARDIOVAS MED, V8, P162, DOI 10.1016/S1050-1738(97)00145-X; AULLO P, 1993, EMBO J, V12, P921, DOI 10.1002/j.1460-2075.1993.tb05733.x; Bae CD, 1998, J BIOL CHEM, V273, P11596, DOI 10.1074/jbc.273.19.11596; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; INOUE S, 1991, BIOCHEM BIOPH RES CO, V174, P459, DOI 10.1016/0006-291X(91)91438-I; JUST I, 1993, BIOCHEM PHARMACOL, V45, P1409, DOI 10.1016/0006-2952(93)90039-Y; JUST I, 1995, BIOCHEMISTRY-US, V34, P334, DOI 10.1021/bi00001a041; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MORIISHI K, 1993, INFECT IMMUN, V61, P5309, DOI 10.1128/IAI.61.12.5309-5314.1993; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pal E.F., 1989, NATURE, V341, P209; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; POPOFF M, 1990, NUCLEIC ACIDS RES, V18, P1291, DOI 10.1093/nar/18.5.1291; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	33	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16478	16483		10.1074/jbc.M910362199	http://dx.doi.org/10.1074/jbc.M910362199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748216	hybrid			2022-12-27	WOS:000087392200013
J	Cuvillier, O; Edsall, L; Spiegel, S				Cuvillier, O; Edsall, L; Spiegel, S			Involvement of sphingosine in mitochondria-dependent Fas-induced apoptosis of type II Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERAMIDE-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; DAMAGE-INDUCED APOPTOSIS; ACIDIC SPHINGOMYELINASE; MEDIATED APOPTOSIS; CD95 FAS/APO-1; LEUKEMIA CELLS; PROTEASE ACTIVATION; CASPASE ACTIVATION; SIGNALING PATHWAYS	Exposure to anti-Fas antibody in Jurkat cells (type II cells), which are characterized by a weak caspase-8 activation at the death-inducing signaling complex (DISC), induced a biphasic increase in ceramide levels. The early generation of ceramide preceded transient activation of acidic ceramidase and subsequent production of sphingosine, followed by cytochrome c release, activation of caspases-2, -3, -6, -7, -8, and -9, Bid cleavage, and a later sustained ceramide accumulation. The caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone inhibited early increases of ceramide and sphingosine, whereas overexpression of Bcl-x(L), had no effect, and both prevented the later sustained ceramide accumulation. Exogenous sphingosine, as well as cell-permeable C-2-ceramide, induced cytochrome c release from mitochondria in a caspase-independent fashion leading to activation of caspase-9 and executioner caspases and, surprisingly, activation of the initiator caspase-8 and processing of its substrate Bid. These effects were also completely abolished by Bcl-x(L) overexpression. Our results suggest that sphingosine might also be involved in the mitochondria-mediated pathway of Fas-induced cell death in type II cells.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Spiegel, S (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 353 Basic Sci Bldg,3900 Reservoir Rd NW, Washington, DC 20007 USA.	spiegel@bc.georgetown.edu	CUVILLIER, Olivier/S-1631-2019; CUVILLIER, Olivier/B-2567-2009	CUVILLIER, Olivier/0000-0003-3346-375X; CUVILLIER, Olivier/0000-0003-3346-375X	NIGMS NIH HHS [GM3880] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Cuvillier O, 1999, BLOOD, V94, P3583, DOI 10.1182/blood.V94.10.3583.422k31_3583_3592; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Edsall LC, 1997, J NEUROSCI, V17, P6952; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; Fulda S, 1998, CANCER RES, V58, P4453; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Gamen S, 1998, CELL DEATH DIFFER, V5, P241, DOI 10.1038/sj.cdd.4400344; Gamen S, 1996, FEBS LETT, V390, P233, DOI 10.1016/0014-5793(96)00666-7; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; Genestier L, 1998, J BIOL CHEM, V273, P5060, DOI 10.1074/jbc.273.9.5060; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; Hung WC, 1999, BIOCHEM J, V338, P161, DOI 10.1042/0264-6021:3380161; Jaffrezou JP, 1998, FASEB J, V12, P999, DOI 10.1096/fasebj.12.11.999; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; Kawahara A, 1998, ONCOGENE, V17, P2549, DOI 10.1038/sj.onc.1202192; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kleuser B, 1998, CANCER RES, V58, P1817; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; Lepple-Wienhues A, 1999, P NATL ACAD SCI USA, V96, P13795, DOI 10.1073/pnas.96.24.13795; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEMON SA, 1995, J IMMUNOL, V155, P4644; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Redondo C, 1996, J CLIN INVEST, V98, P1245, DOI 10.1172/JCI118908; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shirahama T, 1997, FEBS LETT, V407, P97, DOI 10.1016/S0014-5793(97)00304-9; Sillence DJ, 1997, BIOCHEM J, V324, P29, DOI 10.1042/bj3240029; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Sweeney EA, 1998, FEBS LETT, V425, P61, DOI 10.1016/S0014-5793(98)00198-7; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tohyama J, 1999, J INHERIT METAB DIS, V22, P649, DOI 10.1023/A:1005590316064; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Villunger A, 1997, CANCER RES, V57, P3331; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	95	148	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15691	15700		10.1074/jbc.M000280200	http://dx.doi.org/10.1074/jbc.M000280200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747891	hybrid			2022-12-27	WOS:000087291400015
J	Heeneman, S; Haendeler, J; Saito, Y; Ishida, M; Berk, BC				Heeneman, S; Haendeler, J; Saito, Y; Ishida, M; Berk, BC			Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor - Key role for the p66 adaptor protein Shc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; MAP KINASE ACTIVATION; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; EGF RECEPTOR; C-SRC; CELLS; PROLIFERATION; EXPRESSION; INHIBITOR	Several signal transduction events induced by angiotensin II (AngII) binding to the angiotensin II type 1 receptor resemble those evoked by platelet-derived growth factor (PDGF) binding to the PDGF-beta receptor (PDGF beta-R), We report here, in agreement with previous data, that AngII and PDGF-B-chain homodimer (PDGF-BB) stimulate tyrosine phosphorylation of the PDGF beta-R. Both AngII and PDGF-BB stimulated the phosphorylation of PDGF beta-R via the binding of tyrosine-phosphorylated Shc to PDGF beta-R, Both PDGF-BB and AngII-induced phosphorylation of the Shc PDGF beta-R complex was inhibited by antioxidants such as N-acetylcysteine and Tiron, but not by calcium chelation, However, transactivation of PDGF beta-R by AngII (measured by PDGF beta-R tyrosine phosphorylation) differed significantly from PDGF-BB. Evidence to support different mechanisms of PDGF beta-R phosphorylation includes differences in the time course of PDGFP-R phosphorylation, differing effects of inhibitors of the endogenous PDGF beta-R tyrosine kinase and Src family tyrosine kinases, differing results when the PDGFP-R was directly immunoprecipitated (PDGF beta-R-antibody) versus coimmunoprecipitated (Shc-antibody), and cell fractionation studies that suggested that the Shc PDGF beta-R complexes phosphorylated by AngII and PDGF-BB were located in separate subcellular compartments. These studies are the first to suggest that transactivation of tyrosine kinase receptors by G protein-coupled receptors involves a unique pathway that regulates a population of tyrosine kinase receptors different from the endogenous tyrosine kinase ligand.	Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA	University of Rochester	Berk, BC (corresponding author), Univ Rochester, Cardiovasc Res Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.			Berk, Bradford/0000-0002-2767-4115; Haendeler, Judith/0000-0001-8507-4540	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049192] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL59975, R01 HL49192] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Balla T, 1998, ENDOCR RES, V24, P335, DOI 10.3109/07435809809032613; BERK BC, 1986, SCIENCE, V232, P87, DOI 10.1126/science.3485309; BERNSTEIN KE, 1993, AM J KIDNEY DIS, V22, P745, DOI 10.1016/S0272-6386(12)80441-0; Brown MR, 1999, CIRC RES, V85, P524, DOI 10.1161/01.RES.85.6.524; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DIXON BS, 1994, AM J PHYSIOL, V266, pC1406, DOI 10.1152/ajpcell.1994.266.5.C1406; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FLUCK M, 1995, BIOCHEM BIOPH RES CO, V213, P273, DOI 10.1006/bbrc.1995.2126; Griendling KK, 1998, J LAB CLIN MED, V132, P9, DOI 10.1016/S0022-2143(98)90019-1; Griendling KK, 1999, CIRC RES, V85, P562, DOI 10.1161/01.RES.85.6.562; Griendling KK, 1997, HYPERTENSION, V29, P366, DOI 10.1161/01.HYP.29.1.366; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Ishida M, 1998, CIRC RES, V82, P7; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; KOVLENKO M, 1997, BIOCHEMISTRY-US, V36, P6260; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Moriguchi Y, 1999, CIRC RES, V84, P1073, DOI 10.1161/01.RES.84.9.1073; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; OLIVERIO MI, 1997, AM J PHYSIOL, V272, pF516; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; SUDGEN PH, 1997, CELL SIGNAL, V9, P337; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tsai JC, 1996, J BIOL CHEM, V271, P3667; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Waltenberger J, 1999, CIRC RES, V85, P12; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033	41	137	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15926	15932		10.1074/jbc.M909616199	http://dx.doi.org/10.1074/jbc.M909616199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748142	hybrid			2022-12-27	WOS:000087291400044
J	Mora, S; Pessin, JE				Mora, S; Pessin, JE			The MEF2A isoform is required for striated muscle-specific expression of the insulin-responsive GLUT4, glucose transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MEF2; HELIX-LOOP-HELIX; SKELETAL-MUSCLE; ENHANCER FACTOR-2; CONTRACTILE ACTIVITY; MEDIATES REPRESSION; GENE-EXPRESSION; TRANSGENIC MICE; PROTEIN; ACTIVATION	Previously, we have demonstrated that an MEF2 consensus sequence located between -473/-464 in the human GLUT4 gene was essential for both tissue-specific and hormonal/metabolic regulation of GLUT4 expression (Thai, M. V., Guruswamy, S., Cao, K. T., Pessin, J. E., and Olson, A. L. (1998) J. Biol. Chem. 273, 14285-14292). To identify the specific MEF2 isoform(s) responsible for GLUT4 expression, we studied the pattern of expression of the MEF2 isoforms in insulin-sensitive tissues. Both heart and skeletal muscle were found to express the MEF2A, MEF2C, and MEF2D isoforms but not MEF2B. However, only the MEF2A protein was selectively downregulated in insulin-deficient diabetes. Co-immunoprecipitation with isoform-specific antibodies revealed that, in the basal state, essentially all of the MEF2A protein was presented as a MEF2A-MEF2D heterodimer without any detectable MEF2A-MEF2A homodimers or MEF2A-MEF2C and MEF2C-MEF2D heterodimers. Electrophoretic mobility shift assays revealed that nuclear extracts from diabetic animals had reduced binding to the MEF2 binding site compared with extracts from control or insulin-treated animals. Furthermore, immunodepletion of the MEF2A-MEF2D complex from control extracts abolished binding to the MEF2 element. However, addition of MEF2A to diabetic nuclear extracts fully restored binding activity to the MEF2 element. These data strongly suggest that the MEF2A-MEF2D heterodimer is selectively decreased in insulin-deficient diabetes and is responsible for hormonally regulated expression of the GLUT4 gene.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, 51 Newton Rd, Iowa City, IA 52242 USA.		Mora, Silvia/Y-3131-2019	Mora, Silvia/0000-0002-8473-1497	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R37DK033823, R01DK033823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295, DK33823] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; BOUREY RE, 1990, J CLIN INVEST, V86, P542, DOI 10.1172/JCI114742; BRAND N, 1997, INT J BIOCHEM CELL B, V12, P1467; Brand-Saberi B, 1999, CELL TISSUE RES, V296, P199, DOI 10.1007/s004410051281; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CASTELLO A, 1993, J BIOL CHEM, V268, P14998; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; Cooke DW, 1998, J BIOL CHEM, V273, P6210, DOI 10.1074/jbc.273.11.6210; Cripps RM, 1998, GENE DEV, V12, P422, DOI 10.1101/gad.12.3.422; De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; GARVEY WT, 1992, DIABETES CARE, V15, P396, DOI 10.2337/diacare.15.3.396; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kawanaka K, 1996, HORM METAB RES, V28, P75, DOI 10.1055/s-2007-979132; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LIU ML, 1994, J BIOL CHEM, V269, P28514; Martin Sally, 1999, Cell Biochemistry and Biophysics, V30, P89, DOI 10.1007/BF02737886; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Morisaki T, 1997, J BIOCHEM-TOKYO, V122, P939, DOI 10.1093/oxfordjournals.jbchem.a021855; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NEUFER PD, 1993, J BIOL CHEM, V268, P13824; OLSON AL, 1994, ENDOCRINOLOGY, V134, P271, DOI 10.1210/en.134.1.271; OLSON AL, 1995, ENDOCRINOLOGY, V136, P1962, DOI 10.1210/en.136.5.1962; Ornatsky OI, 1997, J BIOL CHEM, V272, P33271, DOI 10.1074/jbc.272.52.33271; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; REN JM, 1994, J BIOL CHEM, V269, P14396; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; STDENIS S, 1998, J BASIC CLIN PHYSL P, V9, P153; SUZUKI E, 1995, MOL CELL BIOL, V15, P3415; TAEHEE H, 1995, MOL CELL BIOL, V15, P2907; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; Tsunoda N, 1997, BIOCHEM BIOPH RES CO, V239, P503, DOI 10.1006/bbrc.1997.7516; Yang SH, 1999, MOL CELL BIOL, V19, P4028; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zorzano A, 1996, DIABETES, V45, pS70, DOI 10.2337/diab.45.1.S70	45	90	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16323	16328		10.1074/jbc.M910259199	http://dx.doi.org/10.1074/jbc.M910259199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748204	hybrid, Green Published			2022-12-27	WOS:000087291400097
J	Chen, A; Wu, K; Fuchs, SY; Tan, P; Gomez, C; Pan, ZQ				Chen, A; Wu, K; Fuchs, SY; Tan, P; Gomez, C; Pan, ZQ			The conserved RING-H2 finger of ROC1 is required for ubiquitin ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; CULLIN PARTNERS; LIGASE ACTIVITY; COMPLEX; E3; CDC53; RBX1; SCF; COMPONENT; BINDING	ROC1 is a common component of a large family of ubiquitin E3 ligases that regulate cell cycle progression and signal transduction pathways. Here we present evidence suggesting that a conserved RING-H2 structure within ROC1 is critical for its ubiquitin ligation function. Mercury-containing sulfhydryl modification agents (rho-hydroxymercuribenzoate and mercuric chloride) irreversibly inhibit the ROC1-CUL1 ubiquitin ligase activity without disrupting the complex. Consistent with this, these reagents also eliminate the ability of the Skp1-CUL1-HOS-ROC1 E3 ligase complex to support the ubiquitination of I kappa B alpha. Site-directed mutagenesis analysis identifies RING-H2 finger residues Cys(42), Cys(45), Cys(75), His(77), His(80), Cys(83), Cys(94), and Asp(97) as being essential for the ROC1-dependent ubiquitin ligase activity, Furthermore, C42S/C45S and H80A mutations reduce the ability of ROC1 to interact with CULT in transfected cells and diminish the capacity of ROC1-CUL1 to form a stable complex with Cdc34 in vitro. However, C75S, H77A, C94S, and D97A substitutions have no detectable effect on ROC1 binding activities. Thus, the ROC1 RING-H2 finger may possess multiple biochemical properties that include stabilizing an interaction with CUL1 and recruiting Cdc34, A possible role of the RING finger in facilitating the Ub transfer reaction is discussed.	Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Pan, ZQ (corresponding author), Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA.				NIGMS NIH HHS [GM55059] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Ohta T, 1999, ONCOGENE, V18, P6758, DOI 10.1038/sj.onc.1203115; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; PETERS JM, 1998, UBIQUITIN BIOL CELL, P345; Riordan J F, 1972, Methods Enzymol, V25, P449, DOI 10.1016/S0076-6879(72)25040-6; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832	22	56	56	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15432	15439		10.1074/jbc.M907300199	http://dx.doi.org/10.1074/jbc.M907300199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748083	hybrid			2022-12-27	WOS:000087128300089
J	Pugazhenthi, S; Nesterova, A; Sable, C; Heidenreich, KA; Boxer, LM; Heasley, LE; Reusch, JEB				Pugazhenthi, S; Nesterova, A; Sable, C; Heidenreich, KA; Boxer, LM; Heasley, LE; Reusch, JEB			Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; C-AKT; ACTIVATION; SURVIVAL; CREB; PHOSPHORYLATION; APOPTOSIS; TRANSLOCATION; RECEPTOR; SIGNALS	In our previous study we showed that insulin-like growth factor-I induces a cAMP-response element (CRE) site-containing Bcl-2 promoter through a novel signaling pathway involving mitogen-activated protein kinase kinase 6/p38 beta mitogen-activated protein kinase/MAP kinase-activated protein kinase-3/cAMP-response element-binding protein (CREB) (Pugazhenthi, S., Miller, E., Sable, C., Young, P., Heidenreich, K. A., Boxer, L. M., and Reusch, J. E.-B. (1999) J. Biol. Chem. 274, 27529-27535), In the present investigation, we define a second pathway contributing to CREB-dependent up-regulation of Bcl-2 expression as a novel anti-apoptotic function of Akt signaling. To examine the role of Akt on Bcl-2 expression, a series of transient transfections using a luciferase reporter gene driven by the promoter region of Bcl-2 containing a CRE were carried out. Pharmacological inhibition of phosphatidylinositol (PI) 3-kinase, the upstream kinase of Akt, with LY294002 led to a 45% decrease in Bcl-2 promoter activity. The reporter activity was enhanced 2.3-fold by overexpression of active p110 subunit of PI 3-kinase and inhibited 44% by the dominant negative p85 subunit of PI 3-kinase, Cotransfection with 3-phosphoinositide-dependent kinase (PDK1), which is required for the full activation of Akt, resulted in enhanced luciferase activity. Insulin-like growth factor-I-mediated induction of Bcl-2 promoter activity was decreased significantly (p < 0.01) by the dominant negative forms of p85 subunit of PI 3-kinase, PDK1, and Akt, These data indicate that regulation of Bcl-2 expression by IGF-I involves a signaling cascade mediated by PI 3-kinase/PDK1/Akt/CREB. Furthermore, we measured the Bcl-2 mRNA in PC12 cells overexpressing Akt by real-time quantitative reverse transcription-polymerase chain reaction using the TaqMan(TM) fluorogenic probe system. We observed a 2.1-fold increase in Bcl-2 mRNA levels in the Akt cell line compared with control PC12 cells, supporting the observation that enhanced CREB activity by Akt signaling leads to increased Bcl-2 promoter activity and cell survival.	Vet Affairs Med Ctr, Sect Endocrinol 111H, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Endocrinol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Stanford University	Reusch, JEB (corresponding author), Vet Affairs Med Ctr, Sect Endocrinol 111H, 1055 Clermont St, Denver, CO 80220 USA.			Reusch, Jane/0000-0001-8620-1003	NIDDK NIH HHS [K08 DK 02351] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002351] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AHMED NN, 1993, ONCOGENE, V8, P1957; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Barthel A, 1997, ENDOCRINOLOGY, V138, P3559, DOI 10.1210/en.138.8.3559; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Minshall C, 1997, J IMMUNOL, V159, P1225; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Shimoke K, 1998, FEBS LETT, V437, P221, DOI 10.1016/S0014-5793(98)01235-6; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	37	676	698	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10761	10766		10.1074/jbc.275.15.10761	http://dx.doi.org/10.1074/jbc.275.15.10761			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753867	hybrid			2022-12-27	WOS:000086466600009
J	Zhang, F; Zhang, WD; Liu, L; Fisher, CL; Hui, D; Childs, S; Dorovini-Zis, K; Ling, V				Zhang, F; Zhang, WD; Liu, L; Fisher, CL; Hui, D; Childs, S; Dorovini-Zis, K; Ling, V			Characterization of ABCB9, an ATP binding cassette protein associated with lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL MEMBRANE-PROTEIN; P-GLYCOPROTEIN; TRANSPORTER; GENE; SEQUENCE; IDENTIFICATION; CELLS; PURIFICATION; SUPERFAMILY; EXPRESSION	We have cloned full-length human and mouse cDNAs of ABCB9, which encodes a predicted multiple-spanning transmembrane domain and a nucleotide binding domain with Walker motifs. It is therefore designated as a "half " ATP binding cassette (ABC) transporter. Northern analysis shows that the ABCB9 mRNA is expressed at a high level in testes and moderate levels in brain and spinal cord. A splice variant mRNA deleted in the last pair of predicted transmembrane segments was shown to be expressed in human tissues. Phylogenetic analysis indicates that ABCB9 is closely related to TAP1 and TAPE, two "half " ABC proteins found in endoplasmic reticulum. ABCB9 protein colocalized with the lysosomal markers, LAMP1 and LAMP2, in transfected cells. ABCB9 protein appears to be most highly expressed in the Sertoli cells of the seminiferous tubules in mouse and rat testes. These cells have high levels of phagocytosis and secretory activities. These findings pave the way for further investigation into the potential novel function of ABCB9 in lysosomes.	Univ British Columbia, British Columbia Canc Agcy, British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Vancouver Gen Hosp, Dept Pathol, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia	Ling, V (corresponding author), Univ British Columbia, British Columbia Canc Agcy, British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada.	vling@bccancer.bc.ca	Childs, Sarah/AAG-5111-2021	Zhang, Wandong/0000-0001-6412-8124; Childs, Sarah/0000-0003-2261-580X; Fisher, Cynthia/0000-0001-6089-4868				Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Childs S, 1998, CANCER RES, V58, P4160; CHILDS S, 1994, IMPARTANT ADV ONCOLO, V2, P21; Clermont Y., 1993, SERTOLI CELL, pxxi; CLOROS M, 1994, COMPUT APPL BIOSCI, V10, P685; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Harlow E., 1988, ANTIBODIES LAB MANUA; Havelaar AC, 1998, FEBS LETT, V436, P223, DOI 10.1016/S0014-5793(98)01133-8; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hogue DL, 1999, J MOL BIOL, V285, P379, DOI 10.1006/jmbi.1998.2259; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V237, P152, DOI 10.1006/bbrc.1997.7102; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V239, P261, DOI 10.1006/bbrc.1997.7391; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; JURANKA P, 1992, J BIOL CHEM, V267, P3764; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; Linstedt AD, 1997, MOL BIOL CELL, V8, P1073, DOI 10.1091/mbc.8.6.1073; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MORALES C, 1986, BIOL REPROD, V34, P207, DOI 10.1095/biolreprod34.1.207; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; RIORDAN JR, 1989, SCIENCE, V245, P1066; Saint-Pol A, 1999, J BIOL CHEM, V274, P13547, DOI 10.1074/jbc.274.19.13547; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Swofford D.L., 1999, PAUP PHYLOGENETIC AN; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; Yamaguchi Y, 1999, FEBS LETT, V457, P231, DOI 10.1016/S0014-5793(99)01042-X	35	82	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23287	23294		10.1074/jbc.M001819200	http://dx.doi.org/10.1074/jbc.M001819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10748049	hybrid			2022-12-27	WOS:000088419400095
J	Buckner, FS; Yokoyama, K; Nguyen, L; Grewal, A; Erdjument-Bromage, H; Tempst, P; Strickland, CL; Xiao, L; Van Voorhis, WC; Gelb, MH				Buckner, FS; Yokoyama, K; Nguyen, L; Grewal, A; Erdjument-Bromage, H; Tempst, P; Strickland, CL; Xiao, L; Van Voorhis, WC; Gelb, MH			Cloning, heterologous expression, and distinct substrate specificity of protein farnesyltransferase from Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYLTRANSFERASE-I; CRYSTAL-STRUCTURE; PRENYLATION; INHIBITORS; PURIFICATION; PRENYLTRANSFERASES; ISOPRENYLATION; TRANSFERASE; TARGET; GROWTH	Protein prenylation occurs in the protozoan that causes African sleeping sickness (Trypanosoma brucei), and the protein farnesyltransferase appears to be a good target for developing drugs. We have cloned the alpha- and beta-subunits of T. brucei protein farnesyltransferase (TB-PFT) using nucleic acid probes designed from partial amino acid sequences obtained from the enzyme purified from insect stage parasites. TB-PFT is expressed in both bloodstream and insect stage parasites. Enzymatically active TB-PFT was produced by heterologous expression in Escherichia coli, Compared with mammalian protein farnesyltransferases, TB-PFT contains a number of inserts of >25 residues in both subunits that reside on the surface of the enzyme in turns linking adjacent alpha-helices, Substrate specificity studies with a series of 20 peptides SSCALX (where X indicates a naturally occurring amino acid) show that the recombinant enzyme behaves identically to the native enzyme and displays distinct specificity compared with mammalian protein farnesyltransferase. TB-PFT prefers Gin and Met at the X position but not Ser, Thr, or Cys, which are good substrates for mammalian protein farnesyltransferase, A structural homology model of the active site of TB-PFT provides a basis for understanding structure-activity relations among substrates and CAAX mimetic inhibitors.	Univ Washington, Dept Biochem & Chem, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Schering Plough Corp, Res Inst, Dept Struct Chem, Kenilworth, NJ 07033 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Memorial Sloan Kettering Cancer Center; Merck & Company; Schering Plough Corporation	Gelb, MH (corresponding author), Univ Washington, Dept Biochem & Chem, Seattle, WA 98195 USA.		Buckner, Frederick/AAF-3938-2020	Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Buckner, Frederick/0000-0001-7796-6477; gelb, michael/0000-0001-7000-5219	NCI NIH HHS [P30 CA008748, P30 CA08748, R01 CA052874-12, CA52874] Funding Source: Medline; NIAID NIH HHS [AI43062, R01 AI043062, U01 AI043062] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052874, P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043062, U01AI043062] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; Field H, 1996, MOL BIOCHEM PARASIT, V82, P67, DOI 10.1016/0166-6851(96)02723-5; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; Koblan KS, 1996, BIOCHEM SOC T, V24, P688, DOI 10.1042/bst0240688; KROLL DJ, 1993, DNA CELL BIOL, V12, P441, DOI 10.1089/dna.1993.12.441; Leonard DM, 1997, J MED CHEM, V40, P2971, DOI 10.1021/jm970226l; Long SB, 1998, BIOCHEMISTRY-US, V37, P9612, DOI 10.1021/bi980708e; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; Njoroge FG, 1997, BIOORGAN MED CHEM, V5, P101, DOI 10.1016/S0968-0896(96)00206-4; OMER CA, 1995, METHOD ENZYMOL, V250, P3; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Sambrook J., 2002, MOL CLONING LAB MANU; Sanchez R, 1997, CURR OPIN STRUC BIOL, V7, P206, DOI 10.1016/S0959-440X(97)80027-9; Strickland CL, 1998, BIOCHEMISTRY-US, V37, P16601, DOI 10.1021/bi981197z; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; Weston D, 1999, MOL BIOCHEM PARASIT, V98, P105, DOI 10.1016/S0166-6851(98)00152-2; Yokoyama K, 1997, MOL BIOCHEM PARASIT, V87, P61, DOI 10.1016/S0166-6851(97)00043-1; Yokoyama K, 1998, J BIOL CHEM, V273, P26497, DOI 10.1074/jbc.273.41.26497; Yokoyama K, 1997, J BIOL CHEM, V272, P3944, DOI 10.1074/jbc.272.7.3944; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; Yokoyama K, 1998, MOL BIOCHEM PARASIT, V94, P87, DOI 10.1016/S0166-6851(98)00053-X; YOKOYAMA K, 1992, BIOCHEM SOC T, V20, P479	29	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21870	21876		10.1074/jbc.M000975200	http://dx.doi.org/10.1074/jbc.M000975200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10749864	Green Accepted, hybrid			2022-12-27	WOS:000088363800018
J	Radominska-Pandya, A; Chen, GP; Czernik, PJ; Little, JM; Samokyszyn, VM; Carter, CA; Nowak, G				Radominska-Pandya, A; Chen, GP; Czernik, PJ; Little, JM; Samokyszyn, VM; Carter, CA; Nowak, G			Direct interaction of all-trans-retinoic acid with protein kinase C (PKC) - Implications for PKC signaling and cancer therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; MOUSE-BRAIN; PHOSPHOLIPID-BINDING; CRYSTAL-STRUCTURE; VITAMIN-A; CELLS; ALPHA; DIFFERENTIATION; TRANSDUCTION; EXPRESSION	Protein kinase C (PKC) regulates fundamental cellular functions including proliferation, differentiation, tumorigenesis, and apoptosis. All-trans-retinoic acid (atRA) modulates PKC activity, but the mechanism of this regulation is unknown. Amino acid alignments and crystal structure analysis of retinoic acid (RA)-binding proteins revealed a putative atRA-binding motif in PKC, suggesting existence of an atRA binding site on the PKC molecule. This was supported by photolabeling studies showing concentration- and UV-dependent photoincorporation of [H-3]atRA into PKC alpha, which was effectively protected by 4-OH-atRA, 9-cis-RA, and atRA glucuronide, but not by retinol, Photoaffinity labeling demonstrated strong competition between atRA and phosphatidylserine (PS) for binding to PKC alpha, a slight competition with phorbol-12-myristate-13-acetate, and none with diacylglycerol, fatty acids, or Ca2+. At pharmacological concentrations (10 mu M), atRA decreased PKC alpha activity through the competition with PS but not phorbol-12-myristate-13-acetate, diacylglycerol, or Ca2+. These results let us hypothesize that in vivo, pharmacological concentrations of atRA may hamper binding of PS to PKC alpha and prevent PKC alpha activation. Thus, this study provides the first evidence for direct binding of atRA to PKC isozymes and suggests the existence of a general mechanism for regulation of PKC activity during exposure to retinoids, as in retinoid-based cancer therapy.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol Pharmacol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Toxicol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Obstet & Gynecol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Pharmaceut Sci, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Radominska-Pandya, A (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol Pharmacol, 4301 W Markham,Slot 516, Little Rock, AR 72205 USA.		Carter, Charleata A./H-3230-2019	Carter, Charleata/0000-0001-6981-6583	NIDDK NIH HHS [DK49715, DK51791] Funding Source: Medline; NIEHS NIH HHS [ES06765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051791, R01DK049715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES006765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ATHAR M, 1991, CARCINOGENESIS, V12, P2325, DOI 10.1093/carcin/12.12.2325; Bell R M, 1986, Methods Enzymol, V124, P353; BERNSTEIN PS, 1995, P NATL ACAD SCI USA, V92, P654, DOI 10.1073/pnas.92.3.654; BRACKE ME, 1991, BRIT J CANCER, V63, P867, DOI 10.1038/bjc.1991.191; Budd GT, 1998, CLIN CANCER RES, V4, P635; Carter CA, 1998, PATHOBIOLOGY, V66, P284, DOI 10.1159/000028035; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; Cho YH, 1997, J CELL PHYSIOL, V172, P306, DOI 10.1002/(SICI)1097-4652(199709)172:3<306::AID-JCP4>3.0.CO;2-S; COPE FO, 1984, BIOCHEM BIOPH RES CO, V120, P593, DOI 10.1016/0006-291X(84)91296-8; COPE FO, 1986, EXPERIENTIA, V42, P1023, DOI 10.1007/BF01940716; COPE FO, 1986, CANCER LETT, V30, P275, DOI 10.1016/0304-3835(86)90052-2; DE LUCA LM, 1991, FASEB J, V5, P2924; DE LUCA LM, 1994, NUTR REV, V52, P45; DULANEY AM, 1993, ANN PHARMACOTHER, V27, P211, DOI 10.1177/106002809302700217; FONTANA JA, 1986, CANCER RES, V46, P2468; *GEN COMP GROUP, WISC PACK VERS 10 0; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; GUNDIMEDA U, 1993, ARCH BIOCHEM BIOPHYS, V300, P526, DOI 10.1006/abbi.1993.1072; HENDRIX MJ, 1990, CANCER RES, V46, P4121; Hsu SL, 1999, EXP CELL RES, V248, P87, DOI 10.1006/excr.1999.4397; ISAKOV N, 1988, CELL IMMUNOL, V115, P288, DOI 10.1016/0008-8749(88)90182-7; KAHLRAINER P, 1994, NUTR CANCER, V21, P157, DOI 10.1080/01635589409514313; KLEYWEGT GJ, 1994, STRUCTURE, V2, P1241, DOI 10.1016/S0969-2126(94)00125-1; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MUINDI JRF, 1992, CANCER RES, V52, P2138; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NINOMIYA M, 1986, BIOCHEM BIOPH RES CO, V138, P330, DOI 10.1016/0006-291X(86)90284-6; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NISHIZUKA Y, 1988, Biofactors, V1, P17; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Radominska-Pandya A, 1999, DRUG METAB REV, V31, P817, DOI 10.1081/DMR-100101944; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; SHKLAR G, 1980, ORAL SURG ORAL MED O, V50, P45, DOI 10.1016/0030-4220(80)90330-8; Srivastava RK, 1999, ONCOGENE, V18, P1755, DOI 10.1038/sj.onc.1202464; STEELE VE, 1990, CANCER RES, V50, P2068; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; THOMPSON JR, 1995, J MOL BIOL, V252, P433, DOI 10.1006/jmbi.1995.0509; TONINI GP, 1991, FEBS LETT, V280, P221, DOI 10.1016/0014-5793(91)80297-G	47	89	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22324	22330		10.1074/jbc.M907722199	http://dx.doi.org/10.1074/jbc.M907722199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10748087	hybrid			2022-12-27	WOS:000088363800078
J	Faber, C; Sticht, H; Schweimer, K; Rosch, P				Faber, C; Sticht, H; Schweimer, K; Rosch, P			Structural rearrangements of HIV-1 Tat-responsive RNA upon binding of neomycin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							16S RIBOSOMAL-RNA; ANTIBIOTIC INHIBITION; CATIONIC ANTIBIOTICS; HAMMERHEAD RIBOZYME; CRYSTAL-STRUCTURE; HIGH-AFFINITY; A-SITE; PROTEIN; COMPLEX; RECOGNITION	finding of human immunodeficiency virus type 1 (HIV-I) transactivator (Tat) protein to Tat-responsive RNA (TAR) is essential for viral replication and is considered a promising starting point for the design of anti-HIV drugs. NMR spectroscopy indicated that the aminoglycosides neomycin B and ribostamycin bind to TAR and that neomycin is able to inhibit Tat binding to TAR. The solution structure of the neomycin-bound TAR has been determined by NMR spectroscopy. Chemical shift mapping and intermolecular nuclear Overhauser effects define the binding region of the aminoglycosides on TAR and give strong evidence for minor groove binding. Based on 15 nuclear Overhauser effect-derived intermolecular distance restraints, a model structure of the TAR-neomycin complex was calculated. Neomycin is bound in a binding pocket formed by the minor groove of the lower stem and the uridine-rich bulge of TAR, which adopts a conformation different from those known. The neamine core of the aminoglycoside (rings I and II) is covered with the bulge, explaining the inhibition of Tat by an allosteric mechanism. Neomycin reduces the volume of the major groove in which Tat is bound and thus impedes essential protein-RNA contacts.	Univ Bayreuth, Lehrstuhl Biopolymere, D-95447 Bayreuth, Germany	University of Bayreuth	Rosch, P (corresponding author), Univ Bayreuth, Lehrstuhl Biopolymere, D-95447 Bayreuth, Germany.		Faber, Cornelius/Q-2689-2016; Rösch, Paul/I-5445-2014	Faber, Cornelius/0000-0001-7683-7710; Rösch, Paul/0000-0003-3330-2446; Schweimer, Kristian/0000-0002-3837-8442; Sticht, Heinrich/0000-0001-5644-045X				AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974; ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; BRUNGER AT, 1996, X PLOR VERSION 3 851; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CAVANAGH J, 1992, J MAGN RESON, V96, P670, DOI 10.1016/0022-2364(92)90357-D; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; Fourmy D, 1998, J MOL BIOL, V277, P333, DOI 10.1006/jmbi.1997.1551; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; HAMY F, 1993, J MOL BIOL, V230, P111, DOI 10.1006/jmbi.1993.1129; Hermann T, 1999, J MED CHEM, V42, P1250, DOI 10.1021/jm981108g; Hermann T, 1998, J MOL BIOL, V276, P903, DOI 10.1006/jmbi.1997.1590; Hoch I, 1998, J MOL BIOL, V282, P557, DOI 10.1006/jmbi.1998.2035; HOFFMANN S, 1998, THESIS U BAYREUTH; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819; JIANG L, 1997, J CHEM BIOL, V4, P35; Jiang LC, 1999, STRUCTURE, V7, P817, DOI 10.1016/S0969-2126(99)80105-1; Jiang LC, 1998, NAT STRUCT BIOL, V5, P769, DOI 10.1038/1804; Leclerc F, 1998, J MED CHEM, V41, P175, DOI 10.1021/jm970372r; Long KS, 1999, BIOCHEMISTRY-US, V38, P10059, DOI 10.1021/bi990590h; MEI HY, 1995, BIOORG MED CHEM LETT, V5, P2755, DOI 10.1016/0960-894X(95)00467-8; Metzger AU, 1996, FEBS LETT, V384, P255, DOI 10.1016/0014-5793(96)00314-6; Metzger AU, 1997, BIOCHEM BIOPH RES CO, V241, P31, DOI 10.1006/bbrc.1997.7770; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Rogers J, 1996, J MOL BIOL, V259, P916, DOI 10.1006/jmbi.1996.0369; ROSCH P, 1989, BIOCHEMISTRY-US, V28, P4318; Saenger W., 1984, PRINCIPLES NUCL ACID; Seewald MJ, 1998, J BIOMOL STRUCT DYN, V16, P683, DOI 10.1080/07391102.1998.10508280; STAGE TK, 1995, RNA, V1, P95; Varani G, 1996, PROG NUCL MAG RES SP, V29, P51, DOI 10.1016/0079-6565(96)01028-X; VONAHSEN U, 1991, NATURE, V353, P368, DOI 10.1038/353368a0; Wang SH, 1998, BIOCHEMISTRY-US, V37, P5549, DOI 10.1021/bi972808a; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yoshizawa S, 1998, EMBO J, V17, P6437, DOI 10.1093/emboj/17.22.6437; ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B	36	125	133	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20660	20666		10.1074/jbc.M000920200	http://dx.doi.org/10.1074/jbc.M000920200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10747964	hybrid			2022-12-27	WOS:000088084500063
J	Langley, DB; Templeton, MD; Fields, BA; Mitchell, RE; Collyer, CA				Langley, DB; Templeton, MD; Fields, BA; Mitchell, RE; Collyer, CA			Mechanism of inactivation of ornithine transcarbamoylase by N-delta-(N '-sulfodiaminophosphinyl)-L-ornithine, a true transition state analogue? Crystal structure and implications for catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI W; ASPARTATE CARBAMOYLTRANSFERASE; BETA-LACTAMASE; PHASEOLOTOXIN; RESOLUTION; INHIBITORS; N-(PHOSPHONACETYL)-L-ASPARTATE; SPECIFICITY; TRANSPORT; ACID	The crystal structure is reported at 1.8 Angstrom resolution of Escherichia coli ornithine transcarbamoylase in complex with the active derivative of phaseolotoxin from Pseudomonas syringae pv. phaseolicola, N-delta-(N'-sulfodiaminophosphinyl)-L-ornithine. Electron density reveals that the complex is not a covalent adduct as previously thought. Kinetic data confirm that N-delta-(N'-sulfodiaminophosphinyl)-L-ornithine exhibits reversible inhibition with a half-life in the order of similar to 22 h and a dissociation constant of K-D = 1.6 x 10(-12) M at 37 degrees C and pH 8.0. Observed hydrogen bonding about the chiral tetrahedral phosphorus of the inhibitor is consistent only with the presence of the R enantiomer, A strong interaction is also observed between Arg(57) N epsilon and the P-N-S bridging nitrogen indicating that imino tautomers of N-delta-(N'-sulfodiaminophosphinyl)-L-ornithine are present in the bound state. An imino tautomer of N-delta-(N'-sulfodiaminophosphinyl)-L-ornithine is structurally analogous to the proposed reaction transition state. Hence, we propose that N-delta-(N'-sulfodiaminophosphinyl)-L-ornithine, with its three unique N-P bonds, represents a true transition state analogue for ornithine transcarbamoylases, consistent with the tight binding kinetics observed.	Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia; Hort & Food Res Inst New Zealand Ltd, Mt Albert Res Ctr, Auckland 1003, New Zealand	University of Sydney; New Zealand Institute for Plant & Food Research Ltd	Collyer, CA (corresponding author), Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia.		Langley, David B/B-1861-2009; Templeton, Matthew/J-6966-2017	Langley, David B/0000-0003-2752-0041; Templeton, Matthew/0000-0003-0192-9041; Fields, Barry/0000-0003-0628-1328				ARISAWA M, 1983, BIOCHEM J, V209, P609, DOI 10.1042/bj2090609; BENCINI DA, 1983, NUCLEIC ACIDS RES, V11, P8509, DOI 10.1093/nar/11.23.8509; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURFORD N, 1991, J CHEM SOC DALTON, P1615, DOI 10.1039/dt9910001615; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; DEMARTINIS ML, 1981, BIOCHEM INT, V3, P371; FERGUSON AR, 1980, PHYSIOL PLANT PATHOL, V16, P269, DOI 10.1016/0048-4059(80)90041-7; Flohr A, 1999, J MED CHEM, V42, P2633, DOI 10.1021/jm991008q; GOLDSMITH JO, 1991, J BIOL CHEM, V266, P18626; GOUAUX JE, 1987, BIOCHEM BIOPH RES CO, V142, P893; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Ha Y, 1997, P NATL ACAD SCI USA, V94, P9550, DOI 10.1073/pnas.94.18.9550; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; HOOGENRAAD NJ, 1978, ARCH BIOCHEM BIOPHYS, V188, P137, DOI 10.1016/0003-9861(78)90366-1; HOUGHTON JE, 1984, P NATL ACAD SCI-BIOL, V81, P4864, DOI 10.1073/pnas.81.15.4864; Jin L, 1997, NAT STRUCT BIOL, V4, P622, DOI 10.1038/nsb0897-622; KE HM, 1984, P NATL ACAD SCI-BIOL, V81, P4037, DOI 10.1073/pnas.81.13.4037; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KNOTTHUNZIKER V, 1980, BIOCHEM J, V187, P797, DOI 10.1042/bj1870797; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; KUO LC, 1985, BIOCHEMISTRY-US, V24, P4754, DOI 10.1021/bi00339a007; LEGRAIN C, 1977, EUR J BIOCHEM, V80, P401, DOI 10.1111/j.1432-1033.1977.tb11895.x; LEGRAIN C, 1976, EUR J BIOCHEM, V63, P289, DOI 10.1111/j.1432-1033.1976.tb10230.x; MILLER AW, 1990, J BIOL CHEM, V265, P15023; MITCHELL RE, 1977, PLANT PHYSIOL, V60, P723, DOI 10.1104/pp.60.5.723; MITCHELL RE, 1976, NATURE, V260, P75, DOI 10.1038/260075a0; MOORE RE, 1984, TETRAHEDRON LETT, V25, P3931, DOI 10.1016/0040-4039(84)80033-7; Murata LB, 1996, PROTEIN SCI, V5, P709; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Parmentier LE, 1998, BBA-PROTEIN STRUCT M, V1382, P333, DOI 10.1016/S0167-4838(97)00177-5; PARMENTIER LE, 1992, BIOCHEMISTRY-US, V31, P6577, DOI 10.1021/bi00143a030; PENNINCKX M, 1978, FEBS LETT, V88, P94, DOI 10.1016/0014-5793(78)80615-2; RADZICKA A, 1995, METHOD ENZYMOL, V249, P284; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Schramm VL, 1999, METHOD ENZYMOL, V308, P301; Shi DS, 1998, J BIOL CHEM, V273, P34247, DOI 10.1074/jbc.273.51.34247; STALON V, 1984, J GEN MICROBIOL, V130, P69; STASKAWICZ BJ, 1980, J BACTERIOL, V142, P474, DOI 10.1128/JB.142.2.474-479.1980; TEMPLETON MD, 1984, BIOCHEM J, V224, P379, DOI 10.1042/bj2240379; TEMPLETON MD, 1985, BIOCHEM J, V228, P347, DOI 10.1042/bj2280347; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P10762, DOI 10.1073/pnas.92.23.10762; WALDROP GL, 1992, J AM CHEM SOC, V114, P5941, DOI 10.1021/ja00041a006; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Williams J W, 1979, Methods Enzymol, V63, P437; WOLFENDEN R, 1983, SCIENCE, V222, P1087, DOI 10.1126/science.6359416	45	32	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20012	20019		10.1074/jbc.M000585200	http://dx.doi.org/10.1074/jbc.M000585200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10747936	hybrid			2022-12-27	WOS:000087941300079
J	Liu, H; Sugiura, M; Nava, VE; Edsall, LC; Kono, K; Poulton, S; Milstien, S; Kohama, T; Spiegel, S				Liu, H; Sugiura, M; Nava, VE; Edsall, LC; Kono, K; Poulton, S; Milstien, S; Kohama, T; Spiegel, S			Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; PROGRAMMED CELL-DEATH; CALCIUM MOBILIZATION; RECEPTOR EDG-1; GROWTH-FACTORS; SMOOTH-MUSCLE; 2ND MESSENGER; 1-PHOSPHATE; SPHINGOSINE-1-PHOSPHATE; ACTIVATION	Sphingosine-1-phosphate (SPP) has diverse biological functions acting inside cells as a second messenger to regulate proliferation and survival, and extracellularly, as a ligand for G protein-coupled receptors of the endothelial differentiation gene-1 subfamily. Based on sequence homology to murine and human sphingosine kinase-1 (SPHK1), which we recently cloned (Kohama, T., Oliver, A., Edsall, L., Nagiec, M. M., Dickson, R., and Spiegel, S. (1998) J. Biol. Chem. 273, 23722-23728), we have now cloned a second type of mouse and human sphingosine kinase (mSPNK2 and hSPHK2). mSPHK2 and hSPHK2 encode proteins of 617 and 618 amino acids, respectively, both much larger than SPHK1, and though diverging considerably, both contain the conserved domains found in all SPHK1s. Northern blot analysis revealed that SPHK2 mRNA expression had a strikingly different tissue distribution from that of SPHK1 and appeared later in embryonic development. Expression of SPHK2 in HEK 293 cells resulted in elevated SPP levels. D-erythro-dihydrosphingosine was a better substrate than D-erythro-sphingosine for SPHK2. Surprisingly, D, L-threo-dihydrosphingosine was also phosphorylated by SPHK2. In contrast to the inhibitory effects on SPHK1, high salt concentrations markedly stimulated SPHK2. Triton X-100 inhibited SPHK2 and stimulated SPHK1, whereas phosphatidylserine stimulated both type 1 and type 2 SPHK. Thus, SPHK2 is another member of a growing class of sphingolipid kinases that may have novel functions.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Sankyo Co Ltd, Pharmacol Res Labs, Tokyo 1408710, Japan; Sankyo Co Ltd, Mol Biol Res Labs, Tokyo 1408710, Japan; NIMH, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	Georgetown University; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 353 Basic Sci Bldg,3900 Reservoir Rd NW, Washington, DC 20007 USA.			Kohama, Takafumi/0000-0002-6822-8170	NIGMS NIH HHS [GM43880] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R01GM043880] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Banno Y, 1998, BIOCHEM J, V335, P301, DOI 10.1042/bj3350301; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Choi OH, 1996, NATURE, V380, P634; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Edsall LC, 1997, J NEUROSCI, V17, P6952; Edsall LC, 1999, ANAL BIOCHEM, V272, P80, DOI 10.1006/abio.1999.4157; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Johnson JE, 1998, BIOCHEMISTRY-US, V37, P12020, DOI 10.1021/bi981107q; Kleuser B, 1998, CANCER RES, V58, P1817; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Machwate M, 1998, MOL PHARMACOL, V54, P70, DOI 10.1124/mol.54.1.70; MacLennan AJ, 1997, NEUROSCIENCE, V79, P217, DOI 10.1016/S0306-4522(96)00601-X; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Olivera A, 1998, Methods Mol Biol, V105, P233; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2000, METHOD ENZYMOL, V311, P215; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830	44	528	568	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19513	19520		10.1074/jbc.M002759200	http://dx.doi.org/10.1074/jbc.M002759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10751414	hybrid			2022-12-27	WOS:000087941300013
J	Dubbs, JM; Bird, TH; Bauer, CE; Tabita, FR				Dubbs, JM; Bird, TH; Bauer, CE; Tabita, FR			Interaction of CbbR and RegA* transcription regulators with the Rhodobacter sphaeroides cbb(I) promoter-operator region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOTROPHIC CO2 FIXATION; SIGNAL-TRANSDUCTION SYSTEM; CENTER GENE-EXPRESSION; CARBOXYLASE-OXYGENASE; RHODOPSEUDOMONAS-SPHAEROIDES; ALCALIGENES-EUTROPHUS; NUCLEOTIDE-SEQUENCE; XANTHOBACTER-FLAVUS; FORM-I; CAPSULATUS	The form I (cbb(I)) Calvin-Benson-Bassham (CBB) reductive pentose phosphate cycle operon of Rhodobacter sphaeroides is regulated by both the transcriptional activator CbbR and the RegA/PrrA (RegB/PrrB) two-component signal transduction system. DNase I footprint analyses indicated that R. sphaeroides CbbR binds to the cbb(I) promoter between -10 and -70 base pairs (bp) relative to the cbb(I) transcription start. A cosmid carrying the R. capsulatus reg locus was capable of complementing an R. sphaeroides regA-deficient mutant to phototrophic growth with restored regulated synthesis of both photopigments and ribulose-bisphosphate carboxylase/oxygenase (Rubisco). DNase I footprint analyses, using R. capsulatus RegA*, a constitutively active mutant version of RegA, detected four RegA* binding sites within the cbb(I) promoter. Two sites were found within a previously identified cbb(I) promoter proximal regulatory region from -61 to -110 bp, One of these proximal RegA* binding sites overlapped that of CbbR. Two sites were within a previously identified promoter distal positive regulatory region between -301 and -415 bp, Expression from promoter insertion mutants showed that the function of the promoter distal regulatory region was helical phase-dependent. These results indicated that RegA exerts its regulatory affect on cbb(I) expression through direct interaction with the cbb(I) promoter.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Plant Biotechnol, Columbus, OH 43210 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Indiana University System; Indiana University Bloomington	Tabita, FR (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040941, R29GM040941, R37GM040941] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040941, GM-45404, R37 GM040941, GM-40941] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BAGESHWAR UK, 1997, CAN J MICROBIOL, V44, P405; Barber RD, 1998, J MOL BIOL, V280, P775, DOI 10.1006/jmbi.1998.1900; Bauer E, 1998, J BACTERIOL, V180, P3853, DOI 10.1128/JB.180.15.3853-3863.1998; Bird TH, 1999, J BIOL CHEM, V274, P16343, DOI 10.1074/jbc.274.23.16343; CHEN JH, 1991, J BIOL CHEM, V266, P20447; Du SY, 1998, J BIOL CHEM, V273, P18509, DOI 10.1074/jbc.273.29.18509; Dubbs JM, 1998, J BACTERIOL, V180, P4903, DOI 10.1128/JB.180.18.4903-4911.1998; Elsen S, 1998, J BIOL CHEM, V273, P30762, DOI 10.1074/jbc.273.46.30762; ERASO JM, 1995, J BACTERIOL, V177, P2695, DOI 10.1128/jb.177.10.2695-2706.1995; FALCONE DL, 1991, J BACTERIOL, V173, P2099, DOI 10.1128/jb.173.6.2099-2108.1991; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; GIBSON JL, 1993, J BACTERIOL, V175, P5778, DOI 10.1128/JB.175.18.5778-5784.1993; GIBSON JL, 1991, J BIOL CHEM, V266, P14646; Gibson JL, 1996, ARCH MICROBIOL, V166, P141, DOI 10.1007/s002030050369; GIBSON JL, 1977, J BIOL CHEM, V252, P943; GIBSON JL, 1995, ADV PHOTOSYNTH, V2, P1107; GOETHALS K, 1992, P NATL ACAD SCI USA, V89, P1646, DOI 10.1073/pnas.89.5.1646; HALLENBECK PL, 1990, J BACTERIOL, V172, P1749, DOI 10.1128/jb.172.4.1749-1761.1990; HALLENBECK PL, 1990, J BACTERIOL, V172, P1736, DOI 10.1128/jb.172.4.1736-1748.1990; INOUE K, 1995, BIOCHEMISTRY-US, V34, P391, DOI 10.1021/bi00002a002; Joshi HM, 1996, P NATL ACAD SCI USA, V93, P14515, DOI 10.1073/pnas.93.25.14515; JOUANNEAU Y, 1986, J BACTERIOL, V165, P620, DOI 10.1128/jb.165.2.620-624.1986; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; KUSIAN B, 1995, J BACTERIOL, V177, P6568, DOI 10.1128/jb.177.22.6568-6574.1995; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MOSLEY CS, 1994, J BACTERIOL, V176, P7566, DOI 10.1128/JB.176.24.7566-7573.1994; ORMEROD JG, 1961, ARCH BIOCHEM BIOPHYS, V94, P449, DOI 10.1016/0003-9861(61)90073-X; Paoli GC, 1998, ARCH MICROBIOL, V170, P8, DOI 10.1007/s002030050609; PerezMartin J, 1997, ANNU REV MICROBIOL, V51, P593, DOI 10.1146/annurev.micro.51.1.593; QIAN Y, 1997, THESIS OHIO STATE U; Qian YL, 1998, J BACTERIOL, V180, P4644, DOI 10.1128/JB.180.17.4644-4649.1998; Qian YL, 1996, J BACTERIOL, V178, P12, DOI 10.1128/jb.178.1.12-18.1996; SGANGA MW, 1992, CELL, V68, P945, DOI 10.1016/0092-8674(92)90037-D; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUWANTO A, 1992, J BACTERIOL, V174, P1135, DOI 10.1128/jb.174.4.1135-1145.1992; SUWANTO A, 1989, J BACTERIOL, V171, P5858; van Keulen G, 1998, J BACTERIOL, V180, P1411, DOI 10.1128/JB.180.6.1411-1417.1998; VANDENBERGH ERE, 1993, J BACTERIOL, V175, P6097, DOI 10.1128/JB.175.19.6097-6104.1993; VIALE AM, 1991, J BACTERIOL, V173, P5224, DOI 10.1128/jb.173.16.5224-5229.1991; WANG L, 1992, CELL, V69, P659, DOI 10.1016/0092-8674(92)90229-6; WINDHOVEL U, 1991, MOL MICROBIOL, V5, P2695, DOI 10.1111/j.1365-2958.1991.tb01978.x; [No title captured]	45	60	63	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19224	19230		10.1074/jbc.M002125200	http://dx.doi.org/10.1074/jbc.M002125200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10748066	hybrid			2022-12-27	WOS:000087815900080
J	Hynes, GM; Willison, KR				Hynes, GM; Willison, KR			Individual subunits of the eukaryotic cytosolic chaperonin mediate interactions with binding sites located on subdomains of beta-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-COMPLEX POLYPEPTIDE-1; CONTAINING TCP-1; II CHAPERONIN; IN-VIVO; CYTOPLASMIC CHAPERONIN; MOLECULAR CHAPERONES; CCT; DOMAIN; GROEL; MODEL	The chaperonin containing TCP-1 (CCT) of eukaryotic cytosol is composed of eight different subunit species that are proposed to have independent functions in folding its in vivo substrates, the actins and tubulins, CCT has been loaded with S-35-beta-actin by in vitro translation in reticulocyte lysate and then subjected to immunoprecipitation with all eight anti-CCT subunit antibodies in mixed micelle buffers, conditions that disrupt CCT into its constituent monomers. Interactions between S-35-beta-actin and isolated CCT alpha, CCT beta, CCT epsilon, or CCT theta subunits are observed, suggesting that polar and electrostatic interactions may mediate actin binding to these four CCT subunits, Additionally, a beta-actin peptide array was screened for CCT-binding sequences. Three regions rich in charged and polar amino acid residues, which map to the surface of native beta-actin, are implicated in interactions between actin and CCT. Several of these biochemical results are consistent with the recent cryo-electron microscopy three-dimensional structure of apo-CCT-alpha-actin, in which alpha-actin is bound by the apical domains of specific CCT subunits, A model is proposed in which actin interacts with several CCT subunits during its CCT-mediated folding cycle.	Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Willison, KR (corresponding author), Inst Canc Res, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.							Archibald JM, 1999, CURR BIOL, V9, P1053, DOI 10.1016/S0960-9822(99)80457-6; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chen LL, 1999, CELL, V99, P757, DOI 10.1016/S0092-8674(00)81673-6; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Dobrzynski JK, 1996, BIOCHEMISTRY-US, V35, P15870, DOI 10.1021/bi961114j; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Grantham J, 2000, J BIOL CHEM, V275, P4587, DOI 10.1074/jbc.275.7.4587; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Hynes G, 1996, FASEB J, V10, P137, DOI 10.1096/fasebj.10.1.8566534; Hynes G, 1996, ELECTROPHORESIS, V17, P1720, DOI 10.1002/elps.1150171109; HYNES G, 1995, FEBS LETT, V358, P129, DOI 10.1016/0014-5793(94)01408-S; ISLAM SA, 1996, PREPI; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; Liou AKF, 1998, BIOL CHEM, V379, P311, DOI 10.1515/bchm.1998.379.3.311; Liou AKF, 1997, EMBO J, V16, P4311, DOI 10.1093/emboj/16.14.4311; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; Llorca O, 1999, NAT STRUCT BIOL, V6, P639; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MARCO S, 1994, BIOPHYS J, V67, P364, DOI 10.1016/S0006-3495(94)80489-8; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Page R, 1998, J MOL BIOL, V280, P463, DOI 10.1006/jmbi.1998.1879; Rommelaere H, 1999, BIOCHEMISTRY-US, V38, P3246, DOI 10.1021/bi9815905; Roobol A, 1999, J BIOL CHEM, V274, P2408, DOI 10.1074/jbc.274.4.2408; Roobol A, 1999, EUR J CELL BIOL, V78, P21, DOI 10.1016/S0171-9335(99)80004-1; Roobol A, 1999, J BIOL CHEM, V274, P19220, DOI 10.1074/jbc.274.27.19220; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TIRION MM, 1995, BIOPHYS J, V68, P5, DOI 10.1016/S0006-3495(95)80156-6; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; Willison Keith R., 1996, P107, DOI 10.1016/B978-012237455-5/50006-3; WILLISON KR, 1999, MOL CHAPERONES FOLDI, P555; Willison KR, 1994, BIOL HEAT SHOCK PROT, P299; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	48	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18985	18994		10.1074/jbc.M910297199	http://dx.doi.org/10.1074/jbc.M910297199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10748209	hybrid			2022-12-27	WOS:000087815900050
J	Korner, K; Muller, R				Korner, K; Muller, R			In vivo structure of the cell cycle-regulated human cdc25C promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-BINDING PROTEIN; NF-Y; IN-VIVO; TRANSCRIPTIONAL REGULATION; GENE; DNA; REPRESSION; COMPLEX; EXPRESSION; CHROMATIN	The cdc25C promoter is regulated during the cell cycle by the transcriptional repressor CDF-1 that inhibits the activation function of upstream transcriptional activators, most notably the nuclear factor Y/CAAT box binding factor (NF-Y/CBF), In this report a detailed analysis of the in vivo structure of the cdc25C promoter was made. Micrococcus nuclease and methidiumpropyl-EDTA footprinting strongly suggest that the proximal promoter encompassing the cell cycle-dependent element/cell cycle genes homology region and the upstream NF-Y sites is organized in a positioned nucleosome throughout the cell cycle. Furthermore, structural perturbations were detected by DNase I, phenanthroline copper, and KMnO4 footprinting at the NF-Y binding sites in vivo, which is in agreement with the reported property of NF-Y to bend DNA in vitro. Similar results were obtained with the structurally and functionally related cyclin A promoter. The structural perturbations seen in DNase I and phenanthroline copper footprints were less pronounced in G(0) cells when compared with cycling cells. This presumably reflects a weakened in vivo interaction of NF-Y with its cognate DNA element in G(0). It is likely that these structural perturbations, together with the reported ability of NF-Y to recruit histone acetyl transferase activity, contribute to an opened chromatin structure as a prerequisite for optimal regulation through activation and repression.	Univ Marburg, Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Caretti G, 1999, MOL CELL BIOL, V19, P8591; CARTWRIGHT IL, 1983, P NATL ACAD SCI-BIOL, V80, P3213, DOI 10.1073/pnas.80.11.3213; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; Good LF, 1996, BIOL SIGNAL, V5, P163; GRALLA JD, 1993, FOOTPRINTING TECHNIQ, P107; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Korner K, 1997, NUCLEIC ACIDS RES, V25, P4933, DOI 10.1093/nar/25.24.4933; LI XY, 1992, J BIOL CHEM, V267, P8984; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; Linhoff MW, 1997, MOL CELL BIOL, V17, P4589, DOI 10.1128/MCB.17.8.4589; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; MORRIS L, 1994, J BIOL CHEM, V269, P11563; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; POPE LE, 1984, P NATL ACAD SCI-BIOL, V81, P3, DOI 10.1073/pnas.81.1.3; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P381; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Zwicker J, 1997, NUCLEIC ACIDS RES, V25, P4926, DOI 10.1093/nar/25.24.4926; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	32	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18676	18681		10.1074/jbc.M001110200	http://dx.doi.org/10.1074/jbc.M001110200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10747986	hybrid			2022-12-27	WOS:000087815900010
J	Kobayashi, YM; Alseikhan, BA; Jones, LR				Kobayashi, YM; Alseikhan, BA; Jones, LR			Localization and characterization of the calsequestrin-binding domain of triadin 1 - Evidence for a charged beta-strand in mediating the protein-protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; CANINE CARDIAC CALSEQUESTRIN; SKELETAL-MUSCLE; BIOCHEMICAL-CHARACTERIZATION; GLYCOPROTEIN TRIADIN; RYANODINE RECEPTOR; MOLECULAR-CLONING; VESICLES; PURIFICATION; ASSOCIATION	Triadin is an integral membrane protein of the junctional sarcoplasmic reticulum that binds to the high capacity Ca2+-binding protein calsequestrin and anchors it to the ryanodine receptor. The lumenal domain of triadin contains multiple repeats of alternating lysine and glutamic acid residues, which have been defined as KEKE motifs and have been proposed to promote protein associations. Here we identified the specific residues of triadin responsible for binding to calsequestrin by mutational analysis of triadin 1, the major cardiac isoform. A series of deletional fusion proteins of triadin 1 was generated, and by using metabolically labeled calsequestrin in filter-overlay assays, the calsequestrin-binding domain of triadin 1 was localized to a single HERE motif comprised of 25 amino acids. Alanine mutagenesis within this motif demonstrated that the critical amino acids of triadin binding to calsequestrin are the even-numbered residues Lys(210), LyS(212), GlU(214), Lys(216), Gly(218), Gln(220), Lys(222), and Lys(221). Replacement of the odd-numbered residues within this motif by alanine had no effect on calsequestrin binding to triadin. The results suggest a model in which residues 210-224 of triadin form a beta-strand, with the even-numbered residues in the strand interacting with charged residues of calsequestrin, stabilizing a "polar zipper" that links the two proteins together, This small, highly charged P-strand of triadin may tether calsequestrin to the junctional face membrane, allowing calsequestrin to sequester Ca2+ in the vicinity of the ryanodine receptor during Ca2+ uptake and Ca2+ release.	Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Jones, LR (corresponding author), Indiana Univ, Sch Med, Krannert Inst Cardiol, 1111 W 10th St, Indianapolis, IN 46202 USA.	lrjones@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028556] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-28556] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CALA SE, 1983, J BIOL CHEM, V258, P1932; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; IKEMOTO N, 1971, BIOCHEM BIOPH RES CO, V44, P1510, DOI 10.1016/S0006-291X(71)80257-7; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; JONES LR, 1981, J BIOL CHEM, V256, P1809; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; Kobayashi YM, 1999, J BIOL CHEM, V274, P28660, DOI 10.1074/jbc.274.40.28660; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PERUTZ M, 1994, PROTEIN SCI, V3, P1629, DOI 10.1002/pro.5560031002; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; REALINI C, 1995, J BIOL CHEM, V270, P29664; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; Shannon TR, 2000, BIOPHYS J, V78, P334, DOI 10.1016/S0006-3495(00)76596-9; TASKE NL, 1995, EUR J BIOCHEM, V233, P258, DOI 10.1111/j.1432-1033.1995.258_1.x; Wang SR, 1998, NAT STRUCT BIOL, V5, P476, DOI 10.1038/nsb0698-476; West RW, 2000, GENE, V243, P195, DOI 10.1016/S0378-1119(99)00510-7; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	28	107	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17639	17646		10.1074/jbc.M002091200	http://dx.doi.org/10.1074/jbc.M002091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748065	hybrid			2022-12-27	WOS:000087485000062
J	Ramsey, AJ; Russell, LC; Whitt, SR; Chinkers, M				Ramsey, AJ; Russell, LC; Whitt, SR; Chinkers, M			Overlapping sites of tetratricopeptide repeat protein binding and chaperone activity in heat shock protein 90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; HSP90; DOMAIN; CYP-40; GROWTH; HETEROCOMPLEXES; IDENTIFICATION; PHOSPHATASE-5	The sequential binding of different tetratricopeptide repeat (TPR) proteins to heat shock protein 90 (hsp90) is essential to its chaperone function in vivo. We have previously shown that three basic residues in the TPR domain of PP5 are required for binding to the acidic C-terminal domain of hsp90. We have now tested which acidic residues in this C-terminal domain are required for binding to three different TPR proteins as follows: PP5, FKBP52, and Hop. Mutation of Glu-729, Glu-730, and Asp-732 at the C terminus of hsp90 interfered with binding of all three TPR proteins. Mutation of Glu-720, Asp-722, Asp-723, and Asp-724 inhibited binding of FKBP52 and PP5 but not of Hop. Mutation of Glu-651 and Asp-653 did not affect binding of FKBP52 or PP5 but inhibited both Hop binding and hsp90 chaperone activity. We also found that a conserved Lys residue required for PP5 binding to hsp90 was critical for the binding of FKBP52 but not for the binding of Hop to hsp90. These results suggest distinct but overlapping binding sites on hsp90 for different TPR proteins and indicate that the binding site for Hop, which is associated with hsp90 in intermediate stages of protein folding, overlaps with a site of chaperone activity.	Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA	University of South Alabama	Chinkers, M (corresponding author), Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA.	michaelc@jaguar1.usouthal.edu			NHLBI NIH HHS [HL 47063] Funding Source: Medline; NIDDK NIH HHS [DK 55877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055877] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Duina AA, 1998, J BIOL CHEM, V273, P10819, DOI 10.1074/jbc.273.18.10819; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Zhang H, 1999, PROTEIN SCI, V8, P1658, DOI 10.1110/ps.8.8.1658; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e	30	67	69	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17857	17862		10.1074/jbc.M001625200	http://dx.doi.org/10.1074/jbc.M001625200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10751404	hybrid			2022-12-27	WOS:000087485000089
J	Schlattner, U; Wallimann, T				Schlattner, U; Wallimann, T			Octamers of mitochondrial creatine kinase isoenzymes differ in stability and membrane binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; FORMS; RESIDUES; FLUORESCENCE; LOCALIZATION; EXPRESSION; INHIBITION; COMPLEXES; PROTEINS; KINETICS	Octamer stability and membrane binding of mitochondrial creatine kinase (MtCK) are important for proper functioning of the enzyme and were suggested as targets for regulatory mechanisms, A quantitative analysis of these properties, using fluorescence spectroscopy, gel filtration, and surface plasmon resonance, revealed substantial differences between the two types of MtCK isoenzymes, sarcomeric (sMtCK) and ubiquitous (uMtCK), As compared with human and chicken sMtCK, human uMtCK showed a 23-34 times slower octamer dissociation rate, a reduced reoctamerization rate and a superior octamer stability as deduced from the octamer/dimer ratios at thermodynamic equilibrium. Octamer stability of sMtCK increased with temperature up to 30 degrees C, indicating a substantial contribution of hydrophobic interactions, while it decreased in the case of uMtCK, indicating the presence of additional polar dimer/dimer interactions. These conclusions are consistent with the recently solved x-ray structure of the human uMtCK (Eder, IM., Fritz-Wolf, K., Kabsch, W., Wallimann, T., and Schlattner, U. (2000) Proteins 39, 216-225), When binding to 16% cardiolipin membranes, sMtCK showed slightly faster on-rates and higher affinities than uMtCK. However, human uMtCK was able to recruit the highest number of binding sites on the vesicle surface. The observed divergence of ubiquitous and sarcomeric MtCK is discussed with respect to their molecular structures and the possible physiological implications.	ETH Zurich, Inst Cell Biol, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Schlattner, U (corresponding author), ETH Zurich, Inst Cell Biol, Swiss Fed Inst Technol, Honggerberg HPM F44, CH-8093 Zurich, Switzerland.		Wallimann, Theo/C-6047-2008; Schlattner, Uwe/D-1267-2009	Wallimann, Theo/0000-0003-4957-5836; Schlattner, Uwe/0000-0003-1159-5911				Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; CHIEN JY, 1948, J AM CHEM SOC, V70, P2256, DOI 10.1021/ja01186a078; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Eder M, 2000, PROTEINS, V39, P216, DOI 10.1002/(SICI)1097-0134(20000515)39:3<216::AID-PROT40>3.0.CO;2-#; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Forstner M, 1998, BIOPHYS J, V75, P1016, DOI 10.1016/S0006-3495(98)77590-3; FritzWolf K, 1996, NATURE, V381, P341, DOI 10.1038/381341a0; FURTER R, 1992, BIOCHEM J, V288, P771, DOI 10.1042/bj2880771; GROSS M, 1995, BIOCHEMISTRY-US, V34, P6660, DOI 10.1021/bi00020a011; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; GROSS M, 1993, BIOCHEMISTRY-US, V32, P13933, DOI 10.1021/bi00213a024; KALDIS P, 1994, BIOCHEMISTRY-US, V33, P952, DOI 10.1021/bi00170a014; KANEMITSU F, 1984, CLIN CHIM ACTA, V138, P175; Khuchua ZA, 1998, J BIOL CHEM, V273, P22990, DOI 10.1074/jbc.273.36.22990; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; MARCILLAT O, 1987, BIOCHIM BIOPHYS ACTA, V890, P233, DOI 10.1016/0005-2728(87)90024-7; MATSUSHITA M, 1993, CLIN CHIM ACTA, V216, P103, DOI 10.1016/0009-8981(93)90143-R; Matthews RT, 1998, J NEUROSCI, V18, P156; MILNERWH.EJ, 1971, BIOCHEM J, V122, P727, DOI 10.1042/bj1220727; MUHLEBACH SM, 1994, MOL CELL BIOCHEM, V133, P245, DOI 10.1007/BF01267958; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; OLIVER IT, 1955, BIOCHEM J, V61, P116, DOI 10.1042/bj0610116; PRATT R, 1987, PATHOLOGY, V19, P162, DOI 10.3109/00313028709077128; ROJO M, 1991, J BIOL CHEM, V266, P20290; Schlattner U, 2000, J BIOENERG BIOMEMBR, V32, P123, DOI 10.1023/A:1005576831968; Schlattner U, 1998, MOL CELL BIOCHEM, V184, P125, DOI 10.1023/A:1006851330913; SCHLEGEL J, 1988, J BIOL CHEM, V263, P16942; SCHLEGEL J, 1990, J BIOL CHEM, V265, P9221; SCHNYDER T, 1988, J BIOL CHEM, V263, P16954; Soboll S, 1999, J MOL CELL CARDIOL, V31, P857, DOI 10.1006/jmcc.1998.0925; Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694; Stachowiak O, 1998, MOL CELL BIOCHEM, V184, P141, DOI 10.1023/A:1006803431821; Stachowiak O, 1996, BIOCHEMISTRY-US, V35, P15522, DOI 10.1021/bi961838v; Vacheron MJ, 1997, ARCH BIOCHEM BIOPHYS, V344, P316, DOI 10.1006/abbi.1997.0181; VANDORSTEN F, 1995, BIOCHIM BIOPHYS ACTA, V1274, P59; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WEGMANN G, 1991, DIFFERENTIATION, V46, P77, DOI 10.1111/j.1432-0436.1991.tb00868.x; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9	42	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17314	17320		10.1074/jbc.M001919200	http://dx.doi.org/10.1074/jbc.M001919200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748055	hybrid			2022-12-27	WOS:000087485000016
J	Seo, EJ; Im, H; Maeng, JS; Kim, KE; Yu, MH				Seo, EJ; Im, H; Maeng, JS; Kim, KE; Yu, MH			Distribution of the native strain in human alpha(1)-antitrypsin and its association with protease inhibitor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; HUMAN ALPHA-1-PROTEINASE INHIBITOR; PLASMINOGEN-ACTIVATOR INHIBITOR-1; PROTEINASE-INHIBITORS; SUICIDE SUBSTRATE; CRYSTAL-STRUCTURE; HINGE REGION; SERPIN; MECHANISM; INSERTION	Serine protease inhibitors (serpins) are metastable in their native state. This strain, which is released upon binding to target proteases, is essential for the inhibitory activity of serpins. To understand the structural basis of the native strain, we previously characterized stabilizing mutations of alpha(1)-antitrypsin, a prototypical inhibitory serpin, in regions such as the hydrophobic core. The present study evaluates the effects of single point mutations throughout the molecule on stability and protease inhibitory activity. We identified stabilizing mutations in most secondary structures, suggesting that the native strain is distributed throughout the molecule. Examination of the substitution patterns and the structures of the mutation sites revealed surface hydrophobic pockets as a component of the native strain in alpha(1)-antitrypsin, in addition to the previously identified unusual interactions such as side chain overpacking and cavities. Interestingly, many of the stabilizing substitutions did not affect the inhibitory activity significantly. Those that affected the activity were confined in the regions that are mobilized during the complex formation with a target enzyme. The results of our study should be useful for designing proteins with strain and for regulating the stability and functions of serpins.	Korea Res Inst Biosci & Biotechnol, Natl Creat Res Initiat Ctr, Taejon 305600, South Korea; Chungnam Natl Univ, Dept Biochem, Taejon 305764, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University	Yu, MH (corresponding author), Korea Res Inst Biosci & Biotechnol, Natl Creat Res Initiat Ctr, POB 115, Taejon 305600, South Korea.			Kim, Kyoon/0000-0001-5133-1692				BEATTY K, 1980, J BIOL CHEM, V255, P3931; BRUCH M, 1988, J BIOL CHEM, V263, P16626; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUBNER P, 1988, GENE, V73, P319, DOI 10.1016/0378-1119(88)90496-9; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Im H, 1999, J BIOL CHEM, V274, P11072, DOI 10.1074/jbc.274.16.11072; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; Kocher JP, 1996, STRUCTURE, V4, P1517, DOI 10.1016/S0969-2126(96)00157-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWON KS, 1994, J BIOL CHEM, V269, P9627; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lee KN, 1998, J BIOL CHEM, V273, P2509, DOI 10.1074/jbc.273.5.2509; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Ryu SE, 1996, STRUCTURE, V4, P1181, DOI 10.1016/S0969-2126(96)00126-8; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; TRAVIS J, 1981, METHOD ENZYMOL, V80, P754; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	36	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16904	16909		10.1074/jbc.M001006200	http://dx.doi.org/10.1074/jbc.M001006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747976	hybrid			2022-12-27	WOS:000087392200072
J	Wexler, M; Sargent, F; Jack, RL; Stanley, NR; Bogsch, EG; Robinson, C; Berks, BC; Palmer, T				Wexler, M; Sargent, F; Jack, RL; Stanley, NR; Bogsch, EG; Robinson, C; Berks, BC; Palmer, T			TatD is a cytoplasmic protein with DNase activity - No requirement for TatD family proteins in Sec-independent protein export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-PH PATHWAY; ESCHERICHIA-COLI; SYSTEM; TRANSPORT; BACTERIOPHAGE; EXPRESSION; EFFICIENT; SEQUENCE; MEMBRANE; IMPORT	The Escherichia coli Tat system mediates Sec-independent export of protein precursors bearing twin arginine signal peptides. Genes known to be involved in this process include tafA, tatB, and tatC that form an operon with a fourth gene, tatD. The tatD gene product has two homologues in E. coli coded by the unlinked ycfH and yjjV genes. An E. coli strain with in-frame chromosomal deletions in all three of tatD, ycfH, and yjjV exhibits no significant defect in the cellular location of five cofactor-containing enzymes that are synthesized with twin arginine signal peptides. Neither these mutations nor overproduction of the TatD protein cause any discernible effect on the export kinetics of an additional E. coli Tat pathway substrate. It is concluded that proteins of the TatD family have no obligate involvement in protein export by the Tat system. TatD is shown to be a cytoplasmic protein. TatD binds to immobilized Ni2+ or Zn2+ affinity columns and exhibits magnesium dependent DNase activity. Features of the tafA operon that may control TatD expression are discussed.	Univ E Anglia, Sch Biol Sci, Ctr Met Prot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of East Anglia; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Warwick	Berks, BC (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Met Prot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.		Wexler, Margaret/G-3423-2011; Jack, Rachael L/E-2869-2017	Stanley-Wall, Nicola/0000-0002-5936-9721; Palmer, Tracy/0000-0001-9043-2592; Berks, Ben/0000-0001-9685-4067; Sargent, Frank/0000-0002-6841-3624; Jack, Rachael/0000-0002-9482-9316				Aravind L, 1998, NUCLEIC ACIDS RES, V26, P3746, DOI 10.1093/nar/26.16.3746; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CERETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599; CLINE K, 1992, J BIOL CHEM, V267, P2688; de Leeuw E, 1999, MOL MICROBIOL, V31, P983, DOI 10.1046/j.1365-2958.1999.01245.x; DOWNING WL, 1990, J BACTERIOL, V172, P1621, DOI 10.1128/jb.172.3.1621-1627.1990; Dykxhoorn DM, 1996, GENE, V177, P133, DOI 10.1016/0378-1119(96)00289-2; ENOCH HG, 1975, J BIOL CHEM, V250, P6693; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kusher S. R., 1996, ESCHERICHIA COLI SAL, P849; LYONS LB, 1972, VIROLOGY, V49, P45, DOI 10.1016/S0042-6822(72)80006-0; Mori H, 1998, J BIOL CHEM, V273, P11405, DOI 10.1074/jbc.273.19.11405; MOULD RM, 1991, J BIOL CHEM, V266, P17286; Sambrook J., 2002, MOL CLONING LAB MANU; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VILLAREJO MR, 1974, J BACTERIOL, V120, P466, DOI 10.1128/JB.120.1.466-474.1974; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 1998, FEBS LETT, V431, P339, DOI 10.1016/S0014-5793(98)00790-X	27	222	229	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16717	16722		10.1074/jbc.M000800200	http://dx.doi.org/10.1074/jbc.M000800200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747959	hybrid			2022-12-27	WOS:000087392200046
J	Hu, HM; Tian, Q; Baer, M; Spooner, CJ; Williams, SC; Johnson, PF; Schwartz, RC				Hu, HM; Tian, Q; Baer, M; Spooner, CJ; Williams, SC; Johnson, PF; Schwartz, RC			The C/EBP bZIP domain can mediate lipopolysaccharide induction of the proinflammatory cytokines interleukin-6 and monocyte chemoattractant protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ENHANCER-BINDING-PROTEIN; LYMPHOBLASTIC CELL-LINE; LEUCINE-ZIPPER; TRANSCRIPTIONAL ACTIVATION; MESSENGER-RNA; GROWTH-FACTOR; BETA ISOFORM; GENE; EXPRESSION	C/EBP alpha, beta, and delta are all expressed by bone marrow-derived macrophages, Ectopic expression of any of these transcription factors is sufficient to confer lipopolysaccharide (LPS)-inducible expression of interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) to a B lymphoblast cell line, which normally lacks C/EBP factors and does not display LPS induction of proinflammatory cytokines. Thus, the activities of C/EBP alpha, beta, and delta are redundant in regard to expression of IL-6 and MCP-1. Surprisingly, the bZIP region of C/EBP beta, which lacks any previously described activation domains, can also confer LPS-inducible expression of IL-6 and MCP-1 in stable transfectants, Transient transfections reveal that the bZIP regions of C/EBP beta, C/EBP delta, and, to a lesser extent, C/EBP alpha can activate the IL-6 promoter and augment its induction by LPS. Furthermore, the transdominant inhibitor, LIP, can activate expression from the IL-6 promoter. The ability of the C/EBP beta bZIP region to activate the IL-6 promoter in transient transfections is completely dependent upon an intact NF-kappa B-binding site, supporting a model where the bZIP protein primarily functions to augment the activity of NF-kappa B. Replacement of the leucine zipper of C/EBP beta with that of GCN4 yields a chimeric protein that can dimerize and specifically bind to a C/EBP consensus sequence, but shows a markedly reduced ability to activate IL-6 and MCP-1 expression. These results implicate the leucine zipper domain in some function other than dimerization with known C/EBP family members, and suggest that C/EBP redundancy in regulating cytokine expression may result from their highly related bZIP regions.	Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA; NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, Eukaryot Transcript Regulat Sect, Ft Detrick, MD 21702 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA	Michigan State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Schwartz, RC (corresponding author), Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA.		Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; An MR, 1996, MOL CELL BIOL, V16, P2295; AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; Baer M, 1998, BLOOD, V92, P4353, DOI 10.1182/blood.V92.11.4353.423k21_4353_4365; BAUER SR, 1986, J IMMUNOL, V136, P4695; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Colangelo AM, 1998, P NATL ACAD SCI USA, V95, P10920, DOI 10.1073/pnas.95.18.10920; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; COOPER CL, 1994, J IMMUNOL, V153, P5049; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FURUTANI Y, 1986, NUCLEIC ACIDS RES, V14, P3167, DOI 10.1093/nar/14.8.3167; Hu HM, 1998, J IMMUNOL, V160, P2334; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KUNSCH C, 1994, J IMMUNOL, V153, P153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; NATSUKA S, 1992, BLOOD, V79, P460; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; Raught B, 1996, CANCER RES, V56, P4382; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RORTH P, 1994, SCIENCE, V266, P1878, DOI 10.1126/science.7997882; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TANABE O, 1988, J IMMUNOL, V141, P3875; Timchenko NA, 1998, NUCLEIC ACIDS RES, V26, P3293, DOI 10.1093/nar/26.13.3293; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831; ZHANOW CA, 1997, J NATL CANCER I, V89, P1887	44	80	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16373	16381		10.1074/jbc.M910269199	http://dx.doi.org/10.1074/jbc.M910269199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748205	hybrid			2022-12-27	WOS:000087291400104
J	Orena, SJ; Torchia, AJ; Garofalo, RS				Orena, SJ; Torchia, AJ; Garofalo, RS			Inhibition of glycogen-synthase kinase 3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; RAT ADIPOCYTES; DIABETIC RATS; INTACT-CELLS; LITHIUM; ACTIVATION; SENSITIVITY; EXPRESSION	The role of glycogen-synthase kinase 3 (GSK3) in insulin-stimulated glucose transport and glycogen synthase activation was investigated in 3T3-L1 adipocytes, GSK3 protein was clearly present in adipocytes and was found to be more abundant than in muscle and liver cell lines. The selective GSK3 inhibitor, LiCl, stimulated glucose transport and glycogen synthase activity (20 and 65%, respectively, of the maximal (1 mu M) insulin response) and potentiated the responses to a submaximal concentration (1 nM) of insulin. LiCl- and insulin-stimulated glucose transport were abolished by the phosphatidylinositol 3-kinase (PIS-kinase) inhibitor, wortmannin; however, LiCl stimulation of glycogen synthase was not. In contrast to the rapid stimulation of glucose transport by insulin, transport stimulated by LiCl increased gradually over 3-5 h reaching 40% of the maximal insulin-stimulated level. Both LiCl- and insulin-stimulated glycogen synthase activity were maximal at 25 min. However, insulin-stimulated glycogen synthase activity returned to basal after 2 h, coincident with reactivation of GSK3, After a 2-h exposure to insulin, glycogen synthase was refractory to restimulation with insulin, indicating selective desensitization of this pathway. However, LiCl could partially stimulate glycogen synthase in desensitized cells. Furthermore, coincubation with LiCl during the 2 h exposure to insulin completely blocked desensitization of glycogen synthase activity. In summary, inhibition of GSK3 by LiCl: 1) stimulated glycogen synthase activity directly and independently of PI3-kinase, 2) stimulated glucose transport at a point upstream of PI3-kinase, 3) stimulated glycogen synthase activity in desensitized cells, and 4) prevented desensitization of glycogen synthase due to chronic insulin treatment. These data are consistent with GSK3 playing a central role in the regulation of glycogen synthase activity and a contributing factor in the regulation of glucose transport in 3T3-L1 adipocytes.	Pfizer Inc, Div Cent Res, Groton, CT 06340 USA	Pfizer	Garofalo, RS (corresponding author), Pfizer Inc, Div Cent Res, MS 8118D-2071, Groton, CT 06340 USA.							Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; CHEN X, 1998, AM J PHYSIOL, V272, pE272; CHENG K, 1983, MOL CELL BIOCHEM, V56, P183; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Furnsinn C, 1997, AM J PHYSIOL-ENDOC M, V273, pE514, DOI 10.1152/ajpendo.1997.273.3.E514; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; HAUGAARD ES, 1974, BIOCHEM PHARMACOL, V23, P1675, DOI 10.1016/0006-2952(74)90394-3; HENINGER GR, 1970, ARCH GEN PSYCHIAT, V23, P310; Henry RR, 1996, J CLIN INVEST, V98, P1231, DOI 10.1172/JCI118906; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Hu M, 1997, BIOL TRACE ELEM RES, V60, P131, DOI 10.1007/BF02783316; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Nikoulina SE, 2000, DIABETES, V49, P263, DOI 10.2337/diabetes.49.2.263; OKADA T, 1994, J BIOL CHEM, V269, P3568; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; RODRIGUEZGIL JE, 1993, ARCH BIOCHEM BIOPHYS, V301, P411, DOI 10.1006/abbi.1993.1164; ROSSETTI L, 1989, DIABETES, V38, P648, DOI 10.2337/diabetes.38.5.648; Shulman GI, 1999, AM J CARDIOL, V84, p3J; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; TABATA I, 1994, DIABETES, V43, P903, DOI 10.2337/diabetes.43.7.903; Taha C, 1999, J MEMBRANE BIOL, V169, P1, DOI 10.1007/PL00005896; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; VANDERVELDE CD, 1969, ARCH GEN PSYCHIAT, V21, P478; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838	34	99	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15765	15772		10.1074/jbc.M910002199	http://dx.doi.org/10.1074/jbc.M910002199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748179	hybrid			2022-12-27	WOS:000087291400024
J	Hostager, BS; Catlett, IM; Bishop, GA				Hostager, BS; Catlett, IM; Bishop, GA			Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; CYTOPLASMIC DOMAIN; MONOCLONAL-ANTIBODIES; CELL LINES; TRAF2; TNF; JNK; TRANSDUCTION; LYMPHOCYTES	Signals delivered to antigen-presenting cells through CD40 are critical for the activation of immune responses. Intracellular tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are key elements of the signal transduction pathways of many TNF receptor family members, including CD40, We show for the first time that engagement of CD40 in intact B cells induces the rapid translocation of TRAF2 from the cytoplasm to the plasma membrane. We found that CD40 engagement also results in its recruitment, together with TRAF2 and TRAF3, to membrane microdomains, regions of the plasma membrane enriched in signaling molecules such as the Src family kinases, Using a membrane-permeable chelator of zinc or a mutant TRAF2 molecule, we show that the putative zinc-binding domains of TRAFs contribute to their recruitment to microdomains and to the downstream activation of c-Jun N-terminal kinase. We suggest that the zinc RING and zinc finger domains of TRAFs are required for communication between CD40 and microdomain-associated signaling molecules and may serve a similar role in the signal transduction pathways of other TNF receptor family members.	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Bishop, GA (corresponding author), Univ Iowa, Dept Microbiol, 3-570 BSB, Iowa City, IA 52242 USA.			Bishop, Gail/0000-0002-1291-5078; Catlett, Ian/0000-0001-6220-2626	NCI NIH HHS [CA66570] Funding Source: Medline; NIAID NIH HHS [AI28847] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028847, R29AI028847, R56AI028847] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BISHOP GA, 1989, P NATL ACAD SCI USA, V86, P5933, DOI 10.1073/pnas.86.15.5933; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; Busch LK, 1999, J IMMUNOL, V162, P2555; Chaudhuri A, 1997, J IMMUNOL, V159, P4244; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HEATH AW, 1994, EUR J IMMUNOL, V24, P1828, DOI 10.1002/eji.1830240816; Hostager BS, 1996, J IMMUNOL, V157, P1047; Hsing Y, 1999, J IMMUNOL, V162, P2804; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Kuhne MR, 1997, J EXP MED, V186, P337, DOI 10.1084/jem.186.2.337; LALMANACHGIRARD AC, 1993, J EXP MED, V177, P1215, DOI 10.1084/jem.177.4.1215; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	46	172	175	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15392	15398		10.1074/jbc.M909520199	http://dx.doi.org/10.1074/jbc.M909520199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748139	hybrid			2022-12-27	WOS:000087128300084
J	Rimerman, RA; Gellert-Randleman, A; Diehl, JA				Rimerman, RA; Gellert-Randleman, A; Diehl, JA			Wnt1 and MEK1 cooperate to promote cyclin D1 accumulation and cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; NIH 3T3 CELLS; BETA-CATENIN; SIGNALING PATHWAY; DEPENDENT KINASES; MAMMALIAN-CELLS; COLON-CARCINOMA; ACTIVATED RAS; G(1) PHASE; AXIN	Members of the Wnt family of signal transducers regulate cellular differentiation/reorganization and cellular proliferation. However, few pro-proliferative targets of Wnt have been identified. We now show that cyclin D1, a critical mediator of cell cycle progression, is a downstream target of Wnt-dependent signaling. NIH-3T3 cell lines engineered to overexpress Wnt1 displayed reduced glycogen synthase kinase-3 beta activity. Wnt1-dependent glycogen synthase kinase-3 beta inhibition corresponded with decreased cyclin D1 proteolysis and, thus, hyperaccumulation of active cyclin D1 . CDK4 (cyclin-dependent kinase 4) kinase. However, in the absence of serum-derived growth factors, Wnt-1 was not sufficient to drive cyclin D1 accumulation or S-phase entry. In contrast, cells engineered to co-express Wnt1 and activated MEK1 accumulated high levels of cyclin D1 and entered the DNA synthetic phase in the absence of serum-derived growth factors, a characteristic of neoplastic transformation. The ability of a dominant-negative cyclin D1 mutant, D1-T156A, to inhibit Wnt1/MEK1-dependent S-phase entry suggests that cyclin D1 is a critical downstream target for Wnt1- and MEK1-dependent cellular proliferation.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Diehl, JA (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	adiehl@unmc.edu						Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dale TC, 1998, BIOCHEM J, V329, P209; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; FILMUS J, 1994, ONCOGENE, V9, P3627; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, ONCOGENE, V9, P323; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Treinies I, 1999, MOL CELL BIOL, V19, P321; Uchimaru K, 1996, JPN J CANCER RES, V87, P459, DOI 10.1111/j.1349-7006.1996.tb00246.x; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926	50	66	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14736	14742		10.1074/jbc.M910241199	http://dx.doi.org/10.1074/jbc.M910241199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10748202	hybrid			2022-12-27	WOS:000087006900097
J	Souza, JM; Giasson, BI; Chen, QP; Lee, VMY; Ischiropoulos, H				Souza, JM; Giasson, BI; Chen, QP; Lee, VMY; Ischiropoulos, H			Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers - Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; LEWY BODY DISEASE; GLIAL CYTOPLASMIC INCLUSIONS; PARKINSONS-DISEASE; NACP/ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; IN-VITRO; TYROSINE NITRATION; NITRIC-OXIDE; BODIES	Intracellular proteinaceous aggregates are hallmarks of many common neurodegenerative disorders, and recent studies have shown that alpha-synuclein is a major component of several pathological intracellular inclusions, including Lewy bodies in Parkinson's disease (PD) and glial cell inclusions in multiple system atrophy. However, the molecular mechanisms underlying alpha-synuclein aggregation into filamentous inclusions remain unknown. Since oxidative and nitrative stresses are potential pathogenic mediators of PD and other neurodegenerative diseases, we asked if oxidative and/or nitrative events alter alpha-synuclein and induce it to aggregate. Here we show that exposure of human recombinant a-synuclein to nitrating agents (peroxynitrite/CO2 or myeloperoxidase/H2O2/nitrite) induces formation of nitrated alpha-synuclein oligomers that are highly stabilized due to covalent cross-linking via the oxidation of tyrosine to form o,o'-dityrosine. We also demonstrate that oxidation and nitration of pre-assembled alpha-synuclein filaments stabilize these filaments to withstand denaturing conditions and enhance formation of SDS-insoluble, heat-stable high molecular mass aggregates. Thus, these data suggest that oxidative and nitrative stresses are involved in mechanisms underlying the pathogenesis of Lewy bodies and glial cell inclusions in PD and multiple system atrophy, respectively, as well as alpha-synuclein pathologies in other synucleinopathies.	Childrens Hosp Philadelphia, Stokes Res Inst, Abramson Ctr 416D, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Republica, Fac Med, Dept Bioquim, Montevideo 11800, Uruguay	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Universidad de la Republica, Uruguay	Ischiropoulos, H (corresponding author), Childrens Hosp Philadelphia, Stokes Res Inst, Abramson Ctr 416D, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	ischirop@mail.med.upenn.edu			NATIONAL INSTITUTE ON AGING [P01AG009215, R01AG013966] Funding Source: NIH RePORTER; NIA NIH HHS [AG13966, AG09215] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABE K, 1995, NEUROSCI LETT, V199, P152, DOI 10.1016/0304-3940(95)12039-7; Arima K, 1998, ACTA NEUROPATHOL, V96, P439, DOI 10.1007/s004010050917; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; Baba M, 1998, AM J PATHOL, V152, P879; BASARGA O, 1995, P NATL ACAD SCI USA, V92, P12041; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; DOOLING EC, 1974, ARCH NEUROL-CHICAGO, V30, P70, DOI 10.1001/archneur.1974.00490310072012; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; Hashimoto M, 1999, J BIOL CHEM, V274, P28849, DOI 10.1074/jbc.274.41.28849; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hensley K, 1998, J NEUROSCI, V18, P8126; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; Lyras L, 1998, J NEUROCHEM, V71, P302; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Papadimitriou A, 1999, NEUROLOGY, V52, P651, DOI 10.1212/WNL.52.3.651; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Przedborski S, 1998, CURR OPIN NEUROL, V11, P335, DOI 10.1097/00019052-199808000-00009; Smith MA, 1997, J NEUROSCI, V17, P2653; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Takeda A, 1998, AM J PATHOL, V152, P367; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	48	470	491	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18344	18349		10.1074/jbc.M000206200	http://dx.doi.org/10.1074/jbc.M000206200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10747881	hybrid			2022-12-27	WOS:000087659400060
J	Chen, XL; Zuo, SJ; Kelman, Z; O'Donnell, M; Hurwitz, J; Goodman, MJ				Chen, XL; Zuo, SJ; Kelman, Z; O'Donnell, M; Hurwitz, J; Goodman, MJ			Fidelity of eucaryotic DNA polymerase delta holoenzyme from Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION-FACTOR-C; GEL KINETIC-ANALYSIS; LAGGING-STRAND DNA; ESCHERICHIA-COLI; III HOLOENZYME; SACCHAROMYCES-CEREVISIAE; LEADING-STRAND; SPONTANEOUS MUTATION; ACCESSORY PROTEINS	The fidelity of Schizosaccharomyces pombe DNA polymerase delta was measured in the presence or absence of its processivity subunits, proliferating cell nuclear antigen (PCNA) sliding clamp and replication factor C (RFC) clamp-loading complex, using a synthetic 30-mer primer/100-mer template. Synthesis by pol delta alone was distributive. Processive synthesis occurred in the presence of PCNA, RFC, and Escherichia coli single strand DNA-binding protein (SSB) and required the presence of ATP. "Passive" self-loading of PCNA onto DNA takes place in the absence of RFC, in an ATP-independent reaction, which was strongly inhibited by SSB, The nucleotide substitution error rate for pol delta holoenzyme (HE) (pol delta + PCNA + RFC) was 4.6 x 10(-4) for T.G mispairs, 5.3 x 10(-5) for G.G mispairs, and 4.5 x 10(-6) for A.G mispairs, The T.G misincorporation frequency for pol delta without the accessory proteins was unchanged. The fidelity of pol delta HE was between 1 and 2 orders of magnitude lower than that measured for the E, coli pol III HE at the same template position. This relatively low fidelity was caused by inefficient proofreading by the S, pombe polymerase-associated proofreading exonuclease, The S. pombe S'-exonuclease activity was also extremely inefficient in excising primer-3'-terminal mismatches in the absence of dNTP substrates and in hydrolyzing single-stranded DNA. A comparison of po; delta HE with E, coli pol III alpha HE (lacking the proofreading exonuclease subunit) showed that both holoenzymes exhibit similar error rates for each mispair.	Univ So Calif, Hedco Mol Biol Labs, Dept Biol Sci & Chem, Los Angeles, CA 90089 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	University of Southern California; Howard Hughes Medical Institute; Rockefeller University; Memorial Sloan Kettering Cancer Center	Goodman, MJ (corresponding author), Univ So Calif, Dept Biol Sci, SHS Rm 172, Los Angeles, CA 90089 USA.				NIGMS NIH HHS [GM38839, GM21422, GM38559] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM021422, R01GM038839, R37GM021422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alleva JL, 2000, BIOCHEMISTRY-US, V39, P2659, DOI 10.1021/bi992751n; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; BESSMAN MJ, 1977, J MOL BIOL, V116, P115, DOI 10.1016/0022-2836(77)90122-X; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; BONNER CA, 1992, J BIOL CHEM, V267, P11431; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Creighton S, 1995, METHOD ENZYMOL, V262, P232; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; Fijalkowska IJ, 1998, P NATL ACAD SCI USA, V95, P10020, DOI 10.1073/pnas.95.17.10020; Fygenson DK, 1997, J BIOL CHEM, V272, P27931, DOI 10.1074/jbc.272.44.27931; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Goodman MF, 1998, GENETICS, V148, P1475; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KORNBERG A, 1992, DNA REPLICATION, P167; LEE MYWT, 1980, BIOCHEMISTRY-US, V19, P2096, DOI 10.1021/bi00551a015; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; MAKI S, 1988, J BIOL CHEM, V263, P6555; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; PETRUSKA J, 1985, J BIOL CHEM, V260, P7533; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; Reynolds N, 1998, CURR GENET, V34, P250, DOI 10.1007/s002940050394; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; VEAUTE X, 1993, SCIENCE, V261, P598, DOI 10.1126/science.8342022; Veaute X, 1997, J BIOL CHEM, V272, P15351, DOI 10.1074/jbc.272.24.15351; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Zuo SJ, 1997, P NATL ACAD SCI USA, V94, P11244, DOI 10.1073/pnas.94.21.11244	48	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17677	17682		10.1074/jbc.M910278199	http://dx.doi.org/10.1074/jbc.M910278199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748208	hybrid			2022-12-27	WOS:000087485000067
J	Ganju, RK; Brubaker, SA; Chernock, RD; Avraham, S; Groopman, JE				Ganju, RK; Brubaker, SA; Chernock, RD; Avraham, S; Groopman, JE			beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; MACROPHAGE-TROPIC HIV-1; FOCAL ADHESION KINASE; COUPLED RECEPTOR; KAPOSIS-SARCOMA; TRANSDUCTION PATHWAYS; HEMATOPOIETIC-CELLS; CROSS-LINKING; P85 SUBUNIT; T-CELLS	The beta-chemokine receptor CCR5 has been shown to modulate cell migration, proliferation, and immune functions and to serve as a co-receptor for the human immunodeficiency virus. We and others have shown that CCR5 activates related adhesion focal tyrosine kinase (RAFTK)/Pyk2/CAK-beta. In this study, we further characterize the signaling molecules activated by CCR5 upon binding to its cognate ligand, macrophage inflammatory protein-1 beta (MIP1 beta). We observed enhanced tyrosine phosphorylation of the phosphatases SHP1 and SHP2 upon MIP1 beta stimulation of CCR5 L1.2 transfectants and T-cells derived from peripheral blood mononuclear cells. Furthermore, we observed that SHP1 associated with RAFTK. However, using a dominant-negative phosphatase-binding mutant of RAFTK (RAFTK(m906)), we found that RAFTK does not mediate SHP1 or SHP2 phosphorylation. SHP1 and SHP2 also associated with the adaptor protein Grb2 and the Src-related kinase Syk. Pretreatment of CCR5 L1.2 transfectants or T-cells with the phosphatase inhibitor orthovanadate markedly abolished MIP1 beta-induced chemotaxis. Syk was also activated upon MIP1 beta stimulation of CCR5 L1.2 transfectants or T-cells and associated with RAFTK. Overexpression of a dominant-negative Src-binding mutant of RAFTK (RAFTK(m402)) significantly attenuated Syk activation, whereas overexpression of wild-type RAFTK enhanced Syk activity, indicating that RAFTK acts upstream of CCR5-mediated Syk activation. Taken together, these results suggest that MIP1 beta stimulation mediated by CCR5 induces the formation of a signaling complex consisting of RAFTK, Syk, SHP1, and Grb2.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Med Sch,Div Expt Med Hematol Oncol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Ganju, RK (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Med Sch,Div Expt Med Hematol Oncol, 4 Blackfan Circle,Suite 351, Boston, MA 02115 USA.			Chernock, Rebecca/0000-0001-6253-0478	NATIONAL CANCER INSTITUTE [R29CA076950] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053745, R01HL061940] Funding Source: NIH RePORTER; NCI NIH HHS [CA76950] Funding Source: Medline; NHLBI NIH HHS [HL61940, HL53745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alfano M, 1999, J EXP MED, V190, P597, DOI 10.1084/jem.190.5.597; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Brumbaugh KM, 1997, J EXP MED, V186, P1965, DOI 10.1084/jem.186.12.1965; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dong Q, 1999, J IMMUNOL, V162, P3220; Dustin LB, 1999, J IMMUNOL, V162, P2717; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Jugloff LS, 1997, J IMMUNOL, V159, P1096; Kim CH, 1999, J EXP MED, V190, P681, DOI 10.1084/jem.190.5.681; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Murphy PM, 1997, NATURE, V385, P296, DOI 10.1038/385296a0; Nakamura K, 1998, J IMMUNOL, V161, P684; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sada K, 1997, EUR J BIOCHEM, V248, P827, DOI 10.1111/j.1432-1033.1997.00827.x; Sagawa K, 1997, J BIOL CHEM, V272, P31086, DOI 10.1074/jbc.272.49.31086; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Shultz LD, 1997, TRENDS BIOTECHNOL, V15, P302, DOI 10.1016/S0167-7799(97)01060-3; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; Zhang SL, 1999, BIOCHEM BIOPH RES CO, V254, P440, DOI 10.1006/bbrc.1998.9959; Zhou YH, 1998, J IMMUNOL, V160, P4018	61	69	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17263	17268		10.1074/jbc.M000689200	http://dx.doi.org/10.1074/jbc.M000689200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747947	hybrid			2022-12-27	WOS:000087485000009
J	Locatelli, F; Bracale, M; Magaraggia, F; Faoro, F; Manzocchi, LA; Coraggio, I				Locatelli, F; Bracale, M; Magaraggia, F; Faoro, F; Manzocchi, LA; Coraggio, I			The product of the rice myb7 unspliced mRNA dimerizes with the maize leucine zipper Opaque2 and stimulates its activity in a transient expression assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TRANSCRIPTION-FACTOR; NUCLEAR-LOCALIZATION; GENE-EXPRESSION; HEAT-SHOCK; TRANSPOSABLE ELEMENT; PLANT-REGENERATION; MESSENGER-RNA; ZEA-MAYS; PROTEIN	myb7 mRNA is present in rice in spliced and unspliced forms, splicing being enhanced by anoxia, The protein (Mybleu) encoded by the unspliced mRNA is composed of an incomplete Myb domain followed by a leucine zipper; however, it lacks canonical sequences for DNA binding, transcriptional activation, and nuclear localization. We show here that in transiently transformed tobacco protoplasts, Mybleu is able to enhance the transcriptional activity of the maize leucine zipper Opaque2 on its target b32 promoter. The Mybleu transactivation effect is strictly dependent on the presence of Opaque2 and is driven by Mybleu-Opaque2 heterodimers, Mybleu is located in the nucleus, both in rice and in transformed tobacco protoplasts, In rice, the protein is expressed in regions corresponding to undifferentiated cells of roots and coleoptiles. Therefore, myb7 mRNA encodes, depending on its splicing, two transcription factors belonging to separate classes. One of them, Mybleu, has novel structural characteristics, suggesting the existence of new mechanisms acting in the activation of transcription.	CNR, Ist Biosintesi Vegetali, I-20133 Milan, Italy; CNR, Ctr Miglioramento Santiario Colture Agrarie, I-20133 Milan, Italy; Univ Insubria, Dipartimento Bol Strutturale & Funzionale, I-21100 Varese, Italy	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Insubria	Coraggio, I (corresponding author), CNR, Ist Biosintesi Vegetali, Via Bassini 15, I-20133 Milan, Italy.	imma@icm.mi.cnr.it	Faoro, Franco/O-6631-2017	Faoro, Franco/0000-0003-2620-9171; LOCATELLI, FRANCA/0000-0003-2537-7288				AVILA J, 1993, PLANT J, V3, P553, DOI 10.1046/j.1365-313X.1993.03040553.x; Bender J, 1998, P NATL ACAD SCI USA, V95, P5655, DOI 10.1073/pnas.95.10.5655; BILANG R, 1994, PLANT MOL BIOL MANUA, P1; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BREVIARIO D, 1994, PLANT CELL ENVIRON, V17, P925, DOI 10.1111/j.1365-3040.1994.tb00321.x; Brown JWS, 1998, ANNU REV PLANT PHYS, V49, P77, DOI 10.1146/annurev.arplant.49.1.77; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; CERIOTTI A, 1991, EUR J BIOCHEM, V202, P959, DOI 10.1111/j.1432-1033.1991.tb16456.x; CHIATANTE D, 1990, PHYSIOL PLANTARUM, V78, P501, DOI 10.1111/j.1399-3054.1990.tb05233.x; Ciceri P, 1997, PLANT CELL, V9, P97, DOI 10.1105/tpc.9.1.97; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; CZARNECKA E, 1988, MOL CELL BIOL, V8, P1113, DOI 10.1128/MCB.8.3.1113; DAMICO L, 1992, PLANT J, V2, P443; DEVETTEN NC, 1995, PLANT J, V7, P589, DOI 10.1046/j.1365-313X.1995.7040589.x; FREY M, 1990, EMBO J, V9, P4037, DOI 10.1002/j.1460-2075.1990.tb07625.x; FROMM M, 1985, P NATL ACAD SCI USA, V82, P5824, DOI 10.1073/pnas.82.17.5824; FROMM ME, 1986, NATURE, V319, P791, DOI 10.1038/319791a0; GIOVINAZZO G, 1992, PLANT MOL BIOL, V19, P257, DOI 10.1007/BF00027347; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; HARLOW E, 1988, ANTIBODIES LAB MANUA, P321; HARTINGS H, 1989, EMBO J, V8, P2795, DOI 10.1002/j.1460-2075.1989.tb08425.x; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; JACKSON D, 1991, PLANT CELL, V3, P115, DOI 10.1105/tpc.3.2.115; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; JUNG JL, 1992, PLANT CELL REP, V11, P346, DOI 10.1007/BF00233363; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kranz HD, 1998, PLANT J, V16, P263, DOI 10.1046/j.1365-313x.1998.00278.x; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMER S, 1991, EMBO J, V10, P617, DOI 10.1002/j.1460-2075.1991.tb07989.x; Magae J, 1996, J CELL SCI, V109, P1717; Magaraggia F, 1997, PLANT MOL BIOL, V35, P1003, DOI 10.1023/A:1005821518242; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MAROCCO A, 1989, MOL GEN GENET, V216, P183, DOI 10.1007/BF00334354; McGonigle B, 1996, GENE DEV, V10, P1812, DOI 10.1101/gad.10.14.1812; MENGUZZATO E, 1995, PLANT PHYSIOL, V109, P1498; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MIAO ZH, 1995, PLANT J, V7, P887, DOI 10.1046/j.1365-313X.1995.07060887.x; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NAGY JI, 1976, Z PFLANZENPHYSIOL, V78, P453, DOI 10.1016/S0044-328X(76)80093-1; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; Olive M, 1996, J BIOL CHEM, V271, P2040, DOI 10.1074/jbc.271.4.2040; ORTIZ DF, 1990, MOL CELL BIOL, V10, P2090, DOI 10.1128/MCB.10.5.2090; Pandolfi D., 1997, PLANT PHYSIOL, V114, P747; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POTRYKUS I, 1986, METHOD ENZYMOL, V118, P549; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; Riechmann JL, 1996, P NATL ACAD SCI USA, V93, P4793, DOI 10.1073/pnas.93.10.4793; RIGGS P, 1992, SHORT PROTOCOLS MOL, P21; Sambrook J., 1989, MOL CLONING LAB MANU, V3rd; SCHMIDT RJ, 1990, P NATL ACAD SCI USA, V87, P46, DOI 10.1073/pnas.87.1.46; SCHMIDT RJ, 1992, PLANT CELL, V4, P689, DOI 10.1105/tpc.4.6.689; Schwechheimer C, 1998, ANNU REV PLANT PHYS, V49, P127, DOI 10.1146/annurev.arplant.49.1.127; Shirakawa H, 1997, BIOCHEMISTRY-US, V36, P5992, DOI 10.1021/bi962487n; SOLINAS G, 1997, PLANT PHYSIOL, V114, P747; SOLINAS G, 1997, PLANT PHYSIOL, V114, P395; SPRINGHORN JP, 1994, J BIOL CHEM, V269, P5132; URAO T, 1993, PLANT CELL, V5, P1529, DOI 10.1105/tpc.5.11.1529; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WIDHOLM JM, 1972, STAIN TECHNOL, V47, P189, DOI 10.3109/10520297209116483; Wu CY, 1998, PLANT J, V14, P673, DOI 10.1046/j.1365-313x.1998.00167.x; Yang YO, 1996, P NATL ACAD SCI USA, V93, P14972, DOI 10.1073/pnas.93.25.14972; YOST HJ, 1988, SCIENCE, V242, P1544, DOI 10.1126/science.3201243; Zandi E, 1997, GENE DEV, V11, P1299, DOI 10.1101/gad.11.10.1299	66	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17619	17625		10.1074/jbc.M000647200	http://dx.doi.org/10.1074/jbc.M000647200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747941	Green Published, hybrid			2022-12-27	WOS:000087485000059
J	Farmer, CS; Kurtz, DM; Phillips, RS; Ai, JY; Sanders-Loehr, J				Farmer, CS; Kurtz, DM; Phillips, RS; Ai, JY; Sanders-Loehr, J			A leucine residue "gates" solvent but not O-2 access to the binding pocket of Phascolopsis gouldii hemerythrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSIBLE DIOXYGEN BINDING; IRON CENTER; OXYHEMERYTHRIN; MYOHEMERYTHRIN; CHEMISTRY; RECONSTITUTION; INTERMEDIATE; MYOGLOBIN; COMPLEXES; KINETICS	A leucine residue, Leu-98, Lines the O-2-binding pocket in all known hemerythrins. Leu-98 in recombinant Phascolopsis gouldii hemerythrin, was mutated to several other residues of varying sizes (Ala, Val), polarities (Thr, Asp, Asn), and aromaticities (Phe, Tyr, Trp). UV-visible and resonance Raman spectra showed that the di-iron sites in these L98X Hrs are very similar to those in the wild type protein, and several of the L98X hemerythrins formed stable oxy adducts, Despite the apparently tight packing in the pocket, all of the L98X Hrs except for L98W, had second order O-2 association rate constants within a factor of 3 of the wild type value. Similarly, the O-2 dissociation rate constant was essentially unaffected by substitutions of larger (Phe) or smaller (Val, Thr) residues for Leu-98, L98Y Hr showed a 170-fold decrease in the O-2 dissociation rate constant and a large D2O effect on this rate, which are attributed to a hydrogen-bonding interaction between the Tyr-98 hydroxyl and the bound O-2. Significant increases in autoxidation rates were observed for all of the L98X Hrs other than X = Tyr. These increases in autoxidation rates are attributed to increased solvent access to the binding pocket caused by inefficient packing (Phe), smaller size (Val, Ala), or increased polarity (Thr, Asp, Asn) of the residue 98 side chain. A leucine at position 98 appears to have the optimal size, shape, and hydrophobicity for inhibition of solvent access. Thus, "gating" of small molecule access to the binding pocket of Hr by Leu-98 is not evident for O-2, but is evident for solvent.	Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA; Oregon Grad Inst Sci & Technol, Portland, OR 97291 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Kurtz, DM (corresponding author), Univ Georgia, Dept Chem, Athens, GA 30602 USA.			Phillips, Robert/0000-0001-8710-562X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040388] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18865, GM40388] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AI J, 1998, THESIS OREGON GRAD I; ALBERDING N, 1981, P NATL ACAD SCI-BIOL, V78, P2307, DOI 10.1073/pnas.78.4.2307; ARMSTRONG GD, 1986, INORG CHEM, V25, P3135, DOI 10.1021/ic00238a008; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; AVERILL BA, 1987, J AM CHEM SOC, V109, P3760, DOI 10.1021/ja00246a039; BATES G, 1968, BIOCHEMISTRY-US, V7, P3016, DOI 10.1021/bi00848a044; BRADIC Z, 1977, J BIOL CHEM, V252, P6069; Brunold TC, 1999, J AM CHEM SOC, V121, P8288, DOI 10.1021/ja992234s; Brunold TC, 1999, J AM CHEM SOC, V121, P8277, DOI 10.1021/ja990334s; Cohen JD, 1997, J AM CHEM SOC, V119, P2960, DOI 10.1021/ja9638871; Coletta M, 1999, J BIOL INORG CHEM, V4, P678, DOI 10.1007/s007750050339; Creighton T. E., 1993, PROTEINS STRUCTURE M; DEWAAL DJA, 1976, J BIOL CHEM, V251, P2339; Feher VA, 1996, NAT STRUCT BIOL, V3, P516, DOI 10.1038/nsb0696-516; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; GARBETT K, 1969, ARCH BIOCHEM BIOPHYS, V135, P419, DOI 10.1016/0003-9861(69)90559-1; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Kim K, 1996, J AM CHEM SOC, V118, P4914, DOI 10.1021/ja9604370; KLIPPENSTEIN GL, 1972, BIOCHEMISTRY-US, V11, P372, DOI 10.1021/bi00753a011; KURTZ DM, 1990, CHEM REV, V90, P585, DOI 10.1021/cr00102a002; LANGERMAN N, 1971, BIOCHEMISTRY-US, V10, P2809, DOI 10.1021/bi00791a001; LAVALETTE D, 1988, EUR J BIOCHEM, V177, P97, DOI 10.1111/j.1432-1033.1988.tb14349.x; LAVALETTE D, 1991, STRUCTURE AND FUNCTION OF INVERTEBRATE OXYGEN CARRIERS, P191; LLOYD CR, 1995, J AM CHEM SOC, V117, P11993, DOI 10.1021/ja00153a021; Martins LJ, 1997, BIOCHEMISTRY-US, V36, P7044, DOI 10.1021/bi9630422; NEGRI A, 1994, BBA-PROTEIN STRUCT M, V1208, P277, DOI 10.1016/0167-4838(94)90114-7; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Pereira AS, 1998, BIOCHEMISTRY-US, V37, P9871, DOI 10.1021/bi980847w; PETROU AL, 1981, BIOCHIM BIOPHYS ACTA, V670, P377, DOI 10.1016/0005-2795(81)90110-0; PROJAHN HD, 1995, INORG CHEM, V34, P5935, DOI 10.1021/ic00128a003; Raner GM, 1997, BIOCHEMISTRY-US, V36, P7037, DOI 10.1021/bi963041+; ROBITAILLE PM, 1988, BIOCHEMISTRY-US, V27, P4458, DOI 10.1021/bi00412a037; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SANDERSLOEHR J, 1989, J AM CHEM SOC, V111, P8084, DOI 10.1021/ja00203a003; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIEMKE AK, 1984, J AM CHEM SOC, V106, P4951, DOI 10.1021/ja00329a054; SOLOMON EI, 1994, CHEM REV, V94, P827, DOI 10.1021/cr00027a013; STENKAMP RE, 1994, CHEM REV, V94, P715, DOI 10.1021/cr00027a008; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TABOR S, 1990, CURRENT PROTOCOLS MO; WARD KB, 1975, NATURE, V257, P818, DOI 10.1038/257818a0; WILKINS PC, 1987, COORDIN CHEM REV, V79, P195, DOI 10.1016/0010-8545(87)80003-6; WILKINS RG, 1983, ADV INORG BIOCHEM, V5, P51; ZHANG JH, 1991, BIOCHEMISTRY-US, V30, P583, DOI 10.1021/bi00216a037; ZHANG JH, 1992, BIOCHIM BIOPHYS ACTA, V1122, P293, DOI 10.1016/0167-4838(92)90407-5	46	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17043	17050		10.1074/jbc.M001289200	http://dx.doi.org/10.1074/jbc.M001289200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748012	hybrid			2022-12-27	WOS:000087392200090
J	Monteil, A; Chemin, J; Leuranguer, V; Altier, C; Mennessier, G; Bourinet, E; Lory, P; Nargeot, J				Monteil, A; Chemin, J; Leuranguer, V; Altier, C; Mennessier, G; Bourinet, E; Lory, P; Nargeot, J			Specific properties of T-type calcium channels generated by the human alpha(1I) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CA2+ CHANNELS; MOLECULAR CHARACTERIZATION; GENE FAMILY; NEURONS; CLONING; EXPRESSION; ALPHA-1H; NUCLEUS; MEMBER; CELLS	We have cloned and expressed a human alpha(1I) subunit that encodes a subtype of T-type calcium channels. The predicted protein is 95% homologous to its rat counter-part but has a distinct COOH-terminal region. Its mRNA is detected almost exclusively in the human brain, as well as in adrenal and thyroid glands. Calcium currents generated by the functional expression of human alpha(1I) and alpha(1G) subunits in HEK-293 cells were compared. The alpha(1I) current activated and inactivated similar to 10 mV more positively. Activation and inactivation kinetics were up to six times slower, while deactivation kinetics was faster and showed little voltage dependence. A slower recovery from inactivation, a lower sensitivity to Ni2+ ions (IC50 similar to 180 mu M), and a larger channel conductance (similar to 11 picosiemens) were the other discriminative features of the alpha(1I) current. These data demonstrate that the alpha(1I) subunit encodes T-type Ca2+ channels functionally distinct from those generated by the human alpha(1G) or alpha(1H) subunits and point out that human and rat alpha(1I) subunits have species-specific properties not only in their primary sequence, but also in their expression profile and electrophysiological behavior.	IGH, CNRS, UPR 1142, F-34396 Montpellier 05, France; Univ Montpellier 2, CNRS, UMR 5825, F-34095 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Lory, P (corresponding author), IGH, CNRS, UPR 1142, 141 Rue Cardonille, F-34396 Montpellier 05, France.		Monteil, Arnaud/G-3113-2012	Monteil, Arnaud/0000-0003-1632-7318; chemin, jean/0000-0002-6089-5964; LORY, philippe/0000-0002-1638-7604; bourinet, emmanuel/0000-0001-8021-0419; Nargeot, Joel/0000-0003-2893-5636				Bean BP, 1998, NEURON, V20, P825, DOI 10.1016/S0896-6273(00)80463-8; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; Burgess DL, 2000, EPILEPSIA, V41, P24, DOI 10.1111/j.1528-1157.2000.tb01500.x; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; ENYEART JJ, 1993, MOL ENDOCRINOL, V7, P1031, DOI 10.1210/me.7.8.1031; Huguenard JR, 1998, TRENDS NEUROSCI, V21, P451, DOI 10.1016/S0166-2236(98)01331-9; HUGUENARD JR, 1992, J NEUROSCI, V12, P3804, DOI 10.1523/jneurosci.12-10-03804.1992; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; Klockner U, 1999, EUR J NEUROSCI, V11, P4171, DOI 10.1046/j.1460-9568.1999.00849.x; Klugbauer N, 1999, PFLUG ARCH EUR J PHY, V437, P710, DOI 10.1007/s004240050836; Kozlov AS, 1999, EUR J NEUROSCI, V11, P4149, DOI 10.1046/j.1460-9568.1999.00841.x; Lee JH, 1999, BIOPHYS J, V77, P3034, DOI 10.1016/S0006-3495(99)77134-1; Lee JH, 1999, J NEUROSCI, V19, P1912; Mittman S, 1999, NEUROSCI LETT, V269, P121, DOI 10.1016/S0304-3940(99)00319-5; Monteil A, 1999, BIOPHYS J, V76, pA408; Monteil A, 2000, J BIOL CHEM, V275, P6090, DOI 10.1074/jbc.275.9.6090; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PULVER AE, 1994, AM J MED GENET, V54, P36, DOI 10.1002/ajmg.1320540108; Randall AD, 1997, NEUROPHARMACOLOGY, V36, P879, DOI 10.1016/S0028-3908(97)00086-5; Talley EM, 1999, J NEUROSCI, V19, P1895; Tarasenko AN, 1997, J PHYSIOL-LONDON, V499, P77, DOI 10.1113/jphysiol.1997.sp021912; TROFATTER JA, 1995, GENOME RES, V5, P214, DOI 10.1101/gr.5.3.214; Williams ME, 1999, J NEUROCHEM, V72, P791, DOI 10.1046/j.1471-4159.1999.0720791.x; XU Y, 1994, ISMB, V2, P376; Zhuravleva SO, 1999, NEUROREPORT, V10, P651, DOI 10.1097/00001756-199902250-00038; Zu L, 1999, AM J HUM GENET, V64, P594, DOI 10.1086/302247	28	114	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16530	16535		10.1074/jbc.C000090200	http://dx.doi.org/10.1074/jbc.C000090200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10749850	hybrid			2022-12-27	WOS:000087392200020
J	Palumbo, A; Poli, A; Di Cosmo, A; d'Ischia, M				Palumbo, A; Poli, A; Di Cosmo, A; d'Ischia, M			N-methyl-D-aspartate receptor stimulation activates tyrosinase and promotes melanin synthesis in the Ink gland of the cuttlefish Sepia officinalis through the nitric oxide/cGMP signal transduction pathway - A novel possible role for glutamate as physiologic activator of melanogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN MELANOCYTES; 5,6-DIHYDROXYINDOLE-2-CARBOXYLIC ACID; MAMMALIAN TYROSINASE; PEROXIDASE; BIOSYNTHESIS; LOCALIZATION; EUMELANIN; SYNTHASE; SYSTEM; CELLS	The tyrosinase-catalyzed conversion of L-tyrosine to melanin represents the most distinctive biochemical pathway in the ink gland of the cuttlefish Sepia officinalis; however, the molecular mechanisms underlying its activation have remained so far largely uncharted. In this paper we demonstrate for the first time that L-glutamate can stimulate tyrosinase activity and promote melanin synthesis in Sepia ink gland via the N-methyl-D-aspartate (NMDA) receptor/NO/cGMP signal transduction pathway. Incubation of intact ink glands with either L-glutamate or NMDA resulted in an up to 18-fold increase of tyrosinase activity and a more than 6-fold elevation of cGMP levels. Comparable stimulation of tyrosinase was induced by an NO donor and by 8-bromo-cGMP. An NMDA receptor antagonist, NO synthase (NOS) inhibitors, and a guanylate cyclase blocker suppressed NMDA-induced effects. Immunohistochemical evidence indicated that enhanced cGMP production was localized largely in the mature part of the ink gland. Increased de novo synthesis of melanin was demonstrated in NMDA- and NO-stimulated ink glands by a combined microanalytical approach based on spectro-photometric determination of pigment levels and high performance liquid chromatography quantitation of pyrrole-2,3,5-tricarboxylic acid, a specific melanin marker, in melanosome containing fractions. These results fill a longstanding gap in the understanding of the complex biochemical mechanisms underlying activation of melanogenesis in the mature ink gland cells of S. officinalis and disclose a novel physiologic role of the excitatory neurotransmitter glutamate mediated by the NMDA receptor/NO/cGMP signaling pathway.	Staz Zool Anton Dohrn, I-80121 Naples, Italy; Univ Naples Federico 2, Dept Zool, I-80134 Naples, Italy; Univ Naples Federico 2, Dept Organ & Biol Chem, I-80134 Naples, Italy	Stazione Zoologica Anton Dohrn di Napoli; University of Naples Federico II; University of Naples Federico II	Palumbo, A (corresponding author), Staz Zool Anton Dohrn, Villa Comunale, I-80121 Naples, Italy.	palumbo@alpha.szn.it; dischia@cds.unina.it	d'Ischia, Marco/C-9837-2011	d'Ischia, Marco/0000-0002-7184-0029; Palumbo, Anna/0000-0002-5972-5589				De Vente Jan, 1993, V14, P409; DISCHIA M, 1991, BIOCHIM BIOPHYS ACTA, V1073, P423, DOI 10.1016/0304-4165(91)90152-7; El-Husseini AE, 1998, J NEUROCHEM, V71, P676; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; Gesualdo I, 1997, BBA-GENE STRUCT EXPR, V1353, P111, DOI 10.1016/S0167-4781(97)00088-2; Hanlon R. T, 1996, CEPHALOPOD BEHAV, P66; Hearing V. J., 1998, PIGMENTARY SYSTEM PH, P423; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; ITO S, 1993, ANAL BIOCHEM, V215, P273, DOI 10.1006/abio.1993.1586; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; KUZUMAKI T, 1993, EXP CELL RES, V207, P33, DOI 10.1006/excr.1993.1159; LUCERO MT, 1994, BIOL BULL, V187, P55, DOI 10.2307/1542165; MACGINITIS GE, 1949, NATURAL HIST MARINE, P395; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; NAEYAERT JM, 1991, BRIT J DERMATOL, V125, P297, DOI 10.1111/j.1365-2133.1991.tb14161.x; NAPOLITANO A, 1995, TETRAHEDRON, V51, P5913, DOI 10.1016/0040-4020(95)00259-B; Okun MR, 1996, PHYSIOL CHEM PHYS ME, V28, P91; Ortonne J.P., 1998, PIGMENTARY SYSTEM, P307; Osanai K., 1975, P26; Palumbo A, 1999, J NEUROCHEM, V73, P1254, DOI 10.1046/j.1471-4159.1999.0731254.x; PALUMBO A, 1988, BIOCHIM BIOPHYS ACTA, V964, P193, DOI 10.1016/0304-4165(88)90166-3; PALUMBO A, 1995, BBA-PROTEIN STRUCT M, V1247, P173, DOI 10.1016/0167-4838(94)00221-2; Palumbo A, 1997, BIOCHEM J, V323, P749, DOI 10.1042/bj3230749; Palumbo A, 1997, BIOCHEM BIOPH RES CO, V235, P429, DOI 10.1006/bbrc.1997.6734; PARK HY, 1993, J BIOL CHEM, V268, P11742; Park HY, 1999, J BIOL CHEM, V274, P16470, DOI 10.1074/jbc.274.23.16470; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Pezzella A, 1997, RAPID COMMUN MASS SP, V11, P368, DOI 10.1002/(SICI)1097-0231(19970228)11:4<368::AID-RCM859>3.0.CO;2-E; Pezzella A, 1997, TETRAHEDRON, V53, P8281, DOI 10.1016/S0040-4020(97)00494-8; PROTA G, 1981, COMP BIOCHEM PHYS B, V68, P415, DOI 10.1016/0305-0491(81)90149-8; Prota G., 1992, MELANINS MELANOGENES, P153, DOI [10.1016/B978-0-12-565970-3.50014-5, DOI 10.1016/B978-0-12-565970-3.50014-5]; RomeroGraillet C, 1996, J BIOL CHEM, V271, P28052, DOI 10.1074/jbc.271.45.28052; Sabattini E, 1998, J CLIN PATHOL, V51, P506, DOI 10.1136/jcp.51.7.506; SHIBATA T, 1993, J INVEST DERMATOL, V100, P274; TSUKAMOTO K, 1992, BIOCHEM J, V286, P491, DOI 10.1042/bj2860491; [No title captured]	37	38	40	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16885	16890		10.1074/jbc.M909509199	http://dx.doi.org/10.1074/jbc.M909509199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748137	hybrid			2022-12-27	WOS:000087392200069
J	Latham, GJ; Forgacs, E; Beard, WA; Prasad, R; Bebenek, K; Kunkel, TA; Wilson, SH; Lloyd, RS				Latham, GJ; Forgacs, E; Beard, WA; Prasad, R; Bebenek, K; Kunkel, TA; Wilson, SH; Lloyd, RS			Vertical-scanning mutagenesis of a critical tryptophan in the "minor groove binding track" of HIV-1 reverse transcriptase - Major groove DNA adducts identify specific protein interactions in the minor groove	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RAS CODON-61 SEQUENCE; DOUBLE-STRANDED DNA; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; OXIDE ADDUCTS; TRANSLESION SYNTHESIS; THUMB SUBDOMAIN; TEMPLATE-PRIMER; IN-VITRO	Biochemical and molecular modeling studies of human immunodeficiency virus type 1 reverse transcriptase (RT) have revealed that a structural element, the minor groove binding track (MGBT), is important for both replication frameshift fidelity and processivity, The MGBT interactions occur in the DNA minor groove from the second through sixth base pair from the primer 3'-terminus where the DNA undergoes a structural transition from A-like to B-form DNA Alanine-scanning mutagenesis had previously demonstrated that Gly(262) and Trp(266) of the MGBT contributes important DNA interactions. To probe the molecular interactions occurring in this critical region, eight mutants of RT were studied in which alternate residues were substituted for Trp(266) These enzymes were characterized in primer extension assays in which the template DNA was adducted at a single adenine by either R- or S-enantiomers of styrene oxide. These lesions failed to block DNA polymerization by wild-type RT, yet the Trp(266) mutants and an alanine mutant of Gly(262) terminated synthesis on styrene oxide-adducted templates. Significantly, the sites of termination occurred primarily 1 and 3 bases following adduct bypass, when the lesion was positioned in the major groove of the template-primer stem. These results indicate that residue 266 serves as a "protein sensor" of altered minor groove interactions and identifies which base pair interactions are altered by these lesions. In addition, the major groove lesion must alter important structural transitions in the template-primer stem, such as minor groove widening, that allow RT access to the minor groove.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Lloyd, RS (corresponding author), Amb Inc, 2130 Woodward St, Austin, TX 78744 USA.	rslloyd@utmb.edu	Wilson, Samuel H/E-6644-2019; Kunkel, Thomas A./D-5088-2019	Wilson, Samuel H/0000-0002-1702-5293; Kunkel, Thomas A./0000-0002-9900-1788; Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [ES05355, ES06766, ES06492] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006492, ZIAES050161, Z01ES050161, R01ES006766] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; Beard WA, 1998, J BIOL CHEM, V273, P30435, DOI 10.1074/jbc.273.46.30435; Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; FENG BB, 1995, BIOCHEMISTRY-US, V34, P14021, DOI 10.1021/bi00043a008; Feng BB, 1996, BIOCHEMISTRY-US, V35, P7316, DOI 10.1021/bi952526f; Forgacs E, 1997, J BIOL CHEM, V272, P8525, DOI 10.1074/jbc.272.13.8525; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; HARRIS CM, 1991, J AM CHEM SOC, V113, P4328, DOI 10.1021/ja00011a044; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LATHAM GJ, 1995, CHEM RES TOXICOL, V8, P422, DOI 10.1021/tx00045a014; LATHAM GJ, 1994, J BIOL CHEM, V269, P28527; Lavigne M, 1997, J MOL BIOL, V266, P507, DOI 10.1006/jmbi.1996.0805; Lavigne M, 1999, J MOL BIOL, V285, P977, DOI 10.1006/jmbi.1998.2367; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P18682; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343	36	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15025	15033		10.1074/jbc.M000279200	http://dx.doi.org/10.1074/jbc.M000279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747890	hybrid			2022-12-27	WOS:000087128300037
J	Pabon-Pena, LM; Goodwin, RL; Cise, LJ; Bader, D				Pabon-Pena, LM; Goodwin, RL; Cise, LJ; Bader, D			Analysis of CMF1 reveals a bone morphogenetic protein-independent component of the cardiomyogenic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTE DIFFERENTIATION; HEART FORMING REGION; MYOSIN HEAVY-CHAIN; ANTERIOR ENDODERM; CELL DIFFERENTIATION; NUCLEAR-LOCALIZATION; AVIAN EMBRYOS; MYOGENESIS; EXPRESSION; OCCURS	Disruption of the CMF1 function in anterior mesoderm inhibits cardiac myogenesis in avian embryos. In the present study, we show that CMF1 is a member of an emerging family of proteins that includes centromeric protein-F, mitosin, and LEK1. These proteins are characterized by their large size (350 kDa), dynamic subcellular distribution, and potential functions in cell division and differentiation. The current data suggest that CMF1 is a unique member of this family by virtue of its restricted protein expression and variant subcellular distribution. Immunochemical analysis demonstrates that CMF1 protein is expressed in cardiogenic cells prior to the activation of cardiac structural gene products. In addition, we show that expression of CMF1 is not dependent on the bone morphogenetic protein (BMP) signaling pathway during development. Still, CMF1 cannot direct cardiomyogenesis in the absence of such factors as NKX-2.5. Taken with our previous data, this study suggests that CMF1 is a BMP-independent component of the cardiomyogenic pathway.	Vanderbilt Univ, Div Cardiovasc Med, Stahlman Cardiovasc Res Labs, Program Dev Biol, Nashville, TN 37232 USA	Vanderbilt University	Bader, D (corresponding author), Vanderbilt Univ, Div Cardiovasc Med, Stahlman Cardiovasc Res Labs, Program Dev Biol, Rm 338,MRB 2,2220 Pierce Ave, Nashville, TN 37232 USA.		Goodwin, Richard L./AAN-5007-2020; Goodwin, Richard/R-6169-2019	Goodwin, Richard/0000-0002-2537-2535	NHLBI NIH HHS [HL09916, HL07723, HL37617] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL007723, F32HL009916, R01HL007723] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTIN PB, 1994, DEV DYNAM, V200, P144, DOI 10.1002/aja.1002000206; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BISAHA JG, 1991, DEV BIOL, V148, P355, DOI 10.1016/0012-1606(91)90343-2; Cleaver OB, 1996, DEVELOPMENT, V122, P3549; CohenGould L, 1996, DEV BIOL, V177, P265, DOI 10.1006/dbio.1996.0161; CONSIGLI SA, 1991, J CELL PHYSIOL, V146, P379, DOI 10.1002/jcp.1041460307; DEHAAN RL, 1965, ORGANOGENESIS, P377; Ehrman LA, 1999, DEV BIOL, V207, P163, DOI 10.1006/dbio.1998.9167; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Fishman MC, 1997, CELL, V91, P153, DOI 10.1016/S0092-8674(00)80397-9; Fishman MC, 1997, DEVELOPMENT, V124, P2099; GANNON M, 1995, DEVELOPMENT, V121, P2439; GARCIAMARTINEZ V, 1993, DEV BIOL, V159, P706, DOI 10.1006/dbio.1993.1276; GONZALEZSANCHEZ A, 1990, DEV BIOL, V139, P197, DOI 10.1016/0012-1606(90)90288-T; Goodwin RL, 1999, J BIOL CHEM, V274, P18597, DOI 10.1074/jbc.274.26.18597; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAN Y, 1992, DEV DYNAM, V193, P257, DOI 10.1002/aja.1001930306; JACOBSON AG, 1960, DEV BIOL, V2, P138, DOI 10.1016/0012-1606(60)90003-8; JETER JR, 1971, J EMBRYOL EXP MORPH, V25, P405; KELLEY C, 1993, DEVELOPMENT, V118, P817; LI H, 1994, J CELL BIOL, V124, P827, DOI 10.1083/jcb.124.5.827; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; SATER AK, 1989, DEVELOPMENT, V105, P821; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; SUGI Y, 1994, DEV DYNAM, V200, P155, DOI 10.1002/aja.1002000207; Wei Y, 1996, DEVELOPMENT, V122, P2779; Weitzer G, 1995, DEV BIOL, V172, P422, DOI 10.1006/dbio.1995.8070; YUTZEY KE, 1994, DEVELOPMENT, V120, P871; ZHU XL, 1995, J BIOL CHEM, V270, P19545, DOI 10.1074/jbc.270.33.19545; ZHU XL, 1995, MOL CELL BIOL, V15, P5017	36	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21453	21459		10.1074/jbc.M000518200	http://dx.doi.org/10.1074/jbc.M000518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10747923	hybrid			2022-12-27	WOS:000088230600067
J	Seo, MS; Kang, SW; Kim, K; Baines, IC; Lee, TH; Rhee, SG				Seo, MS; Kang, SW; Kim, K; Baines, IC; Lee, TH; Rhee, SG			Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; THIOL-SPECIFIC ANTIOXIDANT; ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; THIOREDOXIN PEROXIDASE; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; OXIDATIVE STRESS; CELL-SURVIVAL; CLONING	Peroxidases of the peroxiredoxin (Prx) family contain a Cys residue that is preceded by a conserved sequence in the NH2-terminal region. A new type of mammalian Prx, designated PrxV, has now been identified as the result of a data base search with this conserved Cys-containing sequence. The 162-amino acid PrxV shares only similar to 10% sequence identity with previously identified mammalian Prx enzymes and contains Cys residues at positions 73 and 152 in addition to that (Cys(48)) corresponding to the conserved Cys. Analysis of mutant human PrxV proteins in which each of these three Cys residues was individually replaced with serine suggested that the sulfhydryl group of Cys(48) is the site of oxidation by peroxides and that oxidized Cys(48) reacts with the sulfhydryl group of Cys(152) to form an intramolecular disulfide linkage. The oxidized intermediate of PrxV is thus distinct from those of other Prx enzymes, which form either an intermolecular disulfide or a sulfenic acid intermediate. The disulfide formed by PrxV is reduced by thioredoxin but not by glutaredoxin or glutathione. Thus, PrxV mutants lacking Cys(48) or Cys(152) showed no detectable thioredoxin-dependent peroxidase activity, whereas mutation of Cys(73) had no effect on activity. Immunoblot analysis revealed that PrxV is widely expressed in rat tissues and cultured mammalian cells and is localized intracellularly to cytosol, mitochondria, and peroxisomes. The peroxidase function of PrxV in vivo was demonstrated by the observations that transient expression of the wild-type protein, but not that of the Cys(48) mutant, in NIH 3T3 cells inhibited H2O2 accumulation and activation of c-Jun NH2-terminal kinase induced by tumor necrosis factor-alpha.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; NHLBI, Dept Extramural Affairs, NIH, Bethesda, MD 20892 USA; Chonnam Natl Univ, Dept Food & Nutr, Kwangju 500757, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Chonnam National University	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 3,Rm 120, Bethesda, MD 20892 USA.		Lee, Tae-Hoon/AAR-3708-2021	Lee, Tae-Hoon/0000-0003-0105-1750				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Calzi ML, 1997, BIOCHEMISTRY-US, V36, P13357, DOI 10.1021/bi9713660; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; delArco PG, 1996, J BIOL CHEM, V271, P26335; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIM K, 1985, J BIOL CHEM, V260, P5394; KIM KW, 1988, J BIOL CHEM, V263, P4704; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; Matsumoto A, 1999, FEBS LETT, V443, P246, DOI 10.1016/S0014-5793(98)01736-0; Montemartini M, 1999, EUR J BIOCHEM, V264, P516, DOI 10.1046/j.1432-1327.1999.00656.x; Peshenko IV, 1998, FREE RADICAL BIO MED, V25, P654, DOI 10.1016/S0891-5849(98)00111-7; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; WEBBER KO, 1993, ARCH BIOCHEM BIOPHYS, V300, P88, DOI 10.1006/abbi.1993.1013; Yamashita H, 1999, J BIOL CHEM, V274, P29897, DOI 10.1074/jbc.274.42.29897	38	362	388	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20346	20354		10.1074/jbc.M001943200	http://dx.doi.org/10.1074/jbc.M001943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10751410	hybrid			2022-12-27	WOS:000088084500019
J	Djouder, N; Prepens, U; Aktories, K; Cavalie, A				Djouder, N; Prepens, U; Aktories, K; Cavalie, A			Inhibition of calcium release-activated calcium current by Rac/Cdc42-inactivating clostridial cytotoxins in RBL cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; BINDING PROTEIN-RHO; BASOPHILIC LEUKEMIA-CELLS; ACTIN STRESS FIBERS; DIFFICILE TOXIN-B; RAT MAST-CELLS; RBL-2H3 CELLS; SIMILAR MECHANISMS; ADP-RIBOSYLATION; TYROSINE KINASE	Using large clostridial cytotoxins as tools, the role of Rho GTPases in activation of RBL 2H3 hm1 cells was studied. Clostridium difficile toxin B, which glucosylates Rho, Rac, and Cdc42 and Clostridium sordellii lethal toxin, which glucosylates Rac and Cdc42 but not Rho, inhibited the release of hexosaminidase from RBL cells mediated by the high affinity antigen receptor (Fc epsilon RI). Additionally, toxin B and lethal toxin inhibited the intracellular Ca2+ mobilization induced by Fc epsilon RI-stimulation and thapsigargin, mainly by reducing the influx of extracellular Ca2+. In patch clamp recordings, toxin B and lethal toxin inhibited the calcium release-activated calcium current by about 45%. Calcium release-activated calcium current, the receptor-stimulated Ca2+ influx, and secretion were inhibited neither by the Rho-ADP-ribosylating C3-fusion toxin C2IN-C3 nor by the actin-ADP-ribosylating Clostridium botulinum C2 toxin. The data indicate that Rac and Cdc42 but not Rho are not only involved in late exocytosis events but are also involved in Ca2+ mobilization most likely by regulating the Ca2+ influx through calcium release-activated calcium channels activated via Fc epsilon RI receptor in RBL cells.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany; Univ Saarland, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany	University of Freiburg; Saarland University	Aktories, K (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.	aktories@uni-freiburg.de	Djouder, Nabil/E-4135-2015; Aktories, Klaus/CAJ-5682-2022	Djouder, Nabil/0000-0001-8423-1030; Aktories, Klaus/0000-0002-5397-0436				AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; ALI H, 1994, BIOCHEM J, V304, P431, DOI 10.1042/bj3040431; Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BEAVEN MA, 1997, IGE RECEPTOR FCERI F, P55; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; CHOI OH, 1993, J IMMUNOL, V151, P5586; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Guillemot JC, 1997, J CELL SCI, V110, P2215; Hackam DJ, 1997, J EXP MED, V186, P955, DOI 10.1084/jem.186.6.955; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; JUST I, 1992, J BIOL CHEM, V267, P10274; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; NEHER E, 1992, METHOD ENZYMOL, V207, P123; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Prepens U, 1996, J BIOL CHEM, V271, P7324, DOI 10.1074/jbc.271.13.7324; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHANG L, 1995, J PHYSIOL-LONDON, V483, P59, DOI 10.1113/jphysiol.1995.sp020567	58	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18732	18738		10.1074/jbc.M001425200	http://dx.doi.org/10.1074/jbc.M001425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10749865	hybrid			2022-12-27	WOS:000087815900018
J	Kirkpatrick, LL; Matzuk, MM; Dodds, DC; Perin, MS				Kirkpatrick, LL; Matzuk, MM; Dodds, DC; Perin, MS			Biochemical interactions of the neuronal pentraxins - Neuronal pentraxin (NP) receptor binds to taipoxin and taipoxin-associated calcium-binding protein 49 via NP1 and NP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-P COMPONENT; C-REACTIVE PROTEIN; ACUTE-PHASE PROTEINS; CHROMOSOMAL LOCALIZATION; GENOMIC STRUCTURE; PENTAXIN FAMILY; GENE; MEMBER; CONSERVATION; MOUSE	Neuronal pentraxin 1 (NP1), neuronal pentraxin 2 (NP2), and neuronal pentraxin receptor (NPR) are members of a new family of proteins identified through interaction with a presynaptic snake venom toxin taipoxin. We have proposed that these three neuronal pentraxins represent a novel neuronal uptake pathway that may function during synapse formation and remodeling. We have investigated the mutual interactions of these proteins by characterizing their enrichment on taipoxin affinity columns; by expressing NP1, NP2, and NPR singly and together in Chinese hamster ovary cells; and by generating mice that fail to express NP1. NP1 and NP2 are secreted, exist as higher order multimers (probably pentamers), and interact with taipoxin and taipoxin-associated calcium-binding protein 49 (TCBP49). NPR is expressed on the cell membrane and does not bind taipoxin or TCBP49 by itself, but it can form heteropentamers with NP1 and NP2 that can be released from cell membranes. This is the first demonstration of heteromultimerization of pentraxins and release of a pentraxin complex by proteolysis, These processes are likely to directly effect the localization and function of neuronal pentraxins in neuronal uptake or synapse formation and remodeling.	Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44195 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Cleveland Clinic Foundation; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Perin, MS (corresponding author), Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030541] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30541] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; DODDS D, 1995, J NEUROCHEM, V64, P2339; Dodds DC, 1997, J BIOL CHEM, V272, P21488, DOI 10.1074/jbc.272.34.21488; DOWTON SB, 1990, BIOCHEM J, V270, P553, DOI 10.1042/bj2700553; GEWURZ H, 1995, CURR OPIN IMMUNOL, V7, P54, DOI 10.1016/0952-7915(95)80029-8; HSU YC, 1995, GENOMICS, V28, P220, DOI 10.1006/geno.1995.1134; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LEE GW, 1993, J IMMUNOL, V150, P1804; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; NOLAND TD, 1994, J BIOL CHEM, V269, P32607; O'Brien RJ, 1999, NEURON, V23, P309, DOI 10.1016/S0896-6273(00)80782-5; Omeis IA, 1996, GENOMICS, V36, P543, DOI 10.1006/geno.1996.0503; PERIN MS, 1991, J BIOL CHEM, V266, P623; REID MS, 1994, J BIOL CHEM, V269, P32615; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; Tsui CC, 1996, J NEUROSCI, V16, P2463; WHITEHEAD AS, 1990, BIOCHEM J, V266, P283, DOI 10.1042/bj2660283	18	106	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17786	17792		10.1074/jbc.M002254200	http://dx.doi.org/10.1074/jbc.M002254200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748068	hybrid			2022-12-27	WOS:000087485000080
J	Shih, DM; Xia, YR; Wang, XP; Miller, E; Castellani, LW; Subbanagounder, G; Cheroutre, H; Faull, KF; Berliner, JA; Witztum, JL; Lusis, AJ				Shih, DM; Xia, YR; Wang, XP; Miller, E; Castellani, LW; Subbanagounder, G; Cheroutre, H; Faull, KF; Berliner, JA; Witztum, JL; Lusis, AJ			Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; E-DEFICIENT MICE; ACTIVATING-FACTOR-ACETYLHYDROLASE; MONOCYTE CHEMOTACTIC PROTEIN-1; COLONY-STIMULATING FACTORS; CORONARY-ARTERY DISEASE; HUMAN ENDOTHELIAL-CELLS; LDL RECEPTOR-DEFICIENT; APOLIPOPROTEIN-E; OXIDIZED LDL	Serum paraoxonase (PON1), present on high density lipoprotein, may inhibit low density lipoprotein (LDL) oxidation and protect against atherosclerosis. We generated combined PON1 knockout (KO)/apolipoprotein E (apoE) KO and apoE KO control mice to compare atherogenesis and lipoprotein oxidation. Early lesions were examined in 3-month-old mice fed a chow diet, and advanced lesions were examined in 6-month-old mice fed a high fat diet. In both cases, the PON1 KO/apoE KO mice exhibited significantly more atherosclerosis (50-71% increase) than controls. We examined LDL oxidation and clearance in vivo by injecting human LDL into the mice and following its turnover. LDL clearance was faster in the double KO mice as compared with controls. There was a greater rate of accumulation of oxidized phospholipid epitopes and a greater accumulation of LDL-immunoglobulin complexes in the double KO mice than in controls. Furthermore, the amounts of three bioactive oxidized phospholipids were elevated in the endogenous intermediate density lipoprotein/LDL of double KO mice as compared with the controls. Finally, the expression of heme oxygenase-1, peroxisome proliferator-activated receptor gamma, and oxidized LDL receptors were elevated in the livers of double KO mice as compared with the controls. These data demonstrate that PON1 deficiency promotes LDL oxidation and atherogenesis in apoE KO mice.	Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Psychiat & Biobehav Sci & Neuropsychiat Inst, Los Angeles, CA 90095 USA; Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California San Diego; La Jolla Institute for Immunology	Shih, DM (corresponding author), Univ Calif Los Angeles, Dept Med, Div Cardiol, 47-123 CHS, Los Angeles, CA 90095 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, P50HL056989] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56989, HL30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BLATTER MC, 1993, EUR J BIOCHEM, V211, P871, DOI 10.1111/j.1432-1033.1993.tb17620.x; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; COSTA LG, 1990, TOXICOL APPL PHARM, V103, P66, DOI 10.1016/0041-008X(90)90263-T; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Fluiter K, 1999, J BIOL CHEM, V274, P8893, DOI 10.1074/jbc.274.13.8893; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; Garin MCB, 1997, J CLIN INVEST, V99, P62, DOI 10.1172/JCI119134; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; HEDRICK CC, 1993, J BIOL CHEM, V268, P20676; Horkko S, 1997, P NATL ACAD SCI USA, V94, P10356, DOI 10.1073/pnas.94.19.10356; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; KELSO GJ, 1994, BIOCHEMISTRY-US, V33, P832, DOI 10.1021/bi00169a026; KLIMOV AN, 1985, ATHEROSCLEROSIS, V58, P1, DOI 10.1016/0021-9150(85)90051-6; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291; LI WF, 1993, J TOXICOL ENV HEALTH, V40, P337, DOI 10.1080/15287399309531798; Liu-Wu Y, 1998, ATHEROSCLEROSIS, V137, P351, DOI 10.1016/S0021-9150(97)00295-5; Lopes-Virella MF, 1999, CLIN IMMUNOL, V90, P165, DOI 10.1006/clim.1998.4631; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; Mackness MI, 1998, CURR OPIN LIPIDOL, V9, P319, DOI 10.1097/00041433-199808000-00006; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; Murohara T, 1996, CIRC RES, V78, P780, DOI 10.1161/01.RES.78.5.780; MURPHY SD, 1980, TOXICOLOGY BASIC SCI, P357; NAGELKERKE JF, 1984, ARTERIOSCLEROSIS, V4, P256, DOI 10.1161/01.ATV.4.3.256; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Qiao JH, 1997, AM J PATHOL, V150, P1687; Rajavashisth T, 1998, J CLIN INVEST, V101, P2702, DOI 10.1172/JCI119891; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; RUIZ J, 1995, LANCET, V346, P869, DOI 10.1016/S0140-6736(95)92709-3; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; Sato N, 1998, J BIOCHEM-TOKYO, V123, P1119; Serrato M, 1995, J CLIN INVEST, V96, P3005, DOI 10.1172/JCI118373; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Shih DM, 1996, J CLIN INVEST, V97, P1630, DOI 10.1172/JCI118589; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SMOLEN A, 1991, DRUG METAB DISPOS, V19, P107; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Sugiyama S, 1998, ARTERIOSCL THROM VAS, V18, P568, DOI 10.1161/01.ATV.18.4.568; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TAFURI J, 1987, ANN EMERG MED, V16, P193, DOI 10.1016/S0196-0644(87)80015-X; TANAKA N, 1996, METABOLISM, V45, P559; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; Watson AD, 1999, J BIOL CHEM, V274, P24787, DOI 10.1074/jbc.274.35.24787; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; WIKLUND O, 1987, J LIPID RES, V28, P1098; Witztum JL, 1999, CLIN IMMUNOL, V90, P153, DOI 10.1006/clim.1998.4682; Woollett LA, 1995, P NATL ACAD SCI USA, V92, P12500, DOI 10.1073/pnas.92.26.12500; YLAHERTTUALA S, 1994, ARTERIOSCLER THROMB, V14, P32, DOI 10.1161/01.ATV.14.1.32; Yoshida H, 1998, ARTERIOSCL THROM VAS, V18, P794, DOI 10.1161/01.ATV.18.5.794; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178; YOUNG SG, 1986, CLIN CHEM, V32, P1484; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	85	345	368	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17527	17535		10.1074/jbc.M910376199	http://dx.doi.org/10.1074/jbc.M910376199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748217	hybrid			2022-12-27	WOS:000087485000045
J	Brazil, MI; Chung, H; Maxfield, FR				Brazil, MI; Chung, H; Maxfield, FR			Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBROSPINAL-FLUID ANTIBODIES; MACROPHAGE SCAVENGER RECEPTORS; CENTRAL-NERVOUS-SYSTEM; BETA-PROTEIN; TRANSGENIC MICE; SENILE PLAQUES; CELL-SURFACE; LIPOPROTEIN RECEPTOR; DENSITY-LIPOPROTEIN; PRECURSOR PROTEIN	Microglia are macrophage-like immune system cells found in the brain. They are associated with Alzheimer's Disease plaques, which contain fibrillar beta-amyloid (fA beta) and other components such as complement proteins. We have shown previously that murine microglia bind and internalize fA beta microaggregates via the type A scavenger receptor, but degradation of internalized fA beta is significantly slower than normal degradation. In this study, we compared internalization by microglia of fA beta microaggregates to that of anti-A beta-antibody-coated fA beta (IgG-fA beta) microaggregates and found that the uptake of the latter is increased by about 1.5-fold versus unmodified fA beta. The endocytic trafficking of IgG-fA beta is similar to that of fA beta microaggregates, following an endosomal/ lysosomal pathway. We also compared the internalization of fA beta microaggregates to that of complement protein, Clq-coated fA beta microaggregates, and found that the levels of uptake are also increased by about 1.5-fold. Rates of degradation of both types of modified fA beta microaggregates are unchanged compared with unmodified fA beta microaggregates. We demonstrated by blocking studies that internalization of IgG-fA beta is mediated by Fc receptors. These data suggest that, in vivo, several different microglial receptors may play a part in internalizing fA beta, but the involvement of other receptors may not increase the degradation of fA beta.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Cornell University; Columbia University	Maxfield, FR (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave,Rm E215, New York, NY 10021 USA.		Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019	Maxfield, Fred/0000-0003-4396-8866	NINDS NIH HHS [NS34761] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034761] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; Christie RH, 1996, AM J PATHOL, V148, P399; Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; DAHLSTROM A, 1994, MOL NEUROBIOL, V9, P41, DOI 10.1007/BF02816104; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; EIKELENBOOM P, 1992, RES IMMUNOL, V143, P617, DOI 10.1016/0923-2494(92)80044-L; EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397; ElKhoury J, 1996, NATURE, V382, P716; Frautschy SA, 1998, AM J PATHOL, V152, P307; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GIULIAN D, 1995, J NEUROSCI, V15, P7712; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAGA S, 1989, ACTA NEUROPATHOL, V77, P569, DOI 10.1007/BF00687883; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Huang F, 1999, AM J PATHOL, V155, P1741, DOI 10.1016/S0002-9440(10)65489-2; ISHII T, 1984, ACTA NEUROPATHOL, V63, P296, DOI 10.1007/BF00687336; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JIANG HX, 1994, J IMMUNOL, V152, P5050; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kusumoto Y, 1998, P NATL ACAD SCI USA, V95, P12277, DOI 10.1073/pnas.95.21.12277; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; MCGEER PL, 1987, NEUROSCI LETT, V79, P195, DOI 10.1016/0304-3940(87)90696-3; McRae A, 1996, MOL CHEM NEUROPATHOL, V28, P89, DOI 10.1007/BF02815209; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Papavasiliou AK, 1996, J NEUROSCI RES, V46, P49, DOI 10.1002/(SICI)1097-4547(19961001)46:1<49::AID-JNR7>3.0.CO;2-F; Paresce DM, 1997, J BIOL CHEM, V272, P29390, DOI 10.1074/jbc.272.46.29390; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; RIOHORTEGA P, 1932, CYTOLOGY CELLULAR PA, P481; ROZEMULLER JM, 1990, NEUROSCI LETT, V119, P75, DOI 10.1016/0304-3940(90)90759-3; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SCHMIDTMAYER J, 1994, GLIA, V12, P259, DOI 10.1002/glia.440120403; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEVACH EM, 1985, FUNDAMENTAL IMMUNOLO, P71; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; WEGIEL J, 1990, ACTA NEUROPATHOL, V81, P116, DOI 10.1007/BF00334499; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; YAMASHIRO DJ, 1989, J CELL PHYSIOL, V139, P377, DOI 10.1002/jcp.1041390221; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	52	52	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16941	16947		10.1074/jbc.M000937200	http://dx.doi.org/10.1074/jbc.M000937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747968	hybrid			2022-12-27	WOS:000087392200077
J	Caldas, T; Binet, E; Bouloc, P; Costa, A; Desgres, J; Richarme, G				Caldas, T; Binet, E; Bouloc, P; Costa, A; Desgres, J; Richarme, G			The FtsJ/RrmJ heat shock protein of Escherichia coli is a 23 S ribosomal RNA methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES; M(5)C967 METHYLTRANSFERASE; SEQUENCE MOTIFS; GENE; IDENTIFICATION; PURIFICATION; METHYLATION; ADENOSINE; CLEAVAGE; CLONING	Ribosomal RNAs undergo several nucleotide modifications including methylation. We identify FtsJ, the first encoded protein of the ftsJ-hflB heat shock operon, as an Escherichia coli methyltransferase of the 23 S rRNA. The methylation reaction requires S-adenosylmethionine as donor of methyl groups, purified FtsJ or a S-150 supernatant from an FtsJ-producing strain, and ribosomes from an FtsJ-deficient strain. In vitro, FtsJ does not efficiently methylate ribosomes purified from a strain producing FtsJ, suggesting that these ribosomes are already methylated in vivo by FtsJ. FtsJ is active on ribosomes and on the 50 S ribosomal subunit, but is inactive on free rRNA suggesting that its natural substrate is ribosomes or a pre-ribosomal ribonucleoprotein particle. We identified the methylated nucleotide as 2'-O-methyluridine 2552, by reverse phase high performance liquid chromatography analysis, boronate affinity chromatography, and hybridization-protection experiments. In view of its newly established function, FtsJ is renamed RrmJ and its encoding gene, rrmJ.	Univ Paris 07, Inst Jacques Monod, F-75005 Paris, France; Univ Paris Sud, CNRS, UMR 8621, Inst Genet & Microbiol,Lab Reseaux Regulat, F-91405 Orsay, France; Fac Med & Ctr Hosp Bourgogne, Lab Biochim Med, F-21034 Dijon, France	UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Richarme, G (corresponding author), Univ Paris 07, Inst Jacques Monod, 2 Pl Jussieu, F-75005 Paris, France.		Bouloc, Philippe/ABA-5732-2021	Bouloc, Philippe/0000-0003-4601-3387				ALIX JH, 1974, J MOL BIOL, V86, P139, DOI 10.1016/S0022-2836(74)80013-6; CHELBIALIX MK, 1981, EUR J BIOCHEM, V115, P627; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; COOPERMAN BS, 1990, RIBOSOME STRUCTURE F, V182, P491; CUNDIFFE E, 1990, RIBOSOME STRUCTURE F, V182, P479; DESGRES J, 1989, NUCLEIC ACIDS RES, V17, P865, DOI 10.1093/nar/17.3.865; Durand P, 1997, COMPUT APPL BIOSCI, V13, P407; Escribano V, 1996, YEAST, V12, P887; EXPERTBE.A, 1974, BIOCHIMIE, V56, P77, DOI 10.1016/S0300-9084(74)80357-3; GEHRKE CW, 1990, CHROMATOGRAPHY MOD A, V45, pA159; Gu XR, 1999, BIOCHEMISTRY-US, V38, P4053, DOI 10.1021/bi982364y; Gustafsson C, 1998, J BACTERIOL, V180, P359, DOI 10.1128/JB.180.2.359-365.1998; HALL CC, 1985, BIOCHEMISTRY-US, V24, P5702, DOI 10.1021/bi00342a003; HERMAN C, 1993, P NATL ACAD SCI USA, V90, P10861, DOI 10.1073/pnas.90.22.10861; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; NEGRE D, 1989, P NATL ACAD SCI USA, V86, P4902, DOI 10.1073/pnas.86.13.4902; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OCONNOR M, 1993, P NATL ACAD SCI USA, V90, P9214, DOI 10.1073/pnas.90.19.9214; OGURA T, 1991, RES MICROBIOL, V142, P279, DOI 10.1016/0923-2508(91)90041-8; POLDERMANS B, 1979, J BIOL CHEM, V254, P9094; Raychaudhuri S, 1999, J BIOL CHEM, V274, P18880, DOI 10.1074/jbc.274.27.18880; SMITH JE, 1992, BIOCHEMISTRY-US, V31, P10825, DOI 10.1021/bi00159a025; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; Tscherne JS, 1999, J BIOL CHEM, V274, P924, DOI 10.1074/jbc.274.2.924; Tscherne JS, 1999, BIOCHEMISTRY-US, V38, P1884, DOI 10.1021/bi981880l; VANBUUL CPJJ, 1985, GENE, V38, P65, DOI 10.1016/0378-1119(85)90204-5; VANET A, 1994, MOL MICROBIOL, V14, P947, DOI 10.1111/j.1365-2958.1994.tb01330.x	35	116	120	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16414	16419		10.1074/jbc.M001854200	http://dx.doi.org/10.1074/jbc.M001854200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748051	hybrid			2022-12-27	WOS:000087392200004
J	Hartley, DA; Cooper, GM				Hartley, DA; Cooper, GM			Direct binding and activation of STAT transcription factors by the herpesvirus saimiri protein Tip	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; DNA-BINDING; MAP KINASE; V-SRC; LCK; P56(LCK); REQUIRES	The Tip protein from Herpesvirus saimiri specifically binds to and activates the protein tyrosine kinase, p56(lck). It has been demonstrated that the expression of Tip in T cells is capable of inducing the DNA binding of members of the signal transducers and activators of transcription (STAT) family of transcription factors. We have examined the mechanism behind which STATs 1 and 3 are activated by Tip expression. Tip becomes tyrosine phosphorylated by p56(lck) at two sites in the amino-terminal tail region. One site of phosphorylation lies within a consensus YXPQ binding motif for the SH2 domains of STATs 1 and 3. We demonstrate that tyrosine phosphorylation of Tip at this site is required for the binding of STATs, and the induction of STAT dependent transcription. Furthermore, we demonstrate that, similar to STAT activation by v-Src, the optimum induction of STAT-dependent transcription by Tip requires Ras/ Rac mediated signaling events.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Hartley, DA (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.				NCI NIH HHS [R01 CA18689, CA42350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042350, R01CA018689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER HT, 1992, ONCOGENE, V7, P1191; BIESINGER B, 1995, J BIOL CHEM, V270, P4729, DOI 10.1074/jbc.270.9.4729; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; CHOU CS, 1995, VIROLOGY, V208, P418, DOI 10.1006/viro.1995.1172; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Duboise SM, 1998, J VIROL, V72, P1308, DOI 10.1128/JVI.72.2.1308-1313.1998; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Guo J, 1997, J VIROL, V71, P7092, DOI 10.1128/JVI.71.9.7092-7096.1997; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Hartley DK, 1999, J BIOL CHEM, V274, P20056, DOI 10.1074/jbc.274.29.20056; HURLEY TR, 1989, ONCOGENE, V4, P265; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Lund T, 1997, J VIROL, V71, P378, DOI 10.1128/JVI.71.1.378-382.1997; Lund TC, 1999, J VIROL, V73, P1689, DOI 10.1128/JVI.73.2.1689-1694.1999; Lund TC, 1999, CELL SIGNAL, V11, P789, DOI 10.1016/S0898-6568(99)00045-5; Lund TC, 1999, CELL IMMUNOL, V192, P133, DOI 10.1006/cimm.1999.1466; Lund TC, 1997, J VIROL, V71, P6677, DOI 10.1128/JVI.71.9.6677-6682.1997; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MEDVECZKY MM, 1993, VIROLOGY, V196, P402, DOI 10.1006/viro.1993.1495; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Turkson J, 1999, MOL CELL BIOL, V19, P7519; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	31	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16925	16932		10.1074/jbc.M000709200	http://dx.doi.org/10.1074/jbc.M000709200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747948	hybrid			2022-12-27	WOS:000087392200075
J	Lopes, CMB; Gallagher, PG; Buck, ME; Butler, MH; Goldstein, SAN				Lopes, CMB; Gallagher, PG; Buck, ME; Butler, MH; Goldstein, SAN			Proton block and voltage gating are potassium-dependent in the cardiac leak channel Kcnk3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG VENTRICULAR MYOCYTES; BACKGROUND K+ CHANNEL; 2 PORE DOMAINS; EXTRACELLULAR K+; FUNCTIONAL EXPRESSION; MYELINATED NERVE; ATRIAL MYOCYTES; SODIUM-CHANNELS; ION CHANNELS; CLONING	Potassium leak conductances were recently revealed to exist as independent molecular entities. Here, the genomic structure, cardiac localization, and biophysical properties of a murine example are considered. Kcnk3 subunits have two pore-forming P domains and unique functional attributes. At steady state, Kcnk3 channels behave like open, potassium-selective, transmembrane holes that are inhibited by physiological levels of proton. With voltage steps, Kcnk3 channels open and close in two phases, one appears to be immediate and one is time-dependent (tau = similar to 5 ms). Both proton block and gating are potassium-sensitive; this produces an anomalous increase in outward flux as external potassium levels rise because of decreased proton block. Single Kcnk3 channels open across the physiological voltage range; hence they are "leak" conductances; however, they open only briefly and rarely even after exposure to agents that activate other potassium channels.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat,Sect Dev Biol & Biophys, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cellular & Mol,Sect Dev Biol & Biophys, New Haven, CT 06536 USA	Yale University; Yale University	Goldstein, SAN (corresponding author), 295 Congress Ave, New Haven, CT 06536 USA.	steve.goldstein@yale.edu	Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061				Ahmed A, 1999, CELL, V99, P283, DOI 10.1016/S0092-8674(00)81659-1; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APKON M, 1988, BIOPHYS J, V53, pA458; BACKX PH, 1993, CIRC RES, V72, P890, DOI 10.1161/01.RES.72.4.890; BOACHIEANSAH G, 1992, J CARDIOVASC PHARM, V20, P538, DOI 10.1097/00005344-199210000-00005; BOYLE WA, 1992, J GEN PHYSIOL, V100, P1041, DOI 10.1085/jgp.100.6.1041; Buckler KJ, 1997, J PHYSIOL-LONDON, V498, P649, DOI 10.1113/jphysiol.1997.sp021890; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; Chen TY, 1996, J GEN PHYSIOL, V108, P237, DOI 10.1085/jgp.108.4.237; Choe H, 1998, J GEN PHYSIOL, V112, P433, DOI 10.1085/jgp.112.4.433; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEEMANN L, 1979, J PHYSIOL-LONDON, V286, P113, DOI 10.1113/jphysiol.1979.sp012609; Colquhoun David, 1995, P483; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; EGEBJERG J, 1994, P NATL ACAD SCI USA, V91, P10270, DOI 10.1073/pnas.91.22.10270; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; Goldstein SAN, 1998, J MOL MED-JMM, V76, P13, DOI 10.1007/s109-1998-8100-0; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; Ilan N, 1999, BIOPHYS J, V76, pA411; JONES SW, 1989, NEURON, V3, P153, DOI 10.1016/0896-6273(89)90028-7; KAGIYAMA Y, 1982, CIRC RES, V51, P614, DOI 10.1161/01.RES.51.5.614; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; Kim Y, 2000, BIOPHYS J, V78, p207A; Kim Y, 1999, AM J PHYSIOL-HEART C, V277, pH1669, DOI 10.1152/ajpheart.1999.277.5.H1669; KOH DS, 1992, J MEMBRANE BIOL, V130, P149; KOYANO K, 1992, J PHYSIOL-LONDON, V454, P231, DOI 10.1113/jphysiol.1992.sp019262; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; Leonoudakis D, 1998, J NEUROSCI, V18, P868; LOPES CMB, 1998, J BIOPHYS, V74, P44; Loukin SH, 1999, BIOPHYS J, V77, P3060, DOI 10.1016/S0006-3495(99)77137-7; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; Manjunath NA, 1999, CYTOGENET CELL GENET, V86, P242, DOI 10.1159/000015349; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; NATTEL S, 1981, CIRC RES, V48, P55, DOI 10.1161/01.RES.48.1.55; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; PIERCE JC, 1992, MAMM GENOME, V3, P550, DOI 10.1007/BF00350620; Pountney DJ, 1999, FEBS LETT, V450, P191, DOI 10.1016/S0014-5793(99)00495-0; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Salinas M, 1999, J BIOL CHEM, V274, P11751, DOI 10.1074/jbc.274.17.11751; SCHMIDT H, 1966, PFLUG ARCH GES PHYS, V287, P311, DOI 10.1007/BF00363245; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; VanWagoner DR, 1997, CIRC RES, V80, P772; Vergani P, 1997, FEBS LETT, V405, P337, DOI 10.1016/S0014-5793(97)00211-1; Vergani P, 1998, EMBO J, V17, P7190, DOI 10.1093/emboj/17.24.7190; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; WANG ZG, 1993, CIRC RES, V73, P1061, DOI 10.1161/01.RES.73.6.1061; Wang ZW, 1999, ANN NY ACAD SCI, V868, P286, DOI 10.1111/j.1749-6632.1999.tb11294.x; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; WU JV, 1993, J NEUROSCI, V13, P5153, DOI 10.1523/JNEUROSCI.13-12-05153.1993; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; YUE DT, 1988, PFLUG ARCH EUR J PHY, V413, P127, DOI 10.1007/BF00582522	64	132	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16969	16978		10.1074/jbc.M001948200	http://dx.doi.org/10.1074/jbc.M001948200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748056	Green Published, hybrid			2022-12-27	WOS:000087392200081
J	Pitkanen, J; Doucas, V; Sternsdorf, T; Nakajima, T; Aratani, S; Jensen, K; Will, H; Vahamurto, P; Ollila, J; Vihinen, M; Scott, HS; Antonarakis, SE; Kudoh, J; Shimizu, N; Krohn, K; Peterson, P				Pitkanen, J; Doucas, V; Sternsdorf, T; Nakajima, T; Aratani, S; Jensen, K; Will, H; Vahamurto, P; Ollila, J; Vihinen, M; Scott, HS; Antonarakis, SE; Kudoh, J; Shimizu, N; Krohn, K; Peterson, P			The autoimmune regulator protein has transcriptional transactivating properties and interacts with the common coactivator CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEAR RECEPTOR; HISTONE ACETYLTRANSFERASE; APECED GENE; CBP; PHD; ACTIVATION; COMPLEX; DOMAIN; LOCALIZATION	Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy, caused by mutations in the autoimmune regulator (AIRE) gene, is an autosomal recessive autoimmune disease characterized by the breakdown of tolerance to organ-specific antigens. The 545 amino acid protein encoded by AIRE contains several structural motifs suggestive of a transcriptional regulator and bears similarity to cellular proteins involved in transcriptional control. me show here that AIRE fused to a heterologous DNA binding domain activates transcription from a reporter promoter, and the activation seen requires the full-length protein or more than one activation domain. At the structural level AIRE forms homodimers through the NH2-terminal domain, and molecular modeling for this domain suggests a four-helix bundle structure. In agreement, we show that the common transcriptional coactivator CREB-binding protein (CBP) interacts with AIRE in vitro and in yeast nuclei through the CH1 and CH3 conserved domains. We suggest that the transcriptional transactivation properties of AIRE together with its interaction with CBP might be important in its function as disease-causing mutations almost totally abolish the activation effect.	Tampere Univ, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, FIN-33101 Tampere, Finland; Univ Geneva, Sch Med, Dept Genet & Microbiol, CH-1211 Geneva, Switzerland; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, TARA Ctr, Tsukuba, Ibaraki 3058572, Japan; St Marianna Univ, Inst Med Sci, Japan Sci & Technol Corp, PRESTO, Kawasaki, Kanagawa 2768512, Japan; Univ Helsinki, Dept Biosci, Div Biochem, Helsinki 00014, Finland; Univ Hosp Geneva, Div Med Genet, CH-1211 Geneva, Switzerland; Univ Geneva, Sch Med, Div Med Genet, CH-1211 Geneva, Switzerland; Keio Univ, Sch Med, Dept Mol Biol, Tokyo 1608582, Japan	Tampere University; Tampere University; Tampere University Hospital; University of Geneva; Heinrich Pette Institute; University of Hamburg; University of Tsukuba; University of Tsukuba; Japan Science & Technology Agency (JST); Saint Marianna University; University of Helsinki; University of Geneva; University of Geneva; Keio University	Pitkanen, J (corresponding author), Tampere Univ, Inst Med Technol, Lenkkeilijankatu 6, FIN-33101 Tampere, Finland.		Scott, Hamish/B-2122-2009; Antonarakis, Stylianos E/N-8866-2014; Vihinen, Mauno/A-8452-2012; Peterson, Pärt/A-5788-2009	Scott, Hamish/0000-0002-5813-631X; Antonarakis, Stylianos E/0000-0001-8907-5823; Vihinen, Mauno/0000-0002-9614-7976; Peterson, Pärt/0000-0001-6755-791X				Aaltonen J, 1999, ANN MED, V31, P111, DOI 10.3109/07853899708998786; Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AHONEN P, 1985, CLIN GENET, V27, P535, DOI 10.1111/j.1399-0004.1985.tb02037.x; AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; Bjorses P, 1999, HUM MOL GENET, V8, P259, DOI 10.1093/hmg/8.2.259; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P381; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2633, DOI 10.1073/pnas.96.6.2633; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DOUCAS V, 1996, BIOCHIM BIOPHYS ACTA, V1288, P25; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Gibson TJ, 1998, TRENDS BIOCHEM SCI, V23, P242, DOI 10.1016/S0968-0004(98)01231-6; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Guldner HH, 1999, J CELL SCI, V112, P733; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heino M, 1999, BIOCHEM BIOPH RES CO, V257, P821, DOI 10.1006/bbrc.1999.0308; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LIN SL, 1995, J MOL BIOL, V248, P151, DOI 10.1006/jmbi.1995.0208; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Mittaz L, 1999, BIOCHEM BIOPH RES CO, V255, P483, DOI 10.1006/bbrc.1999.0223; Moulian N, 1998, SEMIN IMMUNOL, V10, P449, DOI 10.1006/smim.1998.0155; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Obermayer-Straub P, 1998, BAILLIERE CLIN GASTR, V12, P293, DOI 10.1016/S0950-3528(98)90136-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perheentupa J, 1996, HORM METAB RES, V28, P353, DOI 10.1055/s-2007-979814; Rinderle C, 1999, HUM MOL GENET, V8, P277, DOI 10.1093/hmg/8.2.277; Rosatelli MC, 1998, HUM GENET, V103, P428, DOI 10.1007/s004390050846; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Winoto A, 1997, Semin Immunol, V9, P51, DOI 10.1006/smim.1996.0053; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; ZLOTOGORA J, 1992, J MED GENET, V29, P824, DOI 10.1136/jmg.29.11.824	56	171	176	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16802	16809		10.1074/jbc.M908944199	http://dx.doi.org/10.1074/jbc.M908944199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748110	hybrid			2022-12-27	WOS:000087392200058
J	Rahimi, N; Dayanir, V; Lashkari, K				Rahimi, N; Dayanir, V; Lashkari, K			Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNAL-TRANSDUCTION; FLT-1 RECEPTOR; MAP KINASE; BINDING; IDENTIFICATION; MICE; KDR; SPECIFICITY; ACTIVATION	Vascular endothelial growth factor (VEGF) provokes angiogenesis in vivo and stimulates growth and differentiation of endothelial cells in vitro. Although VEGF receptor-1 (VEGFR-1) and VEGFR-2 are known to be high affinity receptors for VEGF, it is not clear which of the VEGFRs are responsible for the transmission of the diverse biological responses of VEGF. For this purpose we have constructed a chimeric receptor for VEGFR-1 (CTR) and VEGFR-2 (CKR) in which the extracellular domain of each receptor was replaced with the extracellular domain of human colony-stimulating factor-1 receptor (CSF-1R), and these receptors were expressed in pig aortic endothelial (PAE) cells. We show that CHR individually expressed in PAE cells is readily tyrosine-phosphorylated in vivo, autophosphorylated in vitro, and stimulates cell proliferation in a CSF-1-dependent manner. In contrast, CTR individually expressed in PAE cells showed no significant in vivo, in vitro tyrosine phosphorylation and cell growth in response to CSF-1 stimulation. The kinase activity of CKR was essential for its biological activity, since mutation of lysine 866 to arginine abolished its in vivo, in vitro tyrosine phosphorylation and mitogenic signals. Remarkably, activation of CTR repressed CKR-mediated mitogen-activate protein kinase activation and cell proliferation. Similar effects were observed for VEGFR-2 co-expressed with VEGFR-1. Collectively, these findings demonstrate that VEGFR-8 activation plays a positive role in angiogenesis by promoting endothelial cell proliferation In contrast, activation of VEGFR-1 plays a stationary role in angiogenesis by antagonizing VEGFR-2 responses.	Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA	Boston University; Boston University; Harvard University; Harvard Medical School; Schepens Eye Research Institute	Rahimi, N (corresponding author), Boston Univ, Sch Med, Dept Ophthalmol, 715 Albany St,Room 921L, Boston, MA 02118 USA.	nrahimi@bu.edu		Lashkari, Kameran/0000-0003-3855-0246; Rahimi, Nader/0000-0002-6745-1725				COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Herley MT, 1999, BIOCHEM BIOPH RES CO, V262, P731, DOI 10.1006/bbrc.1999.1282; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KLINT P, 1999, FRONT BIOSCI, V4, P165; Koths K, 1997, MOL REPROD DEV, V46, P31; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PARK JE, 1994, J BIOL CHEM, V269, P25646; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Rahimi N, 1999, MOL BIOL CELL, V10, P3401, DOI 10.1091/mbc.10.10.3401; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 1999, CANCER CHEMOTH PHARM, V43, pS72, DOI 10.1007/s002800051102; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Terman BI, 1996, CANCER METAST REV, V15, P159, DOI 10.1007/BF00437468; TERMAN BI, 1991, ONCOGENE, V6, P1677; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	34	185	205	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16986	16992		10.1074/jbc.M000528200	http://dx.doi.org/10.1074/jbc.M000528200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747927	hybrid			2022-12-27	WOS:000087392200083
J	Steinhusen, U; Badock, V; Bauer, A; Behrens, J; Wittman-Liebold, B; Dorken, B; Bommert, K				Steinhusen, U; Badock, V; Bauer, A; Behrens, J; Wittman-Liebold, B; Dorken, B; Bommert, K			Apoptosis-induced cleavage of beta-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TRANSCRIPTION FACTOR LEF-1; PROGRAMMED CELL-DEATH; EPITHELIAL-CELLS; C-MYC; FUNCTIONAL INTERACTION; MORPHOLOGICAL-CHANGES; EXTRACELLULAR-MATRIX; BINDING PROTEIN; COLON-CARCINOMA	beta-Catenin is a member of the Armadillo repeat protein family with a dual cellular function as a component of both the adherens junction complex and the Wnt/wingless signaling pathway. Here we show that beta-catenin is proteolytically cleaved during anoikis and staurosporine-induced apoptosis, Cleavage of beta-catenin was found to be caspase-dependent. Five cleavage products of beta-catenin were identified in vivo and after in vivo cleavage by caspase-3. Amino acid sequencing and mass spectrometry analysis indicated two caspase-3 cleavage sites at the C terminus and three further sites at the N terminus, whereas the central Armadillo repeat region remained unaffected. All beta-catenin cleavage products were still able to associate with E-cadherin and alpha-catenin and were found to be enriched in the cytoplasm. Functional analysis revealed that beta-catenin deletion constructs resembling the observed proteolytic fragments show a strongly reduced transcription activation potential when analyzed in gene reporter assays. We therefore conclude that an important role of the beta-catenin cleavage during apoptosis is the removal of its transcription activation domains to prevent its transcription activation potential.	Max Delbruck Ctr Mol Med, Dept Med Oncol & Tumorimmunol, D-3092 Berlin, Germany; Dept Prot Chem, D-3092 Berlin, Germany; Dept Epithelial Differentiat Invas & Metastasis, D-3092 Berlin, Germany; Max Planck Inst Immunbiol, Dept Mol Embryol, D-79108 Freiburg, Germany; Humboldt Univ, Med Ctr Charite, Robert Rossle Klin, Dept Hematol Oncol & Tumorimmunol, D-3092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Bommert, K (corresponding author), Max Delbruck Ctr Mol Med, Dept Med Oncol & Tumorimmunol, Robert Rossle Str 10, D-3092 Berlin, Germany.		Bommert, Kurt/G-9247-2011					Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Bauer A, 1998, J BIOL CHEM, V273, P28314, DOI 10.1074/jbc.273.43.28314; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Cavallo R, 1997, CURR OPIN GENET DEV, V7, P459, DOI 10.1016/S0959-437X(97)80071-8; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Crouch DH, 1996, ONCOGENE, V12, P2689; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Geiger B, 1995, ACTA ANAT, V154, P46; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; Laurent MN, 1997, DEVELOPMENT, V124, P4905; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Rickers A, 1998, EUR J IMMUNOL, V28, P296, DOI 10.1002/(SICI)1521-4141(199801)28:01<296::AID-IMMU296>3.0.CO;2-4; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	65	132	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16345	16353		10.1074/jbc.M001458200	http://dx.doi.org/10.1074/jbc.M001458200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748026	hybrid			2022-12-27	WOS:000087291400100
J	Argiriadi, MA; Morisseau, C; Goodrow, MH; Dowdy, DL; Hammock, BD; Christianson, DW				Argiriadi, MA; Morisseau, C; Goodrow, MH; Dowdy, DL; Hammock, BD; Christianson, DW			Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM-RADIOBACTER AD1; HALOALKANE DEHALOGENASE; L-2-HALOACID DEHALOGENASE; CRYSTAL-STRUCTURE; MECHANISM; ENZYME; EVOLUTION; LIVER; FOLD	The structures of two alkylurea inhibitors complexed with murine soluble epoxide hydrolase have been determined by x-ray crystallographic methods, The alkyl substituents of each inhibitor make extensive hydrophobic contacts in the soluble epoxide hydrolase active site, and each urea carbonyl oxygen accepts hydrogen bonds from the phenolic hydroxyl groups of Tyr(381) and Tyr(465). These hydrogen bond interactions suggest that Tyr(381) and/or Tyr(465) are general acid catalysts that facilitate epoxide ring opening in the first step of the hydrolysis reaction; Tyr(485) is highly conserved among all epoxide hydrolases, and Tyr(381) is conserved among the soluble epoxide hydrolases. In one enzyme-inhibitor complex, the urea carbonyl oxygen additionally interacts with Gln(382). If a comparable interaction occurs in catalysis, then Gln(382) may provide electrostatic stabilization of partial negative charge on the epoxide oxygen. The carboxylate side chain of Asp(333) accepts a hydrogen bond from one of the urea NH groups in each enzyme-inhibitor complex. Because Asp(333) is the catalytic nucleophile, its interaction with the partial positive charge on the urea NH group mimics its approach toward the partial positive charge on the electrophilic carbon of an epoxide substrate. Accordingly, alkylurea inhibitors mimic features encountered in the reaction coordinate of epoxide ring opening, and a structure-based mechanism is proposed for leukotoxin epoxide hydrolysis.	Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA; Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA	University of Pennsylvania; University of California System; University of California Davis	Christianson, DW (corresponding author), Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA.	chris@xtal.chem.upenn.edu			NIEHS NIH HHS [2 R01 ES02710-16, 2 P42 ES0469909] Funding Source: Medline; NIGMS NIH HHS [GM56838] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002710, P42ES004699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056838] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arand M, 1996, J BIOL CHEM, V271, P4223; Argiriadi MA, 1999, P NATL ACAD SCI USA, V96, P10637, DOI 10.1073/pnas.96.19.10637; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEETHAM JK, 1995, DNA CELL BIOL, V14, P61, DOI 10.1089/dna.1995.14.61; *BIOS TECHN, 1993, INS 2 US GUID VERS 2; BORHAN B, 1995, J BIOL CHEM, V270, P26923, DOI 10.1074/jbc.270.45.26923; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; Heikinheimo P, 1999, STRUCTURE, V7, pR141, DOI 10.1016/S0969-2126(99)80079-3; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; ISHIZAKI T, 1995, AM J PHYSIOL-LUNG C, V269, pL65, DOI 10.1152/ajplung.1995.269.1.L65; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moghaddam MF, 1997, NAT MED, V3, P562, DOI 10.1038/nm0597-562; Morisseau C, 1999, P NATL ACAD SCI USA, V96, P8849, DOI 10.1073/pnas.96.16.8849; Nardini M, 1999, J BIOL CHEM, V274, P14579, DOI 10.1074/jbc.274.21.14579; OESCH F, 1973, XENOBIOTICA, V3, P305, DOI 10.3109/00498257309151525; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; OTA K, 1980, SCIENCE, V207, P1479, DOI 10.1126/science.7361100; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ridder IS, 1997, J BIOL CHEM, V272, P33015, DOI 10.1074/jbc.272.52.33015; Rink R, 1999, J AM CHEM SOC, V121, P7417, DOI 10.1021/ja990501o; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; VERSCHUEREN KHG, 1993, J MOL BIOL, V232, P856, DOI 10.1006/jmbi.1993.1436; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WIXTROM RN, 1985, BIOCH PHARM TOXICOLO, V1, P1; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V316, P443, DOI 10.1006/abbi.1995.1059; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402; Zou JY, 2000, STRUCTURE, V8, P111, DOI 10.1016/S0969-2126(00)00087-3	31	107	131	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15265	15270		10.1074/jbc.M000278200	http://dx.doi.org/10.1074/jbc.M000278200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747889	hybrid			2022-12-27	WOS:000087128300067
J	Tanikawa, J; Ichikawa-Iwata, E; Kanei-Ishii, C; Nakai, A; Matsuzawa, S; Reed, JC; Ishii, S				Tanikawa, J; Ichikawa-Iwata, E; Kanei-Ishii, C; Nakai, A; Matsuzawa, S; Reed, JC; Ishii, S			p53 suppresses the c-myb-induced activation of heat shock transcription factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; CELL-CYCLE; GENE-TRANSCRIPTION; MOLECULAR-CLONING; TUMOR SUPPRESSION; FACTOR HSF1; STRESS; OLIGOMERIZATION; EXPRESSION; REPRESSION	Expression of heat shock proteins (HSPs) is controlled by heat shock transcription factors (HSFs), Vertebrates express multiple HSFs whose activities may be regulated by distinct signals. HSF3 is specifically activated in unstressed proliferating cells by direct binding to the c-myb proto-oncogene product (c-Myb), which plays an important role in cellular proliferation. This suggests that the c-Myb-induced HSF3 activation may contribute to the growth-regulated expression of HSPs, Here we report that the p53 tumor suppressor protein directly binds to HSF3 and blocks the interaction between c-Myb and HSF3. In addition, p53 stimulates the degradation of c-Myb through a proteasome-dependent mechanism, which is, at least partly, mediated by induction of Siah in certain types of cells. Induction of p53 by a genotoxic reagent in DT40 cells disrupts the HSF3-c-Myb interaction and down-regulates the expression of certain HSPs, Mutated forms of p53 found in certain tumors did not inhibit c-Myb-induced HSF3 activation. The regulation of HSF3 activity by c-Myb and p53 sheds light on the molecular events that govern HSP expression during cellular proliferation and apoptosis.	RIKEN, Tsukuba Life Sci Ctr, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; Japan Sci & Technol, Core Res Evolutionary Sci & Technol Project, Tsukuba, Ibaraki 3050074, Japan; Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cell Biol, Sakyo Ku, Kyoto 6068397, Japan; Burnham Inst, La Jolla, CA 92037 USA	RIKEN; Japan Science & Technology Agency (JST); Kyoto University; Sanford Burnham Prebys Medical Discovery Institute	Ishii, S (corresponding author), RIKEN, Tsukuba Life Sci Ctr, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.go.jp	Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jolly C, 1999, P NATL ACAD SCI USA, V96, P6769, DOI 10.1073/pnas.96.12.6769; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; MENG X, 1993, BIOCHEM BIOPH RES CO, V190, P630, DOI 10.1006/bbrc.1993.1095; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MIYASHITA T, 1995, CELL, V80, P293; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; Tanabe M, 1998, EMBO J, V17, P1750, DOI 10.1093/emboj/17.6.1750; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	56	71	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15578	15585		10.1074/jbc.M000372200	http://dx.doi.org/10.1074/jbc.M000372200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747903	hybrid			2022-12-27	WOS:000087128300108
J	Dunbar, DA; Wormsley, S; Lowe, TM; Baserga, SJ				Dunbar, DA; Wormsley, S; Lowe, TM; Baserga, SJ			Fibrillarin-associated box C/D small nucleolar RNAs in Trypanosoma brucei - Sequence conservation and implications for 2 '-O-ribose methylation of rRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-RIBOSOMAL-RNA; SMALL NUCLEAR-RNA; INTRONIC U14 SNORNA; SACCHAROMYCES-CEREVISIAE; STRUCTURAL ELEMENTS; TRANSCRIBED SPACER; PRERIBOSOMAL RNA; EUGLENA-GRACILIS; MATURE SNORNA; GUIDE SNORNAS	We report the identification of 17 box C/D fibrillarin-associated small nucleolar RNAs (snoRNAs) from the ancient eukaryote, Trypanosoma brucei. To systematically isolate and characterize these snoRNAs, the T. brucei cDNA for the box C/D snoRNA common protein, fibrillarin, was domed and polyclonal antibodies to the recombinant fibrillarin protein were generated in rabbits. Immunoprecipitations from T. brucei extracts with the anti-fibrillarin antibodies indicated that this trypanosomatid has at least 30 fibrillarin-associated snoRNAs. We have sequenced seventeen of them and designated them TBR for T. brucei RNA 1-17. All of them bear conserved box C, D, C', and D' elements, a hallmark of fibrillarin-associated snoRNAs in eukaryotes. Fourteen of them are novel T. brucei snoRNAs. Fifteen bear potential guide regions to mature rRNAs suggesting that they are involved in 2'-O-ribose methylation. Indeed, eight ribose methylations have been mapped in the rRNA at sites predicted by the snoRNA sequences. Comparative genomics indicates that six of the seventeen are the first trypanosome homologs of known yeast and vertebrate methylation guide snoRNAs. Our results indicate that T. brucei has many fibrillarin-associated box C/D snoRNAs with roles in 2'-O-ribose methylation of rRNA and that the mechanism for targeting the nucleotide to be methylated at the fifth nucleotide upstream of box D or D' originated in early eukaryotes.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Yale University; Yale University; Yale University; Washington University (WUSTL)	Baserga, SJ (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St,POB 208040, New Haven, CT 06520 USA.	susan.baserga@yale.edu	Lowe, Todd Michael/ABJ-5261-2022					Bachellerie J. P., 1998, MODIFICATION EDITING, P255; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; CAMPBELL DA, 1987, J MOL BIOL, V196, P113, DOI 10.1016/0022-2836(87)90514-6; CAPPAI R, 1994, MOL BIOCHEM PARASIT, V64, P353, DOI 10.1016/0166-6851(94)00047-6; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; Cavaille J, 1998, NUCLEIC ACIDS RES, V26, P1576, DOI 10.1093/nar/26.7.1576; CLARK CG, 1987, J MOL EVOL, V25, P343, DOI 10.1007/BF02603119; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; David E, 1997, MOL BIOL CELL, V8, P1051, DOI 10.1091/mbc.8.6.1051; Dunbar DA, 1998, RNA, V4, P195; EICHLER DC, 1995, PROG NUCL ACID RES M, V49, P179; England T E, 1980, Methods Enzymol, V65, P65; Enright CA, 1996, RNA, V2, P1094; FANTONI A, 1994, MOL CELL BIOL, V14, P2021, DOI 10.1128/MCB.14.3.2021; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; GRAY MW, 1979, CAN J BIOCHEM CELL B, V57, P914, DOI 10.1139/o79-111; GRAY MW, 1989, HIGHLIGHTS OF MODERN BIOCHEMISTRY, VOLS 1-2, P521; HARTSHORNE T, 1994, NUCLEIC ACIDS RES, V22, P3354, DOI 10.1093/nar/22.16.3354; Hartshorne T, 1998, NUCLEIC ACIDS RES, V26, P2541, DOI 10.1093/nar/26.11.2541; HARTSHORNE T, 1993, MOL CELL BIOL, V13, P144, DOI 10.1128/MCB.13.1.144; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; HUANG GM, 1992, MOL CELL BIOL, V12, P4456, DOI 10.1128/MCB.12.10.4456; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; Kiss-Laszlo Z, 1998, EMBO J, V17, P797, DOI 10.1093/emboj/17.3.797; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KOONIN EV, 1995, P NATL ACAD SCI USA, V92, P11921, DOI 10.1073/pnas.92.25.11921; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Lafontaine DLJ, 1999, RNA, V5, P455, DOI 10.1017/S135583829998192X; Lange TS, 1998, EMBO J, V17, P3176, DOI 10.1093/emboj/17.11.3176; LEADER DJ, 1994, NUCLEIC ACIDS RES, V22, P5196, DOI 10.1093/nar/22.24.5196; Leader DJ, 1997, EMBO J, V16, P5742, DOI 10.1093/emboj/16.18.5742; Levitan A, 1998, NUCLEIC ACIDS RES, V26, P1775, DOI 10.1093/nar/26.7.1775; LI HV, 1992, EMBO J, V11, P683, DOI 10.1002/j.1460-2075.1992.tb05100.x; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; Lyman SK, 1999, RNA, V5, P1597, DOI 10.1017/S1355838299991288; Maden BEH, 1997, NATURE, V389, P129, DOI 10.1038/38134; Maden BEH, 1997, CHROMOSOMA, V105, P391, DOI 10.1007/s004120050200; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; Maden T, 1996, NATURE, V383, P675, DOI 10.1038/383675a0; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NAKAAR V, 1994, MOL CELL BIOL, V14, P6736, DOI 10.1128/MCB.14.10.6736; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Ofengand J., 1998, MODIFICATION EDITING, P229, DOI DOI 10.1128/9781555818296.CH12; Peculis B, 1997, CURR BIOL, V7, pR480, DOI 10.1016/S0960-9822(06)00242-9; Peculis BA, 1996, CURR BIOL, V6, P1413, DOI 10.1016/S0960-9822(96)00745-2; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Roberts TG, 1998, MOL CELL BIOL, V18, P4409, DOI 10.1128/MCB.18.8.4409; Roberts TG, 1996, MOL BIOCHEM PARASIT, V83, P163, DOI 10.1016/S0166-6851(96)02762-4; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SCHNARE MN, 1990, J MOL BIOL, V215, P73, DOI 10.1016/S0022-2836(05)80096-8; SCHNARE MN, 1990, J MOL BIOL, V215, P85, DOI 10.1016/S0022-2836(05)80097-X; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; SPENCER DF, 1987, EMBO J, V6, P1063, DOI 10.1002/j.1460-2075.1987.tb04859.x; TERNS MP, 1995, EMBO J, V14, P4860, DOI 10.1002/j.1460-2075.1995.tb00167.x; Tollervey D, 1996, SCIENCE, V273, P1056, DOI 10.1126/science.273.5278.1056; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025; Tycowski KT, 1996, P NATL ACAD SCI USA, V93, P14480, DOI 10.1073/pnas.93.25.14480; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; Watkins NJ, 1996, RNA, V2, P118; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; Wu P, 1998, J BIOL CHEM, V273, P16453, DOI 10.1074/jbc.273.26.16453; Xia L, 1997, RNA, V3, P17; Yu YT, 1997, RNA, V3, P324	76	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14767	14776		10.1074/jbc.M001180200	http://dx.doi.org/10.1074/jbc.M001180200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10747997	Green Submitted, hybrid			2022-12-27	WOS:000087006900101
J	Kobayashi, S; Akiyama, T; Nata, K; Abe, M; Tajima, M; Shervani, NJ; Unno, M; Matsuno, S; Sasaki, H; Takasawa, S; Okamoto, H				Kobayashi, S; Akiyama, T; Nata, K; Abe, M; Tajima, M; Shervani, NJ; Unno, M; Matsuno, S; Sasaki, H; Takasawa, S; Okamoto, H			Identification of a receptor for Reg (Regenerating gene) protein, a pancreatic beta-cell regeneration factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; POLY(ADP-RIBOSE) SYNTHETASE INHIBITORS; INTRACELLULAR CA2+ MOBILIZATION; HEREDITARY MULTIPLE EXOSTOSES; LEUKOCYTE ANTIGEN CD38; DNA STRAND BREAKS; CHROMOSOMAL LOCALIZATION; PROINSULIN SYNTHESIS; THREAD PROTEIN; EXPRESSION	Reg (regenerating gene) was isolated as a gene specifically expressed in regenerating islets (Terazono, K., Yamamoto, H., Takasawa, S., Shiga, K., Yonemura, Y., Tochino, Y., and Okamoto, H. (1988) J. Biol. Chem, 263, 2111-2114), Rat and human Reg gene products, Reg/REG proteins, have been demonstrated to stimulate islet beta-cell growth in vitro and in vivo and to ameliorate experimental diabetes. In the present study, we isolated a cDNA for the Reg protein receptor from a rat islet cDNA library. The cDNA encoded a cell surface 919-amino acid protein, and the cells into which the cDNA had been introduced bound Reg protein with high affinity. When the cDNA was introduced into RINm5F cells, a pancreatic beta-cell line that shows Reg-dependent growth, the transformants exhibited significant increases in the incorporation of 5'-bromo-2'-deoxyuridine as well as in the cell numbers in response to Reg protein. A homology search revealed that the cDNA is a homologue to a human multiple exostoses-like gene, the function of which has hitherto been unknown. These results strongly suggest that the receptor is encoded by the exostoses-like gene and mediates a growth signal of Reg protein for beta-cell regeneration.	Tohoku Univ, Grad Sch Med, Dept Biochem, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Med, Dept Surg, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Med, Dept Geriatr Med, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University; Tohoku University; Tohoku University	Okamoto, H (corresponding author), Tohoku Univ, Grad Sch Med, Dept Biochem, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	okamotoh@mail.cc.tohoku.ac.jp	Unno, Michiaki/A-8633-2010; Unno, Michiaki/AAX-5246-2020	Unno, Michiaki/0000-0002-2145-6416; Unno, Michiaki/0000-0002-2145-6416				AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Anastasi E, 1999, EUR J ENDOCRINOL, V141, P644, DOI 10.1530/eje.0.1410644; Asahara M, 1996, GASTROENTEROLOGY, V111, P45, DOI 10.1053/gast.1996.v111.pm8698224; Baeza N, 1996, DIABETES METAB, V22, P229; Baeza NJ, 1996, DIABETES, V45, P67, DOI 10.2337/diabetes.45.1.67; Bernard-Perrone FR, 1999, J HISTOCHEM CYTOCHEM, V47, P863, DOI 10.1177/002215549904700703; Christa L, 1996, AM J PHYSIOL-GASTR L, V271, pG993, DOI 10.1152/ajpgi.1996.271.6.G993; Fukui H, 1998, GASTROENTEROLOGY, V115, P1483, DOI 10.1016/S0016-5085(98)70027-7; FURUYA Y, 1995, GENE, V165, P329, DOI 10.1016/0378-1119(95)00540-M; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gross DJ, 1998, ENDOCRINOLOGY, V139, P2369, DOI 10.1210/en.139.5.2369; ISHII C, 1993, ENDOCR J, V40, P269, DOI 10.1507/endocrj.40.269; ITOH T, 1990, FEBS LETT, V272, P85, DOI 10.1016/0014-5793(90)80454-Q; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; Livesey FJ, 1997, NATURE, V390, P614, DOI 10.1038/37615; MIYAURA C, 1991, MOL ENDOCRINOL, V5, P226, DOI 10.1210/mend-5-2-226; Narushima Y, 1997, GENE, V185, P159, DOI 10.1016/S0378-1119(96)00589-6; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; Okamoto H, 1999, J MOL MED, V77, P74, DOI 10.1007/s001090050305; Okamoto H, 1999, J Hepatobiliary Pancreat Surg, V6, P254, DOI 10.1007/s005340050115; Okamoto H, 1997, METHOD ENZYMOL, V280, P306; OKAMOTO H, 1985, BIOESSAYS, V2, P15, DOI 10.1002/bies.950020106; Okamoto H., 2008, MOL BIOL ISLETS LANG, P209; Ortiz EM, 1998, GASTROENTEROLOGY, V114, P808, DOI 10.1016/S0016-5085(98)70595-5; Saito T, 1998, BIOCHEM BIOPH RES CO, V243, P61, DOI 10.1006/bbrc.1997.8062; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; Takasawa S, 1995, J BIOL CHEM, V270, P30257, DOI 10.1074/jbc.270.51.30257; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; TERAZONO K, 1990, DIABETOLOGIA, V33, P250, DOI 10.1007/BF00404804; UCHIGATA Y, 1982, J BIOL CHEM, V257, P6084; UCHIGATA Y, 1983, DIABETES, V32, P316, DOI 10.2337/diabetes.32.4.316; UNNO M, 1993, J BIOL CHEM, V268, P15974; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; WATANABE T, 1990, J BIOL CHEM, V265, P7432; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; Wuyts W, 1997, EUR J HUM GENET, V5, P382, DOI 10.1159/000484796; Wuyts W, 1996, HUM MOL GENET, V5, P1547, DOI 10.1093/hmg/5.10.1547; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0; YONEMURA Y, 1984, DIABETES, V33, P401, DOI 10.2337/diabetes.33.4.401; Zenilman M E, 1997, J Gastrointest Surg, V1, P194, DOI 10.1016/S1091-255X(97)80109-6; Zenilman ME, 1998, PANCREAS, V17, P256, DOI 10.1097/00006676-199810000-00005; Zenilman ME, 1996, GASTROENTEROLOGY, V110, P1208, DOI 10.1053/gast.1996.v110.pm8613011	44	135	144	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10723	10726		10.1074/jbc.275.15.10723	http://dx.doi.org/10.1074/jbc.275.15.10723			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753861	hybrid			2022-12-27	WOS:000086466600003
J	Wang, ZM; Liu, C; Dziarski, R				Wang, ZM; Liu, C; Dziarski, R			Chemokines are the main proinflammatory mediators in human monocytes activated by Staphylococcus aureus, peptidoglycan, and endotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; CELL-WALL COMPONENTS; SIGNAL-REGULATED KINASE; BACTERIAL PEPTIDOGLYCAN; LIPOTEICHOIC ACID; LIPOPOLYSACCHARIDE; CD14; MCP-1; TRANSDUCTION; MACROPHAGES	It is widely believed that the cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1, and IL-6 are the main proinflammatory mediators induced in the host by bacteria and their cell wall components. To test this hypothesis, we compared the level of expression of 600 genes activated in human monocytes by Staphylococcus aureus, peptidoglycan, endotoxin, and interferon-gamma, These stimulants induced expression of over 120 genes, as identified by cDNA arrays. The highest activated genes for proinflammatory mediators induced by all three bacterial stimulants were chemokine genes (IL-8 and macrophage inflammatory protein (MIP)-1 alpha), whereas cytokine genes (TNF-alpha, IL-1, and IL-6) were induced to a lower extent. Genes for other chemokines (MIP-2 alpha, MIP-1 beta, and monocyte chemoattractant protein-1) were also induced higher than the cytokine genes by peptidoglycan, and as high or higher than the cytokine genes by S. aureus and endotoxin. This high induction of chemokine genes was confirmed by quantitative RNase protection assay, and high secretion of chemokines was confirmed by enzyme-linked immunosorbent assays. Although genes for chemokines were the highest and genes for cytokines were the second highest induced genes by all three bacterial stimulants, each stimulus induced a unique pattern of gene expression. By contrast, expression of a completely different gene pattern was induced by a nonbacterial stimulus, interferon-gamma, These results establish chemokines as the main mediators induced by both Gram-positive and Gram-negative bacteria and are consistent with the highly inflammatory nature of bacterial infections.	Indiana Univ, Sch Med, NW Ctr Med Educ, Gary, IN 46408 USA	Indiana University System; Indiana University Northwest	Dziarski, R (corresponding author), Indiana Univ, Sch Med, NW Ctr Med Educ, 3400 Broadway, Gary, IN 46408 USA.				NIAID NIH HHS [AI2879] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bauermeister K, 1998, NEPHROL DIAL TRANSPL, V13, P1412, DOI 10.1093/ndt/13.6.1412; BONE RC, 1994, ARCH INTERN MED, V154, P26, DOI 10.1001/archinte.154.1.26; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359; DZIARSKI R, 1979, INFECT IMMUN, V23, P706, DOI 10.1128/IAI.23.3.706-710.1979; Dziarski R, 2000, CHEM IMMUNOL, V74, P83; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; DZIARSKI R, 2000, CLYCOMICROBIOLOGY, P145; GUPTA D, 1995, J IMMUNOL, V155, P2620; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Horuk R, 1998, NATURE, V393, P524, DOI 10.1038/31116; JANEWAY CA, 1999, IMMUNOBIOLOGY IMMUNE, P375; Jin YP, 1998, J INFECT DIS, V177, P1629, DOI 10.1086/515318; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kopydlowski KM, 1999, J IMMUNOL, V163, P1537; KOYANONAKAGAWA N, 1994, MOL CELL BIOL, V14, P5099, DOI 10.1128/MCB.14.8.5099; Leonard W.J., 1999, FUNDAMENTAL IMMUNOLO, Vfourth, P741; MITCHELL RN, 1999, ROBBINS PATHOLOGIC B, P113; Parrillo J E, 1993, N Engl J Med, V328, P1471; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Proost P, 1996, J LEUKOCYTE BIOL, V59, P67, DOI 10.1002/jlb.59.1.67; Pugin J, 1998, INFECT IMMUN, V66, P1174, DOI 10.1128/IAI.66.3.1174-1180.1998; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SAMUELSON J, 1999, ROBBINS PATHOLOGIC B, P329; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; STANDIFORD TJ, 1995, J IMMUNOL, V155, P1515; Standiford TJ, 1996, J LEUKOCYTE BIOL, V59, P24, DOI 10.1002/jlb.59.1.24; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Walley KR, 1997, INFECT IMMUN, V65, P3847, DOI 10.1128/IAI.65.9.3847-3851.1997; WEIDEMANN B, 1994, INFECT IMMUN, V62, P4709, DOI 10.1128/IAI.62.11.4709-4715.1994; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshimura A, 1999, J IMMUNOL, V163, P1; Young L. S., 1995, PRINCIPLES PRACTICE, P690; Zisman DA, 1997, J CLIN INVEST, V99, P2832, DOI 10.1172/JCI119475	37	152	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20260	20267		10.1074/jbc.M909168199	http://dx.doi.org/10.1074/jbc.M909168199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10751418	hybrid			2022-12-27	WOS:000088084500008
J	Dumas, F; Koebnik, R; Winterhalter, M; Van Gelder, P				Dumas, F; Koebnik, R; Winterhalter, M; Van Gelder, P			Sugar transport through maltoporin of Escherichia coli - Role of polar tracks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL OUTER MEMBRANES; STRUCTURAL BASIS; DIFFUSION CHANNELS; PORINS; SPECIFICITY; PROTEIN; TRANSLOCATION; PERMEATION	The three-dimensional structure of the maltooligosaccharide specific outer membrane channel LamB of Escherichia coli complexed with sugar molecules revealed a hypothetical transport pathway. Sugars are supposed to slide over a stretch of aromatic residues facilitated by continuous making/breaking of hydrogen bonds between the hydroxyl groups of the sugars and charged amino acids, the "polar tracks." The effect of nine single and three multiple mutations in the polar track residues was investigated by current fluctuations, liposome swelling assays, and in vivo uptake of radiolabeled substrates, Additionally, sugar transport through wild-type LamB was investigated by current fluctuation analysis in water and deuterium, This way the effects on k(on) and k(off) could be investigated separately. Analyses of the various mutants revealed a strong effect on the k(on) values, Because steering to the binding site requires only a few interactions, consequently the loss of even one bond will have a strong effect. Deuterium experiments, which changed the characteristic of all hydrogen bonds, showed a strong effect on k(off) rates, because at this stage the sugar has numerous interactions with the channel. Furthermore, all the mutations induces a strong decrease of in vivo uptake of sugars. These results clearly demonstrate the importance of the polar track residues on both on and off rates in sugar transport and reveal a strong cooperative effect of hydrogen bond formation.	Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland; Univ Basel, Biozentrum, Dept Microbiol, CH-4056 Basel, Switzerland; Univ Toulouse, CNRS, Inst Pharmacol & Biol Struct, Toulouse, France	University of Basel; University of Basel; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Dumas, F (corresponding author), Univ Basel, Biozentrum, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	fabricedumas@yahoo.fr	Koebnik, Ralf/J-5627-2014	Koebnik, Ralf/0000-0002-4419-0542; Dumas, Fabrice/0000-0002-9164-4527; Winterhalter, Mathias/0000-0002-1604-3318; Van Gelder, Patrick/0000-0003-1785-4435				AGTERBERG M, 1990, VACCINE, V8, P85, DOI 10.1016/0264-410X(90)90184-N; ARNETT EM, 1969, SOLUTE SOLVENT INTER, P351; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; Dutzler R, 1996, STRUCTURE, V4, P127, DOI 10.1016/S0969-2126(96)00016-0; EISENBERG RS, 1990, J MEMBRANE BIOL, V115, P1, DOI 10.1007/BF01869101; GUTFREUND D, 1995, KINETICS LIFE SCI RE, P275; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; Meyer JEW, 1997, PROTEIN SCI, V6, P1084, DOI 10.1002/pro.5560060515; NEKOLLA S, 1994, BIOPHYS J, V66, P1388, DOI 10.1016/S0006-3495(94)80929-4; NEMETHY G, 1964, J CHEM PHYS, V41, P680, DOI 10.1063/1.1725946; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; Prilipov A, 1998, FEMS MICROBIOL LETT, V163, P65, DOI 10.1111/j.1574-6968.1998.tb13027.x; ROSENBUSCH JP, 1996, HDB BIOL PHYS, V2, P599; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SCHMID K, 1991, MOL MICROBIOL, V5, P941, DOI 10.1111/j.1365-2958.1991.tb00769.x; Schulz GE, 1996, CURR OPIN STRUC BIOL, V6, P485, DOI 10.1016/S0959-440X(96)80113-8; VANGELDER P, 1999, EUR J BIOCHEM, V266, P1; Wang YF, 1997, J MOL BIOL, V272, P56, DOI 10.1006/jmbi.1997.1224	21	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19747	19751		10.1074/jbc.M000268200	http://dx.doi.org/10.1074/jbc.M000268200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10747886	hybrid			2022-12-27	WOS:000087941300044
J	Connor, JH; Frederick, D; Huang, HB; Yang, J; Helps, NR; Cohen, PTW; Nairn, AC; DePaoli-Roach, A; Tatchell, K; Shenolikar, S				Connor, JH; Frederick, D; Huang, HB; Yang, J; Helps, NR; Cohen, PTW; Nairn, AC; DePaoli-Roach, A; Tatchell, K; Shenolikar, S			Cellular mechanisms regulating protein phosphatase-1 - A key functional interaction between inhibitor-2 and the type 1 protein phosphatase catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; MAMMALIAN INHIBITOR-2; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION; CHAPERONE; YEAST; SITE	Inhibitor-1 (I-1) and inhibitor-2 (I-2) selectively inhibit type 1 protein serine/threonine phosphatases (PP1). To define the molecular basis for PP1 inhibition by I-1 and I-2 charged-to-alanine substitutions in the Saccharomyces cerevisiae, PP1 catalytic subunit (GLC7), were analyzed. Two PP1 mutants, E53A/E55A and K165A/E166A/K167A, showed reduced sensitivity to I-2 when compared with wild-type PP1, Both mutants were effectively inhibited by I-1. Two-hybrid analysis and coprecipitation or pull-down assays established that wildtype and mutant PP1 catalytic subunits bound I-2 in an identical manner and suggested a role for the mutated amino acids in enzyme inhibition. Inhibition of wildtype and mutant PP1 enzymes by full-length I-2(1-204), I-2(1-114), and I-2(36-204) indicated that the mutant enzymes were impaired in their interaction with the N-terminal 35 amino acids of I-2. Site-directed mutagenesis of amino acids near the N terminus of I-2 and competition for PP1 binding by a synthetic peptide encompassing an I-2 N-terminal sequence suggested that a PP1 domain composed of amino acids Glu-53, Glu-55, Asp-165, Glu-166, and Lys-167 interacts with the N terminus of I-2. This defined a novel regulatory interaction between I-2 and PP1 that determines I-2 potency and perhaps selectivity as a PPI inhibitor.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Tzu Chi Coll Med & Humanities, Inst Biochem, Hualien 970, Taiwan; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland	Duke University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Tzu Chi University; Rockefeller University; Indiana University System; Indiana University-Purdue University Indianapolis; University of Dundee	Shenolikar, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	sheno001@mc.duke.edu	Tatchell, Kelly/A-9643-2009	Nairn, Angus/0000-0002-7075-0195; Connor, John/0000-0002-8867-7256	NIDDK NIH HHS [DK52054, DK36569] Funding Source: Medline; NIGMS NIH HHS [GM47789] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054, R01DK036569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047789] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; Baker SH, 1997, GENETICS, V145, P615; Bennett D, 1999, BIOCHEMISTRY-US, V38, P16276, DOI 10.1021/bi9917028; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; BOLLEN M, 1994, BIOCHEM J, V311, P17; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BRAUTIGAN DL, 1980, BIOCHEMISTRY-US, V19, P5787, DOI 10.1021/bi00566a019; CANNON JF, 1994, GENETICS, V136, P485; CANNON JF, 1995, ADV PROTEIN PHOSPHAT, V9, P211; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Connor JH, 1998, METH MOL B, V93, P41; DOMBRADI V, 1987, BIOCHEM BIOPH RES CO, V144, P1175, DOI 10.1016/0006-291X(87)91435-5; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; ENDO S, 1995, J NEUROCHEM, V64, P1833; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; FOULKES JG, 1982, FEBS LETT, V150, P155, DOI 10.1016/0014-5793(82)81325-2; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Helps NR, 1999, FEBS LETT, V463, P72, DOI 10.1016/S0014-5793(99)01573-2; Helps NR, 1998, FEBS LETT, V438, P131, DOI 10.1016/S0014-5793(98)01286-1; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; Kakinoki Y, 1997, J BIOL CHEM, V272, P32308, DOI 10.1074/jbc.272.51.32308; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; MacKintosh C, 1996, FEBS LETT, V397, P235, DOI 10.1016/S0014-5793(96)01175-1; MEIJER L, 1986, EXP CELL RES, V163, P489, DOI 10.1016/0014-4827(86)90079-0; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Osawa Y, 1996, EUR J BIOCHEM, V242, P793, DOI 10.1111/j.1432-1033.1996.0793r.x; PARK IK, 1994, J BIOL CHEM, V269, P28919; PARK IK, 1994, J BIOL CHEM, V269, P944; PICKING WD, 1991, BIOCHEMISTRY-US, V30, P10280, DOI 10.1021/bi00106a028; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; STARK MJ, 1994, YEAST, V12, P1647; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; Yang J, 1998, FASEB J, V12, pA1407; Zhang J, 1998, BIOCHEMISTRY-US, V37, P16728, DOI 10.1021/bi981169g; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	45	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18670	18675		10.1074/jbc.M909312199	http://dx.doi.org/10.1074/jbc.M909312199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10748125	hybrid			2022-12-27	WOS:000087815900009
J	Eitinger, T; Degen, O; Bohnke, U; Muller, M				Eitinger, T; Degen, O; Bohnke, U; Muller, M			Nic1p, a relative of bacterial transition metal permeases in Schizosaccharomyces pombe, provides nickel ion for urease biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; MICROBIAL UREASES; TRANSPORT; GENE; FAMILY; SYSTEM; HOXN	The Schizosaccharomgces pombe genome sequencing project identified an open reading frame (O74869 and O74912, named Nic1p in the present study) with significant similarity to members of a family of bacterial transition metal permeases, These uptake systems transport Ni2+ ion with extremely high affinity across the bacterial cytoplasmic membrane, but they differ in selectivity toward divalent transition metal cations, An S. pombe mutant harboring an interrupted nic1 allele (nic1-1) was strongly impaired in Ni-63(2+) uptake in the presence of a high molar ratio of Mg2+ relative to Ni2+, conditions that reflect the natural situation. Under these conditions, the nic1-1 mutant contained only background activities of the nickeI dependent cytoplasmic enzyme urease and could not catabolize urea. Among a series of divalent transition metal cations tested (Cd2+, Co2+ Cu2+, Mn2+ and Zn2+), only Co2+ caused considerable inhibition of Nic1p-mediated Ni2+ uptake. On the other hand, experiments with Co-57(2+) (at nM concentrations) did not show significant differences in Co2+ uptake between the nic1-1 mutant and the parental strain. Our data suggest that Nic1p acts as a plasma-membrane nickel transporter in fission yeast, a finding that invites searches for isologous counterparts in higher eukaryotes.	Humboldt Univ, Inst Biol, D-10115 Berlin, Germany	Humboldt University of Berlin	Eitinger, T (corresponding author), Humboldt Univ, Inst Biol Mikrobiol, Chausseestr 117, D-10115 Berlin, Germany.	thomas.eitinger@rz.hu-berlin.de	Eitinger, Thomas/C-3926-2019	Eitinger, Thomas/0000-0003-1449-6433				Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Degen O, 1999, ARCH MICROBIOL, V171, P139, DOI 10.1007/s002030050691; Eitinger T, 1997, J BIOL CHEM, V272, P17139, DOI 10.1074/jbc.272.27.17139; Eitinger T, 1997, TRANSITION METALS IN MICROBIAL METABOLISM, P235; Eitinger T, 2000, ARCH MICROBIOL, V173, P1, DOI 10.1007/s002030050001; FAWCETT JK, 1960, J CLIN PATHOL, V13, P156, DOI 10.1136/jcp.13.2.156; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Hausinger RP, 1997, J BIOL INORG CHEM, V2, P279, DOI 10.1007/s007750050133; HAUSINGER RP, 1993, BIOCH NICKEL; Kehres D G, 1998, Microb Comp Genomics, V3, P151, DOI 10.1089/omi.1.1998.3.151; Liu XF, 1999, J MOL BIOL, V289, P885, DOI 10.1006/jmbi.1999.2815; Liu XF, 1999, J BIOL CHEM, V274, P4863, DOI 10.1074/jbc.274.8.4863; Lubbers MW, 1996, CAN J MICROBIOL, V42, P132, DOI 10.1139/m96-021; Lubbers MW, 1997, YEAST, V13, P1195, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1195::AID-YEA170>3.0.CO;2-0; MacDiarmid CW, 1998, J BIOL CHEM, V273, P1727, DOI 10.1074/jbc.273.3.1727; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Soriano A, 1999, P NATL ACAD SCI USA, V96, P11140, DOI 10.1073/pnas.96.20.11140; SUMRADA RA, 1982, J BIOL CHEM, V257, P9119; Tange Y, 1997, CURR GENET, V32, P244, DOI 10.1007/s002940050273; WOLFRAM L, 1995, J BACTERIOL, V177, P1840, DOI 10.1128/jb.177.7.1840-1843.1995	26	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18029	18033		10.1074/jbc.M001978200	http://dx.doi.org/10.1074/jbc.M001978200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748059	hybrid			2022-12-27	WOS:000087659400018
J	Geck, MK; Hartman, FC				Geck, MK; Hartman, FC			Kinetic and mutational analyses of the regulation of phosphoribulokinase by thioredoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE INTERCHANGE REACTIONS; OXIDATION-REDUCTION PROPERTIES; ESCHERICHIA-COLI THIOREDOXIN; CALVIN CYCLE ACTIVITY; SPINACH PHOSPHORIBULOKINASE; MULTIENZYME COMPLEX; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CHLOROPLAST PHOSPHORIBULOKINASE; RIBULOSE-5-PHOSPHATE KINASE; EQUILIBRIUM-CONSTANTS	Despite little supportive data, differential target protein susceptibility to redox regulation by thioredoxin (Trx) fend Trx in has been invoked to account for two distinct Trxs in chloroplasts. However, this postulate has not been rigorously tested with phosphoribulokinase (PRK), a fulcrum for redox regulation of the Calvin cycle. Prerequisite to Trx studies, the activation of spinach PRK by dithiothreitol, 2-mercaptoethanol, and glutathione was examined. Contrary to prior reports, each activated PRK, but only dithiothreitol supported Trx-dependent activation. Comparative kinetics of activation of PRK showed Trx m to be more efficient than Trx f because of its 40% higher V-max but similar S-0.5. Activations were insensitive to ribulosebisphosphate carboxylase, which may complex with PRK in vivo. To probe the basis for superiority of Trx m, we characterized site-directed mutants of Trx f, in which unique residues in conserved regions were replaced with Trx m counterparts or deleted. These changes generally resulted in V-max enhancements, the largest (6-fold) of which occurred with T105I, reflective of substitution in a hydrophobic region that opposes the active site. inclusive of the present study activation kinetics of several different Trx-regulated enzymes indicate redundancy in the functions of the chloroplastic Trxs.	Univ Tennessee, Oak Ridge Grad Sch Biomed Sci, Oak Ridge, TN 37830 USA; Oak Ridge Natl Lab, Div Life Sci, Prot Engn Program, Oak Ridge, TN 37831 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory	Hartman, FC (corresponding author), Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA.	ffh@ornl.gov						Avilan L, 1997, EUR J BIOCHEM, V246, P78, DOI 10.1111/j.1432-1033.1997.00078.x; AVRON M, 1974, PLANT PHYSIOL, V53, P136, DOI 10.1104/pp.53.2.136; Brandes HK, 1996, J BIOL CHEM, V271, P6490, DOI 10.1074/jbc.271.11.6490; BRANDES HK, 1992, BIOCHEMISTRY-US, V31, P12833, DOI 10.1021/bi00166a018; Brandes HK, 1996, J BIOL CHEM, V271, P3333; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; BUCHANAN BB, 1986, THIOREDOXIN GLUTARED, P233; CHAMPIGNY ML, 1976, PHYSIOL PLANTARUM, V36, P95, DOI 10.1111/j.1399-3054.1976.tb05034.x; CLASPER S, 1994, BBA-PROTEIN STRUCT M, V1209, P101, DOI 10.1016/0167-4838(94)90143-0; CLASPER S, 1991, EUR J BIOCHEM, V202, P1239, DOI 10.1111/j.1432-1033.1991.tb16496.x; DELAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; FISCHER KH, 1979, BIOCHEM BIOPH RES CO, V89, P300, DOI 10.1016/0006-291X(79)90978-1; GECK MK, 1997, THESIS U TENNESSEE K; Geck RK, 1996, J BIOL CHEM, V271, P24736, DOI 10.1074/jbc.271.40.24736; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GONTERO B, 1993, EUR J BIOCHEM, V217, P1075, DOI 10.1111/j.1432-1033.1993.tb18339.x; GONTERO B, 1988, EUR J BIOCHEM, V173, P437, DOI 10.1111/j.1432-1033.1988.tb14018.x; HATCH MD, 1992, PLANT PHYSIOL, V100, P360, DOI 10.1104/pp.100.1.360; Hirasawa M, 1998, ARCH BIOCHEM BIOPHYS, V350, P127, DOI 10.1006/abbi.1997.0499; Hirasawa M, 1999, BIOCHEMISTRY-US, V38, P5200, DOI 10.1021/bi982783v; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; JACQUOT JP, 1978, FEBS LETT, V96, P243, DOI 10.1016/0014-5793(78)80410-4; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; LAING WA, 1981, BIOCHIM BIOPHYS ACTA, V637, P348, DOI 10.1016/0005-2728(81)90174-2; LATZKO E, 1970, BIOCHEM BIOPH RES CO, V39, P1140, DOI 10.1016/0006-291X(70)90678-9; LAW MY, 1983, BIOCHEM J, V210, P899, DOI 10.1042/bj2100899; LEES WJ, 1993, J ORG CHEM, V58, P642, DOI 10.1021/jo00055a016; MULLER EGD, 1989, J BIOL CHEM, V264, P4008; Navarro F, 1996, PLANT PHYSIOL, V111, P1067, DOI 10.1104/pp.111.4.1067; NICHOLSON S, 1987, EUR J BIOCHEM, V162, P423, DOI 10.1111/j.1432-1033.1987.tb10619.x; NICHOLSON S, 1986, FEBS LETT, V202, P19, DOI 10.1016/0014-5793(86)80640-8; Pohlmeyer K, 1996, PLANT MOL BIOL, V32, P969, DOI 10.1007/BF00020493; PORTER MA, 1990, PLANTA, V181, P349, DOI 10.1007/BF00195887; PORTER MA, 1986, ARCH BIOCHEM BIOPHYS, V245, P14, DOI 10.1016/0003-9861(86)90185-2; PORTER MA, 1988, J BIOL CHEM, V263, P123; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; RAULT M, 1991, EUR J BIOCHEM, V197, P791, DOI 10.1111/j.1432-1033.1991.tb15973.x; RAULT M, 1993, EUR J BIOCHEM, V217, P1065, DOI 10.1111/j.1432-1033.1993.tb18338.x; Romanova AK, 1997, RUSS J PLANT PHYSL+, V44, P230; SAARINEN M, 1995, STRUCTURE, V3, P1097, DOI 10.1016/S0969-2126(01)00245-3; SAINIS JK, 1986, BIOCHEM BIOPH RES CO, V139, P947, DOI 10.1016/S0006-291X(86)80269-8; SAINIS JK, 1989, PLANT PHYSIOL, V89, P368, DOI 10.1104/pp.89.1.368; SCHEIBE R, 1981, BIOCHIM BIOPHYS ACTA, V636, P58, DOI 10.1016/0005-2728(81)90075-X; SCHURMANN P, 1981, EUR J BIOCHEM, V116, P37, DOI 10.1111/j.1432-1033.1981.tb05297.x; SCHURMANN P, 1976, NATURE, V263, P257, DOI 10.1038/263257a0; Schwarz O, 1997, J BIOL CHEM, V272, P16924, DOI 10.1074/jbc.272.27.16924; SUSS KH, 1993, P NATL ACAD SCI USA, V90, P5514, DOI 10.1073/pnas.90.12.5514; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; Wedel N, 1997, P NATL ACAD SCI USA, V94, P10479, DOI 10.1073/pnas.94.19.10479; Wedel N, 1998, P NATL ACAD SCI USA, V95, P9699, DOI 10.1073/pnas.95.16.9699; Wishnick M, 1971, METHODS ENZYMOLOGY, V23, P570; WOLOSIUK RA, 1978, ARCH BIOCHEM BIOPHYS, V189, P97, DOI 10.1016/0003-9861(78)90119-4; WOLOSIUK RA, 1985, FEBS LETT, V189, P212, DOI 10.1016/0014-5793(85)81025-5; WOLOSIUK RA, 1979, J BIOL CHEM, V254, P1627; XIA TH, 1992, PROTEIN SCI, V1, P310	62	23	25	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18034	18039		10.1074/jbc.M001936200	http://dx.doi.org/10.1074/jbc.M001936200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10751409	hybrid			2022-12-27	WOS:000087659400019
J	Nakamura, K; Mitamura, T; Takahashi, T; Kobayashi, T; Mekada, E				Nakamura, K; Mitamura, T; Takahashi, T; Kobayashi, T; Mekada, E			Importance of the major extracellular domain of CD9 and the epidermal growth factor (EGF)-like domain of heparin-binding EGF-like growth factor for up-regulation of binding and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; MIGRATION IN-VITRO; MONOCLONAL-ANTIBODY; MEMBRANE-PROTEIN; NERVOUS-SYSTEM; CELL-SURFACE; HB-EGF; EXPRESSION; ADHESION; INTEGRIN	Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) is a member of the EGF family of growth factors. The membrane-anchored form of HB-EGF (proHB-EGF) is mitogenically active to neighboring cells as well as being a precursor of the soluble form. in addition to its mitogenic activity, proHB-EGF has the property of binding to diphtheria toxin (DT), serving as the specific receptor for DT. Tetramembrane-spanning protein CD9, a member of the TM4 superfamily, is physically associated with proHB-EGF at the cell surface and up-regulates both mitogenic and DT binding activities of proHB-EGF. To understand this up-regulation mechanism, we studied essential regions of both CD9 and proHB-EGF for up-regulation. Immunoprecipitation experiments revealed that not only CD9 but also other TM4 proteins including CD63, CD81, and CD82 associate with proHB-EGF on the cell surface. However, these TM4 proteins did not up-regulate DT binding activity of proHB-EGF. Transfection of a series of chimeric constructs comprising CD9 and CD81 showed that the major extracellular domain of CD9 is essential for up-regulation. Assays of DT binding activity and juxtacrine mitogenic activity of the deletion mutants of proHB-EGF and chimeric molecules, derived from proHB-EGF and TGF-alpha, showed that the essential domain of proHB-EGF for up-regulation is the EGF-like domain. These results indicate that the interaction of the extracellular domains of both molecules is important for up-regulation.	Kurume Univ, Div Cell Biol, Inst Life Sci, Fukuoka 8390861, Japan; Kurume Univ, Res Ctr Innovat Canc Therapy, Fukuoka 8390861, Japan	Kurume University; Kurume University	Mekada, E (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Cell Biol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Mekada, Eisuke/0000-0001-8858-4781				ANTON ES, 1995, J NEUROSCI, V15, P584; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; GRIFFITH L, 1991, BLOOD, V78, P1753; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IMAI T, 1993, J IMMUNOL, V151, P6470; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kagawa T, 1997, J NEUROSCI RES, V50, P312, DOI 10.1002/(SICI)1097-4547(19971015)50:2<312::AID-JNR19>3.0.CO;2-9; KAPRIELIAN Z, 1995, J NEUROSCI, V15, P562; Lagaudriere-Gesbert C, 1997, CELL IMMUNOL, V182, P105, DOI 10.1006/cimm.1997.1223; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; Mitamura T, 1997, J BIOL CHEM, V272, P27084, DOI 10.1074/jbc.272.43.27084; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NAGLICH JG, 1992, P NATL ACAD SCI USA, V89, P2170, DOI 10.1073/pnas.89.6.2170; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Nakamura Y, 1996, AM J PATHOL, V149, P575; Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3; Schmidt C, 1996, J NEUROSCI RES, V43, P12, DOI 10.1002/jnr.490430103; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; SI ZY, 1993, INT J CANCER, V54, P37, DOI 10.1002/ijc.2910540107; Tai XG, 1996, J EXP MED, V184, P753, DOI 10.1084/jem.184.2.753; TOLE S, 1993, DEV DYNAM, V197, P94, DOI 10.1002/aja.1001970203; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; Umata T, 1998, J BIOL CHEM, V273, P8351, DOI 10.1074/jbc.273.14.8351	36	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18284	18290		10.1074/jbc.M907971199	http://dx.doi.org/10.1074/jbc.M907971199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10749879	hybrid			2022-12-27	WOS:000087659400052
J	Matton, N; Simonetti, J; Williams, K				Matton, N; Simonetti, J; Williams, K			Identification of mismatch repair protein complexes in HeLa nuclear extracts and their interaction with heteroduplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; TRANSLOCATION MECHANISM; REPLICATION FIDELITY; ATPASE ACTIVITY; HMUTS-ALPHA; TUMOR-CELLS; BINDING; MUTL; HETERODIMER; MSH2	Deficiencies in DNA mismatch repair (MMR)have been found in hereditary colon cancers (hereditary nonpolyposis colon cancer, HNPCC) as well as in sporadic cancers, illustrating the importance of MMR in maintaining genomic integrity. We have examined the interactions of specific mismatch repair proteins in human nuclear extracts. Western blot and co-immunoprecipitation studies indicate two complexes as follows: one consisting of hMSH2, hMSH6, hMLH1, and hPMS2 and the other consisting of hMSH2, hMSH6, hMLH1, and hPMS1. These interactions occur without the addition of ATP. Furthermore, the protein complexes specifically bind to mismatched DNA and not to a similar homoduplex oligonucleotide, The protein complex-DNA interactions occur primarily through hMSH6, although hMSH2 can also become cross-linked to the mismatched substrate when not participating in the MMR protein complex. In the presence of ATP the binding of hMSH6 to mismatched DNA is decreased. In addition, hMLH1, hPMS2, and hPMS1 no longer interact with each other or with the hMutS alpha complex (hMSH2 and hMSH6). However, the ability of hMLH1 to co-immunoprecipitate mismatched DNA increases in the presence of ATP, This interaction is dependent on the presence of the mismatch and does not appear to involve a direct binding of hMLH1 to the DNA.	Univ Alaska, Biomed Program, Dept Biol Sci, Anchorage, AK 99508 USA	University of Alaska System; University of Alaska Anchorage	Williams, K (corresponding author), Univ Alaska, Biomed Program, Dept Biol Sci, 3211 Providence Dr, Anchorage, AK 99508 USA.				NATIONAL CANCER INSTITUTE [R29CA057495] Funding Source: NIH RePORTER; NCI NIH HHS [CA57495] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; GRADIA S, 1997, CELL, V91, P996; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Jiricny J, 1996, CANCER SURV, V28, P47; KIARIS H, 1995, INT J ONCOL, V7, P413; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Matton N, 1999, CARCINOGENESIS, V20, P1417, DOI 10.1093/carcin/20.8.1417; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Schmutte C, 1998, CANCER RES, V58, P4537; SKANKASI P, 1995, SCIENCE, V267, P1166; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	41	15	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17808	17813		10.1074/jbc.M909794199	http://dx.doi.org/10.1074/jbc.M909794199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748159	hybrid			2022-12-27	WOS:000087485000083
J	Wei, JZ; Theil, EC				Wei, JZ; Theil, EC			Identification and characterization of the iron regulatory element in the ferritin gene of a plant (soybean)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; CITRATE TRANSPORT-SYSTEM; 3' UNTRANSLATED REGION; ESCHERICHIA-COLI; POSTTRANSCRIPTIONAL REGULATION; TRANSCRIPTIONAL REGULATION; RESPONSIVE ELEMENTS; NODULE DEVELOPMENT; OXIDATIVE STRESS; BINDING PROTEIN	Iron increases ferritin synthesis, targeting plant DNA and animal mRNA The ferritin promoter in plants has not been identified, in contrast to the ferritin promoter and mRNA iron-responsive element (IRE) in animals. The soybean leaf, a natural tissue for ferritin expression, and DNA, with promoter deletions and luciferase or glucuronidase reporters, delivered with particle bombardment, were used to show that an 86-base pair fragment (iron regulatory element (FRE)) controlled iron-mediated derepression of the ferritin gene. Mutagenesis with linkers of random sequence detected two subdomains separated by 21 base pairs. FRE has no detectable homology to the animal IRE or to known. promoters in DNA and bound a trans-acting factor in leaf cell extracts, FRE/factor binding was abrogated by increased tissue iron, in analogy to mRNA (IRE)/iron regulatory protein in animals, Maximum ferritin derepression was obtained with 50 mu M iron citrate (1:10) or 500 mu M iron citrate (1:1) but Fe-EDTA was ineffective, although the leaf iron concentration was increased; manganese, zinc, and copper had no effect. The basis for different responses in ferritin expression to different iron complexes, as well as the significance of using DNA but not mRNA as an iron regulatory target in plants, remain unknown.	N Carolina State Univ, Dept Biochem, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Theil, EC (corresponding author), Childrens Hosp, Oakland Res Inst, 5700 Martin Luther King Jr Wy, Oakland, CA 94609 USA.	etheil@chori.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK020251, R01DK020251, R37DK020251] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20251] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED SHAUKAT, 1960, SOIL SCI, V90, P205, DOI 10.1097/00010694-196009000-00009; Alen C, 1999, P NATL ACAD SCI USA, V96, P10412, DOI 10.1073/pnas.96.18.10412; ARUOMA OI, 1987, J INORG BIOCHEM, V29, P289, DOI 10.1016/0162-0134(87)80035-1; Bagnaresi P, 1999, BIOCHEM J, V338, P499, DOI 10.1042/0264-6021:3380499; Briat JF, 1997, CH MICROBIOL SER, P431; Briat JF, 1998, MET IONS BIOL SYST, V35, P563; Buettner GR, 1996, RADIAT RES, V145, P532, DOI 10.2307/3579271; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CASPAR T, 1993, PLANT J, V3, P161, DOI 10.1111/j.1365-313X.1993.tb00019.x; COULSON RMR, 1993, P NATL ACAD SCI USA, V90, P7613, DOI 10.1073/pnas.90.16.7613; Dai LI, 1996, BBA-LIPID LIPID MET, V1304, P223, DOI 10.1016/S0005-2760(96)00121-X; DICKEY LF, 1988, J BIOL CHEM, V263, P3071; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Goralska M, 1997, EXP EYE RES, V64, P413, DOI 10.1006/exer.1996.0227; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hanson ES, 1999, J BIOL CHEM, V274, P5047, DOI 10.1074/jbc.274.8.5047; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; HARLE C, 1995, EMBO J, V14, P1430, DOI 10.1002/j.1460-2075.1995.tb07129.x; Harrison PM, 1998, MET IONS BIOL SYST, V35, P435; HIGSON FK, 1988, FREE RADICAL RES COM, V5, P107, DOI 10.3109/10715768809066918; JEFFERSON RA, 1987, EMBO J, V6, P3901; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; KIMATA Y, 1994, PLANT PHYSIOL, V104, P263, DOI 10.1104/pp.104.1.263; KLEIN TM, 1988, P NATL ACAD SCI USA, V85, P4305, DOI 10.1073/pnas.85.12.4305; LESCURE AM, 1991, P NATL ACAD SCI USA, V88, P8222, DOI 10.1073/pnas.88.18.8222; LOBREAUX S, 1993, EMBO J, V12, P651, DOI 10.1002/j.1460-2075.1993.tb05698.x; LOBREAUX S, 1995, PLANT J, V8, P443, DOI 10.1046/j.1365-313X.1995.08030443.x; LOBREAUX S, 1992, PLANT MOL BIOL, V19, P563, DOI 10.1007/BF00026783; MCCABE DE, 1988, BIO-TECHNOL, V6, P923, DOI 10.1038/nbt0888-923; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; Noctor G, 1998, ANNU REV PLANT PHYS, V49, P249, DOI 10.1146/annurev.arplant.49.1.249; Ochs M, 1996, MOL GEN GENET, V250, P455; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; PROUDHON D, 1989, PLANT PHYSIOL, V90, P586, DOI 10.1104/pp.90.2.586; Proudhon D, 1996, J MOL EVOL, V42, P325, DOI 10.1007/BF02337543; RAGLAND M, 1990, J BIOL CHEM, V265, P18339; RAGLAND M, 1993, PLANT MOL BIOL, V21, P555, DOI 10.1007/BF00028813; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; Rouault TA, 1996, J BIOL INORG CHEM, V1, P494, DOI 10.1007/s007750050083; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Savino G, 1997, J BIOL CHEM, V272, P33319, DOI 10.1074/jbc.272.52.33319; SHULL GE, 1983, J BIOL CHEM, V258, P7921; Theil EC, 1998, MET IONS BIOL SYST, V35, P403; THEIL EC, 1993, BIOFACTORS, V4, P87; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467; TOTH I, 1995, J BIOL CHEM, V270, P2846, DOI 10.1074/jbc.270.6.2846; TOTH I, 1995, J BIOL CHEM, V270, P19540, DOI 10.1074/jbc.270.33.19540; Waldo G. S., 1996, COMPREHENSIVE SUPRAM, V5, P65; WEI J, 1998, THESIS N CAROLINA ST; WRIEDT K, 1995, J BACTERIOL, V177, P3320, DOI 10.1128/jb.177.11.3320-3322.1995	56	49	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17488	17493		10.1074/jbc.M910334199	http://dx.doi.org/10.1074/jbc.M910334199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748212	hybrid			2022-12-27	WOS:000087485000040
J	Buschmann, T; Yin, ZM; Bhoumik, A; Ronai, Z				Buschmann, T; Yin, ZM; Bhoumik, A; Ronai, Z			Amino-terminal-derived JNK fragment alters expression and activity of c-Jun, ATF2, and p53 and increases H2O2-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; STRESS; IDENTIFICATION; APOPTOSIS; CASCADES; INDUCTION	The stress-activated protein kinase JNK plays an important role in the stability and activities of key regulatory proteins, including c-Jun, ATF2, and p53. To better understand mechanisms underlying the regulation of JNK activities, we studied the effect of expression of the amino-terminal JNK fragment (N-JNK; amino acids 1-206) on the stability and activities of JNK substrates under nonstressed growth conditions, as well as after exposure to hydrogen peroxide. Mouse fibroblasts that express N-JNK under tetracycline-off (tet-off) inducible promoter exhibited elevated expression of c-Jun, ATF2, and p53 upon tetracycline removal. This increased coincided with elevated transcriptional activities of p53, but not of c-Jun or ATF2, as reflected in luciferase activities of p21(Waf1/Cip1)-Luc, AP1-Luc, and Jun2-Luc, respectively. Expression of N-JNK; in cells that were treated with H2O2 impaired transcriptional output as reflected in a delayed and lower level of c-Jun-, limited ATF2-, and reduced p53-transcriptional activities. N-JNK elicited an increase in H2O2-induced cell death, which is p53-dependent, because it was not seen in p53 null cells yet could be observed upon coexpression of p53 and N-JNK. The ability to alter the activity of ATF2, c-Jun, and p53 and the degree of stress-induced cell death by a JNK-derived fragment identifies new means to elucidate the nature of JNK regulation and to alter the cellular response to stress.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave RM 15-20, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA78419, CA59008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; FUCHS SY, 1998, GENE DEV, V12, P2543; FUCHS SY, 1996, ONCOGENE, V13, P1529; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SETH A, 1992, J BIOL CHEM, V267, P24796; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIER M, 1994, CELL, V78, P787; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yaglom JA, 1999, J BIOL CHEM, V274, P20223, DOI 10.1074/jbc.274.29.20223; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	66	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16590	16596		10.1074/jbc.M910045199	http://dx.doi.org/10.1074/jbc.M910045199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748185	hybrid			2022-12-27	WOS:000087392200028
J	Schild, D; Lio, YC; Collins, DW; Tsomondo, T; Chen, DJ				Schild, D; Lio, YC; Collins, DW; Tsomondo, T; Chen, DJ			Evidence for simultaneous protein interactions between human Rad51 paralogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR GENE; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; IONIZING-RADIATION; CHROMOSOME STABILITY; STRAND EXCHANGE; BREAK REPAIR; MOUSE GENES; CROSS-LINKS; YEAST	In yeast, the Rad51-related proteins include Rad55 and Rad57, which form a heterodimer that interacts with Rad51. Five human Rad51 paralogs have been identified (XRCC2, XRCC3, RadS1B/Rad51L1, Rad51C/ Rad51L2, and Rad51D/Rad51L3), and each interacts with one or more of the others. Previously we reported that HsRad51 interacts with XRCC3, and Rad51C interacts with XRCC3, Rad51B, and HsRad51, Here we report that in the yeast two-hybrid system, Rad51D interacts with XRCC2 and Rad51C, No other interactions, including self-interactions, were found, indicating that the observed interactions are specific. The yeast Rad51 interacts with human Rad51 and XRCC3, suggesting Rad51 conservation since the human yeast divergence. Data from yeast three-hybrid experiments indicate that a number of the pairs of interactions between human Rad51 parlogs can occur simultaneously. For example, Rad51B expression enhances the binding of Rad51C to XRCC3 and to HsRad51D, and Rad51C expression allows the indirect interaction of Rad51B with Rad51D, Experiments using 6xHis-tagged proteins in the baculovirus system confirm several of our yeast results, including Rad51B interaction with Rad51D only when Rad51C is simultaneously expressed and Rad51C interaction with XRCC2 only when Rad51D is present. These results suggest that these proteins may participate in one complex or multiple smaller ones.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Schild, D (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Mail Stop 70A-1118,1 Cyclotron Rd, Berkeley, CA 94720 USA.				NCI NIH HHS [CA74046] Funding Source: Medline; NIGMS NIH HHS [GM30990] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074046] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; Araujo SJ, 1999, MUTAT RES-DNA REPAIR, V435, P23, DOI 10.1016/S0921-8777(99)00042-7; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bianco P R, 1998, Front Biosci, V3, pD570; Brenneman MA, 2000, MUTAT RES-DNA REPAIR, V459, P89, DOI 10.1016/S0921-8777(00)00002-1; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P1653, DOI 10.1093/nar/26.7.1653; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; Cui X, 1999, MUTAT RES-DNA REPAIR, V434, P75, DOI 10.1016/S0921-8777(99)00010-5; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; HARPER JW, 1993, CELL, V75, P805; Havre PA, 2000, EXP CELL RES, V254, P33, DOI 10.1006/excr.1999.4725; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; James P, 1996, GENETICS, V144, P1425; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; JONES NJ, 1988, MUTAT RES, V193, P139, DOI 10.1016/0167-8817(88)90044-2; Li L, 1999, MOL CELL BIOL, V19, P5619; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Luckow Verne A., 1993, Current Opinion in Biotechnology, V4, P564, DOI 10.1016/0958-1669(93)90078-B; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; Pittman DL, 2000, GENESIS, V26, P167, DOI 10.1002/(SICI)1526-968X(200003)26:3<167::AID-GENE1>3.0.CO;2-M; Rice MC, 1997, P NATL ACAD SCI USA, V94, P7417, DOI 10.1073/pnas.94.14.7417; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shu ZG, 1999, MOL CELL BIOL, V19, P8686; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; TAKATA M, 2000, IN PRESS MOL CELL BI; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; Thacker J, 1999, BIOCHIMIE, V81, P77, DOI 10.1016/S0300-9084(99)80041-8; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; TUCKER JD, 1991, MUTAT RES, V254, P143, DOI 10.1016/0921-8777(91)90005-A; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Warbrick E, 1997, STRUCTURE, V5, P13, DOI 10.1016/S0969-2126(97)00162-7; Zhang J, 1996, ANAL BIOCHEM, V242, P68, DOI 10.1006/abio.1996.0429	44	153	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16443	16449		10.1074/jbc.M001473200	http://dx.doi.org/10.1074/jbc.M001473200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10749867	hybrid			2022-12-27	WOS:000087392200008
J	Luo, P; Canziani, G; Cunto-Amesty, G; Kieber-Emmons, T				Luo, P; Canziani, G; Cunto-Amesty, G; Kieber-Emmons, T			A molecular basis for functional peptide mimicry of a carbohydrate antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; BETA-D-GLUCOSAMINE; CRYPTOCOCCUS-NEOFORMANS; ANTICARBOHYDRATE ANTIBODIES; CAPSULAR POLYSACCHARIDE; IMMUNOLOGICAL MIMICRY; MONOCLONAL-ANTIBODY; BINDING AFFINITIES; LIBRARY; MIMOTOPES	Peptides may substitute for carbohydrate antigens in carbohydrate-specific immunological reactions. Using the recognition properties of an anti-Lewis Y (LeY) antibody, BR55-2, as a model system, we establish a molecular perspective for peptide mimicry by comparing the three-dimensional basis of BR55-2 binding to LeY with the binding of the same antibody to peptides, The peptides compete with LeY, as demonstrated by enzyme-linked immunosorbent assay and Biacore analysis. The computer program LUDI was used to epitope map the antibody-combining site, correlating peptide reactivity patterns. This approach identified amino acids interacting with the same BR55-2 functional residue groups that recognize the Fuc alpha(1-3) moiety of LeY. Molecular modeling indicates that the peptides adopt an extended turn conformation within the BR55-2 combining site, serving to overlap the peptides with the LeY spatial position. Peptide binding is associated with only minor changes in BR55-2, relative to the BR55-2-LeY complex. Anti-peptide serum distinguishes the Fuc alpha(1-3) from the Fuc alpha(1-4) linkage, therefore differentiating difucosylated neolactoseries antigens, These results further confirm that peptides and carbohydrates can bind to the same antibody-binding site and that peptides can structurally and functionally mimic salient features of carbohydrate epitopes.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Kieber-Emmons, T (corresponding author), Univ Penn, Dept Pathol & Lab Med, Rm 205,John Morgan Bldg,36th & Hamilton Walk, Philadelphia, PA 19104 USA.				NIAID NIH HHS [AI45133] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045133] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adamczyk M, 1998, BIOCONJUGATE CHEM, V9, P23, DOI 10.1021/bc9701353; Agadjanyan M, 1997, NAT BIOTECHNOL, V15, P547, DOI 10.1038/nbt0697-547; Appelmelk BJ, 1996, INFECT IMMUN, V64, P2031, DOI 10.1128/IAI.64.6.2031-2040.1996; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P593, DOI 10.1007/BF00126217; Co MS, 1996, CANCER RES, V56, P1118; COOPER LJN, 1993, J IMMUNOL, V150, P2231; Dabelsteen E, 1996, J PATHOL, V179, P358; EVANS SV, 1994, J MOL BIOL, V241, P691, DOI 10.1006/jmbi.1994.1544; Ghiara JB, 1997, J MOL BIOL, V266, P31, DOI 10.1006/jmbi.1996.0768; GILLMOR SA, 1993, RECEPTOR, V3, P155; Harris SL, 1997, P NATL ACAD SCI USA, V94, P2454, DOI 10.1073/pnas.94.6.2454; HOESS R, 1993, GENE, V128, P43, DOI 10.1016/0378-1119(93)90151-R; IMBERTY A, 1995, GLYCOCONJUGATE J, V12, P331, DOI 10.1007/BF00731336; JEFFREY PD, 1995, NAT STRUCT BIOL, V2, P466, DOI 10.1038/nsb0695-466; JONES G, 1995, CURR OPIN BIOTECH, V6, P652, DOI 10.1016/0958-1669(95)80107-3; Kaur KJ, 1997, J BIOL CHEM, V272, P5539, DOI 10.1074/jbc.272.9.5539; Kieber-Emmons T, 1999, J BIOL CHEM, V274, P9648, DOI 10.1074/jbc.274.14.9648; Kieber-Emmons T, 1999, NAT BIOTECHNOL, V17, P660, DOI 10.1038/10870; KITAMURA K, 1994, P NATL ACAD SCI USA, V91, P12957, DOI 10.1073/pnas.91.26.12957; Kudryashov V, 1998, CANCER IMMUNOL IMMUN, V45, P281, DOI 10.1007/s002620050444; Labadia ME, 1996, J LEUKOCYTE BIOL, V59, P740, DOI 10.1002/jlb.59.5.740; LEMIEUX RU, 1983, ARCH BIOCHEM BIOPHYS, V221, P125, DOI 10.1016/0003-9861(83)90128-5; Luo P, 1998, MOL IMMUNOL, V35, P865, DOI 10.1016/S0161-5890(98)00067-4; MONAFO WJ, 1987, J IMMUNOL, V139, P2702; MUKHOPADHYAY C, 1991, BIOPOLYMERS, V31, P1737, DOI 10.1002/bip.360311408; Murali R, 1997, J MOL RECOGNIT, V10, P269, DOI 10.1002/(SICI)1099-1352(199711/12)10:6<269::AID-JMR370>3.0.CO;2-9; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; Phalipon A, 1997, EUR J IMMUNOL, V27, P2620, DOI 10.1002/eji.1830271022; Pincus SH, 1998, J IMMUNOL, V160, P293; Pinilla C, 1998, J MOL BIOL, V283, P1013, DOI 10.1006/jmbi.1998.2137; Qiu JP, 1999, HYBRIDOMA, V18, P103, DOI 10.1089/hyb.1999.18.103; RAYCHAUDHURI S, 1990, J IMMUNOL, V145, P760; SCHOLZ D, 1991, CANCER IMMUNOL IMMUN, V33, P153, DOI 10.1007/BF01756135; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SHIKHMAN AR, 1994, J IMMUNOL, V152, P4375; SHIKHMAN AR, 1994, J IMMUNOL, V153, P5593; STEPLEWSKI Z, 1990, HYBRIDOMA, V9, P201, DOI 10.1089/hyb.1990.9.201; THURINBLASZCZYK M, 1996, PROTEIN ENG, V9, P101; Valadon P, 1998, J IMMUNOL, V161, P1829; Valadon P, 1996, J MOL BIOL, V261, P11, DOI 10.1006/jmbi.1996.0438; Van Regenmortel M H, 1995, Biomed Pept Proteins Nucleic Acids, V1, P109; WESTERINK MAJ, 1995, P NATL ACAD SCI USA, V92, P4021, DOI 10.1073/pnas.92.9.4021; YELTON DE, 1995, J IMMUNOL, V155, P1994; Young ACM, 1997, J MOL BIOL, V274, P622, DOI 10.1006/jmbi.1997.1407; Zhang HL, 1997, INFECT IMMUN, V65, P1158, DOI 10.1128/IAI.65.4.1158-1164.1997	45	50	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16146	16154		10.1074/jbc.M909121199	http://dx.doi.org/10.1074/jbc.M909121199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748116	hybrid			2022-12-27	WOS:000087291400074
J	Taylor, JM; Rovin, JD; Parsons, JT				Taylor, JM; Rovin, JD; Parsons, JT			A role for focal adhesion kinase in phenylephrine-induced hypertrophy of rat ventricular cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR ACTIVATION; MUSCLE CELL HYPERTROPHY; GENE-EXPRESSION; CARDIAC-HYPERTROPHY; TYROSINE KINASE; PROTEIN-KINASE; C-SRC; ALPHA(1)-ADRENERGIC RECEPTOR; MYOCYTE HYPERTROPHY; MECHANICAL-STRESS	A variety of agonists including phenylephrine (PE) induce hypertrophy in neonatal ventricular cardiomyocytes. Here we report that signals provided by extracellular matrix proteins (ECM) augment the PE-induced hypertrophic response of cardiomyocytes and provide evidence that ECM-dependent signaling is mediated in part by the protein tyrosine kinase, focal adhesion kinase (FAK). Addition of PE to cultured neonatal cardiomyocytes stimulated sarcomeric organization, increased cell size, and induced atrial natriuretic factor in cardiomyocytes plated on the ECM protein laminin or fibronectin, In contrast, cardiomyocytes plated on the non-adhesive substrate gelatin exhibited a reduced capacity to undergo these PE-stimulated hypertrophic changes. In cardiomyocytes cultured on ECM, PE stimulated a rapid increase in tyrosine phosphorylation of focal adhesion proteins including FAK, paxillin, and p130 Crk-associated substrate and subsequent formation of peripheral focal complexes. Inhibition of the PE-induced hypertrophic response by genistein and herbimycin-A indicated a requirement for protein tyrosine kinases in PE signaling. To determine whether activation of FAK is required for PE-induced hypertrophy, a dominant-interfering mutant form of FAR, termed FRNK (FAK-related non-kinase), was ectopically expressed in cardiomyocytes using a replication-defective adenovirus expression system. FRNK expression attenuated PE-stimulated hypertrophy as assessed by cell size, sarcomeric organization, and induction of atrial natriuretic factor. These data indicate that the signal transduction pathways leading to cardiomyocyte hypertrophy are strongly influenced by and/or dependent upon an integrin-mediated signaling process requiring FAK.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia	Parsons, JT (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 441, Charlottesville, VA 22908 USA.			Taylor, Joan/0000-0002-8794-5167	NCI NIH HHS [CA29243, CA40042] Funding Source: Medline; NHLBI NIH HHS [HL-F32-GM18297] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029243, R37CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JW, 1998, CIRC RES, V83, P167, DOI 10.1161/01.RES.83.2.167; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Bouton AH, 1997, HYBRIDOMA, V16, P403, DOI 10.1089/hyb.1997.16.403; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fuller SJ, 1998, J BIOL CHEM, V273, P18146, DOI 10.1074/jbc.273.29.18146; Graf K, 1997, CIRCULATION, V96, P3063, DOI 10.1161/01.CIR.96.9.3063; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic D, 1998, J CELL BIOL, V143, P547; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; Kovacic B, 1998, J BIOL CHEM, V273, P35185; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; Lin TH, 1997, J BIOL CHEM, V272, P8849; MAMUYA W, 1992, CIRC RES, V71, P1341, DOI 10.1161/01.RES.71.6.1341; MCDONALD JA, 1998, X7 KEYST S; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ross RS, 1998, CIRC RES, V82, P1160, DOI 10.1161/01.RES.82.11.1160; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sadoshima J, 1996, EMBO J, V15, P5535, DOI 10.1002/j.1460-2075.1996.tb00938.x; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; TERRACIO L, 1991, CIRC RES, V68, P734, DOI 10.1161/01.RES.68.3.734; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J BIOL CHEM, V269, P30580; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	43	114	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19250	19257		10.1074/jbc.M909099199	http://dx.doi.org/10.1074/jbc.M909099199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10749882	hybrid			2022-12-27	WOS:000087815900083
J	Phillips-Mason, PJ; Raben, DM; Baldassare, JJ				Phillips-Mason, PJ; Raben, DM; Baldassare, JJ			Phosphatidylinositol 3-kinase activity regulates alpha-thrombin-stimulated G(1) progression by its effect on cyclin D1 expression and cyclin-dependent kinase 4 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B C-AKT; CELL-CYCLE; RETINOBLASTOMA PROTEIN; DNA-SYNTHESIS; PHOSPHOINOSITIDE 3-KINASES; SIGNAL-TRANSDUCTION; LIPID PRODUCTS; G1 PHASE; ACTIVATION; PATHWAY	In this study, we present evidence that PI 3-kinase is required for alpha-thrombin-stimulated DNA synthesis in Chinese hamster embryonic fibroblasts (IIC9 cells). Previous results from our laboratory demonstrate that the mitogen-activated protein kinase (extracellular signal-regulated kinase (ERK)) pathway controls transit through G(1) phase of the cell cycle by regulating the induction of cyclin Df mRNA levels and cyclin dependent kinase 4 (CDK4)-cyclin D1 activity. In IIC9 cells, PI 3-kinase activation also is an important controller of the expression of cyclin DI protein and CDK4-cyclin DI activity. Pretreatment of HC9 cells with the selective PI 3-kinase inhibitor, LY294002 blocks the alpha-thrombin-stimulated increase in cyclin D1 protein and CDK4 activity. However, LY294002 does not affect alpha-thrombin-induced cyclin D1 steady state message levels, indicating that PI 3-kinase acts independent of the ERK pathway. Interestingly, expression of a dominant-negative Res significantly decreased both ru-thrombin-stimulated ERE and PI 3-kinase activities. These data clearly demonstrate that the alpha-thrombin-induced Ras activation coordinately regulates ERK and PI 3-kinase activities, both of which are required for expression of cyclin D1 protein and progression through G(1).	St Louis Univ, Sch Med, Dept Cell & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Saint Louis University; Saint Louis University; Johns Hopkins University	Baldassare, JJ (corresponding author), St Louis Univ, Sch Med, Dept Cell & Mol Biol, St Louis, MO 63104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046814] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK46814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cheng J, 1997, J BIOL CHEM, V272, P17312, DOI 10.1074/jbc.272.28.17312; Coffer PJ, 1998, BIOCHEM J, V335, P1; COUGHLIN SR, 1989, SCIENCE, V243, P1191; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HU SW, 1996, J BIOL CHEM, V271, P8977; KATO J, 1993, GENE DEV, V7, P331; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Treinies I, 1999, MOL CELL BIOL, V19, P321; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1997, J BIOL CHEM, V272, P17320, DOI 10.1074/jbc.272.28.17320; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	45	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18046	18053		10.1074/jbc.M909194199	http://dx.doi.org/10.1074/jbc.M909194199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10749883	hybrid			2022-12-27	WOS:000087659400021
J	Bi, XP; Goss, DJ				Bi, XP; Goss, DJ			Wheat germ poly(A)-binding protein increases the ATPase and the RNA helicase activity of translation initiation factors eIF4A, eIF4B, and eIF-iso4F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ISOZYME FORM; DEPENDENT TRANSLATION; MAMMALIAN-CELLS; BINDING-PROTEIN; FACTOR 4F; CAP; POLY(A); YEAST; IDENTIFICATION	Recent studies demonstrated that wheat germ poly(A)-binding protein (PBBP) interacted with translation eukaryotic initiation factor (eIF)-iso4G and eIF4B, and these interactions increased the poly(A) binding activity of PABP (Le, H., Tanguay, R, L., Balasta, M. L., Wei, C. C., Browning, K. S., Metz, A. M., Goss, D. J., and Gallie, D. R. (1997) J. Biol. Chen. 272, 16247-16255) and the cap binding activity of eIF-iso4F (Wei, C. C., Balasta, M. L., Ren, J., and Goss, D. J. (1998) Biochemistry 37, 1910-1916). We report here that the interaction between PABP and eIF-iso4G has a substantial effect on the ATPase activity and RNA helicase activity of (eIF4A + eIF4B + eIF-iso4F) complex. ATPase kinetic assays show, in the presence of poly(U), PABP can increase the parameter (k(cat)/K-m) by 3.5-fold with a 2-fold decrease of K-m for the (eIF4A + eIF-iso4F) complex. In the presence of globin messenger RNA, the ATPase activity of the complex (eIF4A + eIF-iso4F) was increased a-fold by the presence of PABP. RNA helicase assays demonstrated that the presence of PABP enhanced the RNA duplex unwinding activity of the initiation factor complex. These results suggest that, in terms of the scanning model of translation initiation, PABP may enhance the mRNA scanning rate of the complex formed by eIF4A, eIF4B, and eIF4F or eIF-(iso)4F and increase the rate of translation.	CUNY Hunter Coll, Dept Chem, New York, NY 10021 USA; CUNY, Grad Ctr, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System	Goss, DJ (corresponding author), CUNY Hunter Coll, Dept Chem, 695 Pk Ave, New York, NY 10021 USA.	dgoss@hejira.hunter.cuny.edu			NCRR NIH HHS [RR-03037] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLEN ML, 1992, J BIOL CHEM, V267, P23232; BALASTA ML, 1993, J BIOL CHEM, V268, P18599; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; Gallie DR, 1997, J BIOL CHEM, V272, P1046, DOI 10.1074/jbc.272.2.1046; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Jagus R, 1981, Prog Nucleic Acid Res Mol Biol, V25, P127, DOI 10.1016/S0079-6603(08)60484-5; Kessler SH, 1998, MOL CELL BIOL, V18, P51, DOI 10.1128/MCB.18.1.51; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAX SR, 1986, J BIOL CHEM, V261, P5632; Le H, 1997, EUR J BIOCHEM, V243, P350, DOI 10.1111/j.1432-1033.1997.0350a.x; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; RHOADS RE, 1994, BIOCHIMIE, V76, P831, DOI 10.1016/0300-9084(94)90184-8; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; YANG JJ, 1992, PLANT PHYSIOL, V98, P1115, DOI 10.1104/pp.98.3.1115	31	57	57	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17740	17746		10.1074/jbc.M909464199	http://dx.doi.org/10.1074/jbc.M909464199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748132	hybrid			2022-12-27	WOS:000087485000074
J	Fryer, CJ; Kinyamu, HK; Rogatsky, I; Garabedian, MJ; Archer, TK				Fryer, CJ; Kinyamu, HK; Rogatsky, I; Garabedian, MJ; Archer, TK			Selective activation of the glucocorticoid receptor by steroid antagonists in human breast cancer and osteosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR VIRUS PROMOTER; ADJUVANT TAMOXIFEN THERAPY; PROGESTERONE-RECEPTOR; IN-VIVO; CHROMATIN STRUCTURE; MMTV PROMOTER; TRANSCRIPTION FACTORS; ESTROGEN-RECEPTOR; MOLECULAR-BIOLOGY; DNA-BINDING	Steroid hormones regulate the transcription of numerous genes via high affinity receptors that act in concert with chromatin remodeling complexes, coactivators and corepressors, We have compared the activities of a variety of glucocorticoid receptor (GR) antagonists in breast cancer and osteosarcoma cell lines engineered to stably maintain the mouse mammary tumor virus promoter. In both cell types, GR activation by dexamethasone occurs via the disruption of mouse mammary tumor virus chromatin structure and the recruitment of receptor coactivator proteins. However, when challenged with a variety of antagonists the GR displays differential ability to activate transcription within the two cell types. For the breast cancer cells, the antagonists fail to activate the promoter and do not promote the association of the GR with either remodeling or coactivator proteins. In contrast, in osteosarcoma cells, the antiglucocorticoids, RU486 and RU43044, exhibit partial agonist activity. The capacity of these antagonists to stimulate transcription in the osteosarcoma cells is reflected in the ability of the RU486-bound receptor to remodel chromatin and associate with chromatin-remodeling proteins. Similarly, the observation that the RU486-bound receptor does not fully activate transcription is consistent with its inability to recruit receptor coactivator proteins.	NIEHS, Chromatin & Gene Express Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Western Ontario, Dept Obstet & Gynaecol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 4L6, Canada; NYU, Med Ctr, Dept Microbiol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Western University (University of Western Ontario); Western University (University of Western Ontario); New York University; New York University	Archer, TK (corresponding author), NIEHS, Chromatin & Gene Express Sect, Reprod & Dev Toxicol Lab, NIH, 111 Alexander Dr,POB 12233,MD E4-06, Res Triangle Pk, NC 27709 USA.	archer1@niehs.nih.gov	kinyamu, Harriet/AAG-9069-2019; Archer, Trevor K/E-5191-2019	kinyamu, Harriet/0000-0002-2377-7408; Archer, Trevor K/0000-0001-7651-3644	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071007, Z01ES071006, ZIAES071006] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allan GF, 1996, MOL ENDOCRINOL, V10, P1206, DOI 10.1210/me.10.10.1206; ARCHER TK, 1995, J STEROID BIOCHEM, V53, P421, DOI 10.1016/0960-0760(95)00088-H; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; Archer TK, 1997, TRENDS ENDOCRIN MET, V8, P384, DOI 10.1016/S1043-2760(97)00159-8; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BOCQUEL MT, 1993, J STEROID BIOCHEM, V45, P205, DOI 10.1016/0960-0760(93)90334-S; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cadepond F, 1997, ANNU REV MED, V48, P129; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Curtis RE, 1996, J NATL CANCER I, V88, P832, DOI 10.1093/jnci/88.12.832; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Dhingra K, 1999, INVEST NEW DRUG, V17, P285, DOI 10.1023/A:1006348907994; Fryer CJ, 1998, J BIOL CHEM, V273, P1175, DOI 10.1074/jbc.273.2.1175; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Fuhrmann U, 1998, J MOL MED, V76, P512, DOI 10.1007/s001090050245; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; Gass EK, 1998, ENDOCRINOLOGY, V139, P1905, DOI 10.1210/en.139.4.1905; Glass CK, 2000, GENE DEV, V14, P121; HAYES JJ, 1992, BIOESSAYS, V14, P597, DOI 10.1002/bies.950140905; HORWITZ KB, 1995, J STEROID BIOCHEM, V53, P9, DOI 10.1016/0960-0760(95)00035-X; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; KLEINHITPASS L, 1991, NUCLEIC ACIDS RES, V19, P1227, DOI 10.1093/nar/19.6.1227; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MIZUTANI T, 1992, J STEROID BIOCHEM, V42, P695, DOI 10.1016/0960-0760(92)90110-5; MYMRYK JS, 1995, GENE DEV, V9, P1366, DOI 10.1101/gad.9.11.1366; MYMRYK JS, 1995, MOL ENDOCRINOL, V9, P1825, DOI 10.1210/me.9.12.1825; NEEF G, 1984, STEROIDS, V44, P349, DOI 10.1016/S0039-128X(84)80027-6; Nichols M, 1998, EMBO J, V17, P765, DOI 10.1093/emboj/17.3.765; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; TEUTSCH G, 1991, BIOCHEM SOC T, V19, P901, DOI 10.1042/bst0190901; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wolffe A P, 1997, Cell Res, V7, P127; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	49	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17771	17777		10.1074/jbc.M908729199	http://dx.doi.org/10.1074/jbc.M908729199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748103	hybrid			2022-12-27	WOS:000087485000078
J	Lai, WS; Carballo, E; Thorn, JM; Kennington, EA; Blackshear, PJ				Lai, WS; Carballo, E; Thorn, JM; Kennington, EA; Blackshear, PJ			Interactions of CCCH zinc finger proteins with mRNA - Binding of tristetraprolin-related zinc finger proteins to Au-rich elements and destabilization of mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' SPLICE-SITE; ABNORMAL BRAIN-DEVELOPMENT; PRIMARY RESPONSE GENE; MESSENGER-RNA; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; FACTOR U2AF(35); HUMAN HOMOLOG; TIS11 FAMILY; CELLS	Macrophages derived from tristetraprolin (TTP)-deficient mice exhibited increased tumor necrosis factor alpha (TNF alpha) release as a consequence of increased stability of TNF alpha mRNA, TTP was then shown to destabilize TNF alpha mRNA after binding directly to the AU-rich region (ARE) of the 3'-untranslated region of the TNF alpha mRNA In mammals and in Xenopus, TTP is the prototype of a small family of three known zinc finger proteins containing two CCCH zinc fingers spaced 18 amino acids apart; a fourth more distantly related family member has been identified in Xenopus and fish. We show here that representatives of all four family members were able to bind to the TNF alpha ARE in a cell-free system and, in most cases, promote the breakdown of TNF alpha mRNA in intact cells. Because the primary sequences of these CCCH proteins are most closely related in their tandem zinc finger domains, we tested whether various fragments of TTP that contained both zinc fingers resembled the intact protein in these assays. We found that amino- and carboxyl-terminal truncated forms of TTP, as well as a 77 amino acid fragment that contained both zinc fingers, could bind to the TNF alpha ARE in cell-free cross-linking and gel shift assays. In addition, these truncated forms of TTP could also stimulate the apparent deadenylation and/or breakdown of TNF alpha mRNA in intact cells. Alignments of the tandem zinc finger domains from all four groups of homologous proteins have identified invariant residues as well as group-specific signature amino acids that presumably contribute to ARE binding and protein-specific activities, respectively.	NIEHS, Off Clin Res, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Blackshear, PJ (corresponding author), NIEHS, Off Clin Res, NIH, A2-05,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	black009@niehs.nih.gov	Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090080, ZIAES090080] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Achsel T, 1996, J BIOCHEM, V120, P53; BARNARD RC, 1993, NUCLEIC ACIDS RES, V21, P3580, DOI 10.1093/nar/21.15.3580; BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; De J, 1999, GENE, V228, P133, DOI 10.1016/S0378-1119(98)00617-9; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FU XD, 1995, RNA, V1, P663; GOMPERTS M, 1990, ONCOGENE, V5, P1081; Gozani O, 1998, MOL CELL BIOL, V18, P4752, DOI 10.1128/MCB.18.8.4752; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Kronnie GT, 1999, DEV GENES EVOL, V209, P443, DOI 10.1007/s004270050276; LAI WS, 1995, J BIOL CHEM, V270, P25266, DOI 10.1074/jbc.270.42.25266; Lai WS, 1998, J BIOL CHEM, V273, P506, DOI 10.1074/jbc.273.1.506; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; MA QF, 1995, ONCOGENE, V10, P487; MA QF, 1994, ONCOGENE, V9, P3329; MA QF, 1991, ONCOGENE, V6, P1277; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; NIE XF, 1995, GENE, V152, P285, DOI 10.1016/0378-1119(94)00696-P; Ning ZQ, 1996, EUR J IMMUNOL, V26, P2356, DOI 10.1002/eji.1830261013; Stevens CJM, 1998, INT J DEV BIOL, V42, P181; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; Thompson MJ, 1996, GENE, V174, P225, DOI 10.1016/0378-1119(96)00084-4; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; Wu M, 1996, P NATL ACAD SCI USA, V93, P2110, DOI 10.1073/pnas.93.5.2110; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	37	290	301	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17827	17837		10.1074/jbc.M001696200	http://dx.doi.org/10.1074/jbc.M001696200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10751406	hybrid			2022-12-27	WOS:000087485000086
J	Singh, S; Stellrecht, CM; Tang, HK; Saunders, GF				Singh, S; Stellrecht, CM; Tang, HK; Saunders, GF			Modulation of PAX6 homeodomain function by the paired domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; HOMEOBOX-CONTAINING GENE; DNA-BINDING ACTIVITY; CRYSTAL-STRUCTURE; SEQUENCE RECOGNITION; LINKER REGION; HUMAN BRAIN; SMALL-EYE; TRANSCRIPTION; EXPRESSION	PAX6 is required for proper development of the eye, central nervous system, and nose. PAX6 has two DNA binding domains, a glycine-rich region that links the two DNA binding domains, and a transactivation domain. There is evidence that the different DNA binding domains of PAX6 have different target genes. However, it is not clear if the two DNA binding domains function independently. We have studied the effect of structural changes in the paired domain on the function of PAX6 mediated through its homeodomain, The R26G and I87R mutations have been reported in different human patients with clinically different phenotypes and are in the N- and the C-terminal halves of the paired domain, respectively. Surprisingly, we found that the I87R mutant protein not only lost the transactivation function but also failed to bind DNA by either of its DNA binding domains. In contrast, the R26G mutant protein lost DNA binding through its paired domain but had greater DNA binding and transactivation than wild-type PAX6 on homeodomain binding sites. Like R26G, the 5a isoform showed higher DNA binding than wild-type PAX6, This study demonstrates that the two subdomains of the paired domain influence the function of the homeodomain differentially and also provides an explanation for the difference in phenotypes associated with these mutations.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Saunders, GF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117, Houston, TX 77030 USA.	gsaunders@odin.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009675, P30EY010608] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672] Funding Source: Medline; NEI NIH HHS [EY09675, EY10608] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDLEY UP, 1994, INVEST OPHTH VIS SCI, V35, P3094; CALZONE FJ, 1988, GENE DEV, V2, P1074, DOI 10.1101/gad.2.9.1074; CHALEPAKIS G, 1994, DNA CELL BIOL, V13, P891, DOI 10.1089/dna.1994.13.891; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CHALEPAKIS G, 1992, J CELL SCI, P61; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Davis JA, 1996, J NEUROSCI, V16, P5082; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; Gehring WJ, 1996, GENES CELLS, V1, P11, DOI 10.1046/j.1365-2443.1996.11011.x; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; Gupta SK, 1998, AM J OPHTHALMOL, V126, P203, DOI 10.1016/S0002-9394(98)00191-3; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Holst BD, 1997, P NATL ACAD SCI USA, V94, P1465, DOI 10.1073/pnas.94.4.1465; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; Jun S, 1996, DEVELOPMENT, V122, P2639; Koroma BM, 1997, INVEST OPHTH VIS SCI, V38, P108; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; Meech R, 1999, P NATL ACAD SCI USA, V96, P2420, DOI 10.1073/pnas.96.5.2420; Niimi T, 1999, DEVELOPMENT, V126, P2253; Okladnova O, 1998, BIOCHEM BIOPH RES CO, V248, P402, DOI 10.1006/bbrc.1998.8972; Okladnova O, 1998, MOL BRAIN RES, V60, P177, DOI 10.1016/S0169-328X(98)00167-3; Piatigorsky J, 1998, ANN NY ACAD SCI, V842, P7, DOI 10.1111/j.1749-6632.1998.tb09626.x; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SCHMAHL W, 1993, ACTA NEUROPATHOL, V86, P126, DOI 10.1007/BF00334879; Sheng GJ, 1997, GENE DEV, V11, P1122, DOI 10.1101/gad.11.9.1122; Singh S, 1998, J BIOL CHEM, V273, P21531, DOI 10.1074/jbc.273.34.21531; Stober G, 1999, BIOL PSYCHIAT, V45, P1585, DOI 10.1016/S0006-3223(99)00024-4; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; Tang HK, 1997, HUM MOL GENET, V6, P381, DOI 10.1093/hmg/6.3.381; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; ZHANG YH, 1995, NATURE, V377, P55, DOI 10.1038/377055a0	49	38	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17306	17313		10.1074/jbc.M000359200	http://dx.doi.org/10.1074/jbc.M000359200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747901	hybrid			2022-12-27	WOS:000087485000015
J	Jin, SQ; Antinore, MJ; Lung, FT; Dong, X; Zhao, HC; Fan, FY; Colchagie, AB; Blanck, P; Roller, PP; Fornace, AJ; Zhan, QM				Jin, SQ; Antinore, MJ; Lung, FT; Dong, X; Zhao, HC; Fan, FY; Colchagie, AB; Blanck, P; Roller, PP; Fornace, AJ; Zhan, QM			The GADD45 inhibition of Cdc2 kinase correlates with GADD45-mediated growth suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; P53-REGULATED PROTEIN GADD45; HUMAN CANCER-CELLS; IONIZING-RADIATION; DEPENDENT KINASES; DAMAGING AGENTS; MAMMALIAN G(1); HELA-CELLS; P53; CHECKPOINTS	Cell cycle growth arrest is an important cellular response to genotoxic stress. Gadd45, a p58-regulated stress protein, plays an important role in the cell cycle G(2)-M checkpoint following exposure to certain types of RNA-damaging agents such as UV radiation and methylmethane sulfonate. Recent findings indicate that Gradd45 interacts with Cdc2 protein and inhibits Cdc2 kinase activity. In the present study, a series of Myc-tagged Gadd45 deletion mutants and a Gadd45 overlapping peptide library were used to define the Gadd45 domains that are involved in the interaction of Gadd45 with Cdc2. Both in vitro and in vivo studies indicate that the interaction of Gadd45 with Cdc2 involves a central region of the Gadd45 protein (amino acids 65-84). The Cdc2-binding domain of Gadd45 is also required for Gadd45 inhibition of Cdc2 kinase activity. Sequence analysis of the central Gadd45 region reveals no homology to inhibitory motifs of known cyclin-dependent kinase inhibitors, indicating that the Cdc2-binding and -inhibitory domains on Gadd45 are a novel motif. The peptide containing the Cdc2-binding domain (amino acids 65-84) disrupted the Cdc2-cyclin B1 protein complex, suggesting that dissociation of this complex results from a direct interaction between the Gadd45 and Cdc2 proteins. GADD45-induced cell cycle G(2)-M arrest was abolished when its Cdc2 binding motif was disrupted. Importantly, a short term survival assay demonstrated that GADD45-induced cell cycle G(2)-M arrest correlates with GADD45-mediated growth suppression. These findings indicate that the cell cycle G(2)-M growth arrest mediated by GADD45 is one of the major mechanisms by which GADD45 suppresses cell growth.	Univ Pittsburgh, Pittsburgh Canc Inst, Dept Radiat Oncol, Sch Med, Pittsburgh, PA 15213 USA; NCI, Med Chem Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NCI, Gene Response Sect, Div Basic Sci, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhan, QM (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Dept Radiat Oncol, Sch Med, Pittsburgh, PA 15213 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA083874] Funding Source: NIH RePORTER; NCI NIH HHS [CA83874] Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chen IT, 1996, ONCOGENE, V12, P595; CHEN IT, 1995, ONCOGENE, V11, P1931; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL PA, 1995, ONCOGENE, V10, P2427; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Khan SH, 1998, CANCER RES, V58, P396; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; MICHIELI P, 1994, CANCER RES, V54, P3391; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; O'Connor P M, 1996, Prog Cell Cycle Res, V2, P165; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OConnor PM, 1997, CANCER SURV, V29, P151; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHANG H, 1994, COLD SPRING HARB SYM, V59, P21, DOI 10.1101/SQB.1994.059.01.005	51	163	173	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16602	16608		10.1074/jbc.M000284200	http://dx.doi.org/10.1074/jbc.M000284200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747892	hybrid			2022-12-27	WOS:000087392200030
J	Kang, SG; Park, HU; Lee, HS; Kim, HT; Lee, KJ				Kang, SG; Park, HU; Lee, HS; Kim, HT; Lee, KJ			New beta-lactamase inhibitory protein (BLIP-I) from Streptomyces exfoliatus SMF19 and its roles on the morphological differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CLAVULANIC ACID; SUBSTRATE-SPECIFICITY; NUCLEOTIDE-SEQUENCE; CLINICAL ISOLATE; GENE; CLONING; CLAVULIGERUS; EXPRESSION; LIVIDANS	A new beta-lactamase inhibitory protein (BLIP-I) from Streptomyces exfoliatus SMF19 was purified and characterized. The molecular mass of BLIP-I was estimated to be 17.5 kDa by gel filtration fast protein liquid chromatography. The N-terminal sequence was NH2-Asn-Ser-Gly-Phe-Ser-Ala-Glu-Lys-Tyr-Glu-Gln-Ile-Gln-Phe-Gly. BLIP-I inhibited Bacto(R) Penase (Difco), and plasmid encoded TEM-1 beta-lactamase, whereas it did not inhibit Enterobacter cloacae beta-lactamases. The K-i value of BLIP-I against TEM-1 beta-lactamase was determined to be 0.047 nM. The gene (bliA) encoding BLIP-I protein was identified by screening a genomic Library using an oligonucleotide probe with a sequence based on the N-terminal sequence of BLIP-I. Analysis of the nucleotide sequence revealed that the gene was 558 base pairs in length and encoded a mature protein of 157 amino acid residues preceded by a 29-amino acid signal sequence. Pairwise comparison of the deduced amino acid sequence showed 38% identity with BLIP of Streptomyces clavuligerus. Furthermore, the 49th amino acid residue of BLIP-I was identical to Asp-49 of BLIP that was characterized to be an important residue for the inhibitory activity of BLIP. A modified BLIP-I in which Asp-49 was replaced by alanine (D49A) was obtained by site directed mutagenesis. The inhibitory activities of recombinant (r) BLIP-I and its D49A mutant derivative, expressed in Escherichia coli, were compared. The K-i value of rBLIP-I against TEM-1 beta-lactamase was similar to that of wild-type BLIP-I, but the D49A mutation increased the K-i of rBLIP-I inhibition approximately 200-fold. A disruption mutant of the bliA gene in S. exfoliatus SMF19 was obtained by replacing the wild-type bliA gene with a copy inactivated by inserting a hygromycin resistance gene. The disruption mutant showed a bald phenotype, indicating that the bliA gene plays a role in morphological differentiation.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	Seoul National University (SNU)	Lee, KJ (corresponding author), Seoul Natl Univ, Dept Microbiol, Seoul 151742, South Korea.			Kim, Hyoung Tae/0000-0002-0270-2749; HyoungTae, Kim/0000-0002-2482-6064				Abraham E. P., 1983, ANTIBIOTICS CONTAINI, V1, P1; AIDOO KA, 1994, GENE, V147, P41, DOI 10.1016/0378-1119(94)90036-1; ARGARANA CE, 1986, NUCLEIC ACIDS RES, V14, P1871, DOI 10.1093/nar/14.4.1871; BIBB MJ, 1982, MOL GEN GENET, V187, P265, DOI 10.1007/BF00331128; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; BLAZQUEZ J, 1993, ANTIMICROB AGENTS CH, V37, P2059, DOI 10.1128/AAC.37.10.2059; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Cantu C, 1996, J BIOL CHEM, V271, P22538, DOI 10.1074/jbc.271.37.22538; CHATER AF, 1989, REGULATION PROKARYOT, P277; CHATER KF, 1993, ANNU REV MICROBIOL, V47, P685, DOI 10.1146/annurev.micro.47.1.685; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; DORAN JL, 1990, J BACTERIOL, V172, P4909, DOI 10.1128/jb.172.9.4909-4918.1990; DUEZ C, 1987, EUR J BIOCHEM, V162, P509, DOI 10.1111/j.1432-1033.1987.tb10669.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATA T, 1972, J ANTIBIOT, V25, P473, DOI 10.7164/antibiotics.25.473; HENDERSON G, 1987, J BACTERIOL, V169, P3779; Hopwood D.A., 1985, GENETIC MANIPULATION; Ishikawa J, 1999, FEMS MICROBIOL LETT, V174, P251, DOI 10.1111/j.1574-6968.1999.tb13576.x; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JONES KL, 1949, J BACTERIOL, V57, P141, DOI 10.1128/JB.57.2.141-145.1949; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; KIM MK, 1994, APPL ENVIRON MICROB, V60, P1029, DOI 10.1128/AEM.60.3.1029-1032.1994; KIM MK, 1991, J MICROBIOL BIOTECHN, V1, P85; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEDEIROS AA, 1997, CLIN INFECT DIS   S1, V24, P19; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Park HU, 1998, MICROBIOL-SGM, V144, P2161, DOI 10.1099/00221287-144-8-2161; PETIT A, 1995, BIOCHEM J, V305, P33, DOI 10.1042/bj3050033; Petrosino J, 1998, TRENDS MICROBIOL, V6, P323, DOI 10.1016/S0966-842X(98)01317-1; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; READING C, 1977, ANTIMICROB AGENTS CH, V11, P852, DOI 10.1128/AAC.11.5.852; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVES I, 1995, J BIOL CHEM, V270, P18240, DOI 10.1074/jbc.270.31.18240; SAWAI T, 1978, ANTIMICROB AGENTS CH, V13, P910, DOI 10.1128/AAC.13.6.910; Sirot D, 1997, ANTIMICROB AGENTS CH, V41, P1322, DOI 10.1128/AAC.41.6.1322; STRYNADKA NCJ, 1994, NATURE, V368, P657, DOI 10.1038/368657a0; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P290, DOI 10.1038/nsb0396-290; TOMASZ A, 1979, ANNU REV MICROBIOL, V33, P113, DOI 10.1146/annurev.mi.33.100179.000553; VENKATACHALAM KV, 1994, J BIOL CHEM, V269, P23444; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WIEDEMANN B, 1989, J ANTIMICROB CHEMOTH, V24, P1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	19	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16851	16856						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747883				2022-12-27	WOS:000087392200064
J	Oakley, RH; Laporte, SA; Holt, JA; Caron, MG; Barak, LS				Oakley, RH; Laporte, SA; Holt, JA; Caron, MG; Barak, LS			Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; PROSTAGLANDIN E-2 RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; WILD-TYPE; RHODOPSIN; KINASE; BINDING; DESENSITIZATION; RESENSITIZATION	Visual arrestin, beta arrestin1, and beta arrestin2 comprise a family of intracellular proteins that desensitize G protein-coupled receptors (GPCRs), In addition, beta arrestin1 and beta arrestin2 target desensitized receptors to clathrin-coated pits for endocytosis. Whether arrestins differ in their ability to interact with GPCRs in cells is not known, In this study, we visualize the interaction of arrestin family members with GPCRs in real time and in live cells using green fluorescent protein-tagged arrestins, In the absence of agonist, visual arrestin and beta arrestin1 were found in both the cytoplasm and nucleus of HEK-293 cells, whereas beta arrestin2 was found only in the cytoplasm. Analysis of agonist-mediated arrestin translocation to multiple GPCRs identified two major classes of receptors, Class A receptors (beta 2 adrenergic receptor, mu opioid receptor, endothelin type A receptor, dopamine D1A receptor, and alb adrenergic receptor) bound beta arrestin2 with higher affinity than beta arrestin1 and did not interact with visual arrestin, In contrast, class B receptors (angiotensin II type 1A receptor, neurotensin receptor 1, vasopressin V2 receptor, thyrotropin-releasing hormone receptor, and substance P receptor) bound both beta arrestin isoforms with similar high affinities and also interacted with visual arrestin. Switching the carboxyl-terminal tails of class A and class B receptors completely reversed the affinity of each receptor for the visual and non-visual arrestins, In addition, exchanging the beta arrestin1 and beta arrestin2 carboxyl termini reversed their extent of binding to class A receptors as well as their subcellular distribution. These results reveal for the first time marked differences in the ability of arrestin family members to bind GPCRs at the plasma membrane, Moreover, they show that visual arrestin can interact in cells with GPCRs other than rhodopsin. These findings suggest that GPCR signaling may be differentially regulated depending on the cellular complement of arrestin isoforms and the ability of arrestins to interact with other cellular proteins.	Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst Labs, Durham, NC 27710 USA	Duke University; Duke University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3287, Durham, NC 27710 USA.	caron002@mc.duke.edu	Laporte, Stephane A/F-3282-2012; Laporte, Stephane/ABC-4228-2021	Laporte, Stephane/0000-0002-0633-543X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61365] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Bhattacharya M, 1998, P NATL ACAD SCI USA, V95, P15792, DOI 10.1073/pnas.95.26.15792; Bhattacharya M, 1999, J BIOL CHEM, V274, P15719, DOI 10.1074/jbc.274.22.15719; BOOZ GW, 1992, ENDOCRINOLOGY, V130, P3641, DOI 10.1210/en.130.6.3641; BREITMAN ML, 1991, J BIOL CHEM, V266, P15505; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; KIESELBACH T, 1994, EUR J BIOCHEM, V226, P87, DOI 10.1111/j.1432-1033.1994.tb20029.x; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LIND GJ, 1993, INVEST OPHTH VIS SCI, V34, P2943; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; SMITH WC, 1994, J BIOL CHEM, V269, P15407; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	43	651	673	2	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17201	17210		10.1074/jbc.M910348199	http://dx.doi.org/10.1074/jbc.M910348199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748214	hybrid			2022-12-27	WOS:000087392200113
J	Sun, SY; Wan, HS; Yue, P; Hong, WK; Lotan, R				Sun, SY; Wan, HS; Yue, P; Hong, WK; Lotan, R			Evidence that retinoic acid receptor beta induction by retinoids is important for tumor cell growth inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG-CANCER; CARCINOMA CELLS; 13-CIS-RETINOIC ACID; UP-REGULATION; DIFFERENTIAL EXPRESSION; SELECTIVE RETINOIDS; IN-VIVO; LINES; APOPTOSIS; CHEMOPREVENTION	Retinoic acid receptor beta (RAR beta) is thought to be involved in suppressing cell growth and tumorigenicity. Many premalignant and malignant cells exhibit a reduced RAR beta expression. However, in some of these cells (e.g. H157 human squamous cell carcinoma cells), RAR beta can be induced by retinoids (e.g. all-trans-retinoic acid, ATRA) because its promoter contains a retinoic acid response element. To examine the hypothesis that RAR beta induction is important for inhibition of cell proliferation by retinoids, we blocked ATRA-induced RAR beta expression in H157 cells using a retroviral vector harboring multiple copies of antisense RAR beta 2 sequences. Antisense RAR beta-transfected cells showed not only decreased expression of ATRA-induced RAR beta protein but also reduced ATRA-induced RAR beta binding activity and transactivation. Importantly, all antisense RAR beta transfectants of H157 cells were less responsive than vector-transfected cells to the growth inhibitory effects of the retinoids ATRA and Ch55 in vitro. These results demonstrate that RAR beta induction may play an important role in mediating growth inhibitory effects of retinoids in cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol 108, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol 108, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [U19CA068437] Funding Source: NIH RePORTER; NCI NIH HHS [U19 CA68437] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayoub J, 1999, J CLIN ONCOL, V17, P3546, DOI 10.1200/JCO.1999.17.11.3546; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Berg WJ, 1999, CLIN CANCER RES, V5, P1671; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DE LUCA LM, 1991, FASEB J, V5, P2924; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; GEBERT JF, 1991, ONCOGENE, V6, P1859; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Hoffman AD, 1996, CLIN CANCER RES, V2, P1077; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1734; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; Li Y, 1998, INT J CANCER, V75, P88, DOI 10.1002/(SICI)1097-0215(19980105)75:1<88::AID-IJC14>3.0.CO;2-9; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Mangelsdorf David J., 1994, P319; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; NERVI C, 1991, EXP CELL RES, V195, P163, DOI 10.1016/0014-4827(91)90512-S; Pergolizzi R, 1999, INT J CANCER, V81, P829; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Shambrook J, 1989, MOL CLONING LAB MANU; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Sun SY, 1997, J CELL PHYSIOL, V173, P279, DOI 10.1002/(SICI)1097-4652(199711)173:2<279::AID-JCP36>3.0.CO;2-8; Sun SY, 1997, CANCER RES, V57, P4931; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Weber E, 1999, INT J CANCER, V80, P935, DOI 10.1002/(SICI)1097-0215(19990315)80:6<935::AID-IJC21>3.0.CO;2-E; Xu XC, 1999, CANCER RES, V59, P2477; Xu XC, 1999, J NATL CANCER I, V91, P1317, DOI 10.1093/jnci/91.15.1317; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; XU XC, 1994, CANCER RES, V54, P3580; ZHANG XK, 1994, CANCER RES, V54, P5663	41	104	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17149	17153		10.1074/jbc.M000527200	http://dx.doi.org/10.1074/jbc.M000527200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747926	hybrid			2022-12-27	WOS:000087392200105
J	Wang, WH; Wang, SB; Yan, L; Madara, P; Cintron, AD; Wesley, RA; Danner, RL				Wang, WH; Wang, SB; Yan, L; Madara, P; Cintron, AD; Wesley, RA; Danner, RL			Superoxide production and reactive oxygen species signaling by endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; U937 CELLS; EXPRESSION; TETRAHYDROBIOPTERIN; PEROXYNITRITE; GENERATION; ACTIVATION; DISMUTASE; ANION; DYSFUNCTION	Reactive oxygen species can function as intracellular messengers, but linking these signaling events with specific enzymes has been difficult. Purified endothelial nitric-oxide synthase (eNOS) can generate superoxide (O-2(<(.)over bar>)) under special conditions but is only known to participate in cell signaling through NO. Here we show that eNOS regulates tumor necrosis factor alpha (TNF alpha) through a mechanism dependent on the production of O-2(<(.)over bar>) and completely independent of NO. Expression of eNOS in transfected U937 cells increased phorbol 12-myristate 13-acetate-induced TNF alpha promoter activity and TNF alpha production. N-omega-Methyl-L-arginine, an inhibitor of eNOS that blocks NO production but not its NADPH oxidase activity, did not prevent TNF alpha up-regulation. Likewise, Gln(361)eNOS, a competent NADPH oxidase that lacks NOS activity, retained the ability to increase TNF alpha. Similar to the effect of eNOS, a O-2(<(.)over bar>) donor dose-dependently increased TNF alpha production in differentiated U937 cells. In contrast, cotransfection of superoxide dismutase with eNOS prevented TNF alpha up-regulation, as did partial deletion of the eNOS NADPH binding site, a mutation associated with loss of O-2(<(.)over bar>) production. Thus, eNOS may straddle a bifurcating pathway that can lead to the formation of either NO or O-2(<(.)over bar>) interrelated but often opposing free radical messengers. This arrangement has possible implications for atherosclerosis and septic shock where endothelial dysfunction results from imbalances in NO and O-2(<(.)over bar>) production.	NIH, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Danner, RL (corresponding author), NIH, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, Bldg 10,Rm 7D43,10 Ctr Dr,MSC 1662, Bethesda, MD 20892 USA.	rdanner@nih.gov			CLINICAL CENTER [ZIACL000188, Z01CL000188] Funding Source: NIH RePORTER	CLINICAL CENTER		Bouloumie A, 1997, HYPERTENSION, V30, P934, DOI 10.1161/01.HYP.30.4.934; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; COSENTINO F, 1995, CIRCULATION, V91, P139, DOI 10.1161/01.CIR.91.1.139; DelAMonte SM, 1997, MOL CHEM NEUROPATHOL, V30, P139, DOI 10.1007/BF02815155; Dimmeler S, 1999, ARTERIOSCL THROM VAS, V19, P656, DOI 10.1161/01.ATV.19.3.656; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GABOURY J, 1993, AM J PHYSIOL, V265, pH862, DOI 10.1152/ajpheart.1993.265.3.H862; GABOURY JP, 1994, AM J PHYSIOL, V266, pH637, DOI 10.1152/ajpheart.1994.266.2.H637; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; HASS R, 1991, LEUKEMIA RES, V15, P327, DOI 10.1016/0145-2126(91)90008-H; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; PRITCHARD KA, 1995, CIRC RES, V77, P510, DOI 10.1161/01.RES.77.3.510; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; SCHOEDON G, 1987, EUR J BIOCHEM, V166, P303, DOI 10.1111/j.1432-1033.1987.tb13515.x; Smith MA, 1997, J NEUROSCI, V17, P2653; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Szabo C, 1996, CIRC RES, V78, P1051, DOI 10.1161/01.RES.78.6.1051; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; WALDMAN SA, 1988, J CARDIOVASC PHARM, V12, pS115; Wang SB, 1997, J BIOL CHEM, V272, P5959, DOI 10.1074/jbc.272.9.5959; Wang WH, 1999, FASEB J, V13, pA132; Wolin Michael S., 1996, Microcirculation (Philadelphia), V3, P1, DOI 10.3109/10739689609146778; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Yan L, 1997, BLOOD, V90, P1160, DOI 10.1182/blood.V90.3.1160.1160_1160_1167	35	71	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16899	16903		10.1074/jbc.M000301200	http://dx.doi.org/10.1074/jbc.M000301200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747895	hybrid			2022-12-27	WOS:000087392200071
J	Lehti, K; Valtanen, H; Wickstrom, SA; Lohi, J; Keski-Oja, J				Lehti, K; Valtanen, H; Wickstrom, SA; Lohi, J; Keski-Oja, J			Regulation of membrane-type-1 matrix metalloproteinase activity by its cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGELATINASE-A; GELATINASE-A; COLLAGEN LATTICES; BREAST-CARCINOMA; MT1-MMP MMP-14; CELL-SURFACE; ACTIVATION; EXPRESSION; LOCALIZATION; INVASION	Membrane-type-1 matrix metalloproteinase (MT1-MMP) has transmembrane and cytoplasmic domains, which target it to invasive fronts. We analyzed the role of the cytoplasmic tail by expressing wild type MT1-MMP and three mutants with progressively truncated C termini in human Bowes melanoma cells. We examined gelatinase A activation and the localization and processing of recombinant proteins in stable cell clones using gelatin zymography, immunoblotting, and immunofluorescence. Cell invasion was analyzed in vitro by Matrigel invasion assays. Gelatinase A was activated in all cell clones. However, the localization of MT1-MMP to the leading edge of migrating cells and cell invasion through Matrigel were strongly enhanced only in cells expressing either wild type or truncated MT1-MMP lacking 6 C-terminal amino acid residues (Delta 577). Truncations of 10 or 16 amino acid residues in the cytoplasmic domain (Delta 567 and Delta 573, respectively) disturbed MT1-MMP localization. The expression of wild type and Delta 577 MT1-MMPs induced also their cleavage to 43-kDa cell surface forms and the release of soluble, similar to 20-kDa N-terminal fragments containing the catalytic center. A synthetic MMP inhibitor but not a gelatinase inhibitor prevented the processing, suggesting that autocatalytic cleavage occurs. Purified soluble MT1-MMP was also autoproteolytically processed to 43- and 20-kDa forms in vitro. Our results indicate that the cytoplasmic domain has an important role in cell invasion by controlling both the targeting and degradation/turnover of MT1-MMP.	Univ Helsinki, Dept Pathol, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Virol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Keski-Oja, J (corresponding author), Univ Helsinki, Dept Pathol, Haartman Inst, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	jorma.keski-oja@helsinki.fi		Wickstrom, Sara/0000-0001-6383-6292; Lehti, Kaisa/0000-0001-9110-8719				Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; ALANKO T, 1994, DEV BIOL, V161, P141, DOI 10.1006/dbio.1994.1016; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Gilles C, 1997, LAB INVEST, V76, P651; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Imai K, 1996, CANCER RES, V56, P2707; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; LIOTTA LA, 1991, CANCER RES, V51, pS5054; LOHI J, 1992, J CELL BIOCHEM, V50, P337, DOI 10.1002/jcb.240500402; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Puente XS, 1996, CANCER RES, V56, P944; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Stanton H, 1998, J CELL SCI, V111, P2789; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Theret N, 1999, HEPATOLOGY, V30, P462, DOI 10.1002/hep.510300236; Ueno H, 1997, CANCER RES, V57, P2055; Urena JM, 1999, J CELL SCI, V112, P773; Valtanen H, 2000, PROTEIN EXPRES PURIF, V19, P66, DOI 10.1006/prep.2000.1216; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119	39	144	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15006	15013		10.1074/jbc.M910220199	http://dx.doi.org/10.1074/jbc.M910220199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748199	hybrid			2022-12-27	WOS:000087128300034
J	Germain, N; Merienne, K; Zinn-Justin, S; Boulain, JC; Ducancel, F; Menez, A				Germain, N; Merienne, K; Zinn-Justin, S; Boulain, JC; Ducancel, F; Menez, A			Molecular and structural basis of the specificity of a neutralizing acetylcholine receptor-mimicking antibody, using combined mutational and molecular modeling analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-MUTANT CYCLES; PROTEIN-PROTEIN COMPLEX; CATION-PI INTERACTIONS; MONOCLONAL-ANTIBODY; BINDING INTERACTIONS; CURAREMIMETIC TOXIN; NICOTINIC RECEPTOR; SNAKE NEUROTOXINS; ALPHA-NEUROTOXIN; ANTIGEN	The antagonist activity of short-chain toxins from snake venoms toward the nicotinic acetylcholine receptor (nAChR) is neutralized upon binding to a toxin-specific monoclonal antibody called M alpha 2-3 (1). To establish the molecular basis of this specificity, we predicted from both mutational analyses and docking procedures the structure of the M alpha 2-3-toxin complex. From knowledge of the functional paratope and epitope, and using a double-mutation cycle procedure, we gathered evidence that Asp(31) in complementarity determining region 1H is close to, and perhaps interacts with, Arg(33) in the antigen. The use of this pair of proximate residues during the selection procedure yielded three models based on docking calculations. The selected models predicted the proximity of Tyr(49) and/or Tyr(50) in the antibody to Lys(47) in the toxin. This was experimentally confirmed using another round of double-mutation cycles. The two models finally selected were submitted to energy minimization in a CHARMM22 force field, and were characterized by a root mean square deviation of 7.0 +/- 2.9 Angstrom. Both models display most features of antibody-antigen structures. Since M alpha 2-3 also partially mimics some binding properties of nAChR, these structural features not only explain its fine specificity of recognition, but may also further clarify how toxins bind to nAChR.	CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Menez, A (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.			Merienne, Karine/0000-0003-2549-2315				Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Ackermann EJ, 1997, BIOCHEMISTRY-US, V36, P12836, DOI 10.1021/bi971513u; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BOULAIN JC, 1982, BIOCHEMISTRY-US, V21, P2910, DOI 10.1021/bi00541a016; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; BRUNGER AT, 1991, J MOL BIOL, V221, P239, DOI 10.1016/0022-2836(91)90817-P; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CHACKO S, 1995, J MOL BIOL, V245, P261, DOI 10.1006/jmbi.1994.0022; CHANH TC, 1987, P NATL ACAD SCI USA, V84, P3891, DOI 10.1073/pnas.84.11.3891; CHERFILS J, 1991, PROTEINS, V11, P271, DOI 10.1002/prot.340110406; CORFIELD PWR, 1989, J BIOL CHEM, V264, P9239; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; Dall'Acqua W, 1998, BIOCHEMISTRY-US, V37, P7981, DOI 10.1021/bi980148j; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DAVIS SJ, 1992, NATURE, V358, P76, DOI 10.1038/358076a0; Dougan DA, 1998, PROTEIN ENG, V11, P65, DOI 10.1093/protein/11.1.65; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Drevet P, 1997, PROTEIN EXPRES PURIF, V10, P293, DOI 10.1006/prep.1997.0740; Ducancel F, 1996, J BIOL CHEM, V271, P31345, DOI 10.1074/jbc.271.49.31345; Dunbrack RL, 1997, FOLD DES, V2, pR27, DOI 10.1016/S1359-0278(97)00011-4; Endo T., 1991, P165; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; Goldman ER, 1997, BIOCHEMISTRY-US, V36, P49, DOI 10.1021/bi961769k; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; Le Novere N, 1999, BIOPHYS J, V76, P2329, DOI 10.1016/S0006-3495(99)77390-X; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MENEZ A, 1984, J PHYSIOLOGY PARIS, V79, P196; Merienne K, 1997, J BIOL CHEM, V272, P23775, DOI 10.1074/jbc.272.38.23775; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; Osaka H, 1999, J BIOL CHEM, V274, P9581, DOI 10.1074/jbc.274.14.9581; Otzen DE, 1999, PROTEIN ENG, V12, P41, DOI 10.1093/protein/12.1.41; Pruett PS, 1998, BIOCHEMISTRY-US, V37, P10660, DOI 10.1021/bi9802059; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; Tenette C, 1996, PROTEINS, V26, P9, DOI 10.1002/(SICI)1097-0134(199609)26:1<9::AID-PROT2>3.0.CO;2-E; Tenette-Souaille C, 1998, PROTEINS, V30, P249; TREMEAU O, 1986, FEBS LETT, V208, P236, DOI 10.1016/0014-5793(86)81024-9; Tsai CJ, 1996, CRIT REV BIOCHEM MOL, V31, P127, DOI 10.3109/10409239609106582; WODAK SJ, 1978, J MOL BIOL, V124, P323, DOI 10.1016/0022-2836(78)90302-9; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088; ZINNJUSTIN S, 1993, BIOCHEMISTRY-US, V32, P6884, DOI 10.1021/bi00078a011; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	48	7	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21578	21586		10.1074/jbc.M001794200	http://dx.doi.org/10.1074/jbc.M001794200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10748046	hybrid			2022-12-27	WOS:000088230600083
J	Verkoczy, LK; Guinn, B; Berinstein, NL				Verkoczy, LK; Guinn, B; Berinstein, NL			Characterization of the human B cell RAG-associated gene, hBRAG, as a B cell receptor signal-enhancing glycoprotein dimer that associates with phosphorylated proteins in resting B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE IG RECEPTOR; ANTIGEN RECEPTOR; TYROSINE KINASE; MOLECULAR-CLONING; BP-1/6C3 ANTIGEN; LYMPHOCYTES-B; TRANSDUCTION; EXPRESSION; CHAIN; HCK	Affinity-purified polyclonal antibodies against the hBRAG (human B cell RAG-associated gene) protein were generated to characterize hBRAG at the biochemical level. Immunoblotting and immunoprecipitation experiments with these antibody reagents demonstrate that this protein can be expressed in B cells as a membrane-integrated glycoprotein disulfide-linked dimer. However, both glycosylated and unglycosylated isoforms of hBRAG are detectable with these reagents. Additionally, their use in cell surface biotinylation and flow cytometry reveals subcellular hBRAG pools both at cell surface and intracellular locations. Co-immunoprecipitation experiments with hBRAG antisera detected the association of hBRAG with phosphorylated proteins in resting B cells, including the protein tyrosine kinase HcK, which is subsequently dephosphorylated upon B cell receptor (BCR) ligation. Consistent with its cell surface expression and possible link to BCR signaling, experiments in which alpha-hBRAG antibodies were used to generate early activation signals suggest a modest but specific element of tyrosine phosphorylation occurring through a putative hBRAG receptor. Additional experiments also suggest that hBRAG may be involved in positively enhancing BCR ligation-mediated early activation events. Collectively, these results are consistent with a function for hBRAG as a B cell surface signaling receptor molecule. Coupled with the earlier observation that hBRAG expression correlates with early and late B cell-specific RAG expression, we submit that hBRAG may mediate regulatory signals key to B cell development and/or regulation of B cell-specific RAG expression.	Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4W 3M5, Canada; Sunnybrook Hlth Sci Ctr, Toronto, ON M4W 3M5, Canada; Univ Toronto, Dept Med, Toronto, ON M4N 3N5, Canada; Univ Toronto, Dept Immunol, Toronto, ON M4N 3N5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto	Berinstein, NL (corresponding author), Toronto Sunnybrook Reg Canc Ctr, 2075 Bayview Ave, Toronto, ON M4W 3M5, Canada.		Guinn, Barbara/B-3509-2009	Guinn, Barbara/0000-0003-0639-4541				Barclay A. N, 1997, LEUKOCYTE ANTIGEN FA; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; CAMBIER JC, 1993, IMMUNOL REV, V132, P85, DOI 10.1111/j.1600-065X.1993.tb00838.x; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CRESSWELL P, 1992, CURR OPIN IMMUNOL, V4, P87, DOI 10.1016/0952-7915(92)90131-W; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KIM KM, 1993, IMMUNOL REV, V132, P126; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LI ZH, 1992, BIOCHEM BIOPH RES CO, V187, P1536, DOI 10.1016/0006-291X(92)90477-3; LUPA MT, 1990, DEV BIOL, V142, P31, DOI 10.1016/0012-1606(90)90148-C; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Ohmori H, 1998, CRIT REV IMMUNOL, V18, P221, DOI 10.1615/CritRevImmunol.v18.i3.30; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; REITHMEIER RAF, 1992, STRUCTURE BIOL MEMBR, P337; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; SAOUAF SJ, 1995, J BIOL CHEM, V270, P27072, DOI 10.1074/jbc.270.45.27072; STIERNHOLM NBJ, 1995, J IMMUNOL, V154, P4583; Tagoh H, 1996, BIOCHEM BIOPH RES CO, V221, P744, DOI 10.1006/bbrc.1996.0667; Tedder TF, 1997, IMMUNITY, V6, P107, DOI 10.1016/S1074-7613(00)80418-5; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; VERCOCZY LK, 1988, NUCLEIC ACIDS RES, V26, P4497; Verkoczy LK, 1998, EUR J IMMUNOL, V28, P2839, DOI 10.1002/(SICI)1521-4141(199809)28:09<2839::AID-IMMU2839>3.0.CO;2-6; VERKOCZY LK, 1995, J IMMUNOL, V154, P5136; VERKOCZY LK, 1999, THESIS U TORONTO; VERKOCZY LK, 1995, THESIS U TORONTO; Wang JY, 1998, IMMUNOL REV, V161, P71, DOI 10.1111/j.1600-065X.1998.tb01572.x; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	32	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					20967	20979		10.1074/jbc.M001866200	http://dx.doi.org/10.1074/jbc.M001866200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10749872	hybrid			2022-12-27	WOS:000088230600003
J	Machado, JD; Segura, F; Brioso, MA; Borges, R				Machado, JD; Segura, F; Brioso, MA; Borges, R			Nitric oxide modulates a late step of exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; DEPENDENT PROTEIN-KINASE; CATECHOLAMINE SECRETION; CHROMOGRANIN-A; NATRIURETIC-PEPTIDE; MEDULLARY CELLS; QUANTAL SIZE; RELEASE; GMP; NITROPRUSSIDE	The effects of nitric oxide (NO) on the late phase of exocytosis have been studied, by amperometry, on Ba2+-stimulated chromaffin cells. Acute incubation with NO or NO donors (sodium nitroprusside, spermine-NO, S-nitrosoglutathione) produced a drastic slowdown of the granule emptying. Conversely, cell treatment with N-omega-nitro-L-arginine methyl ester (a NO synthase inhibitor) or with NO scavengers (methylene blue, 2-(4-carboxy-phhenyl) -4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide potassium) accelerated the extrusion of catecholamines from chromaffin granules, suggesting the presence of a NO modulatory tone. The incubation with phosphodiesterase inhibitors (3-isobutyl-1-methylxanthine or zaprinast) or with the cell-permeant cGMP analog 8-bromo-cGMP, mimicked the effects of NO, suggesting the involvement of the guanylate cyclase cascade. NO effects were not related to changes in intracellular Ba2+ NO did not modify the duration of feet. Effects were evident even on pre-fusioned granules, observed under hypertonic conditions, suggesting that the fusion pore is not the target for NO, which probably acts by modifying the affinity of catecholamines for the intragranular matrix, NO could modify the synaptic transmitter efficacy through a novel mechanism, which involves the regulation of the emptying of secretory vesicles.	Univ La Laguna, Fac Med, Unidad Farmacol, Tenerife 38071, Spain	Universidad de la Laguna	Borges, R (corresponding author), Univ La Laguna, Fac Med, Unidad Farmacol, Tenerife 38071, Spain.		Machado, José David/N-5210-2014; Borges, Ricardo/N-3250-2014	Machado, José David/0000-0003-3531-7051; Borges, Ricardo/0000-0003-3413-4392				AFEWORK M, 1995, NEUROSCI LETT, V190, P109, DOI 10.1016/0304-3940(95)11514-W; Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; Borges R, 1997, J BIOL CHEM, V272, P8325, DOI 10.1074/jbc.272.13.8325; Criado M, 1999, P NATL ACAD SCI USA, V96, P7256, DOI 10.1073/pnas.96.13.7256; Ferrero R, 1999, BRIT J PHARMACOL, V127, P779, DOI 10.1038/sj.bjp.0702607; Finnegan JM, 1996, J NEUROCHEM, V66, P1914; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HARTMANN J, 1995, FEBS LETT, V363, P217, DOI 10.1016/0014-5793(95)00318-4; HELLE KB, 1990, ACTA PHYSIOL SCAND, V138, P565, DOI 10.1111/j.1748-1716.1990.tb08885.x; HELLE KB, 1990, NEUROCHEM INT, V17, P165, DOI 10.1016/0197-0186(90)90139-K; JANKOWSKI JA, 1994, J NEUROCHEM, V63, P1739; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; KOPELL WN, 1982, J BIOL CHEM, V257, P5707; Kumai T, 1998, JPN J PHARMACOL, V77, P205, DOI 10.1254/jjp.77.205; LESZCZYSZYN DJ, 1990, J BIOL CHEM, V265, P14736; MARLEY PD, 1995, J AUTONOM NERV SYST, V54, P184, DOI 10.1016/0165-1838(95)00013-N; MONCK JR, 1995, MOL MEMBR BIOL, V12, P151, DOI 10.3109/09687689509038511; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; MORO MA, 1993, EUR J PHARM-MOLEC PH, V246, P213, DOI 10.1016/0922-4106(93)90033-6; Nagayama T, 1998, EUR J PHARMACOL, V353, P169, DOI 10.1016/S0014-2999(98)00408-7; OSETGASQUE MJ, 1994, J NEUROCHEM, V63, P1693; OSULLIVAN AJ, 1990, J NEUROCHEM, V54, P1805, DOI 10.1111/j.1471-4159.1990.tb01238.x; Pihel K, 1996, BIOPHYS J, V71, P1633, DOI 10.1016/S0006-3495(96)79368-2; Rahamimoff R, 1997, NEURON, V18, P17, DOI 10.1016/S0896-6273(01)80043-X; RODRIGUEZPASCUAL F, 1994, NEUROSCI LETT, V180, P269, DOI 10.1016/0304-3940(94)90536-3; RodriguezPascual F, 1996, MOL PHARMACOL, V49, P1058; Scepek S, 1998, EMBO J, V17, P4340, DOI 10.1093/emboj/17.15.4340; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; Schwarz PM, 1998, NEUROSCIENCE, V82, P255; SEN R, 1982, BIOCHIM BIOPHYS ACTA, V721, P70, DOI 10.1016/0167-4889(82)90025-8; SHARN BR, 1982, BIOPHYS J, V40, P17; Shono M, 1997, J CARDIOVASC PHARM, V30, P419, DOI 10.1097/00005344-199710000-00003; TERAKAWA S, 1999, 10 INT S CHROM CELL, P110; Teraoka H, 1996, JPN J PHARMACOL, V72, P307, DOI 10.1254/jjp.72.307; TORRES M, 1994, J NEUROCHEM, V63, P988; VONRUDEN L, 1993, FEBS LETT, V336, P48, DOI 10.1016/0014-5793(93)81606-Z; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOO SH, 1991, J BIOL CHEM, V266, P7740	41	68	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20274	20279		10.1074/jbc.M000930200	http://dx.doi.org/10.1074/jbc.M000930200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10747967	hybrid			2022-12-27	WOS:000088084500010
J	Thanedar, S; Kumar, NV; Varshney, U				Thanedar, S; Kumar, NV; Varshney, U			The fate of the initiator tRNAs is sensitive to the critical balance between interacting proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; FORMYLMETHIONINE TRANSFER-RNA; ESCHERICHIA-COLI; ACCEPTOR STEM; ANTICODON STEM; HYDROLASE; MUTANTS; TRANSFORMYLASE; RECOGNITION; METHIONINE	Formylation of the initiator tRNA is essential for normal growth of Escherichia coli, The initiator tRNA containing the U35A36 mutation (CUA anticodon) initiates from UAG codon, However, an additional mutation at position 72 (72A --> G) renders the tRNA (G72/U35A36) inactive in initiation because it is defective in formylation, In this study, we isolated U1G72/U35A36 tRNA containing a wobble base pair at 1-72 positions as an intragenic suppressor of the G72 mutation. The U1G72/U35A36 tRNA is formylated and participates in initiation. More importantly, we show that the mismatch at 1-72 positions of the initiator tRNA, which was thus far thought to be the hallmark of the resistance of this tRNA against peptidyl-tRNA hydrolase (PTH), is not sufficient, The amino acid attached to the initiator tRNA is also important in conferring protection against PTH. Further, we show that the relative levels of PTH and IF2 influence the path adopted by the initiator tRNAs in protein synthesis. These findings provide an important clue to understand the dual function of the single tRNA(Met) in initiation and elongation, in the mitochondria of various organisms.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Varshney, U (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	varshney@mcbl.iisc.ernet.in	Varshney, Umesh/A-8062-2009; Varshney, Umesh/Q-6914-2019	Nandicoori, Vinay/0000-0002-5682-4178				ATHERLY AG, 1972, NATURE-NEW BIOL, V240, P245, DOI 10.1038/newbio240245a0; BRENNER S, 1965, J MOL BIOL, V13, P629, DOI 10.1016/S0022-2836(65)80131-0; DUBE SK, 1969, EUR J BIOCHEM, V8, P256, DOI 10.1111/j.1432-1033.1969.tb00522.x; DUTKA S, 1993, NUCLEIC ACIDS RES, V21, P4025, DOI 10.1093/nar/21.17.4025; GARCIAVILLEGAS MR, 1991, EMBO J, V10, P3549, DOI 10.1002/j.1460-2075.1991.tb04919.x; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; GUILLON JM, 1993, J BACTERIOL, V175, P4507, DOI 10.1128/JB.175.14.4507-4514.1993; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; Guillon JM, 1996, J BIOL CHEM, V271, P22321, DOI 10.1074/jbc.271.37.22321; KOSSEL H, 1968, J MOL BIOL, V35, P539, DOI 10.1016/S0022-2836(68)80013-0; KOZAK M, 1983, MICROBIOL REV, V47, P1; LEE CP, 1993, P NATL ACAD SCI USA, V90, P7149, DOI 10.1073/pnas.90.15.7149; LEE CP, 1991, J BIOL CHEM, V266, P18012; LEE CP, 1992, P NATL ACAD SCI USA, V89, P9262, DOI 10.1073/pnas.89.19.9262; MANDAL N, 1992, J BACTERIOL, V174, P7827, DOI 10.1128/JB.174.23.7827-7830.1992; MANGROO D, 1995, J BIOL CHEM, V270, P12203, DOI 10.1074/jbc.270.20.12203; Miller J.H., 1972, EXPT MOL GENETICS; PERONA JJ, 1988, J MOL BIOL, V202, P121, DOI 10.1016/0022-2836(88)90524-4; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Sambrook J., 2002, MOL CLONING LAB MANU; SARIN PS, 1964, BIOCHIM BIOPHYS ACTA, V91, P653, DOI 10.1016/0926-6550(64)90018-0; Schmitt E, 1997, EMBO J, V16, P4760, DOI 10.1093/emboj/16.15.4760; SCHOFIEL.P, 1968, BIOCHIM BIOPHYS ACTA, V155, P410, DOI 10.1016/0005-2787(68)90185-8; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SCHULMAN LH, 1975, J BIOL CHEM, V250, P542; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VARSHNEY U, 1992, J BACTERIOL, V174, P7819, DOI 10.1128/JB.174.23.7819-7826.1992; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; VARSHNEY U, 1990, P NATL ACAD SCI USA, V87, P1586, DOI 10.1073/pnas.87.4.1586; VARSHNEY U, 1993, P NATL ACAD SCI USA, V90, P2305, DOI 10.1073/pnas.90.6.2305; Wu XQ, 1997, J BIOL CHEM, V272, P1891, DOI 10.1074/jbc.272.3.1891	36	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20361	20367		10.1074/jbc.M001238200	http://dx.doi.org/10.1074/jbc.M001238200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10748005	hybrid			2022-12-27	WOS:000088084500021
J	Caffrey, M; Braddock, DT; Louis, JM; Abu-Asab, MA; Kingma, D; Liotta, L; Tsokos, M; Tresser, N; Pannell, LK; Watts, N; Steven, AC; Simon, MN; Stahl, SJ; Wingfield, PT; Clore, GM				Caffrey, M; Braddock, DT; Louis, JM; Abu-Asab, MA; Kingma, D; Liotta, L; Tsokos, M; Tresser, N; Pannell, LK; Watts, N; Steven, AC; Simon, MN; Stahl, SJ; Wingfield, PT; Clore, GM			Biophysical characterization of gp41 aggregates suggests a model for the molecular mechanism of HIV-associated neurological damage and dementia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; AIDS DEMENTIA; NERVOUS-SYSTEM; SIV GP41; SPONGIFORM ENCEPHALOPATHY; CLINICAL-FEATURES; CRYSTAL-STRUCTURE	In human immunodeficiency virus (HIV)-infected individuals, the level of the HIV envelope protein gp41 in brain tissue is correlated with neurological damage and dementia, In this paper we show by biochemical methods and electron microscopy that the extracellular ectodomain of purified HIV and simian immunodeficiency virus gp41 (e-gp41) forms a mixture of soluble high molecular weight aggregate and native trimer at physiological pH. The e-gp41 aggregate is shown to be largely alpha-helical and relatively stable to denaturants, The high molecular weight form of e-gp41 is variable in size ranging from 7 to 70 trimers, which associate by interactions at the interior of the aggregate involving the loop that connects the N- and C-terminal helices of the e-gp41 core. The trimers are predominantly arranged with their long axes oriented radially, and the width of the high molecular weight aggregate corresponds to the length of two e-gp41 trimers (similar to 200 Angstrom). Using both light and electron microscopy combined with immunohistochemistry we show that HIV gp41 accumulates as an extracellular aggregate in the brains of HIV-infected patients diagnosed with dementia, We postulate that the high molecular weight aggregates of e-gp41 are responsible for HIV-associated neurological damage and dementia, consistent with known mechanisms of encephalopathy.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Struct Biol Res Lab, NIH, Bethesda, MD 20892 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; NIAMS, Prot Express Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); United States Department of Energy (DOE); Brookhaven National Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Rm B1-301, Bethesda, MD 20892 USA.	clore@speck.niddk.nih.gov	Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Abu-Asab, Mones/0000-0002-4047-1232; Lipko, Nancy/0000-0001-9267-4587; Louis, John M/0000-0002-0052-1899; Wingfield, Paul/0000-0002-9515-4752	NATIONAL CANCER INSTITUTE [Z01SC009394, ZIDSC009394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR027002, Z01AR027002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032102] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adamson DC, 1996, SCIENCE, V274, P1917, DOI 10.1126/science.274.5294.1917; Adamson DC, 1999, MOL MED, V5, P98, DOI 10.1007/BF03402144; [Anonymous], PATHOLOGICAL BASIS D; ARTIGAS J, 1989, J ACQ IMMUN DEF SYND, V2, P374; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; BREW BJ, 1995, ANN NEUROL, V38, P563, DOI 10.1002/ana.410380404; BRUN A, 1986, ANN NEUROL, V19, P253, DOI 10.1002/ana.410190306; Budka H., 1993, ATLAS NEUROPATHOLOGY, P1; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; Evans TG, 1999, J INFECT DIS, V180, P290, DOI 10.1086/314895; FAULSTICH ME, 1986, INT J NEUROSCI, V30, P249, DOI 10.3109/00207458608985675; GABUZDA DH, 1987, ANN INTERN MED, V107, P383, DOI 10.7326/0003-4819-107-2-383; GABUZDA DH, 1986, ANN NEUROL, V20, P289, DOI 10.1002/ana.410200304; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GLASS JD, 1995, ANN NEUROL, V38, P755, DOI 10.1002/ana.410380510; HAINFELD JF, 1994, PROC ANN MEET MSA, P132; Heinert G, 1999, ACTA PHYSIOL SCAND, V166, P183; JANSSEN RS, 1991, NEUROLOGY, V41, P778; Johnson RT, 1996, ANN NEUROL, V39, P392, DOI 10.1002/ana.410390319; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOKA P, 1995, J EXP MED, V182, P941, DOI 10.1084/jem.182.4.941; KURE K, 1991, HUM PATHOL, V22, P700, DOI 10.1016/0046-8177(91)90293-X; Lane TE, 1996, MOL MED, V2, P27, DOI 10.1007/BF03402200; Letvin NL, 1997, P NATL ACAD SCI USA, V94, P9378, DOI 10.1073/pnas.94.17.9378; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; MCARTHUR JC, 1987, MEDICINE, V66, P407, DOI 10.1097/00005792-198711000-00001; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; ORTIZ JS, 1994, AGE AGEING, V23, P75, DOI 10.1093/ageing/23.1.75; OSBORN AG, 1999, DIAGNOSTIC NEURORADI, P698; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; PUMAROLASUNE T, 1987, ANN NEUROL, V21, P490, DOI 10.1002/ana.410210513; Rabenstein MD, 1996, BIOCHEMISTRY-US, V35, P13922, DOI 10.1021/bi961743t; Rostasy K, 1999, ANN NEUROL, V46, P207, DOI 10.1002/1531-8249(199908)46:2<207::AID-ANA10>3.0.CO;2-4; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SCHWENK J, 1987, ACTA NEUROPATHOL, V74, P389, DOI 10.1007/BF00687217; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; THOMAS D, 1994, BIOL CELL, V80, P181, DOI 10.1016/0248-4900(94)90041-8; Wall JS, 1998, METHOD CELL BIOL, V53, P139; Wallin A, 1993, J Geriatr Psychiatry Neurol, V6, P177; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; Wingfield PT, 1997, PROTEIN SCI, V6, P1653, DOI 10.1002/pro.5560060806; Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255; Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116	52	27	30	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19877	19882		10.1074/jbc.M001036200	http://dx.doi.org/10.1074/jbc.M001036200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10747981	hybrid			2022-12-27	WOS:000087941300061
J	Mummidi, S; Bamshad, M; Ahuja, SS; Gonzalez, E; Feuillet, PM; Begum, K; Galvis, MC; Kostecki, V; Valente, AJ; Murthy, KK; Haro, L; Dolan, MJ; Allan, JS; Ahuja, SK				Mummidi, S; Bamshad, M; Ahuja, SS; Gonzalez, E; Feuillet, PM; Begum, K; Galvis, MC; Kostecki, V; Valente, AJ; Murthy, KK; Haro, L; Dolan, MJ; Allan, JS; Ahuja, SK			Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA - Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and Simian immunodeficiency virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; AFRICAN-GREEN MONKEYS; DISEASE PROGRESSION; MESSENGER-RNA; 5'-END HETEROGENEITY; PROMOTER REGION; ANIMAL-MODELS; INFECTION; PROTEINS; ENTRY	Polymorphisms in CC chemokine receptor 5 (CCR5), the major coreceptor of human immunodeficiency virus 1 (HIV-1) and simian immunodeficiency virus (SIV), have a major influence on HIV-1 transmission and disease progression. The effects of these polymorphisms may, in part, account for the differential pathogenesis of HIV-1 (immunosuppression) and SIV (natural resistance) in humans and non-human primates, respectively. Thus, understanding the genetic basis underlying species-specific responses to HIV-1 and SIV could reveal new anti-HIV-1 therapeutic strategies for humans. To this end, we compared CCR5 structure/evolution and regulation among humans, apes, Old World Monkeys, and New World Monkeys. The evolution of the CCR5 cis-regulatory region versus the open reading frame as well as among different domains of the open reading frame differed from one another. CCR5 cis-regulatory region sequence variation in humans was substantially higher than anticipated. Based on this variation, CCR5 haplotypes could be organized into seven evolutionarily distinct human haplogroups (HH) that we designated HHA, -B, -C, -D, -E, -F, and -G. HHA haplotypes were defined as ancestral to all other haplotypes by comparison to the CCR5 haplotypes of non-human primates. Different human and non-human primate CCR5 haplotypes were associated with differential transcriptional regulation, and various polymorphisms resulted in modified DNA-nuclear protein interactions, including altered binding of members of the NF-KB family of transcription factors. We identified novel CCR5 untranslated mRNA sequences that were conserved in human and non-human primates. In some primates, mutations at exon-intron boundaries caused loss of expression of selected CCR5 mRNA isoforms or production of novel mRNA isoforms. Collectively, these findings suggest that the response to HIV-1 and SN infection in primates may have been driven, in part, by evolution of the elements controlling CCR5 transcription and translation.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Div, Dept Med, San Antonio, TX 78229 USA; Univ Utah, Eccles Inst Human Genet, Dept Pediat, Salt Lake City, UT 84112 USA; SW Fdn Biomed Res, Dept Virol & Immunol, San Antonio, TX 78228 USA; Univ Texas, Dept Life Sci, San Antonio, TX 78249 USA; Wilford Hall USAF Med Ctr, Infect Dis Serv, Lackland AFB, San Antonio, TX 78236 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Utah System of Higher Education; University of Utah; Texas Biomedical Research Institute; University of Texas System; United States Department of Defense; United States Air Force	Ahuja, SK (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.		Mummidi, Srinivas/H-3335-2017; Mummidi, Srinivas/C-1004-2008	Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380	NIAID NIH HHS [R29-AI46326, R01-AI43279, R01-AI41396] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI046326, R01AI046326, R01AI041396, R01AI043279, R37AI046326] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN JS, 1990, AIDS RES HUM RETROV, V6, P275, DOI 10.1089/aid.1990.6.275; ALLAN JS, 1991, J VIROL, V65, P2816, DOI 10.1128/JVI.65.6.2816-2828.1991; ALLAN JS, 1992, J NIH RES, V4, P51; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Boado RJ, 1997, COMP BIOCHEM PHYS B, V118, P309, DOI 10.1016/S0305-0491(97)00170-3; Bream J H, 1999, Science, V284, P223; Carrington M, 1999, HUM MOL GENET, V8, P1939, DOI 10.1093/hmg/8.10.1939; Carrington M, 1997, AM J HUM GENET, V61, P1261, DOI 10.1086/301645; Chen ZW, 1998, J EXP MED, V188, P2057, DOI 10.1084/jem.188.11.2057; Clemens MJ, 1989, CURR OPIN CELL BIOL, V1, P1160, DOI 10.1016/S0955-0674(89)80067-5; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Edinger AL, 1998, VIROLOGY, V249, P367, DOI 10.1006/viro.1998.9306; FOMSGAARD A, 1991, VIROLOGY, V182, P397, DOI 10.1016/0042-6822(91)90689-9; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; GARDNER MB, 1989, FASEB J, V3, P2593, DOI 10.1096/fasebj.3.14.2556312; Garzino-Demo A, 1998, J CLIN IMMUNOL, V18, P243, DOI 10.1023/A:1027329721892; GOJOBORI T, 1990, P NATL ACAD SCI USA, V87, P4108, DOI 10.1073/pnas.87.11.4108; Gonzalez E, 1999, P NATL ACAD SCI USA, V96, P12004, DOI 10.1073/pnas.96.21.12004; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; Goodman M, 1999, AM J HUM GENET, V64, P31, DOI 10.1086/302218; GRILLI M, 1993, INT REV CYTOL, V143, P1; Guignard F, 1998, J IMMUNOL, V160, P985; Hirsch VM, 1999, J VIROL, V73, P1036, DOI 10.1128/JVI.73.2.1036-1045.1999; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Jolly CJ, 1996, J MED PRIMATOL, V25, P78, DOI 10.1111/j.1600-0684.1996.tb00198.x; JORDE LB, 1995, AM J HUM GENET, V57, P523; Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; Kostrikis LG, 1998, NAT MED, V4, P350, DOI 10.1038/nm0398-350; LAZARUS P, 1992, ONCOGENE, V7, P1037; Lee YC, 1999, J NEUROCHEM, V73, P1790, DOI 10.1046/j.1471-4159.1999.0731790.x; LI WH, 1991, GENETICS, V129, P513; Li WQ, 1999, GENETICS, V152, P237; LI Y, 1989, J MED PRIMATOL, V18, P261; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Liu R, 1998, AIDS RES HUM RETROV, V14, P1509, DOI 10.1089/aid.1998.14.1509; Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; Messler W, 1997, NATURE, V385, P151, DOI 10.1038/385151a0; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Moriuchi H, 1997, J IMMUNOL, V159, P5441; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; Mummidi S, 1998, NAT MED, V4, P786, DOI 10.1038/nm0798-786; NEI M, 1986, MOL BIOL EVOL, V3, P418; Norley S, 1997, SPRINGER SEMIN IMMUN, V18, P391, DOI 10.1007/BF00813505; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; Rey-Cuille MA, 1998, J VIROL, V72, P3872; SAINI KS, 1990, MOL CELL BIOCHEM, V96, P15; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stefanovic B, 1999, MOL CELL BIOL, V19, P4334; Tang J, 1999, GENES IMMUN, V1, P20, DOI 10.1038/sj.gene.6363640; Tolner B, 1998, GENE, V211, P331, DOI 10.1016/S0378-1119(98)00123-1; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224; Unutmaz D, 1998, SEMIN IMMUNOL, V10, P225, DOI 10.1006/smim.1998.0134; VOERBAUGH J, 1997, AIDS, V11, P47; Yang ZH, 1998, J MOL EVOL, V46, P409, DOI 10.1007/PL00006320; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Zhang YW, 1999, MOL BIOL EVOL, V16, P1145, DOI 10.1093/oxfordjournals.molbev.a026205; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	67	137	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18946	18961		10.1074/jbc.M000169200	http://dx.doi.org/10.1074/jbc.M000169200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10747879	hybrid			2022-12-27	WOS:000087815900046
J	Eguchi, A; Kondoh, T; Kosaka, H; Suzuki, T; Momota, H; Masago, A; Yoshida, T; Taira, H; Ishii-Watabe, A; Okabe, J; Hu, JH; Miura, N; Ueda, S; Suzuki, Y; Taki, T; Hayakawa, T; Nakanishi, M				Eguchi, A; Kondoh, T; Kosaka, H; Suzuki, T; Momota, H; Masago, A; Yoshida, T; Taira, H; Ishii-Watabe, A; Okabe, J; Hu, JH; Miura, N; Ueda, S; Suzuki, Y; Taki, T; Hayakawa, T; Nakanishi, M			Identification and characterization of cell lines with a defect in a post-adsorption stage of Sendai virus-mediated membrane fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWCASTLE-DISEASE VIRUS; HEMAGGLUTININ-NEURAMINIDASE PROTEIN; HERPES-SIMPLEX VIRUS-1; DIPHTHERIA-TOXIN; RECEPTOR SIALOGLYCOPROTEIN; MONOCLONAL-ANTIBODIES; PARAMYXOVIRUS FUSION; FUSOGENIC LIPOSOMES; GLYCOPROTEIN-D; HN PROTEIN	In the early stage of infection, Sendai virus delivers its genome into the cytoplasm by fusing the viral envelope with the cell membrane. Although the adsorption of virus particles to cell surface receptors has been characterized in detail, the ensuing complex process that leads to the fusion between the lipid bilayers remains mostly obscure. In the present study, we identified and characterized cell lines with a defect in the Sendai virus-mediated membrane fusion, using fusion-mediated delivery of fragment A of diphtheria toxin as an index. These cells, persistently infected with the temperature-sensitive variant Sendai virus, had primary viral receptors indistinguishable in number and affinity from those of parental susceptible cells. However, they proved to be thoroughly defective in the Sendai virus-mediated membrane fusion. We also found that viral HN protein expressed in the defective cells was responsible for the interference with membrane fusion. These results suggested the presence of a previously uncharacterized, HN-dependent intermediate stage in the Sendai virus-mediated membrane fusion.	Osaka Univ, Microbial Dis Res Inst, Dept Neurovirol, Suita, Osaka 5650871, Japan; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem, Shizuoka 4228526, Japan; Otsuka Pharmaceut Co Ltd, Inst Mol Sci Med, Tokushima 7710192, Japan; Hiroshima Univ, Sch Med, Dept Bacteriol, Hiroshima 7348551, Japan; Iwate Univ, Fac Agr, Dept Biosci & Technol, Morioka, Iwate 0208550, Japan; Natl Inst Hlth Sci, Div Biol Chem & Biol, Tokyo 1588501, Japan; Hamamatsu Univ Sch Med, Dept Biochem, Hamamatsu, Shizuoka 4313192, Japan	Osaka University; University of London; University College London; University of Shizuoka; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Otsuka Pharmaceutical; Hiroshima University; Iwate University; National Institute of Health Sciences - Japan; Hamamatsu University School of Medicine	Nakanishi, M (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Neurovirol, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	mahito@biken.osaka-u.ac.jp	Kondo, Toru/F-9420-2012; Eguchi, Akiko/E-3086-2010	Yasuo, Suzuki/0000-0003-3518-5642; Okabe, Jun/0000-0002-7196-0522				ASANO K, 1988, BIOCHEMISTRY-US, V27, P1321, DOI 10.1021/bi00404a035; BOUSSE T, 1994, VIROLOGY, V204, P506, DOI 10.1006/viro.1994.1564; CAMPADELLIFIUME G, 1988, J VIROL, V62, P159, DOI 10.1128/JVI.62.1.159-167.1988; Dahlquist F W, 1978, Methods Enzymol, V48, P270; DALLOCCHIO F, 1995, BIOCHEM BIOPH RES CO, V208, P36, DOI 10.1006/bbrc.1995.1301; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DROCOURT D, 1990, NUCLEIC ACIDS RES, V18, P4009, DOI 10.1093/nar/18.13.4009; Galinski M.S., 1991, PARAMYXOVIRUSES, P41; GERSHONI JM, 1986, BIOCHIM BIOPHYS ACTA, V856, P19, DOI 10.1016/0005-2736(86)90004-0; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HOLMGREN J, 1980, P NATL ACAD SCI-BIOL, V77, P1947, DOI 10.1073/pnas.77.4.1947; HOMMA M, 1973, J VIROL, V12, P1457, DOI 10.1128/JVI.12.6.1457-1465.1973; HORVATH CM, 1992, J VIROL, V66, P4564, DOI 10.1128/JVI.66.7.4564-4569.1992; HU XL, 1992, J VIROL, V66, P1528, DOI 10.1128/JVI.66.3.1528-1534.1992; IORIO RM, 1992, J GEN VIROL, V73, P1167, DOI 10.1099/0022-1317-73-5-1167; JOHNSON RM, 1989, J VIROL, V63, P819, DOI 10.1128/JVI.63.2.819-827.1989; KONDO T, 1993, J BIOL CHEM, V268, P21924; LAMB RA, 1993, VIROLOGY, V197, P1, DOI 10.1006/viro.1993.1561; Margolis L, 1998, FEBS LETT, V433, P5, DOI 10.1016/S0014-5793(98)00858-8; MARKWELL MAK, 1980, P NATL ACAD SCI-BIOL, V77, P5693, DOI 10.1073/pnas.77.10.5693; MARKWELL MAK, 1981, P NATL ACAD SCI-BIOL, V78, P5406, DOI 10.1073/pnas.78.9.5406; MARKWELL MAK, 1986, VIROLOGY, V155, P356, DOI 10.1016/0042-6822(86)90199-6; MARKWELL MAK, 1984, BIOCHIM BIOPHYS ACTA, V775, P7, DOI 10.1016/0005-2736(84)90228-1; MCCLAIN DS, 1994, VIROLOGY, V198, P690, DOI 10.1006/viro.1994.1081; MEKADA E, 1981, J BIOL CHEM, V256, P1225; MIURA N, 1982, EXP CELL RES, V141, P409, DOI 10.1016/0014-4827(82)90229-4; MIURA N, 1993, BIOCHEM BIOPH RES CO, V194, P1051, DOI 10.1006/bbrc.1993.1928; Mizuguchi H, 1996, BRIT J CANCER, V73, P472, DOI 10.1038/bjc.1996.83; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; MOSCONA A, 1991, J VIROL, V65, P2773, DOI 10.1128/JVI.65.6.2773-2777.1991; Nakanishi M, 1998, J CONTROL RELEASE, V54, P61, DOI 10.1016/S0168-3659(97)00220-4; NAKANISHI M, 1985, EXP CELL RES, V159, P399, DOI 10.1016/S0014-4827(85)80013-6; NAKANISHI M, 1982, EXP CELL RES, V142, P95, DOI 10.1016/0014-4827(82)90413-X; OKADA Y, 1993, METHOD ENZYMOL, V221, P18, DOI 10.1016/0076-6879(93)21005-S; OKADA Y, 1963, EXP CELL RES, V32, P417, DOI 10.1016/0014-4827(63)90182-4; OZAWA M, 1976, FEBS LETT, V70, P145, DOI 10.1016/0014-5793(76)80745-4; PORTNER A, 1987, VIROLOGY, V158, P61, DOI 10.1016/0042-6822(87)90238-8; PRINGLE CR, 1991, PARAMYXOVIRUSES, P1; RE GG, 1991, PARAMYXOVIRUSES, P275; Sambrook J., 2002, MOL CLONING LAB MANU; SERGEL T, 1993, VIROLOGY, V196, P831, DOI 10.1006/viro.1993.1541; SERGEL T, 1993, VIROLOGY, V193, P717, DOI 10.1006/viro.1993.1180; SUZUKI T, 1984, J BIOCHEM, V95, P1193, DOI 10.1093/oxfordjournals.jbchem.a134709; SUZUKI Y, 1983, J BIOCHEM-TOKYO, V93, P1621, DOI 10.1093/oxfordjournals.jbchem.a134301; SUZUKI Y, 1985, J BIOCHEM-TOKYO, V98, P1653, DOI 10.1093/oxfordjournals.jbchem.a135436; SUZUKI Y, 1985, J BIOCHEM-TOKYO, V97, P1189, DOI 10.1093/oxfordjournals.jbchem.a135164; TADOKORO J, 1958, BIKEN J, V1, P118; TAIRA H, 1995, ARCH VIROL, V140, P187, DOI 10.1007/BF01309734; TAKI T, 1995, ANAL BIOCHEM, V225, P24, DOI 10.1006/abio.1995.1102; Tanabayashi K, 1996, J VIROL, V70, P6112, DOI 10.1128/JVI.70.9.6112-6118.1996; TSURUDOME M, 1995, VIROLOGY, V213, P190, DOI 10.1006/viro.1995.1559; TSURUDOME M, 1986, J GEN VIROL, V67, P2259, DOI 10.1099/0022-1317-67-10-2259; UCHIDA T, 1979, J CELL BIOL, V80, P10, DOI 10.1083/jcb.80.1.10; UMEDA M, 1984, VIROLOGY, V133, P172, DOI 10.1016/0042-6822(84)90436-7; Watabe A, 1999, BBA-BIOMEMBRANES, V1416, P339, DOI 10.1016/S0005-2736(98)00238-7; WILLINGHAM MC, 1985, ATLAS IMMUNOFLUORESC; WU PS, 1980, J VIROL, V33, P304, DOI 10.1128/JVI.33.1.304-310.1980; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; YOSHIDA T, 1979, VIROLOGY, V92, P139, DOI 10.1016/0042-6822(79)90220-4; YOSHIDA T, 1982, VIROLOGY, V120, P329, DOI 10.1016/0042-6822(82)90034-4; YOUNGNER JS, 1980, COMPREHENSIVE VIROLO, V16, P73	63	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17549	17555		10.1074/jbc.M910004199	http://dx.doi.org/10.1074/jbc.M910004199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748180	hybrid			2022-12-27	WOS:000087485000048
J	Posas, F; Chambers, JR; Heyman, JA; Hoeffler, JP; de Nadal, E; Arino, J				Posas, F; Chambers, JR; Heyman, JA; Hoeffler, JP; de Nadal, E; Arino, J			The transcriptional response of yeast to saline stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE CASCADE; SACCHAROMYCES-CEREVISIAE; OSMOTIC-STRESS; PROTEIN PHOSPHATASE; GENE-EXPRESSION; GLYCOGEN-METABOLISM; PLASMA-MEMBRANE; TOLERANCE; PATHWAYS; ATPASE	Adaptation to changes in extracellular salinity is a critical event for cell survival. Genome-wide DNA chip analysis has been used to analyze the transcriptional response of yeast cells to saline stress. About 7% of the genes encoded in the yeast genome are induced more than 5-fold after a mild and brief saline shock (0.4 M NaCl, 10 min). Interestingly, most responsive genes showed a very transient expression pattern, as mRNA levels dramatically declined after 20 min in the presence of stress. A quite similar set of genes increased expression in cells subjected to higher saline concentrations (0.8 M NaCl), although in this case the response was delayed. Therefore, our data show that cells respond to saline stress by inducing the expression of a very large number of genes and suggest that stress adaptation requires regulation of many cellular aspects. The transcriptional induction of most genes that are strongly responsive to salt stress was highly or fully dependent on the presence of the stress-activated mitogen-activated protein kinase Hog1, indicating that the Hog1-mediated signaling pathway plays a key role in global gene regulation under saline stress conditions.	Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; Univ Pompeu Fabra, Dept Ciencies Expt Salut, Cell Signaling Unit, E-08003 Barcelona, Spain; Invitrogen Corp, Carlsbad, CA 92008 USA	Autonomous University of Barcelona; Pompeu Fabra University; Thermo Fisher Scientific	Arino, J (corresponding author), Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Ed V, E-08193 Barcelona, Spain.	J.Arino@cc.uab.es	Arino, Joaquin/D-3756-2011; de Nadal, Eulàlia/J-8178-2014; Posas, Francesc/K-1364-2013	Arino, Joaquin/0000-0002-6774-2987; de Nadal, Eulàlia/0000-0003-0039-5607; Posas, Francesc/0000-0002-4164-7076; Arino Carmona, Joaquin/0000-0002-0390-4270				Akhtar N, 1997, FEBS LETT, V403, P173, DOI 10.1016/S0014-5793(97)00048-3; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; [Anonymous], [No title captured]; BILSLANDMARCHES.E, 2000, IN PRESS MOL CELL BI; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; CLOTET J, 1995, EUR J BIOCHEM, V229, P207, DOI 10.1111/j.1432-1033.1995.tb20457.x; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dichtl B, 1997, EMBO J, V16, P7184, DOI 10.1093/emboj/16.23.7184; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hounsa CG, 1998, MICROBIOL-UK, V144, P671, DOI 10.1099/00221287-144-3-671; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; Lee JH, 1999, P NATL ACAD SCI USA, V96, P5873, DOI 10.1073/pnas.96.10.5873; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P544; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Mendizabal I, 1998, FEBS LETT, V425, P323, DOI 10.1016/S0014-5793(98)00249-X; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; NARASIMHAN ML, 1991, PLANT PHYSIOL, V97, P562, DOI 10.1104/pp.97.2.562; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nevoigt E, 1997, FEMS MICROBIOL REV, V21, P231, DOI 10.1111/j.1574-6976.1997.tb00352.x; Pardo JM, 1998, P NATL ACAD SCI USA, V95, P9681, DOI 10.1073/pnas.95.16.9681; Parrou JL, 1997, MICROBIOL-UK, V143, P1891, DOI 10.1099/00221287-143-6-1891; Planta RJ, 1999, YEAST, V15, P329, DOI 10.1002/(SICI)1097-0061(19990315)15:4<329::AID-YEA360>3.0.CO;2-C; Planta RJ, 1998, YEAST, V14, P471, DOI 10.1002/(SICI)1097-0061(19980330)14:5<471::AID-YEA241>3.0.CO;2-U; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Proft M, 1999, MOL CELL BIOL, V19, P537; Ramaswamy NT, 1998, GENETICS, V149, P57; Rep M, 1999, MICROBIOL-UK, V145, P715, DOI 10.1099/13500872-145-3-715; Rep M, 1999, MOL CELL BIOL, V19, P5474; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; van Helden J, 1998, J MOL BIOL, V281, P827, DOI 10.1006/jmbi.1998.1947; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x; Winderickx J, 1996, MOL GEN GENET, V252, P470, DOI 10.1007/s004380050252; Zahringer H, 1997, FEBS LETT, V412, P615, DOI 10.1016/S0014-5793(97)00868-5; ZHAO S, 1994, GENE, V146, P215, DOI 10.1016/0378-1119(94)90295-X	47	317	336	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17249	17255		10.1074/jbc.M910016199	http://dx.doi.org/10.1074/jbc.M910016199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748181	hybrid			2022-12-27	WOS:000087485000007
J	Tabuchi, A; Nakaoka, R; Amano, K; Yukimine, M; Andoh, T; Kuraishi, Y; Tsuda, M				Tabuchi, A; Nakaoka, R; Amano, K; Yukimine, M; Andoh, T; Kuraishi, Y; Tsuda, M			Differential activation of brain-derived neurotrophic factor gene promoters I and III by Ca2+ signals evoked via L-type voltage-dependent and N-methyl-D-aspartate receptor Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; BDNF-GENE; GLUTAMATE RECEPTORS; NMDA RECEPTORS; ACID RELEASE; EXPRESSION; TRANSCRIPTION; NEURONS; MECHANISM; PATHWAYS	Although the brain-derived neurotrophic factor (BDNF) gene is activated by the intracellular Ca2+ signals evoked via Ca2+ influx into neurons, little is known about how the activation of alternative BDNF gene promoters is controlled by the Ca2+ signals evoked via N-methyl-D-aspartate receptors (NMDA-R) and L-type voltage-dependent Ca2+ channels (L-VDCC), There is a critical range in the membrane depolarization caused by high K+ concentrations (25-50 mM KCI) for effective BDNF mRNA expression and transcriptional activation of BDNF gene promoters I and III (BDNF-PI and -PIII, respectively) in rat cortical culture. The increase in BDNF mRNA expression induced at high K+ was repressed not only by nicardipine, an antagonist for L-VDCC, but also by DL-amino-5-phosphonovalerate, an antagonist for NMDA-R, which was supported by the effects of antagonists on the Ca2+ influx. Although the promoter activations at 25 and 50 mM KCI were different, BDNF-PIII was activated by either the Ca2+ influx through NMDA-R or L-VDCC, whereas BDNF-PI was predominantly by the Ca2+ influx through L-VDCC. Direct stimulation of NMDA-R supported the activation of BDNF-PIII but not that of BDNF-PI, Thus, the alternative BDNF gene promoters responded differently to the intracellular Ca2+ signals evoked via NMDA-R and L-VDCC.	Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Appl Pharmacol, Toyama 9300194, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1500002, Japan	University of Toyama; University of Toyama; Japan Science & Technology Agency (JST)	Tsuda, M (corresponding author), Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Sugitani 2630, Toyama 9300194, Japan.							Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Berman FW, 1997, J NEUROCHEM, V69, P693; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bruns D, 1997, J NEUROSCI, V17, P1898; Cooper DMF, 1998, J BIOL CHEM, V273, P27703, DOI 10.1074/jbc.273.42.27703; Fujita Y, 1999, MOL BRAIN RES, V63, P316, DOI 10.1016/S0169-328X(98)00299-X; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Ichikawa D, 1998, MOL BRAIN RES, V56, P218, DOI 10.1016/S0169-328X(98)00062-X; Johnson CM, 1997, J NEUROSCI, V17, P6189; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; Sano K, 1996, BIOCHEM BIOPH RES CO, V229, P788, DOI 10.1006/bbrc.1996.1881; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Tabuchi A, 1996, J BIOL CHEM, V271, P31061, DOI 10.1074/jbc.271.49.31061; Tabuchi A, 1999, BIOCHEM BIOPH RES CO, V261, P233, DOI 10.1006/bbrc.1999.0974; Tabuchi A, 1998, BIOCHEM BIOPH RES CO, V253, P818, DOI 10.1006/bbrc.1998.9854; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Xia ZG, 1996, J NEUROSCI, V16, P5425; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	25	115	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17269	17275		10.1074/jbc.M909538199	http://dx.doi.org/10.1074/jbc.M909538199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748141	hybrid			2022-12-27	WOS:000087485000010
J	Galvan, M; Tsuboi, S; Fukuda, M; Baum, LG				Galvan, M; Tsuboi, S; Fukuda, M; Baum, LG			Expression of a specific glycosyltransferase enzyme regulates T cell death mediated by galectin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED OLIGOSACCHARIDES; POLY-N-ACETYLLACTOSAMINE; WISKOTT-ALDRICH SYNDROME; THYMIC EPITHELIAL-CELLS; ACETYLGLUCOSAMINYLTRANSFERASE-V; ENDOGENOUS LECTIN; HUMAN THYMOCYTES; LEUKEMIA-CELLS; GLYCANS; BIOSYNTHESIS	Galectin-1 induces apoptosis of immature thymocytes and activated T cells, suggesting that galectin-1 regulates cell death in the thymus during selection and in the periphery following an immune response. Although it is known that galectin-1 recognizes lactosamine (Gal-GlcNAc) as a minimal ligand, this disaccharide is ubiquitously expressed on a variety of cell surface glycoproteins. Thus, susceptibility to galectin-1 may be regulated by the presentation of lactosamine on specific oligosaccharide structures created by specific glycosyltransferase enzymes. The core 2 beta-1,6-N-acetylglucosaminyltransferase (core 2 GnT) creates a branched structure on O-glycans that can be elongated to present multiple lactosamine sequences. In the thymus, the core 2 GnT is expressed in galectin-1-sensitive thymocyte subsets, In the periphery, an oligosaccharide epitope created by the core 2 GnT is expressed on galectin-1-sensitive activated T-cells. In this report, we demonstrate that expression of the core 2 GnT was necessary and sufficient for galectin-1-induced death of murine T cell lines. In addition, over-expression of the core 2 GnT in mice increased the susceptibility of double positive thymocytes to galectin-1. These data demonstrate that expression of a specific glycosyltransferase can control susceptibility to galectin-1, suggesting that developmentally regulated glycosyltransferase expression may be a mechanism to modulate cell death during T cell development and function.	Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Burnham Inst, Glycobiol Program, La Jolla, CA 92037 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Sanford Burnham Prebys Medical Discovery Institute	Baum, LG (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	lbaum@mednet.ucla.edu			NATIONAL CANCER INSTITUTE [P30CA016042, R37CA033000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040118] Funding Source: NIH RePORTER; NCI NIH HHS [R37CA33000, CA16042] Funding Source: Medline; NIAID NIH HHS [R01AI40118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Barran P, 1997, GLYCOBIOLOGY, V7, P129, DOI 10.1093/glycob/7.1.129; Baum LG, 1996, J BIOL CHEM, V271, P10793, DOI 10.1074/jbc.271.18.10793; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BROCKHAUSEN I, 1991, CANCER RES, V51, P1257; Carlow DA, 1999, J IMMUNOL, V163, P1441; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; Di Virgilio S, 1999, GLYCOBIOLOGY, V9, P353, DOI 10.1093/glycob/9.4.353; DO KY, 1994, J BIOL CHEM, V269, P23456; Ellies LG, 1996, BLOOD, V88, P1725, DOI 10.1182/blood.V88.5.1725.bloodjournal8851725; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; FOX RI, 1983, J IMMUNOL, V131, P762; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; Harrington LE, 2000, J EXP MED, V191, P1241, DOI 10.1084/jem.191.7.1241; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; Jameson SC, 1998, CURR OPIN IMMUNOL, V10, P214, DOI 10.1016/S0952-7915(98)80251-3; Keppler OT, 1999, GLYCOBIOLOGY, V9, P557, DOI 10.1093/glycob/9.6.557; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; Mukasa R, 1999, INT IMMUNOL, V11, P259, DOI 10.1093/intimm/11.2.259; ODA Y, 1984, BIOCHEM BIOPH RES CO, V123, P1215, DOI 10.1016/S0006-291X(84)80262-4; Pace KE, 1999, J IMMUNOL, V163, P3801; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; Saito T, 1998, CRIT REV IMMUNOL, V18, P359, DOI 10.1615/CritRevImmunol.v18.i4.40; SAITOH O, 1991, BLOOD, V77, P1491; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; Sekine M, 1997, J BIOL CHEM, V272, P27246, DOI 10.1074/jbc.272.43.27246; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; Tomlinson-Jones A, 1994, J IMMUNOL, V153, P3426; TROWBRIDGE IS, 1978, EUR J IMMUNOL, V8, P716, DOI 10.1002/eji.1830081009; Tsuboi S, 1997, EMBO J, V16, P6364, DOI 10.1093/emboj/16.21.6364; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; Ujita M, 1999, J BIOL CHEM, V274, P16717, DOI 10.1074/jbc.274.24.16717; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; Vespa GNR, 1999, J IMMUNOL, V162, P799; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	43	110	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16730	16737		10.1074/jbc.M001117200	http://dx.doi.org/10.1074/jbc.M001117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747988	hybrid			2022-12-27	WOS:000087392200048
J	Mukhina, S; Stepanova, V; Traktouev, D; Poliakov, A; Beabealashvilly, R; Gursky, Y; Minashkin, M; Shevelev, A; Tkachuk, V				Mukhina, S; Stepanova, V; Traktouev, D; Poliakov, A; Beabealashvilly, R; Gursky, Y; Minashkin, M; Shevelev, A; Tkachuk, V			The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain - Characterization of interactions and contribution to chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; FIBROBLAST GROWTH-FACTOR; ENDOTHELIAL-CELLS; IN-VITRO; PROTHROMBIN FRAGMENT-1; PROTEOLYTIC CLEAVAGE; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; TYROSINE KINASE; LUNG-CARCINOMA	Urokinase plasminogen activator (uPA) is thought to exert its effects on cell growth, adhesion, and migration by mechanisms involving proteolysis and interaction with its cell surface receptor (uPAR). The functional properties of uPA and the significance of its various domains for chemotactic activity were analyzed using human airway smooth muscle cells (hAWSMC). The wild-type uPA (r-uPAwt), inactive urokinase with single mutation (His(204) to Gln) (r-uPA(H/Q)), urokinase with mutation of His(204) to Gln together with a deletion of growth factor-like domain (r-uPA(H/Q)-GFD), the catalytic domain of urokinase (r-uPA(LMW)), and its kringle domain (r-KD) were expressed in Escherichia coli. We demonstrate that glycosylated uPA, r-uPAFwt, r-uPA(H/Q), and r-uPA(H/Q)-GFD elicited similar chemotactic effects. Half-maximal chemotaxis (EC50) were apparent at approximately 2 nM with all the uPA variants. The kringle domain induced cell migration with an EC50 of about 6 nM, whereas the denaturated r-KD and r-uPA(LMW) were without effect, R-uPAwt-induced chemotaxis was dependent on an association with uPAR and a uPA-kringle domain-binding site, determined using a monoclonal uPAR antibody to prevent the uPA-uPAR interaction, and a monoclonal antibody to the uPA-kringle domain. The binding of iodinated r-uPAwt with hAWSMC was due to interaction with a high affinity binding site on the uPAR, and a lower affinity binding site on an unidentified cell surface target, which was mediated exclusively through the kringle domain of urokinase, Specific binding of r-uPA(H/Q)-GFD to hAWSMC involved an interaction with a single site whose characteristics were similar to those of the low affinity site of r-uPAwt binding to hAWSMC. uPAR-deficient HEK 293 cells specifically bound r-uPAwt and r-uPA(H/Q)-GFD via a single, similar type of binding site. These cells migrated when stimulated by r-uPA(H/Q)-GFD and uPAwt, but not r-uPA(LMW). HER 293 cells transfected with the uPAR cDNA expressed two classes of sites that bound r-uPAwt; however, only a single site was responsible for the binding of r-uPA(H/Q)-GFD. Together, these findings indicate that uPA-induced chemotaxis is dependent on the binding of the uPA-kringle to the membrane surface of cells and the association of uPA with uPAR.	Cardiol Res Ctr, Inst Expt Cardiol, Mol Endocrinol Lab, Moscow 121552, Russia	National Medical Research Center of Cardiology	Stepanova, V (corresponding author), Cardiol Res Ctr, Inst Expt Cardiol, Mol Endocrinol Lab, Cherepkovskaya St 15, Moscow 121552, Russia.	V.Stepanova@cardio.ru	Shevelev, Alexander Y/E-9517-2014; Gursky, Yaroslav/ABE-9915-2021; Bibilashvili, Robert/ABF-1131-2021; Poliakov, Alexei/C-6362-2008; Tkachuk, Vsevolod/AAE-1136-2022	Gursky, Yaroslav/0000-0002-6881-9464; Poliakov, Alexei/0000-0001-7428-4040; Shevelev, Alexander/0000-0003-4305-4132; Tkachuk, Vsevolod/0000-0002-7492-747X				ANICHINI E, 1994, EXP CELL RES, V213, P438, DOI 10.1006/excr.1994.1221; APPELLA E, 1987, J BIOL CHEM, V262, P4437; BARLOW GH, 1981, THROMB RES, V23, P541, DOI 10.1016/0049-3848(81)90177-8; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; Blasi F, 1999, APMIS, V107, P96, DOI 10.1111/j.1699-0463.1999.tb01531.x; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Carmeliet P, 1998, KIDNEY INT, V53, P1519, DOI 10.1046/j.1523-1755.1998.00936.x; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, CIRC RES, V81, P829; Castellino FJ, 1997, CIBA F SYMP, V212, P46; Cavallaro U, 1998, FASEB J, V12, P1027, DOI 10.1096/fasebj.12.11.1027; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; DUDANI AK, 1994, BIOCHEM CELL BIOL, V72, P126, DOI 10.1139/o94-019; Dudani AK, 1996, BRIT J HAEMATOL, V95, P168, DOI 10.1046/j.1365-2141.1996.7482367.x; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Fibbi G, 1998, P ASSOC AM PHYSICIAN, V110, P340; Fischer K, 1998, FEBS LETT, V438, P101, DOI 10.1016/S0014-5793(98)01279-4; FLESS GM, 1994, BIOCHEMISTRY-US, V33, P13492, DOI 10.1021/bi00249a038; Gherardi E, 1993, EXS, V65, P31; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; GYETKO MR, 1995, J LEUKOCYTE BIOL, V58, P533, DOI 10.1002/jlb.58.5.533; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HAJJAR KA, 1991, J BIOL CHEM, V266, P21962; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HARLOS K, 1987, FEBS LETT, V224, P97, DOI 10.1016/0014-5793(87)80429-5; Herbert JM, 1997, J BIOL CHEM, V272, P23585, DOI 10.1074/jbc.272.38.23585; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; ITAKURA Y, 1994, CANCER LETT, V83, P235, DOI 10.1016/0304-3835(94)90325-5; JACKSON CL, 1992, ANN NY ACAD SCI, V667, P141, DOI 10.1111/j.1749-6632.1992.tb51606.x; Ji WR, 1998, BIOCHEM BIOPH RES CO, V247, P414, DOI 10.1006/bbrc.1998.8825; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kindzelskii AL, 1997, BIOPHYS J, V73, P1777, DOI 10.1016/S0006-3495(97)78208-0; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; KRATASYUK G A, 1989, Biopolimery i Kletka, V5, P95; Lee TH, 1998, J BIOL CHEM, V273, P28805, DOI 10.1074/jbc.273.44.28805; MacDonald TJ, 1998, J NEURO-ONCOL, V40, P215, DOI 10.1023/A:1006150506789; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; MAZAR AP, 1992, FIBRINOLYSIS, V6, P49, DOI 10.1016/0268-9499(92)90094-X; Mohanam S, 1999, INT J ONCOL, V14, P169; MONDINO A, 1999, THROMB HAEMOST S, V2, P19; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NOVOKHATNY V, 1992, J BIOL CHEM, V267, P3878; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; Petty HR, 1996, IMMUNOL TODAY, V17, P209, DOI 10.1016/0167-5699(96)30013-3; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; Poliakov AA, 1999, J RECEPT SIGNAL TR R, V19, P939, DOI 10.3109/10799899909038433; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Rhim TY, 1998, BIOCHEM BIOPH RES CO, V252, P513, DOI 10.1006/bbrc.1998.9682; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; Sillaber C, 1997, J BIOL CHEM, V272, P7824, DOI 10.1074/jbc.272.12.7824; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Stepanova V, 1997, FEBS LETT, V414, P471, DOI 10.1016/S0014-5793(97)00993-9; Stepanova V, 1999, MOL CELL BIOCHEM, V195, P199, DOI 10.1023/A:1006936623106; STEPHENS RW, 1992, BIOCHEMISTRY-US, V31, P7572, DOI 10.1021/bi00148a019; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; Tkachuk V, 1996, CLIN EXP PHARMACOL P, V23, P759, DOI 10.1111/j.1440-1681.1996.tb01177.x; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; VANZONNEVELD AJ, 1986, J CELL BIOCHEM, V32, P169, DOI 10.1002/jcb.240320302; WANG WZ, 1995, CIRC RES, V77, P1095, DOI 10.1161/01.RES.77.6.1095; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wijnberg MJ, 1997, THROMB HAEMOSTASIS, V78, P880; Xue W, 1997, CANCER RES, V57, P1682	78	91	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16450	16458		10.1074/jbc.M909080199	http://dx.doi.org/10.1074/jbc.M909080199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10749881	hybrid			2022-12-27	WOS:000087392200009
J	Schmid, JA; Birbach, A; Hofer-Warbinek, R; Pengg, M; Burner, U; Furtmuller, PG; Binder, BR; de Martin, R				Schmid, JA; Birbach, A; Hofer-Warbinek, R; Pengg, M; Burner, U; Furtmuller, PG; Binder, BR; de Martin, R			Dynamics of NF kappa B and I kappa B alpha studied with green fluorescent protein (GFP) fusion proteins - Investigation of GFP-p65 binding to DNA by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; KINASE KINASE-1; 65-KD SUBUNIT; ACTIVATION; COMPLEX; EXPRESSION	We investigated the dynamics of nuclear transcription factor kappa B (NF-kappa KB) by using fusion proteins of the p65 subunit with mutants of green fluorescent protein (GFP). GFP-NF-kappa B chimeras were functional both in vitro and in vivo, as demonstrated by electrophoretic mobility shift assays and reporter gene studies. GFP-p65 was regulated by I kappa B alpha similar to wild type p65 and associated with its inhibitor even if both proteins were linked to a GFP protein. This finding was also verified by fluorescence resonance energy transfer (FRET) microscopy and studies showing mutual regulation of the intracellular localization of both GFP chimerae. Incubation of GFP-p65 with fluorescently labeled NF-kappa B-binding oligonucleotides also resulted in FRET. This effect was DNA sequence-specific and exhibited saturation characteristics. Application of stopped-flow fluorometry to measure the kinetics of FRET between GFP-p65 and oligonucleotides revealed a fast increase of acceptor fluorescence with a plateau after about 10 ms. The observed initial binding rate showed a temperature-dependent linear correlation with the oligonucleotide concentration. The association constant calculated according to pre-steady state kinetics was 3 x 10(6) M-1, although equilibrium binding studies implied significantly higher values. This observation suggests that the binding process involves a rapid association with a rather high off-rate followed by a conformational change resulting in an increase of the association constant.	Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria; Univ Agr Sci, Inst Chem, Dept Biochem, A-1190 Vienna, Austria	University of Vienna; University of Natural Resources & Life Sciences, Vienna	Schmid, JA (corresponding author), Univ Vienna, Dept Vasc Biol & Thrombosis Res, Brunnerstr 59, A-1235 Vienna, Austria.	johannes.schmid@univie.ac.at	Furtmüller, Paul G./Y-5819-2018; Schmid, Johannes A./C-7659-2009	Furtmüller, Paul G./0000-0002-1199-2469; Schmid, Johannes A./0000-0002-6586-3507				ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Carlotti F, 1999, J BIOL CHEM, V274, P37941, DOI 10.1074/jbc.274.53.37941; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Clegg Robert M., 1995, Current Opinion in Biotechnology, V6, P103, DOI 10.1016/0958-1669(95)80016-6; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; de Martin R, 1999, MUTAT RES-REV MUTAT, V437, P231, DOI 10.1016/S1383-5742(99)00089-7; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; HERMAN B, 1989, METHOD CELL BIOL, V30, P219; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Johnson RS, 1998, J MOL BIOL, V283, P353, DOI 10.1006/jmbi.1998.2101; LU T, 1994, J BIOL CHEM, V269, P30694; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Periasamy A, 1999, METHOD CELL BIOL, V58, P293; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Szollosi J, 1998, CYTOMETRY, V34, P159; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; vanLeeuwen HC, 1997, EMBO J, V16, P2043, DOI 10.1093/emboj/16.8.2043; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	46	80	85	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17035	17042		10.1074/jbc.M000291200	http://dx.doi.org/10.1074/jbc.M000291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747893	hybrid			2022-12-27	WOS:000087392200089
J	Xu, Q; Stickel, S; Roberts, RJ; Blaser, MJ; Morgan, RD				Xu, Q; Stickel, S; Roberts, RJ; Blaser, MJ; Morgan, RD			Purification of the novel endonuclease, Hpy188I, and cloning of its restriction-modification genes reveal evidence of its horizontal transfer to the Helicobacter pylori genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODIFICATION SYSTEM; CRYSTAL-STRUCTURE; PATHOGENICITY ISLAND; PVUII ENDONUCLEASE; DNA; SEQUENCE; EXPRESSION; METHYLTRANSFERASE; IDENTIFICATION; SPECIFICITY	We have isolated a novel restriction endonuclease, Hpy188I, from Helicobacter pylori strain J188. Hpy188I recognizes the unique sequence, TCNGA, and cleaves the DNA between nucleotides N and G in its recognition sequence to generate a one-base 3' overhang. Cloning and sequence analysis of the Hpy188I modification gene in strain J188 reveal that hpy188IM has a 1299-base pair (bp) open reading frame (ORF) encoding a 432-amino acid product. The predicted protein sequence of M.Hpy188I contains conserved motifs typical of amino-methyltransferases, and Western blotting indicates that it is an N-6 adenine methyltransferase. Downstream of hpy188IM is a 513-bp ORF encoding a 170-amino acid product, that has a 41-bp overlap with hpy188IM. The predicted protein sequence from this ORF matches the amino acid sequence obtained from purified Hpy188I, indicating that it encodes the endonuclease. The Hpy188I R-M genes are not present in either strain of H. pylori that has been completely sequenced but are found in two of 11 H. pylori strains tested. The significantly lower G + C content of the Hpy188I R-M genes implies that they have been introduced relatively recently during the evolution of the H. pylori genome.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Div Infect Dis, Nashville, TN 37232 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Vanderbilt University; Vanderbilt University	Morgan, RD (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.			Roberts, Richard/0000-0002-4348-0169	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053707] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53707] Funding Source: Medline; NIGMS NIH HHS [GM56534] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x; Akopyants NS, 1998, P NATL ACAD SCI USA, V95, P13108, DOI 10.1073/pnas.95.22.13108; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anton BP, 1997, GENE, V187, P19, DOI 10.1016/S0378-1119(96)00638-5; ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; Belfort M, 1995, J BIOL CHEM, V270, P30237, DOI 10.1074/jbc.270.51.30237; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; Berg DE, 1997, BIOESSAYS, V19, P86, DOI 10.1002/bies.950190114; BERTANI G, 1953, J BACTERIOL, V65, P113, DOI 10.1128/JB.65.2.113-121.1953; BLASER MJ, 1994, J CLIN INVEST, V94, P4, DOI 10.1172/JCI117336; BRASSARD S, 1995, GENE, V157, P69, DOI 10.1016/0378-1119(94)00734-A; BROOKS JE, 1991, NUCLEIC ACIDS RES, V19, P841, DOI 10.1093/nar/19.4.841; BROWN NL, 1980, J MOL BIOL, V140, P143, DOI 10.1016/0022-2836(80)90360-5; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; COVER TL, 1990, INFECT IMMUN, V58, P603, DOI 10.1128/IAI.58.3.603-610.1990; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GINGERAS TR, 1978, NUCLEIC ACIDS RES, V5, P4105, DOI 10.1093/nar/5.11.4105; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GOODWIN CS, 1989, INT J SYST BACTERIOL, V39, P397, DOI 10.1099/00207713-39-4-397; HATTMAN S, 1978, J MOL BIOL, V124, P701, DOI 10.1016/0022-2836(78)90178-X; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; Kita K, 1999, J BACTERIOL, V181, P6822, DOI 10.1128/JB.181.21.6822-6827.1999; LURIA SE, 1952, J BACTERIOL, V64, P557, DOI 10.1128/JB.64.4.557-569.1952; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; Peek RM, 1998, P ASSOC AM PHYSICIAN, V110, P531; RAMAKRISHNA J, 1995, GASTROENTEROLOGY, V108, pA200, DOI 10.1016/0016-5085(95)23460-8; Sambrook J., 2002, MOL CLONING LAB MANU; Schleif R. F., 1981, PRACTICAL METHODS MO; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P4731, DOI 10.1093/nar/10.15.4731; STANKEVICIUS K, 1995, GENE, V157, P49, DOI 10.1016/0378-1119(94)00796-U; Stollar B D, 1980, Methods Enzymol, V70, P70; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TUMMURU MKR, 1993, INFECT IMMUN, V61, P1799, DOI 10.1128/IAI.61.5.1799-1809.1993; VAISVILA R, 1995, GENE, V157, P81, DOI 10.1016/0378-1119(94)00793-R; WAITEREES PA, 1991, J BACTERIOL, V173, P5207, DOI 10.1128/jb.173.16.5207-5219.1991; WILSON GG, 1988, GENE, V74, P281, DOI 10.1016/0378-1119(88)90304-6; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; Xu Q, 1997, J BACTERIOL, V179, P6807, DOI 10.1128/jb.179.21.6807-6815.1997	44	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17086	17093		10.1074/jbc.M910303199	http://dx.doi.org/10.1074/jbc.M910303199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748211	hybrid			2022-12-27	WOS:000087392200096
J	Noraz, N; Schwarz, K; Steinberg, M; Dardalhon, V; Rebouissou, C; Hipskind, R; Friedrich, W; Yssel, H; Bacon, K; Taylor, N				Noraz, N; Schwarz, K; Steinberg, M; Dardalhon, V; Rebouissou, C; Hipskind, R; Friedrich, W; Yssel, H; Bacon, K; Taylor, N			Alternative antigen receptor (TCR) signaling in T cells derived from ZAP-70-deficient patients expressing high levels of Syk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; PROTEIN-TYROSINE KINASES; SERUM-FREE MEDIUM; DIFFERENTIAL ACTIVATION; THYMOCYTE DEVELOPMENT; JNK ACTIVATION; ZAP-70; INTERLEUKIN-2; LYMPHOCYTES; APOPTOSIS	ZAP-70-deficient patients present with nonfunctional CD4+ T cells in the periphery. We find that a subset of primary ZAP-70-deficient T cells, expressing high levels of the related protein-tyrosine kinase Syk, can proliferate in vitro. These cells (denoted herein as Syk(hi)/ZAP-70(-) T cells) provide a unique model in which the contribution of Syk to TCR-mediated responses can be explored in a nontransformed background. Importantly, CD3-induced responses, such as tyrosine phosphorylation of cellular substrates (LAT, SLP76, and PLC-gamma 1), as well as calcium mobilization, which are defective in T cells expressing neither ZAP-70 nor Syk, are observed in Syk(hi)/ZAP-70(-) T cells. However, Sykh'/ZAP-70- T cells differ from control T cells with respect to the T cell antigen receptor (TCR)-mediated activation of the MAPK cascades: extracellular signal-regulated kinase activity and recruitment of the JNK and p38 stress-related MAPK pathways are diminished. This distinct phenotype of Syk(hi)/ZAP-70(-) T cells is associated with a profound decrease in CD3-mediated interleukin 2 secretion and proliferation relative to control T cells. Thus, ZAP-70 and Syk appear to play distinct roles in transducing a TCR-mediated signal.	CNRS, UMR 5535, Inst Genet Mol Montpellier, F-34293 Montpellier 5, France; Univ Ulm, Dept Transfus Med, D-89081 Ulm, Germany; Univ Ulm, Dept Pediat, D-89081 Ulm, Germany; INSERM, U454, F-34295 Montpellier, France; Neurocrine Biosci Inc, Dept Immunol, San Diego, CA 92121 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Ulm University; Ulm University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Neurocrine Biosciences	Noraz, N (corresponding author), CNRS, UMR 5535, Inst Genet Mol Montpellier, 1919 Route de Mende, F-34293 Montpellier 5, France.		Yssel, Hans/C-6406-2009; Yssel, Hans/AFV-2907-2022; Taylor, Naomi/H-4016-2014; noraz, nelly/H-9477-2017	Yssel, Hans/0000-0001-7454-1836; Yssel, Hans/0000-0001-7454-1836; noraz, nelly/0000-0003-4076-9773				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Bosselut R, 1999, J EXP MED, V190, P1517, DOI 10.1084/jem.190.10.1517; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GELFAND EW, 1995, J EXP MED, V182, P1057, DOI 10.1084/jem.182.4.1057; Gong Q, 1997, IMMUNITY, V7, P369, DOI 10.1016/S1074-7613(00)80358-1; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Li YQ, 1999, IMMUNOLOGY, V96, P524; Matsuda S, 1999, J BIOL CHEM, V274, P34515, DOI 10.1074/jbc.274.49.34515; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Nagata K, 1997, IMMUNITY, V7, P559, DOI 10.1016/S1074-7613(00)80377-5; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; PAHWA R, 1989, P NATL ACAD SCI USA, V86, P5069, DOI 10.1073/pnas.86.13.5069; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; RaziWolf Z, 1996, P NATL ACAD SCI USA, V93, P2903, DOI 10.1073/pnas.93.7.2903; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SPITS H, 1982, J IMMUNOL, V128, P95; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Taylor N, 1997, BLOOD, V89, P388, DOI 10.1182/blood.V89.2.388; Taylor N, 1996, BLOOD, V87, P3103, DOI 10.1182/blood.V87.8.3103.bloodjournal8783103; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; VanParijs L, 1997, J IMMUNOL, V158, P3738; Wiest DL, 1997, IMMUNITY, V6, P663, DOI 10.1016/S1074-7613(00)80442-2; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	40	49	50	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15832	15838		10.1074/jbc.M908568199	http://dx.doi.org/10.1074/jbc.M908568199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748099	Green Published, hybrid			2022-12-27	WOS:000087291400032
J	Takami, Y; Nakayama, T				Takami, Y; Nakayama, T			N-terminal region, C-terminal region, nuclear export signal, and deacetylation activity of histone deacetylase-3 are essential for the viability of the DT40 chicken B cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT CAUSES CHANGES; TRANSCRIPTIONAL REPRESSION; TARGETED DISRUPTION; GEL-ELECTROPHORESIS; PROTEIN-PATTERNS; GENE-EXPRESSION; MAMMALIAN-CELLS; RPD3; CHROMATIN; COMPLEX	Histone deacetylases (HDACs) are involved in the deacetylation of core histones, which is related to transcription regulation in eukaryotes through alterations in the chromatin structure. We cloned cDNA and genomic DNA encoding a chicken HDAC, chHDAC-3, which was localized in both the nuclei and cytoplasm in DT40 cells. Although one of the two chHDAC-3 alleles could be disrupted with high efficiency, no homozygous mutants were obtained after a second round of the gene-targeting technique due to its necessity for DT40 cells. We introduced a chHDAC-3 transgene under the control of a tetracycline-responsive promoter into the heterozygous mutant and subsequently disrupted the remaining endogenous chHDAC-3 allele to generate the homozygous chHDAC-3-deficient mutant, Delta chHDAC-3/FHDAC3. Inhibition of the expression of the regulatable chHDAC-3 transgene caused apoptotic cell death of the mutant. Complementation experiments involving truncated and missense chHDAC-3 mutant proteins revealed that the 1-23 N-terminal sequence, the 389-417 C-terminal sequence, the nuclear export signal, and the deacetylation activity of chHDAC-3 were essential for the cell viability. Taken together, these results indicate that chHDAC-3 plays an essential role, probably as a scavenger in the cytoplasm, in the proliferation of DT40 cells.	Miyazaki Med Coll, Dept Biochem, Kiyotake, Miyazaki 8891692, Japan	University of Miyazaki	Nakayama, T (corresponding author), Miyazaki Med Coll, Dept Biochem, Kiyotake, Miyazaki 8891692, Japan.							Ahmad A, 1999, J BIOL CHEM, V274, P16646, DOI 10.1074/jbc.274.23.16646; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Khochbin S, 1997, FEBS LETT, V419, P157, DOI 10.1016/S0014-5793(97)01423-3; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mannervik M, 1999, P NATL ACAD SCI USA, V96, P6797, DOI 10.1073/pnas.96.12.6797; MIYAZAKI J, 1989, GENE, V79, P269; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Pennisi E, 1997, SCIENCE, V275, P155, DOI 10.1126/science.275.5297.155; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sambrook J., 2002, MOL CLONING LAB MANU; SEGUCHI K, 1995, J MOL BIOL, V254, P869, DOI 10.1006/jmbi.1995.0662; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Takami Y, 1997, J MOL BIOL, V265, P394, DOI 10.1006/jmbi.1996.0733; Takami Y, 1997, GENES CELLS, V2, P711, DOI 10.1046/j.1365-2443.1997.1550353.x; Takami Y, 1999, J BIOL CHEM, V274, P23977, DOI 10.1074/jbc.274.34.23977; Takami Y, 1995, J BIOL CHEM, V270, P30664, DOI 10.1074/jbc.270.51.30664; TAKAMI Y, 1995, J MOL BIOL, V250, P420, DOI 10.1006/jmbi.1995.0387; Takami Y, 1997, BBA-GENE STRUCT EXPR, V1354, P105, DOI 10.1016/S0167-4781(97)00077-8; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKEDA S, 1992, P NATL ACAD SCI USA, V89, P4023, DOI 10.1073/pnas.89.9.4023; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolffe AP, 1997, GENES CELLS, V2, P291, DOI 10.1046/j.1365-2443.1997.1260323.x; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	51	84	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16191	16201		10.1074/jbc.M908066199	http://dx.doi.org/10.1074/jbc.M908066199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748092	hybrid			2022-12-27	WOS:000087291400080
J	Madge, LA; Pober, JS				Madge, LA; Pober, JS			A phosphatidylinositol 3-kinase/Akt pathway, activated by tumor necrosis factor or interleukin-1, inhibits apoptosis but does not activate NF kappa B in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-BETA-RECEPTOR; PROTEIN-KINASE-B; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; PHOSPHOINOSITIDE 3-KINASE; ADHESION MOLECULES; TYROSINE KINASE; SKELETAL-MUSCLE; SH2 DOMAIN	Tumor necrosis factor (TNF) and interleukin-1 (IL-1) activate the transcription of both anti-apoptotic and pro-inflammatory gene products in human endothelial cells (EC) via NF kappa B. Here we report that both TNF and IL-1 activate the anti-apoptotic protein kinase Akt in growth factor and serum-deprived EC, assessed by Western blotting for phospho-Akt, Phosphorylation of Akt is blocked by LY294002 or wortmannin, inhibitors of phosphatidylinositol 3-kinase (PIS-kinase), Consistent with these biochemical observations, TNF and IL-1 reduce apoptosis caused by growth factor and serum deprivation, and this action is also blocked by LY294002. Although Akt has been reported to activate NF kappa B, LY294002 does not prevent TNF- or IL-1-induced degradation of I kappa B alpha, beta, or epsilon, transcription of NF kappa B-dependent E-selectin or ICAM-1 promoter-reporter genes, or surface expression of E-selectin or ICAM-1 in human EC, LY294002 potentiates the activation of mitogen-activated protein kinases and stress-activated protein kinases by TNF and IL-1, suggesting Akt inhibits these responses. We conclude that TNF and IL-1 activate a PI 3-kinase/Akt anti-apoptotic pathway and that the anti-apoptotic effects of Akt are independent of NF kappa B. Moreover, the PI 3-kinase/Akt pathway does not play a major role in the pro-inflammatory responses of EC to TNF or IL-1.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT 06536 USA	Yale University	Pober, JS (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol & Transplanta, 333 Cedar St, New Haven, CT 06536 USA.	Jordan.Pober@yale.edu			NHLBI NIH HHS [HL-36007] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeLisser HM, 1998, AM J RESP CELL MOL, V19, P533, DOI 10.1165/ajrcmb.19.4.f145; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hanna AN, 1999, J BIOL CHEM, V274, P12722, DOI 10.1074/jbc.274.18.12722; Hildt E, 1999, J EXP MED, V189, P1707, DOI 10.1084/jem.189.11.1707; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Karmann K, 1996, J EXP MED, V184, P173, DOI 10.1084/jem.184.1.173; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Min W, 1997, J IMMUNOL, V159, P3508; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Ozes ON, 1999, NATURE, V401, P82; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Saklatvala J, 1999, BIOCHEM SOC SYMP, P63; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SLOWIK MR, 1993, AM J PATHOL, V143, P1724; STOLPEN AH, 1986, AM J PATHOL, V123, P16; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu XXS, 1998, J BIOL CHEM, V273, P33230, DOI 10.1074/jbc.273.50.33230; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	82	188	208	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15458	15465		10.1074/jbc.M001237200	http://dx.doi.org/10.1074/jbc.M001237200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748004	hybrid			2022-12-27	WOS:000087128300092
J	Arlotta, P; Tai, AKF; Manfioletti, G; Clifford, C; Jay, G; Ono, SJ				Arlotta, P; Tai, AKF; Manfioletti, G; Clifford, C; Jay, G; Ono, SJ			Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR HMGI-C; INTERFERON-BETA ENHANCEOSOME; TRANSCRIPTION FACTORS; CHROMOSOMAL-PROTEINS; MESENCHYMAL TUMORS; GENE-EXPRESSION; DNA-BINDING; HISTONE H1; MOUSE; I/Y	Chromosomal translocations in human lipomas frequently create fusion transcripts encoding high mobility group (HMG) I-C DNA-binding domains and C-terminal sequences from different presumed transcription factors, suggesting a potential role for HMG I-C in the development of lipomas. To evaluate the role of the HMG I-C component, the three DNA-binding domains of HMG I-C have now been expressed in transgenic mice. Despite the ubiquitous expression of the truncated HMG I-C protein, the transgenic mice develop a selective abundance of fat tissue early in life, show marked adipose tissue inflammation, and have an abnormally high incidence of lipomas. These findings demonstrate that the DNA-binding domains of HMG I-C, in the absence of a C-terminal fusion partner, are sufficient to perturb adipogenesis and predispose to lipomas. We provide data supporting the central utility of this animal model as a tool to understand the molecular mechanisms underlying the development of one of the most common kind of human benign tumors.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Comm Immunol, Boston, MA 02114 USA; Brigham & Womens Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Schepens Eye Res Inst, Boston, MA 02114 USA; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34127 Trieste, Italy; Charles River Labs, Dept Pathol, Wilmington, MA 01887 USA; OriGene Technol Inc, Rockville, MD 20850 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; Harvard University; Brigham & Women's Hospital; Schepens Eye Research Institute; University of Trieste	Ono, SJ (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, Comm Immunol, 20 Staniford St, Boston, MA 02114 USA.			MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601; Jay, Gregory/0000-0003-1517-8488	Fondazione Telethon Funding Source: Custom; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049661] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM49661] Funding Source: Medline; Telethon [196/B] Funding Source: Medline	Fondazione Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon)		Abdulkadir SA, 1998, J LEUKOCYTE BIOL, V64, P681, DOI 10.1002/jlb.64.5.681; ABDULKADIR SA, 1995, J EXP MED, V182, P487, DOI 10.1084/jem.182.2.487; Arlotta P, 1997, J BIOL CHEM, V272, P29904, DOI 10.1074/jbc.272.47.29904; ASHAR HR, 1995, CELL, V82, P57; Battista S, 1999, CANCER RES, V59, P4793; BIEBERICH C, 1986, MOL CELL BIOL, V6, P1339, DOI 10.1128/MCB.6.4.1339; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHAU KY, 1995, NUCLEIC ACIDS RES, V23, P4262, DOI 10.1093/nar/23.21.4262; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fedele M, 1996, CANCER RES, V56, P1896; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; Geurts JMW, 1998, ONCOGENE, V16, P865, DOI 10.1038/sj.onc.1201609; GIANCOTTI V, 1993, EUR J BIOCHEM, V213, P825, DOI 10.1111/j.1432-1033.1993.tb17825.x; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; Goodwin G, 1998, INT J BIOCHEM CELL B, V30, P761, DOI 10.1016/S1357-2725(98)00016-8; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KAZMIERCZAK B, 1995, CANCER RES, V55, P2497; Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; LEGER H, 1995, MOL CELL BIOL, V15, P3738; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; PAULAUSKIS JD, 1989, BIOCHEM BIOPH RES CO, V158, P690, DOI 10.1016/0006-291X(89)92776-9; REEVES R, 1990, J BIOL CHEM, V265, P8573; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; ROBBINS T, 1989, PATHOLOGIC BASIS DIS, P1374; Rogalla P, 1996, AM J PATHOL, V149, P775; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Shannon MF, 1998, IMMUNOL CELL BIOL, V76, P461, DOI 10.1046/j.1440-1711.1998.00770.x; Tallini G, 1997, AM J PATHOL, V151, P37; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Ward SB, 1998, NUCLEIC ACIDS RES, V26, P2923, DOI 10.1093/nar/26.12.2923; Wunderlich V, 1997, J CANCER RES CLIN, V123, P133, DOI 10.1007/BF01214665; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; YOSHIOKA T, 1991, MOL CELL BIOL, V11, P5479, DOI 10.1128/MCB.11.11.5479; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	49	123	127	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14394	14400		10.1074/jbc.M000564200	http://dx.doi.org/10.1074/jbc.M000564200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10747931	hybrid			2022-12-27	WOS:000087006900054
J	Colpas, GJ; Hausinger, RP				Colpas, GJ; Hausinger, RP			In vivo and in vitro kinetics of metal transfer by the Klebsiella aerogenes urease nickel metallochaperone, UreE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; RHODOSPIRILLUM-RUBRUM; ACCESSORY PROTEIN; COPPER CHAPERONE; PURIFICATION; METALLOCENTER; GENE; HYPB	The urease accessory protein encoded by ureE from Klebsiella aerogenes is proposed to deliver Ni(II) to the urease apoprotein during enzyme activation. Native UreE possesses a histidine-rich region at its carboxyl terminus that binds several equivalents of Ni2+; however, a truncated form of this protein (H144*UreE) binds only 2 Ni2+ per dimer and is functionally active (Brayman, T. G., and Hausinger, R. P. (1996) J. Bacteriol. 178, 5410-5416), The urease activation kinetics were studied in vivo by monitoring the development of urease activity upon adding Ni2+ to spectinomycin-treated Escherichia coli cells that expressed the complete K. aerogenes urease gene cluster with altered forms of ureE. Site-specific alterations of H144*UreE decrease the rate of in vivo urease activation, with the most dramatic changes observed for the H96A, H110A, D111A, and H112A substitutions. Notably, urease activity in cells producing H96A/H144*UreE was lower than cells containing a ureE deletion. Prior studies had shown that H110A and H112A variants each bound a single Ni2+ per dimer with elevated K-d values compared with control H144*UreE, whereas the H96A and D111A variants bound 2 Ni2+ per dimer with unperturbed R, values (Colpas, G. J., Brayman, T. G., Ming, L.-J., and Hausinger, R. P. (1999) Biochemistry 38, 4078-4088). To understand why cells containing the latter two proteins showed reduced rates of urease activation, we characterized their metal binding/dissociation kinetics and compared the results to those obtained for H144*UreE. The truncated protein was shown to sequentially bind two Ni2+ with k(1) similar to 18 and k(2) similar to 100 M-1 s(-1) and with dissociation rates k(-1) similar to 3 x 10(-3) and k(-2) similar to 10(-4) s(-1). Similar apparent rates of binding and dissociation were noted for the two mutant proteins, suggesting that altered H144*UreE interactions with Ni2+ do not account for the changes in cellular urease activation. These conclusions are further supported by in vitro experiments demonstrating that addition of H144*UreE to urease apoprotein. activation mixtures inhibited the rate and extent of urease formation. Our results highlight the importance of other urease accessory proteins in assisting UreE-dependent urease maturation.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Hausinger, RP (corresponding author), Michigan State Univ, Dept Biochem, 160 Giltner Hall, E Lansing, MI 48824 USA.			Hausinger, Robert/0000-0002-3643-2054	NIDDK NIH HHS [DK 45686, R01 DK045686] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045686] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brayman TG, 1996, J BACTERIOL, V178, P5410, DOI 10.1128/jb.178.18.5410-5416.1996; Cobine P, 1999, FEBS LETT, V445, P27, DOI 10.1016/S0014-5793(99)00091-5; Colpas GJ, 1998, J BIOL INORG CHEM, V3, P150, DOI 10.1007/s007750050216; Colpas GJ, 1999, BIOCHEMISTRY-US, V38, P4078, DOI 10.1021/bi982435t; CORSINI A, 1962, ANAL CHEM, V34, P1090, DOI 10.1021/ac60189a018; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DIEBLER H, 1969, Pure and Applied Chemistry, V20, P93, DOI 10.1351/pac196920010093; FROST JW, 1984, BIOCHEMISTRY-US, V23, P4470, DOI 10.1021/bi00314a036; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; FURAHASHI S, 1969, INORG CHEM, V10, P2159; Hausinger RP, 1997, J BIOL INORG CHEM, V2, P279, DOI 10.1007/s007750050133; Hausinger RP, 1996, MECH METALLOCENTER A; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; Kerby RL, 1997, J BACTERIOL, V179, P2259, DOI 10.1128/jb.179.7.2259-2266.1997; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; LEE MH, 1990, J BACTERIOL, V172, P4427, DOI 10.1128/jb.172.8.4427-4431.1990; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; MAIER T, 1995, EUR J BIOCHEM, V230, P133, DOI 10.1111/j.1432-1033.1995.tb20543.x; MULROONEY SB, 1989, J GEN MICROBIOL, V135, P1769; PARK IS, 1995, SCIENCE, V267, P1156, DOI 10.1126/science.7855593; Press W.H., 1992, NUMERICAL RECIPES C, P683; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Soriano A, 1999, P NATL ACAD SCI USA, V96, P11140, DOI 10.1073/pnas.96.20.11140; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; TANAKA M, 1967, ANAL CHIM ACTA, V39, P437, DOI 10.1016/S0003-2670(01)80538-9; Watt RK, 1998, J BIOL CHEM, V273, P10019, DOI 10.1074/jbc.273.16.10019; WAUGH R, 1986, BIOCHIMIE, V68, P157, DOI 10.1016/S0300-9084(86)81080-X; WEATHERBURN MW, 1967, ANAL CHEM, V39, P971, DOI 10.1021/ac60252a045; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597	36	49	50	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10731	10737		10.1074/jbc.275.15.10731	http://dx.doi.org/10.1074/jbc.275.15.10731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753863	hybrid			2022-12-27	WOS:000086466600005
J	Andersen, OM; Christensen, LL; Christensen, PA; Sorensen, ES; Jacobsen, C; Moestrup, SK; Etzerodt, M; Thogersen, HC				Andersen, OM; Christensen, LL; Christensen, PA; Sorensen, ES; Jacobsen, C; Moestrup, SK; Etzerodt, M; Thogersen, HC			Identification of the minimal functional unit in the low density lipoprotein receptor-related protein for binding the receptor-associated protein (RAP) - A conserved acidic residue in the complement-type repeats is important for recognition of RAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH REPEAT; APOLIPOPROTEIN-E RECEPTOR-2; GROWTH-FACTOR PRECURSOR; LDL-RECEPTOR; LIGAND-BINDING; ALPHA-2-MACROGLOBULIN RECEPTOR; TERMINAL DOMAIN; HIGH-AFFINITY; 3-DIMENSIONAL STRUCTURE; MOLECULAR CHAPERONE	The low density lipoprotein receptor-related protein (LRP), a member of the low density lipoprotein receptor family, mediates the internalization of a diverse set of ligands, The ligand binding sites are located in different regions of clusters consisting of similar to 40 residues, cysteine-rich complement-type repeats (CRs), The 39-40-kDa receptor-associated protein, a folding chaperone/escort protein required for efficient transport of functional LRP to the cell surface, is an antagonist of all identified ligands. To analyze the multisite inhibition by RAP in ligand binding of LRP, we have used an Escherichia coli expression system to produce fragments of the entire second ligand binding cluster of LRP (CR3-10). By ligand affinity chromatography and surface plasmon resonance analysis, we show that RAP binds to all two-repeat modules except CR910, CR10 differs from other repeats in cluster II by not containing a surface-exposed conserved acidic residue between Cys(IV) and Cys(V). By site-directed mutagenesis and ligand competition analysis, we provide evidence for a crucial importance of this conserved residue for RAP binding. We provide experimental evidence showing that two adjacent complement-type repeats, both containing a conserved acidic residue, represent a minimal unit required for efficient binding to RAP.	Aarhus Univ, Gene Express Lab, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Biol Mol & Struct, Prot Chem Lab, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Biochem Med, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University; Aarhus University	Thogersen, HC (corresponding author), Aarhus Univ, Gene Express Lab, Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.		Moestrup, Søren Kragh/AAD-1735-2019; Moestrup, Søren Kragh/A-1403-2014; Christensen, Peter/AAW-5221-2020; Andersen, Olav/N-2777-2017	Moestrup, Søren Kragh/0000-0003-3862-2107; Andersen, Olav/0000-0003-4226-3354; Sorensen, Esben Skipper/0000-0002-7050-3354; Christensen, Peter Astrup/0000-0001-7380-1237				BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BIERI S, 1995, FEBS LETT, V371, P341, DOI 10.1016/0014-5793(95)00939-7; BIERI S, 1995, BIOCHEMISTRY-US, V34, P13059, DOI 10.1021/bi00040a017; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Christie RH, 1996, J NEUROPATH EXP NEUR, V55, P491, DOI 10.1097/00005072-199604000-00012; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; Dong Y, 1998, BIOCHEM BIOPH RES CO, V251, P784, DOI 10.1006/bbrc.1998.9545; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; ELLGAARD L, 1995, J IMMUNOL METHODS, V180, P53, DOI 10.1016/0022-1759(94)00298-B; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; HEARN MTW, 1987, METHOD ENZYMOL, V135, P102; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Hey PJ, 1998, GENE, V216, P103, DOI 10.1016/S0378-1119(98)00311-4; Hjalm G, 1996, EUR J BIOCHEM, V239, P132, DOI 10.1111/j.1432-1033.1996.0132u.x; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; Huang W, 1999, J BIOL CHEM, V274, P14130, DOI 10.1074/jbc.274.20.14130; Jacobsen L, 1996, J BIOL CHEM, V271, P31379, DOI 10.1074/jbc.271.49.31379; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Medved LV, 1999, J BIOL CHEM, V274, P717, DOI 10.1074/jbc.274.2.717; Mikhailenko I, 1999, J CELL SCI, V112, P3269; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; Neels JG, 1998, FIBRINOLYSIS PROTEOL, V12, P219, DOI 10.1016/S0268-9499(98)80016-7; Nielsen PR, 1997, P NATL ACAD SCI USA, V94, P7521, DOI 10.1073/pnas.94.14.7521; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; Petersen CM, 1996, EMBO J, V15, P4165, DOI 10.1002/j.1460-2075.1996.tb00791.x; Rall SC, 1998, J BIOL CHEM, V273, P24152, DOI 10.1074/jbc.273.37.24152; Rettenberger PM, 1999, J BIOL CHEM, V274, P8973, DOI 10.1074/jbc.274.13.8973; Rong LJ, 1998, P NATL ACAD SCI USA, V95, P8467, DOI 10.1073/pnas.95.15.8467; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; Savonen R, 1999, J BIOL CHEM, V274, P25877, DOI 10.1074/jbc.274.36.25877; Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; Sun XM, 1999, EUR J BIOCHEM, V262, P230, DOI 10.1046/j.1432-1327.1999.00394.x; Tauris J, 1998, FEBS LETT, V429, P27, DOI 10.1016/S0014-5793(98)00559-6; Vash B, 1998, BLOOD, V92, P3277, DOI 10.1182/blood.V92.9.3277.421k50_3277_3285; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531	53	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21017	21024		10.1074/jbc.M000507200	http://dx.doi.org/10.1074/jbc.M000507200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10747921	hybrid			2022-12-27	WOS:000088230600009
J	Sjoholm, A; Zhang, QM; Welsh, N; Hansson, A; Larsson, O; Tally, M; Berggren, PO				Sjoholm, A; Zhang, QM; Welsh, N; Hansson, A; Larsson, O; Tally, M; Berggren, PO			Rapid Ca2+ influx and diacylglycerol synthesis in growth hormone-mediated islet beta-cell mitogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEINS; HA-RAS ONCOGENE; PHOSPHOLIPASE-D; CYCLIC-AMP; SIGNAL TRANSDUCTION; PANCREATIC-ISLETS; INSULIN-SECRETION; TISSUE-CULTURE; FREE CALCIUM	Growth hormone (GH) is an important mitogenic stimulus for the insulin-producing beta-cell. We investigated the effects of GH on Ca2+ handling and diacylglycerol (DAG) and cAMP formation in the beta-cell. GH elicited a rapid increase in the cytoplasmic free [Ca2+], which required extracellular Ca2+ and was also blocked by pertussis toxin or protein kinase C (PKC) inhibition. GH also elevated islet DAG content, which should lead to PKC activation. Pertussis toxin and PKC inhibitors obliterated the mitogenicity of GH, suggesting involvement of GTP-binding proteins. PKC activation stimulated beta-cell proliferation, and it also activated phospholipase D. Islet cAMP content was not elevated by GH. Addition of a specific protein kinase A antagonist failed to influence the mitogenicity of GH, whereas a stimulatory cAMP agonist stimulated beta-cell replication. We conclude that GH rapidly increases the beta-cell cytoplasmic free [Ca2+] and also evokes a similar increase in DAG content via a phosphatidylcholine-specific phospholipase C, but does not affect mitogen-activated protein kinases, phospholipase D, or the cAMP signaling pathway. This rise in DAG may be of importance in translation of the stimulatory signal of GH into a proliferative response by the beta-cell, which seems to occur through GTP-binding proteins and PKC-dependent mechanisms.	Karolinska Inst, Karolinska Hosp, Rolf Luft Ctr Diabet Res, Dept Mol Med,Endocrine& Diabet Unit, S-17176 Stockholm, Sweden; Uppsala Univ, Dept Med Cell Biol, S-75123 Uppsala, Sweden	Karolinska Institutet; Karolinska University Hospital; Uppsala University	Sjoholm, A (corresponding author), Karolinska Inst, Karolinska Hosp, Rolf Luft Ctr Diabet Res, Dept Mol Med,Endocrine& Diabet Unit, L6-01B, S-17176 Stockholm, Sweden.	ake@enk.ks.se		Berggren, Per-Olof/0000-0001-8991-413X				AHN NG, 1990, J BIOL CHEM, V265, P11487; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; ARKHAMMAR P, 1994, J BIOL CHEM, V269, P2743; BERGGREN PO, 1989, BIOCHEM J, V259, P701, DOI 10.1042/bj2590701; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; BRELJE TC, 1994, DIABETES, V43, P263, DOI 10.2337/diabetes.43.2.263; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CATALIOTO RM, 1990, BIOCHEM BIOPH RES CO, V173, P840, DOI 10.1016/S0006-291X(05)80863-0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; DUNLOP M, 1992, ENDOCRINOLOGY, V130, P93, DOI 10.1210/en.130.1.93; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; ESTACION M, 1993, CELL CALCIUM, V14, P439, DOI 10.1016/0143-4160(93)90003-O; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; Gaur S, 1996, AM J PHYSIOL-CELL PH, V270, pC1485, DOI 10.1152/ajpcell.1996.270.5.C1485; Gaur S, 1996, AM J PHYSIOL-CELL PH, V270, pC1478, DOI 10.1152/ajpcell.1996.270.5.C1478; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HARPUR AG, 1992, ONCOGENE, V7, P1347; HELLERSTROM C, 1979, DIABETES, V28, P769, DOI 10.2337/diab.28.8.769; HELLERSTROM C, 1991, ACTA PAEDIATR SCAND, P55; HELLERSTROM C, 1988, PATHOGENESIS NONINSU, P79; HERINGTON AC, 1994, MOL CELL ENDOCRINOL, V100, P39, DOI 10.1016/0303-7207(94)90276-3; HINEGARDNER RT, 1971, ANAL BIOCHEM, V39, P197, DOI 10.1016/0003-2697(71)90476-3; HORSEMAN ND, 1994, ENDOCRINOLOGY, V135, P1289, DOI 10.1210/en.135.4.1289; ILONDO MM, 1994, BIOCHEM BIOPH RES CO, V202, P391, DOI 10.1006/bbrc.1994.1940; JOHNSON RM, 1990, ENDOCRINOLOGY, V127, P2099, DOI 10.1210/endo-127-5-2099; KISSANE JM, 1958, J BIOL CHEM, V233, P184; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; LOBIE PE, 1994, J BIOL CHEM, V269, P21330; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MOLDRUP A, 1990, J BIOL CHEM, V265, P8686; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; MOOLENAAR WH, 1986, ANN NY ACAD SCI, V488, P491; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NIVET V, 1993, METABOLISM, V42, P1291, DOI 10.1016/0026-0495(93)90127-A; Persaud SJ, 1996, BIOCHEM J, V313, P119, DOI 10.1042/bj3130119; PREISS J, 1986, J BIOL CHEM, V261, P8597; RABINOVITCH A, 1980, J CLIN INVEST, V66, P1065, DOI 10.1172/JCI109935; ROGERS SA, 1989, P NATL ACAD SCI USA, V86, P6363, DOI 10.1073/pnas.86.16.6363; ROSENBERG L, 1988, DIABETES, V37, P334, DOI 10.2337/diabetes.37.3.334; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; ROUPAS P, 1994, TRENDS ENDOCRIN MET, V5, P154, DOI 10.1016/1043-2760(94)90012-4; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCHWARTZ Y, 1992, ENDOCRINOLOGY, V131, P772, DOI 10.1210/en.131.2.772; Sekine N, 1996, ENDOCRINOLOGY, V137, P1841, DOI 10.1210/en.137.5.1841; Sjoholm A, 1996, DIABETES, V45, P1057, DOI 10.2337/diabetes.45.8.1057; SJOHOLM A, 1992, FEBS LETT, V311, P85, DOI 10.1016/0014-5793(92)81373-T; SJOHOLM A, 1990, AM J PHYSIOL, V259, pC828, DOI 10.1152/ajpcell.1990.259.5.C828; SJOHOLM A, 1993, AM J PHYSIOL, V264, pC501, DOI 10.1152/ajpcell.1993.264.3.C501; Sjoholm A, 1997, DIABETES, V46, P1141, DOI 10.2337/diabetes.46.7.1141; SJOHOLM A, 1994, EUR J ENDOCRINOL S1, V130, P35; SMAL J, 1989, P NATL ACAD SCI USA, V86, P4705, DOI 10.1073/pnas.86.12.4705; SMAL J, 1989, FEBS LETT, V244, P465, DOI 10.1016/0014-5793(89)80584-8; Stout LE, 1997, ENDOCRINOLOGY, V138, P1592, DOI 10.1210/en.138.4.1592; SWENNE I, 1982, BIOSCIENCE REP, V2, P867, DOI 10.1007/BF01114892; SWENNE I, 1982, DIABETES, V31, P754, DOI 10.2337/diab.31.9.754; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; TURK J, 1993, DIABETES, V42, P367, DOI 10.2337/diabetes.42.3.367; VILLEREAL ML, 1992, REV PHYSIOL BIOCH P, V119, P67; WANG Z, 1993, AM J PHYSIOL, V265, pC1239, DOI 10.1152/ajpcell.1993.265.5.C1239	69	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21033	21040		10.1074/jbc.M001212200	http://dx.doi.org/10.1074/jbc.M001212200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10748000	hybrid			2022-12-27	WOS:000088230600011
J	Howard, KM; Olson, MS				Howard, KM; Olson, MS			The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PAF ACETYLHYDROLASE; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; CELLS; HYPERTENSION; LIPOPROTEIN; SECRETION; NECROSIS; KUPFFER; SEPSIS	The production of platelet-activating factor (PAF) and PAF-like phospholipids that also bind the PAF receptor are implicated in numerous pathological situations including bacterial endotoxemia and injury-induced oxidative damage. PAF and PAF-like phospholipids are hydrolyzed and inactivated by the enzyme PAF acetylhydrolase, In the intact rat, infusion of lipopolysaccharide (LPS) into a mesenteric vein served as an acute, liver-focused model of endotoxemia. We determined that the liver responds to LPS exposure with the production of plasma-type PAF acetylhydrolase mRNA and protein expression specifically in the resident macrophages of the liver. Liver macrophages, defined immunohistochemically using antibodies against ED1, present in livers from saline-treated animals contained no detectable PAF acetylhydrolase, Twenty-four hours following in vivo LPS administration, immunohistochemistry detected a slight increase in the number of ED1 staining cells and the ED1-positive cells now contained an abundance of PAF acetylhydrolase. The systemic administration of LPS resulted in increased expression of PAF acetylhydrolase in several tissues. Of the tissues examined, the greatest increase in PAF acetylhydrolase expression was observed in lung followed by increases in spleen, liver, kidney, and thymus, Additionally, the expression of PAF acetylhydrolase mRNA increased in circulating leukocytes and in peritoneal macrophages in response to systemic exposure to LPS, We examined the regulation of PAF acetylhydrolase expression and demonstrated the administration of the PAF receptor antagonists, BN 50739 and WEB 2170, inhibited by 50% the increase in PAF acetylhydrolase expression in response to LPS, The up-regulation of the plasma-type PAF acetylhydrolase expression constitutes an important mechanism for elevating the local and systemic ability to inactivate PAF and oxidized phospholipids in order to minimize PAF-mediated pathophysiology consequent from exposure to endotoxin, The abundance of PAF acetylhydrolase production in the liver lobule likely limits endotoxin-mediated tissue damage due to PAF synthesis.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Howard, KM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NIDDK NIH HHS [DK-33538] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033538] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asano K, 1999, BIOCHEM BIOPH RES CO, V261, P511, DOI 10.1006/bbrc.1999.1066; Cao Y, 1998, J BIOL CHEM, V273, P4012, DOI 10.1074/jbc.273.7.4012; CAPLAN MS, 1990, J PEDIATR-US, V116, P960, DOI 10.1016/S0022-3476(05)80661-4; CAPLAN MS, 1990, AM REV RESPIR DIS, V142, P1258, DOI 10.1164/ajrccm/142.6_Pt_1.1258; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIJKSTRA CD, 1985, ADV EXP MED BIOL, V186, P409; ENDO S, 1994, RES COMMUN CHEM PATH, V83, P289; FURUKAWA M, 1993, PEDIATR RES, V34, P237, DOI 10.1203/00006450-199308000-00027; GANDHI CR, 1992, BIOCHEM J, V281, P485, DOI 10.1042/bj2810485; GRAHAM RM, 1994, CRIT CARE MED, V22, P204, DOI 10.1097/00003246-199402000-00009; Hewett J A, 1993, Pharmacol Rev, V45, P382; Howard KM, 1997, J BIOL CHEM, V272, P27543, DOI 10.1074/jbc.272.44.27543; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; KNOOK DL, 1976, EXP CELL RES, V99, P444, DOI 10.1016/0014-4827(76)90605-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEADE CJ, 1994, J LIPID MEDIAT CELL, V9, P205; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; NARAHARA H, 1993, ARCH BIOCHEM BIOPHYS, V301, P275, DOI 10.1006/abbi.1993.1144; SATOH K, 1991, J CLIN INVEST, V87, P476, DOI 10.1172/JCI115020; SATOH K, 1989, PROSTAGLANDINS, V37, P673; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; Svetlov SI, 1996, ARCH BIOCHEM BIOPHYS, V327, P113, DOI 10.1006/abbi.1996.0099; TETTA C, 1990, INT ARCH ALLER A IMM, V91, P244, DOI 10.1159/000235124; Tew DG, 1996, ARTERIOSCL THROM VAS, V16, P591, DOI 10.1161/01.ATV.16.4.591; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0	28	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19891	19896		10.1074/jbc.M001462200	http://dx.doi.org/10.1074/jbc.M001462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748027	hybrid			2022-12-27	WOS:000087941300063
J	Kinyamu, HK; Fryer, CJ; Horwitz, KB; Archer, TK				Kinyamu, HK; Fryer, CJ; Horwitz, KB; Archer, TK			The mouse mammary tumor virus promoter adopts distinct chromatin structures in human breast cancer cells with and without glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-BINDING; IN-VIVO; HORMONE RECEPTOR; MMTV PROMOTER; HYPERSENSITIVE SITES; GENE-EXPRESSION; ACTIVATION; SEQUENCE; NUCLEOSOME; ELEMENT	Steroid receptors represent a class of transcription regulators that act in part by overcoming the often repressive nature of chromatin to modulate gene activity. The mouse mammary tumor virus (MMTV) promoter is a useful model for studying transcriptional regulation by steroid hormone receptors in the context of chromatin. The chromatin architecture of the promoter prevents the assembly of basal transcription machinery and binding of ubiquitous transcription factors. However, in human breast carcinoma T47D cells lacking the glucocorticoid receptor (GR), but expressing the progesterone receptor (PR), nucleosome B (nuc B) assumes a constitutively hypersensitive chromatin structure. This correlation led us to test the hypothesis that the chromatin structure of nuc B was dependent on GR expression in T47D cells. To examine this possibility, we stably cotransfected the MMTV promoter and the GR into T47D cells that lacked both the GR and the PR. We found that in T47D cells that lack both the GR and the PR or express only the GR, nuc B assumes a constitutively "open" chromatin structure, which allows hormone independent access by restriction endonucleases and transcription factors. These results suggest that in GR(+)/pr(-) T47D cells, the MMTV chromatin structure permits GR transcriptional activation, independent of chromatin remodeling.	NIEHS, Chromatin & Gene Express Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Western Ontario, Dept Obstet & Gynaecol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 4L6, Canada; Univ Colorado, Hlth Sci Ctr, Div Endocrinol Diabet & Metab, Denver, CO 80262 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Archer, TK (corresponding author), NIEHS, Chromatin & Gene Express Sect, Reprod & Dev Toxicol Lab, NIH, 111 Alexander Dr,POB 12233,MD E4-06, Res Triangle Pk, NC 27709 USA.	archer1@niehs.nih.gov	Archer, Trevor K/E-5191-2019; kinyamu, Harriet/AAG-9069-2019	kinyamu, Harriet/0000-0002-2377-7408; Horwitz, Kathryn/0000-0001-7402-6455; Archer, Trevor K/0000-0001-7651-3644	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES071006, Z01ES071007, Z01ES071006] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; Archer TK, 1997, METHODS, V11, P235, DOI 10.1006/meth.1996.0410; ARCHER TK, 1995, J STEROID BIOCHEM, V53, P421, DOI 10.1016/0960-0760(95)00088-H; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; Archer TK, 1997, TRENDS ENDOCRIN MET, V8, P384, DOI 10.1016/S1043-2760(97)00159-8; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARCHER TK, 1989, P 2 INT CBT S STER T, P221; Armenante F, 1999, NUCLEIC ACIDS RES, V27, P4483, DOI 10.1093/nar/27.22.4483; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; ELLSWORTH JL, 1995, J LIPID RES, V36, P383; Fryer CJ, 1998, J BIOL CHEM, V273, P1175, DOI 10.1074/jbc.273.2.1175; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; Giamarchi C, 1999, ONCOGENE, V18, P533, DOI 10.1038/sj.onc.1202317; Graunke DM, 1999, NUCLEIC ACIDS RES, V27, P3881, DOI 10.1093/nar/27.19.3881; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Hager G L, 1988, Cancer Treat Res, V40, P267; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kornberg Roger D., 1999, Trends in Cell Biology, V9, pM46, DOI 10.1016/S0962-8924(99)01679-7; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; LU Q, 1992, J MOL BIOL, V225, P985, DOI 10.1016/0022-2836(92)90099-6; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MYMRYK JS, 1995, MOL ENDOCRINOL, V9, P1825, DOI 10.1210/me.9.12.1825; MYMRYK JS, 1995, MOL CELL BIOL, V15, P26, DOI 10.1128/MCB.15.1.26; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; ONATE SA, 1995, SCIENCE, V270, P1354; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PRIOLEAU MN, 1995, EMBO J, V14, P5073, DOI 10.1002/j.1460-2075.1995.tb00189.x; Quivy JP, 1996, J MOL BIOL, V256, P249, DOI 10.1006/jmbi.1996.0083; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; SARTORIUS CA, 1994, CANCER RES, V54, P3868; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TRUSS M, 1992, J STEROID BIOCHEM, V43, P365, DOI 10.1016/0960-0760(92)90071-P; VANHOLDE K, 1995, CHROMATIN STRUCTURE, P1; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WOLFFE AP, 1992, FASEB J, V6, P3354, DOI 10.1096/fasebj.6.15.1464369; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	50	22	23	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20061	20068		10.1074/jbc.M001142200	http://dx.doi.org/10.1074/jbc.M001142200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10751396	hybrid			2022-12-27	WOS:000087941300085
J	Atsumi, G; Murakami, M; Kojima, K; Hadano, A; Tajima, M; Kudo, I				Atsumi, G; Murakami, M; Kojima, K; Hadano, A; Tajima, M; Kudo, I			Distinct roles of two intracellular phospholipase A(2)s in fatty acid release in the cell death pathway - Proteolytic fragment of type IVA cytosolic phospholipase A(2)alpha inhibits stimulus-induced arachidonate release, whereas that of type VICa2+-independent phospholipase A(2) augments spontaneous fatty acid release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR ACETYLHYDROLASE; PROSTAGLANDIN E-2 GENERATION; MURINE P388D(1) MACROPHAGES; TUMOR-NECROSIS-FACTOR; HL-60 CELLS; APOPTOSIS; CALCIUM; EXPRESSION; CLONING; IIA	Cytosolic phospholipase A(2)alpha (cPLA(2)alpha; type IVA), an essential initiator of stimulus-dependent arachidonic acid (AA) metabolism, underwent caspase-mediated cleavage at Asp(522) during apoptosis. Although the resultant catalytically inactive N-terminal fragment, cPLA(2)(1-522), was inessential for cell growth and the apoptotic process, it was constitutively associated with cellular membranes and attenuated both the A23187-elicited immediate and the interleukin-1-dependent delayed phases of AA release by several phospholipase A(2)s (PLA(2)s) involved in eicosanoid generation, without affecting spontaneous AA release by PLA(2)s implicated in phospholipid remodeling. Confocal microscopic analysis revealed that cPLA(2)(1-522) was distributed in the nucleus. Pharmacological and transfection studies revealed that Ca2+-independent PLA(2) (iPLA(2); type VI), a phospholipid remodeling PLA(2), contributes to the cell death-associated increase in fatty acid release. iPLA(2) was cleaved at Asp(183) by caspase-3 to a truncated enzyme lacking most of the first ankyrin repeat, and this cleavage resulted in increased iPLA(2) functions, iPLA(2) had a significant influence on cell growth or death, according to cell type. Collectively, the caspase-truncated form of cPLA(2)alpha behaves like a naturally occurring dominant-negative molecule for stimulus-induced AA release, rendering apoptotic: cells no longer able to produce lipid mediators, whereas the caspase-truncated form of iPLA(2) accelerates phospholipid turnover that may lead to apoptotic membranous changes.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan	Showa University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.							ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Adam-Klages S, 1998, J IMMUNOL, V161, P5687; Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; Alzola E, 1998, J BIOL CHEM, V273, P30208, DOI 10.1074/jbc.273.46.30208; Atsumi G, 1997, BBA-LIPID LIPID MET, V1349, P43, DOI 10.1016/S0005-2760(97)00082-9; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; DOLE VP, 1960, J BIOL CHEM, V235, P2595; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Luschen S, 1998, BIOCHEM BIOPH RES CO, V253, P92, DOI 10.1006/bbrc.1998.9754; Ma ZM, 1999, J BIOL CHEM, V274, P9607, DOI 10.1074/jbc.274.14.9607; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; Tada K, 1998, J IMMUNOL, V161, P5008; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; VoelkelJohnson C, 1996, J IMMUNOL, V156, P201; Winkler JD, 1996, J PHARMACOL EXP THER, V279, P956; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	58	146	152	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18248	18258		10.1074/jbc.M000271200	http://dx.doi.org/10.1074/jbc.M000271200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10747887	hybrid			2022-12-27	WOS:000087659400047
J	Chang, DK; Ricciardiello, L; Goel, A; Chang, CL; Boland, CR				Chang, DK; Ricciardiello, L; Goel, A; Chang, CL; Boland, CR			Steady-state regulation of the human DNA mismatch repair system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; TUMOR-CELLS; GENE HMSH2; EXPRESSION; HMLH1; BETA; HETERODIMER; DEFICIENCY; MUTATIONS	Steady-state levels of human DNA mismatch repair (MMR) transcripts and proteins were measured in MMR-proficient and -deficient cell lines by the newly developed competitive quantitative reverse transcription- polymerase chain reaction and Western analysis normalized with purified proteins. In MMR-proficient cells, hMSH2 is the most abundant MMR protein and is expressed 3 to 5 times more than hMLH1. The hMLH1 protein was expressed 1.5 to 2.5 times more than hPMS2. Steady-state levels of mRNA expression correlated well with protein expression, hMSH2-mutated LoVo cells did not express detectable hMSH3 or hMSH6 proteins, Similarly, hMLH1-mutated HCT116 cells did not express detectable hMLH1 or hPMS2 protein, whereas in hMLH1-restored HCT116+ch3 cells, hPMS2 protein was reexpressed. In hMSH6-mutated HCT15 cells, both hMSH3 protein and mRNA were Increased. In SV40-transformed lung fibroblasts, all MMR mRNAs and proteins examined were expressed at levels 1.5-5-fold higher than in their nontransformed counterpart. The steady-state levels of MMR proteins indicate that substantially more hMutS proteins, which are involved in DNA mismatch recognition, are present in comparison with the hMutL proteins. Stability of hMSH3 and hMSH6 proteins appears to depend upon the presence of the hMSH2 protein, and, similarly, the stability of the hPMS2 protein depends upon hMLH1. When the hMSH6 is mutationally inactivated, hMSH3 increases by both transcriptional up-regulation and enhanced protein stability. A balanced up-regulation of all of the components was seen after viral transformation in a fibroblast model. Quantitative changes of the MMR components are a potential mechanism to modify the DNA MMR capabilities of a cell.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Vet Affairs Med Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Boland, CR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.		Chang, Christina/B-9650-2009; Ricciardiello, Luigi/K-7269-2016	Ricciardiello, Luigi/0000-0003-2568-6208; Goel, Ajay/0000-0003-1396-6341	NATIONAL CANCER INSTITUTE [R01CA072851] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA72851] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; BOYER JC, 1995, CANCER RES, V55, P6063; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; GIRARDI AJ, 1966, ANN MED EXP BIOL FEN, V44, P242; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; Ito E, 1999, BIOCHEM BIOPH RES CO, V256, P488, DOI 10.1006/bbrc.1999.0368; Iwahashi Y, 1998, GENE, V213, P141, DOI 10.1016/S0378-1119(98)00187-5; Kane MF, 1997, CANCER RES, V57, P808; KOI M, 1994, CANCER RES, V54, P4308; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kolodner RD, 1999, CANCER RES, V59, P5068; Leach FS, 1996, CANCER RES, V56, P235; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Marra G, 1996, ONCOGENE, V13, P2189; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; NICOLAIDES NC, 1995, GENOMICS, V29, P329, DOI 10.1006/geno.1995.9997; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Perucho M, 1996, NAT MED, V2, P630, DOI 10.1038/nm0696-630; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Umar A, 1998, GENETICS, V148, P1637; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; Wei QY, 1997, CANCER RES, V57, P1673; Wei QY, 1998, CANCER EPIDEM BIOMAR, V7, P309; WILSON TM, 1995, CANCER RES, V55, P5146; Yanagisawa Y, 1998, BIOCHEM BIOPH RES CO, V243, P738, DOI 10.1006/bbrc.1998.8165; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	39	131	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18424	18431		10.1074/jbc.M001140200	http://dx.doi.org/10.1074/jbc.M001140200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10747992	hybrid			2022-12-27	WOS:000087659400070
J	O'Brien, TW; Liu, JG; Sylvester, JE; Mougey, EB; Fischel-Ghodsian, N; Thiede, B; Wittmann-Liebold, B; Graack, HR				O'Brien, TW; Liu, JG; Sylvester, JE; Mougey, EB; Fischel-Ghodsian, N; Thiede, B; Wittmann-Liebold, B; Graack, HR			Mammalian mitochondrial ribosomal proteins (4) - Amino acid sequencing, characterization, and identification of corresponding gene sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; TRANSLATION; PREDICTION; EXPRESSION; HOMOLOG; FETAL; S12	Mitochondrial ribosomal proteins (MRPs) are required for the translation of all 13 mitochondrial encoded genes in humans. It has been speculated that mutations and polymorphisms in the human MRPs may be a primary cause of some oxidative phosphorylation disorders or modulate the severity and tissue specificity of pathogenic mitochondrial DNA mutations. Although the sequences of most of the yeast MRPs are known, only very few mammalian and nearly no human MRPs have been completely characterized, MRPs differ greatly in sequence, and sometimes biochemical properties, between different species, not allowing easy recognition by sequence homology, Therefore, the Mammalian Mitochondrial Ribosomal Consortium is using a direct approach of purifying individual mammalian (bovine) MRPs, determining their N-terminal and/or internal peptide sequences using different protein sequencing techniques, and using the resulting sequence information for screening expressed sequence tags and genomic data bases to determine human, mouse, and rat homologues of the bovine proteins, Two proteins of the large and three proteins of the small ribosomal subunit have been analyzed in this manner, Three of them represent "new," i.e. formerly unknown mammalian mitochondrial ribosomal protein classes. Only one of these three different MRPs shows significant sequence similarities to known ribosomal proteins. In one case, the corresponding human genomic DNA sequences were found in the data bases, and the exon/intron structure was determined.	Free Univ Berlin, Inst Biol Genet, AG Kress, D-14195 Berlin, Germany; Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Nemours Childrens Clin, Jacksonville, FL 32207 USA; Cedars Sinai Med Ctr, Ahmanson Dept Pediat, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90048 USA; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	Free University of Berlin; State University System of Florida; University of Florida; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Graack, HR (corresponding author), Free Univ Berlin, Inst Biol Genet, AG Kress, Arnimallee 7, D-14195 Berlin, Germany.			Mougey, Edward/0000-0003-1190-6660	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004092] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01-DC04092] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRANDA SS, 1995, J BIOL CHEM, V270, P27366, DOI 10.1074/jbc.270.45.27366; CAHILL A, 1995, ANAL BIOCHEM, V232, P47, DOI 10.1006/abio.1995.9962; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; Fischel-Ghodsian N, 1998, MOL GENET METAB, V65, P97, DOI 10.1006/mgme.1998.2751; *GCG WISC PACK, 1997, GCG WISC SOFTW PACK; Goldschmidt-Reisin S, 1998, J BIOL CHEM, V273, P34828, DOI 10.1074/jbc.273.52.34828; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; GRAACK HR, 1988, FEBS LETT, V242, P4, DOI 10.1016/0014-5793(88)80975-X; GRAACK HR, 1992, EUR J BIOCHEM, V206, P373, DOI 10.1111/j.1432-1033.1992.tb16937.x; Graack HR, 1999, BIOCHEMISTRY-US, V38, P16569, DOI 10.1021/bi991543s; Grossman LI, 1996, BIOESSAYS, V18, P983, DOI 10.1002/bies.950181208; HEROLD M, 1987, J BIOL CHEM, V262, P8826; Johnson DF, 1998, GENOMICS, V52, P363, DOI 10.1006/geno.1998.5448; KITAKAWA M, 1991, BIOCHIMIE, V73, P813, DOI 10.1016/0300-9084(91)90061-5; Koc EC, 1999, BIOCHEM BIOPH RES CO, V266, P141, DOI 10.1006/bbrc.1999.1785; Martinez R, 1997, CANCER RES, V57, P1180; Marty L, 1996, J BIOL CHEM, V271, P11468, DOI 10.1074/jbc.271.19.11468; MATTHEWS DE, 1978, FEBS LETT, V86, P76, DOI 10.1016/0014-5793(78)80102-1; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; O'Brien T W, 1996, Methods Enzymol, V264, P237, DOI 10.1016/S0076-6879(96)64024-5; O'Brien TW, 1999, J BIOL CHEM, V274, P36043, DOI 10.1074/jbc.274.51.36043; OBRIEN TW, 1990, BIOCHIM BIOPHYS ACTA, V1050, P174, DOI 10.1016/0167-4781(90)90162-U; Otto A, 1996, ELECTROPHORESIS, V17, P1643, DOI 10.1002/elps.1150171027; OU JH, 1987, NUCLEIC ACIDS RES, V15, P8919, DOI 10.1093/nar/15.21.8919; PIETROMONACO SF, 1986, J MOL EVOL, V24, P110, DOI 10.1007/BF02099958; SCHIEBER GL, 1982, J BIOL CHEM, V257, P8781; Shah ZH, 1997, GENE, V204, P55, DOI 10.1016/S0378-1119(97)00521-0; TSANG P, 1995, HUM MOL GENET, V4, P1499, DOI 10.1093/hmg/4.9.1499; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482	34	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18153	18159		10.1074/jbc.M909762199	http://dx.doi.org/10.1074/jbc.M909762199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10751423	hybrid			2022-12-27	WOS:000087659400035
J	Seelig, A; Blatter, XL; Frentzel, A; Isenberg, C				Seelig, A; Blatter, XL; Frentzel, A; Isenberg, C			Phospholipid binding of synthetic talin peptides provides evidence for an intrinsic membrane anchor of talin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-MEMBRANES; SUBSTANCE-P; PHOSPHATIDYLCHOLINE MEMBRANES; CIRCULAR-DICHROISM; ADHESION PLAQUES; TAIL FRAGMENT; ACTIN-BINDING; INTACT TALIN; VINCULIN; PROTEIN	Talin, an actin-binding protein, is assumed to anchor at the membrane via an intrinsic amino acid sequence, Three N-terminal talin fragments, 21-39 (S19), 287-301 (H18), and 385-406 (H17) hare been proposed as potential membrane anchors. The interaction of the corresponding synthetic peptides with lipid model systems was investigated with CD spectroscopy, isothermal titration calorimetry and monolayer expansion measurements. The membrane model systems were neutral or negatively charged small unilamellar vesicles or monolayers with a lateral packing density of bilayers (32 mN/ m), S19 partitions into charged monolayers/bilayers with a penetration area A(p) = 140 +/- 30 Angstrom(2) and a free energy of binding of Delta G(0) = -5.7 kcal/mol, thereby forming a partially alpha-helical structure. H18 does not interact with Lipid monolayers or bilayers. H17 penetrates into neutral and charged monolayers/bilayers with A(p) = 148 +/- 23 Angstrom(2) and A(p) = 160 +/- 15 Angstrom(2), respectively, forming an cu-helix in the membrane-bound state. Membrane partitioning is mainly entropy-driven. Under physiological conditions the free energy of binding to negatively charged membranes is Delta G(0) = -9.4 kcal/mol with a hydrophobic contribution of Delta G(h) = -7.8 kcal/mol, comparable to that of post-translationally attached membrane anchors, and an electrostatic contribution of Delta G(h) = -1.6 kcal/mol. The latter becomes more negative with decreasing pH. We show that H17 provides the binding energy required for a membrane anchor.	Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland; Tech Univ Munich, Dept Biophys, D-85747 Garching, Germany	University of Basel; Technical University of Munich	Seelig, A (corresponding author), Univ Basel, Bioctr, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.							ALBIGESRIZO C, 1995, J CELL SCI, V108, P3317; BERKERIE MC, 1989, J CELL BIOL, V109, P3333; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P52, DOI 10.1021/bi00453a007; BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; Borowsky ML, 1998, J CELL BIOL, V143, P429, DOI 10.1083/jcb.143.2.429; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1351, DOI 10.1083/jcb.113.6.1351; Doebler R, 1999, BIOPHYS J, V76, P928, DOI 10.1016/S0006-3495(99)77256-5; DUYSENS LNM, 1956, BIOCHIM BIOPHYS ACTA, V19, P1; EVANS RW, 1987, BIOCHEM J, V245, P455, DOI 10.1042/bj2450455; FROMHERZ P, 1975, REV SCI INSTRUM, V46, P1380, DOI 10.1063/1.1134025; Goldmann WH, 1999, EUR J BIOCHEM, V260, P439, DOI 10.1046/j.1432-1327.1999.00177.x; GOLDMANN WH, 1994, J STRUCT BIOL, V112, P3, DOI 10.1006/jsbi.1994.1002; Goldmann WH, 1997, EUR J BIOCHEM, V250, P447, DOI 10.1111/j.1432-1033.1997.0447a.x; GOLDMANN WH, 1995, FEBS LETT, V368, P516, DOI 10.1016/0014-5793(95)00678-3; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hanakam F, 1996, BIOCHEMISTRY-US, V35, P11036, DOI 10.1021/bi960789j; Hemmings L, 1996, J CELL SCI, V109, P2715; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Isenberg G, 1998, FEBS LETT, V426, P165, DOI 10.1016/S0014-5793(98)00336-6; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; KAUFMANN S, 1992, FEBS LETT, V314, P203, DOI 10.1016/0014-5793(92)80975-M; KAUFMANN S, 1991, FEBS LETT, V284, P187, DOI 10.1016/0014-5793(91)80681-R; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; KREITMEIER M, 1995, J CELL BIOL, V129, P179, DOI 10.1083/jcb.129.1.179; KUCHINKA E, 1989, BIOCHEMISTRY-US, V28, P4216, DOI 10.1021/bi00436a014; McCann RO, 1997, P NATL ACAD SCI USA, V94, P5679, DOI 10.1073/pnas.94.11.5679; MONTICH G, 1993, BIOCHIM BIOPHYS ACTA, V1146, P17, DOI 10.1016/0005-2736(93)90333-U; Moulder GL, 1996, MOL BIOL CELL, V7, P1181, DOI 10.1091/mbc.7.8.1181; Niewohner J, 1997, J CELL BIOL, V138, P349, DOI 10.1083/jcb.138.2.349; NIGGLI V, 1994, EUR J BIOCHEM, V224, P951, DOI 10.1111/j.1432-1033.1994.00951.x; NUCKOLLS GH, 1992, J CELL SCI, V102, P753; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SEELIG A, 1992, BIOCHEMISTRY-US, V31, P2897, DOI 10.1021/bi00126a008; SEELIG A, 1989, BIOCHEMISTRY-US, V28, P2490, DOI 10.1021/bi00432a021; SEELIG A, 1990, BIOCHIM BIOPHYS ACTA, V1030, P111, DOI 10.1016/0005-2736(90)90245-J; SEELIG A, 1987, BIOCHIM BIOPHYS ACTA, V899, P196, DOI 10.1016/0005-2736(87)90400-7; SEELIG A, 1993, PEPTIDES 1992, P113; SEELIG J, 1993, BIOCHEMISTRY-US, V32, P9714, DOI 10.1021/bi00088a025; Seelig J, 1997, BBA-REV BIOMEMBRANES, V1331, P103, DOI 10.1016/S0304-4157(97)00002-6; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; TEMPEL M, 1995, BIOPHYS J, V69, P228, DOI 10.1016/S0006-3495(95)79894-0; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; Wieprecht T, 2000, BIOCHEMISTRY-US, V39, P442, DOI 10.1021/bi992146k; WIEPRECHT T, 2000, BIOPHYS J, V78, P959; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YANG JT, 1986, METHOD ENZYMOL, V130, P208	52	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17954	17961		10.1074/jbc.M002264200	http://dx.doi.org/10.1074/jbc.M002264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748069	Green Accepted, hybrid			2022-12-27	WOS:000087659400008
J	Kehlenbach, RH; Gerace, L				Kehlenbach, RH; Gerace, L			Phosphorylation of the nuclear transport machinery down-regulates nuclear protein import in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE COMPLEX PROTEIN; BALB/C 3T3 CELLS; NUCLEOPORIN NUP153; EXPORT SIGNAL; BINDING-SITES; P62 COMPLEX; IN-VITRO; NF-ATC; RAN; LOCALIZATION	We have examined whether signal-mediated nucleocytoplasmic transport can be regulated by phosphorylation of the nuclear transport machinery. Using digitonin-permeabilized cell assays to measure nuclear import and export, we found that the phosphatase inhibitors okadaic acid and microcystin inhibit transport mediated by the import receptors importin beta and transportin, but not by the export receptor CRM1. Several lines of evidence, including the finding that transport inhibition is partially reversed by the broad specificity protein kinase inhibitor staurosporine, indicate that transport inhibition is due to elevated phosphorylation of a component of the nuclear transport machinery. The kinases and phosphatases involved in this regulation are present in the permeabilized cells. A phosphorylation-sensitive component of the nuclear transport machinery also is present in permeabilized cells and is most likely a component of the nuclear pore complex. Substrate binding by the importin alpha.beta complex and the association of the complex with the nucleoporins Nup358/RanBP2 and Nup153 are not affected by phosphatase inhibitors, suggesting that transport inhibition by protein phosphorylation does not involve these steps. These results suggest that cells have mechanisms to negatively regulate entire nuclear transport pathways, thus providing a means to globally control cellular activity through effects on nucleocytoplasmic trafficking.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Gerace, L (corresponding author), Scripps Res Inst, Dept Cell Biol, 10506 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Kehlenbach, Ralph/0000-0003-4920-9916	NIGMS NIH HHS [GM41955] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041955] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Azuma Y, 1997, BIOCHIMIE, V79, P247, DOI 10.1016/S0300-9084(97)83512-2; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; CORDES VC, 1993, J CELL BIOL, V123, P1333, DOI 10.1083/jcb.123.6.1333; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; Czubryt MP, 2000, J CELL BIOL, V148, P7, DOI 10.1083/jcb.148.1.7; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ECKSTEIN F, 1975, ANGEW CHEM INT EDIT, V14, P160, DOI 10.1002/anie.197501601; Favreau C, 1996, BIOCHEMISTRY-US, V35, P8035, DOI 10.1021/bi9600660; FELDHERR C, 1995, MOL CELL BIOL, V15, P7043; FELDHERR CM, 1994, EXP CELL RES, V215, P206, DOI 10.1006/excr.1994.1333; FELDHERR CM, 1991, J CELL BIOL, V115, P933, DOI 10.1083/jcb.115.4.933; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GUAN TL, 1995, MOL BIOL CELL, V6, P1591, DOI 10.1091/mbc.6.11.1591; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; Miller MW, 1999, ARCH BIOCHEM BIOPHYS, V367, P51, DOI 10.1006/abbi.1999.1237; MISHRA K, 1995, EXP CELL RES, V216, P124, DOI 10.1006/excr.1995.1016; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Robinson J.P., 1997, CURRENT PROTOCOLS CY; Shah S, 1998, J CELL BIOL, V141, P31, DOI 10.1083/jcb.141.1.31; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WILKEN N, 1995, EUR J CELL BIOL, V68, P211; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	54	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17848	17856		10.1074/jbc.M001455200	http://dx.doi.org/10.1074/jbc.M001455200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10749866	hybrid			2022-12-27	WOS:000087485000088
J	Lange, Y; Ye, J; Rigney, R; Steck, T				Lange, Y; Ye, J; Rigney, R; Steck, T			Cholesterol movement in Niemann-Pick type C cells and in cells treated with amphiphiles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN-DERIVED CHOLESTEROL; CULTURED HUMAN-FIBROBLASTS; DISEASE TYPE-C; PLASMA-MEMBRANE; INTRACELLULAR CHOLESTEROL; COENZYME-A; TRANSPORT; ACCUMULATION; HOMEOSTASIS; ESTERIFICATION	Cholesterol accumulates to massive levels in cells from Niemann-Pick type C (NP-C) patients and in cells treated with class 2 amphiphiles that mimic NP-C disease. This behavior has been attributed to the failure of cholesterol released from ingested low density lipoproteins to exit the lysosomes. However, we now show that the rate of movement of cholesterol from lysosomes to plasma membranes in NP-C cells is at least as great as normal, as was also found previously for amphiphiletreated cells. Furthermore, the lysosomes in these cells filled with plasma membrane cholesterol in the absence of lipoproteins. In addition, we showed that the size of the endoplasmic reticulum cholesterol pool and the set point of the homeostatic sensor of cell cholesterol were approximately normal in NP-C cells. The plasma membrane cholesterol pools in both NP-C and amphiphiletreated cells were also normal. Furthermore, the build up of cholesterol in NP-C lysosomes was not a physiological response to cholesterol overload. Rather, it appeared that the accumulation in NP-C lysosomes results from an imbalance in the brisk now of cholesterol among membrane compartments. In related experiments, we found that NP-C cells did not respond to class 2 amphiphiles (e,g, trifluoperazine, imipramine, and U18666A); these agents may therefore act directly on the NPC1 protein or on its pathway. Finally, we showed that the lysosomal cholesterol pool in NP-C cells was substantially and preferentially reduced by incubating cells with the oxysterols, 25-hydroxycholesterol and 7-ketocholesterol; these findings suggest a new pharmacological approach to the treatment of NP-C disease.	Rush Presbyterian St Lukes Med Ctr, Dept Pathol, Chicago, IL 60612 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Rush University; University of Chicago	Lange, Y (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Pathol, 1653 W Congress Pkwy, Chicago, IL 60612 USA.		Lange, Yvonne/A-7794-2009					ARGOFF CE, 1991, BIOCHIM BIOPHYS ACTA, V1096, P319, DOI 10.1016/0925-4439(91)90068-K; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1974, J BIOL CHEM, V249, P7306; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; COXEY RA, 1993, J LIPID RES, V34, P1165; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; DAHL NK, 1992, J BIOL CHEM, V267, P4889; Debry P, 1997, J BIOL CHEM, V272, P1026, DOI 10.1074/jbc.272.2.1026; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; KINSKY SC, 1970, ANNU REV PHARMACOLOG, V10, P119, DOI 10.1146/annurev.pa.10.040170.001003; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LANGE Y, 1993, J BIOL CHEM, V268, P13838; Lange Y, 1996, TRENDS CELL BIOL, V6, P205, DOI 10.1016/0962-8924(96)20016-9; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Lange Y, 1998, CURR OPIN STRUC BIOL, V8, P435, DOI 10.1016/S0959-440X(98)80119-X; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LANGE Y, 1991, J LIPID RES, V32, P329; Lange Y, 1998, J BIOL CHEM, V273, P18915, DOI 10.1074/jbc.273.30.18915; Lange Y, 1999, J LIPID RES, V40, P2264; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; Pentchev P G, 1997, Subcell Biochem, V28, P437; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; Pentchev Peter G., 1994, Trends in Cell Biology, V4, P365, DOI 10.1016/0962-8924(94)90086-8; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PENTCHEV PG, 1984, J BIOL CHEM, V259, P5784; Sato M, 1998, BRAIN DEV-JPN, V20, P50, DOI 10.1016/S0387-7604(97)00099-5; SCHUCHMAN EH, 1995, METABOLIC MOL BASIS, V2, P2601; Shamburek RD, 1997, J LIPID RES, V38, P2422; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOKOL J, 1988, J BIOL CHEM, V263, P3411; THILO L, 1985, BIOCHIM BIOPHYS ACTA, V822, P243, DOI 10.1016/0304-4157(85)90010-3; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805; Xie CL, 1999, AM J PHYSIOL-ENDOC M, V276, pE336, DOI 10.1152/ajpendo.1999.276.2.E336; Xie CL, 1999, P NATL ACAD SCI USA, V96, P11992, DOI 10.1073/pnas.96.21.11992	53	154	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17468	17475		10.1074/jbc.M000875200	http://dx.doi.org/10.1074/jbc.M000875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10751394	hybrid			2022-12-27	WOS:000087485000037
J	Herdick, M; Steinmeyer, A; Carlberg, C				Herdick, M; Steinmeyer, A; Carlberg, C			Antagonistic action of a 25-carboxylic ester analogue of 1 alpha,25-dihydroxyvitamin D-3 is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D ENDOCRINE SYSTEM; NUCLEAR RECEPTORS; HISTONE ACETYLTRANSFERASE; ESTROGEN-RECEPTOR; 20-EPI ANALOGS; ACTIVATION; BINDING; SUPERFAMILY; TRANSCRIPTION; COMPLEX	A 25-carboxylic ester analogue of 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25-(OH)(2)D-3), ZK159222, was described as a novel type of antagonist of 1 alpha,25-(OH)(2)D-3 signaling. The ligand sensitivity of ZK159222, in facilitating complex formation between 1 alpha,25-(OH)(2)D-3 receptor (VDR) and the retinoid X receptor (RXR) on a 1 alpha,25-(OH)(2)D-3 response element (VDRE), was approximately 7-fold lower when compared with 1 alpha,25-(OH)(2)D-3. However, ZK159222 was not able to promote a ligand-dependent interaction of the VDR with the coactivator proteins SRC-1, TIF2, and RACE, neither in solution nor in a complex with RXR on DNA. Functional analysis in HeLa and COS-7 cells demonstrated a 10-100-fold lower ligand sensitivity for ZR159222 than for 1 alpha,25-(OH)(2)D-3 and, most interestingly, a potency that was drastically reduced compared with 1 alpha,25-(OH)(2)D-3. A cotreatment of 1 alpha,25-(OH)(2)D-3 with a 100-fold higher concentration of ZK159222 resulted in a prominent antagonistic effect both in functional in vivo and in in vitro assays. These data suggest that the antagonistic action of ZK159222 is due to a lack of ligand-induced interaction of the VDR with coactivators with a parallel ligand sensitivity, which is sufficient for competition with the natural hormone for VDR binding.	Univ Dusseldorf, Inst Physiol Chem 1, D-40001 Dusseldorf, Germany; Univ Dusseldorf, Biomed Forschungszentrum, D-40001 Dusseldorf, Germany; Schering AG, Inst Arzneimittelchem, D-13342 Berlin, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Schering AG	Carlberg, C (corresponding author), Univ Dusseldorf, Inst Physiol Chem 1, Postfach 10 10 07, D-40001 Dusseldorf, Germany.		Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Carlberg C, 1998, CRIT REV EUKAR GENE, V8, P19, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.20; Carlberg C, 1996, ENDOCRINE, V4, P91, DOI 10.1007/BF02782754; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DELUCA HF, 1990, KIDNEY INT, V38, pS2; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fuhrmann U, 1998, J MOL MED, V76, P512, DOI 10.1007/s001090050245; Gill RK, 1998, MOL ENDOCRINOL, V12, P57, DOI 10.1210/mend.12.1.0048; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HERDICK M, 2000, IN PRESS MOL PHARM, V57; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kahlen JP, 1996, BIOCHEM BIOPH RES CO, V218, P882, DOI 10.1006/bbrc.1996.0157; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liu YY, 1997, J BIOL CHEM, V272, P3336, DOI 10.1074/jbc.272.6.3336; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Miura D, 1999, J BIOL CHEM, V274, P16392, DOI 10.1074/jbc.274.23.16392; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nayeri S, 1996, J CELL BIOCHEM, V62, P325, DOI 10.1002/(SICI)1097-4644(199609)62:3<325::AID-JCB3>3.0.CO;2-T; Nayeri S, 1996, NUCLEIC ACIDS RES, V24, P4513, DOI 10.1093/nar/24.22.4513; NAYERI S, 1997, BIOCHEM J, V235, P561; ONATE SA, 1995, SCIENCE, V270, P1354; Ozono K, 1999, J BIOL CHEM, V274, P32376, DOI 10.1074/jbc.274.45.32376; PELEG S, 1995, J BIOL CHEM, V270, P10551, DOI 10.1074/jbc.270.18.10551; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Wiesinger H, 1998, J INVEST DERMATOL, V110, P532	37	66	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16506	16512		10.1074/jbc.M910000199	http://dx.doi.org/10.1074/jbc.M910000199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748178	hybrid			2022-12-27	WOS:000087392200017
J	Kambampati, R; Pellegrino, C; Paiva, A; Huang, L; Mende-Mueller, L; Chakraburtty, K				Kambampati, R; Pellegrino, C; Paiva, A; Huang, L; Mende-Mueller, L; Chakraburtty, K			Limited proteolysis of yeast elongation factor 3 - Sequence and location of the subdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-III; SACCHAROMYCES-CEREVISIAE; PROTEIN-SYNTHESIS; CHAIN ELONGATION; CYSTIC-FIBROSIS; RIBOSOMAL-RNA; ATPASE; DOMAIN; GTPASE; MODEL	Elongation factor 3 (EF-3) is an ATPase essential for polypeptide chain synthesis in a variety of yeasts and fungi. We used limited proteolysis to study the organization of the subdomains of EF-3. Trypsinolysis of EF-3 at 30 degrees C resulted in the formation of three fragments with estimated molecular masses of 90, 70, and 50 kDa. Yeast ribosomes protected EF-3 and the large fragments from further degradation. ATP exposed a new tryptic cleavage site and stabilized the 70- and 50-kDa fragments. The conformation of EF-3 as measured by fluorescence spectroscopy did not change upon ATP binding. Poly(G) stimulated proteolysis and quenched the intrinsic fluorescence of EF-3, Using gel mobility shift, we demonstrated a direct interaction between EF-3 and tRNA. Neither tRNA nor rRNA altered the tryptic cleavage pattern. The proteolytic products were sequenced by mass spectrometric analysis, EF-3 is blocked NH2-terminally by an acetylated serine. The 90-, 70-, and 50-kDa fragments are also blocked NH2-terminally, confirming their origin. The 50-kDa fragment (Ser(2)-Lys(443)) is the most stable domain in EF-3 with no known function. The 70-kDa fragment (Ser(2)-Lys(668)) containing the first nucleotide-binding sequence motif forms the core ATP binding subdomain within the 90-kDa domain. The primary ribosome binding site is located near the loosely structured carboxyl-terminal end.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Magellan Labs, Cabrillo Facil, San Diego, CA 92126 USA; Bayer Corp, W Haven, CT 06516 USA; Univ Wisconsin, Dept Pharm, Madison, WI 53706 USA	Medical College of Wisconsin; Bayer AG; University of Wisconsin System; University of Wisconsin Madison	Chakraburtty, K (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Waterton Plank Rd, Milwaukee, WI 53226 USA.							BELFIELD GP, 1995, J MOL EVOL, V41, P376, DOI 10.1007/BF01215185; BELFIELD GP, 1993, MOL MICROBIOL, V9, P411, DOI 10.1111/j.1365-2958.1993.tb01702.x; DASMAHAPATRA B, 1981, J BIOL CHEM, V256, P9999; Gontarek RR, 1998, J BIOL CHEM, V273, P10249, DOI 10.1074/jbc.273.17.10249; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KAMATH A, 1989, J BIOL CHEM, V264, P15423; Kambampati R, 1997, J BIOL CHEM, V272, P6377, DOI 10.1074/jbc.272.10.6377; KAMBAMPATI R, 1996, PROTEIN EXPRES PURIF, V10, P209; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KOVALCHUKE O, 1995, INDIAN J BIOCHEM BIO, V32, P336; KOVALCHUKE O, 1994, FASEB J, V8, pA1307; KOVALCHUKE O, 1994, EUR J BIOCHEM, V226, P133, DOI 10.1111/j.1432-1033.1994.tb20034.x; Ladror US, 1998, PROTEIN SCI, V7, P2595, DOI 10.1002/pro.5560071213; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; Masahiro U, 1996, BIOCHEM MOL BIOL INT, V39, P227; MIYAZAKI M, 1988, J BIOCHEM-TOKYO, V104, P445, DOI 10.1093/oxfordjournals.jbchem.a122487; QIN SL, 1990, J BIOL CHEM, V265, P1903; SANDBAKEN MG, 1990, J BIOL CHEM, V265, P15838; SKOGERSON L, 1977, J BIOL CHEM, V252, P1471; SKOGERSON L, 1976, P NATL ACAD SCI USA, V73, P73, DOI 10.1073/pnas.73.1.73; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIANA FJ, 1993, TRANSLATIONAL APPARATUS, P327; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; URITANI M, 1988, J BIOCHEM-TOKYO, V103, P522, DOI 10.1093/oxfordjournals.jbchem.a122302; Yike I, 1996, PROTEIN SCI, V5, P89	27	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16963	16968		10.1074/jbc.M001157200	http://dx.doi.org/10.1074/jbc.M001157200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747994	hybrid			2022-12-27	WOS:000087392200080
J	Kucharski, LM; Lubbe, WJ; Maguire, ME				Kucharski, LM; Lubbe, WJ; Maguire, ME			Cation hexaammines are selective and potent inhibitors of the CorA magnesium transport system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; BINDING-SITES; MG2+; ION; PROTEIN; METALLOBIOCHEMISTRY; IDENTIFICATION; ENZYMES; CLONING	Cation hexaammines and related compounds are chemically stable analogs of the hydrated form of cations, particularly Mg2+: We tested the ability of several of these compounds to inhibit transport by the CorA or MgtB Mg2+ transport systems or the PhoQ receptor kinase for Mg2+ in Salmonella typhimurium. Cobalt(III)-, ruthenium(II)-, and ruthenium(III)-hexaammines were potent inhibitors of CorA-mediated influx, Cobalt(III)-and ruthenium(III)chloropentaammines were slightly less potent inhibitors of CorA. The compounds inhibited uptake by the bacterial S. typhimurium CorA and by the archaeal Methanococcus jannaschii CorA, which bear only 12% identity in the extracellular periplasmic domain. Cation hexaammines also inhibited growth of S. typhimurium strains dependent on CorA for Mg2+ up- take but not of isogenic strains carrying a second Mg2+ uptake system. In contrast, hexacyano-cobaltate (III) and ruthenate(II)- and nickel(II)hexaammine had little effect on uptake, The inhibition by the cation hexaammines was selective for CorA because none of the compounds had any effect on transport by the MgtB P-type ATPase Mg2+ transporter or the PhoQ Mg2+ receptor kinase. These results demonstrate that cation hexaammines are potent and highly selective inhibitors of the CorA Mg2+ transport system and further indicate that the initial interaction of the CorA transporter is with a fully hydrated Mg2+ cation.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	Kucharski, LM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	lmk10@po.cwru.edu			NIGMS NIH HHS [GM39447] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039447] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASOLO F, 1967, MECHANISMS INORGANIC, P158; Black CB, 1997, EUR J BIOCHEM, V243, P684, DOI 10.1111/j.1432-1033.1997.00684.x; Cowan JA, 1998, CHEM REV, V98, P1067, DOI 10.1021/cr960436q; COWAN JA, 1993, J INORG BIOCHEM, V49, P171, DOI 10.1016/0162-0134(93)80002-Q; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; GRUBBS RD, 1989, METHOD ENZYMOL, V173, P546; Hampel A, 1997, CHEM BIOL, V4, P513, DOI 10.1016/S1074-5521(97)90323-9; Hendry P, 1990, ADV INORG CHEM RA<D>, V35, P117, DOI 10.1016/S0898-8838(08)60162-2; HMIEL SP, 1989, J BACTERIOL, V171, P4742, DOI 10.1128/jb.171.9.4742-4751.1989; HMIEL SP, 1986, J BACTERIOL, V168, P1444, DOI 10.1128/jb.168.3.1444-1450.1986; HUANG HW, 1994, EUR J BIOCHEM, V219, P253, DOI 10.1111/j.1432-1033.1994.tb19936.x; HUMMEL HU, 1988, Z ANORG ALLG CHEM, V565, P147, DOI 10.1002/zaac.19885650116; IWATA M, 1973, ACTA CRYSTALLOGR B, VB 29, P822, DOI 10.1107/S0567740873003407; Kehres D G, 1998, Microb Comp Genomics, V3, P151, DOI 10.1089/omi.1.1998.3.151; LLEWELLYN DR, 1964, J CHEM SOC, P196, DOI 10.1039/jr9640000196; MARTIN RB, 1990, MET IONS BIOL SYST, V26, P1; Meek DW, 1970, INORG CHEM, V9, P465, DOI 10.1021/ic50085a007; MESSMER GG, 1968, ACTA CRYSTALL B-STRU, VB 24, P417, DOI 10.1107/S0567740868002475; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Moncrief MBC, 1998, INFECT IMMUN, V66, P3802, DOI 10.1128/IAI.66.8.3802-3809.1998; NELSON DL, 1971, J BIOL CHEM, V246, P3042; RUTENBERG AC, 1963, INORG CHEM, V2, P219, DOI 10.1021/ic50005a057; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Smith RL, 1998, J BACTERIOL, V180, P2788, DOI 10.1128/JB.180.10.2788-2791.1998; SMITH RL, 1993, J BIOL CHEM, V268, P14071; Smith RL, 1998, J BIOL CHEM, V273, P28663, DOI 10.1074/jbc.273.44.28663; Smith RL, 1998, MOL MICROBIOL, V28, P217, DOI 10.1046/j.1365-2958.1998.00810.x; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; SNAVELY MD, 1989, J BACTERIOL, V171, P4761, DOI 10.1128/jb.171.9.4761-4766.1989; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; Szegedy MA, 1999, J BIOL CHEM, V274, P36973, DOI 10.1074/jbc.274.52.36973; Tao T, 1998, MICROBIOL-SGM, V144, P655, DOI 10.1099/00221287-144-3-655; UCHIYAMA Y, 1994, J BIOCHEM-TOKYO, V116, P1322, DOI 10.1093/oxfordjournals.jbchem.a124682; Vescovi EG, 1997, J BIOL CHEM, V272, P1440, DOI 10.1074/jbc.272.3.1440	34	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16767	16773		10.1074/jbc.M001507200	http://dx.doi.org/10.1074/jbc.M001507200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748031	hybrid			2022-12-27	WOS:000087392200053
J	Kohl, R; Antoine, M; Olwin, BB; Dickson, C; Kiefer, P				Kohl, R; Antoine, M; Olwin, BB; Dickson, C; Kiefer, P			Cysteine-rich fibroblast growth factor receptor alters secretion and intracellular routing of fibroblast growth factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-SELECTIN-LIGAND; HAMSTER OVARY CELLS; GOLGI-APPARATUS; FGF RECEPTOR; MEMBRANE SIALOGLYCOPROTEIN; MEDIAL CISTERNAE; COMPLEX; FAMILY; MG-160; IDENTIFICATION	Expression of the cysteine-rich fibroblast growth factor (FGF) receptor (CFR) in COS-1 cells strongly inhibits the secretion of co-expressed FGF3. By using a column retention assay and affinity chromatography, we demonstrate that at physiological salt concentrations FGF3 binds with strong affinity to CFR in vivo and in vitro. Furthermore, to show that FGF3 binds to CFR in vivo, truncation mutants of CFR with changed subcellular distributions were shown to cause a similar redistribution of FGF3. Although CFR is a 150-kDa integral membrane glycoprotein that is primarily located in the Golgi apparatus, we show here that in COS-1 cells a substantial proportion of CFR is secreted. This is due to a carboxyl-terminal proteolytic cleavage that releases the intraluminal portion of the protein, for secretion. However, the apparent size of the integral membrane and secreted CFR appears similar, since the loss of protein mass is balanced by a gain of complex carbohydrates. The released CFR is associated with the extracellular matrix through its affinity for glycosaminoglycans. These findings show that CFR can modulate the secretion of FGF3 and may control its biological activity by regulating its secretion.	Ruhr Univ Bochum, Fak Med, Abt Virol, D-44780 Bochum, Germany; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80308 USA; Imperial Canc Res Fund Labs, London WC2A 3PX, England	Ruhr University Bochum; University of Colorado System; University of Colorado Boulder; Cancer Research UK	Kiefer, P (corresponding author), Ruhr Univ Bochum, Fak Med, Abt Virol, Universitatsstr 150,Gebauole MA 6-130, D-44780 Bochum, Germany.		Olwin, Bradley B/A-1333-2014					BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GONATAS JO, 1995, J CELL SCI, V108, P457; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KIEFER P, 1991, MOL CELL BIOL, V11, P5929, DOI 10.1128/MCB.11.12.5929; KIEFER P, 1993, MOL CELL BIOL, V13, P5781, DOI 10.1128/MCB.13.9.5781; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MIYAZONO K, 1992, J BIOL CHEM, V267, P5668; Mourelatos Z, 1996, DNA CELL BIOL, V15, P1121, DOI 10.1089/dna.1996.15.1121; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Olofsson A, 1997, BIOCHEM J, V324, P427, DOI 10.1042/bj3240427; Steegmaier M, 1997, J CELL SCI, V110, P687; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; STIEBER A, 1995, EXP CELL RES, V219, P562, DOI 10.1006/excr.1995.1265; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J; Zhou ZH, 1997, J BIOL CHEM, V272, P5167, DOI 10.1074/jbc.272.8.5167; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002; Zuber ME, 1997, J CELL PHYSIOL, V170, P217	23	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15741	15748		10.1074/jbc.M903271199	http://dx.doi.org/10.1074/jbc.M903271199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748074	hybrid			2022-12-27	WOS:000087291400021
J	Piluso, G; Mirabella, M; Ricci, E; Belsito, A; Abbondanza, C; Servidei, S; Puca, AA; Tonali, P; Puca, GA; Nigro, V				Piluso, G; Mirabella, M; Ricci, E; Belsito, A; Abbondanza, C; Servidei, S; Puca, AA; Tonali, P; Puca, GA; Nigro, V			gamma 1-and gamma 2-syntrophins, two novel dystrophin-binding proteins localized in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE MUSCULAR-DYSTROPHY; SARCOGLYCAN-DEFICIENT MICE; GLYCOPROTEIN COMPLEX; BETA-SARCOGLYCAN; GAMMA-SARCOGLYCAN; 2-HYBRID SYSTEM; SHORT FORMS; GENE; SYNTROPHIN; MUTATIONS	Dystrophin is the scaffold of a protein complex, disrupted in inherited muscular dystrophies. At the last 3' terminus of the gene, a protein domain is encoded, where syntrophins are tightly bound. These are a family of cytoplasmic peripheral membrane proteins. Three genes have been described encoding one acidic (alpha 1) and two basic (beta 1 and beta 2) proteins of similar to 57-60 kDa. Here, we describe the characterization of two novel putative members of the syntrophin family, named gamma 1- and gamma 2-syntrophins. The human gamma 1-syntrophin gene is composed of 19 exons and encodes a brain-specific protein of 517 amino acids. The human gamma 2-syntrophin gene is composed of at least 17 exons, and its transcript is expressed in brain and, to a lesser degree, in other tissues. We mapped the gamma 1-syntrophin gene to human chromosome 8q11 and the gamma 2-syntrophin gene to chromosome 2p25. Yeast two-hybrid experiments and pull-down studies showed that both proteins can bind the C-terminal region of dystrophin and related proteins. We raised antibodies against these proteins and recognized expression in both rat and human central neurons, coincident with RNA in situ hybridization of adjacent sections. Our present findings suggest a differentiated role of a modified dystrophin-associated complex in the central nervous system.	Univ Naples, Fac Med, Ist Patol Gen & Oncol, I-80138 Naples, Italy; Univ Cattolica A Gemelli, Ist Neurol, I-00168 Rome, Italy; Unione Italiana Lotta Distrofia Muscolare, Rome Sect, Ctr Neuromuscular Dis, I-00167 Rome, Italy; Childrens Hosp, Div Genet, Boston, MA 02115 USA	University of Naples Federico II; Catholic University of the Sacred Heart; Harvard University; Boston Children's Hospital	Nigro, V (corresponding author), Univ Naples, Fac Med, Ist Patol Gen & Oncol, Larghetto S Aniello Caponapoli 2, I-80138 Naples, Italy.		Puca, Annibale Alessandro/K-2099-2018; MIRABELLA, Massimiliano/AAC-4016-2020; PILUSO, Giulio/AAA-3400-2019; Piluso, Giulio/AAA-3661-2019; Ricci, Enzo/AAC-4448-2020; Nigro, Vincenzo/AAB-2274-2022; Servidei, Serenella/ABC-4262-2021	MIRABELLA, Massimiliano/0000-0002-7783-114X; PILUSO, Giulio/0000-0001-9418-125X; ABBONDANZA, Ciro/0000-0001-5346-4835; Nigro, Vincenzo/0000-0002-3378-5006; SERVIDEI, Serenella/0000-0001-8478-2799; RICCI, Enzo/0000-0003-3092-3597				ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; ANGERER LM, 1987, IN SITU HYBRIDIZATIO; Araishi K, 1999, HUM MOL GENET, V8, P1589, DOI 10.1093/hmg/8.9.1589; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Castello A, 1996, FEBS LETT, V383, P124, DOI 10.1016/0014-5793(96)00214-1; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; COX GA, 1994, NAT GENET, V8, P333, DOI 10.1038/ng1294-333; Crosbie RH, 1997, J BIOL CHEM, V272, P31221, DOI 10.1074/jbc.272.50.31221; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; DWYER TM, 1995, FEBS LETT, V375, P91, DOI 10.1016/0014-5793(95)01176-F; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GREENBERG DS, 1994, NAT GENET, V8, P340, DOI 10.1038/ng1294-340; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Hopf C, 1996, J BIOL CHEM, V271, P5231; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; LEDERFEIN D, 1992, P NATL ACAD SCI USA, V89, P5346, DOI 10.1073/pnas.89.12.5346; LENK U, 1993, HUM MOL GENET, V2, P1877, DOI 10.1093/hmg/2.11.1877; LIDOV HGW, 1995, HUM MOL GENET, V4, P329, DOI 10.1093/hmg/4.3.329; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; McNally EM, 1998, HUM MOL GENET, V7, P871, DOI 10.1093/hmg/7.5.871; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; Nigro V, 1996, HUM MOL GENET, V5, P1179, DOI 10.1093/hmg/5.8.1179; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; Peters MF, 1997, J BIOL CHEM, V272, P31561, DOI 10.1074/jbc.272.50.31561; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Puca AA, 1998, FEBS LETT, V425, P7, DOI 10.1016/S0014-5793(98)00097-0; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wilson J, 1999, HUM MOL GENET, V8, P1271, DOI 10.1093/hmg/8.7.1271; YAMAMOTO H, 1993, J BIOCHEM-TOKYO, V114, P132, DOI 10.1093/oxfordjournals.jbchem.a124128; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x	66	106	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15851	15860		10.1074/jbc.M000439200	http://dx.doi.org/10.1074/jbc.M000439200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747910	hybrid			2022-12-27	WOS:000087291400035
J	Hu, E; Chen, ZX; Fredrickson, T; Zhu, Y; Kirkpatrick, R; Zhang, GF; Johanson, K; Sung, CM; Liu, RG; Winkler, J				Hu, E; Chen, ZX; Fredrickson, T; Zhu, Y; Kirkpatrick, R; Zhang, GF; Johanson, K; Sung, CM; Liu, RG; Winkler, J			Cloning and characterization of a novel human. Class I histone deacetylase that functions as a transcription repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR COACTIVATOR; ACUTE PROMYELOCYTIC LEUKEMIA; CHROMATIN STRUCTURE; SACCHAROMYCES-CEREVISIAE; ANTITUMOR-ACTIVITY; GENE ACTIVATION; RNA-POLYMERASE; TRICHOSTATIN-A; N-COR; ACETYLATION	Histone acetylation alters chromatin state by modifying lysines on histone and plays an important role in modulating gene transcription. A dynamic balance of histone acetylation/deacetylation is maintained by histone acetyltransferases and histone deacetylases. Emerging evidence suggests that a family of histone deacetylases may exist to regulate diverse cellular functions, including chromatin structure, gene expression, cell cycle progression, and oncogenesis. We describe here a novel human histone deacetylase, named HDAC8, cloned from human kidney. HDAC8 encodes 377 amino acid residues and shares extensive homology to several known HDACs, in particular a histone deacetylase from Arabidopsis thaliana. Northern blot analyses revealed that HDAC8 expression pattern for HDAC8 is distinct from that for HDAC1 and HDAC3, and expression of HDAC8 mRNA occurs in multiple organs including heart, lung, kidney, and pancreas. HDAC8 mRNA was also observed in several cell lines derived from cancerous tissues. When expressed in HEK293 cells, HDAC8 exhibited deacetylase activity toward acetylated histone, indicating that this protein is a bona fide histone deacetylase. Its histone deacetylase activity was inhibited by trichostatin and other known histone deacetylase inhibitors. Furthermore, active recombinant HDAC8 was expressed and purified from Escherichia coli. When ectopically expressed in cells, HDAC8 was found to be localized to the nucleus. Co-transfection experiments demonstrated that expression of HDAC8 repressed a viral SV40 early promoter activity. These results indicate that HDAC8 is a novel member of the histone deacetylase family, which may play a role in the development of a broad range of tissues and potentially in the etiology of cancer.	SmithKline Beecham Pharmaceut, Dept Renal Pharmacol, King Of Prussia, PA 19403 USA; SmithKline Beecham Pharmaceut, Dept Oncol, King Of Prussia, PA 19403 USA; SmithKline Beecham Pharmaceut, Dept Biol Mol, King Of Prussia, PA 19403 USA; SmithKline Beecham Pharmaceut, Dept Med Chem, King Of Prussia, PA 19403 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19403 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Hu, E (corresponding author), SmithKline Beecham Pharmaceut, Dept Renal Pharmacol, 709 Swedeland Rd, King Of Prussia, PA 19403 USA.	erding_hu-1@sbphrd.com						Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; INNIS JW, 1983, MOL CELL BIOL, V3, P2203, DOI 10.1128/MCB.3.12.2203; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kao HY, 2000, GENE DEV, V14, P55; KIRKPATRICK RB, 1994, DEV GENET, V15, P188, DOI 10.1002/dvg.1020150209; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Leipe DD, 1997, NUCLEIC ACIDS RES, V25, P3693, DOI 10.1093/nar/25.18.3693; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LOIDL P, 1988, FEBS LETT, V227, P91, DOI 10.1016/0014-5793(88)80874-3; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lusser A, 1997, SCIENCE, V277, P88, DOI 10.1126/science.277.5322.88; Mahlknecht U, 1999, GENOMICS, V56, P197, DOI 10.1006/geno.1998.5645; Mannervik M, 1999, P NATL ACAD SCI USA, V96, P6797, DOI 10.1073/pnas.96.12.6797; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Qiu L, 1999, BRIT J CANCER, V80, P1252, DOI 10.1038/sj.bjc.6690493; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Saunders N, 1999, CANCER RES, V59, P399; Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Sun ZW, 1999, GENETICS, V152, P921; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; WONG LJC, 1991, BIOCHEM GENET, V29, P461; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	77	230	262	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15254	15264		10.1074/jbc.M908988199	http://dx.doi.org/10.1074/jbc.M908988199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748112	hybrid			2022-12-27	WOS:000087128300066
J	Kojima, Y; Fukumoto, S; Furukawa, K; Okajima, T; Wiels, J; Yokoyama, K; Suzuki, Y; Urano, T; Ohta, M; Furukawa, K				Kojima, Y; Fukumoto, S; Furukawa, K; Okajima, T; Wiels, J; Yokoyama, K; Suzuki, Y; Urano, T; Ohta, M; Furukawa, K			Molecular cloning of globotriaosylceramide/CD77 synthase, a glycosyltransferase that initiates the synthesis of globo series glycosphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA-ASSOCIATED ANTIGEN; CENTER B-CELLS; BURKITTS-LYMPHOMA; MONOCLONAL-ANTIBODY; UDP-GALACTOSE; EUKARYOTIC RIBOSOMES; GLYCOLIPID ANTIGEN; APOPTOSIS; BIOSYNTHESIS; EXPRESSION	The expression cloning of a cDNA for globotriaosylceramide (Gb3)/CD77 synthase (alpha 1,4-galactosyltransferase) was achieved using an anti-Gb3 antibody and mouse L cells as a recipient cell line for the transfection. The isolated cDNA clone designated pVTR1 predicted a type II membrane protein with 19 amino acids of cytoplasmic domain, 26 amino acids of transmembrane region, and a catalytic domain with 308 amino acids. Introduction of the cDNA clone into L cells resulted in the neosynthesis of Gb3/CD77, and the extracts of the transfectant cells showed alpha 1,4-galactosyltransferase activity only on lactosylceramide and galactosylceramide, In Northern blotting, a 2.3-kilobase mRNA was strongly expressed in heart, kidney, spleen, and placenta and weakly in colon, small intestine, and brain. Transfection of the cDNA into L cells resulted in the constitution of sensitivity to the apoptosis with Shiga-like toxins (verotoxins). Since Gh3/CD77 synthase initiates the synthesis of globe series glycolipids, the isolation of this cDNA will make possible further investigations into the function of its important series of glycolipids.	Nagoya Univ, Sch Med, Dept Biochem 2, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Sch Med, Dept Bacteriol, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 8528588, Japan; Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem, Shizuoka 4228526, Japan; Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France	Nagoya University; Nagoya University; Nagasaki University; University of Shizuoka; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Okajima, Tetsuya/I-7332-2014; Wiels, Joëlle/AGL-2319-2022	Okajima, Tetsuya/0000-0002-3677-648X; Wiels, Joëlle/0000-0002-3313-2937; Fukumoto, Satoshi/0000-0002-5046-6891; Urano, Takeshi/0000-0003-3383-3554				Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; BALANA A, 1985, INT J CANCER, V36, P453, DOI 10.1002/ijc.2910360407; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; Hammache D, 1999, J VIROL, V73, P5244, DOI 10.1128/JVI.73.6.5244-5248.1999; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; KLEIN G, 1983, INT J CANCER, V31, P535, DOI 10.1002/ijc.2910310503; KNAPPER W, 1989, LEUKOCYTE TYPING, P118; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; Lloyd KO, 1998, GLYCOCONJUGATE J, V15, P627, DOI 10.1023/A:1006924128550; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANGENEY M, 1993, CANCER RES, V53, P5314; MANGENEY M, 1991, EUR J IMMUNOL, V21, P1131, DOI 10.1002/eji.1830210507; MANGENEY M, 1995, MOL IMMUNOL, V32, P333, DOI 10.1016/0161-5890(95)00004-X; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; Miyamoto D, 1997, GLYCOCONJUGATE J, V14, P379, DOI 10.1023/A:1018578829997; MURRAY LJ, 1985, INT J CANCER, V36, P453; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NUDELMAN E, 1983, SCIENCE, V220, P509, DOI 10.1126/science.6836295; OBRIEN AD, 1983, LANCET, V1, P702; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Puri A, 1998, P NATL ACAD SCI USA, V95, P14435, DOI 10.1073/pnas.95.24.14435; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TAGA S, 1995, INT J CANCER, V61, P261, DOI 10.1002/ijc.2910610220; Taga S, 1997, BLOOD, V90, P2757, DOI 10.1182/blood.V90.7.2757.2757_2757_2767; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; TANIGUCHI N, 1985, J BIOL CHEM, V260, P4908; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WIELS J, 1981, P NATL ACAD SCI-BIOL, V78, P6485, DOI 10.1073/pnas.78.10.6485; WIELS J, 1984, J BIOL CHEM, V259, P4783; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149	39	110	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15152	15156		10.1074/jbc.M909620199	http://dx.doi.org/10.1074/jbc.M909620199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748143	hybrid			2022-12-27	WOS:000087128300053
J	Bennett, BD; Babu-Khan, S; Loeloff, R; Louis, JC; Curran, E; Citron, M; Vassar, R				Bennett, BD; Babu-Khan, S; Loeloff, R; Louis, JC; Curran, E; Citron, M; Vassar, R			Expression analysis of BACE2 in brain and peripheral tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALPHA-SECRETASE CLEAVAGE; ALZHEIMERS-DISEASE; BETA-SECRETASE; ASPARTYL PROTEASE; CONVERTING-ENZYME; YEAST; PURIFICATION; PEPTIDE; RECEPTOR	Beta-site amyloid precursor protein cleaving enzyme (BACE) is a novel transmembrane aspartic protease that possesses all the known characteristics of the beta-secretase involved in Alzheimer's disease (Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Boss, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J.-C., Collins, F., Treanor, J., Rogers, G., and Citron, M. (1999) Science 286, 735-741). We have analyzed the sequence and expression pattern of a BACE homolog termed BACE2. BACE and BACE2 are unique among aspartic proteases in that they possess a carboxyl-terminal extension with a predicted transmembrane region and together they define a new family. Northern analysis reveals that BACE2 mRNA is expressed at low levels in most human peripheral tissues and at higher levels in colon, kidney, pancreas, placenta, prostate, stomach, and trachea. Human adult and fetal whole brain and most adult brain subregions express very low or undetectable levels of BACE2 mRNA In addition, in situ hybridization of adult rat brain shows that BACE2 mRNA is expressed at very low levels in most brain regions. The very low or undetectable levels of BACE2 mRNA in the brain are not consistent with the expression pattern predicted for beta-secretase.	Amgen Inc, Thousand Oaks, CA 91320 USA	Amgen	Vassar, R (corresponding author), Amgen Inc, 1 Amgen Ctr Dr,M-S 29-2-B, Thousand Oaks, CA 91320 USA.	rvassar@amgen.com						Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CURRAN EJ, 1995, J COMP NEUROL, V361, P57, DOI 10.1002/cne.903610106; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Khan AR, 1998, PROTEIN SCI, V7, P815; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; Komano H, 1998, J BIOL CHEM, V273, P31648, DOI 10.1074/jbc.273.48.31648; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; LIN XL, 1994, METHOD ENZYMOL, V241, P195; LOH YP, 1985, J BIOL CHEM, V260, P7194; Olsen V, 1999, BIOCHEM J, V339, P407, DOI 10.1042/0264-6021:3390407; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P105; Saunders AJ, 1999, SCIENCE, V286; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Zhang W, 1997, BBA-MOL CELL RES, V1359, P110, DOI 10.1016/S0167-4889(97)00082-7; Zhao J, 1996, J BIOL CHEM, V271, P31407, DOI 10.1074/jbc.271.49.31407	28	243	266	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20647	20651		10.1074/jbc.M002688200	http://dx.doi.org/10.1074/jbc.M002688200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10749877	hybrid			2022-12-27	WOS:000088084500061
J	Askarian-Amiri, ME; Pel, HJ; Guevremont, D; McCaughan, KK; Poole, ES; Sumpter, VG; Tate, WP				Askarian-Amiri, ME; Pel, HJ; Guevremont, D; McCaughan, KK; Poole, ES; Sumpter, VG; Tate, WP			Functional characterization of yeast mitochondrial release factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL STOP SIGNAL; PEPTIDYL-TRANSFER-RNA; 16-S RIBOSOMAL-RNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENETIC-CODE; TERMINATION; BINDING; RECOGNITION; ENCODES	The yeast Saccharomyces cerevisiae mitochondrial release factor was expressed from the cloned MRF1 gene, purified from inclusion bodies, and refolded to give functional activity. The gene encoded a factor with release activity that recognized cognate stop codons in a termination assay with mitochondrial ribosomes and in an assay with Escherichia coli ribosomes. The noncognate stop codon, UGA, encoding tryptophan in mitochondria, was recognized weakly in the heterologous assay. The mitochondrial release factor 1 protein bound to bacterial ribosomes and formed a cross-link with the stop codon within a mRNA bound in a termination complex. The affinity was strongly dependent on the identity of stop signal. Two alleles of MRF1 that contained point mutations in a release factor 1 specific region of the primary structure and that in vivo compensated for mutations in the decoding site rRNA of mitochondrial ribosomes were cloned, and the expressed proteins were purified and refolded, The variant proteins showed impaired binding to the ribosome compared with mitochondrial release factor 1, This structural region in release factors is likely to be involved in codon-dependent specific ribosomal interactions.	Univ Otago, Dept Biochem, Dunedin 9015, New Zealand; Univ Otago, Ctr Gene Res, Dunedin 9015, New Zealand	University of Otago; University of Otago	Tate, WP (corresponding author), Univ Otago, Dept Biochem, POB 56, Dunedin 9015, New Zealand.	warren.tate@stonebow.otago.ac.nz	Askarian-Amiri, Marjan E./F-7910-2010	Askarian-Amiri, Marjan E./0000-0003-3524-9626				BROWN CM, 1994, J BIOL CHEM, V269, P33164; CASKEY CT, 1971, P NATL ACAD SCI USA, V68, P3163, DOI 10.1073/pnas.68.12.3163; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; CRAIGEN WJ, 1985, P NATL ACAD SCI USA, V82, P3616, DOI 10.1073/pnas.82.11.3616; DAHLQUIST K, 1995, NUCL ACIDS S SER, V33, P170; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V14, P387; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Ito K, 2000, NATURE, V403, P680, DOI 10.1038/35001115; Ito K, 1996, P NATL ACAD SCI USA, V93, P5443, DOI 10.1073/pnas.93.11.5443; JOHN UP, 1986, NUCLEIC ACIDS RES, V14, P7437, DOI 10.1093/nar/14.18.7437; JUKES TH, 1993, COMP BIOCHEM PHYS B, V106, P489, DOI 10.1016/0305-0491(93)90122-L; LEE CC, 1987, J BIOL CHEM, V262, P3548; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; McCaughan KK, 1998, BIOL CHEM, V379, P857, DOI 10.1515/bchm.1998.379.7.857; MIKUNI O, 1994, P NATL ACAD SCI USA, V91, P5798, DOI 10.1073/pnas.91.13.5798; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1995, J MOL BIOL, V248, P207, DOI 10.1016/S0022-2836(95)80042-5; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOFFAT JG, 1994, J BIOL CHEM, V269, P18899; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Nakamura Y, 1998, GENES CELLS, V3, P265, DOI 10.1046/j.1365-2443.1998.00191.x; PAPADOPOULOU B, 1990, EMBO J, V9, P4135, DOI 10.1002/j.1460-2075.1990.tb07636.x; PEL HJ, 1993, NUCLEIC ACIDS RES, V21, P5308, DOI 10.1093/nar/21.23.5308; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P4423, DOI 10.1093/nar/20.17.4423; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P6339, DOI 10.1093/nar/20.23.6339; Pel HJ, 1996, CURR GENET, V30, P19, DOI 10.1007/s002940050095; Poole ES, 1997, RNA, V3, P974; SPURIO R, 1991, BIOCHIMIE, V73, P1001, DOI 10.1016/0300-9084(91)90141-M; TATE WP, 1973, P NATL ACAD SCI USA, V70, P2350, DOI 10.1073/pnas.70.8.2350; Tate WP, 1996, MOL MICROBIOL, V21, P213, DOI 10.1046/j.1365-2958.1996.6391352.x; Tate WP, 1996, PROG NUCLEIC ACID RE, V52, P293, DOI 10.1016/S0079-6603(08)60970-8; WEISSBRUMMER B, 1984, MOL GEN GENET, V198, P62, DOI 10.1007/BF00328702; Wilson DN, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P495; Yoshimura K, 1999, GENES CELLS, V4, P253, DOI 10.1046/j.1365-2443.1999.00260.x; Yoshizawa S, 1999, SCIENCE, V285, P1722, DOI 10.1126/science.285.5434.1722; Zhang YL, 1998, BBA-GENE STRUCT EXPR, V1443, P245, DOI 10.1016/S0167-4781(98)00223-1; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	41	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17241	17248		10.1074/jbc.M910448199	http://dx.doi.org/10.1074/jbc.M910448199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748224	hybrid			2022-12-27	WOS:000087485000006
J	del Castillo-Olivares, A; Gil, G				del Castillo-Olivares, A; Gil, G			alpha(1)-fetoprotein transcription factor is required for the expression of sterol 12 alpha-hydroxylase, the specific enzyme for cholic acid synthesis - Potential role in the bile acid-mediated regulation of gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; NUCLEAR RECEPTOR; IDENTIFICATION; HORMONE; LIVER; RAT; 6-BETA-HYDROXYLASE; CLONING; CYP8B1; FTZ-F1	Cholesterol conversion to bile acids occurs via the "classic" (neutral) or the "alternative" (acidic) bile acid biosynthesis pathways. Sterol 12 alpha-hydroxylase/CYP8b1 is the specific enzyme required for cholic acid synthesis. The levels of this enzyme determine the ratio of cholic acid to chenodeoxycholic acid and thus the hydrophobicity of the circulating bile acid pool. Expression of the 12 alpha-hydroxylase gene is tightly down-regulated by hydrophobic bile acids. In this study, we report the characterization of two DNA elements that are required for both the 12 alpha-hydroxylase promoter activity and bile acid-mediated regulation. Mutation of these elements suppresses 12 alpha-hydroxylase promoter activity. Mutations of any other part of the promoter do not alter substantially the promoter activity or alter regulation by bile acids relative to the wild type promoter. These two DNA elements bind alpha(1)-fetoprotein transcription factor (FTF), a member of the nuclear receptor family. We also show that overexpression of FTF in a non-liver cell line activates the sterol 12 alpha-hydroxylase promoter. These studies demonstrate the crucial role of FTF for the expression and regulation of a critical gene in the bile acid biosynthetic pathways.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	Virginia Commonwealth University	Gil, G (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, POB 980614, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044218] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44218] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson U, 1999, BBA-MOL CELL BIOL L, V1438, P167, DOI 10.1016/S1388-1981(99)00036-0; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Carey M.C., 1988, LIVER BIOL PATHOBIOL, V2nd, P573; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; DANIELSSON H, 1967, EUR J BIOCHEM, V2, P44, DOI 10.1111/j.1432-1033.1967.tb00103.x; DIETSCHY JM, 1970, NEW ENGL J MED, V282, P1128, DOI 10.1056/NEJM197005142822005; Eggertsen G, 1996, J BIOL CHEM, V271, P32269, DOI 10.1074/jbc.271.50.32269; Gafvels M, 1999, GENOMICS, V56, P184, DOI 10.1006/geno.1998.5606; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; HEUMAN DM, 1989, J LIPID RES, V30, P1161; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JAVITT NB, 1994, FASEB J, V8, P1308, DOI 10.1096/fasebj.8.15.8001744; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; RAMIREZ MI, 1994, MOL CELL BIOL, V14, P2809, DOI 10.1128/MCB.14.4.2809; Rao YP, 1999, J STEROID BIOCHEM, V70, P1, DOI 10.1016/S0960-0760(99)00099-0; SHAW R, 1979, J BIOL CHEM, V254, P7177; Stroup D, 1997, AM J PHYSIOL-GASTR L, V273, pG508, DOI 10.1152/ajpgi.1997.273.2.G508; Subramanian A, 1998, NUCLEIC ACIDS RES, V26, P2173, DOI 10.1093/nar/26.9.2173; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; TEIXEIRA J, 1991, J BIOL CHEM, V266, P21030; TURLEY SD, 1982, LIVER BIOL PATHOBIOL, P467; Vlahcevic ZR, 2000, GASTROENTEROLOGY, V118, P599, DOI 10.1016/S0016-5085(00)70267-8; Vlahcevic ZR, 1996, AM J PHYSIOL-GASTR L, V270, pG646, DOI 10.1152/ajpgi.1996.270.4.G646; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2	28	90	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17793	17799		10.1074/jbc.M000996200	http://dx.doi.org/10.1074/jbc.M000996200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747975	hybrid			2022-12-27	WOS:000087485000081
J	Hermann, M; Mahon, MG; Lindstedt, KA; Nimpf, J; Schneider, WJ				Hermann, M; Mahon, MG; Lindstedt, KA; Nimpf, J; Schneider, WJ			Lipoprotein receptors in extraembryonic tissues of the chicken	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-VLDL-II; YOLK-SAC; LIPID-METABOLISM; OOCYTE RECEPTOR; LDL RECEPTOR; MEDIATED ENDOCYTOSIS; MOLECULAR-CLONING; CELLS EXPRESS; FAMILY MEMBER	Yolk is the major source of nutrients for the developing chicken embryo, but molecular details of the delivery mechanisms are largely unknown. During oogenesis in the chicken, the main yolk components vitellogenin and very low density lipoprotein (VLDL) are taken up into the oocytes via a member of the low density lipoprotein receptor gene family termed LR8 (Bujo, H., Hermann, M., Kaderli, M. O., Jacobsen, L., Sugawara, S., Nimpf, J., Yamamoto, T., and Schneider, W.J. (1994) EMBO J. 13, 5165-5175). This endocytosis is accompanied by partial degradation of the yolk precursor protein moieties; however, fragmentation does not abolish binding of VLDL to LR8. The receptor exists in two isoforms that differ by a so-called O-linked sugar domain; the shorter form (LR8-) is the major form in oocytes, and the longer protein (LR8+) predominates in somatic cells. Here we show that both LR8 isoforms are expressed at ratios that vary with embryonic age in the extraembryonic yolk sac, which mobilizes yolk for utilization by the embryo, and in the allantois, the embryo's catabolic sink. Stored yolk VLDL interacts with LR8 localized on the surface of the yolk sac endodermal endothelial cells (EEC), is internalized, and degraded, as demonstrated by the catabolism of fluorescently labeled VLDL, in cultured EEC. Addition to the incubation medium of the 39-kDa receptor-associated protein, which inhibits all known LR8/ligand interactions, blocks the uptake of VLDL by EEC. The levels of endogenous receptor-associated protein correspond to those of LR8+ but not LR8-, suggesting that it may play a role in the modulation of surface presentation of LR8+. Importantly, EEC express significant levels of microsomal triglyceride transfer protein and protein disulfide isomerase, key components required for lipoprotein synthesis. Because the apolipoprotein pattern of VLDL isolated from the yolk sac-efferent omphalomesenteric vein is very different from that of yolk VLDL, these data strongly suggest that embryo plasma VLDL is resynthesized in the EEC. LR8 is a key mediator of a two-step pathway, which affects the uptake of VLDL from the yolk sac and the subsequent delivery of its components to the growing embryo.	Bioctr, Dept Mol Genet, Inst Med Biochem, A-1030 Vienna, Austria; Univ Vienna, A-1030 Vienna, Austria	University of Vienna	Hermann, M (corresponding author), Bioctr, Dept Mol Genet, Inst Med Biochem, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	mhermann@mol.univie.ac.at		Hermann, Marcela/0000-0003-2298-4269; Nimpf, Johannes/0000-0002-9273-3492				BARBER DL, 1991, J BIOL CHEM, V266, P18761; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BELLAIRS R, 1962, EXP CELL RES, V26, P275, DOI 10.1016/0014-4827(62)90178-7; BELLAIRS RUTH, 1964, ADVANCE MORPHO GENESIS, V4, P217; BENGTSSON G, 1977, EUR J BIOCHEM, V79, P211, DOI 10.1111/j.1432-1033.1977.tb11799.x; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHAN L, 1976, J CLIN INVEST, V58, P368, DOI 10.1172/JCI108481; DONALDSON JG, 1990, EUR J CELL BIOL, V53, P246; Elkin RG, 1997, COMP BIOCHEM PHYS B, V118, P913, DOI 10.1016/S0305-0491(97)00293-9; Evans R. J., 1972, MICRON, V3, P328; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1977, CELL, V12, P629, DOI 10.1016/0092-8674(77)90263-X; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HAYASHI K, 1989, J LIPID RES, V30, P1421; Hermann M, 1997, J LIPID RES, V38, P1308; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; Kanai M, 1996, MICROSC RES TECHNIQ, V35, P340, DOI 10.1002/(SICI)1097-0029(19961101)35:4<340::AID-JEMT5>3.0.CO;2-Q; Kanai M, 1997, MICROSC RES TECHNIQ, V39, P444, DOI 10.1002/(SICI)1097-0029(19971201)39:5<444::AID-JEMT7>3.3.CO;2-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBSON RO, 1970, AM J ANAT, V129, P1, DOI 10.1002/aja.1001290102; LAZIER CB, 1994, MOL CELL ENDOCRINOL, V106, P187, DOI 10.1016/0303-7207(94)90202-X; Lindstedt KA, 1997, J BIOL CHEM, V272, P30221, DOI 10.1074/jbc.272.48.30221; Lindstedt KA, 1997, DNA CELL BIOL, V16, P35, DOI 10.1089/dna.1997.16.35; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacLachlan I, 1996, BIOCHEM J, V317, P599, DOI 10.1042/bj3170599; MACLACHLAN I, 1994, J BIOL CHEM, V269, P24127; Magrane J, 1998, J LIPID RES, V39, P2172; MOBBS IG, 1981, AM J ANAT, V160, P285, DOI 10.1002/aja.1001600307; NIMPF J, 1989, P NATL ACAD SCI USA, V86, P906, DOI 10.1073/pnas.86.3.906; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1989, J BIOL CHEM, V264, P1393; NOBLE RC, 1984, WORLD POULTRY SCI J, V40, P114, DOI 10.1079/WPS19840009; NOBLE RC, 1984, POULTRY SCI, V63, P558, DOI 10.3382/ps.0630558; NOBLE RC, 1990, PROG LIPID RES, V29, P107, DOI 10.1016/0163-7827(90)90014-C; NOBLE RC, 1987, J EXP ZOOL, P65; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; RETZEK H, 1992, DNA CELL BIOL, V11, P661, DOI 10.1089/dna.1992.11.661; RUGH R, 1977, GUIDE VERTEBRATE DEV, P123; SCHJEIDE OA, 1963, PROGRESS CHEMISTRY F, V6, P251; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; SCHNEIDER WJ, 1990, J LIPID RES, V31, P507; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; Schneider Wolfgang J., 1995, Current Opinion in Lipidology, V6, P92, DOI 10.1097/00041433-199504000-00006; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WISKOCIL R, 1980, P NATL ACAD SCI-BIOL, V77, P4474, DOI 10.1073/pnas.77.8.4474; XIE Y, 1993, P NATL ACAD SCI USA, V90, P5569, DOI 10.1073/pnas.90.12.5569; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; YOUNG MF, 1983, DEV BIOL, V100, P50, DOI 10.1016/0012-1606(83)90199-9	53	32	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16837	16844		10.1074/jbc.M000163200	http://dx.doi.org/10.1074/jbc.M000163200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747878	hybrid			2022-12-27	WOS:000087392200062
J	Mainardi, JL; Legrand, R; Arthur, M; Schoot, B; van Heijenoort, J; Gutmann, L				Mainardi, JL; Legrand, R; Arthur, M; Schoot, B; van Heijenoort, J; Gutmann, L			Novel mechanism of beta-lactam resistance due to bypass of DD-transpeptidation in Enterococcus faecium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING-PROTEINS; ESCHERICHIA-COLI; PEPTIDOGLYCAN COMPOSITION; MUREIN SACCULUS; GROWTH; SHAPE; STRAINS; PHASE	The peptidoglycan structure of in vitro selected ampicillin-resistant mutant Enterococcus faecium D344M512 and of the susceptible parental strain D344S was determined by reverse phase high performance liquid chromatography and mass spectrometry. The muropeptide monomers were almost identical in the two strains. The substantial majority (99.3%) of the oligomers from the susceptible strain D344S contained the usual D-alanyl --> D-asparasginyl (or D-aspartyl)-L-lysyl cross-link (D-Ala --> D-Asx-L-Lys) generated by beta-lactam-sensitive DD-transpeptidation. The remaining oligomers (0.7%) were produced by beta-lactam-insensitive LD-transpeptidation, because they contained L-Lys --> D-ASX-L-Lys cross-links. The muropeptide oligomers of the ampicillin-resistant mutant D344M512 contained only these L-Lys --> D-ASX-L-Lys cross-links indicating that resistance was due to the bypass of the beta-lactam-sensitive DD-transpeptidation reaction. The discovery of this novel resistance mechanism indicates that DD-transpeptidases cannot be considered anymore as the sole essential transpeptidase enzymes.	Univ Paris 06, UFR Broussais Hotel Dieu, LRMA, F-75270 Paris, France; Hoechst Marion Roussel, Dept Phys, F-93235 Romainville, France; CNRS, F-91405 Orsay, France	UDICE-French Research Universities; Sorbonne Universite; Sanofi-Aventis; Sanofi France; Centre National de la Recherche Scientifique (CNRS)	Mainardi, JL (corresponding author), Univ Paris 06, UFR Broussais Hotel Dieu, LRMA, 15 Rue Ecole Med, F-75270 Paris, France.		Arthur, Michel/G-3680-2013; MAINARDI, Jean-Luc/E-2714-2014	Arthur, Michel/0000-0003-1007-636X; MAINARDI, Jean-Luc/0000-0002-4159-0129				BillotKlein D, 1997, J BACTERIOL, V179, P6208, DOI 10.1128/jb.179.19.6208-6212.1997; BillotKlein D, 1996, BIOCHEM J, V313, P711, DOI 10.1042/bj3130711; BLASCO B, 1988, J BACTERIOL, V170, P5224, DOI 10.1128/jb.170.11.5224-5228.1988; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; COYETTE J, 1994, EUR J BIOCHEM, V44, P459; deJonge BLM, 1996, MICROB DRUG RESIST, V2, P225, DOI 10.1089/mdr.1996.2.225; DRIEHUIS F, 1987, J BACTERIOL, V169, P97, DOI 10.1128/jb.169.1.97-101.1987; GEORGOPAPADAKOU NH, 1993, ANTIMICROB AGENTS CH, V37, P2045, DOI 10.1128/AAC.37.10.2045; Ghuysen Jean-Marie, 1994, Trends in Microbiology, V2, P372, DOI 10.1016/0966-842X(94)90614-9; Ghuysen JM, 1973, BACTERIAL MEMBRANES, P37; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; HARTMAN BJ, 1986, ANTIMICROB AGENTS CH, V29, P85, DOI 10.1128/AAC.29.1.85; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; HOLTJE JV, 1990, RES MICROBIOL, V141, P75, DOI 10.1016/0923-2508(90)90100-5; Mainardi JL, 1998, MICROBIOL-UK, V144, P2679, DOI 10.1099/00221287-144-10-2679; NIKAIDO H, 1989, ANTIMICROB AGENTS CH, V33, P1831, DOI 10.1128/AAC.33.11.1831; PISABARRO AG, 1985, J BACTERIOL, V161, P238, DOI 10.1128/JB.161.1.238-242.1985; RASMUSSEN JR, 1978, P NATL ACAD SCI USA, V75, P84, DOI 10.1073/pnas.75.1.84; Rybkine T, 1998, J INFECT DIS, V178, P159, DOI 10.1086/515605; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; Templin MF, 1999, EMBO J, V18, P4108, DOI 10.1093/emboj/18.15.4108; van Heijenoort J, 1998, CELL MOL LIFE SCI, V54, P300, DOI 10.1007/s000180050155; WILLIAMSON R, 1985, J GEN MICROBIOL, V131, P1933; Zorzi W, 1996, J BACTERIOL, V178, P4948, DOI 10.1128/jb.178.16.4948-4957.1996	25	108	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16490	16496		10.1074/jbc.M909877199	http://dx.doi.org/10.1074/jbc.M909877199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748168	hybrid			2022-12-27	WOS:000087392200015
J	Sergeant, N; Lyon, M; Rudland, PS; Fernig, DG; Delehedde, M				Sergeant, N; Lyon, M; Rudland, PS; Fernig, DG; Delehedde, M			Stimulation of DNA synthesis and cell proliferation of human mammary myoepithelial-like cells by hepatocyte growth factor/scatter factor depends on heparan sulfate proteoglycans and sustained phosphorylation of mitogen-activated protein kinases p42/44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						y	FACTOR SCATTER FACTOR; FIBROBLAST GROWTH; HUMAN BREAST; MAP KINASE; IN-VIVO; FACTOR-RECEPTOR; FACTOR BINDS; BASIC FGF; PATHWAYS; SITES	Hepatocyte growth factor/scatter factor (HGF/SF) is a heparan/dermatan sulfate-binding growth factor produced by stromal cells that acts as a paracrine effector on neighboring epithelia, HGF/SF stimulated DNA synthesis in human mammary (Huma) 109 myoepithelial-like cells grown on collagen I and fibronectin substrata but not when grown on plastic. Dual phosphorylation of mitogen-activated protein kinases (p42/44(MAPK)) was required for this stimulation of DNA synthesis. In Huma 109 cells cultured on plastic, HGF/SF stimulated a transient phosphorylation of p42/44(MAPK), which reached a maximum at 10 min after addition of the growth factor and returned to near basal levels after 20 min. In contrast, the phosphorylation of p42/44(MAPK) stimulated by HGF/SF in cells cultured on collagen I or fibronectin was sustained over 45 min. In Huma 109 cells deficient in sulfated glycosaminoglycans, HGF/SF failed to stimulate p42/44(MAPK) phosphorylation or DNA synthesis on any substratum, even when soluble heparan sulfate proteoglycans purified from the cells or from the culture medium were added. However, HGF/SF stimulated DNA synthesis and a sustained phosphorylation of p42/ 44(MAPK) in sulfated glycosaminoglycan-deficient Huma 109 cells plated on a substratum of medium HSPGs but not cell HSPGs. The HGF/SF-induced proliferation is thus highly dependent on heparan sulfate proteoglycans in myoepithelial-like cells.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Manchester, Christie Hosp NHS Trust, Canc Res Campaign, Dept Med Oncol, Manchester M20 4BX, Lancs, England	University of Liverpool; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Delehedde, M (corresponding author), Univ Liverpool, Sch Biol Sci, Life Sci Bldg,Crown St, Liverpool L69 7BZ, Merseyside, England.	dgfernig@liv.ac.uk	Fernig, David G/A-3590-2008; Sergeant, Nicolas/O-5467-2017	Fernig, David G/0000-0003-4875-4293; Sergeant, Nicolas/0000-0003-1448-124X; Lyon, Malcolm/0000-0001-9575-6879; DELEHEDDE, Maryse/0000-0003-2724-143X				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Beviglia L, 1997, INT J CANCER, V74, P301, DOI 10.1002/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; Day RM, 1999, ONCOGENE, V18, P3399, DOI 10.1038/sj.onc.1202683; Deakin JA, 1999, J CELL SCI, V112, P1999; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Kamalati T, 1999, J MAMMARY GLAND BIOL, V4, P69, DOI 10.1023/A:1018756620265; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; Lamszus K, 1996, AM J PATHOL, V149, P805; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELICCI G, 1995, ONCOGENE, V10, P1631; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Richardson L, 1996, TRENDS GLYCOSCI GLYC, V8, P167, DOI 10.4052/tigg.8.167; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RUDLAND PS, 1993, HISTOL HISTOPATHOL, V8, P385; RUDLAND PS, 1993, J HISTOCHEM CYTOCHEM, V41, P887, DOI 10.1177/41.6.7686196; Rudland PS, 1998, BIOCHEM SOC SYMP, P1; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; Sakata H, 1997, J BIOL CHEM, V272, P9457; Schuppan D, 1998, GASTROENTEROLOGY, V114, P139, DOI 10.1016/S0016-5085(98)70642-0; Shima N, 1998, J CELL PHYSIOL, V177, P130, DOI 10.1002/(SICI)1097-4652(199810)177:1<130::AID-JCP14>3.3.CO;2-O; SMITH JA, 1984, J CELL PHYSIOL, V119, P320, DOI 10.1002/jcp.1041190310; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; SUNITHA I, 1994, CLIN EXP METASTAS, V12, P143, DOI 10.1007/BF01753981; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; WILSON SE, 1994, CELL MOL BIOL RES, V40, P337; Yant J, 1998, EXP CELL RES, V241, P476, DOI 10.1006/excr.1998.4028	45	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17094	17099		10.1074/jbc.M000237200	http://dx.doi.org/10.1074/jbc.M000237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747885	hybrid			2022-12-27	WOS:000087392200097
J	Dam, TK; Cavada, BS; Grangeiro, TB; Santos, CF; Ceccatto, VM; de Sousa, FAM; Oscarson, S; Brewer, CF				Dam, TK; Cavada, BS; Grangeiro, TB; Santos, CF; Ceccatto, VM; de Sousa, FAM; Oscarson, S; Brewer, CF			Thermodynamic binding studies of lectins from the diocleinae subtribe to deoxy analogs of the core trimannoside of asparagine-linked oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCANAVALIN-A; GRANDIFLORA LECTIN; PLANT-LECTINS; TITRATION MICROCALORIMETRY; CARBOHYDRATE INTERACTIONS; CRYSTAL-STRUCTURE; LEGUME LECTINS; SITE; SPECIFICITIES; STIMULATION	Lectins from seven different species of the Diocleinae subtribe have been recently isolated and characterized in terms of their carbohydrate binding specificities (Dam, T. K., Cavada, B. S., Grangeiro, T. B., Santos, C. F., de Sousa, F. k M., Oscarson, S., and Brewer, C. F. (1998) J. Biol Chem. 273, 12082-12088). The lectins included those from Canavalia brasiliensis, Cratylia floribunda, Dioclea rostrata, Dioclea virgata, Dioclea violacea, and Dioclea guianensis. All of the lectins exhibited specificity for Man and Glc residues, but much higher affinities for the branched chain trimannoside, 3,6-di-O-(alpha-D-mannopyranosyl)-D-mannose, which is found in the core region of all asparagine-linked carbohydrates. In the present study, isothermal titration microcalorimetry is used to determine the binding thermodynamics of the above lectins, including a new lectin from Canavalia grandiflora, to a complete series of monodeoxy analogs of the core trimannoside. From losses in the affinity constants and enthalpies of binding of certain deoxy analogs, assignments are made of the hydroxyl epitopes on the trimannoside that are involved in binding to the lectins. The pattern of binding of the deoxy analogs is similar for all seven lectins, and similar to that of concanavalin A which is also a member of the Diocleinae subtribe. However, differences in the magnitude of the thermodynamic binding parameters of the lectins are observed, even though the lectins possess conserved contact residues in many cases, and highly conserved primary sequences. The results indicate that non-contact residues in the lectins, even those distant from the binding sites, modulate their thermodynamic binding parameters.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Univ Fed Ceara, Dept Bioquim & Biol Mol, Lab Mol Biologicamente Ativas, BR-60451970 Fortaleza, Ceara, Brazil; Univ Fed Ceara, Dept Biol, BR-60451970 Fortaleza, Ceara, Brazil; Univ Stockholm, Dept Organ Chem, S-10691 Stockholm, Sweden	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Universidade Federal do Ceara; Universidade Federal do Ceara; Stockholm University	Brewer, CF (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Ceccatto, Vânia M/D-1956-2017; Grangeiro, Thalles Barbosa/E-9606-2010; Ceccatto, Vania M/B-2324-2014; Cavada, Benildo/CEA-4997-2022	Grangeiro, Thalles Barbosa/0000-0001-8276-3092; Ceccatto, Vania M/0000-0003-4839-4400; Cavada, Benildo/0000-0002-5791-6170; Oscarson, Stefan/0000-0002-8273-4918	NCI NIH HHS [P30 CA-13330, CA-16054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016054, P30CA013330] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRAWAL BBL, 1967, BIOCHIM BIOPHYS ACTA, V147, P262, DOI 10.1016/0005-2795(67)90404-7; Andrade JL, 1999, CELL IMMUNOL, V194, P98, DOI 10.1006/cimm.1999.1494; BARRALNETTO M, 1992, IMMUNOL INVEST, V21, P297, DOI 10.3109/08820139209069369; BENTO CAM, 1993, AGENTS ACTIONS, V38, P48, DOI 10.1007/BF02027213; BRUMMELL DA, 1993, BIOCHEMISTRY-US, V32, P1180, DOI 10.1021/bi00055a024; Calvete JJ, 1999, BBA-PROTEIN STRUCT M, V1430, P367, DOI 10.1016/S0167-4838(99)00020-5; Cavada Benildo Sousa, 1996, Revista Brasileira de Fisiologia Vegetal, V8, P37; Cavada Benildo Sousa, 1996, Revista Brasileira de Fisiologia Vegetal, V8, P31; CAVADA BS, 1996, LECTINS BIOL BIOCH C, V11, P74; CHERVENAK MC, 1995, BIOCHEMISTRY-US, V34, P5685, DOI 10.1021/bi00016a045; Dam TK, 1998, J BIOL CHEM, V273, P32826, DOI 10.1074/jbc.273.49.32826; Dam TK, 1998, J BIOL CHEM, V273, P32812, DOI 10.1074/jbc.273.49.32812; Dam TK, 1998, J BIOL CHEM, V273, P12082, DOI 10.1074/jbc.273.20.12082; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Goldstein I. J., 1986, LECTINS PROPERTIES F, P35; GOMES JC, 1994, AGENTS ACTIONS, V41, P132, DOI 10.1007/BF02001905; Gupta D, 1996, BIOCHEMISTRY-US, V35, P15236, DOI 10.1021/bi961458+; Gupta D, 1996, EUR J BIOCHEM, V242, P320, DOI 10.1111/j.1432-1033.1996.0320r.x; Gupta D, 1997, J BIOL CHEM, V272, P6388, DOI 10.1074/jbc.272.10.6388; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; LEMIEUX RU, 1991, CIBA F SYMP, V158, P231; Liener I.E., 1986, LECTINS PROPERTIES F; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; MOREIRA RA, 1984, BIOL PLANTARUM, V26, P113, DOI 10.1007/BF02902274; Moreira Renato De Azevedo, 1996, Revista Brasileira de Fisiologia Vegetal, V8, P23; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; OLIVEIRA JTA, 1991, REV BRAS BOT, V14, P61; Oscarson S, 1995, CARBOHYD RES, V278, P271, DOI 10.1016/0008-6215(95)00268-5; RODRIGUEZ D, 1992, BRAZ J MED BIOL RES, V25, P823; Rozwarski DA, 1998, J BIOL CHEM, V273, P32818, DOI 10.1074/jbc.273.49.32818; SAHA SK, 1994, CARBOHYD RES, V254, P157; SanzAparicio J, 1997, FEBS LETT, V405, P114, DOI 10.1016/S0014-5793(97)00137-3; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; VASCONCELOS IM, 1991, J FOOD BIOCHEM, V15, P137, DOI 10.1111/j.1745-4514.1991.tb00150.x; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	37	32	40	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16119	16126		10.1074/jbc.M000670200	http://dx.doi.org/10.1074/jbc.M000670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747944	hybrid			2022-12-27	WOS:000087291400070
J	Liu, J; Brautigan, DL				Liu, J; Brautigan, DL			Insulin-stimulated phosphorylation of the protein phosphatase-1 striated muscle glycogen-targeting subunit and activation of glycogen synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; N-TERMINAL SEQUENCE; S6 KINASE-II; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; BINDING SUBUNIT; INHIBITION; MECHANISM; TRANSLOCATION; OVEREXPRESSION	Protein phosphatase-1 (PP-1) in heart and skeletal muscle binds to a glycogen-targeting subunit (G(M)) in the sarcoplasmic reticulum, Phosphorylation of G(M) has been postulated to govern activity of PP1 in response to adrenaline and insulin. In this study, we used biochemical assays and G, expression in living cells to examine the effects of insulin on the phosphorylation of G(M), and the binding of PP-1 to G(M), We also assayed glycogen synthase activation in cells expressing wild type G(M) and G(M) mutated at the phosphorylation sites. In biochemical assays kinase(s) prepared from insulin-stimulated Chinese hamster ovary (CHO-IR) cells and C2C12 myotubes phosphorylated a glutathione S-transferase (GST) fusion protein, GST-G(M)(1-240), at both site 1 (Ser(48)) and site 2 (Ser(67)), Phosphorylation of both sites was dependent on activation of the mitogen-activated protein kinase pathway, involving in particular ribosomal protein S6 kinase, Full-length G(M) was expressed in CHO-IR cells and metabolic P-32 labeling at sites 1 and 2 was increased by insulin treatment. The G(M) expressed in CHO-IR cells or in C2C12 myotubes co-immunoprecipitated endogenous PP-1, and association was transiently lost following treatment of the cells with insulin. In contrast PP-1 binding to G(M)(S67T), a version of G(M) not phosphorylated at site 2, was unaffected by insulin treatment. Expression of G(M) increased basal activity of endogenous glycogen synthase in CHO-IR cells. Insulin stimulated glycogen synthase activity the same extent in cells expressing wild type G, or G, mutated to eliminate phosphorylation site 1 and/or site 2, Phosphorylation of G, is stimulated by insulin, but this phosphorylation is not involved in insulin control of glycogen metabolism. We speculate that other functions of G(M) at the sarcoplasmic reticulum membrane might be affected by insulin.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Brautigan, DL (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, POB 800577,West Complex 7196, Charlottesville, VA 22908 USA.	db8g@virginia.edu			NCI NIH HHS [CA77584] Funding Source: Medline; NIGMS NIH HHS [GM56362] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azpiazu I, 1996, J BIOL CHEM, V271, P5033; BEGUM N, 1995, ADV PROT PHOSPHATASE, V9, P263; Berman HK, 1998, J BIOL CHEM, V273, P26421, DOI 10.1074/jbc.273.41.26421; Berrebi-Bertrand I, 1998, FEBS LETT, V439, P224, DOI 10.1016/S0014-5793(98)01364-7; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; Cohen P., 1986, ENZYMES, VXVII, P461; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DADD CA, 1993, BIOTECHNIQUES, V14, P266; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ERIKSON E, 1988, SEC MESS PHOSPHOPROT, V12, P135; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; HIRAGA A, 1986, EUR J BIOCHEM, V161, P763, DOI 10.1111/j.1432-1033.1986.tb10505.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LAWRENCE JC, 1994, J BIOL CHEM, V269, P11595; Lawrence JC, 1997, BIOCHEM SOC T, V25, P14, DOI 10.1042/bst0250014; LAWRENCE JC, 1983, J BIOL CHEM, V258, P710; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; MACKINTOSH C, 1988, FEBS LETT, V234, P189, DOI 10.1016/0014-5793(88)81331-0; Mastick CC, 1998, MOL CELL BIOCHEM, V182, P65; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; ROACH PJ, 1976, TRENDS BIOCHEM SCI, V1, P110, DOI 10.1016/0968-0004(76)90321-2; ROACH PJ, 1976, J BIOL CHEM, V251, P1913; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; RYLATT DB, 1980, EUR J BIOCHEM, V107, P529; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SMITH RL, 1985, J BIOL CHEM, V260, P273; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Suzuki Y, 1998, FASEB J, V12, pA1297; TANG PM, 1991, J BIOL CHEM, V266, P15782; VILLARPALASI C, 1960, BIOCHIM BIOPHYS ACTA, V39, P171, DOI 10.1016/0006-3002(60)90142-6; Walker KS, 2000, FEBS LETT, V466, P121, DOI 10.1016/S0014-5793(99)01771-8; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wu J, 1996, BIOCHEMISTRY-US, V35, P13858, DOI 10.1021/bi961669e; Wu J, 1998, FEBS LETT, V439, P185, DOI 10.1016/S0014-5793(98)01371-4; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	58	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15940	15947		10.1074/jbc.M909303199	http://dx.doi.org/10.1074/jbc.M909303199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748124	hybrid			2022-12-27	WOS:000087291400046
J	Albani, D; Mariconti, L; Ricagno, S; Pitto, L; Moroni, C; Helin, K; Cella, R				Albani, D; Mariconti, L; Ricagno, S; Pitto, L; Moroni, C; Helin, K; Cella, R			DcE2F, a functional plant E2F-like transcriptional activator from Daucus carota	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2F FAMILY MEMBERS; S-PHASE ENTRY; CELL-CYCLE; BINDING-PROTEIN; E2F-DEPENDENT TRANSCRIPTION; SUBCELLULAR-LOCALIZATION; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; DNA-BINDING; GENE	in animal cells the progression of the cell cycle through G(1)/S transition and S phase is under the control of the pRB/E2F regulatory pathway. The E2F transcription factors are key activators of genes coding for several regulatory proteins and for enzymes involved in nucleotide and DNA synthesis. In this report we have detected the presence of E2F-like DNA binding activities in carrot nuclear extracts, and we have isolated a carrot cDNA (DcE2F) encoding a plant E2F homologue. The DcE2F gene is expressed in proliferating cells and is induced during the G(1)/S transition of the cell cycle, Supershift experiments using anti-DcE2F antiserum have confirmed that the DcE2F protein is a component of the carrot E2F-like nuclear activities. DNA binding assays have demonstrated that the DcE2F protein can recognize a canonical E2F cis-element in association with a mammalian DP protein. Furthermore, transactivation assays have revealed that DcE2F is a functional transcription factor that can transactivate, together with a DP partner, an E2F-responsive reporter gene in both plant and mammalian cells.	Univ Sassari, Dept Bot & Plant Ecol, I-07100 Sassari, Italy; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy; CNR, Ist Mutagenesi & Differenziamento, I-56124 Pisa, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	University of Sassari; University of Pavia; Consiglio Nazionale delle Ricerche (CNR); IRCCS European Institute of Oncology (IEO)	Albani, D (corresponding author), Univ Sassari, Dept Bot & Plant Ecol, Via Muroni 25, I-07100 Sassari, Italy.		Pitto, Letizia/A-3070-2014; Moroni, Maria Cristina/H-7044-2018; Ricagno, Stefano/AAH-9763-2020; Ricagno, Stefano/G-1456-2015; Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Pitto, Letizia/0000-0002-8660-9516; Moroni, Maria Cristina/0000-0003-2409-5764; Ricagno, Stefano/0000-0001-6678-5873; Ricagno, Stefano/0000-0001-6678-5873; Helin, Kristian/0000-0003-1975-6097; Albani, Diego/0000-0002-1793-9212				Ach RA, 1997, MOL CELL BIOL, V17, P5077, DOI 10.1128/MCB.17.9.5077; Albani D, 1997, PLANT CELL, V9, P171, DOI 10.1105/tpc.9.2.171; BALESTRAZZI A, 1998, PLANT PHYSIOL, V117, P720; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANKS MS, 1976, PLANT SCI LETT, V7, P409, DOI 10.1016/0304-4211(76)90162-0; BARTELS D, 1983, NUCLEIC ACIDS RES, V11, P2961, DOI 10.1093/nar/11.10.2961; Bernacchia G, 1998, PLANT J, V13, P317, DOI 10.1046/j.1365-313X.1998.00034.x; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Doonan J, 1997, CURR OPIN CELL BIOL, V9, P824, DOI 10.1016/S0955-0674(97)80083-X; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GALLIE DR, 1989, PLANT CELL, V1, P301, DOI 10.1105/tpc.1.3.301; Grafi G, 1996, P NATL ACAD SCI USA, V93, P8962, DOI 10.1073/pnas.93.17.8962; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Huntley R, 1998, PLANT MOL BIOL, V37, P155, DOI 10.1023/A:1005902226256; Jost CA, 1996, VIROLOGY, V220, P78, DOI 10.1006/viro.1996.0288; Kosugi S, 1997, PLANT CELL, V9, P1607, DOI 10.1105/tpc.9.9.1607; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Lavia P, 1999, BIOESSAYS, V21, P221; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Meyerowitz EM, 1997, CELL, V88, P299, DOI 10.1016/S0092-8674(00)81868-1; Muller H, 1997, MOL CELL BIOL, V17, P5508; NIELSEN E, 1979, PLANT SCI LETT, V15, P113, DOI 10.1016/0304-4211(79)90063-4; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; Ramirez-Parra E, 1999, NUCLEIC ACIDS RES, V27, P3527, DOI 10.1093/nar/27.17.3527; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sekine M, 1999, FEBS LETT, V460, P117, DOI 10.1016/S0014-5793(99)01296-X; SHIRZADEGAN M, 1991, NUCLEIC ACIDS RES, V19, P6055, DOI 10.1093/nar/19.21.6055; Suzuki M, 1998, ONCOGENE, V17, P853, DOI 10.1038/sj.onc.1202163; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; TIMMERMANS MCP, 1990, J BIOTECHNOL, V14, P333, DOI 10.1016/0168-1656(90)90117-T; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Xie Q, 1996, EMBO J, V15, P4900, DOI 10.1002/j.1460-2075.1996.tb00870.x; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	46	50	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19258	19267		10.1074/jbc.M909390199	http://dx.doi.org/10.1074/jbc.M909390199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10748129	hybrid			2022-12-27	WOS:000087815900084
J	Marini, S; Fasciglione, GF; de Sanctis, G; D'Alessio, S; Politi, V; Coletta, M				Marini, S; Fasciglione, GF; de Sanctis, G; D'Alessio, S; Politi, V; Coletta, M			Cleavage of bovine collagen I by neutrophil collagenase MMP-8 - Effect of pH on the catalytic properties as compared to synthetic substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MATRIX METALLOPROTEINASES; INHIBITORS; SPECIFICITY; STABILITY; PEPTIDES; PROTEINS; BINDING	The enzymatic processing of bovine collagen I by neutrophil collagenase (MMP-8) has been monitored at 37 degrees C, envisaging the occurrence of multiple intermediate steps, following the initial cleavage, which leads to the formation of 1/4 and 3/4 fragments. Further, the first cleavage event has been investigated at 37 degrees C as a function of pH, and catalytic parameters have been obtained through a global analysis of steady-state kinetic data, such as to get an overall consistent picture of k(cat)/K-m, k(cat), and K-m. These data have been compared with those obtained from the catalysis by MMP-8 of two synthetic fluorogenic substrates under the same experimental conditions. The overall behavior can be accounted for by the existence of five protonating groups, which vary to a different extent their pK(a) values for the three substrates investigated. The main observation concerns the fact the two of these residues, which play a relevant role in the enzymatic activity of MMP-8, are relatively far from the primary recognition site, and they are coming into action only for large macromolecular substrates, such as bovine collagen I. This finding opens the question of appropriate testing for inhibitors of the enzymatic action of MMP-8, which must take into account, and also of these relevant interactions occurring only with natural substrates.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Camerino, Dept Mol Cellular & Anim Biol, I-62032 Camerino, MC, Italy; PoliFarma, I-00155 Rome, Italy	University of Rome Tor Vergata; University of Camerino	Coletta, M (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Bldg F Nord,Rm 65,Via Tor Vergata 135, I-00133 Rome, Italy.		Marini, Stefano/B-1161-2012; Coletta, Massimo/N-9049-2015; Coletta, Massimiliano/GSN-5927-2022; Danese, Silvio/ABH-9571-2020; Fasciglione, Giovanni Francesco/ABF-7738-2020	Marini, Stefano/0000-0003-1299-6696; Danese, Silvio/0000-0001-7341-1351; COLETTA, Massimiliano/0000-0002-5489-9467				Ackerman MS, 1999, J BIOL CHEM, V274, P7668, DOI 10.1074/jbc.274.12.7668; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BRADFORD MM, 1975, ANAL BIOCHEM, V72, P241; Cha J, 1997, BIOCHEMISTRY-US, V36, P16019, DOI 10.1021/bi972223g; CRAWFORD HC, 1994, INVAS METAST, V14, P234; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; GUTHRIE N, 1995, MOL CELL BIOCHEM, V144, P117, DOI 10.1007/BF00944390; HASTY KA, 1987, J BIOL CHEM, V262, P10048; Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573; KNAUPER V, 1993, BIOCHEM J, V291, P847; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin H, 1999, BIOCHEMISTRY-US, V38, P9956, DOI 10.1021/bi990800q; MALLYA SK, 1990, BIOCHEMISTRY-US, V29, P10628, DOI 10.1021/bi00499a008; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MCANULTY RJ, 1990, METHODS CARTILAGE RE, P140; Messent AJ, 1998, J CELL SCI, V111, P1127; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; STACK MS, 1990, ARCH BIOCHEM BIOPHYS, V281, P257, DOI 10.1016/0003-9861(90)90441-Z; Wess TJ, 1998, J MOL BIOL, V275, P255, DOI 10.1006/jmbi.1997.1449; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WU H, 1990, P NATL ACAD SCI USA, V87, P5888, DOI 10.1073/pnas.87.15.5888	27	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18657	18663		10.1074/jbc.M000283200	http://dx.doi.org/10.1074/jbc.M000283200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10749856	hybrid			2022-12-27	WOS:000087815900007
J	Su, C; Sahlin, M; Oliw, EH				Su, C; Sahlin, M; Oliw, EH			Kinetics of manganese lipoxygenase with a catalytic mononuclear redox center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN RESONANCE; SOYBEAN LIPOXYGENASE; HUMAN 5-LIPOXYGENASE; FATTY-ACIDS; IRON; HYDROPEROXIDES; SPECTROSCOPY; DIOXYGENASE; SEQUENCE; CLONING	Manganese lipoxygenase was isolated from the take-all fungus, Gaeumannomyces graminis, and the oxygenation mechanism was investigated, A kinetic isotope effect, k(H)/k(D) = 21-24, was observed with [U-H-2]linoleic acid as a substrate, The relative biosynthesis of (13R)-hydroperoxylinoleate (11S-HPODE) and (13R)-hydroperoxylinoleate (13R-HPODE) was pH-dependent and changed by [U-H-2]linoleic acid. Stopped-flow kinetic traces of linoleic and alpha-linolenic acids indicated catalytic lag times of similar to 45 ms, which were followed by bursts of enzyme activity for similar to 60 ms and then by steady state (k(cat) similar to 26 and similar to 47 s(-1), respectively). 11S-HPODE was isomerized by manganese lipoxygenase to 13R-HPODE and formed from linoleic acid at the same rates (k(cat) 7-9 s(-1)). Catalysis was accompanied by collisional quenching of the long wavelength fluorescence (640-685 nm) by fatty acid substrates and 13R-HPODE, Electron paramagnetic resonance (EPR) of native manganese lipoxygenase showed weak 6-fold hyperfine splitting superimposed on a broad resonance indicating two populations of Mn-II bound to protein. The addition of linoleic acid decreased both components, and denaturation of the lipoxygenase liberated similar to 0.8 Mn2+ atoms/lipoxygenase molecule. These observations are consistent with a mononuclear Mn-II center in the native state, which is converted during catalysis to an EPR silent Mn-III state. We propose that manganese lipoxygenase has kinetic and redox properties similar to iron lipoxygenases.	Uppsala Univ, Uppsala Biomed Ctr, Dept Pharmaceut Biosci, Div Biochem Pharmacol, SE-75124 Uppsala, Sweden; Stockholm Univ, Dept Mol Biol, SE-10691 Stockholm, Sweden	Uppsala University; Stockholm University	Oliw, EH (corresponding author), Uppsala Univ, Uppsala Biomed Ctr, Dept Pharmaceut Biosci, Div Biochem Pharmacol, POB 591, SE-75124 Uppsala, Sweden.			Oliw, Ernst/0000-0002-7986-8130				BELL RP, 1970, TUNNEL EFFECT CHEM; BOLDT YR, 1995, J BACTERIOL, V177, P1225, DOI 10.1128/jb.177.5.1225-1232.1995; Boldt YR, 1997, BIOCHEMISTRY-US, V36, P2147, DOI 10.1021/bi962362i; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P20968; CHAN HWS, 1979, CHEM PHYS LIPIDS, V24, P245, DOI 10.1016/0009-3084(79)90030-6; CHASTEEN ND, 1993, BIOCHEMISTRY-US, V32, P9763, DOI 10.1021/bi00088a031; CHEN XS, 1994, J BIOL CHEM, V269, P13979; Christianson DW, 1997, PROG BIOPHYS MOL BIO, V67, P217, DOI 10.1016/S0079-6107(97)88477-5; CHRISTOP.J, 1970, BIOCHIM BIOPHYS ACTA, V198, P12, DOI 10.1016/0005-2744(70)90028-8; COREY EJ, 1987, J AM CHEM SOC, V109, P8107, DOI 10.1021/ja00260a038; DASILVA JJR, 1990, INORGANIC CHEM LIFE, P370; DEGROOT JJM, 1975, BIOCHIM BIOPHYS ACTA, V377, P71, DOI 10.1016/0005-2744(75)90287-9; GLICKMAN MH, 1994, J AM CHEM SOC, V116, P793, DOI 10.1021/ja00081a060; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; Hamberg M, 1998, J BIOL CHEM, V273, P13080, DOI 10.1074/jbc.273.21.13080; HWANG CC, 1994, J AM CHEM SOC, V116, P795, DOI 10.1021/ja00081a061; Kohen A, 1999, CHEM BIOL, V6, pR191, DOI 10.1016/S1074-5521(99)80058-1; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; MACIAS P, 1988, COMP BIOCHEM PHYS B, V89, P531, DOI 10.1016/0305-0491(88)90170-8; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; Oliw EH, 1998, LIPIDS, V33, P843, DOI 10.1007/s11745-998-0280-0; PISTORIUS EK, 1976, J BIOL CHEM, V251, P7144; Prigge ST, 1996, PROTEINS, V24, P275; REED GH, 1970, J BIOL CHEM, V245, P662; Rickert KW, 1999, BIOCHEMISTRY-US, V38, P12218, DOI 10.1021/bi990834y; SHIBATA D, 1987, J BIOL CHEM, V262, P10080; Su C, 1998, J BIOL CHEM, V273, P20744, DOI 10.1074/jbc.273.33.20744; Su C, 1998, J BIOL CHEM, V273, P13072, DOI 10.1074/jbc.273.21.13072; Veldink G. A., 1998, EICOSANOIDS RELATED, P69; WIEGHARDT K, 1989, ANGEW CHEM INT EDIT, V28, P1153, DOI 10.1002/anie.198911531	32	66	68	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18830	18835		10.1074/jbc.M001408200	http://dx.doi.org/10.1074/jbc.M001408200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10751400	hybrid			2022-12-27	WOS:000087815900031
J	Asano, T; Kanda, A; Katagiri, H; Nawano, M; Ogihara, T; Inukai, K; Anai, M; Fukushima, Y; Yazaki, Y; Kikuchi, M; Hooshmand-Rad, R; Heldin, CH; Oka, Y; Funaki, M				Asano, T; Kanda, A; Katagiri, H; Nawano, M; Ogihara, T; Inukai, K; Anai, M; Fukushima, Y; Yazaki, Y; Kikuchi, M; Hooshmand-Rad, R; Heldin, CH; Oka, Y; Funaki, M			p110 beta is up-regulated during differentiation of 3T3-L1 cells and contributes to the highly insulin-responsive glucose transport activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; GLUT4 TRANSLOCATION; DNA-SYNTHESIS; INDUCED APOPTOSIS; SKELETAL-MUSCLE; P85-ALPHA GENE; PC12 CELLS; ADIPOCYTES	Activation of p85/p110 type phosphatidylinositol kinase is essential for aspects of insulin-induced glucose metabolism, including translocation of GLUT4 to the cell surface and glycogen synthesis. The enzyme exists as a heterodimer containing a regulatory subunit (e.g. p85 alpha) and one of two widely distributed isoforms of the p110 catalytic subunit: p110 alpha or p110 beta, In the present study, we compared the two isoforms in the regulation of insulin action. During differentiation of 3T3-L1 cells into adipocytes, p110 beta was up-regulated similar to 10-fold, whereas expression of p110 alpha was unaltered. The effects of the increased p110 expression were further assessed by expressing epitope tagged p110 beta and p110 alpha in 3T3-L1 cells using adenovirus transduction systems, respectively. In vitro, the basal lipid kinase activity of p110 beta was lower than that of p110 alpha. When p110 alpha and p110 beta were overexpressed in 3T3-L1 adipocytes, exposing cells to insulin induced each of the subunits to form complexes with p85 alpha and tyrosine-phosphorylated IRS-1 with similar efficiency. However, whereas the kinase activity of p110 beta, either endogenous or exogeneous, was markedly enhanced by insulin stimulation, only very small increases of the activity of p110 alpha were observed. Interestingly, overexpression of p110 beta increased insulin-induced glucose uptake by 3T3-L1 cells without significantly affecting basal glucose transport, whereas overexpression of p110 alpha increased both basal and insulin-stimulated glucose uptake. Finally, microinjection of anti-p110 beta neutralizing antibody into 3T3-L1 adipocytes abolished insulin-induced translocation of GLUT4 to the cell surface almost completely, whereas anti-p110 alpha neutralizing antibody did only slightly. Together, these findings suggest that p110 beta plays a crucial role in cellular activities evoked acutely by insulin.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 1130031, Japan; Ashai Life Fdn, Inst Adult Dis, Tokyo 1600023, Japan; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Yamaguchi Univ, Sch Med, Dept Internal Med 3, Ube, Yamaguchi 7550067, Japan	University of Tokyo; Asahi Life Foundation; Ludwig Institute for Cancer Research; Yamaguchi University	Asano, T (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130031, Japan.							Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; EVANS JL, 1995, CELL SIGNAL, V7, P365, DOI 10.1016/0898-6568(95)00007-C; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; Funaki M, 1999, J BIOL CHEM, V274, P22019, DOI 10.1074/jbc.274.31.22019; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Hooshmand-Rad R, 2000, J CELL SCI, V113, P207; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Liu Q, 1997, J IMMUNOL, V159, P829; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PONS S, 1995, MOL CELL BIOL, V15, P4453; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shepherd PR, 1997, J BIOL CHEM, V272, P19000, DOI 10.1074/jbc.272.30.19000; Shimoke K, 1997, DEV BRAIN RES, V101, P197, DOI 10.1016/S0165-3806(97)00065-5; Spear N, 1997, J NEUROCHEM, V69, P53; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	36	51	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17671	17676		10.1074/jbc.M910391199	http://dx.doi.org/10.1074/jbc.M910391199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748220	hybrid			2022-12-27	WOS:000087485000066
J	Nilsson, I; von Heijne, G				Nilsson, I; von Heijne, G			Glycosylation efficiency of Asn-Xaa-Thr sequons depends both on the distance from the C terminus and on the presence of a downstream transmembrane segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; LINKED CORE-GLYCOSYLATION; SEMLIKI FOREST VIRUS; EXTRACYTOSOLIC LOOPS; PROTEIN; MUTAGENESIS; SIGNAL; SITE; TRANSLOCATION; SEQUENCES	Statistical studies of N-glycosylated proteins have indicated that the frequency of nonglycosylated Asn-Xaa-(Thr/Ser) sequons increases toward the C terminus (Gavel, Y., and von Heijne, G. (1990) Protein Eng. 3, 433-442), Using in vitro transcription/translation of a truncated model protein in the presence of dog pancreas microsomes, we find that glycosylation efficiency of Asn-Xaa-Thr sequons indeed is reduced when the sequon is within similar to 60 residues of the C terminus. Surprisingly, the presence of a hydrophobic stop transfer sequence between the Asn-Xaa-Thr sequon and the C terminus results in a very different dependence of glycosylation efficiency on the distance to the C terminus, where the presence of the stop transfer segment inside the ribosome appears to cause a drastic drop in the level of glycosylation. We speculate that this may reflect a change in the structure of the ribosome/translocon complex induced by the stop transfer segment.	Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden	Stockholm University	von Heijne, G (corresponding author), Univ Stockholm, Dept Biochem, S-10691 Stockholm, Sweden.		von Heijne, Gunnar/AAH-9389-2019; Nilsson, IngMarie/H-2887-2012; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAROFF H, 1990, J CELL BIOL, V111, P867, DOI 10.1083/jcb.111.3.867; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LILJESTROM P, 1991, J VIROL, V65, P147; Monne M, 1998, J MOL BIOL, V284, P1177, DOI 10.1006/jmbi.1998.2218; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Nilsson I, 2000, J BIOL CHEM, V275, P6207, DOI 10.1074/jbc.275.9.6207; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ShakinEshleman SH, 1996, TRENDS GLYCOSCI GLYC, V8, P115, DOI 10.4052/tigg.8.115; SHAKINESHLEMAN SH, 1993, BIOCHEMISTRY-US, V32, P9465, DOI 10.1021/bi00087a026; Tam LY, 1996, BIOCHEM J, V318, P645, DOI 10.1042/bj3180645; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241	22	63	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17338	17343		10.1074/jbc.M002317200	http://dx.doi.org/10.1074/jbc.M002317200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748070	hybrid			2022-12-27	WOS:000087485000019
J	Callus, BA; Mathey-Prevot, B				Callus, BA; Mathey-Prevot, B			Hydrophobic residues Phe(751) and Leu(753) are essential for STAT5 transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL TRANSACTIVATION DOMAIN; DNA-BINDING; IFN-GAMMA; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ACTIVATION DOMAIN; ERYTHROPOIETIN RECEPTOR; CYTOKINE RECEPTORS; CRYSTAL-STRUCTURE; INTERFERON-GAMMA	One facet of cytokine signaling is relayed to the nucleus by the activation, through tyrosine phosphorylation, of latent cytoplasmic signal transducers and activators of transcription (STAT) family members. It has been demonstrated that the C termini of STATs contain the transactivation domain and are essential for the transactivation of target genes. To better understand the function of the STAT C terminus, we have generated a series of C-terminal mutants in STAT5a and examined their effects on transactivation, tyrosine phosphorylation, and DNA binding. Using GAZA chimerae with the C terminus of STATE, we have defined a 12-amino acid region essential for STATE transactivation, Surprisingly, deletion of these 12 amino acids in the context of the native STATE backbone presented the overall transcriptional activity of the protein. Further analysis revealed that deletion of this region resulted in hyper-DNA binding activity, thus compensating for the weakened transactivation domain. Using site-directed mutagenesis, we show that within this 12-amino acid region the acidic residues were non-essential for transactivation. In contrast, the non-acidic residues were crucial for transactivation. Mutating either Phe(751) or Leu(763) to alanine abolished transactivation suggesting that these residues were essential for connecting STAT5 to the basal transcriptional machinery.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Callus, BA (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062434] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL62434-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMOF T, 1995, J BIOL CHEM, V270, P17535; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P11; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; Callus BA, 1999, BIOCHEM BIOPH RES CO, V257, P874, DOI 10.1006/bbrc.1999.0558; CHEN RH, 1995, ONCOGENE, V11, P1771; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HELM MH, 1995, SCIENCE, V267, P1347; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu Y, 1999, GENE DEV, V13, P1692, DOI 10.1101/gad.13.13.1692; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; PARVIN JD, 1995, NATURE, V373, P742; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sainz MB, 1997, MOL CELL BIOL, V17, P115, DOI 10.1128/MCB.17.1.115; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Taylor DS, 1996, J BIOL CHEM, V271, P14020, DOI 10.1074/jbc.271.24.14020; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	61	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16954	16962		10.1074/jbc.M909976199	http://dx.doi.org/10.1074/jbc.M909976199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748177	hybrid			2022-12-27	WOS:000087392200079
J	Kirsch, M; de Groot, H				Kirsch, M; de Groot, H			Ascorbate is a potent antioxidant against peroxynitrite-induced oxidation reactions - Evidence that ascorbate acts by re-reducing substrate radicals produced by peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; LASER FLASH-PHOTOLYSIS; ACUTE LUNG INJURY; NITRIC-OXIDE; HYDROGEN-PEROXIDE; PULSE-RADIOLYSIS; CARBON-DIOXIDE; TYROSINE NITRATION; ELECTRON-TRANSFER; SUPEROXIDE	Peroxynitrite (ONOO-/ONOOH) is expected in vivo to react predominantly with CO2, thereby yielding NO2. and CO3<(.)over bar> radicals. We studied the inhibitory effects of ascorbate on both NADH and dihydrorhodamine 123 (DHR) oxidation by peroxynitrite generated in situ from 3-morpholinosydnonimine N-ethylcarbamide (SIN-1). SIN-1 (150 mu M)-mediated oxidation of NADH (200 mu M) was half-maximally inhibited by low ascorbate concentrations (61-75 mu M), both in the absence and presence of CO2. Control experiments performed with thiols indicated both the very high antioxidative efficiency of ascorbate and that in the presence of CO2 in situ-generated peroxynitrite exclusively oxidized NADH via the CO3<(.)over bar> radical. This fact is attributed to the formation of peroxynitrate (O2NOO-/O2NOOH) from reaction of NO2. with O-2(<(.)over bar>) which is formed from reaction of CO3<(.)over bar> with NADH. SIN-1 (25 mu M)-derived oxidation of DHR was half-maximally inhibited by surprisingly low ascorbate concentrations (6-7 mu M), irrespective of the presence of CO2. Control experiments performed with authentic peroxynitrite revealed that ascorbate was in regard to both thiols and selenocompounds much more effective to protect DHR. The present results demonstrate that ascorbate is highly effective to counteract the oxidizing properties of peroxynitrite in the absence and presence of CO2 by both terminating CO3<(.)over bar>/HO . reactions and by its repair function. Ascorbate is therefore expected to act intracellulary as a major peroxynitrite antagonist. In addition, a novel, ascorbate-independent protection pathway exists: scavenging of NO2. by O-2(<(.)over bar>) to yield O2NOO-, which further decomposes into NO2- and O-2.	Univ Essen Gesamthsch Klinikum, Inst Physiol Chem, D-45122 Essen, Germany	University of Duisburg Essen	Kirsch, M (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Physiol Chem, Hufelandstr 55, D-45122 Essen, Germany.							Alfassi ZB, 1999, RADIAT PHYS CHEM, V56, P475, DOI 10.1016/S0969-806X(99)00331-X; Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b; APPELMAN EH, 1995, INORG CHEM, V34, P787, DOI 10.1021/ic00108a007; Balavoine GGA, 1999, NITRIC OXIDE-BIOL CH, V3, P40, DOI 10.1006/niox.1999.0206; BARTLETT D, 1995, FREE RADICAL BIO MED, V18, P85, DOI 10.1016/0891-5849(94)E0133-4; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; BROWN LAS, 1996, ANTIOX HEALTH DIS, V3, P117; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; CARLSON BW, 1984, J AM CHEM SOC, V106, P7233, DOI 10.1021/ja00335a062; CHALLIS BC, 1978, J CHEM SOC PERK T 2, P1296, DOI 10.1039/p29780001296; Crow JP, 1997, J NEUROCHEM, V69, P1936; FORNI LG, 1986, J CHEM SOC PERK T 2, P1, DOI 10.1039/p29860000001; Goldstein S, 1998, INORG CHEM, V37, P3943, DOI 10.1021/ic980051l; Goldstein S, 1997, INORG CHEM, V36, P4156, DOI 10.1021/ic961186z; Goldstein S, 1998, J AM CHEM SOC, V120, P3458, DOI 10.1021/ja9733043; GRATZEL M, 1969, BERICH BUNSEN GESELL, V73, P646; GRODKOWSKI J, 1987, J PHYS CHEM-US, V87, P3135; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HADDAD IY, 1994, AM J PHYSIOL, V267, pL242, DOI 10.1152/ajplung.1994.267.3.L242; HALLIWELL B, 1978, PLANTA, V140, P81, DOI 10.1007/BF00389384; Hodges GR, 1999, J AM CHEM SOC, V121, P10695, DOI 10.1021/ja991077u; HORNIG D, 1975, ANN NY ACAD SCI, V258, P103, DOI 10.1111/j.1749-6632.1975.tb29271.x; HUNTER EPL, 1989, FREE RADICAL BIO MED, V6, P581, DOI 10.1016/0891-5849(89)90064-6; Kirsch M, 1999, J BIOL CHEM, V274, P24664, DOI 10.1074/jbc.274.35.24664; Kirsch M, 1998, J BIOL CHEM, V273, P12716, DOI 10.1074/jbc.273.21.12716; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KLINGENBERG M, 1985, METHOD ENZYMAT AN, V7, P251; Kok AB, 1997, MED HYPOTHESES, V48, P281, DOI 10.1016/S0306-9877(97)90097-9; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Lehnig M, 1999, ARCH BIOCHEM BIOPHYS, V368, P303, DOI 10.1006/abbi.1999.1268; LOGAGER T, 1993, J PHYS CHEM-US, V97, P10047; Lymar SV, 1998, CHEM RES TOXICOL, V11, P714, DOI 10.1021/tx980076x; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; MARTENS FM, 1983, J PHOTOCHEM, V22, P99, DOI 10.1016/0047-2670(83)80032-X; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Meli R, 1999, HELV CHIM ACTA, V82, P722, DOI 10.1002/(SICI)1522-2675(19990505)82:5<722::AID-HLCA722>3.3.CO;2-R; MEREDITH J, 1982, J BIOL CHEM, V257, P3747; MOORE JW, 1981, KINETICS MECHANISM; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; Padmaja S, 1996, REDOX REP, V2, P173, DOI 10.1080/13510002.1996.11747045; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Richeson CE, 1998, J AM CHEM SOC, V120, P7211, DOI 10.1021/ja980871x; ROSS AB, 1998, NDRL NIST SOLUTION K; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; Sies H, 1997, J BIOL CHEM, V272, P27812, DOI 10.1074/jbc.272.44.27812; Sies H., 1982, METABOLIC COMPARTMEN, P205; SLADE R, 1985, AM REV RESPIR DIS, V131, P742; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; SQUADRITO GL, 1995, ARCH BIOCHEM BIOPHYS, V322, P53, DOI 10.1006/abbi.1995.1435; Stanbury D. M., 1989, ADV INORG CHEM RA, V33, P69, DOI 10.1016/S0898-8838(08)60194-4; Sturgeon BE, 1998, J BIOL CHEM, V273, P30116, DOI 10.1074/jbc.273.46.30116; Uppu RM, 1996, ANAL BIOCHEM, V236, P242, DOI 10.1006/abio.1996.0162; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WILLIAMS DLH, 1986, NITROSATION	64	78	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16702	16708		10.1074/jbc.M909228199	http://dx.doi.org/10.1074/jbc.M909228199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748119	hybrid			2022-12-27	WOS:000087392200044
J	Sayed, M; Kim, SO; Salh, BS; Issinger, OG; Pelech, SL				Sayed, M; Kim, SO; Salh, BS; Issinger, OG; Pelech, SL			Stress-induced activation of protein kinase CK2 by direct interaction with p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CASEIN KINASE; II ACTIVITY; CELLULAR STRESSES; BETA-SUBUNIT; SWISS 3T3; CELLS; PHOSPHORYLATION; INSULIN; P53	Protein kinase CK2 has been implicated in the regulation of a wide range of proteins that are important in cell proliferation and differentiation. Here we demonstrate that the stress signaling agents anisomycin, arsenite, and tumor necrosis factor-alpha stimulate the specific enzyme activity of CK2 in the human cervical carcinoma HeLa cells by up to 8-fold, and this could be blocked by the p38 MAP kinase inhibitor SB203580. We show that p38 alpha MAP kinase, in a phosphorylation-de pendent manner, can directly interact with the alpha and beta subunits of CK2 to activate the holoenzyme through what appears to be an allosteric mechanism. Furthermore, we demonstrate that anisomycin- and tumor necrosis factor-alpha-induced phosphorylation of p53 at Ser-392, which is important for the transcriptional activity of this growth suppressor protein, requires p38 MAP kinase and CK2 activities.	Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Jack Bell Res Ctr, Dept Med, Vancouver, BC V6H 3Z6, Canada; SDU, Biokem Inst, Dept Biomed Res & Mol Cell Biol, DK-5230 Odense, Denmark	University of British Columbia; University of British Columbia; University of Southern Denmark	Pelech, SL (corresponding author), Univ British Columbia, Dept Med, Room S125,2nd Floor,Koerner Pavil,2211 Wesbrook M, Vancouver, BC V6T 1Z3, Canada.							ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AGOSTINIS P, 1992, J BIOL CHEM, V267, P9732; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOZZETTI MP, 1995, P NATL ACAD SCI USA, V92, P6067, DOI 10.1073/pnas.92.13.6067; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETT G, 1954, J BIOL CHEM, V211, P969; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHARLTON LA, 1992, J BIOL CHEM, V267, P8840; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dobrowolska G, 1999, MOL CELL BIOCHEM, V191, P3, DOI 10.1023/A:1006882910351; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; Heriche JK, 1998, ONCOGENE, V17, P13, DOI 10.1038/sj.onc.1201900; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KRAISS S, 1990, ONCOGENE, V5, P845; Kusk M, 1999, MOL CELL BIOCHEM, V191, P51, DOI 10.1023/A:1006840613986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PROWALD K, 1984, FEBS LETT, V176, P479, DOI 10.1016/0014-5793(84)81222-3; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VILLAMORUZZI E, 1991, BIOCHEM BIOPH RES CO, V177, P1019, DOI 10.1016/0006-291X(91)90640-S; WANG LG, 1995, J LEUKOCYTE BIOL, V57, P332, DOI 10.1002/jlb.57.2.332	33	121	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16569	16573		10.1074/jbc.M000312200	http://dx.doi.org/10.1074/jbc.M000312200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747897	hybrid			2022-12-27	WOS:000087392200025
J	Hironaka, K; Umemori, H; Tezuka, T; Mishina, M; Yamamoto, T				Hironaka, K; Umemori, H; Tezuka, T; Mishina, M; Yamamoto, T			The protein-tyrosine phosphatase PTPMEG interacts with glutamate receptor delta 2 and epsilon subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; POSTSYNAPTIC DENSITY; DEVELOPMENTAL-CHANGES; PURKINJE-CELLS; PSD-95 FAMILY; DOMAIN; EXPRESSION; KINASES; SRC; ACTIVATION	Glutamate receptor (GluR) delta 2 is selectively expressed in cerebellar Purkinje cells and plays a crucial role in cerebellum-dependent motor learning. Although GluR delta 2 belongs to an ionotropic GluR family, little is known about its pharmacological features and downstream signaling cascade. To study molecular mechanisms underlying GluR delta 2-dependent motor learning, we employed yeast two-hybrid screening to isolate GluR delta 2-interacting molecules and identified protein-tyrosine phosphatase PTPMEG. PTPMEG is a family member of band 4.1 domain-containing protein-tyrosine phosphatases and is expressed prominently in brain. Here, we showed by in situ hybridization analysis that the PTPMEG mRNA was enriched in mouse thalamus and Purkinje cells. We also showed that PTPMEG interacted with GluR delta 2 as well as with N-methyl-D-aspartate receptor GluR epsilon 1 in cultured cells and in brain. PTPMEG bound to the putative C-terminal PDZ target sequence of GluR delta 2 and GluR epsilon 1 via its PDZ domain. Examination of the effect of PTPMEG on tyrosine phosphorylation of GluR epsilon 1 unexpectedly revealed that PTPMEG enhanced Fyn-mediated tyrosine phosphorylation of GluR epsilon 1 in its PTPase activity-dependent manner. Thus, we conclude that PTPMEG associates directly with GluR delta 2 and GluR epsilon 1. Moreover, our data suggest that PTPMEG plays a role in signaling downstream of the GluRs and/or in regulation of their activities through tyrosine dephosphorylation.	Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Sch Med, Dept Mol Neurobiol & Pharmacol, Tokyo 1138655, Japan; Japan Sci & Tech Corp, CREST, Saitama 3220012, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan.			Umemori, Hisashi/0000-0001-7198-2062				ARAKI K, 1993, BIOCHEM BIOPH RES CO, V197, P1267, DOI 10.1006/bbrc.1993.2614; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; Gu MX, 1996, J BIOL CHEM, V271, P27751, DOI 10.1074/jbc.271.44.27751; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; Kato S, 1998, ACTA NEUROPATHOL, V96, P67, DOI 10.1007/s004010050861; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MAYAT E, 1995, J NEUROSCI, V15, P2533, DOI 10.1523/JNEUROSCI.15-03-02533.1995; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Niethammer M, 1996, J NEUROSCI, V16, P2157; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Roche KW, 1999, J NEUROSCI, V19, P3926; SAHIN M, 1995, P NATL ACAD SCI USA, V92, P7859, DOI 10.1073/pnas.92.17.7859; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Takayama C, 1996, DEV BRAIN RES, V92, P147, DOI 10.1016/0165-3806(95)00212-X; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	42	74	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16167	16173		10.1074/jbc.M909302199	http://dx.doi.org/10.1074/jbc.M909302199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748123	hybrid			2022-12-27	WOS:000087291400077
J	Regnard, C; Desbruyeres, E; Huet, JC; Beauvallet, C; Pernollet, JC; Edde, B				Regnard, C; Desbruyeres, E; Huet, JC; Beauvallet, C; Pernollet, JC; Edde, B			Polyglutamylation of nucleosome assembly proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TUBULIN; POSTTRANSLATIONAL MODIFICATIONS; BETA-TUBULIN; MASS-SPECTROMETRY; HISTONE CHAPERONE; AP-I; BRAIN; GLUTAMYLATION; PURIFICATION; BINDING	Polyglutamylation is an original posttranslational modification, discovered on tubulin, consisting in side chains composed of several glutamyl units and leading to a very unusual protein structure. A monoclonal antibody directed against glutamylated tubulin (GT335) was found to react with other proteins present in HeLa cells. After immunopurification on a GT335 affinity column, two prominent proteins of similar to 50 kDa were observed. They were identified by microsequencing and mass spectrometry as NAP-1 and NAP-2, two members of the nucleosome assembly protein family that are implicated in the deposition of core histone complexes onto chromatin, Strikingly, NAP-1 and NAP-2 were found to be substrates of an ATP-dependent glutamylation enzyme copurifying on the same column. We took advantage of this property to specifically label and purify the polyglutamylated peptides, NAP-1 and NAP-2 are modified in their C-terminal domain by the addition of up to 9 and 10 glutamyl units, respectively. Two putative glutamylation sites were localized for NAP-1 at Glu-356 and Glu-357 and, for NAP-2, at Glu-347 and Glu-348. These results demonstrate for the first time that proteins other than tubulin are polyglutamylated and open new perspectives for studying NAP function.	Coll France, F-75005 Paris, France; INRA, F-78352 Jouy En Josas, France	UDICE-French Research Universities; PSL Research University Paris; College de France; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Edde, B (corresponding author), Coll France, 11 Pl Marcelin Berthelot, F-75005 Paris, France.	edde@ext.jussieu.fr		Regnard, Catherine/0000-0001-9915-7494				Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; AUDEBERT S, 1994, J CELL SCI, V107, P2313; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; Bobinnec Y, 1998, CELL MOTIL CYTOSKEL, V39, P223, DOI 10.1002/(SICI)1097-0169(1998)39:3<223::AID-CM5>3.3.CO;2-3; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; BOUCHER D, 1994, BIOCHEMISTRY-US, V33, P12471, DOI 10.1021/bi00207a014; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; DEWOLFF A, 1992, EUR J CELL BIOL, V59, P425; EDDE B, 1992, BIOCHEMISTRY-US, V31, P403, DOI 10.1021/bi00117a014; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; EDDE B, 1991, J CELL BIOCHEM, V46, P134, DOI 10.1002/jcb.240460207; EDDE B, 1989, BIOL CELL, V65, P109; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; Gagnon C, 1996, J CELL SCI, V109, P1545; Geimer S, 1997, CELL MOTIL CYTOSKEL, V37, P72; Hu RJ, 1996, HUM MOL GENET, V5, P1743, DOI 10.1093/hmg/5.11.1743; ISHIMI Y, 1985, CELL STRUCT FUNCT, V10, P373, DOI 10.1247/csf.10.373; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KELLOGG DR, 1995, J CELL BIOL, V130, P675, DOI 10.1083/jcb.130.3.675; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larcher JC, 1996, J BIOL CHEM, V271, P22117, DOI 10.1074/jbc.271.36.22117; MacRae TH, 1997, EUR J BIOCHEM, V244, P265, DOI 10.1111/j.1432-1033.1997.00265.x; Marheineke K, 1998, J BIOL CHEM, V273, P15279, DOI 10.1074/jbc.273.24.15279; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; REDEKER V, 1992, FEBS LETT, V313, P185, DOI 10.1016/0014-5793(92)81441-N; Redeker V, 1998, BIOCHEMISTRY-US, V37, P14838, DOI 10.1021/bi981335k; REDEKER V, 1994, SCIENCE, V266, P1688, DOI 10.1126/science.7992051; Regnard C, 1998, BIOCHEMISTRY-US, V37, P8395, DOI 10.1021/bi9804131; Regnard C, 1999, J CELL SCI, V112, P4281; Rodriguez P, 1997, GENOMICS, V44, P253, DOI 10.1006/geno.1997.4868; RUDIGER M, 1992, FEBS LETT, V308, P101, DOI 10.1016/0014-5793(92)81061-P; Schneider A, 1998, FEBS LETT, V429, P399, DOI 10.1016/S0014-5793(98)00644-9; SIMON HU, 1994, BIOCHEM J, V297, P389, DOI 10.1042/bj2970389; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vinh J, 1999, BIOCHEMISTRY-US, V38, P3133, DOI 10.1021/bi982304s; WALTER PP, 1995, MOL CELL BIOL, V15, P6178	41	72	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15969	15976		10.1074/jbc.M000045200	http://dx.doi.org/10.1074/jbc.M000045200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747868	Green Published, hybrid			2022-12-27	WOS:000087291400050
J	Song, BW; Sung, P				Song, BW; Sung, P			Functional interactions among yeast Rad51 recombinase, Rad52 mediator, and replication protein A in DNA strand exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BREAK REPAIR; BINDING-PROTEIN; RECA; GENE; BACTERIOPHAGE-T4; FILAMENT; UVSY; CATALYSIS; SEQUENCE	Rad51-catalyzed DNA strand exchange is greatly enhanced by the single-stranded (ss) DNA binding factor RPA if the latter is introduced after Rad51 has already nucleated onto the initiating ssDNA substrate. Paradoxically, co-addition of RPA with Rad51 to the ssDNA to mimic the in vivo situation diminishes the level of strand exchange, revealing competition between RPA and Rad51 for binding sites on ssDNA Rad52 promotes strand exchange but only when there is a need for Rad51 to compete with RPA for loading onto ssDNA Rad52 is multimeric, binds ssDNA, and targets Rad51 to ssDNA. Maximal restoration of pairing and strand exchange requires amounts of Rad52 substoichiometric to Rad51 and involves a stable, equimolar complex between Rad51 and Rad52, The Rad51-Rad52 complex efficiently utilizes a ssDNA template saturated with RPA for homologous pairing but does not appear to be more active than Rad51 when an RPA-free ssDNA template is used. Rad52 does not substitute for RPA in the pairing and strand exchange reaction nor does it lower the dependence of the reaction on Rad51 or RPA.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Sung, P (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	sung@uthscsa.edu			NIEHS NIH HHS [ES07061] Funding Source: Medline; NIGMS NIH HHS [GM57814] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; Gupta RC, 1998, P NATL ACAD SCI USA, V95, P9843, DOI 10.1073/pnas.95.17.9843; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; Ivanov EL, 1996, GENETICS, V142, P693; JIANG H, 1993, J BIOL CHEM, V268, P7904; Kanaar R, 1998, NATURE, V391, P335, DOI 10.1038/34790; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Sweezy MA, 1997, J MOL BIOL, V266, P927, DOI 10.1006/jmbi.1996.0829; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; VOELKELMEIMAN K, 1990, GENETICS, V124, P561; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; Zaitsev EN, 2000, GENE DEV, V14, P740; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	34	133	136	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15895	15904		10.1074/jbc.M910244199	http://dx.doi.org/10.1074/jbc.M910244199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748203	hybrid			2022-12-27	WOS:000087291400040
J	Faik, A; Bar-Peled, M; DeRocher, AE; Zeng, WQ; Perrin, RM; Wilkerson, C; Raikhel, NV; Keegstra, K				Faik, A; Bar-Peled, M; DeRocher, AE; Zeng, WQ; Perrin, RM; Wilkerson, C; Raikhel, NV; Keegstra, K			Biochemical characterization and molecular cloning of an alpha-1,2-fucosyltransferase that catalyzes the last step of cell wall xyloglucan biosynthesis in pea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUCOSYL-TRANSFERASE; GDP-FUCOSE; MICROSOMAL-MEMBRANES; IDENTIFICATION; POLYSACCHARIDE; ALPHA-1,3/4-FUCOSYL-TRANSFERASES; GALACTOSYLTRANSFERASE; GLYCOSYLTRANSFERASES; SPECIFICITY; PROTEINS	Pea microsomes contain an alpha-fucosyltransferase that incorporates fucose from GDP-fucose into xyloglucan, adding it preferentially to the 2-O-position of the galactosyl residue closest to the reducing end of the repeating subunit, This enzyme was solubilized with detergent and purified by affinity chromatography on GDP-hexanolamine-agarose followed by gel filtration. By utilizing peptide sequences obtained from the purified enzyme, a cDNA clone was isolated that encodes a 565-amino acid protein with a predicted molecular mass of 64 kDa and shows 62.3% identity to its Arabidopsis homolog. The purified transferase migrates at similar to 63 kDa by SDS-polyacrylamide gel electrophoresis but elutes from the gel filtration column as an active protein of higher molecular weight (similar to 250 kDa), indicating that the active form is an oligomer, The enzyme is specific for xyloglucan and is inhibited by xyloglucan oligosaccharides and by the by-product GDP, The enzyme has a neutral pH optimum and does not require divalent ions. Kinetic analysis indicates that GDP-fucose and xyloglucan associate with the enzyme in a random order. N-Ethylmaleimide, a cysteine-specific modifying reagent, had little effect on activity, although several other amino acid-modifying reagents strongly inhibited activity.	Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Cell & Mol Biol Program, E Lansing, MI 48824 USA; Michigan State Univ, Dept Bot & Plant Pathol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University; Michigan State University	Keegstra, K (corresponding author), Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA.		Faik, Ahmed/ABB-9120-2020; Zeng, Weiqing/AAA-7045-2019	Zeng, Weiqing/0000-0002-5466-8693				BEYER TA, 1980, J BIOL CHEM, V255, P5373; BOLWELL GP, 1984, PLANTA, V162, P139, DOI 10.1007/BF00410210; Britten CJ, 1997, BBA-GEN SUBJECTS, V1334, P57, DOI 10.1016/S0304-4165(96)00076-1; BRUMMELL DA, 1990, J CELL SCI, V96, P705; CAMIRAND A, 1986, PLANT PHYSIOL, V82, P379, DOI 10.1104/pp.82.2.379; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; DARVILL AG, 1978, PLANT PHYSIOL, V62, P418, DOI 10.1104/pp.62.3.418; Desveaux D, 1998, PLANT PHYSIOL, V118, P885, DOI 10.1104/pp.118.3.885; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DOONG RL, 1995, PLANT PHYSIOL, V109, P141, DOI 10.1104/pp.109.1.141; EDWARDS M, 1985, PLANTA, V163, P133, DOI 10.1007/BF00395907; Edwards ME, 1999, PLANT J, V19, P691, DOI 10.1046/j.1365-313x.1999.00566.x; Faik A, 1997, PLANT PHYSIOL, V114, P245, DOI 10.1104/pp.114.1.245; FARKAS V, 1988, ARCH BIOCHEM BIOPHYS, V264, P48, DOI 10.1016/0003-9861(88)90568-1; FRY SC, 1993, PHYSIOL PLANTARUM, V89, P1; GUILLEN R, 1995, CARBOHYD RES, V277, P291, DOI 10.1016/0008-6215(95)00220-N; HANNA R, 1991, ARCH BIOCHEM BIOPHYS, V290, P7, DOI 10.1016/0003-9861(91)90584-6; HAYASHI T, 1984, PLANT PHYSIOL, V75, P596, DOI 10.1104/pp.75.3.596; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HISAMATSU M, 1991, CARBOHYD RES, V211, P117, DOI 10.1016/0008-6215(91)84150-D; Hokke CH, 1998, GLYCOBIOLOGY, V8, P393, DOI 10.1093/glycob/8.4.393; HOLMES EH, 1992, ARCH BIOCHEM BIOPHYS, V296, P562, DOI 10.1016/0003-9861(92)90611-Y; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; MARCHER BA, 1991, GLYCOBIOLOGY, V1, P577; MCNEIL M, 1984, ANNU REV BIOCHEM, V53, P625, DOI 10.1146/annurev.bi.53.070184.003205; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; Perrin RM, 1999, SCIENCE, V284, P1976, DOI 10.1126/science.284.5422.1976; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; Sherwood AL, 1998, J BIOL CHEM, V273, P25256, DOI 10.1074/jbc.273.39.25256; Simons JF, 1998, EMBO J, V17, P396, DOI 10.1093/emboj/17.2.396; Vincken JP, 1996, CARBOHYD POLYM, V29, P75, DOI 10.1016/0144-8617(95)00149-2; WALDRON K W, 1985, P79; ZABLACKIS E, 1995, PLANT PHYSIOL, V107, P1129, DOI 10.1104/pp.107.4.1129; ZHANG GF, 1992, PLANT PHYSIOL, V99, P1070, DOI 10.1104/pp.99.3.1070	39	70	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15082	15089		10.1074/jbc.M000677200	http://dx.doi.org/10.1074/jbc.M000677200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747946	hybrid			2022-12-27	WOS:000087128300044
J	Westberg, C; Yang, JP; Tang, HL; Reddy, TR; Wong-Staal, F				Westberg, C; Yang, JP; Tang, HL; Reddy, TR; Wong-Staal, F			A novel shuttle protein binds to RNA helicase A and activates the retroviral constitutive transport element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; HIV-1 REV; HUMAN TAP; TYPE-1; MEX67P; PORES; REPLICATION; CONTAINS; CLONING; HOMOLOG	The constitutive transport element (CTE) of type D retroviruses mediates the nuclear export of unspliced viral transcripts. We previously showed that RNA helicase A functionally interacts with CTE and contains a bidirectional nuclear transport domain at the carboxyl terminus. Here we report the identification of a novel human protein, helicase A-binding protein 95 (HAP95), which specifically binds to the carboxyl terminus of RNA helicase A HAP95 is partially homologous to AKAP95, a member of the A kinase-anchoring protein family, but lacks the protein kinase A binding domain characteristic of this family. HAP95 is a nuclear protein at steady state but shuttles between the nucleus and cytoplasm. Overexpression of HAP95 significantly increases CTE-dependent gene expression but has no effect on general gene expression or that mediated by the Rev/Rev response element of human immunodeficiency virus type 1.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wong-Staal, F (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Tang, Hengli/F-2085-2014		NIAID NIH HHS [P30 AI 36214] Funding Source: Medline; NIGMS NIH HHS [GM056089] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bear J, 1999, MOL CELL BIOL, V19, P6306; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Eide T, 1998, EXP CELL RES, V238, P305, DOI 10.1006/excr.1997.3855; Farjot G, 1999, J BIOL CHEM, V274, P17309, DOI 10.1074/jbc.274.24.17309; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Hope TJ, 1999, ARCH BIOCHEM BIOPHYS, V365, P186, DOI 10.1006/abbi.1999.1207; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; LEE CG, 1992, J BIOL CHEM, V267, P4398; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; MICHAEL WM, 1995, CELL, V83, P415; Orstavik S, 2000, BIOL CELL, V92, P27, DOI 10.1016/S0248-4900(00)88761-4; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Sambrook J., 2002, MOL CLONING LAB MANU; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; ZOLOTUKHIN AS, 1994, J VIROL, V68, P7944, DOI 10.1128/JVI.68.12.7944-7952.1994	24	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21396	21401		10.1074/jbc.M909887199	http://dx.doi.org/10.1074/jbc.M909887199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10748171	hybrid			2022-12-27	WOS:000088230600059
J	Bouckaert, J; Dewallef, Y; Poortmans, F; Wyns, L; Loris, R				Bouckaert, J; Dewallef, Y; Poortmans, F; Wyns, L; Loris, R			The structural features of concanavalin A governing non-proline peptide isomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; LEGUME LECTINS; BINDING-SITE; ION BINDING; PROTEINS; BONDS; PEA; CONFORMATION; TRANSITIONS; RECOGNITION	The reversible binding of manganese and calcium to concanavalin A determines the carbohydrate binding of the lectin by inducing large conformational changes. These changes are governed by the isomerization of a non-proline peptide bond, Ala-207-Asp-208, positioned in a beta-strand in between the calcium binding site 52 and the carbohydrate specificity-determining loop. The replacement of calcium by manganese allowed us to investigate the structures of the carbohydrate binding, locked state and the inactive, unlocked state of concanavalin A, both with and without metal ions bound. Crystals of unlocked metal-free concanavalin A convert to the locked form with the binding of two Mn2+ ions. Removal of these ions from the crystals traps metal-free concanavalin A in its locked state, a minority species in solution. The ligation of a metal ion in 52 to unlocked concanavalin A causes bending of the beta-strand foregoing the 52 ligand residues Asp-10 and Tyr-12. This bending disrupts conventional beta-sheet hydrogen bonding and forces the Thr-11 side chain against the Ala-207-Asp-208 peptide bond. The steric strain exerted by Thr-ll is presumed to drive the trans-to-cis isomerization, Upon isomerization, Asp-208 flips into its carbohydrate binding position, and the conformation of the carbohydrate specificity determining loop changes dramatically.	Free Univ Brussels VIB, Lab Ultrastruct, B-1640 Rhode St Genese, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Bouckaert, J (corresponding author), Free Univ Brussels VIB, Lab Ultrastruct, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	bouckaej@vub.ac.be	Loris, Remy/GPG-0894-2022	Bouckaert, Julie/0000-0001-8112-1442; Loris, Remy/0000-0002-8862-3338				ANTANAITIS BC, 1987, BIOCHEMISTRY-US, V26, P7932, DOI 10.1021/bi00398a058; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bouckaert J, 1995, PROTEINS, V23, P510, DOI 10.1002/prot.340230406; Bouckaert J, 1996, J BIOL CHEM, V271, P16144, DOI 10.1074/jbc.271.27.16144; BREWER CF, 1983, BIOCHEMISTRY-US, V22, P3691, DOI 10.1021/bi00284a024; BREWER CF, 1983, J BIOMOL STRUCT DYN, V1, P961, DOI 10.1080/07391102.1983.10507497; BROWN RD, 1977, BIOCHEMISTRY-US, V16, P3883, DOI 10.1021/bi00636a026; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, X PLOR VERSION 3 1; DRICKAMER K, 1995, CURR OPIN STRUC BIOL, V5, P612, DOI 10.1016/0959-440X(95)80052-2; EINHOFF W, 1986, BIOL CHEM H-S, V367, P15, DOI 10.1515/bchm3.1986.367.1.15; EINSPAHR H, 1985, ACTA CRYSTALLOGR B, V41, P336, DOI 10.1107/S0108768185002233; EMMERICH C, 1994, ACTA CRYSTALLOGR D, V50, P749, DOI 10.1107/S0907444994002143; Evans W, 1997, CHEM BRIT, V33, P22; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; He XL, 1999, J MOL BIOL, V292, P125, DOI 10.1006/jmbi.1999.3036; Jabs A, 1999, J MOL BIOL, V286, P291, DOI 10.1006/jmbi.1998.2459; KALB AJ, 1999, METAL IONS BIOL SYST; KOENIG SH, 1978, BIOCHEMISTRY-US, V17, P4251, DOI 10.1021/bi00613a022; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; MARCHETTI PS, 1988, J MAGN RESON, V80, P417, DOI 10.1016/0022-2364(88)90238-7; NAISMITH JH, 1993, ACTA CRYSTALLOGR D, V49, P561, DOI 10.1107/S0907444993006390; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17977, DOI 10.1021/bi9819733; NISHIMURA M, 1982, PLANT PHYSIOL, V70, P742, DOI 10.1104/pp.70.3.742; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAULOVA M, 1971, BIOCHIM BIOPHYS ACTA, V252, P388, DOI 10.1016/0304-4165(71)90019-5; PEUMANS WJ, 1995, PLANT PHYSIOL, V109, P347, DOI 10.1104/pp.109.2.347; SCHECHER G, 1994, BIOL CHEM H-S, V375, P829; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; WEISGERBER S, 1993, J CHEM SOC FARADAY T, V89, P2667, DOI 10.1039/ft9938902667; Weiss MS, 1998, NAT STRUCT BIOL, V5, P676, DOI 10.1038/1368; WENZEL M, 1995, J PLANT PHYSIOL, V145, P191, DOI 10.1016/S0176-1617(11)81871-7; YOUNG NM, 1992, J MOL BIOL, V228, P924, DOI 10.1016/0022-2836(92)90875-K	37	66	68	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19778	19787		10.1074/jbc.M001251200	http://dx.doi.org/10.1074/jbc.M001251200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748006	hybrid			2022-12-27	WOS:000087941300048
J	Cho, GW; Kim, MH; Chai, YG; Gilmor, ML; Levey, AI; Hersh, LB				Cho, GW; Kim, MH; Chai, YG; Gilmor, ML; Levey, AI; Hersh, LB			Phosphorylation of the rat vesicular acetylcholine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHOLINERGIC GENE LOCUS; FACTOR-II RECEPTOR; DI-LEUCINE MOTIF; SYNAPTIC VESICLES; CAENORHABDITIS-ELEGANS; MONOAMINE TRANSPORTER; CYTOPLASMIC TAIL; EXPRESSION; ENDOCYTOSIS	Metabolic labeling of a mutant PC12 cell line, A123.7, expressing recombinant rat vesicular acetylcholine transporter (VAChT) with radiolabeled inorganic phosphate was used to demonstrate phosphorylation of the transporter on a serine residue. Mutational analysis was used to demonstrate that serine 480, which is located on the COOH-terminal cytoplasmic tail, is the sole phosphorylation site. Phosphorylation of serine 480 was attributable to the action of protein kinase C. Using a permanently dephosphorylated form of rat VAChT, S480A rVAChT, it was shown that this mutant displays the same kinetics for the transport of acetylcholine and the binding of the inhibitor vesamicol as does the wild type transporter. However, sucrose gradient density centrifugation showed that, unlike wild type VAChT, the S480A mutant did not localize to synaptic vesicles. These results suggest that phosphorylation of serine 480 of VAChT is involved in the trafficking of this transporter.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Biochem, Lexington, KY 40536 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; Hanyang Univ, Dept Biochem, Ansan 425791, South Korea	University of Kentucky; Emory University; Hanyang University	Hersh, LB (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Biochem, 800 Rose St, Lexington, KY 40536 USA.	lhersh@pop.uky.edu	Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X	NATIONAL INSTITUTE ON AGING [R01AG005893, R55AG005893] Funding Source: NIH RePORTER; NIA NIH HHS [AG05893, AG05144] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXANDER DR, 1990, BIOCHEM J, V268, P303, DOI 10.1042/bj2680303; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; Barbosa J, 1997, J NEUROCHEM, V69, P2608; Chen H, 1999, J BIOL CHEM, V274, P3257, DOI 10.1074/jbc.274.6.3257; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FARIN CE, 1994, MOL REPROD DEV, V37, P284, DOI 10.1002/mrd.1080370307; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Gilmor ML, 1996, J NEUROSCI, V16, P2179; GINTY DD, 1991, J BIOL CHEM, V266, P15325; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; INOUE H, 1995, J NEUROCHEM, V64, P985; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; Kim MH, 1999, J BIOL CHEM, V274, P673, DOI 10.1074/jbc.274.2.673; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Krantz DE, 1997, J BIOL CHEM, V272, P6752, DOI 10.1074/jbc.272.10.6752; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Liu JP, 1997, CLIN EXP PHARMACOL P, V24, P611, DOI 10.1111/j.1440-1681.1997.tb02101.x; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; NGUYEN ML, 1995, J NEUROCHEM, V64, P1137; PARSONS SM, 1993, INT REV NEUROBIOL, V35, P279, DOI 10.1016/S0074-7742(08)60572-3; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; RUDNICK G, 1986, ANNU REV PHYSIOL, V48, P403; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEFTON B, 1997, CURR PROT MOL BIOL, V40; Shimojo M, 1998, J NEUROCHEM, V71, P1118; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SMITH AD, 1992, BIOCH SOC S, V36, P103; Song HJ, 1997, NEURON, V18, P815, DOI 10.1016/S0896-6273(00)80320-7; Tan PK, 1998, J BIOL CHEM, V273, P17351, DOI 10.1074/jbc.273.28.17351; USDIN TB, 1995, TRENDS NEUROSCI, V18, P281; Varoqui H, 1998, J BIOL CHEM, V273, P9094, DOI 10.1074/jbc.273.15.9094; Varoqui H, 1997, MOL NEUROBIOL, V15, P165, DOI 10.1007/BF02740633; VAROQUI H, 1994, FEBS LETT, V342, P97, DOI 10.1016/0014-5793(94)80592-X; Varoqui H, 1996, J BIOL CHEM, V271, P27229, DOI 10.1074/jbc.271.44.27229; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	46	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19942	19948		10.1074/jbc.M902174199	http://dx.doi.org/10.1074/jbc.M902174199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748073	hybrid			2022-12-27	WOS:000087941300070
J	Valenzuela, JG; Charlab, R; Mather, TN; Ribeiro, JMC				Valenzuela, JG; Charlab, R; Mather, TN; Ribeiro, JMC			Purification, cloning, and expression of a novel salivary anticomplement protein from the tick, Ixodes scapularis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-H; COMPLEMENT; DAMMINI; PARASITES; EVASION	The alternative pathway of complement is an important defense against pathogens and in tick rejection reactions. The tick Ixodes scapularis is able to feed repeatedly on its natural host and has a salivary anticomplement activity that presumably facilitates feeding. In this study, we purified and then obtained the aminoterminal sequence of the I. scapularis salivary anticomplement (Isac), We found a full-length clone coding for Isac by random screening of a salivary gland cDNA library. Expressing Isac cDNA in COS cells reproduced the activity found in tick saliva, namely, inhibition of rabbit erythrocyte lysis by human serum in the presence of Mg2+ and EGTA, inhibition of C3b binding to agarose in the presence of Mg2+ and EGTA, and acceleration of factor Bb uncoupling from the C3 convertase generated by the alternative pathway. Recombinant Isac had no effect on the recalcification time of human platelet-poor plasma or in the classical complement pathway, indicating that it is a specific inhibitor similar to the regulators of complement activation of the alternative pathway such as factor H. Isac, however, has no similarity to any protein in the GenBank(TM) data base, indicating that it is a novel and relatively small (18.5 kDa) anticomplement molecule.	NIAID, NIH, Parasit Dis Lab, Sect Med Entomol, Bethesda, MD 20892 USA; Univ Rhode Isl, Ctr Vector Borne Dis, Kingston, RI 02881 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Rhode Island	Ribeiro, JMC (corresponding author), NIAID, NIH, Parasit Dis Lab, Sect Med Entomol, Bldg 4,Rm 126,4 Ctr Dr,MSC 0425, Bethesda, MD 20892 USA.			Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000810, Z01AI000810, R01AI037230, R21AI037230] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 37230] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; DAMERAU B, 1987, REV PHYSL BIOCH PHAR, V108, P152; DAVIDAR P, 1989, J PARASITOL, V75, P898, DOI 10.2307/3282868; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; JOINER KA, 1988, ANNU REV MICROBIOL, V42, P201, DOI 10.1146/annurev.mi.42.100188.001221; JOKIRANTA TS, 1995, SCAND J IMMUNOL, V42, P9, DOI 10.1111/j.1365-3083.1995.tb03620.x; Kirschfink M, 1997, IMMUNOPHARMACOLOGY, V38, P51, DOI 10.1016/S0162-3109(97)00057-X; Lawrie CH, 1999, EXP PARASITOL, V93, P207, DOI 10.1006/expr.1999.4456; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PLATTSMI.TA, 1974, J IMMUNOL, V113, P348; RIBEIRO JMC, 1986, EXP PARASITOL, V62, P292, DOI 10.1016/0014-4894(86)90034-2; RIBEIRO JMC, 1987, EXP PARASITOL, V64, P347, DOI 10.1016/0014-4894(87)90046-4; RIBEIRO JMC, 1989, EXP APPL ACAROL, V7, P15, DOI 10.1007/BF01200449; Rosengard AM, 1999, IMMUNOPHARMACOLOGY, V42, P99, DOI 10.1016/S0162-3109(99)00012-0; TATCHELL RJ, 1967, J PARASITOL, V53, P1106, DOI 10.2307/3276849; TRAGER WILLIAM, 1939, JOUR PARASITOL, V25, P57, DOI 10.2307/3272160; Valenzuela JG, 1998, J BIOL CHEM, V273, P30583, DOI 10.1074/jbc.273.46.30583; VOGT W, 1974, PHARMACOL REV, V26, P125; WIKEL SK, 1979, AM J TROP MED HYG, V28, P586, DOI 10.4269/ajtmh.1979.28.586; WIKEL SK, 1977, IMMUNOLOGY, V32, P457; Wikel SK, 1996, ANNU REV ENTOMOL, V41, P1, DOI 10.1146/annurev.en.41.010196.000245; WILLADSEN P, 1980, BIOCHEM J, V189, P295, DOI 10.1042/bj1890295; Wurzner R, 1999, MOL IMMUNOL, V36, P249, DOI 10.1016/S0161-5890(99)00049-8; Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3; Zipfel PF, 1999, IMMUNOPHARMACOLOGY, V42, P53, DOI 10.1016/S0162-3109(99)00015-6	25	199	213	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18717	18723		10.1074/jbc.M001486200	http://dx.doi.org/10.1074/jbc.M001486200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10749868	hybrid, Green Published			2022-12-27	WOS:000087815900016
J	Cichy, J; Pure, E				Cichy, J; Pure, E			Oncostatin M and transforming growth factor-beta 1 induce post-translational modification and hyaluronan binding to CD44 in lung-derived epithelial tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE; EXTRACELLULAR DOMAIN; CARCINOMA-CELLS; AMINO-TERMINUS; P-SELECTIN; RECEPTOR; EXPRESSION; GLYCOSYLATION; RECOGNITION; ADHESION	CD44, a receptor for hyaluronan (HA), has been implicated in tumor growth and metastasis. Most CD44-positive cells fail to exhibit constitutive HA receptor function but CD44-mediated HA binding on hematopoetic cells can be induced by antibody cross-linking of the receptor and by physiologic stimuli, including cytokines. me now demonstrate that oncostatin M (OSM) and transforming growth factor-beta 1, cytokines known to regulate the growth of tumor cells, stimulate HA binding in lung epithelial-derived tumor cells. In lung epithelial-derived tumor cells, cytokine-induced binding resulted from post-translational modification of the receptor. OSM-induced HA binding was associated with a reduction in N-linked carbohydrate content of CD44. In addition, OSM induced Hcl binding via a novel mechanism requiring sulfation of chondroitin sulfate chains linked to CD44. The mechanism underlying transforming growth factor-beta 1 induced HA binding was distinct from the effects of OSM. The data presented indicate that modulation of the glycosylation and sulfation of CD44 by cytokines provides mechanisms for regulating cell adhesion during tumor growth and metastasis.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Jagiellonian Univ, Inst Mol Biol, PL-31120 Krakow, Poland; Ludwig Inst Canc Res, New York, NY 10158 USA	The Wistar Institute; Jagiellonian University; Ludwig Institute for Cancer Research	Cichy, J (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.			Cichy, Joanna/0000-0002-0552-8344				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Chiu RK, 1999, EXP CELL RES, V248, P314, DOI 10.1006/excr.1999.4391; CICHY J, 1995, J CLIN INVEST, V95, P2729, DOI 10.1172/JCI117975; Cichy J, 1998, FEBS LETT, V429, P412, DOI 10.1016/S0014-5793(98)00643-7; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; Esford LE, 1998, J CELL SCI, V111, P1021; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; JALKANEN S, 1988, J IMMUNOL, V141, P1615; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Ladeda V, 1998, EXP CELL RES, V242, P515, DOI 10.1006/excr.1998.4094; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; LESLEY J, 1993, EUR J IMMUNOL, V23, P1902, DOI 10.1002/eji.1830230826; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; Levesque MC, 1996, J IMMUNOL, V156, P1557; LIAO HX, 1995, J IMMUNOL, V155, P3938; Maiti A, 1998, SCIENCE, V282, P941, DOI 10.1126/science.282.5390.941; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; MURAKAMIMORI K, 1995, J CLIN INVEST, V96, P1319, DOI 10.1172/JCI118167; NAOT D, 1997, ADV CANCER RES, V71, P241; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; PURE E, 1995, J EXP MED, V181, P55, DOI 10.1084/jem.181.1.55; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SCHLOSSMAN SF, 1995, WHITE CELL DIFFERENT; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; TOYAMASORIMACHI N, 1994, INT IMMUNOL, V6, P655, DOI 10.1093/intimm/6.4.655; Yeo TK, 1996, AM J PATHOL, V148, P1733; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985	39	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18061	18069		10.1074/jbc.M907962199	http://dx.doi.org/10.1074/jbc.M907962199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10751416	hybrid			2022-12-27	WOS:000087659400023
J	Dai, RJ; Frejtag, W; He, B; Zhang, Y; Mivechi, NF				Dai, RJ; Frejtag, W; He, B; Zhang, Y; Mivechi, NF			c-Jun NH2-terminal kinase targeting and phosphorylation of heat shock factor-1 suppress its transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; STRESS-INDUCED APOPTOSIS; MAP KINASE; DNA-BINDING; FACTOR HSF1; FACTOR-I; CELLS; FAMILY; GENE; REPRESSION	The mammalian heat shock transcription factor HSF-1 regulates the expression of the heat shock proteins, molecular chaperones that are involved in cellular processes from higher order assembly to protein degradation. HSF-1 is a phosphorylated monomer under physiological growth conditions and is located mainly in the cytoplasm. Upon activation by a variety of environmental stresses, HSF-I is translocated into the nucleus, forms trimers, acquires DNA binding activity, is hyperphosphorylated, appears as punctate granules, and increases transcriptional activity of target genes. As cells recover from stress, the punctate granules gradually disappear, and HSF-I appears in a diffused staining pattern in the cytoplasm and nucleus. We have previously shown that the mitogen-activated protein kinase ERK phosphorylates and suppresses HSF-l-driven transcription. Here, Re show that c-Jun NH2-terminal kinase (JNK) also phosphorylates and inactivates HSF-I. Overexpression of JNK facilitates the rapid disappearance of HSF-1 punctate granules after heat shock Similar to ERE, JNK binds to HSF-1 in the conserved mitogen-activated protein kinases binding motifs and phosphorylates HSF-1 in the regulatory domain. The overexpression of an HSF-l-green fluorescent protein fusion construct lacking JNK phosphorylation sites causes this HSF-1 mutant to form nuclear granules that remain longer in the nucleus after heat shock. Taken together, these findings indicate that JNK phosphorylates HSF-1 and suppresses its transcriptional activity by rapidly clearing HSF-1 hom the sites of transcription.	Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Grp, Augusta, GA 30912 USA; Med Coll Georgia, Dept Radiol, Augusta, GA 30912 USA; Ctr Dis Control & Prevent, NIOSH, Morgantown, WV 26505 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Mivechi, NF (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Grp, 1120 15th St,CB2803, Augusta, GA 30912 USA.	mivechi@immag.mcg.edu			NATIONAL CANCER INSTITUTE [R01CA062130] Funding Source: NIH RePORTER; NCI NIH HHS [CA62130] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANTOR L, 1987, ANAL BIOCHEM, V100, P414; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Cotto JJ, 1997, J CELL SCI, V110, P2925; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MIVECHI NF, 1994, J CELL BIOCHEM, V54, P186, DOI 10.1002/jcb.240540207; MIVECHI NF, 1995, CANCER RES, V55, P5512; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; Strahl T, 1996, P NATL ACAD SCI USA, V93, P11563, DOI 10.1073/pnas.93.21.11563; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; Wu YL, 1997, CARCINOGENESIS, V18, P1069, DOI 10.1093/carcin/18.5.1069; Xia WL, 1998, J BIOL CHEM, V273, P8749, DOI 10.1074/jbc.273.15.8749; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	56	98	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18210	18218		10.1074/jbc.M000958200	http://dx.doi.org/10.1074/jbc.M000958200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10747973	hybrid			2022-12-27	WOS:000087659400042
J	Cournac, L; Redding, K; Ravenel, J; Rumeau, D; Josse, EM; Kuntz, M; Peltier, G				Cournac, L; Redding, K; Ravenel, J; Rumeau, D; Josse, EM; Kuntz, M; Peltier, G			Electron flow between photosystem II and oxygen in chloroplasts of photosystem I-deficient algae is mediated by a quinol oxidase involved in chlororespiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASTID NDH GENES; CHLAMYDOMONAS-REINHARDTII; TOBACCO CHLOROPLASTS; ARABIDOPSIS DEFINES; THYLAKOID MEMBRANES; TRANSPORT CHAINS; CO2 FIXATION; REDOX STATE; DEHYDROGENASE; PLASTOQUINONE	In Chlamydomonas reinhardtii mutants deficient in photosystem I because of inactivation of the chloroplast genes psaA or psaB, oxygen evolution from photosystem II occurs at significant rates and is coupled to a stimulation of oxygen uptake. Both activities can be simultaneously monitored by continuous mass spectrometry in the presence of O-18(2), The light-driven O-2 exchange was shown to involve the plastoquinone pool as an electron carrier, but not cytochrome b(6)f, Photosystem II-dependent O-2 production and O-2 uptake were observed in isolated chloroplast fractions. Photosystem II-dependent oxygen exchange was insensitive to a variety of inhibitors (azide, carbon monoxide, cyanide, antimycin A, and salicylhydroxamic acid) and radical scavengers. It was, however, sensitive to propyl gallate, From inhibitors effects and electronic requirements of the O-2 uptake process, we conclude that an oxidase catalyzing oxidation of plastoquinol and reduction of oxygen to water is present in thylakoid membranes. From the sensitivity of flash-induced O-2 exchange to propyl gallate, we conclude that this oxidase is involved in chlororespiration, Clues to the identity of the protein implied in this process are given by pharmacological and immunological similarities with a protein (IMMUTANS) identified in Arabidopsis chloroplasts.	CEA, Ctr Cadarache, LEP, DEVM,DSV, F-13108 St Paul Les Durance, France; Univ Alabama, Dept Chem & Coalit BioMol Prod, Tuscaloosa, AL 35487 USA; CEA Cadarache, CNRS, UMR 163, DEVM,DSV, F-13108 St Paul Les Durance, France; Univ Grenoble 1, CNRS, UMR 5575, Lab Genet Mol Plantes, F-38041 Grenoble 09, France	CEA; University of Alabama System; University of Alabama Tuscaloosa; CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Cournac, L (corresponding author), CEA, Ctr Cadarache, LEP, DEVM,DSV, Batiment 161,, F-13108 St Paul Les Durance, France.	laurent.cournac@cea.fr	Cournac, Laurent/G-2564-2010; PELTIER, Gilles/ABD-4484-2021	PELTIER, Gilles/0000-0002-2226-3931; Cournac, Laurent/0000-0003-0371-938X; Josse, Eve-Marie/0000-0002-3286-8264; Redding, Kevin/0000-0003-2819-4022				BELKNAP WR, 1981, P NATL ACAD SCI-BIOL, V78, P2310, DOI 10.1073/pnas.78.4.2310; BENNOUN P, 1991, GENETICS, V127, P335; BENNOUN P, 1982, P NATL ACAD SCI-BIOL, V79, P4352, DOI 10.1073/pnas.79.14.4352; BENNOUN P, 1994, BBA-BIOENERGETICS, V1186, P59, DOI 10.1016/0005-2728(94)90135-X; Berthold DA, 1998, BBA-BIOENERGETICS, V1364, P73, DOI 10.1016/S0005-2728(98)00015-2; BOUDREAU E, 1994, PLANT MOL BIOL, V24, P585, DOI 10.1007/BF00023556; Buchel C, 1998, PHOTOSYNTHETICA, V35, P223, DOI 10.1023/A:1006958706540; Burrows PA, 1998, EMBO J, V17, P868, DOI 10.1093/emboj/17.4.868; Carol P, 1999, PLANT CELL, V11, P57, DOI 10.1105/tpc.11.1.57; Corneille S, 1998, BBA-BIOENERGETICS, V1363, P59, DOI 10.1016/S0005-2728(97)00074-1; Cournac L, 1997, FEBS LETT, V416, P65, DOI 10.1016/S0014-5793(97)01170-8; Elortza F, 1999, PLANT CELL PHYSIOL, V40, P149, DOI 10.1093/oxfordjournals.pcp.a029522; Endo T, 1998, PLANT CELL PHYSIOL, V39, P1226, DOI 10.1093/oxfordjournals.pcp.a029324; Fischer N, 1996, MOL GEN GENET, V251, P373, DOI 10.1007/s004380050179; GANS P, 1990, BIOCHIM BIOPHYS ACTA, V1015, P150, DOI 10.1016/0005-2728(90)90226-T; GARAB G, 1989, PLANTA, V179, P349, DOI 10.1007/BF00391080; GODDE D, 1980, ARCH MICROBIOL, V127, P245, DOI 10.1007/BF00427200; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; Guedeney G, 1996, FEBS LETT, V378, P277, DOI 10.1016/0014-5793(95)01473-X; Harlow E., 1988, ANTIBODIES LAB MANUA; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HAVAUX M, 1987, PLANT PHYSIOL BIOCH, V25, P735; Howitt CA, 1998, BIOCHEMISTRY-US, V37, P17944, DOI 10.1021/bi981486n; KAHL R, 1990, ADV EXP MED BIOL, V264, P283; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lichtenthaler H.K., 1983, BIOCHEM SOC T, V11, P591, DOI [10.1042/bst0110591, DOI 10.1042/BST0110591]; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Norris SR, 1995, PLANT CELL, V7, P2139, DOI 10.1105/tpc.7.12.2139; PELTIER G, 1991, P NATL ACAD SCI USA, V88, P4791, DOI 10.1073/pnas.88.11.4791; PELTIER G, 1988, BIOCHIM BIOPHYS ACTA, V936, P319, DOI 10.1016/0005-2728(88)90007-2; PELTIER G, 1987, BIOCHIM BIOPHYS ACTA, V893, P83, DOI 10.1016/0005-2728(87)90151-4; Peltier G, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P887; Rappaport F, 1999, BIOCHEMISTRY-US, V38, P2040, DOI 10.1021/bi982351k; RAVENEL J, 1992, BIOCHIM BIOPHYS ACTA, V1101, P57, DOI 10.1016/0167-4838(92)90466-Q; Redding K, 1999, J BIOL CHEM, V274, P10466, DOI 10.1074/jbc.274.15.10466; REDDING K, 1998, MOL BIOL CHLOROPLAST, P349; Rolland N, 1997, EMBO J, V16, P6713, DOI 10.1093/emboj/16.22.6713; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sazanov LA, 1998, P NATL ACAD SCI USA, V95, P1319, DOI 10.1073/pnas.95.3.1319; SCHERER S, 1990, TRENDS BIOCHEM SCI, V15, P458, DOI 10.1016/0968-0004(90)90296-N; SCHMID GH, 1979, Z NATURFORSCH C, V34, P414; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SIEDOW JN, 1980, PLANT PHYSIOL, V65, P669, DOI 10.1104/pp.65.4.669; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLEFORD KO, 1989, PLANT PHYSIOL, V90, P1084, DOI 10.1104/pp.90.3.1084; Wu DY, 1999, PLANT CELL, V11, P43, DOI 10.1105/tpc.11.1.43	47	120	130	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17256	17262		10.1074/jbc.M908732199	http://dx.doi.org/10.1074/jbc.M908732199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748104	hybrid			2022-12-27	WOS:000087485000008
J	Hink, MA; Griep, RA; Borst, JW; van Hoek, A; Eppink, MHM; Schots, A; Visser, AJWG				Hink, MA; Griep, RA; Borst, JW; van Hoek, A; Eppink, MHM; Schots, A; Visser, AJWG			Structural dynamics of green fluorescent protein alone and fused with a single chain Fv protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME-RESOLVED FLUORESCENCE; CORRELATION SPECTROSCOPY; LIVING CELLS; WILD-TYPE; ANISOTROPY; MOLECULES; DIAGNOSTICS; EXCITATION; MUTATIONS; MUTANTS	Structural information on intracellular fusions of the green fluorescent protein (GFP) of the jellyfish Aequorea victoria with endogenous proteins is required as they are increasingly used in cell biology and biochemistry, We have investigated the dynamic properties of GFP alone and fused to a single chain antibody raised against lipopolysaccharide of the outer cell wall of Gram-negative bacteria (abbreviated as scFv-GFP), The scFv moiety was functional as was proven in binding assays, which involved the use of both fluorescence correlation spectroscopy observing the binding of scFv-GFP to Gram-negative bacteria and a surface plasmon resonance cell containing adsorbed lipopolysaccharide antigen. The rotational motion of scFv-GFP has been investigated with time-resolved fluorescence anisotropy. However, the rotational correlation time of scFv-GFP is too short to account for globular rotation of the whole protein. This result can only be explained by assuming a fast hinge motion between the two fused proteins. A modeled structure of scFv-GFP supports this observation.	Agr Univ Wageningen, Dept Biomol Sci, Biochem Lab, Microspect Ctr, NL-6703 HA Wageningen, Netherlands; Agr Univ Wageningen, Dept Plant Sci, Lab Monoclonal Antibodies, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research; Wageningen University & Research	Visser, AJWG (corresponding author), Agr Univ Wageningen, Dept Biomol Sci, Biochem Lab, Microspect Ctr, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.	Ton.Visser@laser.bc.wau.nl	Schots, Arjen/U-1839-2017; Borst, Jan Willem/B-1259-2011; Schots, Arjen/ABF-8014-2020; Eppink, Michel/AAB-6866-2022	Schots, Arjen/0000-0002-6036-7088; Schots, Arjen/0000-0002-6036-7088; Eppink, Michel/0000-0001-8297-9985				Beechem JM., 2002, TOPICS FLUORESCENCE, P241, DOI DOI 10.1007/0-306-47058-6_5; Brejc K, 1997, P NATL ACAD SCI USA, V94, P2306, DOI 10.1073/pnas.94.6.2306; BRUNGER AT, 1991, J MOL BIOL, V221, P239, DOI 10.1016/0022-2836(91)90817-P; BRUNGER AT, 1992, X PLOR VERSION 3 1; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chattoraj M, 1996, P NATL ACAD SCI USA, V93, P8362, DOI 10.1073/pnas.93.16.8362; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DELAGRAVE S, 1995, BIO-TECHNOL, V13, P151, DOI 10.1038/nbt0295-151; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; EIGENBROT C, 1993, J MOL BIOL, V229, P969, DOI 10.1006/jmbi.1993.1099; ELSIGER MA, 1999, BIOCHEMISTRY-US, V38, P5296; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Griep RA, 1998, PHYTOPATHOLOGY, V88, P795, DOI 10.1094/PHYTO.1998.88.8.795; Haraguchi T, 1999, CELL STRUCT FUNCT, V24, P291, DOI 10.1247/csf.24.291; HARVEY SC, 1979, BIOPOLYMERS, V18, P1081, DOI 10.1002/bip.1979.360180506; HARVEY SC, 1980, BIOPOLYMERS, V19, P913, DOI 10.1002/bip.1980.360190414; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HELM R, 1995, NATURE, V373, P663; Hink MA, 1999, LANGMUIR, V15, P992, DOI 10.1021/la980949n; Kamiuchi T, 1998, BIOCHEMISTRY-US, V37, P13827, DOI 10.1021/bi9811112; KLEYWEGT GJ, 1995, ESF CCP4 NEWSLETT, V31, P45; KRETSCHM.E, 1968, Z NATURFORSCH PT A, VA 23, P2135, DOI 10.1515/zna-1968-1247; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee, 1991, CHEM BIOCH FLAVOENZY, V2, P109; LEENDERS R, 1993, EUR J BIOCHEM, V211, P37, DOI 10.1111/j.1432-1033.1993.tb19867.x; Lossau H, 1996, CHEM PHYS, V213, P1, DOI 10.1016/S0301-0104(96)00340-0; Maiti S, 1997, P NATL ACAD SCI USA, V94, P11753, DOI 10.1073/pnas.94.22.11753; McLean AJ, 1999, MOL PHARMACOL, V56, P1182, DOI 10.1124/mol.56.6.1182; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Otsuki M, 1999, BIOCHEM BIOPH RES CO, V266, P97, DOI 10.1006/bbrc.1999.1784; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rigler R., 1993, FLUORESCENCE SPECTRO, P13; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; TERRY BR, 1995, BIOCHEM BIOPH RES CO, V217, P21, DOI 10.1006/bbrc.1995.2740; Thompson NL, 1991, TOPICS FLUORESCENCE, P337; TORMO J, 1992, PROTEIN SCI, V1, P1154, DOI 10.1002/pro.5560010909; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VANHOEK A, 1992, P SOC PHOTO-OPT INS, V1640, P325, DOI 10.1117/12.58281; Visser AJWG, 1997, PHOTOCHEM PHOTOBIOL, V65, P570, DOI 10.1111/j.1751-1097.1997.tb08607.x; Visser AJWG, 1999, J FLUORESC, V9, P81, DOI 10.1023/A:1020595926133; Walker D, 1999, METHODS, V19, P386, DOI 10.1006/meth.1999.0874; Wall JG, 1999, PROTEIN ENG, V12, P605, DOI 10.1093/protein/12.7.605; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Zhu HY, 1999, ARCH VIROL, V144, P1923, DOI 10.1007/s007050050715	48	153	156	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17556	17560		10.1074/jbc.M001348200	http://dx.doi.org/10.1074/jbc.M001348200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748019	hybrid			2022-12-27	WOS:000087485000049
J	Nieslanik, BS; Atkins, WM				Nieslanik, BS; Atkins, WM			The catalytic Tyr-9 of glutathione S-transferase A1-1 controls the dynamics of the C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; ACTIVE-SITE; FOLDING FUNNELS; BINDING-PROTEIN; HYDROGEN-BOND; TYROSINE-9; LIGAND; ACID; RAT; HELIX	The glutathione S-transferase enzymes (GSTs) have a tyrosine or serine residue at their active site that hydrogen bonds to and stabilizes the thiolate anion of glutathione, GS(-). The importance of this hydrogen bond is obvious, in light of the enhanced nucleophilicity of GS(-)versus the protonated thiol. Several A-class GSTs contain a C-terminal segment that undergoes a ligand-dependent local folding reaction. Here, we demonstrate the effects of the Y9F substitution on binding affinity for glutathione conjugates and on rates of the order-disorder transition of the C terminus in rat GST A1-1. The equilibrium binding affinity of the glutathione conjugate, GS-NBD (NBD-Cl, 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole), was decreased from 4.09 mu M to 0.641 mu M upon substitution of Tyr-9 with Phe. This result was supported by isothermal titration calorimetry, with Kd values of 1.51 mu M and 0.391 mu M for wild type and Y9F, respectively. The increase in binding affinity for the mutant is associated with dramatic decreases in rates for the C-terminal order-disorder transition, based on a stopped-flow kinetic analysis. The same effects were observed, qualitatively, for a second GSH conjugate, GS-ethacrynic acid. Apparently, the phenolic hydroxyl group of Tyr-9 is critical for orchestrating C-terminal dynamics and efficient product release, in addition to its role in lowering the pK(a) of GSH.	Univ Washington, Dept Med Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Atkins, WM (corresponding author), Univ Washington, Dept Med Chem, Box 357610, Seattle, WA 98195 USA.	winky@u.washington.edu			NIGMS NIH HHS [GM7750] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allardyce CS, 1999, BIOCHEM J, V343, P525, DOI 10.1042/0264-6021:3430525; ARNOLD S, 1998, BIOCHEMISTRY-US, V37, P14683; Atkins WM, 1997, PROTEIN SCI, V6, P873; BIRKETT DJ, 1970, FEBS LETT, V6, P346, DOI 10.1016/0014-5793(70)80095-3; Board PG, 1997, BIOCHEM J, V328, P929; BOARD PG, 1991, BIOCHEM J, V275, P171, DOI 10.1042/bj2750171; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; DELBOCCIO G, 1991, J BIOL CHEM, V266, P13777; Dietze EC, 1996, BIOCHEMISTRY-US, V35, P6745, DOI 10.1021/bi9530346; Dietze EC, 1996, BIOCHEMISTRY-US, V35, P11938, DOI 10.1021/bi961073r; Dirr HW, 1999, BIOCHEMISTRY-US, V38, P15631, DOI 10.1021/bi991179x; Eigen M, 1968, Q Rev Biophys, V1, P3; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; Fitzgerald PMD, 1998, BIOCHEMISTRY-US, V37, P6791, DOI 10.1021/bi9730339; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Gustafsson A, 1999, BIOCHEMISTRY-US, V38, P16268, DOI 10.1021/bi991482y; HALFORD SE, 1972, BIOCHEM J, V126, P727, DOI 10.1042/bj1260727; HUSKEY SEW, 1991, J AM CHEM SOC, V113, P2283, DOI 10.1021/ja00006a056; KONG KH, 1992, BIOCHEM BIOPH RES CO, V184, P194, DOI 10.1016/0006-291X(92)91177-R; LIU SX, 1993, J AM CHEM SOC, V115, P7910, DOI 10.1021/ja00070a060; LIU SX, 1992, J BIOL CHEM, V267, P4296; Loh AP, 1999, BIOCHEMISTRY-US, V38, P12547, DOI 10.1021/bi9913707; Ma BY, 1999, PROTEIN ENG, V12, P713, DOI 10.1093/protein/12.9.713; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; NICHOLSON LK, 1995, NAT STRUCT BIOL, V2, P274, DOI 10.1038/nsb0495-274; Nieslanik BS, 1999, BIOCHEMISTRY-US, V38, P6971, DOI 10.1021/bi9829130; OH BH, 1993, J BIOL CHEM, V268, P11348; Paine MF, 1996, CLIN PHARMACOL THER, V60, P14, DOI 10.1016/S0009-9236(96)90162-9; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; QUAST U, 1982, BIOCHEM PHARMACOL, V31, P2761, DOI 10.1016/0006-2952(82)90130-7; RICCI G, 1994, ANAL BIOCHEM, V218, P463, DOI 10.1006/abio.1994.1209; Rodi DJ, 1999, J MOL BIOL, V285, P197, DOI 10.1006/jmbi.1998.2303; SEMMES RLO, 1990, PHARMACEUT RES, V7, P461, DOI 10.1023/A:1015804413818; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Stayton PS, 1999, NATURE, V397, P20, DOI 10.1038/16145; Tsai CJ, 1998, FOLD DES, V3, pR71, DOI 10.1016/S1359-0278(98)00032-7; Tsai CJ, 1999, PROTEIN SCI, V8, P1181, DOI 10.1110/ps.8.6.1181; Tsai CJ, 1999, P NATL ACAD SCI USA, V96, P9970, DOI 10.1073/pnas.96.18.9970; van Tilborg PJA, 1999, BIOCHEMISTRY-US, V38, P1951, DOI 10.1021/bi982526q; WANG RW, 1992, J BIOL CHEM, V267, P19866	43	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17447	17451		10.1074/jbc.M002083200	http://dx.doi.org/10.1074/jbc.M002083200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10751412	hybrid			2022-12-27	WOS:000087485000034
J	Anderson, PJ; Nesset, A; Dharmawardana, KR; Bock, PE				Anderson, PJ; Nesset, A; Dharmawardana, KR; Bock, PE			Characterization of proexosite I on prothrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ARG CHLOROMETHYLKETONE; BOVINE ALPHA-THROMBIN; ANION-BINDING EXOSITE; HUMAN FACTOR-V; CRYSTAL-STRUCTURE; AFFINITY-CHROMATOGRAPHY; HIRUDIN PEPTIDES; LIGAND-BINDING; SITE; ACTIVATION	Activation of prothrombin by factor Xa is accompanied by expression of regulatory exosites I and II on the blood coagulation proteinase, thrombin, Quantitative affinity chromatography and equilibrium binding studies with a fluorescein-labeled derivative of the exosite I-specific peptide ligand, hirudin(54-65) ([5F]Hir(54-65) (SO3-), were employed to identify and characterize this site on human and bovine prothrombin and its expression on thrombin. [5F]Hir(54-65)(SO3-) showed distinctive fluorescence excitation spectral differences in complexes with prothrombin and thrombin and bound to human prothrombin and thrombin with dissociation constants of 3.2 +/- 0.3 mu M and 25 +/- 2 nM, respectively, demonstrating a 130-fold increase in affinity for the active proteinase. The bovine proteins similarly showed a 150-fold higher affinity of [5F]Hir(54-65)(SO3-) for thrombin compared with prothrombin, despite a 2-5-fold lower affinity of the peptides for the bovine proteins. Unlabeled, Tyr(63)-sulfated and nonsulfated hirudin peptides bound competitively with [5F]Hir(54-65)(SO3-) to human and bovine prothrombin and thrombin, exhibiting similar, 40-70-fold higher affinities for the proteinases, although nonsulfated Hir(54-65) bound with 7-17-fold lower affinity than the sulfated analog. These studies characterize proexosite I for the first time as a specific binding site for hirudin peptides on both human and bovine prothrombin that is present in a conformationally distinct, low affinity state and is activated with a similar to 100-fold increase in affinity when thrombin is formed.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, C3321A Med Ctr N, Nashville, TN 37232 USA.	paul.bock@mcmail.vanderbilt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038779, T32HL007751, R29HL038779] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07751, HL02832, HL38779] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; BERGMAN DA, 1986, ANAL BIOCHEM, V153, P380, DOI 10.1016/0003-2697(86)90106-5; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; BODE W, 1992, THROMBIN STRUCTURE F, P3; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FENTON JW, 1977, J BIOL CHEM, V252, P3587; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; JACKMAN MP, 1992, J BIOL CHEM, V267, P15375; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; KRSTENANSKY JL, 1987, FEBS LETT, V211, P10, DOI 10.1016/0014-5793(87)81264-4; Liaw PCY, 1998, J BIOL CHEM, V273, P8932, DOI 10.1074/jbc.273.15.8932; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LIU LW, 1991, J BIOL CHEM, V266, P16977; LIU LW, 1991, J BIOL CHEM, V266, P23632; Malkowski MG, 1997, PROTEIN SCI, V6, P1438, DOI 10.1002/pro.5560060708; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1990, BLOOD, V76, P1; MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MIHALYI E, 1968, J CHEM ENG DATA, V13, P179, DOI 10.1021/je60037a011; Muramatsu R, 1996, INT J PEPT PROT RES, V48, P167; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NI F, 1993, J BIOL CHEM, V268, P16899; NI F, 1990, BIOCHEMISTRY-US, V29, P4479, DOI 10.1021/bi00470a030; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; Stone SR, 1992, THROMBIN STRUCTURE F, P219; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; VITALI J, 1992, J BIOL CHEM, V267, P17670; Vitali J, 1996, ACTA CRYSTALLOGR D, V52, P453, DOI 10.1107/S0907444996000364; WINZOR DJ, 1995, QUANTITATIVE CHARACT, P62; WU QY, 1994, J BIOL CHEM, V269, P3725; YE J, 1992, J BIOL CHEM, V267, P11023	42	54	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16428	16434		10.1074/jbc.M001254200	http://dx.doi.org/10.1074/jbc.M001254200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748007	hybrid			2022-12-27	WOS:000087392200006
J	Bonny, C; Oberson, A; Steinmann, M; Schorderet, DF; Nicod, P; Waeber, G				Bonny, C; Oberson, A; Steinmann, M; Schorderet, DF; Nicod, P; Waeber, G			IB1 reduces cytokine-induced apoptosis of insulin-secreting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHESIS; BETA-CELLS; TRANSCRIPTION FACTORS; MAP KINASES; IN-VITRO; INTERLEUKIN-1; SENSITIVITY; GENE	IB1/JIP-1 is a scaffold protein that interacts with upstream components of the c-Jun N-terminal kinase (JNK) signaling pathway. IB1 is expressed at high levels in pancreatic beta cells and may therefore exert a tight control on signaling events mediated by JNK in these cells. Activation of JNK by interleukin 1 (IL-1 beta) or by the upstream JNK constitutive activator Delta MEKK1 promoted apoptosis in two pancreatic beta cell Lines and decreased IB1. content by 50-60%. To study the functional consequences of the reduced IB1 content in beta cell lines, we used an insulin-secreting cell line expressing an inducible IB1 antisense RNA that lead to a 38% IB1 decrease. Reducing IB1 levels in these cells increased phosphorylation of c-Jun and increased the apoptotic rate in presence of IL-1 beta. Nitric oxide production was not stimulated by expression of the IB1 antisense RNA. Complementary experiments indicated that overexpression of IB1 in insulin-producing cells prevented JNK-mediated activation of the transcription factors c-Jun, ATF2, and Elk1 and decreased IL-1 beta- and Delta MEKK1-induced apoptosis. These data indicate that IB1 plays an anti-apoptotic function in insulin-producing cells probably by controlling the activity of the JNK signaling pathway.	CHUV Univ Hosp, Div Med Genet, CH-1011 Lausanne, Switzerland; CHUV Univ Hosp, Dept Internal Med, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Bonny, C (corresponding author), CHUV Univ Hosp, Div Med Genet, CH-1011 Lausanne, Switzerland.			Waeber, Gerard/0000-0003-4193-788X				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; CETKOVICCVRLJE M, 1994, CYTOKINE, V6, P399, DOI 10.1016/1043-4666(94)90064-7; Cuenda A, 1998, BIOCHEM J, V333, P11, DOI 10.1042/bj3330011; Delaney CA, 1997, ENDOCRINOLOGY, V138, P2610, DOI 10.1210/en.138.6.2610; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; Flodstrom M, 1999, DIABETES, V48, P706, DOI 10.2337/diabetes.48.4.706; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Hohmeier HE, 1998, J CLIN INVEST, V101, P1811, DOI 10.1172/JCI1489; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; JANJIC D, 1992, J ENDOCRINOL, V132, P67, DOI 10.1677/joe.0.1320067; Kim IJ, 1999, J NEUROCHEM, V72, P1335, DOI 10.1046/j.1471-4159.1999.721335.x; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Liu X, 1997, J BIOL CHEM, V272, P11690, DOI 10.1074/jbc.272.18.11690; MANDRUPPOULSEN T, 1993, CYTOKINE, V5, P185, DOI 10.1016/1043-4666(93)90003-N; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; Mauricio D, 1998, DIABETES, V47, P1537, DOI 10.2337/diabetes.47.10.1537; Mooser V, 1999, GENOMICS, V55, P202, DOI 10.1006/geno.1998.5641; NERUP J, 1994, DIABETOLOGIA, V37, P82; Nielsen K, 1999, DIABETES, V48, P2324, DOI 10.2337/diabetes.48.12.2324; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; Reimers JI, 1996, DIABETES, V45, P771, DOI 10.2337/diabetes.45.6.771; REIMERS JI, 1994, CYTOKINE, V6, P512, DOI 10.1016/1043-4666(94)90079-5; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; SuarezPinzon WL, 1996, ENDOCRINOLOGY, V137, P5290, DOI 10.1210/en.137.12.5290; Thomas HE, 1999, J IMMUNOL, V163, P1562; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740	42	112	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16466	16472		10.1074/jbc.M908297199	http://dx.doi.org/10.1074/jbc.M908297199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748095	hybrid			2022-12-27	WOS:000087392200011
J	Horvath, A; Kingan, TG; Maslov, DA				Horvath, A; Kingan, TG; Maslov, DA			Detection of the mitochondrially encoded cytochrome c oxidase subunit I in the trypanosomatid protozoan Leishmania tarentolae - Evidence for translation of unedited mRNA in the kinetoplast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SEQUENCE ANALYSIS; CRITHIDIA-FASCICULATA; CYSTEINE RESIDUES; RNA; 3-BROMOPROPYLAMINE; ELECTROPHORESIS; ORGANIZATION; COMPLEXES; BRUCEI; GENES	With the aim of identification of kinetoplast-encoded proteins we investigated the subunit composition of cytochrome c oxidase (respiratory complex IV) from kinetoplast mitochondria of the trypanosomatid protozoan Leishmania tarentolae. Eleven stoichiometric subunits were visible in Coomassie-stained, two-dimensional Blue Native/Tricine-SDS electrophoretic gels. Their partial amino acid sequences indicated that these polypeptides are nuclear-encoded. The mitochondrial subunit I was detected with the polyclonal antibodies against an internal region of this polypeptide. In two-dimensional (9 versus 14%) polyacrylamide glycine-SDS gels this subunit is found as a series of spots located off the main diagonal, a property that can be explained by abnormal electrophoretic migration and aggregation. In gels loaded with high amounts of the purified, enzymatically active oxidase, the subunit I spots could be visualized by staining. The determined N-terminal amino acid sequence of the putative monomeric subunit I (MFXLCLVCLSVS) matched with the predicted sequence, thus indicating that the corresponding kinetoplast unedited mRNA is translated into a functional protein.	Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Maslov, DA (corresponding author), Univ Calif Riverside, Dept Biol, 3401 Watkins Dr, Riverside, CA 92521 USA.		Horvath, Anton/V-1097-2018; Horvath, Anton/I-3626-2014	Horvath, Anton/0000-0003-0785-4204; 	NIAID NIH HHS [AI40634] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040634] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADLER BK, 1994, CURR OPIN GENET DEV, V4, P316, DOI 10.1016/S0959-437X(05)80060-7; Alfonzo JD, 1997, NUCLEIC ACIDS RES, V25, P3751, DOI 10.1093/nar/25.19.3751; Beattie DS, 1996, EUR J BIOCHEM, V241, P888, DOI 10.1111/j.1432-1033.1996.00888.x; BENNE R, 1994, EUR J BIOCHEM, V221, P9, DOI 10.1111/j.1432-1033.1994.tb18710.x; BERRY EA, 1991, J BIOL CHEM, V266, P9064; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Breek CKD, 1997, BIOL CHEM, V378, P837, DOI 10.1515/bchm.1997.378.8.837; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; DELACRUZ VF, 1984, J BIOL CHEM, V259, P5136; DZANDU JK, 1988, ANAL BIOCHEM, V174, P157, DOI 10.1016/0003-2697(88)90531-3; Horvath A, 2000, SCIENCE, V287, P1639, DOI 10.1126/science.287.5458.1639; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JUE RA, 1993, ANAL BIOCHEM, V210, P39, DOI 10.1006/abio.1993.1147; JUE RA, 1994, ANAL BIOCHEM, V221, P374, DOI 10.1006/abio.1994.1428; KUHNNENTWIG L, 1985, EUR J BIOCHEM, V149, P147, DOI 10.1111/j.1432-1033.1985.tb08905.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maslov DA, 1999, MOL BIOCHEM PARASIT, V99, P207, DOI 10.1016/S0166-6851(99)00028-6; MERLE P, 1980, EUR J BIOCHEM, V105, P499, DOI 10.1111/j.1432-1033.1980.tb04525.x; Nabholz CE, 1999, PARASITOL RES, V85, P779, DOI 10.1007/s004360050631; PRIEST JW, 1992, J BIOL CHEM, V267, P20188; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SHAW JM, 1989, P NATL ACAD SCI USA, V86, P6220, DOI 10.1073/pnas.86.16.6220; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; Speijer D, 1997, MOL BIOCHEM PARASIT, V85, P171, DOI 10.1016/S0166-6851(96)02823-X; Speijer D, 1996, MOL BIOCHEM PARASIT, V79, P47, DOI 10.1016/0166-6851(96)02648-5; STEFFENS GJ, 1979, H-S Z PHYSIOL CHEM, V360, P613; Stuart K, 1997, MICROBIOL MOL BIOL R, V61, P105, DOI 10.1128/.61.1.105-120.1997; STUART K, 1992, INT REV CYTOL, V141, P65, DOI 10.1016/S0074-7696(08)62063-X; Tittawella I, 1998, FEBS LETT, V423, P351, DOI 10.1016/S0014-5793(98)00132-X	29	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17160	17165		10.1074/jbc.M907246199	http://dx.doi.org/10.1074/jbc.M907246199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748081	hybrid			2022-12-27	WOS:000087392200107
J	Hsu, FF; Ma, ZM; Wohltmann, M; Bohrer, A; Nowatzke, W; Ramanadham, S; Turk, J				Hsu, FF; Ma, ZM; Wohltmann, M; Bohrer, A; Nowatzke, W; Ramanadham, S; Turk, J			Electrospray ionization/mass spectrometric analyses of human promonocytic U937 cell glycerolipids and evidence that differentiation is associated with membrane lipid composition changes that facilitate phospholipase A(2) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ISOLATED PANCREATIC-ISLETS; CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; ARACHIDONIC-ACID MOBILIZATION; TIGHT-BINDING INHIBITORS; P388D(1) MACROPHAGES; SIGNAL-TRANSDUCTION; PHOSPHATIDATE PHOSPHOHYDROLASE; MASS-SPECTROMETRY; INTERFACIAL CATALYSIS	Upon differentiation, U937 promonocytic cells gain the ability to release a large fraction of arachidonate esterified in phospholipids when stimulated, but the mechanism is unclear. U937 cells express group IV phospholipase A(2) (cPLA(2)), but neither its level nor its phosphorylation state increases upon differentiation. A group VI PLA(2) (iPLA(2)) that is sensitive to a bromoenol lactone inhibitor catalyzes arachidonate hydrolysis from phospholipids in some cells and facilitates arachidonate incorporation into glycerophosphocholine (GPC) lipids in others, but it is not known whether U937 cells express iPLA(2). We confirm that ionophore A23187 induces substantial [H-3]arachidonate release from differentiated but not control U937 cells, and electrospray ionization mass spectrometric (ESI/MS) analyses indicate that differentiated cells contain a higher proportion of arachidonate-containing GPC species than control cells. U937 cells express iPLA(2) mRNA and activity, but iPLA(2) inhibition impairs neither [H-3]arachidonate incorporation into nor release from U937 cells. Experiments with phosphatidate phosphohydrolase (PAPH) and phospholipase D (PLD) inhibitors coupled with ESI/MS analyses of PLD-PAPH products indicate that differentiated cells gain the ability to produce diacylglycerol (DAG) via PLD-PAPH. DAG promotes arachidonate release by a mechanism that does not require DAG hydrolysis, is largely independent of protein kinase C, and requires cPLA(2) activity. This may reflect DAG effects on cPLA(2) substrate state.	Washington Univ, Sch Med, Dept Med, Mass Spect Facil,Div Endocrinol Diabet & Metab, St Louis, MO 63110 USA	Washington University (WUSTL)	Turk, J (corresponding author), Washington Univ, Sch Med, Dept Med, Mass Spect Facil,Div Endocrinol Diabet & Metab, Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.			Hsu, Fong-Fu/0000-0001-5368-0183	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR00954] Funding Source: Medline; NHLBI NIH HHS [P01-HL57278] Funding Source: Medline; NIDDK NIH HHS [P60-DK20579] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; BALBOA MA, 1995, J BIOL CHEM, V270, P11738, DOI 10.1074/jbc.270.20.11738; Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Barbieri B, 1998, BIOCHEM MOL BIOL INT, V45, P1105; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Burke JR, 1997, BBA-PROTEIN STRUCT M, V1341, P223, DOI 10.1016/S0167-4838(97)00085-X; BURKE JR, 1995, BIOCHEMISTRY-US, V34, P15165, DOI 10.1021/bi00046a024; Cissel DS, 1998, J PHARMACOL EXP THER, V285, P110; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DAWSON RMC, 1984, BIOCHEM BIOPH RES CO, V125, P836, DOI 10.1016/0006-291X(84)90615-6; DAWSON RMC, 1983, BIOCHB IOPHYS RES CO, V117, P195; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; EASOM RA, 1990, J BIOL CHEM, V265, P14938; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Farooqui AA, 1995, BRAIN RES REV, V21, P152, DOI 10.1016/0165-0173(95)00008-9; Forsell PKAL, 1998, FEBS LETT, V434, P295, DOI 10.1016/S0014-5793(98)00999-5; Gijon MA, 1997, SEMIN CELL DEV BIOL, V8, P297, DOI 10.1006/scdb.1997.0151; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; HALLBERG A, 1984, BIOCHIM BIOPHYS ACTA, V796, P328, DOI 10.1016/0005-2760(84)90134-6; Han XL, 1996, BIOCHEMISTRY-US, V35, P5822, DOI 10.1021/bi952927v; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Hsu FF, 1999, J AM SOC MASS SPECTR, V10, P587, DOI 10.1016/S1044-0305(99)00035-5; Hsu FF, 1998, J AM SOC MASS SPECTR, V9, P516, DOI 10.1016/S1044-0305(98)00012-9; Hullin-Matsuda F, 1997, FEBS LETT, V419, P117, DOI 10.1016/S0014-5793(97)01444-0; KIABUCHI K, 1986, J BIOL CHEM, V258, P6701; KRAMER RM, 1987, BIOCHEM J, V248, P779, DOI 10.1042/bj2480779; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Li C, 1999, J MASS SPECTROM, V34, P521, DOI 10.1002/(SICI)1096-9888(199905)34:5<521::AID-JMS805>3.0.CO;2-2; Lichtenbergova L, 1998, BIOCHEMISTRY-US, V37, P14128, DOI 10.1021/bi980888s; Ma ZM, 1999, J BIOL CHEM, V274, P9607, DOI 10.1074/jbc.274.14.9607; Ma ZM, 1997, J BIOL CHEM, V272, P11118; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MARTIN A, 1993, J BIOL CHEM, V268, P23924; METZ SA, 1991, BIOCHEM PHARMACOL, V41, pR1, DOI 10.1016/0006-2952(91)90470-P; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; Ramanadham S, 1998, BIOCHEMISTRY-US, V37, P4553, DOI 10.1021/bi9722507; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; ROSENTHAL MD, 1993, BIOCHIM BIOPHYS ACTA, V1177, P79, DOI 10.1016/0167-4889(93)90161-H; Rzigalinski BA, 1996, BBA-LIPID LIPID MET, V1299, P342, DOI 10.1016/0005-2760(95)00224-3; RZIGALINSKI BA, 1994, BBA-MOL CELL RES, V1223, P219, DOI 10.1016/0167-4889(94)90229-1; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Trinh K, 1997, J BIOL CHEM, V272, P24837, DOI 10.1074/jbc.272.40.24837; TURK J, 1984, BIOCHIM BIOPHYS ACTA, V794, P125, DOI 10.1016/0005-2760(84)90305-9; WOLF BA, 1990, J CLIN INVEST, V85, P482, DOI 10.1172/JCI114463; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	66	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16579	16589		10.1074/jbc.M908342199	http://dx.doi.org/10.1074/jbc.M908342199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748096	hybrid			2022-12-27	WOS:000087392200027
J	Steffensen, R; Carlier, K; Wiels, J; Levery, SB; Stroud, M; Cedergren, B; Sojka, BN; Bennett, EP; Jersild, G; Clausen, H				Steffensen, R; Carlier, K; Wiels, J; Levery, SB; Stroud, M; Cedergren, B; Sojka, BN; Bennett, EP; Jersild, G; Clausen, H			Cloning and expression of the histo-blood group (PUDP)-U-k-galactose: Gal beta 1-4Glc beta 1-Cer alpha 1,4-galactosyltransferase - Molecular genetic basis of the p phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; BURKITTS-LYMPHOMA CELLS; ALPHA-D-GALACTOSAMINE; MONOCLONAL-ANTIBODY; EMBRYONIC ANTIGEN-3; GLYCOLIPID ANTIGEN; BIOSYNTHESIS; LEWIS; GLYCOSPHINGOLIPIDS; IDENTIFICATION	The molecular genetic basis of the P histo-blood group system has eluded characterization despite extensive studies of the biosynthesis of the P-1, P, and P-k glycolipids. The main controversy has been whether a single or two distinct UDP-Gal:Gal beta 1-R 4-alpha-galactosyltransferases catalyze the syntheses of the structurally related P-1 and P-k antigens. The P-1 polymorphism is linked to 22q11.3-ter. Data base searches with the coding region of an alpha 4GlcNAc-transferase identified a novel homologous gene at 22q13.2 designated alpha 4Gal-T1. Expression of full coding constructs of alpha 4Gal-T1 in insect cells revealed it encoded P-k but not P-1 synthase activity. Northern analysis showed expression of the transcript correlating with pk synthase activity and antigen expression in human B cell lines. Transfection of P-k-negative Namalwa cells with alpha 4Gal-T1 resulted in strong pk expression. A single homozygous missense mutation, M183K, was found in six Swedish individuals of the rare p phenotype, confirming that alpha 4Gal-T1 represented the P-k gene. Sequence analysis of the coding region of alpha 4Gal-T1 in P-1+/- individuals did not reveal polymorphisms correlating with P1P2 typing.	Univ Copenhagen, Sch Dent, DK-2200 Copenhagen N, Denmark; Aalborg Hosp, Reg Ctr Blood Transfus & Clin Immunol, DK-9000 Aalborg, Denmark; Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; NW Hosp, Dept Cell Surface Biochem, Seattle, WA 98125 USA; Univ Umea Hosp, Dept Transfus Med, S-90185 Umea, Sweden	University of Copenhagen; Aalborg University; Aalborg University Hospital; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; University System of Georgia; University of Georgia; Umea University	Clausen, H (corresponding author), Univ Copenhagen, Sch Dent, Norre Alle 20, DK-2200 Copenhagen N, Denmark.		clausen, henrik/AAD-8016-2021; Wiels, Joëlle/AGL-2319-2022; Bennett, Eric/AAG-6120-2020	Wiels, Joëlle/0000-0002-3313-2937; Bennett, Eric/0000-0002-4976-0647	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER; NCRR NIH HHS [5 P41 RR05351] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; BAILLY P, 1992, CARBOHYD RES, V228, P277, DOI 10.1016/S0008-6215(00)90565-2; Bailly Pascal, 1995, V6, P299; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; CEDERGREN B, 1973, HEREDITAS, V73, P27; Charron M, 1998, P NATL ACAD SCI USA, V95, P14805, DOI 10.1073/pnas.95.25.14805; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; Daniels GL, 1999, VOX SANG, V77, P52, DOI 10.1159/000031074; DO KY, 1995, J BIOL CHEM, V270, P18447, DOI 10.1074/jbc.270.31.18447; FLETCHER KS, 1979, J BIOL CHEM, V254, P1196; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; IIZUKA S, 1986, BIOCHEM BIOPH RES CO, V137, P1187, DOI 10.1016/0006-291X(86)90351-7; ISSITT PD, 1998, APPL BLOOD GROUP SER, P295; KANNAGI R, 1983, J BIOL CHEM, V258, P8934; Karlsson KA, 1998, MOL MICROBIOL, V29, P1, DOI 10.1046/j.1365-2958.1998.00854.x; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Landsteiner K, 1927, P SOC EXP BIOL MED, V24, P941; Lopez M, 1998, J BIOL CHEM, V273, P33644, DOI 10.1074/jbc.273.50.33644; MANGENEY M, 1993, CANCER RES, V53, P5314; Marcus D M, 1989, Immunol Ser, V43, P701; Marcus D M, 1980, Prog Clin Biol Res, V43, P55; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; MCALPINE PJ, 1978, CYTOGENET CELL GENET, V22, P629, DOI 10.1159/000131040; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; NAIKI M, 1974, BIOCHEM BIOPH RES CO, V60, P1105, DOI 10.1016/0006-291X(74)90426-4; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4831, DOI 10.1021/bi00693a009; Nakayama J, 1999, P NATL ACAD SCI USA, V96, P8991, DOI 10.1073/pnas.96.16.8991; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; NUDELMAN E, 1983, SCIENCE, V220, P509, DOI 10.1126/science.6836295; Porcellati F, 1999, AM J PHYSIOL-CELL PH, V276, pC1325, DOI 10.1152/ajpcell.1999.276.6.C1325; Puri A, 1999, BIOSCIENCE REP, V19, P317, DOI 10.1023/A:1020554509642; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; TAGA S, 1995, INT J CANCER, V61, P261, DOI 10.1002/ijc.2910610220; TAGA S, 1995, BBA-LIPID LIPID MET, V1254, P56, DOI 10.1016/0005-2760(94)00167-W; Taga S, 1997, BLOOD, V90, P2757, DOI 10.1182/blood.V90.7.2757.2757_2757_2767; TIPPETT P, 1986, VOX SANG, V51, P53, DOI 10.1111/j.1423-0410.1986.tb00209.x; Wakarchuk WW, 1998, PROTEIN ENG, V11, P295, DOI 10.1093/protein/11.4.295; Watkins W M, 1980, Adv Hum Genet, V10, P1; Wiels J, 1996, GLYCOCONJUGATE J, V13, P529, DOI 10.1007/BF00731440; WIELS J, 1997, LEUKOCYTE TYPING, V6, P175; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YOSHIDA H, 1994, TRANSFUSION, V34, P702, DOI 10.1046/j.1537-2995.1994.34894353467.x; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	52	89	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16723	16729		10.1074/jbc.M000728200	http://dx.doi.org/10.1074/jbc.M000728200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747952	hybrid			2022-12-27	WOS:000087392200047
J	Vidal-Puig, AJ; Grujic, D; Zhang, CY; Hagen, T; Boss, O; Ido, Y; Szczepanik, A; Wade, J; Mootha, V; Cortright, R; Muoio, DM; Lowell, BB				Vidal-Puig, AJ; Grujic, D; Zhang, CY; Hagen, T; Boss, O; Ido, Y; Szczepanik, A; Wade, J; Mootha, V; Cortright, R; Muoio, DM; Lowell, BB			Energy metabolism in uncoupling protein 3 gene knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; FREE FATTY-ACIDS; SKELETAL-MUSCLE; SUPEROXIDE ANION; PROTON TRANSPORT; MITOCHONDRIAL CARRIER; TARGETED DISRUPTION; HYDROGEN-PEROXIDE; MESSENGER-RNA; RECEPTOR GENE	Uncoupling protein 3 (UCP3) is a member of the mitochondrial anion carrier superfamily. Based upon its high homology with UCP1 and its restricted tissue distribution to skeletal muscle and brown adipose tissue, UCP3 has been suggested to play important roles in regulating energy expenditure, body weight, and thermoregulation. Other postulated roles for UCP3 include regulation of fatty acid metabolism, adaptive responses to acute exercise and starvation, and prevention of reactive oxygen species (ROS) formation. To address these questions, we have generated mice lacking UCP3 (UCP3 knockout (KO) mice). Here, we provide evidence that skeletal muscle mitochondria lacking UCP3 are more coupled (i.e. increased state 3/state 4 ratio), indicating that UCPB has uncoupling activity. In addition, production of ROS is increased in mitochondria lacking UCP3. This study demonstrates that UCP3 has uncoupling activity and that its absence may lead to increased production of ROS. Despite these effects on mitochondrial function, UCP3 does not seem to be required for body weight regulation, exercise tolerance, fatty acid oxidation, or cold-induced thermogenesis. The absence of such phenotypes in UCP3 KO mice could not be attributed to up-regulation of other UCP mRNAs. However, alternative compensatory mechanisms cannot be excluded. The consequence of increased mitochondrial coupling in UCP3 KO mice on metabolism and the possible role of yet unidentified compensatory mechanisms, remains to be determined.	Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol, Boston, MA 02215 USA; E Carolina Univ, Sch Med, Dept Exercise & Sport Sci, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Dept Biochem & Physiol, Greenville, NC 27858 USA; Boston Med Ctr, Diabet & Metab Unit, Boston, MA 02118 USA	Harvard University; Beth Israel Deaconess Medical Center; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; Boston Medical Center	Lowell, BB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrine, Res N Rm,99 Brookline Ave, Boston, MA 02215 USA.	blowell@caregroup.harvard.edu	Muoio, Debbie Marie/E-1147-2012	Muoio, Deborah/0000-0003-3760-9277; Ido, Yasuo/0000-0002-3036-9971; Vidal-Puig, Antonio/0000-0003-4220-9577	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049569, P30DK046200, R37DK053477] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK053477, DK49569, P30 DK46200] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; Bodrova ME, 1998, FEBS LETT, V435, P269, DOI 10.1016/S0014-5793(98)01072-2; Boss O, 1998, FASEB J, V12, P335, DOI 10.1096/fasebj.12.3.335; Boss O, 1998, LANCET, V351, P1933, DOI 10.1016/S0140-6736(05)78617-7; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bouchard C, 1997, HUM MOL GENET, V6, P1887, DOI 10.1093/hmg/6.11.1887; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brand MD, 1999, INT J OBESITY, V23, pS4, DOI 10.1038/sj.ijo.0800936; Brun S, 1999, FEBS LETT, V453, P205, DOI 10.1016/S0014-5793(99)00722-X; Chung WK, 1999, DIABETES, V48, P1890, DOI 10.2337/diabetes.48.9.1890; Du G, 1998, FREE RADICAL BIO MED, V25, P1066, DOI 10.1016/S0891-5849(98)00148-8; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014-5793(98)01246-0; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1999, BIOCHEM BIOPH RES CO, V256, P27, DOI 10.1006/bbrc.1999.0239; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Hausladen A, 1996, METHOD ENZYMOL, V269, P37; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; Hwang CS, 1999, BIOCHEM BIOPH RES CO, V258, P464, DOI 10.1006/bbrc.1999.0662; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jaworek D, 1974, METHODS ENZYMATIC AN, P2127, DOI 10.1016/B978-0-12-091304-6.50066-5; Jezek P, 1996, J BIOL CHEM, V271, P6199, DOI 10.1074/jbc.271.11.6199; KASTEN TP, 1995, P SOC EXP BIOL MED, V208, P170; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 1999, INT J OBESITY, V23, pS24, DOI 10.1038/sj.ijo.0800939; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LI Y, 1999, BIOCHIM BIOPHYS ACTA, V28, P1; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; LIN CS, 1980, FEBS LETT, V113, P304, DOI 10.1016/0014-5793(80)80614-4; LIN CS, 1980, FEBS LETT, V113, P299, DOI 10.1016/0014-5793(80)80613-2; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NICHOLLS DG, 1984, TRENDS BIOCHEM SCI, V9, P489, DOI 10.1016/0968-0004(84)90319-0; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; Rolfe DFS, 1996, AM J PHYSIOL-CELL PH, V271, pC1380, DOI 10.1152/ajpcell.1996.271.4.C1380; SALMON DMW, 1985, INT J OBESITY, V9, P443; Sanchis D, 1998, J BIOL CHEM, V273, P34611, DOI 10.1074/jbc.273.51.34611; Silva JE, 1997, EUR J ENDOCRINOL, V136, P251, DOI 10.1530/eje.0.1360251; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Skulachev VP, 1997, BIOSCIENCE REP, V17, P347, DOI 10.1023/A:1027344914565; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Tsuboyama-Kasaoka N, 1998, BIOCHEM BIOPH RES CO, V247, P498, DOI 10.1006/bbrc.1998.8818; Urhammer SA, 1998, DIABETOLOGIA, V41, P241, DOI 10.1007/s001250050897; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	60	565	580	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16258	16266		10.1074/jbc.M910179199	http://dx.doi.org/10.1074/jbc.M910179199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748196	hybrid, Green Published			2022-12-27	WOS:000087291400088
J	Zhang, M; Zhao, X; Chen, HC; Catt, KJ; Hunyady, L				Zhang, M; Zhao, X; Chen, HC; Catt, KJ; Hunyady, L			Activation of the AT(1) angiotensin receptor is dependent on adjacent apolar residues in the carboxyl terminus of the third cytoplasmic loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MUSCARINIC ACETYLCHOLINE-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; 3RD INTRACELLULAR LOOP; II TYPE-1 RECEPTOR; SIGNAL-TRANSDUCTION; AMINO-ACID; CONSTITUTIVE ACTIVATION; BINDING-SITE; RAT AT(1A)	The C-terminal region of the third intracellular loop of the AT(1) angiotensin receptor (AT(1)-R) is an important determinant of G protein coupling. The roles of individual residues in agonist-induced activation of G(q/11)-dependent phosphoinositide hydrolysis were determined by mutational analysis of the amino acids in this region. Functional studies on mutant receptors transiently expressed in COS-7 cells showed that alanine substitutions of the amino acids in positions 232-240 of the third loop had no major effect on signal generation. However, deletion mutations that removed Ile(238) or affected its position relative to transmembrane helix VI significantly impaired angiotensin II-induced inositol phosphate responses. Substitution of Ile(238) with an acidic residue abolished the ability of the receptor to mediate inositol phosphate production, whereas its replacement with basic or polar residues reduced the amplitude of inositol phosphate responses. Substitutions of Phe(239) with polar residues had relatively minor effects on inositol phosphate signal generation, but its replacement by aspartic acid reduced, and by positively charged residues (Lys, Arg) significantly increased, angiotensin II-induced inositol phosphate responses. The internalization kinetics of the Ile(238) and Phe239 mutant receptors were impaired in parallel with the reduction in their signaling responses. These findings have identified Ile238 and Phe239 as the critical residues in the C-terminal region of the third intracellular loop of the AT(1)-R for receptor activation. They also suggest that an apolar amino acid corresponding to Ile(238) of the AT(1)-R is a general requirement for activation of other G protein-coupled receptors by their agonist ligands.	Semmelweis Univ, Sch Med, Dept Physiol, H-1444 Budapest, Hungary; NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	Semmelweis University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Hunyady, L (corresponding author), Semmelweis Univ, Sch Med, Dept Physiol, POB 259, H-1444 Budapest, Hungary.	Hunyady@puskin.sote.hu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000035, Z01HD000193, ZIAHD000193] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Berk BC, 1999, J AM SOC NEPHROL, V10, pS62; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; Bohm SK, 1997, BIOCHEM J, V322, P1; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; Conchon S, 1997, J BIOL CHEM, V272, P25566, DOI 10.1074/jbc.272.41.25566; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; Eason MG, 1996, J BIOL CHEM, V271, P12826, DOI 10.1074/jbc.271.22.12826; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; Goodfriend TL, 1996, NEW ENGL J MED, V334, P1649, DOI 10.1056/NEJM199606203342507; GUIRAMAND J, 1995, J BIOL CHEM, V270, P7354, DOI 10.1074/jbc.270.13.7354; Hunyady L, 1999, J AM SOC NEPHROL, V10, pS47; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Hunyady L, 1998, MOL PHARMACOL, V54, P427, DOI 10.1124/mol.54.2.427; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Hunyady L, 1996, P NATL ACAD SCI USA, V93, P10040, DOI 10.1073/pnas.93.19.10040; Inagami T, 1999, J AM SOC NEPHROL, V10, pS57; Inoue Y, 1997, J HYPERTENS, V15, P703, DOI 10.1097/00004872-199715070-00001; Ishizaka N, 1997, J BIOL CHEM, V272, P32482, DOI 10.1074/jbc.272.51.32482; Jagadeesh Gowraganahalli, 1998, Indian Journal of Experimental Biology, V36, P1171; Kai H, 1998, BIOCHEM J, V332, P781, DOI 10.1042/bj3320781; Kim JM, 1997, P NATL ACAD SCI USA, V94, P14273, DOI 10.1073/pnas.94.26.14273; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Laporte SA, 1997, RECEPTOR CHANNEL, V5, P103; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P6172, DOI 10.1074/jbc.271.11.6172; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Sayeski PP, 1998, REGUL PEPTIDES, V78, P19, DOI 10.1016/S0167-0115(98)00137-2; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Smith RD, 1998, MOL ENDOCRINOL, V12, P634, DOI 10.1210/me.12.5.634; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Thomas WG, 1999, REGUL PEPTIDES, V79, P9, DOI 10.1016/S0167-0115(98)00140-2; TSENG MJ, 1995, J BIOL CHEM, V270, P17884, DOI 10.1074/jbc.270.30.17884; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	43	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15782	15788		10.1074/jbc.M000198200	http://dx.doi.org/10.1074/jbc.M000198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747880	hybrid			2022-12-27	WOS:000087291400026
J	Hulit, J; Bash, T; Fu, MF; Galbiati, F; Albanese, C; Sage, DR; Schlegel, A; Zhurinsky, J; Shtutman, M; Ben-Ze'ev, A; Lisanti, MP; Pestell, RG				Hulit, J; Bash, T; Fu, MF; Galbiati, F; Albanese, C; Sage, DR; Schlegel, A; Zhurinsky, J; Shtutman, M; Ben-Ze'ev, A; Lisanti, MP; Pestell, RG			The cyclin D1 gene is transcriptionally repressed by caveolin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; MAP KINASE CASCADE; C-JUN; IN-VIVO; SIGNAL-TRANSDUCTION; SCAFFOLDING DOMAIN; TYROSINE KINASE; BREAST-CANCER; PROTEIN; EXPRESSION	The cyclin D1 gene encodes the regulatory subunit of the holoenzyme that phosphorylates and inactivates the retinoblastoma pRB protein. Cyclin D1 protein levels are elevated by mitogenic and oncogenic signaling pathways, and antisense mRNA to cyclin D1 inhibits transformation by the ras, neu, and src oncogenes, thus linking cyclin D1 regulation to cellular transformation. Caveolins are the principal protein components of caveolae, vesicular plasma membrane invaginations that also function in signal transduction, We show here that caveolin-1 expression levels inversely correlate with cyclin D1 abundance levels in transformed cells. Expression of antisense caveolin-1 increased cyclin D1 levels, whereas caveolin-1 overexpression inhibited expression of the cyclin D1 gene. Cyclin D1 promoter activity was selectively repressed by caveolin-1, but not by caveolin-3, and this repression required the caveolin-1 N terminus, Maximal inhibition of the cyclin D1 gene promoter by caveolin-1 was dependent on the cyclin D1 promoter T-cell factor/lymphoid enhancer factor-1-binding site between -81 to -73. The T-cell factor/lymphoid enhancer factor sequence was sufficient for repression by caveolin-1. We suggest that transcriptional repression of the cyclin D1 gene may contribute to the inhibition of transformation by caveolin-1.	Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Weizmann Institute of Science	Pestell, RG (corresponding author), Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Med, Chanin 302,1300 Morris Pk Ave, Bronx, NY 10461 USA.		Lisanti, Michael P/C-6866-2013; Shtutman, Michael/AAB-8391-2020; Lisanti, Michael/B-6131-2018; Galbiati, Ferruccio/AAF-3527-2020	Shtutman, Michael/0000-0002-2458-3226; Lisanti, Michael/0000-0003-2034-1382; ben-ze'ev, avri/0000-0001-6113-3921; Schlegel, Amnon/0000-0003-4060-2252	NATIONAL CANCER INSTITUTE [K04CA001330, R01CA075503, R01CA070897] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA75503, 5-P30-CA1330-26, R01-CA70897] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bravo R, 1990, Semin Cancer Biol, V1, P37; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Chen X, 1999, MOL CELL BIOL, V19, P4695; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LIN A, 1993, ADV SEC MESS PHOSPH, V28, P255; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUKAS J, 1994, ONCOGENE, V9, P707; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; WOOD WM, 1989, J BIOL CHEM, V264, P14840; Xiong W, 1997, AM J PHYSIOL-LUNG C, V272, pL1205, DOI 10.1152/ajplung.1997.272.6.L1205; Zwicker J, 1999, ONCOGENE, V18, P19, DOI 10.1038/sj.onc.1202286	62	118	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21203	21209		10.1074/jbc.M000321200	http://dx.doi.org/10.1074/jbc.M000321200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10747899	hybrid			2022-12-27	WOS:000088230600034
J	Panzenbock, U; Kritharides, L; Raftery, M; Rye, KA; Stocker, R				Panzenbock, U; Kritharides, L; Raftery, M; Rye, KA; Stocker, R			Oxidation of methionine residues to methionine sulfoxides does not decrease potential antiatherogenic properties of apolipoprotein A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; HUMAN ATHEROSCLEROTIC PLAQUES; ESTER TRANSFER PROTEIN; HUMAN BLOOD-PLASMA; CELLULAR CHOLESTEROL; FUNCTIONAL-PROPERTIES; LIPID HYDROPEROXIDES; AMPHIPATHIC HELIX; ALPHA-TOCOPHEROL	The initial stage of oxidation of high density lipoproteins (HDL) is accompanied by the lipid hydroperoxide-dependent, selective oxidation of two of the three Met residues of apolipoprotein A-I (apoA-I) to Met sulfoxides (Met(O)). Formation of such selectively oxidized apoA-I (i.e. apoA-I+32) may affect the antiatherogenic properties of HDL, because it has been suggested that Met(86) and Met(112) are important for cholesterol efflux and Met(148) is involved in the activation of lecithin:cholesterol acyl transferase (LCAT). We therefore determined which Met residues were oxidized in apoA-I+32 and how such oxidation of apoA-I affects its secondary structure, the affinity for lipids, and its ability to remove lipids from human macrophages. We also assessed the capacity of discoidal reconstituted HDL containing apoA-I+32 to act as substrate for LCAT, and the dissociation of apoA-I and apoA-I+32 from reconstituted HDL. Met(86) and Met(112) were present as Met(O), as determined by amino acid sequencing and mass spectrometry of isolated peptides derived from apoA-I+32. Selective oxidation did not alter the alpha-helicity of lipid-free and lipid-associated apoA-I as assessed by circular dichroism, and the affinity for LCAT was comparable for reconstituted HDL containing apoA-I or apoA-I+32. Cholesteryl ester transfer protein mediated the dissociation of apoA-I more readily from reconstituted HDL containing apoA-I+32 than unoxidized apoA-I. Also, compared with native apoA-I, apoA-I+32 had a 2- to 3-fold greater affinity for lipid (as determined by the rate of clearance of multilamellar phospholipid vesicles) and its ability to cause efflux of [H-3]cholesterol, [H-3]phospholipid, and [C-14]alpha-tocopherol from lipid-laden human monocyte-derived macrophages was significantly enhanced. By contrast, no difference was observed for cholesterol and alpha-tocopheroi efflux to lipid-associated apolipoproteins. Together, these results suggest that selective oxidation of Met residues enhances rather than diminishes known antiatherogenic activities of apoA-I, consistent with the overall hypothesis that detoxification of lipid hydroperoxides by HDL is potentially antiatherogenic.	Heart Res Inst, Biochem Res Grp, Sydney, NSW 2050, Australia; Heart Res Inst, Clin Res Grp, Sydney, NSW 2050, Australia; Concord Hosp, Dept Cardiol, Sydney, NSW 2139, Australia; Univ New S Wales, Sch Pathol, Cytokine Res Unit, Sydney, NSW 2052, Australia; Royal Adelaide Hosp, Lipid Res Lab, Adelaide, SA 5000, Australia	University of Sydney; Heart Research Institute; University of Sydney; Heart Research Institute; Concord Repatriation General Hospital; University of New South Wales Sydney; Royal Adelaide Hospital	Stocker, R (corresponding author), Heart Res Inst, Biochem Res Grp, 145 Missenden Rd, Sydney, NSW 2050, Australia.	r.stocker@hri.org.au	Stocker, Roland/AAV-4489-2021; Kritharides, Leonard/AAQ-2720-2020	Panzenbock, Ute/0000-0002-0545-6758				BANKA CL, 1994, J BIOL CHEM, V269, P10288; BANKA CL, 1991, J BIOL CHEM, V266, P23886; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; Christison J, 1996, BIOCHEM J, V314, P739, DOI 10.1042/bj3140739; CHRISTISON JK, 1995, J LIPID RES, V36, P2017; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fluiter K, 1996, BIOCHEM J, V319, P471, DOI 10.1042/bj3190471; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; Garner B, 1998, J BIOL CHEM, V273, P6080, DOI 10.1074/jbc.273.11.6080; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JONAS A, 1993, BIOCHIM BIOPHYS ACTA, V1166, P202, DOI 10.1016/0005-2760(93)90098-T; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1991, J LIPID RES, V32, P97; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; Laccotripe M, 1997, J BIOL CHEM, V272, P17511, DOI 10.1074/jbc.272.28.17511; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LIANG HQ, 1994, J LIPID RES, V35, P1187; Mashima R, 1998, J LIPID RES, V39, P1133; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; NAGANO Y, 1991, P NATL ACAD SCI USA, V88, P6457, DOI 10.1073/pnas.88.15.6457; Niu XW, 1999, ARTERIOSCL THROM VAS, V19, P1708, DOI 10.1161/01.ATV.19.7.1708; Oram JF, 1996, J LIPID RES, V37, P2473; Panzenboeck U, 1997, J BIOL CHEM, V272, P29711, DOI 10.1074/jbc.272.47.29711; PIRAN U, 1979, J LIPID RES, V20, P1040; POWNALL HJ, 1981, BIOCHEMISTRY-US, V20, P6630, DOI 10.1021/bi00526a017; Rothblat GH, 1999, J LIPID RES, V40, P781; RYE KA, 1994, J BIOL CHEM, V269, P10298; Rye KA, 1996, J BIOL CHEM, V271, P4243; RYE KA, 1995, J BIOL CHEM, V270, P189, DOI 10.1074/jbc.270.1.189; SATTLER W, 1993, BIOCHEM J, V294, P771, DOI 10.1042/bj2940771; SATTLER W, 1995, FREE RADICAL BIO MED, V18, P421, DOI 10.1016/0891-5849(94)00170-O; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SEGREST JP, 1992, J LIPID RES, V33, P141; Sorci-Thomas MG, 1998, J BIOL CHEM, V273, P11776, DOI 10.1074/jbc.273.19.11776; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; THOMAS SR, 1994, J BIOL CHEM, V269, P14457; VONECKARDSTEIN A, 1991, J LIPID RES, V32, P1465; Wang WQ, 1998, J BIOL CHEM, V273, P17391, DOI 10.1074/jbc.273.28.17391; Witting PK, 1999, METHOD ENZYMOL, V299, P362; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0	51	62	64	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19536	19544		10.1074/jbc.M000458200	http://dx.doi.org/10.1074/jbc.M000458200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10751387	hybrid			2022-12-27	WOS:000087941300016
J	Rosado, JA; Sage, SO				Rosado, JA; Sage, SO			Regulation of plasma membrane Ca2+-ATPase by small GTPases and phosphoinositides in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; FURA-2-LOADED HUMAN-PLATELETS; ACTIN POLYMERIZATION; BLOOD-PLATELETS; ACINAR-CELLS; CA2+ INFLUX; ACTIVATION; THAPSIGARGIN; INHIBITORS; ENTRY	We have investigated the restoration of [Ca2+](i) in human platelets following the discharge of the intracellular Ca2+ stores. We found that the plasma membrane Ca2+-ATPase is the main mechanism involved in Ca2+ extrusion in human platelets. Treatment of platelets with the farnesylcysteine analogs, farnesylthioacetic acid and N-acetyl-S-geranylgeranyl-L-cysteine, inhibitors of activation of Ras proteins, accelerated the rate of decay of [Ca2+](i) to basal levels after activation with thapsigargin combined with a low concentration of ionomycin, indicating that Ras proteins are involved in the negative regulation of Ca2+ extrusion. Rho A, which is involved in actin polymerization, was not responsible for this effect. Consistent with this, the actin polymerization inhibitors, cytochalasin D and latrunculin A, did not alter the recovery of [Ca2+](i). Activation of human platelets with thapsigargin and ionomycin stimulated the tyrosine phosphorylation of the plasma membrane Ca2+-ATPase, a mechanism that was inhibited by farnesylcysteine analogs, suggesting that Ras proteins could regulate Ca2+ extrusion by mediating tyrosine phosphorylation of the plasma membrane Ca2+-ATPase. Treatment of platelets with LY294002, a specific inhibitor of phosphatidylinositol 3- and phosphatidylinositol 4-kinase, resulted in a reduction in the rate of recovery of [Ca2+](i) to basal levels, suggesting that the products of these kinases are involved in stimulating Ca2+ extrusion in human platelets.	Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England	University of Cambridge	Sage, SO (corresponding author), Univ Cambridge, Dept Physiol, Downing St, Cambridge CB2 3EG, England.		Rosado, Juan A/H-3488-2015	Rosado, Juan A/0000-0002-9749-2325; Sage, Stewart/0000-0001-8578-3558				BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BRASS LF, 1984, J BIOL CHEM, V259, P2563; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CAVALLINI L, 1995, BIOCHEM J, V310, P449, DOI 10.1042/bj3100449; CHOQUETTE D, 1984, BIOCHEM BIOPH RES CO, V125, P908, DOI 10.1016/0006-291X(84)91369-X; Dean WL, 1997, J BIOL CHEM, V272, P15113, DOI 10.1074/jbc.272.24.15113; DONI MG, 1994, BIOCHEM J, V303, P599, DOI 10.1042/bj3030599; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Fleming I, 1996, J BIOL CHEM, V271, P11009, DOI 10.1074/jbc.271.18.11009; Fox JEB, 1996, HAEMOSTASIS, V26, P102; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; Gasman S, 1998, J BIOL CHEM, V273, P16913, DOI 10.1074/jbc.273.27.16913; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; JOHNSON JS, 1992, BIOCHIM BIOPHYS ACTA, V1105, P19; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263; Molony L, 1996, BIOCHEM BIOPH RES CO, V223, P612, DOI 10.1006/bbrc.1996.0943; MONTEITH GR, 1995, CELL CALCIUM, V18, P459, DOI 10.1016/0143-4160(95)90009-8; MORII N, 1992, J BIOL CHEM, V267, P20921; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; RINK TJ, 1987, J PHYSIOL-LONDON, V393, P513, DOI 10.1113/jphysiol.1987.sp016837; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, BIOCHEM J, V347, P183, DOI 10.1042/0264-6021:3470183; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; SARGEANT P, 1993, FEBS LETT, V315, P242, DOI 10.1016/0014-5793(93)81172-V; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; SOMLYO AP, 1984, NATURE, V309, P516, DOI 10.1038/309516b0; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TOESCU EC, 1995, J BIOL CHEM, V270, P8528, DOI 10.1074/jbc.270.15.8528; TOESCU EC, 1994, PFLUG ARCH EUR J PHY, V427, P325, DOI 10.1007/BF00374541; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; Wang K K, 1992, Trends Cell Biol, V2, P46, DOI 10.1016/0962-8924(92)90162-G; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF592, DOI 10.1152/ajprenal.1994.267.4.F592; WRIGHT LC, 1993, ARCH BIOCHEM BIOPHYS, V306, P277, DOI 10.1006/abbi.1993.1512; XU X, 1996, MOL PHARMACOL, V50, P1495; YULE DI, 1994, BIOCHEM BIOPH RES CO, V202, P1697, DOI 10.1006/bbrc.1994.2130; ZHANG BX, 1992, J BIOL CHEM, V267, P15419	44	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19529	19535		10.1074/jbc.M001319200	http://dx.doi.org/10.1074/jbc.M001319200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748016	hybrid			2022-12-27	WOS:000087941300015
J	Shimizu, M; Carter, PH; Gardella, TJ				Shimizu, M; Carter, PH; Gardella, TJ			Autoactivation of type-1 parathyroid hormone receptors containing a tethered ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PTH)/PTH-RELATED PEPTIDE RECEPTOR; N-TERMINAL REGION; BIOLOGICAL-ACTIVITY; CROSS-LINKING; BINDING; RESIDUES; DETERMINANTS; MUTAGENESIS; ACTIVATION; PTH-(1-34)	Interactions between the N-terminal residues of parathyroid hormone (PTH) and the region of the PTH receptor containing the extracellular loops and transmembrane domains are thought to be critical for receptor activation. We evaluated this hypothesis by replacing the large N-terminal extracellular domain of the human type 1 PTH receptor (hP1Rc-WT) with residues 1-9 of PTH (AVSEIQLMH) using a tetraglycine linker between His-9 of the ligand and Glu-182 of the receptor near the extracellular terminus of transmembrane domain-1. Expression of this construct, hP1Rc-Tether(1-9), in COS-7 cells resulted in basal cAMP levels that were 10-fold higher than those seen in control cells transfected with hP1Rc-WT, Extending the ligand sequence to include Asn-10 and the activity-enhancing substitution of Leu-11 --> Arg yielded hP1Rc-[Arg(11)]Tether(1-11), for which we observed basal cAMP levels that were 50-fold higher than those seen with P1Rc-WT, An alanine-scan analysis of hP1Rc-[Arg(11)]Tether(1-11) revealed that Gln-6 and His-9 were not critical for autoactivation, whereas Val-2, Ile-5, and Met-8 were. The data show that tethered PTH/PTH receptors can autoactivate. Analysis of the structure-activity relationships in these tethered receptor constructs can provide new information concerning how the N-terminal residues of PTH interact with the extracellular loops and transmembrane regions of the PTH-1 receptor, particularly in regard to receptor activation.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Gardella, TJ (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.	gardella@helix.mgh.harvard.edu						Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Carter PH, 1999, J BIOL CHEM, V274, P31955, DOI 10.1074/jbc.274.45.31955; Carter PH, 1999, ENDOCRINOLOGY, V140, P4972, DOI 10.1210/en.140.11.4972; CHEN J, 1994, J BIOL CHEM, V269, P16041; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; FRELINGER AL, 1984, J BIOL CHEM, V259, P5507; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; KRONENBERG H, 1997, GENETICS ENDOCRINE M, P389; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NUSSBAUM SR, 1980, J BIOL CHEM, V255, P183; ROE E, 1999, J BONE MINER S1, V14, P137; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo-93-6-1349; Turner PR, 1996, MOL ENDOCRINOL, V10, P132, DOI 10.1210/me.10.2.132	25	42	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19456	19460		10.1074/jbc.M001596200	http://dx.doi.org/10.1074/jbc.M001596200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10751403	hybrid			2022-12-27	WOS:000087941300005
J	Venning, JD; Peake, SJ; Quirk, PG; Jackson, JB				Venning, JD; Peake, SJ; Quirk, PG; Jackson, JB			Stopped-flow reaction kinetics of recombinant components of proton-translocating transhydrogenase with physiological nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILE LOOP REGION; RHODOSPIRILLUM-RUBRUM; ESCHERICHIA-COLI; DOMAIN-III; NADP(H)-BINDING COMPONENT; NAD(H)-BINDING DOMAIN; CATALYTIC PROPERTIES; HYDRIDE TRANSFER; BINDING; RESOLUTION	New information on the high resolution structure of the membrane proton pump, transhydrogenase, now provides a framework for understanding kinetic descriptions of the enzyme. Here, we have studied redox reactions catalyzed by mixtures of the recombinant NAD(H)-binding component (dI) of Rhodospirillum rubrum transhydrogenase, and the recombinant NADP(H)-binding component (dIII) of either the R. rubrum enzyme or the human enzyme. By recording changes in the fluorescence emission of native and engineered Trp residues, the rates of the redox reaction with physiological nucleotides have been measured under stopped-flow conditions, for the first time. Rate constants for the binding reaction between NAD(+)/NADH and the R. rubrum dI dIII complex are much greater than those between nucleotide and isolated dl. For the redox step between the physiological nucleotides on the R rubrum dI dIII complex, the rate constant in the forward direction, k(f) approximate to 2900 s(-1), and that for the reverse reaction, k(r) approximate to 110 s(-1). Comparisons with reactions involving an analogue of NAD(H) indicate that the rate constants at this step are strongly affected by the redox driving force.	Univ Birmingham, Sch Bioresources, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Jackson, JB (corresponding author), Univ Birmingham, Sch Bioresources, Birmingham B15 2TT, W Midlands, England.							Arkblad EL, 1996, BBA-BIOENERGETICS, V1273, P203; Baker PJ, 1998, NAT STRUCT BIOL, V5, P561, DOI 10.1038/817; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bizouarn T, 1996, EUR J BIOCHEM, V239, P737, DOI 10.1111/j.1432-1033.1996.0737u.x; Bizouarn T, 1996, J BIOL CHEM, V271, P10103, DOI 10.1074/jbc.271.17.10103; Bragg PD, 1998, BBA-BIOENERGETICS, V1365, P98, DOI 10.1016/S0005-2728(98)00049-8; DIGGLE C, 1995, EUR J BIOCHEM, V232, P315, DOI 10.1111/j.1432-1033.1995.tb20814.x; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; Fersht A., 1985, ENZYME STRUCTURE MEC; Fjellstrom O, 1999, BIOCHEMISTRY-US, V38, P415, DOI 10.1021/bi9817111; Fjellstrom O, 1997, BIOCHEMISTRY-US, V36, P11331, DOI 10.1021/bi970958f; Gupta S, 1998, BBA-BIOENERGETICS, V1409, P25, DOI 10.1016/S0005-2728(98)00146-7; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; Jackson JB, 1999, FEBS LETT, V464, P1, DOI 10.1016/S0014-5793(99)01644-0; Jackson JB, 1998, BBA-BIOENERGETICS, V1365, P79; Jeeves M, 1999, J BIOMOL NMR, V13, P305, DOI 10.1023/A:1008300609352; JENKS WP, 1983, CURR TOP MEMBR TRANS, V19, P1; Johnson K. A., 1992, ENZYMES, P1; LEE CHUAN-PU, 1965, BIOCHIM BIOPHYS BIOPHYS ACTA, V105, P397; LEVER TM, 1991, EUR J BIOCHEM, V197, P247, DOI 10.1111/j.1432-1033.1991.tb15905.x; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Peake SJ, 1999, BBA-BIOENERGETICS, V1413, P81, DOI 10.1016/S0005-2728(99)00084-5; Peake SJ, 1999, BBA-BIOENERGETICS, V1411, P159, DOI 10.1016/S0005-2728(99)00013-4; Prasad GS, 1999, NAT STRUCT BIOL, V6, P1126; Quirk PG, 1999, FEBS LETT, V446, P127, DOI 10.1016/S0014-5793(99)00198-2; Quirk PG, 1999, BBA-BIOENERGETICS, V1412, P139, DOI 10.1016/S0005-2728(99)00057-2; Rydstrom J, 1998, BBA-BIOENERGETICS, V1365, P10, DOI 10.1016/S0005-2728(98)00038-3; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; Venning JD, 1997, J BIOL CHEM, V272, P27535, DOI 10.1074/jbc.272.44.27535; Venning JD, 1999, BIOCHEM J, V341, P329, DOI 10.1042/0264-6021:3410329; Venning JD, 1998, EUR J BIOCHEM, V257, P202, DOI 10.1046/j.1432-1327.1998.2570202.x; White SA, 2000, STRUCT FOLD DES, V8, P1, DOI 10.1016/S0969-2126(00)00075-7; WILLIAMS R, 1994, MICROBIOL-UK, V140, P1595, DOI 10.1099/13500872-140-7-1595; Woenckhaus C., 1987, PYRIDINE NUCLEOTID A, P449; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P28165; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	38	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19490	19497		10.1074/jbc.M000577200	http://dx.doi.org/10.1074/jbc.M000577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10747934	hybrid			2022-12-27	WOS:000087941300010
J	Lind, U; Greenidge, P; Gillner, M; Koehler, KF; Wright, A; Carlstedt-Duke, J				Lind, U; Greenidge, P; Gillner, M; Koehler, KF; Wright, A; Carlstedt-Duke, J			Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis - Gln-642 plays an important role in steroid recognition and binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING; ESTROGEN-RECEPTOR; MOLECULAR-DYNAMICS; NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; DOMAIN; ANTAGONISM; ACTIVATION; PROTEINS	To elucidate which amino acids in the glucocorticoid receptor ligand-binding domain might be involved in determining steroid binding specificity by interaction with the D-ring of glucocorticoids, we have performed site-directed mutagenesis of the four amino acids Met-560, Met-639, Gln-642, and Thr-739 based on their proximity to the steroid in a model structure. Mutations of these residues affected steroid binding affinity, specificity, and/or steroid-dependent transactivation. The results indicate that these residues are located in close proximity to the ligand and appear to play a role in steroid recognition and/or transactivating sensitivity, possibly by changes in the steroid-dependent conformational change of this region, resulting in the formation of the AF-2 site. Mutation of Gln-642 resulted in a marked decrease in affinity for steroids containing a 17 alpha-OH group. This effect was alleviated by the presence of a 16 alpha-CH3 group to a varying degree. Thr-739 appears to form a hydrogen bond with the 21-OH group of the steroid, as well as possibly forming hydrophobic interactions with the steroid, Met-EGO and Met-639 appear to form hydrophobic interactions with the D-ring of the steroid, although the nature of these interactions cannot be characterized in more detail at this point.	Karolinska Inst, Novum, Huddinge Hosp, Dept Med Nutr, S-14186 Huddinge, Sweden; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; aKaro Bio AB, Novum, S-14157 Huddinge, Sweden; Sodertorns Hgsk, S-14104 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Sodertorn University	Carlstedt-Duke, J (corresponding author), Karolinska Inst, Novum, Huddinge Hosp, Dept Med Nutr, S-14186 Huddinge, Sweden.		Wright, Anthony/J-8187-2015	Wright, Anthony/0000-0003-1029-9969; Koehler, Konrad/0000-0002-4728-179X				BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; BROOKS CL, 1985, BIOPOLYMERS, V24, P843, DOI 10.1002/bip.360240509; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BURLING FT, 1992, J AM CHEM SOC, V114, P2313, DOI 10.1021/ja00033a004; BURLING FT, 1993, ACTA CRYSTALLOGR B, V49, P738, DOI 10.1107/S0108768193000709; CARLSTEDTDUKE J, 1987, P NATL ACAD SCI USA, V84, P4437, DOI 10.1073/pnas.84.13.4437; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fagart J, 1998, EMBO J, V17, P3317, DOI 10.1093/emboj/17.12.3317; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lind U, 1996, MOL ENDOCRINOL, V10, P1358, DOI 10.1210/me.10.11.1358; Mak HY, 1999, MOL CELL BIOL, V19, P3895; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MCDONALD DQ, 1992, TETRAHEDRON LETT, V33, P7743, DOI 10.1016/0040-4039(93)88034-G; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROSENFIELD RE, 1977, J AM CHEM SOC, V99, P4860, DOI 10.1021/ja00456a072; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SALI A, 1995, CURR OPIN BIOTECH, V6, P437, DOI 10.1016/0958-1669(95)80074-3; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SINGH UC, 1984, J COMPUT CHEM, V5, P129, DOI 10.1002/jcc.540050204; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; WOLFF ME, 1978, BIOCHEMISTRY-US, V17, P3201, DOI 10.1021/bi00609a005; Womble D D, 2000, Methods Mol Biol, V132, P3; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	43	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19041	19049		10.1074/jbc.M000228200	http://dx.doi.org/10.1074/jbc.M000228200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10747884	hybrid			2022-12-27	WOS:000087815900057
J	Gluzman-Poltorak, Z; Cohen, T; Herzog, Y; Neufeld, G				Gluzman-Poltorak, Z; Cohen, T; Herzog, Y; Neufeld, G			Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNAL-TRANSDUCTION; PERMEABILITY FACTOR; SPLICE VARIANTS; SEMAPHORIN-III; TUMOR-CELLS; BINDING; IDENTIFICATION; EXPRESSION; ISOFORM	Neuropilin-1 (np-1) and neuropilin-2 (np-2) are receptors for axon guidance factors belonging to the class 3 semaphorins. np-1 also binds to the 165-amino acid heparin-binding form of VEGF (VEGF(165)) but not to the shorter VEGF(121) form, which lacks a heparin binding ability. We report that human umbilical vein-derived endothelial cells express the a17 and a22 splice forms of the np-2 receptor. Both np-2 forms bind VEGF(165) with high affinity in the presence of heparin (K-D 1.3 x 10(-10) M) but not VEGF(121). np-2 also binds the heparin-binding form of placenta growth factor. These binding characteristics resemble those of np-l. VEGF,, is a secreted heparin binding VEGF form that contains the peptide encoded by exon 6 of VEGF but not the peptide encoded VEGF(145) binds to by exon 7, which is present in VEGF(165).VEGF(145) binds to np-2 with high affinity (K-D 7 x 10(-10) M). Surprisingly, VEGF(145) did not bind to np-1. Indeed, VEGF(145) does not bind to MDA-MB-231 breast cancer cells, which predominantly express np-l. By contrast, VEGF(145) binds to human umbilical rein-derived endothelial cells, which express both np-l and np-2. The binding of VEGF(165) to porcine aortic endothelial cells expressing recombinant np-2 did not affect the proliferation or migration of the cells. Nevertheless, it is possible that VEGF-induced np-2-mediated signaling will take place only in the presence of other VEGF receptors such as VEGF receptor-1 or VEGF receptor-2.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Neufeld, G (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.		Neufeld, Gera/F-1524-2019					Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Burchardt M, 1999, BIOL REPROD, V60, P398, DOI 10.1095/biolreprod60.2.398; Cai HB, 1999, J NEUROSCI, V19, P6519; Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chedotal A, 1998, DEVELOPMENT, V125, P4313; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Kolodkin AL, 1997, NEURON, V19, P1159, DOI 10.1016/S0896-6273(00)80408-0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1993, ONCOGENE, V8, P925; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; PERETZ D, 1992, BIOCHEM BIOPH RES CO, V182, P1340, DOI 10.1016/0006-291X(92)91880-Y; Persico MG, 1999, CURR TOP MICROBIOL, V237, P31; Poliakova L, 1999, J THORAC CARDIOV SUR, V118, P339, DOI 10.1016/S0022-5223(99)70225-4; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; Tober KL, 1998, BIOCHEM BIOPH RES CO, V247, P644, DOI 10.1006/bbrc.1998.8787; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Whittle C, 1999, CLIN SCI, V97, P303, DOI 10.1042/CS19990016; Ziche M, 1997, LAB INVEST, V76, P517	54	274	290	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18040	18045		10.1074/jbc.M909259199	http://dx.doi.org/10.1074/jbc.M909259199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748121	hybrid			2022-12-27	WOS:000087659400020
J	Helluin, O; Chan, C; Vilaire, G; Mousa, S; DeGrado, WF; Bennett, JS				Helluin, O; Chan, C; Vilaire, G; Mousa, S; DeGrado, WF; Bennett, JS			The activation state of alpha(v)beta(3) regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; ALPHA(4)BETA(1) INTEGRIN; BINDING; MIGRATION; LIGAND; FIBRONECTIN; AFFINITY; PROTEIN; DOMAIN; RECEPTOR	Cleavage of osteopontin by thrombin has been reported to enhance cell adhesion. We asked whether thrombin could regulate the alpha(v)beta(3)-mediated adhesion of platelets and B lymphocytes to this substrate. Although there was no difference in the extent or the avidity of thrombin- and ADP-stimulated platelet adhesion to intact or thrombin-cleaved human osteopontin, both the extent and avidity of phorbol ester-stimulated B cell adhesion to thrombin-cleaved osteopontin was significantly increased. Thus, these data suggest that the ability of alpha(v)beta(3) to recognize osteopontin can be differentially regulated in a cell-specific manner. To localize the alpha(v)beta(3) binding site on osteopontin, we measured cell adhesion to the two thrombin cleavage products of osteopontin and to a series of nested RGD-containing osteopontin peptides cross-linked to albumin. Whereas ADP-stimulated platelets adhered to the amino-terminal but not the carboxyl-terminal osteopontin fragment and to the osteopontin peptide RGDSVVYGLR, phorbol ester-stimulated B cells did not adhere to this peptide, although they did so in the presence of 1 mM Mn2+, Thus, our data confirm that thrombin cleavage enhances the accessibility of the binding motif for alpha(v)beta(3) on osteopontin, but this enhancement is also a function of the activation state of alpha(v)beta(3). Moreover, they indicate that the sequence RGDSVVYGLR contains sufficient information to specify activation-dependent alpha(v)beta(3)-mediated platelet and lymphocyte adhesion.	Univ Penn, Sch Med, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; DuPont Pharmaceut, Wilmington, DE 19880 USA	University of Pennsylvania; University of Pennsylvania; DuPont	Bennett, JS (corresponding author), Univ Penn, Sch Med, Div Hematol Oncol, Dept Med, BRB 2-3,Rm 914,421 Curie Blvd, Philadelphia, PA 19104 USA.		Mousa, Shaker A/A-7151-2017	Mousa, Shaker A/0000-0002-9294-015X	NHLBI NIH HHS [HL54000, HL62250] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062250, R29HL054000] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bach AC, 1996, J AM CHEM SOC, V118, P293, DOI 10.1021/ja953163+; Bayless KJ, 1998, J CELL SCI, V111, P1165; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; BELLAVITE P, 1994, ANAL BIOCHEM, V216, P444, DOI 10.1006/abio.1994.1066; Bennett JS, 1997, J BIOL CHEM, V272, P8137, DOI 10.1074/jbc.272.13.8137; BENNETT JS, 1996, TRENDS CARDIOVAS MED, V16, P31; Byzova TV, 1998, J CELL BIOL, V143, P2081, DOI 10.1083/jcb.143.7.2081; COLLER BS, 1991, BLOOD, V78, P2603; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; Denda S, 1998, MOL BIOL CELL, V9, P1425, DOI 10.1091/mbc.9.6.1425; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Garcia AJ, 1998, J BIOL CHEM, V273, P10988, DOI 10.1074/jbc.273.18.10988; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; LOH E, 1995, J BIOL CHEM, V270, P18631, DOI 10.1074/jbc.270.31.18631; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; PLOW EF, 1981, J BIOL CHEM, V256, P9477; Senger DR, 1996, BBA-MOL CELL RES, V1314, P13, DOI 10.1016/S0167-4889(96)00067-5; SENGER DR, 1994, MOL BIOL CELL, V5, P565, DOI 10.1091/mbc.5.5.565; SENGER DR, 1988, CANCER RES, V48, P5770; SIXMA JJ, 1977, SEMIN HEMATOL, V14, P265; Smith LL, 1998, EXP CELL RES, V242, P351, DOI 10.1006/excr.1998.4108; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; XUAN JW, 1995, J CELL BIOCHEM, V57, P680, DOI 10.1002/jcb.240570413; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	27	66	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18337	18343		10.1074/jbc.M001529200	http://dx.doi.org/10.1074/jbc.M001529200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10751402	hybrid			2022-12-27	WOS:000087659400059
J	Huang, Y; Hutter, D; Liu, YS; Wang, XT; Sheikh, MS; Chan, AML; Holbrook, NJ				Huang, Y; Hutter, D; Liu, YS; Wang, XT; Sheikh, MS; Chan, AML; Holbrook, NJ			Transforming growth factor-beta 1 suppresses serum deprivation-induced death of A549 cells through differential effects on c-Jun and JNK activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; TGF-BETA; CYCLE ARREST; MAP KINASES; RETINOBLASTOMA PROTEIN; OXIDATIVE STRESS; UV IRRADIATION; AP-1 FUNCTION; APOPTOSIS	Transforming growth factor (TGF)-beta 1, a pleiotropic cytokine involved in regulating growth and differentiation, can exert both pro-apoptotic and anti-apoptotic effects depending on the cell type or circumstances. We observed that TGF-beta 1 blocked apoptosis resulting from serum withdrawal in A549 human lung carcinoma cells. This was associated with suppression of JNK activation that occurs concomitant with the onset of apoptosis in the absence of TGF-beta 1, suggesting that JNK plays an active role in the death process and that TGF-beta 1 exerts its protective influence by altering JNK activity. Overexpression of a dominant negative mutant form of SEK1, an upstream activator of JNK, likewise suppressed JNK activation and inhibited apoptosis. Investigation of early events following TGF-beta 1 treatment revealed an early induction and phosphorylation of c-Jun that was absent in cells subjected to serum withdrawal alone. That TGF-beta 1-induced expression of c-Jun is important for survival mas supported by the finding that overexpression of non-phosphosphorylatable dominant negative mutant c-Jun, c-Jun(S73A), attenuated the protective influence of TGF-beta 1. Our findings suggest that JNK activation is a late but essential event in serum deprivation-induced apoptosis in A549 cells. TGF-beta 1 prevents apoptosis, in part, through the early induction and phosphorylation of c-Jun, which in turn results in attenuated JNK activation.	NIA, Biol Chem Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; NCI, Gene Response Sect, Div Basic Sci, Bethesda, MD 20892 USA; Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Icahn School of Medicine at Mount Sinai	Holbrook, NJ (corresponding author), NIA, Biol Chem Lab, Gerontol Res Ctr, 5600 Nathan Shock Dr,Box 12, Baltimore, MD 21224 USA.		Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013; Liu, Yusen/E-3527-2011	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464; Liu, Yusen/0000-0002-0994-0109				ARAKI S, 1990, BIOCHEM BIOPH RES CO, V172, P1081, DOI 10.1016/0006-291X(90)91557-9; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Cerwenka A, 1996, J IMMUNOL, V156, P459; Chen JJ, 1998, SCIENCE, V282, P1714, DOI 10.1126/science.282.5394.1714; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Fritz G, 1999, MOL CELL BIOL, V19, P1768; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; GEIER A, 1992, IN VITRO CELL DEV-AN, V28A, P725; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang Y, 1997, APOPTOSIS, V2, P199, DOI 10.1023/A:1026420616484; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KAWAKAMI A, 1996, ARTHRITIS RHEUM, V39, P12677; KOO AS, 1992, J UROLOGY, V148, P1314, DOI 10.1016/S0022-5347(17)36899-4; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI L, 1990, J BIOL CHEM, V265, P1556; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu Y, 1996, CANCER RES, V56, P31; LOMO J, 1995, J IMMUNOL, V154, P1634; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Massague J, 1996, CANCER SURV, V27, P41; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SELVAKUMARAN M, 1994, BLOOD, V84, P1036; SIMM A, 1994, J CELL PHYSIOL, V160, P295, DOI 10.1002/jcp.1041600211; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOTT C, 1994, BLOOD, V84, P1950; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	76	50	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18234	18242		10.1074/jbc.M909431199	http://dx.doi.org/10.1074/jbc.M909431199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748131	hybrid			2022-12-27	WOS:000087659400045
J	Shirk, RA; Parthasarathy, N; San Antonio, JD; Church, FC; Wagner, WD				Shirk, RA; Parthasarathy, N; San Antonio, JD; Church, FC; Wagner, WD			Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; DIFFERENT ORIGINS; ANTITHROMBIN-III; MOLECULAR-WEIGHT; ALPHA-THROMBIN; HUMAN ARTERIES; HUMAN AORTA; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; AFFINITY	Biglycan and decorin are small dermatan sulfate-containing proteoglycans in the extracellular matrix of the artery wall, The dermatan sulfate chains are known to stimulate thrombin inhibition by heparin cofactor II (HCII), a plasma proteinase inhibitor that has been detected within the artery wall. The purpose of this study was to analyze the HCII stimulatory activity of biglycan and decorin isolated from normal human aorta and atherosclerotic lesions type II through VI and to correlate activity with dermatan sulfate chain composition and structure. Biglycan and decorin from plaque exhibited a 24-75% and 38-79% loss of activity, respectively, in thrombin-HCII inhibition assays relative to proteoglycan from normal aorta. A significant negative linear relationship was observed between lesion severity and HCII stimulatory activity (r = 0.79, biglycan; r = 0.63, decorin; p < 0.05), Biglycan, but not decorin, from atherosclerotic plaque contained significantly reduced amounts of iduronic acid and disulfated disaccharides Delta Di-2,4S and Delta Di-4,6S relative to proteoglycan from normal artery. Affinity coelectrophoresis analysis of a subset of samples demonstrated that increased interaction of proteoglycan with HCII in agarose gels paralleled increased activity in thrombin-HCII inhibition assays. In conclusion, both biglycan and decorin from atherosclerotic plaque possessed reduced activity with HCII, but only biglycan demonstrated a correlation between activity and specific glycosaminoglycan structural features, Loss of the ability of biglycan and decorin in atherosclerotic lesions to regulate thrombin activity through HCII may be critical in the progression of the disease.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA; Univ N Carolina, Dept Pathol & Lab Med, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Thrombosis & Hemostasis, Sch Med, Chapel Hill, NC 27599 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Jefferson University; Jefferson University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Wagner, WD (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	wwagner@bgsm.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL053590, R01HL053590, R01HL025161] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-25161, HL-53590, HL-017115] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHERCHI GM, 1990, MATRIX, V10, P362, DOI 10.1016/S0934-8832(11)80143-5; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; Cooper ST, 1996, CLIN APPL THROMB-HEM, V2, P185, DOI 10.1177/107602969600200307; CRAGO AM, 1995, EXP CELL RES, V219, P650, DOI 10.1006/excr.1995.1275; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FRANSSON LA, 1970, J BIOL CHEM, V245, P4770; Fuster V, 1997, ANN NY ACAD SCI, V811, P207, DOI 10.1111/j.1749-6632.1997.tb52003.x; Fuster V, 1998, AM HEART J, V135, pS361, DOI 10.1053/hj.1998.v135.90300; Fuster V, 1998, Vasc Med, V3, P231, DOI 10.1177/1358836X9800300310; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; HARKER LA, 1995, AM J CARDIOL, V75, pB12, DOI 10.1016/0002-9149(95)80004-C; HASCALL VC, 1972, J BIOL CHEM, V247, P4521; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LONGAS MO, 1992, CARBOHYD RES, V237, P319, DOI 10.1016/S0008-6215(92)84255-Q; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; Mann KG., 1994, HEMOSTASIS THROMBOSI, P184; MASCELLANI G, 1994, THROMB RES, V74, P605, DOI 10.1016/0049-3848(94)90217-8; MCGUIRE EA, 1987, J BIOL CHEM, V262, P169; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MELROSE J, 1988, ANAL BIOCHEM, V170, P293, DOI 10.1016/0003-2697(88)90634-3; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; PARTHASARATHY N, 1987, BIOCHEMISTRY-US, V26, P3149, DOI 10.1021/bi00385a031; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; POBLACION CA, 1986, CARBOHYD RES, V147, P87, DOI 10.1016/0008-6215(86)85009-1; PRATT CW, 1989, ANN NY ACAD SCI, V556, P104; SALISBURY BGJ, 1981, J BIOL CHEM, V256, P8050; SCHONHERR E, 1993, ARTERIOSCLER THROMB, V13, P1026, DOI 10.1161/01.ATV.13.7.1026; SCULLY MF, 1988, BIOCHEM J, V254, P547, DOI 10.1042/bj2540547; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; Shirk RA, 1996, ARTERIOSCL THROM VAS, V16, P1138, DOI 10.1161/01.ATV.16.9.1138; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SIE P, 1993, BLOOD, V81, P1771; Silbert JE, 1996, GLYCOCONJUGATE J, V13, P907, DOI 10.1007/BF01053185; STARY HC, 1992, CIRCULATION, V85, P391, DOI 10.1161/01.CIR.85.1.391; TOLLEFSEN DM, 1986, J BIOL CHEM, V261, P8854; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; UCHIYAMA H, 1987, CARBOHYD RES, V159, P263, DOI 10.1016/S0008-6215(00)90220-9; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WAGNER WD, 1981, ARTERIOSCLEROSIS, V1, P192, DOI 10.1161/01.ATV.1.3.192; WAGNER WD, 1985, ANN NY ACAD SCI, V454, P52, DOI 10.1111/j.1749-6632.1985.tb11844.x; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; WIGHT TN, 1995, CURR OPIN LIPIDOL, V6, P326, DOI 10.1097/00041433-199510000-00013; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839	54	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18085	18092		10.1074/jbc.M001659200	http://dx.doi.org/10.1074/jbc.M001659200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10749870	hybrid, Green Published			2022-12-27	WOS:000087659400026
J	Yamada, K; Tanaka, T; Miyamoto, K; Noguchi, T				Yamada, K; Tanaka, T; Miyamoto, K; Noguchi, T			Sp family members and nuclear factor-Y cooperatively stimulate transcription from the rat pyruvate kinase M gene distal promoter region via their direct interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RESPONSE ELEMENT; BOX-BINDING-PROTEINS; FACTOR NF-Y; REGULATORY REGIONS; CYCLE REGULATION; DNA COMPLEX; ALDOLASE-A; EXPRESSION; ACTIVATION; DOMAINS	The three distal transcriptional regulatory elements of the rat pyruvate kinase RI gene, referred to as boxes A, B, and C, are located around -270 base pairs upstream from the transcriptional initiation site. Electrophoretic mobility shift assays with specific competitors and antibodies show that both box A and box B bind to Spl and Sp3 and that box C binds nuclear factor-Y (NF-Y). Luciferase reporter assays revealed that although box A and box B alone have no independent effect on luciferase activities, box C alone stimulates transcription. However, the inclusion of all three elements lead to maximal activity because of a synergistic effect, mainly between box B and box C, suggesting that functional synergism between Sp1/Sp3 and NF-Y is critical for the pyruvate kinase RI (PKM) gene distal promoter activity. In fact, co-transfection of a dominant negative mutant of NF-YA (NF-YA29) resulted in a decrease in reporter activity in a box C-dependent manner. In addition, the overexpression of Spl or Sp3 and NF-Y in Drosophila SL2 cells synergistically stimulated PKM gene distal promoter activity. Using a mammalian two-hybrid system in HeLa cells, it was shown that both Spl and Sp3 interacted with NF-YA but not NF-YB and NF-YC. Moreover, glutathione S-transferase pull-down assays revealed that only in vitro translated S-35-labeled NF-YA interacted with both Spl and Sp3 in vitro. A subunit interaction domain of NF-YA, which forms a heterotrimer with NF-YB and NF-YC, is not required for these interactions with Spl or Sp3. Thus, we conclude that Spl, Sp3, and NF-Y stimulate the transcription of the PKM gene via their interactions.	Nagoya Univ, Dept Appl Mol Biosci, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Fukui Med Univ, Dept Biochem, Fukui 9101193, Japan; Fukui Med Univ, Dept Pharmacol, Fukui 9101193, Japan	Nagoya University; University of Fukui; University of Fukui	Noguchi, T (corresponding author), Nagoya Univ, Dept Appl Mol Biosci, Grad Sch Bioagr Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	tnoguchi@agr.nagoya-u.ac.jp						Ahlgren R, 1999, J BIOL CHEM, V274, P19422, DOI 10.1074/jbc.274.27.19422; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; GREINER EF, 1994, J BIOL CHEM, V269, P31484; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Netzker R, 1997, EUR J BIOCHEM, V245, P174, DOI 10.1111/j.1432-1033.1997.00174.x; Netzker R, 1999, BBA-GENE STRUCT EXPR, V1444, P231, DOI 10.1016/S0167-4781(98)00281-4; NETZKER R, 1992, J BIOL CHEM, V267, P6421; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; PiseMasison CA, 1997, MOL CELL BIOL, V17, P1236, DOI 10.1128/MCB.17.3.1236; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; Roder Karim H., 1997, Biochemical Society Transactions, V25, p72S; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO J, 1965, JPN J EXP MED, V35, P491; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; Schafer D, 1996, FEBS LETT, V391, P35, DOI 10.1016/0014-5793(96)00701-6; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Sorensen P, 1999, J BIOL CHEM, V274, P30943, DOI 10.1074/jbc.274.43.30943; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Steffen ML, 1999, BIOCHEM J, V340, P425, DOI 10.1042/0264-6021:3400425; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; TAKENAKA M, 1991, EUR J BIOCHEM, V198, P101, DOI 10.1111/j.1432-1033.1991.tb15991.x; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; WANG Z, 1994, EUR J BIOCHEM, V220, P301, DOI 10.1111/j.1432-1033.1994.tb18626.x; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; Yamada E, 1999, BIOCHEM BIOPH RES CO, V256, P257, DOI 10.1006/bbrc.1999.0228; Yamada K, 1997, BIOCHEM J, V324, P917, DOI 10.1042/bj3240917; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; YAMADA K, 1990, J BIOL CHEM, V265, P19885; Yamada K, 1999, BIOCHEM J, V337, P1, DOI 10.1042/0264-6021:3370001; Yamada K, 1999, BIOCHEM BIOPH RES CO, V261, P614, DOI 10.1006/bbrc.1999.1087; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822	62	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18129	18137		10.1074/jbc.M001543200	http://dx.doi.org/10.1074/jbc.M001543200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748033	hybrid			2022-12-27	WOS:000087659400032
J	Adak, S; Wang, Q; Stuehr, DJ				Adak, S; Wang, Q; Stuehr, DJ			Molecular basis for hyperactivity in tryptophan 409 mutants of neuronal NO synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ELECTRON-TRANSFER; L-ARGININE; CALMODULIN; HEME; TETRAHYDROBIOPTERIN; COORDINATION; INHIBITION; MECHANISM; CATALYSIS	A ferrous heme-NO complex builds up in rat neuronal NO synthase during catalysis and lowers its activity. Mutation of a tryptophan located directly below the heme (Trp(409)) to phe or Tyr causes hyperactive NO synthesis and less heme-NO complex buildup in the steady state (Adak, S., Crooks, C,, Wang, Q,, Crane, B. R, Tainer, J. A, Getzoff, E. D,, and Stuehr, D. J, (1999) J, Biol. Chem, 274, 26907-26911). To understand the mechanism, we used conventional and stopped flow spectroscopy to compare kinetics of heme-NO complex formation, enzyme activity prior to and after complex formation, NO binding affinity, NO complex stability, and its reaction with O-2 in mutants and wild type nNOS, During the initial phase of NO synthesis, heme-NO complex formation was 3 and 5 times slower in W409F and W409Y, and their rates of NADPH oxidation were 50 and 30% that of wild type, probably due to slower heme reduction. NO complex formation slowed NADPH oxidation in the wild type by 7-fold but reduced mutant activities less than 2-fold, giving mutants higher final activities. NO binding kinetics were similar among mutants and wild type, although in ferrous W409Y land to a lesser extent W409F) the 436-nm NO complex converted to a 417-nm NO complex with time. Oxidation of the ferrous heme-NO complex to ferric enzyme was 7 times faster in Trp(409) mutants than in wild type. Thus, mutant hyperactivity derives from slower formation and faster decay of the heme-NO complex. Together, these minimize partitioning into the NO-bound form.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Immunol NB-3,9500 Euclid Ave, Cleveland, OH 44195 USA.				NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Adak S, 1999, J BIOL CHEM, V274, P26907, DOI 10.1074/jbc.274.38.26907; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; ASCENZI P, 1989, BIOCHEM J, V258, P473, DOI 10.1042/bj2580473; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gerber NC, 1997, J BIOL CHEM, V272, P6285, DOI 10.1074/jbc.272.10.6285; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; Iwanaga T, 1999, BIOCHEMISTRY-US, V38, P16629, DOI 10.1021/bi991277i; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Renodon-Corniere A, 1999, BIOCHEMISTRY-US, V38, P4663, DOI 10.1021/bi982930p; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; StevensTruss R, 1997, BIOCHEMISTRY-US, V36, P12337, DOI 10.1021/bi970973k; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425; YOSHIMURA T, 1984, ARCH BIOCHEM BIOPHYS, V229, P126, DOI 10.1016/0003-9861(84)90137-1	28	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17434	17439		10.1074/jbc.M000846200	http://dx.doi.org/10.1074/jbc.M000846200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747960	hybrid			2022-12-27	WOS:000087485000032
J	Gao, XD; Dean, N				Gao, XD; Dean, N			Distinct protein domains of the yeast golgi GDP-mannose transporter mediate oligomer assembly and export from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SUGAR TRANSPORTERS; MAJOR FACILITATOR SUPERFAMILY; SITE-SPECIFIC PROTEOLYSIS; SACCHAROMYCES-CEREVISIAE; GUANOSINE DIPHOSPHATASE; ESCHERICHIA-COLI; SHUTTLE VECTORS; GENE DELETION; VRG4 GENE; IN-VIVO	The substrates for glycan synthesis in the lumen of the Golgi are nucleotide sugars that must be transported from the cytosol by specific membrane-bound transporters. The principal nucleotide sugar used for glycosylation in the Golgi of the yeast Saccharomyces cerevisiae is GDP-mannose, whose lumenal transport is mediated by the VRG4 gene product. As the sole provider of lumenal mannose, the Vrg4 protein functions as a key regulator of glycosylation in the yeast Golgi, We have undertaken a functional analysis of Vrg4p as a model for understanding nucleotide sugar transport in the Golgi, Here, we analyzed epitope-tagged alleles of VRG4, Gel filtration chromatography and co-immunoprecipitation experiments demonstrate that the Vrg4 protein forms homodimers with specificity and high affinity. Deletion analyses identified two regions essential for VRG4 function. Mutant Vrg4 proteins lacking the predicted C-terminal membrane-spanning domain fail to assemble into oligomers (Abe, M., Hashimoto, H,, and Yoda, K, (1999) FEES Lett, 458, 309-312) and are unstable, while proteins lacking the N-terninal cytosolic tail are stable and multimerize efficiently, but are mislocalized to the endoplasmic reticulum (ER), Fusion of the N terminus of Vrg4p to related ER membrane proteins promote their transport to the Golgi, suggesting that sequences in the N terminus supply information for ER export. The dominant negative phenotype resulting from overexpression of truncated Vrgr4-Delta N proteins provides strong genetic evidence for homodimer formation in vivo, These studies are consistent with a model in which Vrg4p oligomerizes in the ER and is subsequently transported to the Golgi via a mechanism that involves positive sorting rather than passive default.	SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Dean, N (corresponding author), SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	ndean@notes.cc.sunysb.edu			NIGMS NIH HHS [GM48467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe M, 1999, FEBS LETT, V458, P309, DOI 10.1016/S0014-5793(99)01177-1; ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BERNINSONE P, 1995, J BIOL CHEM, V270, P14564, DOI 10.1074/jbc.270.24.14564; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; Chi JH, 1996, J BIOL CHEM, V271, P3132, DOI 10.1074/jbc.271.6.3132; Dean N, 1997, J BIOL CHEM, V272, P31908, DOI 10.1074/jbc.272.50.31908; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; Ehrmann M, 1997, P NATL ACAD SCI USA, V94, P13111, DOI 10.1073/pnas.94.24.13111; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; Gao XD, 1997, GLYCOBIOLOGY, V7, P120; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gilstring CF, 1996, FOLIA MICROBIOL, V41, P93, DOI 10.1007/BF02816353; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; Kawakita M, 1998, J BIOCHEM, V123, P777; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; Mondigler M, 1996, J BACTERIOL, V178, P2986, DOI 10.1128/jb.178.10.2986-2988.1996; Neiman AM, 1997, GENETICS, V145, P637; Nelissen B, 1995, FEBS LETT, V377, P232, DOI 10.1016/0014-5793(95)01380-6; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Poster JB, 1996, J BIOL CHEM, V271, P3837; Powers J, 1998, J CELL BIOL, V142, P1209, DOI 10.1083/jcb.142.5.1209; Puglielli L, 1999, J BIOL CHEM, V274, P35596, DOI 10.1074/jbc.274.50.35596; Puglielli L, 1999, J BIOL CHEM, V274, P4474, DOI 10.1074/jbc.274.7.4474; Rayner JC, 1998, J BIOL CHEM, V273, P26836, DOI 10.1074/jbc.273.41.26836; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Sherwood PW, 1999, P NATL ACAD SCI USA, V96, P7415, DOI 10.1073/pnas.96.13.7415; SIKORSKI RS, 1989, GENETICS, V122, P19; Vowels JJ, 1998, MOL BIOL CELL, V9, P1351, DOI 10.1091/mbc.9.6.1351; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALDMAN BC, 1990, BIOCHEMISTRY-US, V29, P44, DOI 10.1021/bi00453a006	45	73	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17718	17727		10.1074/jbc.M909946199	http://dx.doi.org/10.1074/jbc.M909946199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748175	hybrid			2022-12-27	WOS:000087485000072
J	Lawrence, SM; Huddleston, KA; Pitts, LR; Nguyen, N; Lee, YC; Vann, WF; Coleman, TA; Betenbaugh, MJ				Lawrence, SM; Huddleston, KA; Pitts, LR; Nguyen, N; Lee, YC; Vann, WF; Coleman, TA; Betenbaugh, MJ			Cloning and expression of the human N-acetylneuraminic acid phosphate synthase gene with 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid biosynthetic ability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; ESCHERICHIA-COLI; SIALIC ACIDS; 2-EPIMERASE/N-ACETYLMANNOSAMINE KINASE; LIQUID-CHROMATOGRAPHY; ELEVATED EXPRESSION; INSECT CELLS; SYNTHETASE; GLYCOSYLATION; PURIFICATION	Sialic acids participate in many important biological recognition events, yet eukaryotic sialic acid biosynthetic genes are not well characterized. In this study, we have identified a novel human gene based on homology to the Escherichia coli sialic acid synthase gene (neuB), The human gene is ubiquitously expressed and encodes a 40-kDa enzyme. The gene partially restores sialic acid synthase activity in a neuB-negative mutant of E. coli and results in N-acetylneuraminic acid (Neu5Ac) and 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN) production in insect cells upon recombinant baculovirus infection. In vitro the human enzyme uses N-acetylmannosamine 6-phosphate and mannose 6-phosphate as substrates to generate phosphorylated forms of Neu5Ac and KDN, respectively, but exhibits much higher activity toward the Neu5Ac phosphate product.	Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; US FDA, Lab Bacterial Toxins, Bethesda, MD 20892 USA; US FDA, Lab Bacterial Polysaccharides, Bethesda, MD 20892 USA; Human Genome Sci, Prot Dev, Rockville, MD 20850 USA	Johns Hopkins University; Johns Hopkins University; US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); GlaxoSmithKline; Human Genome Sciences Inc	Betenbaugh, MJ (corresponding author), Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA.	beten@jhu.edu	Betenbaugh, Michael J./A-3252-2010	Betenbaugh, Michael J./0000-0002-6336-4659				Angata T, 1999, J BIOL CHEM, V274, P22949, DOI 10.1074/jbc.274.33.22949; Angata T, 1999, BIOCHEM BIOPH RES CO, V261, P326, DOI 10.1006/bbrc.1999.1033; ANNUNZIATO PW, 1995, J BACTERIOL, V177, P312, DOI 10.1128/jb.177.2.312-319.1995; Coleman TA, 1997, GENE, V190, P163, DOI 10.1016/S0378-1119(96)00711-1; COMB DG, 1960, J BIOL CHEM, V235, P2529; CORFIELD AP, 1985, BIOCHEM J, V226, P163, DOI 10.1042/bj2260163; CUNNINGHAM BA, 1983, P NATL ACAD SCI-BIOL, V80, P3116, DOI 10.1073/pnas.80.10.3116; Effertz K, 1999, J BIOL CHEM, V274, P28771, DOI 10.1074/jbc.274.40.28771; Fukuda M, 1996, CANCER RES, V56, P2237; GHOSH S, 1965, J BIOL CHEM, V240, P1525; Grossmann M, 1997, ENDOCRINOLOGY, V138, P92, DOI 10.1210/en.138.1.92; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; Inoue S, 1998, J BIOL CHEM, V273, P27199, DOI 10.1074/jbc.273.42.27199; INOUE S, 1999, SIALOBIOLOGY OTHER N, P67; JARVIS DL, 1995, VIROLOGY, V212, P500, DOI 10.1006/viro.1995.1508; JOURDIAN GW, 1964, J BIOL CHEM, V239, P2714; KUNDIG W, 1966, J BIOL CHEM, V241, P5619; LILLEY GG, 1992, PROTEIN EXPRES PURIF, V3, P434, DOI 10.1016/S1046-5928(05)80047-6; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MIYAMOTO C, 1985, MOL CELL BIOL, V5, P2860, DOI 10.1128/MCB.5.10.2860; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; NADANO D, 1986, J BIOL CHEM, V261, P1550; Ogonah OW, 1996, BIO-TECHNOL, V14, P197, DOI 10.1038/nbt0296-197; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; Sukhanova MZ, 1998, GENETIKA+, V34, P1239; TAKANO R, 1994, GLYCOBIOLOGY, V4, P665, DOI 10.1093/glycob/4.5.665; Vann WF, 1997, GLYCOBIOLOGY, V7, P697, DOI 10.1093/glycob/7.5.697; VIMR ER, 1992, J BACTERIOL, V174, P6191, DOI 10.1128/JB.174.19.6191-6197.1992; VIMR ER, 1985, J BACTERIOL, V164, P854, DOI 10.1128/JB.164.2.854-860.1985; WATSON DR, 1966, J BIOL CHEM, V241, P5627; ZAPATA G, 1989, J BIOL CHEM, V264, P14769	34	81	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17869	17877		10.1074/jbc.M000217200	http://dx.doi.org/10.1074/jbc.M000217200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10749855	hybrid			2022-12-27	WOS:000087485000091
J	Nagata, K; Nishitani, M; Matsuo, M; Kioka, N; Amachi, T; Ueda, K				Nagata, K; Nishitani, M; Matsuo, M; Kioka, N; Amachi, T; Ueda, K			Nonequivalent nucleotide trapping in the two nucleotide binding folds of the human multidrug resistance protein MRP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; P-GLYCOPROTEIN; SULFONYLUREA RECEPTOR; ATPASE ACTIVITY; GLUTATHIONE; TRANSPORT; GENE; CELLS; EXPRESSION; DRUGS	Multidrug resistance protein 1 (MRP1) and P-glycoprotein, which are ATP-dependent multidrug efflux pumps and involved in multidrug resistance of tumor cells, are members of the ATP binding cassette proteins and contain two nucleotide-binding folds (NSFs), P-glycoprotein hydrolyzes ATP at both NBFs, and vanadate-induced nucleotide trapping occurs at both NBFs, We examined vanadate-induced nucleotide trapping in MRP1 stably expressed in KB cell membrane by using 8-azido-[alpha-P-32]ATP. Vanadate-induced nucleotide trapping in MRP1 was found to be stimulated by reduced glutathione, glutathione disulfide, and etoposide and to be synergistically stimulated by the presence of etoposide and either glutathione. These results suggest that glutathione and etoposide interact with MRP1 at different sites and that those bindings cooperatively stimulate the nucleotide trapping. Mild trypsin digestion of MRP1 revealed that vanadate-induced nucleotide trapping mainly occurs at NBF2, Our results suggest that the two NSFs of MRP1 might be functionally nonequivalent.	Kyoto Univ, Grad Sch Agr, Dept Appl Life Sci, Biochem Lab, Kyoto 6068502, Japan	Kyoto University	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Dept Appl Life Sci, Biochem Lab, Kyoto 6068502, Japan.			Kioka, Noriyuki/0000-0002-2708-537X				Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FLENS MJ, 1994, CANCER RES, V54, P4557; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, 1994, CANCER RES, V54, P357; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; ISHIKAWA T, 1990, TRENDS BIOCHEM SCI, V15, P219, DOI 10.1016/0968-0004(90)90032-7; Ishikawa T, 1997, BIOSCIENCE REP, V17, P189, DOI 10.1023/A:1027385513483; Ito K, 1998, J BIOL CHEM, V273, P1684, DOI 10.1074/jbc.273.3.1684; Keppler D, 1997, FASEB J, V11, P509, DOI 10.1096/fasebj.11.7.9212074; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Rappa G, 1997, CANCER RES, V57, P5232; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Sakamoto H, 1999, CANCER LETT, V135, P113; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	34	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17626	17630		10.1074/jbc.M000792200	http://dx.doi.org/10.1074/jbc.M000792200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747957	hybrid			2022-12-27	WOS:000087485000060
J	Kremer, L; Douglas, JD; Baulard, AR; Morehouse, C; Guy, MR; Alland, D; Dover, LG; Lakey, JH; Jacobs, WR; Brennan, PJ; Minnikin, DE; Besra, GS				Kremer, L; Douglas, JD; Baulard, AR; Morehouse, C; Guy, MR; Alland, D; Dover, LG; Lakey, JH; Jacobs, WR; Brennan, PJ; Minnikin, DE; Besra, GS			Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEIN SYNTHASE; FATTY-ACID SYNTHESIS; ESCHERICHIA-COLI; ANTIBIOTIC THIOLACTOMYCIN; COMPLETE GENOME; RESISTANCE; GENE; BIOSYNTHESIS; SMEGMATIS; MUTATIONS	Prevention efforts and control of tuberculosis are seriously hampered by the appearance of multidrug-resistant strains of Mycobacterium tuberculosis, dictating new approaches to the treatment of the disease. Thiolactomycin (TLM) is a unique thiolactone that has been shown to exhibit anti-mycobacterial activity by specifically inhibiting fatty acid and mycolic acid biosynthesis. In this study, we present evidence that TLM targets two beta-ketoacyl-acyl-carrier protein synthases, KasA and KasB, consistent with the fact that both enzymes belong to the fatty-acid synthase type II system involved in fatty acid and mycolic acid biosynthesis. Overexpression of KasA, KasB, and KasAB in Mycobacterium bovis BCG increased in vivo and in vitro resistance against TLM. In addition, a multidrug-resistant clinical isolate was also found to be highly sensitive to TLM, indicating promise in counteracting multidrug-resistant strains of M. tuberculosis. The design and synthesis of several TLM derivatives have led to compounds more potent both in vitro against fatty acid and mycolic acid biosynthesis and in vivo against M. tuberculosis. Finally, a three-dimensional structural model of KasA has also been generated to improve understanding of the catalytic site of mycobacterial Kas proteins and to provide a more rational approach to the design of new drugs.	Univ Newcastle Upon Tyne, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Dept Chem, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Inst Pasteur, INSERM, U447, F-59019 Lille, France; Montefiore Med Ctr, Dept Med, Div Infect Dis, Bronx, NY 10467 USA; Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Colorado State University	Besra, GS (corresponding author), Univ Newcastle Upon Tyne, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Dover, Lynn George/Q-6778-2019; Dover, Lynn G/F-3021-2010; Kremer, Laurent/M-4935-2017; Baulard, Alain R/E-6830-2017	Dover, Lynn George/0000-0002-4776-2665; Dover, Lynn G/0000-0002-4776-2665; Kremer, Laurent/0000-0002-6604-4458; Baulard, Alain R/0000-0002-0150-5241; Jacobs, William/0000-0003-3321-3080; Besra, Gurdyal/0000-0002-5605-0395; Lakey, Jeremy/0000-0003-4646-9085	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018357, R22AI018357, R01AI043268, R01AI018357, R21AI043268, R01AI033706] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18357, AI-33706, AI-43268] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BAULARD A, 1992, NUCLEIC ACIDS RES, V20, P4105, DOI 10.1093/nar/20.15.4105; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; Bloch K, 1975, Methods Enzymol, V35, P84, DOI 10.1016/0076-6879(75)35141-0; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Edwards P, 1997, FEBS LETT, V402, P62, DOI 10.1016/S0014-5793(96)01437-8; FINKEN M, 1993, MOL MICROBIOL, V9, P1239, DOI 10.1111/j.1365-2958.1993.tb01253.x; FURUKAWA H, 1993, J BACTERIOL, V175, P3723, DOI 10.1128/JB.175.12.3723-3729.1993; HAYASHI T, 1983, BIOCHEM BIOPH RES CO, V115, P1108, DOI 10.1016/S0006-291X(83)80050-3; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JACKOWSKI S, 1992, EMERGING TARGETS ANT, P151; JONES LA, 1994, BIOCHEM SOC T, V22, pS258; KREMER L, 1995, J BACTERIOL, V177, P642, DOI 10.1128/jb.177.3.642-653.1995; Lee ASG, 1999, ANTIMICROB AGENTS CH, V43, P2087, DOI 10.1128/AAC.43.8.2087; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; MIYAKAWA S, 1982, J ANTIBIOT, V35, P411, DOI 10.7164/antibiotics.35.411; NISHIDA I, 1986, J BIOCHEM-TOKYO, V99, P1447, DOI 10.1093/oxfordjournals.jbchem.a135614; Piatek AS, 2000, ANTIMICROB AGENTS CH, V44, P103, DOI 10.1128/AAC.44.1.103-110.2000; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 2002, MOL CLONING LAB MANU; SASAKI H, 1982, J ANTIBIOT, V35, P396, DOI 10.7164/antibiotics.35.396; Sauton B, 1912, CR HEBD ACAD SCI, V155, P860; Scorpio A, 1996, NAT MED, V2, P662, DOI 10.1038/nm0696-662; Seth V, 1993, Indian Pediatr, V30, P1091; Siggaard-Andersen Mads, 1993, Protein Sequences and Data Analysis, V5, P325; SIGGAARDANDERSE.M, 1998, ADV PLANT LIPID RES, P67; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; SLAYDEN RA, 1999, 4 INT C PATH MYC INF, P156; Smith P. G., 1994, P47; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Snider Dixie E. Jr., 1994, P3; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; SUMMERS RG, 1995, BIOCHEMISTRY-US, V34, P9389, DOI 10.1021/bi00029a015; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WHEELER PR, 1993, BIOCHIM BIOPHYS ACTA, V1167, P182, DOI 10.1016/0005-2760(93)90160-B; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	46	226	237	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16857	16864		10.1074/jbc.M000569200	http://dx.doi.org/10.1074/jbc.M000569200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747933	hybrid			2022-12-27	WOS:000087392200065
J	Kusakawa, G; Saito, T; Onuki, R; Ishiguro, K; Kishimoto, T; Hisanaga, S				Kusakawa, G; Saito, T; Onuki, R; Ishiguro, K; Kishimoto, T; Hisanaga, S			Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CDK5 ACTIVATOR; SITE-SPECIFIC PHOSPHORYLATION; CDC2-RELATED PROTEIN-KINASE; PAIRED HELICAL FILAMENTS; BRAIN-SPECIFIC ACTIVATOR; TAU-PROTEIN; BOVINE BRAIN; NEUROFILAMENT PROTEINS; CDC2-LIKE KINASE; CELL-CYCLE	Cyclin-dependent kinase 5 (CDK5) is a unique CDK, the activity of which can be detected in postmitotic neurons. To date, CDK5 purified from mammalian brains has always been associated with a truncated form of the 35-kDa major brain specific activator (p35, also known as nck5a) of CDK5, known as p25. In this study,we report that p35 can be cleaved to p25 both in nitro and in vivo by calpain. In a rat brain extract, p35 was cleaved to p25 by incubation with Ca2+. This cleavage was inhibited by a calpain inhibitor peptide derived from calpastatin and was ablated by separating the p35.CDK5 from calpain by centrifugation. The p35 recovered in the pellet after centrifugation could then be cleaved to p25 by purified calpain. Cleavage of p35 was also induced in primary cultured neurons by treatment with a Ca2+ ionophore and Ca2+ and inhibited by calpain inhibitor I. The cleavage changed the solubility of the CDK5 active complex from the particulate fraction to the soluble fraction but did not affect the histone H1 kinase activity. Increased cleavage was detected in cultured neurons undergoing cell death, suggesting a role of the cleavage in neuronal cell death.	Tokyo Metropolitan Univ, Grad Sch Sci, Dept Biol Sci, Tokyo 1920397, Japan; Tokyo Inst Technol, Fac Biosci, Lab Cell & Dev Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Japan Womens Univ, Dept Chem & Biol Sci, Bunkyo Ku, Tokyo 1128681, Japan; Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan	Tokyo Metropolitan University; Tokyo Institute of Technology; Japan Womens University	Hisanaga, S (corresponding author), Tokyo Metropolitan Univ, Grad Sch Sci, Dept Biol Sci, 1-1 Minami Ohsawa, Tokyo 1920397, Japan.							BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; D'Mello SR, 1998, CURR TOP DEV BIOL, V39, P187, DOI 10.1016/S0070-2153(08)60456-1; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HISANAGA S, 1993, J BIOL CHEM, V268, P15056; HISANAGA S, 1955, CELL MOTIL CYTOSKEL, V31, P283; HOSOI T, 1995, J BIOCHEM, V117, P741, DOI 10.1093/oxfordjournals.jbchem.a124771; INO H, 1994, BRAIN RES, V661, P196, DOI 10.1016/0006-8993(94)91197-5; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Krohn AJ, 1998, J NEUROSCI, V18, P8186; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazaro JB, 1997, J CELL SCI, V110, P1251; Lee KY, 1997, INT J BIOCHEM CELL B, V29, P951, DOI 10.1016/S1357-2725(97)00048-4; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Paglini G, 1998, J NEUROSCI, V18, P9858; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Philpott A, 1999, DEV BIOL, V207, P119, DOI 10.1006/dbio.1998.9146; PIGINO G, 1997, J CELL SCI, V110, P157; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; Qi Z, 1998, J BIOL CHEM, V273, P2329, DOI 10.1074/jbc.273.4.2329; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Saito T, 1998, BIOCHEM BIOPH RES CO, V252, P775, DOI 10.1006/bbrc.1998.9739; Sharma P, 1998, BIOCHEMISTRY-US, V37, P4759, DOI 10.1021/bi972746o; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; UCHIDA T, 1994, FEBS LETT, V355, P35, DOI 10.1016/0014-5793(94)01163-X; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309	48	324	346	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17166	17172		10.1074/jbc.M907757199	http://dx.doi.org/10.1074/jbc.M907757199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748088	hybrid			2022-12-27	WOS:000087392200108
J	Bird, A; Evans-Galea, MV; Blankman, E; Zhao, H; Luo, H; Winge, DR; Eide, DJ				Bird, A; Evans-Galea, MV; Blankman, E; Zhao, H; Luo, H; Winge, DR; Eide, DJ			Mapping the DNA binding domain of the Zap1 zinc-responsive transcriptional activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; CLONED GENES; YEAST; PROTEIN; TRANSPORTER; RECOGNITION; FINGERS; COMPLEX; EXPRESSION	The Zap1 transcriptional activator of Saccharomyces cerevisiae plays a major role in zinc homeostasis by inducing the expression of several genes under zinc-limited growth conditions. This activation of gene expression is mediated by binding of the protein to one or more zinc-responsive elements present in the promoters of its target genes. To better understand how Zap1 functions, we mapped its DNA binding domain using a combined in vivo and in vitro approach. Our results show that the Zap1 DNA binding domain maps to the carboxyl-terminal 194 amino acids of the protein; this region contains five of its seven potential zinc finger domains. Fusing this region to the Ga14 activation domain complemented a zap1 Delta mutation for low zinc growth and also conferred high level expression on a zinc-responsive element-lacZ reporter. In vitro, the purified 194-residue fragment bound to DNA with a high affinity (dissociation constant in the low nanomolar range) similar to that of longer fragments of Zap1. Furthermore, by deletion and site-directed mutagenesis, we demonstrated that each of the five carboxyl-terminal zinc fingers are required for high affinity DNA binding.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Utah, Hlth Sci Ctr, Dept Hematol, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	University of Missouri System; University of Missouri Columbia; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Eide, DJ (corresponding author), Univ Missouri, Dept Nutr Sci, 217 Gwynn Hall, Columbia, MO 65211 USA.		Bird, Amanda Jane/ABD-2295-2021; Winge, Dennis/G-3611-2010; Evans-Galea, Marguerite/A-4673-2013	Bird, Amanda Jane/0000-0002-1846-7050; Evans-Galea, Marguerite/0000-0003-1867-9667	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058265] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; KUNES S, 1987, GENETICS, V115, P73; LIU HP, 1992, GENETICS, V132, P665; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Nolte RT, 1998, P NATL ACAD SCI USA, V95, P2938, DOI 10.1073/pnas.95.6.2938; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	19	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16160	16166		10.1074/jbc.M000664200	http://dx.doi.org/10.1074/jbc.M000664200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747942	hybrid			2022-12-27	WOS:000087291400076
J	Gaul, BS; Harrison, ML; Geahlen, RL; Burton, RK; Post, CB				Gaul, BS; Harrison, ML; Geahlen, RL; Burton, RK; Post, CB			Substrate recognition by the Lyn protein-tyrosine kinase - NMR structure of the immunoreceptor tyrosine-based activation motif signaling region of the B cell antigen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PEPTIDE INHIBITOR; CATALYTIC SUBUNIT; DRUG DISCOVERY; LAVENDUSTIN-A; C-SRC; PHOSPHORYLATION; COMPLEX; SYK; FAMILY	The immunoreceptor tyrosine-based activation motif (ITAM) plays a central role in transmembrane signal transduction in hematopoietic cells by mediating responses leading to proliferation and differentiation. An initial signaling event following activation of the B cell antigen receptor is phosphorylation of the CD79a (Ig-alpha) ITAM by Lyn, a Src family protein-tyrosine kinase. To elucidate the structural basis for recognition between the ITAM substrate and activated Lyn kinase, the structure of an ITAM-derived peptide bound to Lyn was determined using exchange-transferred nuclear Overhauser NMR spectroscopy. The bound substrate structure has an irregular helix-like character. Docking based on the NMR data into the active site of the closely related Lck kinase strongly favors ITAM binding in an orientation similar 60 binding of cyclic AMP-dependent protein kinase rather than that of insulin receptor tyrosine kinase, The model of the complex provides a rationale for conserved ITAM residues, substrate specificity, and suggests that substrate binds only the active conformation of the Src family tyrosine kinase, unlike the ATP cofactor, which can bind the inactive form.	Purdue Univ, Dept Med Chem, W Lafayette, IN 47906 USA; Purdue Univ, Dept Mol Pharmacol, W Lafayette, IN 47906 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Post, CB (corresponding author), Purdue Univ, Dept Med Chem, W Lafayette, IN 47906 USA.	cbp@cc.purdue.edu	Post, Carol/AAD-7910-2021	Geahlen, Robert/0000-0001-8400-2924	NCI NIH HHS [R01CA37372] Funding Source: Medline; NIGMS NIH HHS [K04GM00661, R01GM39478] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039478] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; Bolen JB, 1997, ANNU REV IMMUNOL, V15, P371, DOI 10.1146/annurev.immunol.15.1.371; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, XPLOR VERSION 3 1; BURG DL, 1994, J BIOL CHEM, V269, P28136; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dhalluin C, 1996, J MAGN RESON SER B, V111, P168, DOI 10.1006/jmrb.1996.0075; EISENMESER E, 2000, IN PRESS J BIOMOL NM; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSU CYJ, 1991, J BIOL CHEM, V266, P21105; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Isakov N, 1997, J LEUKOCYTE BIOL, V61, P6, DOI 10.1002/jlb.61.1.6; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Koehl Patrice, 1999, Nature Structural Biology, V6, P108, DOI 10.1038/5794; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; Pao LI, 1998, J IMMUNOL, V160, P3305; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Ruzzene M, 1997, EUR J BIOCHEM, V246, P433, DOI 10.1111/j.1432-1033.1997.t01-1-00433.x; Salemme FR, 1997, STRUCTURE, V5, P319, DOI 10.1016/S0969-2126(97)00189-5; Sali Andrej, 1998, Nature Structural Biology, V5, P1029, DOI 10.1038/4136; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; Schneider ML, 1995, BIOCHEMISTRY-US, V34, P16574, DOI 10.1021/bi00051a005; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sternberg MJE, 1999, CURR OPIN STRUC BIOL, V9, P368, DOI 10.1016/S0959-440X(99)80050-5; Venclovas C, 1999, PROTEINS, P73; WEI L, 1994, CURR OPIN STRUC BIOL, V4, P450, DOI 10.1016/S0959-440X(94)90115-5; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	56	23	25	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16174	16182		10.1074/jbc.M909044199	http://dx.doi.org/10.1074/jbc.M909044199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748115	hybrid			2022-12-27	WOS:000087291400078
J	Kobayashi, Y; Kitamoto, T; Masuhiro, Y; Watanabe, M; Kase, T; Metzger, D; Yanagisawa, J; Kato, S				Kobayashi, Y; Kitamoto, T; Masuhiro, Y; Watanabe, M; Kase, T; Metzger, D; Yanagisawa, J; Kato, S			p300 mediates functional synergism between AF-1 and AF-2 of estrogen receptor alpha and beta by interacting directly with the N-terminal A/B domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION FUNCTIONS; LIGAND-DEPENDENT PHOSPHORYLATION; NUCLEAR RECEPTORS; COACTIVATOR; COMPLEX; CLONING; ACETYLTRANSFERASE; SUPERFAMILY; CBP/P300; PROSTATE	Estrogen receptor (ER) alpha and beta mediate estrogen actions in target cells through transcriptional control of target gene expression. For 17 beta-estradiol-induced transactivation, the N-terminal A/B domain (AF-1) and the C-terminal E/F domain (AF-2) of ERs are required. Ligand binding is considered to induce functional synergism between AF-1 and AF-2, but the molecular mechanism remains unknown. To clarify this synergism, we studied the role of reported AF-2 coactivators, p300/ CREB binding protein, steroid receptor coactivator-1/ transcriptional intermediary factor-2 (SRC-1/TIF2) family proteins and thyroid hormone receptor-associated protein-220/(vitamin D3 receptor-interacting protein205-(TRAP220/DRIP205) on the AF-1 activity in terms of synergism with the AF-2 function. We found that neither any of the SRC-1/TIF2 family coactivators nor TRAP220/ DRIP205 is potent, whereas p300 potentiates the AF-1 function of both human ER alpha and human ERP. Direct interactions of p300 with the A/B domains of ER alpha and ER beta were observed in an in vitro glutathione S-transferase pull-down assay in accordance with the interactions in yeast and mammalian two-hybrid assays. Furthermore, mutations in the p300 binding sites (56-72 amino acids in ER alpha and 62-72 amino acids in ER beta) in the A/B domains caused a reduction in ligand-induced transactivation functions of both ER alpha and E beta. Thus, these findings indicate that ligand-induced functional synergism between AF-1 and AF-2 is mediated through p300 by its direct binding to the A/B regions of ER alpha and ER beta.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; CU Strasbourg, ULP Coll France, CNRS,INSERM, Inst Genet & Biol Med & Cellulaire, F-67404 Illkirch Graffenstaden, France	University of Tokyo; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.	uskato@mail.ecc.u-tokyo.ac.jp		Metzger, Daniel/0000-0002-5555-046X; Kitamoto, Takuya/0000-0002-4008-5497				ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GOFF PL, 1994, J BIOL CHEM, V269, P4458; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATO S, 1995, MOL CELL BIOL, V15, P5858; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; ONATE SA, 1995, SCIENCE, V270, P1354; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Takeyama KI, 1999, MOL CELL BIOL, V19, P1049; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	41	126	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15645	15651		10.1074/jbc.M000042200	http://dx.doi.org/10.1074/jbc.M000042200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747867	hybrid			2022-12-27	WOS:000087291400008
J	Meyer-ter-Vehn, T; Covacci, A; Kist, M; Pahl, HL				Meyer-ter-Vehn, T; Covacci, A; Kist, M; Pahl, HL			Helicobacter pylori activates mitogen-activated protein kinase cascades and induces expression of the proto-oncogenes c-fos and c-jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL LINES; OSTEO-SARCOMA VIRUS; PATHOGENICITY ISLAND; GASTRIC-CANCER; MOLECULAR CHARACTERIZATION; MONGOLIAN GERBILS; COMPLEX-FORMATION; INCREASED RISK; FACTOR P62TCF; GROWTH-FACTOR	Helicobacter pylori is an etiological agent in the development of mucosa-associated lymphoid tissue lymphoma and gastric adenocarcinoma. Patients infected with H. pylori carry a 3-6-fold increased risk of developing cancer compared with uninfected individuals. H. pylori strains expressing the cytotoxin-associated antigen A (CagA) are more frequently associated with the development of neoplasia than cagA-negative strains. However, the molecular mechanism by which H, pylori causes neoplastic transformation remains unclear. Here we report that exposure of gastric epithelial cells to H. pylori induces activation of the transcription factor activator protein 1, Activation of the proto-oncogenes c-fos and c-jun is strongly induced. We show that H. pylori activates the ERK/MAP kinase cascade, resulting in Elk-l phosphorylation and increased c-fos transcription. a. pylori strains that do not express CagA or that are mutated in cog genes encoded by the CagI pathogenicity island do not induce activator protein 1, MAP kinase activity, or c-fos or c-jun activation. Proto-oncogene activation may represent a crucial step in the pathomechanism of H. pylori induced neoplasia.	Univ Hosp Freiburg, Tumor Biol Ctr, Div Expt Anaesthesiol, D-79106 Freiburg, Germany; IRIS, BIOCINE, I-53100 Siena, Italy; Univ Freiburg, Inst Med Mikrobiol & Hyg, D-79104 Freiburg, Germany	University of Freiburg; Novartis; University of Freiburg	Pahl, HL (corresponding author), Univ Hosp Freiburg, Tumor Biol Ctr, Div Expt Anaesthesiol, POB 1120, D-79106 Freiburg, Germany.		Pahl, Heike/AGM-5260-2022					ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; [Anonymous], 1994, IARC MON EV CARC RIS; APEL I, 1988, ZBL BAKT-INT J MED M, V268, P271; Bechi P, 1996, AM J GASTROENTEROL, V91, P271; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BLASER MJ, 1995, CANCER RES, V55, P2111; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Covacci A, 1997, TRENDS MICROBIOL, V5, P205, DOI 10.1016/S0966-842X(97)01035-4; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRABTREE JE, 1995, J CLIN PATHOL, V48, P967, DOI 10.1136/jcp.48.10.967; CRABTREE JE, 1994, J CLIN PATHOL, V47, P61, DOI 10.1136/jcp.47.1.61; CRABTREE JE, 1994, J CLIN PATHOL, V47, P945, DOI 10.1136/jcp.47.10.945; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eck M, 1997, GASTROENTEROLOGY, V112, P1482, DOI 10.1016/S0016-5085(97)70028-3; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FORMAN D, 1993, LANCET, V341, P1359; FRASER AG, 1994, ALIMENT PHARM THERAP, V8, P167; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIONCHETTI P, 1994, AM J GASTROENTEROL, V89, P883; Glocker E, 1998, INFECT IMMUN, V66, P2346, DOI 10.1128/IAI.66.5.2346-2348.1998; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Honda S, 1998, CANCER RES, V58, P4255; HUANG JZ, 1995, INFECT IMMUN, V63, P1732, DOI 10.1128/IAI.63.5.1732-1738.1995; JAHNKNECHT R, 1993, EMBO J, V14, P951; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILLER AD, 1984, CELL, V36, P51; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Munzenmaier A, 1997, J IMMUNOL, V159, P6140; Neugut AI, 1996, SEMIN ONCOL, V23, P281; NOMURA A, 1994, ANN INTERN MED, V120, P977, DOI 10.7326/0003-4819-120-12-199406150-00001; Odenbreit S, 1996, MOL MICROBIOL, V20, P361, DOI 10.1111/j.1365-2958.1996.tb02623.x; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Peek RM, 1997, JNCI-J NATL CANCER I, V89, P863, DOI 10.1093/jnci/89.12.863; PEEK RM, 1995, LAB INVEST, V71, P760; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAIBOWOL KT, 1988, MOL CELL BIOL, V8, P1670; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ramljak D, 1998, CANCER RES, V58, P3590; RINEGAUD J, 1996, MOL CELL BIOL, V16, P1247; Rudi J, 1997, DIGEST DIS SCI, V42, P1652, DOI 10.1023/A:1018849112533; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sawada Y, 1998, J CLIN GASTROENTEROL, V27, pS141, DOI 10.1097/00004836-199800001-00022; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Segal ED, 1997, P NATL ACAD SCI USA, V94, P7595, DOI 10.1073/pnas.94.14.7595; SHARMA SA, 1995, INFECT IMMUN, V63, P1681, DOI 10.1128/IAI.63.5.1681-1687.1995; TALLEY NJ, 1991, J NATL CANCER I, V83, P1734, DOI 10.1093/jnci/83.23.1734; TOBE K, 1991, J BIOL CHEM, V266, P24793; WARREN JR, 1983, LANCET, V1, P1273; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Winans SC, 1996, TRENDS MICROBIOL, V4, P64, DOI 10.1016/0966-842X(96)81513-7; Wong BCY, 1998, J GASTROEN HEPATOL, V13, pS166, DOI 10.1111/j.1440-1746.1998.tb01871.x; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	73	212	225	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16064	16072		10.1074/jbc.M000959200	http://dx.doi.org/10.1074/jbc.M000959200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747974	hybrid			2022-12-27	WOS:000087291400063
J	Petrov, VV; Padmanabha, KP; Nakamoto, RK; Allen, KE; Slayman, CW				Petrov, VV; Padmanabha, KP; Nakamoto, RK; Allen, KE; Slayman, CW			Functional role of charged residues in the transmembrane segments of the yeast plasma membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; P-TYPE ATPASES; ALANINE-SCANNING MUTAGENESIS; SHEEP ALPHA-1 ISOFORM; SARCOPLASMIC-RETICULUM; NEUROSPORA-CRASSA; AMINO-ACIDS; SACCHAROMYCES-CEREVISIAE; PHOSPHORYLATION DOMAIN; CONFORMATIONAL CHANGE	As defined by hydropathy analysis, the membrane-spanning segments of the yeast plasma membrane H+-ATPase contain seven negatively charged amino acids (Asp and Glu) and four positively charged amino acids (Arg and His). To explore the functional role of these residues, site-directed mutants at all 11 positions and at Glu-288, located near the cytoplasmic end of Ma, have been constructed and expressed in yeast secretory vesicles. Substitutions at four of the positions (Glu-129, Glu-288, Asp-833, and Arp-857) had no significant effect on ATP hydrolysis or ATP-dependent proton pumping, substitutions at five additional positions (Arg-695, His-701, Asp-730, Asp-739, and Arg-811) led to misfolding of the ATPase and blockage at an early stage of biogenesis, and substitutions of Asp-143 allowed measurable biogenesis but nearly abolished ATP hydrolysis and proton transport. Of greatest interest were mutations of Glu-703 in M5 and Glu-803 in M8, which altered the apparent coupling between hydrolysis and transport. Three Glu-703 mutants (E703Q, E703L, E703D) showed significantly reduced pumping over a wide range of hydrolysis values and thus appeared to be partially uncoupled. At Glu-803, by contrast, one mutant (E803N) was almost completely uncoupled, while another (E803Q) pumped protons at an enhanced rate relative to the rate of ATP hydrolysis. Both Glu-703 and Glu-803 occupy positions at which amino acid substitutions have been shown to affect transport by mammalian P-ATPases, Taken together, the results provide growing evidence that residues in membrane segments 5 and 8 of the P-ATPases contribute to the cation transport pathway and that the fundamental mechanism of transport has been conserved throughout the group.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	Yale University; Yale University	Petrov, VV (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.	cw_slaymanlab@yale.edu			NIGMS NIH HHS [GM15761] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015761, R01GM015761] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADADIPORTER FM, 1995, BIOCHEMISTRY-US, V34, P16186; Ambesi A, 1997, ANAL BIOCHEM, V251, P127, DOI 10.1006/abio.1997.2257; Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Arguello JM, 1999, ARCH BIOCHEM BIOPHYS, V367, P341, DOI 10.1006/abbi.1999.1278; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Dimroth P, 1995, BIOCHEM SOC T, V23, P770, DOI 10.1042/bst0230770; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FAGAN MJ, 1994, J MOL EVOL, V38, P57; Fillingame RH, 1995, BIOCHEM SOC T, V23, P760, DOI 10.1042/bst0230760; Fiske CH, 1925, J BIOL CHEM, V66, P375; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GREEN NM, 1992, ANN NY ACAD SCI, V671, P104, DOI 10.1111/j.1749-6632.1992.tb43788.x; Guerini D, 1996, BIOCHEMISTRY-US, V35, P3290, DOI 10.1021/bi952572f; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JOHNSON CL, 1995, BIOCHEM J, V309, P187, DOI 10.1042/bj3090187; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P2993, DOI 10.1074/jbc.270.7.2993; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Padmanabha KP, 1997, FOLIA MICROBIOL, V42, P245, DOI 10.1007/BF02818996; Palmgren MG, 1998, BBA-BIOENERGETICS, V1365, P37, DOI 10.1016/S0005-2728(98)00041-3; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; PERLIN DS, 1986, ARCH BIOCHEM BIOPHYS, V248, P53, DOI 10.1016/0003-9861(86)90400-5; PETROV VV, 1995, J BIOL CHEM, V270, P28535, DOI 10.1074/jbc.270.48.28535; POST RL, 1957, BIOCHIM BIOPHYS ACTA, V25, P118, DOI 10.1016/0006-3002(57)90426-2; RAO R, 1993, J BIOL CHEM, V268, P6708; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schekman R, 1982, MOL BIOL YEAST SACCH, VII, P361; Sen Gupta S, 1998, J BIOL CHEM, V273, P34328; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SETOYOUNG D, 1994, J BIOL CHEM, V269, P23988; SLAYMAN CL, 1989, ANN NY ACAD SCI, V574, P233; Stokes DL, 1999, CURR BIOL, V9, P672, DOI 10.1016/S0960-9822(99)80307-8; Strock C, 1998, J BIOL CHEM, V273, P15104, DOI 10.1074/jbc.273.24.15104; SUSSMAN MR, 1983, J BIOL CHEM, V258, P1839; SUSSMAN MR, 1987, J BIOL CHEM, V262, P4569; VanHuysse JW, 1996, FEBS LETT, V389, P179, DOI 10.1016/0014-5793(96)00578-9; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; Wach A, 1996, BIOCHEMISTRY-US, V35, P883, DOI 10.1021/bi951998r; WARNCKE J, 1980, BIOCHIM BIOPHYS ACTA, V591, P224, DOI 10.1016/0005-2728(80)90154-1; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	56	21	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15709	15716		10.1074/jbc.M000546200	http://dx.doi.org/10.1074/jbc.M000546200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747929	hybrid			2022-12-27	WOS:000087291400017
J	Landolt-Marticorena, C; Williams, KM; Correa, J; Chen, WM; Manolson, MF				Landolt-Marticorena, C; Williams, KM; Correa, J; Chen, WM; Manolson, MF			Evidence that the NH2 terminus of Vph1p, an integral subunit of the V-0 sector of the yeast V-ATPase, interacts directly with the Vma1p and Vma13p subunits of the V-1 sector	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; VESICLE PROTON PUMP; SACCHAROMYCES-CEREVISIAE; TRANSLOCATING ATPASE; CATALYTIC SUBUNIT; GENE ENCODES; ELECTRON-MICROSCOPY; ENERGY TRANSDUCTION; NEUROSPORA-CRASSA; CROSS-LINKING	The vacuolar-type H+-ATPase (V-ATPase) is composed of a peripherally bound (V-1) and a membrane-associated (V-0) complex. V-1 ATP hydrolysis is thought to rotate a central stalk, which in turn, is hypothesized to drive V-0 proton translocation. Transduction of torque exerted by the rotating stalk on V-0 requires a fixed structural link (stator) between the complexes to prevent energy loss through futile rotation of V-1 relative to V-0; this work sought to identify stator components. The 95-kDa V-ATPase subunit, Vph1p, has a cytosolic NH2 terminus (Nt-Vph1p) and a membrane-associated COOH terminus. Two-hybrid assays demonstrated that Nt-Vph1p interacts with the catalytic V-1 subunit, Vma1p. Co-immunoprecipitation of Vma1p with Nt-Vph1p confirmed the interaction. Expression of Nt-Vph1p in a Delta vph1 mutant was necessary to recruit Vma13p to V-1. Vma13p bound to Nt-Vph1p in vitro demonstrating direct interaction. Limited trypsin digests cleaves both Nt-Vph1p and Vma13p. The same tryptic treatment results in a loss of proton translocation while not reducing bafilomycin A(1)-sensitive ATP hydrolysis, Trypsin cleaved Vph1p at arginine 53. Elimination of the tryptic cleavage site by substitution of arginine 53 to serine partially protected vacuolar acidification from trypsin digestion. These results suggest that Vph1p may function as a component of a fixed structural link, or stator, coupling V-1 ATP hydrolysis to V-0 proton translocation.	Univ Toronto, Fac Dent, Res Inst, Toronto, ON M5G 1G6, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Manolson, MF (corresponding author), Univ Toronto, Fac Dent, Res Inst, 124 Edward St,Rm 430, Toronto, ON M5G 1G6, Canada.			Manolson, Morris/0000-0001-8755-5460				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; APPERSON M, 1990, BIOCHEM BIOPH RES CO, V168, P574, DOI 10.1016/0006-291X(90)92359-8; ARAI H, 1988, J BIOL CHEM, V263, P8796; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; Boekema EJ, 1999, NATURE, V401, P37, DOI 10.1038/43369; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1992, J EXP BIOL, V172, P57; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landolt-Marticorena C, 1999, J BIOL CHEM, V274, P26057, DOI 10.1074/jbc.274.37.26057; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1989, BIOCHEM CELL BIOL, V67, P306, DOI 10.1139/o89-047; MANOLSON MF, 1992, J EXP BIOL, V172, P105; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Mattsson JP, 1996, BBA-BIOMEMBRANES, V1280, P98, DOI 10.1016/0005-2736(95)00285-5; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Parra KJ, 1996, J BIOL CHEM, V271, P19592, DOI 10.1074/jbc.271.32.19592; Peng SB, 1999, J BIOL CHEM, V274, P2549, DOI 10.1074/jbc.274.4.2549; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; RAUTIALA TJ, 1993, BIOCHEM BIOPH RES CO, V194, P50, DOI 10.1006/bbrc.1993.1783; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SUPEK F, 1994, J BIOL CHEM, V269, P24102; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; XIE XS, 1994, J BIOL CHEM, V269, P25809; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; Zhou ZM, 1998, J BIOL CHEM, V273, P5878, DOI 10.1074/jbc.273.10.5878	64	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15449	15457		10.1074/jbc.M000207200	http://dx.doi.org/10.1074/jbc.M000207200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747882	hybrid			2022-12-27	WOS:000087128300091
J	Yanaka, N; Kobayashi, K; Wakimoto, K; Yamada, E; Imahie, H; Imai, Y; Mori, C				Yanaka, N; Kobayashi, K; Wakimoto, K; Yamada, E; Imahie, H; Imai, Y; Mori, C			Insertional mutation of the murine kisimo locus caused a defect in spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM FLAGELLUM; TRANSGENIC MICE; MALE-STERILITY; COMPLEX; GENE; TUBULIN; DEGENERATION; INFERTILITY; CHAPERONIN; EXPRESSION	Spermatogenesis is a developmental process that occurs in several phases and is regulated by a large number of gene products. An insertional transgenic mouse mutant (termed kisimo mouse) has been isolated that results in abnormal germ-cell development, showing: abnormal elongated spermatids in the lumina of seminiferous tubules. We cloned the disrupted locus of kisimo and identified a novel testis-specific gene, THEG, which is specifically expressed in spermatids and was disrupted in the transgenic mouse. The yeast two-hybrid screening method revealed that THEG protein strongly interacts with chaperonin containing t-complex polypeptide-le, suggesting that THEG protein functions as a regulatory factor in protein assembly. Our findings indicate that the kisimo locus is essential for the maintenance of spermiogenesis and that a gene expression disorder may be involved in male infertility.	Tanabe Seiyaku Co Ltd, Discovers Res Lab, Yodogawa Ku, Osaka 5328505, Japan; Tanabe Seiyaku Co Ltd, Safety Res Lab, Yodogawa Ku, Osaka 5328505, Japan; Tanabe Seiyaku Co Ltd, Dept Adv Med Res, Yodogawa Ku, Osaka 5328505, Japan; Kyoto Univ, Fac Med, Dept Anat, Sakyo Ku, Kyoto 6068501, Japan	Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; Kyoto University	Yanaka, N (corresponding author), Tanabe Seiyaku Co Ltd, Discovers Res Lab, Yodogawa Ku, 16-89 Kashima 3-Chome, Osaka 5328505, Japan.		Yanaka, Noriyuki/P-9096-2016					Chemes HE, 1998, HUM REPROD, V13, P2521, DOI 10.1093/humrep/13.9.2521; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; ESCALIER D, 1984, BIOL CELL, V50, P37, DOI 10.1111/j.1768-322X.1984.tb00253.x; Gentleman S, 1996, HUM PATHOL, V27, P80, DOI 10.1016/S0046-8177(96)90142-2; Ichikawa K, 1997, GENE, V189, P277, DOI 10.1016/S0378-1119(96)00863-3; KELLER SA, 1990, P NATL ACAD SCI USA, V87, P10019, DOI 10.1073/pnas.87.24.10019; KRULEWSKI TF, 1989, P NATL ACAD SCI USA, V86, P3709, DOI 10.1073/pnas.86.10.3709; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; MACGREGOR GR, 1990, P NATL ACAD SCI USA, V87, P5016, DOI 10.1073/pnas.87.13.5016; MAGRAM J, 1991, P NATL ACAD SCI USA, V88, P10327, DOI 10.1073/pnas.88.22.10327; Matsui Hajime, 1995, Journal of Toxicological Sciences, V20, P407; Mitchell DR, 1999, J CELL BIOL, V144, P293, DOI 10.1083/jcb.144.2.293; Nayernia K, 1999, BIOL REPROD, V60, P1488, DOI 10.1095/biolreprod60.6.1488; PELLAS TC, 1991, P NATL ACAD SCI USA, V88, P8787, DOI 10.1073/pnas.88.19.8787; PHILLIPS DM, 1993, BIOL REPROD, V49, P1347, DOI 10.1095/biolreprod49.6.1347; PRATT LF, 1987, MOL CELL BIOL, V7, P552, DOI 10.1128/MCB.7.1.552; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; SILVER LM, 1985, ANNU REV GENET, V19, P179, DOI 10.1146/annurev.ge.19.120185.001143; SILVER LM, 1987, DEV BIOL, V119, P605, DOI 10.1016/0012-1606(87)90063-7; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; Watanabe Y, 1996, EXP ANIM TOKYO, V45, P265, DOI 10.1538/expanim.45.265; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; Yanaka N, 1998, EUR J BIOCHEM, V255, P391, DOI 10.1046/j.1432-1327.1998.2550391.x; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Yuasa K, 2000, J BIOL CHEM, V275, P4897, DOI 10.1074/jbc.275.7.4897	28	23	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14791	14794		10.1074/jbc.C901047199	http://dx.doi.org/10.1074/jbc.C901047199			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747865	hybrid			2022-12-27	WOS:000087128300004
J	Zong, CS; Chan, J; Levy, DE; Horvath, C; Sadowski, HB; Wang, LH				Zong, CS; Chan, J; Levy, DE; Horvath, C; Sadowski, HB; Wang, LH			Mechanism of STAT3 activation by insulin-like growth factor I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; RAT GLIOBLASTOMA; GENE-REGULATION; JANUS KINASES; SRC; TRANSFORMATION; APOPTOSIS; MOUSE	Recent evidence indicates that STAT proteins can be activated by a variety of receptor and non-receptor protein-tyrosine kinases, Unlike cytokine-induced activation of STATs, where JAKs are known to play a pivotal role in phosphorylating STATs, the mechanism for receptor protein-tyrosine kinase-mediated activation of STATs remains elusive. In this study, we investigated the activation of STAT proteins by the insulin-like growth factor I receptor (IGF-IR) in vitro and in vivo and assessed the role of JAKs in the process of activation. We found that STAT3, but not STAT5, was activated in response to IGF-I in 293T cells cotransfected with IGF-IR and STAT expression vectors. Moreover, tyrosine phosphorylation of STATS, JAK1, and JAK2 was increased upon IGF-I stimulation of endogenous IGF-IR in 293T cells transfected with the respective STAT or JAK expression vector. Supporting the observation in 293T cells, endogenous STATS was tyrosine-phosphorylated upon IGF-I stimulation in the muscle cell line C2C12 as well as in various embryonic and adult mouse organs during different stages of development. Dominant-negative JAK1 or JAK2 was able to block the IGF-IR-mediated tyrosine phosphorylation of STATS in 293T cells. A newly identified family of proteins called SOCS (suppressor of cytokine signaling), including SOCS1, SOCS2, SOCS3 and CIS, was able to inhibit the IGF-I-induced STATS activation as well with varying degrees of potency, in which SOCS1 and SOCS3 appeared to have the higher inhibitory ability. Inhibition of STAT3 activation by SOCS could be overcome by overexpression of native JAK1 and JAK2. We conclude that IGF-I/IGF-IR is able to mediate activation of STATS in vitro and in vivo and that JAKs are essential for the process of activation.	CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Immunobiol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; NYU, Dept Pathol, New York, NY 10016 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; New York University	Zong, CS (corresponding author), CUNY Mt Sinai Sch Med, Dept Microbiol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	zongc01@doc.mssm.edu	Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022	Levy, David/0000-0002-7320-7788; 				ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4; ARTERSU C, 1998, RECENT PROG HORM RES, V53, P61; BASERGA R, 1995, CANCER RES, V55, P249; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; De Sepulveda P, 1999, EMBO J, V18, P904; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; Duncan SA, 1997, DEV DYNAM, V208, P190, DOI 10.1002/(SICI)1097-0177(199702)208:2<190::AID-AJA6>3.0.CO;2-D; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Gual P, 1998, ENDOCRINOLOGY, V139, P884, DOI 10.1210/en.139.3.884; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jandziszak K, 1998, AM J PHYSIOL-REG I, V275, pR120, DOI 10.1152/ajpregu.1998.275.1.R120; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LIU DL, 1992, J VIROL, V66, P374, DOI 10.1128/JVI.66.1.374-385.1992; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Resnicoff M, 1998, INT J MOL MED, V1, P883; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; SELL C, 1995, CANCER RES, V55, P303; Sepp-Lorenzino L, 1998, BREAST CANCER RES TR, V47, P235, DOI 10.1023/A:1005955017615; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; Wang LH, 1999, J IMMUNOL, V162, P3897; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	54	185	192	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15099	15105		10.1074/jbc.M000089200	http://dx.doi.org/10.1074/jbc.M000089200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747872	hybrid			2022-12-27	WOS:000087128300046
J	Wang, LQ; Shao, JH; Muhlenkamp, P; Liu, S; Klepcyk, P; Ren, JM; Friedman, JE				Wang, LQ; Shao, JH; Muhlenkamp, P; Liu, S; Klepcyk, P; Ren, JM; Friedman, JE			Increased insulin receptor substrate-1 and enhanced skeletal muscle insulin sensitivity in mice lacking CCAAT/enhancer-binding protein beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; NECROSIS-FACTOR-ALPHA; C/EBP-ALPHA; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; KINASE-B; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; GENE-TRANSCRIPTION; ANIMAL-MODELS; IRS-1 GENE	CCAAT/enhancer-binding protein beta (C/EBP beta) controls gene transcription and metabolic processes in a variety of insulin-sensitive tissues; however, its role in regulating insulin responsiveness in vivo has not been investigated. We performed hyperinsulinemic-euglycemic clamps in awake, non-stressed, chronically catheterized adult mice homozygous for a deletion in the gene for C/EBP beta (C/EBP beta(-/-)). Fasting plasma insulin, glucose, and free fatty acid (FFA) levels were significantly lower in C/EBP beta(-/-) mice compared with wild-type (WT) controls. Acute hyperinsulinemia (4 h) suppressed hepatic glucose production, phosphoenolpyruvate carboxykinase mRNA, and plasma FFA to a similar extent in WT and C/EBP beta(-/-) mice, suggesting that C/EBP beta deletion does not alter the metabolic and gene regulatory response to insulin in liver and adipose tissue. In contrast, using submaximal (5 milliunits/kg/min) and maximal (20 milliunits/kg/min) insulin infusions, whole-body glucose disposal was 77% (p < 0.01) and 33% (p < 0.05) higher in C/EBP beta(-/-) mice,respectively, compared with WT mice. Maximal insulin-stimulated 3-O-methylglucose uptake in isolated soleus muscle was 54% greater in C/EBP beta(-/-) mice (p < 0.05). Furthermore, insulin-stimulated insulin receptor and Akt Ser(473) phosphorylation and phosphatidylinositol 3-kinase activity were 1.6-2.5-fold greater in skeletal muscle from C/EBP beta(-/-) mice compared with WT mice. The level of insulin receptor substrate-1 protein was increased 2-fold in skeletal muscle from C/EBP beta(-/-) mice. These results demonstrate that C/EBP beta deletion decreases plasma FFA levels and increases insulin signal transduction specifically in skeletal muscle, and both contribute to increased whole-body insulin sensitivity.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Bristol Myers Squibb Co, Div Metab Dis, Princeton, NJ 08543 USA	Case Western Reserve University; Bristol-Myers Squibb	Friedman, JE (corresponding author), Case Western Reserve Univ, Sch Med, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050272] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-50272] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Arizmendi C, 1999, J BIOL CHEM, V274, P13033, DOI 10.1074/jbc.274.19.13033; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOSCH F, 1995, DIABETES, V44, P267, DOI 10.2337/diabetes.44.3.267; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Dufner A, 1999, MOL CELL BIOL, V19, P4525; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; Friedman JE, 1997, AM J PHYSIOL-ENDOC M, V273, pE1014, DOI 10.1152/ajpendo.1997.273.5.E1014; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Ishizuka T, 1999, DIABETES, V48, P1061, DOI 10.2337/diabetes.48.5.1061; Jain R, 1999, BIOCHEM J, V338, P737, DOI 10.1042/0264-6021:3380737; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lavoie L, 1999, J BIOL CHEM, V274, P28279, DOI 10.1074/jbc.274.40.28279; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; Londos Constantine, 1996, P223; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; Matsuda K, 1997, DIABETES, V46, P354, DOI 10.2337/diabetes.46.3.354; NIZIELSKI SE, 1966, AM J PHYSIOL, V39, pR1005; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SCREPANTI I, 1995, EMBO J, V14, P100; STRALFORS P, 1987, ENZYMES, V17, P147; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Taha C, 1999, J MEMBRANE BIOL, V169, P1, DOI 10.1007/PL00005896; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WEBSTER NJG, 1994, DIABETES, V43, P305, DOI 10.2337/diabetes.43.2.305; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	50	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14173	14181		10.1074/jbc.M000764200	http://dx.doi.org/10.1074/jbc.M000764200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10747954	hybrid			2022-12-27	WOS:000087006900024
J	Tabuchi, M; Yoshimori, T; Yamaguchi, K; Yoshida, T; Kishi, F				Tabuchi, M; Yoshimori, T; Yamaguchi, K; Yoshida, T; Kishi, F			Human NRAMP2/DMT1, which mediates iron transport across endosomal membranes, is localized to late endosomes and lysosomes in HEp-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-RESISTANCE; TRANSFERRIN RECEPTOR; MICROCYTIC ANEMIA; PROTEIN; ENDOCYTOSIS; INFECTION; CLONING; NRAMP1; YEAST; GENE	NRAMP2 (natural resistance-associated macrophage protein 2)/DMT1 (divalent metal transporter 1) is a divalent metal transporter conserved from prokaryotes to higher eukaryotes that exhibits an unusually broad substrate range, including Fe2+, Zn2+, Mn2+, Cu2+, Cd2+, Co2+, Ni2+, and Pb2+, and mediates active proton-coupled transport. Recently, it has been shown that the microcytic anemia (mk) mouse and the Belgrade (b) rat, which have inherited defects in iron transport that result in iron deficiency anemia, have the same missense mutation (G185R) in Nramp2. These findings strongly suggested that NRAMP2 is the apical membrane iron transporter in intestinal epithelial cells and the endosomal iron transporter in transferrin cycle endosomes of other cells. To investigate the cellular functions of NRAMP2, we generated a polyclonal antibody against the N-terminal cytoplasmic domain of human NRAMP2, The affinity-purified anti-NRAMP2 N-terminal antibody recognized a 90-116-kDa membrane-associated protein, and this band was shifted to 50 kDa by deglycosylation with peptide N-glycosidase F, Subcellular fractionation revealed that NRAMP2 co-sedimented with the late endosomal and lysosomal membrane proteins and LAMP-1 (lysosome-associated membrane protein 1), but not with the transferrin receptor in early endosomes, The intracellular localization of endogenous NRAMP2 and recombinant green fluorescent protein (GFP)-NRAMPS was examined by immunofluorescence staining and by native fluorescence of GFP, respectively. Both endogenous and GFP-NRAMP2 were detected in vesicular structures and were colocalized with LAMP-S, but not with EEA1 (early endosome antigen 1) or the transferrin receptor. These results indicated that NRAMP2 is localized to the late endosomes and lysosomes, where NRAMP2 may function to transfer the endosomal free Fe2+ into the cytoplasm in the transferrin cycle.	Yamaguchi Univ, Ctr Gene Res, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Inst Lab Anim, Ube, Yamaguchi 7558505, Japan; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Fujirebio Inc, Ube Res Lab, Ube, Yamaguchi 7590134, Japan	Yamaguchi University; Yamaguchi University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); H.U. Group Holdings Inc	Kishi, F (corresponding author), Yamaguchi Univ, Ctr Gene Res, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.		Tabuchi, Mitsuaki/AAY-7378-2021; Tabuchi, Mitsuaki/E-9544-2010	Tabuchi, Mitsuaki/0000-0002-2042-691X; Tabuchi, Mitsuaki/0000-0002-2042-691X				Advani RJ, 1999, J CELL BIOL, V146, P765, DOI 10.1083/jcb.146.4.765; Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; Andrews NC, 1998, BLOOD, V92, P1845, DOI 10.1182/blood.V92.6.1845.418k35_1845_1851; Atkinson PGP, 1997, BIOCHEM J, V325, P779, DOI 10.1042/bj3250779; BANNERMAN RM, 1976, FED PROC, V35, P2281; Canonne-Hergaux F, 1999, BLOOD, V93, P4406, DOI 10.1182/blood.V93.12.4406.412k21_4406_4417; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DEISS A, 1983, SEMIN HEMATOL, V20, P81; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; EDWARDS JA, 1975, BLOOD, V46, P381; EDWARDS JA, 1972, P SOC EXP BIOL MED, V141, P81; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Garrick M, 1997, BIOMETALS, V10, P65, DOI 10.1023/A:1018370804882; GHOSH RN, 1994, J CELL SCI, V107, P2177; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; Kishi F, 1997, MOL IMMUNOL, V34, P839, DOI 10.1016/S0161-5890(97)00110-7; Kishi F, 1998, BIOCHEM BIOPH RES CO, V251, P775, DOI 10.1006/bbrc.1998.9415; MERESSE S, 1995, J CELL SCI, V108, P3349; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; Oates PS, 1996, AM J PHYSIOL-GASTR L, V270, pG826, DOI 10.1152/ajpgi.1996.270.5.G826; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; Ponka P, 1998, SEMIN HEMATOL, V35, P35; RAO K, 1983, FEBS LETT, V160, P213, DOI 10.1016/0014-5793(83)80969-7; RUSSELL ES, 1970, BLOOD-J HEMATOL, V35, P838, DOI 10.1182/blood.V35.6.838.838; SCHEEL J, 1990, J CELL SCI, V96, P711; Searle S, 1998, J CELL SCI, V111, P2855; Su MA, 1998, BLOOD, V92, P2157, DOI 10.1182/blood.V92.6.2157.418k16_2157_2163; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; Tabuchi M, 1999, BIOCHEM J, V344, P211, DOI 10.1042/0264-6021:3440211; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; VIDAL S, 1995, MAMM GENOME, V6, P224, DOI 10.1007/BF00352405; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; YOSHIMORI T, 1988, CELL STRUCT FUNCT, V13, P311, DOI 10.1247/csf1975.13.311	43	185	190	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22220	22228		10.1074/jbc.M001478200	http://dx.doi.org/10.1074/jbc.M001478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10751401	hybrid			2022-12-27	WOS:000088363800065
J	Vitale, N; Pacheco-Rodriguez, G; Ferrans, VJ; Riemenschneider, W; Moss, J; Vaughan, M				Vitale, N; Pacheco-Rodriguez, G; Ferrans, VJ; Riemenschneider, W; Moss, J; Vaughan, M			Specific functional interaction of human cytohesin-1 and ADP-ribosylation factor domain protein (ARD1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; GTPASE-ACTIVATING DOMAIN; SEC7 DOMAIN; FACTOR ARNO; CHOLERA-TOXIN; ARF GTPASE; BINDING; GOLGI; GDP; TRANSPORT	Activation of ADP-ribosylation factors (ARFs) is mediated by guanine nucleotide-exchange proteins, which accelerate conversion of inactive ARF-GDP to active ARF-GTP. ARF domain protein (ARD1), a 64-kDa GTPase with a C-terminal ADP-ribosylation factor domain, is localized to lysosomes and the Golgi apparatus. When ARD1 was used as bait to screen a human liver cDNA library using the yeast two-hybrid system, a cDNA for cytohesin-1, a similar to 50-kDa protein with ARF guanine nucleotide-exchange protein activity, was isolated. In this system, ARD1-GDP interacted well with cytohesin-1 but very poorly with cytohesin-2. In agreement, cytohesin-1, but not cytohesin-2, markedly accelerated [S-35]guanosine 5'-3-O-(thio)triphosphate binding to ARD1. The effector region of the ARF domain of ARD1 appeared to be critical for the specific interaction with cytohesin-1. Replacement of single amino acids in the Sec7 domains of cytohesin-1 and -2 showed that residue 30 is critical for specificity. In transfected COS-7 cells, overexpressed ARD1 and cytohesin-1 were partially colocalized, as determined by confocal fluorescence microscopy. It was concluded that cytohesin-1 is likely to be involved in ARD1 activation, consistent with a role for ARD1 in the regulation of vesicular trafficking.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Pacheco-Rodriguez, G (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Rm 5N-307,Bldg 10,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.		Pacheco, Gustavo/Q-6956-2019; Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000656, ZIAHL000627, ZIAHL002541, Z01HL000627, Z01HL000638, Z01HL002541] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Ashery U, 1999, P NATL ACAD SCI USA, V96, P1094, DOI 10.1073/pnas.96.3.1094; Betz SF, 1998, P NATL ACAD SCI USA, V95, P7909, DOI 10.1073/pnas.95.14.7909; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Claude A, 1999, J CELL BIOL, V146, P71, DOI 10.1083/jcb.146.1.71; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HONG JX, 1995, P NATL ACAD SCI USA, V92, P3056, DOI 10.1073/pnas.92.7.3056; HONG JX, 1994, J BIOL CHEM, V269, P9743; Kaiser C, 1998, CURR OPIN CELL BIOL, V10, P477, DOI 10.1016/S0955-0674(98)80062-8; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Le Borgne R, 1998, CURR OPIN CELL BIOL, V10, P499; Lowe M, 1998, BBA-MOL CELL RES, V1404, P53, DOI 10.1016/S0167-4889(98)00046-9; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; Monier S, 1998, J CELL SCI, V111, P3427; Morinaga N, 1999, J BIOL CHEM, V274, P17417, DOI 10.1074/jbc.274.25.17417; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Pacheco-Rodriguez G, 1998, J BIOL CHEM, V273, P26543, DOI 10.1074/jbc.273.41.26543; Pacheco-Rodriguez G, 1999, J BIOL CHEM, V274, P12438, DOI 10.1074/jbc.274.18.12438; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sata M, 1998, P NATL ACAD SCI USA, V95, P4204, DOI 10.1073/pnas.95.8.4204; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Togawa A, 1999, J BIOL CHEM, V274, P12308, DOI 10.1074/jbc.274.18.12308; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; Vitale N, 1997, J BIOL CHEM, V272, P3897, DOI 10.1074/jbc.272.7.3897; Vitale N, 1997, J BIOL CHEM, V272, P25077, DOI 10.1074/jbc.272.40.25077; Vitale N, 1998, J BIOL CHEM, V273, P2553, DOI 10.1074/jbc.273.5.2553; Vitale N, 1998, P NATL ACAD SCI USA, V95, P8613, DOI 10.1073/pnas.95.15.8613; Vitale N, 1996, P NATL ACAD SCI USA, V93, P1941, DOI 10.1073/pnas.93.5.1941	48	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21331	21339		10.1074/jbc.M909642199	http://dx.doi.org/10.1074/jbc.M909642199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10748148	hybrid			2022-12-27	WOS:000088230600051
J	Kuser, PR; Krauchenco, S; Antunes, OAC; Polikarpov, I				Kuser, PR; Krauchenco, S; Antunes, OAC; Polikarpov, I			The high resolution crystal structure of yeast hexokinase PII with the correct primary sequence provides new insights into its mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CRYSTALLOGRAPHY BEAMLINE; SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; SUGAR KINASES; PHOSPHORYLATION; REFINEMENT; ATP; INACTIVATION; SUBUNIT; ENZYME	Hexokinase is the first enzyme in the glycolytic pathway, catalyzing the transfer of a phosphoryl group from ATP to glucose to form glucose 6-phosphate and ADP. Two yeast hexokinase isozymes are known, namely PI and PII. The crystal structure of yeast hexokinase PII from Saccharomyces cerevisiae without substrate or competitive inhibitor is determined and refined in a tetragonal crystal form at 2.2-Angstrom resolution The folding of the peptide chain is very similar to that of Schistosoma mansoni and previous yeast hexokinase models despite only 30% sequence identity between them. Distinct differences in conformation are found that account for the absence of glucose in the binding site. Comparison of the current model with S. mansoni and yeast hexokinase PI structures both complexed with glucose shows in atomic detail the rigid body domain closure and specific loop movements as glucose binds. A hydrophobic channel formed by strictly conserved hydrophobic residues in the small domain of the hexokinase is identified. The channel's mouth is close to the active site and passes through the small domain to its surface. The possible role of the observed channel in proton transfer is discussed.	Lab Nacl Luz Sincrotron, BR-13083970 Campinas, SP, Brazil; UFRJ, Inst Quim, Dept Quim Inorgan, Rio De Janeiro, Brazil	Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade Federal do Rio de Janeiro	Polikarpov, I (corresponding author), Lab Nacl Luz Sincrotron, Caixa Postal 6129, BR-13083970 Campinas, SP, Brazil.		Kuser-Falcão, Paula R/A-5799-2010; Polikarpov, Igor/D-2575-2012	Kuser-Falcão, Paula R/0000-0002-0034-0932; Polikarpov, Igor/0000-0001-9496-4174				Aleshin AE, 1998, FEBS LETT, V434, P42, DOI 10.1016/S0014-5793(98)00952-1; Aleshin AE, 1998, J MOL BIOL, V282, P345, DOI 10.1006/jmbi.1998.2017; Aleshin AE, 1998, STRUCTURE, V6, P39, DOI 10.1016/S0969-2126(98)00006-9; ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; ANDERSON CM, 1978, J MOL BIOL, V123, P15, DOI 10.1016/0022-2836(78)90374-1; ARORA KK, 1991, J BIOL CHEM, V266, P5359; BARRIE SE, 1979, RES COMMUN CHEM PATH, V23, P375; Behlke J, 1998, BIOCHEMISTRY-US, V37, P11989, DOI 10.1021/bi980914m; BENNETT WS, 1980, J MOL BIOL, V140, P183, DOI 10.1016/0022-2836(80)90102-3; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Catanzano F, 1997, J BIOCHEM-TOKYO, V121, P568; Cheng Q, 1997, ADV MATER, V9, P481, DOI 10.1002/adma.19970090605; Colowick SP., 1973, ENZYMES, V9, P1, DOI DOI 10.1016/S1874-6047(08)60113-4; DELAFUEN.G, 1970, EUR J BIOCHEM, V16, P234, DOI 10.1111/j.1432-1033.1970.tb01076.x; DELAFUENTE G, 1970, EUR J BIOCHEM, V16, P240, DOI 10.1111/j.1432-1033.1970.tb01077.x; DeWinde JH, 1996, EUR J BIOCHEM, V241, P633; ENTIAN KD, 1980, MOL GEN GENET, V178, P633, DOI 10.1007/BF00337871; FERNANDEZ R, 1986, J GEN MICROBIOL, V132, P3467; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FROHLICH KU, 1985, GENE, V36, P105, DOI 10.1016/0378-1119(85)90074-5; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GANCEDO JM, 1977, J BIOL CHEM, V252, P4443; GAZITH J, 1968, ANN NY ACAD SCI, V151, P307, DOI 10.1111/j.1749-6632.1968.tb11898.x; Gupta Bihari L., 1997, Indian Journal of Experimental Biology, V35, P792; Heidrich K, 1997, BIOCHEMISTRY-US, V36, P1960, DOI 10.1021/bi9623643; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JONES JP, 1991, BIOCHEMISTRY-US, V30, P3634, DOI 10.1021/bi00229a007; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KOPETZKI E, 1985, GENE, V39, P95, DOI 10.1016/0378-1119(85)90113-1; Koshland D., 1959, ENZYMES, V1, P305; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; MAGNANI M, 1985, BLOOD, V66, P690; Mulichak AM, 1998, NAT STRUCT BIOL, V5, P555, DOI 10.1038/811; MURSHUDOR GN, 1997, ACTA CRYSTALLOGR D, V50, P240; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Polikarpov I, 1998, NUCL INSTRUM METH A, V405, P159, DOI 10.1016/S0168-9002(97)01202-3; Polikarpov I, 1998, J SYNCHROTRON RADIAT, V5, P72, DOI 10.1107/S0909049597014684; POLIKARPOV I, 1993, HASYLAB ANN REPORTD, P777; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSE M, 1991, EUR J BIOCHEM, V199, P511, DOI 10.1111/j.1432-1033.1991.tb16149.x; SCHMIDT JJ, 1969, ARCH BIOCHEM BIOPHYS, V158, P471; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SHOHAM M, 1980, J MOL BIOL, V140, P1, DOI 10.1016/0022-2836(80)90353-8; SHOHAM M, 1982, BIOCHIM BIOPHYS ACTA, V705, P380, DOI 10.1016/0167-4838(82)90260-6; STEITZ TA, 1976, J MOL BIOL, V104, P197, DOI 10.1016/0022-2836(76)90009-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VALENTIN.WN, 1967, NEW ENGL J MED, V276, P1, DOI 10.1056/NEJM196701052760101; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; VOJTEK AB, 1990, EUR J BIOCHEM, V190, P371, DOI 10.1111/j.1432-1033.1990.tb15585.x; Willson M, 1997, J ENZYM INHIB, V12, P101, DOI 10.3109/14756369709035812; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776	62	95	97	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20814	20821		10.1074/jbc.M910412199	http://dx.doi.org/10.1074/jbc.M910412199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10749890	hybrid			2022-12-27	WOS:000088084500084
J	Stewart, DB; Barth, AIM; Nelson, WJ				Stewart, DB; Barth, AIM; Nelson, WJ			Differential regulation of endogenous cadherin expression in Madin-Darby canine kidney cells by cell-cell adhesion and activation of beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR LEF-1; POLYPOSIS-COLI PROTEIN; EPITHELIAL-CELLS; XENOPUS EMBRYOS; N-CADHERIN; METANEPHRIC MESENCHYME; COMPLEMENTARY-DNA; COMPLEX-FORMATION; TISSUE FORMATION	Cadherins mediate cell-cell adhesion, but little is known about how their expression is regulated. In Madin-Darby canine kidney (MDCK) cells, the cadherin-associated cytoplasmic proteins alpha- and beta-catenin form high molecular weight protein complexes with two glycoproteins (Stewart, D. B., and Nelson, W. J. (1997) J, Biol. Chem. 272, 29652-29662), one of which is E-cadherin and the other we show here is the type II cadherin, cadherin-6 (R-cadherin), In low density, motile MDCK cells, the steady-state level of cadherin-6 is low, but protein is synthesized. However, following cell-cell adhesion, cadherin-6 becomes stabilized and accumulates by >50-fold at cell-cell contacts while the E-cadherin level increases only 5-fold during the same period. To investigate a role of beta-catenin in regulation of cadherin expression in MDCK cells, we examined the effects of expressing signaling-active beta-catenin mutants (Delta GSK, Delta N90, and Delta N131). In these cells, while levels of E-cadherin, alpha- and beta-catenin are similar to those in control cells, levels of cadherin-6 are significantly reduced due to rapid degradation of newly synthesized protein. Additionally, these cells appeared more motile and less cohesive, as expression of Delta GSK-beta-catenin delayed the establishment of tight confluent cell monolayers compared with control cells. These results indicate that the level of cadherin-6, but not that of E-cadherin, is strictly regulated post-translationally in response to Wnt signaling, and that E-cadherin and cadherin-6 may contribute different properties to cell-cell adhesion and the epithelial phenotype.	Stanford Univ, Med Ctr,Sch Med, Beckman Ctr, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	Stanford University	Nelson, WJ (corresponding author), Stanford Univ, Med Ctr,Sch Med, Beckman Ctr, Dept Mol & Cellular Physiol, Rm B-121, Stanford, CA 94305 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Cho EA, 1998, DEVELOPMENT, V125, P803; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; DUFOUR S, 1994, J CELL BIOL, V127, P521, DOI 10.1083/jcb.127.2.521; Easwaran V, 1999, J BIOL CHEM, V274, P16641, DOI 10.1074/jbc.274.23.16641; GEIGER B, 1990, J CELL SCI, V97, P607; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hagios C, 1998, PHILOS T R SOC B, V353, P857, DOI 10.1098/rstb.1998.0250; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Inoue T, 1997, DEV BIOL, V183, P183, DOI 10.1006/dbio.1996.8501; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Larue L, 1996, DEVELOPMENT, V122, P3185; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Paul R, 1997, CANCER RES, V57, P2741; PEIFER M, 1994, DEVELOPMENT, V120, P369; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SHIMOYAMA Y, 1995, CANCER RES, V55, P2206; SHORE EM, 1991, J BIOL CHEM, V266, P19672; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; XIANG YY, 1994, CANCER RES, V54, P3034	58	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20707	20716		10.1074/jbc.M000467200	http://dx.doi.org/10.1074/jbc.M000467200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10747916	hybrid			2022-12-27	WOS:000088084500069
J	Cicek, M; Blanchard, D; Bevan, DR; Esen, A				Cicek, M; Blanchard, D; Bevan, DR; Esen, A			The aglycone specificity-determining sites are different in 2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one (DIMBOA)-glucosidase (maize beta-glucosidase) and dhurrinase (sorghum beta-glucosidase)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; GLYCOSYL HYDROLASES; SUBSTRATE-SPECIFICITY; PROTEIN; GLYCOSIDASE; GERMINATION; EXPRESSION; INSIGHTS; THERMOSTABILITY; CONSTRUCTION	The maize beta-glucosidase isozyme Glu1 hydrolyzes a broad spectrum of substrates in addition to its natural substrate DIMBOAGlc (2-O-beta-D-glucopyranosyl-4-hydroxy-7-methoxy-1,4-benzoxazin-3-one), whereas the sorghum beta-glucosidase isozyme Dhr1 hydrolyzes exclusively its natural substrate dhurrin (p-hydroxy-(S)-mandelonitrile-beta-D-glucose). To study the mechanism of substrate specificity further, eight chimeric beta-glucosidases were constructed by replacing peptide sequences within the C-terminal region of Glu1 with the homologous peptide sequences of Dhr1 or vice verse, where the two enzymes differ by 4 to 22 amino acid substitutions, depending on the length of the swapped regions. Five Glu1/Dhr1 chimeras hydrolyzed substrates that are hydrolyzed by both parental enzymes, including dhurrin, which is not hydrolyzed by Glu1, In contrast, three Dhr1/Glu1 chimeras hydrolyzed only dhurrin but with lower catalytic efficiency than Dhr1, Additional domain-swapping within the C-terminal domain of Glu1 showed that replacing the peptide (466)FAGFTERY(473) of Glu1 with the homologous peptide (462)SSGYTERF(469) of Dhr1 or replacing the peptide (NNNCTRYMKE490)-N-481 in Glu1 with the homologous peptide (477)ENGCERTMKR(486) of Dhr1 was sufficient to confer to Glu1 the ability to hydrolyze dhurrin, Data from various reciprocal chimeras, sequence comparisons, and homology modeling suggest that the Dhr1-specific Ser-462-Ser-463 and Phe-469 play a key role in dhurrin hydrolysis. Similar data suggest that DIMBOAGlc hydrolysis determinants are not located within the extreme 47-amino acid-long C-terminal domain of Glu1.	Virginia Polytech Inst & State Univ, Dept Biol, Blacksburg, VA 24061 USA; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University	Esen, A (corresponding author), Virginia Polytech Inst & State Univ, Dept Biol, Blacksburg, VA 24061 USA.	aevatan@vt.edu		Bevan, David/0000-0001-9974-1105				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; BABCOCK GD, 1994, PLANT SCI, V101, P31, DOI 10.1016/0168-9452(94)90162-7; BANDARANAYAKE H, 1996, PLANT PHYSIOL, V110, P1048; BARRETT T, 1995, STRUCTURE, V3, P951, DOI 10.1016/S0969-2126(01)00229-5; BELL AA, 1981, ANNU REV PLANT PHYS, V32, P21, DOI 10.1146/annurev.pp.32.060181.000321; BRZOBOHATY B, 1993, SCIENCE, V262, P1051, DOI 10.1126/science.8235622; Burmeister WP, 1997, STRUCTURE, V5, P663, DOI 10.1016/S0969-2126(97)00221-9; Cahoon EB, 1997, P NATL ACAD SCI USA, V94, P4872, DOI 10.1073/pnas.94.10.4872; Chi YI, 1999, FEBS LETT, V445, P375, DOI 10.1016/S0014-5793(99)00090-3; Cicek M, 1999, BIOTECHNOL BIOENG, V63, P392, DOI 10.1002/(SICI)1097-0290(19990520)63:4&lt;392::AID-BIT2&gt;3.0.CO;2-M; Cicek M, 1998, PLANT PHYSIOL, V116, P1469, DOI 10.1104/pp.116.4.1469; Conn EE, 1981, CYANOGENIC GLYCOSIDE, P479; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Dean AM, 1998, AM SCI, V86, P26; DHARMAWARDHANA DP, 1995, PLANT PHYSIOL, V107, P331, DOI 10.1104/pp.107.2.331; ESEN A, 1990, BIOCHEM GENET, V28, P319, DOI 10.1007/BF02401422; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hopfner KP, 1998, P NATL ACAD SCI USA, V95, P9813, DOI 10.1073/pnas.95.17.9813; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HOSEL W, 1987, ARCH BIOCHEM BIOPHYS, V252, P152, DOI 10.1016/0003-9861(87)90019-1; Kimura M., 1983, NEUTRAL THEORY MOL E; LEAH R, 1995, J BIOL CHEM, V270, P15789, DOI 10.1074/jbc.270.26.15789; Martin T., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P23; MATSUZAKI T, 1986, AGR BIOL CHEM TOKYO, V50, P2193, DOI 10.1080/00021369.1986.10867732; NIEMEYER HM, 1988, PHYTOCHEMISTRY, V27, P3349, DOI 10.1016/0031-9422(88)80731-3; PEARLMAN DA, 1995, AMBER VERSION 4 1; Pinto AL, 1997, P NATL ACAD SCI USA, V94, P5562, DOI 10.1073/pnas.94.11.5562; POULTON JE, 1990, PLANT PHYSIOL, V94, P401, DOI 10.1104/pp.94.2.401; RAABO E, 1960, SCAND J CLIN LAB INV, V12, P402; ROBYT FJ, 1990, BIOCH TECHNIQUES THE, P107; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanz-Aparicio J, 1998, J MOL BIOL, V275, P491, DOI 10.1006/jmbi.1997.1467; SCHLIEMANN W, 1984, J PLANT PHYSIOL, V116, P123, DOI 10.1016/S0176-1617(84)80069-3; SIMOS G, 1994, BBA-GEN SUBJECTS, V1199, P52, DOI 10.1016/0304-4165(94)90095-7; SINGH A, 1995, J BIOL CHEM, V270, P21928, DOI 10.1074/jbc.270.37.21928; SMITH AR, 1978, J EXP BOT, V29, P1067, DOI 10.1093/jxb/29.5.1067; Terashima M, 1997, APPL MICROBIOL BIOT, V47, P364, DOI 10.1007/s002530050941; TRIMBUR D, 1993, ACS SYM SER, V533, P42; TRIMBUR DE, 1992, J BIOL CHEM, V267, P10248; WIESE G, 1986, PHYTOCHEMISTRY, V25, P2451, DOI 10.1016/S0031-9422(00)84487-8; WIESMANN C, 1995, STRUCTURE, V3, P961, DOI 10.1016/S0969-2126(01)00230-1; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242	42	50	51	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20002	20011		10.1074/jbc.M001609200	http://dx.doi.org/10.1074/jbc.M001609200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748038	hybrid			2022-12-27	WOS:000087941300078
J	Eriksson, M; Ansved, T; Edstrom, L; Wells, DJ; Watt, DJ; Anvret, M; Carey, N				Eriksson, M; Ansved, T; Edstrom, L; Wells, DJ; Watt, DJ; Anvret, M; Carey, N			Independent regulation of the myotonic dystrophy 1 locus genes postnatally and during adult skeletal muscle regenerator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; CTG REPEAT; TRIPLET REPEAT; RNA; EXPRESSION; EXPANSION; REGION; KINASE; DMPK; DIFFERENTIATION	Myotonic dystrophy is caused by a CTG, expansion in the 5'-untranslated region of a serine/threonine protein kinase gene (DMPK), which is flanked by two other genes, DMWD and SIX5, One hypothesis to explain the wide-ranging effects of this expansion is that, as the mutation expands, it alters the expression of one or more of these genes. The effects may vary in different tissues and developmental stages, but it has been difficult to develop these hypotheses as the normal postnatal developmental expression patterns of these genes have not been adequately investigated. We have developed accurate transcript quantification based on fluorescent real-time reverse transcription-polymerase chain reaction (TaqMan) to develop gene expression profiles during postnatal development in C57Bl/10 mice. Our results show extensive independent postnatal regulation of the myotonic dystrophy-locus genes in selected tissues and demonstrate which are the most highly expressed of the genes in each tissue, All three genes at the locus are expressed in the adult lens, questioning a previous model of cataractogenesis mediated solely by effects on Six5 expression. Additionally, using an in vivo model, we have shown that Dmpk levels decrease during the early stages of muscle regeneration, Our data provide a framework for investigation of tissue-specific pathological mechanisms in this disorder.	Karolinska Hosp, Dept Mol Med, S-17176 Stockholm, Sweden; Karolinska Hosp, Div Neurol, S-17176 Stockholm, Sweden; Karolinska Hosp, Div Clin Neurophysiol, S-17176 Stockholm, Sweden; Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W6 8RP, England; Charing Cross Hosp, Imperial Coll Sch Med, Div Surg Anaesthesia & Intens Care, London W6 8RP, England	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Imperial College London; Imperial College London	Eriksson, M (corresponding author), Karolinska Hosp, Dept Mol Med, S-17176 Stockholm, Sweden.	Maria.Eriksson@cmm.ki.se		Wells, Dominic/0000-0002-1425-6344				Alwazzan M, 1999, HUM MOL GENET, V8, P1491, DOI 10.1093/hmg/8.8.1491; ANVRET M, 1993, HUM MOL GENET, V2, P1397, DOI 10.1093/hmg/2.9.1397; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BOUCHER CA, 1995, HUM MOL GENET, V4, P1919, DOI 10.1093/hmg/4.10.1919; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BRUNNER HG, 1992, J MED GENET, V29, P780, DOI 10.1136/jmg.29.11.780; BRUNNER HG, 1992, J MED GENET, V29, P791, DOI 10.1136/jmg.29.11.791; Eriksson N, 1999, HUM MOL GENET, V8, P1053, DOI 10.1093/hmg/8.6.1053; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Hamshere MG, 1997, P NATL ACAD SCI USA, V94, P7394, DOI 10.1073/pnas.94.14.7394; HARLEY HG, 1992, LANCET, V339, P1125, DOI 10.1016/0140-6736(92)90729-M; Harper P.S., 1989, MYOTONIC DYSTROPHY; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; JANSEN G, 1995, HUM MOL GENET, V4, P843, DOI 10.1093/hmg/4.5.843; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; Lia AS, 1998, HUM MOL GENET, V7, P1285, DOI 10.1093/hmg/7.8.1285; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Mariappan SVS, 1996, NUCLEIC ACIDS RES, V24, P775, DOI 10.1093/nar/24.4.775; MOXLEY RT, 1984, ANN NEUROL, V15, P157, DOI 10.1002/ana.410150208; Okoli G, 1998, BIOCHEM BIOPH RES CO, V246, P905, DOI 10.1006/bbrc.1998.8723; Perletti L, 1999, J BIOL CHEM, V274, P15301, DOI 10.1074/jbc.274.22.15301; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; Ronnblom A, 1999, J INTERN MED, V245, P91, DOI 10.1046/j.1365-2796.1999.00413.x; Sabourin LA, 1997, J BIOL CHEM, V272, P29626, DOI 10.1074/jbc.272.47.29626; Schmidt EE, 1997, DEV BIOL, V184, P138, DOI 10.1006/dbio.1997.8514; THORNTON CA, 1994, ANN NEUROL, V35, P104, DOI 10.1002/ana.410350116; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Winchester CL, 1999, HUM MOL GENET, V8, P481, DOI 10.1093/hmg/8.3.481; ZATZ M, 1995, HUM MOL GENET, V4, P401, DOI 10.1093/hmg/4.3.401	35	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19964	19969		10.1074/jbc.M001592200	http://dx.doi.org/10.1074/jbc.M001592200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748037	hybrid			2022-12-27	WOS:000087941300073
J	Ruano, D; Araujo, F; Revilla, E; Vela, J; Bergis, O; Vitorica, J				Ruano, D; Araujo, F; Revilla, E; Vela, J; Bergis, O; Vitorica, J			GABA(A) and alpha-amino-3-hydroxy-5-methylsoxazole-4-propionate receptors are differentially affected by aging in the rat hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT MESSENGER-RNAS; AMINOBUTYRIC ACID(A) RECEPTORS; AGE-RELATED-CHANGES; GLUTAMATE-RECEPTORS; PHARMACOLOGICAL CHARACTERIZATION; BENZODIAZEPINE RECEPTOR; CEREBRAL-CORTEX; ION CHANNELS; A RECEPTORS; BRAIN	We have investigated the age-dependent modifications in the expression of eight different subunits of the gamma-aminobutyric acid, type A (GABA(A)) receptor (alpha 1, alpha 2, alpha 3, alpha 5, beta 2, beta 3, gamma 2S, and gamma 2L) and all four subunits of the alpha-amino-3-hydroxy-5-methylsoxazole-4-propionate (AMPA) receptor (GluR1-4) in the hippocampus of 24-month-old rats. All aged hippocampi displayed a remarkable increase (aged/adult ratio, 3.53 +/- 0.54) in the mRNA levels of the short version of the gamma 2 subunit in parallel with a similar increase in the gamma 2 subunit protein (aged/adult ratio, 2.90 +/- 0.62). However, this increase was not observed in the mature receptor. On the other hand, the expression of the different alpha subunit mRNAs increased moderately with aging, displaying a heterogeneous pattern. The most frequent modification consisted in an increase in the expression of the alpha 1 subunit mRNA (aged/adult ratio, 1.26 +/- 0.18), in parallel with a similar increase on the alpha 1 protein (aged/adult ratio, 1.27 +/- 0.12) and in the alpha 1 incorporated to the assembled GABA,receptor (tested by immunoprecipitation; aged/adult ratio, = 1.20 +/- 0.10). However, in the same hippocampal samples, no major modifications were observed on the expression of the AMPA receptor subunits. As a whole, these results indicated the existence of an increased expression of the GABA,receptor subunits and a preservation of the AMPA receptor at the hippocampal formation. These modifications could reflect the existence of specific deficiencies (neuronal loss and/or deafferentiation) on the GABAergic system in the aged rats.	Univ Sevilla, Fac Farm, Dept Bioquim Bromatol & Toxicol, E-41012 Seville, Spain; Cent Nervous Syst Res Dept Synthelab Rech, F-92225 Rueil Malmaison, France	University of Sevilla	Vitorica, J (corresponding author), Univ Sevilla, Fac Farm, Dept Bioquim Bromatol & Toxicol, E-41012 Seville, Spain.		Araujo, Francisco/ABC-6873-2020; IBIS, ALZHEIMER/O-9867-2015; Torres, M Elisa Revilla/K-5897-2014; CABALLERO, DIEGO RUANO/I-4471-2014	Torres, M Elisa Revilla/0000-0001-8867-8446; CABALLERO, DIEGO RUANO/0000-0001-6131-3033; Araujo, Francisco/0000-0001-5737-2938; Vitorica Ferrandez, Javier/0000-0002-0641-7902				ANGELOTTI TP, 1993, J NEUROSCI, V13, P1429; Araujo F, 1996, J BIOL CHEM, V271, P27902, DOI 10.1074/jbc.271.44.27902; Araujo F, 1999, J PHARMACOL EXP THER, V290, P989; Araujo F, 1998, EUR J PHARMACOL, V347, P347, DOI 10.1016/S0014-2999(98)00122-8; BARNES CA, 1987, J COMP NEUROL, V259, P549, DOI 10.1002/cne.902590405; BARNES CA, 1994, TRENDS NEUROSCI, V17, P13, DOI 10.1016/0166-2236(94)90029-9; Benke D, 1996, NEUROPHARMACOLOGY, V35, P1413, DOI 10.1016/S0028-3908(96)00068-8; BOCHET P, 1994, NEURON, V12, P383, DOI 10.1016/0896-6273(94)90279-8; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; BUCHSTALLER A, 1991, NEUROSCI LETT, V129, P237, DOI 10.1016/0304-3940(91)90470-E; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Davies P, 1998, PROG NEUROBIOL, V55, P651, DOI 10.1016/S0301-0082(98)00024-0; DEVAUD LL, 1995, MOL PHARMACOL, V48, P861; Dingledine R, 1999, PHARMACOL REV, V51, P7; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; Gold SJ, 1996, J COMP NEUROL, V365, P541; Gold SJ, 1997, J COMP NEUROL, V385, P491, DOI 10.1002/(SICI)1096-9861(19970908)385:4<491::AID-CNE1>3.0.CO;2-Z; GRAYSON DR, 1993, METHODS NEUROSCI, V12, P191; GREENBLATT DJ, 1989, J CLIN PHARMACOL, V29, P866, DOI 10.1002/j.1552-4604.1989.tb03246.x; GRIFFITH WH, 1995, J NEUROSCI, V15, P2407, DOI 10.1523/JNEUROSCI.15-03-02407.1995; Gutierrez A, 1996, MOL BRAIN RES, V35, P91, DOI 10.1016/0169-328X(95)00187-W; Gutierrez A, 1996, NEUROSCIENCE, V74, P341, DOI 10.1016/0306-4522(96)00137-6; Johnson M, 1996, NEUROBIOL AGING, V17, P639; Lambolez B, 1996, P NATL ACAD SCI USA, V93, P1797, DOI 10.1073/pnas.93.5.1797; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGNUSSON KR, 1993, NEUROBIOL AGING, V14, P197, DOI 10.1016/0197-4580(93)90001-R; Magnusson KR, 1998, MECH AGEING DEV, V104, P227, DOI 10.1016/S0047-6374(98)00076-1; Mathern GW, 1998, J NEUROSCI RES, V54, P734, DOI 10.1002/(SICI)1097-4547(19981215)54:6<734::AID-JNR2>3.0.CO;2-P; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; Mizukami K, 1997, BRAIN RES, V768, P354, DOI 10.1016/S0006-8993(97)00797-X; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Nicholson LFB, 1996, NEUROSCIENCE, V74, P89, DOI 10.1016/0306-4522(96)00080-2; Nicolle MM, 1996, NEUROSCIENCE, V74, P741, DOI 10.1016/0306-4522(96)00147-9; Papatheodoropoulos C, 1996, EUR J NEUROSCI, V8, P510, DOI 10.1111/j.1460-9568.1996.tb01235.x; POLLARD S, 1995, J BIOL CHEM, V270, P21285, DOI 10.1074/jbc.270.36.21285; RUANO D, 1991, J PHARMACOL EXP THER, V256, P902; RUANO D, 1994, EUR J PHARM-MOLEC PH, V267, P123, DOI 10.1016/0922-4106(94)90233-X; RUANO D, 1994, MOL BRAIN RES, V25, P225, DOI 10.1016/0169-328X(94)90157-0; RUANO D, 1995, J NEUROCHEM, V64, P867; Sanna E, 1998, J NEUROCHEM, V70, P2539; Shetty AK, 1998, J COMP NEUROL, V394, P252; SIEGHART W, 1995, PHARMACOL REV, V47, P181; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; WISDEN W, 1992, J NEUROSCI, V12, P1040	44	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19585	19593		10.1074/jbc.M000700200	http://dx.doi.org/10.1074/jbc.M000700200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10751391	Green Published, hybrid			2022-12-27	WOS:000087941300022
J	Brazill, DT; Caprette, DR; Myler, HA; Hatton, RD; Ammann, RR; Lindsey, DF; Brock, DA; Gomer, RH				Brazill, DT; Caprette, DR; Myler, HA; Hatton, RD; Ammann, RR; Lindsey, DF; Brock, DA; Gomer, RH			A protein containing a serine-rich domain with vesicle fusing properties mediates cell cycle-dependent cytosolic pH regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM AMEBAS; CONTRACTILE VACUOLE COMPLEX; PRESTALK GENE-EXPRESSION; MEMBRANE-FUSION; CYTOPLASMIC PH; POLYETHYLENE-GLYCOL; PHASE; DIFFERENTIATION; MORPHOGEN; KINETICS	Initial differentiation in Dictyostelium involves both asymmetric cell division and a cell cycle-dependent mechanism, We previously identified a gene, rtoA, which when disrupted randomizes the cell cycle-dependent mechanism without affecting either the underlying cell cycle or asymmetric differentiation. We find that in wild-type cells, RtoA levels vary during the cell cycle, Cytosolic pH, which normally varies with the cell cycle, is randomized in rtoA cells. The middle 60% of the RtoA protein is 10 tandem repeats of an 11 peptide long serine-rich motif, which we find has a random coil structure. This domain catalyzes the fusion of phospholipid vesicles in vitro. Conversely, rtoA cells have a defect in the fusion of endocytic vesicles. They also have a decreased exocytosis rate, a decreased pH of endocytic/ exocytic vesicles, and an increased average cytosolic pH. Our data indicate that the serine-rich domain of RtoA can mediate membrane fusion and that RtoA can increase the rate of vesicle fusion during processing of endocytic vesicles. We hypothesize that RtoA modulates initial cell type choice by linking vegetative cell physiology to the cell cycle.	Rice Univ, Howard Hughes Med Inst, Houston, TX 77005 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Howard Hughes Medical Institute; Rice University; Rice University	Gomer, RH (corresponding author), Rice Univ, Howard Hughes Med Inst, MS-140,6100 S Main St, Houston, TX 77005 USA.			Hatton, Roberta/0000-0001-8268-874X; Gomer, Richard/0000-0003-2361-4307				ADESSI C, 1995, J CELL SCI, V108, P3331; AERTS RJ, 1987, J CELL SCI, V87, P423; AERTS RJ, 1985, CELL, V43, P653, DOI 10.1016/0092-8674(85)90237-5; Araki T, 1997, DEV BIOL, V192, P645, DOI 10.1006/dbio.1997.8784; ARAKI T, 1994, DEV BIOL, V162, P221, DOI 10.1006/dbio.1994.1080; Aubry L, 1997, J THEOR BIOL, V184, P89, DOI 10.1006/jtbi.1996.0244; AUBRY L, 1993, J CELL SCI, V105, P861; Azhar M, 1996, EXP CELL RES, V227, P344, DOI 10.1006/excr.1996.0283; Brock DA, 1996, DEVELOPMENT, V122, P2569; BROOKMAN JJ, 1987, DEVELOPMENT, V100, P119; Buczynski G, 1997, MOL BIOL CELL, V8, P1343, DOI 10.1091/mbc.8.7.1343; Bush J, 1996, MOL BIOL CELL, V7, P1623, DOI 10.1091/mbc.7.10.1623; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Clay JL, 1995, DEV BIOL, V172, P665, DOI 10.1006/dbio.1995.8045; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; FURUKAWA R, 1988, J CELL BIOL, V107, P2541, DOI 10.1083/jcb.107.6.2541; Giglione C, 1995, BIOCHEM MOL BIOL INT, V36, P1057; GOMER RH, 1987, SCIENCE, V237, P758, DOI 10.1126/science.3039657; Gomer RH, 1996, DEV BIOL, V174, P82, DOI 10.1006/dbio.1996.0053; GROSS JD, 1988, DIFFERENTIATION, V38, P91, DOI 10.1111/j.1432-0436.1988.tb00202.x; GROSS JD, 1983, NATURE, V303, P244, DOI 10.1038/303244a0; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; JAIN R, 1994, J BIOL CHEM, V269, P9128; KAY RR, 1989, DEVELOPMENT, V107, P81; KLEIN G, 1986, BIOCHEM BIOPH RES CO, V138, P1146, DOI 10.1016/S0006-291X(86)80402-8; KREFFT M, 1989, J CELL SCI, V93, P199; KUBOHARA Y, 1994, FASEB J, V8, P869, DOI 10.1096/fasebj.8.11.8070636; KWONG L, 1989, DEV BIOL, V132, P554, DOI 10.1016/0012-1606(89)90250-9; Lentz BR, 1997, BIOCHEMISTRY-US, V36, P2076, DOI 10.1021/bi9623340; LENTZ BR, 1994, CHEM PHYS LIPIDS, V73, P91, DOI 10.1016/0009-3084(94)90176-7; LEWIS PR, 1992, CYTOCHEMICAL STAININ, P54; MACDONALD RI, 1985, BIOCHEMISTRY-US, V24, P4058, DOI 10.1021/bi00336a039; MCDONALD SA, 1984, J CELL SCI, V66, P195; NOLTA KV, 1994, J BIOL CHEM, V269, P2225; NOLTA KV, 1994, BBA-MOL CELL RES, V1224, P237, DOI 10.1016/0167-4889(94)90196-1; OHMORI T, 1987, CELL DIFFER DEV, V22, P11, DOI 10.1016/0045-6039(87)90409-X; Oyama M, 1997, J BIOCHEM-TOKYO, V122, P64; PADH H, 1991, J BIOL CHEM, V266, P5514; SCHAAP P, 1986, CELL, V45, P137, DOI 10.1016/0092-8674(86)90545-3; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Spann TP, 1996, P NATL ACAD SCI USA, V93, P5003, DOI 10.1073/pnas.93.10.5003; STERNFELD J, 1988, DIFFERENTIATION, V37, P173, DOI 10.1111/j.1432-0436.1988.tb00718.x; TEMESVARI L, 1994, J BIOL CHEM, V269, P25719; Temesvari LA, 1996, J CELL SCI, V109, P1479; Tirosh O, 1998, BIOPHYS J, V74, P1371, DOI 10.1016/S0006-3495(98)77849-X; WANG M, 1990, DEV BIOL, V140, P182, DOI 10.1016/0012-1606(90)90065-Q; WEIJER CJ, 1984, J CELL SCI, V70, P111; WEIJER CJ, 1984, J CELL SCI, V70, P133; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WILSCHUT J, 1980, BIOCHEMISTRY-US, V19, P6011, DOI 10.1021/bi00567a011; Wood SA, 1996, DEVELOPMENT, V122, P3677; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P28; XIE YJ, 1991, DEV BIOL, V145, P195, DOI 10.1016/0012-1606(91)90225-R; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347; ZIMMERMAN W, 1993, DEV BIOL, V160, P178, DOI 10.1006/dbio.1993.1296	56	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19231	19240		10.1074/jbc.M000900200	http://dx.doi.org/10.1074/jbc.M000900200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10747962	hybrid			2022-12-27	WOS:000087815900081
J	Creuzenet, C; Belanger, M; Wakarchuk, WW; Lam, JS				Creuzenet, C; Belanger, M; Wakarchuk, WW; Lam, JS			Expression, purification, and biochemical characterization of WbpP, a new UDP-GlcNAc C4 epimerase from Pseudomonas aeruginosa serotype O6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE 2-EPIMERASE; GALACTOSE 4-EPIMERASE; ESCHERICHIA-COLI; POLYSACCHARIDE CHAINS; MOLECULAR-STRUCTURE; EFFLUX OPERON; GENE-CLUSTER; ACTIVE-SITE; BINDING; LIPOPOLYSACCHARIDE	B-band lipopolysaccharide is an important virulence factor of the opportunistic pathogen Pseudomonas aeruginosa. WbpP is an enzyme essential for B-band lipopolysaccharide production in serotype O6, Sequence analysis suggests that it is involved in the formation of N-acetylgalacturonic acid. To test this hypothesis, overexpression and biochemical characterization of WbpP were performed. By using spectrophotometric assays and capillary electrophoresis, we show that WbpP is a UDP-GlcNAc C4 epimerase, The K-m for UDP-GlcNAc and UDP-GalNAc are 197 and 224 mu M, respectively. At equilibrium, 70% of UDP-GalNAc is converted to UDP-GlcNAc, whereas the yield of the reverse reaction is only 30%. The enzyme can also catalyze the interconversion of non-acetylated substrates, although the efficiency of catalysis is significantly lower. Only 15 and 40% of UDP-Glc and UDP-Gal, respectively, are converted at equilibrium. WbpP contains tightly bound NAD(H) and does not require additional cofactors for activity. it exists as a dimer in its native state. This paper is the first report of expression and characterization of a C4 UDP-GlcNAc epimerase at the biochemical level. Moreover, the characterization of the enzymatic function of WbpP will help clarify ambiguous surface carbohydrate biosynthetic pathways in P. aeruginosa and other organisms where homologues of WbpP exist.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Lam, JS (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.	jlam@uoguelph.ca	Wakarchuk, Warren/AAO-2774-2020; Wakarchuk, Warren/Q-9514-2017	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679				BAUER AJ, 1992, PROTEINS, V12, P372, DOI 10.1002/prot.340120409; Belanger M, 1999, MICROBIOL-UK, V145, P3505, DOI 10.1099/00221287-145-12-3505; Burrows LL, 1996, MOL MICROBIOL, V22, P481, DOI 10.1046/j.1365-2958.1996.1351503.x; CREUZENET C, 1999, PSEUDOMONAS 99 BIOTE; CRYZ SJ, 1984, INFECT IMMUN, V44, P508, DOI 10.1128/IAI.44.2.508-513.1984; Dean CR, 1999, J BACTERIOL, V181, P4275, DOI 10.1128/JB.181.14.4275-4284.1999; ENGLES W, 1985, INFECT IMMUN, V49, P182; ESTRELA AI, 1991, J GEN MICROBIOL, V137, P943, DOI 10.1099/00221287-137-4-943; FLENTKE GR, 1990, BIOCHEMISTRY-US, V29, P2430, DOI 10.1021/bi00461a029; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; Goldberg JB, 1996, TRENDS MICROBIOL, V4, P490, DOI 10.1016/S0966-842X(97)82911-3; HANCOCK REW, 1983, INFECT IMMUN, V42, P170, DOI 10.1128/IAI.42.1.170-177.1983; Johnson AE, 1998, BIOCHEMISTRY-US, V37, P5746, DOI 10.1021/bi972984j; Jornvall H, 1999, ADV EXP MED BIOL, V463, P359; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Kiser KB, 1999, J BACTERIOL, V181, P4818, DOI 10.1128/JB.181.16.4818-4824.1999; Knirel' Iu A, 1994, Biokhimiia, V59, P1784; KNIREL YA, 1985, EUR J BIOCHEM, V150, P541, DOI 10.1111/j.1432-1033.1985.tb09055.x; KNIREL YA, 1990, CRIT REV MICROBIOL, V17, P273, DOI 10.3109/10408419009105729; Kochetkov N. K., 1973, ADV CARBOHYD CHEM BI, V28, P307; KONOPKA JM, 1989, BIOCHEMISTRY-US, V28, P2645, DOI 10.1021/bi00432a043; MAROLDA CL, 1995, J BACTERIOL, V177, P5539, DOI 10.1128/jb.177.19.5539-5546.1995; MORENO F, 1981, CELL MOL BIOL, V27, P589; Morgan PM, 1997, J AM CHEM SOC, V119, P10269, DOI 10.1021/ja971718q; Newton DT, 1999, BIOCHEM J, V339, P63, DOI 10.1042/0264-6021:3390063; PIER GB, 1982, J INFECT DIS, V145, P217, DOI 10.1093/infdis/145.2.217; PILLER F, 1983, J BIOL CHEM, V258, P774; Pitt T L, 1989, Antibiot Chemother (1971), V42, P1; Plumbridge J, 1999, J BACTERIOL, V181, P47, DOI 10.1128/JB.181.1.47-54.1999; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; Poole K, 1996, MOL MICROBIOL, V21, P713, DOI 10.1046/j.1365-2958.1996.281397.x; Quimby BB, 1997, AM J HUM GENET, V61, P590, DOI 10.1086/515517; REISSIG JL, 1955, J BIOL CHEM, V217, P959; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; SCHILLER NL, 1983, DIAGN MICR INFEC DIS, V1, P145, DOI 10.1016/0732-8893(83)90044-5; SHIBAEV VN, 1986, ADV CARBOHYD CHEM BI, V44, P277; Srikumar R, 1999, J ANTIMICROB CHEMOTH, V44, P537, DOI 10.1093/jac/44.4.537; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6294, DOI 10.1021/bi970025j; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Virlogeux I, 1995, MICROBIOL-SGM, V141, P3039, DOI 10.1099/13500872-141-12-3039; WILSON DB, 1969, J BIOL CHEM, V244, P2132	46	79	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19060	19067		10.1074/jbc.M001171200	http://dx.doi.org/10.1074/jbc.M001171200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10747995	hybrid			2022-12-27	WOS:000087815900059
J	Caspi, R; Helinski, DR; Pacek, M; Konieczny, I				Caspi, R; Helinski, DR; Pacek, M; Konieczny, I			Interactions of DnaA proteins from distantly related bacteria with the replication origin of the broad host range plasmid RK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; INITIATION PROTEIN; BACILLUS-SUBTILIS; NUCLEOTIDE-SEQUENCE; PSEUDOMONAS-PUTIDA; CLONING VECTORS; TRFA; GENE; REGION; PURIFICATION	Replication initiation of the broad host range plasmid RK2 requires binding of the host-encoded DnaA protein to specific sequences (DnaA boxes) at its replication origin (oriV). In contrast to a chromosomal replication origin, which functionally interacts only with the native DnaA protein of the organism, the ability of RK2 to replicate in a wide range of Gram-negatioe bacterial hosts requires the interaction of oriV with many different DnaA proteins. In this study we compared the interactions of oriV with fine different DnaA proteins. DNase I footprint, gel mobility shift, and surface plasmon resonance analyses showed that the DnaA proteins from Escherichia cell, Pseudomonas putida, and Pseudomonos aeruginosa bind to the DnaA boxes at oriV and are capable of inducing open complex formation, the first step in the replication initiation process. However, DnaA proteins from two Gram-positive bacteria, Bacillus subtilis and Streptomyces lividans, while capable of specifically interacting with the DnaA box sequences at oriV, do not bind stably and fail to induce open complex formation. These results suggest that the inability of the DnaA protein of a host bacterium to form a stable and functional complex with the DnaA boxes at oriV is a limiting step for plasmid host range.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80952 Gdansk, Poland	University of California System; University of California San Diego; Fahrenheit Universities; University of Gdansk	Helinski, DR (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Caspi, Ron/0000-0002-6113-3590; Konieczny, Igor/0000-0002-1588-5601	NIAID NIH HHS [AI-07194] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTINGMEES MA, 1989, NUCLEIC ACIDS RES, V17, P9494, DOI 10.1093/nar/17.22.9494; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAGDASARIAN M, 1981, GENE, V16, P237, DOI 10.1016/0378-1119(81)90080-9; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CALCUTT MJ, 1992, J BACTERIOL, V174, P3220, DOI 10.1128/jb.174.10.3220-3226.1992; Datta HJ, 1999, P NATL ACAD SCI USA, V96, P73, DOI 10.1073/pnas.96.1.73; Doran KS, 1998, J BIOL CHEM, V273, P8447, DOI 10.1074/jbc.273.14.8447; Doran KS, 1999, MOL MICROBIOL, V33, P490, DOI 10.1046/j.1365-2958.1999.01491.x; Doran KS, 1999, J BIOL CHEM, V274, P17918, DOI 10.1074/jbc.274.25.17918; DURLAND RH, 1987, PLASMID, V18, P164, DOI 10.1016/0147-619X(87)90044-8; FANG FC, 1991, J BACTERIOL, V173, P5861, DOI 10.1128/jb.173.18.5861-5868.1991; FUJITA MQ, 1989, MOL GEN GENET, V215, P381, DOI 10.1007/BF00427033; FUKUOKA T, 1990, J BIOCHEM-TOKYO, V107, P732, DOI 10.1093/oxfordjournals.jbchem.a123117; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANSEN EB, 1982, NUCLEIC ACIDS RES, V10, P7373, DOI 10.1093/nar/10.22.7373; HELINSKI DR, 1996, ESCHERICHIA COLI SAL, V2, P2295; INGMER H, 1992, MOL GEN GENET, V232, P431, DOI 10.1007/BF00266248; ISAAC JH, 1968, J BACTERIOL, V96, P1732, DOI 10.1128/JB.96.5.1732-1741.1968; KOBORI JA, 1982, J BIOL CHEM, V257, P13763; KOGOMA T, 1985, MOL GEN GENET, V200, P103, DOI 10.1007/BF00383320; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, J BIOL CHEM, V272, P33312, DOI 10.1074/jbc.272.52.33312; Krause M, 1997, J MOL BIOL, V274, P365, DOI 10.1006/jmbi.1997.1404; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; Messer W, 1999, BIOCHIMIE, V81, P819, DOI 10.1016/S0300-9084(00)87165-5; MORIYA S, 1985, NUCLEIC ACIDS RES, V13, P2251, DOI 10.1093/nar/13.7.2251; NIETO C, 1990, GENE, V87, P145, DOI 10.1016/0378-1119(90)90507-N; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PERRI S, 1991, J BIOL CHEM, V266, P12536; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; SHINGLER V, 1984, J MOL BIOL, V175, P229, DOI 10.1016/0022-2836(84)90346-2; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SKOVGAARD O, 1987, J BACTERIOL, V169, P3976, DOI 10.1128/jb.169.9.3976-3981.1987; STENZEL TT, 1991, GENE DEV, V5, P1453, DOI 10.1101/gad.5.8.1453; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toukdarian AE, 1996, J BIOL CHEM, V271, P7072, DOI 10.1074/jbc.271.12.7072; YOSHIKAWA H, 1991, MOL MICROBIOL, V5, P2589, DOI 10.1111/j.1365-2958.1991.tb01967.x	44	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18454	18461		10.1074/jbc.M000552200	http://dx.doi.org/10.1074/jbc.M000552200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10749858	hybrid			2022-12-27	WOS:000087659400074
J	Chen, CP; Sheng, ST; Shao, ZF; Guo, PX				Chen, CP; Sheng, ST; Shao, ZF; Guo, PX			A dimer as a building block in assembling RNA - A hexamer that gears bacterial virus phi29 DNA-translocating machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE PHI-29 CONNECTOR; KISSING HAIRPIN COMPLEX; PHAGE PHI-29; IN-VITRO; BACILLUS-SUBTILIS; GENOMIC RNA; BIOLOGICAL STRUCTURES; SEQUENCE REQUIREMENT; SECONDARY STRUCTURE; RIBONUCLEASE-P	Six RNA (pRNA) molecules form a hexamer, via hand-in-hand interaction, to gear bacterial virus phi29 DNA translocation machinery. Here we report the pathway and the conditions for the hexamer formation. Stable pRNA dimers and trimers were assembled in solution, isolated from native gels, and separated by sedimentation, providing a model system for the study of RNA dimers and trimers in a protein-free environment. Cryoatomic force microscopy revealed that monomers displayed a (sic) outline, dimers exhibited an elongated shape, and trimers formed a triangle. Dimerization of pRNA was promoted by a variety of cations including spermidine, whereas procapsid binding and DNA packaging required specific divalent cations, including Mg2+, Ca2+, and Mn2+. Both the tandem and fused pRNA dimers with complementary loops designed to form even-numbered rings were active in DNA packaging, whereas those without complementary loops were inactive. We conclude that dimers are the building blocks of the hexamer, and the pathway of building a hexamer is: dimer --> tetramer --> hexamer, The Hill coefficient of 2.5 suggests that there are three binding sites with cooperative binding on the surface of the procapsid, The two interacting loops played a key role in recruiting the incoming dimer, whereas the procapsid served as the foundation for hexamer assembly.	Purdue Univ, Dept Pathobiol, Purdue Canc Ctr, W Lafayette, IN 47907 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Virginia	Guo, PX (corresponding author), Purdue Univ, Dept Pathobiol, Purdue Canc Ctr, B-36 Hansen Life Sci Res Bldg, W Lafayette, IN 47907 USA.	guo@vet.purdue.edu	Guo, Peixuan/AAE-2573-2022; Guo, Peixuan/I-7184-2015; Shao, Zhifeng/B-6075-2013	Guo, Peixuan/0000-0001-5706-2833; Chen, Chaoping/0000-0001-9387-6252	NCRR NIH HHS [RRO7720] Funding Source: Medline; NIGMS NIH HHS [GM59944] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR007720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059944] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAER MF, 1988, J BIOL CHEM, V263, P2344; BAILEY S, 1990, J BIOL CHEM, V265, P22365; BENDER W, 1976, CELL, V7, P595, DOI 10.1016/0092-8674(76)90210-5; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; CHANG KY, 1994, P NATL ACAD SCI USA, V91, P8705, DOI 10.1073/pnas.91.18.8705; Chang KY, 1997, J MOL BIOL, V269, P52, DOI 10.1006/jmbi.1997.1021; Chen CP, 1997, J VIROL, V71, P3864, DOI 10.1128/JVI.71.5.3864-3871.1997; Chen CP, 1999, RNA, V5, P805, DOI 10.1017/S1355838299990350; Chen CP, 1997, J VIROL, V71, P495, DOI 10.1128/JVI.71.1.495-500.1997; Chen T, 1997, J BIOMED MATER RES, V36, P190, DOI 10.1002/(SICI)1097-4636(199708)36:2<190::AID-JBM7>3.3.CO;2-7; Clever JL, 1996, J VIROL, V70, P5902, DOI 10.1128/JVI.70.9.5902-5908.1996; DONATE LE, 1992, J BIOL CHEM, V267, P10919; EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; Frilander MJ, 1999, GENE DEV, V13, P851, DOI 10.1101/gad.13.7.851; Garver K, 1997, RNA, V3, P1068; Garver K, 2000, J BIOL CHEM, V275, P2817, DOI 10.1074/jbc.275.4.2817; Guasch A, 1998, J MOL BIOL, V281, P219, DOI 10.1006/jmbi.1998.1928; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUO PX, 1994, SEMIN VIROL, V5, P27, DOI 10.1006/smvy.1994.1004; GUO PX, 1994, SEMIN VIROL, V5, P1, DOI 10.1006/smvy.1994.1001; GUO PX, 1987, NUCLEIC ACIDS RES, V15, P7081, DOI 10.1093/nar/15.17.7081; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; GUO PX, 1991, VIROLOGY, V185, P395, DOI 10.1016/0042-6822(91)90787-C; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; Guo PX, 1998, MOL CELL, V2, P149, DOI 10.1016/S1097-2765(00)80124-0; GUO PX, 1991, VIROLOGY, V183, P366, DOI 10.1016/0042-6822(91)90149-6; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; HAN WH, 1995, BIOCHEMISTRY-US, V34, P8215, DOI 10.1021/bi00026a001; Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0; Henkin TM, 1996, ANNU REV GENET, V30, P35, DOI 10.1146/annurev.genet.30.1.35; HERRANZ L, 1986, VIROLOGY, V155, P289, DOI 10.1016/0042-6822(86)90191-1; HOMANN M, 1993, J MOL BIOL, V233, P7, DOI 10.1006/jmbi.1993.1480; JIMENEZ J, 1986, SCIENCE, V232, P1113, DOI 10.1126/science.3754654; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Jossinet F, 1999, RNA, V5, P1222, DOI 10.1017/S1355838299990982; Laughrea M, 1997, J VIROL, V71, P3397, DOI 10.1128/JVI.71.5.3397-3406.1997; Lease RA, 1998, P NATL ACAD SCI USA, V95, P12456, DOI 10.1073/pnas.95.21.12456; LEE CS, 1995, J VIROL, V69, P5018, DOI 10.1128/JVI.69.8.5018-5023.1995; LEE CS, 1994, VIROLOGY, V202, P1039, DOI 10.1006/viro.1994.1434; Mohammad T, 1999, BIOORG MED CHEM LETT, V9, P1703, DOI 10.1016/S0960-894X(99)00265-6; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; OH BK, 1994, NUCLEIC ACIDS RES, V22, P4087, DOI 10.1093/nar/22.20.4087; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; PLEIJ CWA, 1989, METHOD ENZYMOL, V180, P289; PRATS AC, 1990, J VIROL, V64, P774, DOI 10.1128/JVI.64.2.774-783.1990; REID RJD, 1994, J BIOL CHEM, V269, P18656; REID RJD, 1994, J BIOL CHEM, V269, P5157; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STUDNICKA GM, 1978, NUCLEIC ACIDS RES, V5, P3365, DOI 10.1093/nar/5.9.3365; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; Trottier M, 1997, J VIROL, V71, P487, DOI 10.1128/JVI.71.1.487-494.1997; Trottier M, 1996, J VIROL, V70, P55, DOI 10.1128/JVI.70.1.55-61.1996; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Valpuesta JM, 1999, STRUCTURE, V7, P289, DOI 10.1016/S0969-2126(99)80039-2; Verma M, 1997, CANCER BIOCHEM BIOPH, V15, P211; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481; WICHITWECHKARN J, 1989, NUCLEIC ACIDS RES, V17, P3459, DOI 10.1093/nar/17.9.3459; Zhang CL, 1995, RNA, V1, P1041; ZHANG CL, 1995, VIROLOGY, V207, P442, DOI 10.1006/viro.1995.1103; ZHANG CL, 1994, VIROLOGY, V201, P77, DOI 10.1006/viro.1994.1267; Zhang CL, 1997, RNA, V3, P315; Zhang F, 1998, MOL CELL, V2, P141, DOI 10.1016/S1097-2765(00)80123-9; Zhang YY, 1996, BIOPHYS J, V71, P2168, DOI 10.1016/S0006-3495(96)79418-3	65	110	116	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17510	17516		10.1074/jbc.M909662199	http://dx.doi.org/10.1074/jbc.M909662199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748150	hybrid			2022-12-27	WOS:000087485000043
J	Weckwerth, W; Miyamoto, K; Iinuma, K; Krause, M; Glinski, M; Storm, T; Bonse, G; Kleinkauf, H; Zocher, R				Weckwerth, W; Miyamoto, K; Iinuma, K; Krause, M; Glinski, M; Storm, T; Bonse, G; Kleinkauf, H; Zocher, R			Biosynthesis of PF1022A and related cyclooctadepsipeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL ENZYME; ENNIATIN SYNTHETASE; CYCLODEPSIPEPTIDES; PURIFICATION; PROTEINS	PF1022A belongs to a recently identified class of N-methylated cyclooctadepsipeptides (CODPs) with strong anthelmintic properties. Described here is the cell-free synthesis of this CODP and related structures, as well as the purification and enzymatic characterization of the responsible synthetase, For PF1022A synthesis extracts of Mycelia sterilia were incubated with the precursors L-leucine, D-lactate, D-phenyllactate, and S-adenosyl-L-methionine in the presence of ATP and MgCl2, A 350-kDa depsipeptide synthetase, PFSYN, responsible for PF1022A synthesis was purified to electrophoretic homogeneity. Like other peptide synthetases, PFSYN follows a thiotemplate mechanism in which the substrates are activated as thioesters via adenylation, N-Methylation of the substrate L-leucine takes place after covalent binding prior to peptide bond formation. The enzyme is capable of synthesizing all known natural cyclooctadepsipeptides of the PF1022 type (A, B, C, and D) differing in the content of D-lactate and D-phenyllactate. In addition to PF1022 types A, B, C, and D, the in vitro incubations produced PF1022F (a CODP consisting of D-lactate and N-methyl-L-leucine), as well as di-, tetra-, and hexa-PF1022 homologs, PFSYN strongly resembles the well documented enniatin synthetase in size and mechanism. Our results suggest that PFSYN, like enniatin synthetase, is an enzyme with two peptide synthetase domains and forms CODP by repeated condensation of dipeptidol building blocks. Due to the low specificity of the D-hydroxy acid binding site, D-lactate or D-phenyllactate can be incorporated into the dipeptidols depending on the concentration of these substrates in the reaction mixture.	Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochem, D-10587 Berlin, Germany; Bayer AG, Business Grp Anim Hlth, D-51368 Leverkusen, Germany; Tech Univ Berlin, Tech Umweltschutz, Fachgebeit Wasserreinhaltung, D-10623 Berlin, Germany; Meiji Seika Kaisha Ltd, Pharmaceut Technol Labs, Odawara 250, Japan	Technical University of Berlin; Bayer AG; Technical University of Berlin; Meiji Holdings Co., Ltd.	Zocher, R (corresponding author), Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochem, Franklinstr 29, D-10587 Berlin, Germany.		Weckwerth, Wolfram/G-5811-2010	Weckwerth, Wolfram/0000-0002-9719-6358				BERGENDORFF O, 1994, J ANTIBIOT, V47, P1560, DOI 10.7164/antibiotics.47.1560; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Eigner E A, 1974, Methods Enzymol, V29, P601; GEVERS W, 1969, P NATL ACAD SCI USA, V63, P1335, DOI 10.1073/pnas.63.4.1335; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; HASUMI K, 1993, J ANTIBIOT, V46, P1782, DOI 10.7164/antibiotics.46.1782; HOFFMANN K, 1994, J BIOL CHEM, V269, P12710; JESCHKE P, 1998, Patent No. 9720945; Kachi S, 1998, JPN J PHARMACOL, V77, P235, DOI 10.1254/jjp.77.235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWEN A, 1990, J BIOL CHEM, V265, P11355; Lee S G, 1975, Methods Enzymol, V43, P585; Ohyama M., 1994, International Patent, Patent No. [WO9419334, 9419334]; PEETERS H, 1988, J ANTIBIOT TOKYO, V12, P1983; PIEPER R, 1995, EUR J BIOCHEM, V230, P119, DOI 10.1111/j.1432-1033.1995.tb20541.x; PIEPER R, 1992, J ANTIBIOT, V45, P1273, DOI 10.7164/antibiotics.45.1273; QUANDT N, 1993, ANAL BIOCHEM, V214, P490, DOI 10.1006/abio.1993.1527; SASAKI T, 1992, J ANTIBIOT, V45, P692, DOI 10.7164/antibiotics.45.692; SUZUKI A, 1977, Tetrahedron Letters, V25, P2167; Terada Mamoru, 1993, Japanese Journal of Parasitology, V42, P199; TOMODA H, 1992, J ANTIBIOT, V45, P1207, DOI 10.7164/antibiotics.45.1207; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; WECKWERTH W, 1998, THESIS TU BERLIN BER; ZOCHER R, 1983, BIOCHEM BIOPH RES CO, V110, P292, DOI 10.1016/0006-291X(83)91294-9; Zocher R, 1997, ADV MICROB PHYSIOL, V38, P85; ZOCHER R, 1986, BIOCHEMISTRY-US, V25, P550, DOI 10.1021/bi00351a005; ZOCHER R, 1982, BIOCHEMISTRY-US, V21, P28	28	52	61	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17909	17915		10.1074/jbc.M001084200	http://dx.doi.org/10.1074/jbc.M001084200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10751395	hybrid			2022-12-27	WOS:000087485000096
J	Heermann, R; Altendorf, K; Jung, K				Heermann, R; Altendorf, K; Jung, K			The hydrophilic N-terminal domain complements the membrane-anchored C-terminal domain of the sensor kinase KdpD of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TURGOR SENSOR; PHOSPHATASE-ACTIVITY; OPERON EXPRESSION; PROTEIN; SIGNAL; SYSTEM; POTASSIUM; TRANSPORT; SEQUENCES; PRESSURE	The putative turgor sensor KdpD is characterized by a large, N-terminal domain of about 400 amino acids, which is not found in any other known sensor kinase. Comparison of 12 KdpD sequences from various microorganisms reveals that this part of the kinase is highly conserved and includes two motifs (Walker A and Walker B) that are very similar to the classical ATP-binding sites of ATP-requiring enzymes. By means of photoaffinity labeling with 8-azido-[alpha-P-32]ATP, direct evidence was obtained for the existence of an ATP-binding site located in the N-terminal domain of KdpD. The N-terminal domain, KdpD/1-395, was overproduced and purified. Although predicted to be hydrophilic, it was found to be membrane-associated and could be solubilized either by treatment with buffer of low ionic strength or detergent. The membrane-associated form, but not the solubilized one, retained the ability to bind 8-azido-[alpha-P-32]ATP. Previously, it was shown that the phosphatase activity of a truncated KdpD, KdpD/Delta 12-395, is deregulated in vitro (Jung, K., and Altendorf, K. (1998) J. Biol. Chem. 273, 17406-17410). Here, we demonstrated that this effect was reversed in vesicles containing both the truncated KdpD and the N-terminal domain. Furthermore, coexpression of kdpD/Delta 12-395 and kdpD/1-395 restored signal transduction in vivo. These results highlight the importance of the N-terminal domain for the function of KdpD and provide evidence for an interaction of this domain and the transmitter domain of the sensor kinase.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany	University Osnabruck	Jung, K (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, Barbarastr 11, D-49069 Osnabruck, Germany.	jung_k@biologie.uni-osnabrueck.de	Heermann, Ralf/E-1793-2013; Heermann, Ralf/CAF-8609-2022	Heermann, Ralf/0000-0003-0631-6156; 				ALTENDORF K, 1996, BIOMEMBR, V5, P403; ASHA H, 1993, J BACTERIOL, V175, P4528, DOI 10.1128/JB.175.14.4528-4537.1993; EPSTEIN W, 1992, ACTA PHYSIOL SCAND, V146, P193; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Heermann R, 1998, BBA-BIOMEMBRANES, V1415, P114, DOI 10.1016/S0005-2736(98)00181-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG WJ, 1995, BIOCHEMISTRY-US, V34, P10985, DOI 10.1021/bi00035a004; Jung K, 1998, J BIOL CHEM, V273, P17406, DOI 10.1074/jbc.273.28.17406; Jung K, 1997, J BIOL CHEM, V272, P10847; Jung K, 1998, BBA-BIOMEMBRANES, V1372, P311, DOI 10.1016/S0005-2736(98)00070-4; Jung K, 1998, J BIOL CHEM, V273, P26415, DOI 10.1074/jbc.273.41.26415; Kaneko T, 1996, DNA Res, V3, P109; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; Malli R, 1998, J BACTERIOL, V180, P5102, DOI 10.1128/JB.180.19.5102-5108.1998; NAKASHIMA K, 1992, MOL MICROBIOL, V6, P1777, DOI 10.1111/j.1365-2958.1992.tb01350.x; OHWADA T, 1987, ARCH BIOCHEM BIOPHYS, V259, P157, DOI 10.1016/0003-9861(87)90481-4; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Puppe W, 1996, J BIOL CHEM, V271, P25027, DOI 10.1074/jbc.271.40.25027; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Stallkamp I, 1999, ARCH MICROBIOL, V172, P295, DOI 10.1007/s002030050783; SUGIURA A, 1992, MOL MICROBIOL, V6, P1769, DOI 10.1111/j.1365-2958.1992.tb01349.x; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; SUTHERLAND L, 1986, J BACTERIOL, V168, P805, DOI 10.1128/jb.168.2.805-814.1986; VOELKNER P, 1993, EUR J BIOCHEM, V217, P1019, DOI 10.1111/j.1432-1033.1993.tb18333.x; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	31	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17080	17085		10.1074/jbc.M000093200	http://dx.doi.org/10.1074/jbc.M000093200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747873	hybrid			2022-12-27	WOS:000087392200095
J	Hwang, JI; Heo, K; Shin, KJ; Kim, E; Yun, CHC; Ryu, SH; Shin, HS; Suh, PG				Hwang, JI; Heo, K; Shin, KJ; Kim, E; Yun, CHC; Ryu, SH; Shin, HS; Suh, PG			Regulation of phospholipase C-beta 3 activity by Na+/H+ exchanger regulatory factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CAMP-MEDIATED INHIBITION; DENSITY PROTEIN PSD-95; PDZ-DOMAIN; BETA(2)-ADRENERGIC RECEPTOR; ALPHA-SUBUNIT; BETA-GAMMA; C ISOZYMES; KINASE-C; ACTIVATION	Among the phospholipase C that catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate, four mammalian phospholipase C-beta (PLC-beta) isotypes (isotypes 1-4) are activated through G protein-coupled receptors (GPCRs). Although the regulation of the PLC-beta s by GPCRs and heterotrimeric G proteins has been extensively studied, little is known about the molecular determinants that regulate their activity. The PLC-beta isozymes carry a putative PSD-95/Dlg/ZO-1 (PDZ) binding motif (X(S/T)X(V/L)COOH) at their carboxyl terminus, which is implicated in specific interactions with anchor proteins. Using the yeast two-hybrid system, me identified Na+/H+ exchanger regulatory factor 2 (NHERF2) as a protein that interacted with a C-terminal heptapeptide of PLC-beta 3. Immunoprecipitation studies revealed that NHERF2 interacts specifically with PLC-beta 3, but not with other PLC-beta isotypes. Furthermore, PLC-beta 3 interacted with NHERF2 rather than with other PDZ-containing proteins. This interaction required the COOH-terminal NTQL sequence of PLC-beta 3 and the second PDZ domain of NHERF2. Interestingly, NHERF2 potentiated the PLC-beta activation by carbachol in COS7 and HeLa cells, while mutant NHERF2, lacking the second PDZ domain, had no such effect. Taken together, the data suggest that NHERF2 may act as a modulator underlying the process of PLC-beta 3-mediated signaling.	Pohang Univ Sci & Technol, Dept Life Sci, Natl Creat Res Initiat Ctr Calcium & Learning, Div Mol & Life Sci, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Sch Environm Engn, Pohang 790784, South Korea; Pusan Natl Univ, Dept Pharmacol, Pusan 609735, South Korea; Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Pusan National University; Johns Hopkins University	Suh, PG (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Natl Creat Res Initiat Ctr Calcium & Learning, Div Mol & Life Sci, Pohang 790784, South Korea.		Suh, Pann-Ghill/F-3610-2010; Kim, Eunjoon/C-1566-2011	Ryu, Sung Ho/0000-0003-0913-3048; Hwang, Jong-Ik/0000-0002-0729-1782				Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; Bahner M, 2000, J BIOL CHEM, V275, P2901, DOI 10.1074/jbc.275.4.2901; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; JHON DY, 1993, J BIOL CHEM, V268, P6654; JIANG HP, 1994, J BIOL CHEM, V269, P7593; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; Kim D, 1997, NATURE, V389, P290, DOI 10.1038/38508; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; LEE CW, 1994, J BIOL CHEM, V269, P25335; LEE YH, 1994, J BIOL CHEM, V269, P26842; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; TANAKA O, 1994, NEUROSCI LETT, V182, P17, DOI 10.1016/0304-3940(94)90194-5; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153	41	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16632	16637		10.1074/jbc.M001410200	http://dx.doi.org/10.1074/jbc.M001410200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748023	hybrid			2022-12-27	WOS:000087392200034
J	Liu, D; Chandy, M; Lee, SK; Le Drean, Y; Ando, H; Xiong, F; Lee, JW; Hew, CL				Liu, D; Chandy, M; Lee, SK; Le Drean, Y; Ando, H; Xiong, F; Lee, JW; Hew, CL			A zebrafish Ftz-F1 (Fushi Tarazu Factor 1) homologue requires multiple subdomains in the D and E regions for its transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; LIGAND-BINDING DOMAIN; BETA SUBUNIT GENE; RETINOID-X-RECEPTOR; NUCLEAR HORMONE RECEPTORS; ESTROGEN-RECEPTOR; THYROID-HORMONE; INDEPENDENT RECRUITMENT; TRANSACTIVATION DOMAIN; CRYSTAL-STRUCTURE	A zebrafish Ftz-F1 homologue, zFF1A (zebrafish Ff1a or Nr5a2, a member of nuclear receptor superfamily) and its C-terminally truncated variant (zFF1B) were previously identified. Due to lack of the identity box (I-box) and activation function 2 (AF-2) domain, zFF1B lacks transactivation function and fails to synergize with estrogen receptor (ER) in regulating promoters. It was speculated that the I-box might be involved in the zFF1A/ER interaction. In the present study, the function of the I-hox was examined. In the absence of the I-box or with an altered heptad 9, the AF-2 of zFF1A was not functional, either in the presence or absence of ER The GST pull-down assay showed that zFF1A and its mutants exerted similar physical contacts with ER-LBD, suggesting that the "dimerization" domain (I-box) is essential for the transcriptional activity of zFF1A Moreover, nuclear receptor coactivator selectively activated zFF1 with the I-box but exerted no effect on zFF1B, indicating that the I-box is able to interact with the coactivators. By deletion study and analysis of the identified domains in GAIA-DNA binding domain, other regions of zFF1A critical for its AF were also delineated. Consistent with the mutation analysis, AF-2 was active only in the presence of the I-box. We also identified a novel AF domain (AF-3) located in the hinge region (amino acids 155-267), although the activity of AF-3 was inhibited by its Banking region. We suggest that the D and E regions of zFF1A possess both positive and negative transactivation functions, and interdomain "cross-talk" may confer the full transcriptional activity of the protein.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L5, Canada; Hosp Sick Children, Div Struct Biol & Biochem, Toronto, ON M5G 1L5, Canada; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Natl Univ Singapore, Dept Biol Sci, Singapore 119260, Singapore; Natl Univ Singapore, Trop Marine Sci Inst, Singapore 119260, Singapore	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Chonnam National University; Chonnam National University; Chonnam National University; National University of Singapore; National University of Singapore	Hew, CL (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, 100 Coll St,Rm 351, Toronto, ON M5G 1L5, Canada.		Chandy, Mark Joseph Koonthanam/GLT-9682-2022; Hew, Choy Leong/I-1501-2012; Le Dréan, Yves/L-4822-2015	Chandy, Mark Joseph Koonthanam/0000-0002-6741-2822; Hew, Choy Leong/0000-0002-9441-0064; 				AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; AUSUBEL EM, 1995, CURRENT PROTOCOLS MO; Auwerx J, 1999, CELL, V97, P161; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Collingwood TN, 1997, J BIOL CHEM, V272, P13060, DOI 10.1074/jbc.272.20.13060; Crawford PA, 1997, MOL ENDOCRINOL, V11, P1626, DOI 10.1210/me.11.11.1626; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; ELLINGERZIEGELBAUER H, 1995, MOL ENDOCRINOL, V9, P872, DOI 10.1210/me.9.7.872; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Jenster G, 1998, MOL CELL ENDOCRINOL, V143, P1, DOI 10.1016/S0303-7207(98)00145-2; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LeDrean Y, 1996, MOL ENDOCRINOL, V10, P217, DOI 10.1210/me.10.3.217; Lee SK, 1998, MOL ENDOCRINOL, V12, P325, DOI 10.1210/me.12.3.325; Lee SK, 1998, MOL ENDOCRINOL, V12, P1184, DOI 10.1210/me.12.8.1184; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; Li LA, 1999, MOL ENDOCRINOL, V13, P1588, DOI 10.1210/me.13.9.1588; Li SL, 1997, BIOTECHNIQUES, V23, P588, DOI 10.2144/97234bm05; Liu D, 1997, MOL ENDOCRINOL, V11, P877, DOI 10.1210/me.11.7.877; LIU D, 1995, ENDOCRINOLOGY, V136, P3486, DOI 10.1210/en.136.8.3486; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mellon SH, 1998, ENDOCRINOLOGY, V139, P3026, DOI 10.1210/en.139.6.3026; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; Oate SA, 1995, SCIENCE, V270, P1354, DOI DOI 10.1126/SCIENCE.270.5240.1354.PUBMED:7481822; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; PIERRAT B, 1994, GENE, V143, P193, DOI 10.1016/0378-1119(94)90096-5; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; XIONG F, 1994, MOL ENDOCRINOL, V8, P782, DOI 10.1210/me.8.6.782; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	49	14	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16758	16766		10.1074/jbc.M000121200	http://dx.doi.org/10.1074/jbc.M000121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747875	hybrid			2022-12-27	WOS:000087392200052
J	Bedford, MT; Frankel, A; Yaffe, MB; Clarke, S; Leder, P; Richard, S				Bedford, MT; Frankel, A; Yaffe, MB; Clarke, S; Leder, P; Richard, S			Arginine methylation inhibits the binding of proline-rich ligands to Src homology 3, but not WW, domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEIC-ACID BINDING; ALDRICH-SYNDROME PROTEIN; SH3 DOMAINS; SUBSTRATE-SPECIFICITY; N-METHYLTRANSFERASE; RNA-BINDING; C-SRC; RIBONUCLEOPROTEIN PARTICLE; TYROSINE PHOSPHORYLATION; ENZYMATIC METHYLATION	Src homology 3 (SH3) and WW domains are known to associate with proline-rich motifs within their respective ligands. Here we demonstrate that the proposed adapter protein for Src kinases, Sam68, is a ligand whose proline-rich motifs interact with the SH3 domains of p59(fyn) and phospholipase C gamma-1 as well as with the WW domains of FBP30 and FBP21. These proline-rich motifs, in turn, are flanked by RG repeats that represent targets for the type I protein arginine N-methyltransferase. The asymmetrical dimethylation of arginine residues within these RG repeats dramatically reduces the binding of the SH3 domains of p59(fyn) and phospholipase C gamma-1, but has no effect on their binding to the WW domain of FBP30. These results suggest that protein arginine methylation can selectively modulate certain protein-protein interactions and that mechanisms exist for the irreversible regulation of SH3 domain-mediated interactions.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Richard, S (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	mcrd@musica.mcgill.ca	Bedford, Mark T/E-7856-2011		NHLBI NIH HHS [HL03601] Funding Source: Medline; NIGMS NIH HHS [GM 07185, GM26020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185, R01GM026020, R37GM026020] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Arning S, 1996, RNA, V2, P794; Arold S, 1997, STRUCTURE, V5, P1361, DOI 10.1016/S0969-2126(97)00286-4; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BOFFA LC, 1977, BIOCHEM BIOPH RES CO, V74, P969, DOI 10.1016/0006-291X(77)91613-8; BROSTOFF S, 1971, P NATL ACAD SCI USA, V68, P765, DOI 10.1073/pnas.68.4.765; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; Di Fruscio M, 1998, J BIOL CHEM, V273, P30122, DOI 10.1074/jbc.273.46.30122; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GARY JD, 1995, J BIOL CHEM, V270, P4076, DOI 10.1074/jbc.270.8.4076; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GHOSH SK, 1990, BIOCHIM BIOPHYS ACTA, V1039, P142, DOI 10.1016/0167-4838(90)90179-J; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kao HY, 1996, MOL CELL BIOL, V16, P960; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Komuro A, 1999, NUCLEIC ACIDS RES, V27, P1957, DOI 10.1093/nar/27.9.1957; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; MERRILL BM, 1987, INT J PEPT PROT RES, V29, P21; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; RAJPUROHIT R, 1994, J BIOL CHEM, V269, P1075; RAJPUROHIT R, 1994, BIOCHEM J, V304, P903, DOI 10.1042/bj3040903; RAWAL N, 1995, BBA-PROTEIN STRUCT M, V1248, P11, DOI 10.1016/0167-4838(94)00213-Z; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Valentini SR, 1999, RNA, V5, P272, DOI 10.1017/S1355838299981633; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	75	202	215	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16030	16036		10.1074/jbc.M909368199	http://dx.doi.org/10.1074/jbc.M909368199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748127	hybrid			2022-12-27	WOS:000087291400058
J	Hu, QH; Zheng, GM; Zweier, JL; Deshpande, S; Irani, K; Ziegelstein, RC				Hu, QH; Zheng, GM; Zweier, JL; Deshpande, S; Irani, K; Ziegelstein, RC			NADPH oxidase activation increases the sensitivity of intracellular Ca2+ stores to inositol 1,4,5-trisphosphate in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NF-KAPPA-B; HYDROGEN-PEROXIDE; NAD(P)H OXIDASE; CALCIUM RELEASE; SUPEROXIDE PRODUCTION; EXPRESSION; OSCILLATIONS; HEPATOCYTES; GENERATION	Many stimuli that activate the vascular NADPH oxidase generate reactive oxygen species and increase intracellular Ca2+, but whether NADPH oxidase activation directly affects Ca2+ signaling is unknown. NADPH stimulated the production of superoxide anion and H2O2 in human aortic endothelial cells that was inhibited by the NADPH oxidase inhibitor diphenyleneiodonium and was significantly attenuated in cells transiently expressing a dominant negative allele of the small GTP-binding protein Rad, which is required for oxidase activity. In permeabilized Mag-indo 1-loaded cells, NADPH and H2O2 each decreased the threshold concentration of inositol 1,4,5-trisphosphate (InsP(3)) required to release intracellularly stored Ca2+ and shifted the InsP(3)-Ca2+ release dose-response curve to the left, Concentrations of H2O2 as low as 3 mu M increased the sensitivity of intracellular Ca2+ stores to InsP(3) and decreased the InsP(3) EC50 from 423.2 +/- 54.9 to 276.9 +/- 14.4 nM. The effect of NADPH on InsP(3)-stimulated Ca2+ release was blocked by catalase and by diphenyleneiodonium and was not observed in cells lacking functional Rac1 protein. Thus, NADPH oxidase-derived H2O2 increases the sensitivity of intracellular Ca2+ stores to InsP(3) in human endothelial cells. Since Ca2+-dependent signaling pathways are critical to normal endothelial function, this effect may be of great importance in endothelial signal transduction.	Johns Hopkins Univ, Sch Med,Johns Hopkins Bayview Med Ctr, Div Cardiol, Dept Med, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Ziegelstein, RC (corresponding author), Johns Hopkins Univ, Sch Med,Johns Hopkins Bayview Med Ctr, Div Cardiol, Dept Med, 4940 Eastern Ave, Baltimore, MD 21224 USA.			Irani, Kaikobad/0000-0001-9194-7387	NHLBI NIH HHS [HL-52315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen S, 1998, J CLIN INVEST, V101, P1064, DOI 10.1172/JCI445; Bayraktutan U, 1998, CARDIOVASC RES, V38, P256, DOI 10.1016/S0008-6363(98)00003-0; Brandes RP, 1999, HYPERTENSION, V33, P1243, DOI 10.1161/01.HYP.33.5.1243; CARTER TD, 1991, BIOCHEM J, V278, P697, DOI 10.1042/bj2780697; DILIBERTO PA, 1991, J BIOL CHEM, V266, P12612; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; Heitzer T, 1999, KIDNEY INT, V55, P252, DOI 10.1046/j.1523-1755.1999.00229.x; Hishikawa K, 1997, CIRCULATION, V96, P3610; Holland JA, 1997, ENDOTHELIUM-NEW YORK, V5, P191, DOI 10.3109/10623329709053398; Honda HM, 1999, ARTERIOSCL THROM VAS, V19, P680, DOI 10.1161/01.ATV.19.3.680; Howard AB, 1997, AM J PHYSIOL-CELL PH, V272, pC421, DOI 10.1152/ajpcell.1997.272.2.C421; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; Hu QH, 1998, CIRCULATION, V97, P268, DOI 10.1161/01.CIR.97.3.268; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; LATTANZIO FA, 1991, BIOCHEM BIOPH RES CO, V177, P184, DOI 10.1016/0006-291X(91)91966-G; Marumo T, 1997, CIRCULATION, V96, P2361; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; Mohazzab HKM, 1994, AM J PHYSIOL, V266, P2568; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; Sokabe M, 1997, HEART VESSELS, P191; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; VERCELLOTTI GM, 1991, J LAB CLIN MED, V117, P15; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Wesson Donald E., 1995, Microcirculation (New York), V2, P195, DOI 10.3109/10739689509146767; Zhao B, 1997, EUR J CLIN INVEST, V27, P48, DOI 10.1046/j.1365-2362.1997.750628.x; ZHAO H, 1990, J BIOL CHEM, V265, P14822; ZULUETA JJ, 1995, AM J RESP CELL MOL, V12, P41, DOI 10.1165/ajrcmb.12.1.7529030	34	81	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15749	15757		10.1074/jbc.M000381200	http://dx.doi.org/10.1074/jbc.M000381200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747906	hybrid			2022-12-27	WOS:000087291400022
J	Lee, SF; Wang, CT; Liang, JYP; Hong, SL; Huang, CC; Chen, SSL				Lee, SF; Wang, CT; Liang, JYP; Hong, SL; Huang, CC; Chen, SSL			Multimerization potential of the cytoplasmic domain of the human immunodeficiency virus type 1 transmembrane glycoprotein gp41	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; ZIPPER-LIKE DOMAIN; ENVELOPE GLYCOPROTEIN; LEUCINE ZIPPER; HIV-1 GP41; OLIGOMERIC STRUCTURE; MEMBRANE-FUSION; HEPTAD REPEAT; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI	We previously demonstrated that an envelope mutant of human immunodeficiency virus type 1 lacking the entire cytoplasmic domain interferes in trans with the production of infectious virus by inclusion of the mutant envelope into the wild-type envelope complex. We also showed that the envelope incorporation into virions is not affected when the wild-type envelope is coexpressed with the mutant envelope. These results suggest that an oligomeric structure of the cytoplasmic domain is functionally required for viral infectivity, To understand whether the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein gp41 has the potential to self-assemble as an oligomer, in the present study we fused the coding sequence of the entire cytoplasmic domain at 3' to the Escherichia coli malE gene, which encodes a monomeric maltose-binding protein. The expressed fusion protein was examined by chemical cross-linking, sucrose gradient centrifugation, and gel filtration. The results showed that the cytoplasmic domain of gp41 assembles into a high-ordered structural complex. The intersubunit interaction of the cytoplasmic domain was also confirmed by a mammalian two-hybrid system that detects protein-protein interactions in eucaryotic cells. A cytoplasmic domain fragment expressed in eucaryotic cells was pulled down by glutathione-Sepharose 4B beads via its association with another cytoplasmic domain fragment fused to the C terminus of the glutathione S-transferase moiety, We also found that sequences encompassing the lentiviral lytic peptide-1 and lentiviral lytic peptide-2, which are located within residues 828-856 and 770-795, respectively, play a critical role in cytoplasmic domain self-assembly. Taken together, the results from the present study indicate that the cytoplasmic domain of gp41 by itself is sufficient to assemble into a multimeric structure. This finding supports the hypothesis that a multimeric form of the gp41 cytoplasmic domain plays a crucial role in virus infectivity.	Acad Sinica, Inst Biomed Sci, Div Infect Dis, Sect 2, Taipei 11529, Taiwan; Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 11217, Taiwan; Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Chen, SSL (corresponding author), Acad Sinica, Inst Biomed Sci, Div Infect Dis, Sect 2, 128,Yen Chiu Yuan Rd, Taipei 11529, Taiwan.	schen@ibms.sinica.edu.tw						ARROYO J, 1995, J VIROL, V69, P4095, DOI 10.1128/JVI.69.7.4095-4102.1995; AUSUBEL FA, 1995, CURRENT PROTOCOLS MO, V2; BERNSTEIN HB, 1995, J VIROL, V69, P2745, DOI 10.1128/JVI.69.5.2745-2750.1995; BLONDEL A, 1990, EUR J BIOCHEM, V193, P325, DOI 10.1111/j.1432-1033.1990.tb19341.x; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHEN SSL, 1994, J VIROL, V68, P2002, DOI 10.1128/JVI.68.3.2002-2010.1994; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; Chen SSL, 1999, J VIROL, V73, P8290, DOI 10.1128/JVI.73.10.8290-8302.1999; Chen SSL, 1996, VIROLOGY, V226, P260, DOI 10.1006/viro.1996.0654; Chen SSL, 1998, J VIROL, V72, P4765, DOI 10.1128/JVI.72.6.4765-4774.1998; CHERNOMORDIK L, 1994, J VIROL, V68, P7115, DOI 10.1128/JVI.68.11.7115-7123.1994; Comardelle AM, 1997, AIDS RES HUM RETROV, V13, P1525, DOI 10.1089/aid.1997.13.1525; Cortes P, 1996, P NATL ACAD SCI USA, V93, P14008, DOI 10.1073/pnas.93.24.14008; DOMS RW, 1990, J VIROL, V64, P3537, DOI 10.1128/JVI.64.7.3537-3540.1990; DUBAY JW, 1992, J VIROL, V66, P6616, DOI 10.1128/JVI.66.11.6616-6625.1992; EARL PL, 1993, AIDS RES HUM RETROV, V9, P589, DOI 10.1089/aid.1993.9.589; EARL PL, 1991, J VIROL, V65, P31, DOI 10.1128/JVI.65.1.31-41.1991; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; EISENBERG D, 1990, BIOPOLYMERS, V29, P171, DOI 10.1002/bip.360290122; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FISHER AG, 1986, SCIENCE, V233, P655, DOI 10.1126/science.3014663; FUJII G, 1992, PROTEIN SCI, V1, P1454, DOI 10.1002/pro.5560011107; GABUZDA DH, 1992, J VIROL, V66, P3306, DOI 10.1128/JVI.66.6.3306-3315.1992; GAWRISCH K, 1993, BIOCHEMISTRY-US, V32, P3112, DOI 10.1021/bi00063a024; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; GUAN C, 1988, GENE, V67, P21; HELSETH E, 1990, J VIROL, V64, P6314, DOI 10.1128/JVI.64.12.6314-6318.1990; Hsu SC, 1997, J IMMUNOL METHODS, V204, P169, DOI 10.1016/S0022-1759(97)00044-6; JOHNSTON PB, 1993, J VIROL, V67, P3077, DOI 10.1128/JVI.67.6.3077-3086.1993; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; LEE SJ, 1989, AIDS RES HUM RETROV, V5, P441, DOI 10.1089/aid.1989.5.441; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MILLER MA, 1991, AIDS RES HUM RETROV, V7, P511, DOI 10.1089/aid.1991.7.511; MILLER MA, 1993, VIROLOGY, V196, P89, DOI 10.1006/viro.1993.1457; MILLER RK, 1992, TROPHOBLAST RES, V6, P351; OWENS RJ, 1990, VIROLOGY, V179, P827, DOI 10.1016/0042-6822(90)90151-G; PINTER A, 1989, J VIROL, V63, P2674, DOI 10.1128/JVI.63.6.2674-2679.1989; POUMBOURIOS P, 1995, J VIROL, V69, P1209, DOI 10.1128/JVI.69.2.1209-1218.1995; Pritsker M, 1999, BIOCHEMISTRY-US, V38, P11359, DOI 10.1021/bi990232e; RABENSTEIN M, 1995, BIOCHEMISTRY-US, V34, P13390, DOI 10.1021/bi00041a016; Rabenstein MD, 1996, BIOCHEMISTRY-US, V35, P13922, DOI 10.1021/bi961743t; SCHAWALLER M, 1989, VIROLOGY, V172, P367, DOI 10.1016/0042-6822(89)90142-6; Shugars DC, 1996, J VIROL, V70, P2982, DOI 10.1128/JVI.70.5.2982-2991.1996; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; TERWILLIGER E, 1986, J VIROL, V60, P754, DOI 10.1128/JVI.60.2.754-760.1986; THOMAS DJ, 1991, J VIROL, V65, P3797, DOI 10.1128/JVI.65.7.3797-3803.1991; VENABLE RM, 1989, AIDS RES HUM RETROV, V5, P7, DOI 10.1089/aid.1989.5.7; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; YU XF, 1993, J VIROL, V67, P213, DOI 10.1128/JVI.67.1.213-221.1993	59	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15809	15819		10.1074/jbc.M000601200	http://dx.doi.org/10.1074/jbc.M000601200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747937	hybrid			2022-12-27	WOS:000087291400029
J	Mullen, RT; Trelease, RN				Mullen, RT; Trelease, RN			The sorting signals for peroxisomal membrane-bound ascorbate peroxidase are within its C-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; YEAST YARROWIA-LIPOLYTICA; TARGETING SIGNAL; IN-VIVO; SACCHAROMYCES-CEREVISIAE; HANSENULA-POLYMORPHA; TRANSMEMBRANE DOMAIN; PROTEIN INSERTION; CYTOCHROME B(5); PICHIA-PASTORIS	Peroxisomal ascorbate peroxidase (APX) is a carboxyl tail-anchored, type II (N-cytosol-C-matrix) integral membrane protein that functions in the regeneration of NAD(+) in glyoxysomes of germinated oilseeds and protection of peroxisomes in other organisms from toxic H2O2. Recently we showed that cottonseed peroxisomal APX was sorted post-translationally from the cytosol to peroxisomes via a novel reticular/circular membranous network that was interpreted to be a subdomain of the endoplasmic reticulum (ER), named peroxisomal ER (pER), Here we report on the molecular signals responsible for sorting peroxisomal APX Deletions or site-specific substitutions of certain amino acid residues within the hydrophilic C-terminal-most eight-amino acid residues (includes a positively charged domain found in most peroxisomal integral membrane-destined proteins) abolished sorting of peroxisomal APX to peroxisomes via pER. However, the C-terminal tail was not sufficient for sorting chloramphenicol acetyltransferase to peroxisomes via pER, whereas the peptide plus most of the immediately adjacent 21-amino acid transmembrane domain (TMD) of peroxisomal APX was sufficient for sorting. Replacement of the peroxisomal APX TMD with an artificial TMD (devoid of putative sorting sequences) plus the peroxisomal APX C-terminal tail also sorted chloramphenicol acetyltransferase to peroxisomes via pER, indicating that the peroxisomal APX TMD does not possess essential sorting information. Instead, the TMD appears to confer the proper context required for the conserved positively charged domain to function within peroxisomal APX as an overlapping pER sorting signal and a membrane peroxisome targeting signal type 2.	Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Trelease, RN (corresponding author), Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA.							Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BANJOKO A, 1995, PLANT PHYSIOL, V107, P1201, DOI 10.1104/pp.107.4.1201; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Brideau AD, 1998, J VIROL, V72, P4560, DOI 10.1128/JVI.72.6.4560-4570.1998; Bunkelmann JR, 1996, PLANT PHYSIOL, V110, P589, DOI 10.1104/pp.110.2.589; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; DESILVESTRIS M, 1995, FEBS LETT, V370, P69, DOI 10.1016/0014-5793(95)00797-D; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dumas F, 1999, FEBS LETT, V458, P271, DOI 10.1016/S0014-5793(99)01148-5; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Egan B, 1999, FEBS LETT, V451, P243, DOI 10.1016/S0014-5793(99)00581-5; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Faber KN, 1998, MOL CELL BIOL, V18, P936, DOI 10.1128/MCB.18.2.936; Flynn CR, 1998, PLANT J, V16, P709, DOI 10.1046/j.1365-313x.1998.00344.x; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Imanaka T, 1996, J BIOL CHEM, V271, P3706; Isenmann S, 1998, MOL BIOL CELL, V9, P1649, DOI 10.1091/mbc.9.7.1649; Just WW, 1996, ANN NY ACAD SCI, V804, P60, DOI 10.1111/j.1749-6632.1996.tb18608.x; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; Kim PK, 1999, J BIOL CHEM, V274, P36876, DOI 10.1074/jbc.274.52.36876; Kim PK, 1997, BIOCHEMISTRY-US, V36, P8873, DOI 10.1021/bi970090t; Koller A, 1999, J CELL BIOL, V146, P99, DOI 10.1083/jcb.146.1.99; KUNCE CM, 1988, BIOCHEM J, V251, P147, DOI 10.1042/bj2510147; Kuroda R, 1998, J BIOL CHEM, V273, P31097, DOI 10.1074/jbc.273.47.31097; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee MS, 1997, PLANT CELL, V9, P185, DOI 10.1105/tpc.9.2.185; LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102; Mandic R, 1999, FEBS LETT, V451, P209, DOI 10.1016/S0014-5793(99)00551-7; MCCAMMON MT, 1994, J CELL BIOL, V124, P915, DOI 10.1083/jcb.124.6.915; Mullen RT, 1996, TRENDS PLANT SCI, V1, P389, DOI 10.1016/S1360-1385(96)80314-1; Mullen RT, 1999, PLANT CELL, V11, P2167, DOI 10.1105/tpc.11.11.2167; Mullen RT, 1997, PLANT J, V12, P313, DOI 10.1046/j.1365-313X.1997.12020313.x; Olsen LJ, 1998, PLANT MOL BIOL, V38, P163, DOI 10.1023/A:1006092830670; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; Pause B, 1997, FEBS LETT, V414, P95, DOI 10.1016/S0014-5793(97)00975-7; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; Salomons FA, 1997, FEBS LETT, V411, P133, DOI 10.1016/S0014-5793(97)00679-0; Sambrook J., 2002, MOL CLONING LAB MANU; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; Stroobants AK, 1999, FEBS LETT, V453, P210, DOI 10.1016/S0014-5793(99)00721-8; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Tabak HF, 1999, TRENDS CELL BIOL, V9, P447, DOI 10.1016/S0962-8924(99)01650-5; Titorenko VI, 1997, MOL CELL BIOL, V17, P5210, DOI 10.1128/MCB.17.9.5210; Titorenko VI, 1998, TRENDS BIOCHEM SCI, V23, P231, DOI 10.1016/S0968-0004(98)01226-2; Titorenko VI, 1998, MOL CELL BIOL, V18, P2789, DOI 10.1128/MCB.18.5.2789; Trelease RN, 1996, EUR J CELL BIOL, V71, P248; Tugal HB, 1999, PLANT PHYSIOL, V120, P309, DOI 10.1104/pp.120.1.309; Whitley P, 1996, J BIOL CHEM, V271, P7583, DOI 10.1074/jbc.271.13.7583; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Yamashita H, 1999, J BIOL CHEM, V274, P29897, DOI 10.1074/jbc.274.42.29897; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970	57	84	87	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16337	16344		10.1074/jbc.M001266200	http://dx.doi.org/10.1074/jbc.M001266200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748009	hybrid			2022-12-27	WOS:000087291400099
J	Tsunekawa, B; Wada, M; Ikeda, M; Banba, S; Kamachi, H; Tanaka, E; Honjo, M				Tsunekawa, B; Wada, M; Ikeda, M; Banba, S; Kamachi, H; Tanaka, E; Honjo, M			The binding between the stem regions of human growth hormone (GH) receptor compensates for the weaker site 1 binding of 20-kDa human GH (hGH) than that of 22-kDa hGH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; 20K HGH; DIMERIZATION; MUTAGENESIS; COMPLEX; VARIANT; PROLACTIN; AFFINITY; EPITOPE; DIFFERS	Despite the lower site 1 affinity of the 20-kDa human growh hormone (20K-hGH) for the hGH receptor (hGHR), 20K-hGH has the same hGHR-mediated activity as 22-kDa human GH (22K-hGH) at low hGH concentration and even higher activity at high hGH concentration. This study was performed to elucidate the reason why 20K-hGH can activate hGHR to the same level as 22K-hGH, To answer the question, we hypothesized that the binding between the stem regions of hGHR could compensate for the weaker site 1 binding of 20K-hGH than that of 22K-hGH in the sequential binding with hGHR, To demonstrate it, we prepared 15 types of alanine-substituted hGHR gene at the stem region and stably transfected them into Ba/F3 cells. Using these cells, we measured and compared the cell proliferation activities between 20K- and 22K-hGH. As a result, the activity of 20K-hGH was markedly reduced than that of 22K-hGH in three types of mutant hGHR (T147A, H150A, and Y200A). Regarding these mutants, the dissociation constant of hGH at the first and second step (KD1 and KD2) in the sequential binding with two hGHRs was predicted based on the mathematical cell proliferation model and computational simulation. Consequently, it was revealed that the reduction of the activity in 20K-hGH was attributed to the change of not KD1 but KD2. In conclusion, these findings support our hypothesis, which can account for the same potencies for activating hGHR between 20K- and 22K-hGH, although the site 1 affinity of 20K-hGH is lower than that of 22K-hGH.	Mitsui Chem Inc, Life Sci Lab, Pharmaceut Sect, Chiba 2970017, Japan; Mitsui Chem Inc, Life Sci Lab, Dept Comp Sci, Chiba 2970017, Japan	Mitsui Chemicals; Mitsui Chemicals	Wada, M (corresponding author), Mitsui Chem Inc, Life Sci Lab, Pharmaceut Sect, 1144 Togo, Chiba 2970017, Japan.							ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAUMANN G, 1991, ENDOCR REV, V12, P424, DOI 10.1210/edrv-12-4-424; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; Chen CM, 1997, J BIOL CHEM, V272, P5133, DOI 10.1074/jbc.272.8.5133; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUQUESNOY P, 1994, EMBO J, V13, P1386, DOI 10.1002/j.1460-2075.1994.tb06392.x; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; LEWIS UJ, 1978, J BIOL CHEM, V253, P2679; LEWIS UJ, 1980, BIOCHEM BIOPH RES CO, V92, P511, DOI 10.1016/0006-291X(80)90363-0; MASUDA N, 1988, BIOCHIM BIOPHYS ACTA, V949, P125, DOI 10.1016/0167-4781(88)90062-0; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pearce KH, 1999, BIOCHEMISTRY-US, V38, P81, DOI 10.1021/bi9817008; ROWLINSON SW, 1995, J BIOL CHEM, V270, P16833, DOI 10.1074/jbc.270.28.16833; Tsunekawa B, 1999, ENDOCRINOLOGY, V140, P3909, DOI 10.1210/en.140.9.3909; Tsushima T, 1999, J CLIN ENDOCR METAB, V84, P317, DOI 10.1210/jc.84.1.317; Uchida H, 1997, J BIOTECHNOL, V55, P101, DOI 10.1016/S0168-1656(97)00062-X; Uchida H, 1999, J MOL ENDOCRINOL, V23, P347, DOI 10.1677/jme.0.0230347; Wada M, 1997, MOL CELL ENDOCRINOL, V133, P99, DOI 10.1016/S0303-7207(97)00151-2; Wada M, 1998, MOL ENDOCRINOL, V12, P146, DOI 10.1210/mend.12.1.0054	27	9	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15652	15656		10.1074/jbc.M001236200	http://dx.doi.org/10.1074/jbc.M001236200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748003	hybrid			2022-12-27	WOS:000087291400009
J	Kwak, YT; Guo, J; Shen, J; Gaynor, RB				Kwak, YT; Guo, J; Shen, J; Gaynor, RB			Analysis of domains in the IKK alpha and IKK beta proteins that regulate their kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-KAPPA-B; SITE-SPECIFIC PHOSPHORYLATION; UBIQUITIN-PROTEASOME PATHWAY; SODIUM-SALICYLATE; ACTIVATION; COMPLEX; ASPIRIN; IDENTIFICATION; COMPONENT; MEKK1	The I kappa B kinases IKK alpha and IKK beta are critical in activating the NF-kappa B pathway. Although these proteins have a similar structure that includes kinase, leucine zipper, and helix-loop-helix domains, they exhibit marked differences in their kinase activity and functional properties. For example, IKK beta has a 10-20-fold higher level of kinase activity for I kappa B alpha than does IKK alpha. Furthermore, disruption of the murine IKK beta gene, but not the IKK alpha gene, results in severe defects in activating the NF-kappa B pathway. Mice lacking IKK beta succumb to severe hepatic apoptosis because of failure to activate the NF-kappa B pathway, whereas mice deficient in IKK alpha exhibit skin and skeletal abnormalities and an embryonic lethal phenotype. To better characterize differences in the functional properties of these kinases, hybrid IKK proteins were constructed by domain swapping, and their kinase activity was assayed. These studies demonstrated that differences in the IKK alpha and IKK beta helix-loop-helix domains are primarily responsible for differences in their kinase activity. In contrast, their kinase and leucine zipper domains exhibited relatively conserved function. These studies further define the properties of IKK alpha and IKK beta, which are involved in their unique regulatory roles.	Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DUGGAN DE, 1977, J PHARMACOL EXP THER, V201, P8; DUGGAN DE, 1980, DRUG METAB DISPOS, V8, P241; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SHEN TY, 1977, ADV DRUG RES, V12, P190; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	47	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14752	14759		10.1074/jbc.M001039200	http://dx.doi.org/10.1074/jbc.M001039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10747982	hybrid			2022-12-27	WOS:000087006900099
J	Kim-Kaneyama, JR; Nose, K; Shibanuma, M				Kim-Kaneyama, JR; Nose, K; Shibanuma, M			Significance of nuclear relocalization of ERK1/2 in reactivation of c-fos transcription and DNA synthesis in senescent fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX-FORMATION; ACTIVATED PROTEIN-KINASE; SERUM RESPONSE FACTOR; MAP KINASE; EXPORT SIGNAL; HUMAN-CELLS; IN-VIVO; PHOSPHORYLATION; TRANSLOCATION; REPRESSION	Two of mitogen-activated protein kinases (MAPK) p44(mapk)/p42(mapk) extracellular signal-regulated kinases (ERK1/2), translocate into nuclei following activation and play critical roles in connecting the signal to gene expression and allowing cell-cycle entry. Here we found that the nuclear translocation of ERK1/2 in response to growth stimuli was significantly inhibited in senescent cells that were irreversibly growth arrested, compared with presenescent cells. The activation step of these enzymes was not impaired, since ERK1/2 were phosphorylated and activated in senescent cells as efficiently as in presenescent cells. By elaborately localizing ERK2 in the nuclei of senescent cells, we could restore c-fos transcriptional activity upon growth stimuli, which was repressed in senescent cells. Furthermore, the nuclear localization of ERK1/2 has been suggested to potentiate the proliferative activity of the senescent cells in collaboration with adenovirus E1A protein. More importantly, SV40 large T antigen, the strong inducer of DNA synthesis, had the inherent ability to restore nuclear relocalization of active ERK1/2 in senescent cells, which was essentially required for the reinitiation of DNA synthesis. Thus, manipulating the relocalization of ERK1/2 into nuclei was expected to open the way to overcome some of the senescent phenotypes.	Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Tokyo 1428555, Japan	Showa University	Shibanuma, M (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Hatanodai 1-5-8, Tokyo 1428555, Japan.							Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ATADJA PW, 1994, MOL CELL BIOL, V14, P4991, DOI 10.1128/MCB.14.7.4991; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEDRANO EE, 1994, MOL BIOL CELL, V5, P497, DOI 10.1091/mbc.5.4.497; NAKAJIMA T, 1992, MOL CELL BIOL, V12, P2837, DOI 10.1128/MCB.12.6.2837; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Stein GH, 1999, MOL CELL BIOL, V19, P2109; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	34	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20685	20692		10.1074/jbc.M908723199	http://dx.doi.org/10.1074/jbc.M908723199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10748101	hybrid			2022-12-27	WOS:000088084500066
J	Zhang, WQ; Geiman, DE; Shields, JM; Dang, DYT; Mahatan, CS; Kaestner, KH; Biggs, JR; Kraft, AS; Yang, VW				Zhang, WQ; Geiman, DE; Shields, JM; Dang, DYT; Mahatan, CS; Kaestner, KH; Biggs, JR; Kraft, AS; Yang, VW			The cut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21(WAF1/Cip1) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; CYCLIN-DEPENDENT KINASES; WAF1/CIP1 GENE PROMOTER; TRANSCRIPTION FACTOR; CELL-GROWTH; DNA-DAMAGE; SP1 SITES; BINDING; EXPRESSION; INHIBITOR	An important mechanism by which the tumor suppressor p53 maintains genomic stability is to induce cell cycle arrest through activation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene. We show that the gene encoding the gut-enriched Kruppel-like factor (GKLF, KLF4) is concurrently induced with p21(WAF1/Cip1) during serum deprivation and DNA damage elicited by methyl methanesulfonate. The increases in expression of both Gklf and p21(WAF1/Cip1) due to DNA damage are dependent on p53. Moreover, during the first 30 min of methyl methanesulfonate treatment, the rise in Gklf mRNA level precedes that in p21(WAF1/Cip1), suggesting that GKLF may be involved in the induction of p21(WAF1/Cip1),pl Indeed, GKLF activates p21(WAF1/Cip1) through a specific Spl-like cis-element in the p21(WAF1/Cip1) proximal pro meter. The same element is also required by p53 to activate the p21(WAF1/Cip1) promoter, although p53 does not bind to it. Potential mechanisms by which p53 activates the p21(WAF1/Cip1) promoter include a physical interaction between p53 and GKLF and the transcriptional induction of Gklf by p53. Consequently, the two transactivators cause a synergistic induction of the p21(WAF1/Cip1) promoter activity. The physiological relevance of GKLF in mediating p53-dependent induction of p21(WAF1/Cip1) is demonstrated by the ability of antisense Gklf oligonucleotides to block the production of p21(WAF1/Cip1) in response to p53 activation. These findings suggest that GKLF is an essential mediator of p53 in the transcriptional induction of p21(WAF1/Cip1) and may be part of a novel pathway by which cellular responses to stress are modulated.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Colorado, Hlth Sci Ctr, Dept Med Oncol, Denver, CO 80262 USA	Johns Hopkins University; Johns Hopkins University; University of Pennsylvania; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Yang, VW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Ross 918,720 Rutland Ave, Baltimore, MD 21205 USA.				NCI NIH HHS [R01 CA084197-09, R01 CA084197-01, R01 CA084197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Eckner R, 1996, BIOL CHEM, V377, P685; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Howe L, 1999, CRIT REV EUKAR GENE, V9, P231, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.80; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; Modiano JF, 1999, DNA CELL BIOL, V18, P357, DOI 10.1089/104454999315259; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Panigada M, 1999, MECH DEVELOP, V81, P103, DOI 10.1016/S0925-4773(98)00237-8; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; von Kleist S, 1975, J Natl Cancer Inst, V55, P555; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	65	278	295	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18391	18398		10.1074/jbc.C000062200	http://dx.doi.org/10.1074/jbc.C000062200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10749849	Green Accepted, hybrid			2022-12-27	WOS:000087659400066
J	Courilleau, D; Chastre, E; Sabbah, M; Redeuilh, G; Atfi, A; Mester, J				Courilleau, D; Chastre, E; Sabbah, M; Redeuilh, G; Atfi, A; Mester, J			B-ind1, a novel mediator of Rac1 signaling cloned from sodium butyrate-treated fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; PROGESTERONE-RECEPTOR; DIFFERENTIAL DISPLAY; HISTONE DEACETYLASE; CYCLIN D1; PROTEINS; GROWTH; INHIBITION; APOPTOSIS; GTPASES	Sodium butyrate is a multifunctional agent known to inhibit cell proliferation and to induce differentiation by modulating transcription. We have performed differential display analysis to identify transcriptional targets of sodium butyrate in Balb/c BP-A31 mouse fibroblasts. A novel butyrate-induced transcript B-ind1 has been cloned by this approach. The human homologue of this transcript contains an open reading frame that codes for a protein of 370 amino acids without known functional motifs, In transfected cells, the B-ind1 protein has been found to potentiate different effects of the small GTPase Rad, such as c-Jun N-terminal kinase activation and transcriptional activity of nuclear factor kappa B (NF-kappa B), In addition, we have demonstrated that B-ind1 forms complexes with the constitutively activated Rad protein, To investigate the role of B-ind1 in Rad signaling, we have constructed several deletion mutants of B-ind1 and tested their ability to affect the activation of NF-kappa B by Rad. Interestingly, the fragment encoding the median region of human B-ind1 acted as a dominant-negative variant to block Rad-mediated NF-kappa B activity. These data define B-ind1 as a novel component of Rac1-signaling pathways leading to the modulation of gene expression.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Mester, J (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.		CHASTRE, Eric/L-8446-2018	CHASTRE, Eric/0000-0002-8993-1228; SABBAH, Michele/0000-0001-5368-9022				Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BuquetFagot C, 1996, J CELL PHYSIOL, V166, P631, DOI 10.1002/(SICI)1097-4652(199603)166:3<631::AID-JCP18>3.0.CO;2-9; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HEERDT BG, 1994, CANCER RES, V54, P3288; HERUTH DP, 1993, J BIOL CHEM, V268, P20466; Janson W, 1997, ONCOGENE, V15, P1395, DOI 10.1038/sj.onc.1201304; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Salminen A, 1998, MOL BRAIN RES, V61, P203, DOI 10.1016/S0169-328X(98)00210-1; SMITH DF, 1990, J BIOL CHEM, V265, P3996; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Uwanogho DA, 1999, GENOMICS, V62, P406, DOI 10.1006/geno.1999.5950; VanLint C, 1996, GENE EXPRESSION, V5, P245; YEIVIN A, 1992, GENE, V116, P159, DOI 10.1016/0378-1119(92)90511-M; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	30	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17344	17348		10.1074/jbc.M000887200	http://dx.doi.org/10.1074/jbc.M000887200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747961	hybrid			2022-12-27	WOS:000087485000020
J	Crechet, JB; Jacquet, E; Bernardi, A; Parmeggiani, A				Crechet, JB; Jacquet, E; Bernardi, A; Parmeggiani, A			Analysis of the role of the hypervariable region of yeast Ras2p and its farnesylation in the interaction with exchange factors and adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GTPASE-ACTIVATING PROTEIN; SWITCH-II REGION; SACCHAROMYCES-CEREVISIAE; CATALYTIC DOMAIN; CDC25 GENE; POSTTRANSLATIONAL MODIFICATION; DOWNSTREAM EFFECTORS; PLASMA-MEMBRANE; WILD-TYPE	Ras proteins from Saccharomyces cerevisiae differ from mammalian Ha-Ras in their extended C-terminal hypervariable region. We have analyzed the function of this region and the effect of its farnesylation with respect to the action of the GDP/GTP exchange factors (GEFs) Cdc25p and Sdc25p and the target adenylyl cyclase, Whereas Ras2p farnesylation had no effect on the interaction with purified GEFs from the Cdc25 family, this modification became a strict requirement for stimulation of the nucleotide exchange on Res using reconstituted cell-free systems with GEFs bound to the cell membrane. Determination of GEF effects showed that in cell membrane the Cdc25p dependent activity on Ras2p was predominant over that of Sdc25p. In contrast to full-length GEFs, a membrane-bound C-terminal region containing the catalytic domain of Cdc25p was still able to react productively with unfarnesylated Ras2p, These results indicate that in membrane-bound full-length GEF the N-terminal moiety regulates the interaction between catalytic domain and farnesylated Ras2p.GDP. Differently from GEF, full activation of adenylyl cyclase did not require farnesylation of Ras2p GTP, even if this step of maturation was found to facilitate the interaction. The use of Ha-Ras/Ras2p chimaeras of different length emphasized the key role of the hypervariable region of Ras2p in inducing maximum activation of adenylyl cyclase and for a productive interaction with membrane-bound GEF.	Ecole Polytech, Grp Biophys, Equine 2, F-91128 Palaiseau, France; CNRS, UPR 9034, F-91198 Gif Sur Yvette, France	Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Parmeggiani, A (corresponding author), Ecole Polytech, Grp Biophys, Equine 2, F-91128 Palaiseau, France.	andrea@pmc.polytechnique.fr		JACQUET, Eric/0000-0001-6366-8436				Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BoyMarcotte E, 1996, MOL BIOL CELL, V7, P529, DOI 10.1091/mbc.7.4.529; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; CRECHET JB, 1993, J BIOL CHEM, V268, P14836; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; DAMAK F, 1991, MOL CELL BIOL, V11, P202, DOI 10.1128/MCB.11.1.202; DEVENDITTIS E, 1986, EMBO J, V5, P3657, DOI 10.1002/j.1460-2075.1986.tb04696.x; Dudler T, 1996, J BIOL CHEM, V271, P11541, DOI 10.1074/jbc.271.19.11541; ENGELBERG D, 1990, EMBO J, V9, P641, DOI 10.1002/j.1460-2075.1990.tb08156.x; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FEGER G, 1991, EMBO J, V10, P349, DOI 10.1002/j.1460-2075.1991.tb07956.x; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FRASCOTTI G, 1991, BIOCHIM BIOPHYS ACTA, V1089, P206, DOI 10.1016/0167-4781(91)90009-B; Freeman NL, 1996, MOL CELL BIOL, V16, P548; Garreau H, 1996, BIOL CELL, V86, P93, DOI 10.1016/0248-4900(96)84771-X; GROSS E, 1992, MOL CELL BIOL, V12, P2653, DOI 10.1128/MCB.12.6.2653; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUET E, 1994, BIOCHEM BIOPH RES CO, V199, P497, DOI 10.1006/bbrc.1994.1256; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL MS, 1988, MOL CELL BIOL, V8, P52, DOI 10.1128/MCB.8.1.52; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MATSUMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2355, DOI 10.1073/pnas.79.7.2355; MAYER MP, 1993, GENE, V132, P41, DOI 10.1016/0378-1119(93)90512-2; MCGEADY P, 1995, J BIOL CHEM, V270, P26347, DOI 10.1074/jbc.270.44.26347; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; MUNDER T, 1989, FEBS LETT, V242, P341, DOI 10.1016/0014-5793(89)80498-3; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Ohnishi M, 1998, J BIOL CHEM, V273, P10210, DOI 10.1074/jbc.273.17.10210; Okada T, 1996, J BIOL CHEM, V271, P4671; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; PARMEGGIANI A, 1993, RAS SUPERFAMILIES GT, P467; Parrini MC, 1996, EMBO J, V15, P1107, DOI 10.1002/j.1460-2075.1996.tb00448.x; POMPON D, 1989, GENE, V83, P15, DOI 10.1016/0378-1119(89)90399-5; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; POULLET P, 1995, EUR J BIOCHEM, V227, P537, DOI 10.1111/j.1432-1033.1995.tb20421.x; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SHERMAN F, 1986, LAB COURSE MANUAL ME, P61; Shima F, 1997, MOL CELL BIOL, V17, P1057, DOI 10.1128/MCB.17.3.1057; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; TAMANOI F, 1988, BIOCHIM BIOPHYS ACTA, V948, P1, DOI 10.1016/0304-419X(88)90002-9; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303	68	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17754	17761		10.1074/jbc.M000729200	http://dx.doi.org/10.1074/jbc.M000729200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747953	hybrid			2022-12-27	WOS:000087485000076
J	Montgomery, RB; Guzman, J; O'Rourke, DM; Stahl, WL				Montgomery, RB; Guzman, J; O'Rourke, DM; Stahl, WL			Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE CARCINOMA-CELLS; EGF RECEPTOR; HUMAN GLIOBLASTOMA; BREAST-CANCER; OVARIAN-CARCINOMA; MESSENGER-RNAS; CLASS-II; TAXOL; GENE; AMPLIFICATION	Oncogenic transformation confers resistance to chemotherapy through a variety of mechanisms, including suppression of apoptosis, increased drug metabolism, and modification of target proteins, Oncogenic epidermal growth factor receptor family members, including EGFRvIII and HER2, are expressed in a broad spectrum of human malignancies. Cell lines transfected with EGFRvIII and HER2 are more resistant to paclitaxel-mediated cytotoxicity, and tubulin polymerization induced by paclitaxel is suppressed compared with cells expressing wild type epidermal growth factor receptor, Because differential expression of beta-tubulin isotypes has been proposed to modulate paclitaxel resistance, we analyzed beta-tubulin isotypes expressed in cell lines transfected with different oncogenes, EGFRvIII- and HER2-expressing cells demonstrated equivalent total beta-tubulin protein compared with cells transfected with wild type receptor or untransfected controls. EGFRvIII-expressing cells demonstrated increases in class Na (2.5-fold) and IVb (3.1-fold) mRNA, and HERB-expressing cells showed increases in class Na (2.95-fold) mRNA. Expression of oncogenic Ha-Ras did not change class IV RNA levels significantly. Inhibition of EGFRvIII kinase activity using a mutant allele with an inactivating mutation in the kinase domain decreased expression of class Na by 50% and partially reversed resistance to paclitaxel, Expression of oncogenic epidermal growth factor receptor family members is associated with modulation of both beta-tubulin isotype expression and paclitaxel resistance in cells transformed by expression of the receptor. This effect on tubulin expression may modulate drug resistance in human malignancies that express these oncogenes.	Univ Washington, Vet Affairs Puget Sound HSC 111ONC, Div Oncol, Dept Med, Seattle, WA 98108 USA; Univ Washington, Vet Affairs Puget Sound HSC 111ONC, Dept Oncol, Seattle, WA 98108 USA; Univ Washington, Vet Affairs Puget Sound HSC 111ONC, Dept Physiol, Seattle, WA 98108 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Pennsylvania	Montgomery, RB (corresponding author), Univ Washington, Vet Affairs Puget Sound HSC 111ONC, Div Oncol, Dept Med, 1660 S COlumbian Way, Seattle, WA 98108 USA.		O'Rourke, Donald/AAC-3376-2021	O'Rourke, Donald/0000-0002-8479-7314	NCI NIH HHS [CA60782] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA060782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHURSKI CJ, 1994, MOL CELL BIOL, V14, P4076, DOI 10.1128/MCB.14.6.4076; Blade K, 1999, J CELL SCI, V112, P2213; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASSONVILLE O, 1993, J CLIN ONCOL, V11, P1873, DOI 10.1200/JCO.1993.11.10.1873; Derry WB, 1997, BIOCHEMISTRY-US, V36, P3554, DOI 10.1021/bi962724m; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Dumontet C, 1996, CELL MOTIL CYTOSKEL, V35, P49, DOI 10.1002/(SICI)1097-0169(1996)35:1<49::AID-CM4>3.0.CO;2-D; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; FischerColbrie J, 1997, ANTICANCER RES, V17, P613; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Goldspiel B.R., 1997, PHARMACOTHERAPY, V17, P110; Haber M, 1995, J BIOL CHEM, V270, P31269, DOI 10.1074/jbc.270.52.31269; HIRONO Y, 1995, ONCOLOGY, V52, P182; Horwitz S. B., 1994, ANN ONCOL, V5, pS3, DOI DOI 10.1093/ANN0NC/5.SUPPL_4.S3; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; Hung MC, 1999, SEMIN ONCOL, V26, P51; HURTT MR, 1992, J NEUROPATH EXP NEUR, V51, P84, DOI 10.1097/00005072-199201000-00010; Jaffrezou JP, 1995, ONCOL RES, V7, P517; JINNO Y, 1988, NUCLEIC ACIDS RES, V16, P4957, DOI 10.1093/nar/16.11.4957; JOSHI HC, 1990, CELL MOTIL CYTOSKEL, V16, P159, DOI 10.1002/cm.970160302; Kavallaris M, 1999, BRIT J CANCER, V80, P1020, DOI 10.1038/sj.bjc.6690507; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KLIJN JGM, 1993, CANCER SURV, V18, P165; Kremser T, 1999, DEV BIOL, V216, P327, DOI 10.1006/dbio.1999.9425; LONG B, 1992, BRIT J CANCER, V65, P865, DOI 10.1038/bjc.1992.182; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Montgomery RB, 1997, BIOCHEM BIOPH RES CO, V232, P111, DOI 10.1006/bbrc.1997.6237; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Narishige T, 1999, J BIOL CHEM, V274, P9692, DOI 10.1074/jbc.274.14.9692; NICHOLSON S, 1989, LANCET, V1, P182; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; OBLINGER MM, 1994, DEV BRAIN RES, V77, P45, DOI 10.1016/0165-3806(94)90212-7; PORTERJORDAN K, 1994, HEMATOL ONCOL CLIN N, V8, P73, DOI 10.1016/S0889-8588(18)30188-6; Qian XL, 1996, ONCOGENE, V13, P2149; Ranganathan S, 1998, BRIT J CANCER, V77, P562, DOI 10.1038/bjc.1998.91; Ranganathan S, 1996, CANCER RES, V56, P2584; SCAMBIA G, 1995, BRIT J CANCER, V72, P361, DOI 10.1038/bjc.1995.339; SCHLEGEL J, 1994, INT J CANCER, V56, P72; Serrano N, 1997, DEVELOPMENT, V124, P2527; SISODIA S S, 1990, New Biologist, V2, P66; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; VANDAM PA, 1994, J CLIN PATHOL, V47, P914, DOI 10.1136/jcp.47.10.914; VEALE D, 1993, BRIT J CANCER, V68, P162, DOI 10.1038/bjc.1993.306; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4	53	97	110	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17358	17363		10.1074/jbc.M000966200	http://dx.doi.org/10.1074/jbc.M000966200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10749863	hybrid			2022-12-27	WOS:000087485000022
J	Weisshart, K; Forster, H; Kremmer, E; Schlott, B; Grosse, F; Nasheuer, HP				Weisshart, K; Forster, H; Kremmer, E; Schlott, B; Grosse, F; Nasheuer, HP			Protein-protein interactions of the primase subunits p58 and p48 with simian virus 40 T antigen are required for efficient primer synthesis in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ALPHA; SINGLE-STRANDED-DNA; REPLICATION IN-VITRO; SPECIES-SPECIFIC REPLICATION; BINDING-PROTEIN; MONOCLONAL-ANTIBODIES; SV40 ORIGIN; DROSOPHILA-MELANOGASTER; TOPOISOMERASE-I; CALF THYMUS	DNA polymerase cu-primase (pol-prim, consisting of p180-p68-p58-p48), and primase p58-p48 (prim(2)) synthesize short RNA primers on single-stranded DNA. In the SV40 DNA replication system, only pol-prim is able to start leading strand DNA replication that needs unwinding of double-stranded (ds) DNA prior to primer synthesis. At high concentrations, pol-prim and prim, indistinguishably reduce the unwinding of dsDNA by SV40 T antigen (Tag), RNA primer synthesis on ssDNA in the presence of replication protein A (RPA) and Tag has served as a model system to study the initiation of Okazaki fragments on the lagging strand in vitro, On ssDNA, Tag stimulates whereas RPA inhibits the initiation reaction of both enzymes. Tag reverses and even overcompensates the inhibition of primase by RPA, Physical binding of Tag to the primase subunits and RPA, respectively, is required for these activities. Each subunit of the primase complex, p58 and p48, performs physical contacts with Tag and RPA independently of p180 and p68, Using surface plasmon resonance, the dissociation constants of the Tag/pol-prim and Tag/primase interactions were 1.2 . 10(-8) M and 1.3 . 10(-8) M, respectively.	Inst Mol Biotechnol eV, Biochem Abt, D-07745 Jena, Germany; GSF Munich, Inst Mol Immunol, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Nasheuer, HP (corresponding author), Inst Mol Biotechnol eV, Biochem Abt, Beutenbergstr 11, D-07745 Jena, Germany.	nasheuer@mb-jena.de	Nasheuer, Heinz P./B-9025-2008	Nasheuer, Heinz Peter/0000-0002-9218-9079				ATRAZHEV A, 1992, EUR J BIOCHEM, V210, P855, DOI 10.1111/j.1432-1033.1992.tb17489.x; BAKKENIST CJ, 1994, J BIOL CHEM, V269, P26759; BISWAS EE, 1987, BIOCHEMISTRY-US, V26, P5377, DOI 10.1021/bi00391a024; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRUCKNER A, 1995, MOL CELL BIOL, V15, P1716; BRUSH GS, 1996, DNA REPLICATION EUKA, P1; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; CLARK R, 1981, J BIOL CHEM, V256, P1854; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; COPELAND WC, 1993, J BIOL CHEM, V268, P26179; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; EKI T, 1992, J BIOL CHEM, V267, P7284; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GROSSE F, 1985, J BIOL CHEM, V260, P1881; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; Han YF, 1999, J VIROL, V73, P4899, DOI 10.1128/JVI.73.6.4899-4907.1999; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harlow E., 1988, ANTIBODIES LAB MANUA; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Huang SG, 1998, BIOCHEMISTRY-US, V37, P15345, DOI 10.1021/bi9810959; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; KAGUNI LS, 1983, J BIOL CHEM, V258, P9037; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; Kolpashchikov DM, 1999, FEBS LETT, V450, P131, DOI 10.1016/S0014-5793(99)00484-6; Kornberg A., 1992, DNA REPLICATION; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LI JJ, 1995, CURR BIOL, V5, P472, DOI 10.1016/S0960-9822(95)00094-7; Lisby M, 1998, BIOCHEMISTRY-US, V37, P10815, DOI 10.1021/bi980757r; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; MOLE SE, 1987, PHILOS T ROY SOC B, V317, P455, DOI 10.1098/rstb.1987.0072; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; NASHEUER HP, 1992, CHROMOSOMA, V102, pS52, DOI 10.1007/BF02451786; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; SALAS M, 1996, DNA REPLICATION EUKA, P131; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTOCANALE C, 1993, J BIOL CHEM, V268, P1343; Schneider A, 1998, J BIOL CHEM, V273, P21608, DOI 10.1074/jbc.273.34.21608; SCHNEIDER C, 1994, MOL CELL BIOL, V14, P3176, DOI 10.1128/MCB.14.5.3176; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; Simmons DT, 1998, VIROLOGY, V242, P435, DOI 10.1006/viro.1997.9024; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Stadlbauer F, 1996, MOL CELL BIOL, V16, P94; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; THOMMES P, 1990, EUR J BIOCHEM, V194, P699, DOI 10.1111/j.1432-1033.1990.tb19460.x; Voitenleitner C, 1997, ONCOGENE, V14, P1611, DOI 10.1038/sj.onc.1200975; Voitenleitner C, 1999, MOL CELL BIOL, V19, P646; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Walther AP, 1999, NUCLEIC ACIDS RES, V27, P656, DOI 10.1093/nar/27.2.656; WANG TSF, 1996, DNA REPLICATION EUKA, P461; Weisshart K, 1998, J VIROL, V72, P9771, DOI 10.1128/JVI.72.12.9771-9781.1998; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189	76	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17328	17337		10.1074/jbc.M000717200	http://dx.doi.org/10.1074/jbc.M000717200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747950	hybrid			2022-12-27	WOS:000087485000018
J	Rajan, S; Wischmeyer, E; Liu, GX; Muller, RP; Daut, J; Karschin, A; Derst, C				Rajan, S; Wischmeyer, E; Liu, GX; Muller, RP; Daut, J; Karschin, A; Derst, C			TASK-3, a novel tandem pore domain acid-sensitive K+ channel - An extracellular histidine as pH sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; OUTWARD RECTIFIER; ELEGANS GENOME; CLONING; IDENTIFICATION; LOCALIZATION; SUBUNITS; FAMILY; KIDNEY	Tandem pore domain acid-sensitive K+ channel 3 (TASK-3) is a new member of the tandem pore domain potassium channel family. A cDNA encoding a 365-amino acid polypeptide with four putative transmembrane segments and two pore regions was isolated from guinea pig brain. An orthologous sequence was cloned hom a human genomic library. Although TASK-3 is 62% identical to TASK-1, the cytosolic C-terminal sequence is only weakly conserved. Analysis of the gene structure identified an intron within the conserved GYG motif of the first pore region. Reverse transcriptase-polymerase chain reaction analysis showed strong expression in brain but very weak mRNA levels in other tissues. Cell-attached patch-clamp recordings of TASK-3 expressed in HER293 cells showed that the single channel current-voltage relation was inwardly rectifying, and open probability increased markedly with depolarization. Removal of external divalent cations increased the mean single channel current measured at -100 mV from -2.3 to -5.8 pA. Expression of TASK-3 in Xenopus oocytes revealed an outwardly rectifying RC current that was strongly decreased in the presence of lower extracellular pH. Substitution of the histidine residue His-98 by asparagine or tyrosine abolished pH sensitivity. This histidine, which is located at the outer part of the pore adjacent to the selectivity filter, may be an essential component of the extracellular pH sensor.	Univ Marburg, Inst Normale & Pathol Physiol, D-35037 Marburg, Germany; Max Planck Inst Biophys Chem, Dept Mol Neurobiol Signal Transduct, D-37070 Gottingen, Germany	Philipps University Marburg; Max Planck Society	Daut, J (corresponding author), Univ Marburg, Inst Physiol, Deutschhausstr 2, D-35037 Marburg, Germany.	daut@mailer.uni-marburg.de						Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; Czempinski K, 1997, EMBO J, V16, P2565, DOI 10.1093/emboj/16.10.2565; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Goldstein SAN, 1998, J MOL MED-JMM, V76, P13, DOI 10.1007/s109-1998-8100-0; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; HORN R, 1983, BIOPHYS J, V43, P207, DOI 10.1016/S0006-3495(83)84341-0; JACKSON MB, 1985, BIOPHYS J, V47, P129, DOI 10.1016/S0006-3495(85)83886-8; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; Kim Y, 1999, AM J PHYSIOL-HEART C, V277, pH1669, DOI 10.1152/ajpheart.1999.277.5.H1669; Kindler CH, 1999, ANESTHESIOLOGY, V90, P1092, DOI 10.1097/00000542-199904000-00024; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; POUTNEY DJ, 1999, FEBS LETT, V450, P191; RAJAN S, 2000, PFLUG ARCH EUR J PHY, V439, pR382; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Salinas M, 1999, J BIOL CHEM, V274, P11751, DOI 10.1074/jbc.274.17.11751; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; Wang ZW, 1999, ANN NY ACAD SCI, V868, P286, DOI 10.1111/j.1749-6632.1999.tb11294.x; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8	32	255	272	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16650	16657		10.1074/jbc.M000030200	http://dx.doi.org/10.1074/jbc.M000030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747866	Green Published, hybrid			2022-12-27	WOS:000087392200037
J	Burch, WL; Herscovitz, H				Burch, WL; Herscovitz, H			Disulfide bonds are required for folding and secretion of apolipoprotein B regardless of its lipidation state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; CONTAINING LIPOPROTEIN PARTICLES; LOW-DENSITY LIPOPROTEIN; ENDOPLASMIC-RETICULUM; APO-B; QUALITY-CONTROL; HEPG2 CELLS; DEGRADATION; EXPRESSION; PROTEASOME	Apolipoprotein (apo) B-100, an essential protein for the assembly and secretion of very low density lipoproteins depends on lipid binding (lipidation) for its secretion. Seven of its 8 disulfides are clustered within the N-terminal 21%. The role of these disulfides in the secretion of lipidated or unlipidated truncated forms of apoB was studied in C127 cells expressing apoB-17, apoB-29, or apoB-41. These cells do not express microsomal triglyceride transfer protein yet secrete apoB-17 on triacylglycerol-rich lipoproteins while apoB-29 and apoB-17 are secreted with little or no lipid, respectively. Dithiothreitol utilized in pulse-chase studies prevented the cotranslational formation of disulfides and when added posttranslationally reduced native disulfides. As a result, the secretion of reduced apoB forms was blocked and they were retained in the cells. Reduced apoB polypeptides were rescued following removal of dithiothreitol, as they underwent post-translational disulfide bonding, attained their mature form, and were subsequently secreted. Together the data suggest that in C127 cells the formation of native disulfides is critical for the folding and secretion of apoB independent of its length, its requirement for lipidation or microsomal triglyceride transfer protein expression. Therefore, these cells provide an appropriate model to study the folding of apoB in great detail.	Boston Univ, Sch Med, Dept Biophys, Ctr Adv Biomed Res, Boston, MA 02118 USA	Boston University	Herscovitz, H (corresponding author), Boston Univ, Sch Med, Dept Biophys, Ctr Adv Biomed Res, 715 Albany St, Boston, MA 02118 USA.			Herscovitz, Haya/0000-0001-8067-6091	NHLBI NIH HHS [HL-58833-03, HL-26335-19] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058833, P01HL026335, R29HL058833] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BOREN J, 1992, J BIOL CHEM, V267, P9858; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DIXON JL, 1993, J LIPID RES, V34, P167; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; Hamilton RL, 1998, J LIPID RES, V39, P1543; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HERSCOVITZ H, 1995, P NATL ACAD SCI USA, V92, P659, DOI 10.1073/pnas.92.3.659; HERSCOVITZ H, 1992, J LIPID RES, V33, P791; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; Huang XF, 1997, J BIOL CHEM, V272, P31872, DOI 10.1074/jbc.272.50.31872; Hussain MM, 1996, BBA-LIPID LIPID MET, V1300, P151, DOI 10.1016/0005-2760(96)00041-0; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAMSA E, 1994, YEAST, V10, P355, DOI 10.1002/yea.320100308; KANE JP, 1995, METABOLIC MOL BASES, P1853; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; LINTON MF, 1993, J LIPID RES, V34, P521; Luz J M, 1996, EXS, V77, P97; Macri J, 1997, ARTERIOSCL THROM VAS, V17, P2982, DOI 10.1161/01.ATV.17.11.2982; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; Nicodeme E, 1999, J BIOL CHEM, V274, P1986, DOI 10.1074/jbc.274.4.1986; Nolte RT, 1994, THESIS BOSTON U; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Rehberg EF, 1996, J BIOL CHEM, V271, P29945, DOI 10.1074/jbc.271.47.29945; Rustaeus S, 1999, J NUTR, V129, p463S, DOI 10.1093/jn/129.2.463S; Sakata N, 1999, BBA-MOL CELL BIOL L, V1437, P71, DOI 10.1016/S1388-1981(98)00006-7; SCHONFELD G, 1995, ANNU REV NUTR, V15, P23, DOI 10.1146/annurev.nu.15.070195.000323; Segrest JP, 1999, J LIPID RES, V40, P1401; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Shelness GS, 1996, J LIPID RES, V37, P408; SMALL DM, 1997, CIRCULATION, V96, P1; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SVENSSON L, 1994, J VIROL, V68, P5204, DOI 10.1128/JVI.68.8.5204-5215.1994; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; Tatu U, 1999, BIOSCIENCE REP, V19, P189, DOI 10.1023/A:1020225803282; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wu XJ, 1997, J BIOL CHEM, V272, P11575; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YAO ZM, 1991, J BIOL CHEM, V266, P3300; Yao ZM, 1997, J LIPID RES, V38, P1937; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	62	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16267	16274		10.1074/jbc.M000446200	http://dx.doi.org/10.1074/jbc.M000446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747912	hybrid			2022-12-27	WOS:000087291400089
J	Dickson, KS; Burns, CM; Richardson, JP				Dickson, KS; Burns, CM; Richardson, JP			Determination of the free-energy change for repair of a DNA phosphodiester bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGASE	The repair of phosphodiester bonds in nicked DNA is catalyzed by DNA ligases, Ligation is coupled to cleavage of a phosphoanhydride bond in a nucleotide cofactor resulting in a thermodynamically favorable process. A free energy value for phosphodiester bond formation was calculated using the reversibility of the T4 DNA ligase reaction. The relative number of DNA nicks to phosphodiester bonds in a circular plasmid DNA, formed during this reaction at fixed concentrations of ATP to AMP and PP,, was quantified. At 25 degrees C, pH 7, the equilibrium constant (K-eq) for the ligation reaction is 3.89 x 10(4) M. This value corresponds to a standard free energy (Delta G degrees') of -6.3 kcal mol(-1). By subtracting the known energy contribution due to hydrolysis of ATP to AMP and PPi, Delta G degrees' for the hydrolysis of a DNA phosphodiester bond is -5.3 kcal mol(-1).	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Richardson, JP (corresponding author), Indiana Univ, Dept Chem, 800 E Kirkwood Ave, Bloomington, IN 47405 USA.				NIGMS NIH HHS [GM 56095] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; BURNS CM, 1995, P NATL ACAD SCI USA, V92, P4738, DOI 10.1073/pnas.92.11.4738; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; Dillon J. R., 1985, RECOMBINANT DNA METH, P1; Engler M., 1982, ENZYMES, V5, P3; FREY PA, 1995, BIOCHEMISTRY-US, V34, P11307, DOI 10.1021/bi00036a001; JENCKS WP, 1970, HDB BIOCH, P4181; KATO KI, 1967, J BIOL CHEM, V242, P2780; LEHMAN IR, 1974, SCIENCE, V186, P790; LEHNINGER AL, 1993, PRINCIPLES BIOCH, P359; MODRICH P, 1972, J BIOL CHEM, V247, P6370; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x	13	52	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15828	15831		10.1074/jbc.M910044199	http://dx.doi.org/10.1074/jbc.M910044199			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748184	hybrid			2022-12-27	WOS:000087291400031
J	Lenarcic, B; Krishnan, G; Borukhovich, R; Ruck, B; Turk, V; Moczydlowski, E				Lenarcic, B; Krishnan, G; Borukhovich, R; Ruck, B; Turk, V; Moczydlowski, E			Saxiphilin, a saxitoxin-binding protein with two thyroglobulin type 1 domains, is an inhibitor of papain-like cysteine proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; CATHEPSIN-B; TRANSFERRIN FAMILY; MOLECULAR-CLONING; RANA-CATESBEIANA; OCCLUDING LOOP; STEFIN-B; BULLFROG; REVEALS; CHROMATOGRAPHY	The type 1 domain of thyroglobulin is a protein module (Thyr-1) that occurs in a variety of secreted and membrane proteins. Several examples of Thyr-1 modules have been previously identified as inhibitors of the papain family of cysteine proteinases, Saxiphilin is a neurotoxin-binding protein from bullfrog and a homolog of transferrin with a pair of such Thyr-1 modules located in the N-lobe. Saxiphilin is now characterized as a potent inhibitor of three cysteine proteinases as follows: papain, human cathepsin B, and cathepsin L, The stoichiometry of enzyme inhibition reveals that both Thyr-1 domains of saxiphilin inhibit papain (apparent K-i = 1.72 naa), but only one of these domains inhibits cathepsin B (K-i = 1.67 nM) and cathepsin L (K-i = 0.02 nM). Physical association of saxiphilin and papain blocked from turnover at the active-site cysteine residue can be detected by cross-linking with glutaraldehyde. The rate of association of saxiphilin and cathepsin B is strongly pH-dependent with an optimum at pH 5.2, reflecting control by at least two H+-titratable groups. These results further demonstrate that various Thyr-1 domains are selective inhibitors of cysteine proteinases with utility in the study of protein interactions and degradation.	Jozef Stefan Inst, Dept Biochem & Mol Biol, Ljubljana 1000, Slovenia; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; Yale University; Yale University	Lenarcic, B (corresponding author), Jozef Stefan Inst, Dept Biochem & Mol Biol, Jamova 39, Ljubljana 1000, Slovenia.	brigita.lenarcic@ijs.si	Moczydlowski, Edward G/A-9304-2009; Moczydlowski, Edward G/D-1734-2013	Lenarcic, Brigita/0000-0002-2508-3776	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051172] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51172] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P771; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Bevec T, 1996, J EXP MED, V183, P1331, DOI 10.1084/jem.183.4.1331; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; BLUMBERG S, 1970, EUR J BIOCHEM, V15, P97, DOI 10.1111/j.1432-1033.1970.tb00981.x; BROCKLEHURST K, 1973, BIOCHEM J, V133, P573, DOI 10.1042/bj1330573; CRAIG WS, 1988, METHOD ENZYMOL, V156, P333; DOYLE DD, 1982, SCIENCE, V215, P1117, DOI 10.1126/science.6278588; FERSHT A, 1984, ENZYME STRUCTURE MEC, P155; Guncar G, 1999, EMBO J, V18, P793, DOI 10.1093/emboj/18.4.793; HALL S, 1990, ACS SYM SER, V418, P29; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; Illy C, 1997, J BIOL CHEM, V272, P1197, DOI 10.1074/jbc.272.2.1197; KOCH N, 1987, EMBO J, V6, P1677, DOI 10.1002/j.1460-2075.1987.tb02417.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenarcic B, 1996, FEBS LETT, V395, P113, DOI 10.1016/0014-5793(96)00984-2; Lenarcic B, 1997, J BIOL CHEM, V272, P13899; Lenarcic B, 1999, J BIOL CHEM, V274, P563, DOI 10.1074/jbc.274.2.563; Lenarcic B, 1998, BIOL CHEM, V379, P105; LI Y, 1991, J BIOL CHEM, V266, P15481; LI Y, 1993, MOL PHARMACOL, V44, P742; LLEWELLYN LE, 1994, BIOCHEMISTRY-US, V33, P12312, DOI 10.1021/bi00206a039; Llewellyn LE, 1997, P ROY SOC B-BIOL SCI, V264, P891, DOI 10.1098/rspb.1997.0124; MAHAR J, 1991, TOXICON, V29, P53, DOI 10.1016/0041-0101(91)90039-T; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MASON RW, 1986, BIOCHEM J, V240, P285, DOI 10.1042/bj2400285; MERRIL CR, 1990, METHOD ENZYMOL, V182, P477; Molina F, 1996, EUR J BIOCHEM, V240, P125, DOI 10.1111/j.1432-1033.1996.0125h.x; MORABITO MA, 1995, BIOCHEMISTRY-US, V34, P13027, DOI 10.1021/bi00040a013; MORABITO MA, 1994, P NATL ACAD SCI USA, V91, P2478, DOI 10.1073/pnas.91.7.2478; MORABITO MA, 1995, P NATL ACAD SCI USA, V92, P6651, DOI 10.1073/pnas.92.14.6651; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; Nagler DK, 1997, BIOCHEMISTRY-US, V36, P12608, DOI 10.1021/bi971264+; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; RITCHIE JM, 1977, REV PHYSIOL BIOCH P, V79, P1, DOI 10.1007/BFb0037088; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TURK B, 1993, BIOCHEMISTRY-US, V32, P375, DOI 10.1021/bi00052a046; WELCH S, 1992, TRANSFERRIN IRON CAR; Yamashita M, 1996, J BIOL CHEM, V271, P1282, DOI 10.1074/jbc.271.3.1282; ZUCKER S, 1985, BIOCHIM BIOPHYS ACTA, V828, P196, DOI 10.1016/0167-4838(85)90057-3	45	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15572	15577		10.1074/jbc.M001406200	http://dx.doi.org/10.1074/jbc.M001406200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748022	hybrid			2022-12-27	WOS:000087128300107
J	Mari, R; Cederbaum, AI				Mari, R; Cederbaum, AI			CYP2E1 overexpression in HepG2 cells induces glutathione synthesis by transcriptional activation of gamma-glutamylcysteine synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-BENZOQUINONE IMINE; HUMAN LIVER-MICROSOMES; HEAVY SUBUNIT CHAIN; OXIDATIVE STRESS; LIPID-PEROXIDATION; MESSENGER-RNA; G2 CELLS; ACETAMINOPHEN ACTIVATION; CYTOCHROME-P450 2E1; RAT-LIVER	Induction of CYP2E1 (cytochrome P450 2E1) by ethanol appears to be one of the central pathways by which ethanol generates a state of oxidative stress. CYP2E1 is a loosely coupled enzyme; formation of reactive oxygen species occurs even in the absence of added substrate. GSH is critical for preserving the proper cellular redox balance and for its role as a cellular protectant, Since cells must maintain optimal GSH levels to cope with a variety of stresses, the goal of this study was to characterize the GSH homeostasis in human hepatocarcinoma cells (HepG2) that overexpress CYP2E1. This study was prompted by the finding that toxicity in CYP2E1-overexpressing cells was markedly enhanced after GSH depletion by buthionine sulfoximine treatment. CYP2E1-overexpressing cells showed a 40-50% increase in intracellular H2O2; a 30% increase in total GSH levels; a 50% increase in the GSH synthesis rate; and a 2-fold increase in gamma-glutamylcysteine synthetase heavy subunit (GCS-HS) mRNA, the rate-limiting enzyme in GSH synthesis. This GCS-HS mRNA increase was due to increased synthesis since nuclear run-on assays showed increased transcription in CYP2E1-expressing cells, and the GCS-HS mRNA decay after actinomycin Il treatment was similar in CYP2E1-expressing cells and empty vector-transfected cells. The facts that treatment with GSH ethyl ester almost completely prevented the increase in GCS-HS mRNA and decreased H2O2 levels and that transient transfection with catalase (but not manganese-superoxide dismutase) produced a decrease in GCS-HS mRNA only in CYP2E1-expressing cells suggest a possible role for H2O2 in the induction of GCS-HS gene transcription. In contrast to results with HepG2 cells expressing CYP2E1, no increase in GCS-HS mRNA was found with a HepG2 cell line engineered to express human cytochrome P450 3A4, In summary, CYP2E1 overexpression in HepG2 cells up-regulates the levels of reduced GSH by transcriptional activation of GCS-HS; this may reflect an adaptive mechanism to remove CYP2E1-derived oxidants such as H2O2.	CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Cederbaum, AI (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, 1 Gustave L Levy Pl,POB 1020, New York, NY 10029 USA.	Arthur.Cederbaum@mssm.edu	MARI, MONTSERRAT/A-7376-2013	MARI, MONTSERRAT/0000-0002-6116-3247	NIAAA NIH HHS [AA06610, AA03312] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA003312, R01AA006610, R01AA003312, R37AA006610] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANUNDI I, 1993, BIOCHEM PHARMACOL, V45, P1251, DOI 10.1016/0006-2952(93)90277-4; BLACK M, 1984, ANNU REV MED, V35, P577, DOI 10.1146/annurev.me.35.020184.003045; BORROZ KI, 1994, TOXICOL APPL PHARM, V126, P150, DOI 10.1006/taap.1994.1101; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; CASTRO VM, 1990, CARCINOGENESIS, V11, P1569, DOI 10.1093/carcin/11.9.1569; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; DAI Y, 1993, BIOCHEMISTRY-US, V32, P6928, DOI 10.1021/bi00078a017; DAI Y, 1995, J PHARMACOL EXP THER, V273, P1497; DELEVE LD, 1991, PHARMACOL THERAPEUT, V52, P287, DOI 10.1016/0163-7258(91)90029-L; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; FERNANDEZCHECA JC, 1991, J CLIN INVEST, V87, P397, DOI 10.1172/JCI115010; FERNANDEZCHECA JC, 1990, ANAL BIOCHEM, V190, P212, DOI 10.1016/0003-2697(90)90183-A; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Galloway DC, 1997, BIOCHEM J, V328, P99; GARCIARUIZ C, 1994, J CLIN INVEST, V94, P193, DOI 10.1172/JCI117306; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hinson JA., 1980, REV BIOCHEM TOXICOL, V2; HOLME JA, 1984, BIOCHEM PHARMACOL, V33, P401, DOI 10.1016/0006-2952(84)90232-6; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KAWASE T, 1989, HEPATOLOGY, V10, P815, DOI 10.1002/hep.1840100511; Kinter M, 1996, FREE RADICAL BIO MED, V21, P457, DOI 10.1016/0891-5849(96)00128-1; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; Kuo PC, 1996, AM J PHYSIOL-CELL PH, V271, pC851, DOI 10.1152/ajpcell.1996.271.3.C851; LEVY EJ, 1993, P NATL ACAD SCI USA, V90, P9171, DOI 10.1073/pnas.90.19.9171; Lieber CS, 1997, PHYSIOL REV, V77, P517, DOI 10.1152/physrev.1997.77.2.517; Liu RM, 1998, AM J PHYSIOL-LUNG C, V275, pL861, DOI 10.1152/ajplung.1998.275.5.L861; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu SC, 1999, HEPATOLOGY, V30, P209, DOI 10.1002/hep.510300134; MOORE M, 1985, J BIOL CHEM, V260, P3035; Morales A, 1998, FEBS LETT, V427, P15, DOI 10.1016/S0014-5793(98)00381-0; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; MORTON S, 1985, BIOCHEM PHARMACOL, V34, P1559, DOI 10.1016/0006-2952(85)90699-9; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; PAOLETTI F, 1990, METHOD ENZYMOL, V186, P209; Parkinson A, 1996, TOXICOL PATHOL, V24, P45, DOI 10.1177/019262339602400107; PATTEN CJ, 1993, CHEM RES TOXICOL, V6, P511, DOI 10.1021/tx00034a019; PICKETT CB, 1994, ANN REV BIOL, V11, P586; Rahman I, 1996, BIOCHEM BIOPH RES CO, V229, P832, DOI 10.1006/bbrc.1996.1888; RAUCY JL, 1989, ARCH BIOCHEM BIOPHYS, V271, P270, DOI 10.1016/0003-9861(89)90278-6; Sakurai K, 1998, MOL PHARMACOL, V54, P1024, DOI 10.1124/mol.54.6.1024; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; Sekhar KR, 1997, BIOCHEM BIOPH RES CO, V234, P588, DOI 10.1006/bbrc.1997.6697; SHAW S, 1983, DIGEST DIS SCI, V28, P585, DOI 10.1007/BF01299917; SZE G, 1993, AM J PHYSIOL, V265, pG1128, DOI 10.1152/ajpgi.1993.265.6.G1128; Tian L, 1997, ARCH BIOCHEM BIOPHYS, V342, P126, DOI 10.1006/abbi.1997.9997; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WOODS JS, 1995, BIOCHEM PHARMACOL, V50, P1719, DOI 10.1016/0006-2952(95)02075-6; YAMAZAKI H, 1992, CARCINOGENESIS, V13, P1789, DOI 10.1093/carcin/13.10.1789; Zhao TJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P216, DOI 10.1006/abbi.1999.1277	55	102	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15563	15571						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748080				2022-12-27	WOS:000087128300106
J	Tribble, G; Ahn, YT; Lee, J; Dandekar, T; Jayaram, M				Tribble, G; Ahn, YT; Lee, J; Dandekar, T; Jayaram, M			DNA recognition, strand selectivity, and cleavage mode during integrase family site-specific recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLP RECOMBINASE; REGIONAL SIMILARITIES; CATALYTIC DOMAIN; PROTEIN; TRANS; TYROSINE; RNA; IDENTIFICATION; EVOLUTION; MECHANISM	We have probed the association of Flp recombinase with its DNA target using protein footprinting assays. The results are consistent with the domain organization of the Flp protein and with the general features of the protein-DNA interactions revealed by the crystal structures of the recombination intermediates formed by Cre, the Flp-related recombinase. The similarity in the organization of the Flp and Cre target sites and in their recognition by the respective recombinases implies that the overall DNA-protein geometry during strand cleavage in the two systems must also be similar. Within the functional recombinase dimer, it is the interaction between two recombinase monomers bound on either side of the strand exchange region (or spacer) that provides the allosteric activation of a single active site. Whereas Cre utilizes the cleavage nucleophile (the active site tyrosine) in cis, Flp utilizes it in trans (one monomer donating the tyrosine to its partner), By using synthetic Cre and Flp DNA substrates that are geometrically restricted in similar ways, we have mapped the positioning of the active and inactive tyrosine residues during cia and trans cleavage events. We find that, for a fixed substrate geometry, Flp and Cre cleave the labile phosphodiester bond at the same spacer end, not at opposite ends. Our results provide a model that accommodates local heterogeneities in peptide orientations in the two systems while preserving the global functional architecture of the reaction complex.	Univ Texas, Dept Microbiol, Austin, TX 78712 USA; Cheju Univ, Fac Appl Marine Sci, Cheju City 690756, South Korea; European Mol Biol Lab, Heidelberg, Germany	University of Texas System; University of Texas Austin; Jeju National University; European Molecular Biology Laboratory (EMBL)	Jayaram, M (corresponding author), Univ Texas, Dept Microbiol, Austin, TX 78712 USA.		Dandekar, Thomas/A-4431-2017; Lee, Jehee/AAS-3229-2021; Tribble, Gena/A-8755-2011	Dandekar, Thomas/0000-0003-1886-7625; Lee, Jehee/0000-0001-9144-3648; Tribble, Gena/0000-0002-6468-2851	NIGMS NIH HHS [F32 GM019687, F32 GM019687-03] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019687] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; Baichoo N, 1997, BIOCHEMISTRY-US, V36, P10830, DOI 10.1021/bi970714v; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BHATTACHARYYA A, 1989, NUCLEIC ACIDS RES, V17, P6821, DOI 10.1093/nar/17.17.6821; CHEN JW, 1991, P NATL ACAD SCI USA, V88, P5944, DOI 10.1073/pnas.88.14.5944; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Cordes MHJ, 1999, SCIENCE, V284, P325, DOI 10.1126/science.284.5412.325; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; EVANS BR, 1990, J BIOL CHEM, V265, P18504; GOHLKE C, 1994, P NATL ACAD SCI USA, V91, P11660, DOI 10.1073/pnas.91.24.11660; Gopaul Deshmukh N., 1999, Current Opinion in Structural Biology, V9, P14, DOI 10.1016/S0959-440X(99)80003-7; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; GREEN SM, 1995, NAT STRUCT BIOL, V2, P746, DOI 10.1038/nsb0995-746; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; JAYARAM M, 1995, TRENDS GENET, V11, P432, DOI 10.1016/S0168-9525(00)89140-4; Jayaram M, 1997, SCIENCE, V276, P49, DOI 10.1126/science.276.5309.49; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; Landry M, 1993, SIGNAL NOISE, V6, P3; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEE J, 1995, J BIOL CHEM, V270, P4042, DOI 10.1074/jbc.270.8.4042; LEE J, 1995, J BIOL CHEM, V270, P23203, DOI 10.1074/jbc.270.39.23203; Lee J, 1997, GENE DEV, V11, P3061, DOI 10.1101/gad.11.22.3061; Lee J, 1999, EMBO J, V18, P784, DOI 10.1093/emboj/18.3.784; LILLEY DMJ, 1995, P NATL ACAD SCI USA, V92, P7140, DOI 10.1073/pnas.92.16.7140; Lilley DMJ, 1997, CHEM BIOL, V4, P717, DOI 10.1016/S1074-5521(97)90309-4; Luetke KH, 1998, MOL MICROBIOL, V29, P199, DOI 10.1046/j.1365-2958.1998.00922.x; Luetke KH, 1998, NUCLEIC ACIDS RES, V26, P1401, DOI 10.1093/nar/26.6.1401; LUETKE KH, 1995, J MOL BIOL, V251, P493, DOI 10.1006/jmbi.1995.0451; Nash H, 1996, ESCHERICHIA COLI SAL, V2, P2363; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; PAN H, 1991, J BIOL CHEM, V266, P11347; PANIGRAHI GB, 1994, J BIOL CHEM, V269, P10940; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4004, DOI 10.1021/bi00131a016; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4015, DOI 10.1021/bi00131a017; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; Saxena P, 1997, BBA-PROTEIN STRUCT M, V1340, P187, DOI 10.1016/S0167-4838(97)00017-4; SENECOFF JF, 1988, J MOL BIOL, V201, P405, DOI 10.1016/0022-2836(88)90147-7; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; STARK WM, 1995, TRENDS GENET, V11, P121; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Tirumalai RS, 1997, P NATL ACAD SCI USA, V94, P6104, DOI 10.1073/pnas.94.12.6104; UTATSU I, 1987, J BACTERIOL, V169, P5537, DOI 10.1128/jb.169.12.5537-5545.1987; Voziyanov Y, 1996, J MOL BIOL, V256, P720, DOI 10.1006/jmbi.1996.0120; ZHU XD, 1995, J BIOL CHEM, V270, P11646, DOI 10.1074/jbc.270.19.11646	50	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22255	22267		10.1074/jbc.M908261199	http://dx.doi.org/10.1074/jbc.M908261199			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10748094	hybrid, Green Accepted			2022-12-27	WOS:000088363800069
J	Schuster, M; Zhao, R; Bourret, RB; Collins, EJ				Schuster, M; Zhao, R; Bourret, RB; Collins, EJ			Correlated switch finding and signaling in bacterial chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE PHOSPHODONORS; RESPONSE REGULATOR; FLAGELLAR SWITCH; ESCHERICHIA-COLI; KINETIC CHARACTERIZATION; PROTEIN CHEY; CRYSTAL-STRUCTURES; PHOSPHORYLATION; BINDING; FLIM	In Escherichia coli, swimming behavior is mediated by the phosphorylation state of the response regulator CheY, In its active, phosphorylated form, CheY exhibits enhanced binding to a switch component, FliM, at the flagellar motor, which induces a change from counterclockwise to clockwise flagellar rotation. When Ile(95) of CheY is replaced by a valine, increased clockwise rotation correlates with enhanced binding to FliM. A possible explanation for the hyperactivity of this mutant is that residue 95 affects the conformation of nearby residues that potentially interact with FliM, In order to assess this possibility directly, the crystal structure of CheY95IV was determined. We found that CheY95IV is structurally almost indistinguishable from wild-type CheY. Several other mutants with substitutions at position 95 were characterized to establish the structural requirements for switch binding and clockwise signaling at this position and to investigate a general relationship between the two properties. The various rotational phenotypes of these mutants can be explained solely by the amount of phosphorylated CheY bound to the switch, which was inferred from the phosphorylation properties of the mutant CheY proteins and their binding affinities to FliM, Combined genetic, biochemical, and crystallographic results suggest that residue 95 itself is critical in mediating the surface complementarity between CheY and FliM.	Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Bourret, RB (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.	bourret@med.unc.edu	Bourret, Robert/X-3606-2019	Bourret, Robert/0000-0002-6666-9220	NIGMS NIH HHS [R01 GM050860, GM50860] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alon U, 1998, EMBO J, V17, P4238, DOI 10.1093/emboj/17.15.4238; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; Birck C, 1999, STRUCTURE, V7, P1505, DOI 10.1016/S0969-2126(00)88341-0; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1993, J BIOL CHEM, V268, P13089; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; Bren A, 1998, J MOL BIOL, V278, P507, DOI 10.1006/jmbi.1998.1730; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cho HS, 2000, J MOL BIOL, V297, P543, DOI 10.1006/jmbi.2000.3595; Da Re SS, 1999, FEBS LETT, V457, P323, DOI 10.1016/S0014-5793(99)01057-1; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; Eisenbach M, 1996, MOL MICROBIOL, V20, P903, DOI 10.1111/j.1365-2958.1996.tb02531.x; GANGULI S, 1995, J BIOL CHEM, V270, P17386, DOI 10.1074/jbc.270.29.17386; HESS JF, 1991, METHOD ENZYMOL, V200, P188; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HORTON RM, 1995, MOL BIOTECHNOL, V3, P93, DOI 10.1007/BF02789105; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kern D, 1999, NATURE, V402, P894, DOI 10.1038/47273; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Lewis RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/jmbi.1999.3261; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; Mathews MAA, 1998, J BACTERIOL, V180, P5580, DOI 10.1128/JB.180.21.5580-5590.1998; Mayover TL, 1999, BIOCHEMISTRY-US, V38, P2259, DOI 10.1021/bi981707p; McEvoy MM, 1999, J MOL BIOL, V289, P1423, DOI 10.1006/jmbi.1999.2830; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; SANNA MG, 1995, MOL MICROBIOL, V15, P1069, DOI 10.1111/j.1365-2958.1995.tb02282.x; Scharf BE, 1998, J BACTERIOL, V180, P5123, DOI 10.1128/JB.180.19.5123-5128.1998; Scharf BE, 1998, P NATL ACAD SCI USA, V95, P201, DOI 10.1073/pnas.95.1.201; Schuster M, 1998, MOL MICROBIOL, V27, P1065, DOI 10.1046/j.1365-2958.1998.00756.x; Sheridan R. C., 2007, INORG SYN, P23; Shukla D, 1998, J BIOL CHEM, V273, P23993, DOI 10.1074/jbc.273.37.23993; Silversmith RE, 1997, BIOCHEMISTRY-US, V36, P14965, DOI 10.1021/bi9715573; Silversmith RE, 1999, TRENDS MICROBIOL, V7, P16, DOI 10.1016/S0966-842X(98)01409-7; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; Stewart RC, 1997, BIOCHEMISTRY-US, V36, P2030, DOI 10.1021/bi962261k; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; VOLZ K, 1991, J BIOL CHEM, V266, P15511; WELCH M, 1994, BIOCHEMISTRY-US, V33, P10470, DOI 10.1021/bi00200a031; WLODAWER A, 1975, P NATL ACAD SCI USA, V72, P398, DOI 10.1073/pnas.72.1.398; Zhu XY, 1996, J BACTERIOL, V178, P4208, DOI 10.1128/jb.178.14.4208-4215.1996; Zhu XY, 1997, J BIOL CHEM, V272, P5000, DOI 10.1074/jbc.272.8.5000	48	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19752	19758		10.1074/jbc.M909908199	http://dx.doi.org/10.1074/jbc.M909908199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748173	hybrid			2022-12-27	WOS:000087941300045
J	Dwir, O; Kansas, GS; Alon, R				Dwir, O; Kansas, GS; Alon, R			An activated L-selectin mutant with conserved equilibrium binding properties but enhanced ligand recognition under shear flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH ENDOTHELIAL VENULES; MEMBRANE-PROXIMAL CLEAVAGE; NODE HOMING RECEPTOR; P-SELECTIN; LEUKOCYTE ADHESION; GLYCOPROTEIN LIGAND-1; CELL-ADHESION; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; HYDRODYNAMIC SHEAR	Selectins mediate the initial tethering and rolling of leukocytes on vessel walls. Adhesion by selectins is a function of both ligand recognition at equilibrium and mechanical properties of the selectin-ligand bond under applied force. We describe an EGF domain mutant of L-selectin with profoundly augmented adhesiveness over that of native L-selectin but conserved ligand specificity. This mutant, termed LPL, was derived by a substitution of the EGF-like domain of L selectin with the homologous domain from P-selectin. The mutant bound soluble carbohydrate L-selectin ligand with affinity comparable with that of native L-selectin but interacted with all surface-bound ligands much more readily than native L-selectin, in particular under elevated shear flow. Tethers mediated by both native and mutant L-selectin exhibited similar lifetimes under a range of shear stresses, but the rate of bond formation by the mutant was at least 10-fold higher than that of native L-selectin toward distinct L-selectin ligands. Enhanced rate of bond formation by the mutant was associated with profoundly stronger rolling interactions and reduced dependence of rolling on a threshold of shear stress. This is the first demonstration that the EGF domain can modulate the binding of the lectin domain of a selectin to surface-immobilized ligands under shear flow without affecting the equilibrium properties of the selectin toward soluble ligands.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Weizmann Institute of Science; Northwestern University	Alon, R (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.		ALON, RONEN/GRX-6987-2022	Alon, Ronen/0000-0001-9161-6369	NHLBI NIH HHS [HL55647] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055647] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akahori T, 1997, J IMMUNOL, V158, P5384; Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; Alon R, 1998, P NATL ACAD SCI USA, V95, P11631, DOI 10.1073/pnas.95.20.11631; Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; ALON R, 1995, J IMMUNOL, V154, P5356; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Berg EL, 1998, AM J PATHOL, V152, P469; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chang KC, 1999, BIOPHYS J, V76, P1280, DOI 10.1016/S0006-3495(99)77291-7; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; Chen SQ, 1997, P NATL ACAD SCI USA, V94, P3172, DOI 10.1073/pnas.94.7.3172; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; Clark RA, 1998, J CELL BIOL, V140, P721, DOI 10.1083/jcb.140.3.721; Dwir O, 1998, CELL ADHES COMMUN, V6, P349, DOI 10.3109/15419069809010793; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; Finger EB, 1996, J IMMUNOL, V157, P5085; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Fuhlbrigge RC, 1996, J CELL BIOL, V135, P837, DOI 10.1083/jcb.135.3.837; GLABE CG, 1983, ANAL BIOCHEM, V130, P287, DOI 10.1016/0003-2697(83)90590-0; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; HERMANSON GT, 1996, ANTIBODY MODIFICATIO, P478; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; KANSAS GS, 1991, J CELL BIOL, V114, P351, DOI 10.1083/jcb.114.2.351; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KAPLANSKI G, 1993, BIOPHYS J, V64, P1922, DOI 10.1016/S0006-3495(93)81563-7; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1992, COLD SPRING HARB SYM, V57, P259, DOI 10.1101/SQB.1992.057.01.031; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEY K, 1993, BLOOD, V82, P1632; LEY K, 1991, BLOOD, V77, P2553; Li X, 1998, J EXP MED, V188, P1385, DOI 10.1084/jem.188.7.1385; Lim YC, 1998, J IMMUNOL, V161, P2501; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Patel KD, 1997, J IMMUNOL, V159, P4555; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; Pierres A, 1997, FEBS LETT, V403, P239, DOI 10.1016/S0014-5793(97)00060-4; Pierres A, 1996, P NATL ACAD SCI USA, V93, P15114, DOI 10.1073/pnas.93.26.15114; PIGOTT R, 1991, J IMMUNOL, V147, P130; Puri KD, 1998, NATURE, V392, P930, DOI 10.1038/31954; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; Ramos CL, 1998, BLOOD, V91, P1067, DOI 10.1182/blood.V91.3.1067.1067_1067_1075; ROCHON YP, 1994, J IMMUNOL, V152, P1385; Rosen S D, 1993, Semin Immunol, V5, P237, DOI 10.1006/smim.1993.1028; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; SPERTINI O, 1991, J IMMUNOL, V147, P2565; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steeber DA, 1997, J IMMUNOL, V159, P952; Stein JV, 1999, J EXP MED, V189, P37, DOI 10.1084/jem.189.1.37; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; TEMPELMAN LA, 1994, BIOTECHNOL PROGR, V10, P97, DOI 10.1021/bp00025a012; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VONANDRIAN UH, 1993, BLOOD, V82, P182, DOI 10.1182/blood.V82.1.182.bloodjournal821182; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; WILLIAMS AF, 1991, NATURE, V352, P473, DOI 10.1038/352473a0	72	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18682	18691		10.1074/jbc.M001103200	http://dx.doi.org/10.1074/jbc.M001103200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10747985	hybrid			2022-12-27	WOS:000087815900011
J	Ji, BA; Kopin, AS; Logsdon, CD				Ji, BA; Kopin, AS; Logsdon, CD			Species differences between rat and mouse CCKA receptors determine the divergent acinar cell response to the cholecystokinin analog JMV-180	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ENZYME SECRETION; ACTIVATED PROTEIN-KINASE; MOLECULAR-CLONING; EXPRESSION; MOBILIZATION; CCK-JMV-180; INHIBITION	The cholecystokinin (CCK) analog JMV-180 acts as a partial agonist in rats and a full agonist in mice. Whether this functional variability is due to species differences in CCK receptor structure or to alterations in the cellular environment is unknown. To address this question, an adenoviral construct encoding the rat CCKA receptor (AdCCK(A)R) was used to express the rat receptor in acini from CCK, receptor-deficient mice (CCKAR -/-). Infection of CCKAR -/- acini in vitro with pAdCCK(A)R led to a time-dependent increase in I-125-CCK8 binding. The affinity for JMV-180 of the adenovirally transferred rat and the endogenous mouse CCKA receptors was not different. In native mouse acini, JMV-180 acted as a full agonist (both stimulation and inhibition of amylase release). In contrast, in mouse acini expressing pAdCCKAR JMV-180 acted as a partial agonist (only stimulation of amylase release). In addition, the pattern of protein synthesis induced by JMV-180 in CCKAR -/- mouse acini infected with AdCCK(A)R resembled the pattern observed in wild-type rats (lack of inhibition) rather than the respective pattern in wild-type mice (inhibition). These data suggest that species differences in the CCKA receptor of rats and mice account for the observed divergence in the acinar cell response to JMV-180.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; New England Med Ctr, Tupper Res Inst, Boston, MA 02111 USA	University of Michigan System; University of Michigan; Tufts Medical Center	Logsdon, CD (corresponding author), Univ Michigan, Dept Physiol, Box 0622,7710 Med Sci Bldg 2, Ann Arbor, MI 48109 USA.				NIDDK NIH HHS [DK34933, DK46767, DK52067] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046767, R01DK052067, P30DK034933] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIANCHI BR, 1994, J PHARMACOL EXP THER, V268, P996; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; DUAN RD, 1994, AM J PHYSIOL, V267, pG401, DOI 10.1152/ajpgi.1994.267.3.G401; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; Ghanekar D, 1997, J PHARMACOL EXP THER, V282, P1206; Han B, 1999, AM J PHYSIOL-CELL PH, V277, pC74, DOI 10.1152/ajpcell.1999.277.1.C74; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HUANG S, 1994, J BIOL CHEM, V269, P26121; Kopin AS, 1999, J CLIN INVEST, V103, P383, DOI 10.1172/JCI4901; KOPIN AS, 1996, REGUL PEPTIDES, V64, P96; LOGSDON CD, 1986, AM J PHYSIOL, V250, pG440, DOI 10.1152/ajpgi.1986.250.4.G440; Logsdon CD, 1999, LIFE SCI, V64, P369, DOI 10.1016/S0024-3205(98)00576-1; MATOZAKI T, 1989, AM J PHYSIOL, V257, pG594, DOI 10.1152/ajpgi.1989.257.4.G594; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; Nicke B, 1999, AM J PHYSIOL-GASTR L, V276, pG499, DOI 10.1152/ajpgi.1999.276.2.G499; Padfield PJ, 1998, PFLUG ARCH EUR J PHY, V436, P782, DOI 10.1007/s004240050702; ROTH NS, 1991, ADV EXP MED BIOL, V308, P223; SATO S, 1989, AM J PHYSIOL, V257, pG202, DOI 10.1152/ajpgi.1989.257.2.G202; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; STARK HA, 1989, BIOCHIM BIOPHYS ACTA, V1010, P145, DOI 10.1016/0167-4889(89)90154-7; Steer Michael L., 1993, P489; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; YULE DI, 1993, AM J PHYSIOL, V265, pG999, DOI 10.1152/ajpgi.1993.265.5.G999; Yule DI, 1999, AM J PHYSIOL-GASTR L, V276, pG271, DOI 10.1152/ajpgi.1999.276.1.G271; YULE DI, 1992, J BIOL CHEM, V267, P13830	27	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19115	19120		10.1074/jbc.M001685200	http://dx.doi.org/10.1074/jbc.M001685200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10748042	hybrid			2022-12-27	WOS:000087815900066
J	Klink, TA; Raines, RT				Klink, TA; Raines, RT			Conformational stability is a determinant of ribonuclease A cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENGINEERED DISULFIDE BONDS; BOVINE SEMINAL RIBONUCLEASE; ESCHERICHIA-COLI; INTRACELLULAR STABILITY; ENDOPLASMIC-RETICULUM; STRUCTURAL STABILITY; PRECURSOR PROTEINS; CATALYTIC ACTIVITY; DIPHTHERIA-TOXIN; HELA-CELLS	Onconase(TM), a homolog of bovine pancreatic ribonuclease A (RNase A) with high conformational stability, is cytotoxic and has efficacy as a cancer chemotherapeutic agent. Unlike wild-type RNase A, the G88R variant is toxic to cancer cells. Here, variants in which disulfide bonds were removed from or added to G88R RNase A were used to probe the relationship between conformational stability and cytotoxicity in a methodical manner. The conformational stability of the C40A/G88R/C95A and C65A/C72A/G88R variants is less than that of G88R RNase A. In contrast, a new disulfide bond that links the N and C termini (residues 4 and 118) increases the conformational stability of G88R RNase A and C65A/C72A/G88R RNase A. These changes have little effect on the ribonucleolytic activity of the enzyme or on its ability to evade the cytosolic ribonuclease inhibitor protein. The changes do, however, have a substantial effect on toxicity toward human erythroleukemia cells. Specifically, conformational stability correlates directly with cytotoxicity as well as with resistance to proteolysis. These data indicate that conformational stability is a key determinant of RNase A cytotoxicity and suggest that cytotoxicity relies on avoiding proteolysis. This finding suggests a means to produce new cancer chemotherapeutic agents based on mammalian ribonucleases.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Raines, RT (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	raines@biochem.wisc.edu	Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719				Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; Arnold U, 1997, BIOCHEMISTRY-US, V36, P2166, DOI 10.1021/bi962723u; Betz SF, 1996, BIOCHEMISTRY-US, V35, P7422, DOI 10.1021/bi9528558; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; Bretscher LE, 2000, J BIOL CHEM, V275, P9893, DOI 10.1074/jbc.275.14.9893; DELCARDAYRE SB, 1995, PROTEIN ENG, V8, P261, DOI 10.1093/protein/8.3.261; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Falnes PO, 1998, EMBO J, V17, P615, DOI 10.1093/emboj/17.2.615; FIANI ML, 1993, ARCH BIOCHEM BIOPHYS, V307, P225, DOI 10.1006/abbi.1993.1583; FLORY PJ, 1956, J AM CHEM SOC, V78, P5222, DOI 10.1021/ja01601a025; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P10328, DOI 10.1021/bi960309o; Hofsteenge J., 1997, RIBONUCLEASES STRUCT, P621, DOI [10.1016/b978-012588945-2/50020-0, DOI 10.1016/B978-012588945-2/50020-0]; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; ISENMAN LD, 1989, J BIOL CHEM, V264, P21591; Kelemen BR, 1999, NUCLEIC ACIDS RES, V27, P3696, DOI 10.1093/nar/27.18.3696; KIM JS, 1995, BIOCHEM J, V308, P547, DOI 10.1042/bj3080547; KIM JS, 1993, J BIOL CHEM, V268, P17392; Kim JS, 1995, J BIOL CHEM, V270, P31097, DOI 10.1074/jbc.270.52.31097; Klink TA, 2000, EUR J BIOCHEM, V267, P566, DOI 10.1046/j.1432-1327.2000.01037.x; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; Krupakar J, 1999, BIOCHEM J, V338, P273, DOI 10.1042/0264-6021:3380273; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUROKI R, 1992, BIOCHEMISTRY-US, V31, P8323, DOI 10.1021/bi00150a028; LAITY JH, 1993, P NATL ACAD SCI USA, V90, P615, DOI 10.1073/pnas.90.2.615; Laity JH, 1997, BIOCHEMISTRY-US, V36, P12683, DOI 10.1021/bi970878b; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; LI YJ, 1995, NAT STRUCT BIOL, V2, P489, DOI 10.1038/nsb0695-489; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MCELLIGOTT MA, 1985, J BIOL CHEM, V260, P1986; MCLENDON G, 1978, J BIOL CHEM, V253, P6335; MCLENDON G, 1977, BIOCHEM BIOPH RES CO, V77, P959, DOI 10.1016/S0006-291X(77)80071-5; MIHALYI E, 1959, BIOCHIM BIOPHYS ACTA, V36, P447, DOI 10.1016/0006-3002(59)90186-6; OOI T, 1963, BIOCHEMISTRY-US, V2, P432, DOI 10.1021/bi00903a006; PACE CN, 1984, BIOCHEM J, V219, P411, DOI 10.1042/bj2190411; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; Raines RT, 1999, BIOM HLTH R, V27, P235; RAMSAY G, 1990, BIOCHEMISTRY-US, V29, P8677, DOI 10.1021/bi00489a024; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; RECHSTEINER M, 1987, TRENDS BIOCHEM SCI, V12, P390; Richards FM, 1997, CELL MOL LIFE SCI, V53, P790, DOI 10.1007/s000180050100; ROGERS SW, 1988, J BIOL CHEM, V263, P19850; ROTE K, 1989, J BIOL CHEM, V264, P9772; RUPLEY JA, 1963, BIOCHEMISTRY-US, V2, P421, DOI 10.1021/bi00903a005; Rybak SM, 1999, EXP CELL RES, V253, P325, DOI 10.1006/excr.1999.4718; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; Schwartz MP, 1999, J BIOL CHEM, V274, P12759, DOI 10.1074/jbc.274.18.12759; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; VandenAkker F, 1997, PROTEIN SCI, V6, P2644; VINDIGNI A, 1994, EUR J BIOCHEM, V226, P323, DOI 10.1111/j.1432-1033.1994.tb20056.x; WELLS JA, 1986, J BIOL CHEM, V261, P6564; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010; WU YN, 1993, J BIOL CHEM, V268, P10686; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491; ZHU HX, 1995, BIOCHEMISTRY-US, V34, P15307, DOI 10.1021/bi00046a040	61	85	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17463	17467		10.1074/jbc.M001132200	http://dx.doi.org/10.1074/jbc.M001132200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747991	hybrid			2022-12-27	WOS:000087485000036
J	Scacco, S; Vergari, R; Scarpulla, RC; Technikova-Dobrova, Z; Sardanelli, A; Lambo, R; Lorusso, V; Papa, S				Scacco, S; Vergari, R; Scarpulla, RC; Technikova-Dobrova, Z; Sardanelli, A; Lambo, R; Lorusso, V; Papa, S			cAMP-dependent phosphorylation of the nuclear encoded 18-kDa (IP) subunit of respiratory complex I and activation of the complex in serum-starved mouse fibroblast cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE-NATIVE-ELECTROPHORESIS; BOVINE HEART-MITOCHONDRIA; PROTEIN-KINASE; CYCLIC-AMP; UBIQUINONE OXIDOREDUCTASE; SIGNAL-TRANSDUCTION; CYTOCHROME-C; AQDQ SUBUNIT; SEQUENCES; NADH	A study is presented on the in vivo effect of elevated cAMP levels induced by cholera toxin on the phosphorylation of subunits of the mitochondrial respiratory complexes and their activities in Balb/c 3T3 mouse fibroblast cultures. Treatment of serum-starved fibroblasts with cholera toxin promoted serine phosphorylation in the 18-kDa subunit of complex I. Phosphorylation of the 18-kDa subunit, in response to cholera toxin treatment of fibroblasts, was accompanied by a 2-3-fold enhancement of the rotenone-sensitive endogenous respiration of fibroblasts, of the rotenone-sensitive NADH oxidase, and of the NADH:ubiquinone oxidoreductase activity of complex I. Direct exposure of fibroblasts to dibutyryl cAMP resulted in an equally potent stimulation of the NADH:ubiquinone oxidoreductase activity. Stimulation of complex I activity and respiration with NAD-linked substrates were also observed upon short incubation of isolated fibroblast mitoplasts with dibutyryl cAMP and ATP, which also promoted phosphorylation of the 18-kDa subunit. These observations document an extension of cAMP-mediated intracellular signal transduction to the regulation of cellular respiration.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Univ Bari, Dept Med Biochem & Biol, I-70124 Bari, Italy	Northwestern University; Universita degli Studi di Bari Aldo Moro	Scarpulla, RC (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	rsc248@nwu.edu	Scacco, Salvatore/AAC-7406-2022; Sardanelli, Anna Maria/AAD-4745-2021	Scacco, Salvatore/0000-0003-2717-2489; Sardanelli, Anna Maria/0000-0002-8535-7601; Papa, Sergio/0000-0002-4417-1763	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM032525, R01GM032525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32525-17] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZEVEDO JE, 1994, BBA-BIOENERGETICS, V1188, P159, DOI 10.1016/0005-2728(94)90034-5; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P31, DOI 10.1093/nar/25.1.31; BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2; BURGESS JW, 1987, BIOCHEM CELL BIOL, V65, P137, DOI 10.1139/o87-019; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; DellaFazia MA, 1997, FEBS LETT, V410, P22, DOI 10.1016/S0014-5793(97)00445-6; FISCHER JC, 1986, CLIN CHIM ACTA, V155, P263, DOI 10.1016/0009-8981(86)90246-9; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GOPALAKRISHNAN L, 1994, J BIOL CHEM, V269, P105; Gugneja S, 1997, J BIOL CHEM, V272, P18732, DOI 10.1074/jbc.272.30.18732; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Herzig RP, 2000, J BIOL CHEM, V275, P13134, DOI 10.1074/jbc.275.17.13134; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523; KREBS EG, 1994, TRENDS BIOCHEM SCI, V19, P439, DOI 10.1016/0968-0004(94)90125-2; Lambeng N, 1999, BRAIN RES, V821, P60, DOI 10.1016/S0006-8993(99)01061-6; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; McKnight GS, 1998, RECENT PROG HORM RES, V53, P139; Papa S, 1999, FEBS LETT, V444, P245, DOI 10.1016/S0014-5793(99)00070-8; Papa S, 1996, FEBS LETT, V379, P299, DOI 10.1016/0014-5793(95)01532-9; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Sardanelli AM, 1995, FEBS LETT, V377, P470, DOI 10.1016/0014-5793(95)01407-1; Sardanelli AM, 1996, FEBS LETT, V396, P276, DOI 10.1016/0014-5793(96)01112-X; SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125; SCHWOCH G, 1990, BIOCHEM J, V270, P181, DOI 10.1042/bj2700181; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; TECHNIKOVADOBROVA Z, 1994, FEBS LETT, V350, P187, DOI 10.1016/0014-5793(94)00760-8; TECHNIKOVADOBROVA Z, 1991, FEBS LETT, V292, P69, DOI 10.1016/0014-5793(91)80836-R; van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X	34	111	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17578	17582		10.1074/jbc.M001174200	http://dx.doi.org/10.1074/jbc.M001174200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747996	hybrid			2022-12-27	WOS:000087485000053
J	Kelly, JA; Slator, GR; Tipton, KF; Williams, CH; Bauer, K				Kelly, JA; Slator, GR; Tipton, KF; Williams, CH; Bauer, K			Kinetic investigation of the specificity of porcine brain thyrotropin-releasing hormone-degrading ectoenzyme for thyrotropin-releasing hormone-like peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG BRAIN; HYDROLYZING PYROGLUTAMATE AMINOPEPTIDASE; ANTERIOR-PITUITARY GLAND; GLUTAMYL-PROLINEAMIDE; PRIMARY CULTURES; HUMAN PROSTATE; BOVINE BRAIN; RAT-BRAIN; TRH; LOCALIZATION	Evidence indicates that neuronally released thyrotropin-releasing hormone (TRH) is selectively inactivated by TRH-degrading ectoenzyme (TRH-DE) (EC 3.4.19.6). TRH-DE inhibitors may be used to enhance the therapeutic actions of TRH and to investigate the functions of TRH and TRH-DE in the central nervous system. Although TRH-DE appears to exhibit a high degree of specificity toward TRH, systematic specificity studies, which would facilitate inhibitor design, have not been previously conducted for this enzyme. In this paper we present the first description of TRH-DE specificity across a directed peptide Library in which the histidyl (P-1') residue of TRH was replaced by a series of amino acids. Peptides were synthesized using standard solid phase chemistry. Kinetic parameters were measured either by continuous or discontinuous fluorometric assays or by quantitative high pressure liquid chromatography. The P-1' residue was found to influence significantly both the ability of the peptides to bind to TRH-DE, as measured by their K-i values, and the ability of TRH-DE to catalyze their hydrolysis. Moderately bulky, uncharged P-1' residues were found to bind preferentially to TRH-DE, Results from this screen provide valuable information for the development of TRH-DE inhibitors and have led to the identification of two potent, reversible TRH-DE inhibitors, L-pyroglutamyl-L-asparaginyl-L-prolineamide (K-i = 17.5 mu M) and Glp-Asn-Pro-7-amido-4-methyl coumarin (K-i = 0.97 mu M).	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Queens Univ Belfast, Ctr Med Biol, Sch Biol & Biochem, Belfast BT9 7BL, Antrim, North Ireland; Max Planck Inst Expt Endokrinol, D-30603 Hannover, Germany	Trinity College Dublin; Queens University Belfast; Max Planck Society	Kelly, JA (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.	kellyja@tcd.ie						BAUER K, 1994, EUR J BIOCHEM, V224, P387, DOI 10.1111/j.1432-1033.1994.00387.x; BAUER K, 1990, ENDOCRINOLOGY, V127, P1224, DOI 10.1210/endo-127-3-1224; Bauer K., 1995, METABOLISM BRAIN PEP, P201; Bauer K., 1997, CELL SURFACE PEPTIDA, P239; BEAUMONT A, 1997, CELL SURFACE PEPTIDA, P59; BROWNLEES J, 1992, BIOL CHEM H-S, V373, P911, DOI 10.1515/bchm3.1992.373.2.911; Charli J L, 1998, Neurobiology (Bp), V6, P45; CHARLI JL, 1988, NEUROCHEM INT, V13, P237, DOI 10.1016/0197-0186(88)90060-5; CHARLI JL, 1989, NEUROPEPTIDES, V14, P191, DOI 10.1016/0143-4179(89)90044-9; COCKLE SM, 1994, BBA-MOL BASIS DIS, V1227, P60, DOI 10.1016/0925-4439(94)90107-4; Cremades A, 1998, EUR J PHARMACOL, V358, P63, DOI 10.1016/S0014-2999(98)00593-7; CRUZ C, 1991, J NEUROCHEM, V56, P1594, DOI 10.1111/j.1471-4159.1991.tb02056.x; CUSHMAN DW, 1977, BIOCHEMISTRY-US, V16, P5484, DOI 10.1021/bi00644a014; CZEKAY G, 1993, BIOCHEM J, V290, P921, DOI 10.1042/bj2900921; Dick F, 1994, Methods Mol Biol, V35, P63; DIXON M, 1979, ENZYMES, P72; ELMORE MA, 1990, NEUROPEPTIDES, V15, P31, DOI 10.1016/0143-4179(90)90157-T; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196, DOI 10.1152/ajpregu.1999.277.4.R1196; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Gallagher SP, 1998, INT J BIOCHEM CELL B, V30, P115, DOI 10.1016/S1357-2725(97)00074-5; GKONOS PJ, 1994, PEPTIDES, V15, P1281, DOI 10.1016/0196-9781(94)90154-6; GRIFFITHS EC, 1985, PSYCHONEUROENDOCRINO, V10, P225, DOI 10.1016/0306-4530(85)90001-0; Heuer H, 1998, THYROID, V8, P915, DOI 10.1089/thy.1998.8.915; Horita A, 1998, LIFE SCI, V62, P1443, DOI 10.1016/S0024-3205(98)00087-3; HORITA A, 1986, ANNU REV PHARMACOL, V26, P311; Kelly JA, 1999, ANAL BIOCHEM, V274, P195, DOI 10.1006/abio.1999.4276; Kelly JA, 1995, ESSAYS BIOCHEM, V30, P133; KELLY JA, 1999, ABSTR J NEUR S, V73; KELLY JA, 1999, ANAL BIOCHEM, V25, pS114; KHAN Z, 1992, J BIOL CHEM, V267, P7464; KULKARNI RN, 1995, ENDOCRINOLOGY, V136, P5155, DOI 10.1210/en.136.11.5155; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; LANZARA R, 1989, ANN NY ACAD SCI, V553, P559; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; OCONNOR B, 1984, EUR J BIOCHEM, V144, P271, DOI 10.1111/j.1432-1033.1984.tb08460.x; OCONNOR B, 1985, EUR J BIOCHEM, V150, P47, DOI 10.1111/j.1432-1033.1985.tb08986.x; OCUINN G, 1990, J NEUROCHEM, V54, P1, DOI 10.1111/j.1471-4159.1990.tb13276.x; OLEARY RM, 1995, INT J BIOCHEM CELL B, V27, P881, DOI 10.1016/1357-2725(95)00065-W; OLSON GL, 1993, J MED CHEM, V36, P3039, DOI 10.1021/jm00073a001; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RONDEEL JMM, 1995, J ENDOCRINOL, V146, P293, DOI 10.1677/joe.0.1460293; RONDEEL JMM, 1995, J ENDOCRINOL, V145, P43, DOI 10.1677/joe.0.1450043; SCHAUDER B, 1994, P NATL ACAD SCI USA, V91, P9534, DOI 10.1073/pnas.91.20.9534; TURNER AJ, 1997, CELL SURFACE PEPTIDA, P275; WALKER B, 1994, PEPTIDE ANTIGENS PRA, P27; WILK S, 1989, NEUROCHEM INT, V15, P81, DOI 10.1016/0197-0186(89)90079-X; WILK S, 1989, ANN NY ACAD SCI, V553, P252	48	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16746	16751		10.1074/jbc.M910386199	http://dx.doi.org/10.1074/jbc.M910386199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748219	hybrid			2022-12-27	WOS:000087392200050
J	Kovac, CR; Emelyanov, A; Singh, M; Ashouian, N; Birshtein, BK				Kovac, CR; Emelyanov, A; Singh, M; Ashouian, N; Birshtein, BK			BSAP (Pax5)-importin alpha 1 (Rch1) interaction identifies a nuclear localization sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL-DEVELOPMENT; IMPORTIN-ALPHA; TRANSCRIPTION FACTOR; RETINOBLASTOMA PROTEIN; ACTIVATING PROTEIN; KARYOPHERIN-ALPHA; ESCHERICHIA-COLI; GENE-EXPRESSION; BINDING-SITE; DNA-BINDING	BSAP (Pax5) is an essential transcription factor for early B cell and central nervous system development. In later B cell development, BSAP has been implicated in the regulation of 3' Ig enhancers and a number of B cell-specific genes. Previous studies hate suggested a role for BSAP-interacting proteins in the regulation of the function of BSAP. Using the yeast two-hybrid system, we identified importin alpha 1 (Rch1) as a BSAP-interacting protein, Importin alpha proteins have been shown to escort proteins into the nucleus through interaction with a nuclear localization signal (NLS), composed of short stretches of basic amino acids. A predicted NLS in BSAP (NKRKRDE, located at amino acids 195-201 in the central domain) was confirmed to be essential for interaction with importin alpha 1 by the yeast two-hybrid assay. Physical interaction between BSAP and importin alpha 1 was detected in vitro by a glutathione S-transferase (GST) pulldown assay. The NLS sequence in BSAP conferred nuclear localization to green fluorescent protein (GFP)-BSAP fusion proteins. Although the N-terminal paired (DNA-binding) domain of BSAP also conferred nuclear localization when coupled to green fluorescent protein, this domain did not bind to importin alpha 1 in the yeast two-hybrid assay. The NLS sequence in the central domain of BSAP binds to the C-terminal 98-amino acid fragment of importin alpha 1.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Long Isl Univ, Dept Biol, Brooklyn, NY 11201 USA	Yeshiva University; Albert Einstein College of Medicine; Long Island University-Brooklyn Campus	Birshtein, BK (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [PC30CA13330] Funding Source: Medline; NIAID NIH HHS [R37AI13509] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013509] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; CARRIERE C, 1995, CELL GROWTH DIFFER, V6, P1531; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; Cvekl A, 1999, INVEST OPHTH VIS SCI, V40, P1343; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eberhard D, 1999, CANCER RES, V59, p1716S; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Hagman J, 2000, CURR TOP MICROBIOL, V245, P169; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Kim AL, 1997, VIROLOGY, V239, P340, DOI 10.1006/viro.1997.8874; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Koepp DM, 1998, BBA-REV CANCER, V1377, pM39, DOI 10.1016/S0304-419X(97)00036-X; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; Lauring J, 1999, MOL CELL BIOL, V19, P2601; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Maitra S, 2000, MOL CELL BIOL, V20, P1911, DOI 10.1128/MCB.20.6.1911-1922.2000; MANSOURI A, 1999, CANCER RES, V59, P1707; Michaelson JS, 1996, J IMMUNOL, V156, P2349; Miller J.H., 1972, EXPT MOL GENETICS; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; Phelps DE, 1996, J BIOL CHEM, V271, P7978, DOI 10.1074/jbc.271.14.7978; Poleev A, 1997, EUR J BIOCHEM, V247, P860, DOI 10.1111/j.1432-1033.1997.00860.x; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; Prieve MG, 1998, MOL CELL BIOL, V18, P4819, DOI 10.1128/MCB.18.8.4819; Rinkenberger JL, 1996, IMMUNITY, V5, P377, DOI 10.1016/S1074-7613(00)80263-0; Roque MC, 1996, MOL CELL BIOL, V16, P3138; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Singh M, 1996, P NATL ACAD SCI USA, V93, P4392, DOI 10.1073/pnas.93.9.4392; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Welch K, 1999, MOL CELL BIOL, V19, P8400; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Ying H, 1998, J IMMUNOL, V161, P4760; Zhang YH, 1998, MECH DEVELOP, V78, P179, DOI 10.1016/S0925-4773(98)00171-3; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310	53	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16752	16757		10.1074/jbc.M001551200	http://dx.doi.org/10.1074/jbc.M001551200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748034	hybrid			2022-12-27	WOS:000087392200051
J	Kurooka, K; Honjo, T				Kurooka, K; Honjo, T			Functional interaction between the mouse Notch1 intracellular region and histone acetyltransferases PCAF and GCN5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RBP-J-KAPPA; NUCLEAR RECEPTOR COACTIVATOR; ADENOVIRAL ONCOPROTEIN E1A; SPLIT COMPLEX GENES; BARR-VIRUS EBNA2; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; REPRESS TRANSCRIPTION; ACETYLASE PCAF; BINDING	The Notch receptor that plays an important role in cell fate determination is intracellularly cleaved by interaction with the ligand. The cleaved intracellular region (RAMIC) of Notch is translocated into the nucleus and interacts with a DNA-binding protein RBP-J to activate transcription of genes that regulate cell differentiation. Although RAMIC has been shown to facilitate the RBP-J-mediated transactivation by displacing the histone deacetylase corepressor complex from RBP-J, there is no evidence demonstrating the involvement of histone acetyltransferases (HATs) in the transactivation. Here we show that mouse Notch1 RAMIC interacts with two conserved HATs, mouse PCAF and GCN5, and recruits each of the HATs to RBP-J. The ankyrin repeats and the transactivation domain of RAMIC and the N-terminal regions of PCAF and GCN5, respectively, are required for the interaction. We also show that not only mouse Notch1 but also Drosophila Notch RAMIC interacts with mouse PCAF and GCN5 in mammalian cells. Furthermore, the RBP-J-mediated transactivation activity of RAMIC is repressed by two HAT inhibitor proteins, E1A and Twist. These results suggest that HATs including PCAF and GCN5 play an important role in the RBP-J-mediated transactivation by RAMIC.	Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Honjo, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan.	honjo@mfour.med.kyoto-u.ac.jp	Honjo, Tasuku/N-4470-2016					Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Candau R, 1996, MOL CELL BIOL, V16, P593; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382; COHEN JI, 1992, P NATL ACAD SCI USA, V89, P8030, DOI 10.1073/pnas.89.17.8030; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kato H, 1997, DEVELOPMENT, V124, P4133; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; LINT CV, 1996, EMBO J, V15, P1112; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Radkov SA, 1999, J VIROL, V73, P5688, DOI 10.1128/JVI.73.7.5688-5697.1999; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; Sakai T, 1998, J VIROL, V72, P6034, DOI 10.1128/JVI.72.7.6034-6039.1998; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Smith ER, 1998, NUCLEIC ACIDS RES, V26, P2948, DOI 10.1093/nar/26.12.2948; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	67	190	194	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17211	17220		10.1074/jbc.M000909200	http://dx.doi.org/10.1074/jbc.M000909200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747963	hybrid			2022-12-27	WOS:000087392200114
J	Matsuo, T; Stauffer, JK; Walker, RL; Meltzer, P; Thiele, CJ				Matsuo, T; Stauffer, JK; Walker, RL; Meltzer, P; Thiele, CJ			Structure and promoter analysis of the human unc-33-like phosphoprotein gene - E-box required for maximal expression in neuroblastoma and myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; AXONAL GUIDANCE; RETINOIC ACID; NERVOUS-SYSTEM; DIFFERENTIATION; IDENTIFICATION; OUTGROWTH; PROTEINS; HOMOLOG; FAMILY	The human unc-33-like phosphoprotein (hUlip/ CRMP-4) is a member of a family of developmentally regulated genes that are highly expressed in the nervous system. Mutations in the C. elegans unc-33 gene lead to worms with abnormal movements. The hUlip gene encodes a 570-amino acid protein with 98% homology 60 its murine (Ulip) (Byk, T., Dobransky, T., Cifuentes-Diaz, C., and Sobel, A. (1996) J. Neurosci. 16, 688-701) and rat (CRMP-4) (Wang, L. H., and Strittmatter, S. M. (1996) J. Neurosci, 16, 6197-6207) counterparts (Gaetano, C., Matsuo, T., and Thiele, C. J. (1997) J.. Biol. Chem. 272, 12195-12201). The hUlip gene was isolated from a human genomic library. It contains 15 exons, including an exon defined by an anaplastic oligodendroglioma expressed sequence tag, and spans at least 61.7 kilobases. hUlip lacks sequences corresponding to the first six exons found in unc-33. unc-33 exons correspond to homologous hUlip exons as follows: VII to 1 and 2, VIII to 3-9, IX to 10-12, and X to 13 and 14. Using the hUlip clone 1 phage, fluorescence in situ hybridization analysis indicates that the hybridization signal localizes to human chromosome 5q32. Deletion analysis of 5'-flanking sequences delineated the sequences sufficient to express a reporter gene in both neuroblastoma cells and myoblasts. A consensus MyoD/myogenin binding site is located in a region of the downstream promoter that is nearly identical to its mouse homologue. Mutagenesis shows that this conserved MyoD/myogenin site is necessary for full promoter activity in both myoblasts and neuroblastoma cells.	NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, Div Clin Sci,NIH, Bethesda, MD 20892 USA; NIH, Natl Human Genome Res Inst, Mol Genet Sect, Canc Genet Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Thiele, CJ (corresponding author), NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, Div Clin Sci,NIH, Bldg 10-13N240, Bethesda, MD 20892 USA.			Walker, Robert/0000-0001-8235-4686				BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRENNER S, 1974, GENETICS, V77, P71; BRENNER S, 1973, BRIT MED BULL, V29, P269, DOI 10.1093/oxfordjournals.bmb.a071019; Byk T, 1996, J NEUROSCI, V16, P688; Gaetano C, 1997, J BIOL CHEM, V272, P12195, DOI 10.1074/jbc.272.18.12195; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; LI W, 1992, GENETICS, V132, P675; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MINTURN JE, 1995, J NEUROSCI, V15, P6757; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; REESE MG, 1995, 7 INT GEN SEQ AN C H, P152; REESE MG, 1996, BIOCOMPUTING, P120; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Torres R, 1998, DNA Res, V5, P393, DOI 10.1093/dnares/5.6.393; Wang LH, 1996, J NEUROSCI, V16, P6197; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	24	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16560	16568		10.1074/jbc.M001312200	http://dx.doi.org/10.1074/jbc.M001312200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748015	hybrid			2022-12-27	WOS:000087392200024
J	McMahon, TJ; Stone, AE; Bonaventura, J; Singel, DJ; Stamler, JS				McMahon, TJ; Stone, AE; Bonaventura, J; Singel, DJ; Stamler, JS			Functional coupling of oxygen binding and vasoactivity in S-nitrosohemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHALED NITRIC-OXIDE; NICOTINAMIDE ADENINE DINUCLEOTIDES; ELECTRON-PARAMAGNETIC-RESONANCE; SICKLE-CELL HEMOGLOBIN; SMOOTH-MUSCLE; BIOCHEMICAL-CHARACTERIZATION; PLATELET-AGGREGATION; IN-VITRO; BLOOD; NITROSOTHIOLS	S-Nitrosohemoglobin (SNO-Hb) is a vasodilator whose activity is allosterically modulated by oxygen ("thermodynamic linkage"). Blood vessel contractions are favored in the oxygenated structure, and vasorelaxant activity is 'linked" to deoxygenation, as illustrated herein. We further show that transnitrosation reactions between SNO-Hb and ambient thiols transduce the NO-related bioactivity, whereas NO itself is inactive. One remaining problem is that the amounts of SNO-Hb present in vivo are so large as to be incompatible with Life were all the S-nitrosothiols transformed into bioactive equivalents during each arterial-venous cycle. Experiments were therefore undertaken to address how SNO-Hb, conserves its NO-related activity. Our studies show that 1) increased O-2 affinity of SNO-Hb (which otherwise retains allosteric responsivity) restricts the hypoxia-induced allosteric transition that exchanges NO groups with ambient thiols for vasorelaxation; 2) some NO groups released from Cys(beta 93) upon transition to T structure are autocaptured by the hemes, even in the presence of glutathione; and 3) an O-2-dependent equilibrium between SNO-Hb and iron nitrosylhemoglobin acts to conserve NO. Thus, by sequestering a significant fraction of NO liberated upon transition to T structure, Hb can conserve NO groups that would otherwise be released in an untimely or deleterious manner.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Nicholas Sch Environm, Durham, NC 27710 USA; Montana State Univ, Dept Chem, Bozeman, MT 59717 USA	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; Montana State University System; Montana State University Bozeman	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, POB 2612 MSRB Rm 321, Durham, NC 27710 USA.	STAML001@mc.duke.edu	McMahon, Tim/K-3986-2012	McMahon, Tim/0000-0002-3404-3223; Stamler, Jonathan/0000-0002-6866-1572	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059130, R01HL052529, K08HL004014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59130-02, HL52529-05, K08 HL04014-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P11; Bettati S, 1998, J MOL BIOL, V281, P581, DOI 10.1006/jmbi.1998.1983; BEUTLER E, 1994, RED CELL METABOLISM, P231; Bonaventura C, 1999, J BIOL CHEM, V274, P24742, DOI 10.1074/jbc.274.35.24742; Carter TD, 1997, BRIT J PHARMACOL, V122, P971, DOI 10.1038/sj.bjp.0701549; CASHON R, 1986, J BIOL CHEM, V261, P2700; Castillo L, 1996, P NATL ACAD SCI USA, V93, P11460, DOI 10.1073/pnas.93.21.11460; Chan NL, 1998, BIOCHEMISTRY-US, V37, P16459, DOI 10.1021/bi9816711; CRAESCU CT, 1986, J BIOL CHEM, V261, P4710; CRAESCU CT, 1985, J BIOL CHEM, V260, P5616; DEBELDER AJ, 1994, CARDIOVASC RES, V28, P691; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; Eaton WA, 1999, NAT STRUCT BIOL, V6, P351, DOI 10.1038/7586; FEELISCH M, 1994, NATURE, V368, P62, DOI 10.1038/368062a0; Ferranti P, 1997, FEBS LETT, V400, P19, DOI 10.1016/S0014-5793(96)01258-6; Fox-Robichaud A, 1998, J CLIN INVEST, V101, P2497, DOI 10.1172/JCI2736; Funai EF, 1997, BIOCHEM BIOPH RES CO, V239, P875, DOI 10.1006/bbrc.1997.7565; Gaston B, 1998, BIOCHEM BIOPH RES CO, V253, P899, DOI 10.1006/bbrc.1998.9865; GASTON B, 1994, J PHARMACOL EXP THER, V268, P978; Gladwin MT, 1999, J CLIN INVEST, V104, P937, DOI 10.1172/JCI7637; Gorren ACF, 1996, ARCH BIOCHEM BIOPHYS, V330, P219, DOI 10.1006/abbi.1996.0247; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Gross SS, 1999, P NATL ACAD SCI USA, V96, P9967, DOI 10.1073/pnas.96.18.9967; GUYTON AC, 1981, TXB MED PHYSL, P53; HALL DM, 1994, J APPL PHYSIOL, V77, P548, DOI 10.1152/jappl.1994.77.2.548; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Heyman SN, 1999, MICROCIRCULATION, V6, P199; IMAI K, 1983, J MOL BIOL, V167, P741, DOI 10.1016/S0022-2836(83)80107-7; IMAI K, 1977, BIOCHIM BIOPHYS ACTA, V490, P164, DOI 10.1016/0005-2795(77)90116-7; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KashibaIwatsuki M, 1997, J BIOCHEM-TOKYO, V122, P1208; Kermarrec N, 1998, AM J RESP CRIT CARE, V158, P833, DOI 10.1164/ajrccm.158.3.9709097; KERR SW, 1992, J PHARMACOL EXP THER, V263, P285; KILMARTIN JV, 1973, P NATL ACAD SCI USA, V70, P1246, DOI 10.1073/pnas.70.4.1246; KOWALUK EA, 1990, J PHARMACOL EXP THER, V255, P1256; Kubes P, 1999, AM J PHYSIOL-HEART C, V277, pH676, DOI 10.1152/ajpheart.1999.277.2.H676; MACALLISTER RJ, 1995, J PHARMACOL EXP THER, V273, P154; Mamone G, 1999, FEBS LETT, V462, P241, DOI 10.1016/S0014-5793(99)01527-6; McMahon TJ, 1999, METHOD ENZYMOL, V301, P99; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; OGO S, 1989, J BIOL CHEM, V264, P11302; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; Pawloski JR, 1998, CIRCULATION, V97, P263, DOI 10.1161/01.CIR.97.3.263; Perutz MF, 1996, NATURE, V380, P205, DOI 10.1038/380205b0; PERUTZ MF, 1969, NATURE, V222, P1240, DOI 10.1038/2221240a0; PERUTZ MF, 1987, MOL BASIS BLOOD DISE, P140; Reddy PL, 1997, CLIN CHEM, V43, P1442; RIGGS AF, 1956, J GEN PHYSIOL, V39, P585, DOI 10.1085/jgp.39.4.585; Rossi R, 1997, ANAL BIOCHEM, V254, P215, DOI 10.1006/abio.1997.2424; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1996, METHODS NITRIC OXIDE, P521; Togashi H., 1999, Acta Physiologica Scandinavica, V167, P12; Troncy E, 1997, BRIT J ANAESTH, V79, P631, DOI 10.1093/bja/79.5.631; WESSEL DL, 1993, CIRCULATION, V88, P2128, DOI 10.1161/01.CIR.88.5.2128; Wolzt M, 1999, J BIOL CHEM, V274, P28983, DOI 10.1074/jbc.274.41.28983; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Yonetani T, 1998, J BIOL CHEM, V273, P20323, DOI 10.1074/jbc.273.32.20323	62	128	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16738	16745		10.1074/jbc.M000532200	http://dx.doi.org/10.1074/jbc.M000532200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747928	hybrid			2022-12-27	WOS:000087392200049
J	Neve, EPA; Ingelman-Sundberg, M				Neve, EPA; Ingelman-Sundberg, M			Molecular basis for the transport of cytochrome P450 2E1 to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM AUTOANTIBODIES; INDUCED AUTOIMMUNE HEPATITIS; RAT-LIVER; MICROSOMAL CYTOCHROME-P-450; GOLGI-APPARATUS; ANTI-LIVER; INSERTION; PROTEIN; TOPOLOGY; SURFACE	Endoplasmic reticulum-resident cytochrome P450 enzymes that face the cytosol are present on the plasma membrane of hepatocytes, but the molecular origin for their transport to this compartment has until now remained unknown. The molecular basis for the transport of rat ethanol-inducible cytochrome P450 2E1 (CYP2E1) to the plasma membrane was investigated by transfection of several different mutant cDNAs into mouse H2.35 hepatoma cells. Two NH2-terminal CYP2E1 mutants were constructed: N(++)2E1, which carried two positive charges in the NH, terminus, and 2C-2E1, in which the transmembrane domain of CYP2E1 was replaced with that of CYP2C1, which was previously described to cause retention of CYP2C1 in the endoplasmic reticulum, as well as CYP2E1 COOH-terminally tagged with the vesicular stomatitis virus G protein (VSV-G) epitope (2E1-VSV-G). Immunofluorescent microscopy and cell surface biotinylation experiments revealed that all CYP2E1 variants were present on the extracellular side of the plasma membrane. The VSV-G epitope on CYP2E1 was detected on the outside of the plasma membrane using VSV-G-specific antibodies, indicating that the large COOH-terminal part of CYP2E1 is indeed exposed on the outside of the plasma membrane. The relative levels of CYP2E1, 2C-2E1, and 2E1-VSV-G on the cell surface were found to be about 2% of total cellular enzyme, whereas twice this amount of N(++)2E1 was recovered at the cell surface. Protease protection experiments performed on microsomes isolated from cDNA transfected cells revealed that a small fraction of CYP2E1 and all variant proteins was found to be located in the lumen of the endoplasmic reticulum (type II orientation), whereas the majority of the proteins were in the expected cytosolic or type I orientation. It is concluded that the NH2-terminal transmembrane domain of CYP2E1 plays a critical role in directing the protein to the cell surface and that topological inversion of a small fraction of CYP2E1 in the endoplasmic reticulum directs the protein to the plasma membrane.	Karolinska Inst, Natl Inst Environm Med, Div Mol Toxicol, S-17177 Stockholm, Sweden	Karolinska Institutet	Neve, EPA (corresponding author), Karolinska Inst, Natl Inst Environm Med, Div Mol Toxicol, Box 210, S-17177 Stockholm, Sweden.		Ingelman-Sundberg, Magnus/ABD-9302-2021					Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; AHN KS, 1993, J BIOL CHEM, V268, P18726; Amarneh BA, 1996, MOL CELL ENDOCRINOL, V119, P69, DOI 10.1016/0303-7207(96)03796-3; BARNUN S, 1980, P NATL ACAD SCI-BIOL, V77, P965, DOI 10.1073/pnas.77.2.965; BEAUNE P, 1987, P NATL ACAD SCI USA, V84, P551, DOI 10.1073/pnas.84.2.551; Beaune P, 1994, Adv Pharmacol, V30, P199, DOI 10.1016/S1054-3589(08)60175-1; Belloc C, 1997, PHARMACOGENETICS, V7, P181, DOI 10.1097/00008571-199706000-00002; Bondoc FY, 1999, BIOCHEM PHARMACOL, V58, P461, DOI 10.1016/S0006-2952(99)00111-2; BOURDI M, 1990, J CLIN INVEST, V85, P1967, DOI 10.1172/JCI114660; Clot P, 1996, GASTROENTEROLOGY, V111, P206, DOI 10.1053/gast.1996.v111.pm8698201; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; Eliasson E, 1996, MOL PHARMACOL, V50, P573; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Ingelman-Sundberg M, 1986, CYTOCHROME P450 STRU, P119; INGELMANSUNDBERG M, 1993, ALCOHOL, V10, P447, DOI 10.1016/0741-8329(93)90063-T; Lecoeur S, 1996, MOL PHARMACOL, V50, P326; Loeper J, 1998, MOL PHARMACOL, V53, P408, DOI 10.1124/mol.53.3.408; LOEPER J, 1993, GASTROENTEROLOGY, V104, P203, DOI 10.1016/0016-5085(93)90853-5; Loeper J, 1998, MOL PHARMACOL, V54, P8, DOI 10.1124/mol.54.1.8; LOEPER J, 1990, HEPATOLOGY, V11, P850, DOI 10.1002/hep.1840110521; Lytton SD, 1999, MOL PHARMACOL, V55, P223, DOI 10.1124/mol.55.2.223; Mkrtchian S, 1998, EUR J BIOCHEM, V251, P304, DOI 10.1046/j.1432-1327.1998.2510304.x; Mkrtchiana S, 1998, FEBS LETT, V431, P322, DOI 10.1016/S0014-5793(98)00786-8; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MURAKAMI K, 1994, J BIOCHEM, V116, P164, DOI 10.1093/oxfordjournals.jbchem.a124489; MYASOEDOVA KN, 1990, FEBS LETT, V275, P235, DOI 10.1016/0014-5793(90)81479-8; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Neve EPA, 1999, FEBS LETT, V460, P309, DOI 10.1016/S0014-5793(99)01361-7; Neve EPA, 1996, ARCH BIOCHEM BIOPHYS, V333, P459, DOI 10.1006/abbi.1996.0415; Omura T, 1999, BIOCHEM BIOPH RES CO, V266, P690, DOI 10.1006/bbrc.1999.1887; Pahan K, 1997, FREE RADICAL BIO MED, V23, P963, DOI 10.1016/S0891-5849(97)00017-8; Pirmohamed M, 1996, CYTOCHROMES P450 MET, P329; ROBIN MA, 1995, GASTROENTEROLOGY, V108, P1110, DOI 10.1016/0016-5085(95)90210-4; RONIS MJJ, 1991, EUR J BIOCHEM, V198, P383, DOI 10.1111/j.1432-1033.1991.tb16026.x; Ronis MJJ, 1996, CYTOCHROMES P450 MET, P211; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SCHWARZ D, 1990, BIOCHEM BIOPH RES CO, V171, P175, DOI 10.1016/0006-291X(90)91373-Z; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; WU DF, 1992, HEPATOLOGY, V15, P515, DOI 10.1002/hep.1840150326; Zhu QS, 1999, J BIOL CHEM, V274, P27898, DOI 10.1074/jbc.274.39.27898	44	55	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17130	17135		10.1074/jbc.M000957200	http://dx.doi.org/10.1074/jbc.M000957200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747972	hybrid			2022-12-27	WOS:000087392200102
J	Wolfgang, CD; Liang, GS; Okamoto, Y; Allen, AE; Hai, T				Wolfgang, CD; Liang, GS; Okamoto, Y; Allen, AE; Hai, T			Transcriptional autorepression of the stress-inducible gene ATF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; NEGATIVE AUTOREGULATION; REGENERATING LIVER; GROWTH-FACTOR; IDENTIFICATION; EXPRESSION; PROMOTER; PROTEIN; PHOSPHORYLATION; GADD153/CHOP10	Previously, we demonstrated that ATF3 ((a) under bar ctivating (t) under bar ranscription (f) under bar actor-(3) under bar) is a stress-inducible gene, and the protein it encodes is a transcriptional repressor. In this report, we present evidence suggesting that ATF3 represses the transcription of its own gene. Interestingly, efficient repression requires a consensus ATF/ cAMP-responsive element site in the promoter and a previously unidentified ATF3-binding site immediately downstream from the TATA box. Although this new site resembles the known ATF/cAMP-responsive element sequences at the flanking sequence, it differs from them at the center key residues. These observations indicate that ATF3 can tolerate variations in the center of the binding sites if the flanking sequences are favorable. The repression of the ATF3 promoter by its own gene product provides a mechanistic explanation, at least in part, for the transient expression pattern of the ATF3 gene upon stress induction.	Ohio State Univ, Neurobiotechnol Ctr, Dept Biochem Med, Columbus, OH 43210 USA; Ohio State Univ, Biochem Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Hai, T (corresponding author), Ohio State Univ, Neurobiotechnol Ctr, Dept Biochem Med, Rightmire Hall,Rm 174,1060 Carmack Rd, Columbus, OH 43210 USA.		Hai, Tsonwin/E-3185-2011; Hai, Tsonwin/H-4480-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315	NIEHS NIH HHS [R01 ES08690] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008690] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; Hai T, 1999, GENE EXPRESSION, V7, P321; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HANNINK M, 1990, ONCOGENE, V5, P1843; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Sambrook J., 2002, MOL CLONING LAB MANU; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WEIR E, 1994, HEPATOLOGY, V20, P955, DOI 10.1002/hep.1840200426; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943	29	83	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16865	16870		10.1074/jbc.M909637199	http://dx.doi.org/10.1074/jbc.M909637199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748147	hybrid			2022-12-27	WOS:000087392200066
J	Oliveira, AC; Gomes, AMO; Almeida, FCL; Mohana-Borges, R; Valente, AP; Reddy, VS; Johnson, JE; Silva, JL				Oliveira, AC; Gomes, AMO; Almeida, FCL; Mohana-Borges, R; Valente, AP; Reddy, VS; Johnson, JE; Silva, JL			Virus maturation targets the protein capsid to concerted disassembly and unfolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLOCK-HOUSE VIRUS; INFLUENZA HEMAGGLUTININ; FUNCTIONAL IMPLICATIONS; 3-DIMENSIONAL STRUCTURE; PRESSURE DENATURATION; MEMBRANE-FUSION; ARC REPRESSOR; MOSAIC-VIRUS; STABILITY; PICORNAVIRUSES	Many animal viruses undergo post-assembly proteolytic cleavage that is required for infectivity, The role of maturation cleavage on Flock House virus was evaluated by comparing wild type (wt) and cleavage-defective mutant (D75N) Flock House virus virus-like particles. A concerted dissociation and unfolding of the mature wt particle was observed under treatment by urea, whereas the cleavage-defective mutant dissociated to folded subunits as determined by steady-state and dynamic fluorescence spectroscopy, circular dichroism, and nuclear magnetic resonance. The folded D75N a subunit could reassemble into capsids, whereas the yield of reassembly from unfolded cleaved alpha subunits was very low. Overall, our results demonstrate that the maturation/cleavage process targets the particle for an "off pathway" disassembly, because dissociation is coupled to unfolding. The increased motions in the cleaved capsid, revealed by fluorescence and NMR, and the concerted nature of dissociation/unfolding may be crucial to make the mature particle infectious.	Univ Fed Rio de Janeiro, Ctr Nacl Ressonancia Magnet Nucl Macromol, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Universidade Federal do Rio de Janeiro; Scripps Research Institute	Silva, JL (corresponding author), Univ Fed Rio de Janeiro, Ctr Nacl Ressonancia Magnet Nucl Macromol, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.		Oliveira, Andrea C/O-6695-2018; Almeida, Fabio/O-4989-2018; Borges, Ronaldo S Mohana/C-5575-2013; Valente, Ana Paula/J-3010-2017; Gomes, Andre M.O./C-4009-2014; SILVA, JERSON Lima/GRF-1442-2022; Silva, Jerson/J-8984-2014	Almeida, Fabio/0000-0001-6046-7006; Valente, Ana Paula/0000-0001-7219-1123; Gomes, Andre M.O./0000-0003-1052-8004; SILVA, JERSON Lima/0000-0001-9523-9441; Silva, Jerson/0000-0001-9523-9441				ALCALA JR, 1985, ANAL INSTRUM, V14, P225; Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X; BAVASAPPA R, 1994, PROTEIN SCI, V3, P1651; Beechem JM., 2002, TOPICS FLUORESCENCE, P241, DOI DOI 10.1007/0-306-47058-6_5; Bong DT, 1999, CHEM BIOL, V6, P473, DOI 10.1016/S1074-5521(99)80065-9; Bothner B, 1999, NAT STRUCT BIOL, V6, P114; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHENG RH, 1994, STRUCTURE, V2, P271; COOPER A, 1976, P NATL ACAD SCI USA, V73, P2740, DOI 10.1073/pnas.73.8.2740; DAPOIAN AT, 1995, BIOCHEMISTRY-US, V34, P2672, DOI 10.1021/bi00008a034; Dimitrov DS, 1997, CELL, V91, P721, DOI 10.1016/S0092-8674(00)80460-2; FOGUEL D, 1995, BIOCHEMISTRY-US, V34, P120; GALLAGHER TM, 1988, J VIROL, V62, P3399, DOI 10.1128/JVI.62.9.3399-3406.1988; Gaspar LP, 1997, J MOL BIOL, V273, P456, DOI 10.1006/jmbi.1997.1299; GRATTON E, 1986, BIOCHEM SOC T, V14, P835, DOI 10.1042/bst0140835; Harrison Stephen C., 1996, P59; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; Janshoff A, 1999, BIOCHEMISTRY-US, V38, P5328, DOI 10.1021/bi982976i; Johnson JE, 1996, P NATL ACAD SCI USA, V93, P27, DOI 10.1073/pnas.93.1.27; LIANG H, 1993, P NATL ACAD SCI USA, V90, P7010, DOI 10.1073/pnas.90.15.7010; Mohana-Borges R, 1999, J BIOL CHEM, V274, P7732, DOI 10.1074/jbc.274.12.7732; Oliveira AC, 1999, BIOPHYS J, V76, P1270, DOI 10.1016/S0006-3495(99)77290-5; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PREDKI PF, 1995, BIOCHEMISTRY-US, V34, P9834, DOI 10.1021/bi00031a003; PREVELIGE PE, 1994, BIOPHYS J, V66, P1631, DOI 10.1016/S0006-3495(94)80955-5; Robinson CR, 1996, BIOCHEMISTRY-US, V35, P13878, DOI 10.1021/bi961375t; Robinson CR, 1995, METHOD ENZYMOL, V259, P395; ROSSMANN MG, 1994, PROTEIN SCI, V3, P1712, DOI 10.1002/pro.5560031010; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; Rueckert R., 1996, FIELDS VIROLOGY, P609; Schneemann A, 1998, ADV VIRUS RES, V50, P381, DOI 10.1016/S0065-3527(08)60812-X; SCHNEEMANN A, 1994, J VIROL, V68, P4547, DOI 10.1128/JVI.68.7.4547-4556.1994; SCHNEEMANN A, 1993, J VIROL, V67, P2756, DOI 10.1128/JVI.67.5.2756-2763.1993; SILVA JL, 1988, J MOL BIOL, V199, P149, DOI 10.1016/0022-2836(88)90385-3; Silva JL, 1996, CURR OPIN STRUC BIOL, V6, P166, DOI 10.1016/S0959-440X(96)80071-6; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; Smith TJ, 1999, ADV VIRUS RES, V52, P1, DOI 10.1016/S0065-3527(08)60297-3; WERY JP, 1994, J MOL BIOL, V235, P565, DOI 10.1006/jmbi.1994.1014; ZLOTNICK A, 1994, J BIOL CHEM, V269, P13680	44	26	27	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16037	16043		10.1074/jbc.M910145199	http://dx.doi.org/10.1074/jbc.M910145199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748191	hybrid			2022-12-27	WOS:000087291400059
J	Yung, YV; Yao, Z; Hanoch, T; Seger, R				Yung, YV; Yao, Z; Hanoch, T; Seger, R			RETRACTED: ERK1b, a 46-kDa ERK isoform that is differentially regulated by MEK (Retracted article. See vol. 292, pg. 8854, 2017)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							ACTIVATED PROTEIN-KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; NUCLEAR TRANSLOCATION; TYROSINE-PHOSPHATASE; NIH 3T3-CELLS; PC12 CELLS; PHOSPHORYLATION; EXPRESSION; IDENTIFICATION	We identified a 46-kDa ERK, whose kinetics of activation was similar to that of ERK1 and ERK2 in most cell lines and conditions, but showed higher fold activation in response to osmotic shock and epidermal growth factor treatments of Ras-transformed cells. We purified and cloned this novel ERK (ERK1b), which is an alternatively spliced form of ERK1 with a 26-amino acid insertion between residues 340 and 341 of ERK1. When expressed in COS7 cells, ERK1b exhibited kinetics of activation and kinase activity similar to those of ERK1. Unlike the uniform pattern of expression of ERK1 and ERK2, ERK1b was detected only in some of the tissues examined and seems to be abundant in the rat and human heart. Interestingly, in has-transformed Rat1 cells, there was a 7-fold higher expression of ERK1b, which was also more responsive than ERK1 and ERK2 to various extracellular treatments. Unlike ERK1 and ERK2, ERK1b failed to interact with MEK1 as judged from its nuclear localization in resting cells overexpressing ERK1b together with MEK1 or by lack of coimmunoprecipitation of the two proteins. Thus, ERK1b is a novel 46-kDa ERK isoform, which seems to be the major ERK isoform that responds to exogenous stimulation in Ras-transformed cells probably due to its differential regulation by MEK.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Seger, R (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	bmseger@weizmann.weizmann.ac.il						ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Berman DE, 1998, J NEUROSCI, V18, P10037; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; Gopalbhai K, 1998, J CELL PHYSIOL, V174, P35, DOI 10.1002/(SICI)1097-4652(199801)174:1<35::AID-JCP5>3.0.CO;2-H; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; JUCKER M, 1992, ONCOGENE, V7, P943; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Michael D, 1998, P NATL ACAD SCI USA, V95, P1864, DOI 10.1073/pnas.95.4.1864; Misteli T, 1999, CURR BIOL, V9, pR198, DOI 10.1016/S0960-9822(99)80128-6; PAGES G, 1995, J BIOL CHEM, V270, P26986, DOI 10.1074/jbc.270.45.26986; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Peng X, 1996, J NEUROCHEM, V66, P1191; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rong X, 1996, IMMUNOL LETT, V54, P105, DOI 10.1016/S0165-2478(96)02657-0; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Sadot E, 1998, J NEUROCHEM, V70, P428; Salh B, 1999, ANTICANCER RES, V19, P731; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1992, J BIOL CHEM, V267, P14373; Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	54	63	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15799	15808		10.1074/jbc.M910060199	http://dx.doi.org/10.1074/jbc.M910060199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748187	hybrid, Green Published			2022-12-27	WOS:000087291400028
J	Becker, NA; Kelm, RJ; Vrana, JA; Getz, MJ; Maher, LJ				Becker, NA; Kelm, RJ; Vrana, JA; Getz, MJ; Maher, LJ			Altered sensitivity to single-strand-specific reagents associated with the genomic vascular smooth muscle alpha-actin promoter during myofibroblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; LIGATION MEDIATED PCR; FAR UPSTREAM ELEMENT; ENHANCER FACTOR-I; GENE PROMOTER; GRANULATION TISSUE; M-CAT; PUR-ALPHA; C-MYC; FIBROBLASTS	Stimulation of quiescent AKR-2B mouse fibroblasts with transforming growth factor beta 1 results in uniform conversion to a myofibroblast-like phenotype as judged by a rapid accumulation of smooth muscle alpha-actin mRNA and protein. Because transcriptional regulation of the smooth muscle alpha-actin gene in these cells might be mediated by single-stranded DNA-binding proteins, we have examined the sensitivity of genomic DNA to chemical reagents with specificity for unpaired bases in a region of the promoter previously implicated in Pur alpha, Pur beta, and MSY1 binding in vitro (Kelm, R. J., Jr., Cogan, J. G., Elder, P. K., Strauch, A. R., and Getz, M. J. (1999) J, Biol. Chem. 274, 14238-14245), Our data reveal specific differences between purified DNA treated in vitro and nucleoprotein complexes treated in living cells. Although some differences were observed in quiescent cells, treatment with transforming growth factor beta 1 resulted in the development of additional sensitivity within 1 h. This enhancement was most pronounced in bases immediately upstream of an MCAT enhancer element-containing polypurine-polypyrimidine tract. A TATA-proximal element of similar base distribution showed no such hyperreactivities, These results suggest that activation of the endogenous smooth muscle alpha-actin gene during myofibroblast conversion is accompanied by specific structural changes in the promoter that are consistent with a decline in single-stranded DNA repressor protein binding.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Maher, LJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	maher@mayo.edu			NHLBI NIH HHS [HL54281] Funding Source: Medline; NIGMS NIH HHS [GM54411, GM48714] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054411, R01GM048714] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; DARBY I, 1990, LAB INVEST, V63, P21; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; DESMOULIERE A, 1992, EXP CELL RES, V201, P64, DOI 10.1016/0014-4827(92)90348-C; Duncan R, 1996, MOL CELL BIOL, V16, P2274; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; GABBIANI G, 1971, EXPERIENTIA, V27, P549, DOI 10.1007/BF02147594; GABBIANI G, 1972, J EXP MED, V135, P719, DOI 10.1084/jem.135.4.719; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MAJNO G, 1971, SCIENCE, V173, P548, DOI 10.1126/science.173.3996.548; Maxam A M, 1980, Methods Enzymol, V65, P499; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; RONNOVJESSEN L, 1993, LAB INVEST, V68, P696; Rothman-Denes LB, 1998, COLD SPRING HARB SYM, V63, P63, DOI 10.1101/sqb.1998.63.63; ROWE WP, 1971, VIROLOGY, V46, P866, DOI 10.1016/0042-6822(71)90087-0; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SAPPINO AP, 1990, LAB INVEST, V63, P144; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; SINDEN RR, 1994, DNA STRUCTURE FUNCTI, P134; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; Skalli O, 1988, MOL CELLULAR BIOL WO, P373; SPIRO C, 1999, TRANSCRIPTION FACTOR, P27; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; SWARTZ EA, 1998, AM J PHYSIOL, V275, P608; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791	51	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15384	15391		10.1074/jbc.M909687199	http://dx.doi.org/10.1074/jbc.M909687199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748152	hybrid			2022-12-27	WOS:000087128300083
J	Szeltner, Z; Renner, V; Polgar, L				Szeltner, Z; Renner, V; Polgar, L			The noncatalytic beta-propeller domain of prolyl oligopeptidase enhances the catalytic capability of the peptidase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVOBACTERIUM-MENINGOSEPTICUM; ENDOPEPTIDASE INHIBITORS; SERINE; ENZYME; MECHANISM; CLONING	Prolyl oligopeptidase, which is involved in memory disorders, is a member of a new family of serine peptidases, In addition to the peptidase domain, the enzyme contains a beta-propeller, which excludes large peptides from the active site. The enzyme is inhibited with thiol reagents, possibly by reacting with Cys-255 located close to the substrate binding site. This assumption was tested with the Cys-255 --> Thr, Cys-255 --> Ala, and Cys-255 --> Ser variants of prolyl oligopeptidase, In contrast to the wild type enzyme, the Cys-255 --> Thr variant was not inhibited with N-ethylmaleimide, indicating that Cys-255, of the 16 free cysteine residues, exclusively accounts for the enzyme inhibition. Unlike the wild type enzyme that showed a doubly bell-shaped pH rate profile, the modified enzyme displayed a single bell-shaped pH dependence with benzyloxycarbonyl-Gly-Pro-naphthylamide, It was the high pH form of the enzyme that virtually disappeared with all three enzyme variants. A substantial reduction was also observed in k(cat)/K-m for the aminobenzoyl-Ser-Pro-Phe (NO2)-Ala-OH substrate. The high pK(a) (9.77) of Cys-255 determined by titration with N-ethylmaleimide excluded the possibility that ionization of the thiol group was responsible for generation of the two active enzyme forms. The impaired activity of the enzyme variants could be rationalized in terms of weaker binding, which manifests itself in high K-m for substrates and high K-i for inhibitors, like benzyloxycarbonyl-Grly-Pro-OH and aminobenzoyl-Ser-D-Pro-Phe(NO2)-Ala-OH. It was concluded that, besides selecting substrates by size, the beta-propeller domain containing Cys-255 remarkably contributed to catalysis of the peptidase domain.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Polgar, L (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, POB 7, H-1518 Budapest, Hungary.	polgar@enzim.hu						ATACK JR, 1991, EUR J PHARMACOL, V205, P157, DOI 10.1016/0014-2999(91)90814-7; BENDER ML, 1965, ANNU REV BIOCHEM, V34, P49, DOI 10.1146/annurev.bi.34.070165.000405; CHEVALLIER S, 1992, J BIOL CHEM, V267, P8192; Cunningham DF, 1997, BBA-PROTEIN STRUCT M, V1343, P160, DOI 10.1016/S0167-4838(97)00134-9; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; JAMES MNG, 1980, J MOL BIOL, V144, P43, DOI 10.1016/0022-2836(80)90214-4; KRIEG F, 1995, APPL MICROBIOL BIOT, V42, P844; LEATHERBARROW RJ, 1990, GRAFIT VERSION 2; MAES M, 1994, BIOL PSYCHIAT, V35, P545, DOI 10.1016/0006-3223(94)90101-5; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; MIURA N, 1995, NEUROSCI LETT, V196, P128, DOI 10.1016/0304-3940(95)11821-D; POLGAR L, 1995, BIOCHEM J, V312, P267, DOI 10.1042/bj3120267; POLGAR L, 1991, EUR J BIOCHEM, V197, P441, DOI 10.1111/j.1432-1033.1991.tb15930.x; POLGAR L, 1994, METHOD ENZYMOL, V244, P188; POLGAR L, 1989, MECHANISMS PROTEASE, P87; Portevin B, 1996, J MED CHEM, V39, P2379, DOI 10.1021/jm950858c; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; SCALONI A, 1994, J BIOL CHEM, V269, P15076; Szeltner Z, 2000, PROTEIN SCI, V9, P353; WELCHES WR, 1993, LIFE SCI, V52, P1461, DOI 10.1016/0024-3205(93)90108-F; WILK S, 1983, LIFE SCI, V33, P2149, DOI 10.1016/0024-3205(83)90285-0; Williams RSB, 1999, EMBO J, V18, P2734, DOI 10.1093/emboj/18.10.2734; YOSHIMOTO T, 1991, J BIOCHEM-TOKYO, V110, P873, DOI 10.1093/oxfordjournals.jbchem.a123682; YOSHIMOTO T, 1987, J PHARMACOBIO-DYNAM, V10, P730, DOI 10.1248/bpb1978.10.730; YOSHIMOTO T, 1988, J BIOCHEM, V104, P622, DOI 10.1093/oxfordjournals.jbchem.a122522	26	31	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15000	15005		10.1074/jbc.M000942200	http://dx.doi.org/10.1074/jbc.M000942200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747969	hybrid			2022-12-27	WOS:000087128300033
J	Pack-Chung, E; Meyers, MB; Pettingell, WP; Moir, RD; Brownawell, AM; Cheng, I; Tanzi, RE; Kim, TW				Pack-Chung, E; Meyers, MB; Pettingell, WP; Moir, RD; Brownawell, AM; Cheng, I; Tanzi, RE; Kim, TW			Presenilin 2 interacts with sorcin, a modulator of the ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; BETA-CATENIN; CELLS; ASSOCIATION; MUTATIONS; COMPLEX; RELEASE; NOTCH	Perturbed Ca2+ homeostasis is a common molecular consequence of familial Alzheimer's disease-linked presenilin mutations. We report here the molecular interaction of the large hydrophilic loop region of presenilin 2 (PS2) with sorcin, a penta-EF-hand Ca2+-binding protein that serves as a modulator of the ryanodine receptor intracellular Ca2+ channel. The association of endogenous sorcin and PS2 was demonstrated in cultured cells and human brain tissues. Membrane-associated sorcin and a subset of the functional PS2 complexes were co-localized to a novel subcellular fraction that is distinctively positive for calcineurin B. Sorcin was found to interact with PS2 endoproteolytic fragments but not full-length PS2, and the sorcin/PS2 interaction was greatly enhanced by treatment with the Ca2+ ionophore A23187. Our findings reveal a molecular link between PS2 and intracellular Ca2+ channels (i.e. ryanodine receptor) and substantiate normal and/or pathological roles of PS2 in intracellular Ca2+ homeostasis.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Genet & Aging Res Unit, Charlestown, MA 02129 USA; CUNY Mt Sinai Sch Med, Cardiovasc Inst, Dept Med, New York, NY 10029 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	Harvard University; Massachusetts General Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Virginia	Kim, TW (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Genet & Aging Res Unit, Charlestown, MA 02129 USA.	kim@helix.mgh.harvard.edu	Tanzi, Rudolph/AAE-9622-2019; Moir, Robert D./M-7612-2017	Tanzi, Rudolph/0000-0002-7032-1454; Moir, Robert D./0000-0001-5431-3553				Alkon DL, 1998, TRENDS NEUROSCI, V21, P529, DOI 10.1016/S0166-2236(98)01277-6; Balschun D, 1999, EMBO J, V18, P5264, DOI 10.1093/emboj/18.19.5264; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BOYHAN A, 1992, J BIOL CHEM, V267, P2928; Brownawell AM, 1997, J BIOL CHEM, V272, P22182, DOI 10.1074/jbc.272.35.22182; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; DRASER PE, 1998, NEUROBIOL AGING, V19, P19; Dumanchin C, 1999, HUM MOL GENET, V8, P1263, DOI 10.1093/hmg/8.7.1263; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Honda T, 1999, J NEUROCHEM, V72, P255, DOI 10.1046/j.1471-4159.1999.0720255.x; Imafuku I, 1999, J CELL BIOL, V147, P121, DOI 10.1083/jcb.147.1.121; Kang DE, 1999, J NEUROSCI, V19, P4229; Kelliher M, 1999, NEUROSCIENCE, V92, P499, DOI 10.1016/S0306-4522(99)00042-1; Kim M, 1999, NEUROSCIENCE, V89, P1159, DOI 10.1016/S0306-4522(98)00400-X; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Leissring MA, 1999, J BIOL CHEM, V274, P32535, DOI 10.1074/jbc.274.46.32535; Lokuta AJ, 1997, J BIOL CHEM, V272, P25333, DOI 10.1074/jbc.272.40.25333; Maki M, 1997, BIOCHEM J, V328, P718; Marambaud P, 1998, MOL MED, V4, P147, DOI 10.1007/BF03401912; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Pickel VM, 1997, J COMP NEUROL, V386, P625, DOI 10.1002/(SICI)1096-9861(19971006)386:4<625::AID-CNE8>3.0.CO;2-4; Querfurth HW, 1997, J NEUROCHEM, V69, P1580; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Saura C. A., 1999, Society for Neuroscience Abstracts, V25, P56; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Stabler SM, 1999, J CELL BIOL, V145, P1277, DOI 10.1083/jcb.145.6.1277; Stahl B, 1999, J BIOL CHEM, V274, P9141, DOI 10.1074/jbc.274.14.9141; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Tesco G, 1998, J BIOL CHEM, V273, P33909, DOI 10.1074/jbc.273.51.33909; Thinakaran G, 1999, J CLIN INVEST, V104, P1321, DOI 10.1172/JCI8728; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Valdivia HH, 1998, TRENDS PHARMACOL SCI, V19, P479, DOI 10.1016/S0165-6147(98)01269-3; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zhang WJ, 1998, J NEUROSCI, V18, P914; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	60	88	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14440	14445		10.1074/jbc.M909882199	http://dx.doi.org/10.1074/jbc.M909882199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10748169	hybrid			2022-12-27	WOS:000087006900060
J	Abele, R; Keinanen, K; Madden, DR				Abele, R; Keinanen, K; Madden, DR			Agonist-induced isomerization in a glutamate receptor ligand-binding domain - A kinetic and mutagenetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPA KAINATE RECEPTORS; HIPPOCAMPAL-NEURONS; CONFORMATIONAL-CHANGES; ANGSTROM RESOLUTION; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; ACID RECEPTORS; NMDA RECEPTOR; ION CHANNELS; NR1 SUBUNIT	Agonist binding to glutamate receptor ion channels occurs within an extracellular domain (S1S2) that retains ligand affinity when expressed separately. S1S2 is homologous to periplasmic binding proteins, and it has been proposed that a Venus flytrap-style cleft closure triggers opening of glutamate receptor ion channels. Here we compare the kinetics of S1S2-agonist binding to those of the periplasmic binding proteins and show that the reaction involves an initial rapid association, followed by slower conformational changes that stabilize the complex: "docking" followed by "locking." The motion detected here reflects the mechanism by which the energy of glutamate binding is converted into protein conformational changes within S1S2 alone. In the intact channel, these load-free conformational changes are harnessed and possibly modified as the agonist binding reaction is used to drive channel opening and subsequent desensitization. Using mutagenesis, key residues in each step were identified, and their roles were interpreted in light of a published S1S2 crystal structure. In contrast to the Venus flytrap proposal, which focuses on motion between the two lobes as the readout for agonist binding, we argue that smaller, localized conformational rearrangements allow agonists to bridge the cleft, consistent with published hydrodynamic measurements.	Max Planck Inst Med Res, Ion Channel Struct Res Gr, D-69120 Heidelberg, Germany; Univ Helsinki, Viikki Bioctr, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	Max Planck Society; University of Helsinki; University of Helsinki	Madden, DR (corresponding author), Max Planck Inst Med Res, Ion Channel Struct Res Gr, Jahnstr 29, D-69120 Heidelberg, Germany.		Keinanen, Kari/E-9122-2010					Abele R, 1999, BIOCHEMISTRY-US, V38, P10949, DOI 10.1021/bi982928y; Abele R, 1998, J BIOL CHEM, V273, P25132, DOI 10.1074/jbc.273.39.25132; ABELE R, 1998, THESIS R KARLS U HEI; ARAI A, 1995, NEUROSCIENCE, V66, P815, DOI 10.1016/0306-4522(94)00616-D; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Clements JD, 1998, J NEUROSCI, V18, P119; Colquhoun D, 1998, NEURON, V20, P381, DOI 10.1016/S0896-6273(00)80982-4; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; HIROMI K, 1979, KINETICS FAST ENZYME, P187; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Jayaraman V, 1998, BIOCHEMISTRY-US, V37, P16735, DOI 10.1021/bi9813328; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawamoto Susumu, 1997, Molecular Brain Research, V47, P339, DOI 10.1016/S0169-328X(97)00103-4; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KISKIN NI, 1986, NEUROSCI LETT, V63, P225, DOI 10.1016/0304-3940(86)90360-5; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Lampinen M, 1998, EMBO J, V17, P4704, DOI 10.1093/emboj/17.16.4704; LARSON J, 1994, NEUROREPORT, V5, P389, DOI 10.1097/00001756-199401120-00004; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Lawrence MC, 1998, STRUCTURE, V6, P1553, DOI 10.1016/S0969-2126(98)00153-1; Ledvina PS, 1998, PROTEIN SCI, V7, P2550, DOI 10.1002/pro.5560071208; LESTER RAJ, 1993, J NEUROSCI, V13, P1088; Mano I, 1996, J BIOL CHEM, V271, P15299, DOI 10.1074/jbc.271.26.15299; MAO B, 1982, J BIOL CHEM, V257, P1131; MAYER ML, 1989, P NATL ACAD SCI USA, V86, P1411, DOI 10.1073/pnas.86.4.1411; MILLER DM, 1983, J BIOL CHEM, V258, P3665; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Mowbray SL, 1999, J MOL BIOL, V294, P487, DOI 10.1006/jmbi.1999.3271; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NEWCOMER ME, 1981, J BIOL CHEM, V256, P3218; OH BH, 1993, J BIOL CHEM, V268, P11348; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OLAH GA, 1993, J BIOL CHEM, V268, P16241; Paas Y, 1996, NEURON, V17, P979, DOI 10.1016/S0896-6273(00)80228-7; PATNEAU DK, 1993, J NEUROSCI, V13, P3496; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SAPER MA, 1983, J BIOL CHEM, V258, P1057; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; Shilton BH, 1996, J MOL BIOL, V264, P350, DOI 10.1006/jmbi.1996.0645; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sun YJ, 1998, J MOL BIOL, V278, P219, DOI 10.1006/jmbi.1998.1675; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; UCHINO S, 1992, FEBS LETT, V308, P252; VERMERSCH PS, 1990, J BIOL CHEM, V265, P16592; VYKLICKY L, 1991, NEURON, V7, P971, DOI 10.1016/0896-6273(91)90342-W; WAFFORD KA, 1995, MOL PHARMACOL, V47, P374; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WALMSLEY AR, 1992, J BIOL CHEM, V267, P8064; WEINER JH, 1971, J BIOL CHEM, V246, P6933; Williams K, 1996, MOL PHARMACOL, V50, P701; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; YAMADA KA, 1993, J NEUROSCI, V13, P3904; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004	59	97	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21355	21363		10.1074/jbc.M909883199	http://dx.doi.org/10.1074/jbc.M909883199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10748170	hybrid			2022-12-27	WOS:000088230600054
J	Wang, Y; Sugita, S; Sudhof, TC				Wang, Y; Sugita, S; Sudhof, TC			The RIM/NIM family of neuronal C-2 domain proteins - Interactions with Rab3 and a new class of Src homology 3 domain proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC-VESICLE FUSION; PERIPHERAL BENZODIAZEPINE RECEPTOR; ADRENAL CHROMAFFIN CELLS; NEUROTRANSMITTER RELEASE; BINDING PROTEIN; CA2+-DEPENDENT EXOCYTOSIS; NEUROENDOCRINE CELLS; MEMBRANE; RABPHILIN-3A; GTPASES	RIM1 is a putative effector protein for Rab3s, synaptic GTP-binding proteins. RIM1 is localized close to the active zone at the synapse, where it interacts in a GTP-dependent manner with Rab3 located on synaptic vesicles. We now describe a second RIM protein, called RIM2, that is highly homologous to RIM1 and also expressed primarily in brain. Like RIM1, RIM2 contains an N-terminal zinc finger domain that binds to Rab3 as a function of GTP, a central PDZ domain, and two C-terminal C-2 domains that are separated by long alternatively spliced sequences. Unexpectedly, the 3'-end of the RIM2 gene produces an independent mRNA that encodes a smaller protein referred as NIM2. NIM2 is composed of a unique N-terminal sequence followed by the C-terminal part of RIM2. Data bank searches identified a third RIM/NIM-related gene, which encodes a NIM isoform referred to as NIM3; no RIM transcript from this gene was detected. To test if NIMs, like RIMs, may function in secretion, we investigated the effect of NIM3 on calcium-triggered exocytosis in PC12 cells. NIM3 induced a dramatic increase in calcium-evoked exocytosis (50%), with no significant effect on base-line release, suggesting that NIMs, like RIMs, regulate exocytosis The combination of conserved and variable sequences in RIMs and NIMs indicates that the individual domains of these proteins provide binding sites for interacting molecules during exocytosis, as shown for the zinc finger domain of RIM, which binds to GTP-bound Rab3s, To search for additional interacting proteins for RIMs, we employed yeast two-hybrid screens with the C-terminal half of RIM1. Two members of a new family of homologous brain proteins, referred to as RIM-binding proteins (RIM-BPs), were identified, RIM-BPs bind to RIM in yeast two-hybrid and GST pull-down assays, suggesting a specific interaction. In RIMs, the binding site for RIM-BPs consists of a conserved proline-rich sequence between the two C-2 domains, N-terminal to the beginning of NIMs, RIM-BPs are composed of multiple domains, including three fibronectin type III-domains and three Src homology 3 domains, of which the second Src homology 3 domain binds to RIMs, With the RIM-BPs, we have identified a partner for RIMs that may bind to RIMs at the synapse in addition to Rab3.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.			Sugita, Shuzo/0000-0002-9182-873X				Burns ME, 1998, J GEN PHYSIOL, V111, P243, DOI 10.1085/jgp.111.2.243; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Chung SH, 1998, J BIOL CHEM, V273, P10240, DOI 10.1074/jbc.273.17.10240; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Galiegue S, 1999, J BIOL CHEM, V274, P2938, DOI 10.1074/jbc.274.5.2938; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MADISON DL, 1995, NEUROSCI RES, V45, P258; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; Mohrmann K, 1999, MOL MEMBR BIOL, V16, P81, DOI 10.1080/096876899294797; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Sambrook J., 2002, MOL CLONING LAB MANU; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SKEHEL PA, 1995, SCIENCE, V269, P1580, DOI 10.1126/science.7667638; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; STETTLER O, 1995, EUR J NEUROSCI, V7, P702, DOI 10.1111/j.1460-9568.1995.tb00674.x; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUDHOF TC, 1987, NUCLEIC ACIDS RES, V15, P9607, DOI 10.1093/nar/15.22.9607; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tzounopoulos T, 1998, NEURON, V21, P837, DOI 10.1016/S0896-6273(00)80599-1; Ubach J, 1999, NAT CELL BIOL, V1, P106, DOI 10.1038/10076; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Weber E, 1996, J BIOL CHEM, V271, P6963, DOI 10.1074/jbc.271.12.6963	42	184	200	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20033	20044		10.1074/jbc.M909008199	http://dx.doi.org/10.1074/jbc.M909008199			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748113	hybrid			2022-12-27	WOS:000087941300082
J	Kimura-Someya, T; Iwaki, S; Konishi, S; Tamura, N; Kubo, Y; Yamaguchi, A				Kimura-Someya, T; Iwaki, S; Konishi, S; Tamura, N; Kubo, Y; Yamaguchi, A			Cysteine-scanning mutagenesis around transmembrane segments 1 and 11 and their flanking loop regions of Tn10-encoded metal-tetracycline/H+ antiporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RESISTANCE PROTEIN; MEMBRANE TOPOLOGY; TRANSPOSON TN10; HELICES; MUTATION; RESIDUES; MUTANTS; REVEALS; CHANNEL	Putative transmembrane helices (TM) 1 and 11 in the metal-tetracycline/H+ antiporter are predicted to be close to each other on the basis of disulfide cross-linking experiments of the double-cysteine mutants in the periplasmic loop regions (Kubo, Y., Konishi, S., Kawabe, T., Nada, S., and Yamaguchi, A, (2000) J. Biol. Chem. 275, 5270-5274). In this study, each amino acid from Asn-2 to Gly-44 in the putative TM1 and loop1-2 regions or that from Ser-328 to Gly-366 in TM11 and its flanking regions was individually replaced with cysteine. With respect to the TMI region, 10 mutants, from T5C to L14C, were all not reactive with N-ethylmaleimide (NEM), and from D15C to I22C, NEM-reactive and non-reactive mutations periodically appeared every two residues. Three mutants, M23C to V25C, were all NEM-reactive, but the degree of the latter two mutants was very low. Seven mutants, from L26C to E32C, were all highly reactive with NEM. Therefore, the region of TM1 is composed of the 21 amino acid residues from Thr-5 to Val-25. It is a partially amphiphilic helix, that is, the N-terminal (cytoplasmic) half is embedded in the hydrophobic interior, and the C-terminal (periplasmic) half faces a water-filled channel. With respect to TM11, nine mutants, from S328C to G336C, and six mutants, from L361C to G366C, were all reactive with NEM. On the other hand, out of the 24 mutants, from L337C to S360C, 17 were not reactive with NEM, and the 7 NEM-reactive mutants were scattered, indicating that this region is a transmembrane segment. The 7 residues from Val-347 to Phe-353 including Pro-350 formed a central hydrophobic core, and the 7 NEM-reactive mutations were periodically distributed in its flanking regions, indicating that both ends of TM11 face a water-filled channel. Ala-354 is located at about 1/3 of the length from the periplasmic end of TM11. Disulfide cross-linking experiments on double-cysteine mutants having the combination of A354C and a cysteine-scanning mutation in the loop1-2 region indicated that loop1-2 is very flexible and close to the pepiplasmic end of TM11. Tetracycline prevented the cross-linking formation between the periplasmic ends of TM1 and TM11; however, it did not affect the crosslinking between loop1-2 and TM11, indicating that the substrate-induced conformational change involves a shift in the relative locations of TM1 and TM11.	Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Ibaraki, Osaka 5670047, Japan; Osaka Univ, Fac Pharmaceut Sci, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Osaka 5670047, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Yamaguchi, A (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, 8-1 Mihogaoka, Ibaraki, Osaka 5670047, Japan.		Kimura-Someya, Tomomi/C-4169-2017; Kubo, Yoshiyuki/Q-6069-2019	Kimura-Someya, Tomomi/0000-0003-2232-1801; Kubo, Yoshiyuki/0000-0002-7905-5666				ALLARD JD, 1992, J BIOL CHEM, V267, P17809; ECKERT B, 1989, J BIOL CHEM, V264, P11663; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; IWAKI S, 2000, IN PRESS J BIOL CHEM, V275; Kaback HR, 1997, CURR OPIN STRUC BIOL, V7, P537, DOI 10.1016/S0959-440X(97)80119-4; Kawabe T, 1999, FEBS LETT, V457, P169, DOI 10.1016/S0014-5793(99)01032-7; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1997, BIOCHEMISTRY-US, V36, P6941, DOI 10.1021/bi9631879; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; Kimura-Someya T, 1998, J BIOL CHEM, V273, P32806, DOI 10.1074/jbc.273.49.32806; Konishi S, 1999, FEBS LETT, V461, P315, DOI 10.1016/S0014-5793(99)01490-8; Kubo Y, 2000, J BIOL CHEM, V275, P5270, DOI 10.1074/jbc.275.8.5270; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; PHILIPSON L, 1978, CELL, V13, P189, DOI 10.1016/0092-8674(78)90149-6; SANSOM MSP, 1992, PROTEIN ENG, V5, P53, DOI 10.1093/protein/5.1.53; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; Yamaguchi A, 1996, BIOCHEMISTRY-US, V35, P4359, DOI 10.1021/bi952116r; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490	25	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18692	18697		10.1074/jbc.M000354200	http://dx.doi.org/10.1074/jbc.M000354200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10747900	hybrid			2022-12-27	WOS:000087815900012
J	Kuster, B; Shainskaya, A; Pu, HX; Goldshleger, R; Blostein, R; Mann, M; Karlish, SJD				Kuster, B; Shainskaya, A; Pu, HX; Goldshleger, R; Blostein, R; Mann, M; Karlish, SJD			A new variant of the gamma subunit of renal Na,K-ATPase - Identification by mass spectrometry, antibody binding, and expression in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; ENDOGENOUS OUABAIN; TRYPTIC FRAGMENTS; CHANNEL ACTIVITY; XENOPUS OOCYTES; MAMMALIAN-CELLS; SODIUM-PUMP; PURIFICATION; PROTEINS; PEPTIDE	The gamma subunit is a specific regulator of Na,K-ATPase expressed mainly in kidney, On SDS-polyacryylamide gel electrophoresis, gamma runs as a doublet, but the origin and significance of the doublet is obscure. Mass spectrometry of the gamma chains of rat kidney Na,K-ATPase shows that gamma(a) (upper) has a mass of 7184.0 +/- 1 Da (carbamidomethyl cysteine), corresponding closely to that for the published sequence without the initiator methionine, while gamma(b) (lower) has a mass of 7337.9 +/- 1Da Tryptic peptide mapping and sequencing by mass spectrometry reveals that the seven N-terminal residues of gamma(a), TELSANH, are replaced by Ac-MDRWYL in gamma(b), but otherwise the chains are identical. Antibodies raised against peptides TELSANHC and MDRWYLC recognize either gamma(a) or gamma(b) of the Na,K-ATPase, respectively, gamma(a) or gamma(b) cDNAs have been expressed in human embryonic kidney and HeLa cells, The major bands expressed correspond to gamma(a), or gamma(b) of renal Na,K-ATPase, Additional minor bands seen after transfection, namely gamma(a)' in human embryonic kidney and gamma(b)' in HeLa, are presumably cell-specific modifications, The present work clarifies earlier uncertainty regarding doublets seen in kidney and in transfected cells. In particular, the results show that renal Na,K-ATPase contains two variants of the gamma sub unit with different sequences but otherwise are unmodified. We discuss the possible functional significance of the two variants.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Serv, IL-76100 Rehovot, Israel; Univ So Denmark, Prot Interact Lab, DK-5230 Odense, Denmark; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada	Weizmann Institute of Science; Weizmann Institute of Science; University of Southern Denmark; McGill University	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Mann, Matthias/A-3454-2013; Kuster, Bernhard/Q-6031-2016	Mann, Matthias/0000-0003-1292-4799; Kuster, Bernhard/0000-0002-9094-1677				ALLEN G, 1990, SEQUENCING PROTEINS, P82; Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Blaustein MP, 1996, KIDNEY INT, V49, P1748, DOI 10.1038/ki.1996.260; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; Cohen SL, 1997, ANAL BIOCHEM, V247, P257, DOI 10.1006/abio.1997.2072; COLLINS JH, 1982, BIOCHIM BIOPHYS ACTA, V686, P7, DOI 10.1016/0005-2736(82)90145-6; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; Hamlyn JM, 1996, J HYPERTENS, V14, P151, DOI 10.1097/00004872-199602000-00002; HARDWICKE PMD, 1981, BIOCHEM BIOPH RES CO, V102, P250, DOI 10.1016/0006-291X(81)91514-X; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; Jones DH, 1997, J CELL BIOL, V139, P1545, DOI 10.1083/jcb.139.6.1545; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; Kussmann M, 1997, J MASS SPECTROM, V32, P593; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; Minor NT, 1998, P NATL ACAD SCI USA, V95, P6521, DOI 10.1073/pnas.95.11.6521; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; Or E, 1996, BIOCHEMISTRY-US, V35, P6853, DOI 10.1021/bi960093q; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; REEVES AS, 1980, BIOCHEM BIOPH RES CO, V95, P1591, DOI 10.1016/S0006-291X(80)80080-5; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SWEADNER KJ, 2000, IN PRESS P 9 INT C N; Therien AG, 1999, AM J PHYSIOL-CELL PH, V277, pC891, DOI 10.1152/ajpcell.1999.277.5.C891; Therien AG, 1996, J BIOL CHEM, V271, P7104, DOI 10.1074/jbc.271.12.7104; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; THERIEN AG, 2000, IN PRESS P 9 INT C N; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0	34	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18441	18446		10.1074/jbc.M001411200	http://dx.doi.org/10.1074/jbc.M001411200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748024	hybrid			2022-12-27	WOS:000087659400072
J	Steer, JH; Kroeger, KM; Abraham, LJ; Joyce, DA				Steer, JH; Kroeger, KM; Abraham, LJ; Joyce, DA			Glucocorticoids suppress tumor necrosis factor-alpha expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-kappa B and c-Jun-activating transcription factor-2 binding sites in the promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN-INTERACTION; TNF-ALPHA; NUCLEAR FACTOR; GENE-REGULATION; T-CELLS; FUNCTIONAL ANTAGONISM; RESPONSIVE ELEMENT; CROHNS-DISEASE; C/EBP FAMILY; DNA-BINDING	Glucocorticoid drags suppress tumor necrosis factor-alpha (TNF-alpha) synthesis by activated monocyte/macrophages, contributing to an anti-inflammatory action in vivo. In lipopolysaccharide (LPS)-activated human monocytic THP-1 cells, glucocorticoids acted primarily on the TNF-alpha promoter to suppress a burst of transcriptional activity that occurred between 90 min and 3 h after LPS exposure. LPS increased nuclear c-Jun/ATF-2, NF-kappa B-1/Rel-A, and Rel-A/C-Rel transcription factor complexes, which bound specifically to oligonucleotide sequences from the -106 to -88 base pair (bp) region of the promoter. The glucocorticoid, dexamethasone, suppressed nuclear binding activity of these complexes prior to and during the critical phase of TNF-alpha transcription. Site-directed mutagenesis in TNF-alpha promoter-luciferase reporter constructs showed that the adjacent c-Jun/ATF-2 (-106 to -99 bp) and NF-KB (-97 to -88 bp) binding sites each contributed to the LPS-stimulated expression. Mutating both sites largely prevented dexamethasone from suppressing TNF-alpha promoter-luciferase reporters. LPS exposure also increased nuclear Egr-1 and PU.1 abundance. The Egr-1/Sp1. (-172 to -161 bp) binding sites and the PU.1-binding Ets site (-116 to -110 bp) each contributed to the LPS-stimulated expression but not to glucocorticoid response. Dexamethasone suppressed the abundance of the c-Fos/c-Jun complex in THP-1 cell nuclei, but there was no direct evidence for c-Fos/c-Jun transactivation through sites in the -172 to -52 bp region. Small contributions to glucocorticoid response were attributable to promoter sequences outside the -172 to -88 bp region and to sequences in the TNF-alpha 3'-untranslated region. We conclude that glucocorticoids suppress LPS-stimulated secretion of TNF-alpha from human monocytic cells largely through antagonizing transactivation by c-Jun/ATF-2 and NF-kappa B complexes at binding sites in the -106 to -88 bp region of the TNF-alpha promoter.	Univ Western Australia, Dept Pharmacol, Nedlands, WA 6907, Australia; Univ Western Australia, Dept Biochem, Nedlands, WA 6907, Australia	University of Western Australia; University of Western Australia	Joyce, DA (corresponding author), Univ Western Australia, Dept Pharmacol, Nedlands, WA 6907, Australia.		Joyce, David/H-5156-2014					Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AMANO Y, 1993, MOL PHARMACOL, V43, P176; ANDERSSON O, 1991, CHEST, V99, P1336, DOI 10.1378/chest.99.6.1336; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BERTANI A, 1989, BLOOD, V74, P1811; BRYNSKOV J, 1994, DIGEST DIS, V12, P290, DOI 10.1159/000171464; ECKERT RL, 1982, CANCER RES, V42, P139; FELDMANN M, 1994, CIRC SHOCK, V43, P179; Geist LJ, 1997, AM J RESP CELL MOL, V16, P31, DOI 10.1165/ajrcmb.16.1.8998076; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Han J, 1990, Eur Cytokine Netw, V1, P71; HAN J, 1991, J IMMUNOL, V146, P1843; HAN J, 1990, J EXP MED, V172, P391, DOI 10.1084/jem.172.1.391; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONGENEEL CV, 1992, TUMOR NECROSIS FACTO, P539; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Joyce DA, 1997, INFLAMM RES, V46, P447, DOI 10.1007/s000110050222; JOYCE DA, 1996, J INTERFERON CYTOKIN, V16, P513; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; KRAMER B, 1995, J INFLAMM, V45, P183; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7; KUPRASH DV, 1995, ONCOGENE, V11, P97; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; MEAGER A, 1987, HYBRIDOMA, V6, P305, DOI 10.1089/hyb.1987.6.305; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; RAINE CS, 1995, NAT MED, V1, P211, DOI 10.1038/nm0395-211; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RHOADES KL, 1995, CELL IMMUNOL, V161, P125, DOI 10.1006/cimm.1995.1016; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; Solomon KA, 1997, J IMMUNOL, V159, P4524; Steer JH, 1997, BRIT J CLIN PHARMACO, V43, P383, DOI 10.1111/j.1365-2125.1997.00586.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STRIETER RM, 1993, CRIT CARE MED, V21, pS447, DOI 10.1097/00003246-199310001-00006; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; TREDE NS, 1995, J IMMUNOL, V155, P902; TREDE NS, 1993, J IMMUNOL, V150, P5604; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178; Unlap MT, 1997, MOL BRAIN RES, V45, P83, DOI 10.1016/S0169-328X(96)00240-9; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Wedel A, 1996, CYTOKINE, V8, P335, DOI 10.1006/cyto.1996.0046; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815	68	115	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18432	18440		10.1074/jbc.M906304199	http://dx.doi.org/10.1074/jbc.M906304199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748079	hybrid			2022-12-27	WOS:000087659400071
J	Venable, CL; Frevert, EU; Kim, YB; Fischer, BM; Kamatkar, S; Neel, BG; Kahn, BB				Venable, CL; Frevert, EU; Kim, YB; Fischer, BM; Kamatkar, S; Neel, BG; Kahn, BB			Overexpression of protein-tyrosine phosphatase-1B in adipocytes inhibits insulin-stimulated phosphoinositide 3-kinase activity without altering glucose transport or Akt/protein kinase B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SUBSTRATE FAMILY; 3T3-L1 ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; SKELETAL-MUSCLE; GROWTH-FACTOR; SIGNALING PATHWAY; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHOTYROSINE PROTEIN; GLUT4 TRANSLOCATION; INCREASED ABUNDANCE	Previous studies suggested that protein-tyrosine phosphatase IB (PTP1B) antagonizes insulin action by catalyzing dephosphorylation of the insulin receptor (IR) and/or other key proteins in the insulin signaling pathway. In adipose tissue and muscle of obese humans and rodents, PTP1B expression is increased, which led to the hypothesis that PTP1B plays a role in the pathogenesis of insulin resistance. Consistent with this, mice in which the PTP1B gene was disrupted exhibit increased insulin sensitivity. To test whether increased expression of PTP1B in an insulin-sensitive cell type could contribute to insulin resistance, we overexpressed wild-type PTP1B in 3T3L1 adipocytes using adenovirus-mediated gene delivery. PTP1B expression was increased similar to 3-5-fold above endogenous levels at 16 h, similar to 14-fold at 40 h, and similar to 20-fold at 72 h post-transduction, Total protein-tyrosine phosphatase activity was increased by 50% at 16 h, 3-4-fold at 40 h, and 5-6-fold at 72 h post-transduction Compared with control cells, cells expressing high levels of PTP1B showed a 50-60% decrease in maximally insulin-stimulated tyrosyl phosphorylation of IR and insulin receptor substrate-1 (IRS-1) and phosphoinositide 3-kinase (PI3K) activity associated with IRS-I or with phosphotyrosine. Akt phosphorylation and activity were unchanged. Phosphorylation of p42 and p44 MAP kinase (MAPK) was reduced similar to 32%. Overexpression of PTP1B had no effect on basal, submaximally or maximally (100 nM) insulin-stimulated glucose transport or on the EC,, for transport. Our results suggest that: 1) insulin stimulation of glucose transport in adipocytes requires less than or equal to 45% of maximal tyrosyl phosphorylation of IR or IRS-1 and <50% of maximal activation of PI3K, 2) a novel PI3K-independent, pathway may play a role in insulin-induced glucose transport in adipocytes, and 3) overexpression of PTP1B alone in adipocytes does not impair glucose transport.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Diabet Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Neel, BG (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, 330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043051] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 49152] Funding Source: Medline; NIA NIH HHS [AG 00294] Funding Source: Medline; NIDDK NIH HHS [R01 DK043051, R01 DK-43051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad F, 1997, METABOLISM, V46, P1140, DOI 10.1016/S0026-0495(97)90206-7; Ahmad F, 1997, J CLIN INVEST, V100, P449, DOI 10.1172/JCI119552; AHMAD F, 1995, J CLIN INVEST, V95, P2806, DOI 10.1172/JCI117985; AHMAD F, 1995, METABOLISM, V44, P1175, DOI 10.1016/0026-0495(95)90012-8; BECKER TC, 1994, METHOD CELL BIOL, V43, P262; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; ELEHEBLY M, 1999, SCIENCE, V283, P1544; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frevert EU, 1998, J BIOL CHEM, V273, P25480, DOI 10.1074/jbc.273.39.25480; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KELLY KL, 1993, J BIOL CHEM, V268, P4391; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; KLAMAN LD, 2000, IN PRESS MOL CELL BI; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Krook A, 1996, J BIOL CHEM, V271, P7134, DOI 10.1074/jbc.271.12.7134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; MCGUIRE MC, 1991, DIABETES, V40, P939, DOI 10.2337/diabetes.40.7.939; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLEFSKY JM, 1982, AM J PHYSIOL, V243, pE15, DOI 10.1152/ajpendo.1982.243.1.E15; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Smith J, 1999, DIABETES, V48, pA219; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang QH, 1999, MOL CELL BIOL, V19, P4008; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; Worm D, 1999, DIABETOLOGIA, V42, P1146; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	52	87	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18318	18326		10.1074/jbc.M908392199	http://dx.doi.org/10.1074/jbc.M908392199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10751417	hybrid			2022-12-27	WOS:000087659400057
J	Higashio, H; Kimata, Y; Kiriyama, T; Hirata, A; Kohno, K				Higashio, H; Kimata, Y; Kiriyama, T; Hirata, A; Kohno, K			Sfb2p, a yeast protein related to sec24p, can function as a constituent of COPII coats required for vesicle budding from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAR2 BIP GENE; SACCHAROMYCES-CEREVISIAE; TRANSPORT VESICLES; SUBUNIT INTERACTIONS; UNFOLDED PROTEINS; SELECTIVE EXPORT; GOLGI TRANSPORT; SHUTTLE VECTORS; PLASMA-MEMBRANE; HOST STRAINS	The COPII coat is required for vesicle budding from the endoplasmic reticulum (ER), and consists of two heterodimeric subcomplexes, Sec23p/Sec24p, Sec13p/Sec31p, and a small GTPase, Sar1p. We characterized a yeast mutant, anu1 (abnormal nuclear morphology) exhibiting proliferated ER as well as abnormal nuclear morphology at the restrictive temperature. Based on the finding that ANU1 is identical to SEC24, we confirmed a temperature-sensitive protein transport from the ER to the Golgi in anu1-1/sec24-20 cells. Overexpression of SFB2, a SEC24 homologue with 56% identity, partially suppressed not only the mutant phenotype of sec24-20 cells but also rescued the SEC24-disrupted cells. Moreover, the yeast two-hybrid assay revealed that Sfb2p, similarly to Sec24p, interacted with Sec23p. In SEC24-disrupted cells rescued by overexpression of SFB2, some cargo proteins were still retained in the ER, while most of the protein transport was restored. Together, these findings strongly suggest that Sfb2p functions as the component of COPII coats in place of Sec24p, and raise the possibility that each member of the SEC24 family of proteins participates directly and/or indirectly in cargo-recognition events with its own cargo specificity at forming ER-derived vesicles.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1010062, Japan	Nara Institute of Science & Technology; University of Tokyo; Japan Science & Technology Agency (JST)	Kohno, K (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, 8916-5 Takayama, Nara 6300101, Japan.		Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551				Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Ausubel FM, 1995, CURRENT PROTOCOL MOL; Barlowe C, 1998, BBA-MOL CELL RES, V1404, P67, DOI 10.1016/S0167-4889(98)00047-0; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Cherry J, 1997, SACCHAROMYCES GENOME; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; ESMON B, 1984, J BIOL CHEM, V259, P322; ESMON PC, 1987, J BIOL CHEM, V262, P4387; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; Herrmann JM, 1999, TRENDS CELL BIOL, V9, P5, DOI 10.1016/S0962-8924(98)01414-7; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; James P, 1996, GENETICS, V144, P1425; Kaiser C, 1998, CURR OPIN CELL BIOL, V10, P477, DOI 10.1016/S0955-0674(98)80062-8; Kaiser C., 1994, METHODS YEAST GENETI; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Kimata Y, 1999, CELL STRUCT FUNCT, V24, P197, DOI 10.1247/csf.24.197; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LIU ES, 1992, J BIOL CHEM, V267, P7128; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Matsuoka K, 1998, MOL CELL, V2, P703, DOI 10.1016/S1097-2765(00)80168-9; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1998, MOL BIOL CELL, V9, P3493, DOI 10.1091/mbc.9.12.3493; NISHIKAWA S, 1994, MOL BIOL CELL, V5, P1129, DOI 10.1091/mbc.5.10.1129; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; ORRWEAVER TL, 1983, P NATL ACAD SCI-BIOL, V80, P4417, DOI 10.1073/pnas.80.14.4417; Pagano A, 1999, J BIOL CHEM, V274, P7833, DOI 10.1074/jbc.274.12.7833; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; Powers J, 1998, J CELL BIOL, V142, P1209, DOI 10.1083/jcb.142.5.1209; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; SIKORSKI RS, 1989, GENETICS, V122, P19; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; SUN GH, 1992, J CELL BIOL, V119, P1625, DOI 10.1083/jcb.119.6.1625; TOKUNAGA M, 1992, J BIOL CHEM, V267, P17553; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469	56	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17900	17908		10.1074/jbc.M000751200	http://dx.doi.org/10.1074/jbc.M000751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10749860	hybrid			2022-12-27	WOS:000087485000095
J	Fedarko, NS; Fohr, B; Robey, PG; Young, MF; Fisher, LW				Fedarko, NS; Fohr, B; Robey, PG; Young, MF; Fisher, LW			Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; CLASS-I ANTIGEN; BTA STAT TEST; SECRETED PHOSPHOPROTEIN; IMMUNE EVASION; MESSENGER-RNA; SIALIC-ACID; ECHINOCOCCUS-GRANULOSUS; NEISSERIA-GONORRHOEAE; REGULATORY PROTEINS	Metastatic cancer cells, like trophoblasts of the developing placenta, are invasive and must escape immune surveillance to survive. Complement has long been thought to play a significant role in the tumor surveillance mechanism. Bone sialoprotein (BSP) and osteopontin (OPN, ETA-1) are expressed by trophoblasts and are strongly up-regulated by many tumors. Indeed, BSP has been shown to be a positive indicator of the invasive potential of some tumors. In this report, we show that BSP and OPN form rapid and tight complexes with complement Factor H. Besides its key role in regulating complement-mediated cell lysis, Factor H also appears to play a role when "hijacked'' by invading organisms in enabling cellular evasion of complement, me have investigated whether BSP and OPN may play a similar role in tumor cell complement evasion by testing to see whether these glycoproteins could promote tumor cell survival. Recombinant OPN and BSP can protect murine erythroleukemia cells from attack by human complement as web as human MCF-7 breast cancer cells and U-266 myeloma cells from attack by guinea pig complement. The mechanism of this gain of function by tumor cell expression of BSP or OPN has been defined using specific peptides and antibodies to block BSP and OPN protective activity. The expression of BSP and OPN in tumor cells provides a selective advantage for survival via initial binding to alpha(V)beta(3) integrin (both) or CD44 (OPN) on the cell surface, followed by sequestration of Factor H to the cell surface and inhibition of complement-mediated cell lysis.	Johns Hopkins Univ, Dept Med, Div Geriatr, Baltimore, MD 21224 USA; NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Fedarko, NS (corresponding author), Rm 5A-64 JHAAC,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	ndarko@welch.jhu.edu	Robey, Pamela Gehron/H-1429-2011	Robey, Pamela Gehron/0000-0002-5316-5576; Young, Marian F/0000-0003-0929-8854; Fedarko, Neal/0000-0001-6055-6279	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000074] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bellahcene A, 1996, LAB INVEST, V75, P203; Bellahcene A, 1997, B CANCER, V84, P17; Bellahcene A, 1996, INT J CANCER, V69, P350; BELLAHCENE A, 1994, CANCER RES, V54, P2823; Bellahcene A, 1997, CALCIFIED TISSUE INT, V61, P183, DOI 10.1007/s002239900320; Bellahcene A, 1998, THYROID, V8, P637, DOI 10.1089/thy.1998.8.637; Bellahcene A, 1996, J BONE MINER RES, V11, P665; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998; Castronovo V, 1998, INT J ONCOL, V12, P305; Chambers AF, 1996, LUNG CANCER-J IASLC, V15, P311, DOI 10.1016/0169-5002(95)00595-1; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; Chen J, 1998, HISTOCHEM J, V30, P1, DOI 10.1023/A:1003228910529; COOPER PD, 1985, ADV IMMUNITY CANC TH, V1, P127; Coumans B, 1999, J IMMUNOL METHODS, V224, P185, DOI 10.1016/S0022-1759(99)00021-6; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; CUMMINGS KB, 1977, J UROLOGY, V118, P720, DOI 10.1016/S0022-5347(17)58172-0; Diaz A, 1997, J IMMUNOL, V158, P3779; DIAZ A, 1995, EXP PARASITOL, V80, P473, DOI 10.1006/expr.1995.1059; Donelson JE, 1998, MOL BIOCHEM PARASIT, V91, P51, DOI 10.1016/S0166-6851(97)00209-0; FAULK WP, 1976, NATURE, V262, P799, DOI 10.1038/262799a0; FISHER LW, 1990, J BIOL CHEM, V265, P2347; FISHER LW, 1987, J BIOL CHEM, V262, P9702; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Gillespie MT, 1997, INT J CANCER, V73, P812; Gutierrez LS, 1999, BREAST CANCER RES TR, V54, P245, DOI 10.1023/A:1006102601215; HALL BF, 1993, J EUKARYOT MICROBIOL, V40, P207, DOI 10.1111/j.1550-7408.1993.tb04905.x; HIROTA S, 1995, J NEUROPATH EXP NEUR, V54, P698, DOI 10.1097/00005072-199509000-00012; HUEMER HP, 1993, IMMUNOLOGY, V79, P639; HUSBY G, 1977, CANCER-AM CANCER SOC, V40, P1629, DOI 10.1002/1097-0142(197710)40:4<1629::AID-CNCR2820400436>3.0.CO;2-S; Irani J, 1999, EUR UROL, V35, P89, DOI 10.1159/000019824; ISAACS SN, 1992, P NATL ACAD SCI USA, V89, P628, DOI 10.1073/pnas.89.2.628; JARVIS GA, 1987, INFECT IMMUN, V55, P174, DOI 10.1128/IAI.55.1.174-180.1987; Kauma SW, 1999, J CLIN ENDOCR METAB, V84, P2188, DOI 10.1210/jc.84.6.2188; Kinders R, 1998, CLIN CANCER RES, V4, P2511; KIPNIS TL, 1989, BRAZ J MED BIOL RES, V22, P1; Koeneman KS, 1999, PROSTATE, V39, P246; Kotarsky H, 1998, J IMMUNOL, V160, P3349; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; Krushkal J, 1998, J MOL EVOL, V47, P625, DOI 10.1007/PL00013152; Meri S, 1998, VOX SANG, V74, P291, DOI 10.1111/j.1423-0410.1998.tb05434.x; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; MOLLER P, 1992, CANCER SURV, V13, P101; Munz C, 1997, J EXP MED, V185, P385, DOI 10.1084/jem.185.3.385; Nasuti JF, 1999, DIAGN CYTOPATHOL, V21, P27, DOI 10.1002/(SICI)1097-0339(199907)21:1<27::AID-DC8>3.3.CO;2-#; Oates AJ, 1997, INVAS METAST, V17, P1; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OMIGBODUN A, 1995, ANN NY ACAD SCI, V760, P346, DOI 10.1111/j.1749-6632.1995.tb44653.x; Pellegrini P, 1996, CANCER IMMUNOL IMMUN, V42, P1, DOI 10.1007/s002620050244; PENA J, 1990, EUR J IMMUNOL, V20, P2445, DOI 10.1002/eji.1830201113; Raitanen MP, 1999, SCAND J UROL NEPHROL, V33, P234; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Ram S, 1998, J EXP MED, V188, P671, DOI 10.1084/jem.188.4.671; Ross GD, 1999, IMMUNOPHARMACOLOGY, V42, P61, DOI 10.1016/S0162-3109(99)00013-2; Roussel E, 1996, CLIN EXP IMMUNOL, V105, P344, DOI 10.1046/j.1365-2249.1996.d01-753.x; RYDEN C, 1989, EUR J BIOCHEM, V184, P331, DOI 10.1111/j.1432-1033.1989.tb15023.x; Schmitt CA, 1999, EUR J CANCER, V35, P117, DOI 10.1016/S0959-8049(98)00290-1; Seibel MJ, 1996, J CLIN ENDOCR METAB, V81, P3289, DOI 10.1210/jc.81.9.3289; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1989, ANTICANCER RES, V9, P1291; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; Simpson KL, 1997, AM J PATHOL, V151, P1455; SMITH MEF, 1989, P NATL ACAD SCI USA, V86, P5557, DOI 10.1073/pnas.86.14.5557; Spendlove I, 1999, CANCER RES, V59, P2282; Strand S, 1998, MOL MED TODAY, V4, P63, DOI 10.1016/S1357-4310(97)01191-X; Stubbs JT, 1997, J BONE MINER RES, V12, P1210, DOI 10.1359/jbmr.1997.12.8.1210; Sung V, 1998, J CELL PHYSIOL, V176, P482, DOI 10.1002/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO;2-K; Sung V, 1998, EXP CELL RES, V241, P273, DOI 10.1006/excr.1998.4029; Thomas L, 1999, CLIN CHEM, V45, P472; THORBURN GD, 1991, REPROD FERT DEVELOP, V3, P277, DOI 10.1071/RD9910277; Tiniakos DG, 1998, HUM PATHOL, V29, P1250, DOI 10.1016/S0046-8177(98)90253-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tunio GM, 1998, ARCH PATHOL LAB MED, V122, P1087; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; van der Pluijm G, 1997, LAB INVEST, V77, P665; vanderPluijm G, 1996, CANCER RES, V56, P1948; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; VETTER U, 1991, J BONE MINER RES, V6, P501; Volanakis JE, 1998, HUMAN COMPLEMENT SYS, V20, P9, DOI DOI 10.1201/B14212-3; Waltregny D, 1998, J NATL CANCER I, V90, P1000, DOI 10.1093/jnci/90.13.1000; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; WRIGHT GL, 1990, INT J CANCER, V46, P39, DOI 10.1002/ijc.2910460110; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; Yu J, 1999, CLIN EXP IMMUNOL, V115, P13	88	172	186	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16666	16672		10.1074/jbc.M001123200	http://dx.doi.org/10.1074/jbc.M001123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747989	hybrid			2022-12-27	WOS:000087392200039
J	Kasparkova, J; Farrell, N; Brabec, V				Kasparkova, J; Farrell, N; Brabec, V			Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICANCER DRUG CISPLATIN; CHEMICAL-REACTIVITY; GEOMETRIC ISOMERISM; BINDING; CIS-DIAMMINEDICHLOROPLATINUM(II); ADDUCTS; TRANS-DIAMMINEDICHLOROPLATINUM(II); DUPLEX; ISOMERIZATION; D(GPG)	Interactions of high mobility group (HMG) domain proteins with DNA modified by cisplatin plays a role in mechanisms underlying its antitumor activity. A structural motif recognized by HMG domain proteins on cisplatin-modified DNA is a stable, directional bend of the helix axis. In the present work, bending induced in DNA by major adducts of a novel class of antitumor compounds, represented by the formula [(trans-PtCl(NH3)(2))H2N(CH2)(2-6)NH2]Cl-2, was investigated. The oligodeoxyribonucleotide duplexes containing various site-specific interstrand cross-links of these bifunctional dinuclear platinum drugs were purified and characterized by Maxam-Gilbert footprinting, chemical probing, and phasing assay. It was demonstrated that the crosslinks of the dinuclear compounds bent the helix much less than those of cisplatin, Gel retardation assay revealed very weak recognition of DNA adducts of dinuclear complexes by HMG1 protein. Hence, the mediation of antitumor properties of dinuclear platinum complexes by HMG domain proteins is unlikely so that polynuclear platinum compounds may represent a novel class of platinum anticancer drugs acting by a different mechanism than cisplatin and its analogues. A further understanding of how polynuclear platinum compounds modify DNA and how these modifications are processed in cells should provide a rational basis for the design of new platinum drugs rather than searching for cisplatin analogues.	Acad Sci Czech Republ, Inst Biophys, CZ-61265 Brno, Czech Republic; Virginia Commonwealth Univ, Dept Chem, Richmond, VA 23284 USA	Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences; Virginia Commonwealth University	Brabec, V (corresponding author), Acad Sci Czech Republ, Inst Biophys, Kravolopolska 135, CZ-61265 Brno, Czech Republic.		Brabec, Viktor/H-1946-2014	Brabec, Viktor/0000-0002-8233-1393				BAILLY C, 1994, BIOCHEM J, V300, P165, DOI 10.1042/bj3000165; BAILLY C, 1997, DRUG DNA INTERACTION, P51; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BLOMMAERT FA, 1995, BIOCHEMISTRY-US, V34, P8474, DOI 10.1021/bi00026a031; BRABEC V, 1993, P NATL ACAD SCI USA, V90, P5345, DOI 10.1073/pnas.90.11.5345; BRABEC V, 1993, BIOCHEMISTRY-US, V32, P11676, DOI 10.1021/bi00094a025; Brabec V, 1999, BIOCHEMISTRY-US, V38, P6781, DOI 10.1021/bi990124s; BRABEC V, 1992, BIOCHEMISTRY-US, V31, P12397, DOI 10.1021/bi00164a014; BRABEC V, 1994, BIOCHEMISTRY-US, V32, P1316; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; COMESS KM, 1990, BIOCHEMISTRY-US, V29, P2102, DOI 10.1021/bi00460a020; DALBIES R, 1994, P NATL ACAD SCI USA, V91, P8147, DOI 10.1073/pnas.91.17.8147; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; FARRELL N, 1990, BIOCHEMISTRY-US, V29, P9522, DOI 10.1021/bi00493a005; FARRELL N, 1995, BIOCHEMISTRY-US, V34, P15480, DOI 10.1021/bi00047a013; Farrell N., 1999, 30 YEARS CISPLATIN C, P479; Gelasco A, 1998, BIOCHEMISTRY-US, V37, P9230, DOI 10.1021/bi973176v; HUANG HF, 1995, SCIENCE, V270, P1842, DOI 10.1126/science.270.5243.1842; Johnson N.P., 1989, PROG CLIN BIOCH MED, V10, P1, DOI [DOI 10.1007/978-3-642-74760-1, 10.1007/978-3-642-74760-1_1, DOI 10.1007/978-3-642-74760-1_1]; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; KASPARKOVA J, 1995, BIOCHEMISTRY-US, V34, P12379, DOI 10.1021/bi00038a035; Kasparkova J, 1996, BIOCHEMISTRY-US, V35, P16705, DOI 10.1021/bi961160j; Kasparkova J, 1999, BIOCHEMISTRY-US, V38, P10997, DOI 10.1021/bi990245s; KECK MV, 1992, J AM CHEM SOC, V114, P3386, DOI 10.1021/ja00035a033; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; LEMAIRE M, 1990, BIOCHEM J, V267, P431, DOI 10.1042/bj2670431; LEMAIRE MA, 1991, P NATL ACAD SCI USA, V88, P1982, DOI 10.1073/pnas.88.5.1982; LENG M, 1990, BIOPHYS CHEM, V35, P155, DOI 10.1016/0301-4622(90)80005-R; LENG M, 1994, IARC SCI PUBL, V125, P339; LEPRE CA, 1990, NUCL ACIDS MOL BIOL, V4, P9, DOI [DOI 10.1007/978-3-642-84150-7-2, DOI 10.1007/978-3-642-84150-7]; Lokich J, 1998, ANN ONCOL, V9, P13, DOI 10.1023/A:1008215213739; MALINGE JM, 1994, NUCLEIC ACIDS RES, V22, P3834, DOI 10.1093/nar/22.19.3834; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCARTHY JG, 1991, NUCLEIC ACIDS RES, V19, P3421, DOI 10.1093/nar/19.12.3421; MCCARTHY JG, 1990, BIOCHEMISTRY-US, V29, P6071, DOI 10.1021/bi00477a027; Mellish KJ, 1997, NUCLEIC ACIDS RES, V25, P1265, DOI 10.1093/nar/25.6.1265; Nielsen P E, 1990, J Mol Recognit, V3, P1, DOI 10.1002/jmr.300030102; O'Dwyer P. J., 1999, CISPLATIN CHEM BIOCH, P31; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Raymond E, 1998, ANN ONCOL, V9, P1053, DOI 10.1023/A:1008213732429; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; Ross SA, 1996, NUCLEIC ACIDS RES, V24, P5062, DOI 10.1093/nar/24.24.5062; STROS M, 1990, INT J BIOL MACROMOL, V12, P282, DOI 10.1016/0141-8130(90)90014-2; STROS M, 1994, FEBS LETT, V344, P201, DOI 10.1016/0014-5793(94)00364-5; Takahara PM, 1996, J AM CHEM SOC, V118, P12309, DOI 10.1021/ja9625079; Vrana O, 1996, NUCLEIC ACIDS RES, V24, P3918, DOI 10.1093/nar/24.20.3918; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; Woynarowski JM, 1998, MOL PHARMACOL, V54, P770, DOI 10.1124/mol.54.5.770; Wu PK, 1996, J INORG BIOCHEM, V63, P9, DOI 10.1016/0162-0134(95)00163-8; YANG DZ, 1995, BIOCHEMISTRY-US, V34, P12912, DOI 10.1021/bi00039a054; Zaludova R, 1997, EUR J BIOCHEM, V246, P508, DOI 10.1111/j.1432-1033.1997.00508.x; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; ZAMBLE DB, 1999, CISPLATIN CHEM BIOCH, P73; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791; ZOU Y, 1994, BIOCHEMISTRY-US, V33, P5404, DOI 10.1021/bi00184a007	62	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15789	15798		10.1074/jbc.M000777200	http://dx.doi.org/10.1074/jbc.M000777200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747955	hybrid			2022-12-27	WOS:000087291400027
J	Ranocha, P; Bourgis, F; Ziemak, MJ; Rhodes, D; Gage, DA; Hanson, AD				Ranocha, P; Bourgis, F; Ziemak, MJ; Rhodes, D; Gage, DA; Hanson, AD			Characterization and functional expression of cDNAs encoding methionine-sensitive and -insensitive homocysteine S-methyltransferases from Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; LEMNA-PAUCICOSTATA; SELENIUM TOLERANCE; ESCHERICHIA-COLI; METHYLMETHIONINE; BIOSYNTHESIS; METABOLISM; ADENOSYLMETHIONINE; PURIFICATION; TRANSPORT	Plants synthesize S-methylmethionine (SMM) from S-adenosylmethionine (AdoMet), and methionine (Met) by a unique reaction and, like other organisms, use SMM as a methyl donor for Met synthesis from homocysteine (Hcy), These reactions comprise the SMM cycle. Two Arabidopsis cDNAs specifying enzymes that mediate the SMM --> Met reaction (SMM:Hcy S-methyltransferase, HMT) were identified by homology and authenticated by complementing an Escherichia coli yagD mutant and by detecting HMT activity in complemented cells. Gel blot analyses indicate that these enzymes, AtHMT-1 and -2, are encoded by single copy genes. The deduced polypeptides are similar in size (36 kDa), share a zinc-binding motif, lack obvious targeting sequences, and are 55% identical to each other. The recombinant enzymes exist as monomers, AtHMT-1 and -2 both utilize L-SMM or (S,S)-AdoMet as a methyl donor in vitro and have higher affinities for SMM, Both enzymes also use either methyl donor in vivo because both restore the ability to utilize AdoMet or SMM to a yeast HMT mutant. However, AtHMT-1 is strongly inhibited by Met, whereas AtHMT-2 is not, a difference that could be crucial to the control of flux through the HMT reaction and the SMM cycle. Plant HMT is known to transfer the pro-R methyl group of SMM, This enabled us to use recombinant AtHMT-1 to establish that the other enzyme of the SMM cycle, AdoMet:Met S-methyltransferase, introduces the pro-S methyl group. These opposing stereoselectivities suggest a way to measure in vivo flux through the SMM cycle.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Purdue Univ, Dept Hort, W Lafayette, IN 47907 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	State University System of Florida; University of Florida; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Michigan State University	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, POB 110690, Gainesville, FL 32611 USA.		Rhodes, David/L-4602-2019					ABRAHAMSON L, 1965, ARCH BIOCHEM BIOPHYS, V109, P376, DOI 10.1016/0003-9861(65)90376-0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALAGHI M, 1993, BIOCHEM J, V291, P145, DOI 10.1042/bj2910145; BEAUDOUIN C, 1993, J NEUROCHEM, V61, P928, DOI 10.1111/j.1471-4159.1993.tb03604.x; BOERJAN W, 1994, PLANT CELL, V6, P1401, DOI 10.1105/tpc.6.10.1401; Bourgis F, 1999, PLANT CELL, V11, P1485, DOI 10.1105/tpc.11.8.1485; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DATKO AH, 1984, PLANT PHYSIOL, V75, P474, DOI 10.1104/pp.75.2.474; DODD WA, 1970, BIOCHIM BIOPHYS ACTA, V201, P461, DOI 10.1016/0304-4165(70)90166-2; DUERRE JA, 1966, ANAL BIOCHEM, V17, P310, DOI 10.1016/0003-2697(66)90209-0; FRANKARD V, 1991, THEOR APPL GENET, V82, P273, DOI 10.1007/BF02190612; Gage DA, 1997, NATURE, V387, P891, DOI 10.1038/43160; Giovanelli J., 1980, BIOCH PLANTS, VVolume 5, P453, DOI [DOI 10.1016/B978-0-12-675405-6.50018-8, 10.1016/b978-0-12-675405-6.50018-8]; GRUESORENSEN G, 1984, J CHEM SOC P1, V1, P1091; HANSON AD, 1976, PLANT PHYSIOL, V57, P528, DOI 10.1104/pp.57.4.528; HANSON AD, 1994, PLANT PHYSIOL, V105, P103, DOI 10.1104/pp.105.1.103; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; INABA K, 1994, PLANT PHYSIOL, V104, P881, DOI 10.1104/pp.104.3.881; JAMES F, 1995, J BIOL CHEM, V270, P22344, DOI 10.1074/jbc.270.38.22344; Kocsis MG, 1998, PLANT PHYSIOL, V117, P273, DOI 10.1104/pp.117.1.273; Lassner MW., 1989, PLANT MOL BIOL REP, V7, P116, DOI DOI 10.1007/BF02669627; MACNICOL PK, 1983, PLANT PHYSIOL, V72, P492, DOI 10.1104/pp.72.2.492; MACNICOL PK, 1986, ANAL BIOCHEM, V158, P93, DOI 10.1016/0003-2697(86)90594-4; Millian NS, 1998, ARCH BIOCHEM BIOPHYS, V356, P93, DOI 10.1006/abbi.1998.0757; MUDD SH, 1990, PLANT PHYSIOL, V93, P623, DOI 10.1104/pp.93.2.623; Neuhierl B, 1999, J BIOL CHEM, V274, P5407, DOI 10.1074/jbc.274.9.5407; Neuhierl B, 1996, EUR J BIOCHEM, V239, P235, DOI 10.1111/j.1432-1033.1996.0235u.x; Peariso K, 1998, J AM CHEM SOC, V120, P8410, DOI 10.1021/ja980581g; Pimenta MJ, 1998, PLANT PHYSIOL, V118, P431, DOI 10.1104/pp.118.2.431; Ravanel S, 1998, P NATL ACAD SCI USA, V95, P7805, DOI 10.1073/pnas.95.13.7805; Raymond RK, 1999, ARCH BIOCHEM BIOPHYS, V372, P300, DOI 10.1006/abbi.1999.1498; Rouillon A, 1999, J BIOL CHEM, V274, P28096, DOI 10.1074/jbc.274.40.28096; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO SK, 1959, BIOCHIM BIOPHYS ACTA, V36, P241, DOI 10.1016/0006-3002(59)90089-7; SHAPIRO SK, 1971, METHODS ENZYMOLOGY B, V17, P400; Thanbichler M, 1999, J BACTERIOL, V181, P662, DOI 10.1128/JB.181.2.662-665.1999; THOMPSON JF, 1966, PLANT PHYSIOL, V41, P1301, DOI 10.1104/pp.41.8.1301; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WINTER H, 1994, PLANTA, V193, P530, DOI 10.1007/BF02411558	40	60	68	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15962	15968		10.1074/jbc.M001116200	http://dx.doi.org/10.1074/jbc.M001116200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747987	hybrid			2022-12-27	WOS:000087291400049
J	Wagner, S; Hess, MA; Ormonde-Hanson, P; Malandro, J; Hu, HP; Chen, M; Kehrer, R; Frodsham, M; Schumacher, C; Beluch, M; Honer, C; Skolnick, M; Ballinger, D; Bowen, BR				Wagner, S; Hess, MA; Ormonde-Hanson, P; Malandro, J; Hu, HP; Chen, M; Kehrer, R; Frodsham, M; Schumacher, C; Beluch, M; Honer, C; Skolnick, M; Ballinger, D; Bowen, BR			A broad role for the zinc finger protein ZNF202 in human lipid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; TANGIER-DISEASE; REPRESSOR DOMAIN; GENE; RECEPTOR; OBESITY; MUTATIONS; SEQUENCES	The ZNF202 gene resides in a chromosomal region linked genetically to low high density lipoprotein cholesterol in Utah families. Here we show that the ZNF202 gene product is a transcriptional repressor that binds to elements found predominantly in genes that participate in lipid metabolism. Among its targets are structural components of lipoprotein particles (apolipoproteins AIV, CIII, and E), enzymes involved in lipid processing (lipoprotein lipase, lecithin cholesteryl ester transferase), and several genes involved in processes related to energy metabolism and vascular disease. Based on the linkage and apparent transcriptional function of ZNF202, we propose that ZNF202 is a candidate susceptibility gene for human dyslipidemia.	Myriad Genet Inc, Salt Lake City, UT 84108 USA; Novartis Inst Biomed Res, Summit, NJ 07901 USA	Myriad Genetics, Inc; Novartis	Wagner, S (corresponding author), Myriad Genet Inc, 320 Wakara Way, Salt Lake City, UT 84108 USA.	swagner@myriad.com	Wilson, Matthew H/K-3193-2013					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Funke H, 1997, CURR OPIN LIPIDOL, V8, P189, DOI 10.1097/00041433-199706000-00010; Garcia-Rubi E, 1998, J CLIN ENDOCR METAB, V83, P4002, DOI 10.1210/jc.83.11.4002; Hanson RL, 1998, AM J HUM GENET, V63, P1130, DOI 10.1086/302061; Hoffstedt J, 1999, DIABETES, V48, P203, DOI 10.2337/diabetes.48.1.203; JAQUISH CE, 1998, AM SOC HUM GENET S, V63, P329; Kardassis D, 1996, HYPERTENSION, V27, P980, DOI 10.1161/01.HYP.27.4.980; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KimMotoyama H, 1997, DIABETOLOGIA, V40, P469, DOI 10.1007/s001250050702; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; MAHLEY RW, 1991, JAMA-J AM MED ASSOC, V265, P78, DOI 10.1001/jama.265.1.78; Monaco C, 1998, GENOMICS, V52, P358, DOI 10.1006/geno.1998.5419; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Taylor BA, 1999, MAMM GENOME, V10, P963, DOI 10.1007/s003359901141; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; WILLIAMS RR, 1990, ARCH INTERN MED, V150, P582, DOI 10.1001/archinte.150.3.582	28	72	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15685	15690		10.1074/jbc.M910152199	http://dx.doi.org/10.1074/jbc.M910152199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748193	hybrid			2022-12-27	WOS:000087291400014
J	Bastien, J; Adam-Stitah, S; Riedl, T; Egly, JM; Chambon, P; Rochette-Egly, C				Bastien, J; Adam-Stitah, S; Riedl, T; Egly, JM; Chambon, P; Rochette-Egly, C			TFIIH interacts with the retinoic acid receptor gamma and phosphorylates its AF-1-activating domain through cdk7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIH; ACTIVATED PROTEIN-KINASE; RNA-POLYMERASE-II; RAR-ALPHA; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; BINDING DOMAIN; FUNCTIONS AF-1; F9 CELLS; REPAIR	Retinoic acid receptor gamma (RAR gamma) is phosphorylated in COS-1 cells at two conserved serine residues located in the N-terminal region (serines 77 and 79 in RAR gamma 1 and serines 66 and 68 in RAR gamma 2) that contains the activation function AF-1. These serines are phosphorylated in vitro by cdk7, a cyclin-dependent kinase associated to cyclin H and MAT1 in the CAK complex (cdk7 cyclin H MAT1), that is found either free or as a component of the transcription/DNA repair factor TFIIH, RAR gamma is more efficiently phosphorylated by TFIIH than by CAK. and interacts not only with cdk7 but also with several additional subunits of TFIIH. RAR gamma phosphorylation and interaction with TFIIH occur in a ligand-independent manner. Our data demonstrate also that phosphorylation of the AF-1 function modulates RAR gamma transcriptional activity in a response gene-dependent manner.	Univ Strasbourg 1, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rochette-Egly, C (corresponding author), Univ Strasbourg 1, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr						Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; Dilworth FJ, 1999, P NATL ACAD SCI USA, V96, P1995, DOI 10.1073/pnas.96.5.1995; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GAUB MP, 1989, P NATL ACAD SCI USA, V86, P3089, DOI 10.1073/pnas.86.9.3089; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; Warbrick E, 1996, CURR BIOL, V6, P1057, DOI 10.1016/S0960-9822(02)70663-5; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	56	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21896	21904		10.1074/jbc.M001985200	http://dx.doi.org/10.1074/jbc.M001985200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10748061	hybrid			2022-12-27	WOS:000088363800022
J	Carucci, DJ; Witney, AA; Muhia, DK; Warhurst, DC; Schaap, P; Meima, M; Li, JL; Taylor, MC; Kelly, JM; Baker, DA				Carucci, DJ; Witney, AA; Muhia, DK; Warhurst, DC; Schaap, P; Meima, M; Li, JL; Taylor, MC; Kelly, JM; Baker, DA			Guanylyl cyclase activity associated with putative bifunctional integral membrane proteins in Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MALARIA PARASITE; MAMMALIAN ADENYLYL CYCLASES; THYMIDYLATE SYNTHASE GENE; AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; SARCOPLASMIC-RETICULUM; CATALYTIC MECHANISM; EXPRESSION; ATPASE; DOMAIN	We report here that guanylyl cyclase activity is associated with two large integral membrane proteins (PfGC alpha and PfGC beta) in the human malaria parasite Plasmodium falciparum. Unusually, the proteins appear to be bifunctional; their amino-terminal regions have strong similarity with P-type ATPases, and the sequence and structure of the carboxyl-terminal regions conform to that of G protein-dependent adenylyl cyclases, with two sets of six transmembrane sequences, each followed by a catalytic domain (C1 and C2), However, amino acids that are enzymatically important and present in the C2 domain of mammalian adenylyl cyclases are located in the C1 domain of the P. falciparam proteins and vice versa, In addition, certain key residues in these domains are more characteristic of guanylyl cyclases, Consistent with this, guanylyl cyclase activity was obtained following expression of the catalytic domains of PfGC beta in Escherichia coli, In P. falciparum, expression of both genes was detectable in the sexual but not the asexual blood stages of the life cycle, and PfGC alpha was localized to the parasite/parasitophorous vacuole membrane region of gametocytes, The profound structural differences identified between mammalian and parasite guanylyl cyclases suggest that aspects of this signaling pathway may be mechanistically distinct.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1E 7HT, England; Univ Dundee, Dept Biochem, MSI, WTB Complex, Dundee DD1 5EH, Scotland; Leiden Univ, Cell Biol Sect, Inst Mol Plant Sci, NL-2333 AL Leiden, Netherlands	University of London; London School of Hygiene & Tropical Medicine; University of Dundee; Leiden University; Leiden University - Excl LUMC	Baker, DA (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, Keppel St, London WC1E 7HT, England.	david.baker@lshtm.ac.uk	Schaap, Pauline/M-5355-2019; warhurst, david c/C-3428-2013	Schaap, Pauline/0000-0003-4500-2555; Witney, Adam/0000-0003-4561-7170; Taylor, Martin/0000-0003-4147-0693; Baker, David/0000-0002-5490-8933				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BAKER DA, 1994, PARASITOLOGY, V108, P129, DOI 10.1017/S0031182000068219; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; BROOKS DR, 1994, EUR J BIOCHEM, V224, P397, DOI 10.1111/j.1432-1033.1994.00397.x; BZIK DJ, 1987, P NATL ACAD SCI USA, V84, P8360, DOI 10.1073/pnas.84.23.8360; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; COWMAN AF, 1988, P NATL ACAD SCI USA, V85, P9109, DOI 10.1073/pnas.85.23.9109; DEFER N, 1994, FEBS LETT, V351, P109, DOI 10.1016/0014-5793(94)00836-1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GILMAN AG, 1972, ADV CYCL NUCL RES<D>, V2, P9; HARTE PG, 1985, IMMUNOLOGY, V56, P1; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JANSSENS PMW, 1988, BIOCHEM BIOPH RES CO, V150, P405, DOI 10.1016/0006-291X(88)90535-9; JENCKS WP, 1992, ANN NY ACAD SCI, V671, P49, DOI 10.1111/j.1749-6632.1992.tb43783.x; KAWAMOTO F, 1990, MOL BIOCHEM PARASIT, V42, P101, DOI 10.1016/0166-6851(90)90117-5; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; Li JL, 1998, MOL BIOCHEM PARASIT, V95, P287, DOI 10.1016/S0166-6851(98)00106-6; Li JL, 1996, EUR J BIOCHEM, V241, P805, DOI 10.1111/j.1432-1033.1996.00805.x; Li JL, 1997, EUR J BIOCHEM, V249, P98, DOI 10.1111/j.1432-1033.1997.t01-2-00098.x; Linder JU, 1999, EMBO J, V18, P4222, DOI 10.1093/emboj/18.15.4222; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; NAKANE M, 1990, J BIOL CHEM, V265, P16841; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; RIPMASTER TL, 1993, MOL CELL BIOL, V13, P7901, DOI 10.1128/MCB.13.12.7901; ROBSON KJH, 1991, MOL BIOCHEM PARASIT, V46, P19, DOI 10.1016/0166-6851(91)90195-C; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZ MA, 1995, J BIOL CHEM, V270, P17551, DOI 10.1074/jbc.270.29.17551; SAUL A, 1990, MOL BIOCHEM PARASIT, V42, P55, DOI 10.1016/0166-6851(90)90112-Y; SCHULKES CCGM, 1992, BIOCHIM BIOPHYS ACTA, V1135, P73, DOI 10.1016/0167-4889(92)90168-B; Schultz J E, 1994, Adv Pharmacol, V26, P285, DOI 10.1016/S1054-3589(08)60058-7; SCHULTZ JE, 1991, METHODS ENZYMOL, V195, P466; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; Taylor MC, 1999, MOL BIOCHEM PARASIT, V104, P205, DOI 10.1016/S0166-6851(99)00154-1; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; THAITHONG S, 1984, T ROY SOC TROP MED H, V78, P242, DOI 10.1016/0035-9203(84)90287-6; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; TRIGLIA T, 1994, P NATL ACAD SCI USA, V91, P7149, DOI 10.1073/pnas.91.15.7149; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; TRIGLIA T, 1992, PARASITOL TODAY, V8, P225, DOI 10.1016/0169-4758(92)90118-L; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; vanEs S, 1996, J BIOL CHEM, V271, P23623, DOI 10.1074/jbc.271.39.23623; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; Ward G.E., 1986, Advances in Experimental Medicine and Biology, V207, P359; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	53	66	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22147	22156		10.1074/jbc.M001021200	http://dx.doi.org/10.1074/jbc.M001021200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10747978	hybrid, Green Published			2022-12-27	WOS:000088363800056
J	Bang, H; Kim, Y; Kim, D				Bang, H; Kim, Y; Kim, D			TREK-2, a new member of the mechanosensitive tandem-pore K+ channel family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE FATTY-ACIDS; POTASSIUM CHANNELS; ARACHIDONIC-ACID; EXPRESSION; CLONING; BRAIN; SEQUENCE; CELLS; ACTIVATION; HOMOLOG	Recently, several mammalian K+ channel subunits (TWIK, TREK-1, TRAAK, and TASK) possessing four transmembrane segments and two pore-forming domains have been identified. We report the cloning of a new member of this tandem-pore K+ channel from a rat cerebellum cDNA library. It is a 538-amino acid protein and shares 65% amino acid sequence identity with TREK-1. Therefore, the new clone was named TREK-2, Unlike TREK-1, whose mRNA has been reported to be expressed in many different tissues, TREK-2 mRNA is expressed mainly in the cerebellum, spleen, and testis as judged by reverse transcriptase-polymerase chain reaction and Northern blot analysis, Expression of TREK-2 in COS-7 cells induced a time-independent and non-inactivating K+-selective current. TREK-2 was partially blocked (36%) by 2 mM Ba2+. In symmetrical 150 mM KCl, the single-channel conductances were 110 picosiemens at -40 mV and 68 picosiemens at +40 mV, and the mean open time was 0.9 ms at -40 mV, TREK-2 was activated by membrane stretch or acidic pH. At -40 mm Hg pressure, channel activity increased 10-fold above the basal level. TREK-2 was also activated by arachidonic acid and other naturally occurring unsaturated free fatty acids. These results show that TREK-2 is a new member of the tandem-pore K+ channel family and belongs to the class of mechanosensitive and fatty acid-stimulated K+ channels.	Finch Univ Hlth Sci Chicago Med Sch, Dept Physiol & Biophys, N Chicago, IL 60064 USA	Chicago Medical School	Kim, D (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Physiol & Biophys, 3333 Green Bay Rd, N Chicago, IL 60064 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAZAN NG, 1971, J NEUROCHEM, V18, P1387, DOI 10.1111/j.1471-4159.1971.tb00003.x; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; Devor DC, 1998, AM J PHYSIOL-CELL PH, V274, pC149, DOI 10.1152/ajpcell.1998.274.1.C149; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Goldstein SAN, 1998, J MOL MED-JMM, V76, P13, DOI 10.1007/s109-1998-8100-0; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KIM D, 1992, J GEN PHYSIOL, V100, P1; KIM DH, 1990, CIRC RES, V67, P1040, DOI 10.1161/01.RES.67.4.1040; KIM DH, 1995, J PHYSIOL-LONDON, V484, P643, DOI 10.1113/jphysiol.1995.sp020693; Kim Y, 1999, AM J PHYSIOL-HEART C, V277, pH1669, DOI 10.1152/ajpheart.1999.277.5.H1669; KYTE J, 1982, J MOL BIOL, V157, P162; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; PONGS O, 1992, PHYSIOL REV, V72, P569; Pountney DJ, 1999, FEBS LETT, V450, P191, DOI 10.1016/S0014-5793(99)00495-0; PREMKUMAR LS, 1990, P ROY SOC B-BIOL SCI, V242, P17, DOI 10.1098/rspb.1990.0097; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; SACHS F, 1986, MEMBRANE BIOCHEM, V6, P173, DOI 10.3109/09687688609065448; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; Salinas M, 1999, J BIOL CHEM, V274, P11751, DOI 10.1074/jbc.274.17.11751; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; VANDERVUSSE GJ, 1992, PHYSIOL REV, V72, P881, DOI 10.1152/physrev.1992.72.4.881; Wang ZW, 1999, ANN NY ACAD SCI, V868, P286, DOI 10.1111/j.1749-6632.1999.tb11294.x; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8	39	211	221	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17412	17419		10.1074/jbc.M000445200	http://dx.doi.org/10.1074/jbc.M000445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747911	hybrid			2022-12-27	WOS:000087485000029
J	Chen, RH; Ding, WV; McCormick, F				Chen, RH; Ding, WV; McCormick, F			Wnt signaling to beta-catenin involves two interactive components - Glycogen synthase kinase-3 beta inhibition and activation of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; MAMMARY EPITHELIAL-CELLS; TUMOR-SUPPRESSOR PROTEIN; RABBIT SKELETAL-MUSCLE; NEGATIVE REGULATOR; XENOPUS EMBRYOS; MOLECULAR MECHANISM; COLORECTAL-CANCER; INTACT-CELLS; PATHWAY	Wnt signaling involves inhibition of glycogen synthase kinase-3 beta (GSK-3 beta) and elevation of cytoplasmic beta-catenin, This pathway is essential during embryonic development and oncogenesis, Previous studies on both Xenopus and mammalian cells indicate that lithium mimics Wnt signaling by inactivating GSK-3 beta, Here we show that serum enhances accumulation of cytoplasmic beta-catenin induced by lithium in both 293 and C57MG cell lines and that growth factors are responsible for this enhancing activity. Growth factors mediate this effect through activation of protein kinase C (PKC), not through Ras or phosphatidylinositol 3-kinase. In addition, Wnt-induced accumulation of cytoplasmic beta-catenin is partially inhibited by PKC inhibitors and by chronic treatment of cells with phorbol eater. Both calphostin C, a PKC inhibitor, and a dominant negative PKC exhibit partial inhibition on Wnt-mediated transcriptional activation. We therefore propose that Wnt signaling to beta-catenin consists of two interactive components: one involves inhibition of GSK-3 beta and is mimicked by lithium, and the other involves PKC and serves to augment the effects of GSK-3 beta inhibition.	Univ Calif San Francisco, Sch Med, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	McCormick, F (corresponding author), Univ Calif San Francisco, Sch Med, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94115 USA.							Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CAMPAGNE MMV, 1988, DEV GENET, V9, P589, DOI 10.1002/dvg.1020090435; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; CHENG K, 1983, MOL CELL BIOCHEM, V56, P183; COHEN P, 1982, EUR J BIOCHEM, V124, P21, DOI 10.1111/j.1432-1033.1982.tb05902.x; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cui H, 1998, DEV BRAIN RES, V111, P177, DOI 10.1016/S0165-3806(98)00136-9; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GOODE N, 1992, J BIOL CHEM, V267, P16878; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; Kao KR, 1998, BIOL CELL, V90, P585, DOI 10.1016/S0248-4900(99)80016-1; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Murray NR, 1999, J CELL BIOL, V145, P699, DOI 10.1083/jcb.145.4.699; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1994, DEVELOPMENT, V120, P369; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Sparks AB, 1998, CANCER RES, V58, P1130; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1994, SEMIN CANCER BIOL, V5, P269; Zurawel RH, 1998, CANCER RES, V58, P896	72	198	203	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17894	17899		10.1074/jbc.M905336199	http://dx.doi.org/10.1074/jbc.M905336199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10749878	hybrid			2022-12-27	WOS:000087485000094
J	Chu, GC; Katakura, K; Tomita, T; Zhang, XH; Sun, DY; Sato, M; Sasahara, M; Kayama, T; Ikeda-Saito, M; Yoshida, T				Chu, GC; Katakura, K; Tomita, T; Zhang, XH; Sun, DY; Sato, M; Sasahara, M; Kayama, T; Ikeda-Saito, M; Yoshida, T			Histidine 20, the crucial proximal axial heme ligand of bacterial heme oxygenase Hmu O from Corynebacterium diphtheriae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN; CATALYTIC SITE; YERSINIA-ENTEROCOLITICA; PATHOGENIC BACTERIA; IRON TRANSPORT; COMPLEX; EXPRESSION; PROTEINS; SYSTEM; IDENTIFICATION	The hemin complex of Hmu O, a 24-kDa soluble heme degradation enzyme in Corynebacterium diphtheriae, is coordinated axially to a neutral imidazole of a proximal histidine residue in Hmu O. To identify which of the eight histidines in Hmu O is the proximal heme ligand, we have constructed and expressed the plasmids for eight His --> Ala Hmu O mutants. Reconstituted with hemin, the active site structures and enzymatic activity of these mutants have been examined by EPR, resonance Raman, and optical absorption spectroscopy. EPR of the NO-bound ferrous heme-Hmu O mutant complexes reveals His(20) as the proximal heme ligand in Hmu O, and this is confirmed by resonance Raman results from the ligand-free ferrous heme-H20A All eight His --> Ala mutants bind hemin stoichiometrically, proving that none of the histidines is essential for hemin-Hmu O formation. However, His(20) is crucial to Hmu O catalysis. Its absence by point mutation has inhibited the conversion of hemin to biliverdin. The ferric heme-H20A complex is pentacoordinate. Resonance Raman of the CO-bound ferrous heme-H20A corroborates this and reveals an Fe-C-O bending mode, delta(Fe-C-O), the first reported for a pentacoordinate GO-bound hemeprotein. The appearance of delta(Fe-C-O) in C. diphtheriae Hmu O H20A but not mammalian HO-1 mutant H25A indicates that the heme environment between the two heme oxgygenases is different.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Yamagata Univ, Sch Med, Dept Biochem, Yamagata 9909585, Japan; Yamagata Univ, Sch Med, Cent Lab Res & Educ, Yamagata 9909585, Japan; Yamagata Univ, Sch Med, Dept Neurosurg, Yamagata 9909585, Japan; Tohoku Univ, Inst Chem React Sci, Sendai, Miyagi 9808577, Japan	Case Western Reserve University; Yamagata University; Yamagata University; Yamagata University; Tohoku University	Yoshida, T (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.		Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008	Tomita, Takeshi/0000-0001-6815-2244	NIGMS NIH HHS [GM57272] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057272] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Braun V, 1997, BIOL CHEM, V378, P779; BULLEN JJ, 1999, IRON INFECT; Chu GC, 1999, J STRUCT BIOL, V126, P171, DOI 10.1006/jsbi.1999.4122; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; Chu GC, 1999, J BIOL CHEM, V274, P24490, DOI 10.1074/jbc.274.35.24490; DENBLAAUWEN T, 1993, J AM CHEM SOC, V115, P1121, DOI 10.1021/ja00056a042; DEPILLIS GD, 1994, J AM CHEM SOC, V116, P6981, DOI 10.1021/ja00094a081; GRIFFITHS E, 1999, IRON INFECT MOL PHYS, P87; ISHIKAWA K, 1995, J BIOL CHEM, V270, P6345, DOI 10.1074/jbc.270.11.6345; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; KON H, 1975, BIOCHIM BIOPHYS ACTA, V379, P103, DOI 10.1016/0005-2795(75)90012-4; LEE BC, 1995, MOL MICROBIOL, V18, P383, DOI 10.1111/j.1365-2958.1995.mmi_18030383.x; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Matera KM, 1997, BIOCHEMISTRY-US, V36, P4909, DOI 10.1021/bi962321m; MILLS M, 1995, J BACTERIOL, V177, P3004, DOI 10.1128/jb.177.11.3004-3009.1995; OTTO BR, 1992, CRIT REV MICROBIOL, V18, P217, DOI 10.3109/10408419209114559; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; SMULEVICH G, 1988, BIOCHEMISTRY-US, V27, P5477, DOI 10.1021/bi00415a014; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; STOJILJKOVIC I, 1992, EMBO J, V11, P4359, DOI 10.1002/j.1460-2075.1992.tb05535.x; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; Takahashi S, 1997, BIOCHEMISTRY-US, V36, P1402, DOI 10.1021/bi962361q; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TAO X, 1994, MOL MICROBIOL, V14, P191, DOI 10.1111/j.1365-2958.1994.tb01280.x; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; UNO T, 1987, J BIOL CHEM, V262, P4549; WILKS A, 1995, J AM CHEM SOC, V117, P2925, DOI 10.1021/ja00115a027; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; WILKS A, 1993, J BIOL CHEM, V268, P22357; WOOLDRIDGE KG, 1993, FEMS MICROBIOL REV, V12, P325, DOI 10.1016/0168-6445(93)90011-W; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; YOSHIDA T, 1982, J BIOL CHEM, V257, P9345; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	39	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17494	17500		10.1074/jbc.M000830200	http://dx.doi.org/10.1074/jbc.M000830200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10751393	hybrid			2022-12-27	WOS:000087485000041
J	Collinet, B; Herve, M; Pecorari, F; Minard, P; Eder, O; Desmadril, M				Collinet, B; Herve, M; Pecorari, F; Minard, P; Eder, O; Desmadril, M			Functionally accepted insertions of proteins within protein domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PHOSPHOGLYCERATE KINASE; INDUCED CONFORMATIONAL-CHANGES; SITE-DIRECTED MUTAGENESIS; DIHYDROFOLATE-REDUCTASE; RESIDUAL STRUCTURES; POLYPEPTIDE-CHAIN; ESCHERICHIA-COLI; BETA-LACTAMASE; UNFOLDED FORM; IN-VIVO	Experiments were designed to explore the tolerance of protein structure and folding to very large insertions of folded protein within a structural domain. Dihydrofolate reductase and p-lactamase have been inserted in four different positions of phosphoglycerate kinase. The resultant chimeric proteins are all overexpressed, and the host as well as the inserted partners are functional, Although not explicitly designed, functional coupling between the two fused partners was observed in some of the chimeras. These results show that the tolerance of protein structures to very large structured insertions is more general than previously expected and supports the idea that the natural sequence continuity of a structural domain is not required for the folding process. These results directly suggest a new experimental approach to screen, for example, for folded protein in randomized polypeptide sequences.	Univ Paris 11, Lab Modelisat & Ingn Prot, EP1088, F-91405 Orsay, France	UDICE-French Research Universities; Universite Paris Saclay	Desmadril, M (corresponding author), Univ Paris 11, Lab Modelisat & Ingn Prot, EP1088, F-91405 Orsay, France.	michel.desmadril@mip.u-psud.fr	Desmadril, Michel/AAC-8174-2020; Wood, David W/B-2992-2012; Minard, Philippe/GRS-4797-2022; Pecorari, Frederic/L-2942-2015	Minard, Philippe/0000-0002-3256-528X; Pecorari, Frederic/0000-0002-7854-0643				Adams B, 1996, FEBS LETT, V385, P101, DOI 10.1016/0014-5793(96)00348-1; Ay J, 1998, P NATL ACAD SCI USA, V95, P6613, DOI 10.1073/pnas.95.12.6613; Benito A, 1996, J BIOL CHEM, V271, P21251, DOI 10.1074/jbc.271.35.21251; Bernstein BE, 1997, NATURE, V385, P275, DOI 10.1038/385275a0; Betton JM, 1997, NAT BIOTECHNOL, V15, P1276, DOI 10.1038/nbt1197-1276; BETTON JM, 1993, FEBS LETT, V325, P34, DOI 10.1016/0014-5793(93)81409-S; DAMASCHUN G, 1993, BIOCHEMISTRY-US, V32, P7739, DOI 10.1021/bi00081a019; DEBERNARDEZCLARK E, 1991, ACS SYM SER, V470, P1; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; dePratGay G, 1996, PROTEIN ENG, V9, P843, DOI 10.1093/protein/9.10.843; GARCIA P, 1995, BIOCHEMISTRY-US, V34, P397, DOI 10.1021/bi00002a003; Garcia P, 1998, BIOCHEMISTRY-US, V37, P7444, DOI 10.1021/bi973161x; Gegg CV, 1997, PROTEIN SCI, V6, P1885, DOI 10.1002/pro.5560060909; Grattinger M, 1998, J MOL BIOL, V280, P525, DOI 10.1006/jmbi.1998.1861; HARRISON SC, 1985, P NATL ACAD SCI USA, V82, P4028, DOI 10.1073/pnas.82.12.4028; Heinemann U, 1995, PROG BIOPHYS MOL BIO, V64, P121, DOI 10.1016/0079-6107(95)00013-5; Hosszu LLP, 1997, BIOCHEMISTRY-US, V36, P333, DOI 10.1021/bi961784p; Hosszu LLP, 1997, NAT STRUCT BIOL, V4, P801, DOI 10.1038/nsb1097-801; IWAKURA M, 1992, PROTEIN ENG, V5, P791, DOI 10.1093/protein/5.8.791; Jaenicke R, 1998, BIOL CHEM, V379, P237; JENNINGS PA, 1993, BIOCHEMISTRY-US, V32, P3783, DOI 10.1021/bi00065a034; Jones S, 1998, PROTEIN SCI, V7, P233; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LEVINE M, 1978, NATURE, V271, P626, DOI 10.1038/271626a0; Lillo MP, 1997, BIOCHEMISTRY-US, V36, P11273, DOI 10.1021/bi970789z; MARKOVICHOUSLEY Z, 1994, BIOCHEMISTRY-US, V33, P10977, DOI 10.1021/bi00202a017; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; Mayr EM, 1997, J MOL BIOL, V269, P260, DOI 10.1006/jmbi.1997.1033; MINARD P, 1989, PROTEIN ENG, V3, P55, DOI 10.1093/protein/3.1.55; MINARD P, 1990, PROTEIN ENG, V3, P515, DOI 10.1093/protein/3.6.515; NOCK S, 1995, EUR J BIOCHEM, V234, P132, DOI 10.1111/j.1432-1033.1995.00132.x; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pecorari F, 1996, BIOCHEMISTRY-US, V35, P3465, DOI 10.1021/bi951973s; PIPER PW, 1990, CURR GENET, V17, P119, DOI 10.1007/BF00312855; PRESS WH, 1986, NUMERICAL RECIPES AR, P523; RitcoVonsovici M, 1995, BIOCHEMISTRY-US, V34, P16543, DOI 10.1021/bi00051a002; Russell RB, 1998, CURR OPIN STRUC BIOL, V8, P364, DOI 10.1016/S0959-440X(98)80071-7; RUSSELL RB, 1994, PROTEIN ENG, V7, P1407, DOI 10.1093/protein/7.12.1407; Vanhove M, 1996, PROTEINS, V25, P104, DOI 10.1002/(SICI)1097-0134(199605)25:1<104::AID-PROT8>3.3.CO;2-H	39	37	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17428	17433		10.1074/jbc.M000666200	http://dx.doi.org/10.1074/jbc.M000666200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747943	hybrid			2022-12-27	WOS:000087485000031
J	Gales, C; Kowalski-Chauvel, A; Dufour, MN; Seva, C; Moroder, L; Pradayrol, L; Vaysse, N; Fourmy, D; Silvente-Poirot, S				Gales, C; Kowalski-Chauvel, A; Dufour, MN; Seva, C; Moroder, L; Pradayrol, L; Vaysse, N; Fourmy, D; Silvente-Poirot, S			Mutation of Asn-391 within the conserved NPXXY motif of the cholecystokinin B receptor abolishes G(q) protein activation without affecting its association with the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND EXTRACELLULAR LOOP; SIGNAL-TRANSDUCTION; HORMONE RECEPTOR; ALPHA-SUBUNITS; TRANSMEMBRANE DOMAIN; COUPLED RECEPTORS; RHODOPSIN MUTANTS; AGONIST BINDING; PHOSPHOLIPASE-C; LIGAND-BINDING	Among the most conserved regions in the G-protein-coupled receptors is the (N/D)PX2-3Y motif of the seventh transmembrane domain (X represents any amino acid). The mutation of the Asn/Asp residue of this motif in different G-protein-coupled receptors was shown to affect the activation of either adenylyl cyclase or phospholipase C. We have mutated the Asn residue (Asn-391) of the NPXXY motif in the CCKBR to Ala and determined the effects of the mutation on binding, signaling, and G-proteins coupling after expression of the mutated receptor in COS cells. The mutated receptor displayed similar expression levels and high affinity CCK binding compared with the wild type CCKBR, However, unlike the wild type CCKBR, the mutated receptor was completely unable to mediate activation of either phospholipase C and protein kinase C-dependent and -independent mitogen-activated protein kinase pathways, indicating an essential role of Asn-391 in CCKBR signaling. Coimmunoprecipitation experiments allowed us to show that the inactive mutant retains an intact capacity to form stable complexes with G(q)alpha subunits in response to CCK. These results indicate that the formation of high affinity CCK-receptor-G(q) protein complexes is not sufficient to activate G(q) and suggest that Asn-391 is specifically involved in G(q),proteins activation.	CHU Rangueil, INSERM, U531, Inst Louis Bugnard, F-31403 Toulouse, France; CNRS, UPR 9023, CCIPE, Montpellier, France; Max Planck Inst Biochem, D-82152 Martinsried, Germany	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Max Planck Society	Silvente-Poirot, S (corresponding author), CHU Rangueil, INSERM, U531, Inst Louis Bugnard, Bat L3, F-31403 Toulouse, France.	Sandrine.Poirot@rangueil.inserm.fr	Fourmy, Daniel/AAE-3703-2019; Poirot, Sandrine/D-5448-2017; SEVA, Catherine/O-9166-2014; Kowalski-Chauvel, Aline/O-9212-2014	Fourmy, Daniel/0000-0001-9910-4827; SEVA, Catherine/0000-0002-4265-7372; Moroder, Luis/0000-0001-9570-5713; Silvente-Poirot, Sandrine/0000-0003-2245-9069; GALES, Celine/0000-0002-4938-1583				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arora KK, 1996, MOL ENDOCRINOL, V10, P979, DOI 10.1210/me.10.8.979; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; COOK JV, 1993, J ENDOCRINOL, V139, pR1, DOI 10.1677/joe.0.139R001; CRAWLEY JN, 1994, PEPTIDES, V15, P731, DOI 10.1016/0196-9781(94)90104-X; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daulhac L, 1997, BIOCHEM J, V325, P383, DOI 10.1042/bj3250383; Dufresne M, 1996, EUR J PHARMACOL, V297, P165, DOI 10.1016/0014-2999(95)00737-7; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOURMY D, 1989, EUR J BIOCHEM, V185, P397, DOI 10.1111/j.1432-1033.1989.tb15128.x; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; JAGERSCHMIDT A, 1995, MOL PHARMACOL, V48, P783; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; Konvicka K, 1998, BIOPHYS J, V75, P601, DOI 10.1016/S0006-3495(98)77551-4; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; MORODER L, 1981, H-S Z PHYSIOL CHEM, V362, P929, DOI 10.1515/bchm2.1981.362.2.929; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Parent JL, 1996, J BIOL CHEM, V271, P23298, DOI 10.1074/jbc.271.38.23298; Perlman JH, 1997, J BIOL CHEM, V272, P11937, DOI 10.1074/jbc.272.18.11937; Pohl M, 1997, J BIOL CHEM, V272, P18179, DOI 10.1074/jbc.272.29.18179; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Silvente-Poirot S, 1999, J BIOL CHEM, V274, P23191, DOI 10.1074/jbc.274.33.23191; Silvente-Poirot S, 1996, J BIOL CHEM, V271, P14698, DOI 10.1074/jbc.271.25.14698; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TANIGUCHI T, 1994, ONCOGENE, V9, P861; TODISCO A, 1995, J BIOL CHEM, V270, P28337; Wank SA, 1998, AM J PHYSIOL-GASTR L, V274, pG607, DOI 10.1152/ajpgi.1998.274.4.G607; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WU DQ, 1992, J BIOL CHEM, V267, P1811; Xu W, 1999, FEBS LETT, V447, P318, DOI 10.1016/S0014-5793(99)00316-6; ZHOU W, 1994, MOL PHARMACOL, V45, P165	37	50	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17321	17327		10.1074/jbc.M909801199	http://dx.doi.org/10.1074/jbc.M909801199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748160	hybrid			2022-12-27	WOS:000087485000017
J	Huang, A; Vita, JA; Venema, RC; Keaney, JF				Huang, A; Vita, JA; Venema, RC; Keaney, JF			Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL-FED RABBITS; CORONARY-ARTERY DISEASE; VASCULAR SMOOTH-MUSCLE; DEPENDENT VASODILATION; L-ARGININE; SUPEROXIDE GENERATION; MICE LACKING; IN-VITRO; CELLS; INHIBITION	Ascorbic acid enhances NO bioactivity in patients with vascular disease through unclear mechanism(s). We investigated the role of intracellular ascorbic acid in endothelium-derived NO bioactivity. Incubation of porcine aortic endothelial cells (PAECs) with ascorbic acid produced time- and dose-dependent intracellular ascorbic acid accumulation that enhanced NO bioactivity by 70% measured as A23187-induced cGMP accumulation. This effect was due to enhanced NO production because ascorbate stimulated both PAEC nitrogen oxide (NO2- + NO3-) production and L-arginine to L-citrulline conversion by 59 and 72%, respectively, without altering the cGMP response to authentic NO. Ascorbic acid also stimulated the catalytic activity of eNOS derived from either PAEC membrane fractions or baculovirus-infected Sf9 cells. Ascorbic acid enhanced bovine eNOS V-max by similar to 50% without altering the K-m for L-arginine. The effect of ascorbate was tetrahydrobiopterin (BH4)-dependent, because ascorbate was ineffective with BH4 concentrations >10 mu M or in PAECs treated with sepiapterin to increase intracellular BH4. The effect of ascorbic acid was also specific because A23187-stimulated cGMP accumulation in PAECs was insensitive to intracellular glutathione manipulation and only ascorbic acid, not glutathione, increased the intracellular concentration of BH4. These data suggest that ascorbic acid enhances NO bioactivity in a BH,-dependent manner by increasing intracellular BH4 content.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Mem Dept Med, Boston, MA 02118 USA; Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA	Boston University; Boston University; University System of Georgia; Augusta University	Keaney, JF (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,Rm W507, Boston, MA 02118 USA.			Vita, Joseph/0000-0001-5607-1797; Keaney, John/0000-0002-0866-1837	NHLBI NIH HHS [HL53398, HL59346, HL52936] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052936, R01HL059346, R01HL053398] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZUMA H, 1986, BRIT J PHARMACOL, V88, P411, DOI 10.1111/j.1476-5381.1986.tb10218.x; BJUR RA, 1975, J PHARMACOL EXP THER, V194, P9; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Freedman JE, 1998, CIRCULATION, V98, P1481, DOI 10.1161/01.CIR.98.15.1481; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GIRERD XJ, 1990, CIRC RES, V67, P1301, DOI 10.1161/01.RES.67.6.1301; Gokce N, 1999, CIRCULATION, V99, P3234, DOI 10.1161/01.CIR.99.25.3234; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HAUSMANN E, 1967, BIOCHIM BIOPHYS ACTA, V133, P591, DOI 10.1016/0005-2795(67)90566-1; Heitzer T, 1996, CIRCULATION, V94, P6, DOI 10.1161/01.CIR.94.1.6; Heller R, 1999, J BIOL CHEM, V274, P8254, DOI 10.1074/jbc.274.12.8254; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; Hornig B, 1998, CIRCULATION, V97, P363; HOWELLS DW, 1987, CLIN CHIM ACTA, V167, P23, DOI 10.1016/0009-8981(87)90081-7; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Jackson TS, 1998, CIRC RES, V83, P916; Jackson TS, 1996, AM J PHYSIOL-HEART C, V271, pH924, DOI 10.1152/ajpheart.1996.271.3.H924; KEANEY JF, 1995, J CLIN INVEST, V95, P2520, DOI 10.1172/JCI117953; KIVIRIKKO KI, 1967, J BIOL CHEM, V242, P4007; KOMORI Y, 1995, J BIOCHEM-TOKYO, V117, P923, DOI 10.1093/oxfordjournals.jbchem.a124797; Laursen JB, 1997, CIRCULATION, V95, P588, DOI 10.1161/01.CIR.95.3.588; LEFROY DC, 1993, CIRCULATION, V88, P43, DOI 10.1161/01.CIR.88.1.43; Levine GN, 1996, CIRCULATION, V93, P1107, DOI 10.1161/01.CIR.93.6.1107; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; LEVINE M, 1986, J BIOL CHEM, V261, P7347; LINDBLAD B, 1977, J BIOL CHEM, V252, P5073; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; Lynch SM, 1997, ARTERIOSCL THROM VAS, V17, P2975, DOI 10.1161/01.ATV.17.11.2975; Martin A, 1997, ARTERIOSCL THROM VAS, V17, P1583, DOI 10.1161/01.ATV.17.8.1583; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; Miles AM, 1996, METHOD ENZYMOL, V268, P105; MILSTIEN S, 1975, J BIOL CHEM, V250, P4777; MUGGE A, 1991, CIRC RES, V69, P1293, DOI 10.1161/01.RES.69.5.1293; MUGGE A, 1991, AM J PHYSIOL, V260, pC219, DOI 10.1152/ajpcell.1991.260.2.C219; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; OMAR HA, 1991, CIRC RES, V69, P601, DOI 10.1161/01.RES.69.3.601; PETERKOF.B, 1965, P NATL ACAD SCI USA, V53, P335, DOI 10.1073/pnas.53.2.335; PETRACK B, 1968, J BIOL CHEM, V243, P743; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; PUISTOLA U, 1980, BIOCHIM BIOPHYS ACTA, V611, P51, DOI 10.1016/0005-2744(80)90041-8; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; Reif A, 1999, J BIOL CHEM, V274, P24921, DOI 10.1074/jbc.274.35.24921; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; STUEHR DJ, 1989, BIOCHEM BIOPH RES CO, V161, P420, DOI 10.1016/0006-291X(89)92615-6; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Taddei S, 1998, CIRCULATION, V97, P2222, DOI 10.1161/01.CIR.97.22.2222; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; Ting HH, 1997, CIRCULATION, V95, P2617, DOI 10.1161/01.CIR.95.12.2617; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; Witteveen CFB, 1999, J BIOL CHEM, V274, P29755, DOI 10.1074/jbc.274.42.29755; Zhang YY, 1996, J BIOL CHEM, V271, P14271, DOI 10.1074/jbc.271.24.14271	66	286	294	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17399	17406		10.1074/jbc.M002248200	http://dx.doi.org/10.1074/jbc.M002248200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10749876	hybrid			2022-12-27	WOS:000087485000027
J	Maiorano, JN; Davidson, WS				Maiorano, JN; Davidson, WS			The orientation of helix 4 in apolipoprotein A-I-containing reconstituted high density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PENETRATION DEPTH; PLASMA LIPOPROTEINS; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; AMPHIPATHIC HELIX; FLUORESCENCE; PROTEIN; MODEL; CONFORMATION; PEPTIDE	The three-dimensional structure of the high density lipoprotein (HDL) component apolipoprotein (apo) A-I and the molecular basis for its protection against coronary artery disease are unknown. In terms of discoidal HDL particles, there has been a debate as to the orientation of the apoA-I alpha-helices around the disc edge. The "picket fence" model states that the alpha-helical repeats, separated by turns, are arranged parallel to the phospholipid acyl chains of the enclosed lipid bilayer, On the other hand, the "belt" model states that the helical segments run perpendicular to the acyl chains. To distinguish between these models, we used nitroxide spin labels present at various depths in the bilayer of reconstituted HDL (rHDL) to measure the position of Trp residues in single Trp mutants of human proapoA-I. Two mutants were studied; the first contained a Trp at position 108, which was located near the center of helix 4, The second contained a Trp at position 115, two turns along the same helix. The picket fence model predicts that these Trp residues should be at different depths in the bilayer, whereas the belt model predicts that they should be at similar depths. Different sized rHDL particles were produced that contained 2, 3, and >4 molecules of proapoA-I per complex. Tn each case, parallax analysis indicated that Trp-108 and Trp-115 were present at similar depths of about 6 Angstrom from the center of the bilayer, consistent with helix 4 being oriented perpendicular to the acyl chains (in agreement with the belt model). Similar experiments showed that control transmembrane peptides were oriented parallel to the acyl chains in vesicles, demonstrating that the method was capable of distinguishing between the two models. This study provides one of the first experimental measurements of the location of an apoA-I helix with respect to the bilayer edge.	Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Davidson, WS (corresponding author), Univ Cincinnati, Dept Pathol & Lab Med, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	sean.davidson@UC.edu		Davidson, William/0000-0003-2756-2989	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062542] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL62542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS FS, 1993, BIOCHEMISTRY-US, V32, P10826, DOI 10.1021/bi00091a038; ANDREWS AL, 1976, EUR J BIOCHEM, V64, P549, DOI 10.1111/j.1432-1033.1976.tb10335.x; BAKER HN, 1975, J BIOL CHEM, V250, P2725; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHUNG LA, 1992, BIOCHEMISTRY-US, V31, P6608, DOI 10.1021/bi00143a035; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; Davidson WS, 1999, BIOCHEMISTRY-US, V38, P14387, DOI 10.1021/bi991428h; Ghosh AK, 1997, BIOCHEMISTRY-US, V36, P14291, DOI 10.1021/bi971933j; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Ladokhin AS, 1999, BIOPHYS J, V76, P946, DOI 10.1016/S0006-3495(99)77258-9; Lecompte MF, 1998, BIOCHEMISTRY-US, V37, P16165, DOI 10.1021/bi9813072; LUX SE, 1972, J BIOL CHEM, V247, P2598; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; McGuire KA, 1996, J LIPID RES, V37, P1519; MCLACHLAN AD, 1977, NATURE, V267, P465, DOI 10.1038/267465a0; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; Ren JH, 1999, BIOCHEMISTRY-US, V38, P5905, DOI 10.1021/bi982942a; Roberts LM, 1997, BIOCHEMISTRY-US, V36, P7615, DOI 10.1021/bi962952g; SCANU AM, 1972, ANNU REV BIOCHEM, V41, P703, DOI 10.1146/annurev.bi.41.070172.003415; SEGREST JP, 1977, CHEM PHYS LIPIDS, V18, P7, DOI 10.1016/0009-3084(77)90023-8; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; SEGREST JP, 1992, J LIPID RES, V33, P141; SMALL DM, 1986, PHYSICAL CHEM LIPIDS, P475; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; TALL AR, 1977, J BIOL CHEM, V252, P4701; WALD JH, 1990, J BIOL CHEM, V265, P20037; WALD JH, 1990, J BIOL CHEM, V265, P20044; WLODAWER A, 1979, FEBS LETT, V104, P231, DOI 10.1016/0014-5793(79)80821-2	38	42	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17374	17380		10.1074/jbc.M000044200	http://dx.doi.org/10.1074/jbc.M000044200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10751383	hybrid			2022-12-27	WOS:000087485000024
J	Hamel, P; Olive, J; Pierre, Y; Wollman, FA; de Vitry, C				Hamel, P; Olive, J; Pierre, Y; Wollman, FA; de Vitry, C			A new subunit of cytochrome b(6)f complex undergoes reversible phosphorylation upon state transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; ALGA CHLAMYDOMONAS-REINHARDTII; OPEN READING FRAME; PHOTOSYSTEM-II; CHLOROPLAST GENES; ELECTRON-TRANSFER; BF COMPLEX; LIGHT; MEMBRANE; KINASE	A 15.2-kDa polypeptide, encoded by the nuclear gene PETO, was identified as a novel cytochrome b(6)f subunit in Chlamydomonas reinhardtii. The PETO gene product is a bona fide subunit, subunit V, of the cytochrome b(6)f complex, because (i) it copurifies with the other cytochrome b(6)f subunits in the early stages of the purification procedure, (ii) it is deficient in cytochrome b(6)f mutants accumulating little of the complex, and (iii) it colocalizes with cytochrome f, which migrates between stacked and unstacked membrane regions upon state transition. Sequence analysis and biochemical characterization of subunit V shows that it has a one transmembrane alpha-helix topology with two large hydrophilic domains extending on the stromal and lumenal side of the thylakoid membranes, with a lumenal location of the N terminus. Subunit V is reversibly phosphorylated upon state transition, a unique feature that, together with its topological organization, points to the possible role of subunit V in signal transduction during redox-controlled short term and long term adaptation of the photosynthetic apparatus in eukaryotes.	Inst Biol Physicochim, CNRS, UPR 1261, F-75005 Paris, France; Inst Biol Physicochim, CNRS, UPR 9052, Lab Physicochim Mol Membranes Biol, F-75005 Paris, France; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Paris 07, Inst Jacques Monod, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California Los Angeles; UDICE-French Research Universities; Universite Paris Cite	de Vitry, C (corresponding author), Inst Biol Physicochim, CNRS, UPR 1261, 13 Rue Pierre & Marie Curie, F-75005 Paris, France.	catherine.devitry@ibpc.fr			NIGMS NIH HHS [GM48350] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JF, 1997, PHYSIOL PLANTARUM, V100, P863, DOI 10.1034/j.1399-3054.1997.1000412.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asamizu E, 1999, DNA Res, V6, P369, DOI 10.1093/dnares/6.6.369; ATTEIA A, 1992, J BIOL CHEM, V267, P226; Atteia A, 1996, EUR J BIOCHEM, V237, P792, DOI 10.1111/j.1432-1033.1996.0792p.x; BENNETT J, 1988, EUR J BIOCHEM, V171, P95, DOI 10.1111/j.1432-1033.1988.tb13763.x; BERTHOLD DA, 1995, J BIOL CHEM, V270, P29293, DOI 10.1074/jbc.270.49.29293; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BRUCE D, 1989, BIOCHIM BIOPHYS ACTA, V974, P66, DOI 10.1016/S0005-2728(89)80166-5; BULTE L, 1990, BIOCHIM BIOPHYS ACTA, V1020, P72, DOI 10.1016/0005-2728(90)90095-L; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; CHOW WS, 1990, P NATL ACAD SCI USA, V87, P7502, DOI 10.1073/pnas.87.19.7502; COUGHLAN SJ, 1988, BIOCHIM BIOPHYS ACTA, V933, P413, DOI 10.1016/0005-2728(88)90076-X; de Vitry C, 1999, PLANT CELL, V11, P2031, DOI 10.1105/tpc.11.10.2031; deVitry C, 1996, J BIOL CHEM, V271, P10667, DOI 10.1074/jbc.271.18.10667; DEVITRY C, 1994, J BIOL CHEM, V269, P7603; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; DRAPIER D, 1992, PLANT CELL, V4, P283, DOI 10.2307/3869540; ESCOUBAS JM, 1995, P NATL ACAD SCI USA, V92, P10237, DOI 10.1073/pnas.92.22.10237; Finazzi G, 1999, BBA-BIOENERGETICS, V1413, P117, DOI 10.1016/S0005-2728(99)00089-4; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; Fulgosi H, 1998, EMBO J, V17, P1577, DOI 10.1093/emboj/17.6.1577; GAL A, 1992, FEBS LETT, V298, P33, DOI 10.1016/0014-5793(92)80016-A; Hager M, 1999, EMBO J, V18, P5834, DOI 10.1093/emboj/18.21.5834; JOLIOT P, 1988, BIOCHIM BIOPHYS ACTA, V933, P319, DOI 10.1016/0005-2728(88)90039-4; KEREN N, 1999, MOL BIOL CHLOROPLAST, P569; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; LAVERGNE J, 1983, BIOCHIM BIOPHYS ACTA, V725, P25, DOI 10.1016/0005-2728(83)90220-7; LEMAIRE C, 1989, J BIOL CHEM, V264, P10235; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; MAXWELL DP, 1995, PLANT PHYSIOL, V109, P787, DOI 10.1104/pp.109.3.787; Meissner M, 1999, CURR GENET, V36, P363, DOI 10.1007/s002940050511; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; Rintamaki E, 1997, J BIOL CHEM, V272, P30476, DOI 10.1074/jbc.272.48.30476; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Soriano GM, 1999, J BIOENERG BIOMEMBR, V31, P201, DOI 10.1023/A:1005463527752; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; Testi MG, 1996, FEBS LETT, V399, P245, DOI 10.1016/S0014-5793(96)01333-6; VALLON O, 1991, P NATL ACAD SCI USA, V88, P8262, DOI 10.1073/pnas.88.18.8262; VALLON O, 1989, BIOCHIM BIOPHYS ACTA, V975, P132, DOI 10.1016/S0005-2728(89)80211-7; Vener AV, 1998, CURR OPIN PLANT BIOL, V1, P217, DOI 10.1016/S1369-5266(98)80107-6; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; Vener AV, 1999, BIOCHEMISTRY-US, V38, P14955, DOI 10.1021/bi990971v; Vermeglio A, 1999, TRENDS MICROBIOL, V7, P435, DOI 10.1016/S0966-842X(99)01625-X; WOLLMAN FA, 1984, J CELL BIOL, V98, P1, DOI 10.1083/jcb.98.1.1; WOLLMAN FA, 1988, BIOCHIM BIOPHYS ACTA, V933, P85, DOI 10.1016/0005-2728(88)90058-8; WOLLMAN FA, 1999, MOL BIOL CHLOROPLAST, P459; WYNN RM, 1988, BIOCHIM BIOPHYS ACTA, V935, P115, DOI 10.1016/0005-2728(88)90208-3; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zito F, 1999, EMBO J, V18, P2961, DOI 10.1093/emboj/18.11.2961	52	75	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17072	17079		10.1074/jbc.M001468200	http://dx.doi.org/10.1074/jbc.M001468200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748028	hybrid			2022-12-27	WOS:000087392200094
J	Pyle, RA; Schivell, AE; Hidaka, H; Bajjalieh, SM				Pyle, RA; Schivell, AE; Hidaka, H; Bajjalieh, SM			Phosphorylation of synaptic vesicle protein 2 modulates binding to synaptotagmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-I; 2ND C2 DOMAIN; BRAIN; SV2; IDENTIFICATION; FUSION; PURIFICATION; TRANSMISSION; LOCALIZATION; TRANSPORTER	Synaptic vesicle protein 2 (SV2) is a component of all synaptic vesicles that is required for normal neurotransmission. Here we report that in intact synaptic terminals SV2 is a phosphoprotein. Phosphopeptide mapping studies indicate that a major site of phosphorylation is located on the cytoplasmic amino terminus. SV2 is phosphorylated on serine and threonine but not on tyrosine residues, indicating that it is a substrate for serine/threonine kinases. Phosphopeptide mapping, in gel kinase assays, and surveys of kinase inhibitors suggest that casein kinase I is a primary SV2 kinase. The amino terminus of SV2 was previously shown to mediate its interaction with synaptotagmin, a calcium-binding protein also required for normal neurotransmission. Comparison of synaptotagmin binding with phosphorylated and unphosphorylated SV2 amino-terminal peptides reveals an increase in binding with phosphorylation. These results suggest that the affinity of SV2 for synaptotagmin is modulated by phosphorylation of SV2.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Program Mol & Cellular Biol, Seattle, WA 98195 USA; Univ Washington, Grad Program Neurobiol & Behav, Seattle, WA 98195 USA; D Western Therapeut Inst, Showa Ku, Nagoya, Aichi 4660825, Japan	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bajjalieh, SM (corresponding author), Univ Washington, Dept Pharmacol, D431 HSB,Box 357280, Seattle, WA 98195 USA.				NINDS NIH HHS [1 RO1 NS37387-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037387] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bajjalieh SM, 1999, CURR OPIN NEUROBIOL, V9, P321, DOI 10.1016/S0959-4388(99)80047-6; BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BAJJALIEH SM, 1993, P NATL ACAD SCI USA, V90, P2150, DOI 10.1073/pnas.90.6.2150; BAJJALIEH SM, 1994, J NEUROSCI, V14, P5223, DOI 10.1523/jneurosci.14-09-05223.1994; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; Crowder KM, 1999, P NATL ACAD SCI USA, V96, P15268, DOI 10.1073/pnas.96.26.15268; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GINGRICH JA, 1992, FEBS LETT, V312, P115, DOI 10.1016/0014-5793(92)80917-6; GRANT SG, 1993, SCIENCE, V258, P1903; GREENGARD P, 1994, MOL CELLULAR MECH NE, P31; GROSS SD, 1995, J CELL BIOL, V130, P711, DOI 10.1083/jcb.130.3.711; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; HUTTNER WB, 1983, J CELL BIOL, V96, P1373; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Janz R, 1999, NEUROSCIENCE, V94, P1279, DOI 10.1016/S0306-4522(99)00370-X; Janz R, 1998, J NEUROSCI, V18, P9269; Janz R, 1999, NEURON, V24, P1003, DOI 10.1016/S0896-6273(00)81046-6; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OREGAN S, 1995, MOL BRAIN RES, V32, P135, DOI 10.1016/0169-328X(95)00071-Y; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; SHENG ZH, 1997, P NATL ACAD SCI USA, V94, P5404; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; TUAZON PT, 1991, ADV 2 MESSENGER PHOS, V23, P13; WALAAS SI, 1993, NEUROCHEM RES, V18, P43, DOI 10.1007/BF00966921; Yokoyama CT, 1997, J NEUROSCI, V17, P6929; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	46	56	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17195	17200		10.1074/jbc.M000674200	http://dx.doi.org/10.1074/jbc.M000674200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747945	hybrid			2022-12-27	WOS:000087392200112
J	Baker, JC; Yan, XH; Peng, T; Kasten, S; Roche, TE				Baker, JC; Yan, XH; Peng, T; Kasten, S; Roche, TE			Marked differences between two isoforms of human pyruvate dehydrogenase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOYL ACETYLTRANSFERASE COMPONENT; PROTEIN-X COMPONENT; ACETYL-COENZYME-A; LIPOYL DOMAIN; BOVINE KIDNEY; SACCHAROMYCES-CEREVISIAE; TRANSACETYLASE CORE; ACTIVATOR PROTEIN; MOLECULAR-CLONING; ESCHERICHIA-COLI	Pyruvate dehydrogenase kinase (PDK) isoforms 2 and 3 were produced via co-expression with the chaperonins GroEL and GroES and purified with high specific activities in affinity tag-free forms. By using human components, we have evaluated how binding to the lipoyl domains of the dihydrolipoyl acetyltransferase (E2) produces the predominant changes in the rates of phosphorylation of the pyruvate dehydrogenase (E1) component by PDK2 and PDK3. E2 assembles as a 60-mer via its C-terminal domain and has mobile connections to an E1-binding domain and then two lipoyl domains, L2 and L1 at the N terminus. PDK3 was activated 17-fold by E2; the majority of this activation was facilitated by the free L2 domain (half-maximal activation at 3.3 mu M L2). The direct activation of PDK3 by the L2 domain resulted in a 12.8-fold increase in k(cat) along with about a 2-fold decrease in the K-m of PDK3 for E1. PDK3 was poorly inhibited by pyruvate or dichloroacetate (DCA). PDK3 activity was stimulated upon reductive acetylation of L1 and L2 when full activation of PDK3 by E2 was avoided (e.g. using free lipoyl domains or ADP-inhibited ES-activated PDK3), In marked contrast, PDK2 was not responsive to free lipoyl domains, but the E2-60-mer enhanced PDK2 activity by 10-fold, E2 activation of PDK2 resulted in a greatly enhanced sensitivity to inhibition by pyruvate or DCA; pyruvate was effective at significantly lower levels than DCA. ES-activated PDK2 activity was stimulated greater than or equal to 3-fold by reductive acetylation of E2; stimulated PDK2 retained high sensitivity to inhibition by ADP and DCA. Thus, PDK3 is directly activated by the L2 domain, and fully activated PDK3 is relatively insensitive to feed-forward (pyruvate) and feed-back (acetylating) effecters. PDK2 was activated only by assembled E2, and this activated state beget high responsiveness to those effectors.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Roche, TE (corresponding author), Kansas State Univ, Dept Biochem, 104 Willard Hall, Manhattan, KS 66506 USA.			Kasten, Shane/0000-0003-1986-8064	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018320, R55DK018320] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18320] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bowker-Kinley M, 1999, BIOCHEM J, V344, P47, DOI 10.1042/0264-6021:3440047; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P2958, DOI 10.1021/bi00281a027; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P2966, DOI 10.1021/bi00281a028; CATE RL, 1978, J BIOL CHEM, V253, P496; Chen W, 1999, BIOCHEM J, V339, P103, DOI 10.1042/0264-6021:3390103; CORDINGLEY MG, 1990, J BIOL CHEM, V265, P9062; DAVIE JR, 1995, J BIOL CHEM, V270, P19861, DOI 10.1074/jbc.270.34.19861; DENYER GS, 1986, BIOCHEM J, V239, P347, DOI 10.1042/bj2390347; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; Gong XM, 2000, J BIOL CHEM, V275, P13645, DOI 10.1074/jbc.275.18.13645; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Harris RA, 1997, J BIOL CHEM, V272, P19746, DOI 10.1074/jbc.272.32.19746; Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; HUTSON NJ, 1978, FEBS LETT, V92, P73, DOI 10.1016/0014-5793(78)80724-8; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KERBEY AL, 1984, FEBS LETT, V176, P115, DOI 10.1016/0014-5793(84)80923-0; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; KOROTCHKINA LG, 1995, PROTEIN EXPRES PURIF, V6, P79, DOI 10.1006/prep.1995.1011; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; LIU SJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P926, DOI 10.1006/abbi.1995.1124; LIU TC, 1995, J BIOL CHEM, V270, P15545, DOI 10.1074/jbc.270.26.15545; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; ONO K, 1993, J BIOL CHEM, V268, P26135; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PETTIT FH, 1975, BIOCHEM BIOPH RES CO, V65, P575, DOI 10.1016/S0006-291X(75)80185-9; Popov KM, 1997, FEBS LETT, V419, P197, DOI 10.1016/S0014-5793(97)01453-1; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; PRATT ML, 1979, J BIOL CHEM, V254, P7191; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1988, J BIOL CHEM, V263, P8106; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P1245; RAHMATULLAH M, 1985, J BIOL CHEM, V260, P146; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; RANDLE PJ, 1996, ALPHA KETO ACID DEHY, P151; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; REED LJ, 1990, J BIOL CHEM, V265, P8971; ROCHE TE, 1974, BIOCHEM BIOPH RES CO, V59, P1341, DOI 10.1016/0006-291X(74)90461-6; ROCHE TE, 1976, BIOCHEM BIOPH RES CO, V72, P1375, DOI 10.1016/S0006-291X(76)80166-0; ROCHE TE, 1996, ALPHA KETO ACID DEHY, P33; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Stanley WC, 1997, CARDIOVASC RES, V34, P25, DOI 10.1016/S0008-6363(97)00047-3; STEPP LR, 1983, J BIOL CHEM, V258, P9454; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; SUGDEN MC, 1995, J NUTR, V125, pS1746; SUGDEN MC, 1995, BIOCHEM SOC T, V23, P314, DOI 10.1042/bst0230314; Sugden MC, 1997, J MOL CELL CARDIOL, V29, P1867, DOI 10.1006/jmcc.1997.0425; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5; WAGENKNECHT T, 1991, J BIOL CHEM, V266, P24650; WHITEHOUSE S, 1974, BIOCHEM J, V141, P761, DOI 10.1042/bj1410761; Wu PF, 1998, DIABETES, V47, pA425; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197; WU TL, 1984, BIOCHEMISTRY-US, V22, P2958; Yang DQ, 1998, J BIOL CHEM, V273, P14130, DOI 10.1074/jbc.273.23.14130; Yang DQ, 1997, J BIOL CHEM, V272, P6361, DOI 10.1074/jbc.272.10.6361	63	84	91	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15773	15781		10.1074/jbc.M909488199	http://dx.doi.org/10.1074/jbc.M909488199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748134	hybrid			2022-12-27	WOS:000087291400025
J	Caumon, AS; Vitale, N; Gensse, M; Galas, MC; Casanova, JE; Bader, MF				Caumon, AS; Vitale, N; Gensse, M; Galas, MC; Casanova, JE; Bader, MF			Identification of a plasma membrane-associated guanine nucleotide exchange factor for ARF6 in chromaffin cells - Possible role in the regulated exocytotic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PLECKSTRIN-HOMOLOGY DOMAINS; GTP-BINDING-PROTEIN; PHOSPHOLIPASE-D; SEC7 DOMAIN; PC12 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; CATECHOLAMINE RELEASE; POSSIBLE INVOLVEMENT; ACTIN CYTOSKELETON	ADP-ribosylation factors (ARFs) constitute a family of structurally related proteins that forms a subset of the Ras superfamily of regulatory GTP-binding proteins. Like other GTPases, activation of ARFs is facilitated by specific guanine nucleotide exchange factors (GEFs), In chromaffin cells, ARF6 is associated with the membrane of secretory granules. Stimulation of intact cells or direct elevation of cytosolic calcium in permeabilized cells triggers the rapid translocation of ARF6 to the plasma membrane and the concomitant activation of phospholipase D (PLD) in the plasma membrane. Both calcium-evoked PLD activation and catecholamine secretion in permeabilized cells are strongly inhibited by a synthetic peptide corresponding to the N-terminal domain of ARF6, suggesting that the ARF6-dependent PLD activation near the exocytotic sites represents a key event in the exocytotic reaction in chromaffin cells. In the present study, we demonstrate the occurrence of a brefeldin A-insensitive ARF6-GEF activity in the plasma membrane and in the cytosol of chromaffin cells, Furthermore, reverse transcriptase-polymerase chain reaction and immunoreplica analysis indicate that ARNO, a member of the brefeldin A-insensitive ARF-GEF family, is expressed and predominantly localized in the cytosol and in the plasma membrane of chromaffin cells. Using permeabilized chromaffin cells, we found that the introduction of anti-ARNO antibodies into the cytosol inhibits, in a dose-dependent manner, both PLD activation and catecholamine secretion in calcium-stimulated cells. Furthermore, co-expression in PC12 cells of a catalytically inactive ARNO mutant with human growth hormone as a marker of secretory granules in transfected cells resulted in a 50% inhibition of growth hormone secretion evoked by depolarization with high K+. The possibility that the plasma membrane-associated ARNO participates in the exocytotic pathway by activating ARF6 and downstream PLD is discussed.	INSERM, Biol Commun Cellulaire U338, F-67084 Strasbourg, France; Massachusetts Gen Hosp, Combined Program Pediat Gastroenterol & Nutr, Charlestown, MA 02129 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Harvard University; Massachusetts General Hospital	Bader, MF (corresponding author), INSERM, Biol Commun Cellulaire U338, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.		Bader, Marie-France/O-2098-2016; Vitale, Nicolas/G-5967-2014; Galas, Marie-Christine/AAL-9812-2020	Vitale, Nicolas/0000-0002-4752-4907; Galas, Marie-Christine/0000-0002-3766-7103				ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chasserot-Golaz S, 1998, J NEUROCHEM, V70, P2347; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COLOMBO MI, 1995, J BIOL CHEM, V270, P24564, DOI 10.1074/jbc.270.41.24564; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; FRANCO M, 1995, FEBS LETT, V362, P286, DOI 10.1016/0014-5793(95)00258-B; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; Gasman S, 1998, J BIOL CHEM, V273, P16913, DOI 10.1074/jbc.273.27.16913; Gasman S, 1999, J CELL SCI, V112, P4763; HAUN RS, 1993, J BIOL CHEM, V268, P7064; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kowluru A, 1997, BIOCHEM PHARMACOL, V54, P1097, DOI 10.1016/S0006-2952(97)00314-6; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; LINSTEDT AD, 1987, TRENDS NEUROSCI, V10, P446, DOI 10.1016/0166-2236(87)90095-6; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Millar CA, 1999, J BIOL CHEM, V274, P17619, DOI 10.1074/jbc.274.25.17619; Monier S, 1998, J CELL SCI, V111, P3427; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; Pacheco-Rodriguez G, 1998, J BIOL CHEM, V273, P26543, DOI 10.1074/jbc.273.41.26543; PERLETTI LK, 1997, GENOMICS, V46, P215; PERRIN D, 1987, NATURE, V326, P498, DOI 10.1038/326498a0; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Song J, 1998, J CELL SCI, V111, P2257; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; STREARNS T, 1990, P NATL ACAD SCI USA, V87, P1238; TERUI T, 1994, J BIOL CHEM, V269, P28130; Togawa A, 1999, J BIOL CHEM, V274, P12308, DOI 10.1074/jbc.274.18.12308; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Vitale N, 1996, EUR J NEUROSCI, V8, P1275, DOI 10.1111/j.1460-9568.1996.tb01296.x; VITALE N, 1993, J BIOL CHEM, V268, P14715; WICK PF, 1993, J BIOL CHEM, V268, P10983; Xu JH, 1999, J BIOL CHEM, V274, P19095, DOI 10.1074/jbc.274.27.19095	60	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15637	15644		10.1074/jbc.M908347199	http://dx.doi.org/10.1074/jbc.M908347199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748097	hybrid			2022-12-27	WOS:000087291400007
J	Newton, AL; Sharpe, BK; Kwan, A; Mackay, JP; Crossley, M				Newton, AL; Sharpe, BK; Kwan, A; Mackay, JP; Crossley, M			The transactivation domain within cysteine/histidine-rich region 1 of CBP comprises two novel zinc-binding modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; NUCLEAR-PROTEIN CBP; RNA-POLYMERASE-II; CREB; CHROMATIN; P300/CBP; COACTIVATOR; COMPLEX; FAMILY; IDENTIFICATION	cAMP-response element-binding protein-binding protein (CBP) is a transcriptional coactivator that interacts with a number of DNA-binding proteins and cofactor proteins involved in the regulation of transcription. Relatively little is known about the structure of CBP, but it has been noted that it contains three domains that are rich in cysteine and histidine (CH1, CH2, and CH3), The sequence of CH2 conforms to that of a leukemia-associated protein domain (PHD finger), and it has been postulated that this and both CH1 and CH3 may be zinc finger domains. This has not, however, been demonstrated experimentally. We have studied CH1 and show that it is composed of two novel zinc-binding modules, which we term "zinc bundles." Each bundle contains the sequence Cys-X-4-Cys-X-8-His-X-3-Cys, and we show that a synthetic peptide comprising one zinc bundle from CH1 can fold in a zinc-dependent manner. CH3 also appears to contain two zinc bundles, one with the variant sequence Cys-X-4-Cys-X-8-His-X-3-Cys, and we demonstrate that this variant motif also undergoes Zn(II)-induced folding. CH1 acts as a transcriptional activation domain in cellular assays. We show that mutations in any of the four zinc-chelating residues in either zinc bundle of CH1 significantly impair this activity and that these mutations also interfere with certain protein-protein interactions mediated by CH1. Our results indicate that CBP is a genuine zinc-binding protein and introduce zinc bundles as novel protein interaction domains.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	University of Sydney	Crossley, M (corresponding author), Univ Sydney, Dept Biochem, G08, Sydney, NSW 2006, Australia.		Mackay, Joel P/D-6834-2011; Crossley, Merlin/D-7888-2011	Mackay, Joel P/0000-0001-7508-8033; Crossley, Merlin/0000-0003-2057-3642; Kwan, Ann/0000-0002-1506-2226				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Ausubel F, 1997, SHORT PROTOCOLS MOL; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bisotto S, 1996, J BIOL CHEM, V271, P17746, DOI 10.1074/jbc.271.30.17746; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; Hayes D. B., 1995, SEDNTERP; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hung HL, 1999, MOL CELL BIOL, V19, P3496; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Parker D, 1996, MOL CELL BIOL, V16, P694; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Sambrook J., 2002, MOL CLONING LAB MANU; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yoshida E, 1998, GENE, V208, P307, DOI 10.1016/S0378-1119(98)00008-0; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	45	40	41	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15128	15134		10.1074/jbc.M910396199	http://dx.doi.org/10.1074/jbc.M910396199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748221	hybrid			2022-12-27	WOS:000087128300050
J	Nguyen, T; Huang, HC; Pickett, CB				Nguyen, T; Huang, HC; Pickett, CB			Transcriptional regulation of the antioxidant response element - Activation by Nrf2 and repression by MafK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; PHENOLIC ANTIOXIDANTS; INDUCIBLE EXPRESSION; MEDIATED EXPRESSION; DETOXIFYING ENZYMES; OXIDATIVE STRESS; INDUCTION; PROTEINS; BINDING; JUN	The antioxidant response element (ARE) mediates the transcriptional activation of many genes encoding phase II drug-metabolizing enzymes in response to oxidative stress. Recent studies using knockout mice suggest that NF-E2-related factor 2 (Nrf2), along with small Maf proteins, binds and activates the ARE. In this study, using in vitro binding assays, Nrf2/MafK heterodimers were found to interact with high affinity to the ARE. However, distinct differences were observed when this interaction was compared with that formed with nuclear proteins from H4II EC3 or HepG2 cells. Overexpression of Nrf2 activated ARE-mediated transcription in HepG2 cells, and this activation was further increased by tert-butylhydroquinone. In HeLa cells, overexpression of Nrf2 resulted in activation of the ARE, but this activation was no longer induced by tert-butylhydroquinone. Using ARE constructs with point mutations in the core sequence, we found that only mutations at the T or G nucleotides within the core (TGAC) render the ARE unresponsive to Nrf2. Overexpression of MafK led to dose-dependent repression of ARE activity. Activation of the ARE by Nrf2 was similarly antagonized by MafK. These data suggest that Nrf2 plays an important role mediating basal activity of the ARE but that small Maf proteins are repressors and not activators of ARE-mediated transcription.	Schering Plough Res Inst, Kenilworth, NJ 07033 USA	Merck & Company; Schering-Plough Research Institute	Pickett, CB (corresponding author), Schering Plough Res Inst, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.							ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Johnsen O, 1996, NUCLEIC ACIDS RES, V24, P4289, DOI 10.1093/nar/24.21.4289; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; LI Y, 1992, J BIOL CHEM, V267, P15097; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yu R, 1997, J BIOL CHEM, V272, P28962, DOI 10.1074/jbc.272.46.28962	29	303	310	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15466	15473		10.1074/jbc.M000361200	http://dx.doi.org/10.1074/jbc.M000361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747902	hybrid			2022-12-27	WOS:000087128300093
J	Shechter, DF; Ying, CY; Gautier, J				Shechter, DF; Ying, CY; Gautier, J			The intrinsic DNA helicase activity of Methanobacterium thermoautotrophicum Delta H minichromosome maintenance protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION LICENSING SYSTEM; COMPLETE GENOME SEQUENCE; LARGE TUMOR-ANTIGEN; FISSION YEAST; MCM PROTEIN; CELL-CYCLE; S-PHASE; NUCLEAR-LOCALIZATION; SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS	Minichromosome maintenance proteins (MCMs) form a family of conserved molecules that are essential for initiation of DNA replication. All eukaryotes contain six orthologous MCM proteins that function as heteromultimeric complexes. The sequencing of the complete genomes of several archaebacteria has shown that MCM proteins are also present in archaea. The archaea Methanobacterium thermoautotrophicum contains a single MCM-related sequence. Here we report on the expression and purification of the recombinant M. thermoautotrophicum MCM protein (MtMCM) in both Escherichia coli and baculovirus-infected cells. We show that purified MtMCM protein assembles in large macromolecular complexes consistent in size with being double hexamers. We demonstrate that MtMCM contains helicase activity that preferentially uses dATP and DNA-dependent dATPase and ATPase activities. The intrinsic helicase activity of MtMCM is abolished when a conserved lysine in the helicase domain I/nucleotide binding site is mutated. MtMCM helicase unwinds DNA duplexes in a 3' --> 5' direction and can unwind up to 500 base pairs in vitro. The kinetics, processivity, and directionality of MtMCM support its role as a replicative helicase in M. thermoautotrophicum. This strongly suggests that this function is conserved for MCM proteins in eukaryotes where a replicative helicase has yet to be identified.	Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Dept Dermatol, New York, NY 10032 USA; Columbia Univ, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Gautier, J (corresponding author), Columbia Univ, Dept Genet & Dev, VC15-1526,630 W 168th St, New York, NY 10032 USA.	jg130@columbia.edu	Gautier, jean/A-2774-2008; Shechter, David/B-4660-2008	Shechter, David/0000-0001-9388-6004				Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; FEGER G, 1995, EMBO J, V14, P5387, DOI 10.1002/j.1460-2075.1995.tb00223.x; FORSBURG SL, 1994, J CELL SCI, V107, P2779; Forsburg SL, 1997, GENETICS, V147, P1025; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; Fujita M, 1996, BIOCHEM BIOPH RES CO, V219, P604, DOI 10.1006/bbrc.1996.0280; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; LEE MS, 1989, J BIOL CHEM, V264, P14531; Liang DT, 1999, J CELL SCI, V112, P559; Lopez P, 1999, MOL MICROBIOL, V32, P883, DOI 10.1046/j.1365-2958.1999.01370.x; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 1996, EMBO J, V15, P861, DOI 10.1002/j.1460-2075.1996.tb00421.x; Okishio N, 1996, J CELL SCI, V109, P319; Pasion SG, 1999, MOL BIOL CELL, V10, P4043, DOI 10.1091/mbc.10.12.4043; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Schulte D, 1996, EUR J BIOCHEM, V235, P144, DOI 10.1111/j.1432-1033.1996.00144.x; Sherman DA, 1998, NUCLEIC ACIDS RES, V26, P3955, DOI 10.1093/nar/26.17.3955; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.3.CO;2-V; Sible JC, 1998, CURR BIOL, V8, P347, DOI 10.1016/S0960-9822(98)70136-8; SIEGAL G, 1992, J BIOL CHEM, V267, P13629; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Thommes P, 1997, CANCER SURV, V29, P75; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tye BK, 1999, METHODS, V18, P329, DOI 10.1006/meth.1999.0793; WANG EH, 1991, VIROLOGY, V184, P399, DOI 10.1016/0042-6822(91)90858-9; WANG EH, 1991, J BIOL CHEM, V266, P12668; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; You ZY, 1999, MOL CELL BIOL, V19, P8003; ZEIKUS JG, 1972, J BACTERIOL, V109, P707, DOI 10.1128/JB.109.2.707-713.1972	65	124	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15049	15059		10.1074/jbc.M000398200	http://dx.doi.org/10.1074/jbc.M000398200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747908	hybrid			2022-12-27	WOS:000087128300040
J	Kambampati, R; Lauhon, CT				Kambampati, R; Lauhon, CT			Evidence for the transfer of sulfane sulfur from IscS to ThiI during the in vitro biosynthesis of 4-thiouridine in Escherichia coli tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; RNA	IscS from Escherichia coli is a cysteine desulfurase that has been shown to be involved in Fe-S cluster formation. The enzyme converts L-cysteine to L-alanine and sulfane sulfur (S-0) in the form of a cysteine persulfide in its active site. Recently, we reported that IscS can donate sulfur for the in vitro biosynthesis of 4-thiouridine (s(4)U), modified nucleotide in tRNA. In addition to IscS, s(4)U synthesis in E. coli also requires the thiamin biosynthetic enzyme ThiI, Mg-ATP, and L-cysteine as the sulfur donor. We now report evidence that the sulfane sulfur generated by IscS is transferred sequentially to ThiI and then to tRNA during the in vitro synthesis of s(4)U. Treatment of ThiI with 5-((2-iodoacetamido)ethyl)-1-aminonapthalene sulfonic acid (I-AEDANS) results in irreversible inhibition, suggesting the presence of a reactive cysteine that is required for binding and/or catalysis. Both ATP and tRNA can protect ThiI from I-AEDANS inhibition. Finally, using gel shift and protease protection assays, we show that ThiI binds to unmodified E. coli tRNA(Phe). Together, these results suggest that ThiI is a recipient of S-0 from IscS and catalyzes the ultimate sulfur transfer step in the biosynthesis of s(4)U.	Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Lauhon, CT (corresponding author), Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA.	clauhon@facstaff.wisc.edu			NIGMS NIH HHS [GM57002] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057002] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRELL JW, 1971, J BIOL CHEM, V246, P294; Flint DH, 1996, J BIOL CHEM, V271, P16068; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; LIPSETT MN, 1978, J BACTERIOL, V135, P993, DOI 10.1128/JB.135.3.993-997.1978; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Mueller EG, 1998, NUCLEIC ACIDS RES, V26, P2606, DOI 10.1093/nar/26.11.2606; Mueller EG, 1999, PROTEIN SCI, V8, P2424; RYALS J, 1982, J BACTERIOL, V151, P899, DOI 10.1128/JB.151.2.899-904.1982; TOOHEY JI, 1989, BIOCHEM J, V264, P625, DOI 10.1042/bj2640625; Webb E, 1997, J BACTERIOL, V179, P4399, DOI 10.1128/jb.179.13.4399-4402.1997	10	113	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10727	10730		10.1074/jbc.275.15.10727	http://dx.doi.org/10.1074/jbc.275.15.10727			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753862	hybrid			2022-12-27	WOS:000086466600004
J	Caspersen, C; Pedersen, PS; Treiman, M				Caspersen, C; Pedersen, PS; Treiman, M			The sarco/endoplasmic reticulum calcium-ATPase 2b is an endoplasmic reticulum stress-inducible protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; RESPONSE ELEMENT; MAMMALIAN-CELLS; SARCOPLASMIC-RETICULUM; COORDINATED REGULATION; GENE-EXPRESSION; MESSENGER-RNA; CA-2+ PUMP; CA2+; INDUCTION	The sarco/endoplasmic reticulum calcium-ATPase (SERCA) translocates Ca2+ from the cytosol to the lumen of the endoplasmic reticulum, This Ca2+ storage is important for cellular processes such as calcium signaling and endoplasmic reticulum (ER)-associated posttranslational protein modifications. We investigated the expression of the SERCA2 and SERCA3 isozymes in PC12 cells exposed to agents interfering with different aspects of the posttranslational protein processing within the ER, thereby activating the ER stress-induced unfolded protein response (UPR). All agents increased the SERCA2b mRNA level 3-4-fold, in parallel with increasing mRNA levels for the EB stress marker proteins BiP/GRP78 and CHOP/GADD153, In contrast, SERCA3 mRNA levels did not change. SERCA2b mRNA stability was not changed, indicating that the mechanism of its up-regulation was transcriptional, in accordance with the presence of ER stress response elements in the promoter region of the SERCA2 gene, SERCA2b was also increased at the protein level upon ER stress treatments. Induction of ER stress by tunicamycin, dithiothreitol, or L-azetidine 2-carboxylic acid did not result in depletion of ER calcium, showing that such depletion was not necessary for up-regulation of SERCA2b expression or UPR activation in general. We conclude that the SERCA2b expression can be controlled by the UPR pathway independently of ER Ca2+ depletion.	Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Biotechnol Ctr Cellular Commun, DK-2200 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen	Treiman, M (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Physiol, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.							Ausubel FM, 1988, MOL REPROD DEV; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BERS DM, 1988, CALCIUM DRUG ACTIONS, V83, P491; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; BURK SE, 1989, J BIOL CHEM, V264, P18561; Caspersen C, 1995, FEBS LETT, V377, P31, DOI 10.1016/0014-5793(95)01304-0; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper GR, 1997, BIOCHEM J, V325, P601, DOI 10.1042/bj3250601; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; Foti DM, 1999, J BIOL CHEM, V274, P30402, DOI 10.1074/jbc.274.43.30402; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Koivunen P, 1997, GENOMICS, V42, P397, DOI 10.1006/geno.1997.4750; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Kuo TH, 1997, CELL CALCIUM, V21, P399, DOI 10.1016/S0143-4160(97)90051-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Launay S, 1997, J BIOL CHEM, V272, P10746; LEE AS, 1983, J BIOL CHEM, V258, P597; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Lee SY, 1997, J MICROBIOL BIOTECHN, V7, P272; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LYTTON J, 1988, J BIOL CHEM, V263, P15024; Martin V, 2000, HYPERTENSION, V35, P91, DOI 10.1161/01.HYP.35.1.91; Mattson MP, 2000, J NEUROSCI, V20, P1358; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Mori K, 1998, J BIOL CHEM, V273, P9912, DOI 10.1074/jbc.273.16.9912; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; RESENDEZ E, 1986, J CELL BIOL, V103, P2145, DOI 10.1083/jcb.103.6.2145; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Varadi A, 1996, BIOCHEM J, V319, P521, DOI 10.1042/bj3190521; WADKINS RM, 1991, BIOCHEMISTRY-US, V30, P9469, DOI 10.1021/bi00103a012; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	58	109	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22363	22372		10.1074/jbc.M001569200	http://dx.doi.org/10.1074/jbc.M001569200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10748035	hybrid			2022-12-27	WOS:000088363800083
J	Schapiro, FB; Grinstein, S				Schapiro, FB; Grinstein, S			Determinants of the pH of the Golgi complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVING CELLS; PROTON PUMP; ENDOPLASMIC-RETICULUM; INTRACELLULAR PH; NA+/H+ EXCHANGER; CYSTIC-FIBROSIS; RETROGRADE TRANSPORT; PLASMA-MEMBRANE; IRON TRANSPORT; SHIGA TOXIN	The factors contributing to the establishment of the steady state Golgi pH (pH(G)) were studied in intact and permeabilized mammalian cells by fluorescence ratio imaging. Retrograde transport of the nontoxic B subunit of verotoxin 1 was used to deliver pH-sensitive probes to the Golgi complex. To evaluate whether counter-ion permeability limited the activity of the electrogenic V-ATPase, we determined the concentration of K+ in the lumen of the Golgi using a null point titration method. The [K+] inside the Golgi was found to be close to that of the cytosol, and increasing its permeability had no effect on pH,. Moreover, the capacity of the endogenous counter-ion permeability exceeded the rate of H+ pumping, implying that the potential across the Golgi membrane is negligible and has little influence on pH,. The V-ATPase does not reach thermodynamic equilibrium nor does it seem to be allosterically inactivated at the steady state pH(G). In fact, active H+ pumping was detectable even below the resting pH(G). A steady state pH was attained when the rate of pumping was matched by the passive backflux of H+ (equivalents) or "leak." The nature of this leak pathway was investigated in detail. Neither vesicular traffic nor H+/cation antiporters or symporters were found to contribute to the net loss of H+ from the Golgi. Instead, the leak was sensitive to voltage changes and was inhibited by Zn2+, resembling the H+ conductive pathway of the plasma membrane. We conclude that a balance between an endogenous leak, which includes a conductive component, and the H+ pump determines the pH at which the Golgi lumen attains a steady state.	Hosp Sick Children, Res Inst, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Grinstein, S (corresponding author), Hosp Sick Children, Res Inst, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.on.ca						ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ALAWQATI Q, 1992, J EXP BIOL, V172, P245; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; BABCOCK DF, 1983, J BIOL CHEM, V258, P6380; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BOULANGER J, 1994, ANAL BIOCHEM, V217, P1, DOI 10.1006/abio.1994.1075; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; DAVOUST J, 1987, EMBO J, V6, P3601, DOI 10.1002/j.1460-2075.1987.tb02691.x; DECOURSEY TE, 1998, FRONTIERS BIOSCI, V1, P477; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; DIXON TE, 1980, J BIOL CHEM, V255, P3237; EISNER DA, 1989, PFLUG ARCH EUR J PHY, V413, P553, DOI 10.1007/BF00594188; Farinas J, 1999, J BIOL CHEM, V274, P7603, DOI 10.1074/jbc.274.12.7603; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Harris C, 1999, INT J MOL MED, V3, P315; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Johannes L, 1998, TRENDS CELL BIOL, V8, P158, DOI 10.1016/S0962-8924(97)01209-9; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Kinsella JL, 1998, BIOCHEM CELL BIOL, V76, P743, DOI 10.1139/bcb-76-5-743; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; LUKACS GL, 1993, AM J PHYSIOL, V265, pC3, DOI 10.1152/ajpcell.1993.265.1.C3; MAHAUTSMITH MP, 1989, J EXP BIOL, V145, P455; MARKIN VS, 1975, J MEMBRANE BIOL, V25, P23, DOI 10.1007/BF01868566; Maxfield FR, 1991, INTRACELLULAR TRAFFI, P157; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, J EXP BIOL, V172, P39; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; NOVIKOFF PM, 1983, P NATL ACAD SCI-BIOL, V80, P4364, DOI 10.1073/pnas.80.14.4364; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; ORCI L, 1987, NATURE, V326, P77, DOI 10.1038/326077a0; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; RABOUILLE C, 1995, J CELL SCI, V108, P1617; ROBINSON JD, 1983, BIOCHIM BIOPHYS ACTA, V731, P406, DOI 10.1016/0005-2736(83)90035-4; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Rybak SL, 1997, BIOPHYS J, V73, P674, DOI 10.1016/S0006-3495(97)78102-5; SABOLIC I, 1986, AM J PHYSIOL, V250, pF817, DOI 10.1152/ajprenal.1986.250.5.F817; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Seksek O, 1996, J BIOL CHEM, V271, P15542, DOI 10.1074/jbc.271.26.15542; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; XU HX, 1994, J BIOL CHEM, V269, P22875; YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929	54	99	101	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21025	21032		10.1074/jbc.M002386200	http://dx.doi.org/10.1074/jbc.M002386200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10748071	hybrid			2022-12-27	WOS:000088230600010
J	Brzin, J; Rogelj, B; Popovic, T; Strukelj, B; Ritonja, A				Brzin, J; Rogelj, B; Popovic, T; Strukelj, B; Ritonja, A			Clitocypin, a new type of cysteine proteinase inhibitor from fruit bodies of mushroom Clitocybe nebularis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; CATHEPSIN-L; AFFINITY CHROMATOGRAPHY; PROTEASE INHIBITORS; PROCATHEPSIN-B; PINEAPPLE STEM; PAPAIN; PURIFICATION; LECTINS; POTATO	A novel inhibitor of cysteine proteinases has been isolated from fruit bodies of a mushroom Clitocybe nebularis, The inhibitor was purified to homogeneity by affinity chromatography and gel filtration, followed by reverse-phase high pressure liquid chromatography, The active inhibitor has an apparent molecular mass of about 34 kDa by gel filtration and by SDS-polyacrylamide gel electrophoresis without prior boiling of the sample. Boiling in 2.5% SDS or incubation in 6 M guanidine hydrochloride resulted in a single band of 17 kDa, indicating homodimer composition with no intersubunit disulfide bonds. The inhibitor in nondenaturing buffer is resistant to boiling in water, retaining its activity and dimer composition. The mushroom protein is a tight binding inhibitor of papain (K(i) = 0.59 nM), cathepsin L (K(i) = 0.41 nM), cathepsin B (K(i) = 0.48 mu M), and bromelain (K(i) = 0.16 mu M) but is inactive toward cathepsin H, trypsin, and pepsin, Its isoelectric point is 4.4, and sugar analysis indicates the absence of carbohydrate, A single protein sequence of 150 amino acids, containing no cysteine or methionine residues, was obtained by amino acid sequencing. The calculated molecular mass of 16854 Da corresponds well with the value obtained by mass spectrometry, A major part of this sequence was verified by molecular cloning. The monomer sequence is clearly devoid of typical cystatin structure elements and has no similarity to any other known cysteine proteinase inhibitors but bears some similarity to a lectin-like family of proteins from mushrooms. The inhibitor, which is present in at least two other members of the Clitocybe genus, has been named clitocypin (Clitocybe cysteine proteinase inhibitor).	Jozef Stefan Inst, Dept Biochem & Mol Biol, Ljubljana 1000, Slovenia; Univ Ljubljana, Fac Pharm, Dept Pharmaceut Biol, Ljubljana 1000, Slovenia	Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; University of Ljubljana	Brzin, J (corresponding author), Jozef Stefan Inst, Dept Biochem & Mol Biol, Jamova 39, Ljubljana 1000, Slovenia.	joze.brzin@ijs.si	Rogelj, Boris/G-9252-2011	Rogelj, Boris/0000-0003-3898-1943				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARRETT AJ, 1972, ANAL BIOCHEM, V47, P280, DOI 10.1016/0003-2697(72)90302-8; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BLUMBERG S, 1970, EUR J BIOCHEM, V15, P97, DOI 10.1111/j.1432-1033.1970.tb00981.x; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BRZIN J, 1984, BIOCHEM BIOPH RES CO, V118, P103, DOI 10.1016/0006-291X(84)91073-8; BUTTLE DJ, 1990, FEBS LETT, V260, P195, DOI 10.1016/0014-5793(90)80100-W; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; Christeller JT, 1998, EUR J BIOCHEM, V254, P160, DOI 10.1046/j.1432-1327.1998.2540160.x; COX SW, 1989, J PERIODONTAL RES, V24, P353, DOI 10.1111/j.1600-0765.1989.tb00882.x; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; ESSER RE, 1994, ARTHRITIS RHEUM, V37, P236, DOI 10.1002/art.1780370213; Gruden K, 1998, INSECT BIOCHEM MOLEC, V28, P549, DOI 10.1016/S0965-1748(98)00051-4; Guillot J, 1997, BIOCHEM SYST ECOL, V25, P203, DOI 10.1016/S0305-1978(96)00110-X; Guncar G, 1999, EMBO J, V18, P793, DOI 10.1093/emboj/18.4.793; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HOREJSI V, 1978, BIOCHIM BIOPHYS ACTA, V538, P299, DOI 10.1016/0304-4165(78)90358-6; Kawagishi H, 1997, PHYTOCHEMISTRY, V44, P7, DOI 10.1016/S0031-9422(96)00492-X; KINO K, 1989, J BIOL CHEM, V264, P472; KRIZAJ I, 1993, FEBS LETT, V333, P15, DOI 10.1016/0014-5793(93)80366-3; LAVENIER D, 1996, PI988 IRISA; LAVENIER D, 1996, RR2845 INRIA; Lenarcic B, 1998, BIOL CHEM, V379, P105; LENARCIC B, 1992, BIOL CHEM H-S, V373, P459, DOI 10.1515/bchm3.1992.373.2.459; MANZI AE, 1995, CURRENT PROTOCOLS MO, V3; MASON RW, 1986, BIOCHEM J, V240, P285, DOI 10.1042/bj2400285; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; OGURI S, 1994, BIOSCI BIOTECH BIOCH, V58, P507, DOI 10.1271/bbb.58.507; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Popovic T, 1996, J CHROMATOGR B, V681, P251, DOI 10.1016/0378-4347(95)00555-2; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RAWLINGS ND, 1990, COMPUT APPL BIOSCI, V6, P118; REDDY MN, 1975, J BIOL CHEM, V250, P1741; Rosen S, 1996, EUR J BIOCHEM, V238, P822, DOI 10.1111/j.1432-1033.1996.0822w.x; ROWAN AD, 1994, METHOD ENZYMOL, V244, P555; ROWAN AD, 1990, FEBS LETT, V269, P328, DOI 10.1016/0014-5793(90)81186-R; RYAN CA, 1978, TRENDS BIOCHEM SCI, V5, P148; Sambrook J., 2002, MOL CLONING LAB MANU; SLOANE BF, 1994, BIOCH MOL ASPECTS SE, V2, P411; STROP P, 1981, J CHROMATOGR, V207, P55; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; SUEYOSHI S, 1985, BIOL CHEM H-S, V366, P213, DOI 10.1515/bchm3.1985.366.1.213; TCHOUPE JR, 1991, BIOCHIM BIOPHYS ACTA, V1076, P149, DOI 10.1016/0167-4838(91)90232-O; TURK B, 1995, FEBS LETT, V360, P101, DOI 10.1016/0014-5793(95)00060-M; TURK B, 1993, J BIOL CHEM, V268, P7323; Turk D, 1996, FEBS LETT, V384, P211, DOI 10.1016/0014-5793(96)00309-2; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Turk V, 1997, BIOM HLTH R, V15, P3; WEIL LH, 1996, STROKE, V27, P2080; Yamamoto Y, 1999, FEBS LETT, V448, P257, DOI 10.1016/S0014-5793(99)00382-8	52	64	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20104	20109		10.1074/jbc.M001392200	http://dx.doi.org/10.1074/jbc.M001392200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748021	hybrid			2022-12-27	WOS:000087941300091
J	Niggeweg, R; Thurow, C; Kegler, C; Gatz, C				Niggeweg, R; Thurow, C; Kegler, C; Gatz, C			Tobacco transcription factor TGA2.2 is the main component of as-1-binding factor ASF-1 and is involved in salicylic acid- and auxin-inducible expression of as-1-containing target promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; TISSUE-SPECIFIC EXPRESSION; TRANSGENIC TOBACCO; ARABIDOPSIS-THALIANA; DNA-BINDING; PARA GENE; G-BOX; PROTEINS; ELEMENT; PLANTS	In higher plants, activating sequence-1 (as-1) of the cauliflower mosaic virus 35 S promoter mediates both salicylic acid (SA)- and auxin-inducible transcriptional activation. Originally found in promoters of several viral and bacterial plant pathogens, as-1-like elements are also functional elements of plant promoters activated in the course of a defense response upon pathogen attack. Nuclear as-1-binding factor (ASF-1) and cellular salicylic acid response protein (SARP) bind specifically to as-1. Four different tobacco bZIP transcription factors (TGA1a, PG13, TGA2.1, and TGA2.2) are potential components of either ASF-1 or SARP. Here we show that ASF-1 and SARP are very similar in their composition. TGA2.2 is a major component of either complex, as shown by supershift analysis and Western blot analysis of DNA affinity-purified SARP. Minor amounts of a protein immunologically related to TGA2.1 were detected, whereas TGA1a was not detectable. Overexpression of either TGA2.2 or a dominant negative TGA2.2 mutant affected both SA and auxin (2,4D) inducibility of various target promoters encoding as-1-like elements, albeit to different extents. This indicates that TGA2.2 is a component of the enhancosome assembling on these target promoters, both under elevated SA and 2,4D concentrations. However, the effect of altered TGA2.2 levels on gene expression was more pronounced upon SA treatment than upon 2,4D treatment.	Univ Gottingen, Albrecht von Haller Inst Pflanzenwissensch, D-37073 Gottingen, Germany	University of Gottingen	Gatz, C (corresponding author), Univ Gottingen, Albrecht von Haller Inst Pflanzenwissensch, Untere Karspuele 2, D-37073 Gottingen, Germany.							Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; Chuang CF, 1999, GENE DEV, V13, P334, DOI 10.1101/gad.13.3.334; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; Droog F, 1995, PLANT MOL BIOL, V29, P413, DOI 10.1007/BF00020974; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fourney R.M., 1988, FOCUS, V10, P5; FROMM H, 1991, MOL GEN GENET, V229, P181, DOI 10.1007/BF00272154; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; GATZ C, 1992, PLANT J, V2, P397, DOI 10.1046/j.1365-313X.1992.t01-37-00999.x; Glazebrook J, 1999, CURR OPIN PLANT BIOL, V2, P280, DOI 10.1016/S1369-5266(99)80050-8; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Horvath DM, 1996, PLANT MOL BIOL, V31, P1061, DOI 10.1007/BF00040724; Jupin I, 1996, EMBO J, V15, P5679, DOI 10.1002/j.1460-2075.1996.tb00952.x; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KAWATA T, 1992, NUCLEIC ACIDS RES, V20, P1141, DOI 10.1093/nar/20.5.1141; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Kusaba M, 1996, PLANT PHYSIOL, V111, P1161, DOI 10.1104/pp.111.4.1161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM E, 1995, NUCLEIC ACIDS RES, V23, P3778, DOI 10.1093/nar/23.18.3778; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; LIU XJ, 1994, J BIOL CHEM, V269, P668; MENKENS AE, 1995, TRENDS BIOCHEM SCI, V20, P506, DOI 10.1016/S0968-0004(00)89118-5; MIAO ZH, 1995, PLANT J, V7, P887, DOI 10.1046/j.1365-313X.1995.07060887.x; MIAO ZH, 1994, PLANT MOL BIOL, V25, P1, DOI 10.1007/BF00024193; NEUHAUS G, 1994, PLANT CELL, V6, P827, DOI 10.1105/tpc.6.6.827; Niggeweg R, 2000, PLANT MOL BIOL, V42, P775, DOI 10.1023/A:1006319113205; NIGGEWEG R, 1997, PLANT PHYSIOL, V113, P1464; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Pascuzzi P, 1998, J BIOL CHEM, V273, P26631, DOI 10.1074/jbc.273.41.26631; PAYNE G, 1988, PLANT MOL BIOL, V11, P89, DOI 10.1007/BF00015662; PRAT S, 1989, MOL GEN GENET, V17, P209; QIN XF, 1994, PLANT CELL, V6, P863, DOI 10.1105/tpc.6.6.863; Rauscher M, 1999, PLANT J, V19, P625, DOI 10.1046/j.1365-313x.1999.00545.x; RIEPING M, 1994, PLANT CELL, V6, P1087, DOI 10.1105/tpc.6.8.1087; Ryals J, 1997, PLANT CELL, V9, P425, DOI 10.1105/tpc.9.3.425; RYALS J, 1994, PLANT PHYSIOL, V104, P1109, DOI 10.1104/pp.104.4.1109; Sakai T, 1998, PLANT CELL PHYSIOL, V39, P731, DOI 10.1093/oxfordjournals.pcp.a029427; SCHINDLER U, 1992, PLANT CELL, V4, P1309, DOI 10.1105/tpc.4.10.1309; Stange C, 1997, PLANT J, V11, P1315, DOI 10.1046/j.1365-313X.1997.11061315.x; Strompen G, 1998, PLANT MOL BIOL, V37, P871, DOI 10.1023/A:1006003916284; TAKAHASHI Y, 1995, PLANTA, V196, P111, DOI 10.1007/BF00193224; TAKAHASHI Y, 1989, P NATL ACAD SCI USA, V86, P9279, DOI 10.1073/pnas.86.23.9279; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vanderZaal BJ, 1996, PLANT PHYSIOL, V110, P79, DOI 10.1104/pp.110.1.79; VANDERZAAL EJ, 1991, PLANT MOL BIOL, V16, P983, DOI 10.1007/BF00016071; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; Xiang CB, 1996, PLANT MOL BIOL, V32, P415, DOI 10.1007/BF00019093; Xiang CB, 1997, PLANT MOL BIOL, V34, P403, DOI 10.1023/A:1005873500238; ZHANG B, 1993, PLANT J, V4, P711, DOI 10.1046/j.1365-313X.1993.04040711.x; Zhang YL, 1999, P NATL ACAD SCI USA, V96, P6523, DOI 10.1073/pnas.96.11.6523	50	102	115	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19897	19905		10.1074/jbc.M909267199	http://dx.doi.org/10.1074/jbc.M909267199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10751419	hybrid			2022-12-27	WOS:000087941300064
J	Liang, M; Mallari, C; Rosser, M; Ng, HP; May, K; Monahan, S; Bauman, JG; Islam, I; Ghannam, A; Buckman, B; Shaw, K; Wei, GP; Xu, W; Zhao, Z; Ho, E; Shen, J; Oanh, H; Subramanyam, B; Vergona, R; Taub, D; Dunning, L; Harvey, S; Snider, RM; Hesselgesser, J; Morrissey, MM; Perez, HD; Horuk, R				Liang, M; Mallari, C; Rosser, M; Ng, HP; May, K; Monahan, S; Bauman, JG; Islam, I; Ghannam, A; Buckman, B; Shaw, K; Wei, GP; Xu, W; Zhao, Z; Ho, E; Shen, J; Oanh, H; Subramanyam, B; Vergona, R; Taub, D; Dunning, L; Harvey, S; Snider, RM; Hesselgesser, J; Morrissey, MM; Perez, HD; Horuk, R			Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; TRANSPLANT REJECTION; MULTIPLE-SCLEROSIS; INDUCED ARTHRITIS; RANTES CHEMOKINE; T-CELLS; EXPRESSION; INTEGRIN	The CC chemokine receptor-1 (CCR1) is a prime therapeutic target for treating autoimmune diseases. Through high capacity screening followed by chemical optimization, we identified a novel non-peptide CCR1 antagonist, R-N-[5-chloro-2-[2-[4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]phenyl]urea hydrochloric acid salt (BX 471), Competition binding studies revealed that BX 471 was able to displace the CCR1 ligands macrophage inflammatory protein-1 alpha (MIP-1 alpha), RANTES, and monocyte chemotactic protein-3 (MCP-3) with high affinity (K-i ranged from 1 nM to 5.5 nM), BX 471 was a potent functional antagonist based on its ability to inhibit a number of CCR1-mediated effects including Ca2+ mobilization, increase in extracellular acidification rate, CD11b expression, and leukocyte migration, BX 471 demonstrated a greater than 10,000-fold selectivity for CCR1 compared with 28 G-protein-coupled receptors, Pharmacokinetic studies demonstrated that BX 471 was orally active with a bioavailability of 60% in dogs. Furthermore, BX 471 effectively reduces disease in a rat experimental allergic encephalomyelitis model of multiple sclerosis, This study is the first to demonstrate that a non-peptide chemokine receptor antagonist is efficacious in an animal model of an autoimmune disease. In summary, we have identified a potent, selective, and orally available CCR1 antagonist that may be useful in the treatment of chronic inflammatory diseases.	Berlex Biosci, Dept Discovery Res, Richmond, CA 94804 USA; Berlex Biosci, Dept Biol Res, Richmond, CA 94804 USA; Berlex Biosci, Dept Pharmacol, Richmond, CA 94804 USA; Berlex Biosci, Dept Immunol, Richmond, CA 94804 USA; NIA, Immunol Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Liang, M (corresponding author), Berlex Biosci, Dept Mol Pharmacol, 15049 San Pablo Ave, Richmond, CA 94804 USA.	meina_liang@berlex.com			NATIONAL INSTITUTE ON AGING [ZIAAG000764, Z01AG000764] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Barnes DA, 1998, J CLIN INVEST, V101, P2910, DOI 10.1172/JCI2172; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; CANNELLA B, 1993, J NEUROIMMUNOL, V46, P43, DOI 10.1016/0165-5728(93)90232-N; Conklyn MJ, 1996, CYTOKINE, V8, P762, DOI 10.1006/cyto.1996.0101; EBERS GC, 1986, DIS NERV SYST, P1268; Gao W, 2000, J CLIN INVEST, V105, P35, DOI 10.1172/JCI8126; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; Grone HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687; Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; KARPUS WJ, 1995, J IMMUNOL, V155, P5003; Karpus WJ, 1997, J LEUKOCYTE BIOL, V62, P681, DOI 10.1002/jlb.62.5.681; KATO K, 1997, Patent No. 9724325; KENT SJ, 1995, J NEUROIMMUNOL, V58, P1, DOI 10.1016/0165-5728(94)00165-K; Keszthelyi E, 1996, NEUROLOGY, V47, P1053, DOI 10.1212/WNL.47.4.1053; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; Leger Olivier J. P., 1997, Human Antibodies, V8, P3; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MERRILL JE, 1987, IMMUNOL TODAY, V8, P146, DOI 10.1016/0167-5699(87)90144-7; NAYA A, 1998, Patent No. 9804554; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Ng HP, 1999, J MED CHEM, V42, P4680, DOI 10.1021/jm990316l; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; PATTISON J, 1994, LANCET, V343, P209, DOI 10.1016/S0140-6736(94)90992-X; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Rottman JB, 1999, FASEB J, V13, pA666; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; TAUB DD, 1995, J IMMUNOL METHODS, V184, P187, DOI 10.1016/0022-1759(95)00087-Q; WIEDERMANN CJ, 1993, CURR BIOL, V3, P735, DOI 10.1016/0960-9822(93)90020-O; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	39	162	188	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19000	19008		10.1074/jbc.M001222200	http://dx.doi.org/10.1074/jbc.M001222200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10748002	hybrid			2022-12-27	WOS:000087815900052
J	Schwartz, PT; Perez-Villamil, B; Rivera, A; Moratalla, R; Vallejo, M				Schwartz, PT; Perez-Villamil, B; Rivera, A; Moratalla, R; Vallejo, M			Pancreatic homeodomain transcription factor IDX1/IPF1 expressed in developing brain regulates somatostatin gene transcription in embryonic neural cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX GENES; VENTROMEDIAL HYPOTHALAMUS; MAMMALIAN TELENCEPHALON; IMMUNOREACTIVE NEURONS; UPSTREAM ENHANCER; PRECURSOR CELLS; NEUROPEPTIDE-Y; MICE LACKING; ISLET CELLS; BETA-CELLS	Hox-like homeodomain proteins play a critical role during embryonic development by regulating the transcription of genes that are important for the generation of specific organs or cell types. The homeodomain transcription factor IDX1/IPF1, the expression of which was thought until recently to be restricted to the pancreas and foregut, is required for pancreas development and for the expression of genes controlling glucose homeostasis. We report that IDX1/IPF1 is also expressed in embryonic rat brain at a time coincident with active neurogenesis. Electrophoretic mobility shift assays with nuclear extracts of embryonic brains indicated that IDX1/IPF1 binds to two somatostatin promoter elements, SMS-UE-B and the recently discovered SMS-TAAT3, The requirement of these elements for IDX1/IPF1 transactivation of the somatostatin gene in neural cells was confirmed in transfection studies using embryonic cerebral cortex-derived RC2.E10 cells. Immunohistochemical staining of rat embryos showed IDX1/IPF1-positive cells located near the ventricular surface in germinative areas of the developing central nervous system. Cellular colocalization of IDX1/IPF1 and somatostatin was found in several areas of the developing brain, including cortex, ganglionic eminence, hypothalamus, and inferior colliculus. These results support the notion that IDX1/IPF1 regulates gene expression during development of the central nervous system independent of its role on pancreas development and function.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrine Unit, Boston, MA 02114 USA; CSIC, Inst Ramon Y Cajal, Madrid 28002, Spain; Univ Autonoma Madrid, Inst Invest Biomed, CSIC, E-28029 Madrid, Spain	Harvard University; Harvard Medical School; Massachusetts General Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Vallejo, M (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrine Unit, Boston, MA 02114 USA.	mvallejo@iib.uam.es	Moratalla, Rosario V/H-9280-2015; Rivera, Alicia/L-2098-2014; Vallejo, Mario/ABG-4610-2020; Perez-Villamil, Beatriz/AAB-3572-2019	Moratalla, Rosario V/0000-0002-7623-8010; Rivera, Alicia/0000-0002-7282-0441; Vallejo, Mario/0000-0002-6422-0323; Perez-Villamil, Beatriz/0000-0002-6881-7442	NIDDK NIH HHS [DK-49670] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049670] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; Acampora D, 1996, NAT GENET, V14, P218, DOI 10.1038/ng1096-218; ADACHI A, 1991, BRAIN RES BULL, V26, P137, DOI 10.1016/0361-9230(91)90198-S; Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; ALVAREZBOLADO G, 1995, J COMP NEUROL, V355, P237, DOI 10.1002/cne.903550207; Andersen FG, 1999, FEBS LETT, V445, P315, DOI 10.1016/S0014-5793(99)00144-1; Anderson SA, 1997, NEURON, V19, P27, DOI 10.1016/S0896-6273(00)80345-1; Bayer S.A., 1991, NEOCORTICAL DEV; Borg MA, 1999, DIABETES, V48, P584, DOI 10.2337/diabetes.48.3.584; BOUILLET P, 1995, DEV DYNAM, V204, P372, DOI 10.1002/aja.1002040404; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; BULFONE A, 1993, J NEUROSCI, V13, P3155; BURGUNDER JM, 1994, DEV BRAIN RES, V78, P109, DOI 10.1016/0165-3806(94)90015-9; Carty MD, 1997, J BIOL CHEM, V272, P11986, DOI 10.1074/jbc.272.18.11986; CHUN JJM, 1987, NATURE, V325, P617, DOI 10.1038/325617a0; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; FITZPATRICKMCELLIGOTT S, 1991, SYNAPSE, V7, P123, DOI 10.1002/syn.890070206; Friedman MI, 1991, CHEM SENSES, V4, P19; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; Heller RS, 1998, GASTROENTEROLOGY, V115, P381, DOI 10.1016/S0016-5085(98)70204-5; JAMES R, 1991, J BIOL CHEM, V266, P3246; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KOWALL NW, 1987, NEUROSCIENCE, V20, P817, DOI 10.1016/0306-4522(87)90242-9; Larsen PJ, 1997, ENDOCRINOLOGY, V138, P4445, DOI 10.1210/en.138.10.4445; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MARCHAND R, 1986, NEUROSCIENCE, V17, P573, DOI 10.1016/0306-4522(86)90031-X; McManus MF, 1999, J NEUROSCI, V19, P9004, DOI 10.1523/JNEUROSCI.19-20-09004.1999; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Minokoshi Y, 1999, DIABETES, V48, P287, DOI 10.2337/diabetes.48.2.287; Moratalla R, 1996, NEURON, V17, P147, DOI 10.1016/S0896-6273(00)80288-3; Morrow EM, 1999, DEVELOPMENT, V126, P23; MURTHA MT, 1991, P NATL ACAD SCI USA, V88, P10711, DOI 10.1073/pnas.88.23.10711; NAUS CCG, 1988, J COMP NEUROL, V269, P448, DOI 10.1002/cne.902690311; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Olsson M, 1998, NEUROSCIENCE, V84, P867, DOI 10.1016/S0306-4522(97)00532-0; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Perez-Villamil B, 1999, ENDOCRINOLOGY, V140, P3857, DOI 10.1210/en.140.8.3857; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; QIU MS, 1995, GENE DEV, V9, P2523, DOI 10.1101/gad.9.20.2523; Retaux S, 1999, J NEUROSCI, V19, P783; Robel L, 1995, J NEUROSCI, V15, P7879; Rubenstein JLR, 1998, ANNU REV NEUROSCI, V21, P445, DOI 10.1146/annurev.neuro.21.1.445; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sadikot AF, 1997, J COMP NEUROL, V389, P193; Schwartz PT, 1998, MOL ENDOCRINOL, V12, P1280, DOI 10.1210/me.12.9.1280; SEMBA K, 1988, J NEUROSCI, V8, P3937; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; Shimamura K, 1995, DEVELOPMENT, V121, P3923; Shimazaki T, 1999, EMBO J, V18, P444, DOI 10.1093/emboj/18.2.444; SHIOSAKA S, 1982, J COMP NEUROL, V204, P211, DOI 10.1002/cne.902040302; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; Stoffers DA, 1998, J CLIN INVEST, V102, P232, DOI 10.1172/JCI2242; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; Sussel L, 1998, DEVELOPMENT, V125, P2213; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; VALLEJO M, 1995, MOL CELL BIOL, V15, P415, DOI 10.1128/MCB.15.1.415; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; VALLEJO M, 1987, NEUROSCI LETT, V73, P155, DOI 10.1016/0304-3940(87)90010-3; VINCENT SR, 1985, J COMP NEUROL, V238, P169, DOI 10.1002/cne.902380205; VONMUHLENDAHL E, 1995, NEW ENGL J MED, V333, P704, DOI 10.1056/NEJM199509143331105; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; WURST W, 1994, DEVELOPMENT, V120, P2065; Yoshida M, 1997, DEVELOPMENT, V124, P101	73	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19106	19114		10.1074/jbc.M000655200	http://dx.doi.org/10.1074/jbc.M000655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10751390	hybrid, Green Submitted			2022-12-27	WOS:000087815900065
J	White, EL; Ross, LJ; Davis, RL; Zywno-van Ginkel, S; Vasanthakumar, G; Borhani, DW				White, EL; Ross, LJ; Davis, RL; Zywno-van Ginkel, S; Vasanthakumar, G; Borhani, DW			The two Toxoplasma gondii hypoxanthine-guanine phosphoribosyltransferase isozymes form heterotetramers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; CRYSTAL-STRUCTURES; FLEXIBLE LOOP; EXPRESSION; BINDING; CDNA; PARASITE; COMPLEX; PROTEIN; CLONING	Two isozymes of the purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) of the apicomplexan protozoan Toxoplasma gondii are encoded by the single HGPRT gene as a result of differential splicing. Western blotting of total T. gondii protein shows that both isozymes I and II, which differ by 49 amino acids, are expressed. Both form enzymatically active homotetramers when overexpressed in Escherichia coli. The specific activity of HGPRT-I is five times that of HGPRT-II. When both isozymes are co-expressed in E. coli, HGPRT-I HGPRT-II heterotetramers form. The predominant heterotetramer has enzymatic activity similar to HGPRT-II, and gel filtration chromatography demonstrates that its size is intermediate between the sizes of HGPRT-I and HGPRT-II. Mass spectrometric analysis of cross-linked homo- and heterotetramers reveals species of distinct molecular mass for HGPRT-I, HGPRT-II, and HGPRT-I.HGPRT-II and suggests that the predominant heterotetramer consists of one HGPRT-I subunit and three HGPRT-II subunits. The implications of this finding are discussed.	So Res Inst, Dept Organ Chem, Drug Discovery Div, Birmingham, AL 35205 USA		Borhani, DW (corresponding author), So Res Inst, Dept Organ Chem, Drug Discovery Div, 2000 9th Ave S, Birmingham, AL 35205 USA.	borhani@sri.org	Borhani, David/O-2692-2019	Borhani, David/0000-0002-8486-8792	NCI NIH HHS [CA13148] Funding Source: Medline; NIAID NIH HHS [AI39952, AI30279] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030279, R01AI039952] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ackers G K, 1970, Adv Protein Chem, V24, P343, DOI 10.1016/S0065-3233(08)60245-4; Balendiran GK, 1999, PROTEIN SCI, V8, P1023, DOI 10.1110/ps.8.5.1023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cantor CR, 1980, BIOPHYSICAL CHEM 2; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; HASSAN HF, 1988, FEMS MICROBIOL LETT, V54, P47, DOI 10.1111/j.1574-6968.1988.tb02709.x; Heroux A, 1999, BIOCHEMISTRY-US, V38, P14485, DOI 10.1021/bi990507q; Heroux A, 1999, BIOCHEMISTRY-US, V38, P14495, DOI 10.1021/bi990508i; KING A, 1987, NUCLEIC ACIDS RES, V15, P10469, DOI 10.1093/nar/15.24.10469; KRUG EC, 1989, J BIOL CHEM, V264, P10601; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE HC, 1994, ANN INTERN MED, V120, P945, DOI 10.7326/0003-4819-120-11-199406010-00007; LIGHTFOOT T, 1994, HUM MOL GENET, V3, P1377, DOI 10.1093/hmg/3.8.1377; MURRAY HW, 1991, HARRISONS PRINCIPLES, P795; Schumacher MA, 1996, NAT STRUCT BIOL, V3, P881, DOI 10.1038/nsb1096-881; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TUAZON CU, 1989, J ANTIMICROB CHEMOTH, V23, P77, DOI 10.1093/jac/23.suppl_A.77; ULLMAN B, 1995, INFECT AGENT DIS, V4, P29; VASANTHAKUMAR G, 1990, GENE, V91, P63, DOI 10.1016/0378-1119(90)90163-L; VASANTHAKUMAR G, 1994, GENE, V147, P153, DOI 10.1016/0378-1119(94)90058-2; WANG CC, 1984, J MED CHEM, V27, P1, DOI 10.1021/jm00367a001	21	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19218	19223		10.1074/jbc.M908879199	http://dx.doi.org/10.1074/jbc.M908879199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10748107	hybrid			2022-12-27	WOS:000087815900079
J	Kahlert, S; Nuedling, S; van Eickels, M; Vetter, H; Meyer, R; Grohe, C				Kahlert, S; Nuedling, S; van Eickels, M; Vetter, H; Meyer, R; Grohe, C			Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; ISOLATED CARDIAC MYOCYTES; HUMAN BREAST-CANCER; ER-BETA; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; INTRACELLULAR CALCIUM; SIGNALING PATHWAYS; THYROID-HORMONE; GUINEA-PIG	Estrogen and insulin-like-growth factor 1 (IGF-1) are potent mitogenic stimuli that share important properties in the control of cellular proliferation. However, the coupling between the signaling cascades of estrogen receptors alpha and beta and the IGF-1 receptor (IGF-1R) is poorly understood. Therefore, we selectively transfected estrogen receptor alpha or beta in COS7 and HEK293 cells, which contain IGF-1R. In presence of estrogen receptor alpha but not beta, 17 beta-estradiol (E2) rapidly induces phosphorylation of the IGF-IR and the extracellular signal-regulated kinases 1/2, Furthermore, upon stimulation with E2, estrogen receptor alpha but not beta bound rapidly to the IGF-1R in COS7 as well as L6 cells, which express all investigated receptors endogenously, Control experiments in the IGF-1R-deficient fibroblast cell line R- showed that after stimulation with E2 only estrogen receptor alpha bound to the transfected IGF-IR, Overexpression of dominant negative mitogen-activated protein kinases kinase inhibited this effect, Finally, estrogen receptor alpha but not beta is required to induce the activation of the estrogen receptor-responsive reporter ERE-LUC in IGF-1-stimulated cells. Taken together, these data demonstrate that ligand bound estrogen receptor alpha is required for rapid activation of the IGF-1R signaling cascade.	Univ Bonn, Med Poliklin, D-53111 Bonn, Germany; Univ Bonn, Inst Physiol 2, D-53111 Bonn, Germany	University of Bonn; University of Bonn	Grohe, C (corresponding author), Univ Bonn, Med Poliklin, Wilhelmstr 35-37, D-53111 Bonn, Germany.		Meyer, Rainer/H-5871-2013					ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BEGUINOT F, 1985, J BIOL CHEM, V260, P5892; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAULINGLASER T, 1997, CRIC RES, V81, P8885; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GOTOH Y, 1994, ONCOGENE, V9, P1891; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GROHE C, 1999, CARDIOVASCULAR SPECI, P227; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; JIANG C, 1992, BRIT J PHARMACOL, V106, P739, DOI 10.1111/j.1476-5381.1992.tb14403.x; Jones PS, 1999, J BIOL CHEM, V274, P32008, DOI 10.1074/jbc.274.45.32008; Kahlert S, 1997, BIOCHEM BIOPH RES CO, V232, P373, DOI 10.1006/bbrc.1997.6223; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; KLEINMAN D, 1995, ENDOCRINOLOGY, V136, P2531, DOI 10.1210/en.136.6.2531; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee AV, 1997, J ENDOCRINOL, V152, P39, DOI 10.1677/joe.0.1520039; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; Makela S, 1999, P NATL ACAD SCI USA, V96, P7077, DOI 10.1073/pnas.96.12.7077; Meyer R, 1998, EXP PHYSIOL, V83, P305, DOI 10.1113/expphysiol.1998.sp004115; MIGLIACCIO A, 1989, MOL ENDOCRINOL, V3, P1061, DOI 10.1210/mend-3-7-1061; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; NAKHLA AM, 1994, P NATL ACAD SCI USA, V91, P5402, DOI 10.1073/pnas.91.12.5402; Nuedling S, 1999, FEBS LETT, V454, P271, DOI 10.1016/S0014-5793(99)00816-9; Ogawa S, 1999, P NATL ACAD SCI USA, V96, P12887, DOI 10.1073/pnas.96.22.12887; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Richards RG, 1998, J BIOL CHEM, V273, P11962, DOI 10.1074/jbc.273.19.11962; Richards RG, 1996, P NATL ACAD SCI USA, V93, P12002, DOI 10.1073/pnas.93.21.12002; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; RUBIN R, 1995, LAB INVEST, V73, P311; Sahlin L, 1996, J STEROID BIOCHEM, V58, P359, DOI 10.1016/0960-0760(96)00053-2; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; Stefano GB, 1999, J IMMUNOL, V163, P3758; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; WAKELING AE, 1992, J STEROID BIOCHEM, V43, P173, DOI 10.1016/0960-0760(92)90204-V; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Warner M, 1999, CURR OPIN OBSTET GYN, V11, P249, DOI 10.1097/00001703-199906000-00003; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P1783; Zheng JB, 1997, J STEROID BIOCHEM, V62, P327, DOI 10.1016/S0960-0760(97)00037-X	59	384	398	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18447	18453		10.1074/jbc.M910345199	http://dx.doi.org/10.1074/jbc.M910345199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10749889	hybrid			2022-12-27	WOS:000087659400073
J	Wang, JCW; Waltner-Law, M; Yamada, K; Osawa, H; Stifani, S; Granner, DK				Wang, JCW; Waltner-Law, M; Yamada, K; Osawa, H; Stifani, S; Granner, DK			Transducin-like enhancer of split proteins, the human homologs of Drosophila Groucho, interact with hepatic nuclear factor 3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; GLUCOCORTICOID RESPONSE UNIT; FACTOR-BINDING PROTEIN-1; PHOSPHOENOLPYRUVATE CARBOXYKINASE; TRANSCRIPTIONAL REPRESSION; FORK-HEAD; B GENE; EXPRESSION; FAMILY; INSULIN	Members of the hepatic nuclear factor 3 (HNF3) family, including HNF3 alpha, HNF3 beta, and HNF3 gamma, play important roles in embryonic development, the establishment of tissue-specific gene expression, and the regulation of gene expression in differentiated tissues. We found, using the glutathione S-transferase pull-down method, that the transducin-like Enhancer of split (TLE) proteins, which are the human homologs of Drosophila Groucho, directly associate with HNF3 beta. Conserved region II of HNF3 beta (amino acids 361-388) is responsible for the interaction with TLE1. A mammalian two-hybrid assay was used to confirm that this interaction occurs in vivo. Overexpression of TLE1 in HepG2 and HeLa cells decreases transactivation mediated through the C-terminal domain of HNF3 beta, and Grg5, a naturally occurring dominant negative form of Groucho/TLE, also increases the transcriptional activity of this region of HNF3. These results lead us to suggest that TLE proteins could influence the expression of mammalian genes regulated by HNF3.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada	Vanderbilt University; McGill University	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 707 Light Hall, Nashville, TN 37232 USA.		Wang, Jen-Chywan/AAX-4445-2020	Wang, Jen-Chywan/0000-0001-6030-6886; Stifani, Stefano/0000-0002-2376-7701	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R37DK035107, R01DK035107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20593, DK35107] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; Grbavec D, 1998, EUR J BIOCHEM, V258, P339, DOI 10.1046/j.1432-1327.1998.2580339.x; Harnish DC, 1996, J BIOL CHEM, V271, P13621, DOI 10.1074/jbc.271.23.13621; HARNISH DC, 1994, J BIOL CHEM, V269, P28220; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Jimenez G, 1999, MOL CELL BIOL, V19, P2080; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Kaestner KH, 1998, MOL CELL BIOL, V18, P4245, DOI 10.1128/MCB.18.7.4245; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; MARTELLI AM, 1994, CELL BIOCHEM FUNCT, V12, P37, DOI 10.1002/cbf.290120106; MIYASAKA H, 1993, EUR J BIOCHEM, V216, P343, DOI 10.1111/j.1432-1033.1993.tb18151.x; NITSCH D, 1993, MOL CELL BIOL, V13, P4494, DOI 10.1128/MCB.13.8.4494; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; Paroush Z, 1997, DEVELOPMENT, V124, P3827; Pinto M, 1996, J BIOL CHEM, V271, P33026, DOI 10.1074/jbc.271.51.33026; Price JV, 1997, GENETICS, V147, P1139; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SAWAYA PL, 1994, J BIOL CHEM, V269, P22211; SCHMIDT CJ, 1993, J BIOL CHEM, V268, P25681; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; SUWANICHKUL A, 1994, J BIOL CHEM, V269, P30835; VALLET V, 1995, MOL CELL BIOL, V15, P5453; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; WU J, 1993, J VIROL, V67, P7547, DOI 10.1128/JVI.67.12.7547-7555.1993; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yamada K, 1997, BIOCHEM J, V324, P917, DOI 10.1042/bj3240917; Yao J, 1998, DEV GROWTH DIFFER, V40, P133; Zimmermann PL, 1997, DNA CELL BIOL, V16, P713, DOI 10.1089/dna.1997.16.713	50	50	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18418	18423		10.1074/jbc.M910211199	http://dx.doi.org/10.1074/jbc.M910211199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748198	hybrid			2022-12-27	WOS:000087659400069
J	Giusti, AF; Xu, WQ; Hinkle, B; Terasaki, M; Jaffe, LA				Giusti, AF; Xu, WQ; Hinkle, B; Terasaki, M; Jaffe, LA			Evidence that fertilization activates starfish eggs by sequential activation of a Src-like kinase and phospholipase C gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; FOCAL ADHESION KINASE; DOMAIN-MEDIATED ACTIVATION; PROTEIN-TYROSINE KINASE; CALCIUM-RELEASE; XENOPUS-LAEVIS; INTRACELLULAR CALCIUM; CRYSTAL-STRUCTURE; PLC-GAMMA; OOCYTES	Recent evidence has indicated a requirement for a Src family kinase in initiating Ca2+ release at fertilization in starfish eggs (Giusti, A. F., Carroll, D, J., Abassi, Y. A, Terasaki, M., Foltz, K. R, and Jaffe, L. A. (1999) J. Biol. Chem. 274, 29318-29322). We now show that injection of Src protein into starfish eggs initiates Ca2+ release and DNA synthesis, as occur at fertilization. These responses depend on the phosphorylation state of the Src protein; only the kinase active form is effective. Like Ca2+ release at fertilization, the Ca2+ release in response to Src protein injection is inhibited by prior injection of the SH2 domains of phospholipase C gamma. These findings support the conclusion that in starfish, sperm-egg interaction causes egg activation by sequential activation of a Src-like kinase and phospholipase C gamma. Injection of the SH2 domain of Src, which inhibits Ca2+ release at fertilization, does not inhibit Ca2+ release caused by Src protein injection. This indicates that the requirement for a Src SH2 domain interaction is upstream of Src activation in the pathway leading to Ca2+ release at fertilization.	Univ Connecticut, Ctr Hlth, Dept Physiol L5004, Farmington, CT 06032 USA; Marine Biol Lab, Woods Hole, MA 02543 USA; Univ Washington, Dept Biol Struct, Biomol Struct Ctr, Seattle, WA 98195 USA	University of Connecticut; Marine Biological Laboratory - Woods Hole; University of Washington; University of Washington Seattle	Jaffe, LA (corresponding author), Univ Connecticut, Ctr Hlth, Dept Physiol L5004, 263 Farmington Ave, Farmington, CT 06032 USA.	ljaffe@neuron.uchc.edu		Xu, Wenqing/0000-0002-2884-3101				Abassi YA, 2000, DEV BIOL, V218, P206, DOI 10.1006/dbio.1999.9582; ARKINSTALL S, 1995, MOL CELL BIOL, V15, P1431; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARROLL DJ, 1995, DEV BIOL, V170, P690, DOI 10.1006/dbio.1995.1247; Carroll DJ, 1997, J CELL BIOL, V138, P1303, DOI 10.1083/jcb.138.6.1303; Carroll DJ, 1999, DEV BIOL, V206, P232, DOI 10.1006/dbio.1998.9145; Carroll DJ, 2000, DEV BIOL, V217, P179, DOI 10.1006/dbio.1999.9526; CIAPA B, 1986, FEBS LETT, V195, P347, DOI 10.1016/0014-5793(86)80191-0; CIAPA B, 1991, FEBS LETT, V295, P167, DOI 10.1016/0014-5793(91)81410-A; Clements JL, 1999, J CLIN INVEST, V103, P925, DOI 10.1172/JCI6562; De Nadai C, 1998, DEV GROWTH DIFFER, V40, P669; Dupont G, 1996, BIOCHEM J, V316, P583, DOI 10.1042/bj3160583; EPEL D, 1969, EXP CELL RES, V58, P312, DOI 10.1016/0014-4827(69)90510-2; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Ferrell JE, 1999, BIOESSAYS, V21, P866, DOI 10.1002/(SICI)1521-1878(199910)21:10<866::AID-BIES9>3.0.CO;2-1; Giusti AF, 1999, DEV BIOL, V208, P189, DOI 10.1006/dbio.1998.9187; Giusti AF, 1999, J BIOL CHEM, V274, P29318, DOI 10.1074/jbc.274.41.29318; Glahn D, 1999, DEV BIOL, V205, P171, DOI 10.1006/dbio.1998.9042; Hardwick JS, 1997, J BIOL CHEM, V272, P25429, DOI 10.1074/jbc.272.41.25429; HIRAMOTO Y, 1962, EXP CELL RES, V27, P416, DOI 10.1016/0014-4827(62)90006-X; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; Kamat Asha, 1997, Cytokine and Growth Factor Reviews, V8, P109, DOI 10.1016/S1359-6101(97)00003-8; KIEHART DP, 1982, METHOD CELL BIOL, V25, P13, DOI 10.1016/S0091-679X(08)61418-1; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; KLINE D, 1988, DEV BIOL, V126, P346, DOI 10.1016/0012-1606(88)90145-5; Law CL, 1996, MOL CELL BIOL, V16, P1305; MCCULLOH DH, 1992, J GEN PHYSIOL, V99, P137, DOI 10.1085/jgp.99.2.137; Mehlmann LM, 1998, DEV BIOL, V203, P221, DOI 10.1006/dbio.1998.9051; Melford SK, 1997, J BIOL CHEM, V272, P27539, DOI 10.1074/jbc.272.44.27539; MIYAZAKI S, 1979, DEV BIOL, V70, P327, DOI 10.1016/0012-1606(79)90031-9; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MIYAZAKI SI, 1975, J PHYSIOL-LONDON, V246, P37, DOI 10.1113/jphysiol.1975.sp010879; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MOHRI T, 1995, DEV BIOL, V172, P139, DOI 10.1006/dbio.1995.0011; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RIDGWAY EB, 1977, P NATL ACAD SCI USA, V74, P623, DOI 10.1073/pnas.74.2.623; Rongish BJ, 1999, DEV BIOL, V215, P147, DOI 10.1006/dbio.1999.9472; Runft LL, 1999, DEV BIOL, V214, P399, DOI 10.1006/dbio.1999.9415; Sadler KC, 1998, DEV BIOL, V197, P25, DOI 10.1006/dbio.1998.8869; Sato K, 1999, DEV BIOL, V209, P308, DOI 10.1006/dbio.1999.9255; Sato K, 1998, FEBS LETT, V424, P113, DOI 10.1016/S0014-5793(98)00123-9; Sato K, 1996, J BIOL CHEM, V271, P13250, DOI 10.1074/jbc.271.22.13250; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Shearer J, 1999, DEVELOPMENT, V126, P2273; SHEN SS, 1990, DEV BIOL, V140, P272, DOI 10.1016/0012-1606(90)90077-V; Shen SS, 1999, DEV GROWTH DIFFER, V41, P345; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; STITH BJ, 1993, MOL BIOL CELL, V4, P435, DOI 10.1091/mbc.4.4.435; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; Tachibana K, 1997, EMBO J, V16, P4333, DOI 10.1093/emboj/16.14.4333; TERASAKI M, 1991, J CELL BIOL, V115, P1031, DOI 10.1083/jcb.115.4.1031; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Thomas ML, 1999, CURR OPIN IMMUNOL, V11, P270, DOI 10.1016/S0952-7915(99)80044-2; Thorn JM, 1999, ZYGOTE, V7, P113, DOI 10.1017/S0967199499000465; UNGER TF, 1992, MOL CELL BIOL, V12, P5485, DOI 10.1128/MCB.12.12.5485; WASHITANINEMOTO S, 1994, DEV BIOL, V163, P293, DOI 10.1006/dbio.1994.1148; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; ZUCKER RS, 1978, BIOCHIM BIOPHYS ACTA, V541, P459, DOI 10.1016/0304-4165(78)90155-1	67	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16788	16794		10.1074/jbc.M001091200	http://dx.doi.org/10.1074/jbc.M001091200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747984	hybrid			2022-12-27	WOS:000087392200056
J	Graceffa, P				Graceffa, P			Phosphorylation of smooth muscle myosin heads regulates the head-induced movement of tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHORYLATION; THIN-FILAMENTS; SKELETAL-MUSCLE; CROSS-LINKING; ADP RELEASE; 3-DIMENSIONAL RECONSTRUCTION; NH2-TERMINAL DOMAINS; SUBFRAGMENT-1 ATPASE; MOLECULAR-WEIGHT; ENERGY-TRANSFER	It has been shown that skeletal and smooth muscle myosin heads binding to actin results in the movement of smooth muscle tropomyosin, as revealed by a change in fluorescence resonance energy transfer between a fluorescence donor on tropomyosin and an acceptor on actin (Graceffa, P. (1999) Biochemistry 38, 11984-11992), In this work, tropomyosin movement was similarly monitored as a function of unphosphorylated and phosphorylated smooth muscle myosin double-headed fragment smHMM. In the absence of nucleotide and at low myosin head/actin ratios, only phosphorylated heads induced a change in energy transfer. In the presence of ADP, the effect of head phosphorylation was even more dramatic, in that at all levels of myosin head/actin, phosphorylation was necessary to affect energy transfer, It is proposed that the regulation of tropomyosin position on actin by phosphorylation of myosin heads plays a key role in the regulation of smooth muscle contraction. In contrast, actin-bound caldesmon was not moved by myosin heads at low head/actin ratios, as uncovered by fluorescence resonance energy transfer and disulfide cross-linking between caldesmon and actin, At higher head concentration caldesmon was dissociated from actin, consistent with the multiple binding model for the binding of caldesmon and myosin heads to actin (Chen, Y., and Chalovich, J. M. (1992) Biophys. J. 63, 1063-1070).	Boston Biomed Res Inst, Muscle & Motil Grp, Watertown, MA 02472 USA	Boston Biomedical Research Institute	Graceffa, P (corresponding author), Boston Biomed Res Inst, Muscle & Motil Grp, 64 Grove St, Watertown, MA 02472 USA.				NIAMS NIH HHS [AR41637, AR30917] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030917, P01AR041637] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adelstein R. S., 1996, BIOCH SMOOTH MUSCLE, P3; ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; BARANY M, 1996, BIOCH SMOOTH MUSCLE, P321; CHACKO S, 1990, J BIOL CHEM, V265, P2105; CHEN YD, 1992, BIOPHYS J, V63, P1063, DOI 10.1016/S0006-3495(92)81687-9; Conibear PB, 1998, BIOPHYS J, V75, P926, DOI 10.1016/S0006-3495(98)77581-2; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; GERTHOFFER WT, 1991, AM J PHYSIOL, V261, pL15, DOI 10.1152/ajplung.1991.261.2.L15; Golitsina N. L., 1995, Biophysical Journal, V68, pA60; Gollub J, 1996, NAT STRUCT BIOL, V3, P796, DOI 10.1038/nsb0996-796; Graceffa P, 1999, BIOCHEMISTRY-US, V38, P11984, DOI 10.1021/bi9825495; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; GRACEFFA P, 1995, J BIOL CHEM, V270, P30187; Graceffa P, 1997, BIOCHEMISTRY-US, V36, P3792, DOI 10.1021/bi961652w; GRACEFFA P, 1999, J MUSCLE RES CELL M, V20, P592; HAAS E, 1978, BIOCHEMISTRY-US, V17, P5064, DOI 10.1021/bi00616a032; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KAMM KE, 1996, BIOCH SMOOTH MUSCLE, P355; KHALIL RA, 1996, BIOCH SMOOTH MUSCLE, P307; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P44; LASH JA, 1986, J BIOL CHEM, V261, P6155; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; Lehrer SS, 1997, BIOCHEMISTRY-US, V36, P13449, DOI 10.1021/bi971568w; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; LYNCH WP, 1987, J BIOL CHEM, V262, P7429; MARSTON SB, 1982, PROG BIOPHYS MOL BIO, V41, P1; Murphy RA, 1998, ACTA PHYSIOL SCAND, V164, P373; MURPHY RA, 1998, INT J CARDIOVASC MED, V1, P149; NABER N, 1994, J MOL BIOL, V236, P703, DOI 10.1006/jmbi.1994.1183; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; PERRIE WT, 1973, BIOCHEM J, V135, P151, DOI 10.1042/bj1350151; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; SMALL JV, 1980, INT REV CYTOL, V64, P241, DOI 10.1016/S0074-7696(08)60239-9; SMALL JV, 1983, BIOCH SMOOTH MUSCLE, V1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUZUKI H, 1988, J BIOL CHEM, V263, P10974; TAO T, 1983, BIOCHEMISTRY-US, V22, P3059, DOI 10.1021/bi00282a006; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; VIBERT P, 1993, J CELL BIOL, V123, P313, DOI 10.1083/jcb.123.2.313; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; VIBERT PJ, 1972, J MOL BIOL, V71, P757, DOI 10.1016/S0022-2836(72)80036-6; WALSH MP, 1994, CAN J PHYSIOL PHARM, V72, P919, DOI 10.1139/y94-130; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022; Xu C, 1999, BIOPHYS J, V77, P985, DOI 10.1016/S0006-3495(99)76949-3; ZHANG YW, 1994, CAN J PHYSIOL PHARM, V72, P1386, DOI 10.1139/y94-200	58	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17143	17148		10.1074/jbc.M001979200	http://dx.doi.org/10.1074/jbc.M001979200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748060	hybrid			2022-12-27	WOS:000087392200104
J	Kolb, VA; Makeyev, EV; Spirin, AS				Kolb, VA; Makeyev, EV; Spirin, AS			Co-translational folding of an eukaryotic multidomain protein in a prokaryotic translation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; NASCENT POLYPEPTIDE; RIBOSOME; RNA; CHAINS; CHAPERONES	Continuous monitoring of the enzymatic activity of newly synthesized firefly luciferase in Escherichia coli cell-free translation system was performed to record folding kinetics of this multidomain eukaryotic protein in the prokaryotic cytosol. Whereas in vitro refolding of denatured luciferase in prokaryotic cytosol occurred with a low yield of active enzyme and took about an hour, the enzyme acquired its native structure immediately upon release from the ribosome, as seen from the immediate halt of active luciferase accumulation upon blocking of translation with inhibitors. The nascent luciferase was also capable of acquiring the active conformation prior to release from the ribosome, when its C terminus was extended with a polypeptide segment. Specific enzymatic activity of the firefly luciferase was found to be equally high irrespective of whether this protein was synthesized in eukaryotic or prokaryotic translation systems. The data presented demonstrate the fundamental ability of prokaryotic cytosol to support effective co-translational protein folding in general and co-translational folding of multidomain proteins in particular.	Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia	Russian Academy of Sciences	Spirin, AS (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia.		Spirin, Alexander/A-7307-2016; Kolb, Vyacheslav/A-7438-2016	Makeyev, Eugene/0000-0001-6034-6896				BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; FEDOROV AN, 1995, P NATL ACAD SCI USA, V92, P1227, DOI 10.1073/pnas.92.4.1227; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Gilmore R, 1996, EMBO J, V15, P2651, DOI 10.1002/j.1460-2075.1996.tb00625.x; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HAMLIN J, 1972, P NATL ACAD SCI USA, V69, P412, DOI 10.1073/pnas.69.2.412; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; KIHO Y, 1964, P NATL ACAD SCI USA, V51, P111, DOI 10.1073/pnas.51.1.111; KIM JM, 1991, J BIOL CHEM, V266, P14931; Kolb VA, 1995, BIOCHEM CELL BIOL, V73, P1217, DOI 10.1139/o95-131; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; Komar AA, 1997, J BIOL CHEM, V272, P10646; KUDLICKI W, 1995, BIOCHEMISTRY-US, V34, P14284, DOI 10.1021/bi00044a003; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Makeyev EV, 1996, FEBS LETT, V378, P166, DOI 10.1016/0014-5793(95)01438-1; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; PETERS T, 1982, J BIOL CHEM, V257, P8847; ROBERTS BE, 1973, P NATL ACAD SCI USA, V70, P2330, DOI 10.1073/pnas.70.8.2330; Ryabova LA, 1997, NAT BIOTECHNOL, V15, P79, DOI 10.1038/nbt0197-79; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; ZIPSER D, 1963, COLD SPRING HARB SYM, V28, P533, DOI 10.1101/SQB.1963.028.01.071; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	24	75	80	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16597	16601		10.1074/jbc.M002030200	http://dx.doi.org/10.1074/jbc.M002030200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748063	hybrid			2022-12-27	WOS:000087392200029
J	Yokoyama, K; Erickson, HP; Ikeda, Y; Takada, Y				Yokoyama, K; Erickson, HP; Ikeda, Y; Takada, Y			Identification of amino acid sequences in fibrinogen gamma-chain and tenascin CC-terminal domains critical for binding to integrin alpha(v)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE MONOCLONAL-ANTIBODY; TUMOR STROMA GENERATION; GLYCOPROTEIN-IIB-IIIA; ENDOTHELIAL-CELLS; CLOT RETRACTION; LEUKOCYTE ADHESION; CRYSTAL-STRUCTURE; BETA-SUBUNIT; EXPRESSION; ANGIOGENESIS	Integrin alpha(V)beta(3) recognizes fibrinogen gamma and alpha(E) chain C-terminal domains (gamma C and alpha(E)C) but does not require the gamma C dodecapeptide sequence HHLGGAKQAGDV(400-411) for binding to gamma C. We have localized the alpha(V)beta(3) binding sites in gamma C using gamma C-derived synthetic peptides. We found that two peptides GWTVFQKRLDGSV(190-202) and GVYYQGGTYSKAS(346-358) block the alpha(V)beta(3) binding to gamma C or alpha(E)C, block the alpha(V)beta(3)-mediated clot retraction, and induce the ligand-induced binding site 2 (LIBS2) epitope in alpha(V)beta(3). Neither peptide affects fibrinogen binding to alpha(IIb)beta(3). Scrambled or inverted peptides were not effective. These results suggest that the two gamma C-derived peptides directly interact with alpha(V)beta(3) and specifically block alpha(V)beta(3)-gamma C or alpha(E)C interaction. The two sequences are located next to each other in the gamma C crystal structure, although they are separate in the primary structure. Asp-199, Ser-201, Gln-350, Thr-353, Lys-356, Ala-357, and Ser-358 residues are exposed to the surface, This suggests that the two sequences are part of alpha(V)beta(3) binding sites in fibrinogen gamma C domain. We also found that tenascin C C-terminal fibrinogen-like domain specifically binds to alpha(V)beta(3). Notably, a peptide WYRNCHRVNLMG-RYGDNNHSQGVNWFHWKG from this domain that includes the sequence corresponding to gamma C GVYYQGGTY-SKAS(346-358) specifically binds to alpha(V)beta(3), suggesting that fibrinogen and tenascin C C-terminal domains interact with alpha(V)beta(3) in a similar manner.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Duke Univ, Sch Med, Dept Cell Biol, Durham, NC 27710 USA; Keio Univ, Sch Med, Dept Internal Med, Div Hematol,Shinjuku Ku, Tokyo 1608582, Japan	Scripps Research Institute; Duke University; Keio University	Takada, Y (corresponding author), Scripps Res Inst, Dept Vasc Biol, CAL-10,10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.			takada, yoshikazu/0000-0001-5481-9589	NIGMS NIH HHS [GM49899, GM47157] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHIQUETEHRISMANN R, 1993, SEMIN CANCER BIOL, V4, P301; Clark RAF, 1996, AM J PATHOL, V148, P1407; CUTOLO M, 1992, J RHEUMATOL, V19, P1439; DECKMYN H, 1994, BRIT J HAEMATOL, V87, P562, DOI 10.1111/j.1365-2141.1994.tb08313.x; DU XP, 1993, J BIOL CHEM, V268, P23087; DVORAK HF, 1987, LAB INVEST, V57, P673; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FU YP, 1992, BIOCHEMISTRY-US, V31, P11968, DOI 10.1021/bi00163a002; GARTNER TK, 1988, THROMB RES, V49, P43; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; HANTGAN RR, 1988, BIOCHIM BIOPHYS ACTA, V968, P36, DOI 10.1016/0167-4889(88)90041-9; HIGUCHI M, 1993, ACTA NEUROPATHOL, V85, P481; HONDA S, 1995, J BIOL CHEM, V270, P11948; JONES FS, 1988, P NATL ACAD SCI USA, V85, P2186, DOI 10.1073/pnas.85.7.2186; JOSHI P, 1993, J CELL SCI, V106, P389; Juliano D, 1996, EXP CELL RES, V225, P132, DOI 10.1006/excr.1996.0164; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; KATAGIRI Y, 1995, J BIOL CHEM, V270, P1785, DOI 10.1074/jbc.270.4.1785; LaFleur DW, 1997, J BIOL CHEM, V272, P32798, DOI 10.1074/jbc.272.52.32798; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; NATALI PG, 1991, INT J CANCER, V47, P811, DOI 10.1002/ijc.2910470603; NIES DE, 1991, J BIOL CHEM, V266, P2818; OIKE Y, 1990, International Journal of Developmental Biology, V34, P309; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; Pratt KP, 1997, P NATL ACAD SCI USA, V94, P7176, DOI 10.1073/pnas.94.14.7176; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; SALTER DM, 1993, BRIT J RHEUMATOL, V32, P780; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schenk S, 1999, MOL BIOL CELL, V10, P2933, DOI 10.1091/mbc.10.9.2933; Smith RA, 1997, J BIOL CHEM, V272, P22080, DOI 10.1074/jbc.272.35.22080; Spraggon G, 1998, P NATL ACAD SCI USA, V95, P9099, DOI 10.1073/pnas.95.16.9099; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Tokuhira M, 1996, THROMB HAEMOSTASIS, V76, P1038; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; Wallner K, 1999, CIRCULATION, V99, P1284, DOI 10.1161/01.CIR.99.10.1284; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; Yokoyama K, 1999, BIOCHEMISTRY-US, V38, P5872, DOI 10.1021/bi9827619; ZAGZAG D, 1995, CANCER RES, V55, P907	51	60	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16891	16898		10.1074/jbc.M000610200	http://dx.doi.org/10.1074/jbc.M000610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747940	hybrid			2022-12-27	WOS:000087392200070
J	Datta, K; Nambudripad, R; Pal, S; Zhou, M; Cohen, HT; Mukhopadhyay, D				Datta, K; Nambudripad, R; Pal, S; Zhou, M; Cohen, HT; Mukhopadhyay, D			Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; KINASE C-DELTA; CARCINOMA-CELLS; FACTOR EXPRESSION; CRYSTAL-STRUCTURE; FACTOR RECEPTOR; MESSENGER-RNA; IGF-I; OVEREXPRESSION; DISEASE	Insulin-like growth factor-I (IGF-I)-mediated signaling is thought to be involved in the regulation of multiple cellular functions in different tumors including renal cell carcinoma (RCC). Blocking IGF-I signaling by any of the several strategies abolishes or delays the progression of a variety of tumors in animal models. Herein, me demonstrate that in RCC cell lines, IGF-I-mediated signaling is found to be inhibited in the presence of wild type von Hippel-Lindau (VHL) tumor suppresser gene. Moreover, molecular modeling and biochemical approaches have revealed that beta-domain of the VHL gene product by interacting directly with protein kinase C delta inhibits its association with IGF-IR for downstream signaling. We also demonstrated that RCC has IGF-I-mediated invasive activity where protein kinase C delta is an important downstream molecule, and this invasiveness can be blocked by wild type VHL. These experiments thus elucidate a novel tumor suppresser function of VHL with its unique kinase inhibitory domain.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Mol Comp Facil, Boston, MA 02215 USA; Boston Univ, Med Ctr, Renal Sect, Boston, MA 02118 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Boston University	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, RN270H,99 Brookline Ave, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R29CA078383, R01CA079830, R01CA078383] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA079830, CA78383] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi Y, 1998, CANCER RES, V58, P4008; Baserga R, 1997, BBA-REV CANCER, V1332, pF105, DOI 10.1016/S0304-419X(97)00007-3; Braun C, 1999, INT J CANCER, V84, P6, DOI 10.1002/(SICI)1097-0215(19990219)84:1<6::AID-IJC2>3.3.CO;2-K; CHEN F, 1995, CANCER RES, V55, P4804; Clifford SC, 1998, BRIT J CANCER, V77, P1420, DOI 10.1038/bjc.1998.235; Cohen HT, 1999, BIOCHEM BIOPH RES CO, V266, P43, DOI 10.1006/bbrc.1999.1767; Ferragut J, 1999, J PEDIATR ENDOCR MET, V12, P579; Fischer C, 1999, ANTICANCER RES, V19, P1513; GNARRA JR, 1993, UROL CLIN N AM, V20, P207; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Hammerman MR, 1997, J PEDIATR-US, V131, pS17, DOI 10.1016/S0022-3476(97)70004-0; Hoffmann R, 1999, BRIT J CANCER, V79, P1742, DOI 10.1038/sj.bjc.6690277; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Horie S, 1999, UROLOGY, V53, P561, DOI 10.1016/S0090-4295(98)00541-X; KALEBIC T, 1994, CANCER RES, V54, P5531; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kolenko V, 1999, CANCER RES, V59, P2838; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee CT, 1996, CANCER RES, V56, P3038; Li JJ, 1999, CANCER RES, V59, P2340; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Long L, 1998, CANCER RES, V58, P3243; Manousos O, 1999, INT J CANCER, V83, P15, DOI 10.1002/(SICI)1097-0215(19990924)83:1<15::AID-IJC4>3.0.CO;2-Y; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Okuda H, 1999, BIOCHEM BIOPH RES CO, V263, P491, DOI 10.1006/bbrc.1999.1347; Osgerby JC, 1999, J ENDOCRINOL, V162, P279, DOI 10.1677/joe.0.1620279; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P181; Rogers SA, 1999, DEV GENET, V24, P293, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<293::AID-DVG12>3.0.CO;2-S; Siemeister G, 1996, CANCER RES, V56, P2299; Simmons JG, 1999, AM J PHYSIOL-GASTR L, V276, pG817, DOI 10.1152/ajpgi.1999.276.4.G817; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; TAYLOR SS, 1996, CYCLIC AMP DEPENDENT; Uhlman DL, 1995, CLIN CANCER RES, V1, P913; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vortmeyer AO, 1999, GRAEF ARCH CLIN EXP, V237, P513, DOI 10.1007/s004170050271; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; Yoshimoto H, 1999, AM J PATHOL, V154, P883, DOI 10.1016/S0002-9440(10)65335-7; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	47	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20700	20706		10.1074/jbc.M909970199	http://dx.doi.org/10.1074/jbc.M909970199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10748176	hybrid			2022-12-27	WOS:000088084500068
J	Andersson, J; Westman, M; Hofer, A; Sjoberg, BM				Andersson, J; Westman, M; Hofer, A; Sjoberg, BM			Allosteric regulation of the class III anaerobic ribonucleotide reductase from bacteriophage T4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-BINDING; PROTEIN R1; SUBSTRATE-SPECIFICITY; VIRUS; SITE; TYPE-1; ENZYME; ASSAY; POOLS	Ribonucleotide reductase (RNR) is an essential enzyme in all organisms, It provides precursors for DNA synthesis by reducing all four ribonucleotides to deoxyribonucleotides, The overall activity and the substrate specificity of RNR are allosterically regulated by deoxyribonucleoside triphosphates and ATP, thereby providing balanced dNTP pools, We have characterized the allosteric regulation of the class III RNR from bacteriophage T4. Our results show that the T4 enzyme has a single type of allosteric site to which dGTP, dTTP, dATP, and ATP bind competitively. The dissociation constants are in the micromolar range, except for ATP, which has a dissociation constant in the millimolar range. ATP and dATP are positive effecters for CTP reduction, dGTP is a positive effector for ATP reduction, and dTTP is a positive effector for GTP reduction. dATP is not a general negative allosteric effector, These effects are similar to the allosteric regulation of class Ib and class II RNRs, and to the class Ia RNR of bacteriophage T4, but differ from that of the class III RNRs from the host bacterium Escherichia coli and from Lactococcus lactis. The relative rate of reduction of the four substrates was measured simultaneously in a mixed-substrate assay, which mimics the physiological situation and illustrates the interplay between the different effecters in vivo Surprisingly, we did not observe any significant UTP reduction under the conditions used, Balancing of the pyrimidine deoxyribonucleotide pools may be achieved via the dCMP deaminase and dCMP hydroxymethylase pathways.	Stockholm Univ, Dept Mol Biol, SE-10691 Stockholm, Sweden; Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Stockholm University; Umea University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Mol Biol, SE-10691 Stockholm, Sweden.	bitte@molbio.su.se		Hofer, Anders/0000-0003-2890-2957; Sjoberg, Britt-Marie/0000-0001-5953-3360				ANDERSSON J, 2000, IN PRESS J BIOL CHEM; AVERETT DR, 1984, J VIROL, V52, P981, DOI 10.1128/JVI.52.3.981-983.1984; AVERETT DR, 1983, J BIOL CHEM, V258, P9831; BECK WS, 1967, J BIOL CHEM, V242, P3148; BERGLUND O, 1975, J BIOL CHEM, V250, P7450; BERGLUND O, 1972, J BIOL CHEM, V247, P7276; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CHEN AK, 1974, BIOCHEMISTRY-US, V13, P654, DOI 10.1021/bi00701a004; CHIU CS, 1977, J BIOL CHEM, V252, P8603; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; Eliasson R, 1999, J BIOL CHEM, V274, P7182, DOI 10.1074/jbc.274.11.7182; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; Eliasson R, 1996, J BIOL CHEM, V271, P26582, DOI 10.1074/jbc.271.43.26582; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; ERIKSSON S, 1986, J BIOL CHEM, V261, P1878; GOULIAN M, 1966, J BIOL CHEM, V241, P4233; GREENBERG RG, 1994, MOL BIOL BACTERIOP T, V4, P14; Hendricks SP, 1998, J BIOL CHEM, V273, P29512, DOI 10.1074/jbc.273.45.29512; Hendricks SP, 1997, J BIOL CHEM, V272, P2861, DOI 10.1074/jbc.272.5.2861; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; LARSSON A, 1966, J BIOL CHEM, V241, P2540; LARSSON A, 1966, J BIOL CHEM, V241, P2533; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; LU Q, 1995, J MOL BIOL, V254, P337, DOI 10.1006/jmbi.1995.0620; Maley F, 1990, Prog Nucleic Acid Res Mol Biol, V39, P49, DOI 10.1016/S0079-6603(08)60623-6; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MATHEWS CK, 1982, P NATL ACAD SCI-BIOL, V79, P302, DOI 10.1073/pnas.79.2.302; NEUHARD J, 1987, ESCHERICHIA COLI SAL, V1, P445; Olcott MC, 1998, J BIOL CHEM, V273, P24853, DOI 10.1074/jbc.273.38.24853; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Ormo M, 1996, EUR J BIOCHEM, V241, P363, DOI 10.1111/j.1432-1033.1996.00363.x; Sjoberg BM, 1997, STRUCT BOND, V88, P139; Torrents E, 2000, J BIOL CHEM, V275, P2463, DOI 10.1074/jbc.275.4.2463; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Young P, 1996, J BIOL CHEM, V271, P20770, DOI 10.1074/jbc.271.34.20770; Zhang XL, 1996, J BACTERIOL, V178, P4115, DOI 10.1128/jb.178.14.4115-4121.1996	39	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19443	19448		10.1074/jbc.M001490200	http://dx.doi.org/10.1074/jbc.M001490200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748029	hybrid			2022-12-27	WOS:000087941300003
J	Craven, SE; Bredt, DS				Craven, SE; Bredt, DS			Synaptic targeting of the postsynaptic density protein PSD-95 mediated by a tyrosine-based trafficking signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL-NEURONS; SORTING SIGNALS; ENDOCYTOSIS; MOTIFS; FAMILY; DETERMINANTS; INTERACTS; MOLECULES; CHANNEL; MUTANT	Synaptic function requires proper localization of proteins at synaptic sites. Targeting of the postsynaptic density protein 95 (PSD-95) relies on multiple signals within the protein, including twelve C-terminal amino acids. We now show that this C-terminal targeting domain of PSD-95 mediates postsynaptic localization through a short tyrosine-based motif followed by a pair of hydrophobic amino acids. Consistent with a role in cellular trafficking, the tyrosine motif resembles the canonical motif for interactions with clathrin adaptor proteins. In fact, we find that the C-terminal targeting domain of PSD-95 is sufficient to mediate clathrin-dependent endocytosis when appended to a transmembrane protein. Furthermore, systematic mutagenesis reveals that endocytosis mediated by this domain depends on both the tyrosine motif and the dihydrophobic amino acid pair. Thus, postsynaptic targeting of PSD-95 requires a tyrosine-based signal that can mediate clathrin-coated vesicle formation.	Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bredt, DS (corresponding author), Univ Calif San Francisco, Sch Med, Dept Physiol, 513 Parnassus Ave, San Francisco, CA 94143 USA.	bredt@itsa.ucsf.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039884, R01NS036017] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36017, NS39884] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1998, J NEUROSCI, V18, P8805; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim H. Y., 1988, Korean Journal of Food Science and Technology, V20, P683; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; Naisbitt S, 1997, J NEUROSCI, V17, P5687; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tan PK, 1998, J BIOL CHEM, V273, P17351, DOI 10.1074/jbc.273.28.17351	27	28	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20045	20051		10.1074/jbc.M910153199	http://dx.doi.org/10.1074/jbc.M910153199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748194	hybrid			2022-12-27	WOS:000087941300083
J	Kalluri, R; Cantley, LG; Kerjaschki, D; Neilson, EG				Kalluri, R; Cantley, LG; Kerjaschki, D; Neilson, EG			Reactive oxygen species expose cryptic epitopes associated with autoimmune goodpasture syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR-BASEMENT-MEMBRANE; ISOLATED RAT GLOMERULI; IV COLLAGEN MOLECULES; ANTI-GBM NEPHRITIS; ALPHA-3(IV) CHAIN; GLOBULAR DOMAIN; PROTEIN DAMAGE; ALPORT SYNDROME; DEGRADATION; RADICALS	Goodpasture syndrome is an autoimmune disease of the kidneys and lungs mediated by antibodies and T-cells directed to cryptic epitopes hidden within basement membrane hexamers rich in alpha 3 non-collagenous globular (NC1) domains of type IV collagen. These epitopes are normally invisible to the immune system, but this privilege can be obviated by chemical modification. Endogenous drivers of immune activation consequent to the loss of privilege have long been suspected. We have examined the ability of reactive oxygen species (ROS) to expose Goodpasture epitopes buried within NC1 hexamers obtained from renal glomeruli abundant in alpha 3(IV) NC1 domains. For some hexameric epitopes, like the Goodpasture epitopes, exposure to ROS specifically enhanced recognition by Goodpasture antibodies in a sequential and time-dependent fashion; control binding of epitopes to alpha 3(IV) alloantibodies from renal transplant recipients with Alport syndrome was decreased, whereas epitope binding to heterologous antibodies recognizing all alpha 3 NC1 epitopes remained the same. Inhibitors of hydrogen peroxide and hydroxyl radical scavengers were capable of attenuating the effects of ROS in cells and kidney by 30-50%, respectively, thereby keeping the Goodpasture epitopes largely concealed when compared with a 70% maximum inhibition by iron chelators. Hydrogen peroxide administration to rodents was sufficient to expose Goodpasture epitope in vivo and initiate autoantibody production. Our findings collectively suggest that ROS can alter the hexameric structure of type IV collagen to expose or destroy selectively immunologic epitopes embedded in basement membrane. The reasons for autoimmunity in Goodpasture syndrome may lie in an age-dependent deterioration in inhibitor function modulating oxidative damage to structural molecules. ROS therefore may play an important role in shaping post-translational epitope diversity or neoantigen formation in organ tissues.	Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Vienna, Inst Clin Pathol, A-1090 Vienna, Austria; Univ Penn, Dept Med, Penn Ctr Mol Studies Kidney Dis, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; Vanderbilt Univ, Div Nephrol & Hypertens, Nashville, TN 37240 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Vienna; University of Pennsylvania; Vanderbilt University	Kalluri, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, DANA 563A,330 Brookline Ave, Boston, MA 02215 USA.		Wilson, Matthew H/K-3193-2013; Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X	NIDDK NIH HHS [DK-51711, DK-46282, DK-55001] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046282, R01DK051711] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYCE NW, 1986, KIDNEY INT, V30, P813, DOI 10.1038/ki.1986.260; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; COUSER WG, 1988, AM J KIDNEY DIS, V11, P449, DOI 10.1016/S0272-6386(88)80079-9; COUSER WG, 1985, AM J PHYSIOL, V249, P241; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DIAMOND JR, 1992, AM J KIDNEY DIS, V19, P292, DOI 10.1016/S0272-6386(13)80013-3; DILEEPAN KN, 1993, J LAB CLIN MED, V121, P797; FLIGIEL SEG, 1984, AM J PATHOL, V115, P418; FREEMAN BA, 1982, LAB INVEST, V47, P412; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; HELLMARK T, 1994, KIDNEY INT, V46, P823, DOI 10.1038/ki.1994.338; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; HUDSON BG, 1993, KIDNEY INT, V43, P135, DOI 10.1038/ki.1993.22; HUDSON BG, 1989, LAB INVEST, V61, P256; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; HUEY B, 1993, KIDNEY INT, V44, P307, DOI 10.1038/ki.1993.245; JENNETTE C, 1991, IMMUNOGENETICS AUTOI, P263; KALLURI R, 1991, J BIOL CHEM, V266, P24018; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; KALLURI R, 1994, P NATL ACAD SCI USA, V91, P6201, DOI 10.1073/pnas.91.13.6201; Kalluri R, 1996, ANN INTERN MED, V124, P651, DOI 10.7326/0003-4819-124-7-199604010-00005; Kalluri R, 1997, J CLIN INVEST, V100, P2263, DOI 10.1172/JCI119764; Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431; KALLURI R, 1995, J AM SOC NEPHROL, V6, P1178; MARSDEN PA, 1996, KIDNEY, P713; MCCORD JM, 1978, ANN INTERN MED, V89, P122, DOI 10.7326/0003-4819-89-1-122; NEALE TJ, 1993, P NATL ACAD SCI USA, V90, P3645, DOI 10.1073/pnas.90.8.3645; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; Pacifici R E, 1988, Basic Life Sci, V49, P531; REES AJ, 1984, KIDNEY INT, V26, P444, DOI 10.1038/ki.1984.194; REES AJ, 1984, HUM IMMUNOL, V10, P213, DOI 10.1016/0198-8859(84)90087-9; Riedle B, 1997, AM J PATHOL, V151, P215; Ryan JJ, 1998, CLIN EXP IMMUNOL, V113, P17, DOI 10.1046/j.1365-2249.1998.00623.x; SCHEINMAN JI, 1980, LAB INVEST, V43, P373; SHAH SV, 1981, J LAB CLIN MED, V98, P46; SHAH SV, 1989, KIDNEY INT, V35, P1093, DOI 10.1038/ki.1989.96; SHAH SV, 1987, J CLIN INVEST, V79, P25, DOI 10.1172/JCI112790; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TIMPL R, 1985, ANN NY ACAD SCI, V460, P58, DOI 10.1111/j.1749-6632.1985.tb51157.x; TRYGGVASON K, 1990, ANN NY ACAD SCI, V580, P97, DOI 10.1111/j.1749-6632.1990.tb17922.x; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; WIESLANDER J, 1987, CLIN EXP IMMUNOL, V69, P332; Wilson C B, 1981, Aust N Z J Med, V11, P94, DOI 10.1111/j.1445-5994.1981.tb03570.x; WILSON CB, 1973, KIDNEY INT, V3, P74, DOI 10.1038/ki.1973.14; WILSON CB, 1996, KIDNEY, P1253; YOSHIOKA T, 1991, J AM SOC NEPHROL, V2, P902	51	65	67	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					20027	20032		10.1074/jbc.M904549199	http://dx.doi.org/10.1074/jbc.M904549199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748075	hybrid			2022-12-27	WOS:000087941300081
J	Pietri, S; Miollan, M; Martel, S; Le Moigne, F; Blaive, B; Culcasi, M				Pietri, S; Miollan, M; Martel, S; Le Moigne, F; Blaive, B; Culcasi, M			alpha- and beta-phosphorylated amines and pyrrolidines, a new class of low toxic highly sensitive P-31 NMR pH indicators - Modeling of pK alpha and chemical shift values as a function of substituents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; 5-(DIETHOXYPHOSPHORYL)-5-METHYL-1-PYRROLINE N-OXIDE; INTRACELLULAR PH; RAT-HEART; SPIN TRAP; PHOSPHONATE; PROBE; METHYLPHOSPHONATE; SPECTROSCOPY; METABOLITES	Fourteen linear and cyclic alpha- and beta-aminophosphonates in which the P-atom is substituted by alkoxy groups have been synthesized and evaluated as P-31 NMR pH markers in Krebs-Henseleit buffer. pK(a) values varied with substitution in the range 1.3-9.1, giving potentially access to a wide range of pH, Temperature had a weak influence on pH and a dramatic increase in ionic strength slightly modified the pK(a) of the pyrrolidine diethyl(2-methylpyrrolidin-2-yl)phosphonate (DEPMPH). All compounds displayed a 4-fold better NMR sensitivity than inorganic phosphate or other commonly used phosphonates, as assessed by differences delta(b)-delta(a), between the chemical shifts of the protonated and the unprotonated forms. In isolated perfused rat hearts, a non-toxic concentration window of 1.5-15 mM was determined for three representative compounds, Using empirical linear relationships, the experimental values of pK(a), delta(a), and delta(b) have been correlated with the two-dimensional structure, i.e. the chemical nature of substituents bonded to the secondary amine and P-atom, The data suggest that DEPMPH and its cyclic and linear variants are ideal versatile P-31 NMR probes for the study of tenuous pH changes in biological processes.	Univ Aix Marseille 1, Fac Sci St Jerome, CNRS, UMR Struct & react especes Paramagnet 6517, F-13397 Marseille 20, France; Univ Aix Marseille 3, Fac Sci St Jerome, CNRS, UMR Struct & react especes Paramagnet 6517, F-13397 Marseille 20, France; Univ Aix Marseille 1, Fac Sci St Jerome, Ecole Natl Super Chim, F-13397 Marseille 20, France; Univ Aix Marseille 3, Fac Sci St Jerome, Ecole Natl Super Chim, F-13397 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Pietri, S (corresponding author), Univ Aix Marseille 1, Fac Sci St Jerome, CNRS, UMR Struct & react especes Paramagnet 6517, Ave Escadrille Normadie Niemen, F-13397 Marseille 20, France.	pietri@srepirl.univ-mrs.fr						ABDELMAGID AF, 1990, TETRAHEDRON LETT, V31, P5595, DOI 10.1016/S0040-4039(00)97905-X; AFARINKIA K, 1990, TETRAHEDRON, V46, P7175, DOI 10.1016/S0040-4020(01)87899-6; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; Barbati S, 1997, NATO ASI 3 HIGH TECH, V27, P39; BRENOT F, 1992, BIOCHIMIE, V74, P883, DOI 10.1016/0300-9084(92)90072-M; Bruynseels K, 1997, NMR BIOMED, V10, P263, DOI 10.1002/(SICI)1099-1492(199709)10:6<263::AID-NBM472>3.0.CO;2-J; CLARKE K, 1994, MAGNET RESON MED, V32, P181, DOI 10.1002/mrm.1910320206; CLARKE K, 1993, NMR BIOMED, V6, P278, DOI 10.1002/nbm.1940060407; DAWSON ND, 1952, J AM CHEM SOC, V74, P5312, DOI 10.1021/ja01141a025; DEFRONZO M, 1987, J BIOL CHEM, V262, P11032; DEUTSCH CJ, 1989, BIOPHYS J, V55, P799, DOI 10.1016/S0006-3495(89)82879-6; DEUTSCH CJ, 1987, ANN NY ACAD SCI, V508, P33, DOI 10.1111/j.1749-6632.1987.tb32892.x; FIELDS EK, 1952, J AM CHEM SOC, V74, P1528, DOI 10.1021/ja01126a054; FISHER MJ, 1987, CIRC RES, V60, P472, DOI 10.1161/01.RES.60.4.472; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; GILLIES RJ, 1994, AM J PHYSIOL, V267, pC195, DOI 10.1152/ajpcell.1994.267.1.C195; GILLIES RJ, 1982, INTRACELLULAR PH ITS, P79; GORDON AJ, 1972, HDB PRACTICAL DATA T, P55; Gorenstein D.G., 1984, PHOSPHORUS 31 NMR PR, P7; GRABENSTETTER RJ, 1967, J PHYS CHEM-US, V71, P4194, DOI 10.1021/j100872a006; GRIMALDI S, 1997, THESIS U AIXMARSEILL; Karoui H, 1999, J ORG CHEM, V64, P1471, DOI 10.1021/jo981875n; LABOTKA RJ, 1983, BIOCHEMISTRY-US, V22, P6089, DOI 10.1021/bi00295a008; Maurelli E, 1999, FREE RADICAL BIO MED, V27, P34, DOI 10.1016/S0891-5849(99)00033-7; MEDVED TY, 1954, B ACAD SCI USSR CH+, P314; MOON RB, 1973, J BIOL CHEM, V248, P7276; OHIA K, 1992, B CHEM SOC JPN, V65, P2543; PIETRI S, 1998, Patent No. 03317; ROBERTS JKM, 1981, BIOCHEMISTRY-US, V20, P5389, DOI 10.1021/bi00522a006; ROBITAILLE PML, 1991, J MAGN RESON, V92, P73, DOI 10.1016/0022-2364(91)90248-R; SATRE M, 1989, BIOCHIMIE, V71, P941, DOI 10.1016/0300-9084(89)90076-X; SCHLISELFELD LH, 1982, BIOCHEMISTRY-US, V21, P317, DOI 10.1021/bi00531a018; SEO Y, 1983, J BIOCHEM-TOKYO, V94, P729, DOI 10.1093/oxfordjournals.jbchem.a134413; Sosnovsky G, 1998, LIFE SCI, V62, P639, DOI 10.1016/S0024-3205(97)01159-4; STEWART IM, 1986, BIOCHIM BIOPHYS ACTA, V885, P23, DOI 10.1016/0167-4889(86)90034-0; SZWERGOLD BS, 1992, ANNU REV PHYSIOL, V54, P775, DOI 10.1146/annurev.ph.54.030192.004015; SZWERGOLD BS, 1989, J CELL PHYSIOL, V138, P227, DOI 10.1002/jcp.1041380203; THOMA WJ, 1986, BIOCHEM BIOPH RES CO, V138, P1106, DOI 10.1016/S0006-291X(86)80396-5; *US DEP HHS, 1985, NIH PUBL, V8523; WADSWORTH SJ, 1994, J MEMBRANE BIOL, V142, P21, DOI 10.1007/BF00233380	40	32	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19505	19512		10.1074/jbc.M001784200	http://dx.doi.org/10.1074/jbc.M001784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10748044	hybrid			2022-12-27	WOS:000087941300012
J	Shi, YG; Ullrich, SJ; Zhang, J; Connolly, K; Grzegorzewski, KJ; Barber, MC; Wang, W; Wathen, K; Hodge, V; Fisher, CL; Olsen, H; Ruben, SM; Knyazev, I; Cho, YH; Kao, V; Wilkinson, KA; Carrell, JA; Ebner, R				Shi, YG; Ullrich, SJ; Zhang, J; Connolly, K; Grzegorzewski, KJ; Barber, MC; Wang, W; Wathen, K; Hodge, V; Fisher, CL; Olsen, H; Ruben, SM; Knyazev, I; Cho, YH; Kao, V; Wilkinson, KA; Carrell, JA; Ebner, R			A novel cytokine receptor-ligand pair - Identification, molecular characterization, and in vivo immunomodulatory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; NITRIC-OXIDE PRODUCTION; RHEUMATOID-ARTHRITIS; GENE-EXPRESSION; NEUTROPHIL RECRUITMENT; ALLOGRAFT-REJECTION; MONONUCLEAR-CELLS; IL-17 PROMOTES; TH2 CYTOKINES; TNF-ALPHA	As part of a large scale effort to discover novel secreted proteins, a cDNA encoding a novel cytokine was identified. Alignments of the sequence of the new protein, designated IL-17B, suggest it to be a homolog of the recently described T cell-derived cytokine, IL-17. By Northern analysis, EST distribution and real-time quantitative polymerase chain reaction analysis, mRNA was detected in many cell types. A novel type I transmembrane protein, identified in an EST data base by homology to IL-17R, was found to bind specifically IL-17B, as determined by surface plasmon resonance analysis, flow cytometry, and co-immunoprecipitation experiments. Readily detectable transcription of IL-17BR was restricted to human kidney, pancreas, liver, brain, and intestines and only a few of the many cell lines tested. By using. a rodent ortholog of IL-17BR as a probe, IL-17BR message was found to be drastically up-regulated during intestinal inflammation elicited by indomethacin treatment in rats. In addition, intraperitoneal injection of IL-17B purified from Chinese hamster ovary cells caused marked neutrophil migration in normal mice, in a specific and dose-dependent manner. Together these results suggest that IL-17B may be a novel proinflammatory cytokine acting on a restricted set of target cell types. They also demonstrate the strength of genomic approaches in the unraveling of novel biological pathways.	Human Genome Sci Inc, Dept Mol Biol, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Prot Dev, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Strateg Drug Dev, Rockville, MD 20850 USA; Human Genome Sci Inc, Dept Cell Biol, Rockville, MD 20850 USA	GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc; GlaxoSmithKline; Human Genome Sciences Inc	Ebner, R (corresponding author), Therapeut Genom Inc, 9700 Great Seneca Hwy, Rockville, MD 20850 USA.	rebner@theragenomics.com						Aarvak T, 1999, SCAND J IMMUNOL, V50, P1; Albanesi C, 1999, J IMMUNOL, V162, P494; Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; Antonysamy MA, 1999, J IMMUNOL, V162, P577; Antonysamy MA, 1997, HUM IMMUNOL, V55, P15; Attur MG, 1997, ARTHRITIS RHEUM, V40, P1050, DOI 10.1002/art.1780400609; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; Cai XY, 1998, IMMUNOL LETT, V62, P51, DOI 10.1016/S0165-2478(98)00027-3; Chabaud M, 1999, ARTHRITIS RHEUM-US, V42, P963, DOI 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E; Chabaud M, 1998, J IMMUNOL, V161, P409; Eddy S R, 1995, J Comput Biol, V2, P9, DOI 10.1089/cmb.1995.2.9; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; Fine JS, 1997, J ALLERGY CLIN IMMUN, V99, P225; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Fridman WH, 1998, RES IMMUNOL, V149, P651, DOI 10.1016/S0923-2494(99)80033-9; Hoshino H, 1999, AM J RESP CRIT CARE, V159, P1423, DOI 10.1164/ajrccm.159.5.9806008; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Kawaguchi M, 1999, Arerugi, V48, P1184; KIM HS, 1992, SCAND J GASTROENTERO, V27, P529, DOI 10.3109/00365529209000116; Kostulas N, 1999, STROKE, V30, P2174, DOI 10.1161/01.STR.30.10.2174; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Laan M, 1999, J IMMUNOL, V162, P2347; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Lotz M, 1996, ARTHRITIS RHEUM, V39, P559; Malmqvist M, 1999, BIOCHEM SOC T, V27, P335, DOI 10.1042/bst0270335; Martel-Pelletier J, 1999, ARTHRITIS RHEUM-US, V42, P2399, DOI 10.1002/1529-0131(199911)42:11<2399::AID-ANR19>3.0.CO;2-Y; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; SAYERS TJ, 1988, J IMMUNOL, V141, P1670; SchulzKnappe P, 1996, J EXP MED, V183, P295, DOI 10.1084/jem.183.1.295; Schwarzenberger P, 1998, J IMMUNOL, V161, P6383; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Tartour E, 1999, CANCER RES, V59, P3698; THOMSON A, 1998, CYTOKINE HDB, P1; Van Bezooijen RL, 1999, J BONE MINER RES, V14, P1513, DOI 10.1359/jbmr.1999.14.9.1513; Van Kooten C, 1998, J AM SOC NEPHROL, V9, P1526; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Yao ZB, 1997, CYTOKINE, V9, P794, DOI 10.1006/cyto.1997.0240; YOO ZB, 1995, J IMMUNOL, V155, P5483	40	171	213	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19167	19176		10.1074/jbc.M910228199	http://dx.doi.org/10.1074/jbc.M910228199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10749887	hybrid			2022-12-27	WOS:000087815900073
J	Ulloa, F; Franci, C; Real, FX				Ulloa, F; Franci, C; Real, FX			GalNAc-alpha-O-benzyl inhibits sialylation of de novo synthesized apical but not basolateral sialoglycoproteins and blocks lysosomal enzyme processing in a post-trans-Golgi network compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CANCER-CELLS; CARCINOMA CACO-2 CELLS; POLARIZED MDCK CELLS; ACID STORAGE DISEASE; EPITHELIAL-CELLS; INTRACELLULAR-TRANSPORT; MEMBRANE-PROTEINS; HT-29 CELLS; SIALIC-ACID; TRANSMEMBRANE DOMAIN	Glycosylation plays an important role in glycoprotein traffic, Our previous work has shown that long term treatment of mucus-secreting HT-29 cells with GalNAc-alpha-O-benzyl reversibly inhibits sialylation and causes the accumulation of apical glycoproteins in cytoplasmic vesicles. We have analyzed at the biochemical level the effects of GalNAc-alpha-O-benzyl on glycoprotein processing. Both apical and basolateral membrane glycoproteins were sialylated, but GalNAc-alpha-O-benzyl selectively inhibited the sialylation of apical glycoproteins. In addition, lysosomal alpha-glucosidase, which is partially targeted to the apical membrane, was abnormally processed leading to the accumulation of an immature molecular species. Several findings support the conclusion that accumulation of this protein occurs in a post-trans-Golgi network (TGN) compartment: 1) it is partially sialylated; 2) it does not occur when glycoprotein exit from the TGN is blocked at 20 degrees C; 3) upon Triton X-114 partition, it distributes to the aqueous phase, a characteristic that is acquired in a post-TGN compartment; and 4) its appearance is inhibited when cells are cultured in the presence of NH4Cl. The processing of cathepsin D was also found to be affected by GalNAc-alpha-O-benzyl treatment. In conclusion, GalNAc-alpha-O-benzyl selectively inhibits sialylation of apical glycoproteins and perturbs lysosomal enzyme processing; these effects occur in a post-TGN acidic compartment and are reminiscent of the alterations found in sialic acid storage diseases.	Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Barcelona 08003, Spain	Pompeu Fabra University	Real, FX (corresponding author), Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Carrer Dr Aiguader 80, Barcelona 08003, Spain.		Arribas, Francisco X Real/H-5275-2015; Ulloa, Fausto/AAB-2787-2019	Arribas, Francisco X Real/0000-0001-9501-498X; 				Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bright NA, 1997, J CELL SCI, V110, P2027; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Burger PC, 1998, GLYCOBIOLOGY, V8, P245, DOI 10.1093/glycob/8.3.245; DALLOLIO F, 1992, BIOCHEM BIOPH RES CO, V184, P1405, DOI 10.1016/S0006-291X(05)80039-7; DallOlio F, 1996, GLYCOCONJUGATE J, V13, P115, DOI 10.1007/BF01049687; DECOURCY K, 1991, EXP CELL RES, V192, P52, DOI 10.1016/0014-4827(91)90156-O; Delannoy P, 1996, GLYCOCONJUGATE J, V13, P717, DOI 10.1007/BF00702335; EGEA G, 1993, J CELL SCI, V105, P819; ELFERINK RPJO, 1989, EUR J CELL BIOL, V50, P299; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Fiedler K, 1996, J CELL SCI, V109, P271; Franci C, 1996, BIOCHEM J, V314, P33, DOI 10.1042/bj3140033; Fullekrug J, 1999, J CELL SCI, V112, P2813; Gahl WASJ, 1995, METABOLIC MOL BASIS, V7th, P3763; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; Hennebicq-Reig S, 1998, BIOCHEM J, V334, P283, DOI 10.1042/bj3340283; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; Huang XF, 1997, J BIOL CHEM, V272, P27598, DOI 10.1074/jbc.272.44.27598; HUET G, 1995, J CELL SCI, V108, P1275; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; KLUMPERMAN J, 1991, J CELL SCI, V100, P339; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LESUFFLEUR T, 1991, J CELL BIOL, V115, P1409, DOI 10.1083/jcb.115.5.1409; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; MONTGOMERY RR, 1991, J IMMUNOL, V147, P3087; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; RABOUILLE C, 1995, J CELL SCI, V108, P1617; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; ROTH J, 1993, HISTOCHEM J, V25, P687; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Schmid JA, 1999, J BIOL CHEM, V274, P19063, DOI 10.1074/jbc.274.27.19063; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TIETZE F, 1989, J BIOL CHEM, V264, P15316; UEDA R, 1981, P NATL ACAD SCI-BIOL, V78, P5122, DOI 10.1073/pnas.78.8.5122; VANWAES C, 1991, CANCER RES, V51, P2395; Verheijen FW, 1999, NAT GENET, V23, P462, DOI 10.1038/70585; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	56	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					18785	18793		10.1074/jbc.M000510200	http://dx.doi.org/10.1074/jbc.M000510200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10751388	hybrid			2022-12-27	WOS:000087815900025
J	Chun, KY; Vinarov, DA; Zajicek, J; Miziorko, HM				Chun, KY; Vinarov, DA; Zajicek, J; Miziorko, HM			3-Hydroxy-3-methylglutaryl-CoA synthase - A role for glutamate 95 in general acid/base catalysis of C-C bond formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COENZYME-A SYNTHASE; CITRATE SYNTHASE; OXALOACETATE; MECHANISM; RESIDUES; BINDING; ENZYMES; LIVER; COA	Replacement of 3-hydroxy-3-methylglutaryl-CoA synthase's glutamate 95 with alanine diminishes catalytic activity by over 5 orders of magnitude. The structural integrity of E95A enzyme is suggested by the observation that this protein contains a full complement of acyl-CoA binding sites, as indicated by binding studies using a spin-labeled acyl-CoA Active site integrity is also demonstrated by (NMR)-N-13 studies, which indicate that E95A forms an acetyl-S-enzyme reaction intermediate with the same distinctive spectroscopic characteristics measured using wild type enzyme. The initial reaction steps are not disrupted in E95A, which exhibits normal levels of Michaelis complex and acetyl-S-enzyme intermediate. Likewise, E95A is not impaired in catalysis of the terminal reaction step, as indicated by efficient catalysis of a hydrolysis partial reaction. Single turnover experiments indicate defective C-C bond formation, The mechanism-based inhibitor, 3-chloropropionyl-CoA, efficiently alkylates E95A This is compatible with the presence of a functional general base, raising the possibility that Glu(95) functions as a general acid. Demonstration of a significant upfield shift for the methyl protons of HMG-CoA synthase's acetyl-S-enzyme reaction intermediate suggests a hydrophobic active site environment that could elevate the pK(a) of Glu(95) as required to support its function as a general acid.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	Medical College of Wisconsin; University of Notre Dame	Miziorko, HM (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NCRR NIH HHS [RR01008] Funding Source: Medline; NIDDK NIH HHS [DK-21491] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021491, R01DK021491] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER GM, 1990, BIOCHEMISTRY-US, V29, P7557, DOI 10.1021/bi00485a003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chun K, 1998, FASEB J, V12, pA1359; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3108; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JUNCOSA M, 1994, J BIOL CHEM, V269, P14530; KARPUSAS M, 1990, BIOCHEMISTRY-US, V29, P2213, DOI 10.1021/bi00461a002; KURZ LC, 1995, BIOCHEMISTRY-US, V34, P13278, DOI 10.1021/bi00041a003; MCCALLEY RC, 1972, CHEM PHYS LETT, V13, P115, DOI 10.1016/0009-2614(72)80057-5; McIntosh LP, 1996, BIOCHEMISTRY-US, V35, P9958, DOI 10.1021/bi9613234; MELOCHE HP, 1983, J PROTEIN CHEM, V2, P399, DOI 10.1007/BF01025238; Misra I, 1996, BIOCHEMISTRY-US, V35, P9610, DOI 10.1021/bi9605797; MISRA I, 1995, BBA-PROTEIN STRUCT M, V1247, P253, DOI 10.1016/0167-4838(94)00223-4; MISRA I, 1993, J BIOL CHEM, V268, P12129; MIZIORKO HM, 1977, J BIOL CHEM, V252, P1414; MIZIORKO HM, 1975, J BIOL CHEM, V250, P5768; MIZIORKO HM, 1979, BIOCHEMISTRY-US, V18, P399, DOI 10.1021/bi00570a001; MIZIORKO HM, 1985, J BIOL CHEM, V260, P3513; MIZIORKO HM, 1985, BIOCHEMISTRY-US, V24, P3174, DOI 10.1021/bi00334a015; MIZIORKO HM, 1989, BIOCHEMISTRY-US, V28, P5759, DOI 10.1021/bi00440a009; MORRIS AJ, 1993, J BIOL CHEM, V268, P1095; PACI M, 1984, J BIOL CHEM, V259, P9628; Richard JP, 1998, BIOCHEMISTRY-US, V37, P4305, DOI 10.1021/bi972655r; ROKOSZ LL, 1994, ARCH BIOCHEM BIOPHYS, V312, P1, DOI 10.1006/abbi.1994.1273; Vinarov D, 1999, J AM CHEM SOC, V121, P270, DOI 10.1021/ja983511i; VOLLMER SH, 1988, BIOCHEMISTRY-US, V27, P4288, DOI 10.1021/bi00412a014	26	27	29	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17946	17953		10.1074/jbc.M909725199	http://dx.doi.org/10.1074/jbc.M909725199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748155	hybrid			2022-12-27	WOS:000087659400007
J	Dmitrieva, N; Kultz, D; Michea, L; Ferraris, J; Burg, M				Dmitrieva, N; Kultz, D; Michea, L; Ferraris, J; Burg, M			Protection of renal inner medullary epithelial cells from apoptosis by hypertonic stress-induced p53 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER-SCANNING CYTOMETRY; HYPEROSMOTIC STRESS; RESPONSE ELEMENT; GENE; PROMOTER; MOUSE; PHOSPHORYLATION; FIBROBLASTS; INDUCTION; SIGNALS	Acute hypertonicity causes cell cycle delay and apoptosis in mouse renal inner medullary collecting duct cells (mIMCD3) and increases GADD45 expression. Be cause the tumor suppressor protein p53 may be involved in these effects, we have investigated the role of p53 in mIMCD3 response to hyperosmotic stress. Acute elevation of osmolality with NaCl addition from the control level of 320 mosmol/kg to 500-600 mosmol/kg greatly increased the levels of total and Ser(15)-phosphorylated p53 within 15 min. However, similar elevation of osmolality with urea did not increase p53 levels. Our studies indicate that induced p53 is transcriptionally active because NaCl addition to 500-600 mosmol/kg stimulated transcription of a luciferase reporter containing a p53 consensus element and appropriately altered mRNA levels of known transcriptional targets of p53, i.e. increased MDM-2 and decreased BCL-2 levels. Elevating NaCl further to 700-800 mosmol/kg rapidly killed most of the cells by apoptosis, At these higher NaCl concentrations, p53 levels were further increased although Ser(15) phosphorylation and transcriptional activity were significantly lower than levels at 500-600 mosmol/kg. At NaCl-induced 500 mosmol/kg, apoptosis was rare in the presence of control, nonspecific oligonucleotide but highly prevalent upon addition of p53 antisense oligonucleotide that substantially reduced p53 levels. We conclude that induction of active p53 in mIMCD3 cells by hypertonic stress contributes to cell survival.	NHLBI, NIH, Bethesda, MD 20892 USA; Univ Florida, Whitney Lab, St Augustine, FL 32086 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University System of Florida; University of Florida	Dmitrieva, N (corresponding author), NHLBI, NIH, Bldg 10,Rm 6N260, Bethesda, MD 20892 USA.	dmitrien@nhlbi.nih.gov	, DK/AAU-3163-2021; Dmitrieva, Natalia/A-2924-2013; Dmitrieva, Natalia/Q-9175-2019	Dmitrieva, Natalia/0000-0001-8074-6950; Dmitrieva, Natalia/0000-0001-8074-6950				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1994, COLD SPRING HARB SYM, V59, P225, DOI 10.1101/SQB.1994.059.01.027; Bedner E, 1999, CYTOMETRY, V35, P181, DOI 10.1002/(SICI)1097-0320(19990301)35:3<181::AID-CYTO1>3.0.CO;2-5; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cohen DM, 1999, CLIN EXP PHARMACOL P, V26, P69, DOI 10.1046/j.1440-1681.1999.02991.x; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; Furuya T, 1997, CYTOMETRY, V29, P173; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; Meek DW, 1997, PATHOL BIOL, V45, P804; Michea L, 2000, AM J PHYSIOL-RENAL, V278, pF209, DOI 10.1152/ajprenal.2000.278.2.F209; MIYASHITA T, 1994, CANCER RES, V54, P3131; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Santos BC, 1998, AM J PHYSIOL-RENAL, V274, pF1167, DOI 10.1152/ajprenal.1998.274.6.F1167; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768	29	94	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18243	18247		10.1074/jbc.M000522200	http://dx.doi.org/10.1074/jbc.M000522200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10747924	hybrid			2022-12-27	WOS:000087659400046
J	Iismaa, SE; Wu, MJ; Nanda, N; Church, WB; Graham, RM				Iismaa, SE; Wu, MJ; Nanda, N; Church, WB; Graham, RM			GTP binding and signaling by G(h)/transglutaminase II involves distinct residues in a unique GTP-binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; COAGULATION FACTOR-XIII; CROSS-LINKING ENZYMES; TISSUE TRANSGLUTAMINASE; PHOSPHOLIPASE C-DELTA-1; CALCIUM-BINDING; PROTEIN; RECEPTOR; G(H); CELL	G(h) is a dual function protein. It has receptor signaling activity that requires GTP binding and Ca2+-activated transglutaminase (TGase) activity that is inhibited by GTP binding. G(h) shows no homology with other GTP-binding proteins, and its GTP-binding site has not been defined. Based on sequence analysis of [alpha-P-32]GTP-photolabeled and proteolytically released internal peptide fragments, we report localization of GTP binding to a 15-residue segment ((159)YLTQQGFIYQGSVK(173)) of the Gr, core domain. This was confirmed by site-directed mutagenesis; a G(h)/fXIIIA chimera tin which residues 162-179 of G(h) were substituted with the equivalent but nonhomologous region of the non-GTP-binding TGase factor XIIIA) and a G(h) point mutant, S171E, retained TGase activity but failed to bind and hydrolyze GTP and did not support alpha(1B)-adrenergic receptor signaling. Slight impairment of GTP binding (1.5-fold) and hydrolysis (10-fold) in the absence of altered TGase activity did not affect signaling by the mutant K173N, However, greater impairment of GTP binding (g-fold) and hydrolysis (50-fold) abolished signaling by the mutant H173L, Mutant S171C exhibited enhanced GTP binding and signaling. Thus, residues Ser(171) and Lys(173) are critical for both GTP binding and signaling but not TGase activity. Mutagenesis of residues N-terminal to Gly(170) impaired both GTP binding and TGase activity. From computer modeling of G(h), it is evident that the GTP-binding region identified here is distinct from, but interacts with, the TGase active site. Together with structural considerations of G(h) versus other GTP-binding proteins, these findings indicate that G(h) has a unique GTP-binding pocket and provide for the first time a mechanism for GTP-mediated regulation of the TGase activity of G(h).	Victor Chang Cardiac Res Inst, Mol Cardiol Unit, Darlinghurst, NSW 2010, Australia; St Vincents Hosp, Garvan Inst Med Res, Arthrit & Inflammat Program, Darlinghurst, NSW 2010, Australia; Univ New S Wales, Sch Biochem & Mol Genet, Kensington, NSW 2054, Australia	Victor Chang Cardiac Research Institute; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Iismaa, SE (corresponding author), Victor Chang Cardiac Res Inst, Mol Cardiol Unit, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	s.iismaa@victorchang.unsw.edu.au	Iismaa, Siiri/C-9300-2013; Church, William/H-6040-2013; Iismaa, Siiri/A-9924-2008	Iismaa, Siiri/0000-0003-2409-7356; Church, William/0000-0002-8033-5518; 				ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Aeschlimann Daniel, 1996, Seminars in Thrombosis and Hemostasis, V22, P437; Baek KJ, 1996, BIOCHEMISTRY-US, V35, P2651, DOI 10.1021/bi9522965; BERGAMINI CM, 1988, FEBS LETT, V239, P255, DOI 10.1016/0014-5793(88)80928-1; BERGAMINI CM, 1993, BIOCHEM J, V291, P37, DOI 10.1042/bj2910037; BYLUND DB, 1993, AM J PHYSIOL, V265, pL421, DOI 10.1152/ajplung.1993.265.5.L421; Casadio R, 1999, EUR J BIOCHEM, V262, P672, DOI 10.1046/j.1432-1327.1999.00437.x; Chen SH, 1999, J BIOL CHEM, V274, P16320, DOI 10.1074/jbc.274.23.16320; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1967, J BIOL CHEM, V242, P1838; FOLK JE, 1967, J BIOL CHEM, V242, P2615; Fox BA, 1999, J BIOL CHEM, V274, P4917, DOI 10.1074/jbc.274.8.4917; Gaudry CA, 1999, J BIOL CHEM, V274, P30707, DOI 10.1074/jbc.274.43.30707; Gentile V, 1997, BBA-MOL CELL RES, V1357, P115, DOI 10.1016/S0167-4889(97)00024-4; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hitomi K, 1999, J BIOCHEM-TOKYO, V125, P1048, DOI 10.1093/oxfordjournals.jbchem.a022385; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; IKURA K, 1995, ARCH BIOCHEM BIOPHYS, V318, P307, DOI 10.1006/abbi.1995.1234; IM MJ, 1990, J BIOL CHEM, V265, P18944; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Lai TS, 1997, J BIOL CHEM, V272, P16295, DOI 10.1074/jbc.272.26.16295; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Lee MY, 1997, PFLUG ARCH EUR J PHY, V433, P671, DOI 10.1007/s004240050330; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; Murthy SNP, 1999, P NATL ACAD SCI USA, V96, P11815, DOI 10.1073/pnas.96.21.11815; NAKANISHI K, 1991, EUR J BIOCHEM, V202, P15, DOI 10.1111/j.1432-1033.1991.tb16338.x; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Park ES, 1998, BIOCHEM J, V331, P283, DOI 10.1042/bj3310283; Small K, 1999, J BIOL CHEM, V274, P21291, DOI 10.1074/jbc.274.30.21291; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; Vezza R, 1999, J BIOL CHEM, V274, P12774, DOI 10.1074/jbc.274.18.12774; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Zhang JW, 1999, BIOCHEM J, V343, P541, DOI 10.1042/0264-6021:3430541	38	82	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18259	18265		10.1074/jbc.M000583200	http://dx.doi.org/10.1074/jbc.M000583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10747935	hybrid			2022-12-27	WOS:000087659400048
J	Makkinje, A; Quinn, DA; Chen, A; Cadilla, CL; Force, T; Bonventre, JV; Kyriakis, JM				Makkinje, A; Quinn, DA; Chen, A; Cadilla, CL; Force, T; Bonventre, JV; Kyriakis, JM			Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK - A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; SIGNAL-REGULATED KINASE; GERMINAL CENTER KINASE; TYROSINE KINASE; CELL-ADHESION; MEK KINASES; PATHWAYS; IDENTIFICATION; CDC42; P38	Chronic stresses, including the mechanical strain caused by hypertension or excess pulmonary ventilation pressure, lead to important clinical consequences, including hypertrophy and acute respiratory distress syndrome. Pathologic hypertrophy contributes to decreased organ function and, ultimately, organ failure; and cardiac and diabetic renal hypertrophy are major causes of morbidity and morality in the developed world. Likewise, acute respiratory distress syndrome is a serious potential side effect of mechanical pulmonary ventilation. Whereas the deleterious effects of chronic stress are well established, the molecular mechanisms by which these stresses affect cell function are still poorly characterized. gene 33 (also called mitogen-inducible gene-6, mig-6) is an immediate early gene that is transcriptionally induced by a divergent array of extracellular stimuli. The physiologic function of Gene 33 is unknown. Here we show that gene 33 mRNA levels increase sharply in response to a set of commonly occurring chronic stress stimuli: mechanical strain, vasoactive peptides, and diabetic nephropathy. Induction of gene 33 requires the stress-activated protein kinases (SAPKs)/c-Jun NH2-terminal kinases, This expression pattern suggests that gene 33 is a potential marker for diabetic nephropathy and other pathologic responses to persistent sublethal stress. The structure of Gene 33 indicates an adapter protein capable of binding monomeric GTPases of the Rho subfamily. Consistent with this, Gene 33 interacts in vivo and, in a GTP-dependent manner, in vitro with Cdc42Hs; and transient expression of Gene 33 results in the selective activation of the SAPKs, These results imply a reciprocal, positive feedback relationship between Gene 33 expression and SAPK activation. Expression of Gene 33 at sufficient levels may enable a compensatory reprogramming of cellular function in response to chronic stress, which may have pathophysiological consequences.	Massachusetts Gen Hosp E, Diabet Res Lab, Med Serv, Diabet Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp E, Med Serv, Pulm Crit Care Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp E, Med Serv, Renal Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp E, Med Serv, Cardiol Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Charlestown, MA USA; Univ Puerto Rico, Sch Med, Dept Biochem, San Juan, PR 00936 USA	Harvard University; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Kyriakis, JM (corresponding author), Massachusetts Gen Hosp E, Diabet Res Lab, Med Serv, Diabet Unit, 149 13th St, Charlestown, MA 02129 USA.			Force, Thomas/0000-0002-0450-8659	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002655, R01DK041513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008224] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08-HL03920-02] Funding Source: Medline; NIDDK NIH HHS [R01-DK41513, K01-DK02655] Funding Source: Medline; NIGMS NIH HHS [S06 GM008224] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fine L. G., 1992, KIDNEY PHYSL PATHOPH, P3113; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KREISBERG JI, 1986, AM J PHYSIOL, V251, pC505, DOI 10.1152/ajpcell.1986.251.4.C505; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE KL, 1989, ARCH BIOCHEM BIOPHYS, V276, P106; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Messina Joseph L., 1994, P263; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOLNAR A, 1997, J BIOL CHEM, V272, P13299; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFFER JL, 1994, J ORTHOP RES, V12, P709, DOI 10.1002/jor.1100120514; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WICK M, 1995, EXP CELL RES, V219, P527, DOI 10.1006/excr.1995.1261; Wyncoll DLA, 1999, LANCET, V354, P497, DOI 10.1016/S0140-6736(98)08129-X; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	52	114	118	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17838	17847		10.1074/jbc.M909735199	http://dx.doi.org/10.1074/jbc.M909735199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10749885	Green Accepted, hybrid			2022-12-27	WOS:000087485000087
J	Oh, JW; Sheu, GT; Lai, MMC				Oh, JW; Sheu, GT; Lai, MMC			Template requirement and initiation site selection by hepatitis C virus polymerase on a minimal viral RNA template	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Q-BETA-REPLICASE; CDNA CLONE; 3'-UNTRANSLATED REGION; 3'-NONCODING REGION; SECONDARY STRUCTURE; GENOME RNA; IN-VITRO; IDENTIFICATION; 3'-TERMINUS; SEQUENCE	RNA-dependent RNA polymerase, NS5B protein, catalyzes replication of viral genomic RNA, which presumably initiates from the 3'-end, We have previously shown that NS5B can utilize the 3'-end 98-nucleotide (nt) X region of the hepatitis C virus (HCV) genome as a minimal authentic template. In this study, we used this RNA to characterize the mechanism of RNA synthesis by the recombinant NS5B, We first showed that NS5B formed a complex with the 3'-end of HCV RNA by binding to both the poly(U-U/C)-rich and X regions of the 3'-untranslated region as well as part of the NS5B-coding sequences. Within the X region, NS5B bound stem II and the single-stranded region connecting stem-loops I and II. Truncation of 40 nt or more from the 3'-end of the X region abolished its template activity, whereas X RNA lacking 35 nt or less from the 3'-end retained template activity, consistent with the NS5B-binding site mapped. Furthermore, NS5B initiated RNA synthesis from a specific site within the single-stranded loop I. All of the RNA templates that have a double-stranded stem at the 3'-end had the same RNA initiation site. However, the addition of single-stranded nucleotides to the 5'-end of X RNA or removal of double-stranded structure in stem I generated RNA products of template size. These results indicate that HCV NS5B initiates RNA synthesis from a single-stranded region closest to the 3'-end of the X region. These results have implications for the mechanism of HCV RNA replication and the nature of HCV RNA templates in the infected cells.	Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90033 USA	University of Southern California; Howard Hughes Medical Institute; University of Southern California	Lai, MMC (corresponding author), Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, 2011 Zonal Ave,HMR-401, Los Angeles, CA 90033 USA.	michlai@hsc.usc.edu	Lai, Michael M. C./I-7001-2012; Sheu, Gwo-Tarng/H-8855-2019	Sheu, Gwo-Tarng/0000-0002-1299-3375	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040038, R01AI047348] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 40038, AI 47348] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkins S, 1997, RNA, V3, P634; ALTER HJ, 1995, BLOOD, V85, P1681, DOI 10.1182/blood.V85.7.1681.bloodjournal8571681; BARRERA I, 1993, J MOL BIOL, V232, P512, DOI 10.1006/jmbi.1993.1407; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 1997, J VIROL, V71, P7345, DOI 10.1128/JVI.71.10.7345-7352.1997; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; Brown D, 1996, P NATL ACAD SCI USA, V93, P11558, DOI 10.1073/pnas.93.21.11558; BROWN D, 1995, BIOCHEMISTRY-US, V34, P14765, DOI 10.1021/bi00045a018; BROWN D, 1995, BIOCHEMISTRY-US, V34, P14775, DOI 10.1021/bi00045a019; Chao L, 1999, J VIROL, V73, P8798, DOI 10.1128/JVI.73.10.8798-8807.1999; Cheng JC, 1999, J VIROL, V73, P7044, DOI 10.1128/JVI.73.8.7044-7049.1999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CUI T, 1995, NUCLEIC ACIDS RES, V23, P377, DOI 10.1093/nar/23.3.377; CUI T, 1993, J BIOL CHEM, V268, P26093; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; Gonzalez S, 1999, EMBO J, V18, P3767, DOI 10.1093/emboj/18.13.3767; HOUGHTON M, 1996, VIROLOGY, P1035; Ito T, 1998, J VIROL, V72, P8789, DOI 10.1128/JVI.72.11.8789-8796.1998; Ito T, 1997, J VIROL, V71, P8698, DOI 10.1128/JVI.71.11.8698-8706.1997; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; Lai MMC, 1998, VIROLOGY, V244, P1, DOI 10.1006/viro.1998.9098; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; PATA JD, 1995, RNA, V1, P466; Porter DJT, 1998, J BIOL CHEM, V273, P18906, DOI 10.1074/jbc.273.30.18906; QUADT R, 1993, P NATL ACAD SCI USA, V90, P1498, DOI 10.1073/pnas.90.4.1498; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SCHUPPLI D, 1994, J MOL BIOL, V243, P811, DOI 10.1006/jmbi.1994.1682; Siegel RW, 1998, P NATL ACAD SCI USA, V95, P11613, DOI 10.1073/pnas.95.20.11613; Strauss JH, 1999, SCIENCE, V283, P802, DOI 10.1126/science.283.5403.802; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; Yamada N, 1996, VIROLOGY, V223, P255, DOI 10.1006/viro.1996.0476; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Yanagi M, 1998, VIROLOGY, V244, P161, DOI 10.1006/viro.1998.9092; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yanagi M, 1999, P NATL ACAD SCI USA, V96, P2291, DOI 10.1073/pnas.96.5.2291	38	92	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17710	17717		10.1074/jbc.M908781199	http://dx.doi.org/10.1074/jbc.M908781199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10749880	hybrid			2022-12-27	WOS:000087485000071
J	Pooggin, MM; Hohn, T; Futterer, J				Pooggin, MM; Hohn, T; Futterer, J			Role of a short open reading frame in ribosome shunt on the cauliflower mosaic virus RNA leader	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCISTRONIC MESSENGER-RNA; TRANSLATIONAL REGULATION; EUKARYOTIC RIBOSOMES; SECONDARY STRUCTURE; STABLE HAIRPIN; SACCHAROMYCES-CEREVISIAE; PLANT-CELLS; 35S RNA; INITIATION; GENE	The pregenomic 35 S RNA of cauliflower mosaic virus (CaMV) belongs to the growing number of mRNAs known to have a complex leader sequence. The 612-nucleotide leader contains several short open reading frames (sORFs) and forms an extended hairpin structure. Downstream translation of 35 S RNA is nevertheless possible due to the ribosome shunt mechanism, by which ribosomes are directly transferred from a take-off site near the capped 5' end of the leader to a landing site near its 3' end. There they resume scanning and reach the first long open reading frame. We investigated in detail how the multiple sORFs influence ribosome migration either via shunting or linear scanning along the CaMV leader. The sORFs together constituted a major barrier for the linear ribosome migration, whereas the most 5'-proximal sORF, sORF A, in combination with sORFs B and C, played a positive role in translation downstream of the leader by diverting scanning ribosomes to the shunt route. A simplified, shunt-competent leader was constructed with the most part of the hairpin including all the sORFs except sORF A replaced by a scanning-inhibiting structure. In this leader as well as in the wild type leader, proper translation and termination of sORF A was required for efficient shunt and also for the level of shunt enhancement by a CaMV-encoded translation transactivator. sORF A could be replaced by heterologous sORFs, but a one-codon (start/stop) sORF was not functional. The results implicate that in CaMV, shunt-mediated translation requires reinitiation. The efficiency of the shunt process is influenced by translational properties of the sORF.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Russian Acad Sci, Ctr Bioengn, Moscow 117312, Russia; ETH Zentrum, Inst Plant Sci, CH-8092 Zurich, Switzerland	Friedrich Miescher Institute for Biomedical Research; Research Center of Biotechnology RAS; Russian Academy of Sciences; Swiss Federal Institutes of Technology Domain; ETH Zurich	Hohn, T (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.			Pooggin, Mikhail/0000-0003-2308-393X				ABASTADO JP, 1991, NEW BIOL, V3, P511; Alderete JP, 1999, J VIROL, V73, P8330, DOI 10.1128/JVI.73.10.8330-8337.1999; ANTHONY DD, 1992, J BIOL CHEM, V267, P1554; BONNEVILLE JM, 1989, CELL, V59, P1135, DOI 10.1016/0092-8674(89)90769-1; Carter PS, 1999, ONCOGENE, V18, P4326, DOI 10.1038/sj.onc.1202890; CURRAN J, 1988, EMBO J, V7, P2869, DOI 10.1002/j.1460-2075.1988.tb03143.x; DELBECQ P, 1994, MOL CELL BIOL, V14, P2378, DOI 10.1128/MCB.14.4.2378; Dominguez DI, 1998, J BIOL CHEM, V273, P3669, DOI 10.1074/jbc.273.6.3669; DONZE O, 1995, NUCLEIC ACIDS RES, V23, P861, DOI 10.1093/nar/23.5.861; FUTTERER J, 1990, EMBO J, V9, P1697, DOI 10.1002/j.1460-2075.1990.tb08293.x; Futterer J, 1989, Virus Genes, V3, P45, DOI 10.1007/BF00301986; FUTTERER J, 1992, NUCLEIC ACIDS RES, V20, P3851, DOI 10.1093/nar/20.15.3851; FUTTERER J, 1991, EMBO J, V10, P3887, DOI 10.1002/j.1460-2075.1991.tb04958.x; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; Futterer J, 1996, J VIROL, V70, P2999; GALVEZ AF, 1995, PLANT MOL BIOL REP, V13, P232, DOI 10.1007/BF02670902; GORDON K, 1992, PLANT J, V2, P809, DOI 10.1046/j.1365-313X.1992.t01-17-00999.x; GRANT CM, 1994, MOL CELL BIOL, V14, P608; Hemmings-Mieszczak M, 1999, RNA, V5, P1149, DOI 10.1017/S1355838299990325; Hemmings-Mieszczak M, 1998, RNA, V4, P101; HemmingsMieszczak M, 1997, J MOL BIOL, V267, P1075, DOI 10.1006/jmbi.1997.0929; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; Jackson RJ, 1995, RNA, V1, P985; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; LI J, 1996, THESIS U GIESSEN GER, P1; Merrick WC., 1996, TRANSLATION CONTROL, P31; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; Muckenthaler M, 1998, MOL CELL, V2, P383, DOI 10.1016/S1097-2765(00)80282-8; Mueller PP, 1998, J BIOL CHEM, V273, P32870, DOI 10.1074/jbc.273.49.32870; Pestova TV, 1999, TRENDS BIOCHEM SCI, V24, P85, DOI 10.1016/S0968-0004(99)01356-0; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Pooggin MM, 1999, J GEN VIROL, V80, P2217, DOI 10.1099/0022-1317-80-8-2217; Pooggin MM, 1998, J VIROL, V72, P4157, DOI 10.1128/JVI.72.5.4157-4169.1998; RAMAIAH KVA, 1992, P NATL ACAD SCI USA, V89, P12063, DOI 10.1073/pnas.89.24.12063; Remm M, 1999, J VIROL, V73, P3062, DOI 10.1128/JVI.73.4.3062-3070.1999; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; Ryabova LA, 2000, GENE DEV, V14, P817; Scharer-Hernandez N, 1998, VIROLOGY, V242, P403, DOI 10.1006/viro.1998.9038; SchmidtPuchta W, 1997, NUCLEIC ACIDS RES, V25, P2854, DOI 10.1093/nar/25.14.2854; Sonstegard TS, 1996, J VIROL, V70, P6642, DOI 10.1128/JVI.70.10.6542-6552.1996; Wang Z, 1998, MOL CELL BIOL, V18, P7528, DOI 10.1128/MCB.18.12.7528; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557	51	44	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17288	17296		10.1074/jbc.M001143200	http://dx.doi.org/10.1074/jbc.M001143200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747993	hybrid			2022-12-27	WOS:000087485000013
J	Suokas, M; Myllyla, R; Kellokumpu, S				Suokas, M; Myllyla, R; Kellokumpu, S			A single C-terminal peptide segment mediates both membrane association and localization of lysyl hydroxylase in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; HUMAN PROLYL 4-HYDROXYLASE; LUMINAL ER PROTEINS; MONOCLONAL-ANTIBODIES; QUALITY-CONTROL; GENE PLOD; RETENTION; RETRIEVAL; CLONING; ISOFORM	Hydroxylation of lysyl residues is crucial for the unique glycosylation pattern found in collagens and for the mechanical strength of fully assembled extracellular collagen fibers. Hydroxylation is catalyzed in the lumen of the endoplasmic reticulum (ER) by a specific enzyme, lysyl hydroxylase (LH). The absence of the known ER-specific retrieval motifs in its primary structure and its association with the ER membranes in vivo have suggested that the enzyme is localized in the ER via a novel retention/retrieval mechanism. We have identified here a 40-amino acid C-terminal peptide segment of LH that is able to convert cathepsin D, normally a soluble lysosomal protease, into a membrane-associated protein. The same segment also markedly slows down the transport of the reporter protein from the ER into post-ER compartments, as assessed by our pulse-chase experiments. The retardation efficiency mediated by this C-terminal peptide segment is comparable with that of the intact LH but lower than that of the KDEL receptor-based retrieval mechanism. Within this 40-amino acid segment, the first 25 amino acids appear to be the most crucial ones in terms of membrane association and ER localization, because the last 15 C-terminal amino acids did not possess substantial retardation activity alone. Our findings thus define a short peptide segment very close to the extreme C terminus of LH as the only necessary determinant both for its membrane association and localization in the ER.	Univ Oulu, Dept Anat & Cell Biol, FIN-90401 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Kellokumpu, S (corresponding author), Univ Oulu, Dept Biochem, PL 5000, FIN-90401 Oulu, Finland.							BRAULKE T, 1987, EUR J CELL BIOL, V43, P316; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; HEIKKINEN J, 1994, GENOMICS, V24, P464, DOI 10.1006/geno.1994.1654; HOYHTYA M, 1984, EUR J BIOCHEM, V141, P477, DOI 10.1111/j.1432-1033.1984.tb08217.x; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; Kellokumpu S, 1997, J BIOL CHEM, V272, P2770, DOI 10.1074/jbc.272.5.2770; KELLOKUMPU S, 1988, SCIENCE, V242, P1308, DOI 10.1126/science.2461589; KELLOKUMPU S, 1994, J BIOL CHEM, V269, P30524; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Parodi AJ, 1999, BBA-GEN SUBJECTS, V1426, P287, DOI 10.1016/S0304-4165(98)00130-5; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; PELHAM HR, 1991, CURR OPIN CELL BIOL, V4, P585; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ruotsalainen H, 1999, MATRIX BIOL, V18, P325, DOI 10.1016/S0945-053X(99)00016-5; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Soriano S, 1997, BIOCHEM J, V324, P579, DOI 10.1042/bj3240579; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; ZHU Y, 1994, J BIOL CHEM, V269, P3846	34	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17863	17868		10.1074/jbc.M908025199	http://dx.doi.org/10.1074/jbc.M908025199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748089	hybrid			2022-12-27	WOS:000087485000090
J	Li-Hawkins, J; Lund, EG; Bronson, AD; Russell, DW				Li-Hawkins, J; Lund, EG; Bronson, AD; Russell, DW			Expression cloning of an oxysterol 7 alpha-hydroxylase selective for 24-hydroxycholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID BIOSYNTHESIS; CHOLESTEROL HOMEOSTASIS; STEROL 27-HYDROXYLASE; CDNA CLONING; HUMAN BRAIN; GENE; CIRCULATION; METABOLISM; 24S-HYDROXYCHOLESTEROL; IDENTIFICATION	The synthesis of 7 alpha-hydroxylated bile acids from oxysterols requires an oxysterol 7 alpha-hydroxylase encoded by the Cyp7b1 locus. As expected, mice deficient in this enzyme have elevated plasma and tissue levels of 25- and 27-hydroxycholesterol; however, levels of another major oxysterol, 24-hydroxycholesterol, are not increased in these mice, suggesting the presence of another oxysterol 7 alpha-hydroxylase. Here, we describe the cloning and char acterization of murine and human cDNAs and genes that encode a second oxysterol 7 alpha-hydroxylase. The genes contain 12 exons and are located on chromosome 6 in the human (CYP39A1 locus) and in a syntenic position on chromosome 17 in the mouse (Cyp39a1 locus). CYP39A1 is a microsomal cytochrome P450 enzyme that has preference for 24-hydroxycholesterol and is expressed in the liver. The levels of hepatic CYP39A1 mRNA do not change in response to dietary cholesterol, bile acids, or a bile acid-binding resin, unlike those encoding other sterol 7 alpha-hydroxylases. Hepatic CYP39A1 expression is sexually dimorphic (female > male), which is opposite that of CYP7B1 (male > female). We conclude that oxysterol 7 alpha-hydroxylases with different substrate specificities exist in mice and humans and that sexually dimorphic expression patterns of these enzymes in the mouse may underlie differences in bile acid metabolism between the sexes.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Russell, DW (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	Russell@utsw.swmed.edu		Russell, David/0000-0002-0277-403X	NHLBI NIH HHS [HL 20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Babiker A, 1999, J LIPID RES, V40, P1417; Bjorkhem I, 1998, J LIPID RES, V39, P1594; Bjorkhem I, 1997, J BIOL CHEM, V272, P30178, DOI 10.1074/jbc.272.48.30178; COHEN JC, 1992, GENOMICS, V14, P153, DOI 10.1016/S0888-7543(05)80298-8; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16536, DOI 10.1074/jbc.M001811200; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Martin KO, 1997, J LIPID RES, V38, P1053; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OGISHIMA T, 1987, J BIOL CHEM, V262, P7646; PAYNE DW, 1995, J BIOL CHEM, V270, P18888, DOI 10.1074/jbc.270.32.18888; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SAUCIER SE, 1993, BIOCHIM BIOPHYS ACTA, V1166, P115, DOI 10.1016/0005-2760(93)90291-G; Schwarz M, 1998, CURR OPIN LIPIDOL, V9, P113, DOI 10.1097/00041433-199804000-00006; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; Setchell KDR, 1998, J CLIN INVEST, V102, P1690, DOI 10.1172/JCI2962; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; Turley SD, 1998, HEPATOLOGY, V28, P1088, DOI 10.1002/hep.510280425; vanNieuwerk CMJ, 1997, J HEPATOL, V26, P138, DOI 10.1016/S0168-8278(97)80020-7; Wu ZL, 1999, J LIPID RES, V40, P2195; ZHANG J, 1995, BBA-LIPID LIPID MET, V1256, P353	27	141	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16543	16549		10.1074/jbc.M001810200	http://dx.doi.org/10.1074/jbc.M001810200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748047	hybrid			2022-12-27	WOS:000087392200022
J	Liu, XY; Robinson, D; Veach, RA; Liu, D; Timmons, S; Collins, RD; Hawiger, J				Liu, XY; Robinson, D; Veach, RA; Liu, D; Timmons, S; Collins, RD; Hawiger, J			Peptide-directed suppression of a pro-inflammatory cytokine response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; NUCLEAR-LOCALIZATION SEQUENCE; TISSUE FACTOR GENE; FACTOR-ALPHA GENE; T-LYMPHOCYTES; SIGNAL-TRANSDUCTION; ENDOTOXIC-SHOCK; DEFICIENT MICE; LIPOPOLYSACCHARIDE	Signal-dependent nuclear translocation of transcription factor nuclear factor kappa B (NF-kappa B) is required for the activation of downstream target genes encoding the mediators of immune and inflammatory responses. To inhibit this inducible signaling to the nucleus, we designed a cyclic peptide (cSN50) containing a cell-permeable motif and a cyclized form of the nuclear localization sequence for the p50-NF-kappa B1 subunit of NF-kappa B. When delivered into cultured macrophages treated with the pro-inflammatory agonist lipopolysaccharide, cSN50 was a more efficient inhibitor of NF-kappa B nuclear import than its linear analog. When delivered into mice challenged with lipopolysaccharide, cSN50 potently blocked the production of proinflammatory cytokines (tumor necrosis factor alpha and interferon gamma) and significantly reduced the lethality associated with ensuing endotoxic shock. Based on specificity studies conducted with a mutated form of cSN50, a functional nuclear localization motif is required for this protective effect. Taken together, our findings demonstrate effective targeting of a cell-permeable peptide that attenuates cytokine signaling in vivo. This new class of biological response modifiers may be applicable to the control of systemic inflammatory reactions.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Hawiger, J (corresponding author), Vanderbilt Univ, Med Ctr, MCN 5326, Nashville, TN 37232 USA.	jacek.hawiger@mcmail.vanderbilt.edu		Veach, Ruth Ann/0000-0003-0038-8802	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054072] Funding Source: NIH RePORTER; NCI NIH HHS [2P30 CA68485-05] Funding Source: Medline; NIDDK NIH HHS [R01 DK54072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abate A, 1998, PROSTAG OTH LIPID M, V56, P277, DOI 10.1016/S0090-6980(98)00061-6; ALEXANDER HR, 1991, J EXP MED, V173, P1029, DOI 10.1084/jem.173.4.1029; Altman DG, 1991, PRACTICAL STAT MED R, P430, DOI Chapman and Hall/CRC; Amiot F, 1997, MOL MED, V3, P864, DOI 10.1007/BF03401722; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; DAWSONSAUNDERS B, 1994, BASIC CLIN BIOSTATIS, P200; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; HAWIGER J, 1994, LUNG BIOL HEALTH DIS, V77, P69; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kovanen PE, 1999, CURR BIOL, V9, pR899, DOI 10.1016/S0960-9822(00)80079-2; KUHNS DB, 1995, J INFECT DIS, V171, P145, DOI 10.1093/infdis/171.1.145; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; REMICK DG, 1990, AM J PATHOL, V136, P49; RICHARDSON RP, 1989, ANN SURG, V210, P239, DOI 10.1097/00000658-198908000-00018; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Torgerson TR, 1998, J IMMUNOL, V161, P6084; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; Zhang LS, 1998, P NATL ACAD SCI USA, V95, P9184, DOI 10.1073/pnas.95.16.9184	42	45	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16774	16778						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10751381				2022-12-27	WOS:000087392200054
J	Somasundaram, T; Bhat, SP				Somasundaram, T; Bhat, SP			Canonical heat shock element in the alpha B-crystallin gene shows tissue-specific and developmentally controlled interactions with heat shock factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; ACTIVATION; EXPRESSION; PROTEIN; LENS; STRESS; OLIGOMERIZATION; INDUCTION; PROMOTER	Oligomerization of the heat shock factor (HSF) and its interaction with the heat shock element (HSE) are the hallmark of active transcriptional response to tangible physical or chemical stress. It is unknown if these interactions are subject to control and modulation by developmental cues and thus have tissue or stage specificity. By using promoter sequences containing a canonical HSE from the alpha B-crystallin gene, we demonstrate a tissue-specific transition from monomeric (in fetal and early neonatal stages that lack oligomeric HSF.HSE complexes) to oligomeric HSF-HSE interactions by postnatal day 10-21 in the ocular lens. Developmental control of these interactions is further demonstrated by induction of oligomeric HSF.HSE complexes in neonatal extracts by in vitro manipulations, interestingly, only in the lens and not in the brain, heart, or liver extracts. The exclusive presence of oligomeric HSF HSE complexes in the postnatal/adult lens corresponds to known highly increased number of alpha B-crystallin transcripts in this tissue.	Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Bhat, SP (corresponding author), Univ Calif Los Angeles, Sch Med, 100 Stein Plaza,Rm BH 623, Los Angeles, CA 90095 USA.							BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUBIN RA, 1990, GENOMICS, V7, P594, DOI 10.1016/0888-7543(90)90204-8; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; FAWCETT TW, 1994, J BIOL CHEM, V269, P32272; FIORENZA MT, 1995, NUCLEIC ACIDS RES, V23, P467, DOI 10.1093/nar/23.3.467; FREDERIKSE PH, 1994, NUCLEIC ACIDS RES, V22, P5686, DOI 10.1093/nar/22.25.5686; GOPALSRIVASTAVA R, 1994, NUCLEIC ACIDS RES, V22, P1281, DOI 10.1093/nar/22.7.1281; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Head MW, 1996, J CELL SCI, V109, P1029; HEIKKILA JJ, 1993, DEV GENET, V14, P87, DOI 10.1002/dvg.1020140202; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; Loones MT, 1997, CELL MOL LIFE SCI, V53, P179, DOI 10.1007/PL00000590; Maniatis T., 1989, MOL CLONING LAB MANU; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Michaud S, 1997, CELL MOL LIFE SCI, V53, P104, DOI 10.1007/PL00000572; Morimoto R I, 1996, EXS, V77, P139; NAGINENI CN, 1992, EXP EYE RES, V54, P193, DOI 10.1016/S0014-4835(05)80208-8; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SRINIVASAN AN, 1994, DNA CELL BIOL, V13, P651, DOI 10.1089/dna.1994.13.651; TAKAHASHI R, 1994, BIOCHEM BIOPH RES CO, V201, P552, DOI 10.1006/bbrc.1994.1737; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Walsh D, 1997, CELL MOL LIFE SCI, V53, P198, DOI 10.1007/PL00000592; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Yoshima T, 1998, J BIOL CHEM, V273, P25466, DOI 10.1074/jbc.273.39.25466; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	43	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17154	17159		10.1074/jbc.M000304200	http://dx.doi.org/10.1074/jbc.M000304200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747896	hybrid			2022-12-27	WOS:000087392200106
J	Maas, T; Eidenmuller, J; Brandt, R				Maas, T; Eidenmuller, J; Brandt, R			Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; DYNAMIC INSTABILITY; ACTIN-FILAMENTS; BUNDLE FORMATION; OKADAIC ACID; BINDING; IDENTIFICATION; KINASE; ORGANIZATION; EXPRESSION	The axonal microtubule-associated phosphoprotein tau interacts with neural plasma membrane (PM) components during neuronal development (Brandt, R., Leger, J., and Lee, G. (1995) J. Cell Biol. 131, 1327-1340). To analyze the mechanism and potential regulation of tau's PM association, a method was developed to isolate PM-associated tau using microsphere separation of surface-biotinylated cells. We show that tan's PM association requires an intact membrane cortex and that PM-associated tau and cytosolic tau are differentially phosphorylated at sites detected by several Alzheimer's disease (AD) diagnostic antibodies (Ser(199)/Ser(202), Thr(231), and Ser(396)/Ser(404)). In polar neurons, the association of endogenous tau phosphoisoforms with the membrane cortex correlates with an enrichment in the axonal compartment. To test for a direct effect of AD-specific tau modifications in determining tau's interactions, a phosphomutant that simulates an AD-like hyperphosphorylation of tau was produced by site-directed mutagenesis of Ser/Thr residues to negatively charged amino acids (Glu). These mutations completely abolish tau's association with the membrane cortex; however, the construct retains its capability to bind to microtubules. The data suggest that a loss of tau's association with the membrane cortex as a result of phosphorylation at sites that are modified during disease contributes to somatodendritic tau accumulation, axonal microtubule disintegration, and neuronal death characteristic for AD.	Heidelberg Univ, IZN, Dept Neurobiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Brandt, R (corresponding author), Heidelberg Univ, IZN, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.	Brandt@sun0.urz.uni-heidelberg.de		Brandt, Roland/0000-0003-0101-1257				BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Black MM, 1996, J NEUROSCI, V16, P3601; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; BRANDT R, 1994, J BIOL CHEM, V269, P11776; BRANDT R, 1993, J BIOL CHEM, V268, P3414; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CARRAWAY C A C, 1992, P123; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CORREAS I, 1990, BIOCHEM J, V269, P61, DOI 10.1042/bj2690061; DITELLA M, 1994, CELL MOTIL CYTOSKEL, V29, P117, DOI 10.1002/cm.970290204; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GRIFFITH LM, 1982, J BIOL CHEM, V257, P9143; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Ilschner S, 1996, GLIA, V18, P129, DOI 10.1002/(SICI)1098-1136(199610)18:2<129::AID-GLIA5>3.3.CO;2-G; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; Kempf M, 1996, J NEUROSCI, V16, P5583; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Kwei SL, 1998, NEUROREPORT, V9, P1035, DOI 10.1097/00001756-199804200-00015; Lee G, 1998, J CELL SCI, V111, P3167; LEE G, 1992, J CELL SCI, V102, P227; Leger J, 1997, J BIOL CHEM, V272, P8441, DOI 10.1074/jbc.272.13.8441; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; Mandelkow EM, 1996, ANN NY ACAD SCI, V777, P96, DOI 10.1111/j.1749-6632.1996.tb34407.x; Mandell JW, 1996, J NEUROSCI, V16, P5727; Mikkola I, 1999, J BIOL CHEM, V274, P15115, DOI 10.1074/jbc.274.21.15115; MORAGA DM, 1993, J NEUROCHEM, V61, P979, DOI 10.1111/j.1471-4159.1993.tb03611.x; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Piontek J, 1999, J NEUROCHEM, V73, P139, DOI 10.1046/j.1471-4159.1999.0730139.x; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SCOTT CW, 1993, BRAIN RES, V611, P237, DOI 10.1016/0006-8993(93)90508-K; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; Wang ZY, 1998, P NATL ACAD SCI USA, V95, P15200, DOI 10.1073/pnas.95.26.15200; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WHITE S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P28, DOI 10.1016/0167-4889(92)90081-L	50	187	191	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15733	15740		10.1074/jbc.M000389200	http://dx.doi.org/10.1074/jbc.M000389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747907	hybrid			2022-12-27	WOS:000087291400020
J	Zajchowski, DA; Kauser, K; Zhu, DG; Webster, L; Aberle, S; White, FA; Liu, HL; Humm, R; MacRobbie, J; Ponte, P; Hegele-Hartung, C; Knauthe, R; Fritzemeier, KH; Vergona, R; Rubanyi, GM				Zajchowski, DA; Kauser, K; Zhu, DG; Webster, L; Aberle, S; White, FA; Liu, HL; Humm, R; MacRobbie, J; Ponte, P; Hegele-Hartung, C; Knauthe, R; Fritzemeier, KH; Vergona, R; Rubanyi, GM			Identification of selective estrogen receptor modulators by their gene expression fingerprints	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; HORMONE REPLACEMENT THERAPY; MESSENGER-RIBONUCLEIC-ACID; RAT PITUITARY-CELLS; OVARIECTOMIZED RATS; REGULATED GENES; RNA LEVELS; IN-VITRO; BINDING; TAMOXIFEN	Clinical studies have shown that estrogen replacement therapy (ERT) reduces the incidence and severity of osteoporosis and cardiovascular disease in postmenopausal women. However, long term estrogen treatment also increases the risk of endometrial and breast cancer. The selective estrogen receptor (ER) modulators (SERMs) tamoxifen and raloxifene, cause antagonistic and agonistic responses when bound to the ER, Their predominantly antagonistic actions in the mammary gland form the rationale for their therapeutic utility in estrogen-responsive breast cancer, while their agonistic estrogen-like effects in bone and the cardiovascular system make them candidates for ERT regimens. Of these two SERMs, raloxifene is preferred because it has markedly less uterine-stimulatory activity than either estrogen or tamoxifen, To identify additional SERMs, a method to classify compounds based on differential gene expression modulation was developed. By analysis of 24 different combinations of genes and cells, a selected set of assays that permitted discrimination between estrogen, tamoxifen, raloxifene, and the pure ER antagonist ICI164384 was generated. This assay panel was employed to measure the activity of 38 compounds, and the gene expression fingerprints (GEFs) obtained for each compound were used to classify all compounds into eight groups, The compound's GEF predicted its uterine-stimulatory activity, One group of compounds was evaluated for activity in attenuating bone loss in ovariectomized rats. Most compounds with similar GEFs had similar in vivo activities, thereby suggesting that GEF-based screens could be useful in predicting a compound's in vivo pharmacological profile.	Berlex Biosci, Dept Canc Res, Richmond, CA 94804 USA; Berlex Biosci, Dept Cardiovasc Res, Richmond, CA 94804 USA; Berlex Biosci, Dept Biol Discovery Res, Richmond, CA 94804 USA; Berlex Biosci, Dept Anim Pharmacol, Richmond, CA 94804 USA; Schering AG, Schering Res Labs, D-13342 Berlin, Germany	Schering AG	Zajchowski, DA (corresponding author), Berlex Biosci, Dept Canc Res, 15049 San Pablo Ave, Richmond, CA 94804 USA.							BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; Bhavnani BR, 1998, P SOC EXP BIOL MED, V217, P6; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; BRANHAM WS, 1995, BIOL REPROD, V53, P863, DOI 10.1095/biolreprod53.4.863; Bryant HU, 1998, P SOC EXP BIOL MED, V217, P45; Cai WZ, 1996, CURR OPIN BIOTECH, V7, P608, DOI 10.1016/S0958-1669(96)80071-1; Diel P, 1995, J STEROID BIOCHEM, V55, P363, DOI 10.1016/0960-0760(95)00186-7; ENGEL LW, 1978, CANCER RES, V38, P4327; EPPENBERGER U, 1991, AM J CLIN ONCOL S2, V14, P5; FRITZEMEIER KH, 1999, HDB EXPT PHARM ESTRO, V135, P54; FUHRMANN U, 1995, CONTRACEPTION, V51, P45, DOI 10.1016/0010-7824(94)00003-F; GEISINGER KR, 1989, CANCER-AM CANCER SOC, V63, P280, DOI 10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N; Genazzani AR, 1999, MATURITAS, V32, P11, DOI 10.1016/S0378-5122(98)00109-1; GOTTARDIS MM, 1989, CANCER RES, V49, P4090; Grainger DJ, 1996, NAT MED, V2, P381, DOI 10.1038/nm0496-381; HALL TJ, 1995, BIOCHEM BIOPH RES CO, V216, P662, DOI 10.1006/bbrc.1995.2673; HAUG E, 1978, MOL CELL ENDOCRINOL, V12, P81, DOI 10.1016/0303-7207(78)90103-X; KALING M, 1990, MOL CELL ENDOCRINOL, V69, P167, DOI 10.1016/0303-7207(90)90010-6; KATZENELLENBOGEN BS, 1984, J STEROID BIOCHEM, V20, P1033, DOI 10.1016/0022-4731(84)90015-3; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KIMURA N, 1994, ENDOCRINOLOGY, V134, P432, DOI 10.1210/en.134.1.432; KORENMANN S, 1970, METHOD ENZYMOL, V36, P49; Liu HLC, 1998, MOL ENDOCRINOL, V12, P1733, DOI 10.1210/me.12.11.1733; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; MARTINOLI MG, 1991, ACTA ENDOCRINOL-COP, V124, P83, DOI 10.1530/acta.0.1240083; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MCDONNELL DP, 1993, J CLIN PHARMACOL, V33, P1165, DOI 10.1002/j.1552-4604.1993.tb03916.x; Mitlak BH, 1999, DRUGS, V57, P653, DOI 10.2165/00003495-199957050-00001; MOLNAR P, 1994, J MOL ENDOCRINOL, V13, P59, DOI 10.1677/jme.0.0130059; NISHINO Y, 1991, J ENDOCRINOL, V130, P409, DOI 10.1677/joe.0.1300409; Parker MG, 1995, VITAM HORM, V51, P267, DOI 10.1016/S0083-6729(08)61041-9; PONS M, 1984, J STEROID BIOCHEM, V20, P137, DOI 10.1016/0022-4731(84)90200-0; Pritchard KI, 1998, RECENT RES CANCER, V152, P22; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; RHODE PR, 1991, MOL CELL ENDOCRINOL, V82, P1, DOI 10.1016/0303-7207(91)90003-B; Rosano GMC, 1999, DRUG AGING, V15, P219, DOI 10.2165/00002512-199915030-00005; Sato M, 1996, FASEB J, V10, P905, DOI 10.1096/fasebj.10.8.8666168; SATO M, 1995, BONE, V17, pS157, DOI 10.1016/8756-3282(95)00288-O; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; WAKELING AE, 1987, J ENDOCRINOL, V112, pR7, DOI 10.1677/joe.0.112R007; WAKELING AE, 1991, CANCER RES, V51, P3867; WESTLEY BR, 1987, NUCLEIC ACIDS RES, V15, P3773, DOI 10.1093/nar/15.9.3773; ZAJCHOWSKI DA, 1991, MOL ENDOCRINOL, V5, P1613, DOI 10.1210/mend-5-11-1613	45	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15885	15894		10.1074/jbc.M909865199	http://dx.doi.org/10.1074/jbc.M909865199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748166	hybrid			2022-12-27	WOS:000087291400039
J	Boyer, JL; Ketner, G				Boyer, JL; Ketner, G			Genetic analysis of a potential zinc-binding domain of the adenovirus E4 34k protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGION-4 34-KILODALTON PROTEIN; PRODUCTIVELY INFECTED-CELLS; P53 TUMOR-SUPPRESSOR; 55-KILODALTON PROTEIN; E4ORF6 PROTEIN; MONOCLONAL-ANTIBODIES; NUCLEAR-LOCALIZATION; TRANSFORMED-CELLS; DNA-REPLICATION; LYTIC INFECTION	E4 34k, the product of adenovirus early region 4 (E4) open reading frame 6, modulates viral late gene expression, viral DNA replication, apoptosis, double strand break repair, and transformation through multiple interactions with components in infected and transformed cells. Conservation of several cysteine and histidine residues among E4 34k sequences from a variety of adenovirus serotypes suggests the presence of a zinc binding domain important for function. Consistent with the hypothesis that E4 34k is a zinc metalloprotein, zinc binding by baculovirus-expressed E4 34k protein was demonstrated in a zinc blotting assay, To investigate the relationship between the potential zinc-binding region and E4 34k function, a series of mutant genes containing single amino acid substitutions at each of the conserved cysteine and histidine residues in E4 34k were constructed. The mutant proteins were examined for the ability to complement the late protein synthetic defect of an E4 deletion mutant, to physically interact with the viral E1b 55-kDa protein (E1b 55k) and cellular p53 protein, to relocalize E1b 55k, and to destabilize the p53 protein, These analyses identified a subset of cysteine and histidine residues required for stimulation of late gene expression, physical interaction with E1b 55k, and p53 destabilization, These data suggest that a zinc-binding domain participates in the formation of the E4 34k-E1b 55k physical complex and that the complex is required in late gene expression and for p53 destabilization.	Johns Hopkins Univ, Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA	Johns Hopkins University	Ketner, G (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Mol Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.	gketner@jhsph.edu			NIAID NIH HHS [AI26239, T32AI07417] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026239, T32AI007417] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BASSET DE, 1995, TRENDS GENET, V11, P372, DOI 10.1016/S0168-9525(00)89109-X; BELTZ GA, 1979, J MOL BIOL, V131, P353, DOI 10.1016/0022-2836(79)90081-0; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Boivin D, 1999, J VIROL, V73, P1245, DOI 10.1128/JVI.73.2.1245-1253.1999; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Boyer J, 1999, VIROLOGY, V263, P307, DOI 10.1006/viro.1999.9866; BRIDGE E, 1990, VIROLOGY, V174, P345, DOI 10.1016/0042-6822(90)90088-9; BRIDGE E, 1993, VIROLOGY, V193, P794, DOI 10.1006/viro.1993.1188; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; CUTT JR, 1987, J VIROL, V61, P543, DOI 10.1128/JVI.61.2.543-552.1987; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HARLOW E, 1999, USING ANTIBODIES LAB, P471; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HEMSTROM C, 1988, J VIROL, V62, P3258; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; JONES DH, 1992, BIOTECHNIQUES, V12, P528; KETNER G, 1989, NUCLEIC ACIDS RES, V17, P3037, DOI 10.1093/nar/17.8.3037; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Medghalchi S, 1997, VIROLOGY, V236, P8, DOI 10.1006/viro.1997.8737; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; NORDQVIST K, 1994, MOL CELL BIOL, V14, P437, DOI 10.1128/MCB.14.1.437; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; Orlando JS, 1999, J VIROL, V73, P4600, DOI 10.1128/JVI.73.6.4600-4610.1999; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SANDLER AB, 1989, J VIROL, V63, P624, DOI 10.1128/JVI.63.2.624-630.1989; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WEIDEN MD, 1994, P NATL ACAD SCI USA, V91, P153, DOI 10.1073/pnas.91.1.153; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	53	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14969	14978		10.1074/jbc.M000566200	http://dx.doi.org/10.1074/jbc.M000566200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747932	hybrid			2022-12-27	WOS:000087128300029
J	Burkart, V; Liu, H; Bellmann, K; Wissing, D; Jaattela, M; Cavallo, MG; Pozzilli, P; Briviba, K; Kolb, H				Burkart, V; Liu, H; Bellmann, K; Wissing, D; Jaattela, M; Cavallo, MG; Pozzilli, P; Briviba, K; Kolb, H			Natural resistance of human beta cells toward nitric oxide is mediated by heat shock protein 70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLET CELLS; DEPENDENT DIABETES-MELLITUS; OXYGEN RADICALS; RAT; EXPRESSION; HSP70; CYTOKINES; APOPTOSIS; INJURY; OVEREXPRESSION	Human beta cells exhibit increased resistance against nitric oxide (NO) radicals as compared with rodent islet cells. Here we tested whether endogenous heat shock protein 70 (hsp70) accounts for the resistance of human cells. Stable transfection of the human beta cell line CM with an antisense hsp70 mRNA-expressing plasmid (ashsp70) caused selective suppression (>95%) of spontaneously expressed hsp70 but not of hsc70 or GRP75 protein. ashsp70 transfection abolished the resistance of CIM cells to the NO donors (Z)-1-(2-(2-aminoethyl)-N-(2-ammonioethyl)amino)diazen-1-ium-1,2-diolate and sodium nitroprusside and increased the proportions of necrotic cells 3-5-fold (p < 0.05) and of apoptotic cells about S-fold (p < 0.01), Re-induction of hsp70 expression by heat shock re-established resistance to NO toxicity. hsp70 did not exert its protective effect at the level of membrane lipid integrity because radical induced lipid peroxidation appeared independent of hsp70 expression. However, after NO exposure only hsp70-deficient cells showed significantly decreased mitochondrial activity, by 40-80% (p < 0.01). These results suggest a key role of hsp70 in the natural resistance of human beta cells against NO induced injury, by preserving mitochondrial function. These findings provide important implications for the development of beta cell protective strategies in type 1 diabetes and islet transplantation.	Univ Dusseldorf, German Diabet Res Inst, Clin Dept, D-40225 Dusseldorf, Germany; Danish Canc Soc, Res Ctr, Div Canc Biol, DK-2100 Copenhagen, Denmark; Univ London St Bartholomews Hosp Med Coll, Dept Diabet & Metab, London EC1A 7BE, England; Univ Dusseldorf, Inst Physiol Chem 1, D-40225 Dusseldorf, Germany	Deutsches Diabetes-Zentrum (DDZ); Heinrich Heine University Dusseldorf; Danish Cancer Society; University of London; Queen Mary University London; Heinrich Heine University Dusseldorf	Kolb, H (corresponding author), Univ Dusseldorf, German Diabet Res Inst, Clin Dept, Hennekamp 65, D-40225 Dusseldorf, Germany.		Jäättelä, Marja/AAT-7932-2021; Pozzilli, Paolo/A-5235-2010	Jäättelä, Marja/0000-0001-5950-7111; cavallo, maria gisella/0000-0001-6630-8049; Briviba, Karlis/0000-0003-3338-7515				Bellmann K, 1997, DIABETES, V46, P232, DOI 10.2337/diabetes.46.2.232; BELLMANN K, 1995, J CLIN INVEST, V95, P2840, DOI 10.1172/JCI117989; Bellmann K, 1996, FEBS LETT, V391, P185, DOI 10.1016/0014-5793(96)00730-2; BURKART V, 1992, DIABETOLOGIA, V35, P1028, DOI 10.1007/BF02221677; Cavallo MG, 1996, J ENDOCRINOL, V150, P113, DOI 10.1677/joe.0.1500113; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Eizirik DL, 1996, HORM METAB RES, V28, P302, DOI 10.1055/s-2007-979799; Eizirik DL, 1996, MOL CELL ENDOCRINOL, V118, P71, DOI 10.1016/0303-7207(96)03768-9; EIZIRIK DL, 1994, P NATL ACAD SCI USA, V91, P9253, DOI 10.1073/pnas.91.20.9253; EIZIRIK DL, 1994, J CLIN INVEST, V93, P1968, DOI 10.1172/JCI117188; GUELI N, 1987, J EXP CLIN CANC RES, V4, P281; GUNTHER E, 1994, EXPERIENTIA, V50, P987, DOI 10.1007/BF01923453; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; JANJIC D, 1992, DIABETOLOGIA, V35, P482, DOI 10.1007/BF02342448; JATTELA M, 1992, EMBO J, V11, P231; KALLMANN B, 1992, LIFE SCI, V51, P671, DOI 10.1016/0024-3205(92)90240-P; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; KOLB H, 1992, DIABETOLOGIA, V35, P796; KOLB H, 1992, IMMUNOL TODAY, V13, P157, DOI 10.1016/0167-5699(92)90118-Q; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LEPAGE G, 1991, ANAL BIOCHEM, V197, P277, DOI 10.1016/0003-2697(91)90392-7; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; Liang P, 1997, J CELL SCI, V110, P1431; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Mauricio D, 1998, DIABETES, V47, P1537, DOI 10.2337/diabetes.47.10.1537; MEHROTRA S, 1991, FREE RADICAL BIO MED, V10, P277, DOI 10.1016/0891-5849(91)90034-Z; Mihara K, 1996, EXPERIENTIA, V52, P1063, DOI 10.1007/BF01952103; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; RABINOVITCH A, 1992, DIABETOLOGIA, V35, P409, DOI 10.1007/BF02342435; Rabinovitch A, 1996, J CLIN ENDOCR METAB, V81, P3197, DOI 10.1210/jc.81.9.3197; Ramakrishna RDN, 1996, BIOCHIM BIOPHYS ACTA, V1289, P195; Robertson JD, 1999, BIOCHEM J, V344, P477, DOI 10.1042/0264-6021:3440477; Segu VBG, 1998, METABOLISM, V47, P824, DOI 10.1016/S0026-0495(98)90120-2; STUART RA, 1994, EXPERIENTIA, V50, P1002, DOI 10.1007/BF01923454; WELSH N, 1995, MOL MED, V1, P806, DOI 10.1007/BF03401895; Wilson GL, 1997, DIABETES, V46, P1291, DOI 10.2337/diabetes.46.8.1291	38	78	82	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19521	19528		10.1074/jbc.M002265200	http://dx.doi.org/10.1074/jbc.M002265200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10751413	hybrid			2022-12-27	WOS:000087941300014
J	Hauser, S; Adelmant, G; Sarraf, P; Wright, HM; Mueller, E; Spiegelman, BM				Hauser, S; Adelmant, G; Sarraf, P; Wright, HM; Mueller, E; Spiegelman, BM			Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-MEDIATED PHOSPHORYLATION; PPAR-GAMMA; ESTROGEN-RECEPTOR; GENE-EXPRESSION; PROTEIN-KINASE; PROTEASOME; DIFFERENTIATION; ALPHA; THIAZOLIDINEDIONES; ADIPOGENESIS	The nuclear hormone receptor peroxisome proliferator-activated receptor (PPAR) gamma is a ligand-activated transcription factor that regulates several crucial biological processes such as adipogenesis, glucose homeostasis, and cell growth. It is also the functional receptor for a new class of insulin-sensitizing drugs, the thiazolidinediones, now widely used in the treatment of type 2 diabetes mellitus. Here we report that PPAR gamma protein levels are significantly reduced in adipose cells and fibroblasts in response to specific ligands such as thiazolidinediones. Studies with several doses of different ligands illustrate that degradation of PPAR gamma correlates well with the ability of ligands to activate this receptor. However, analyses of PPAR gamma mutants show that, although degradation does not strictly depend on the transcriptional activity of the receptor, it is dependent upon the ligand-gated activation function 2 (AF2) domain. Proteasome inhibitors inhibited the down-regulation of PPAR gamma and ligand activation enhanced the ubiquitination of this receptor. These data indicate that, although ligand binding and activation of the AF2 domain increase the transcriptional function of PPAR gamma, these same processes also induce ubiquitination and subsequent degradation of this receptor by the proteasome.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Spiegelman, BM (corresponding author), Dana Farber Canc Inst, 1 Jimmy Fund Way, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu			NIDDK NIH HHS [DKY1305] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Camp HS, 1999, FEBS LETT, V447, P186, DOI 10.1016/S0014-5793(99)00268-9; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Henry RR, 1997, ENDOCRIN METAB CLIN, V26, P553, DOI 10.1016/S0889-8529(05)70267-X; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ricote M, 1999, J LEUKOCYTE BIOL, V66, P733, DOI 10.1002/jlb.66.5.733; Rocchi S, 1999, ANN MED, V31, P342, DOI 10.3109/07853899908995901; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosenbaum SE, 1998, MOL ENDOCRINOL, V12, P1150, DOI 10.1210/me.12.8.1150; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Strous GJ, 1999, J CELL SCI, V112, P1417; Syvala H, 1998, LIFE SCI, V63, P1505, DOI 10.1016/S0024-3205(98)00417-2; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Wu ZD, 1999, CURR OPIN CELL BIOL, V11, P689, DOI 10.1016/S0955-0674(99)00037-X; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; Zhou YC, 1999, J BIOL CHEM, V274, P2672, DOI 10.1074/jbc.274.5.2672; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	40	297	300	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18527	18533		10.1074/jbc.M001297200	http://dx.doi.org/10.1074/jbc.M001297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748014	hybrid, Green Published			2022-12-27	WOS:000087659400084
J	Hong, SY; Yoon, WH; Park, JH; Kang, SG; Ahn, JH; Lee, TH				Hong, SY; Yoon, WH; Park, JH; Kang, SG; Ahn, JH; Lee, TH			Involvement of two NF-kappa B binding elements in tumor necrosis factor alpha, CD40, and Epstein-Barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED FACTOR-1; REED-STERNBERG CELLS; ZINC-FINGER PROTEIN; FACTOR TNF RECEPTOR; BCL-X EXPRESSION; SIGNALING COMPLEX; HODGKINS-DISEASE; LYMPHOID-CELLS; ACTIVATION; DEATH	The antiapoptotic function of NF-kappa B is believed to be mediated through the induction of antiapoptotic genes. Among the antiapoptotic genes, cellular inhibitor of apoptosis protein 2 (c-IAP2/HIAP-1/MHC) is originally identified as a molecule recruited to the tumor necrosis factor (TNF) receptor complex, and its expression is preferentially up-regulated by TNF and other stimuli activating NF-kappa B. However, direct evidence of transcriptional regulation of NF-kappa B on the c-IAP2 gene is still missing. Here, we have cloned and characterized the promoter region required for NF-kappa B-dependent transcription of the c-IAP2 gene. Sequencing of a 3.5-kilobase fragment of the 5'-flanking region of the c-IAP2 gene has identified a TATA-like sequence and potential binding sites for nuclear factor of activated T cells, interferon regulatory factor 1, activator protein 1, glucocorticoid response element, and three putative NF-kappa B binding elements. Deletion and mutational analysis of the 5'-flanking region linked to the luciferase gene revealed that transcriptional activation by TNF or interleukin 1 is mediated cooperatively by two NF-kappa B binding sites. Electrophoretic mobility shift assays characterized that the two NF-kappa B sites can be recognized and bound by the NF-kappa B p50/p65 heterodimer. In addition, the transcription of c-IAP2 promoter was strongly up-regulated when CD40 or Epstein-Barr virus latent membrane protein 1 was overexpressed.	Yonsei Univ, Coll Sci, Dept Biol, Sudaemoon Gu, Seoul 120749, South Korea	Yonsei University	Lee, TH (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Sudaemoon Gu, 134 Shinchon Dong, Seoul 120749, South Korea.			Kang, Seung Goo/0000-0003-3981-1399; Yoon, Wan Hee/0000-0002-9459-3139				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CANTRELL D, 1996, ANNU REV IMMUNOL, V7, P679; Chen F, 1999, J BIOL CHEM, V274, P35591, DOI 10.1074/jbc.274.50.35591; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Craxton A, 1998, J IMMUNOL, V161, P3225; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Durkop H, 1999, BLOOD, V93, P617, DOI 10.1182/blood.V93.2.617.402k14_617_623; Erl W, 1999, CIRC RES, V84, P668, DOI 10.1161/01.RES.84.6.668; Fenton SE, 1996, J BIOL CHEM, V271, P30870, DOI 10.1074/jbc.271.48.30870; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERBST H, 1993, INT J CLIN LAB RES, V23, P13, DOI 10.1007/BF02592274; HOBSON GM, 1990, MOL CELL BIOL, V10, P6533, DOI 10.1128/MCB.10.12.6533; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kim CH, 1995, J INFLAMM, V45, P312; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEE TH, 1993, J BIOL CHEM, V268, P6154; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Messineo C, 1998, BLOOD, V91, P2443, DOI 10.1182/blood.V91.7.2443.2443_2443_2451; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Speiser DE, 1997, J EXP MED, V185, P1777, DOI 10.1084/jem.185.10.1777; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WEN LP, 1997, AM J PHYSIOL, V273, P921; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Young SS, 1999, MAMM GENOME, V10, P44	41	103	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18022	18028		10.1074/jbc.M001202200	http://dx.doi.org/10.1074/jbc.M001202200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10751398	hybrid			2022-12-27	WOS:000087659400017
J	D'Souza, I; Schellenberg, GD				D'Souza, I; Schellenberg, GD			Determinants of 4-repeat tau expression - coordination between enhancing and inhibitory splicing sequences for exon 10 inclusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MULTIPLE-SYSTEM TAUOPATHY; MICROTUBULE-ASSOCIATED PROTEINS; FAMILIAL PRESENILE-DEMENTIA; FRONTOTEMPORAL DEMENTIA; REGULATORY ELEMENTS; ALZHEIMERS-DISEASE; FTDP-17 MUTATIONS; NERVOUS-SYSTEM; CHROMOSOME-17	Mutations in the tau gene are pathogenic causing autosomal dominant frontotemporal dementia with Parkinsonism-chromosome 17 type (FTDP-17). Some mutations in tau exon 10 (E10) and immediately adjacent sequences cause disease by altering E10 splicing. To determine the mechanism of normal E10 splicing regulation and how FTDP-17 mutations alter splicing, mutational analysis of E10 was performed. The results show that E10 contains a complex array of both enhancer and inhibitor cia-acting elements that modulate usage of a weak 5' splice site. The 5' end of E10 contains a previously unrecognized multipartite exon splicing enhancer (ESE) composed of an SC35-like binding sequence, a purine-rich sequence, and an AC-rich element. Downstream of this ESE is a purine-rich exon splicing inhibitor. Intronic sequences immediately downstream of E10 also are inhibitory. The results support an alternative model in which I10 inhibitory sequences appear to function as a linear sequence. The cia-elements described are not redundant, and all appear required for normal E10 splicing. Results with double mutations demonstrate that the ESE and the intronic inhibitory element collaborate to regulate splicing. Thus splicing of tau E10 is regulated by a complex set of cia-acting elements that span nearly the entire exon and also include intronic sequences.	Seattle Div, Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA; Univ Washington, Dept Med, Div Gerontol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Div Geriatr Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Schellenberg, GD (corresponding author), Seattle Div, Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA.				NATIONAL INSTITUTE ON AGING [R01AG011762] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG11762] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; Bugiani O, 1999, J NEUROPATH EXP NEUR, V58, P667, DOI 10.1097/00005072-199906000-00011; BURN TC, 1995, GENE, V161, P183, DOI 10.1016/0378-1119(95)00223-S; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; GOEDERT M, 1992, P NATL ACAD SCI USA, V89, P1983, DOI 10.1073/pnas.89.5.1983; Goedert M, 1996, COLD SPRING HARB SYM, V61, P565; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hasegawa M, 1999, FEBS LETT, V443, P93, DOI 10.1016/S0014-5793(98)01696-2; Hertel KJ, 1996, RNA, V2, P969; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; Murrell JR, 1997, AM J HUM GENET, V61, P1131, DOI 10.1086/301594; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; Si ZH, 1998, MOL CELL BIOL, V18, P5404, DOI 10.1128/MCB.18.9.5404; Spillantini MG, 1996, ACTA NEUROPATHOL, V92, P42, DOI 10.1007/s004010050487; Spillantini MG, 1998, AM J PATHOL, V153, P1359, DOI 10.1016/S0002-9440(10)65721-5; Spillantini MG, 1997, P NATL ACAD SCI USA, V94, P4113, DOI 10.1073/pnas.94.8.4113; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Staffa A, 1997, J BIOL CHEM, V272, P33394, DOI 10.1074/jbc.272.52.33394; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; SUMI SM, 1992, NEUROLOGY, V42, P120, DOI 10.1212/WNL.42.1.120; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TARN WY, 1994, GENE DEV, V8, P2704, DOI 10.1101/gad.8.22.2704; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	35	103	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17700	17709		10.1074/jbc.M909470199	http://dx.doi.org/10.1074/jbc.M909470199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748133	hybrid			2022-12-27	WOS:000087485000070
J	Poe, JC; Fujimoto, M; Jansen, PJ; Miller, AS; Tedder, TF				Poe, JC; Fujimoto, M; Jansen, PJ; Miller, AS; Tedder, TF			CD22 forms a quaternary complex with SHIP, Grb2, and Shc - A pathway for regulation of B lymphocyte antigen receptor-induced calcium flux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; ACTIVATED PROTEIN-KINASE; TYROSINE-PHOSPHORYLATED PROTEIN; SIGNAL-TRANSDUCTION; CELL ACTIVATION; NEGATIVE REGULATOR; CROSS-LINKING; CD22-DEFICIENT MICE; PHOSPHATASE 1C; ASSOCIATION	CD22 is a cell surface molecule that regulates signal transduction in B lymphocytes, Tyrosine-phosphorylated CD22 recruits numerous cytoplasmic effector molecules including SHP-1, a potent phosphotyrosine phosphatase that down-regulates B cell antigen receptor (BCR)- and CD19-generated signals. Paradoxically, B cells from CD22-deficient mice generate augmented intracellular calcium responses following BCR ligation, yet proliferation is decreased. To understand further the mechanisms through which CD22 regulates BCR-dependent calcium flux and proliferation, interactions between CD22 and effector molecules involved in these processes were assessed. The adapter proteins Grb2 and Shc were found to interact with distinct and specific regions of the CD22 cytoplasmic domain. Src homology-2 domain-containing inositol polyphosphate-5'-phosphatase (SHIP) also bound phosphorylated CD22, but binding required an intact CD22 cytoplasmic domain. Ail three molecules were bound to CD22 when isolated from BCR-stimulated splenic B cells, indicating the formation of a CD22 Grb2 Shc SHIP quaternary complex. Therefore, SHIP associating with CD22 may be important for SHIP recruitment to the cell surface where it negatively regulates calcium influx, Although augmented calcium responses in CD22-deficient mice should facilitate enhanced c-Jun N-terminal kinase (JNK) activation, BCR ligation did not induce JNK activation in CD22-deficient B cells. These data demonstrate that CD22 functions as a molecular "scaffold" that specifically coordinates the docking of multiple effector molecules, in addition to SHP-1, in a context necessary for BCR-dependent SHIP activity and JNK stimulation.	Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University	Tedder, TF (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Box 3010, Durham, NC 27710 USA.			Poe, Jonathan/0000-0002-7789-1564; Fujimoto, Manabu/0000-0002-3062-4872	NCI NIH HHS [CA-81776, CA-54464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA054464, R01CA054464, R01CA081776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blasioli J, 1999, J BIOL CHEM, V274, P2303, DOI 10.1074/jbc.274.4.2303; Blery M, 1997, J BIOL CHEM, V272, P8989; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; Chacko GW, 1996, J IMMUNOL, V157, P2234; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; Fujimoto M, 1999, IMMUNITY, V11, P191, DOI 10.1016/S1074-7613(00)80094-1; Fujimoto M, 1999, J IMMUNOL, V162, P7088; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Harmer SL, 1999, J BIOL CHEM, V274, P12183, DOI 10.1074/jbc.274.17.12183; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; LAW CL, 1993, J IMMUNOL, V151, P175; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Sato S, 1998, SEMIN IMMUNOL, V10, P287, DOI 10.1006/smim.1998.0121; Sato S, 1997, P NATL ACAD SCI USA, V94, P13158, DOI 10.1073/pnas.94.24.13158; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; SAXTON TM, 1994, J IMMUNOL, V153, P623; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; Tedder TF, 1998, SEMIN IMMUNOL, V10, P259, DOI 10.1006/smim.1998.0118; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; TORDAI A, 1994, J BIOL CHEM, V269, P7538; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; Tridandapani S, 1997, J IMMUNOL, V158, P1125; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Tuscano J, 1996, BLOOD, V87, P4723, DOI 10.1182/blood.V87.11.4723.bloodjournal87114723; Tuscano JM, 1999, BLOOD, V94, P1382, DOI 10.1182/blood.V94.4.1382.416k14_1382_1392; Tuscano JM, 1996, EUR J IMMUNOL, V26, P1246, DOI 10.1002/eji.1830260610; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; Yohannan J, 1999, J BIOL CHEM, V274, P18769, DOI 10.1074/jbc.274.26.18769	59	94	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17420	17427		10.1074/jbc.M001892200	http://dx.doi.org/10.1074/jbc.M001892200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748054	hybrid			2022-12-27	WOS:000087485000030
J	Kim, T; Kim, TY; Lee, WG; Yim, J; Kim, TK				Kim, T; Kim, TY; Lee, WG; Yim, J; Kim, TK			Signaling pathways to the assembly of an interferon-beta enhanceosome - Chemical genetic studies with a small molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; REGULATORY FACTOR-3; TRANSCRIPTIONAL SYNERGY; MEK KINASE-1; DNA-DAMAGE; IN-VITRO; ACTIVATION; PROTEIN; P53; TRANSDUCTION	Small molecules that modulate specific protein functions are valuable tools for dissecting complex signaling pathways. Here, we identified a small molecule that induces the assembly of the interferon-beta (IFN-beta) enhanceosome by stimulating all the enhancer-binding activator proteins: ATF2/c-JUN, IRF3, and p50/p65 of NF-kappa B. This compound stimulates mitogen-activated protein kinase kinase kinase 1 (MEKK1), which is a member of a family of proteins involved in stress-mediated signaling pathways. Consistent with this, MEKK1 activates IRF3 in addition to ATF2/c-JUN and NF-kappa B for the assembly of the IFN-beta enhanceosome. MEKK1 activates IRF3 through the c-JUN amino-terminal kinase (JNK) pathway but not the p38 and I kappa B kinase (IKK) pathway. Taken together with previous observations, these results implicate that, for the assembly of an IFN-beta enhanceosome, MEKK1 can induce IRF3 and ATF2/c-JUN through the JNK pathway, whereas it can induce NF-kappa B through the IKK pathway. Thus, specific MEKK family proteins may be able to integrate some of multiple signal transduction pathways leading to the specific activation of the IFN-beta enhanceosome.	Seoul Natl Univ, Inst Mol Biol & Genet, Natl Creat Res Initiat Ctr Genet Reprogramming, Seoul 151742, South Korea; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Inst Chem & Cell Biol, Boston, MA 02115 USA	Seoul National University (SNU); Harvard University; Harvard Medical School	Kim, TK (corresponding author), Seoul Natl Univ, Inst Mol Biol & Genet, Natl Creat Res Initiat Ctr Genet Reprogramming, Seoul 151742, South Korea.				NATIONAL CANCER INSTITUTE [P01CA078048] Funding Source: NIH RePORTER; NCI NIH HHS [CA78048] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Crews CM, 1999, TRENDS BIOCHEM SCI, V24, P317, DOI 10.1016/S0968-0004(99)01425-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; Kim TK, 1998, P NATL ACAD SCI USA, V95, P12191, DOI 10.1073/pnas.95.21.12191; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Mitchison TJ, 1994, CHEM BIOL, V1, P3, DOI 10.1016/1074-5521(94)90034-5; Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 2002, MOL CLONING LAB MANU; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schreiber SL, 1998, BIOORGAN MED CHEM, V6, P1127, DOI 10.1016/S0968-0896(98)00126-6; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	41	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16910	16917		10.1074/jbc.M000524200	http://dx.doi.org/10.1074/jbc.M000524200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747925	hybrid			2022-12-27	WOS:000087392200073
J	Baes, M; Huyghe, S; Carmeliet, P; Declercq, PE; Collen, D; Mannaerts, GP; Van Veldhoven, PP				Baes, M; Huyghe, S; Carmeliet, P; Declercq, PE; Collen, D; Mannaerts, GP; Van Veldhoven, PP			Inactivation of the peroxisomal multifunctional protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty acids and bile acid intermediates but also of very long chain fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; RAT-LIVER PEROXISOMES; ACTIVATED RECEPTOR-ALPHA; BETA-OXIDATION; D-3-HYDROXYACYL-COA DEHYDRATASE; ZELLWEGER-SYNDROME; CDNA CLONING; MOLECULAR CHARACTERIZATION; SUBSTRATE SPECIFICITIES; CHOLESTEROL HOMEOSTASIS	According to current views, peroxisomal beta-oxidation is organized as two parallel pathways: the classical pathway that is responsible for the degradation of straight chain fatty acids and a more recently identified pathway that degrades branched chain fatty acids and bile acid intermediates. Multifunctional protein-2 (MFP-2), also called D-bifunctional protein, catalyzes the second (hydration) and third (dehydrogenation) reactions of the latter pathway. In order to further clarify the physiological role of this enzyme in the degradation of fatty carboxylates, MFP-2 knockout mice were generated. MFP-S deficiency caused a severe growth retardation during the first weeks of life, resulting in the premature death of one-third of the MFP-2(-/-) mice. Furthermore, MFP-2-deficient mice accumulated VLCFA in brain and liver phospholipids, immature C-27 bile acids in bile, and, after supplementation with phytol, pristanic and phytanic acid in liver triacylglycerols. These changes correlated with a severe impairment of peroxisomal beta-oxidation of very long straight chain fatty acids (C-24), 2-methyl-branched chain fatty acids, and the bile acid intermediate trihydroxycoprostanic acid in fibroblast cultures or liver homogenates derived from the MFP-2 knockout mice. In contrast, peroxisomal beta-oxidation of long straight chain fatty acids (C-16) was enhanced in liver tissue from MFP-2(-/-) mice, due to the up-regulation of the enzymes of the classical peroxisomal beta-oxidation pathway, The present data indicate that MFP-2 is not only essential for the degradation of 2-methyl-branched fatty acids and the bile acid intermediates di- and trihydroxycoprostanic acid but also for the breakdown of very long chain fatty acids.	Katholieke Univ Leuven, Clin Chem Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Pharmacol Lab, B-3000 Louvain, Belgium; Flemish Inst Biotechnol, Ctr Transgene & Gene Therapy, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Baes, M (corresponding author), Katholieke Univ Leuven, Clin Chem Lab, Herestr 49 O-N, B-3000 Louvain, Belgium.	myriam.baes@uz.kuleuven.ac.be	Carmeliet, Peter/AAQ-5140-2020; , Van Veldhoven Paul/U-6359-2019	Carmeliet, Peter/0000-0001-7961-1821; , Van Veldhoven Paul/0000-0002-4478-2564; Baes, Myriam/0000-0002-2525-2269				ADAMSKI J, 1995, BIOCHEM J, V311, P437, DOI 10.1042/bj3110437; Antonenkov VD, 1997, J BIOL CHEM, V272, P26023, DOI 10.1074/jbc.272.41.26023; Baes M, 1997, NAT GENET, V17, P49, DOI 10.1038/ng0997-49; Baumgart E, 1996, BIOCHEM J, V320, P115, DOI 10.1042/bj3200115; Baumgart E, 1996, P NATL ACAD SCI USA, V93, P13748, DOI 10.1073/pnas.93.24.13748; Bjorkhem I, 1998, J LIPID RES, V39, P1594; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; CASTEELS M, 1994, BIOCHEM PHARMACOL, V48, P1973, DOI 10.1016/0006-2952(94)90596-7; CASTEELS M, 1989, J INHERIT METAB DIS, V12, P415, DOI 10.1007/BF01802036; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUEBAS D, 1999, J INHER METAB DIS S1, V21, P37; DICZFALUSY U, 1990, BIOCHIM BIOPHYS ACTA, V1043, P182, DOI 10.1016/0005-2760(90)90294-8; DieuaideNoubhani M, 1997, BIOCHEM J, V321, P253, DOI 10.1042/bj3210253; DieuaideNoubhani M, 1996, EUR J BIOCHEM, V240, P660, DOI 10.1111/j.1432-1033.1996.0660h.x; DieuaideNoubhani M, 1997, BIOCHEM J, V325, P367, DOI 10.1042/bj3250367; Ellinghaus P, 1999, J BIOL CHEM, V274, P2766, DOI 10.1074/jbc.274.5.2766; Fan CY, 1996, J BIOL CHEM, V271, P24698, DOI 10.1074/jbc.271.40.24698; Hashimoto T, 1999, J BIOL CHEM, V274, P19228, DOI 10.1074/jbc.274.27.19228; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Janssen A, 2000, LAB INVEST, V80, P31, DOI 10.1038/labinvest.3780005; Jiang LL, 1997, J BIOCHEM-TOKYO, V121, P506; Jiang LL, 1996, J BIOCHEM-TOKYO, V120, P624; Kannenberg F, 1999, J BIOL CHEM, V274, P35455, DOI 10.1074/jbc.274.50.35455; LAPIDOT Y, 1967, J LIPID RES, V8, P142; LIBERT R, 1991, CLIN CHEM, V37, P2102; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; Mannaerts GP, 1996, ANN NY ACAD SCI, V804, P99, DOI 10.1111/j.1749-6632.1996.tb18611.x; MANNAERTS GP, 1999, IN PRESS CELL BIOCH; MAO LF, 1994, BIOCHEMISTRY-US, V33, P3320, DOI 10.1021/bi00177a024; Moser AB, 1999, ANN NEUROL, V45, P100, DOI 10.1002/1531-8249(199901)45:1<100::AID-ART16>3.0.CO;2-U; Normand T, 1995, J STEROID BIOCHEM, V55, P541, DOI 10.1016/0960-0760(95)00204-9; Novikov D, 1997, BBA-MOL BASIS DIS, V1360, P229, DOI 10.1016/S0925-4439(97)00003-3; NOVIKOV DK, 1994, J BIOL CHEM, V269, P27125; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; Qi C, 1999, J BIOL CHEM, V274, P15775, DOI 10.1074/jbc.274.22.15775; Qin YM, 1997, BIOCHEM J, V321, P21, DOI 10.1042/bj3210021; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SCHEPERS L, 1990, J BIOL CHEM, V265, P5242; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Suzuki Y, 1997, AM J HUM GENET, V61, P1153, DOI 10.1086/301599; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Une M, 1997, J BIOCHEM-TOKYO, V122, P655; van Grunsven EG, 1998, P NATL ACAD SCI USA, V95, P2128, DOI 10.1073/pnas.95.5.2128; Van Veldhoven PP, 1997, LIPIDS, V32, P1297, DOI 10.1007/s11745-006-0166-1; Vanhooren JCT, 1996, EUR J BIOCHEM, V239, P302, DOI 10.1111/j.1432-1033.1996.0302u.x; VANHOVE GF, 1993, J BIOL CHEM, V268, P10335; VANVELDHOVEN PP, 1994, EUR J BIOCHEM, V222, P795; VANVELDHOVEN PP, 1993, J INHERIT METAB DIS, V16, P381, DOI 10.1007/BF00710285; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; VanVeldhoven PP, 1995, J INHERIT METAB DIS, V18, P125, DOI 10.1007/BF00711435; VANVELDHOVEN PP, 1994, BIOCHEM J, V304, P195, DOI 10.1042/bj3040195; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P24676; VANVELDHOVEN PP, 1992, J BIOL CHEM, V267, P20065; Wanders RJA, 1997, BIOCHEM BIOPH RES CO, V236, P565, DOI 10.1006/bbrc.1997.7007	57	153	164	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16329	16336		10.1074/jbc.M001994200	http://dx.doi.org/10.1074/jbc.M001994200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748062	hybrid			2022-12-27	WOS:000087291400098
J	Einolf, HJ; Guengerich, FP				Einolf, HJ; Guengerich, FP			Kinetic analysis of nucleotide incorporation by mammalian DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; TEMPLATE-PRIMER COMPLEX; REPLICATION-FACTOR-C; CALF THYMUS; STEADY-STATE; SACCHAROMYCES-CEREVISIAE; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; EXCISION-REPAIR; PURIFICATION	The kinetics of nucleotide incorporation into 24/36-mer primer/template DNA by purified fetal calf thymus DNA polymerase (pol) delta was examined using steady-state and pre-steady-state kinetics. The role of the pol delta accessory protein, proliferating cell nuclear antigen (PCNA), on DNA replication by pol delta was also examined by kinetic analysis. The steady-state parameter k(cat) was similar for pol delta in the presence and absence of PCNA (0.36 and 0.30 min(-1), respectively); however, the K-m for dNTP was 20-fold higher in the absence of PCNA (0.067 versus 1.2 mu M), decreasing the efficiency of nucleotide insertion. Pre-steady-state bursts of nucleotide incorporation were observed for pol delta in the presence and absence of PCNA (rates of polymerization (k(pol)) of 1260 and 400 min(-1), respectively). The reduction in polymerization rate in the absence of PCNA was also accompanied by a 2-fold decrease in burst amplitude. The steady-state exonuclease rate of pol delta was 0.56 min(-1) (no burst, 10(3)-fold lower than the rate of polymerization). The small phosphorothioate effect of 2 for correct nucleotide incorporation into DNA by pol delta.PCNA indicated that the rate-limiting step in the polymerization cycle occurs prior to phosphodiester bond formation. A K-d(dNTP) value of 0.93 mu M for pol delta.dNTP binding was determined by pre-steady-state kinetics. A 5-fold increase in K-d(DNA) for the pol delta.DNA complex was measured in the absence of PCNA. We conclude that the major replicative mammalian polymerase, pol delta, exhibits kinetic behavior generally similar to that observed for several prokaryotic model polymerases, particularly a rate-limiting step following product formation in the steady state (dissociation of oligonucleotides) and a rate-limiting step (probably conformational change) preceding phosphodiester bond formation. PCNA appears to affect pol delta replication in this model mainly by decreasing the dissociation of the polymerase from the DNA.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638B Med Res Bldg 1,23rd & Pierce Ave, Nashville, TN 37232 USA.				NCI NIH HHS [F32 CA75731, R35 CA44353] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA075731, R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Benkovic S. J, 1973, ENZYMES, P201; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; Downey KM, 1995, METHOD ENZYMOL, V262, P84; Einolf HJ, 1998, BIOCHEMISTRY-US, V37, P13300, DOI 10.1021/bi981346d; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; Guengerich F. Peter, 1994, P1259; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; Hindges R, 1997, BIOL CHEM, V378, P345; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P635; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kornberg A., 1992, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEGENDRE N, 1993, PRACTICAL GUIDE PROT, P71; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Lowe LG, 1996, BIOCHEMISTRY-US, V35, P9840, DOI 10.1021/bi960485x; McConnell M, 1996, BIOCHEMISTRY-US, V35, P8268, DOI 10.1021/bi9530649; MIZRAHI V, 1985, BIOCHEMISTRY-US, V24, P4010, DOI 10.1021/bi00336a031; Mozzherin DJ, 1999, J BIOL CHEM, V274, P19862, DOI 10.1074/jbc.274.28.19862; NG L, 1991, J BIOL CHEM, V266, P11699; NG L, 1993, J BIOL CHEM, V268, P13571; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; TAN CK, 1986, J BIOL CHEM, V261, P2310; TAN HB, 1994, BIOCHEMISTRY-US, V33, P5335, DOI 10.1021/bi00183a042; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; ZHANG J, 1991, BIOCHEMISTRY-US, V30, P11742, DOI 10.1021/bi00115a002; Zhou JQ, 1996, J BIOL CHEM, V271, P29740, DOI 10.1074/jbc.271.47.29740; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094	44	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16316	16322		10.1074/jbc.M001291200	http://dx.doi.org/10.1074/jbc.M001291200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748013	hybrid			2022-12-27	WOS:000087291400096
J	Moore, LB; Parks, DJ; Jones, SA; Bledsoe, RK; Consler, TG; Stimmel, JB; Goodwin, B; Liddle, C; Blanchard, SG; Willson, TM; Collins, JL; Kliewer, SA				Moore, LB; Parks, DJ; Jones, SA; Bledsoe, RK; Consler, TG; Stimmel, JB; Goodwin, B; Liddle, C; Blanchard, SG; Willson, TM; Collins, JL; Kliewer, SA			Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P450 GENE INDUCTION; SIGNALING PATHWAY; HUMAN HEPATOCYTES; ENHANCER MODULE; CYP2B GENE; CAR; DEFINES; CYP3A4; PXR	Xenobiotics induce the transcription of cytochromes P450 (CYPs) 2B and 3A through the constitutive androstane receptor (CAR; NR1I3) and pregnane X receptor (PXR; NR1I2), respectively, In this report, we have systematically compared a series of xenobiotics and natural steroids for their effects on mouse and human CAR and PXR, Our results demonstrate dual regulation of PXR and CAR by a subset of compounds that affect CYP expression, Moreover, there are marked pharmacological differences between the mouse (m) and human (h) orthologs of both CAR and PXR, For example, the planar hydrocarbon 1,4-bis[2-(3,5-dichloropyridyl-oxy)]benzene activates mCAR and hPXR but has little or no activity on hCAR and mPXR, In contrast, the CAR deactivator androstanol activates both mouse and human PXR, Similarly, the PXR activator clotrimazole is a potent deactivator of hCAR, Using radioligand binding and fluorescence resonance energy transfer assays, we demonstrate that several of the compounds that regulate mouse and human CAR, including natural steroids, bind directly to the receptors, Our results suggest that CAR, like PXR, is a steroid receptor that is capable of recognizing structurally diverse compounds, Moreover, our findings underscore the complexity in the physiologic response to xenobiotics.	Glaxo Wellcome Inc, Res & Dev, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Mol Sci, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA; Univ Sydney, Dept Clin Pharmacol, Westmead Hosp, Westmead, NSW 2145, Australia; Univ Sydney, Storr Liver Unit, Westmead Hosp, Westmead, NSW 2145, Australia	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; University of Sydney; University of Sydney	Kliewer, SA (corresponding author), Glaxo Wellcome Inc, Res & Dev, Dept Mol Endocrinol, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	sak15922@glaxowellcome.com	feinstein, doug/M-9414-2019					BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; KOCAREK TA, 1995, DRUG METAB DISPOS, V23, P415; KOCAREK TA, 1993, BIOCHEM PHARMACOL, V48, P1815; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Nichols JS, 1998, ANAL BIOCHEM, V257, P112, DOI 10.1006/abio.1997.2557; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Strom SC, 1996, METHOD ENZYMOL, V272, P388, DOI 10.1016/S0076-6879(96)72044-X; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351	20	700	730	2	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15122	15127		10.1074/jbc.M001215200	http://dx.doi.org/10.1074/jbc.M001215200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748001	hybrid			2022-12-27	WOS:000087128300049
J	Qiao, DH; Chen, WX; Stratagoules, ED; Martinez, JD				Qiao, DH; Chen, WX; Stratagoules, ED; Martinez, JD			Bile acid-induced activation of activator protein-1 requires both extracellular signal-regulated kinase and protein kinase C signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; COLON-CANCER; GROWTH-FACTOR; URSODEOXYCHOLIC ACID; CELL-PROLIFERATION; GADD153 PROMOTER; AP-1 ACTIVITY; DNA-BINDING; PHOSPHORYLATION; TRANSFORMATION	Elevated concentrations of fecal bile aids are known to promote colon cancer and increasing evidence suggests that alterations in cellular signaling and gene expression may play an important role in this process. In this study, we examined the molecular mechanisms underlying bile acid-mediated gene regulation using GADD153 as our model gene, Promoter deletion analyses revealed that the activator protein-1 (AP-1) transcription factor was crucial for deoxycholic acid (DCA)mediated GADD153 gene transcription. Electrophoretic mobility shift assays and transient transfection analyses demonstrated that both DNA binding and transactivation activities of AP-1 were induced by DCA in a dose-dependent manner. The AP-1 complex induced by DCA consisted of JunD, Fra-1, and c-Fos. Examination of the signaling pathways stimulated by DCA showed that extracellular signal-regulated kinases (ERKs) were required for AP-1 activation. Inhibition of ERK by the mitogen-activated protein kinase/ERK kinase inhibitor PD 98059 or by expression of a dominant negative mutant ERK suppressed AP-1 activation. Notably, the PKC inhibitor, calphostin C, also abolished DCA-induced AP-1 activation but did not affect DCA-mediated ERK activation, suggesting that ERK and PKC function in separate signaling pathways that cooperatively mediate DCA-induced AP-1 activation. Hence, bile acid-stimulated signaling appears to converge on the AP-1 protooncogene.	Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, 1501 N Campbell Ave,POB 245024, Tucson, AZ 85724 USA.				NATIONAL CANCER INSTITUTE [P01CA072008, P30CA023074] Funding Source: NIH RePORTER; NCI NIH HHS [CA-23074, CA-72008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRANTING C, 1995, IN VITRO CELL DEV-AN, V31, P790; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CHEAH PY, 1990, CANCER LETT, V49, P207, DOI 10.1016/0304-3835(90)90160-Y; COHEN BI, 1981, CANCER RES, V41, P3759; CRAVEN PA, 1987, J CLIN INVEST, V79, P532, DOI 10.1172/JCI112844; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322; HIRANO F, 1995, BIOCHEM BIOPH RES CO, V208, P935, DOI 10.1006/bbrc.1995.1424; HUANG XP, 1992, INT J CANCER, V52, P444, DOI 10.1002/ijc.2910520319; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KAIBARA N, 1984, CANCER RES, V44, P5482; KANDELL RL, 1991, NUTR CANCER, V16, P227, DOI 10.1080/01635589109514161; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LUETHY JD, 1992, CANCER RES, V52, P5; Martinez JD, 1998, NUTR CANCER, V31, P111, DOI 10.1080/01635589809514689; Narisawa T, 1999, J EXP CLIN CANC RES, V18, P259; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; Rao YP, 1997, J LIPID RES, V38, P2446; REDDY BS, 1992, LIPIDS, V27, P807, DOI 10.1007/BF02535855; Rosenberger SF, 1999, ONCOGENE, V18, P3626, DOI 10.1038/sj.onc.1202695; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; ROTENBERG SA, 1995, MOL CARCINOGEN, V12, P42, DOI 10.1002/mc.2940120107; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SETH A, 1992, J BIOL CHEM, V267, P24796; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; STRAVITZ RT, 1995, J LIPID RES, V36, P1359; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424; Zheng ZY, 1996, CELL DEATH DIFFER, V3, P407	48	97	98	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15090	15098		10.1074/jbc.M908890199	http://dx.doi.org/10.1074/jbc.M908890199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748108	hybrid			2022-12-27	WOS:000087128300045
J	Warnmark, A; Gustafsson, JA; Wright, APH				Warnmark, A; Gustafsson, JA; Wright, APH			Architectural principles for the structure and function of the glucocorticoid receptor tau 1 core activation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC AMINO-ACIDS; HERPES-SIMPLEX VIRUS; TERMINAL TRANSACTIVATION DOMAIN; STEROID-HORMONE RECEPTORS; BINDING PROTEIN-ALPHA; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; IN-VITRO	A 58-amino acid region mediates the core transactivation activity of the glucocorticoid receptor tau 1 activation domain. This tau 1 core domain is unstructured in aqueous buffers, but in the presence of trifluoroethanol three Alpha-helical segments are induced. Two of these putative structural modules have been tested in different combinations with regard to transactivation potential in vivo and binding capacity to the coactivators in vitro, The results show that whereas single modules are not transcriptionally active, any combination of two or three modules is sufficient, with trimodular constructs having the highest activity. However, proteins containing one, two, or three segments bind Ada2 and cAMP-response element-binding protein with similar affinity. A single segment is thus able to bind a target factor but cannot transactivate target genes significantly. The results are consistent with models in which activation domains are comprised of short activation modules that allow multiple interactions with coactivators. Our results also suggest that an increased number of modules may not result in correspondingly higher affinity but instead that the concentration of binding sites is increased, which gives rise to a higher association rate. This is consistent with a model where the association rate for activator-target factor interactions rather than the equilibrium constant is the most relevant measure of activator potency.	Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden; Sodertorns Hogskola, S-14104 Huddinge, Sweden	Karolinska Institutet; Sodertorn University	Warnmark, A (corresponding author), Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden.		Wright, Anthony/J-8187-2015	Wright, Anthony/0000-0003-1029-9969				Almlof T, 1998, BIOCHEMISTRY-US, V37, P9586, DOI 10.1021/bi973029x; Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BROWN T, 1994, CURRENT PROTOCOLS MO, V1; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DahlmanWright K, 1996, BIOCHEMISTRY-US, V35, P1323, DOI 10.1021/bi952409k; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; Ford J, 1997, MOL ENDOCRINOL, V11, P1467, DOI 10.1210/me.11.10.1467; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Green VJ, 1998, J BIOL CHEM, V273, P29950, DOI 10.1074/jbc.273.45.29950; Henriksson A, 1997, MOL CELL BIOL, V17, P3065, DOI 10.1128/MCB.17.6.3065; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; Jackson BM, 1996, MOL CELL BIOL, V16, P5557; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McEwan IJ, 1996, BIOCHEMISTRY-US, V35, P9584, DOI 10.1021/bi960793v; MCEWAN IJ, 1993, MOL CELL BIOL, V13, P399, DOI 10.1128/MCB.13.1.399; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Shen F, 1996, J BIOL CHEM, V271, P4827; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Sullivan SM, 1998, NUCLEIC ACIDS RES, V26, P4487, DOI 10.1093/nar/26.19.4487; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WRIGHT APH, 1991, P NATL ACAD SCI USA, V88, P8283, DOI 10.1073/pnas.88.19.8283; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; WRIGHT APH, 1991, MOL ENDOCRINOL, V5, P1366, DOI 10.1210/mend-5-10-1366	42	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15014	15018		10.1074/jbc.M001007200	http://dx.doi.org/10.1074/jbc.M001007200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747977	hybrid			2022-12-27	WOS:000087128300035
J	Bonfils, C; Beaulieu, N; Chan, E; Cotton-Montpetit, J; MacLeod, AR				Bonfils, C; Beaulieu, N; Chan, E; Cotton-Montpetit, J; MacLeod, AR			Characterization of the human DNA methyltransferase splice variant Dnmt1b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; MESSENGER-RNA; METHYLATION; EXPRESSION; GENE; CANCER; CELLS; MECHANISM; TARGET; TIME	Tissue- and gene-specific patterns of cytosine-DNA methylation are characteristic features of vertebrate genomes, The generation and proper maintenance of DNA methylation patterns are essential for embryonic development, as demonstrated by the lethal phenotypes of mice with either a targeted disruption of Dnmt1, the gene responsible for the maintenance of DNA methylation, or targeted disruption of Dnmt3a or Dnmt3b, the genes involved in generation of newly formed methylation patterns. Recently, a novel mRNA, Dnmt1b, resulting from alternative splicing of Dnmt1 was identified (Hsu, D. W., Lin, M. J., Lee, T. L., Wen, S. C., Chen, X., and Shen, C. K., (1999) Proc. Natl. Acad Sci. U. S. A. 96, 9751-9756). The abundance of Dnmt1b mRNA was estimated by semiquantitative reverse transcription polymerase chain reaction and was suggested to encode a major C-5 DNA methyltransferase isoform, Here we report characterization of this novel DNA methyltransferase transcript, Dnmt1b, and its protein product in human cell lines and in freshly isolated human peripheral blood mononuclear cells. The abundance of Dnmt1b transcript, as determined by quantitative RNase protection analysis, was determined to range from 6% to 25% of Dnmt1 in human cells. Second generation antisense inhibitors targeted to the 5'- and 3'-ends of Dnmt1 inhibited the accumulation of both Dnmt1 and Dnmt1b in cells. Dnmt1b protein purified from a baculovirus expression system was demonstrated to be a functional DNA methyltransferase, and to have Michaelis constants for both DNA and S-adenosyl-L-methionine similar to baculovirus-expressed Dnmt1, However, antibodies raised against Dnmt1b epitopes demonstrated that Dnmt1b protein was present at approximately 2-5% of the level of Dnmt1 and therefore represents only a minor DNA methyltransferase isoform in human cells.	MethylGene Inc, Montreal, PQ H4S 2A1, Canada	MethylGene Inc	MacLeod, AR (corresponding author), MethylGene Inc, 7220 Frederick Banting, Montreal, PQ H4S 2A1, Canada.	macleodr@methylgene.com						ADAMS RLP, 1979, BIOCHIM BIOPHYS ACTA, V561, P345, DOI 10.1016/0005-2787(79)90143-6; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; Deng J, 1998, J BIOL CHEM, V273, P22869, DOI 10.1074/jbc.273.36.22869; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Gaudet F, 1998, J BIOL CHEM, V273, P32725, DOI 10.1074/jbc.273.49.32725; Glickman JF, 1997, BIOCHEM BIOPH RES CO, V230, P280, DOI 10.1006/bbrc.1996.5943; Hsu DW, 1999, P NATL ACAD SCI USA, V96, P9751, DOI 10.1073/pnas.96.17.9751; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; Ramchandani S, 1998, BIOL CHEM, V379, P535; Razin A., 1993, Experientia Supplementum (Basel), V64, P343; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Scott PAE, 1998, BRIT J CANCER, V77, P2120, DOI 10.1038/bjc.1998.356; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; Souaze F, 1996, BIOTECHNIQUES, V21, P280; SZYF M, 1991, J BIOL CHEM, V266, P10027; Szyf M, 1996, PHARMACOL THERAPEUT, V70, P1, DOI 10.1016/0163-7258(96)00002-2; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Yeivin A, 1993, EXS, V64, P523; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125; Zimmermann K, 1996, BIOTECHNIQUES, V21, P268	38	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2000	275	15					10754	10760		10.1074/jbc.275.15.10754	http://dx.doi.org/10.1074/jbc.275.15.10754			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304DB	10753866	hybrid			2022-12-27	WOS:000086466600008
J	Califano, D; Rizzo, C; D'Alessio, A; Colucci-D'Amato, GL; Cali, G; Bartoli, PC; Santelli, G; Vecchio, G; de Franciscis, V				Califano, D; Rizzo, C; D'Alessio, A; Colucci-D'Amato, GL; Cali, G; Bartoli, PC; Santelli, G; Vecchio, G; de Franciscis, V			Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; NERVE GROWTH-FACTOR; NEOPLASIA TYPE 2B; ADAPTER PROTEINS; ACTIVATION; MUTATION; PROTOONCOGENE; GENE; STIMULATION; EXPRESSION	Specific germline mutations of the receptor tyrosine kinase, Ret, predispose to multiple endocrine neoplasia types 2A and 2B and familial medullary thyroid carcinoma. The mechanisms by which different Ret isoforms (Ret-2A and Ret-2B) cause distinct neoplastic diseases remain largely unknown. On the other hand, forced expression of these mutated versions of Ret induces the rat pheochromocytoma cell line, PC12, to differentiate. Here we used an inducible vector encoding a dominant-negative Ras (Ras p21(N17)) to investigate the contributions of the Ras pathway to the phenotype induced in PC12 cells by the expression of either Ret-2A or Ret-2B mutants. We show that the Ret-induced molecular and morphological changes are both mediated by Ras-dependent pathways. However, even though inhibition of Ras activity was sufficient to revert Ret-induced differentiation, the kinetics of morphological reversion of the Ret-2B- was more rapid than the Ret-SA-transfected cells, Further, we show that in Ret-transfected cells the suc1-associated neurotrophic factor-induced tyrosine phosphorylation target, SNT, is chronically phosphorylated in tyrosine residues, and associates with the Sos substrate. These results indicate the activation of the Res cascade as an essential pathway triggered by the chronic active Ret mutants in PC12 cells, Moreover, our data indicate SNT as a substrate for both Ret mutants, which might mediate the activation of this cascade.	Univ Naples Federico II, CNR,Ctr Endocrinol & Oncol Sperimentale, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Fdn G Pascale, Ist Nazl Tumori, I-80131 Naples, Italy; CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Fondazione Pascale; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	de Franciscis, V (corresponding author), Univ Naples Federico II, CNR,Ctr Endocrinol & Oncol Sperimentale, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.		Califano, Daniela/Y-6313-2018	Califano, Daniela/0000-0001-6945-3209	Telethon [A.097] Funding Source: Medline	Telethon(Fondazione Telethon)		Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; Borrello MG, 1995, ONCOGENE, V11, P2419; CALIFANO D, 1995, ONCOGENE, V11, P107; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Colucci-D'Amato GL, 2000, J BIOL CHEM, V275, P19306, DOI 10.1074/jbc.275.25.19306; ColucciDAmato GL, 1996, CELL GROWTH DIFFER, V7, P1081; DALESSIO A, 1995, CELL GROWTH DIFFER, V6, P1387; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Rizzo C, 1996, J BIOL CHEM, V271, P29497, DOI 10.1074/jbc.271.46.29497; Rosenthal A, 1999, NEURON, V22, P201, DOI 10.1016/S0896-6273(00)81077-6; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; SMITH TD, 1994, HIST PHOTOGR, V18, P13, DOI 10.1080/03087298.1994.10442325; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAHIRA T, 1990, ONCOGENE, V5, P97; TSUZUKI T, 1995, ONCOGENE, V10, P191; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang JK, 1996, ONCOGENE, V13, P721	41	45	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19297	19305		10.1074/jbc.M905866199	http://dx.doi.org/10.1074/jbc.M905866199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10748077	hybrid			2022-12-27	WOS:000087815900089
J	Flanary, PL; DiBello, PR; Estrada, P; Dohlman, HG				Flanary, PL; DiBello, PR; Estrada, P; Dohlman, HG			Functional analysis of plp1 and plp2, two homologues of phosducin in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR KINASE; HETEROTRIMERIC G-PROTEINS; SACCHAROMYCES-CEREVISIAE; PHOTORECEPTOR CELLS; CRYSTAL-STRUCTURE; BINDING DOMAIN; RGS PROTEINS; PHOSPHORYLATION; TRANSDUCIN	Mammalian phosducins are known to bind G protein beta gamma subunits in vitro, and are postulated to regulate their signaling function in vivo. Here we describe two homologues of phosducin in yeast, called PLP1 and PLP2. Both gene products were cloned, expressed, and purified as glutathione S-transferase fusions. Of the two isoforms, Plp1 bound most preferentially to G beta gamma. Binding was enhanced by pheromone stimulation and by the addition of GTP gamma S, conditions that favor dissociation of G beta gamma from G alpha. Gene disruption mutants and gene over expression plasmids were prepared and analyzed for changes in signaling and non-signaling phenotypes. Haploid spore products bearing the plp2 Delta mutant failed to grow, suggesting that PLP2 is an essential gene. Cell viability was not restored bg a mutation in STE7 that blocks signaling downstream of the G protein. Haploid products bearing the plp1 Delta mutant were viable and exhibited a 6-7% increase in pheromone-mediated gene induction. Cells overexpressing PLP1 or PLP2 exhibited a 70-80% decrease in gene induction but no change in pheromone-mediated growth arrest. These data indicate that phosducin can selectively regulate early signaling events following pheromone stimulation and has an essential role in cell growth independent of its regulatory role in cell signaling.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cell Biol, New Haven, CT 06536 USA	Yale University; Yale University	Dohlman, HG (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA.	henrik.dohlman@yale.edu		Dohlman, Henrik/0000-0003-2443-0729	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055316, R29GM055316, R01GM059167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007136] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55316, R01 GM059167, R01 GM055316, GM59167] Funding Source: Medline; NINDS NIH HHS [T32-NS07136] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Barhite S, 1998, BBA-MOL CELL RES, V1402, P95, DOI 10.1016/S0167-4889(97)00141-9; Bauer PH, 1998, J BIOL CHEM, V273, P9465, DOI 10.1074/jbc.273.16.9465; Bauer PH, 1998, N-S ARCH PHARMACOL, V357, P371, DOI 10.1007/PL00005181; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; Boekhoff I, 1997, J BIOL CHEM, V272, P4606, DOI 10.1074/jbc.272.7.4606; Bohm A, 1997, CURR OPIN BIOTECH, V8, P480, DOI 10.1016/S0958-1669(97)80072-9; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; CRAFT CM, 1991, GENOMICS, V10, P400, DOI 10.1016/0888-7543(91)90325-9; Craft CM, 1998, BIOCHEMISTRY-US, V37, P15758, DOI 10.1021/bi980921a; Danner S, 1996, P NATL ACAD SCI USA, V93, P10145, DOI 10.1073/pnas.93.19.10145; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Dohlman HG, 1998, SEMIN CELL DEV BIOL, V9, P135, DOI 10.1006/scdb.1998.0218; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAWES BE, 1994, J BIOL CHEM, V269, P29825; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kasahara S, 2000, P NATL ACAD SCI USA, V97, P412, DOI 10.1073/pnas.97.1.412; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUO CH, 1993, BIOCHEM BIOPH RES CO, V191, P1097, DOI 10.1006/bbrc.1993.1329; KUO CH, 1989, MOL BRAIN RES, V6, P1, DOI 10.1016/0169-328X(89)90022-3; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE RH, 1990, J BIOL CHEM, V265, P15867; LEE RH, 1990, EXP EYE RES, V51, P325, DOI 10.1016/0014-4835(90)90029-T; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1988, EXP EYE RES, V46, P829, DOI 10.1016/S0014-4835(88)80035-6; LEE RH, 1992, J BIOL CHEM, V267, P25104; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; LOLLEY RN, 1977, BIOCHEM BIOPH RES CO, V78, P572, DOI 10.1016/0006-291X(77)90217-0; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; Muller S, 1996, J BIOL CHEM, V271, P11781, DOI 10.1074/jbc.271.20.11781; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Sarvazyan NA, 1998, J BIOL CHEM, V273, P7934, DOI 10.1074/jbc.273.14.7934; Schroder S, 1997, FEBS LETT, V401, P243, DOI 10.1016/S0014-5793(96)01483-4; Schroder S, 1996, P NATL ACAD SCI USA, V93, P2100, DOI 10.1073/pnas.93.5.2100; Schulz K, 1996, J BIOL CHEM, V271, P22546, DOI 10.1074/jbc.271.37.22546; SIKORSKI RS, 1989, GENETICS, V122, P19; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Tanaka H, 1997, NEUROCHEM INT, V31, P625, DOI 10.1016/S0197-0186(96)00053-8; Tanaka H, 1996, BIOCHEM BIOPH RES CO, V223, P587, DOI 10.1006/bbrc.1996.0939; Thibault C, 1997, J BIOL CHEM, V272, P12253, DOI 10.1074/jbc.272.19.12253; UEDA N, 1994, J BIOL CHEM, V269, P4388; Wilkins JF, 1996, J BIOL CHEM, V271, P19232, DOI 10.1074/jbc.271.32.19232; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050; Zhu X, 1998, Mol Vis, V4, P13	63	51	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18462	18469		10.1074/jbc.M002163200	http://dx.doi.org/10.1074/jbc.M002163200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10749875	hybrid			2022-12-27	WOS:000087659400075
J	Geraghty, DS; Ding, M; Heintz, NH; Pederson, DS				Geraghty, DS; Ding, M; Heintz, NH; Pederson, DS			Premature structural changes at replication origins in a yeast minichromosome maintenance (MCM) mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC7 PROTEIN-KINASE; CELL-CYCLE REGULATION; SIMIAN VIRUS 40; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; S-PHASE; BUDDING YEAST; IN-VIVO; RECOGNITION COMPLEX; THYMIDYLATE KINASE	The Cdc7p protein kinase in the budding yeast Sac charomgces cerevisiae is thought to help trigger DNA replication by modifying one or more of the factors that assemble at replication origins (ARSs), To investigate events catalyzed by Cdc7p, we compared the structure of replication origins in cells containing conditional mutations in Cdc7p and Cdc8p, a thymidylate kinase that is required for DNA synthesis. High resolution genomic footprinting indicated that the presumptive lagging strand template in ARSI became highly sensitive to KMnO4 modification after the CDC7 execution point. These results suggested that Cdc7p triggers DNA unwinding. The transition from late G(1) phase to the CDC7 execution point and from the CDC7 to the CDC8 execution points was accompanied by small but ARS-dependent changes in DNA topology. These results suggested that DNA unwinding before the CDC8 execution point either is highly localized or that the torsional stress associated with initial DNA unwinding is minimized by compensatory protein-DNA structural changes, The ARS DNA structural attributes evident in cells blocked at the CDC8 execution point were also evident in alpha-factor-blocked, G(1) phase cells containing the CDC7 bypass mutant mcm5/cdc46-bob1. This result strongly suggests that the structural changes during the transition from the CDC7 to CDC8 execution points depend on the Cdc7p protein kinase and involve alteration of the minichromosome maintenance protein complex.	Univ Vermont, Sch Med, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; Univ Vermont, Sch Med, Dept Pathol, Burlington, VT 05405 USA; Univ Vermont, Sch Med, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont; University of Vermont; University of Vermont	Pederson, DS (corresponding author), Univ Vermont, Sch Med, Dept Microbiol & Mol Genet, Staford Hall,Rm 302, Burlington, VT 05405 USA.	dpederso@zoo.uvm.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BAUER W, 1968, J MOL BIOL, V33, P141, DOI 10.1016/0022-2836(68)90286-6; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bielinsky AK, 1999, MOL CELL, V3, P477, DOI 10.1016/S1097-2765(00)80475-X; Bielinsky AK, 1998, SCIENCE, V279, P95, DOI 10.1126/science.279.5347.95; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; BROWN JA, 1991, MOL CELL BIOL, V11, P5301, DOI 10.1128/MCB.11.10.5301; CAMPBELL JL, 1991, MOL CELLULAR BIOL YE, V1, P41; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; CHAPMAN JW, 1989, EXP CELL RES, V67, P389; CHEN JJ, 1993, J BIOL CHEM, V268, P7442; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; DEAN FB, 1991, J BIOL CHEM, V266, P5062; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Geraghty DS, 1998, J BIOL CHEM, V273, P20463, DOI 10.1074/jbc.273.32.20463; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; Haase SB, 1997, METHOD ENZYMOL, V283, P322; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; HARTWELL LH, 1971, J MOL BIOL, V59, P183, DOI 10.1016/0022-2836(71)90420-7; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HEREFORD LM, 1971, NATURE-NEW BIOL, V234, P171, DOI 10.1038/newbio234171a0; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; JONG AYS, 1984, J BIOL CHEM, V259, P4394; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; KUO CL, 1982, P NATL ACAD SCI-BIOL, V79, P4243, DOI 10.1073/pnas.79.14.4243; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MATSUZAKI H, 1990, J BACTERIOL, V172, P610, DOI 10.1128/jb.172.2.610-618.1990; MCCARTHY JG, 1991, NUCLEIC ACIDS RES, V19, P3421, DOI 10.1093/nar/19.12.3421; Mirabella A, 1997, EMBO J, V16, P523, DOI 10.1093/emboj/16.3.523; MORSE RH, 1987, NUCLEIC ACIDS RES, V15, P10311, DOI 10.1093/nar/15.24.10311; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NATALE DA, 1992, P NATL ACAD SCI USA, V89, P2654, DOI 10.1073/pnas.89.7.2654; Newlon CS, 1997, CELL, V91, P717, DOI 10.1016/S0092-8674(00)80459-6; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; Oshiro G, 1999, MOL CELL BIOL, V19, P4888; Park K, 1998, J BIOL CHEM, V273, P24906, DOI 10.1074/jbc.273.38.24906; Park K, 1998, J BIOL CHEM, V273, P5260, DOI 10.1074/jbc.273.9.5260; PEDERSON DS, 1986, P NATL ACAD SCI USA, V83, P7206, DOI 10.1073/pnas.83.19.7206; Peter BJ, 1998, CELL, V94, P819, DOI 10.1016/S0092-8674(00)81740-7; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; REDDY GPV, 1978, J BIOL CHEM, V253, P3461; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; Roberts BT, 1999, P NATL ACAD SCI USA, V96, P2800, DOI 10.1073/pnas.96.6.2800; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCLAFANI RA, 1984, P NATL ACAD SCI-BIOL, V81, P5821, DOI 10.1073/pnas.81.18.5821; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; TAHERI MR, 1981, BIOCHEM J, V196, P225, DOI 10.1042/bj1960225; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; UMEK RM, 1990, NUCLEIC ACIDS RES, V18, P6601, DOI 10.1093/nar/18.22.6601; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; YOON HJ, 1991, P NATL ACAD SCI USA, V88, P3574, DOI 10.1073/pnas.88.9.3574; YOON HJ, 1993, MOL BIOL CELL, V4, P195, DOI 10.1091/mbc.4.2.195; You ZY, 1999, MOL CELL BIOL, V19, P8003; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	83	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18011	18021		10.1074/jbc.M909787199	http://dx.doi.org/10.1074/jbc.M909787199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10751424	hybrid			2022-12-27	WOS:000087659400016
J	Li, T; Yang, CT; Jin, DY; Stafford, DW				Li, T; Yang, CT; Jin, DY; Stafford, DW			Identification of a Drosophila vitamin K-dependent gamma-glutamyl carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-S; RECOGNITION SITE; PROPEPTIDE; GAS6; ANTICOAGULATION; SNAIL	Using reduced vitamin K, oxygen, and carbon dioxide, gamma-glutamyl carboxylase post-translationally modifies certain glutamates by adding carbon dioxide to the gamma position of those amino acids. In vertebrates, the modification of glutamate residues of target proteins is facilitated by an interaction between a propeptide present on target proteins and the gamma-glutamyl carboxylase, Previously, the gastropod Conus was the only known invertebrate with a demonstrated vitamin K-dependent carboxylase. We report here the discovery of a gamma-glutamyl carboxylase in Drosophila, This Drosophila enzyme is remarkably similar in amino acid sequence to the known mammalian carboxylases; it has 33% sequence identity and 45% sequence similarity to human gamma-glutamyl carboxylase, The Drosophila carboxylase is vitamin K-dependent, and it has a K-m toward a model pentapeptide substrate, FLEEL, of about 4 mM. However, unlike the human gamma-glutamyl carboxylase, it is not stimulated by human blood coagulation factor IX propeptides. We found the mRNA for Drosophila gamma-glutamyl carboxylase in virtually every embryonic and adult stage that we investigated, with the highest concentration evident in the adult head.	Univ N Carolina, Dept Biol, Ctr Thrombosis & Hemostasis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Stafford, DW (corresponding author), Univ N Carolina, Dept Biol, Ctr Thrombosis & Hemostasis, Chapel Hill, NC 27599 USA.							Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Bush KA, 1999, BIOCHEMISTRY-US, V38, P14660, DOI 10.1021/bi991640l; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; Furie BC, 1997, J BIOL CHEM, V272, P28258, DOI 10.1074/jbc.272.45.28258; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Li RH, 1996, J NEUROSCI, V16, P2012; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MALICKI J, 1992, NATURE, V358, P345, DOI 10.1038/358345a0; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Nevill-Manning CG, 1998, P NATL ACAD SCI USA, V95, P5865, DOI 10.1073/pnas.95.11.5865; Olivera BM, 1999, ANN NY ACAD SCI, V870, P223, DOI 10.1111/j.1749-6632.1999.tb08883.x; Price P A, 1989, Connect Tissue Res, V21, P51, DOI 10.3109/03008208909049995; ROTH DA, 1995, J BIOL CHEM, V270, P5305, DOI 10.1074/jbc.270.10.5305; Sambrook J., 2002, MOL CLONING LAB MANU; Simmonds RE, 1998, ANN INTERN MED, V128, P8, DOI 10.7326/0003-4819-128-1-199801010-00002; Stanley TB, 1997, FEBS LETT, V407, P85, DOI 10.1016/S0014-5793(97)00299-8; Stanley TB, 1998, BIOCHEMISTRY-US, V37, P13262, DOI 10.1021/bi981031y; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Wu SM, 1997, J BIOL CHEM, V272, P11718, DOI 10.1074/jbc.272.18.11718; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236; Xu JA, 1998, PROTEIN SCI, V7, P158, DOI 10.1002/pro.5560070117	23	46	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18291	18296		10.1074/jbc.M001790200	http://dx.doi.org/10.1074/jbc.M001790200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10748045	Green Published, hybrid			2022-12-27	WOS:000087659400053
J	Hogan, KA; Gorkun, OV; Lounes, KC; Coates, AI; Weisel, JW; Hantgan, RR; Lord, ST				Hogan, KA; Gorkun, OV; Lounes, KC; Coates, AI; Weisel, JW; Hantgan, RR; Lord, ST			Recombinant fibrinogen Vlissingen/Frankfurt IV - The deletion of residues 319 and 320 from the gamma chain of fibrinogen alters calcium binding, fibrin polymerization, cross-linking and platelet aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-PRO-AMIDE; ELECTRON-MICROSCOPY; LATERAL AGGREGATION; LIGHT-SCATTERING; FIBRINOPEPTIDE-B; FRAGMENT-D; SITE; PEPTIDES; SEQUENCE; CHROMATOGRAPHY	We synthesized a variant, recombinant fibrinogen modeled after the heterozygous dysfibrinogen Vlissingen/Frankfurt IV, a deletion of two residues, gamma Asn-319 and gamma Asp-320, located within the high affinity calcium-binding pocket. Turbidity studies showed no evidence of fibrin polymerization, although size exclusion chromatography, transmission electron microscopy, and dynamic light scattering studies showed small aggregates. These aggregates did not resemble normal protofibrils nor did they clot. Fibrinopeptide A release was normal, whereas fibrinopeptide B release was delayed approximately 3-fold. Plasmin cleavage of this fibrinogen was not changed by the presence of calcium or Gly-Pro-Arg-Pro, indicating that both the calcium-binding site and the "a" polymerization site were non-functional. We conclude that the loss of normal polymerization was due to the lack of "A-a" interactions. Moreover, functions associated with the C-terminal end of the gamma chain, such as platelet aggregation and factor XIII cross-linking, were also disrupted, suggesting that this deletion of two residues affected the overall structure of the C-terminal domain of the gamma chain.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC 27157 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; Wake Forest University; Wake Forest Baptist Medical Center	Lord, ST (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Rm 603,Brinkhous-Bullitt Bldg,CB 7525, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [HL 31048, HL 52706, HL 30954] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031048, R01HL030954, R23HL031048, R01HL052706] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berne B, 1990, DYNAMIC LIGHT SCATTE; BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; Blomback B, 1996, THROMB RES, V83, P1, DOI 10.1016/0049-3848(96)00111-9; Brown JH, 2000, P NATL ACAD SCI USA, V97, P85, DOI 10.1073/pnas.97.1.85; BUDZYNSKI AZ, 1980, P NATL ACAD SCI USA, V77, P1374; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Everse SJ, 1999, BIOCHEMISTRY-US, V38, P2941, DOI 10.1021/bi982626w; FERRY JD, 1952, P NATL ACAD SCI USA, V38, P566, DOI 10.1073/pnas.38.7.566; FOWLER WE, 1981, P NATL ACAD SCI-BIOL, V78, P4872, DOI 10.1073/pnas.78.8.4872; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; GALANAKIS DK, 1993, THROMB HAEMOSTASIS, V69, P1261; GORKUN OV, 1994, BIOCHEMISTRY-US, V33, P6986, DOI 10.1021/bi00188a031; Gorkun OV, 1997, BLOOD, V89, P4407, DOI 10.1182/blood.V89.12.4407; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; HANTGAN RR, 1993, BIOCHEMISTRY-US, V32, P3935, DOI 10.1021/bi00066a013; HASEGAWA N, 1990, THROMB RES, V57, P183, DOI 10.1016/0049-3848(90)90318-7; HAVERKATE F, 1977, THROMB RES, V10, P803, DOI 10.1016/0049-3848(77)90137-2; Hogan KA, 2000, THROMB HAEMOSTASIS, V83, P592, DOI 10.1055/s-0037-1613869; JOHNSON CS, 1981, SPECTROSCOPY BIOCH, V2, P177; KLOCZEWIAK M, 1989, BIOCHEMISTRY-US, V28, P2915, DOI 10.1021/bi00433a025; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KNOLL DA, 1983, APPL LIGHT SCATTERIN; KOOPMAN J, 1991, J BIOL CHEM, V266, P13456; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; Lord ST, 1996, BIOCHEMISTRY-US, V35, P2342, DOI 10.1021/bi952353u; MARGUERIE G, 1977, BIOCHIM BIOPHYS ACTA, V490, P94, DOI 10.1016/0005-2795(77)90109-X; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MEDVED L, 1990, J MOL BIOL, V216, P503, DOI 10.1016/0022-2836(90)90376-W; MEDVED LV, 1993, FEBS LETT, V320, P239, DOI 10.1016/0014-5793(93)80594-K; MOSESSON MW, 1987, BLOOD, V69, P1073; NG AS, 1993, METHOD ENZYMOL, V222, P341; NIEUWENHUIZEN W, 1983, ANN NY ACAD SCI, V408, P92, DOI 10.1111/j.1749-6632.1983.tb23236.x; Okumura N, 1997, J BIOL CHEM, V272, P29596, DOI 10.1074/jbc.272.47.29596; Pratt KP, 1997, P NATL ACAD SCI USA, V94, P7176, DOI 10.1073/pnas.94.14.7176; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; Rooney MM, 1996, J BIOL CHEM, V271, P8553, DOI 10.1074/jbc.271.15.8553; SHAINOFF JR, 1979, SCIENCE, V204, P200, DOI 10.1126/science.155308; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; Ware S, 1999, PROTEIN SCI, V8, P2663, DOI 10.1110/ps.8.12.2663; WEISEL JW, 1986, BIOPHYS J, V50, P1079, DOI 10.1016/S0006-3495(86)83552-4; WEISEL JW, 1993, J MOL BIOL, V232, P285, DOI 10.1006/jmbi.1993.1382; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; YAMAZUMI K, 1992, PROTEIN SCI, V1, P1719, DOI 10.1002/pro.5560011220; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8	52	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17778	17785		10.1074/jbc.M001618200	http://dx.doi.org/10.1074/jbc.M001618200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10748039	hybrid			2022-12-27	WOS:000087485000079
J	McLachlin, DT; Coveny, AM; Clark, SM; Dunn, SD				McLachlin, DT; Coveny, AM; Clark, SM; Dunn, SD			Site-directed cross-linking of b to the alpha, beta, and a subunits of the Escherichia coli ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; DELTA-SUBUNIT; F1 ATPASE; 2ND STALK; MONOCLONAL-ANTIBODIES; MOLECULAR GRAPHICS; F1F0-ATP SYNTHASE; H+-ATPASE; F-0; BINDING	The b subunit dimer of the Escherichia coli ATP synthase, along with the delta subunit, is thought to act as a stator to hold the alpha(3)beta(3) hexamer stationary relative to the a subunit as the gamma is an element of c(9-12) complex rotates. Despite their essential nature, the contacts between b and the alpha, beta, and a subunits remain largely undefined. We have introduced cysteine residues individually at various positions within the wild type membrane-bound b subunit, or within b(24)-(156), a truncated, soluble version consisting only of the hydrophilic C-terminal domain. The introduced cysteine residues were modified with a photoactivatable cross-linking agent, and cross-linking to subunits of the F-1 sector or to complete F1F0 was attempted. Cross-linking in both the full-length and truncated forms of b was obtained at positions 92 (to alpha and beta), and 109 and 110 (to alpha only). Mass spectrometric analysis of peptide fragments derived from the b(24-156)A92C crosslink revealed that cross-linking took place within the region of alpha between Ile-464 and Met-483, This result indicates that the b dimer interacts with the alpha subunit near a non-catalytic alpha/beta interface. A cysteine residue introduced in place of the highly conserved arginine at position 36 of the b subunit could be cross-linked to the a subunit of F-0 in membrane-bound ATP synthase, implying that at least 10 residues of the polar domain of b are adjacent to residues of a. Sites of cross-linking between b(24-156)A92C and beta as well as b(24-156)I109C and alpha are proposed based on the mass spectrometric data, and these sites are discussed in terms of the structure of b and its interactions with the rest of the complex.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Dunn, SD (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	sdunn@julian.uwo.ca	Dunn, Stanley/D-3418-2013					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; ARIS JP, 1983, J BIOL CHEM, V258, P4599; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; Blair A, 1996, MICROBIOL-SGM, V142, P17, DOI 10.1099/13500872-142-1-17; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUSILOW WSA, 1993, MOL MICROBIOL, V9, P419, DOI 10.1111/j.1365-2958.1993.tb01703.x; Caviston TL, 1998, FEBS LETT, V429, P201, DOI 10.1016/S0014-5793(98)00597-3; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; DUNN SD, 1980, J BIOL CHEM, V255, P6891; DUNN SD, 1985, J BIOL CHEM, V260, P418; Dunn SD, 1997, BBA-BIOENERGETICS, V1319, P177, DOI 10.1016/S0005-2728(96)00159-4; DUNN SD, 1992, J BIOL CHEM, V267, P7630; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; DUNN SD, 2000, IN PRESS BIOCH BIOPH; Engelbrecht S, 1998, EUR J BIOCHEM, V252, P277, DOI 10.1046/j.1432-1327.1998.2520277.x; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAMOTO CA, 1986, J BIOL CHEM, V261, P37; Kuo PH, 1998, FEBS LETT, V426, P217, DOI 10.1016/S0014-5793(98)00337-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERER F, 1981, J MOL BIOL, V148, P427, DOI 10.1016/0022-2836(81)90185-6; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Ogilvie I, 1998, ACTA PHYSIOL SCAND, V163, P169; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PRIVE GG, 1994, ACTA CRYSTALLOGR D, V50, P375, DOI 10.1107/S0907444993014301; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sawada K, 1997, J BIOL CHEM, V272, P30047, DOI 10.1074/jbc.272.48.30047; SCHNEIDER E, 1984, P NATL ACAD SCI-BIOL, V81, P7279, DOI 10.1073/pnas.81.23.7279; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; TAKEYAMA M, 1988, J BIOL CHEM, V263, P16106; TROWER MK, 1993, BIOCHIM BIOPHYS ACTA, V1143, P109, DOI 10.1016/0005-2728(93)90223-3; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381	52	51	52	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17571	17577		10.1074/jbc.M000375200	http://dx.doi.org/10.1074/jbc.M000375200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747904	hybrid			2022-12-27	WOS:000087485000052
J	Weber, RE; Fago, A; Val, AL; Bang, A; Van Hauwaert, ML; Dewilde, S; Zal, F; Moens, L				Weber, RE; Fago, A; Val, AL; Bang, A; Van Hauwaert, ML; Dewilde, S; Zal, F; Moens, L			Isohemoglobin differentiation in the bimodal-breathing amazon catfish Hoplosternum littorale	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; OXYGEN EQUILIBRIA; HUMAN HEMOGLOBIN; ORGANIC-PHOSPHATES; NUCLEOSIDE TRIPHOSPHATES; ERYTHROCYTE-MEMBRANE; TROUT ERYTHROCYTES; CYTOPLASMIC DOMAIN; ANGUILLA-ANGUILLA; FISH HEMOGLOBINS	The bimodal gill(water)/gut(air)-breathing Amazonian catfish Hoplosternum littorale that frequents hypoxic habitats uses "mammalian" 2,3-diphosphoglycerate (DPG) in addition to "piscine" ATP and GTP as erythrocytic O-2 affinity modulators. Its electrophoretically distinct anodic and cathodic hemoglobins (Hb(An) and Hb(Ca)) were isolated for functional and molecular characterization. In contrast to HbAn, phosphate-free Hb(Ca) exhibits a pronounced reverse Bohr effect (increased O-2 affinity with decreasing pH) that is obliterated by ATP, and opposite pH dependences of K-T (O-2 association constant of low affinity, tense state) and the overall heat of oxygenation. Dose-response curves indicate small chloride effects and pronounced and differentiated phosphate effects, DPG < ATP < GTP < IHP, Hb(Ca)-O-2 equilibria analyzed in terms of the Monod-Wyman-Changeux model show that small T state bond energy differences underlie the differentiated phosphate effects. Synthetic peptides, corresponding to N-terminal fragment of the cytoplasmic domain of trout band 3 protein, undergo oxygenation-linked binding to Hb(Ca), suggesting a metabolic regulatory role for this hemoglobin. The amino acid sequences for the alpha and beta chains of Hb(Ca) obtained by Edman degradation and cDNA sequencing show unusual substitutions at the phosphate-binding site that are discussed in terms of its reverse Bohr effect and anion sensitivities.	Aarhus Univ, Dept Zoophysiol, DK-8000 Aarhus C, Denmark; Inst Nacl Pesquisas Amazonia, Lab Ecophysiol & Mol Evolut, BR-69083 Manaus, Amazonas, Brazil; Univ Antwerp, Dept Biochem, B-2610 Wilrijk, Belgium; CNRS, Biol Stn, Equipe Ecophysiol, UPMC,INSU, F-29682 Roscoff, France	Aarhus University; Institute Nacional de Pesquisas da Amazonia; University of Antwerp; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Sorbonne Universite	Weber, RE (corresponding author), Aarhus Univ, Dept Zoophysiol, DK-8000 Aarhus C, Denmark.		Val, Adalberto/AAE-3983-2020; Val, Adalberto Luis/I-3377-2014; Fago, Angela/J-5946-2013	Val, Adalberto/0000-0002-3823-3868; Fago, Angela/0000-0001-7315-2628				AFFONSO EG, 1990, THESIS INPA MANAUS; ALLEN G, 1989, LAB TECHNIQUES BIOCH, V9, P1; AMICONI G, 1985, EUR J BIOCHEM, V150, P387, DOI 10.1111/j.1432-1033.1985.tb09032.x; [Anonymous], ZOOL J; Bardgard AJ, 1997, COMP BIOCHEM PHYS A, V117, P367, DOI 10.1016/S0300-9629(96)00286-1; BARRA D, 1983, BIOCHIM BIOPHYS ACTA, V742, P72, DOI 10.1016/0167-4838(83)90360-6; BRUNORI M, 1975, ARCH BIOCHEM BIOPHYS, V168, P512, DOI 10.1016/0003-9861(75)90281-7; BUNN HF, 1971, J BIOL CHEM, V246, P5273; CARTER G. S., 1931, JOUR LINN SOC LONDON ZOOL, V37, P327; CHANUTIN A, 1967, ARCH BIOCHEM BIOPHYS, V121, P96, DOI 10.1016/0003-9861(67)90013-6; CHIEN JCW, 1980, J BIOL CHEM, V255, P9790; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; Fago A, 1997, J BIOL CHEM, V272, P15628, DOI 10.1074/jbc.272.25.15628; FAGO A, 1992, EUR J BIOCHEM, V210, P963, DOI 10.1111/j.1432-1033.1992.tb17501.x; FAGO A, 1995, J BIOL CHEM, V270, P18897, DOI 10.1074/jbc.270.32.18897; Fang TY, 1999, BIOCHEMISTRY-US, V38, P13423, DOI 10.1021/bi9911379; Feuerlein RJ, 1996, J COMP PHYSIOL B, V165, P597, DOI 10.1007/BF00301127; FRONTICELLI C, 1994, J BIOL CHEM, V269, P23965; GARLICK RL, 1979, COMP BIOCHEM PHYS A, V62, P219, DOI 10.1016/0300-9629(79)90759-X; GARRETT RH, 1995, BIOCHEMISTRY-US, P1; GIARDINA B, 1990, BIOCHEM J, V266, P897; GIARDINA B, 1990, EUR J BIOCHEM, V194, P61, DOI 10.1111/j.1432-1033.1990.tb19427.x; GIARDINA B, 1995, CRIT REV BIOCHEM MOL, V30, P165, DOI 10.3109/10409239509085142; GRONENBORN AM, 1984, J MOL BIOL, V178, P731, DOI 10.1016/0022-2836(84)90249-3; HUBNER S, 1992, BIOCHEM J, V285, P17; IMAI K, 1975, J BIOL CHEM, V250, P2227; IMAI K, 1982, ALLOSTERIC EFFECTS H, P1; ISAACKS RE, 1978, CAN J ZOOL, V56, P1014, DOI 10.1139/z78-143; Jensen FB, 1998, J EXP BIOL, V201, P2685; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P579; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; MARTIN JP, 1979, COMP BIOCHEM PHYS A, V62, P155, DOI 10.1016/0300-9629(79)90748-5; Messana I, 1996, FEBS LETT, V390, P25, DOI 10.1016/0014-5793(96)00624-2; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOTAIS R, 1987, J GEN PHYSIOL, V90, P197, DOI 10.1085/jgp.90.2.197; Nikinmaa Mikko, 1998, Fish Physiology, V17, P141, DOI 10.1016/S1546-5098(08)60261-7; NONNOTTE G, 1993, RESP PHYSIOL, V91, P71, DOI 10.1016/0034-5687(93)90090-W; PELSTER B, 1990, J EXP BIOL, V149, P425; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; PERUTZ MF, 1982, NATURE, V299, P421, DOI 10.1038/299421a0; POWERS DA, 1972, SCIENCE, V177, P360, DOI 10.1126/science.177.4046.360; RIGGS AF, 1988, ANNU REV PHYSIOL, V50, P181, DOI 10.1146/annurev.ph.50.030188.001145; ROLLEMA HS, 1975, J BIOL CHEM, V250, P1333; Rossi-Fanelli A., 1958, BIOCHIM BIOPHYS ACTA, V30, P608; SHIH DTB, 1993, J MOL BIOL, V230, P1291; TYUMA I, 1973, BIOCHEMISTRY-US, V12, P1491, DOI 10.1021/bi00732a004; VAL AL, 1993, VERTEBRATE GAS TRANSPORT CASCADE, P43; VAL AL, 1990, COMP BIOCHEM PHYS B, V97, P435, DOI 10.1016/0305-0491(90)90140-O; WALDER JA, 1984, J BIOL CHEM, V259, P238; WEBER RE, 1987, J COMP PHYSIOL B, V157, P145, DOI 10.1007/BF00692358; WEBER RE, 1995, J MOL BIOL, V251, P703, DOI 10.1006/jmbi.1995.0466; WEBER RE, 1979, COMP BIOCHEM PHYS A, V62, P179, DOI 10.1016/0300-9629(79)90752-7; WEBER RE, 1990, COMP PHYSIOL, V6, P58; WEBER RE, 1988, ANNU REV PHYSIOL, V50, P161, DOI 10.1146/annurev.ph.50.030188.001113; WEBER RE, 1979, COMP BIOCHEM PHYS A, V62, P125, DOI 10.1016/0300-9629(79)90744-8; WEBER RE, 1976, J EXP BIOL, V65, P333; WEBER RE, 1978, J COMP PHYSIOL, V128, P127, DOI 10.1007/BF00689476; WEBER RE, 1981, NATURE, V292, P386, DOI 10.1038/292386a0; WEBER RE, 1983, J EXP BIOL, V103, P109; WEBER RE, 1976, J EXP BIOL, V64, P75; WEBER RE, 1992, J APPL PHYSIOL, V72, P1611, DOI 10.1152/jappl.1992.72.4.1611; WEBER RE, 1982, EXOGENOUS ENDOGENOUS, V1, P87	63	45	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17297	17305		10.1074/jbc.M001209200	http://dx.doi.org/10.1074/jbc.M001209200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747999	hybrid			2022-12-27	WOS:000087485000014
J	Andersen, AS; Hansen, PH; Schaffer, L; Kristensen, C				Andersen, AS; Hansen, PH; Schaffer, L; Kristensen, C			A new secreted insect protein belonging to the immunoglobulin superfamily binds insulin and related peptides and inhibits their activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; RECEPTOR-BINDING; HIGH-AFFINITY; DROSOPHILA; CLONING; EVOLUTION; HOMOLOG; FAMILY	Insulin and related peptides are key hormones for the regulation of growth and metabolism. Here we describe a novel high affinity insulin-related peptide-binding protein (IBP) secreted from cells of the insect Spodoptera frugiperda. This IBP is composed of two Ig-like C2 domains, has a molecular mass of 27 kDa, binds human insulin with an affinity of 79 pM and inhibits insulin signaling through the insulin receptor. The binding protein also binds insulin-like growth factors I and II, proinsulin, mini-proinsulin, and an insulin analog lacking the last 8 amino acids of the B-chain (des-octa peptide insulin) with high affinity, whereas an insulin analog with a Asp-B10 mutation bound with only 1% of the affinity of human insulin. This binding profile suggests that IBP recognizes a region that is highly conserved in the insulin superfamily but distinct from the classical insulin receptor binding site. The closest homologue of the Spodoptera frugiperda binding protein is the essential gene product IMP-L2, found in Drosophila, where it is implicated in neural and ectodermal development (Garbe, J. C., Yang, E., and Fristrom, J. W. (1993) Development 119, 1237-1250). Here we show that the IMP-L2 protein also binds insulin and related peptides, offering a possible functional explanation to the IMP-L2 null lethality.	Novo Nordisk AS, Insulin Res, Novo Alle, DK-2880 Bagsvaerd, Denmark	Novo Nordisk	Andersen, AS (corresponding author), Novo Nordisk AS, Insulin Res, Novo Alle, 6B1-74, DK-2880 Bagsvaerd, Denmark.		Kristensen, Claus/O-8047-2015	Kristensen, Claus/0000-0002-2594-7722				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; CHAN SJ, 1990, P NATL ACAD SCI USA, V87, P9319, DOI 10.1073/pnas.87.23.9319; DEMEYTS P, 1978, NATURE, V273, P504; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; Doverskog M, 1999, BIOCHEM BIOPH RES CO, V265, P674, DOI 10.1006/bbrc.1999.1745; Duret L, 1998, GENOME RES, V8, P348, DOI 10.1101/gr.8.4.348; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; Fullbright G, 1997, EUR J BIOCHEM, V245, P774, DOI 10.1111/j.1432-1033.1997.t01-1-00774.x; GARBE JC, 1993, DEVELOPMENT, V119, P1237; Graf R, 1997, INSECT MOL BIOL, V6, P151, DOI 10.1111/j.1365-2583.1997.tb00083.x; Gregoire FM, 1998, BIOCHEM BIOPH RES CO, V249, P385, DOI 10.1006/bbrc.1998.9164; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; ISHIZAKI H, 1988, HORM METAB RES, V20, P426, DOI 10.1055/s-2007-1010852; KAWAKAMI A, 1989, P NATL ACAD SCI USA, V86, P6843, DOI 10.1073/pnas.86.18.6843; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; KRISTENSEN C, 1995, BIOCHEM J, V305, P981, DOI 10.1042/bj3050981; Kristensen C, 1999, J BIOL CHEM, V274, P37351, DOI 10.1074/jbc.274.52.37351; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; MURRAYRUST J, 1992, BIOESSAYS, V14, P325, DOI 10.1002/bies.950140507; Nagata K, 1999, BIOCHEM BIOPH RES CO, V266, P575, DOI 10.1006/bbrc.1999.1865; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OSTERBUR DL, 1988, DEV BIOL, V129, P439, DOI 10.1016/0012-1606(88)90391-0; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PETRUZZELLI L, 1985, J BIOL CHEM, V260, P6072; Pimentel B, 1996, BIOCHEM BIOPH RES CO, V226, P855, DOI 10.1006/bbrc.1996.1440; RUAN YM, 1995, J BIOL CHEM, V270, P4236, DOI 10.1074/jbc.270.9.4236; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; SMIT AB, 1993, J MOL ENDOCRINOL, V11, P103, DOI 10.1677/jme.0.0110103; STEINER DF, 1988, HORM METAB RES, V20, P443, DOI 10.1055/s-2007-1010855; Yamanaka Y, 1997, J BIOL CHEM, V272, P30729, DOI 10.1074/jbc.272.49.30729	34	51	53	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16948	16953		10.1074/jbc.M001578200	http://dx.doi.org/10.1074/jbc.M001578200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748036				2022-12-27	WOS:000087392200078
J	Goyette, P; Chen, CF; Wang, W; Seguin, F; Lohnes, D				Goyette, P; Chen, CF; Wang, W; Seguin, F; Lohnes, D			Characterization of retinoic acid receptor-deficient keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMA; BREAST-CANCER CELLS; X-RECEPTOR; SKIN CARCINOGENESIS; DEPENDENT ACTIVATION; NUCLEAR RECEPTORS; EPIDERMAL-CELLS; DNA-BINDING; VITAMIN-A; IN-VIVO	Retinoids are essential for normal epidermal growth and differentiation and show potential for the prevention or treatment of various epithelial neoplasms. The retinoic acid receptors (RAR alpha, -beta, and -gamma) are transducers of the retinoid signal. The epidermis expresses RAR gamma and RAR alpha, both of which are potential mediators of the effects of retinoids in the epidermis. To further investigate the role(s) of these receptors, we derived transformed keratinocyte lines from wild-type, RAR alpha RAR gamma, and RAR alpha gamma null mice and investigated their response to retinoids, including growth inhibition, markers of growth and differentiation, and AP-1 activity. Our results indicate that RAR gamma is the principle receptor contributing to all-trans-retinoic acid (RA)-mediated growth arrest in this system. This effect partially correlated with inhibition of AP-1 activity. in the absence of RARs, the synthetic retinoid N-(4-hydroxyphenyl)-retinamide inhibited growth; this was not observed with Rtl 9-cis RA, or the synthetic retinoid (E)-4-[2-(5, 5, 8, 8 tetramethyl-5,6,7,8-tetrahydro-2- naphthalenyl)-1-propenyl] benzoic acid. Finally, both RAR alpha and RAR gamma differently affected the expression of some genes suggesting both specific and overlapping roles for the RARs in keratinocytes.	Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Mol Biol, Montreal, PQ H2W 1R7, Canada; McGill Univ, Div Expt Med, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University	Lohnes, D (corresponding author), Clin Res Inst Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	lohnesd@irem.qc.ca						ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Angel P, 1992, Matrix Suppl, V1, P156; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN LC, 1994, CARCINOGENESIS, V15, P2383, DOI 10.1093/carcin/15.10.2383; Chen YC, 1999, ONCOGENE, V18, P139, DOI 10.1038/sj.onc.1202272; Clifford JL, 1999, CANCER RES, V59, P14; DARWICHE N, 1995, CANCER RES, V55, P2774; De Luca LM, 1997, J NUTR BIOCHEM, V8, P426, DOI 10.1016/S0955-2863(97)00063-6; DE LUCA LM, 1991, FASEB J, V5, P2924; DE LUCA LM, 1994, NUTR REV, V52, P45; DECENSI A, 1994, ONCOL REP, V1, P817; DECENSI A, 1994, EUR J CANCER, V30A, P1909, DOI 10.1016/0959-8049(94)00336-4; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Giandomenico V, 1999, CARCINOGENESIS, V20, P1133, DOI 10.1093/carcin/20.6.1133; Gottardis MM, 1996, CANCER RES, V56, P5566; Greenberg R. P., 1989, J PERSONALITY DISORD, V3, P199; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Helland A, 1998, NATURE, V396, P530, DOI 10.1038/25034; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Iulianella A, 1999, DEV BIOL, V205, P33, DOI 10.1006/dbio.1998.9110; Johnson BS, 1999, MOL CELL BIOL, V19, P3372; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; Kaiser A, 1999, FEBS LETT, V448, P45, DOI 10.1016/S0014-5793(99)00326-9; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Khuri FR, 1997, JNCI-J NATL CANCER I, V89, P199, DOI 10.1093/jnci/89.3.199; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Lee HY, 1999, MOL CELL BIOL, V19, P1973; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Lemon BD, 1996, MOL CELL BIOL, V16, P1006; Li Y, 1999, J BIOL CHEM, V274, P15360, DOI 10.1074/jbc.274.22.15360; LOHNES D, 1995, J STEROID BIOCHEM, V53, P475, DOI 10.1016/0960-0760(95)00094-G; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1994, CANCER RES, V54, pS1987; LOTAN R, 1991, CANCER BIOL, V2, P197; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MORRISSKAY G, 1994, ARCH TOX S, V16, P112; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Oridate N, 1995, J CELL BIOCHEM, P80; ORIDATE N, 1995, INT J ONCOL, V7, P433; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Pignatello MA, 1997, TOXICOL APPL PHARM, V142, P319, DOI 10.1006/taap.1996.8047; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Shiohara M, 1999, BLOOD, V93, P2057, DOI 10.1182/blood.V93.6.2057.406k04_2057_2066; SPORN MB, 1994, RETINOIDS; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; Wang TTY, 1996, CANCER LETT, V107, P65, DOI 10.1016/0304-3835(96)04344-3; Webber MM, 1999, CLIN EXP METASTAS, V17, P255, DOI 10.1023/A:1006665616932; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x	76	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16497	16505		10.1074/jbc.M909382199	http://dx.doi.org/10.1074/jbc.M909382199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748128	hybrid			2022-12-27	WOS:000087392200016
J	Li-Hawkins, J; Lund, EG; Turley, SD; Russell, DW				Li-Hawkins, J; Lund, EG; Turley, SD; Russell, DW			Disruption of the oxysterol 7 alpha-hydroxylase gene in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID SYNTHESIS; NUCLEAR RECEPTOR LXR; COENZYME-A REDUCTASE; DIETARY-CHOLESTEROL; BINDING-PROTEIN; LIVER; MOUSE; METABOLISM; IDENTIFICATION; ALPHA	Mice without oxysterol 7 alpha-hydroxylase, an enzyme of the alternate bile acid synthesis pathway with a sexually dimorphic expression pattern, were constructed by the introduction of a null mutation at the Cyp7b1 locus. Animals heterozygous (Cyp7b1(+/-)) and homozygous (Cyp7b1(-/-)) for this mutation were grossly indistinguishable from wild-type mice. Plasma and tissue levels of 25- and 27-hydroxycholesterol, two oxysterol substrates of this enzyme with potent regulatory actions in cultured cells, were markedly elevated in Cyp7b1(-/-) knockout animals. Parameters of bile acid metabolism as well as plasma cholesterol and triglyceride levels in male and female Cyp7b1(-/-) mice were normal. The cholesterol contents of major tissues mere not altered. In vivo sterol biosynthetic rates were unaffected in multiple tissues with the exception of the male kidney, which showed a similar to 40% decrease in de novo synthesis versus controls. We conclude that the major physiological role of the CYP7B1 oxysterol 7 alpha-hydroxylase is to metabolize 25- and 27-hydroxycholesterol and that loss of this enzyme in the liver is compensated for by increases in the synthesis of bile acids by other pathways. A failure to catabolize oxysterols in the male kidney may lead to a decrease in de novo sterol synthesis.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Russell, DW (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	Russell@utsw.swmed.edu		Russell, David/0000-0002-0277-403X	NHLBI NIH HHS [HL 09610, HL 20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL009610, R37HL009610] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN MS, 1974, J BIOL CHEM, V249, P7306; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; DAWSON PA, 1989, J BIOL CHEM, V264, P9046; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; Lammert F, 1999, J LIPID RES, V40, P2080; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16543, DOI 10.1074/jbc.M001810200; LUND E, 1992, J BIOL CHEM, V267, P25092; Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316; Mahendroo MS, 1996, MOL ENDOCRINOL, V10, P380, DOI 10.1210/me.10.4.380; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAUCIER SE, 1989, J BIOL CHEM, V264, P6863; Schwarz M, 1998, CURR OPIN LIPIDOL, V9, P113, DOI 10.1097/00041433-199804000-00006; Schwarz M, 1998, J LIPID RES, V39, P1833; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; Setchell KDR, 1998, J CLIN INVEST, V102, P1690, DOI 10.1172/JCI2962; SMITH LL, 1987, CHEM PHYS LIPIDS, V44, P87, DOI 10.1016/0009-3084(87)90046-6; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; Turley SD, 1998, HEPATOLOGY, V28, P1088, DOI 10.1002/hep.510280425; TURLEY SD, 1994, GASTROENTEROLOGY, V107, P444, DOI 10.1016/0016-5085(94)90170-8; Vlahcevic ZR, 1996, AM J PHYSIOL-GASTR L, V270, pG646, DOI 10.1152/ajpgi.1996.270.4.G646; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Xu GR, 1999, J CLIN INVEST, V103, P89, DOI 10.1172/JCI4414	33	140	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16536	16542		10.1074/jbc.M001811200	http://dx.doi.org/10.1074/jbc.M001811200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748048	hybrid			2022-12-27	WOS:000087392200021
J	Penkov, D; Tanaka, S; Di Rocco, G; Berthelsen, J; Blasi, F; Ramirez, F				Penkov, D; Tanaka, S; Di Rocco, G; Berthelsen, J; Blasi, F; Ramirez, F			Cooperative interactions between PBX, PREP, and HOX proteins modulate the activity of the alpha 2(V) collagen (COL5A2) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; HOMEODOMAIN PROTEINS; TRANSCRIPTIONAL ACTIVATOR; ENHANCER ACTIVITY; HOMEOBOX GENES; EXTRADENTICLE; COMPLEX; SPECIFICITY; EXPRESSION; REGION	Cell type-specific expression of the human (alpha 2(V) collagen (COL5A2) gene depends on a cis-acting element that consists of two contiguous protein binding sites (FPA and FPB) located between nucleotides -149 and -95, relative to the transcription start site. The present study focused on the characterization of the FPB-bound complex. DNA binding assays and cell transfection experiments revealed that the bipartite core sequence of FPB (5'-ATCAATCA-3') binds the PBX1/2, PREP1, and HOXB1 proteins, and this in turn leads to promoter transactivation. In the presence of all three nuclear factors, cooperative interactions between recombinant PBX1 and PREP1 or PBX1 and HOXB1 result in binding of the heterodimers to FPB in vitro. Similarly, overexpression of different combinations of PBX1, PREP1, and HOXB1 transactivates FPB driven transcription. In contrast to the composition of the FPB complex purified from COL5A2-positive cells, the FPB complex from COL5A2-negative cells contains PBX2 and PREP1 but lacks PBX1. However, PBX1 exogenously introduced into COL5A2-negative cells cannot stimulate FPB-driven transcription unless co-expressed with PREP1. Within the intrinsic limitations of the experimental model, our results indicate that combinatorial interactions among PBX and PREP or HOX proteins are involved in regulating tissue-specific production of collagen V.	NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, Brookdale Ctr, New York, NY 10029 USA; Univ Vita Salute San Raffaele, TIGET, I-20132 Milan, Italy; Univ Vita Salute San Raffaele, DIBIT, I-20132 Milan, Italy	Icahn School of Medicine at Mount Sinai; New York University; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; Vita-Salute San Raffaele University	Ramirez, F (corresponding author), NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, Brookdale Ctr, 1 Gustave Levy L Pl,Box 1020, New York, NY 10029 USA.	ramirf01@doc.mssm.edu	Di Rocco, Giuliana/J-4776-2018; Di Rocco, Giuliana/G-5682-2012; Di Rocco, Giuliana/P-1413-2019	Di Rocco, Giuliana/0000-0003-1210-6008; Di Rocco, Giuliana/0000-0003-1210-6008; Blasi, Francesco/0000-0001-9406-1784	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR042766] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42766, AR-386481] Funding Source: Medline; Telethon [E.0485] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Telethon(Fondazione Telethon)		ANDRIKOPOULOS K, 1992, DEV DYNAM, V195, P113, DOI 10.1002/aja.1001950205; ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Cecconi F, 1997, DEV DYNAM, V210, P184, DOI 10.1002/(SICI)1097-0177(199710)210:2<184::AID-AJA10>3.0.CO;2-E; Chan SK, 1997, DEVELOPMENT, V124, P2007; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; DeCesare D, 1996, ONCOGENE, V13, P2551; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; Ferretti E, 2000, DEVELOPMENT, V127, P155; Ferretti E, 1999, MECH DEVELOP, V83, P53, DOI 10.1016/S0925-4773(99)00031-3; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Karsenty G, 1995, Int Rev Immunol, V12, P177, DOI 10.3109/08830189509056711; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Kurant E, 1998, DEVELOPMENT, V125, P1037; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maconochie MK, 1997, GENE DEV, V11, P1885, DOI 10.1101/gad.11.14.1885; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; Ryoo HD, 1999, GENE DEV, V13, P1704, DOI 10.1101/gad.13.13.1704; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; SAMBROOK J, 1983, MOL CLONING LAB MANU, P545; Sandell LJ, 1996, CONNECT TISSUE RES, V35, P1, DOI 10.3109/03008209609029168; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; TRUTER S, 1992, J BIOL CHEM, V267, P25389; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; YOSHIOKA H, 1995, J BIOL CHEM, V270, P418, DOI 10.1074/jbc.270.1.418	50	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16681	16689		10.1074/jbc.M909345199	http://dx.doi.org/10.1074/jbc.M909345199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10748126	hybrid			2022-12-27	WOS:000087392200041
J	Schumacher, C; Wang, H; Honer, C; Ding, W; Koehn, J; Lawrence, Q; Coulis, CM; Wang, LL; Ballinger, D; Bowen, BR; Wagner, S				Schumacher, C; Wang, H; Honer, C; Ding, W; Koehn, J; Lawrence, Q; Coulis, CM; Wang, LL; Ballinger, D; Bowen, BR; Wagner, S			The SCAN domain mediates selective oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; PROTEIN INTERACTION MOTIF; FINGER DNA RECOGNITION; CRYSTAL-STRUCTURE; TRANSCRIPTION FACTORS; BINDING PROTEINS; ESCHERICHIA-COLI; FUSION PROTEINS; BTB/POZ DOMAIN; POZ DOMAIN	The SCAN domain is described as a highly conserved, leucine-rich motif of approximately 60 amino acids found at the amino-terminal end of zinc finger transcription factors. Although no specific biological function has been attributed to the SCAN domain, its predicted amphipathic secondary structure led to the suggestion that this domain may mediate protein-protein associations. A yeast two-hybrid screen identified members of two SCAN domain protein families that interact with the SCAN domain of the zinc finger protein ZNF202. The interacting ZNF191 protein represents the family of SCAN domain-containing zinc finger proteins, whereas the novel SDP1 protein establishes a new family of genes that encode an isolated SCAN domain. Isolated SCAN domain proteins may form asymmetric homodimers in solution. Biochemical binding studies confirmed the associations of ZNF191 and SDP1 with ZNF202 and established the SCAN domain as a selective hetero- and homotypic oligomerization domain. SCAN mediated protein associations might therefore represent a new regulatory mechanism of transcriptional activity.	Novartis Inst Biomed Res, MCD Res, Summit, NJ 07901 USA; Myriad Genet, Salt Lake City, UT 84108 USA	Novartis; Myriad Genetics, Inc	Schumacher, C (corresponding author), Novartis Inst Biomed Res, MCD Res, 556 Morris Ave, Summit, NJ 07901 USA.							Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Castillo G, 1999, EMBO J, V18, P3676, DOI 10.1093/emboj/18.13.3676; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FELLER SM, 1995, METHOD ENZYMOL, V255, P369; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Kim KI, 1999, J MOL BIOL, V294, P1363, DOI 10.1006/jmbi.1999.3320; Kobayashi A, 2000, MOL CELL BIOL, V20, P1733, DOI 10.1128/MCB.20.5.1733-1746.2000; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Li XM, 1999, CANCER RES, V59, P5275; Monaco C, 1998, GENOMICS, V52, P358, DOI 10.1006/geno.1998.5419; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith Donald B., 1993, Methods in Molecular and Cellular Biology, V4, P220; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Tan S, 1998, CURR OPIN STRUC BIOL, V8, P41, DOI 10.1016/S0959-440X(98)80008-0; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; Williams AJ, 1999, MOL CELL BIOL, V19, P8526; Wolberger C, 1998, CURR OPIN GENET DEV, V8, P552, DOI 10.1016/S0959-437X(98)80010-5	27	67	75	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17173	17179		10.1074/jbc.M000119200	http://dx.doi.org/10.1074/jbc.M000119200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747874	hybrid			2022-12-27	WOS:000087392200109
J	Fayadat, L; Siffroi-Fernandez, S; Lanet, J; Franc, JL				Fayadat, L; Siffroi-Fernandez, S; Lanet, J; Franc, JL			Degradation of human thyroperoxidase in the endoplasmic reticulum involves two different pathways depending on the folding state of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR TRAFFICKING; THYROID PEROXIDASE; PLASMA-MEMBRANE; QUALITY-CONTROL; PROTEASOME; CLEAVAGE; CELLS; GLYCOPROTEIN; INVOLVEMENT; EXPRESSION	Human thyroperoxidase (hTPO), a type I transmembrane glycoprotein, plays a key role in thyroid hormone synthesis. In a previous paper (Fayadat, L., Niccoli, P., Lanet, J., and Franc, J. L. (1998) Endocrinology 139, 4277-4285) we established that after the synthesis, only 15-20% of the hTPO molecules were recognized by a monoclonal antibody (mAb15) directed against a conformational structure and that only 2% were able to reach the cell surface. In the present study using pulse-chase experiments in the presence or absence of protease inhibitors followed by immunoprecipitation procedures with monoclonal antibodies recognizing unfolded or partially folded hTPO forms we show that: (i) unfolded hTPO forms are degraded by the proteasome and (ii) partially folded hTPO forms are degraded by other proteases. It was also established upon incubating endoplasmic reticulum (ER) membranes in vitro that the degradation of the partially folded hTPO was carried out by serine and cysteine integral ER membrane proteases, These data provide valuable insights into the quality control mechanisms whereby the cells get rid of misfolded or unfolded proteins. Moreover, this is the first study describing a protein degradation process involving two distinct degradation pathways (proteasome and ER cysteine/serine proteases) at the ER level, depending on the folding state of the protein.	Univ Mediterranee, Fac Med, INSERM, U38, F-13385 Marseille 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Franc, JL (corresponding author), Univ Mediterranee, Fac Med, INSERM, U38, 27 Bd J Moulin, F-13385 Marseille 5, France.		Franc, Jean-Louis/C-8861-2009	Franc, Jean-Louis/0000-0002-2900-5468				Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; ECKHOLM R, 1981, MOL CELL ENDOCRINOL, V24, P141; Fayadat L, 1998, ENDOCRINOLOGY, V139, P4277, DOI 10.1210/en.139.10.4277; Fayadat L, 2000, ENDOCRINOLOGY, V141, P959, DOI 10.1210/en.141.3.959; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; FINKE R, 1991, J CLIN ENDOCR METAB, V73, P919, DOI 10.1210/jcem-73-4-919; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; Heinemann FS, 1998, MOL BIOL CELL, V9, P3445, DOI 10.1091/mbc.9.12.3445; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KULIAWAT R, 1995, J BIOL CHEM, V270, P2478, DOI 10.1074/jbc.270.6.2478; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; Lopez D, 1997, J IMMUNOL, V159, P5769; Moriyama T, 1998, J BIOL CHEM, V273, P22037, DOI 10.1074/jbc.273.34.22037; Penel C, 1998, J CELL PHYSIOL, V174, P160, DOI 10.1002/(SICI)1097-4652(199802)174:2<160::AID-JCP3>3.0.CO;2-M; Rasmussen AK, 1999, AUTOIMMUNITY, V29, P323, DOI 10.3109/08916939908994752; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; RUF J, 1989, ENDOCRINOLOGY, V125, P1211, DOI 10.1210/endo-125-3-1211; Teckman JH, 1996, J BIOL CHEM, V271, P13215, DOI 10.1074/jbc.271.22.13215; URBANI L, 1990, J BIOL CHEM, V265, P1919; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	26	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15948	15954		10.1074/jbc.M905763199	http://dx.doi.org/10.1074/jbc.M905763199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748076	hybrid			2022-12-27	WOS:000087291400047
J	Hu, JX; Hauache, O; Spiegel, AM				Hu, JX; Hauache, O; Spiegel, AM			Human Ca2+ receptor cysteine-rich domain - Analysis of function of mutant and chimeric receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; CELL-SURFACE EXPRESSION; METABOTROPIC GLUTAMATE RECEPTORS; TERMINAL EXTRACELLULAR DOMAIN; PUTATIVE PHEROMONE RECEPTORS; CA2+-SENSING RECEPTOR; SIGNAL-TRANSDUCTION; LIGAND-BINDING; MOLECULAR-CLONING; GABA(B) RECEPTOR	The 612-residue extracellular domain of the human Ca2+ receptor (hCaR) has been speculated to consist of a Venus's-flytrap domain (VFT) and a cysteine-rich domain. We studied the function of the hCaR Cys-rich domain by using mutagenesis and chimera approaches. A chimeric hCaR with the sequence from residues 540-601 replaced by the corresponding sequence from the Fugu CaR remained fully functional. Another chimeric hCaR with the same region of sequence replaced by the corresponding sequence from metabotropic glutamate receptor subtype 1 (mGluR1) still was activated by extracellular Ca2+ ([Ca2+](o)), but its function was severely compromised. Chimeric receptors with the hCaR VFT and mGluR1 seven-transmembrane domain plus C-tail domain retained good response to [Ca2+](o) whether the Cys-rich domain was from hCaR or from mGluR1, Mutant hCaR with the Cys-rich domain deleted failed to respond to [Ca2+](o), although it was expressed at the cell surface and capable of dimerization. Our results indicate that the hCaR Cys-rich domain plays a critical role in signal transmission from VFT to seven-transmembrane domain. This domain tolerates a significant degree of amino acid substitution and may not be directly involved in the binding of [Ca2+](o).	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hu, JX (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 8C-101, Bethesda, MD 20892 USA.	jianxinh@intra.niddk.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000061] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1999, AM J MED, V106, P238, DOI 10.1016/S0002-9343(98)00418-5; Brown EM, 1998, ANNU REV MED, V49, P15, DOI 10.1146/annurev.med.49.1.15; Butters RR, 1997, J BONE MINER RES, V12, P568, DOI 10.1359/jbmr.1997.12.4.568; Diaz R, 1997, AM J PHYSIOL-REG I, V273, pR1008, DOI 10.1152/ajpregu.1997.273.3.R1008; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Goldsmith PK, 1999, J BIOL CHEM, V274, P11303, DOI 10.1074/jbc.274.16.11303; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; LI LD, 1998, ASBMR IBMS 2 JOINT M; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Naito T, 1998, P NATL ACAD SCI USA, V95, P5178, DOI 10.1073/pnas.95.9.5178; NAKAE J, 1998, HORM RES S, V48, P179; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Resnick D, 1996, J BIOL CHEM, V271, P26924, DOI 10.1074/jbc.271.43.26924; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Watanabe T, 1998, J CLIN ENDOCR METAB, V83, P2497, DOI 10.1210/jc.83.7.2497; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zhao XM, 1999, FEBS LETT, V448, P180, DOI 10.1016/S0014-5793(99)00368-3	33	86	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16382	16389		10.1074/jbc.M000277200	http://dx.doi.org/10.1074/jbc.M000277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747888	hybrid			2022-12-27	WOS:000087291400105
J	Ishimi, Y; Komamura-Kohno, Y; You, ZY; Omori, A; Kitagawa, M				Ishimi, Y; Komamura-Kohno, Y; You, ZY; Omori, A; Kitagawa, M			Inhibition of Mcm4,6,7 helicase activity by phosphorylation with cyclin A/Cdk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ALPHA; REPLICATION LICENSING SYSTEM; MCM HETEROHEXAMERIC COMPLEXES; XENOPUS EGG EXTRACTS; S-PHASE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; NUCLEAR-LOCALIZATION; CHROMATIN BINDING	A strong body of evidence indicates that cyclin-dependent protein kinases are required not only for the initiation of DNA replication but also for preventing over-replication in eukaryotic cells. Mcm proteins are one of the components of the replication licensing system that permits only a single round of DNA replication per cell cycle. It has been reported that Mcm proteins are phosphorylated by the cyclin-dependent kinases in vivo, suggesting that these two factors are cooperatively involved in the regulation of DNA replication. Our group has reported that a 600-kDa Mcm4,6,7 complex has a DNA helicase activity that is probably necessary for the initiation of DNA replication. Here, we examined the in vitro phosphorylation of the Mcm complexes with cyclin A/Cdk2 to understand the interplay between Mcm proteins and cyclin-dependent kinases, The cyclin A/Cdk2 mainly phosphorylated the amino-terminal region of Mcm4 in the Mcm4,6,7 complex. The phosphorylation was associated with the inactivation of its DNA helicase activity. These results raise the possibility that the inactivation of Mcm4,6,7 helicase activity by Cdk2 is a part of the system for regulating DNA replication.	Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Ishimi, Y (corresponding author), Mitsubishi Kasei Inst Life Sci, 11 Minamiooya, Machida, Tokyo 1948511, Japan.							Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Desdouets C, 1998, EMBO J, V17, P4139, DOI 10.1093/emboj/17.14.4139; Detweiler CS, 1998, P NATL ACAD SCI USA, V95, P2384, DOI 10.1073/pnas.95.5.2384; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Fujita M, 1997, J BIOL CHEM, V272, P10928; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jallepalli PV, 1997, CURR OPIN CELL BIOL, V9, P358, DOI 10.1016/S0955-0674(97)80008-7; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; NASMYTH K, 1996, DNA REPLICATION EUKA, P331; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Stern B, 1996, TRENDS GENET, V12, P345; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Thommes P, 1997, CANCER SURV, V29, P75; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Voitenleitner C, 1999, MOL CELL BIOL, V19, P646; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; You ZY, 1999, MOL CELL BIOL, V19, P8003	48	78	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16235	16241		10.1074/jbc.M909040199	http://dx.doi.org/10.1074/jbc.M909040199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748114	hybrid			2022-12-27	WOS:000087291400085
J	Kipp, H; Arias, IM				Kipp, H; Arias, IM			Newly synthesized canalicular ABC transporters are directly targeted from the Golgi to the hepatocyte apical domain in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE PROTEINS; ATP-DEPENDENT TRANSPORT; MDCK CELLS; EPITHELIAL-CELLS; BIOCHEMICAL-CHARACTERIZATION; PHOSPHOINOSITIDE 3-KINASE; P-GLYCOPROTEIN; MDR2 GENE; VESICLES; RECEPTOR	Newly synthesized canalicular ectoenzymes and a cell adhesion molecule (cCAM105) have been shown to traffic from the Golgi to the basolateral plasma membrane, from where they transcytose to the apical bile canalicular domain. It has been proposed that all canalicular proteins are targeted via this indirect route in hepatocytes, We studied the membrane targeting of rat canalicular proteins by in vivo [S-35]methionine metabolic labeling followed by preparation of highly purified Golgi membranes and canalicular (CMVs) and sinusoidal/basolateral (SMVs) membrane vesicles and subsequent immunoprecipitation, In particular, we compared membrane targeting of newly synthesized canalicular ABC (ATP-binding cassette) transporters MDR1, MDR2, and SPGP (Sister of P-glycoprotein) with that of cCAM105. Significant differences were observed in metabolic pulse-chase labeling experiments with regard to membrane targeting of these apical proteins. After a chase time of 15 min, cCAM105 appeared exclusively in SMVs, peaked at 1 h, and progressively declined thereafter. In CMVs, cCAM105 was first detected after Ih and subsequently increased for 3 h, This findings confirm the transcytotic targeting of cCAM105 reported in earlier studies. In contrast, at no time point investigated were MDR1, MDR2, and SPGP detected in SMVs. In CMVs, MDR1 and MDR2 appeared after 30 min, whereas SPGP appeared after 2 h of labeling. In Golgi membranes, each of the ABC transporters peaked at 30 min and was virtually absent thereafter. These data suggest rapid, direct targeting of newly synthesized MDR1 and MDR2 from the Golgi to the bile canaliculus and transient sequestering of SPGP in an intracellular pool en route from the Golgi to the apical plasma membrane. This study provides biochemical evidence for direct targeting of newly synthesized apical ABC transporters from the Golgi to the bile canaliculus in vivo.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Arias, IM (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.				NIDDK NIH HHS [DK35652, 30DK34928] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928, R37DK035652, R01DK035652] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BARTLES JR, 1990, METHOD ENZYMOL, V191, P825; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BRANDLI AW, 1990, J CELL BIOL, V111, P2902; BROWN PC, 1993, NUCLEIC ACIDS RES, V21, P3885, DOI 10.1093/nar/21.16.3885; Buchler M, 1996, J BIOL CHEM, V271, P15091; GATMAITAN ZC, 1995, PHYSIOL REV, V75, P261, DOI 10.1152/physrev.1995.75.2.261; Gatmaitan ZC, 1997, AM J PHYSIOL-GASTR L, V272, pG1041, DOI 10.1152/ajpgi.1997.272.5.G1041; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; Gibson A, 1998, J CELL BIOL, V143, P81, DOI 10.1083/jcb.143.1.81; HEIDRICH H, 1972, J CELL BIOL, V54, P232, DOI 10.1083/jcb.54.2.232; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HUGHSON EJ, 1990, J CELL BIOL, V110, P337, DOI 10.1083/jcb.110.2.337; Ihrke G, 1998, J CELL BIOL, V141, P115, DOI 10.1083/jcb.141.1.115; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; INOUE M, 1982, HEPATOLOGY, V2, P572; INOUE M, 1983, J BIOL CHEM, V258, P5183; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; Keller P, 1997, J CELL SCI, V110, P3001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; NAKADA H, 1986, J BIOCHEM-TOKYO, V99, P867, DOI 10.1093/oxfordjournals.jbchem.a135547; Nies AT, 1996, J LIPID RES, V37, P1125; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P679; Roelofsen H, 1998, J CELL SCI, V111, P1137; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Sai Y, 1999, J CELL SCI, V112, P4535; SCHELL MJ, 1992, J CELL BIOL, V119, P1173, DOI 10.1083/jcb.119.5.1173; SCHLEIFFLE P, 1995, NATURE, V378, P96; SHANKS MR, 1994, J CELL SCI, V107, P813; SILVERMAN JA, 1991, GENE, V106, P229, DOI 10.1016/0378-1119(91)90203-N; Soroka CJ, 1999, J BIOL CHEM, V274, P26416, DOI 10.1074/jbc.274.37.26416; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; STOCKERT RJ, 1990, J BIOL CHEM, V265, P1841; SUBRAMANIAM VN, 1992, J BIOL CHEM, V267, P12016; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104; Walter K., 1974, METHODS ENZYMATIC AN, V2nd ed., P856	54	119	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15917	15925		10.1074/jbc.M909875199	http://dx.doi.org/10.1074/jbc.M909875199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748167	hybrid			2022-12-27	WOS:000087291400043
J	Takano, R; Hisahara, S; Namikawa, K; Kiyama, H; Okano, H; Miura, M				Takano, R; Hisahara, S; Namikawa, K; Kiyama, H; Okano, H; Miura, M			Nerve growth factor protects oligodendrocytes from tumor necrosis factor-alpha-induced injury through Akt-mediated signaling mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; FACTOR-INDUCED APOPTOSIS; SERINE-THREONINE KINASE; SPINAL-CORD INJURY; CELL-DEATH PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; INHIBITS APOPTOSIS; CYTOCHROME-C; AUTOIMMUNE DEMYELINATION	Tumor necrosis factor-alpha is thought to be one of the most important inflammatory cytokines associated with the demyelinating disease multiple sclerosis, We determined whether neurotrophins could protect oligodendrocytes from tumor necrosis factor-alpha-mediated cytotoxicity. Among the neurotrophins tested, nerve growth factor was most effective at preventing cell death. Nerve growth factor also prevented the tumor necrosis factor-induced loss of mitochondrial membrane potential. Overexpression of constitutively active Akt, a downstream target of phosphatidylinositol 3-kinase, but not of constitutively active MEK, protected oligodendrocytes from tumor necrosis factor-induced injury. Moreover, overexpression of dominant-negative Akt negated the protective effects of nerve growth factor on tumor necrosis factor-mediated oligodendrocyte cytotoxicity. These findings indicate that the Akt pathway is crucial in nerve growth factor-mediated oligodendrocyte protection.	Osaka Univ, Grad Sch Med, Div Neuroanat D12, Suita, Osaka 5650871, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Asahikawa Med Coll, Dept Anat, Asahikawa, Hokkaido 0788510, Japan	Osaka University; Tohoku University; Asahikawa Medical College	Miura, M (corresponding author), Osaka Univ, Grad Sch Med, Div Neuroanat D12, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	mmiura@nana.med.osaka-u.ac.jp	Hisahara, Shin/AAS-8094-2021; Kiyama, Hiroshi/M-8867-2014; Okano, Hideyuki/I-7584-2019	Kiyama, Hiroshi/0000-0001-5963-046X; 				Althaus HH, 1997, J NEUROSCI RES, V50, P729, DOI 10.1002/(SICI)1097-4547(19971201)50:5<729::AID-JNR10>3.3.CO;2-0; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BARRES BA, 1994, NEURON, V12, P935, DOI 10.1016/0896-6273(94)90305-0; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; BARRES BA, 1993, DEVELOPMENT, V118, P283; Bothwell M, 1996, SCIENCE, V272, P506, DOI 10.1126/science.272.5261.506; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRACCI-LAUDIERO L, 1992, NEUROSCI LETT, V147, P9; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Cohen RI, 1996, J NEUROSCI, V16, P6433; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dowling P, 1997, J NEUROL SCI, V149, P1, DOI 10.1016/S0022-510X(97)05213-1; DSouza SD, 1996, J NEUROSCI RES, V43, P289, DOI 10.1002/(SICI)1097-4547(19960201)43:3<289::AID-JNR4>3.0.CO;2-F; DSOUZA SD, 1996, J NEUROSCI, V15, P7293; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Frade JM, 1996, NATURE, V383, P166; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GENAIN CP, 1995, P NATL ACAD SCI USA, V92, P3601, DOI 10.1073/pnas.92.8.3601; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Haviv R, 1999, J NEUROSCI RES, V55, P269; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; Hisahara S, 1997, J NEUROCHEM, V69, P10; Hisahara S, 2000, EMBO J, V19, P341, DOI 10.1093/emboj/19.3.341; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Ladiwala U, 1998, J NEUROSCI, V18, P1297; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Massaro AR, 1997, EUR NEUROL, V37, P243, DOI 10.1159/000117451; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; Ozes ON, 1999, NATURE, V401, P82; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; Poot M, 1999, CYTOMETRY, V35, P311, DOI 10.1002/(SICI)1097-0320(19990401)35:4<311::AID-CYTO3>3.3.CO;2-5; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; RUDGE JS, 1994, EUR J NEUROSCI, V6, P218, DOI 10.1111/j.1460-9568.1994.tb00264.x; Sato N, 1998, MOL CELL NEUROSCI, V12, P65, DOI 10.1006/mcne.1998.0703; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SELMAJ K, 1991, ANN NEUROL, V30, P694, DOI 10.1002/ana.410300510; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Vemuri GS, 1996, DEVELOPMENT, V122, P2529; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Virdee K, 1996, J NEUROCHEM, V67, P1801; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAKUNI T, 1987, FEBS LETT, V223, P117, DOI 10.1016/0014-5793(87)80520-3; Yoon SO, 1998, J NEUROSCI, V18, P3273; YOSHIDA K, 1992, J NEUROCHEM, V59, P919, DOI 10.1111/j.1471-4159.1992.tb08331.x; YOSHIDA K, 1991, BRAIN RES, V538, P118, DOI 10.1016/0006-8993(91)90385-9; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	88	40	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16360	16365		10.1074/jbc.M910419199	http://dx.doi.org/10.1074/jbc.M910419199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748222	hybrid			2022-12-27	WOS:000087291400102
J	Yun, CW; Tiedeman, JS; Moore, RE; Philpott, CC				Yun, CW; Tiedeman, JS; Moore, RE; Philpott, CC			Siderophore-iron uptake in Saccharomyces cerevisiae - Identification of ferrichrome and fusarinine transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR FACILITATOR SUPERFAMILY; FET3 GENE; YEAST; PROTEIN; MECHANISMS; PATHWAYS; PERMEASE; ENCODES; FUNGI; CYCLE	A family of four putative transporters (Arn1p-4p) in Saccharomyces cerevisiae is expressed under conditions of iron deprivation and is regulated by Aft1p, the major iron-dependent transcription factor in yeast. One of these, Arn3p/Sit1p, facilitates the uptake of ferrioxamine B, a siderophore of the hydroxamate class. Here we report that ARN family members facilitated the uptake of iron from the trihydroxamate siderophores ferrichrome, ferrichrome A, and triacetylfusarinine C. Uptake of siderophore-bound iron was dependent on either the high-affinity ferrous iron transport system or the ARN family of transporters. The specificity of each siderophore for individual transporters was determined. Uptake of ferrichrome and ferrichrome A was facilitated by both Arn1p and Arn3p. Uptake of triacetylfusarinine C was facilitated by Arn2p, although small amounts of uptake also occurred through Arn1p and Arn3p. In contrast to the trihydroxamates, uptake of iron from the dihydroxamate rhodotorulic acid occurred only via the high-affinity ferrous iron system. Epitope-tagged Arn1p was expressed in intracellular vesicles in a pattern that was indistinguishable from that of Arn3p, whereas Ftr1p, a component of the high-affinity ferrous system, was expressed on the plasma membrane. These data indicate that S. cerevisiae maintains two systems of siderophore uptake, only one of which is located on the plasma membrane.	NIDDK, Liver Dis Sect, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Dept Chem, Oshkosh, WI 54901 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Wisconsin System	Philpott, CC (corresponding author), NIDDK, Liver Dis Sect, NIH, Bldg 10,Rm 9B16,10 Ctr Dr, Bethesda, MD 20892 USA.	carolinep@intra.niddk.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK054507, Z01DK054507] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albrecht-Gary AM, 1998, MET IONS BIOL SYST, V35, P239; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1998, J BIOL CHEM, V273, P22415, DOI 10.1074/jbc.273.35.22415; ATKIN CL, 1968, BIOCHEMISTRY-US, V7, P3734, DOI 10.1021/bi00850a054; Braun V, 1998, MET IONS BIOL SYST, V35, P67; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Byers BR, 1998, MET IONS BIOL SYST, V35, P37; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DIEKMANN H, 1967, EUR J BIOCHEM, V3, P213, DOI 10.1111/j.1432-1033.1967.tb19518.x; EMERY T, 1965, BIOCHEMISTRY-US, V4, P1410, DOI 10.1021/bi00883a028; GARIBALDI JA, 1955, J AM CHEM SOC, V77, P2429, DOI 10.1021/ja01614a021; HERSHKO C, 1994, IRON METABOLISM HLTH, P391; HESSELTINE CW, 1952, J AM CHEM SOC, V74, P1362, DOI 10.1021/ja01125a525; Jones EW., 1997, MOL CELLULAR BIOL YE, VIII, P363; KEBERLE H, 1964, ANN NY ACAD SCI, V119, P758; Leong SA, 1998, MET IONS BIOL SYST, V35, P147; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; MOORE RE, 1976, BIOCHEMISTRY-US, V15, P2719, DOI 10.1021/bi00658a001; MOORE RE, 1976, THESIS UTAH STATE U; MOORE RE, 1979, CHEM ENG NEWS, V57, P61; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Philpott CC, 1998, EMBO J, V17, P5026, DOI 10.1093/emboj/17.17.5026; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Van der Helm D., 1994, METAL IONS FUNGI, V11, P39; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	36	126	130	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16354	16359		10.1074/jbc.M001456200	http://dx.doi.org/10.1074/jbc.M001456200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10748025	hybrid			2022-12-27	WOS:000087291400101
J	Das, B; Shu, XD; Day, GJ; Han, J; Krishna, UM; Falck, JR; Broek, D				Das, B; Shu, XD; Day, GJ; Han, J; Krishna, UM; Falck, JR; Broek, D			Control of intramolecular interactions between the pleckstrin homology and Db1 homology domains of Vav and Sos1 regulates Rac binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REQUIRES PHOSPHATIDYLINOSITOL 3-KINASE; BRUTONS TYROSINE KINASE; PROTEIN-KINASE; PHOSPHOINOSITIDE BINDING; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; EXCHANGE FACTOR; ACTIVATION; CELLS	Vav and Sos1 are Dbl family guanine nucleotide exchange factors, which activate Rho family GTPases in response to phosphatidylinositol 3-kinase products. A pleckstrin homology domain adjacent to the catalytic Dbl homology domain via an unknown mechanism mediates the effects of phosphoinositides on guanine nucleotide exchange activity. Here we tested the possibility that phosphatidylinositol 3-kinase substrates and products control an interaction between the pleckstrin homology domain and the Dbl homology domain, thereby explaining the inhibitory effects of phosphatidylinositol 3-kinase substrates and stimulatory effects of the products. Binding studies using isolated fragments of Vav and Sos indicate phosphatidylinositol 3-kinase substrate promotes the binding of the pleckstrin homology domain to the Dbl homology domain and blocks Rac binding to the DH domain, whereas phosphatidylinositol 3-kinase products disrupt the Dbl homology/pleckstrin homology interactions and permit Rac binding. Additionally, Lck phosphorylation of Vav, a known activating event, reduces the affinities between the Vav Dbl homology and pleckstrin homology domains and permits Rac binding, We also show Vav activation in cells, as monitored by phosphorylation of Vav, Vav association with phosphatidylinositol 3,4,5-trisphosphate, and Vav guanine nucleotide exchange activity, is blocked by the phosphatidylinositol 3-kinase inhibitor wortmannin, These results suggest the molecular mechanisms for activation of Vav and Sos1 require disruption of inhibitory intramolecular interactions involving the pleckstrin homology and Dbl homology domains.	Univ So Calif, Dept Biochem & Mol Biol, Norris Canc Ctr NOR 524, Keck Sch Med, Los Angeles, CA 90089 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Broek, D (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Norris Canc Ctr NOR 524, Keck Sch Med, Los Angeles, CA 90089 USA.	broek@hsc.usc.edu		Falck, John/0000-0002-9219-7845	NATIONAL CANCER INSTITUTE [R01CA050261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NCI NIH HHS [CA50261] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Buhl AM, 1999, J IMMUNOL, V162, P4438; Cantrell D, 1998, CURR BIOL, V8, pR535, DOI 10.1016/S0960-9822(07)00341-7; Carpenter CL, 1997, ADV ENZYME REGUL, V37, P377, DOI 10.1016/S0065-2571(96)00005-2; Coffer PJ, 1998, BIOCHEM J, V329, P121; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fischer KD, 1998, SEMIN IMMUNOL, V10, P317, DOI 10.1006/smim.1998.0124; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Michel F, 1998, J BIOL CHEM, V273, P31932, DOI 10.1074/jbc.273.48.31932; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; POWIS G, 1994, CANCER RES, V54, P2419; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; REDDY KK, 1995, J ORG CHEM, V60, P3385, DOI 10.1021/jo00116a023; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Schacht J, 1981, Methods Enzymol, V72, P626; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; WENG WK, 1994, J BIOL CHEM, V269, P32514; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Zhang X, 1997, LEUKEMIA RES, V21, P849, DOI 10.1016/S0145-2126(97)00055-6; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340	40	156	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15074	15081		10.1074/jbc.M907269199	http://dx.doi.org/10.1074/jbc.M907269199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10748082	hybrid			2022-12-27	WOS:000087128300043
J	Li, YH; Marzolo, MP; van Kerkhof, P; Strous, GJ; Bu, GJ				Li, YH; Marzolo, MP; van Kerkhof, P; Strous, GJ; Bu, GJ			The YXXL motif, but not the two NPXY motifs, serves as the dominant endocytosis signal for low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MEDIATED INTERNALIZATION; SORTING SIGNALS; BINDING-PROTEIN; VLDL RECEPTOR; APOE RECEPTOR; CELL-LINE; IN-VIVO; SYSTEM; LRP	All members of the low density lipoprotein (LDL) receptor family contain at least one copy of the NPXY sequence within their cytoplasmic tails. For the LDL receptor, it has been demonstrated that the NPXY motif serves as a signal for rapid endocytosis through coated pits. Thus, it is generally believed that the NPXY sequences function as endocytosis signals for an the LDL receptor family members. The primary aim of this study is to define the endocytosis signal(s) within the cytoplasmic tail of LDL receptor-related protein (LRP). By using LRP minireceptors, which mimic the function and trafficking of full-length endogenous LRP, we demonstrate that the YXXL motif, but not the two NPXY motifs, serves as the dominant signal for LRP endocytosis. We also found that the distal di-leucine motif within the LRP tail contributes to its endocytosis, and its function is independent of the YXXL motif. Although the proximal NPXY motif and the proximal di-leucine motif each play a limited role in LRP endocytosis in the context of the full-length tail, these motifs were functional within the truncated receptor tail. In addition, we show that LRP minireceptor mutants defective in endocytosis signal(s) accumulate at the cell surface and are less efficient in delivery of ligand for degradation.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Univ Chile, Dept Biol, Santiago, Chile; Univ Utrecht, Dept Cell Biol, Utrecht, Netherlands	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Universidad de Chile; Utrecht University	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, Box 8116,1 Childrens Pl, St Louis, MO 63110 USA.		Eckhardt, Erik/G-1567-2010	van Kerkhof, Peter/0000-0002-8954-2230	NHLBI NIH HHS [R01 HL52753-07] Funding Source: Medline; NHLBI NIH HHS [HL59150] Funding Source: Medline; NINDS NIH HHS [NS37525] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1994, J BIOL CHEM, V269, P18521; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1994, J BIOL CHEM, V269, P29874; BU GJ, 1993, J BIOL CHEM, V268, P13002; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; Govers P, 1998, J BIOL CHEM, V273, P16426, DOI 10.1074/jbc.273.26.16426; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li YH, 1997, BIOCHEM BIOPH RES CO, V240, P122, DOI 10.1006/bbrc.1997.7619; MORTON PA, 1990, J BIOL CHEM, V265, P14093; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Strous GJ, 1999, J CELL SCI, V112, P1417; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Vilhardt F, 1999, MOL BIOL CELL, V10, P179, DOI 10.1091/mbc.10.1.179; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 2000, J CELL SCI, V113, P123; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164; ZAGURSKY RJ, 1995, BIOTECHNIQUES, V18, P504; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	51	236	242	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17187	17194		10.1074/jbc.M000490200	http://dx.doi.org/10.1074/jbc.M000490200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747918	hybrid			2022-12-27	WOS:000087392200111
J	Li, YS; Liu, JL; Zhan, X				Li, YS; Liu, JL; Zhan, X			Tyrosine phosphorylation of cortactin is required for H2O2-mediated injury of human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; OXIDANT INJURY; CROSS-LINKING; STRESS; SRC; RECEPTOR; H2O2; IDENTIFICATION; CYTOSKELETON; LOCOMOTION	Injury of endothelial cells induced by reactive oxygen species plays an important role in the development of early stages of vascular diseases such as hypertension and atherosclerosis. Exposure of human umbilical vein endothelial cells to hydrogen peroxide (H2O2), a common form of reaction oxygen species, triggers a series of intracellular events, including actin cytoskeletal reorganization, cytoplasm shrinkage, membrane blebbing and protein-tyrosine phosphorylation. The effect of H2O2 on endothelial cells is dramatically enhanced when a survival pathway involving extracellular signal-regulated kinase is blocked by PD098059. In contrast, the injury of endothelial cells mediated by H2O2, is inhibited by PP2, a selective specific inhibitor for protein-tyrosine kinase Src. Cortactin, a filamentous actin (F-actin)-associated protein, becomes phosphorylated at tyrosine residues upon stimulation by H2O2 in a manner dependent on the activity of Src. The level of tyrosine phosphorylation of cortactin is correlated with the formation of membrane blebs, Overexpression of wild-type cortactin tagged with green fluorescent protein in endothelial cells via a retroviral vector substantiates the H2O2,-induced morphological changes, whereas overexpression of a green fluorescent protein-cortactin mutant deficient in tyrosine phosphorylation renders endothelial cells resistant to H2O2. The functional role of cortactin in H2O2-mediated shape changes was also evaluated in NIH 3T3 cells. Stable 3T3 transfectants expressing wild-type cortactin in the presence of either H2O2/ PD098059 or H2O2 alone at 200 muM exhibited a dramatic shape change characterized by rounding up or aggregation, However, the similar changes were not detected with cells overexpressing a cortactin mutant deficient in tyrosine phosphorylation. These data demonstrate an important role of the Src/cortactin-dependent actin reorganization in the injury of endothelial cells mediated by reactive oxygen species.	Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA	American Red Cross	Zhan, X (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Expt Pathol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	zhanx@usa.redcross.org	Eckhardt, Erik/G-1567-2010	van Kerkhof, Peter/0000-0002-8954-2230	NHLBI NIH HHS [R01 HL52753-07] Funding Source: Medline; NHLBI NIH HHS [HL59150] Funding Source: Medline; NINDS NIH HHS [NS37525] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barchowsky A, 1995, AM J PHYSIOL-LUNG C, V269, pL829, DOI 10.1152/ajplung.1995.269.6.L829; Berk BC, 1999, THROMB HAEMOSTASIS, V82, P810; Carbajal JM, 1998, BIOCHEM BIOPH RES CO, V249, P461, DOI 10.1006/bbrc.1998.9172; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hagmann J, 1999, J CELL BIOCHEM, V73, P488, DOI 10.1002/(SICI)1097-4644(19990615)73:4<488::AID-JCB7>3.0.CO;2-P; Hastie LE, 1998, J CELL BIOCHEM, V68, P511, DOI 10.1002/(SICI)1097-4644(19980315)68:4<511::AID-JCB10>3.0.CO;2-C; HINSHAW DB, 1986, AM J PATHOL, V123, P454; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; HULL DS, 1984, INVEST OPHTH VIS SCI, V25, P1246; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; KURODA K, 1995, J IMMUNOL, V155, P4427; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LEVYTOLEDANO S, 1995, THROMB HAEMOSTASIS, V73, P857; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Natarajan V, 1998, ENVIRON HEALTH PERSP, V106, P1205, DOI 10.2307/3433987; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Peus D, 1998, J INVEST DERMATOL, V110, P966, DOI 10.1046/j.1523-1747.1998.00210.x; SACKS T, 1978, J CLIN INVEST, V61, P1161, DOI 10.1172/JCI109031; SCHROR K, 1988, N-S ARCH PHARMACOL, V338, P268; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; ZHAN X, 1993, J BIOL CHEM, V268, P24427; Zhan X, 1997, BLOOD, V89, P457, DOI 10.1182/blood.V89.2.457	33	236	242	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37187	37193		10.1074/jbc.M000490200	http://dx.doi.org/10.1074/jbc.M000490200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10747918	hybrid			2022-12-27	WOS:000165577700100
